HHS Owned Patents,,,,,,,,,,,,,,,,,,,,,,,,,,
US_PatentNumber,GrantDate,GrantYear,GrantMonth,GrantDay,PV_patent_title,PV_patent_abstract,number_of_claims,Assignee_1,Assignee_2,Assignee_3,Assignee_4,Assignee_5,Assignee_6,Assignee_7,Assignee_8,Assignee_9,Assignee_10,Assignee_11,number_of_assignees,WIPOFieldName_1,WIPOFieldName_2,WIPOFieldName_3,WIPOFieldName_4,WIPOFieldName_5,WIPOFieldName_6,PV_cpc_subgroup_id
4182678,8-Jan-80,1980,1,8,Micro-scale countercurrent chromatograph,"A flow-through coil planet centrifuge having a hollow-walled, vertical-axis rotating bowl with a helically-coiled long separation column spirally contained in the hollow wall of the bowl. A stationary, vertical-axis drive motor is located in axial alignment with the bowl. The bowl is rotatably coaxially supported in a cage-like frame. The bowl is rotated by the motor via the frame by a system of belts and gearing which compensates for the rotation of the bowl and column relative to the motor and frame to avoid the twisting of the flow tubes of the column. The outer portion of the frame is provided with a vertical support tube for the flow tubes to prevent excessive strain on the tubes during high speed revolution of the frame.",13,"The United States of America as represented by the Secretary of the Department of Health, Education & Welfare",,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/42
4183360,15-Jan-80,1980,1,15,Multifinger photocell plethysmography system,"A photoplethysmographic instrument for simultaneous recordings of multifinger blood flow. The instrument consists of a plurality of suitably spaced and angled finger-receiving housings, each containing a photodetector, with respective light pipe bundles conducting light from a common source to the housings. The photodetectors respond to differences in light transmission through the patient's fingers inserted in the housings. The photodetectors are connected through respective preamplifiers to the respective inputs of a multichannel recorder, thereby providing recorded traces of the respective optical transmissions through the fingers. The photodetectors may also be connected to the respective inputs of a multichannel tape recorder, thereby providing magnetic tape recordings of the respective optical transmissions.",15,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Medical technology,,,,,,A61B/02416
4183864,15-Jan-80,1980,1,15,Cobalt catalyzed steroid synthesis,"Steroid compounds obtained by co-oligomerization of a side chain functionalized 1,5-hexadiyne with bis(trimethylsilyl)acetylene catalyzed by cyclopentadiene cobalt dicarbonyl, CpCO(CO).sub.2, via intermediate benzocyclobutene formation followed by intramolecular cycloaddition to the sterospecific formation of the steroid nucleus. This constitutes a short steroid synthesis, five steps from commercially available acyclic precursor 1,5-hexadiyne and three steps from 2-methyl-cyclopent-2-enone.",3,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07J/00
4184258,22-Jan-80,1980,1,22,Powder blower device,"A device for blowing powder onto teeth, the device consisting of a handpiece in the form of a housing connected to a compressed air source and having a discharge nozzle member which can be inserted in a patient's mouth and can be directed towards the patient's teeth. The housing has a powder reservoir with a bottom supply duct. An apertured shuttle bar is reciprocably slidably mounted beneath said duct and has a metering hole registrable with said supply duct and then, by longitudinally moving the bar, with a discharge conduit arranged to receive compressed air from the source so as to discharge a metered amount of powder in said hole into the nozzle member for delivery to the patient's teeth.",10,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Medical technology,,,,,,A61C/025
4188378,12-Feb-80,1980,2,12,Anticancer and antiviral activity of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine,"A method of utilizing 9-.beta.-D-arabinofuranosyl-2-fluoroadenine, known as 2-F-AraA (NSC 118218), in the treatment of murine leukemia and as an antiviral agent for DNA viruses, such as DNA viruses Herpes Simplex Virus Type I and Vaccinia virus grown in H.Ep-2 cells in culture. An operable dosage for utilization of 2-F-AraA is a treatment span of 1-10 days with the dosage 2-8 times per day at 8-400 mg/kg/dose. It has been further found that a single dosage on days 1, 5, and 9 based on a 10-day treatment schedule gave satisfactory results.",6,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
4189583,19-Feb-80,1980,2,19,Synthesis of 4A-aryl-decahydroisoquinolines,"This invention relates to a process for the production of 4a-aryldecahydroisoquinolines where the aryl group is selected as 3-methoxy phenyl. These compounds are morphine analogs and show utility similar to the known morphine, codeine, and thebaine. In this process particular novelty is asserted for the production of a nipecotic ester ethyl 4-(3'-methoxyphenyl)-1-methyl piperidine-3-carboxylate. Furthermore, novelty is asserted for the step of conversion of the nipecotates through cyclization to cis- or trans-tert-butyl 1,6-dioxo-4a-(3'-methoxyphenyl)-2-methyldecahydroisoquinoline-7-carboxylat e, which may also be easily converted to the keto amide, trans-1,6-dioxo-4a-(3'-methoxyphenyl)-2-methyldecahydroisoquinoline.",2,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
4192584,11-Mar-80,1980,3,11,System for creating motion effects employing still projection equipment,"A system for creating projected visual motion effects for filming or videotaping, with the use of still projection equipment, involves projecting a still image on a screen from a slide projector, projecting a second image on the screen, superimposed on the first image, and causing the projected second image to move rectilinearly at a controlled variable speed and in a selected direction over the first projected still image. This movement is accomplished with a ""crawler"" assembly having a transparent rectilinearly movable carrier panel carrying the second image over the stage surface of a standard overhead projector, or a light box, constituting the second image light source. The illuminated second image is directed to the screen by an overhead lens and suitably angled mirror. The transparent carrier is driven by a variable-speed reversible motor through a changeable worm gear drive assembly coupled to friction drive rollers engaging the carrier, which is slidably supportingly retained in a guide frame. The guide frame may be disposed at different desired angles over the light box to obtain different desired directions of movement of the projected second image.",19,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Optics,,,,,,G03B/26
4196085,1-Apr-80,1980,4,1,Dialysis solution handling device,"A handling device for enabling a technician to dialyze a solution without direct contact with the solution to be dialyzed. The device comprises a polycarbonate rod having an internal bore and a test tube gripping element at one end. At the other end is clamped a section of dialysis tubing, there being a passageway from the test tube-gripping end through the internal bore and into the dialysis tubing. The dialysis tubing is knotted to form a dialysis bag. The rod is manipulated to grippingly engage over a test tube containing the solution to be dialyzed and the test tube is inverted to transfer its contents to the dialysis bag, after which the device is supported in inverted position with the bag in a dialysis bath. After dialysis, the device is removed and reversed, returning the dialyzed solution to the test tube.",10,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Chemical engineering,,,,,,B01D/30
4200806,29-Apr-80,1980,4,29,Scanning flow indicator for rotameters,"A flow indicating attachment for a transparent rotameter column containing a visible float movable in accordance with the rate of fluid flow through the column consists of a reciprocating scanner moving parallel to the column in a flow rate range including the range of float movement and coupled to a potentiometer forming a synchronous analog scanning signal which is furnished to a recorder. The scanner has a photoelectric float-sensing assembly including a photocell connected in the analog scanning signal circuit. When the sensing assembly is shaded by the rotameter float, it produces an abrupt dip in the recorded analog scanning signal, thus providing a recorded indication of the float's position in the range covered by the track of the reciprocating scanner.",11,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Measurement,,,,,,G01F/24
4201773,6-May-80,1980,5,6,"7-O-(2,6-Dideoxy-.alpha.-L-lyxo-hexopyranosyl)-daunomycinone, desmethoxy daunomycinone, adriamycinone, and carminomycinone","A series of compounds showing high antileukemic activity against P388 murine leukemia and increased aqueous solubility due to substitution of --OH for the known --NH.sub.2 at the 3' position of the hexopyranose sugar, i.e., daunosamine. These compounds are coupled products of aglycon selected from daunomycinone, desmethoxy daunomycinone, adriamycinone and carminomycinone. These compounds are coupled at the 0-7 position of the aglycon with an .alpha.-L-lyxo hexopyranose sugar, which sugar isomer particularly sustains or potentiates the biological activity of the coupled compound as well as ameliorates the dose related cardiotoxicity of the parent and known compounds set out below: ##STR1##",11,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07H/04
4202890,13-May-80,1980,5,13,"4-Carboxy-phthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof with cyclophosphamide and hydroxyurea in alleviating L1210 murine leukemia","##STR1## 4-Carboxyphthalato(1,2-diaminocyclohexane)platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C.) of the desired product which is preferably utilized as the alkali metal salt. The 4-carboxyphthalato(1,2-diaminocyclohexane)-platinum(II) and a alkali metal salts thereof may be combined in multiple drug regimen with substantially improved yield cures over the parent compound. For example, the compound denoted Pt-307 may be combined in a dual regimen with cyclophosphamide (CY and in a triple drug regimen of Pt-307 plus cyclophosphamide (CY) and either 5-fluorouracil (5-FU) or hydroxyurea (HU) as the third component. Additionally, the present compound (NSC 271674) has shown superior results in testing for renal toxicity against the parent compound (NSC 119875, cis-dichlorodiamino platinum II) and further the present compound appears to be active against strains of murine leukemia wherein the same NSC 119875 has exhausted its activity.",2,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/0093
4206160,3-Jun-80,1980,6,3,Mechanical device to produce a finely dispersed aerosol,"A nebulizer to produce a finely dispersed aerosol from a solution passing over its surface comprises a chamber through which a gas, such as air, is adapted to be blown. The chamber has an outlet conduit, and mounted in the chamber facing the outlet conduit is an inclined upright bar formed with a longitudinal V-groove having a central gas exit port to which is connected a gas input delivery tube. A sample introduction tube is connected to the top end of the bar at said V-groove to admit sample solution thereto. The side walls of the V-groove below the gas exit port are lower in height than above the gas exit port to prevent aerosol droplets from settling on the walls and from interfering with the entry of the aerosol into the exit port. An impactor rod is adjustably mounted on the lower portion of the bar and is adjusted so that its top end is in front of the gas exit port. A protective cover is provided on the upper portion of the bar, above the gas exit port, and prevents aerosol droplets from settling on the bar and from again flowing over the gas exit port.",15,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Chemical engineering,Measurement,,,,,B05B/2483
4206207,3-Jun-80,1980,6,3,"Use of 4-carboxy-phthalato(1,2-diaminocyclohexane)-platinum (II) and alkali metal salts thereof with cyclophosphamide in alleviating L1210 murine leukemia","##STR1## 4-Carboxyphthalato(1,2-diaminocyclohexane)platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C.) of the desired product which is preferably utilized as the alkali metal salt. The 4-carboxyphthalato(1,2-diaminocyclohexane)platinum(II) and alkali metal salts thereof may be combined in multiple drug regimen with substantially improved yield cures over the parent compound. For example, the compound denoted Pt-307 may be combined in a dual regimen with cyclophosphamide (CY) and in a triple drug regimen of Pt-307 plus cyclophosphamide (CY) and either 5-fluorouracil (5-FU) or hydroxyurea (HU) as the third component. Additionally, the present compound (NSC 271674) has shown superior results in testing for renal toxicity against the parent compound (NSC 119875, cis-dichlorodiamino platinum II) and further the present compound appears to be active against strains of murine leukemia wherein the same NSC 119875 has exhausted its activity.",2,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/0093
4206208,3-Jun-80,1980,6,3,"Use of 4-carboxy-phthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof with cyclophosphamide and 5-fluorouracil in alleviating L1210 murine leukemia","##STR1## 4-Carboxyphthalato(1,2-diaminocyclohexane)platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C.) of the desired product which is preferably utilized as the alkali metal salt. The 4-carboxyphthalato(1,2-diaminocyclohexane)platinum(II) and alkali metal salts thereof may be combined in multiple drug regimen with substantially improved yield cures over the parent compound. For example, the compound denoted Pt-307 may be combined in a dual regimen with cyclophosphamide (CY) and in a triple drug regimen of Pt-307 plus cyclophosphamide (CY) and either 5-fluorouracil (5-FU) or hydroxyurea (HU) as the third component. Additionally, the present compound (NSC 271674) has shown superior results in testing for renal toxicity against the parent compound (NSC 119875, cis-dichlorodiamino platinum II) and further the present compound appears to be active against strains of murine leukemia wherein the same NSC 119875 has exhausted its activity.",3,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/0093
4206226,3-Jun-80,1980,6,3,"Use of 4-carboxy-phthalato-(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof in alleviating L1210 murine leukemia","##STR1## Y=H, alk met 4-Carboxyphthalato(1,2-diaminocyclohexane) platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach. The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane) platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C.) of the desired product which is preferably utilized as the alkali metal salt. The 4-carboxyphthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof may be combined in multiple drug regimen with substantially improved yield cures over the parent compound. For example, the compound denoted Pt-307 may be combined in a dual regimen with cyclophosphamide (CY) and in a triple drug regimen of Pt-307 plus cyclophosphamide (CY) and either 5-fluorouracil (5-FU) or hydroxyurea (HU) as the third component. Additionally, the present compound (NSC 271674) has shown superior results in testing for renal toxicity against the parent compound (NSC 119875, cis-dichlorodiamino platinum II) and further the present compound appears to be active against strains of murine leukemia wherein the same NSC 119875 has exhausted its activity.",4,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07F/0093
4209300,24-Jun-80,1980,6,24,Hemoglobin-oxygen equilibrium curve analyzer,"A system for obtaining a hemoglobin-oxygen equilibrium curve for a sample of concentrated hemoglobin solution or whole blood. Gaseous oxygen and/or nitrogen is used to oxygenate or deoxygenate the sample. The exchange takes place across a gas-receiving cup-shaped semipermeable membrane in a temperature-controlled chamber containing the sample, in an annular space defined between the cup-shaped gas-receiving membrane and the chamber wall. The rate of oxygen transport into and out of the sample is continuously calculated by means of a microcomputer. Simultaneously the solution pO.sub.2 is measured by means of a Clark electrode exposed to the sample. From the oxygen transport rate calculation and the pO.sub.2 measurement, the percent O.sub.2 saturation is calculated and is plotted against the change in pO.sub.2. Oxygen can be exchanged bidirectionally with the sample across the semipermeable membrane, which is positioned concentrically in a cylindrical sample cavity. The sample solution is maintained well-stirred by a magnetic stirrer provided in the cavity.",15,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/4925
4210639,1-Jul-80,1980,7,1,"5'-Deoxy-5'-(isobutylthio)-3-deazaadenosine, method of making same and its antiviral effect on Rous sarcoma virus and Gross murine leukemia virus","5'-Deoxy-5'-(isobutylthio)-3-deazaadenosine and a method for preparation of same. In the preparation, 3-deazaadenosine is utilized as a starting material and is chlorinated at the 5' position. Subsequently, the chloro group is converted to isobutylthio by reaction with isobutyl mercaptan in ethanol containing sodium methoxide giving the desired compound. A most preferred starting material, i.e., 3-deazaadenosine, was prepared according to the method of Montgomery et al, J. Heterocyclic Chem., 14:195 (1977). The key fusion of this process is 4,6-dichloroimidazo[4,5-c]pyridine with 1,2,3,5-tetra-O-acetyl-.beta.-D-ribofuranose, which, after removal of protective groups and reductive dechlorination of the chlorine at 6, gives 3-deazaadenosine. This new compound has good activity as an adenosylhomocysteine (AdoHcy) hydrolase inhibitor and has shown activity against Rous sarcoma virus (RSV) in chick embryo cells and Gross murine leukemia virus (Gross MLV) in mouse embryo cells, where the activity is as a non-competitive inhibitor of AdoHcy hydrolase showing A K.sub.i of 0.4 mM.",3,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/052
4210745,1-Jul-80,1980,7,1,Procedure for the preparation of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine,"The present invention is an improved multi-step process for the production of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine (2-F-AraA) and an improvement over the process of Montgomery and Hewson, J. Med. Chem., 12:498 (1969). This compound is an important tool in antitumor therapy and has shown activity against leukemia L1210 and P388 in animals as well as being a potent antiviral agent. Its therapeutic effectiveness occurs because 2-F-AraA is not a substrate for adenosine deaminase which vitiated against the activity of the parent compound 9-.beta.-D-arabinofuranosyladenine (araA) as indicated in experimental animal cancers. An advantage of making 2-F-AraA by the present process is that there is a sharply increased yield based on the chlorosugar up to about 400 percent. In the present improved process the differences lie in utilizing as a reactant 2,4,5,6-tetraaminopyrimidine; the acetylation of 2-aminoadenine in acetic acid and pyridine; the reaction of 2,6-diacetamidopurine with chlorosugar in ethylene chloride in the presence of a molecular sieve and subsequent deacetylation with methanolic sodium methoxide. Further, the diazotization step is carried out in a homogenous mixture of tetrahydrofuran and fluoboric acids. Finally, the O-benzyl groups are removed by the use of boron trichloride in ether.",5,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
4217496,12-Aug-80,1980,8,12,Portable instrument for measuring neutron energy spectra and neutron dose in a mixed n-.gamma. field,"A portable high-speed neutron spectrometer consisting of an organic scintillator, a true zero-crossing pulse shape discriminator, a 1 MHz conversion-rate multichannel analyzer, an 8-bit microcomputer, and appropriate displays. The device can be used to measure neutron energy spectra and kerma rate in intense n-.gamma. radiation fields in which the neutron energy is from 0.5 to 15 MeV.",14,"The United States of America as represented by the Secretary of Health, Education and Welfare",,,,,,,,,,,1,Environmental technology,,,,,,G01T/00
4217497,12-Aug-80,1980,8,12,Portable instrument for measuring neutron energy spectra and neutron dose in a mixed n-.gamma. field,"A portable neutron spectrometer/kerma-rate meter for the measurement of the fast neutron component of mixed n-.gamma. fields in the 1 to 15 MeV neutron energy range. The system includes an organic scintillation detector, pulse shape discrimination circuitry, a 1.4 .mu.sec multichannel analyzer, an 8-bit microcomputer, and appropriate displays. The instrument is capable of both gathering and processing recoil-proton pulse-height data in the field.",18,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Environmental technology,,,,,,G01T/00
4217798,19-Aug-80,1980,8,19,Automated test tube stopper remover,"A device for removing the stopper from the top of a test tube without exposing the user to hazardous aerosols. The stoppered test tube is inserted upwardly through a vertical passage leading to a chamber. A horizontal air cylinder has a piston rod extending into the chamber, with a pivoted stopper-removing plunger member extending over the passage and having a tail portion which is sealingly engageable with a normally vented sensor nozzle responsive to contact of the top of the stoppered test tube with the plunger member. Closure of the sensor nozzle activates a fluidic back pressure switch, which in turn actuates a fluidic control circuit having two slide valves which respectively operates the air cylinder and simultaneously connects a vacuum source to the chamber. A horizontal slide sensor in the vertical passage is extended to engage the test tube and prevents retraction of the plunger member. Upon withdrawal of the unstoppered test tube, the slide sensor is released and is further extended, causing resetting of the fluidic control circuit to its normal condition, retraction of the plunger member, venting of the sensor nozzle, and retraction of the slide sensor.",14,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Chemical engineering,Handling,,,,,B01L/50825
4220552,2-Sep-80,1980,9,2,Method of producing delayed release of sodium fluoride,"A process of pretreating a lower alkyl cellulose, such as ethyl cellulose, which is to be used in microencapsulation of sodium fluoride for dental purposes. This process comprises dispersing a predetermined quantity of lower alkyl cellulose in an aqueous mineral acid, such as HCl, and stirring and aqueous washing of the cellulose such that the pH of the product is adjusted to 6.0 or less. This product is later dissolved in a BTX (benzene, toluene, xylene) solvent such as toluene. Sodium fluoride is added and process steps such as baffle stirring and drying are utilized to produce microencapsulation of the sodium fluoride with the lower alkyl cellulose. The process produces an encapsulating material of optimum sodium content and gives release time in water of 2.3-7.0 hours for the sodium fluoride.",5,"The United States of America as represented by the Department of Health, Education & Welfare",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,Chemical engineering,,,,A61Q/00
4222126,16-Sep-80,1980,9,16,Unitized three leaflet heart valve,"A polyurethane heart valve has a semirigid frame composed of a base ring and three struts, and an elastomeric membrane integral and unitary with the frame, the contours of which make up three leaflets of the valve. The leading edges of the leaflets which form the commissure line are reinforced with a narrow elastomer band. The leaflets are further reinforced by radiating lines projected from the frame into the leaflet and which simulate collagen formation in natural leaflets. In addition, the transition between the frame and the leaflets is tapered.",5,"The United States of America as represented by the Secretary of the Department of Health, Education & Welfare",,,,,,,,,,,1,Medical technology,Mechanical elements,,,,,A61F/2412
4227937,14-Oct-80,1980,10,14,Additive composition for making dental materials,"Addition of ammonium stabilized colloidal silica, borax and boric acid to the distilled water in which dental porcelain is fired greatly increases the firing range by reducing ""balling"" or edge rounding, and flow deformation. Greatly increased machinability and indefinitely prolonged green-biscuit strength is also obtained by the use of the present additive without deleterious effects on the porcelain.",2,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/802
4228009,14-Oct-80,1980,10,14,Toroidal coil planet centrifuge,"An apparatus for countercurrent chromatography consisting of a coiled separation column which is rotated about the axis about which is it wound and the axis is also rotated about a main axis. The embodiments of the invention are based on the fact that the pattern of the centrifugal force field greatly changes with the ratio of the two radii of rotation and depending on the particular effect desired, the apparatus is configured to achieve the most effective force field to gain the effect. The separation column is a tube helix wound around a flexible core member which can be wound onto the coil holder in various orientations to further effect the desired results.",12,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Chemical engineering,Measurement,,,,,B01D/0273
4228950,21-Oct-80,1980,10,21,Horizontal flow-through coil planet centrifuge,"A horizontal flow-through coil planet centrifuge wherein flow-through separation columns are rotatably mounted on both sides of a rotor formed by a pair of spaced parallel rotary wings, with suitable intercoupling to avoid the need for rotary seals. Fluid circuit and adjustable valving arrangements are provided for (1) allowing two separations to be simultaneously performed, (2) for connecting the two columns in series to double the partition efficiency, or (3) using one column to separate samples in an ordinary manner while a desired portion of the eluate can be introduced into the second column to recycle.",15,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Chemical engineering,Measurement,,,,,G01N/42
4235677,25-Nov-80,1980,11,25,Distillation flask and apparatus for producing high-purity water having overflow liquid trap means,"An apparatus for the continuous production of high-purity water includes a distillation flask, a carboy and a condenser unit, all of borosilicate glass. A respective filter, preferably in the form of a polytetrafluoroethylene sheet, is provided between the ambient atmosphere and the interiors of the flask, the carboy and the condenser unit to remove airborne bacteria and dust particles. An inlet valve is provided for feeding water to be purified into the flask, all water-contacting parts of this valve being of polytetrafluoroethylene. The open parts are interconnected with flexible, polytetrafluoroethylene tubing. A two-way, stopcock allows high-purity water to be removed from the carboy. The flask is provided with a glass overflow trap. In one variant, the water is fed into the flask via members between the trap and the flask. In a preferred variant, the water is fed into the flask via a separate inlet and allowed to flow out through the overflow trap, thereby allowing precipitate to be constantly washed out of the flask.",21,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Environmental technology,Chemical engineering,,,,,C02F/045
4239755,16-Dec-80,1980,12,16,Steroidal cyclotriphosphazenes,"Steroidal cyclotriphosphazenes of the formula ##STR1## wherein R is the residue of a 3- or 17-hydroxysteroid and R.sub.2 is alkyl, are hydrolytically labile compounds adapted for slow release in vivo of active steroidal compounds of the formula ROH.",9,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/65815
4244787,13-Jan-81,1981,1,13,Apparatus and method for determining serum concentrates of metabolites by monitoring dialysate fluid,"An apparatus and method are disclosed for monitoring, analyzing and quantitating in real time the concentrations of metabolites in serum by analyzing the dialysate solutions which are being equilibrated with the blood via a hemodialyzer. Thus, access to certain metabolically important species is provided without the necessity of blood sampling. The apparatus includes at least one ion-selective electrode coupled with the dialysate effluent stream, and the electrode EMF is converted to dialysate concentrations based on precalibration. The dialysate concentrations, in turn, are related to serum levels by factors governing mass transfer through the dialyzer.",12,"The United States of America as represented by the Secretary of the Department of Health, Education & Welfare",,,,,,,,,,,1,Medical technology,,,,,,A61M/16
4247646,27-Jan-81,1981,1,27,Laboratory apparatus for cloning mammalian cells,"Laboratory apparatus for cloning mammalian cells includes a support plate and a plurality of tubular cylinders fixedly secured within the plate and projecting from one face thereof. All of the cylinders, with the exception of one pair, are disposed within a concentrated array defined within a predetermined sector region of the plate, the remaining pair of cylinders being located remote from the sector array yet equidistantly spaced from each other and from the sector array so as to complete the distribution pattern. A substantially C-shaped ring member is fixedly secured to, or integrally formed with, the opposite face of the support plate, in order to facilitate maneuverability of the assemblage when placing the same onto a Petri dish for isolating the colonies developing thereon. The plate and ring member are fabricated from transparent polycarbonate in order to permit the colonies to be identified or viewed by background lighting techniques. The distal ends of the isolating cylinders are also sharply beveled in order to cut into or penetrate the Petri dish so as to sealingly isolate the colonies.",13,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Biotechnology,,,,,,C12M/22
4247774,27-Jan-81,1981,1,27,Simultaneous dual-energy computer assisted tomography,"A dual-energy detector system for use in computer assisted tomography. This system produces two independent sets of information from one scan, namely, high-energy and low-energy data. The system employs two cooperating detectors. The first one responds primarily to low-energy photons, allowing most high-energy photons to pass through. The second detector lies behind the first and detects the remaining photons. Thus, two electrical signals are generated which contain information in two different energy ranges, which signals can be computer-processed. The attenuation coefficients at these two energies are sufficiently different so that differential diagnosis and chemical identification may be aided. The computer-processed signals may be employed to provide any of (a) beam-hardening correction, (b) chemical identification and composition of tissues, such as lesions, bone, etc., (c) localization of injected contrast material, or (d) attenuation coefficients for radiation therapy planning.",13,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Medical technology,Environmental technology,,,,,A61B/032
4247780,27-Jan-81,1981,1,27,Feedback controlled geometry registration system for radiographs,"A system for reproducibly aiming an X-ray source array to provide substantial registration of exposure geometry through an organ or a portion of tissue from one examination to the next. The system derives functions or signals based on computer controlled X-ray source point geometries to create multiple images produced from known positions via a detector array which feeds this information to a computer image storage system and which provides for comparison of the detected signals with reference signals originally stored in a memory; the comparison yields correction signals which act to shift the X-ray raster toward restoration of the original effective geometry. Thus, the X-ray sources are coupled to the detector array through a feedback loop circuit including a computer which, by sequentially activating each X-ray point source and noting the resulting functions generated by the detector array, can compare the results with the stored functions and revise the working geometry to simulate that of the original geometry from which the stored reference functions were obtained. The computer also activates a visual display device providing a crude X-ray scan through the tissue of interest, which can be used to create low resolution tomograms of the irradiated structures.",10,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Medical technology,Audio-visual technology,,,,,A61B/4028
4250891,17-Feb-81,1981,2,17,Depth-sense perception and two-point discrimination aesthesiometers,"A finger tip sensitivity-testing instrument consisting of a tunnel-shaped track member used as a support for the hand and forearm of a patient, the track member having a longitudinal cavity slidably receiving a feeler bar which is formed on its top surface with surface profile structure varying progressively longitudinally in sensible magnitude. The patient's finger is received in a notch in the edge of the tunnel top wall so as to allow the finger to engage the surface profile bar as it is extended from the tunnel. Graduations are inscribed along the side margin of the feeler bar which represent specific increments of differential surface profile relative to the mouth of the tunnel. The feeler bar rests slidably on a spring-supported plastic thin plate, thus simulating a floating support surface for the feeler bar.",18,"The United States of America as represented by the Department of Health, Education & Welfare",,,,,,,,,,,1,Medical technology,,,,,,A61B/441
4254774,10-Mar-81,1981,3,10,Balloon catheter and technique for the manufacture thereof,"A single-lumen, one piece catheter approximately 0.04 inch in diameter with an integral balloon at its end having a wall thickness of 0.005 inch or less, sufficiently small to be retractible by suction into the catheter and to be extensible at a desired site by fluid pressure. The balloon may have a calibrated restricted leak aperture. The balloon portion of the catheter is made by heating a portion of the catheter tubing, stretching the tubing lengthwise, and applying fluid pressure to the tubing. The apparatus for forming the balloon includes a spring-loaded clamp to hold the tubing at one end, a capstan to hold the tubing at the other end, a heating coil wrapped around the tubing near the clamped end thereof and mounted with the clamp, and a mechanism for controlling the pressure and volume of the pressurizing gas entering the lumen of the tube in accordance with the retractile movement of the spring-loaded clamp.",6,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Medical technology,,,,,,A61M/1027
4255386,10-Mar-81,1981,3,10,Method and apparatus for destroying organic matter to facilitate trace inorganic element analysis,"The apparatus of the present invention includes a quartz flask for containing 71% nitric acid and the organic matrix to be destroyed, a Soxhlet extractor disposed above the flask, and a Friedrich coldfinger reflux condenser disposed above the extractor. A Meeker or Fisher burner is employed to provide heat to the flask and distill the acid, and the vapors are condensed within the condenser and transmitted to the extractor. An adjustable volume displacement cylinder is disposed within the extractor so as to control siphoning of the acid condensate from the extractor back into the flask. The distillation-condensation-siphoning procedure of the present invention is automatically operative once the displacement cylinder is adjusted. The organic matrix is completely destroyed so as to produce a clear, colorless acid solution within which the trace inorganic salts are disposed. The acid solution may be subsequently qualitatively and quantitatively analyzed in accordance with known techniques.",1,"The United States of America as represented by the Deptartment of Health, Education and Welfare",,,,,,,,,,,1,Analysis of biological materials,Measurement,,,,,G01N/84
4255443,10-Mar-81,1981,3,10,Homocysteine thiolactone perchlorate as a tumor promotor,"Homocysteine thiolactone perchlorate is prepared from the corresponding homocysteine thiolactone hydrochloride and optimally about two equivalents of perchloric acid as reactants. A preferred solvent utilized is chloroform-methanol (4:1) solution and a preferred temperature range is 0.degree.-85.degree. C. with the lower limit dependent upon the particular solvent and the upper limit of about 186.degree. C. dependent upon the melting point of the product crystals. The preferred perchloric acid reactant may be replaced with perchlorate salts such as AgClO.sub.4 or KClO.sub.4. The product perchlorate salt is soluble in organic solvents, whereas other known salts such as the hydrochloride are only water soluble. This property is thought to influence the growth effect of the perchlorate salt in animals, such as rabbits, and to influence the unique effect of the perchlorate salt on the growth of malignant tumors in animals, such as mice.",1,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/38
4256646,17-Mar-81,1981,3,17,Synthesis of optically pure thromboxanes,"In an elegant stepwise process for the production of intermediates of thromboxanes such as TXB.sub.2 from a chiral glucose starting material such as .alpha.-methylglucoside, those steps comprising: ##STR1## A key modification introduced in this synthetic sequence is the use of 4-dimethylaminopyridine for the selective alkylation of primary alcohols in the presence of unprotected secondary alcohols and for the controlled acylation of methylglucoside. The former application has large potential use in the synthesis of nucleosides, polynucleotides, and carbohydrate derivatives.",2,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4258191,24-Mar-81,1981,3,24,"Multi-step process for the production of methanesulfon-m-anisidide, 4'-(9-acridinylamino)-","A multi-step method of producing the compound methanesulfon-m-anisidide, 4'-(9-acridinylamino)-, acetate (VII), which may be in free base form and designated NSC 249992, also known as AMSA. This compound is produced by an elegant process from a starting material, 4-butyrylamino-3-methoxy-nitrobenzene, which is later transformed to methanesulfon-m-anisidide, 4'-amino- (IV) and is coupled or joined to 9-chloro-acridine, producing the chloride salt which is later converted to the acetate.",6,"The United States of America as represented by the Secretary of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/10
4262194,14-Apr-81,1981,4,14,High resolution electron microscope cold stage,"A cold stage for an electron microscope, said cold stage being arranged to reduce relative motion between the sample holder and the objective lens. The cold stage consists of an annular stainless steel body on which is coaxially bolted a plastic insulator ring with a plurality of spaced upstanding short vertical posts. A central arbor of gold-plated copper has outwardly projecting radial lugs engaged on and bolted to said posts. Connected to another radial lug projecting from the arbor is a laminated thermally conducting strap member consisting of 40 superposed thin flexible leaves of heat-softened copper, with a 180.degree. blend to absorb vibrations from the associated cold finger, or heat transfer rod, leading from a liquid nitrogen cooling source.",14,"The United States of America as represented by the Department of Health, Education & Welfare",,,,,,,,,,,1,"Electrical machinery, apparatus, energy",,,,,,H01J/20
4265694,5-May-81,1981,5,5,Method of making unitized three leaflet heart valve,"An artificial heart valve comprising a semi-rigid framework having three projecting symmetrical struts and open axially therethrough, as well as a polyurethane elastomeric membrane attached to the struts and constituting three leaflets, is formed by molding the framework, including the base and strut, using polyurethane resin; forming the elastomeric membrane, of polyurethane resin which is thin relative to the framework, and forming a thickened commissure along the leading edge of the membrane as well as reinforcing lines radiating from its base; then joining the framework with the elastomeric membrane using an adhesive cement so as to permanently bond the membrane to the framework.",9,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Mechanical elements,Medical technology,Other special machines,,,,F16K/147
4266048,5-May-81,1981,5,5,Synthesis of analogs of 3'-phosphoadenosine 5'-phosphosulfate (PAPS),"Analogs of 3'-phosphoadenosine 5'-phosphosulfate, also known as PAPS, are useful in establishing sulfate transfer mechanisms in animals and may be produced by a chemical process yielding an analog B of a pure adenosine 2',3'-cyclic phosphate 5'-phosphate, which compound is initially prepared from the reaction of adenosine and pyrophosphoryl chloride. In the present process an analog B is selected from 8-bromoadenine, purine, hypoxanthine, 4-aminopyrrolo[2,3-d]pyrimidine (tubercidin), and 7-amino-pyrazolopyrimidine (formycin). In the pilot procedure the pure cyclic phosphate is reacted with triethylamine-N-sulfonic acid to produce 2',3'-cyclic phosphate 5'-phosphosulfate. Subsequently, by hydrolysis with the enzyme ribonuclease-T.sub.2, the desired compound, an analog of PAPS, is produced. Alternatively, the 2'-phosphoadenosine 5'-phosphosulfate, known as iso-PAPS, may be produced from 2',3'-cyclic phosphate 5'-phosphosulfate by treatment with a different enzyme, PDase II or spleen phosphodiesterase.",5,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12P/32
4275057,23-Jun-81,1981,6,23,Seven-membered ring compounds as inhibitors of cytidine deaminase,Seven-membered heterocyclic nucleosides used to inhibit the deamination enzyme responsible for the inactivation of arabinosylcytosine (ara--C). Preferred nucleosides containing a seven-member aglycone are as follows: ##STR1## Preferred aglycones are as follows: ##STR2## Active components utilized against pyrimidine deaminases from mammalian tissues (mouse kidney and human liver) showed optimum advantage when compared with tetrahydrouridine (THU).,7,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/10
4276383,30-Jun-81,1981,6,30,Clot lysing timer,"A clot lysing timing device consisting of a thermostatically controlled assembly including heated blocks formed with wells to receive precooled test tubes containing liquid with clots formed by the addition of thrombin to plasma (or to a mixture of fibrinogen and plasminogen) containing varying quantities of urokinase, streptokinase or plasmin. The blocks are maintained at 37.degree. C. when a precooled test tube with such contents is placed in one of the 37.degree. C. wells it activates a microswitch which starts a corresponding timer channel. An opaque sphere is placed on top of the clot. As the clot dissolves (at a rate depending on the quantity of lytic agent incorporated in the clot) the sphere travels to the bottom of the test tube, interrupting an infra red light beam, which stops the corresponding timer channel. The time counts from the respective timer channels can be selectively displayed on an LED digital readout device.",14,"The United States of America as represented by the Department of Health, Education & Welfare",,,,,,,,,,,1,Analysis of biological materials,Measurement,,,,,G01N/48
4277017,7-Jul-81,1981,7,7,Gear drive for seal-less counter current chromatography,"A flow-through coil planet centrifuge mechanism with variable rotation-revolution (r/R) speed ratios, which does not employ rotating seals. The rotation and revolution rates are continuously adjustable by using separate variable-speed drive motors. A system of gearing and belts compensates for the rotation and revolution of the centrifuge column relative to a stationary supporting frame structure to avoid twisting of the flow tubes. A first motor drives a pair of spider assemblies arranged coaxially with a column-supporting spool. One spider assembly has planetary gearing cooperating with a fixed gear belt to rotate the column relative to the spool. The other spider assembly has planetary gearing driven by a second motor and coupled to the column support spool so that the spool revolves relative to the stationary frame structure and simultaneously the column rotates relative to the spool.",12,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/42
4277604,7-Jul-81,1981,7,7,Facile synthesis of codeine precursors from thebaine,"Thebaine is converted to a mixture of codeinone and neopinone in aqueous formic acid solution containing as catalyst a mercuric salt. Thebaine is converted to a neopinone ketal by irradiation in an alkanol or to a mixture of neopinone and codeinone in an acidic aqueous solution. Neopinone ketals, codeinone and neopinone can be converted to codeine.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/02
4279817,21-Jul-81,1981,7,21,Method for producing dimer alkaloids,"A concerted process for the synthesis of a dimer consisting of an indole unit and a dihydroindole unit possessing natural stereochemistry which comprises: PA1 (a) forming an N-oxide intermediate from said indole unit; PA1 (b) treating said N-oxide indole intermediate in the presence of acetic anhydride or halogenated derivative thereof to effect a Polonovski-type fragmentation reaction; PA1 (c) without isolating the N-oxide indole intermediate and at a temperature of about -10.degree. C. to +10.degree. C., coupling said reaction product with a dihydroindole unit in the presence of acetic anhydride or a halogenated derivative thereof at a low temperature of about -10.degree. C. to +10.degree. C. under inert conditions; and PA1 (d) subsequently reducing the immonium nitrogen on the indole unit by reacting with aqueous alkali metal borohydride to produce a dimer.",5,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4284537,18-Aug-81,1981,8,18,Conjugate of streptococcal M protein peptide vaccine,Certain peptide fragments of streptococcal M protein named CB6 and CB7 have been linked to a protein carrier which is polylysine. The conjugate has proved immunogenic in rabbits producing protective antibodies against the whole group A streptococcus.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1275
4284579,18-Aug-81,1981,8,18,"(N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt","##STR1## where X is Na.sup.+, K.sup.+, Li.sup.+ or H (N-phosphonacetyl-L-aspartato)(1,2-diaminocyclohexane)platinum(II) or alkali metal salt thereof has shown antitumor activity in animals such as activity against murine leukemia L1210. Additionally, this agent is used against B-16 and Colon 38 tumors and also Ehrlich ascites tumor. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added hydroxyurea (HU) (1000-1500 mg/kg of body weight). In binary treatment with cis-dichlorodiamine-platinum(II) (or cisplatin) the preferred ratio of the present compound to cisplatin is about 10:1 with a range of about 10:1 to 1:10 in mg/kg of body weight. As to the variations in the formula on the left hand side of the formula, it may be varied as monodentate, such as cisplatin containing a single amine group proceeding from the ring, or bidentate, such as the present compound. The saturated cyclo ring may be C.sub.4 or C.sub.5 -C.sub.7 in addition to the present cyclohexane. The present platinum compound may be prepared by reacting the known L-aspartic acid, N-(phosphonacetyl-) disodium salt (PALA; NSC-224131), with dinitrato(1,2-diaminocyclohexane)platinum(II) (NSC-239851). This compound N-phosphonacetyl-L-aspartato(1,2-diaminocyclohexane)platinum(II) may be combined in multiple drug regimen with substantially improved yield cures over the parent compounds. For example, the compound denoted Pt-268 may be combined in a dual regimen with cyclophosphamide (CY), hydroxyurea (HU), and cisplatin.",2,The United States of America as represented by the of the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/0093
4289882,15-Sep-81,1981,9,15,4A-Aryl-decahydroisoquinolines,"This invention relates to the production of 4a-aryldecahydroisoquinolines where the aryl group is selected as 3-methoxy phenyl and intermediates. These compounds are morphine analogs and show utility similar to the known morphine, codeine, and thebaine.",5,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
4291020,22-Sep-81,1981,9,22,"Inactivation of non-A, non-B hepatitis agent","This invention relates to a method of inactivating a non-A, non-B hepatitis agent by means of formalin utilized in extended treatment. The range of formalin treatment utilizes a concentration of 1:1,000-1:10,000, preferred 1:1,000, and the duration of treatment is from 24-120 hours at any temperature with a preferred 96 hours (4 days) at 37.degree..+-.4.degree. C. This formalin-treated or otherwise inactivated agent, or portions of the agent, may be later used to produce a vaccine against non-A, non-B hepatitis.",4,The United States of America as represented by the Secretary of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/29
4295730,20-Oct-81,1981,10,20,Washer for resin-coated photographic prints,"A print-washing tank with generally rectangular spirally-looped pipes in parallel vertical arrays, fed by a horizontal input conduit in the upper portion of the tank, the arms of the pipes having holes to spray photographic prints on both sides with jets of water, the prints being supported between the vertical spray loops, using either wire baskets or being supported directly in the narrow vertical spaces between the spirally looped pipes. A drain pipe array is provided at the bottom of the tank, having a plurality of widely spaced intake ports and leading to a vertical siphon exit conduit near the back wall of the tank and which may be either inside the tank or may be located externally. The top loop of the siphon drain system is located slightly below the level of the water input pipe.",16,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Optics,,,,,,G03D/04
4300557,17-Nov-81,1981,11,17,Method for treating intraocular malignancies,"An improved process for dispensing a lipid soluble labile drug, i.e. 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) by diffusion through a silicone capsule implanted at a periocular site to an intraocular site within an animal body being treated with the drug, the improvements wherein the silicone capsule is provided with a tube sealed at the distal end thereof and provided with longitudinal slit cut through the tube wall inside the capsule for filling the capsule following implantation of the capsule, wherein the capsule is implanted surgically near the site being treated so that the tube is accessible for filling without further surgical procedures and wherein the drug is injected into the capsule through the tube in the form of a solution in a solvent which is non-toxic to the animal being treated, inert with respect to the drug dissolved therein and capable of diffusing from the capsule within 5 hours to leave a residue of the drug in the capsule.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,,,,,A61K/0051
4306071,15-Dec-81,1981,12,15,"1,4-Bis(2-haloethyl)-1,4-diazabicyclo[2.2.1]-heptane dihydrogen dimaleate and selected salts","1,4-Bis(2'-haloethyl)-1,4-diazabicyclo[2.2.1]-heptane derivatives, such as diperchlorate, dichloride, diacetate, dibenzoate, diascorbate, disalicylate, ditartrate, disaccharin, dihydrogen dimaleate, together with ethyl sulfonate and periodate.",4,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
4312920,26-Jan-82,1982,1,26,Polymer alloy blood compatible surface,"A blood contacting layer and a blood contacting interface consisting of a solvent cast polyurethane alloyed with a filler-free silicone rubber. In the above, the alloy interface comprises an interpenetrating polymer network consisting of polyurethane and filler-free silicone rubber at the molecular level. The process or method of making the layer consists of preheating a metal mold such as an aluminum mold and filling it with a wax. After the wax form is removed, polished and cleaned, it is dipped first in a filler-free silicone rubber which is cured. It is then dipped in segmented polyurethane with curing of 150.degree. F. for about one hour to evaporate the polyurethane solvent. Multiple dips are utilized up to 5 or 7 for implementing the polyurethane. The form containing both silicone rubber and polyurethane is finally cured for a day or 24 hours at about 150.degree. F. and the wax form is removed. Finally, the silicone rubber lining is removed, leaving the binary alloy blood contacting surfaced polyurethane sac.",3,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Other special machines,Medical technology,"Macromolecular chemistry, polymers",,,,B29C/14
4313446,2-Feb-82,1982,2,2,Steel wire pressure aesthesiometer,"An aesthesiometer consisting of an elongated length-calibrated support bar with a handle at one end. The bar has a longitudinal groove communicating with a hole near the other end of the bar. A steel wire is fastened to the handle and lies in the groove, the wire having a right-angled bend forming a depending skin probe arm which extends through the hole. An adjustable wire-retaining block is slidably engaged on the support bar and has a flange depending into the groove and holding down the wire, thus regulating the length of the flexible portion of the wire and thus controlling the effective stiffness of the flexible portion. The upward deflection of the right-angled bend is read quantitatively on an arcuate concentric series of scale lines on a scale card attached to the free end of the support bar. The deflection readings relative to the arcuate scale lines and the longitudinal position settings of the wire-retaining block on the support bar are used in conjunction with a top loading balance platform scale to form calibration curves to measure the stress on a skin area of the patient in terms of the readings obtained from the deflection scale and the longitudinally set positions of the wire-retaining block on the support bar.",16,"The United States of America as represented by the Secretary of the Department of Health, Education and Welfare",,,,,,,,,,,1,Medical technology,,,,,,A61B/4827
4321138,23-Mar-82,1982,3,23,Method and apparatus for preparative countercurrent chromatography employing a rotating column assembly,"A flow-through liquid chromatography system wherein a motor directly drives a rotary frame rotatably and coaxially carrying a column assembly consisting of chromatography column segments annularly arranged around the rotational axis, which are serially connected. A countershaft journalled on the frame has a gearing arrangement which drivingly couples the column assembly to a fixed sun gear on the frame via a planetary gear on the column assembly and which is arranged to cause the column assembly to rotate twice as fast as the frame, in the same direction, and around the same axis, the arrangement being such as to avoid the need for rotating seals for the flow tubes. The column assembly is dynamically balanced so that there is also no need for counterweights.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/42
4321251,23-Mar-82,1982,3,23,Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse,"A method of clinical diagnosis and a composition for detecting malignant lesions of the oral cavity by utilizing as a rinse, toluidine blue preferably in acetic solution of water and ethanol. A preferred rinse is 5 cc 1% toluidine blue solution which is utilized in 1% acetic acid and water. In the method the solution (5-10 cc) is poured into floor of mouth and patient is advised to rinse and gargle.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61Q/00
4321915,30-Mar-82,1982,3,30,Everting tube device with relative advance control,"An everting tube device for introducing an elongated tool into a body cavity through a body opening for diagnostic or other purposes comprises an elongated housing containing a folded evertable flexible tube through which an elongated tool, such as a fiber optic bundle, sealingly extends. The flexible tube can be everted from the housing by applying fluid pressure to the housing interior, and the eversion of the tube carries the tool along with it at twice the rate. The tool can be retracted by applying vacuum to the housing interior which draws the tube away from the tool. The alternate use of pressure and vacuum, along with the intermediate steps of manually retracting the tool, result in projecting the tool and tube into the appropriate cavity at substantially the same rate. When the tool used is a fiber optic bundle, it provides a means of continuously viewing the path of travel immediately ahead of the advancing tube.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/31
4324661,13-Apr-82,1982,4,13,Apparatus and method for continuous countercurrent extraction and particle separation,"A flow-through continuous countercurrent extraction system consisting of a coiled tube or spiral coplanar channel revolving around a main axis and rotating around its own axis at the same angular velocity and in the same direction. With two solvent phases A and B, there are 5 flow tubes: (1) a feed tube for phase B located at the head end of the column, (2) a return tube for phase A located at the head end, (3) a feed tube for phase A located at the tail end, (4) a return tube for phase B located at the tail end, and (5) a sample feed tube located at the middle portion of the column. The column is mounted on a hollow rotary shaft and the axis of revolution is defined by a stationary hollow central shaft. The 5 flow tubes are led through the hollow rotary shaft, and then through the stationary central shaft. In this way, the flow tubes from the rotary shaft are allowed to rotate freely without interference or twisting. Either a single column may be used, with a counterweight, or there may be two opposite columns operating simultaneously. The ingredients of the sample are separated according to the partition coefficients; when the partition coefficients favor phase A, the solutes are eluted through the head end, and when the partition coefficients favor phase B they may be eluted through the tail end, or they may be retained in the column when the partition coefficients fall between the above values. When the operation is aimed at enrichment and/or stripping of a particular substance or substances, the sample flow tube may not be used, and the sample solution is directly introduced through the head or tail feed tube, while the enriched or stripped solution is continuously collected through either the head or tail outlet tube.",2,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Chemical engineering,Measurement,,,,,B04B/06
4328309,4-May-82,1982,5,4,"Method for producing tripdiolide, triptolide and celastrol","A process for the production of tripdiolide, triptolide and celastrol comprises the steps of: (a) preparing a cellular inoculum from Tripterygium wilfordii Hook F; (b) inoculating a nutrient growth medium with the cellular inoculum and incubating the inoculated growth medium at 20.degree.-30.degree. C. for up to 8 weeks to produce a cellular product; (c) harvesting the cellular product from the inoculated growth medium; and (d) isolating tripdiolide, triptolide and celastrol from the cellular product and supernatant inoculated growth medium.",9,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12R/91
4328343,4-May-82,1982,5,4,Cobalt-catalyzed one-step synthesis of annulated pyridines,"A method of synthesizing fused ring pyridines (annulated) by co-oligomerization of .alpha.,.omega.-diynes with about molar equivalents of nitriles using a Co.sup.+1 catalyst preferably cyclopentadienyl cobalt dicarbonyl. Additionally, new compounds of tricyclic quinolizine-4-ones were produced where excess cyanoacetic ester starting materials were utilized (about 2:1 equivalent nitriles:diyne). The results with the catalyst employed indicated a stepwise mechanism in which cobalt(I) catalyst first forms a metallocycle intermediate derived from the bisacetylene. This cobalt(III) intermediate reacts preferentially with nitriles to give the product annulated pyridines in good yield. Generally, preferred conditions indicated roughly molar equivalents of reactants with no substantial excess of either reactant for the bicyclic compounds. Preferred conditions include a moderate temperature (solvent reflux temperature) and a preferred solvent such as BTX-type solvent (xylene) or an alkane (N-octane) under an inert blanket (nitrogen) for a multi-day period.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4331021,25-May-82,1982,5,25,Contrast resolution tissue equivalent ultrasound test object,"A contrast resolution tissue-equivalent ultrasound test phantom comprises a block of material having ultrasonic propagation characteristics similar to that of human or animal tissue. A plurality of contrast objects are embedded in the block, each having a different reflectivity. The contrast objects have at least one dimension wherein the size of the object in cross-section decreases so that periodic ultrasonic scans of all of the objects simultaneously produce successive displays of plural cross-sectional patterns, the pattern in each display having the same size but different contrasts whereas the pattern size changes for successive displays.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Medical technology,,,,,G01H/005
4331054,25-May-82,1982,5,25,Electric gel slicer,"A gel slicer consisting of a support with a gel guide trough and a feed screw journalled parallel to the trough. A feed plunger assembly is threadedly engaged on the feed screw and has a plunger portion slidably engaged in the trough. The feed screw is intermittently driven by a power shaft via selectable identical-diameter gear discs with different-length tooth configuration for varying the increment of feed of the gel per revolution of the power shaft. The gear discs have smooth peripheral portions providing dwell periods of the feed screw. A pivoted transverse cutting blade is spring-biased toward cutting position over the trough and is held elevated by a follower lug engaging a cam on the power shaft, the cam having a blade-release notch. The cam is synchronized to release the cutting blade during the dwell period of the feed screw. Thus, the thickness of the slice depends on the amount of teeth on that gear disc which is selected to drive the feed screw. The selected gear provides desired incremental steps of longitudinal movement of the gel.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Machine tools,,,,,,B26D/30
4331648,25-May-82,1982,5,25,N-Acetyl-cysteine protects against cardiac damage from subsequently-administered cardio-toxic anthra-cycline in cancer therapy,"The cardiac damage, occurring after treatment with an anthracycline, such as adriamycin, is prevented when N-acetyl-cysteine is orally administered about one hour prior to the treatment with the anthracycline.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
4332244,1-Jun-82,1982,6,1,Mask for the safe delivery of inhalation gases to small laboratory animals,An anesthesia mask for laboratory animals comprising a supply tube having a generally conical mask at one end into which the animal's snout is inserted. Pressurized anesthesia gas is delivered through the tube and is prevented from leaking into the ambient environment by means of a second tube which concentrically surrounds the supply tube and is annularly spaced therefrom so that the space can be evacuated by a vacuum source. A holding bar is slidable transversely into the mask to hook onto the animal's incisors.,7,The Government of the United States as represented by the Secretary of Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61D/04
4337763,6-Jul-82,1982,7,6,Illuminated surgical instrument,A medical implement and more particularly a surgical retractor or speculum having an improved functional configuration and further provided with means for illuminating the interior of a natural body cavity or a cavity formed by incision or a wound.,4,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Medical technology,,,,,,A61B/32
4339295,13-Jul-82,1982,7,13,Hydrogel adhesives and sandwiches or laminates using microwave energy,A method of bonding a material to a substrate utilizing a hydrogel adhesive and a source of microwave energy of at least 100 MHz through a waveguide. The bonding may be temporary and frangible by water or may be permanent where it is achieved in a pressure vessel.,2,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Other special machines,Basic materials chemistry,"Macromolecular chemistry, polymers",,,,C09J/04
4341870,27-Jul-82,1982,7,27,Cultivatable human rotavirus type 2,"This invention relates to a precursor or intermediate for a rotavirus vaccine to protect infants and young children against diarrhea caused by rotavirus. The invention is the efficient propagation of a strain of human rotavirus type 2 prepared by a method of cultivation by multiple passages in vivo in gnotobiotic piglets and by multiple passages in vitro subsequently in AGMK (African green monkey kidney) cell cultures. Additionally, rotavirus is treated with a biologically active amount of trypsin prior to growth in AGMK cells, and the inoculated cell cultures are centrifuged at a low centrifugal force before incubation.",2,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
4343262,10-Aug-82,1982,8,10,Laboratory rat feeder,"A feeding device and feed storage hopper for laboratory rats, adapted to be hung from the top and inside the animal cage, comprises a substantially rectangular feed chamber containing an open top and a downwardly sloped back panel. A generally U-shaped ""floating"" wire screen overlies a rectangular opening in the lower front face of the rectangular feed box and is rigidly attached to the feed box to cover the opening therein except along the bottom edge of the screen. Feed which is to be ingested by the rat rests on the face of the wire mesh screen which has been designed in a manner that the weight of the feed is forced to collapse onto the screen surface as the animal consumes the feed, thus providing a continual flow and availability of feed to the rat. The screen openings are rectangular and are longer in the vertical direction to permit the use of commercially available autoclavable mash feeds and to allow the rat to contact the feed either by inserting his tongue through the screen openings or by slightly moving and flexing the lower unattached edge of the ""floating screen"" structure. The screened feeder is designed to restrict the entry of the rat into the feeder and thus prevent both contamination of the feed through feces or urine or uneconomical spillage of the feed which, in either case, could distort research results. The bottom surface of the screen is substantially horizontal and allows for the collection of feed spillage.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,,,,,,A01K/0356
4344438,17-Aug-82,1982,8,17,Optical sensor of plasma constituents,"A system for monitoring low molecular weight compounds in blood plasma in the body by optical means includes a chamber which can be inserted into the blood stream and which contains specific receptor sites for the plasma constituent to be analyzed. The chamber interior is isolated from the blood by a dialysis membrane which permits the plasma constituents to diffuse into the chamber. A competing ligand for the receptor sites is placed within the chamber, but due to its relatively large molecular size the competing ligand cannot escape through the dialysis membrane into the bloodstream. Light emitted or absorbed by the competing ligand gives a measure of the concentration of the selected low molecular weight compounds in the blood.",14,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Medical technology,Measurement,,,,,A61B/1459
4346073,24-Aug-82,1982,8,24,Hepatitis B immune globulin used to inactivate hepatitis B virus in injectable biological products,"The utilization of hepatitis B immune globulin as a preparation for preventing transmission of the hepatitis B virus (HBV) by injectable biologics, by incubation of the injectable biologics and hepatitis B immune globulin together in vitro prior to administration to patient. The hepatitis B immune globulin is utilized in a dosage of 5 ml and in a preferred titer of 1 to 100,000. The titer may vary to a range of 1 to 100 concentration with an intermediate range of 1 to 1,000 ranging down to 1 to 100,000. Also there may be used other immune globulins such as immune serum globulin (ISG).",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/082
4346224,24-Aug-82,1982,8,24,4a-Aryl-decahydroisoquinolines,"This invention relates to the production of 4a-aryldecahydroisoquinolines where the aryl group is selected as 3-methoxy phenyl and intermediates. These compounds are morphine analogs and show utility similar to the known morphine, codeine, and thebaine.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
4346346,24-Aug-82,1982,8,24,Instrument for measuring true-RMS A.C. voltage and A.C. voltage fluctuations,"A line voltage monitor which can measure d.c. and RMS a.c. voltage and frequency, maximum and minimum RMS voltage, which displays input voltage, and computes and displays % regulation from the measured maximum and minimum voltage values. Analog input circuitry attenuates and squares the input voltage. A voltage-to-frequency converter produces logic pulses at a rate proportional to the squared signal. A 16-bit counter integrates V.sup.2 by accumulating pulses from the voltage-to-frequency converter. A second 16-bit counter increments at a 1 MHz rate to determine the cycle period T of the input. A microcomputer divides the .intg.V.sup.2 value by the period T and then takes the square root, yielding the RMS value of the input voltage. The microcomputer can be switched to determine the % regulation and the input frequency, and can be used to enable display of V.sub.max, V.sub.RMS (t) or V.sub.min, as well as the regulation.",16,"The United States of America as represented by the Department of Health, Education and Welfare",,,,,,,,,,,1,Measurement,,,,,,G01R/252
4348333,7-Sep-82,1982,9,7,.beta.-Ketocarboxyl and phosphonate dihydro-chalcone sweeteners,"Dihydrochalcones of the formula ##STR1## are disclosed wherein M.sup.+ is a physiologically acceptable cation, X is H or OH, R is a lower alkyl and R' is ##STR2## and n and q, respectively, may have a numerical value of 1 to 6. These materials are useful as sweeteners for edibles.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/32
4349538,14-Sep-82,1982,9,14,Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid,"A nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid, poly-1-lysine, and carboxymethylcellulose, and injectable preparations thereof in a pharmaceutically acceptable aqueous carrier such as saline solution. When administered to a human or non-human primate host, the complex is effective in inducing the synthesis in such host of antiviral levels of interferon.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
4353375,12-Oct-82,1982,10,12,Activity monitor for ambulatory subjects,"Disclosed is a monitor apparatus which can be worn by a patient and will provide an indication of activity levels over a number of subsequent time periods. A transducer which is energized by the ambulatory subject's movement, provides an activity pulse into a temporary memory. At the end of a standard timing interval, for example fifteen (15) minutes, a digital code word representative of the total number of activity pulses in that standard timing interval is fed into a solid state memory. The temporary memory is then reset and counts the activity pulses over the next standard timing interval. In this manner, activity levels for any number of sequential time intervals can be recorded without hindering the patient's movement. A contol logic circuit, which is externally triggered, causes the permanent memory to sequentially readout the activity levels of subsequent standard timing intervals for use in studying the activity levels of ambulatory subjects.",20,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/1118
4356117,26-Oct-82,1982,10,26,Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells,"A new reagent effective in inhibiting cholesterol synthesis 75% in human fibroblasts derived from patients suffering from the disease familial hypercholestrolemia is mannose-6-phosphate-low density lipoprotein and is effective in tissue culture test systems at 100 .mu.g/ml after a ten-hour exposure. The broad purpose of this invention is to modify the receptor specificity of a protein so that it will enter cells which were previously impermeable and exert new effects or reverse a pathological condition. Toxins may also be modified in this manner producing cell type specific and tumor suppressive reagents which are effective in a dose range of 0.3-3 .mu.g. The object here is to use the reagent to selectively kill one cell type which is exerting a pathological effect without affecting normal cells. Among others to which this invention is applicable are Man6P-low density lipoprotein, Man6P-ricin, Man6P-Modeccin, anti Thy 1.2 monoclonal antibody-ricin and anti Thy 1.1 monoclonal antibody-ricin.",1,"U.S. Govt., Dept. of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/415
4356164,26-Oct-82,1982,10,26,"Detection of non-A, non-B hepatitis associated antigen","In the detection of the highly transmittable agent of non-A, non-B hepatitis there is described a method utilizing antigen-antibody reaction and a preferred counterelectrophoresis method for the detection of said antigen. The method may be applied as in the recipients of blood transfusions and also may be applied to screening blood donors where the blood donor had transmitted by transfusion non-A, non-B hepatitis antigen several years previously or there was at least a 1-5 year retrospective period from donating blood to retention of active transmittable agent.",9,"Govt. of the U.S., as represented by the Secretary, Dept. of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/29
4356958,2-Nov-82,1982,11,2,Blood cell separator,"A centrifugal blood component separator with a spiral helically inclined rotor chamber. The apparatus uses continuous blood flow-through without rotating seals. At the lower end of the helical rotor chamber there are terminals for blood input and packed red blood cell output, whereas at the higher end there is a terminal for plasma. Intermediate outlet terminals may be provided for white blood cells and platelets.",28,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B04B/0442
4357088,2-Nov-82,1982,11,2,Macula-disc camera with improved resolution,"A macula-disc camera records the first aerial image of the patient's fundus to provide an actual increase in resolution of retinal detail not obtainable by merely magnifying this image with the recording optics. An array of optical fibers surrounds the contact lens to illuminate a limied field of the fundus, on the order of 18.degree.. A high degree of contrast is achieved by tightly separating the observation and illumination beams throughout the lens of the cornea and crystalline lens. Magnification, is on the order of 6.8 times.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/14
4357324,2-Nov-82,1982,11,2,Prodrug derivatives of 9.beta.-D-arabinofuranosyl-2-fluoroadenine,"The 5'-formate and the 5'-phosphate derivatives of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine have been prepared as prodrug forms of the anti-cancer agent 9-.beta.-D-arabinofuranosyl-2-fluoroadenine, known as F-ara-A. These derivatives are quite water soluble whereas F-ara-A itself is sparingly soluble in water or in any organic solvents. Delivery of these prodrug forms to mice with L1210 leukemia results in the formation of higher levels of the triphosphate of F-ara-A, the active form of the drug, in the target L1210 leukemia cells. These prodrug forms are much more active chemotherapeutically than 9-.beta.-D-arabinofuranosyladenine, known as ara-A, and equivalent in activity to the combination of ara-A and 2'-deoxycoformycin, known as 2'-dCF, an effective in vivo inhibitor of adenosine deaminase, a ubiquitous enzyme that destroys ara-A in vivo.",7,The United States of America as represented by the Department of health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
4357341,2-Nov-82,1982,11,2,Specific irreversible antagonism of histamine receptors by photoaffinity actuated compounds,"Specific method of irreversible antagonism of histamine receptors, especially H.sub.1 receptors, in, for example, isolated guinea pig vas deferens by 4(5)-[2-(4-azido-2-nitroanilino)ethyl]imidazole (AAH), which is a photoaffinity analog of histamine actuated unusually by light in the visible spectrum. Additionally, compounds of the present invention are represented by the formula ##STR1## wherein R.sub.1 and R.sub.2 represent an electron withdrawing group of the formula, H, --NO.sub.2, --Cl, --F, --Br, --I, --SO.sub.3 H. When two groups occur, it is not necessary that those groups be identical. In preferred compounds R.sub.1 is --NO.sub.2 and R.sub.2 is H and R.sub.1 is ortho to amine group. R.sub.3, R.sub.4, R.sub.5 and R.sub.6 represent a proton or lower alkyl of straight and branched carbon chains. In preferred compounds R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are protons or methyl groups with not more than two of the four positions substituted with an alkyl group. Preference is given for R.sub.4 and R.sub.5.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/64
4362510,7-Dec-82,1982,12,7,Cementitious dental compositions which do not inhibit polymerization,"Cementitious dental compositions suitable for use as luting agents, sedative and insulating bases, temporary and long term restoratives, endodontic sealants, pulp capping materials, tissue packs, impression pastes and adhesives for dental composites and hard tissues comprising a solid phase which includes a metal oxide or hydroxide of tin or a Group II metal and a liquid phase which includes a chelating compound, the chelating compound being an ester of a vanillic acid moiety in which the ester is the product of a reaction of one of an alcohol, a polyhydric alcohol or a polyalkylene glycol and at least one of either vanillic acid or its isomers or homoloynes. The compositions may additionally contain a second chelating compound, Al.sub.2 O.sub.3, an hydrogenated rosin, polymeric materials and polymerizable monomeric materials.",46,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/90
4371463,1-Feb-83,1983,2,1,Enzyme-resistant opiate pentapeptides,"Pentapeptides having the formula EQU H-L-Tyr-A-Gly-L-Phe-B-R wherein A is a D-amino acid residue, Sar or L-Pro, B is L-Met of L-Leu, and R is NH.sub.2 or OH. These pentapeptides are synthetic analogues of the naturally-occurring Met-and Leu-enkephalins and possess opiate activity which is resistant to destruction by body enzymes.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/702
4371540,1-Feb-83,1983,2,1,Nitroimidazoles of low toxicity and high activity as radiosensitizers of hypoxic tumor cells,Two compounds represented by the formula ##STR1## wherein R is hydrogen or a 2-hydroxyethyl radical are reported to have minimum penetration into the brain and nerve tissues combined with maximum penetration into hypoxic tumor cells. This combination of properties makes these compounds the optimal radiosensitizers among electron-affinic 1-substituted 2-nitroinidazoles.,6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/24
4371673,1-Feb-83,1983,2,1,Water soluble forms of retinoids,Two types of water soluble complexes of retinoids possessing vitamin A-like biological activity and use but of lower toxicity are disclosed: (A) Cyclodextrin complexes of retinoid-polymers and (B) Complexes of retinoids with ether type derivatives of cyclodextrins.,21,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,"Macromolecular chemistry, polymers",Pharmaceuticals,Micro-structural and nano-technology,,,,C08B/0021
4372888,8-Feb-83,1983,2,8,Nondenaturing zwitterionic detergents,"A nondenaturing zwitterionic detergent for proteins which, for example, consists of an effective amount of 3-[(3-chloamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). This detergent is of extreme interest in the biological study of proteins due to its nondenaturing characteristic. Other examples of the group may be prepared from different alicyclic compounds, for example, utilizing cholic acid and in others deoxycholic acid and dehydroabietic acid. A process for the preparation of these compounds starts with cholic or the equivalent and from this is prepared the triethylammonium salt in tetrahydrofuran (THF). After the salt is completely dissolved in THF, ethyl chloroformate is added and the flask cooled to 0.degree. C. Then the mixed anhydride which forms is reacted with dimethylaminopropylamine to form the dimethylaminopropyl derivative of a carboxylic acid amide. Finally, the tertiary amine group is reacted with propanesultone to give the sulfobetaine product. An improved procedure for preparation of these compounds and especially for the last step (as for CHAPSO) to react the N-(3-dimethylaminopropyl)cholamide with sodium-1-chloro-2-hydroxy-3-propanesulfonate.",6,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Basic materials chemistry,Organic fine chemistry,,,,,C11D/92
4377958,29-Mar-83,1983,3,29,Remotely operated microtome,"A miniature microtome assembly with a bellows-operated blade on an arm swingably mounted on a flexible hinge. The specimen is secured in a chuck on a support arm pivoted on a flexible hinge. The specimen is fed toward the cutting path of the blade by a suitably supported feed screw operatively driven by a nut gear actuated by a bellows for coarse advancement steps, and has a fine advance provided by a piezoelectric crystal mounted between the specimen stage and the top end of the feed screw, thereby providing coarse and fine feed of the specimen. The assembly may be contained in a vacuum chamber and the active parts are operated by remote control.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/06
4386093,31-May-83,1983,5,31,(.+-.)3-Deazaaristeromycin and uses,"(.+-.)3-Deazaaristeromycin, also known as (.+-.)-4-amino-1-[(1.alpha., 2.beta., 3.beta., 4.alpha.)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]imidazo[4,5-c]pyridin e, utilized as a novel antiviral agent and inhibiting S-adenosylhomocysteine hydrolase in a pharmacological target in effective concentrations.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4388463,14-Jun-83,1983,6,14,6-Keto-morphinan analgesics,"This patent application describes the preparation and properties of novel and highly potent morphinan analgesics. The compounds include narcotic agnoists as well as narcotic antagonists and are represented by the following formula: ##STR1## R.sub.1 =OCH.sub.3, OCOCH.sub.3, H R.sub.2 =CH.sub.3, CH.sub.2 --CH.dbd.CH.sub.2, ##STR2## CH.sub.2 CH.sub.2 C.sub.6 H.sub.5",12,The United States of America as represented by Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/28
4390026,28-Jun-83,1983,6,28,Ultrasonic therapy applicator that measures dosage,"An ultrasonic therapy applicator wherein therapeutic heating is provided by creating a diffuse ultrasonic field in a liquid, such as water, in a tank in which living tissue may be immersed. The diffuse acoustic energy is produced by frequency-modulating the driving ultrasonic frequency in a band employing ""white noise"" modulation. The apparatus consists of a reverberation tank suspended from a support by four wires. The support is used to mount a transducer, a hydrophone, a specimen holder and a stirrer. The tank is surrounded by a temperature bath. The hydrophone is used for measuring decay rates. The transducer is acoustically matched to the water. Ultrasound is coupled from the transducer via an ellipsoidal vertical reflector vertically aligned below the acoustic window of the transducer. To calibrate integral dosage a temperature sensing probe is used, of the differential temperature analysis type. The probe consists of two thermocouples, one embedded at the center of a RHO-C rubber sphere and the other mounted outside near the sphere. Measuring the differential temperature signal that results when the sphere is irradiated enables determination of the acoustic energy density. The RHO-C rubber has an acoustic impedance nearly equal to that of water, and therefore the probe does not significantly change the exposure field. The absorption coefficient of the rubber is satisfactorily high. Also, the RHO-C rubber holds its thermocouple firmly in place during comparative measurements. The probe minimizes disruption of the exposure and has an omnidirectional response.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Other consumer goods,Medical technology,Measurement,,,,G10K/20
4390699,28-Jun-83,1983,6,28,6-Keto-morphinans belonging to the 14-hydroxy-series,"6-Keto-hydroxymorphinans having at the 4 position a substituent which is R.sub.1 =H, O lower alkyl, or O lower acyl, and N may be substituted by R.sub.2, which for agonist properties may be lower alkyl, lower alkenyl, cyclopropylmethyl, or phenyl lower alkyl, etc. Additionally, the nitrogen may be substituted by R.sub.2, which is allyl, cyclopropylmethyl, cyclobutylmethyl, dimethylallyl, etc., which function as antagonists to the morphine-like activity of the compound. Such activity is known as antinociceptive.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/28
4395395,26-Jul-83,1983,7,26,"Detection of non-A, non-B hepatitis associated antigen","In the detection of the highly transmittable agent of non-A, non-B hepatitis there is described a method utilizing antigen-antibody reaction and preferred counterelectrophoresis method for the detection of said antigen. This method may also be applied to producing a vaccine.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,G01N/5767
4395635,26-Jul-83,1983,7,26,Gamma ray coincidence analysis system,"A gamma ray coincidence analysis system for a multichannel nuclear imaging device of the type employing scintillation detectors in ring-like arrays, with the detectors arranged in quadrants of the rings. The scintillation detectors in a ring have output circuits including respective timing discriminators and OR gates, and respective energy discriminators providing delayed energy pulses, and wherein timing pulses from the respective quadrants are fed via the OR gates to the inputs of a four-input coincidence detector without any delay except for a small delay internal to the discriminators and the very small delay of the OR gates. The delay of the energy pulses at the energy discriminators is for an energy validation period of 500 nsec. The output pulse from the coincidence detector is subsequently delayed for a similar period for verification of the energy levels of the two channels causing the coincidence. A data output signal is generated responsive to the concurrence of the delayed coincidence signal and the delayed energy verification pulses.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Environmental technology,Medical technology,,,,,G01T/2985
4396628,2-Aug-83,1983,8,2,Antiviral activities of dansylcadaverine and closely related compounds,"The entry of animal viruses into their host cells proceeds via a specialized internalization pathway involving clathrin coated regions of the plasma membrane. In the present invention, there has been examined the effect of dansylcadaverine compared with amantadine and other antiviral agents as to the entry of vesicular stomatitis virus (VSV) into mouse cells. It was found that both compounds inhibit VSV entry. Both compounds inhibit the uptake of .alpha..sub.2 macroglobulin (.alpha.2M), a protein that binds to specific membrane receptors and follows the same route of internalization. Dansylcadaverine is 20 fold more potent than amantadine to the blocking virus and also to the .alpha..sub.2 macroglobulin uptake.",3,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/18
4397310,9-Aug-83,1983,8,9,"Anastigmatic high magnification, wide-angle binocular indirect attachment for laser photocoagulator","An improved method and apparatus for photocoagulation of the fundus of a patient's eye eliminates the contact lens and provides for binocular viewing. The technique is characterized by the utilization of a common ophthalmoscopic lens for each of the illumination beam, the observation beam, and the laser beam. A scanning mirror for the laser beam is disposed on the optical axis and is rotatable in two dimensions about a fixed point which is conjugated with the nodal point of the patient's eye with respect to the ophthalmoscopic lens. The binocular viewing paths are converged onto a point on the optical axis in the plane of the first aerial image of the fundus provided by the ophthalmoscopic lens; the laser beam reflected by the scanning mirror is also focused onto that point.",14,The Government of the United States of America as represented by the Secretary of Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61F/008
4397552,9-Aug-83,1983,8,9,Instrument for measurement of exposure from a laser radiation,"An instrument for measuring laser energy in the visible range and which determines when the optical energy exceeds the accessible emission limit for a Class I laser. The instrument employs a photoelectric detector and a filter for a range of 476 to 633 nm. The instrument measures the optical energy as a function of time and compares the measured value with the accessible emission limit for a Class I laser at various critical points in time. A 3-digit engineering-notation display format is used to output the computed time at which the laser energy exceeds the Class I limit, as well as the total energy measured in 10 seconds. The instrument is adapted to measure either CW laser radiation, pulsed laser radiation, or each pulse of laser radiation, computes and applies a correction factor for optical error conditions or variations between optical detectors, and measures and compensates for background energy. Mode and scale information, and sensed data, are read into a micro computer and are read out on a LCD display.",24,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Measurement,,,,,,G01J/4257
4397843,9-Aug-83,1983,8,9,Mannose-6-phosphate-low density protein reagent effective against hypercholesterolemia,"A new reagent effective in inhibiting cholesterol synthesis 75% in human fibroblasts derived from patients suffering from the disease familial hypercholestrolemia is Man6P-low density lipoprotein and is effective in tissue culture test systems at 100 .mu.g/ml after a ten-hour exposure. The broad purpose of this invention is to modify the receptor specificity of a protein so that it will enter cells which were previously impermeable and exert new effects or reverse a pathological condition. That is, the compound of this invention is a useful reagent in the selective cytotoxic treatment of hypercholesterolemia.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/415
4398101,9-Aug-83,1983,8,9,Four input coincidence detector,"A gamma ray scintillation coincidence detection circuit having four inputs connected to two gating configurations, fed by gamma ray detector units. Detection in any one of the four inputs develops a disabling signal in one signal path leading to an AND gate. Detection in any two of the four inputs results in a system output in another signal path. When any input goes high, the AND gate is disabled after a predetermined settable time delay T. If a second input goes high before the expiration of the delay time T, then the signal in the other path can pass through the AND gate and sets a latch, signifying that detector coincidence has occurred.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Environmental technology,,,,,,G01T/2985
4403985,13-Sep-83,1983,9,13,Jet controlled catheter,"The leading end of a catheter tube is directionally controlled by reactive forces imparted to the tube by pressurized control fluid issued from selected control ports defined through the tube proximate its forward end. The reactive forces can be used to bend, turn, propel and otherwise maneuver the advancing catheter. A circumferentially pleated section of the tube may be provided to facilitate bending. A flexible and annular flow baffle may be disposed in the control port outflow path to minimize control flow impact on the vessel wall and/or to affect thrust direction.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/0122
4404182,13-Sep-83,1983,9,13,Ethiodized oil emulsion for intravenous hepatography,"The present invention is directed towards the examination of formulations and evaluations of ethiodized oil emulsions. It is also concerned with formulations of ethiodized oil emulsified with lecithin which show about 30-35% of oil particles in the range 2-3 microns. A dosage utilized for animals, such as rabbits and monkeys for this ethiodized emulsion is 0.1-0.5 ml/kg utilizing computerized tomography, with a preferred dosage of 0.2 ml/kg for computerized tomography, and a dosage of 2 ml/kg for conventional X-rays.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0461
4405611,20-Sep-83,1983,9,20,Bisulfite stabilization of 5-azacytidine,"A bisulfite addition product of 5-azacytidine and method wherein bisulfite is added to the azacytidine molecule at the 5-6 protonated imine bond. It is significant and advantageous to maintain the compound in this pro-drug form. At a pH above 6 and including higher physiological pH in animals, the bisulfite form reverts to the parent compound, rendering it readily available for utilization in the body. This product is produced as the bisulfite addition product at preferably a pH of 2.5.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/12
4405712,20-Sep-83,1983,9,20,LTR-Vectors,"The production of vectors composed of portions of retrovirus, particularly of Moloney sarcoma virus DNA including the ""LTR"" sequence which can activate genes and additional viral sequences which can ""rescue"" these genes into a replicating virus particle.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
4405720,20-Sep-83,1983,9,20,Silver stains for protein in gels,"A silver stain method for polypeptides in gels comprising the sequential steps of photo-reversing the polypeptide-gel by treatment with an oxidizing agent, forming a latent stain image by treating the polypeptide-gel with a photosensitive salt, and developing the stain image by treating the polypeptide-gel with a reducing agent.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Measurement,,,,,G01N/6836
4408124,4-Oct-83,1983,10,4,BRH Test pattern for gamma camera performance (an evaluator),"A test phantom for testing the performance of gamma cameras comprises a plate impervious to gamma rays having an orthogonal array of apertures defined therethrough. The apertures are uniform in size and are arranged in columns and rows. The columns are grouped such that the spacing between adjacent columns in each group differs from the spacing between adjacent columns in all of the groups, and such that the spacing between adjacent columns within each group is uniform throughout that group. The groups are arranged such that the more densely spaced groups are positioned proximate the middle of the array and the more widely spaced columns are disposed at the ends of the array. The resulting test pattern permits changes in the intrinsic resolution, uniformity and spatial distortion of a gamma camera to be observed simultaneously from a single transmission of the test pattern.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Environmental technology,,,,,G01D/00
4410630,18-Oct-83,1983,10,18,Lysis filtration culture chamber,"An apparatus for blood sample treatment involves lysis, filtration and culture, the apparatus being in the form of a unitary culture chamber assembly consisting of an upper chamber for receiving a blood sample, this upper chamber receiving lysing solution squeezed from an attached bag which is subsequently detached. The upper chamber is located over and is in telescopic engagement with a lower chamber having a pointed hollow needle engageable through a rubber diaphragm in the bottom of the upper chamber when the upper chamber is pressed down. This is done after complete blood lysis, and then vacuum is applied to the lower chamber to accomplish filtration. The lower chamber is then detached and discarded. The diaphragm is sealingly covered and an attached bag of culture medium is squeezed to introduce the medium into the upper chamber from the bag. This second bag is detached, leaving the upper chamber as a complete blood culture system.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12M/04
4410700,18-Oct-83,1983,10,18,"Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution","In a short total synthesis of morphinan compounds, derivatives of 1-benzyl-1,2,3,4-tetrahydroisoquinoline are produced. Certain of these compounds, although highly aromatic and functionalized, can be optically resolved. The optically active enantiomers can serve as important intermediates for both natural and unnatural opioids.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/28
4412066,25-Oct-83,1983,10,25,Polymer bound dyes prepared by diazo coupling reactions with poly(organophosphazenes),"Polymer-bound dyes have been prepared by the diazotization of high polymeric [NP(OC.sub.6 H.sub.5).sub.x - (OC.sub.6 H.sub.4 NH.sub.2 -p).sub.y ]n, followed by coupling to phenol, .beta.-naphthol, 6'-NaO.sub.3 S-.beta.-naphthol, and p-aminophenylnaphthalene. These reactions were preceded by model compound studies with the cyclic trimer [NP(OC.sub.6 H.sub.4 NH.sub.2 -p-).sub.2 ].sub.3. In both cases, the aminophenoxy units were generated by reduction of 4-nitrophenoxy groups with the use of PtO.sub.2 and hydrogen. The phosphazene skeleton was unaffected by the reduction, diazotization, and diazo coupling processes. The physical characteristics of the trimers and high polymers are described.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Basic materials chemistry,"Macromolecular chemistry, polymers",Optics,,,,C09B/106
4413985,8-Nov-83,1983,11,8,Hydrocephalic antenatal vent for intrauterine treatment (HAVIT),"A hydrocephalic drainage valve consisting of a hollow shank with a pointed conical tip. The shank has an intake port adjacent the conical tip. A ball check valve in the shank is urged by a coiled spring toward closing relationship with the port. A hollow set screw is adjustably mounted in the shank to vary the biasing force on the valve ball. In one form, for manual implantation, a sleeve is slidably mounted on the shank, has a centrally apertured enlarged head and has implantation enlarged threads near the head. The head has aligned opposite radial grooves which are engageable by a manual insertion tool. In other forms, for pneumatic insertion, the shank has an enlarged head, employed as a driving piston in a pneumatic insertion tube. A washer member with implantation barbs is slidably mounted on the shank and is arranged to be locked to the shank subjacent the head responsive to the pneumatic driving action, with its barbs embedded in the fetal skin around the implantation puncture, thus holding the shank in operating position with the intake port exposed in the cranial vault.",15,The United States of America as represented by the Dept. of Health & Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/0247
4414108,8-Nov-83,1983,11,8,Apparatus and method for continuous countercurrent extraction and particle separation,"A flow-through continuous countercurrent extraction system consisting of a coiled tube or spiral coplanar channel revolving around a main axis and rotating around its own axis at the same angular velocity and in the same direction. With two solvent phases A and B, there are 5 flow tubes: (1) a feed tube for phase B located at the head end of the column, (2) a return tube for phase A located at the head end, (3) a feed tube for phase A located at the tail end, (4) a return tube for phase B located at the tail end, and (5) a sample feed tube located at the middle portion of the column. The column is mounted on a hollow rotary shaft and the axis of revolution is defined by a stationary hollow central shaft. The 5 flow tubes are led through the hollow rotary shaft, and then through the stationary central shaft. In this way, the flow tubes from the rotary shaft are allowed to rotate freely without interference or twisting. Either a single column may be used, with a counterweight, or there may be two opposite columns operating simultaneously. The ingredients of the sample are separated according to the partition coefficients; when the partition coefficients favor phase A, the solutes are eluted through the head end, and when the partition coefficients favor phase B they may be eluted through the tail end, or they may be retained in the column when the partition coefficient fall between the above values. When the operation is aimed at enrichment and/or stripping of a particular substance or substances, the sample flow tube may not be used, and the sample solution is directly introduced through the head or tail feed tube, while the enriched or stripped solution is continuously collected through either the head or tail outlet tube.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Measurement,,,,,G01N/42
4415807,15-Nov-83,1983,11,15,Cross-slice data acquisition system for pet scanner,A positron emission tomographic scanner is provided with cross-slice event data handling capability by adding only a coincidence detector and register in common to the circuitry for two adjacent planar detector arrays and adding an OR gate to the circuitry for each array. The improvement permits the same circuitry to be utilized for both cross-slice event processing and intra-slice event processing. Selection of the identification code for a detector is determined by a first coincidence detector in the case of an intra-slice event and the added coincidence detector in the case of an inter-slice event.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Environmental technology,Environmental technology,,,,,G01T/2985
4416662,22-Nov-83,1983,11,22,Roller infusion apparatus,"An infusion apparatus consisting of a housing containing an electric motor, the housing having a channel-shaped chassis integrally connected thereto and laterally offset therefrom. A toothed drive roller is transversely journalled in the chassis and is drivingly coupled to the motor by meshing bevel gears. The chassis side walls have opposing vertical grooves receiving the peripheral radial flange of the barrel of a syringe, holding the barrel so that its plunger is transversely engaged on the toothed drive roller. A clamping rod is pivoted to the upper portion of one of the side walls and is lockingly engageable with the other side wall. The clamping rod carries a pressure pad which clampingly engages on the plunger to hold it in driving engagement with the toothed roller. A cannula is detachably connected to the discharge end conduit of the barrel. The discharge conduit is provided with a needle penetrable through a self-closing septum provided in the cannula connector member. The leading end of the cannula may be formed with a solid reduced end suture connectable to a needle which can be passed through a patient's skin tissue to draw the cannula with it. The cannula is formed with a slit adjacent the suture portion to allow air expulsion and then drug expulsion after the cannula has been adjusted to locate the slit subcutaneously.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/1452
4416761,22-Nov-83,1983,11,22,Multi slab gel casting electrophoresis apparatus,"An electrophoresis system which provides enhanced resolution and ability to identify nucleases through use of a two-dimensional technique involving isoelectric focussing of tube gels followed by the electrophoresis of second-dimension slab gels formed by the use of a holder allowing slab gels to be cast directly on the sides of the tube gels. DNA is employed as the enzyme substrate within the slab gels. The slab gels are electrophoresed for the second dimension in a chamber wherein the rack containing a stack of slab gels forms the partition between the anolyte and catholyte compartments. After the second-dimension electrophoresis, the slab gels are incubated in incubation buffer and placed in Pyronin Y to stain the unhydrolized DNA. After staining, they are destained in acetic acid. The DNAses are then visible as colorless spots in a reddish-colored gel.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/44721
4416871,22-Nov-83,1983,11,22,Inhibition by peptides of tolerance to and physical dependence on morphine,"Certain peptides administered during chronic morphine treatment were found to be effective in preventing development of tolerance and physical dependence. Particularly effective are prolyl-leucyl-glycinamide, cyclo(leucylglycine), and the protected peptide N-carbobenzoxy-prolyl-D-leucine, which, injected daily into mice receiving chronic morphine treatment, prevented the development of physical dependency as measured by changes in body temperature and body weight, either during abrupt or naloxone-induced withdrawal. But injection of peptide only on the last day of morphine treatment did not alter the overt signs of withdrawal. Daily injection of peptide was also effective in blocking the development of tolerance to analgesic and hypothermic effects of subsequent challenge doses of morphine. The peptide treatment did not alter the acute effects of morphine on either analgesia or body temperature. No effects on memory were noted, as evaulated in a one-trial passive avoidance task.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/12
4419089,6-Dec-83,1983,12,6,Blood cell separator,"A centrifugal blood component separator with a spiral helically inclined rotor chamber. The apparatus uses continuous blood flow-through without rotating seals. At the lower end of the helical rotor chamber there are terminals for blood input and packed red blood cell output, whereas at the higher end there is a terminal for plasma. Intermediate outlet terminals may be provided for white blood cells and platelets.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B04B/0442
4419446,6-Dec-83,1983,12,6,Recombinant DNA process utilizing a papilloma virus DNA as a vector,"A novel method and composition are provided for the replication and expression of exogenous genes in eukaryotic cells. A segment of a papilloma virus genome capable of extrachromosomal replication is linked to the foreign gene(s) using recombinant DNA techniques to provide a biologically functional replicon with a desired phenotypical property. The replicon is inserted into a eukaryotic cell by transformation, and the isolation of transformant provides cells for replication and expression of the DNA molecules present in the modified plasmid. The transforming region of the bovine papilloma virus provides a unique vector in that it provides both the capability of autonomous extrachromosomal replication but also the malignant transformed phenotype. Thus, genes which of themselves provide no selectable phenotypical property can be conveniently and efficiently introduced into eukaryotic cells and the transformants selected. The method is useful in that the foreign DNA is faithfully expressed and the gene products (proteins), such as pro-insulin (an insulin precursor) is synthesized.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
4421913,20-Dec-83,1983,12,20,Separation of triphenylphosphine oxide from methotrexate ester and purification of said ester,"An improvement in the production of methotrexate as set out in Ellard U.S. Pat. No. 4,080,325. It has been found that magnesium oxide facilitates the coupling reaction by acting as an acid acceptor. The dense grade of magnesium oxide is preferred in molar proportions of 2 to 4 moles of magnesium oxide per mole of 2,4-diamino-6-hydroxymethylpteridine. Further, the triphenylphosphine oxide which is generated by hydrolysis of the protecting groups is removed from the reaction stream by utilization of toluene or BTX-type solvents.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
4421986,20-Dec-83,1983,12,20,Nuclear pulse discriminator,"A discriminator circuit for use with a scintillation detector, wherein the scintillation detector output is fed to a time discriminator and the output of the time discriminator is fed via a short precision delay device to one input terminal of a transmission gate device. The detector output signal is also fed to a fast energy discriminator whose output is furnished as an enable signal to the other input terminal of the transmission gate device, providing time output pulses. Timing pulses from the transmission gate device are furnished to a long non-precision delay device and then to one input terminal of a transmission gate. The detector output signal is also fed through a slow energy discriminator and an enable line to another input terminal of the last-named transmission gate, providing energy output pulses in an energy output line which are furnished to the subsequent portion of the system.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Environmental technology,,,,,,G01T/208
4425112,10-Jan-84,1984,1,10,Flow-through centrifuge,"A flow-through centrifuge free of rotating seals. The centrifuge includes a frame having three spaced apart horizontal plates which carry a central bowl, a countershaft and a tube-supporting hollow shaft. A motor is arranged to drive the frame at an angular velocity of .omega.. The countershaft is driven by a stationary pulley on the motor and drives the bowl at an angular velocity of 2.omega.. The motion of the countershaft is also transferred to the tube-supporting hollow shaft by a pulley coupling having a ratio which effects rotation of the hollow shaft, with respect to the frame, at an angular velocity of -.omega..",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Medical technology,,,,,B04B/0442
4427664,24-Jan-84,1984,1,24,"2'Halo derivatives of daunomycin, desmethoxy daunomycin, adriamycin and carminomycin","The compounds are derived from aglycons which may be daunomycin, desmethoxy daunomycin, adriamycin and carminomycin. A preferred compound is ##STR1## (1) R'=H; R.sup.2 =OMe; X; Y (2) R'=OH; R.sup.2 =OMe; X; Y PA1 (3) R'=H; R.sup.2 =H; X; Y PA1 (4) R'=H; R.sup.2 =OH; X; Y where PA1 X=I, Cl, Br, or F and PA1 Y=OH or AcO (acetoxy) where Y is AcO or OH and R'=H and R.sup.2 =OMe. These compounds are effective showing high anti-leukemic activity against P388 murine leukemia.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/252
4428943,31-Jan-84,1984,1,31,"(N-Phosphonacetyl-L-aspartato) (1,2-diaminocyclohexane)platinum(II) or alkali metal salt","##STR1## where X is Na.sup.+, K.sup.+, Li.sup.+ or H (N-phosphonacetyl-L-asparato) (1,2-diaminocyclohexane)platinum(II) or alkali metal salt thereof has shown antitumor activity in animals such as activity against murine leukemia L1210. Additionally, this agent is used against B-16 and Colon 38 tumors and also Ehrlich ascites tumor. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added hydroxyurea (HU) (1000-1500 mg/kg of body weight). In binary treatment with cis-dichlorodiamine-platinum(II) (or cisplatin) the preferred ratio of the present compound to cisplatin is about 10:1 with a range of about 10:1 to 1:10 in mg/kg of body weight. As to the variations in the formula on the left hand side of the formula, it may be varied as monodentate, such as cisplatin containing a single amine group proceeding from the ring, or bidentate, such as the present compound. The saturated cyclo ring may be C.sub.4 or C.sub.5 -C.sub.7 in addition to the present cyclohexane. The present platinum compound may be prepared by reacting the known L-aspartic acid, N-(phosphonacetyl-)disodium salt (PALA; NSC-224131), with dinitrato(1,2-diaminocyclohexane)platinum(II) (NSC-239851). This compound N-phosphonacetyl-L-asparato (1,2-diaminocyclohexane)platinum(II) may be combined in multiple drug regimen with substantially improved yield cures over the parent compounds. For example, the compound denoted Pt-268 may be combined in a dual regimen with cyclophosphamide (CY), hydroxyurea (HU), and cisplatin.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/0093
4430216,7-Feb-84,1984,2,7,High speed preparative countercurrent chromatography with a multiple layer coiled column,"A horizontal flow-through apparatus for two-phase countercurrent chromatography consisting of a horizontal multi-layer helically coiled column carried on a flanged reel which is rotated about its own axis and simultaneously revolved around a stationary central parallel horizontal pipe at the same angular velocity and in the same direction to prevent twisting of its inlet and outlet flow tubes, which extend through the stationary central pipe. The multi-layer array can retain a large volume of the stationary phase against a high flow rate of the mobile phase, enabling the separation of the sample components to be completed in a relatively short period of time.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/42
4430318,7-Feb-84,1984,2,7,Immunoassay utilizing .sup.125 I Protein A,"An improved method for the preparation of .sup.125 I-labelled Protein A (.sup.125 I PA) of high specific and functional activity. .sup.125 I PA has been used in combination with purified rabbit IgG (immunoglobulin G) bound to a solid support to develop a competitive binding assay capable of detecting Protein A or human, rabbit and guinea pig IgG at the nanogram level. Additionally, .sup.125 I PA may be used to detect methotrexate, leucovorin and similar substances. .sup.125 I PA has also been used to detect IgG anti-Forssman antibody bound to sheep erythrocytes and to line-1 and line-10 tumor cells and as an indirect assay for tumor associated antigen in the ascitic fluid of tumor-bearing guinea pigs. Additionally, an improved method of preparation of iodination of Protein A is utilized. This procedure used the Bolton-Hunter (1973) reagent of radioactive iodine in benzene which carrier is evaporated. The PA is added or attached while in an amino acid mixture and separation is per column utilizing Sephadex G-25 and VBS-gel.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/534
4430437,7-Feb-84,1984,2,7,Test methods employing monoclonal antibodies against Herpes simplex virus types 1 and 2 nucleocapsids proteins,The method of producing clinical assays for use of monoclonal antibodies in the diagnosis of Herpes simplex virus (HSV) infections and the differentiation of Herpes Simplex virus types 1 and 2 as a diagnostic kit for differentiating HSV-1 and HSV-2 utilizing clone 1D4 against HSV-1 and clone 3E1 against HSV-2.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56994
4431742,14-Feb-84,1984,2,14,Radioreceptor assay for benzodiazepines in saliva,"A radioreceptor assay for benzodiazepines in saliva which comprises measuring the diminution of attachment of a known quantity of radio labeled benzodiazepine to a receptor carrier in the presence of an unknown quantity of unlabeled benzodiazepine in a known amount of human saliva. Benzodiazepines are selected from the following oft-utilized drugs which are also representative types of benzodiazepine; namely, diazepam (Valium), chlordiazepoxide (Librium), nitrazepam (Benzalin), oxazepam (Serax), flurazepam (Dalmane), and clorazepate. Competitive receptors suitable for the present benzodiazepine radioreceptor assay are from fresh rat frontal cortex. Utilizable receptors are whole brain cortex, human cortex, and striatum.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/948
4433400,21-Feb-84,1984,2,21,Acoustically transparent hydrophone probe,"An acoustically transparent hydrophone probe consisting of a rigid hoop structure in which is secured an assembly of very thin piezoelectric polymer sheet material, such as polyvinylidene fluoride, with one or more very small central sensitive portions. In its simplest form it consists of a single sheet with a small central poled piezoelectric area and with very thin metallic electrodes deposited on the sheet on opposite sides of the piezoelectric area and having fine conductive leads extending from the electrodes and adapted to be connected to a suitable amplifier or transmission line. The sheet is of biaxially stretched material, and is held taut in the hoop structure. Other embodiments may employ multiple sheets. With two sheets, the outermost surfaces are metallized and are at common ground potential, and the inner surfaces have superimposed deposited metallic electrodes with poled piezoelectric areas adjacent thereto. The electrodes have superimposed deposited metallic leads which have a common electrical connection to a transmission line or to an amplifier. With four sheets, the two innermost sheets form a bilaminate subassembly similar to the 2-sheet embodiment. The outer sheets have metallized outer surfaces which are grounded. Between said outer sheets and the bilaminate subassembly, guard rings coaxial with the piezoelectric active areas are provided. The guard rings can be driven electrically in a manner to eliminate the effects of the capacitance of the electrical leads.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B06B/0688
4435505,6-Mar-84,1984,3,6,Lysis filtration culture chamber,"An apparatus for blood sample treatment involves lysis, filtration and culture, the apparatus being in the form of a unitary culture chamber assembly consisting of an upper chamber for receiving a blood sample, this upper chamber receiving lysing solution squeezed from an attached bag which is subsequently detached. The upper chamber is located over and is in telescopic engagement with a lower chamber, and then vacuum is applied to the lower chamber to accomplish filtration. The lower chamber is then detached and discarded. The upper chamber is sealed and an attached bag of culture medium is squeezed to introduce the medium into the upper chamber from the bag. This second bag is detached, leaving the upper chamber as a complete blood culture system.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12M/06
4435572,6-Mar-84,1984,3,6,Synthesis of ethyl-4(3'-methoxyphenyl)-1-methyl piperidine-3-carboxylate,"This invention relates to a process for the production of 4a-aryldecahydroisoquinolines where the aryl group is selected as 3-methoxy phenyl. These compounds are morphine analogs and show utility similar to the known morphine, codeine, and thebaine. In this process particular novelty is asserted for the production of a nipecotic ester ethyl 4-(3'-methoxyphenyl)-1-methyl piperidine-3-carboxylate. Furthermore, novelty is asserted for the step of conversion of the nipecotates through cyclization to cis- or trans-tert-butyl 1,6-dioxo-4a-(3'-methoxyphenyl)-2-methyldecahydroisoquinoline-7-carboxylat e, which may also be easily converted to the keto amide, trans-1,6-dioxo-4a-(3'-methoxyphenyl)-2-methyldecahydroisoquinoline.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
4437857,20-Mar-84,1984,3,20,Method and apparatus for traversing blood vessels,"Disclosed is a method for obtaining access to a relatively inaccessible region of a blood vessel for diagnostic or therapeutic purposes in which a primary catheter tube is inserted into the vascular system at an entry point remote from the relatively inaccessible region, the leading end of the tube is worked towards the inaccessible region in a conventional manner and then a secondary catheter tube contained within the primary tube is everted from the leading end of the primary tube to approach more closely to the required region. A catheter assembly for performing the method is also disclosed.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/1006
4438098,20-Mar-84,1984,3,20,"Heat treatment of a non-A, non-B hepatitis agent to prepare a vaccine","A method of treating the agent of human non-A, non-B hepatitis to render it incapable of causing infection which comprises heating said agent at about 60.degree. C. for about 10 hours and recovering the treated protective agent. Furthermore, this treated agent may be utilized as a vaccine, as, for example, inoculating chimpanzees by i.v. inoculation with the heat treated non-A, non-B agent and the animals have been found protected from later challenge by non-A, non-B hepatitis agent. Thus, the second part of the invention resides in the utilization of a heat-treated agent from human plasma later utilized to protect chimpanzees by incoluation and utilization as a vaccine.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
4440747,3-Apr-84,1984,4,3,Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease,The receptor specificity of toxins can be altered by coupling the intact toxin to monoclonal antibodies directed to the cell surface antigen Thy 1.2. Monoclonal antibody Thy 1.2-ricin (or ricin A chain) is a pretreatment reagent used to eliminate graft-versus-host disease (GVHD) in bone marrow transplants.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/2803
4442205,10-Apr-84,1984,4,10,Simian virus recombinant that directs the synthesis of hepatitis B surface antigen,"A process for producing a recombinant between simian virus 40 (SV40) and hepatitis B virus (HBV) is given. When tissue culture cells are infected with the recombinant, hepatitis B surface antigen is produced. Because a single cloned gene is used, the surface antigen produced is homogeneous and can be produced without conventional dependence on human sera. The antigen is excreted into the culture medium as 22 nm particles with the same physical properties, antigenic composition and constituent polypeptides as those found in the sera of patients with Type B hepatitis. The antigen is useful for the preparation of vaccines.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
4443431,17-Apr-84,1984,4,17,Neisseria gonorrhoeae vaccine,"A vaccine affording protection against attachment of Neisseria gonorrhoeae (N.g.) to human cells, and consequent infection, is prepared from a fragment of pili protein isolated from gonococci. This fragment contains the shared antigens between pili from different N.g., in an exposed form.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/22
4446234,1-May-84,1984,5,1,Vitro cellular interaction with amnion membrane substrate,"Amnion membranes derived from mammalian placentas are employed as the substrate tissue in in vitro assay methods for evaluating cellular interaction with natural barrier tissues. The amnion is also employed as a growth substrate, particularly for the culture of cells difficult to culture on conventional substrates. A diagnostic apparatus including an amnion membrane is also disclosed.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Biotechnology,Analysis of biological materials,,,,A61L/3604
4446315,1-May-84,1984,5,1,Adenosine 5'-triphosphate-4-carboxamide-ribofuranosylthiazole,"The present invention relates to the preparation of and the antitumor compound, adenosine 5'-(trihydrogen diphosphate) 5'.fwdarw.5'-ester with 4-carboxamide-2-.beta.-D-ribofuranosylthiazole.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/207
4447537,8-May-84,1984,5,8,Tick cell lines,"Six new cell lines of Acari: Ixodidae are provided, four from embryonic tissue of Dermacentor variabilis and two from embryonic tissue of Dermacentor parumapertus; and the use of these cell lines for replicating representative microorganisms is shown.",18,The United States of Americas as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
4451648,29-May-84,1984,5,29,Process for the production of 2-.beta.-D-ribofuranosylthiazole-4-carboxamide,An improved multi-step process for the production of 2-.beta.-D-ribofuranosylthiazole-4-carboxamide.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4462252,31-Jul-84,1984,7,31,Trunk dynamometer,"A trunk dynamometer measures isometric and concentric strength and muscular endurance of the extensors and flexors of the lumbar and thoracic spine. A stabilization seat assembly immobilizes the pelvis, thighs, knees, and feet of the subject and is movable relative to a mainframe to permit the subject's axis of spinal flexion and extension to be aligned with the rotation axis of a torque transducer shaft. A laser alignment arrangement cooperates with a sacral stabilizer pad to assure proper alignment of the axes. Anterior and posterior trunk pads are adjustable in height and are linked to the torque transducer shaft to transmit the subject's spinal flexion and extension efforts as torque to the transducer shaft. An accessory shaft, also linked to the trunk pads and aligned with the transducer shaft axis, has a counterweight rigidly suspended therefrom to compensate for torque applied to the transducer by the trunk pads alone.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/224
4465769,14-Aug-84,1984,8,14,Non-transformed thymidine kinaseless cell line and its use for testing tumorigenic potential of genes,A non-transformed cell line is produced by treating BALB/c derived 10E2 cells with 5-bromodeoxyuridine and 5-iodo-2'-deoxyuridine to produce thymidine kinaseless cells which upon multiple cloning show a flat epitheloid appearance indicative of their non-transforming potential. These cells are used to determine the tumorigenic transforming potential of any gene by introducing the gene into the cells of the non-transformed cell line along with the Herpes simplex virus thymidine kinase gene which serves as a vehicle for cotransfection. The transformation of the cells is indicative of tumorigenic potential.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/68
4468383,28-Aug-84,1984,8,28,Dimeric enkephalins,"The compounds of the invention are symmetrical dimers of enkephalin polypeptides comprising enkephalin polypeptide monomers linked at the C-termini thereof with a difunctional amino bridging group. The compounds are useful as investigative tools for probing the opiate receptor membranes, particularly as radiolabelled ligands for exploring the delta opiate receptor, and also have particular use as narcotic and/or analgesic agents.",20,The United States of America as represented by the Secretary of the Department of Health and Human Service,,,,,,,,,,,1,Biotechnology,,,,,,C07K/702
4468466,28-Aug-84,1984,8,28,Silver stains for protein in gels--a modified procedure,"In a silver stain method for protein in gels utilizing treatment with a reducing agent followed by treatment with a silver salt and actuating irradiation, the improvement comprising the use of a reducing agent consisting essentially of dithiothreitol in an amount effective to stain the protein but keep background staining to a minimum.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6836
4471646,18-Sep-84,1984,9,18,Blood pressure cuff calibration system,"An apparatus for measuring the pressure-transmitting characteristics of a blood pressure cuff in terms of delivered cuff pressure. It consists of a somewhat flexible cylindrical supporting tube containing a non-compressible liquid, connected to a pressure transducer. The cuff is wrapped around the tube, and the remaining exposed area of the tube is covered by a rigid cylindrical tube to prevent bulging of the supporting tube when cuff pressure is applied thereto. The cuff is pressurized while simultaneously recording its pressure and the transducer detected pressure. The resulting X-Y curve is compared with one taken of the supporting tube alone.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,,,,,A61B/02141
4474772,2-Oct-84,1984,10,2,Lysis of trypanosoma cruzi,"Trypanosoma cruzi, a protozoan parasite and the causative agent of Chagas' disease (producing chronic symptoms such as cardiomyopathy with heart failure and arrythmia), are lysed within 24 hours by an extracellular substance produced by Pseudomonas fluorescens. This substance, antitrypanosome factor (ATF-II) of a molecular weight approximately 1,000, actively kills the parasites at doses not toxic on mammals such as mice.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/74
4475401,9-Oct-84,1984,10,9,Vibration dosimeter,"An apparatus to monitor and record, for an industrial environment, two natural frequencies with respect to a ""seated spinal system"", namely, approximately 10 Hz and approximately 4 Hz, the natural resonant frequencies of the spine. Raw acceleration signals are amplified, conditioned and filtered to allow only 20 Hz or less to pass. The signals are then divided into two respective channels, namely, below 20 Hz and below 8 Hz, following parallel paths through an amplitude detector and through a zero crossover detector, rectifier and digital filter. In each path the amplitude detector controls a storage flip-flop, which enables an associated decade counter when amplitude criteria are met. The digital filter supplies an output, via an AND gate, to the counter if both amplitude and frequency criteria are met. Thus, a count is stored in the counter if both amplitude and frequency criteria are met. Each channel has an LED display which can be turned on, after exposure, to display the number of events recorded.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01H/14
4476462,9-Oct-84,1984,10,9,Use of context to simplify two-dimensional computer input,"The number of key strokes required to enter two-dimensional figures, such as chemical structures, into a computer from a keyboard display is reduced by utilizing contextual relationships between the character being typed at a specific location and the characters surrounding that location to predict the next character and/or location of that character to be typed. For example, when a horizontal bond between chemical elements is to be typed, the keyboard carriage moves horizontally to the next position, as with a conventional keyboard; but when a vertical or diagonal bond is typed, the carriage moves in the direction of the bond. In addition, symbols representing various atoms are predicted and automatically displayed at a next position location following typing of a bond when the contextual relationship at that location so requires.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06F/0227
4476870,16-Oct-84,1984,10,16,Fiber optic P.sub.O.sbsb.2 probe,"A fiber optic probe to be implanted in human body tissue for physiologic studies involving measurement and monitoring of the partial pressure of gaseous oxygen in the blood stream, which is coursing through a particular blood vessel in the body. The use of the probe is based on the principle of dye fluorescence oxygen quenching. Structurally the probe comprises two 150-micrometer strands of plastic optical fiber ending in a section of porous polymer tubing serving as a jacket or envelope for the fibers. The tubing is packed with a suitable fluorescent light-excitable dye placed on a porous adsorptive particulate polymeric support. The tubing or jacket is usually made of a hydrophobic, gas-permeable commercial material, known as Celgard, but other suitable hydrophobic gas-permeable material could be used for such structure. The fiber optic probe of the invention is of very small size and flexible so that it can easily be threaded through small blood vessels which are located in a variety of tissues of the body.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Medical technology,,,,,G01N/7703
4486179,4-Dec-84,1984,12,4,Biocompatible cementitious dental compositions,"Dental cements with syringate esters such as 2-ethylhexyl syringate with or without vanillate esters dissolved in o-ethoxybenzoic acid as ingredients of the liquid when mixed with metal oxide powder yield rapid setting, insoluble cements that have high strength, do not inhibit free radical polymerization, adhere strongly to metal, and reduce carries. Use of silanized glass filler to the powder in conjunction with the addition of monomer to the liquid gives an even stronger cement.",26,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/20
4487693,11-Dec-84,1984,12,11,Multi-layer coil countercurrent chromatograph with adjustable revolutional radius,"A flow-through apparatus for two-phase countercurrent chromatography consisting of a multi-layer helically coiled column carried on a flanged reel mounted on a frame revolving on a first axis. The reel rotates on a second axis parallel to and spaced from the first axis, at the same angular velocity and in the same direction as the frame to prevent twisting of its inlet and outlet flow tubes, which extend through an axial passage in a shaft portion of the reel. The reel has opposite shaft portions which are journalled in detachable opposite bearing blocks carried by the frame. The bearing blocks have a plurality of sets of bearings spaced to define different spaced positions of the second axis relative to the first axis, enabling adjustment of the .beta. value for the system as required. A counterweight is detachably mounted on the frame opposite the multi-layer coiled column by means of detachable supporting blocks, enabling the counterweight to be readily replaced as required by the .beta. adjustment.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Measurement,,,,,G01N/42
4495279,22-Jan-85,1985,1,22,Isoelectric focussing-polynucleotide/polyacrylamide gel electrophoresis,"An electrophoresis system which provides enhanced resolution and ability to identify nucleases through use of a two-dimensional technique involving isoelectric focussing of tube gels followed by the electrophoresis of second-dimension slab gels formed by the use of a holder allowing slab gels to be cast directly on the sides of the tube gels. DNA is employed as the substrate for casting the slab gels. The slab gels are electrophoresed for the second dimension in a chamber wherein the rack containing a stack of slab gels forms the partition between the anolyte and catholyte compartments. After the second-dimension electrophoresis, the slab gels are incubated in incubation buffer and placed in Pyronin Y to stain the unhydrolized DNA. After staining, they are destained in acetic acid. The DNAses are then visible as colorless spots in a reddish-colored gel.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Biotechnology,,,,,C12Q/44
4497730,5-Feb-85,1985,2,5,Method for obtaining periplasmic proteins from bacterial cells using chloroform,The present invention discloses a method of extracting periplasmic protein comprising treating a cellular suspension of an organism possessing said periplasmic proteins with a periplasmic protein releasing volume of chloroform for a sufficient time to release said protein and then separating said protein from said cellular suspension.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/005
4500637,19-Feb-85,1985,2,19,Prevention of graft versus host disease following bone marrow transplantation,A monoclonal antibody known as TA-1 directed against human T-cells is covalently linked to the toxin ricin and used to treat human donor bone marrow before the marrow is infused into a human recipient.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/28
4501151,26-Feb-85,1985,2,26,Ultrasonic therapy applicator that measures dosage,"An ultrasonic therapy applicator wherein therapeutic heating is provided by creating a diffuse ultrasonic field in a liquid, such as water, in a tank in which living tissue may be immersed. The diffuse acoustic energy is produced by frequency-modulating the driving ultrasonic frequency in a band employing ""white noise"" modulation. The apparatus consists of a reverberation tank suspended from a support by four wires. The support is used to mount a transducer, a hydrophone, a specimen holder and a stirrer. The tank is surrounded by a temperature bath. The hydrophone is used for measuring decay rates. The transducer is acoustically matched to the water. Ultrasound is coupled from the transducer via an ellipsoidal vertical reflector vertically aligned below the acoustic window of the transducer. To calibrate integral dosage a temperature sensing probe is used, of the differential temperature analysis type. The probe consists of two thermocouples, one embedded at the center of a RHO-C rubber sphere and the other mounted outside near the sphere. Measuring the differential temperature signal that results when the sphere is irradiated enables determination of the acoustic energy density. The RHO-C rubber has an acoustic impedance nearly equal to that of water, and therefore the probe does not significantly change the exposure field. The absorption coefficient of the rubber is satisfactorily high. Also, the RHO-C rubber holds its thermocouple firmly in place during comparative measurements. The probe minimizes disruption of the exposure and has an omnidirectional response.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,Other consumer goods,,,,A61N/02
4502475,5-Mar-85,1985,3,5,Drill guide for bone plate fixation,"A drill guide device for bone plate fixation, consisting of an elongated drill guide block having a longitudinal recess for receiving and positioning a bone plate having screw openings. The guide block has spaced openings axially aligned with the bone plate screw openings and containing removable drill guide bushings. The guide block is longitudinally slotted at its ends for adjustable attachment to clamp blocks carrying respective bone-engaging scissor clamp assemblies connected by tie rods. The tie rods have oppositely threaded ends which are threadedly engaged with the respective clamp blocks. The tie rods have hexagonal center portions shaped for driving engagement by a wrench. The scissor clamp assemblies have upstanding opposite top handle portions connected by clamping screws, each clamping screw being pivotally connected to one handle portion and extending through the opposite handle portion. The outer end portion of each clamping screw is provided with a clamping nut. The clamp assemblies have opposing bone-engaging jaw elements moved towards each other when the associated clamping nuts are tightened. Delrin pad elements are provided on the bone-contacting surfaces.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/1728
4508820,2-Apr-85,1985,4,2,Method for simultaneously monitoring turnover rate in multiple proteins,"The invention provides an assay method for cellular and extracellular protein biodynamics comprising the use of radiochemical techniques in combination with high resolution protein separation procedures and recently developed silver stain techniques, to assess turnover of polypeptides over time. Quenching of polypeptide radiolables in silver stained gels is obviated by the use of .sup.14 C-labelled amino acids as precursors.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/60
4511556,16-Apr-85,1985,4,16,Inactivation of a lipid virus,"A method of inactivating a lipid virus in a protein carrier selected from the group consisting of Hepatitis B virus (HBV) and non-A, non-B hepatitis (NANBH) by contacting said virus for an extended period of time and ambient temperature with a halohydrocarbon treating agent preferably chloroform in an amount of 5% v/v to 50% v/v.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C12N/00
4514506,30-Apr-85,1985,4,30,Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens,"The invention comprises a method for the purification of a human lung tumor-associated antigen (hLTAA) specific to human lung tumors of diverse histological characteristics; serum levels of hLTAA correlate with lung tumor incidence, and appear to usefully discriminate between various stages of the malignancies. The invention further comprises an immunoassay predicated on purified hLTAA for the detection and quantitative determination of hLTAA in biological fluids, particularly blood serum, and diagnostic systems for clinical immunoassay procedures.",17,The Government of the United States as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/57423
4514632,30-Apr-85,1985,4,30,Modular scintillation camera,"Improved optical coupling modules to be used in coded-aperture-type radiographic imaging systems. In a first system, a rotating slit coded-aperture is employed between the radioactive object and the module. The module consists of one pair of side-by-side photomultipliers receiving light rays from a scintillation crystal exposed to the object via the coded-aperture. The light rays are guided to the photomultipliers by a mask having a central transverse transparent window, or by a cylindrical lens, the mask or lens being mounted in a light-conveying quartz block assembly providing internal reflections at opposite faces of the assembly. This generates output signals from the photomultipliers which can be utilized to compute one-dimensional coordinate values for restoring the image of the radioactive object on a display screen. In another form of optical coupling module, usable with other types of coded-apertures, four square photomultipliers form a substantially square block and receive light rays from scintillations from a scintillation crystal exposed to the radioactive object via the coded-aperture. The light rays are guided to the photomultipliers by a square mask or a centrally transparent square lens configuration mounted in a light-conveying assembly formed by internally reflecting quartz blocks, the optical rays being directed to the respective photomultipliers so as to generate resultant output signals which can be utilized to compute image coordinate values for two-dimensional representation of the radioactive object being examined.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Environmental technology,,,,,,G01T/295
4515781,7-May-85,1985,5,7,"2',5'-Riboadenylate-morpholinoadenylate nucleotides","Novel nucleotide compounds are afforded, having at least one 2',5'-riboadenylate unit and a terminal morpholinoadenylate unit. These compounds have potentiated biological activity in the 2,5-A system and increased resistance to degradation.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07H/00
4517665,14-May-85,1985,5,14,Acoustically transparent hydrophone probe,"An acoustically transparent hydrophone probe consisting of a rigid hoop structure in which is secured an assembly of very thin piezoelectric polymer sheet material, such as polyvinylidene fluoride, with one or more very small central sensitive portions. In its simplest form it consists of a single sheet with a small central poled piezoelectric area and with very thin metallic electrodes deposited on the sheet on opposite sides of the piezoelectric area and having fine conductive leads extending from the electrodes and adapted to be connected to a suitable amplifier or transmission line. The sheet is of biaxially stretched material, and is held taut in the hoop structure. Other embodiments may employ multiple sheets. With two sheets, the outermost surfaces are metallized and are at common ground potential, and the inner surfaces have superimposed deposited metallic electrodes with poled piezoelectric areas adjacent thereto. The electrodes have superimposed deposited metallic leads which have a common electrical connection to a transmission line or to an amplifier. With four sheets, the two innermost sheets form a bilaminate subassembly similar to the 2-sheet embodiment. The outer sheets have metallized outer surfaces which are grounded. Between said outer sheets and the bilaminate subassembly, guard rings coaxial with the piezoelectric active areas are provided. The guard rings can be driven electrically in a manner to eliminate the effects of the capacitance of the electrical leads.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B06B/0688
4520011,28-May-85,1985,5,28,Inactivating protein synthesis by incubating anti-Thy 1.1-ricin a chain monoclonal antibody hybrids with target protein cells,The rate of protein synthesis inhibition is significantly increased by adding excess ricin B chain to target cells independent of the amount of ricin A chain bound to the cell surface membrane. Ricin is a known toxin from albumin of the castor oil bean and contains an A chain and a B chain for binding to receptors. The present invention is concerned with ricin hybrids such as OX-7-ricin A chain and 19E12-F(ab) ricin A chain which were produced by conjugation of the ricin A chains with anti-Thy 1.1 monoclonal antibodies. The conjugates were utilized in pharmaceutical amounts in mice.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/6827
4520031,28-May-85,1985,5,28,Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone,"A method of treating cancers or advanced malignant disease involving the weekly administration of methyl-glyoxal bis-guanylhydrazone in amounts of 250-1,000 mg/m.sup.2 per week. In particular the administration involves a weekly dosing regimen and dose escalation over the series of treatments from an initial dosage which may be 250 mg/m.sup.2.",3,The United States of America as represented by the Secretary of Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/155
4520113,28-May-85,1985,5,28,Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions,"This invention relates to the detection of antibodies in sera of AIDS and pre-AIDS patients and describes the biochemical and immunological analysis of antigens associated with the virus HTLV-III Human T-Cell Leukemia Virus. It is shown that antigens associated with the infection of human cells by this virus are specifically recognized by antibodies from AIDS patients. Specifically, HTLV-III isolated from AIDS patients and transmitted by cocultivation with an HT cell line is specifically detected by antibodies from human sera taken from AIDS patients. The method of detection of antibodies preferred is a strip radioimmunoassay (RIA) based on the Western Blot technique or an ELISA (an enzyme-linked immunosorbent assay) or an indirect immunofluorescence assay.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56988
4520226,28-May-85,1985,5,28,Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates,"A reagent and the protocol for the treatment of Graft Versus Host Disease is disclosed. Monoclonal antibodies specific for T-lymphocytes in human donor bone marrow are covalently linked to separate ricin toxin, combined in a mixture to form a treatment reagent, and combined with bone marrow removed from a human donor. The bone marrow-reagent mixture is then infused into an irradiated recipient. This protocol virtually eliminates T-lymphocyte activity, the cause of Graft Versus Host Disease.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/28
4521601,4-Jun-85,1985,6,4,Practical total synthesis unnatural enantiomers of opium-derived morphinans,"This invention relates to compounds which may be described as the unnatural enantiomers of morphine agonists and antagonists, which are useful as antitussives. The synthesis utilized is capable of producing all of the unnatural enantiomers of medically important opium derivatives of the morphinan type, including thebaine.",1,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/20
4522494,11-Jun-85,1985,6,11,Non-invasive optical assessment of platelet viability,"A system for assessing platelet viability in a transparent flexible bag. The apparatus employed consists of a support for clampingly receiving the bag and defining an optically exposed constricted region in the bag. A laser beam is passed perpendicularly through the constricted region of the bag. The opposite side portions of the bag are alternately periodically compressed and released to provide laminar fluid flow through the constricted region to align platelet discs face-on with respect to the beam. Scattered light from the beam is passed through an annular gate, defining a selected scatter angle relative to the beam axis. The selected scattered light is directed by a lens onto a photodiode detector. The output of the detector is processed and furnished to a computer, which is employed to derive respective quantities indicating the concentration of non-aggregated platelets and the percentage that are discs. These quantities are obtainable by (1) averaging the output during a period when said laminar flow is provided, to obtain a value I.sub.l, and (2) stopping the periodic compression and allowing the platelets to thereafter become randomly oriented, to obtain a value I.sub.o. The quantity representing disc percentage is calculated for (I.sub.l -I.sub.o)/I.sub.o, whereas the concentration of non-aggregated platelets is calculated from I.sub.o.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/51
4527550,9-Jul-85,1985,7,9,Helical coil for diathermy apparatus,"A deep-heating diathermy apparatus consisting of a hollow tube adapted to receive a part of the body, or other dielectric material to be treated. An rf coil coaxially surrounds the tube and is driven by an rf generator. The total wire length of the coil is approximately 0.7 to 1.3 (depending on specific electrical properties and volume of the treated material) times the wavelength of a basic driving frequency provided by the generator. The output of the generator is supplied to the coil via a 50-ohm coaxial cable and a matching impedance. The coil may be driven by frequencies corresponding to integral multiples of one-half the basic wavelength, to enable shifting the heat focus volume along the coil axis from the normal centered location on the axis produced by full-wave excitation.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61N/403
4528196,9-Jul-85,1985,7,9,Chelating agents for the treatment of iron overload,"The present invention consists of chelating agents for the treatment of iron overload and methods of using these agents in mammals such as mice and rats. These agents or compositions comprise diesters of dicarboxylic acids, which are phenolic derived and otherwise resemble ethylene and propylenediamine diacetic acids. The acids are known as: HBED [N,N'-bis(2-hydroxybenzyl)ethylenediamine N,N-diacetic acid]; EHPG [ethylenediamine N,N'-bis(2-hydroxyphenylacetic acid)]; HBPD [N,N'- bis(2-hydoxybenzyl)propylenediamine-N,N'-diacetic acid]; HBHPD [N,N'- bis(2-hydroxybenzyl)-2-hydroxy-1,3-propylenediamine-N,N'-diacetic acid]. Mineral acid addition salts are also included in the spirit of this invention. Such salts as sulfuric, hydrochloric and nitric may be utilized. In activity it has been found that the odd-numbered carbon atom esters, such a dimethyl and dipentyl, specially of HBED, are of highest activity, as well as the dipentyl ester of the HBPD. In summation, the HBED esters were found to have the highest activity of those esters studied.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/195
4530698,23-Jul-85,1985,7,23,Method and apparatus for traversing blood vessels,"Disclosed is a method for obtaining access to a relatively inaccessible region of a blood vessel for diagnostic or therapeutic purposes in which a primary catheter tube is inserted into the vascular system at an entry point remote from the relatively inaccessible region, the leading end of the tube is worked towards the inaccessible region in a conventional manner and then a secondary catheter tube contained within the primary tube is everted from the leading end of the primary tube to approach more closely to the required region. A catheter assembly for performing the method is also disclosed.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/1006
4532039,30-Jul-85,1985,7,30,Multi-layer coil assembly coaxially mounted around the rotary axis for preparatory countercurrent chromatography,"A horizontal flow-through apparatus for countercurrent chromatography consisting of a horizontal multi-layer helically coiled column coaxially carried on a flanged spool which is rotated around its own axis in a frame which is simultaneously rotated by a motor about the same main axis. The column assembly rotates at a rate twice that of the rotary frame in the same direction, the arrangement being such that the inlet and outlet flow tubes are twist-free. The effluent through the outlet tube of the column is continuously monitored by a UV monitor and then fractionated into test tubes by a fraction collector. The apparatus is driven by the motor, which is drivingly connected to the frame on the main axis, and the column assembly is driven by gearing via a countershaft journalled in the frame and having a toothed pulley drivingly coupled by a toothed belt to a fixed toothed pulley coaxial with the column.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
4532215,30-Jul-85,1985,7,30,Isolation of hepatitis A virus strain HM-175,"Human hepatitis A virus (HAV), taken directly from human clinical specimens, can be isolated and serially passaged in primary African green monkey kidney (AGMK) cell cultures. This strain induced antibody to HAV in inoculated chimpanzees and is useful for vaccine.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
4533675,6-Aug-85,1985,8,6,Carbamates of colchicine for treatment of gout,"The present invention consists of derivatives of colchicine and thiocolchicine which are carbamates of the same and are illustrated by the formula below: ##STR1## where either X.sub.1 or X.sub.2 is a hydroxy group and the other a lower alkoxy group and R.sub.1 can be H or an alkyl, R.sub.2 an alkyl, alkenyl or aryl which may be substituted and R.sub.3 is either OCH.sub.3 or SCH.sub.3 ; alkyl and alkoxy=C.sub.1 -C.sub.6 ; aryl=monoaryl. These compounds are not only new but have exhibited antitumor activity binding to tubulin protein and tests against P388 lymphocytic leukemia and also active against gouty arthritis. Further, they are far less toxic than colchicine.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/24
4536523,20-Aug-85,1985,8,20,Dental composite formulation from acrylate monomer and polythiol accelerator,"A two paste dental composite formulation is disclosed, wherein one paste comprises a polymerizable monomer and a stable organic hydroperoxide initiator, and the other paste comprises a polymerizable monomer and a polythiol accelerator, the hydroperoxide having a ten-hour half-life temperature in excess of about 100.degree. C., and the polythiol being capable of accelerating the decomposition of the hydroperoxide into polymerization initiating free radicals at ambient temperatures.",10,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/887
4544231,1-Oct-85,1985,10,1,Method of joining plastic optical fibers and connections obtained,Plastic optical fibers are joined by heat-flaring their ends in a first tubular sleeve and joining the flared ends within a tubular sleeve of about the same size with a U.V.-curable optical cement. The fibers may be joined side-by-side or end-to-end. Different diameter tubes may also be joined together by the method of the present invention.,16,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Optics,,,,,,G02B/241
4545985,8-Oct-85,1985,10,8,Pseudomonas exotoxin conjugate immunotoxins,"A method of modifying Pseudomonas exotoxin (PE) with methyl-4-mercaptobutyrimidate is disclosed so that after conjugating the exotoxin to a monoclonal antibody (ab) such as the antibody to the transferrin receptor, the PE-ab conjugate becomes a highly potent immunotoxin suitable for use against human tumor cells. This same method has been used to conjugate PE to epidermal growth factor (EGF) to create a highly potent growth factor-toxin conjugate for use against cells having large numbers of EGF receptors. Also disclosed are the immunotoxin conjugates for Pseudomonas exotoxin coupled to anti-TFR (antibody to the transferrin receptor) and anti-TAC (antibody to the human T-cell growth factor receptor) and to EGF.",16,"The United States of America as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/6829
4546097,8-Oct-85,1985,10,8,"Saponin-based polyether polyols, pharmaceutical compositions and a method of using same","Digitonin and digitonin-related saponins are derivatized by alkoxylation. The adducts have lower toxicity, higher solubility, and reduced ability to form insoluble complexes with cholesterol, as compared to the starting material. The adducts are particularly useful as solubilizing agents for lipophilic drugs and as mycoplasma suppressors in cell cultures.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07J/0005
4547367,15-Oct-85,1985,10,15,Hepatitis B core antigen vaccine,Disclosed is a vaccine against hepatitis B virus (HBV) using purified hepatitis B core antigen (HBcAg). Chimpanzees immunized with the vaccine were protected against hepatitis B.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
4547368,15-Oct-85,1985,10,15,Hepatitis B core antigen vaccine made by recombinant DNA,"Disclosed is a a vaccine effective for primates, such as chimpanzees, and against hepatitis B virus (HBV) using hepatitis B core antigen (HBcAg) made by recombinant DNA. Chimpanzees immunized with the vaccine were protected against hepatitis B.",3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
4547569,15-Oct-85,1985,10,15,Intercalating agents specifying nucleotides,"This invention discloses a molecule bearing a biologically active group (a phenanthridinium moiety) joined covalently to an oligonucleotide recognition system (a phosphorus nucleoside group) by a linker that permits intercalation of the active group in the pocket formed by the nucleotide and complementary bases in another polynucleotide strand. This class of compounds is illustrated by the following: ##STR1## where R is selected from the group consisting of --NH.sub.2, methylamino, or ethylamino or hydrogen; PA0 where R' is selected from the group consisting of --NH.sub.2, methylamino, or ethylamino or hydrogen; PA0 where the chain linking the linker group to the phenanthridinium group (R"") consists of 2-8 --CH.sub.2 -- groups.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/00
4550422,29-Oct-85,1985,10,29,Process and device for x-ray system quality assurance,"A method and apparatus for evaluating the performance of diagnostic x-ray systems. The method consists of using an x-ray generator under standard conditions and making a test x-ray film, for example, of the dental intra-oral type and comparing its density with a calibrated step density strip, using a test tool member consisting of a sleeve-like body with opaque parallel flat top and bottom walls receiving the step density strip slidably therebetween. The flat walls have registering transverse rectangular windows, in the forward parts of which can be exposed a selected density step. The rear portion of the body, between the flat walls, has spacer blocks defining therebetween a transverse channel overlapped by the windows through which the test x-ray film can be inserted to compare its density with that of the selected step density. This can be utilized to determine if the test film density is within an optical density in a desired range including certain steps of the calibrated density strip. The step density tablet can have steps ranging from 0.7 optical density to 1.5 optical density. A metal filter plate may be mounted on one end portion of the tool body of a thickness selected to match the output of the x-ray generator to the response of the film so as to produce a test film of optical density of about 1.00 O.D. when the x-ray system is known to operate satisfactorily.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/04
4551251,5-Nov-85,1985,11,5,Monolithic integrated flow circuit,"A monolithic multi-channel integrated flow circuit comprising a support matrix sheet or plate impressed or embossed with the desired circuitry; the desired circuit elements such as transfer conduit and separation columns are integral with and defined by the support matrix, which conveniently comprises a first deformable support sheet embossed with the circuits elements by thermoforming techniques, and bonded to a support blank or correspondingly embossed second support sheet to complete and define the circuit.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
4552962,12-Nov-85,1985,11,12,Antitussive 6-keto morphinans of the (+)-series,"The present invention is concerned with dextrorotatory morphinans, which are illustrated by (+)-4-methoxy-6-keto-N-methylmorphinan. Related compounds which also have been introduced as cough-suppressing agents include the (+)-3-methoxy-N-methylmorphinans (ROMILAR-Roche).",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/28
4555490,26-Nov-85,1985,11,26,Rapid visualization system for gel electrophoresis,"A method using light (""photodevelopment"") to develop a metallic silver image of biopolymers, particularly nucleic acids and proteins separated on polyacrylamide gels, whereby it is possible to visualize protein and nucleic acid patterns within 10 minutes after electrophoretic separation. This ""photodevelopment"" method requires only two solutions: a solution to ""fix"" the proteins and a solution containing silver ions, which produces an image when exposed to light. This type of protein stain has achieved a sensitivity of about 0.5 ng of protein. DNA separated on polyacrylamide may also be visualized with this stain.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/44726
4556712,3-Dec-85,1985,12,3,"Preparation and racemization of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines","In a short total synthesis of morphinan compounds, derivatives of 1-benzyl-1,2,3,4-tetrahydroisoquinoline are produced. Certain of these compounds, although highly aromatic and functionalized, can be optically resolved. The optically active enantiomers can serve as important intermediates for both natural and unnatural opioids.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/20
4565789,21-Jan-86,1986,1,21,Cell matrix receptor system and use in cancer diagnosis and management,"A cell matrix receptor specific for laminin expressed on the surface of carcinoma and epithelial cells is provided. The binding of these cells to extracellular matrix is mediated by the laminin molecule, which has binding domains for type IV collagen of the matrix and the cell surface receptor. Fragments of the laminin molecule lacking the type IV collagen binding domain and antibodies to the receptor are useful in conjunction with the cell receptor as ligands in binding assays for cancer diagnosis and in cancer management.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5743
4569788,11-Feb-86,1986,2,11,Monoclonal antibodies against non small cell lung cancer,Monoclonal antibodies 703D4 and 704A1 detect human non-small cell lung cancer (non-SCLC) and distinguish non-SCLC from all other types of lung cancer and normal tissue cells. These two antibodies may be utilized in kit form to distinguish non-SCLC from other forms of lung cancer. These monoclonal antibodies bind to S.sup.35 methionine-incorporating protein doublets under reduced and unreduced conditions. The determinants bound by these antibodies on the 31 kiladalton protein are independent of each other as determined in radiolabelled competition assays.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/3023
4571385,18-Feb-86,1986,2,18,Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors,"This invention relates to processes which are used to produce, isolate, and characterize human rotavirus/animal rotavirus reassortants and to produce live attenuated vaccines and vaccine precursors. In the present strategy there is involved the new use of either (1) high titer hyperimmune antisera or (2) monoclonal antisera to select reassortants with the desired human phenotype. A point of novelty is the finding that antiserum or monoclonal antisera alone, so long as it possesses high titer neutralizing activity against only the 34-38Kd glycoprotein or of the animal parent, is sufficient to use for selection of reassortant rotaviruses with human phenotype. Also, the novel products are live attenuated vaccine precursors and vaccines.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
4572896,25-Feb-86,1986,2,25,Monoclonal antibodies to herpes simplex virus type I polypeptides,"A method for producing monoclonal antibody reagents against novel proteins induced by herpes simplex virus type 1 (HSV-1). The method consists of preparing HSV-1 antigen populations by infecting mammalian cells either with HSV-1 alone or with HSV-1 in the presence of an inhibitor of protein synthesis, allowing virus replication to proceed by reversing the action of said inhibitor, inoculating said antigen mixture in mice to induce the production of antibodies, fusing the spleen cells of said mice with myeloma cells to obtain hybrid cells, and screening said cells by radioimmunoprecipitation-polyacrylamide gel electrophoresis (RIP-PAGE) to identify hybrid cells producing monoclonal antibodies against HSV-1 proteins. The method teaches the production of unique monoclonal antibody reagents directed against novel HSV-1 proteins; including a 132,000 molecular weight (mw) DNA-binding protein, a 175,000 mw immediate-early protein, and a previously unknown 110,000 mw glycoprotein.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/569
4573467,4-Mar-86,1986,3,4,Optical coupling device for biomicroscope,"An apparatus is provided for permitting high power laser pulses to be controllably focused in the center of a biomicroscope field of observation by means of a mirror movable in three dimensions. The shutter mechanism, synchronized to the generation of each laser pulse, closes to protect the eyes of an observer against damage from the laser. The mirror is mounted on a shaft disposed on a housing for movement longituinally of its axis, rotationally about that axis, and pivotably about a point on the axis. The apparatus is portable so as to be easily transported to various locations in a medical facility.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Machine tools,,,,,B23K/032
4576477,18-Mar-86,1986,3,18,Method and apparatus for measuring density profiles in microscopic tube flow,Particle distribution in a fluid flowing through a microscopic tube is achieved by flowing the fluid vertically-downward through a transparent capillary tube and passing light through the flowing fluid. A linear array of photodiodes responds to light passing through the fluid by registering a series of signals representing the linear projection of particles passing through the plane defined by the light source and the photodiode array. The fluid is supplied from a reservoir which can be selectively pressurized by a gas to control the egress flow rate of fluid. A syringe serves as the egress path from the reservoir and a rotatable stirring rod is disposed in the syringe to stir the egressing fluid. The syringe feeds a disposable assembly which includes a hypodermic needle feeding the capillary tube which is mounted between a microscope slide and cover in the path of the sensing light.,23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0227
4578355,25-Mar-86,1986,3,25,Plasmid cloning vector pAS1,"A plasmid cloning vector containing both transcriptional and translational regulatory sequences derived from the bacteriophage lambda genome was constructed to achieve high level expression of prokaryotic and eukaryotic genes. The system utilizes a plasmid vehicle carrying the strong, regulatable lambda promoter, P.sub.L, and host lysogens into which this vector can be stabily transformed. The lysogen synthesizes sufficient repressor (cI) to control P.sub.L expression and thereby stabilize plasmids which carry such a highly efficient promoter. Use of a temperature sensitive repressor permits simple, rapid induction of P.sub.L transcripts at any given time. Efficient transcription of essentially any coding sequence is assured by providing the phage lambda antitermination factor, N, and a site on the transcription unit for its utilization (Nut site). This pAS1 plasmid closely resembles the earlier constructed pKC30cII, also a regulatory protein which activates promoters for lysogenic development.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/73
4581231,8-Apr-86,1986,4,8,Inactivation of viruses containing essential lipids,"A method of inactivating a lipid virus in a protein carrier by contacting said virus for an abbreviated period of time and ambient temperature with a halohydrocarbon solvent or treating agent, preferably chloroform, in an amount of 5% v/v to 50% v/v. Preferred lipid viruses are Hepatitis B virus (HBV) and non-A, non-B Hepatitis (NANBH).",4,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Medical technology,,,,C12N/00
4582802,15-Apr-86,1986,4,15,Stimulation of enzymatic ligation of DNA by high concentrations of nonspecific polymers,"DNA ligase activity is strongly accelerated in the presence of high concentrations of non-specific polymers, with an accompanying change in product distribution characteristics. The rate of blunt-end ligation of DNA substrate by T4 DNA ligase is particularly affected, with a product shift from closed circular species to linear oligomers. The method provides a way to increase the rate of enzymatic DNA ligation and the size of the linear products. It may be useful when preparing large amounts of polymers by ligation of oligomers or when ligating amounts of DNA or deoxyribooligomers so low in concentration that a reduced yield would otherwise result.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12P/34
4588993,13-May-86,1986,5,13,Broadband isotropic probe system for simultaneous measurement of complex E- and H-fields,"A broadband isotropic probe system simultaneously measuring the E- and H-field intensities of rf complex, near-field electromagnetic radiation comprises a set of three mutually orthogonal dipole antennas and a set of three mutually orthogonal loop antennas located within the same volume of space. Each antenna has associated circuitry comprising a frequency-response-shaping filter and diode detector to provide a frequency response which is flat over the desired frequency bandwidth. The lengths of the dipoles are kept electrically small so that the EM fields are not perturbed. The diameters of the loops are kept electrically small so that the E-field pickup will be negligible. Coupling between any of the probe's antennas is also minimized by the use of electrically small antennas. Circuit means based on the use of square law detectors is also provided, the circuit including an arrangement of analog or digital data processing portions leading into a display means and a data recorder.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Telecommunications,Measurement,,,,,G01R/028
4596795,24-Jun-86,1986,6,24,Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives,"The administration of sex hormones, particularly testosteorne, progesterone and estradiol in the form of their complexes or inclusions with specific derivatives of cyclodextrins by the sublingual or buccal route results in effective transfer of these hormones into the systemic circulation, followed by only gradual elimination. To be effective in the above mode of administration, the derivatives of cyclodextrins must carry one or several substituents, each containing one or several hydroxy groups. Specially preferred are the following complexes: hydroxypropylbeta-cyclodextrin and poly-beta-cyclodextrin.",3,"The United States of America as represented by the Secretary, Dept. of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,"Macromolecular chemistry, polymers",,,,B82Y/00
4598153,1-Jul-86,1986,7,1,"Metaphit, a specific acylating agent for the [.sup.3 H] phencyclidine",A derivative of phencyclidine (1) bearing an isothiocyanate moiety of the meta position of the aromatic ring (2; Metaphit) has been synthesized and identified as a rapid and specific site-directed acylating agent of the [.sup.3 H]-phencyclidine binding site in rat brain homogenates.,1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Analysis of biological materials,,,,,G01N/9486
4599352,8-Jul-86,1986,7,8,Antineoplastic platinum (IV) complexes and compositions,"New substantially isomerically pure tetrahalo (1,2-diaminocyclohexane) Pt (IV) complexes having antineoplastic activity are disclosed.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07F/0093
4601903,22-Jul-86,1986,7,22,Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease,"The present invention discloses a vaccine against Neisseria meningitidis Group B, serotype 2b strain. More particularly, the present invention is related to an aluminum hydroxide adjuvanted vaccine containing only a single serotype 2 antigen being protective against both 2a and 2b meningococcal disease.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/095
4604094,5-Aug-86,1986,8,5,Toposcopic catheter and method of fabrication,"An everting catheter assembly includes a primary catheter tube inside which an everting or toposcopic element is secured spaced from the distal end of the primary catheter tube and with the open head end of the toposcopic element facing away from the open distal end of the primary catheter. The bonding of the toposcopic element to the interior of the primary catheter is effected with the use of a hollow mandrel through which the toposcopic element extends so that a short length of the toposcopic element projects out from the mandrel and is folded back over a length of the outer surface of the mandrel at the mandrel forward end. The mandrel is withdrawn into the primary catheter tube to the desired location for bonding at which point a bond is effected by means of heat conducted to the mating surfaces through the catheter wall or deposited locally by a radiative technique and heating between the mating surfaces. The tail end of the everting catheter is secured to a seal tube of greater rigidity by disposing the open tail end of the toposcopic element over a bias-cut end of the seal tube. Bonding is effected by application of heat to the mating surfaces. The bias-cut on the seal tube permits complete collapse of the toposcopic element upon pressurization of the annular cylindrical region from which the eversion is effected. Since the protruding bias-cut does not preferentially bend so as to evert within itself, a geometrically unbalanced collapse of the toposcopic element occurs. Introduction of pressurized sterile eversion fluid media into the annular region is facilitated by means of a bleed tube extending to the lead end of the annular region so as to permit pre-existing gas to be bled from the annular region during pressurization.",34,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/0119
4609991,2-Sep-86,1986,9,2,Automated system for determining the molecular weight and/or concentration of macromolecules via sedimentation equilibrium,"An automated system for measuring the concentration gradient of centrifuged solute and directly calculating the molecular weight and/or sedimentation coefficient of an optically absorbing solute. Monochromatic light passes through a stationary slit and a previously centrifuged sample in a tube while the tube is moved vertically at a uniform rate by a platform which is driven by a motor and gearing, including a gear nut which drives a vertical screw attached to the platform. The transmitted light impinges on a photodetector which provides absorbance readings. This provides data of absorbance vs. time through the scanning cycle, which is processed digitally. A microcomputer is used to calculate the molecular weight and/or sedimentation coefficient from this data. The centrifuge tube is supported in a transparent cuvette containing a black plastic adaptor block which conformably receives the tube and supports it in upright position, allowing the light beam to pass through opposite vertical slot portions in the block. The cuvette rests on the platform, which is moved vertically relative to the slit defining the fixed beam path. A microswitch is operated at the upper limit of travel to stop the drive motor. The motor is external to the housing in which the optical components and the sample tube are located. The external motor is coupled by a flexible shaft to the drive gearing. Alternatively, a stepping motor may be employed instead of a synchronous motor to move the centrifuge tube in an incremental fashion rather than at uniform velocity.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/04
4612282,16-Sep-86,1986,9,16,Monoclonal antibodies reactive with human breast cancer,"Monoclonal antibodies demonstrating a reactivity with human breast cancer are produced. The hybridoma cultures secreting immunoglobins are produced by hydridoma technology. Splenic lymphocytes of mice, immunized with membrane-enriched fractions of metastatic human mammary carcinoma tissue are fused with the NS-1 non-immunoglobulin-secreting murine myeloma cell line. Screening of immunoglobulin reactivities and double cloning of cultures yielded 11 monoclonal antibodies that demonstrated activities with the surface of human mammary tumor cells and not with the surface of apparently normal human tissues. These monoclonal antibodies aid in the diagnosis, prognosis and treatment of human breast cancer.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/3015
4612315,16-Sep-86,1986,9,16,"Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives","Certain functionalized congeners of 1,3-dialkylxanthine exhibit high potency and selectivity as antagonists for A.sub.1 - and A.sub.2 -adenosine receptors and are suitable for attachment to probes, drug carriers, or solid supports. These derivatives are characterized by the presence of a phenyl at the 8 position para-substituted with a functionalized chain to provide high water solubility and high receptor affinity to such an extent that these compounds are suitable for use as antiallergenic, antiasthmatic, or cardiotonic drugs, central nervous system stimulants, and diuretics.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C07K/06026
4613668,23-Sep-86,1986,9,23,Short total synthesis or morphinan compounds which uses cyclization of a cycloalkylcarbonyl compound selected from cyclopropylcarbonyl and cyclobutylcarbonyl,"There is disclosed herewith a method of producing morphinan compounds by total synthesis which incorporates utilization of N-cycloalkylcarbonyl compounds, which show certain advantages over the prior art which has been previously expressed in U.S. Pat. No. 4,368,326.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/10
4615183,7-Oct-86,1986,10,7,Cold plate for laboratory use,"A cold plate for maintaining specimen samples for dissection at desired cooled temperatures includes a metal plate having an aperture therethrough to receive a removable dark frosted glass piece capable of transmitting light therethrough. The metal plate is equipped with an integrally embedded hollow matrix of tubing to circulate a cooling medium delivered from a remotely operated refrigeration system. In addition, a remotely-operated lighting system is provided to illuminate the dark frosted glass piece and the surrounding regions.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Other consumer goods,Measurement,,,,,F25D/00
4615805,7-Oct-86,1986,10,7,Method for continuous countercurrent foam separation,"A method of performing foam separation utilizes a gas-liquid dual countercurrent flow through a helical column subjected to a particular type of synchronous planetary motion. Samples introduced at the middle portion of the column, either continuously or batch wise, are separated according to the foam affinity. Any material having an affinity to the foam is quickly carried with the foaming stream and eluted through one end of the column, whereas other materials are carried with the liquid stream in the opposite direction and eluted out through the other end of the column.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/42
4615886,7-Oct-86,1986,10,7,Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus,"A method of inactivating a lipid virus contained in a dry protein carrier by contacting said virus-containing protein carrier for an abbreviated period of time at from 4.degree.-40.degree. C. with a composition including a halohydrocarbon treating agent and water dissolved in said treating agent. Preferred lipid viruses are Hepatitis B virus (HBV) and non-A, non-B Hepatitis (NANBH) virus.",11,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61L/0088
4616073,7-Oct-86,1986,10,7,Hydrophobic dental composites based on a polyfluorinated dental resin,"Dental resin systems prepared from polyfunctional or monofunctional highly-fluorinated methacrylate prepolymers are described. Preferred systems comprise (a) a major amount of a polyfluorinated aligomeric polyfunctional methacrylate such as (PFMA), preferably in combination with a diluent monomer such as 1,10-decamethylene dimethacrylate (DMDMA), methyl methacrylate (MMA), neopentyl dimethacrylate (NPDMA), 1,6-hexamethylene dimethacrylate (HMDMA), etc., or mixtures thereof; and (b) a minor amount of a polyfluorinated monofunctional methacrylate (PFMMA), such as 1,1-dihydropentadecafluorooctyl methacrylate (PDFOMA) as a minor or secondary diluent monomer in a non-hydroxylated bis-GMA resin system. The products are generally useful as hydrophobic dental materials, esepcially as composited (with fillers), sealants and cements.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/887
4620971,4-Nov-86,1986,11,4,Indium-bleomycin complex,"A new .sup.111 In-BLM complex designated .sup.111 In-BLMC is described. The complex is characterized by a lack of capacity for binding to serum transferrin, a high selective affinity for viable tumor tissue, in vivo stability, improved activity ratios of tumor to tissues over known .sup.111 In-BLM complexes, tumor imaging flexibility and distinctness, and rapid clearance from the body. The new .sup.111 In-BLM Complex thus has clinical use as a radiopharmaceutical for combining radiotherapy and chemotherapy, and as a tumor-imaging agent for diagnosis.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/08
4620978,4-Nov-86,1986,11,4,Hepatitis A virus purified and triply cloned,Human hepatitis A virus (HAV) can be purified by a process in which master seed lots of HM-175 strain of hepatitis A virus are prepared from triply cloned virus by terminal dilution at passage level about 20 or preferably at least 20-30. The clones tested induced minimal or no hepatitis although significant antibody response was provoked in inoculated primates. A method of preparing the triply cloned inoculum is also described.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
4622291,11-Nov-86,1986,11,11,Method and device for quantitative end point determination in immunofluorescence using microfluorophotometry,"The present invention discloses a device and a process for quantitation of end point in the formation of fluorescent reaction product in microfluorophotometry. The process comprises: PA1 (a) incorporating a protective agent in a suitable mounting medium in an amount sufficient to reduce fading of fluorescent reaction product less than 25% of initial fluorescent intensity; PA1 (b) calibrating photometer used in said microscopy with a stable emitter; and PA1 (c) recording the intensity of fluorescence of said fluorescent reaction product by means for measuring light intensity. The invention also includes a device for calibration of the photometer and a kit comprising separate containers for suitable mounting medium, buffer, suitable immunofluorescent reagents, fading retardant means, a photometer calibrating device and the like and optional instructions.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Analysis of biological materials,Biotechnology,,,,G01N/6458
4632909,30-Dec-86,1986,12,30,Monoclonal antibodies which block infectivity of malarial parasites to mosquitoes,"Monoclonal antibodies have been developed that bind with one or more proteins located on the surface of gametes or zygotes of malaria parasites. These antibodies are specific for antigens on mosquito midgut stages of malaria parasite and sterilize the parasites in mosquitoes otherwise capable of transmitting the disease. The monoclonal antibodies are specific for the 255, 59 and 53 kilodalton surface proteins on Plasmodium falciparum and for the 25 kilodalton surface protein on zygotes and ookinetes of Plasmodium gallinaceum.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/205
4632922,30-Dec-86,1986,12,30,Oxomorpholinyl dimer and rescue of anthracycline and mitomycin C damage,"The present invention discloses a bi(3,5-dimethyl-5-hydroxymethyl-2-oxomorpholin-3-yl) compound and its efficacy as a rescue agent against anthracycline and mitomycin C induced tissue damage. A method of synthesizing said compound has also been described.",2,The United States of America as represented by the Department of Health and Human Services,"University of Colorado Foundation, Inc.",,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/32
4636469,13-Jan-87,1987,1,13,Isolation of hepatitis A virus strain HM-175,"Human hepatitis A virus (HAV), taken directly from human clinical specimens, can be isolated and serially passaged in primary African green monkey kidney (AGMK) cell cultures. This strain induced antibody to HAV in inoculated chimpanzees and is useful for vaccine.",3,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
4647773,3-Mar-87,1987,3,3,Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS,"A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with the new variants of HTLV, which are transformed and providing T-cell populations which are highly susceptible and permissive from HTLV-III, and convenience for large scale production, isolation and biological detection of the virus.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0694
4649040,10-Mar-87,1987,3,10,Therapy for retinoid pathogenesis,"The present invention discloses a pharmaceutical composition and a method of treating retinoid induced pathogenesis. The pathological effect of retinoid is ameliorated by a suitable dose of a rescuing agent selected from the group consisting of choline chloride, methionine, betaine, biotin and inositol, the rescuing agent having the property of preventing formation of fatty liver.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/415
4652599,24-Mar-87,1987,3,24,Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS using permissive cells,"A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with HTLV-III, which is transformed and provides T-cell populations which are highly susceptible to and permissive for HTLV-III, and convenient for large scale production, isolation, and biological detection of the virus. Other operational neoplastic T-cell lines which are positive for OKT4 marker, e.g., Molt 3, CEM, Ti7.4 and HUT78, can produce HTLV-III in a large amount and retain its unlimited capability for growth.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
4653036,24-Mar-87,1987,3,24,Transducer hydrophone with filled reservoir,"A hydrophone device with one or more very small active spots located on a large continuous ferroelectric sheet, such as PVDF, overcomes many of the problems in prior art constructions associated with the high dielectric constant of various media in which the device is used. Additional improvements include increased signal to noise ratio and a sensitivity independent of the medium properties. The hydrophone device includes a piezoelectrically active sheet stretched and clamped on over the top of a hoop ring. A backing is attached to the back of the hoop ring. A low-dielectric material fills the space between the backing and the sheet. This material eliminates the capacitive loading effect which would otherwise be presented by the medium being probed.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B06B/0688
4656033,7-Apr-87,1987,4,7,"Isolated, soluble immunogen against Schistosoma mansoni and a method of vaccination employing same","The present invention discloses a method of vaccination against Schistosoma mansoni employing membrane-free, soluble immunogens. It has been found that the route of administering the vaccine and fortification thereof with a suitable adjuvant are quite critical in eliciting immunity in the host.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0003
4658047,14-Apr-87,1987,4,14,"Method of preparing 1,2-diaminocyclohexane tetrachloro platinum (IV) isomers","The present invention is a method of preparing tetrachlorodiamine cyclohexane platinum (IV) by reacting a diamine selected from the group consisting of 1,2-diaminocyclohexane and operable isomers thereof in the form of a dihydrohalide with alkali metal or hydrogen hexachloroplatinate. The preferred hexachloroplatinate is potassium salt and the isomers utilized from the diamine are selected from the group consisting of cis, trans (d,l), trans-l, and trans-d. The process noted is where the 1,2-diaminocyclohexane is used in about equimolar amounts with hexachloroplatinate which is subjected to heating at reflux temperature for 12-24 hours in aqueous solvent, cooled and filtered.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/0093
4670394,2-Jun-87,1987,6,2,Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor VIII:C,The present invention discloses a new line of endothelial cell of adrenal medullary origin capable of producing blood clotting Factor VIII:C. A method of isolating and culturing said cell line has also been disclosed. Factor VIII:C is useful in treating hemophilia.,10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/069
4670461,2-Jun-87,1987,6,2,Formaldehyde derivatives of mitindomide,"New substituted, formaldehyde derived mitindomide and methods of preparing the same are disclosed. The novel compounds are water soluble and have anti-neoplastic activity. The formaldehyde derived mitindomide is prepared by reacting mitindomide with formaldehyde and further acetylating the derived hydroxymethyl compound. The amido compounds can be derived by reacting mitindomide in mannich fashion, i.e-formaldehyde and secondary amines.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
4670467,2-Jun-87,1987,6,2,Method of controlling graft versus host reaction,"The present invention discloses a method of controlling graft versus host disease, resulting from bone marrow transplantation by treating the host with succinylacetone. A dosage of about 800 mg/kg body weight every 4 days is found optimal.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/19
4673634,16-Jun-87,1987,6,16,"Purified antigen from non-A, non-B hepatitis causing factor","The present invention discloses an isolated and purified antigen specific to non-A, non-B hepatitis (NANBH) causing agent. The utility of the antigen as a diagnostic serologic marker and as a screening device for detecting the carrier or source of non-A, non-B hepatitis or infective factor thereof, particularly in a blood bank or plasmapheresis setting and preventing transmission of NANBH by isolating the source is described. Use of the antigen as vaccine to induce protective antibodies capable of neutralizing NANBH infectivity is also disclosed. A kit for detecting the presence or identifying the carriers or sources of non-A, non-B hepatitis or causative agent thereof is also disclosed.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/29
4673678,16-Jun-87,1987,6,16,Water soluble derivatives of fredericamycin A,"Water soluble, biologically active derivatives of Fredericamycin A (FMA) and method of synthesizing the same are described. Antibiotic pharmaceutical compositions of the new water soluble compounds of FMA are useful antimicrobial and antitumor preparations.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/20
4676980,30-Jun-87,1987,6,30,Target specific cross-linked heteroantibodies,"The present invention discloses a target specific cross-linked heteroantibody and a method of producing the same. The cross-linked heteroantibodies of the present invention can cause normal autologous cells of the immune system to destroy any unwanted cell for which an antibody is available. Treatment or control of tumors, viral infected cells, fungi, bacteria, parasites and the like is now made possible through the use of the heteroantibody complex of the present invention.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/468
4677678,30-Jun-87,1987,6,30,Active hearing protectors,"A hearing protective device consisting of a headset having opposite earmuff and/or earplug assemblies resiliently connected by a headband assembly including a normally open power switch closed when the headband assembly is put on the user's head. The switch controls the energizing of the electrical circuitry of the device. Each earmuff and/or earplug assembly has an outwardly-facing microphone and an inwardly-facing sound reproducer, connected to circuitry defining respective stereo channels, each channel including preamplifier circuitry and a respective power amplifier drivingly connected to one of the sound reproducers. The circuitry also includes a hyper AGC circuit which receives and sums signals from the amplifier chain and derives attenuation signals therefrom which are fed back to the amplifier circuitry and which reduces the gain of this circuitry when the input sound exceeds a certain level. This causes the inputs to the power amplifiers to fall when the input to the preamplifiers increases beyond a certain level. A balanced attenuation circuit arrangement is employed which reduces the size of too-large sound waves without altering their shape, whereby the volumes of the two stereo channels are maintained in the proper relation to each other to preserve binaural hearing.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Basic communication processes,Basic communication processes,,,,,H03G/3015
4687001,18-Aug-87,1987,8,18,Subcutaneous fluid and culture chamber and implant technique,"A subcutaneous culture chamber for providing a priviledged site for studying infectious disease processes of microorganisms in laboratory animals consists of a pliable polyethylene cylinder with holes at each end. The cylinder can be collapsed and inserted in a flat injector of the plunger type which is employed to force the flattened cylinder through an incision in the skin of an animal into a subcutaneous site. After insertion, the chamber soon expands to operational size and the incision is closed. Thereafter the chamber is suitable for use as an infection site to study the pathogenesis and immunology of microorganisms or for obtaining, with a syringe and needle, tissue fluid usable in a serum bacteriological assay or other study.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/02
4690131,1-Sep-87,1987,9,1,Medical apparatus,"An improved device of a combination of elements is adapted to be used with an elongated flexible instrument, such as an endoscope, and capable of at least partially extending with the instrument into the lumen of a tubular body part, such as the large intestines. A sheath is adapted to be mounted on the instrument. The instrument and sheath are provided with selectively inflatable cuffs movable with respect to one another by axially sliding the sheath on the instrument. The movable relationship of the sheath and instrument and the selective control of air to the cuffs allows the user to more easily navigate the front of the instrument through the lumen of the body part with less discomfort to the patient.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/31
4690915,1-Sep-87,1987,9,1,Adoptive immunotherapy as a treatment modality in humans,"The present invention discloses a new approach to the therapy of cancer in humans based on the administration of lymphokine activated killer (LAK) cells and interleukin-2 (IL-2). Twelve patients with metastatic cancer who had failed standard available therapy were treated. LAK cells were generated from peripheral blood mononuclear cells obtained at multiple leukaphereses and incubated in the recombinant-derived lymphokine, IL-2. Following three to four days of incubation in IL-2, the resulting LAK cells were capable of lysing fresh tumor cells but not normal cells. These LAK cells were reinfused into the autologous patient, along with the intravenous administration of recombinant IL-2 every 8 hours. Patients received up to 90 doses of IL-2 and from 2.8 to 12.6.times.10.sup.10 activated cells from up to 14 sequential leukaphereses. Six patients showed objective regression of established cancer.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/17
4692463,8-Sep-87,1987,9,8,"Antiinflammatory 2,3-didemethylcolchicine and additional derivatives","The present invention describes the finding of potent antiinflammatory properties in 2,3-didemethylcolchicine and its analogs.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/165
4693606,15-Sep-87,1987,9,15,Apparatus and method for measuring muscle sarcomere length in vivo,"A laser diffraction apparatus for measuring muscle sarcomere length IN VIVO, primarily useful for tendon transfer procedures, includes a screen and laser assembly adapted to direct a laser beam through a muscle tissue supported by a 180.degree. deflection prism towards the screen which receives the resultant diffraction pattern. This diffraction pattern determines the length of the muscle's sarcomere. A mechanism is provided for adjustably positioning the laser assembly and the 180.degree. deflection muscle tissue supporting prism relative to the operative field.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0211
4693984,15-Sep-87,1987,9,15,Method and apparatus for sequential fractionation,"An apparatus for sequentially fractionating a centrifuge tube includes a capillary tube and a means for applying positive pressure. The capillary tube has an O-ring at the lower end thereof. As the capillary tube is placed within the centrifuge tube, the O-ring forms a seal within the tube. Movement of the capillary tube within the centrifuge tube places the liquid in the centrifuge tube under pressure, thus forcing the liquid to flow up through the capillary tube and into a chamber. A chase fluid is then pumped horizontally through the chamber to force the liquid therein through an exit port and into a fraction collector. The apparatus and method of the present invention may be entirely automated and controlled by a single microprocessor.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/28
4693994,15-Sep-87,1987,9,15,Protective synthetic peptide against malaria and encoding gene,"The present invention discloses a synthetic peptide capable of inducing antibodies protective against human malarial infection caused by Plasmodium vivax sporozoites and the cloning of a gene encoding said peptide. The amino acid and nucleotide sequences of the peptide and the gene, respectively, have been determined and described.",4,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/445
4694007,15-Sep-87,1987,9,15,Use of trimetrexate as antiparasitic agent,"A method of treating infections of Toxoplasmosis or P. carini comprising administering to the host an effective amount of trimetrexate, (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/505
4696932,29-Sep-87,1987,9,29,Biologically-active xanthine derivatives,"Certain functionalized cogeners of 1,3-dialkylxanthine exhibit high potency and selectivity as antagonists for A.sub.1 - and A.sub.2 -adenosine receptors and are suitable for attachment to probes, drug carriers, or solid supports. These derivatives are characterized by the presence of a phenyl at the 8 position para-substituted with a functionalized chain to provide high water solubility and high receptor affinity. Some of these analogs, containing a distal amino- or carboxylic-functionalized chain, are suitable for synthesis of amino acid conjugates. The compounds of this invention are suitable for use as antiallergenic, antiasthmatic, or cardiotonic drugs, central nervous system stimulants, and diuretics.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07D/06
4703016,27-Oct-87,1987,10,27,"Silver stain for rapid, quantitative detection of polypeptides and nucleic acids","A simple, positive image forming silver stain which takes less than 15 minutes to perform is disclosed for the detection of nanogram quantities of proteins and DNA on membranes and thin layer plates. This stain demonstrates a reproducible curvilinear relationship between silver density and the amount of protein or DNA, over an averaged concentration range from 1 nanogram to 300 nanograms for proteins and 10 nanograms to 700 nanograms for DNA. The ease of staining proteins and DNA on membranes, combined with the stain's sensitivity and reproducibility, permits quantitative determination and assay of proteins and DNA.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Biotechnology,Analysis of biological materials,,,,G01N/44726
4704275,3-Nov-87,1987,11,3,Vaccine against rotavirus diseases,"The present invention discloses a vaccine for the prevention of rotavirus caused diseases in humans. The vaccine is prepared from attenuated, immunogenic rhesus rotavirus which has been characterized to be antigenically similar, if not identical, to human rotavirus serotype 3.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
4704357,3-Nov-87,1987,11,3,Immortalized T-lymphocyte cell line for testing HTLV-III inactivation,"This invention is an immortalized T-cell clone, designated ATH8, which is highly sensitive to the cytopathic effect of HTLV-III. The ATH8 T-cell clone is used in mass screening systems to rapidly and easily determine the in vitro capacity of new drugs or other agents to inactivate or inhibit HTLV-III or related cytopathic retroviruses.",4,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56988
4704384,3-Nov-87,1987,11,3,Aziridinyl quinone antitumor agents,"The use of aziridinyl quinones as antitumor agents is disclosed. A compound which has been found to be particularly effective is the compound 2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone. Treatment is described in connection with various forms of leukemia, for example, as well as B16 melanoma, Lewis lung carcinoma, and the ependymoblastoma brain tumor system.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/14
4707439,17-Nov-87,1987,11,17,"Screening test for reverse-transcriptase containing virus such as non-A, non-B hepatitis, NANBH","The present invention discloses a screening test for detecting the presence of contaminating or infectious agents causing non-A, non-B hepatitis or AIDS in a blood donor setting. A kit for the detection of contaminating agents belonging to the group of retroviruses is also disclosed. Screening blood or blood related products so as to prevent spreading of infection or contamination due to retroviruses is now made possible by the present invention.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/48
4707443,17-Nov-87,1987,11,17,Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same,"The present invention discloses a sandwich method and a kit for assaying interleukin-2 receptor (IL-2R) in a sample. The method comprises determining reactivity of said sample with a plurality of ligands, each said ligand having binding affinity for a specific site on the receptor, said site being different for each said ligand and distinct from interleukin-2 binding site on the receptor. The invention also discloses a method of detecting such disturbed or abnormal conditions in humans which release soluble IL-2R in the body fluid.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/6869
4707445,17-Nov-87,1987,11,17,Intact gene and method of excising and cloning same,"The present invention discloses isolated functionally intact whole genes and method of obtaining the same. The method includes treating genomic DNA with mung bean nuclease and formamide under controlled conditions. The invention also discloses cloning of said intact whole genes and a library of such cloned genes or any recombinations thereof. The invention is useful in deriving gene products as m-RNA, S-RNA, t-RNA, polypeptides and the like.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/10
4707448,17-Nov-87,1987,11,17,Immortal line of human fetal glial cells,"The present invention discloses permanent establishment of an immortal line of fetal glial cells. The fetal glial cell line is capable of mitotically proliferating and continually growing in vitro under suitable culture media and environmental conditions. A method of producing immortalized human fetal glial cell line is also disclosed. The method comprises transfecting primary human fetal glial cells with an origin-defective mutant of SV40 virus, passaging the resulting astroglial cells through suitable number of cycles and obtaining the desired cell line. The cell line of the present invention is capable of supporting multiplication of JC virus.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0622
4708818,24-Nov-87,1987,11,24,"Human immunodeficiency viruses associated with Acquired Immune Deficiency Syndrome (AIDS), a diagnostic method for AIDS and pre-AIDS, and a kit therefor","Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.",12,Institut Pasteur,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/005
4708948,24-Nov-87,1987,11,24,Substantially purified tumor growth inhibitory factor,"A substantially purified substance having the property of inhibiting tumor cell growth without inhibiting the growth of normal human cells and without having antiviral effect, further having the properties of: (a) ranging from about 3,500 to 45,000 daltons in molecular weight; (b) being heat stable at about 56.degree. C. when exposed for about 30 minutes; (c) possessing isoelectric point ranging from pI 4-8; and (d) eluting on high pressure liquid chromatography at about 10-35% of 2-propanol or about 25-50% of acetonitrile gradient, has been disclosed. The substance has utility as an antitumor or antineoplastic agent. The substance may also be useful as an index or tumorgenic activity in an organism. The mitogenic and growth stimulatory activity possessed by the substance of the present invention may be useful in wound healing and treating burn-victims.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/52
4714554,22-Dec-87,1987,12,22,Cross-axis synchronous flow-through coil planet centrifuge free of rotary seals: apparatus and method for performing countercurrent chromatography,"Countercurrent chromatography is performed with an apparatus producing a hitherto unused mode of synchronous planetary motion. The axis of rotation remains tangent to the path of revolution about the axis of rotation. By this planetary motion, symmetrically distributed force vectors are created.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Measurement,,,,,G01N/42
4716105,29-Dec-87,1987,12,29,Mini Mu containing plasmid and a method for rapid DNA sequencing,The present invention discloses a rapid method of sequencing a relatively large segment of deoxyribonucleic acid. The method in part comprises high frequency insertion of a suitable transposon into a segment of DNA of interest. Preferable use of Mu transposons is described. A plasmid having mini-Mu transposons has been prepared and disclosed.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6869
4717548,5-Jan-88,1988,1,5,Analytically controlled blood perfusion system,"A blood gas analyzer system for monitoring real-time blood gas conditions in a patient perfusion circuit during open-heart surgery and other extracorporeal blood flow situations. Sensing electrodes are employed in the blood flow path for sensing pH, pCO.sub.2, pO.sub.2 and temperature, and electrical circuitry is provided for generating and processing the sensed signal and also for computing a signal representing HCO.sub.3.sup.- ; also, these signals are monitored in real time. When situations of metabolic acidosis, metabolic alkalosis, respiratory acidosis or respiratory alkalosis occur, the system activates a corresponding alarm and automatically switches into a compensation mode of effect a change in pump speed, which in turn changes the delivery rate of oxygenated blood to the patient. When the blood gas level returns to normal, the pump speed is likewise automatically returned to a normal value.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Analysis of biological materials,,,,,G01N/4925
4719349,12-Jan-88,1988,1,12,Electrochemical sample probe for use in fast-atom bombardment mass spectrometry,"The utilization of a dual electrode sample probe in a mass spectrometer allows several distinct advantages in chemical analysis when compared to common conventional single electrode sample probes, including production of structurally significant ions, and the ability to provide a direct means to study electrochemical reactions.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Electrical machinery, apparatus, energy",,,,,,H01J/142
4722888,2-Feb-88,1988,2,2,Cell line producing human monoclonal antibody which binds to HTLV-I producing cells,"The present invention is an immortalized B-cell line which produces a human monoclonal antibody IgG-Kk which specifically binds to the envelope antigen of human T-cell leukemia virus Type 1 (HTLV-I). This monoclonal antibody is useful as a diagnostic reagent by binding to the antigen specifically expressed on the surface of HTLV producing cells. Furthermore, this monoclonal antibody is useful as a therapeutic reagent, in combination with complement, for the lysis of HTLV-1 producing cells.",9,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1036
4722890,2-Feb-88,1988,2,2,Quantitative assay for human terminal complement cascade activation,"The present invention discloses an enzyme-linked immunosorbent assay (ELISA) to quantitate fluid phase terminal complement activation. Upon activation to form C5b-9, terminal complement components express neoantigens not present in the unassembled individual components. Rabbit antiserum to polymerized C9 was rendered specific for C9 neoantigenic determinants by serial immunosorbtion with human serum, human C9, and other terminal complement components bound to Sepharose. Using the IgG from this antiserum, a sandwich ELISA was devised to bind SC5b-9 from solution onto polystyrene plates. The ELISA plates were developed with the use of goat antiserum to native C9 epitopes followed by a swine anti-goat IgG alkaline phosphatase conjugate. Quantitation of SC5b-9 in solution was performed by comparing sample OD to a standard curve generated with human SC5b-9 that was purified from zymosan-activated serum. The assay is sensitive to as little as 100 ng of SC5b-9/ml and is useful for screening plasma, serum, cerebrospinal fluid, or other biological fluids for the presence of terminal complement cascade activation.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/564
4722895,2-Feb-88,1988,2,2,Synthetic peptides for the production of specific keratin protein antibodies,"A process is disclosed for the construction of synthetic peptides corresponding to amino acid sequences of 55-, 59-, 60-, 67-kilodalton keratin proteins. These synthetic peptides make possible the development of monospecific antisera for individual keratin proteins. The process involves preparing cDNA libraries and reducing the amino sequences of cDNA clones.",16,"The United States of America as represented by the Secretary, Dept. of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/4741
4727064,23-Feb-88,1988,2,23,Pharmaceutical preparations containing cyclodextrin derivatives,"The invention comprises pharmaceutical preparations consisting generally of a drug with a substantially low water solubility and an amorphous, water-soluble cyclodextrin-based mixtures. In these preparations a stable amorphous state can be achieved. This improves the dissolution properties of the drug and hence its absorption by the body. The required cyclodextrin-based mixtures were prepared from .alpha.-, .beta.-, or .gamma.-cyclodextrin which were rendered amorphous through non-selective alkylation. The alkylation agents suitable for that purposes are exemplified by propylene oxide, glycidol, iodoacetamide, chloroacetate, or 2-diethylaminoethylchloride; their reactions with cyclodextrins were performed in a manner to yield mixtures containing many components, a circumstance which effectively prevents crystallization processes within the above pharmaceutical preparation.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,"Macromolecular chemistry, polymers",,,,B82Y/00
4727146,23-Feb-88,1988,2,23,"Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by asymmetric reduction","In a short total synthesis of morphinan compounds, derivatives of 1-benzyl-1,2,3,4-tetrahydroisoquinoline are produced. Certain of these compounds, although highly aromatic and functionalized, can be optically resolved. The optically active enantiomers can serve as important intermediates for both natural and unnatural opioids. As a special function of this invention, certain of the derivatives, namely 4'-6' and 7'-9', may be hydrogenated to 1'-3' derivative by asymmetric reduction either of the catalytic or chemical type.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/10
4729957,8-Mar-88,1988,3,8,Process for manufacture of L-asparaginase from erwinia chrysanthemi,A process for the recovery and purification of L-asparaginase from Erwinia chrysanthemi is disclosed. The process involves the preparation of cellular acetone powder extract followed by either an ion exchange and affinity chromatography purification steps or by affinity chromatography alone. The column eluent is then dialyzed to produce substantially pure L-asparaginase.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/82
4740709,26-Apr-88,1988,4,26,Method of sensing fluid properties independent of bubble concentrations,"A sensing device for obtaining optical density or light scattering measurements or other, in a turbulent liquid comprising a light source and a facing sensor located within a housing. The housing is provided with orifices through which liquid flows into the housing for measurement. The liquid entering the housing is slowed by passage through the orifice, and the bubbles of the liquid rise to the upper region of the housing, out of the measurement region, e.g. out of the line of the sight between the light source and the sensor.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/05
4751080,14-Jun-88,1988,6,14,Vaccine against rotavirus diseases,"The present invention discloses a vaccine for the prevention of rotavirus caused diseases in humans. The vaccine is prepared from attenuated, immunogenic rhesus rotavirus which has been characterized to be antigenically similar, if not identical, to human rotavirus serotype 3.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
4752565,21-Jun-88,1988,6,21,Cell line producing AIDS viral antigens without producing infectious virus particles,"Leu-3.sup.- cells surviving infection with the AIDS retrovirus can be induced with IUdR to express infectious virus. A cellular clone (8E5), isolated by limiting dilution of a mass culture of survivor cells, was found to contain a single, integrated, defective provirus that was consitutively expressed. Although IUdR treatment of 8E5 cells failed to induce infectious virus, cocultivation with Leu-3.sup.+ generated the characteristic syncytia associated with acute AIDS retrovirus infention. The single integrated copy of proviral DNA directs the synthesis of all major viral structural proteins except p64 and p34 as monitored by immunoblotting. Diagnostic reagents and kits in accordance with the present invention are also described.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
4753734,28-Jun-88,1988,6,28,Angle rotor coil planet centrifuge for countercurrent chromatography and particle separation,"An apparatus for performing efficient and stable separation of one material from the other using countercurrent chromatography. The apparatus includes a column holder, which is inclined at an optimum angle between 0.degree. and 90.degree., having a column wrapped thereabout. The configuration and orientation of the column may be varied depending on the properties of two-phase solvent system. A major feature is that the column holder rotates about its central longitudinal axis and the central vertical axis at the same angular velocity and in the same direction.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
4755515,5-Jul-88,1988,7,5,"Chemotherapeutic 1-(2-chloroethyl)-4-(3-chloropropyl)-piperazine, dihydrochloride","New nitrogen mustard analogs with arms of unequal reactivity on different nitrogen atoms have been made. The new analogs are less toxic, potent, cancer chemotherapentic agents.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/067
4756346,12-Jul-88,1988,7,12,Process and apparatus for the preparation of multiple gradients,"Method and apparatus are provided for making multiple continuous or discontinuous gradients. Individual vacuum systems draw the gradient material from a common mixing chamber and deliver it into identical receptacles where each gradient is formed. A battery of syringes can be used to create vacuums on each individual chamber, and an opposing battery of syringes can be used to deliver gradient material to the mixing chamber. By varying the ratio of syringes generating vacuums to syringes delivering gradient material and/or initial solution volumes, gradients of various shapes can be produced.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Handling,Chemical engineering,Measurement,,,,B67D/0277
4762710,9-Aug-88,1988,8,9,Novel method of preparing toxoid by oxidation and metal ions,A method of preparing toxoid by treating a toxin with an oxidizing agent is described. Preparation of a vaccine against pertussis in accordance with the method is illustrated.,18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/099
4762846,9-Aug-88,1988,8,9,Metaphit and related compounds as acylating agents for the (3H)phencyclidine receptors,"A derivative of phencyclidine (1) bearing an isothiocyanate moiety on the meta position of the aromatic ring (3; Metaphit as methanesulfonate and HCl salt) has been synthesized and identified as a rapid and specific site-directed acylating agent of the [.sup.3 H]-phencyclidine binding site in rat brain homogenates. Additional related compounds to Metaphit are Thiophit (oxalate salt), Ethylphit (HCl salt), and Isopropylphit (HCl salt).",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Analysis of biological materials,,,,,C07D/36
4764459,16-Aug-88,1988,8,16,Enzyme-linked immunosorbent assay (ELISA) for determining anti-bodies against herpes simplex virus (HSV) types 1 and 2 in human sera,"A method and test kit for the serological diagnosis of human infection by herpes sipmlex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) using immunoaffinity purified virus-coded glycoproteins as target antigens. A preferred embodiment of the method employs a variation of the enzyme-linked immunosorbent assay (ELISA) whereby monoclonal antibodies are used to purify target antigens, and test sera are absorbed with virus-infected cell extracts to remove intertypic cross-reacting antibodies.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56994
4765972,23-Aug-88,1988,8,23,Vinca alkaloid photoactive analogs and their uses,"Pharmacologically active, radioactive, and photoactive vinblastine analogs are provided which can be used to bind covalently to cellular polypeptides which have high affinity for Vinca alkaloids. The compounds are N-(p-azido[3,4-.sup.3 H]benzoyl)-N'beta-aminoethylvindesine and N-p-azido-[3-.sup.125 I]-salicyl-N'-beta-aminoethylvindesine. The compounds can be used to identify cellular Vinca alkaloid receptors which may be involved in antineoplastic, cytotoxic and drug resistant mechanisms of actions. In addition to specific interaction with tubulin, these compounds specifically bind to a 150-180 kDa surface membrane glycoprotein which is overexpressed in multidrug resistant cells.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4769756,6-Sep-88,1988,9,6,Systematic method for matching existing radiographic projections with radiographs to be produced from a specified region of interest in cancellous bone,"A method to synthesize arbitrary projection images from a basis set of projections bearing a known geometric relationship to each other. In order to determine retrospectively the projection angle of a radiograph of interest with repect to the set of basis projections, similarity measures based on the gray-level standard deviations in corresponding images are used. An iterative coordinate estimation procedure is implemented incorporating these methods with radiographs obtained from dry skull specimens.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/005
4772632,20-Sep-88,1988,9,20,"Antineoplastic, system - L specific amino acid nitrogen mustards","New antineoplastic, system - L specific amino acid nitrogen mustards with reduced myelosuppressive effect are disclosed. A method for identifying and isolating the cellular component comprising the L - amino acid transport system is also described.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/02
4774088,27-Sep-88,1988,9,27,Method and additives for improving the quality and shelf life of stored blood,"A method for improving the quality and/or increasing the shelf-life of whole blood and red blood cell concentrates during storage thereof comprising manipulating the activities of the key red cell enzymes involved in the biosynthesis and degradation of 2,3-DPG (DPGM, DPGP, PGP) and in regulation of glycolysis (PK and PFK). The enzymes are manipulated, i.e. activated or inhibited, either singly or in combination. Such manipulations are achieved by adding to the whole blood or red blood cell concentrates an effective amount of one or more compounds which primarily inhibit the activity of PK and secondarily inhibit the activity of DPG phosphatase and maintain those of phosphofructokinase, phosphoglycolate phosphatase and DPG mutase. Among the compounds which can be used are L-amino acids, free fatty acids, glycolytic intermediates including analogs and derivatives of phosphoenolpyruvate, and free bases, inhibitors of DPGP as well as structural analogs and derivatives of all of the above compounds. Another compound which can be used to improve the quality of stored blood is a pyrophosphate compound.",1,The United States of America as represented by the Deptment of Health and Human Services,,,,,,,,,,,1,Basic materials chemistry,Pharmaceuticals,,,,,A01N/0226
4775759,4-Oct-88,1988,10,4,"Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5.alpha.-epoxy 6.beta.-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT)","Fluorinated derivatives 3,14-dihydroxy-4,5.alpha.-epoxy-6.beta.-fluoro-17-methylmorphinan (""fluorooxymorphone""; FOXY, compound 10) and 17-cyclopropylmethyl-3,14-dihydroxy-4,5.alpha.-epoxy-6.beta.-fluoromorphin an (CYCLOFOXY, compound 18) are prepared based upon the structures of the potent opioid agonist oxymorphone 4 and the antagonist naltrexone 11, respectively. Fluorine was introduced in the final stages of synthesis by a facile nucleophilic displacement with fluoride ion of the 6.alpha.-triflate functions in 8 and 16. The synthetic procedures were suitable for the production of the corresponding positron emitting .sup.18 F-labeled analogs .sup.18 F-FOXY and .sup.18 F-CYCLOFOXY, which are useful for in vivo studies of the opioid receptor system using positron emission transaxial tomography. In addition, the tritiation of FOXY (10) to high specific activity is noted.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
4777133,11-Oct-88,1988,10,11,Device for quantitative endpoint determination in immunofluorescence using microfluorophotometry,"The present invention discloses a device and a process for quantitation of Toxoplasma gondii and Treponema pallidum antibody titer in a biological sample by immunofluorescent photometric microscopy. The process comprises: PA0 (a) reacting a specimen of said sample with an immunofluorescent reagent in a mounting medium containing a protective agent in an amount sufficient to reduce fading of a fluorescent reaction product less than 25% of initial fluorescent intensity; PA0 (b) localizing the specimen under transmitted, visible light; PA0 (c) reducing the effect of counterstain intensity by filters in emission light path; PA0 (d) measuring the sample using a fast shutter; PA0 (e) calibrating the photometer used in said microscopy by a stable fluorophore; PA0 (f) recording intensity of fluorescence of said specimen compared to standard negative and positive controls; PA0 (g) reducing effect of polar staining by substracting the corrected intensity of corresponding dilution of the negative control from the sample reading; PA0 and (h) assigning a numerical endpoint for serum antibody levels against Toxoplasma gondii or Treponema pallidum.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Analysis of biological materials,Biotechnology,,,,G01N/6458
4788181,29-Nov-88,1988,11,29,"5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity","5-substituted 2',3'-dideoxycytidine compounds and their monophosphates are disclosed which have been found to have potent activity against retroviruses. The 5-fluoro-and 5-aza-substituted 2',3'-dideoycytidine compounds have been found to be effective against HTLV-III/LAV virus.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4792689,20-Dec-88,1988,12,20,Method for obtaining a ratio measurement for correcting common path variations in intensity in fiber optic sensors,"A method for correcting common path variations in intensity in fiber optic chemical sensing devices uses a device for spatially separating light of different wavelength regions and a dye system selected so that light passing back to a measuring system along the fiber optic sensor consists of two wavelength regions. The first wavelength region varies with the concentration of analyte, and the other wavelength region is insensitive to the concentration of analyte.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/643
4794074,27-Dec-88,1988,12,27,Method and kit for detecting human exposure to genotoxic agents,The present invention discloses a method and a kit for monitoring human exposure to genotoxic agents. The method comprises an immunoassay for detecting in human serum specific antibodies against DNA adducted to an agent suspected of being genotoxic. A kit comprising various components for performing the assay is also disclosed.,1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/574
4796622,10-Jan-89,1989,1,10,Catheter with oxyhydrogen catalytic thermal tip,"A catalytic thermal tip double catheter provides an alternative energy source for thermal angioplasty without the expense and technical support required for laser or electrical thermal angioplastic devices. The catalytic thermal tip catheter utilizes heat generated by the reactive of a stoichiometric ratio of oxygen and hydrogen gases catalyzed by a small piece of palladium sponge situated in a chamber adjacent to and enclosed by the metallic tip of the catheter, the vapors formed in the chamber generated being evacuated by a vacuum applied to an inner tube. Gas flow regulates catalytic thermal tip temperature which is monitored by a thermocouple positioned within the chamber. Vacuum and gas flow are controlled by an automatic or manual controller which is in direct communication with the temperature monitor.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/00
4797368,10-Jan-89,1989,1,10,Adeno-associated virus as eukaryotic expression vector,The present invention relates to a vector comprising part of AAV DNA contained in a plasmid and capable of being packaged into AAV particles and functioning as a vector for stable integration and expression of a gene in eukaryotic cells when under control of an AAV transcription promoter. A method of preparing such plasmids which are packagable and rescuable is also described.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
4800078,24-Jan-89,1989,1,24,Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb,A new immunotherapeutic method of treating lower respiratory tract infection caused by respiratory syncytial virus (RSV) is disclosed. The method employs topical application of RSV antibodies into the lower respiratory tract. The new treatment modality is more effective and rapid than the conventional therapy.,1,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/1027
4803202,7-Feb-89,1989,2,7,Substituted N-methyl derivatives of mitindomide,New substituted N-methyl derivatives of mitindomide and methods of preparing the same are disclosed. The novel compounds are water soluble and have anti-neoplastic activity.,5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
4806494,21-Feb-89,1989,2,21,Monoclonal antibody against ovarian cancer cells (OVB-3),Monoclonal antibodies are produced which specifically bind to human ovarian cancer cells. These antibodies are conjugated to Pseudomonas exotoxin in order to produce an immunotoxin suitable for the chemotherapeutic treatment of human ovarian cancer.,5,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/30
4810777,7-Mar-89,1989,3,7,Antimicrobial compounds,"A new class of broad spectrum antibiotic polypeptides termed ""Magainin"" have been described. These peptides have a molecular weight of about 2500 or less, are highly water soluble, non-cytolyic to animal cells including red-blood cells and are amphiphilic.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/46
4817015,28-Mar-89,1989,3,28,High speed texture discriminator for ultrasonic imaging,"Tissue signatures are obtained from first and second order statistics of an image texture to discriminate between different normal tissues and to detect abnormal conditions. These signatures describe intrinsic backscatter properties of the tissue imaged, and are used as the basis of an automatic tissue characterization algorithm. A device for on-line classifying of the texture of an image measures a total of four first and second order statistical properties of echo signals of a region of interest (ROI) selected by an operator, the echo signals being contained in an image memory. These can be used to obtain the tissue signatures, to detect low contrast lesions by machine, and to produce parametric images.",20,The United States Government as represented by the Secretary of the Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,,,,,G01S/52036
4820631,11-Apr-89,1989,4,11,Deletion mutants and monoclonal antibodies against ras proteins,Specific deletion mutants of ras p21 gene and specific monoclonal antibodies which recognize specific regions of the ras p21 protein have been prepared. A kit for detecting the presence of specific ras p21 proteins and their levels in a body sample has been described.,7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
4820635,11-Apr-89,1989,4,11,Kit for assaying activation of terminal complement cascade,"A kit for assaying the activation of terminal complement cascade is disclosed. The kit includes a plurality of containers which contain a first antibody having a specificity for poly C9 neoantigen. The containers further have a second antibody which is different from the first antibody and has a specificity for a constituent of terminal complement cascade. A third antibody is optionally present which recognizes the second antibody. The kit also includes a substrate splitting enzyme, a substrate for the enzyme which produces a color reaction when split, and a SCb-9 standard microtiter plate. Pipettes and instructions for performing the assay are also included.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/564
4824986,25-Apr-89,1989,4,25,Metal chelate protein conjugate,A method of forming a novel metal chelate protein conjugate is described. Also described are metal chelates and precursor compounds to the metal chelates. The novel metal chelate protein conjugates are particularly useful in the diagnostic imaging of tumors and in tumor therapy.,2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1093
4825330,25-Apr-89,1989,4,25,Ultra-fast solid state power interrupter,"A power interrupter for non-destructively protecting for instance 120 Vac equipment test when that equipment is likely (i.e., expected or designed) to develop a short circuit across the ac power line. The speed of response (50-microsecond turn-off) is significantly faster than that of ordinary line circuit breakers or fuses, both of which react in milliseconds. The device can be applied to any circuit protection problem where speed of response is crucial.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Electrical machinery, apparatus, energy",Basic communication processes,,,,,H02H/08
4827125,2-May-89,1989,5,2,Confocal scanning laser microscope having no moving parts,A confocal scanning laser microscope has no moving parts and displays real time video images. The image of the scanned laser spot on the specimen is focused on the photocathode of an image dissector tube having an electron image deflection that is synchronized and aligned with the laser scan. This permits the confocal pinhole to be scanned at video rates. Acousto-optic deflectors are responsive to the frequencies of respective scan control signals to effect horizontal and vertical laser beam deflection.,22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Optics,,,,,,G02B/0036
4829000,9-May-89,1989,5,9,Reconstituted basement membrane complex with biological activity,"The present invention discloses a biologically active basement membrane composition. When polymerized under physiological conditions, the composition forms gel-like structures whose ultrastructure resembles interconnected thin sheets of the lamina densa zone of basement membrane. The major components of the composition include laminin, type IV collagen, heparin sulfate proteoglycan, entactin and nidogen. These components polymerize in constant proportions when redissolved and allowed to reconstitute. Molecular sieve studies on the soluble extract demonstrate that laminin, entactin and nidogen are associated in a large but dissociable complex. The reconstituted matrix is biologically active and stimulates the growth and differentiation of a variety of cells, including epithelial cells, nerve cells, hair follicles and the like. The reconstituted matrix can also be used for determining metastatic potential of tumor cells and for isolating metastatic tumor cells.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C12N/0018
4831175,16-May-89,1989,5,16,Backbone polysubstituted chelates for forming a metal chelate-protein conjugate,New polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates of the same are described together with the methods of preparing such compounds. A method of delivering radiolabelled compound of the present invention to a target site while minimizing the distribution of the compound to non-targeted organs or tissues is also disclosed.,8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07C/24
4832745,23-May-89,1989,5,23,Non-aqueous dental cements based on dimer and trimer acids,"Non-aqueous polycarboxylic acids such as dimer and trimer acids are reacted with a variety of polyvalent metal bases to yield a new, versatile class of cements. Many of these cements have unique energy-absorbing properties and excellent dimensional stability yielding mechanically tough and ductile materials. They also do not inhibit the polymerization of resin-based dental materials and thus can be formulated to yield hybrid resin-composite-cement materials. The bulky, hydrophobic nature of these acids with their relatively low carboxylic content results in cements that are low shrinking, hydrolytically resistant and biocompatible.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/876
4835182,30-May-89,1989,5,30,Enhancing drug delivery to the brain,"Tertiary butyl esters of anticancer drugs are provided which have the following formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of H, F, Cl, Br, and I and R.sub.2 can also be NH.sub.2 ; PA1 R.sub.3, R.sub.4, and R.sub.5 are the same or different and are selected from the group consisting of H, F, Cl, Br, I, and C.sub.1 -C.sub.3 alkyl; wherein alkyl may be substituted with F, Cl, Br, or I, with the proviso that at least two of R.sub.3, R.sub.4, and R.sub.5 are alkyl or substituted alkyl; and PA1 n=0-4. The compounds of the present invention can be used in treating cancer by significantly increasing the brain levels of the drugs of the invention and their active metabolites.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/42
4836206,6-Jun-89,1989,6,6,Method and device for determining viability of intact teeth,"An optical technique and device for assessing tooth vitality, involving the use of trans-illumination to detect differentially the relative absence of light absorbed by hemoglobin in circulating blood inside a healthy tooth. White light received from an illuminated healthy tooth is relatively devoid of intensity at a wavelength characteristic of absorption by hemoglobin, when compared with light following the same path in the tooth but of a longer wavelength, by taking the ratio of intensities of the two wavelengths the light of one wavelength is relatively more absorbed by hemoglobin or oxyhemoglobin than the other, indicating the relative amount of blood or oxygen in the blood present in the tooth at the time of the measurement. A broad-spectrum light source is rigidly coupled to a split-beam, differentially-filtered photometer incorporating relatively narrow band filters. Vitality is assessed from the ratio of the scattered light at the two wavelengths, and in change of this ratio overtime.",42,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/14551
4845036,4-Jul-89,1989,7,4,Process for isolation of the B oligomer of pertussis toxin,"A method for dissociating the B oligomer of pertussis toxin comprising incubating pertussis toxin in an aqueous solution of urea, sodium phosphate buffer, and a nucleotide selected from the group consisting of ATP and ADP, and optional zwitterionic detergent; applying the incubated solution to a CM-Sepharose column; and eluting the B oligomer from the column with potassium phosphate buffer containing urea.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/235
4852577,1-Aug-89,1989,8,1,High speed adaptive ultrasonic phased array imaging system,An ultrasonic phased array imaging system is provided which includes a normal mode and an adaptive mode of operation. The adaptive mode adjusts the delay associated with each element in the transducer such that the average image brightness of the region of interest is maximized. A motion detector is provided for determining when the transducer has been moved a distance sufficient to render the previous adaptive measurements possibly invalid whereupon the system automatically reenters the normal mode. A method of operating the ultrasonic phased array imaging system is also provided.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,,,,,A61B/0858
4857187,15-Aug-89,1989,8,15,Multistage mixer-settler centrifuge,A method and apparatus for chromatography employ a vibration driven mixing device mounted inside a column. One end of the mixing device is held in place by a stopper while the other end is free to vibrate back and forth. The mixture at the free end is efficiently mixed while the mixture at the held end remains undisturbed. The undisturbed portion can then be removed. This invention is particularly applicable to centrifugal chromatography where the vibration is produced by high frequency oscillation in the centrifugal force field.,7,The Government of the U.S. as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Measurement,,,,,B01D/08
4861710,29-Aug-89,1989,8,29,Recombinant DNA clone encoding laminin receptor,"The invention provides a recombinant cDNA clone encoding cell surface receptor for laminin, as well as a probe and methods of using that probe to diagnose the aggressiveness of a carcinoma or the effectiveness of an agent for treating cancer cells.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/705
4861759,29-Aug-89,1989,8,29,Antiviral compositions and methods,"Compositions containing 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, and dideoxyguanosine and their triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytopathic effects of human immunodeficiency virus (HIV).",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
4867404,19-Sep-89,1989,9,19,Flexible holder for a cystoscope or the like,"A flexible holder and clamping assembly for adjustably holding cystoscopes or other endoscopic instruments and retractors or the like adjacent to or on an examination tables or the like is equipped with a unique clamping assembly which permits the holding of various sized instrument shafts. The clamping assembly is equipped with a vertically adjustable spring-biased C-shaped, open-sided region which is urged into a normally open position. The instrument shaft is, after positioning relative to the patient, slid sideways into the C-shaped jaw and retained between the jaw and a pair of circumferentially opposing notches of a tubular housing. The clamp also includes a head portion having various openings and a cavity for receiving the parts and connections of the clamping assembly.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Mechanical elements,Medical technology,,,,,F16M/2085
4868107,19-Sep-89,1989,9,19,Method for detecting antibodies against neuropeptides and drugs in human body fluid,"An immunochemical assay, particularly an enzyme-linked immunosorbent assay has been developed to detect in a sample of human body fluid the presence of antibodies against neuropeptides or drugs. The assay makes it possible to correlate and diagnose psychobiological disorders related to the alteration in the normal level of neuropeptides or their receptors.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6896
4870161,26-Sep-89,1989,9,26,Reagents and probes for distinguishing and isolating different GTP-binding proteins,"Substantially pure, synthetic peptides corresponding to specific epitopic sites of various G-proteins and antibodies having binding affinity specifically for said epitopic sites have been prepared. Kit and method for identifying various G-proteins are also disclosed.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/18
4873192,10-Oct-89,1989,10,10,Process for site specific mutagenesis without phenotypic selection,"The present invention discloses several DNA mutagenesis processes using a DNA template containing several uracil residues in place of thymine, which can be applied without selection techniques to produce altered DNA sequences with approximately 10-fold greater efficiency than current methods of site-specific mutagenesis. This template has relatively normal coding potential in the in vitro reactions typical of standard site-directed mutagenesis protocols but is not biologically active upon transfection into a wild type (i.e., ung.sup.+) E. coli host cell. Expression of a desired change, present in the newly synthesized non-uracil-containing covalently closed circular complementary strand, is thus favored. The procedure has been applied to mutations introduced via both obligonucleotides and error-prone polymerization. The inclusion of two additional simple treatment steps before transfection results in a site-specific mutation frequency approaching 100%.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6827
4877774,31-Oct-89,1989,10,31,Administration of steroid hormones,"Crystalline complexes of steroid hormones with gamma-cyclodextrin are prepared by mixing the components together. Tablets can be formed from the complexes, which can be administered by contact with the mucosa to provide effective transfer of the hormones into the systemic circulation, gradually eliminating the hormones therefrom.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,,,,,B82Y/00
4879277,7-Nov-89,1989,11,7,Antiviral compositions and methods,"Compositions containing 2',3'-dideoxycytidine and its triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytophatic effects of human immunodeficiency virus (HIV).",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
4882346,21-Nov-89,1989,11,21,Chemical differentiating agents,"Several analogues of hexamethylene bis[acetamide] were found to be effective differentiating agents. The most effective of these compounds was 3,3'-(1,6-hexandiyl)bis[5,5-dimethyl-2,4-imidazolinedione].",4,The United States of America as reprsented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/415
4883761,28-Nov-89,1989,11,28,Pertussis toxin gene: cloning and expression of protective antigen,"The complete nucleotide sequence of the pertussis toxin gene and the deduced amino acid sequences of the individual subunits have been determined. All five subunits are coded by closely linked cistrons and possibly expressed through a polycistronic mRNA, since a promotor-like structure was found in the 5' flanking region. The order of the cistrons is S1, S2, S3, S4, S5, and S3. All subunits contain signal peptides of variable length. The calculated molecular weights of the mature subunits are 25,024 for S1, 21,924 for S2, 21,873 for S3, 12,058 for S4 and 11,013 for S5. All subunits contain signal peptides of variable length. Subunits S2 and S3 share 70% amino acid homology and 75% nucleotide homology. Subunit S1 contains two regions of eight amino acids homologous to analogous regions in the A subunit of both cholera and E. coli heat labile toxins. Functional domains in relation to the primary structure and the development of a safer, new generation vaccine against whooping cough are presented.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/235
4885238,5-Dec-89,1989,12,5,Immortalized human bronchial epitherial mesothelial cell lines,Immortalized human bronchial epithelial and human mesothelial cell lines have been obtained. Various uses of these cell lines have been described.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/0071
4886782,12-Dec-89,1989,12,12,Malarial immunogen,"The circumsporozoite (CS) protein of Plasmodium falciparum has been analyzed to develop a new anti-sporozoite malarial vaccine. Localization of sites for T-cell recognition on this molecule is critical for vaccine design. By using an algorithm designed to predict T-cell sites and a large panel of H-2 congenic mice, a major nonrepetitive T-cell was located. When a synthetic peptide corresponding to this site was covalently linked to the major B-cell site on the molecule, an immunogen capable of eliciting a high titer antibody response was formed. This peptide sequence is capable of priming helper T-cells for a secondary response to the intact CS protein. This site represents the first helper T-cell site described for the CS molecule outside of the repetitive region, and is a major immunodominant T-site on the molecule. The approach described herein is useful in the rational design and construction of more efficacious vaccines.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
4889137,26-Dec-89,1989,12,26,Method for improved use of heart/lung machine,Long term closed chest partial and total cardiopulmonary bypass by peripheral cannulation for severe right and/or left ventricular failure is achieved by the use of a percutaneous coil positioned in the pulmonary artery across the pulmonary artery valve to decompress the left heart.,7,The United States of America as reprsented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61F/95
4892814,9-Jan-90,1990,1,9,Method for distinguishing Creutzfeldt-Jakob disease from other dementias,A method for distinguishing Creutzfeldt-Jakob disease from other causes of human dementia by analyzing the cerebrospinal fluid of patients for proteins 130 and 131. The presence of these proteins indicates the presence of Creutzfeldt-Jakob disease.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6896
4892827,9-Jan-90,1990,1,9,Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects,Modified Pseudomonas exotaxins which comprise deletions in at least domain 1A are taught. The toxins exhibit reduced cytotoxicity.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/62
4892829,9-Jan-90,1990,1,9,Human plasma cell line having rearranged c-myc proto-oncogene,"Using a serum-free defined medium, a human cell line, NCI-H929, was established from a malignant effusion occuring in a patient with IgAk myeloma. The cultured cells have the morphologic, ultrastructural, biochemical, immunologic and cytochemical features of plasma cells. The cells have rearranged alpha and kappa genes and synthesize and secrete very high amounts of IgAk (>80 .mu.g/10.sup.6 cells/24 hr). The cells express surface immunoglobulin (alpha and kappa), the plasma cell antigen PCA-1, the transferrin receptor (T9) and T10, but lack antigens associated with earlier stages of B cell development (HLA-DR, B1, B2, B4, CALLA), as well as other leukocyte-macrophage antigens and Epstein-Barr virus nuclear antigen. While the tumor cells were predominantly near-diploid, the cultured cells are predominantly near-tetraploid with six copies of chromosome 8, four to six of which have an 8q+ abnormality. The cultured cells have a rearrangement of the cellular c-myc proto-oncogene (located at 8q24) and express c-myc RNA.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/163
4894013,16-Jan-90,1990,1,16,Anthropomorphic cardiac ultrasound phantom,"Apparatus and method are disclosed for producing ultrasound readings of simulated blood flow through a model left ventricle or larger portion of the human heart, held inside a fluid filled chamber with membrane-covered windows, and through mitral and aortic valves cooperating therewith to provide a simulated human circulation flow free of reverberation artifacts and the like. Adjustable flow of a selected hydraulic fluid into and out of the chamber that also contains a plurality of ultrasound absorbing elements disposed oppositely to the ultrasound viewing windows is utilized to produce ultrasound signals picked up by an ultrasound transducer for processing in any known manner. A range of flow rate and systolic characteristics of a heart are readily simulated, to provide outputs substantially free of reverberations and ultrasound reflections from the inside walls of the chamber as well as the ultrasound absorbing elements.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Control,,,,,G09B/286
4894228,16-Jan-90,1990,1,16,Vaccine against hepatitis A virus,The present invention provides an attenuated hepatitis A virus useful as a vaccine.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
4900748,13-Feb-90,1990,2,13,Carbamates related to (-)-physostigmine as cholinergic agents,"Highly potent analogs of (-)-physostigmine are provided which are potent inhibitors of acetylcholinesterase and butyrylcholinesterase. These compounds are useful in treatment of glaucoma, Alzheimer's disease, myasthenia gravis, and organophosphate poisoning.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4902495,20-Feb-90,1990,2,20,IgE Fc directed delivery system,An immunotoxin comprising a conjugate of a toxin with immunoglobulin E or a part thereof and a method delivering the same to a target site is described. Mast cell related abnormalities can be detected by the immunotoxin of the present invention.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1093
4908322,13-Mar-90,1990,3,13,Derivatization of amines for electrochemical detection,"Primary and secondary amines in biological fluids are selectively derivitized by reaction with esters of N-hydroxysuccinimide or N-hydroxysulfosuccinimide to form an N-acylated derivative. Those N-acylated derivatives may then be extracted into a polar organic phase and extracted. Non-electroactive amines may be made suitable for coulometric analysis by selecting the ester used so as to attach an electroactive group to the amine. For example, histamine may be reacted with the Bolton-Hunter reagent to form a suitable derivative in high yield.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/52
4911166,27-Mar-90,1990,3,27,Portable light delivery system,"A device for delivering high intensity light to a patient's eyes for treating seasonal affective disorder and the like uses a point source of light such as a high intensity halogen or other incandescent bulb, and directs a large fraction of the light from the bulb directly into the patient's eyes without focusing the light in such a way as to cause damage to the eye or discomfort to the patient. This is accomplished by the use of a positive lens which focuses the light from the high intensity bulb directly in front of the patient's eyes. The light appears to the patient to be coming from an area much larger than the actual point source, and hence is more comfortable for the patient. The patient is assured of receiving a significant dosage of light no matter which way he is directing his gaze.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/00
4911690,27-Mar-90,1990,3,27,Treatment or diagnosis by endoscopic administration into the lymphatics,The invention provides a method of delivering therapeutic or diagnostic reagents to the lymphatic system. In the preferred method the delivery is accomplished by use of a fiberoptic endoscope equipped with an aspiration cytology needle. The method provides an especially useful means of delivering labeled monoclonal antibodies.,23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,,,,,A61M/00
4912111,27-Mar-90,1990,3,27,Use of minoxidil for wound healing,"A method for the promotion or acceleration of wound healing by a treatment with minoxidil is disclosed. The minoxidial can be administered by topical application, oral administration, injection or any combination thereof. Treatment with minoxidil is effective for promoting the migration of epithelial cells in a wound or in tissues such as cornea and the like. Methods for identifying binding sites for minoxidil in cells based on their affinity for the compound in attachment or chemotactic assays are described.",14,The Upjohn Company,NIDR NIH,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/505
4912206,27-Mar-90,1990,3,27,CDNA clone encoding brain amyloid of alzheimer's disease,Four clones have been isolated from an adult human brain cDNA library using an oligonucleotide probe corresponding to the first 20 amino acids of the brain amyloid polypeptide of the Alzheimer's disease. The open reading frame of the sequenced clone coded for 97 amino acids including the known amino acid sequence of this polypeptide. The 3.5 kb messenger RNA has been detected in mammalian brains and human thymus. The gene is highly conserved in evolution and been mapped to human chromosome 21.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4711
4914608,3-Apr-90,1990,4,3,In-vivo method for determining and imaging temperature of an object/subject from diffusion coefficients obtained by nuclear magnetic resonance,"A method of determining and imaging the temperature or temperature change of a liquid or solid object by NMR placing the object in a magnetic field B.sub.o at a temperature T.sub.o.sup.i, subjecting the object or a limited volume thereof to a first series of NMR imaging sequences to obtain first numerical values or images of molecular diffusion coefficients D.sub.o for individual points of the object or the limited volume thereof and recording the first series of images, maintaining the object or limited volume thereof at a temperature T.sup.i or waiting for a spontaneous change to the temperature, subjecting the object to a second series of magnetic resonance imaging sequences to obtain second numerical values or images of molecular diffusion coefficients D.sup.i for the same points of the object or the limited volume thereof and recording the second series of images, comparing point-by point the values or images of the diffusion coefficients D.sub.o.sup.i with the values or images of the diffusion coefficients D.sup.i to generate a third series of values or images representing temperature changes dT.sub.i and recording the third series of images for each point of the object or limited volume thereof from the formula EQU dT.sub.i =(kT.sub.o.sup.2 /E) Log (D/D.sub.o).sub.i wherein k is Boltzman's constant (1.38 10.sup.-23 J/K) and E is the activation energy (.apprxeq.0.2 eV at 20.degree. C.), provided dT.sub.i <<T.sub.o.sup.i and E.apprxeq.constant, repeating the steps for different points of the object to monitor temperature changes dT.sub.i at the various points, and determining the absolute temperature T.sub.o.sup.i for each measured point of the object or limited volume thereof and obtaining the absolute temperature T.sup.i for each measured point from the formula T.sup.i =T.sub.o.sup.i +dT.sub.i.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/4804
4919803,24-Apr-90,1990,4,24,Liquid chromatographic chiral stationary phase,"A novel packing material for liquid chromatographic use is disclosed. This packing material is prepared by covalently bonding (S)- or (R)-6-methoxy-.alpha.-methyl-2-naphthaleneacetic acid (naproxen) to aminopropylsilanized silica. The resulting chiral stationary phase is effective for the resolution of enantiomeric (RS)-naproxen, and of other racemic .alpha.-methylarylacetic acids.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Organic fine chemistry,,,,,B01J/3204
4923985,8-May-90,1990,5,8,Process for synthesizing macrocyclic chelates,"A process for synthesizing a 12 membered ring tetraaza macromolecule comprising. The process involves condensing an amide of ethylene diamine having a general formula A: ##STR1## wherein n is an integer from 1 to 5 and w is a member selected from the group consisting of --NO.sub.2, --NH.sub.2, --NCS, --COOH, --OCH.sub.2 OOCH.sub.3, --NCOCH.sub.2 --Z with Z being a member selected from the group consisting of Br and I with a nitrogen blocked active ester of a general formula B: ##STR2## wherein PG is an amino protecting group and E is a leaving group.",6,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/02
4925799,15-May-90,1990,5,15,Plasmid cloning vector pAS1,"A plasmid cloning vector containing both transcriptional and translational regulatory sequences derived from the bacteriophage lambda genome was constructed to achieve high level expression of prokaryotic and eukaryotic genes. The system utilizes a plasmid vehicle carrying the strong, regulatable lambda promoter, P.sub.L, and host lysogens into which this vector can be stabily transformed. The lysogen synthesizes sufficient repressor (cI) to control P.sub.L expression and thereby stabilize plasmids which carry such a highly efficient promoter. Use of a temperature sensitive repressor permits simple, rapid induction of P.sub.L transcripts at any given time. Efficient transcription of essentially any coding sequence is assured by providing the phage lambda antitermination factor, N, and a site on the transcription unit for its utilization (Nut site). This pAS1 plasmic closely resembles the earlier constructed pKC30cII, also a regulatory protein which activates promoters for lysogenic development.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/73
4925800,15-May-90,1990,5,15,Monoclonal antibody against human pneumocystis carinii,Hybridomas producing antibodies having specific binding affinity against Pneumocystis carinii having been obtained and a method and kit for detecting P. carinii infection in humans having been described.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/14
4927628,22-May-90,1990,5,22,Vaccine against rotavirus diseases and method of preparing same,"A new method for producing live, attenuated rotavirus strains suitable for preparing a vaccine is described. It is demonstrated that a naturally attenuated rotavirus recovered from newborns or other individuals whos have undergone asymptomatic infection can be used for immunization or that a virulent rotavirus can be converted into an attenuated strain by substituting the conserved fourth rotavirus gene segments of a naturally attenuated rotavirus in the genome of the virulent rotavirus.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
4931393,5-Jun-90,1990,6,5,Non-infectious mutant clone of HIV,The present invention is related to providing a non-infectious molecular clone of a mutant HIV and HIV proteins useful as immunogens and reagents for diagnostic kit.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
4933274,12-Jun-90,1990,6,12,Process for detecting genetic susceptibility to cancer,"A process for determining genetic susceptibility to cancer is disclosed in which the frequency of chromatid breaks and gaps is calculated in metaphase skin fibroblasts or stimulated peripheral blood lymphocytes after x-irradiation or fluorescent light exposure. Susceptibility to cancer is found when the frequency of breaks and gaps in the cell sample is two to three-fold higher than that occurring in comparable cells from control individuals. Various factors have been found which influence the accuracy of the test results. These factors include pH, temperature, cell density, culture medium or serum, microbial contamination and visible light exposure (effective wavelength 500 nm). Additionally, because of experimental variability, known normal controls are suggested for use in each test group.",11,United States of America Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/68
4935367,19-Jun-90,1990,6,19,Novel restriction endonuclease,"A new restriction enzyme, Mfe I, has been discovered. Mfe I recognizes the sequence CAATTG and cuts at the recognition sequence C'AATTG and generates compatible cohesive ends with EcoRI cleaved fragments. Various utilities of the enzyme have been described.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/22
4935427,19-Jun-90,1990,6,19,"Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents","Compounds which are active against retroviruses have the following formula EQU HOH.sub.2 C--CH.dbd.C.dbd.CH--B wherein B is a purine or pyrimidine heterocyclic ring which is preferably selected from the group consisting of cytosine, 5-halo substituted cytosine, 5-alkyl substituted cytosine, 6-aminopurine, 2,6-diaminopurine, 6-hydroxypurine, 2-amino-6-hydroxypurine, 3-deazapurines, 7-deazapurines, 8-azapurines, and 6-azapyrimidines.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
4939149,3-Jul-90,1990,7,3,Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization,"The present invention relates to a method for desensitizing a subject animal, which comprises administering to the subject animal a therapeutically effective desensitizing amount of resiniferatoxin for desensitizing the subject animal to neurogenic inflammation, to chemically and thermally induced pain and to responses involving sensory afferent pathways sensitive to capsaicin and to responses involving the hypothalamic temperature control region, and a pharmaceutically acceptable carrier therefor.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/335
4940896,10-Jul-90,1990,7,10,Pyroelectric calorimeter,"A pyroelectric detector comprises a support member having a tapered through-hole therein, a first polyester film positioned on said support member, across said through-hole, an aluminum foil member located on an opposite side of said polyester film from said support member, a pyroelectric film located on an opposite side of said aluminum foil member from said first polyester film, at least one additional polyester film located on an opposite side of said pyroelectric film from said aluminum foil member, and two pyroelectrical leads connected to opposite sides of said pyroelectric film.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/482
4942184,17-Jul-90,1990,7,17,"Water soluble, antineoplastic derivatives of taxol","Antineoplastic, water soluble, taxol derivatives and methods for preparing the same are described.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/495
4943579,24-Jul-90,1990,7,24,Water soluble prodrugs of camptothecin,Water-soluble derivatives of camptothecin have the formulae: ##STR1## wherein R' is selected from the group consisting of R=CO CH.sub.2 NH.sub.2.HCl PA1 R=CO CH.sub.2 NHCH.sub.3.HCl PA1 R=CO CH.sub.2 NHC.sub.2 H.sub.5.HCl PA1 R=CO CH.sub.2 N(C.sub.2 H.sub.5).sub.2.HCl PA1 R=CO CH(NH.sub.2) CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 NH.sub.2.2HCl PA1 R=CO CH(NH.sub.2) CH.sub.2 CH.sub.2 COOH. HCl PA1 R=CO CH.sub.2 CH.sub.2.COO.sup.- Na.sup.+ PA1 R=HPO.sub.3.sup.- Na.sup.+,3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/22
4954526,4-Sep-90,1990,9,4,Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents,"A method of treating cardiovascular disorders in a mammal, by administering to said mammal an effective amount of a compound of the formula: EQU [R--N(H)N(NO)O--].sub.y X wherein R is loweralkyl, aryl, arylalkyl, or cycloalkyl, any of which R groups may be optionally substituted by one to three substituents selected from the group consisting of: halo, hydroxyl, alkoxy, amino, amido, formyl, carboxyl, or nitro; and wherein X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from loweralkyl, acyl or amido, and Y is 1 to 3 consistent with the valence of X. Pharmaceutical compositions containing the compounds are also provided.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/13
4963497,16-Oct-90,1990,10,16,Isolation and purification of the eighth gene of HTLV-III,"The present invention is the isolation and purification of a newly discovered gene of the AIDS virus, HTLV-III, which encodes a protein which is immunogenic and recognized by sera of some HTLV-III seropositive people. Furthermore, the gene is highly conserved among all known HTLV-III isolates and exhibits a polymorphism at the 3' end which distinguishes molecular clones of the HTLV-III cell line from viral genomes of related viruses (i.e., other HTLV-III isolates, LAV, ARV, etc.).",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
4967372,30-Oct-90,1990,10,30,Automatic orientation and interactive addressing of display,"Automatic orientation of predefined chemical structures in conjunction with a computer terminal employs respective protocols corresponding to a system state. The system states can include a chain state, ring state, library state, and retrieve state. Upon orientation, the object is attached according to a specified attachment command to a parent graph. The protocols corresponding to connection of the object to the parent includes rules regarding angles at which the structures can be attached to one another, and another protocol governs rules respecting rotation of the stored object through predetermined angles. Nodes of the object recalled are automatically provided with markers in alphabetic order from the most recently used marker corresponding to a letter of alphabet. Multiple alphabet sequences are used. Specification of position is indicated by inputting the lower case letter of the alphabet corresponding to the location desired. Bonds can be specified between two markers.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/60
4967764,6-Nov-90,1990,11,6,Pressure sensor element to measure contact stress,"A biological inplantable pressure sensor element comprises a fixed volume pouch formed by a sealed, flexible, impermeable membrane comprising therewithin a gel mass contained in a gel volume, said gel being hydrated with an aqueous solution comprising an agent having at least a first and a second NMR-detectable form, the proportion of the first to the second form of the agent in the gel volume being determined by their electrolytic interaction with the gel, whereby when an external pressure is applied to the sensor element a d(chemical shift)/d(.sigma./K) greater than 0.0001 ppm is attained, wherein .sigma. is the external pressure and K is the modulus of the gel. A kit contains sterile, individually wrapped sensor elements. A method of measuring in vivo contact stress applied to an implanted pressure sensor element, comprises implanting the pressure sensor of the invention into a situs of a subject in need of such measurement, non-invasively subjecting the subject situs to a nuclear magnetic resonance source effective to detect said NMR-detectible agent, obtaining the NMR spectrum of said agent, obtaining the chemical shifts from the spectrum, repeating steps (b) to (d) at least once at a desired time interval, comparing the chemical shifts obtaining in step (d) at different time intervals, and calculating the contact stress applied to said sensor element at a desired time from a correlation of observed chemical shifts for normalized stresses (.sigma./K) for the sensor element. A method of measuring in vitro contact stress applied to a pressure sensor element, comprises placing the stress sensor element of the invention in contact with a biological tissue in culture, non-invasively subjecting the biological tissue to a nuclear magnetic resonance source effective to detect said NMR-detectible agent, obtaining the NMR spectrum of said agent, obtaining the chemical shifts from the spectrum, repeating steps (b) to (d) at least once at a desired time interval, comparing the chemical shifts obtained in step (d) at different time intervals, and calculating the contact stress applied to said sensor element at a desired time from a correlation of observed chemical shifts to normalized stresses (.sigma./K) for the sensor element.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Medical technology,,,,,A61B/03
4968601,6-Nov-90,1990,11,6,Method for diagnosing latent viral infection,A method for diagnosing latent viral infection is described. The method utilizes an agent such as OKT3 to stimulate CD3 receptor complex on T-cell line so that the latent virus harbored in the T cells is expressed and then the virus is identified by standard techniques.,13,The United States of America as represented by the Dept. of Health & Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/70
4968672,6-Nov-90,1990,11,6,Adenosine receptor prodrugs,"A functionalized congener approach to drugs acting at A.sub.1 and A.sub.2 adenosine receptor types is applicable to prodrug design. The prodrugs affect a more efficient delivery of the drug at the particular site of the body affected and take advantage of selective biochemical cleavages and alteration in distribution characteristics. In particular, kidney functions and lipid functions are stressed in the invention.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
4968690,6-Nov-90,1990,11,6,"3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it","The new compound 3-deazaneplanocin A has been discovered to have potent anti-viral, anti-tumor activity and differentiating activity. A simple method for preparing 3-deazaneplanocin A has been developed involving nucleophilic substitution, which method can also be used to prepare a great variety of carbocyclic nucleosides.",4,United States Government as represented by the Secretary of the Dept. of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
4968692,6-Nov-90,1990,11,6,Attenuation of ethyl alcohol intoxication with alpha-2 adrenoceptor antagonists,"A method is provided for attenuating the intoxicating effects of ethyl alcohol in a patient, by administering to a patient in need thereof, an alpha-2 adrenoceptor antagonist compound. Two preferred compounds useful in the present invention, each being a highly potent and selective alpha-2 adrenoceptor antagonist, are atipamezole and idazoxan.",9,"The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/415
4970162,13-Nov-90,1990,11,13,Human-mouse hybrid cell line expressing monocyte-macrophage properties,"Human leukocytes, which contain monocytes and neutrophils that exhibit chemotaxis to N-formylmethionine-leucine-phenylalanine (FMLP), were fused with the mouse macrophage RAW264-TG3 cell line which exhibits chemotaxis to endotoxin-activated mouse serum (EAMS) but not to FMLP. From such fusions twelve cell lines were isolated, all of which migrated to EAMS. Four of the cell lines also exhibited chemotaxis to FMLP, and of these cell lines only one, WBC264-9, retained the capacity to migrate to FMLP after culture for 20 or more passages. WBC264-9 exhibits chemotaxis to FMLP and provides a novel system to investigate attractant-specific biochemical reactions necessary for chemotaxis.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/166
4974461,4-Dec-90,1990,12,4,Anthropomorphic cardiac ultrasound phantom,"Apparatus and method are disclosed for producing ultrasound readings of simulated blood flow through a model left ventricle or larger portion of the human heart, held inside a fluid filled chamber with membrane-covered windows, and through mitral and aortic valves cooperating therewith to provide a simulated human circulation flow free of reverberation artifacts and the like. Adjustable flow of a selected hydraulic fluid into and out of the chamber that also contains a plurality of ultrasound absorbing elements disposed oppositely to the ultrasound viewing windows is utilized to produce ultrasound signals picked up by an ultrasound transducer for processing in any known manner. A range of flow rate and systolic characteristics of a heart are readily simulated, to provide outputs substantially free of reverberations and ultrasound reflections from the inside walls of the chamber as well as the ultrasound absorbing elements.",6,The United States of America as represented by Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Control,,,,,A61B/587
4975434,4-Dec-90,1990,12,4,Antiviral and anticancer cyclopentenyl cytosine,"Cyclopentenyl pyrimidine compounds have potent anti-viral, anti-tumor and differentiating activity. Of these compounds, cyclopentenyl cytosine has proved to be particularly effective in a variety of tumors, as well as having good antiviral activity and potent differentiating properties.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/47
4977244,11-Dec-90,1990,12,11,Uromodulin and a process of purifying it,"This invention relates to processes for producing uromodulin, a glycoprotein having a molecular weight of 85 kilo daltons. This glycoprotein, which is isolated from crude urine, as well as its carbohydrate derivatives, are useful as immunosuppressive agents or anti-inflammatory agents.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/22
4982339,1-Jan-91,1991,1,1,High speed texture discriminator for ultrasonic imaging,"Tissue signatures are obtained from first and second order statistics of an image texture to discriminate between different normal tissues and to detect abnormal conditions. These signatures described intrinsic backscatter properties of the tissue imaged and are used as the basis of an automatic tissue characterization algorithm. A device for on-line classifying of the texture of an image measures a total of four first and second order statistical properties of echo signals of a region of interest (ROI) selected by an operator, the echo signals being contained in an image memory. These can be used to obtain the tissue signatures, to detect low contrast lesions by machine, and to produce parametric images.",20,The United States of America as represented by Department of Health and Human Service,,,,,,,,,,,1,Medical technology,Measurement,,,,,A61B/463
4986256,22-Jan-91,1991,1,22,Use of paramagnetic metalloporphyrins as contrast agents for tumors in MRI imaging,"Water-soluble paramagnetic metalloporphyrins are used as contrast enhancing agents for magnetic resonance imaging. These agents exhibit excellent localization, non-toxicity and suprisingly high contrast enhancement in magnetic resonance imaging applications.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Pharmaceuticals,,,,,G01R/5601
4986703,22-Jan-91,1991,1,22,Auxiliary control technology for routers,"A dust collecting assembly for use with a machine tool having a rotating tool bit, which includes means for applying a plurality of parallel jets of air in the direction of particles as they are removed from a workpiece by the tooling operation. The jets of air are directed to slow down the particles so that they may be removed by a vacuum exhaust system. In applying the method to multi-directional tooling operations a plurality of jets surround the entire work area and selected subgroups of the jets are activated which oppose the trajectory of removed particles as the direction of the tooling operation changes.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Machine tools,,,,,,B23Q/006
4992472,12-Feb-91,1991,2,12,Chemical differentiating agents,"Several analogues of hexamethylene bis[acetamide] were found to be effective differentiating agents. The most effective of these compounds was 3,3'-(1,6-hexandiyl)bis[5,5-dimethyl-2,4-imidazolinedione].",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/415
4994370,19-Feb-91,1991,2,19,DNA amplification technique,"A modification of the polymerase chain reaction (PCR) technique is described. The method allows the amplification of regions of DNA flanking a single region of known sequence, in contrast to standard PCR which requires two regions of known sequence at opposite ends of the fragment to be amplified. Various advantages of the new method are described.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/686
5003097,26-Mar-91,1991,3,26,Method for the sulfurization of phosphorous groups in compounds,"A method is disclosed for the sulfurization of a phosphorus containing compound, which comprises: solubilizing the phosphorous containing compound and then contacting the phosphorous containing compound, with a sulfur containing compound of the solution formula: ##STR1## wherein, B is selected from the group consisting of --CH.sub.2 --, --C(O)-- or --C(S)--; PA1 Q is a non-interfering moiety or radical; and PA1 m and n, same or different, are selected from the group consisting of zero or one.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
5004457,2-Apr-91,1991,4,2,Tissue transplantation system,"The transplantation of donor tissue into the brain is effected by locking the head relative to a stereotaxic unit; penetrating the brain with a first cannula to a predetermined depth to create a transplant site within the brain while the first cannula is fixed by the stereotaxic unit relative to the brain; then feeding a second cannula, which contains donor tissue at its distal end, through the already fixed first cannula so that the distal end of the second cannula comes to rest at the transplant site; and finally withdrawing the first cannula and the second cannula so as to leave the donor tissue at the transplant site.",4,The United States of Americas as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/11
5006122,9-Apr-91,1991,4,9,Tissue transplantation system,"The transplantation of donor tissue into the brain is effected by locking the head relative to a stereotaxic unit; penetrating the brain with a first cannula to a predetermined depth to create a transplant site within the brain while the first cannula is fixed by the stereotaxic unit relative to the brain; then feeding a second cannula, which contains donor tissue at its distal end, through the already fixed first cannula so that the distal end of the second cannula comes to rest at the transplant site; and finally withdrawing the first cannula and the second cannula so as to leave the donor tissue at the transplant site.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/11
5006330,9-Apr-91,1991,4,9,Evaluative means for detecting inflammatory reactivity,"Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis. Conversely, treatment of F344/N rats with the glucocorticoid receptor antagonist, RU 486, or the serotonin (5-HT.sub.2) antagonist, LY53857, was associated with development of severe inflammatory disease, including arthritis, in response to SCW. These findings support the concept that susceptibility of LEW/N rats to SCW arthritis is related to abnormal hypothalamic-pituitary-adrenal (HPA) axis responsiveness to inflammatory and other stress mediators and that resistance of F344/N rats to SCW arthritis is regulated by an intact HPA axis-immune system feedback loop.",11,The United States of America as represented by the of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,G01N/5091
5008262,16-Apr-91,1991,4,16,Method of treating trichotillomania and onchyphagia,The instant invention is drawn to the use of clomipramine for treating trichotillomania and onchyphagia.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/55
5008449,16-Apr-91,1991,4,16,Method of synthesis of hydroxy-substituted-4-alkoxyphenylacetic acids,A process for preparing hydroxy-substituted-4-alkoxyphenylacetic acids by reacting a 4-alkoxyphenylacetic acid with bromine and then treating the brominated acid with a strong base and a copper salt to form the desired hydroxy-substituted-4-alkoxyphenylacetic acid.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07C/363
5008831,16-Apr-91,1991,4,16,Method for producing high quality chemical structure diagrams,A computer operated method for transforming the appearance of a chemical structure entered into a computer wherein at least one alternate equivalent structure is generated within the computer (or by keyboard entry). A series of parameters applicable to chemical structures are established along with values for such parameters. Following that it is established which of such parameters are present in the first structure and the values thereof are summed to obtain a score. The parameters present in the alternate structures are then established and summed to establish a score for each. The scores are then compared and the highest score is selected and the structure corresponding to the highest score is outputted or printed.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/206
5010020,23-Apr-91,1991,4,23,Quick color test to detect lead release from glaze and enamel coatings,A color test is presented for the purpose of quickly identifying glaze or enamel coatings which releases excessive Pb. Citric acid solution on filter paper is used to extract Pb from the coatings and a Pb sensitive chromogen indicates the presence of Pb on the paper. The quick color test takes approximately 30 minutes to complete. The kits are also provided for determining whether excessive Pb is present in a glaze or enamel coating.,22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/22
5010080,23-Apr-91,1991,4,23,Use of heterocyclic amides to inhibit tumor metastasis,"A method of inhibiting tumor metastasis in an animal without treating the tumor cells by administering to said animal a metastasis inhibiting effective amount of a heterocyclic amide represented by the formula: ##STR1## wherein: R.sub.1 and R.sub.2 are the same or different members of the group consisting of halo, phenyl, substituted phenyl and a ##STR2## group wherein q, r and t are independently an integer of from 1 to 8 provided that q+r+t is equal to or less than 10; Y is thio or sulfinyl; alk is straight or branched chain lower alkylene, and R.sub.3 is a heterocyclic amine represented by the formula: ##STR3## wherein R.sub.4 is selected from the group consisting of hydrogen, lower alkyl, phenyl, substituted phenyl, benzyl, or substituted benzyl; p is 0 to 2; or a pharmaceutically acceptable salt thereof.",6,G. D. Searle & Co.,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/495
5021450,4-Jun-91,1991,6,4,"New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof","The present invention relates to a new class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions thereof, processes for preparing the same, and uses thereof. Compounds of the invention are prepared by combining phorbol related diterpenses and homovanillac acid analogs via esterification at the exocyclic hydroxy group of the diterpene. Examples of these compounds include 20-homovanillyl-mezerein and 20-homovanillyl-12-deoxyphorbol-13-phenylacetate.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/10
5024758,18-Jun-91,1991,6,18,"Horizontal flow-through coil planet centrifuge with multilayer plural coils in eccentric synchronous rotation, suitable for counter-current chromatography","A horizontal flow-through coil centrifuge provides a very long continuous partition facilitating passage through a plurality of serially connected multilayer helical tubing coils subjected to a rotary motion at a selected angular velocity about a column assembly axis and, simultaneously, a revolving motion of that axis about a stationary horizontal axis at the same angular velocity therearound. The passage of a fluid mobile phase containing solute through the very long length of tubing generates a commensurately long dwell time of the solutes in the complex gravitational/centrifugal acceleration field through a relatively large volume of a fluid stationary phase held in the moving tubing, thus enabling very sensitive chromatographic separations of constituents between the two fluid phases. Gearing and speed and temperature controls are provided in the apparatus to ensure that inflow/outflow tubing remains free of twisting and allowing use at a variety of operational speeds and fluid temperatures.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
5025796,25-Jun-91,1991,6,25,Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject,A method for discerning a peripherally-mediated response to thermal simulation caused by a drug in an unrestrained subject is disclosed whereby it can be determined if the drug acts substantially like the placebo. Also disclosed is a method of determining the response to thermal stimulation caused by a drug in an unrestrained subject by determining the difference between the drug withdrawal latency time period and the placebo withdrawal latency time period. Also disclosed is a method of discerning a peripheral response to thermal stimulation in an unrestrained subject by comparing the withdrawal latency time period of one site with that of a second site.,12,The United States of America as represented by the Department of Health and Human Services STA WA COD 06,,,,,,,,,,,1,Medical technology,,,,,,A61B/4824
5026687,25-Jun-91,1991,6,25,"Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds","A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2',3'-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2',3'-dideoxyinosine to minimize certain side effects.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
5026785,25-Jun-91,1991,6,25,"Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates","Avidin and streptavidin modified water-soluble polymers are provided, such modified polymers being exemplified by, but not limited to, water-soluble polyacrylamides being substituted by multiple substituents of avidin or streptavidin. The avidin and streptavidin modified polymers provided, may be stored, and later used to bind biotinylated antibiodies, biotinylated toxins, or biotinylated isotope-labelled proteins, thus producing homo- or heteroconjugates of known composition. A process for the preparation of certain of the avidin or streptavidin modified polymers and conjugates thereof is also provided.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,"Macromolecular chemistry, polymers",,,,,G01N/545
5026826,25-Jun-91,1991,6,25,Human neutrophilic granulocyte end-stage maturation factor and its preparation and use,A purified inhibitor free human neutrophilic granulocyte end-stage maturation factor (GMF) inhibitor-free human neutrophilic granulocyte end-stage maturation factor is disclosed. The GMF is distinct from granulocyte colony stimulating factor (G-CSF) in both physical and biological properties.,6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/52
5027694,2-Jul-91,1991,7,2,Variable air flow eddy control,"Methods and apparatus for controlling the flow of fluid around an object which include means to periodically vary or fluctuate the direction, speed or magnitude of the fluid flow. The fluid flow is particularly controlled to control eddy formation. The fluid is preferably a gas or vapor.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B08B/02
5028425,2-Jul-91,1991,7,2,Synthetic vaccine against P. falciparum malaria,A purified peptide which induces proliferation or activation of cytotoxic T cells specifically against circumsporozoite protein of P. falciparum is described. The peptide has an amino acid sequence KPKDELDYENDIEKKICKMEKCS in single letter amino acid code.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
5030012,9-Jul-91,1991,7,9,Pyroelectric calorimeter,"A pyroelectric calorimeter including a detector having a support member with a tapered through-hole therein, a first polyester film positioned on said support member, across said through-hole, an aluminum foil member located on an opposite side of said polyester film from said support member, a pyroelectric film located on an opposite side of said aluminum foil member from said first polyester film, at least one additional polyester film located on an opposite side of said pyroelectric film from said aluminum foil member, two pyroelectrical leads connected to opposite sides of said pyroelectric film, a support for the detector and electrical circuitry for receiving a signal produced from the detector and for generating an output signal therefrom.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/482
5030449,9-Jul-91,1991,7,9,Synthetic vaccine against AIDS virus,"The invention relates to peptide antigens which stimulate helper T lympocytes which specifically recognize HIV envelope protein, thereby enhancing antibody production and cytotoxic T cells to inhibit expression of an infection caused by HIV virus.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5030578,9-Jul-91,1991,7,9,Process for the purification of C1-inhibitor,"C1-inhibitor (C1-Inh), the major regulatory protein of the classical pathway of complement activation, can be purified in a new, simplied three step procedure which includes PEG fractionation, jacalin-agarose chromatography and hydrophobic interaction chromatography on phenyl-Sepharose which takes advantage of the marked hydrophilicity of the inhibitor. This procedure has major advantages over those which have been the most frequently used. This method may be highly adaptable to bulk purification for clinical use or for performing analytical or functional studies on genetically or pathologically altered C1-Inh from clinical specimens.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Biotechnology,,,,,G01N/84
5030642,9-Jul-91,1991,7,9,Acylaminoalkylpyridineamides as inhibitors of metastasis,"The present invention relates to a method of inhibiting tumor metastasis in an aminal by administering to an animal in need of such treatment an acrylaminoalkylpryridineamides represented by the formula ##STR1## wherein: R.sub.1 and R.sub.2 are the same or different members of the group consisting of halo, phenyl, substituted phenyl and a ##STR2## group wherein n, m and p are independently an integer of from 1 to 8 provided n+m+p is equal to or less than 10; x is thio or sulfinyl; Alk.sub.1 is straight or branched chain lower alkylene of 1 to 6 carbon atoms, R.sub.3 is hydrogen or lower alkyl, Alk.sub.2 is straight or branched chain alkylene of 1 to 4 carbon atoms; R.sub.4 is selected from the group consisting of hydrogen, halo, hydroxy, lower alkyl and lower alkoxy; or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit tumor metastasis.",9,G. D. Searle & Co.,"The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/44
5037376,6-Aug-91,1991,8,6,Apparatus and method for transmitting prosthetic information to the brain,"An apparatus and method for transmitting prosthetic information to the brain contains an array of sensory elements that receive energy from an external stimulus and process those signals via neural filters and neural waveforms to produce a pulse or `spike` train that is temporally encoded with information that is functionally related to the external stimulus. The simulated spike trains, when applied to an appropriate area of the brain, produce perceptions that are functionally related to the sensed external stimuli so that a subject can discriminate between different spike trains representative of different external stimuli.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61N/36046
5039705,13-Aug-91,1991,8,13,Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof,"This invention concerns anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are independently chosen from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl groups; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group, M.sup.+ is a pharmaceutically acceptable cation, wherein X is the valence of the cation.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/30
5039801,13-Aug-91,1991,8,13,Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines,"The invention provides an improved method for obtaining optically active amines, carbamates, and isocyanates by thermal fragmentation of optically active ureas through refluxing the ureas in C.sub.3 -C.sub.7 alcohol solution with or without catalytic amounts of alkali metal.",16,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5041372,20-Aug-91,1991,8,20,Probe to identify enteroinvasive E. coli and Shigella species,The invention provides a method for preparation of probes for use in detecting enteroinvasive Escherichia coli and Shigella species. The small probes provide reliable and inexpensive means for detecting the pathogens in food samples and in environmental and clinical samples.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/24
5044363,3-Sep-91,1991,9,3,Adsorption system for scavenging anesthetic agents from waste gas released during surgical activity,"A cartridge loosely containing powdered activated charcoal is connected to a conventional anesthetic administration system of the type commonly used in veterinary surgical facilities. The cartridge is readily supported by a conventional anesthetic cart and is usable in both rebreathing and pass-through operation of the anesthetic-administration system. Gases of vaporized anesthetic substances that typically are released from the pop-off valve of liquid anesthetic containers or in the exhalations from the animal patient are both selectively directed through the activated charcoal without the need for motors, blowers, or other devices requiring power. The invention utilizes commonly available materials such as PVC pipe and end fittings, powdered activated charcoal and fiberglass filter elements, and assorted commercially available pipe fittings. In relatively compact form, this invention enables the removal of approximately 95% of anesthetic substances that otherwise would be released where they would likely be breathed in by and do harm to surgery personnel. The cartridge may be shaken to rearrange the particles of activated charcoal, to thereby generate new gas-flow paths between newly-exposed surfaces that can adsorb more anesthetic substances.",13,The United States of America as represented by the Department of Health and Human services,,,,,,,,,,,1,Medical technology,,,,,,A61M/009
5049662,17-Sep-91,1991,9,17,Kit for diagnosing cancer metastatic potential,A new NM23 gene and its relationship with metastatic potential of tumor cells is described.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5050609,24-Sep-91,1991,9,24,Magnetization transfer contrast and proton relaxation and use thereof in magnetic resonance imaging,"A nuclear magnetic resonance method is provided for monitoring and imaging the exchange of magnetization between protons in free water and protons in a relatively immobilized pool of protons in a sample. The method provides a new form of contrast for nuclear magnetic resonance imaging of samples such as biological tissues, polymers, and geological samples.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/5605
5050616,24-Sep-91,1991,9,24,Universal collector for submandibular-sublingual saliva,"A fluid sampling device for sampling and collecting biological fluids from membrane bounded areas of a subject includes a buffering chamber to which a vacuum is applied, a sampling tube connector, a storage tube connector and a vent. In operation the vent is closed to apply the vacuum to a sampling tube connected to the sample tube connector to draw a sample into the buffering chamber. The drawn fluid flows under gravitational force into a storage tube attached to the storage tube connector. The device is particularly useful for sampling and collecting submandibular and sublingual saliva.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/0001
5051557,24-Sep-91,1991,9,24,Microwave induced plasma torch with tantalum injector probe,"A stable, low gas-flow microwave induce plasma torch for use with a helium microwave induced plasma system provides a toroidal plasma with central analyte injection obtained by the addition of a tantalum coupling probe injector. This, injector which penetrates through 100% of the total cavity depth, aids in plasma initiation, in the efficiency of power transfer to the cavity, and in eliminating the effects of a lack of homogeneity in the microwave field on analyte distribution in the plasma. In the preferred embodiment the microwave induced plasma torch includes a stainless steel body, a threaded aluminum insert, a PTFE insulator, a tantalum injector probe, and a quartz containment tube.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,"Electrical machinery, apparatus, energy",,,,,,H01J/105
5052934,1-Oct-91,1991,10,1,Phantom for evaluation of prosthetic valves and cardiac ultrasound procedures,"Apparatus is provided to serve as a phantom for evaluation of prosthetic valves and cardiac ultrasound procedures, wherein a controlled pulsatile flow of a blood-mimicking fluid is passed through a multi-chambered region into which are mounted mitral and aortic valves and adjustably positionable ultrasound transducers. A low friction, drive which involves very low levels of extraneous vibrational inputs, is provided with adjustment of both the volume flow rate of blood-mimicking fluid moved in each operational pulse with further control provided by relatively easily adjusted screws to selectively regulate the systolic and diastolic times of the pulsatile flow generated by a bellows arrangement. Windows made of silicone elastomer material presenting both tissue-equivalent impedance for ultrasound transmission and tissue-equivalent attenuation of the ultrasound are provided in controlled thickness to permit detailed observation of valvular flow parameters of interest, e.g., flow velocity distributions observed in the transesophogeal and apical directions. The apparatus is suitable for clinical ultrasound examination of prosthetic heart valves, the measurement of simulated blood flow velocity profiles, calibration of Doppler ultrasound parameters related to heart valve and related blood flow characteristics, and the fluid mechanical evaluation of cardiovascular devices to compare their performance for comparing competing systems.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Control,,,,,,G09B/286
5052997,1-Oct-91,1991,10,1,Diathermy coil,"A short but large apertured coil of the sloped-helix type allows deep heating of a part of the human body by RF waves, for example with a three-turn coil having a central part wherein parts of a pair of turns are parallel. The length of the coil equals two wavelengths of the RF wave. Each loop or turn is widened with for instance a conducting ribbon, having specific twists to provide corresponding vertical and horizontal parts if the coil is considered to have its axis aligned vertically.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61N/403
5055267,8-Oct-91,1991,10,8,Thin film environmental monitor,"A thin film environmental monitor for monitoring a person's exposure to an analyte in an environment, comprising a portable casing for housing the monitor, a pump in the casing for obtaining an air sample, and a sensor in the casing for sensing the concentration of the analyte in the air sample obtained by the pump. The sensor includes an active film portion coated with a dry coating adapted to cause a chemical reaction with the analyte, and a reference film portion for transmitting incident light independently of the concentration of analyte in the air sample. The sensor generates an active signal representing the amount of light transmitted by the active film portion and a reference signal representing the amount of light transmitted by the reference film portion. A control circuit is provided in the casing for providing voltage to the sensor and for processing the active and reference signals from the sensor and producing an output signal representative of the concentration of the analyte in the air sample. Indicators are provided connected to the casing responsive to the control circuit for indicating the amount of analyte sensed based on the representative output signal.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/783
5058441,22-Oct-91,1991,10,22,Safety pipette and adaptor tip,"A disposable pipette comprises a tube having first and second ends, a porous barrier plug mounted in the tube at the second end, and a sealing device mounted in the tube between the second end and the barrier plug. The sealing device has a closed position and an open position into which it must be forced. The pipette further comprises a closure mounted in the tube between the second end and the sealing device, wherein the first end is immersed in a fluid, when the sealing device is forced to the open position and when the second end is connected to a suction, fluid is suctioned into the pipette. A safety pipette adaptor comprises an annular sleeve for mounting on the suction end of a pipette. A rod is provided in the sleeve in the direction of an axis for insertion into a pipette or pipette insert and is capable of displacing a sealing device in a pipette or pipette insert into an open position. A disposable pipette insert comprises a tube having first and second ends and sealably fitting in the suction end of a pipette with the second end of the tube being flush with the pipette' s suction end, a porous barrier plug mounted in the tube at the first end, and a sealing device mounted in the tube between the second end and the barrier plug. The sealing device has a closed position and an open position into which it must be forced. The pipette further includes a closure mounted in the tube at a position between the second end and the sealing device, wherein when the sealing device is forced into the open position, air can flow in and out of the tube.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B01L/0213
5061488,29-Oct-91,1991,10,29,Flavone-8-acetic acid and interleukin-2 for cancer therapy,A treatment regimen for cancer comprises administering to a patient an effective amount of a combination of interleukin 2 and flavone-8-acetic acid. The treatment regime is particularly effective in the treatment of renal cracinoma.,11,The United States of America as represented Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
5063053,5-Nov-91,1991,11,5,Isolation and purification of the R18 antigen of HTLV-III,"The isolation and purification of a newly discovered gene of the AIDS virus, HTLV-III, which encodes a portein which is immunogenic and recognized by sera of some HTLV-III seropositive people. Furthermore, the gene is highly conserved among all known HTLV-III isolates and exhibits a polymorphism at the 3' end which distinguishes molecular clones of the HTLV-IIIB cell line from viral genomes of related viruses.",3,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5063206,5-Nov-91,1991,11,5,Compositions having use as treatment of neuropsychiatric deficits,"The present invention relates to methods of treating mental disorders and memory deficits not caused by HIV infection. The methods involve administration of a thymoleptic effective amount of defined linear peptides to patients. The peptides can be administered for example, as a powder or a solution obtained by dissolving a powder in a pharmaceutically acceptable solvent.",11,The United States of Americas as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/08
5066490,19-Nov-91,1991,11,19,Protein crosslinking reagents cleavable within acidified intracellular vesicles,"Crosslinking reagents for amino group-containing compounds are provided, which crosslinkers can be cleaved under mildly acidic conditions. The crosslinkers can be used to crosslink biologically active substances to be delivered to the cells, wherein the crosslinker will be cleaved in the mildly acidic conditions within the cell.",21,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/452
5066716,19-Nov-91,1991,11,19,"Synthesis of chloroacetyl and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides","A method to incorporate bromoacetyl and chloroacetyl moieties on amino groups of synthetic peptides using a standard program with an automated peptide synthesizer has been developed. The bromoacetyl and chloroacetyl-derivatized peptides react well with sulfhydryl-containing proteins and with peptides containing cysteine residues. Autopolymerization or cyclization occurs by reaction of the free sulfhydryl of cysteine in a peptide with the bromoacetyl group (or chloroacetyl group) and reactions can generally be controlled by controlling the concentrations of starting peptide in neutral pH buffers. Analytical methods for evaluating the polymers or cyclized peptides include gel filtration chromatography, reverse phase HPLC, SDS-PAGE and amino acid analysis where the degree of reaction can be evaluated by quantifying the amount of S-carboxymethylcysteine formed after HCl hydrolysis. N-bromoacetyl-derivatized peptides are useful as reagents for potential peptide immunogens, vaccines and therapeutics, and for substances such as peptides linked to polymers, plastics, enamels, and ceramics.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1077
5068253,26-Nov-91,1991,11,26,Treatment of a microbial infection with drugs containing para-acetamidobenzoic acid,"The present invention relates to a method of treating or preventing a microbial infection, such as Pneumocystis carinii or Toxoplasma gondii, in a patient comprising administering to the patient an antimicrobially effective amount of p-acetamidobenzoic acid or a pharmaceutically acceptable salt thereof so that the microbial infection is inhibited. P-acetamidobenzoic acid or an acceptable salt thereof can be used to treat infections caused by Pneumocystis carinii, Toxoplasma gondii, Plasmodium species and other microorganisms containing the enzyme dihydropteroate synthetase such as most bacteria and some yeasts. The method of the present invention is particularly applicable in situations where the patient is immunosuppressed.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/195
5071962,10-Dec-91,1991,12,10,"Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins","The present invention relates to novel polypeptides comprising a unique ""chlamydial-specific"" primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokaryotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.",4,The United State of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/295
5071977,10-Dec-91,1991,12,10,Plaque inhibiting oligosaccharide,"A purified oligosaccharide consisting of a hexasaccharide with a native molecular weight of 959 which can be isolated from the cell walls of Streptococcus sanguis. The oligosaccharide is able to significantly block the interaction between the human oral plaque bacteria Streptococcus sanguis H1 and Capnocytophaga ochracea ATCC 33596. This purified oligosaccharide contains saccharide components found to inhibit many known interactions between plaque bacteria and may be effective in prevention, inhibition and reversal of dental plaque deposits. The oligosaccharide may be applied effectively when incorporated in toothpastes, mouth wash, etc.",1,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C12P/04
5073486,17-Dec-91,1991,12,17,Assay for Mycoplasma fermentans,"An assay for detecting the presence of Mycoplasma fermentans is disclosed, along with a diagnostic kit that uses the assay. The presence of Mycoplasma fermentans is indicated by the presence of the restriction endonuclease MfeI. This endonuclease recognizes the sequence CAATTG and cleaves between the C and the first A.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/44
5078553,7-Jan-92,1992,1,7,Compact drill sampler for quantitation of microorganisms in wood,An apparatus for sampling and collecting wood samples for analysis purposes which includes a boring bit surrounded by a chamber into which the boring bit draws samples and from which the samples are passed to a collection container. The boring bit is housed in a pair of slidably connected housing members which determine the depth that the boring bit enters a wood sample. Collected samples are analyzed for microbial contaminates.,9,"The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Machine tools,,,,,,B23B/008
5081226,14-Jan-92,1992,1,14,Synthetic peptides sharing sequence homology with the HIV envelope protein,"This invention relates to the identification of short peptide segments of AIDS virus proteins which elicit T cellular immunity, and to a method of inducing cellular immunity to native proteins of the AIDS virus by immunization with short synthetic peptides. Five potential peptides have been identified by searching for regions which can fold as a maximally amphipathic helix. These may be useful to include in either a synthetic peptide- or recombinant fragment- based vaccine.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5081871,21-Jan-92,1992,1,21,Breath sampler,"An apparatus for sampling volumetric quantities of human exhaled breath has three conduits and may be provided in ""Y"" or ""T"" shaped configuration. The free end of one of the conduits is adapted to connect with the mouth of the subject being tested. Another of the conduits is adapted to pass ambient air to the subject, this conduit being provided with a suitable filtering mechanism such as a charcoal inhalation canister and an inlet check valve. The third of the three conduits supports an appropriate sampling canister for receiving exhaled breath from the subject, and this conduit also is provided with a one-way check valve. In another aspect of the invention, there is also provided a method for collecting a sample of exhaled breath from a subject to collect therefrom a selected analyte and to accurately quantify its presence in the subject's breath.",21,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Analysis of biological materials,,,,,A61B/083
5082927,21-Jan-92,1992,1,21,Selectively cytotoxic IL-4-PE40 fusion protein,The present invention provides a chimeric protein IL4-PE40 which selectively kills IL4 receptor bearing cells. A mutant form of the protein is also provided.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/495
5086072,4-Feb-92,1992,2,4,Treatment of mood disorders with functional antagonists of the glycine/NMDA receptor complex,"A method is disclosed for the treatment of mood disorders, including major depression, by administering an effective mood disorder treating amount of a compound possessing functional antagonist properties for the N-methyl-D-aspartate receptor complex.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/66
5088980,18-Feb-92,1992,2,18,Intra-urethral valve with integral spring,"A prosthetic urethral sphincter valve with an integral spring valve member which comprises an elastic valve element having an upper portion which defines a central fluid passage and a lower diaphragm portion which includes a rolling diaphragm. The prosthetic urethral sphincter valve is placed totally within a patient's urethra. The lower diaphragm portion of the elastic valve element includes a tapered wall structure which provides for a spring action which demonstrates a non-linear force curve. The central fluid passage assumes a kinked or closed position, or a straighten or open position depending upon the position of the rolling diaphragm. Applied bladder pressure effects the position of the rolling diaphragm and thus the opening and closing of the central fluid passage.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61F/0036
5089392,18-Feb-92,1992,2,18,Fluorogenic substrates for measurement of lysosomal enzyme activities within intact cells,"Fluorogenic substrates and compositions containing the same are useful for detecting enzymatic activity within intact cells. The fluorogenic substrates are lysosomotropic derivatives of 2,3-dicyano-hydroquinone (DCH). These derivatives may be employed for detecting lysosomal enzymatic activity within intact cells using fluorescent microscopy and cytometry.",30,The United States of America as represented by of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Analysis of biological materials,,,,C07H/203
5091430,25-Feb-92,1992,2,25,O.sup.6 -substituted guanine compounds and methods for depleting O.sup.6 -alkylguanine-DNA alkyltransferase levels,"O.sup.6 -substituted guanine compounds of the formula ##STR1## wherein R is a benzyl group or a substituted benzyl group, cause a depletion of O.sup.6 -alkylguanine-DNA alkyltransferase (AGT) activity in mammalian cells. These compounds may be administered to a host so as to reduce AGT levels in tumor cells of the host in order to increase host responsiveness to anti-neoplastic alkylating agents, including chloroethylating agents, such as chloroethylnitrosoureas, for chemotherapeutic treatment of a number of neoplasms.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
5092876,3-Mar-92,1992,3,3,Cell attachment peptides derived from amyloid P component,"The present invention is directed to a human serum amyloid P component peptide sequence having 12 ammo acid residues and having the sequence identified as Glu-Lys-Pro-Leu-Gln-Asn-Phe-Thr-Leu-Cys-Phe-Arg. The invention is also directed to fragments of the above peptide. Two fragments useful in the present invention have the sequence Phe-Thr-Leu-Cys-Phe-Arg and Leu-Cys-Phe-Arg. The above peptides are useful for attaching cells to substrates such as ceramics, tissue culture, dishes, polymers or enamels and thus are useful as research tools for studying particular cells. The above peptides are also useful in vivo as artificial organ replacements which attach surrounding natural cells.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Medical technology,,,,,C07K/4711
5092885,3-Mar-92,1992,3,3,Peptides with laminin activity,"Peptides with laminin activity are provided as follows: PA1 tyrosine-isoleucine-glycine-serine-arginine; PA1 proline-aspartine-serine-glycine-arginine; and PA1 cysteine -aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine. These peptides block angiogenesis, alter the formation of capillary structures by endothelial cells, prevent the formation of excess blood vessels in tissues, and inhibit in vivo tumor cell colonization of tissues.",60,The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/78
5093115,3-Mar-92,1992,3,3,Method of preparing activated killer monocytes for treating colorectal cancer,The present invention discloses a method of preparing activated killer monocytes for treating colorectal cancer. Activated killer monocytes are prepared in serum free medium in polypropylene containers.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/57446
5096707,17-Mar-92,1992,3,17,Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers,"A treatment regimen for cancers having cells which are susceptible to an interleukin-2 activated natural killer cell mediated anti-cancer effect, the method comprises administering to a patient an effective amount of a combination of interleukin 2 and flavone-8-acetic acid. The treatment regimen is particularly effective in the treatment of renal carcinoma. Synergistic pharmaceutical compositions are also provided. effective in the treatment of renal carcinoma. Synergistic pharmaceutical compositions are also provided.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
5096733,17-Mar-92,1992,3,17,Prevention of the acute cytotoxicity associated with silica containing minerals,"Cytotoxic effects associated with ground fractured silica-containing minerals and silicates, including asbestos, are prevented by coating the silica-containing minerals and silicates with an aqueous solution containing an aqueously compatible silane coupling agent so that a monomolecular film is formed on the surface of the silica-containing minerals and silicates.",10,The United States of America as represented by the Secretary of the Dept. of Health and Human Services,,,,,,,,,,,1,"Materials, metallurgy",Micro-structural and nano-technology,Machine tools,,,,B82Y/00
5096808,17-Mar-92,1992,3,17,Method and kit for detecting human exposure to genotoxic agents,The present invention discloses a method and a kit for monitoring human exposure to genotoxic agents. The method comprises an immunoassay for detecting in human serum specific antibodies against DNA adducted to an agent suspected of being genotoxic. A kit comprising various components for performing the assay is also disclosed.,2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5308
5096893,17-Mar-92,1992,3,17,Regioselective substitutions in cyclodextrins,"A method for obtaining a desired pattern of substitution of hydroxyalkyl groups on cyclodextrins which comprises controlling the basicity of a reaction mixture comprising epoxide and cyclodextrins and a suitable solvent. Through the proper control of basicity with, e.g., sodium hydroxide, hydroxyalkyl substitution may be directed either toward the narrow or wide opening of the cavity of cyclodextrins.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Macromolecular chemistry, polymers",,,,,,C08B/0012
5098996,24-Mar-92,1992,3,24,Process for introducing fluorine into biologically active materials,"Radioactive fluorine can be easily introduced into biologically active molecules containing amino groups. A p-bromomethyl benzoyl group is coupled to the amino group of the biologically active molecule, and bromine is displaced by fluorine. Alternatively, the bromine on the bromomethylbenzoyl group is first displaced by fluorine, and the fluoromethyl benzoyl group is then coupled to the amino group of the biologically active molecule. The compounds so produced are useful in diagnostic nuclear medicine.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07D/06
5099069,24-Mar-92,1992,3,24,Backbone polysubstituted chelates for forming a metal chelate-protein conjugate,New polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates of the same are described together with the methods of preparing such compounds. A method of delivering radiolabelled compound of the present invention to a target site while minimizing the distribution of the compound to non-targeted organs or tissues is also disclosed.,4,,,,,,,,,,,,,Pharmaceuticals,Organic fine chemistry,,,,,C07C/24
5099616,31-Mar-92,1992,3,31,Apparatus and method for reducing wood dust emissions from large diameter disc sanders while cleaning a sanding disc thereof,"For improved removal of dust generated in sanding with a rotating disk sander, while simutaneously maintaining a sanding surface thereof free of clogging by dust particles, there is provided a plurality of compressed gas nozzles distributed lengthwise along an elongated common compressed gas supply manifold. The nozzles preferable are disposed to deliver high velocity jets of a compressed gas into a rotating boundary layer at the rotating sanding disk surface to thereby interact with the boundary layer and to simultaneously forcibly dislodge any dust particles tending to adhere to the air sanding disk surface. Suction is provided around a portion of the sanding disk to remove the dust particles that are entrained in the boundary layer and any dust particles dislodged from the sanding disk surface. In one aspect of this invention, the apparatus thereof may be added to a conventional disk sander apparatus to improve dust collection therefrom.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Machine tools,,,,,,B24B/06
5100646,31-Mar-92,1992,3,31,NMR glomerular filtration test,"A method of determining the glomerular filtration rate of a subject comprises (1) obtaining a serum sample S.sub.pre and a urine sample U.sub.pre from a subject; (2) administering to the subject an amount of a paramagnetic substance that is filtered by the kidneys and is readily detectable by NMR in serum and urine; (3) allowing for the concentration of the substance to equilibrate between the blood and the extravascular spaces; (4) separating an aliquot of the urine sample v.sub.A and obtaining a serum sample from the subject at the time t.sub.A ; (5) calculating a urine rate (v/a).sub.A from the formula (v/a).sub.A =V.sub.A /a.sub.A ; (6) measuring the magnetic resonance relaxation times of the serum and urine samples, (7) obtaining the concentrations of the paramagnetic substance in the serum samples and the urine samples by comparing their relaxation times to a standard; and (8) calculating GFR from the formula ##EQU1##",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
5104531,14-Apr-92,1992,4,14,Cross-axis synchronous flow through coil planet centrifuge for large scale preparative countercurrent chromatography,"A countercurrent chromatography apparatus and method where the column rotates about an axis spaced apart from, parallel to, and in the same radial plane as a radius extending from the central axis of revolution. The apparatus generates a unique force field which enables excellent separation.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
5104792,14-Apr-92,1992,4,14,Method for amplifying unknown nucleic acid sequences,"A modification of the PCR technique is described which allows fragments of RNA or DNA to be amplified without prior knowledge of their sequence. The technique can be used to amplify viral nucleic acids present in small amounts in clinical material allowing, for example, the diagnosis of a particular virus infection or the discovery of new viruses.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6853
5104898,14-Apr-92,1992,4,14,Method of preventing graft rejection in solid organ transplantation,"A method is disclosed for preventing graft rejection of transplanted solid organs, in mammal recipients thereof, by administering an effective graft rejection preventative amount of succinylacetone to said mammals.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/19
5104977,14-Apr-92,1992,4,14,Purified transforming growth factor beta,A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-.beta. which is activated by either a TGF-.alpha. or an EGF or both; and methods for administration. As another embodiment these active ingredients can be admixed with other (secondary) growth factors.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/65
5105585,21-Apr-92,1992,4,21,Dust emissions control mechanism for hand sanders,"A mechanism is provided to significantly enhance control over the emission of particulate dust typically generated during operation of a hand-held sander. A suction manifold coupled to any conventional means for providing suction is fitted to the outside of the sander body and communicates through a plurality of connection tubes with a plenum through which particulates generated during sanding are sucked in through apertures in a sanding pad of the sander. Further enhancement of removal of the particulates is obtained by a plurality of grooves in the sanding surface of the sanding pad of the sander, such grooves each having an inside end communicating with a corresponding one of a plurality of apertures through the sanding disk, each groove also having an outside end at an outer periphery of the sanding pad. The provision of supplemental suction through the suction manifold and the use of a grooved sanding disk, as described, significantly reduces particulate emissions and, simultaneously, reduces the suction-induced tendency for the sander to be drawn toward the surface of a workpiece being sanded thereby.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Machine tools,,,,,,B24B/102
5106731,21-Apr-92,1992,4,21,Kaposi's sarcoma endothelial cells and growth factor,The present invention relates to a growth factor found in HTLV-II conditioned media and to compositions containing same. The growth factor of the present invention supports the growth of Kaposi's sarcoma endothelial-like cells. The factor has a molecular weight of 30K to 35K in monomeric form and a molecular weight of about 70K in dimeric form.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/475
5108708,28-Apr-92,1992,4,28,Aliquot collection adapter for HPLC automatic injector enabling simultaneous sample analysis and sample collection,"A method and apparatus permitting automated tablet dissolution testing are provided. A multi-channel pump removes liquid dissolution media from a plurality of kettles and transfers this media to a plurality of vials held within the carousel of an autoinjector for HPLC analysis. Passages for returning dissolution media is provided between the supply pump or pumps and the vials. A mechanism is provided for cyclically switching the media flow from one mode, where the media flows from kettles to the vials, and another mode, where the media flows from the kettles to the return passages. Each vial in the apparatus may thus be simultaneously filled from a separate respective kettle at an appropriate time and the supply passages may be rinsed with the new dissolution media after a set of vials are filled with the previous dissolution media. The filled vials can be analyzed without manual transfer to an HPLC column. Cycling between filling and rinsing may be accomplished by a microprocessor.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/1067
5109007,28-Apr-92,1992,4,28,Attenuation of ethyl alcohol intoxication with alpha-2 adrenoceptor antagonists,"A method is provided for attenuating the intoxicating effects of ethyl alcohol in a patient, by administering to a patient in need thereof, an alpha-2 adrenoceptor antagonist compound. Two preferred compounds useful in the present invention, each being a highly potent and selective alpha-2 adrenoceptor antagonist, are atipamezole and idazoxan.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/00
5109115,28-Apr-92,1992,4,28,Monoclonal antibody specific for bombesin,The present invention discloses anti-bombesin monoclonal antibody and a method of detecting autocrine growth factor. A method and kit for screening and controlling growth of human SCLC has also been disclosed.,2,The United States of America as represented by the Secretary of the Dept. of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/086
5110927,5-May-92,1992,5,5,Prazosin analog with increased selectivity and duration of action,"Alkylating analogs of prazosin were synthesized and found to compete with nanomolar potency at .sup.3 H-prazosin binding sites of rat tissues. The compounds were found to be irreversible ligands at .sup.3 H-prazosin binding sites, and denoted a subtype of alpha.sub.1 -adrenoceptors.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/12
5114589,19-May-92,1992,5,19,Type-XLL cross-axis synchronous flow-through coil planet centrifuge for separation of biopolymers,A type-XLL cross-axis synchronous flow-through coil planet centrifuge including exclusively left-handed column coils and a method of separating macromolecules utilizing the same. The exclusive use of left-handed column coils allows retention of the stationary phase when utilizing aqueous-aqueous two-phase solvent systems. The cross-axis synchronous flow-through coil planet centrifuge has been utilized to separate proteins utilizing an aqueous-aqueous polymer phase solvent system. Technical Field,14,The United States Government as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Measurement,,,,,C07K/30
5114973,19-May-92,1992,5,19,Method for treating autoimmune disease using succinylacetone,The invention is a method of modulating or controlling autoimmune disease in a host. The method includes the step of administering to the diseased host a pharmaceutical effective amount of succinylacetone. The pharmaceutically effective amount of succinylacetone is desirably infused by an osmotic minipump in order to modulate the effects of autoimmune disease in the host.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/19
5116867,26-May-92,1992,5,26,D-propranolol as a selective adenosine antagonist,"Chemicals are disclosed which are useful for inhibiting the actions of adenosine in mammals, comprising: L-propranolol, or D-propranolol, or alprenolol and derivatives thereof for parenteral or topical administration are disclosed for purposes of achieving desired circulating concentrations in the range of 10 nanogram to 10 milligrams per kilogram. D-Propranolol is of special interest because it is relatively inactive as a .beta.-adrenergic blocking agent. Specific uses of D-propranolol include the treatment of asthma, chronic obstructive pulmonary disease, A-V node conduction disturbances; apnea of preterm infants, pulmonary hypertension, headaches, migraine, and in attention-deficit disorder. D-Propranolol might also be used as a substitute for xanthines in beverages to produce a feeling of well being, awakeness, awareness and increased performance.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/135
5117854,2-Jun-92,1992,6,2,Stopcock holder,"A valve holder and a method of use thereof enables convenient securing and releasing of a valve, such as a stopcock valve. The valve holder allows an operator to operate a valve utilizing one hand. The valve holder includes a support block and a chamber fixed to the support block. In operation, the chamber receives a valve to be secured by the valve holder and a clamp member is tightened to the support block to thereby secure the valve in the chamber. A hand operated mechanical fastener such as a thumb screw is utilized to tighten the clamp member to the support block. Cooperating recesses in the chamber and clamp member secure the valve in the holder and prevent movement of the valve within the holder.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Mechanical elements,,,,,,F16K/12
5120720,9-Jun-92,1992,6,9,Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers,"The dissolution of lipophilic compounds in aqueous solutions of hydroxypropylcyclodextrins can be accelerated by the addition of co-solubilizers, such as ethanol or ammonia, which again can be removed, together with water, by evaporation or by freeze-drying leaving lipophile: hydroxypropylcyclodextrin complexes as a residue. The co-solubilizer method was used successfully with steroid drugs (5-androstene-3.beta.,17.beta.-diol, 4-androstene-3,17-dione, dehydroepiandrosterone, dexamethasone, 5-.alpha.-dihydro-testosterone, 6-methylprednisolone, and testosterone), peptides (gramicidin S) and a macrocyclic antibiotic (amphotericin B). The complexes prepared in this manner were amorphous and possessed satisfactory stability.",19,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Micro-structural and nano-technology,Pharmaceuticals,,,,,B82Y/00
5123201,23-Jun-92,1992,6,23,Sensor-triggered suction trap for collecting gravid mosquitoes,"A trap for collecting gravid mosquitos includes a smooth surfaced vessel containing oviposition attractant, such as an infusion of hay in water. A strip of rough material is located above the surface of the oviposition attractant. An infrared sensor adjacent the strip and above the surface of the oviposition attractant activates a trigger circuit which turns on a fan. The smooth surfaced vessel is unsuitable for oviposition by a gravid mosquito. The rough strip, however, provides a mosquito attempting to lay eggs with a good purchase above the water. When a mosquito finds the rough strip and moves towards the water, the mosquito interrupts an infrared beam. The infrared sensor activates the trigger circuit to turn on the fan for a short period. The fan produces an air flow through a suction tube to draw the mosquito through the suction tube into a collection tube. The inventive trap is fully automated, robust, and does not damage mosquitos during capture.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,,,,,,A01M/026
5123378,23-Jun-92,1992,6,23,Grooming and or foraging apparatus for reduction of stress in caged animals,"Grooming and/or foraging opportunities are provided for caged animals, specifically to nonhuman primates, in order to enrich the environment thereof thus to reduce boredom and stress of the animals. By increasing normative behavior, the inventive method and apparatus reduce abnormal behavior and broaden the behavioral repertoire of the animal. The inventive structure includes a hard backing board of Plexiglass, Lexan, metal or other similar materials, covered with a natural or artificial cloth, fur, fleece, carpeting or the like. Food particles of different sizes with rough edges may be rubbed into the cloth material to elicit foraging activities from the animal.",8,The United Stats of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Other special machines,,,,,,A01K/025
5124340,23-Jun-92,1992,6,23,Use of calcium channel blocker to prevent cocaine induced craving and reinforcement,"A method of treating cocaine addiction by administering to a patient in need thereof, an anti-cocaine addicting effective amount of a calcium channel blocking agent.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/44
5124351,23-Jun-92,1992,6,23,Pharmaceutical compositions for the treatment of cancers susceptible to treatment with the copper complex of S-(methylthio)-DL-homocysteine or the L-enantimorph thereof,"An injectable pharmaceutical composition for the treatment of cancers susceptible to treatment therewith, the composition comprising: PA1 (a) an effective amount of S-(methylthio)-DL-homocysteine or the L-enantimorph thereof; PA1 (b) an effective amount of a copper chelate of nitrilotriacetic acid or an effective amount of a copper chelate of a bis-thiosemicarbazone; and PA1 (c) a pharmaceutically acceptable carrier.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/30
5124471,23-Jun-92,1992,6,23,Bifunctional DTPA-type ligand,The subject matter of the present invention relates to bifunctional cyclohexyl DPTA ligands and methods for utilizing these compounds.,2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,,G01N/534
5125408,30-Jun-92,1992,6,30,Pressure sensor element and method to measure contact stress,"A biological implantable pressure sensor element comprises a fixed volume pouch formed by a sealed, flexible, impermeable membrane comprising therewithin a gel mass contained in a gel volume, said gel being hydrated with an aqueous solution comprising an agent having at least a first and a second NMR-detectable form, the proportion of the first to the second form of the agent in the gel volume being determined by their electrolytic interaction with the gel, whereby when an external pressure is applied to the sensor element a d (chemical shift)/d(.sigma./K) greater than 0.0001 ppm is attained, wherein .sigma. is the external pressure and K is the modulus of the gel. A kit contains sterile, individually wrapped sensor elements. A method of measuring in vivo contact stress applied to an implanted pressure sensor element, comprises implanting the pressure sensor of the invention into a situs of a subject in need of such measurement, non-invasively subjecting the subject situs to a nuclear magnetic resonance source effective to detect said NMR-detectible agent, obtaining the NMR spectrum of said agent, obtaining the chemical shifts from the spectrum, repeating steps (b) to (d) at least once at a desired time interval, comparing the chemical shifts obtained in step (d) at different time intervals, and calculating the contact stress applied to said sensor element at a desired time from a correlation of observed chemical shifts for normalized stresses (.sigma./K) for the sensor element. A method of measuring in vitro contact stress applied to a pressure sensor element, comprises placing the stress sensor element of the invention in contact with a biological tissue in culture, non-invasively subjecting the biological tissue to a nuclear magnetic resonance source effective to detect said NMR-detectible agent, obtaining the NMR spectrum of said agent, obtaining the chemical shifts from the spectrum, repeating steps (b) to (d) at least once at a desired time interval, comparing the chemical shifts obtained in step (d) at different time intervals, and calculating the contact stress applied to said sensor element of a desired time from a correlation of observed chemical shifts to normalized stresses (.pi./K) for the sensor element.",15,The United States of America as represented by the of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Medical technology,,,,,G01R/28
5126129,30-Jun-92,1992,6,30,Cancer therapy using interleukin-2 and flavone compounds,Treatment of Cancer with Flavones and Interleukin 2.,18,The Government of the United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
5126132,30-Jun-92,1992,6,30,Tumor infiltrating lymphocytes as a treatment modality for human cancer,A new immunotherapeutic method of treating cancer with a combination of tumor infiltrating lymphocytes and IL-2 has been described.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
5126251,30-Jun-92,1992,6,30,Stable mammalian cell line expressing a bacteriophage RNA polymerase,The present invention relates to a eukaryotic cell line which expresses a foreign RNA polymerase gene. The invention further relates to a method of expressing a foreign protein in a eukaryotic environment utilizing the cell line. The present invention allows for the expression of a foreign protein in a eukaryotic cell without requiring transfecting or infecting the cell with a vector carrying the RNA polymerase gene.,13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5128254,7-Jul-92,1992,7,7,cDNA encoding the long isoform of the D.sub.2 dopamine receptor,"In the present investigation, we report the identification and cloning of a cDNA encoding an RNA splice variant of the rat D.sub.2 receptor cDNA.sup.12. This cDNA codes for a receptor isoform which is predominantly expressed in the brain and contains an additional 29 amino acids in the 3rd cytoplasmic loop, a region believed to be involved with G protein coupling. This is the first example of a novel G-protein coupled receptor isoform generated by alternative RNA splicing.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
5130416,14-Jul-92,1992,7,14,Recombinant DNA clone containing a genomic fragment of PfHRP-II gene from plasmodium falciparum,"A histidine rich antigen, designated PfHRP-II, has been synthesized from a recombinant DNA clone containing a genomic fragment of Plasmodium falciparum. PfHRP-II is a protein exported from the parasite into the body fluid. This protein passes through the host erythrocyte in concentrated packets and is released from the infected erythrocyte into the body fluid. The antigen has been isolated and is useful for protection against malaria.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
5132212,21-Jul-92,1992,7,21,"SCL gene, and a hematopoietic growth and differentiation factor encoded thereby","We have identified a new human gene, SCL. We discovered this gene because of its involvement in a chromosomal translocation associated with the occurrence of a stem cell leukemia manifesting myeloid and lymphoid differentiation capabilities. Here we report the sequence of a cDNA for the normal SCL transcript, as well as for an aberrant fusion transcript produced in the leukemic cells. Although different at their 3' untranslated regions, both cDNAs predict a protein with primary amino acid sequence homology to the previously described amphipathic helix-loop-helix DNA binding and dimerization motif of the Lyl-1, myc, MyoD, Ig enhancer binding, daughterless, and achaete-scute families of genes. For these cDNAs, two forms of the SCL protein (greater than 20 and 30 kD) are predicted, both of which retain this putative DNA binding domain. The pattern of expression of SCL mRNA is primarily predominant in early hematopoietic tissues. Taken together, these studies lead to the speculation that SCL plays a role in differentiation and/or commitment events during hematopoiesis.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
5132315,21-Jul-92,1992,7,21,Therapeutic application of an anti-invasive compound,"Tumor invasion and metastasis is the most life threatening aspect of cancer. Invasion and metastasis is a multistep process. Cellular functions required for invasion are attachment, locomotion and directed migration. Regulation of these processes may be independent of cell growth. A carboxylamino-imidazole compound was found to be potent inhibitor of tumor cell attachment, motility, invasion, proliferation, and metastasis. This compound and equivalents thereof constitute a cancer treatment agent of particular use in the treatment of peritoneal carcinomatosis of ovarian cancer.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/41
5134969,4-Aug-92,1992,8,4,Cage configuration for arboreal reptiles,"A cage for arboreal animals includes two compartments, each having a hinged, latched, door. The two compartments are separated by a sliding panel to enable maintenance to be performed easily and safely, minimizing unwanted contact between hazardous animals, such as venomous snakes, for example, and the investigators or maintenance personnel. The structure is further ventilated to provide air flow from bottom to top, and could maintain a humidity level in accordance with needs of caged animals. The sides of the cage are transparent to permit simple monitoring of the reptiles as well as to meet the social needs of those animals which need visual contact with other animals in adjacent cages. This cage meets or exceeds all current Federal principles and regulations for animal housing units.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,,,,,,A01K/031
5135855,4-Aug-92,1992,8,4,"Rapid, versatile and simple system for expressing genes in eukaryotic cells","An efficient, versatile and simple expression system which confers cap-independent translation to prokaryotic RNAs in eukaryotic cells has been described. The utility of recombinant vaccinia virus for this purpose has been illustrated.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5135864,4-Aug-92,1992,8,4,"Human Immunodeficiency Virus (HIV) associated with Acquired Immunual Deficiency Syndrome (AIDS), a diagnostic method for aids and pre-aids, and a kit therefor","Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.",49,Institut Pasteur,The United States of America as represented by the Secretary of The Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
5137712,11-Aug-92,1992,8,11,"Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment","A method for reversing or preventing the onset of tolerance and the development of extrapyramidal side effects in humans due to prolonged treatment with neuroleptics, comprising including S-adenosyl-L-methionine (SAMe) in the treatment regime. By utilizing SAMe in combination with tolerance-inducing neurolepitcs to maintain a minimum dosage of the drug while retaining its efficacy, the potential for the development of neuroleptic-induced, extrapyramidal side effects is minimized.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
5138871,18-Aug-92,1992,8,18,Method and apparatus for testing the permeability of prophylactics,"An apparatus and method for evaluating the permeability of membrane articles, particularly condoms and gloves, is designed to quantify physiologic conditions which exist during use of the articles. Permeability is determined by monitoring fluorescent microspheres of approximately the size of HIV which pass through the membrane articles.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01M/227
5141849,25-Aug-92,1992,8,25,Marker for early detection of human hydatidiform moles and choriocarcinomas,"The present invention relates to a DNA segment comprising linked pregnancy-specific beta.sub.1 -glycoprotein (PS.beta.G) genes encoding PSGGA protein and PSGGB protein. The invention further relates to a probe (DNA, RNA or peptide probe) specific for PSGGB mRNA or protein expressed in human hydatidiform molar trophoblastic tissue and to a bioassay for the detection of gestational trophoblastic diseases. The PSGGB-specific probes of the present invention hybridized most strongly with RNA from molar trophoblastic tissue, suggesting that the PSGGB-like species may be the gene preferentially expressed in gestational trophoblastic diseases.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5141852,25-Aug-92,1992,8,25,Assay of protein kinases with peptide substrates,"A method for assaying protein kinases that phosphorylate peptides such as Kemptide, such as cAMP-dependent protein kinase, or a glycogen synthase peptide, which is an excellent substrate for protein kinase C. Upon sequentially processing of reaction mixtures through tandem columns of cation and anion exchange resins improved separation of ATP from phosphorylated peptides is achieved such that radioactivity in background samples is nearly nil and the yield of phosphorylated peptides is high. This method is generally applicable to any protein kinase so long as the substrate peptide is appropriately structured such that the peptide retains a net positive charge when fully phosphorylated so that the peptide will adhere to the cation exchange resin and pass through the anion exchange resin. This method reduces labor, radioactivity, enzyme requirements, and costs of assaying protein kinases.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/48
5148679,22-Sep-92,1992,9,22,Portable device for producing solid carbon dioxide,"A compact, inexpensive and light-weight apparatus, for quick connection to a standard supply of liquid carbon dioxide at room temperature, includes a stiff length of tubing quickly connectable to the source of liquid carbon dioxide. This tube, in a preferred embodiment of the invention, provides all the support needed for the rest of the apparatus, which includes a manual control valve to regulate a flow of the liquid carbon dioxide, a heat exchange coil across which heat transfer takes place to cool the flow of liquid carbon dioxide, an expansion nozzle and a foraminous bag attached to the outlet of the expansion nozzle. An insulation cover is provided to surround the foraminous bag and heat exchange coil and to allow passage of gases therethrough. A portion of the liquid carbon dioxide which expands through the expansion nozzle is immediately converted into solid carbon dioxide collected at the bottom of the foraminous bag, while the rest of the liquid carbon dioxide evaporates into gaseous carbon dioxide which flows out of the foraminous bag to atmosphere. Many of the components of the apparatus are conveniently made of plastics materials for durability and low weight.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Materials, metallurgy",,,,,,C01B/55
5151188,29-Sep-92,1992,9,29,Supercritical fluid extraction enhancer,A method for enhancing supercritical fluid extraction of sample matrices which contain water. The method involves mixing the samples with an extraction enhancing aid comprising flux-calcined diatomaceous earth which increases the permeability of the sample in a supercritical fluid and controls water during the extraction procedure.,16,"The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Chemical engineering,,,,,,B01D/0203
5153309,6-Oct-92,1992,10,6,Process of making tetrahydropteroylpoly-L-glutamic acid derivatives,The invention is a method of synthesizing tetrahydropteroylpoly-L-glutamic acid derivatives starting from the mono-L-glutamic acid derivatives. The method has the advantage of not requiring any enzymes.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/14
5155137,13-Oct-92,1992,10,13,Complexes of nitric oxide with polyamines,"There are disclosed novel complexes of nitric oxide and polyamines which are useful in treating cardiovascular disorders, including hypertension. The disclosed compounds release nitric oxide (endothelium-derived relaxing factor) under physiological conditions in a sustained and controllable fashion, and possess long mechanisms of action.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/06
5157049,20-Oct-92,1992,10,20,Method of treating cancers sensitive to treatment with water soluble derivatives of taxol,The invention involves the treatment of cancer in humans by administering water soluble derivatives of taxol. The types of cancer so treatable are those sensitive to treatment with taxol.,7,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/495
5158874,27-Oct-92,1992,10,27,Determining metastic potential of tumor cells and isolating metastic tumor cells,"The present invention discloses a biologically active basement membrane composition. When polymerized under physiogical conditions, the composition forms gel-like structures whose ultrastructure resembles interconnected thin sheets of the lamina densa zone of basement membrane. The major components of the composition include laminin, type IV collagen, heparan sulfate proteoglycan, entactin and nidogen. These components polymerize in constant proportions when redissolved and allowed to reconstitute. Molecular sieve studies on the soluble extract demonstrate that laminin, entactin and nidogen are associated in a large but dissociable complex. The reconstituted matrix is biologically active and stimulates the growth and differentiation of a variety of cells, including epithelial cells, nerve cells, hair follicles and the like. The reconstituted matrix can also be used for determining metastatic potential of tumor cells and for isolating metastatic tumor cells.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/50
5158940,27-Oct-92,1992,10,27,Use of suramin to treat rheumatologic diseases,Polysulfonated compounds such as suramin are used to treat immunoregulatory isorders. Particular use in the treatment of rheumatologic diseases such as rheumatoid arthritis is shown.,11,"The United States Government as represented by the Secretary, DHHS",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/715
5159063,27-Oct-92,1992,10,27,Isolation and characterization of a 120 kDa glycoprotein plasma,"A substantially pure, single chain plasma protein of approximately 120 kDa having an N-terminal amino acid sequence EKNGIDIYSLTD, and a mixture of protein fragments having vasodilatory activity which fragments are generated by activated Kallikrein cleavage of the 120 kDa protein.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4703
5162223,10-Nov-92,1992,11,10,Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis,"A panel of monoclonal antibody (Mab) producing hybridomas directed against various antigens of Bordetella pertussis are disclosed herein. The hybridomas and the antigens that the resulting monoclonals are directed against include: (1) BPG10F8C3 and BPE8D8B1--lipooligosaccharide A (LOS A), serotype 1; (2) BPD5, BPE6, and BPF2--fimbriae, serotype 2; (3) BPE3, BPE8 and BPD8--69 kDa nonfimbrial protein, serotype 3; and (4) BPB7, BPC10, BPD4, BPD6, BPD9, and BPF5--fimbriae, serotype 6.",18,The United States of America as represented by the Secretary of the Department of Health and Human Resources,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1225
5162361,10-Nov-92,1992,11,10,Method of treating diseases associated with elevated levels of interleukin 1,"The present invention relates to a method of treating diseases associated with elevated levels of interleukin 1 (IL-1) including inflammatory diseases such as arthritis, skin hypersensitivity and endotoxemia. More specifically, the invention relates to a method for the treatment of such diseases in warm-blooded animals, such as humans, which comprises the administration of a therapeutically effective amount of an aromatic diamidine, sufficient to inhibit IL-1 release from IL-1 producing cells. The aromatic diamidine can also be used to block interleukin 6 (IL-6) and tumor necrosis factor from cells producing these cytokines.",28,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/415
5163617,17-Nov-92,1992,11,17,Low-cost ultrasonic nebulizer for atomic spectrometry,"An ultrasonic humidifier is converted to a low-cost, geyser-type ultrasonic nebulizer for atomic spectrometry. The device may be operated in either a batch or the continuous mode. Long-term precisions of 1-2% were achieved for 14 elements. For a sample uptake rate of 1 mL/min., detection limits measured with the geyser-type ultrasonic nebulizer were superior to those obtained with a PN by a factor of 8-50. While detection limits measured utilizing the converted nebulizer of the present invention were similar to those reported for commercial ultrasonic nebulizers, the converted nebulizer of the present invention is much less expensive.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B05B/0607
5164313,17-Nov-92,1992,11,17,Recombinant vaccinia virus encoding cytochromes P-450,The present invention is related to the construction and application of vaccinia virus containing DNA sequences for encoding and efficient expression of enzymatically active cytochrome P-450 polypeptides in mammalian cells. Preparation and use of pure P1-450 and P3-450 cytochromes have been described.,8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5166059,24-Nov-92,1992,11,24,Gene therapy using gene fusions for genetic or acquired disorders,Gene therapy utilizing an MDR1 linked fusion coding sequence has been disclosed. ADA activity has been introduced into cells using MDR1 linked fusion gene.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Other special machines,,,,,C12N/78
5167956,1-Dec-92,1992,12,1,Immunotoxin with in-vivo T cell suppressant activity,"The present invention relates to an immunotoxin. The invention further relates to a method of treating T cell leukemias and lymphomas, graft-versus-host diseases, and autoimmune diseases by administering an immunotoxin.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/00
5169521,8-Dec-92,1992,12,8,Apparatus for countercurrent chromatography separations,"The invention relates to an improved continuous countercurrent chromatography apparatus. The invention further relates to an improved method of countercurrent chromatography comprises filling a separation column with a first solvent, introducing into the column a sample solute to be separated, continuously pumping a second solvent into the column, the second solvent being substantially immiscible with the first solvent, maintaining the solvent flowing out of the column at a temperature effective to avoid clouding thereof, spectrophotometrically monitoring the temperature-maintained separating fractions flowing out of the column, and applying back-pressure to the solvent flowing into and out of the monitor.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/42
5169984,8-Dec-92,1992,12,8,"Synthesis and characterization of N-bromoacetyl-3,3'5-triiodo-L-thyronine using high speed countercurrent chromatography","A method for synthesizing N-bromoacetyl-3,3',5-triiodo-L-thyronine which involves subjecting 3,3', 5-triiodo-L-thyronine to a one-step bromacetylation reaction wherein 3,3', 5-triiodo-L-thyronine and bromoacetyl bromide are refluxed together in a solution of ethyl acetate. After formation the N-bromoacetyl-3,3'-triiodo-L-thyronine is purified by fractionation utilizing high speed countercurrent chromatography. Labeled N-bromoacetyl-3,3'-5-triiodo-L-thryonine may be made by a one-step bromacetylation reaction by reducing either [.sup.125 I]T.sub.3 or [.sup.14 C]T.sub.3 with bromoacetyl bromide.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07C/47
5170286,8-Dec-92,1992,12,8,Rapid exchange imaging chamber for stop-flow microscopy,"A specimen chamber comprising a central chamber element sandwiched between a base plate and a cover plate, which base plate and cover plate secure cover slips within recessed areas on opposite surfaces of the central chamber portion which face the base and cover plate. The central chamber element includes a central flow passage, which terminates at opposite ends into tee channels. The sandwiched arrangement of the elements is secured by locking pins, which are insertable into alignment post elements that extend from the base plate though the central chamber element and the cover plate. The locking pins include a plurality of locking cams.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Optics,,,,,,G02B/34
5171663,15-Dec-92,1992,12,15,"Monoclonal antibody against regulatory protein, sgp 120",Monoclonal antibodies against complement regulatory protein sgp 120 are provided.,6,The United Stated of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/6863
5171676,15-Dec-92,1992,12,15,Method of introducing hydroxyl groups into artemisinin and its derivatives,"The fungus Beauveria sulfurescens has been employed to introduce hydroxyl groups into artemisinin and derivatives of artemisinin, an antimalarial. Hydroxylated derivatives of artemisinin and derivatives of artemisinin produced thereby possess antimalarial activity, and can serve as intermediates in the synthesis of further derivatives useful in treating malaria.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12P/181
5171750,15-Dec-92,1992,12,15,Substituted phenserines as specific inhibitors of acetylcholinesterase,"The present invention relates to substituted phenylcarbamate or naphthylcarbamate tricyclic compounds which provide highly potent and selective cholinergic agonist and blocking activity and their use as pharmaceutical agents. The invention further relates to improvements in therapy relative to cholinergic diseases such as glacuoma, Myasthenia Gravis, Alzheimer's disease and to improvements in therapy and organophosphate poisoning. The invention further provides for a selective acetylcholinesterase and butyrylcholinesterase agents and a method for inhibiting these esterases.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5173405,22-Dec-92,1992,12,22,Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors,"The present invention is directed to a method for selectively blocking or inactivating glucocorticoid receptors by administering a glucocorticoid receptor blocking effective amount of arsenite or methyl methanethiolsulfonate (MMTS) in a sample. Thus, arsenite and MMTS constitute new, simple, reversible, and inexpensive reagents for assaying glucocorticoid receptors in the presence of other receptors and for eliminating the complications of assaying other receptors in the presence of glucocorticoid receptors.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/57415
5173481,22-Dec-92,1992,12,22,Preparation of specifically substituted cyclodextrins,"A process for producing monosubstituted alpha-, beta-, and gamma-cyclodextrins includes the step of condensing an excess of a cyclodextrin with an epoxide under alkaline conditions. A process for increasing the solubility of cyclodextrins includes the step of reacting a cyclodextrin with an amine under heterogenous catalytic conditions, or subjecting the cyclodextrin to sulfatation. Compositions useful in these processes include one containing at least one cyclodextrin, ammonia and Raney nickel, and a second composition containing at least one cyclodextrin, chlorosulfonic acid and pyridine.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Macromolecular chemistry, polymers",,,,,,C08B/0012
5173509,22-Dec-92,1992,12,22,Suramin and active analogues thereof in the treatment of hypercalcemia,"A method is disclosed for the treatment of hypercalcemia in a patient, by administering to the patient an effective amount of suramin, or an active analogue thereof, for lowering calcium plasma levels in the patient. Human data shows a single course of treatment lowers plasma calcium levels to normal for three months.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/185
5175342,29-Dec-92,1992,12,29,Esters of 3-demethylthiocolchicine and n-acyl analogs,"The present invention relates to esters of 3-demethylthiocolchicine and N-acyl analogs thereof having the following formula: ##STR1## wherein R is O-CO-alkyl, O-CO-CH.sub.2 Oalkyl, O-CO-Phenyl, O-COOalkyl; the alkyl group having from 1 to 4 carbon atoms and the Ac group representing acetyl and its higher homologs, benzoyl, alkoxyacetyl, or haloacetyl. The invention further relates to processes for preparing these ester compounds, pharmaceutical compositions thereof and methods for treating diseases such as gout, Mediterranean fever and liver disorders.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07C/41
5176566,5-Jan-93,1993,1,5,Variable air flow eddy control,"Methods and apparatus for controlling the flow of fluid around an object which include means to periodically vary or fluctuate the direction, speed or magnitude of the fluid flow. The fluid flow is particularly controlled to control eddy formation. The fluid is preferably a gas or vapor.",3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B08B/02
5180662,19-Jan-93,1993,1,19,Cytotoxic T lymphocyte activation assay,A method is provided for the quantitative study of cytotoxic T-lymphocyte activation by measuring secreted granule-associated BLT esterase activity after incubating the cytotoxic T-lymphocytes with activating stimuli. This method can be used to screen inhibiting (drugs) or activating agents (monoclonal antibodies) (at selected sub-optimal levels of activation of cytotoxic T-lymphocytes.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5008
5182215,26-Jan-93,1993,1,26,Screening test for pineocytoma,A novel method of diagnosing pineal cell tumors by detecting S-antigen in CSF is described.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/57407
5182262,26-Jan-93,1993,1,26,Calmodulin binding peptide derivatives of non-erythroid alpha spectrin,"The present invention relates to a polypeptide and derivatives thereof deduced from the native structure of non-erythroid alpha spectrin and compositions thereof. One embodiment of the invention is 24 amino acids in length and composed of the following linear sequence of residues: Lys-Thr-Ala-Ser-Pro-Trp-Lys-Ser-Ala-Arg-Leu- Met-Val-His-Thr-Val-Ala-Thr-Phe-Asn-Ser-Ile-Lys-Glu. The invention further relates to methods of using the polypeptide, such as methods for treating disorders including prophylaxis against organ and tissue transplant rejection or treatment of autoimmune disorders.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5183756,2-Feb-93,1993,2,2,Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same,The present invention relates to the monoclonal antibody (termed D612) having selective reactivity for gastrointestinal carcinoma and methods for employing the same. A hybridoma producing such antibodies has been prepared.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/3046
5183949,2-Feb-93,1993,2,2,Rabbit model for diagnosing and testing vaccines or therapeutic agents against AIDS,"A rabbit model for testing anti-AIDS therapeutic agents, vaccines, and HIV-1 infection is described.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56988
5185142,9-Feb-93,1993,2,9,Antigen-specific composition and in vivo methods for detecting and localizing an antigenic site and for radiotherapy,"A composition comprises an antigen-specific antibody or antigen-binding fragment thereof labeled with Iodine-124 at a site other than, and which does not significantly interfere with, the antibody-antigen binding site. An in vivo method of radiotherapy directed to an antigenic site comprises administering to a subject in need of the therapy an amount of the antigen-specific composition described above effective to attain a reduction of the size of a tumor associated with the antigen. An in vivo method for detecting and localizing an antigenic site in a subject in need of such detection comprises administering to the subject an amount of the antigen-specific composition of the invention effective to localize the antigen-antibody binding site and scanning the subject's body with a positron-emitter detector to attain the localization of the site. An in situ method of radiotherapy directed to an antigenic site in a subject in need of such therapy comprises detecting and localizing the site by the in vivo method described above and thereafter in situ delivering a positron-emitting labeled antibody chelate capable of binding to either the I-124 labeled antibody or fragment thereof, or to the antigen at a site other than the antibody-antigen binding site.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1066
5185376,9-Feb-93,1993,2,9,Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof,"A method of inhibiting platelet aggregation in vivo with physiologically compatible compounds containing at least one N-oxo-N-nitrosoamine moiety in a molecule thereof, wherein the physiologically compatible compound releases nitric oxide in a sustained and controllable fashion in vivo.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/13
5185576,9-Feb-93,1993,2,9,Local gradient coil,"A compact local gradient coil is combined with a local RF coil to provide lower powered, higher strength gradient fields and faster gradient response as is useful in magnetic resonance imaging. Interference between the RF coil and gradient coil is minimized by placement of the gradient coil external to the RF coil and by gradient coils that are axially symmetric and/or have conductors substantially orthogonal to the RF coil conductors. Acoustic noise in these smaller, stronger coils is reduced with ports cut into the coil forms.",12,General Electric Company,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Measurement,,,,,,G01R/34046
5186167,16-Feb-93,1993,2,16,Catheter tip for intratracheal ventilation and intratracheal pulmonary ventilation,"A method and apparatus for intratracheal ventilation (ITV) and intratracheal pulmonary ventilation (ITPV) in which a catheter positioned in a patient's trachea at the carina supplies a constant supply of fresh oxygen containing gas to flush anatomical dead space. By positioning the catheter in the patient's trachea, the dead space of the trachea is bypassed and the trachea is only utilized for expiration. The catheter includes a catheter tip which directs the constant supply of fresh oxygen containing gas in a manner so as to create sub-atmospheric pressures near the carina and thus allows control of intratracheal airway pressures during the entire respiratory cycle and prevents overinflation of the lungs.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/04
5189022,23-Feb-93,1993,2,23,Composition for the treatment of chronic fatigue syndrome,"The present invention relates to a method of treating chronic fatigue syndrome not associated with an HIV infection. In the method of the present invention patients are administered a pharmaceutically acceptable carrier together with PA1 (1) a neuropsychiatrically effective amount of a linear peptide of formula (I): EQU R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.6 (I) wherein PA1 R.sup.a is Ala, D-Ala or Cys-Ala-, and PA1 R.sup.6 is Thr, Thr-amide, Thr-Cys or Thr-Cys-amide, or a derivative of the peptide or a physiologically acceptable salt thereof; or PA1 (2) a neuropsychiatrically effective amount of a linear peptide of formula (II): EQU R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II) wherein PA1 R.sup.1 is X-Y or Y when Y is Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu-, and X is Cys; PA1 R.sup.2 is Thr-, Ser- or Asp; PA1 R.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp; PA1 R.sup.4 is Tyr; and PA1 R.sup.5 is Z-X or Z wherein Z is any amino acid and X is Cys, or a derivative of the peptide or a physiologically acceptable salt thereof; or PA1 (e) a neuropsychiatrically effective amount of a linear peptide of formula (III): EQU R.sup.x -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.y (III) wherein PA1 R.sup.x is Ala-R.sup.1, D-Ala-R.sup.1 or X-Ala-R.sup.1 wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 are as defined above, and R.sup.y is Thr-, Thr-amide or Thr-Cys, or a derivative of the peptide or a physiologically acceptable salt thereof.",5,The United States of America as represented by the Secretary of Health and Human Services STA DC COD 06,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70514
5190746,2-Mar-93,1993,3,2,Plaque inhibiting oligosaccharide,"A purified oligosaccharide consisting of a hexasaccharide with a native molecular weight of 959 which can be isolated from the cell walls of Streptococcus oralis. The oligosaccharide is able to significantly block the interaction between the human oral plaque bacteria Streptococcus oralis H1 and Capnocytophaga ochracea ATCC 33596. This purified oligosaccharide contains saccharide components found to inhibit many know interactions between plaque bacteria and may be effective in prevention, inhibition and reversal of dental plaque deposits. The oligosaccharide may be applied effectively when incorporated in toothpastes, mouth wash, etc.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C12P/04
5190969,2-Mar-93,1993,3,2,"2,3-epoxy derivatives as anti retrovital chemotherapeutic agents","The present invention is related to compounds, compositions and methods of treating viral infections. Compounds of the present invention have the following general formula: ##STR1## wherein R is selected from --CH.sub.2 OH, --CO.sub.2 R.sup.2, --CONR.sup.3 R.sup.4, or COR.sup.5, wherein R.sup.2 is hydrogen or a lower alkyl group, R.sup.3 and R.sup.4 are each independently hydrogen or a lower alkyl group, R.sup.5 is an amino acid residue bound via a terminal nitrogen or peptide having at least two amino acid residues; and wherein R.sup.1 is C.sub.5 -C.sub.13 alkyl, aryl, aralkyl, aralkyl(lower alkyl) ether, or C.sub.5 -C.sub.13 alkyl (lower alkyl)ether.",9,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,Biotechnology,,,,C07D/22
5192660,9-Mar-93,1993,3,9,ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids,"Enzyme linked immunosorbent assay (ELISA) methods for quantitatively determining the level of PDGF-BB and PDGF-AB, or, PDGF-AA and PDGF-AB present in a human's bodily fluids, tissue extracts, or a fluid contacting humans cells in culture, are disclosed.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/74
5192679,9-Mar-93,1993,3,9,Growing Ehrlichia species in a continuous cell line,The present invention relates to a method of continually propagating Ehrlichia canis in a microphage-monocyte cell line referred to as DH82.,5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/20
5196415,23-Mar-93,1993,3,23,"5-aminocarbonyl-5H-dibenzo[a.d]cyclohepten-5,10-imines for treatment of epilepsy and cocaine addiction","This invention is in the field of clinical neurology and relates specifically to compounds, compositions and methods for treatment of patients with generalized epilepsy or partial (symptomatic) epilepsy using compounds of the formula: ##STR1## This invention also relates to compounds, compositions and methods of treatment for drug craving in patients addicted to cocaine.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/00
5196799,23-Mar-93,1993,3,23,Method and apparatus for testing a protective barrier material for pinholes and tear strength,"A method and apparatus for the non-destructive testing of a protective baer material. In a preferred embodiment, the method comprises applying an alternating electrical current across the protective barrier material for establishing a conductivity, G, of the protective barrier material and/or a quality factor, Q, of the protective barrier material. The conductivity, G, and/or the quality factor, Q, are measured at more than one frequency. The quality factor and/or conductivity measurements so obtained at the more than one frequency are compared to predetermined quality factor and/or conductivity limits.",34,Drexel University,United States of America as represented by the Food & Drug Administration,,,,,,,,,,2,Measurement,Medical technology,,,,,G01M/40
5198347,30-Mar-93,1993,3,30,DNA encoding Plasmodium vivax and Plasmodium knowlesi Duffy receptor,"The present invention relates to DNA segments encoding the Duffy receptor of a Plasmodium parasite, the recombinant DNA and to recombinantly produced Duffy receptor. The Duffy receptor can be utilized as a vaccine for humans against malaria.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
5200546,6-Apr-93,1993,4,6,Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis,"There are disclosed novel compounds of the formula: ##STR1## wherein, x is --CH.sub.2 --, --CHF--, --CF.sub.2, --CHOH-- or --C(O)--; PA0 R.sup.6 is hydrogen, benzyl, pentafluorophenyl, nitrophenyl, 1-benzotriazolyl or 1-succinimidoyl; PA0 Fmoc is 9-fluorenylmethyloxycarbonyl; and PA0 * indicates a chiral carbon atom. The Formula (I) compounds are useful in synthesizing peptides. There are also disclosed novel synthesis methods which include the step of hydrogenating a compound of the Formula ##STR2## wherein R.sup.4 and R.sup.5 are C.sub.1-8 lower alkyl, to give a compound of the formula ##STR3## wherein R.sup.4 and R.sup.5 are as defined above. The compounds of formula (II) are useful as intermediates in preparing certain formula (I) compounds.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/4056
5202113,13-Apr-93,1993,4,13,Plaque-inhibiting protein from bacteroides loeschei and methods for using the same,"A purified, characterized surface protein from Bacteroides loeschei is an adhesin which is useful in inhibiting plaque formation. The adhesin is also useful in a diagnostic assay for gingivitis, a diagnostic indicator for changes in the surface components of certain human tissues, and as a binding agent to purify polysaccharides.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/195
5203339,20-Apr-93,1993,4,20,Method and apparatus for imaging a physical parameter in turbid media using diffuse waves,"Imaging of a turbid object utilizes interference among the modulation wavefronts of a plurality of modulated light rays propagating through the object by diffusion and having predetermined phases relative to one another. A computer controlled phase and amplitude selecting device, such as a zone plate, is used to modulate light rays at appropriate phases in order to obtain constructive interference only at a predetermined portion of the object, including one or more preselected voxels. The rays reflected from (or diffusively transmitted through) the predetermined portion are received simultaneously at a detector, thus providing simultaneously all the data necessary to describe or image the portion. A single detector element may be used to detect the scattered reflected or transmitted light from the portion and to generate a signal representing the amplitude and phase characteristics for the modulation wavefront, thereby to provide absorption (and other) characteristics descriptive of the portion. An array of detectors may be used to detect the light from a plurality of individual voxels simultaneously and to provide such characteristics for each of the voxels. By dynamically controlling the phase and amplitude selecting device, the voxels selected for imaging are changed without mechanical scanning. Light rays having different frequencies may be modulated to provide complete absorption spectra for an arbitrarily selected portion of the object.",21,The Government of the United States of America as represented by the Secretary of the Department Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01J/04
5204098,20-Apr-93,1993,4,20,Polysaccharide-protein conjugates,"Vi capsular polysaccharides conjugated to toxin-dependent proteins can be used to enhance antibody response and to convert T-dependent properties to the Vi capsular polysaccharide. A heterobifunctional crosslinking agent can be used to bind thiol derivatives of the Vi capsular polysaccharides to the proteins, such as diphtheria, tetanus toxoids, cholera toxin and Haemophilus influenzae.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0275
5206353,27-Apr-93,1993,4,27,CD-4/cytotoxic gene fusions,A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70514
5208021,4-May-93,1993,5,4,Method of preparing diphtheria immunotoxins,"A potent and specific immunotoxin is prepared by coupling an inactivated diphteria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,Cetus Corporation,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/34
5208233,4-May-93,1993,5,4,Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof,"There are disclosed anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component in the anti-hypertensive compositions is a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl group; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a heterocyclic ring; M.sup.+X is a pharmaceutically acceptable cation, wherein x is the valence of the cation.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/30
5208338,4-May-93,1993,5,4,"Radiolabeled N-substituted-6-iodo-3,14-dihydroxy-4,5.alpha.-epoxymorphinans","The present invention is directed to radiolabeled N-substituted-6-iodo-3,14-dihydroxy-4,5.alpha.-epoxymorphinans, intermediates for producing the same, and a process for the preparation and methods of detecting opioid receptors. The radioimaging agent of the present invention has the following formula: ##STR1## wherein I is selected from the group consisting of .sup.123 I and .sup.125 I; and where R is alkyl, cycloalkylloweralkyl or allyl.",5,The United States of America as represented by the Department of Health & Human Services.,,,,,,,,,,,1,Analysis of biological materials,Organic fine chemistry,,,,,G01N/534
5209128,11-May-93,1993,5,11,Safety pipette and adaptor tip,"A safety pipette is characterized in that an openable seal (6) is present within the pipette, necessitating the use of a forcing element (9) to hold the seal in an open position in order to use the pipette. Pipette inserts provide the seal in standard pipettes. Pipette adaptors provide the necessary forcing element. Pipette supports or nosepieces for pipetting devices are modified with a pipette adapter (8) allowing the use of safety pipettes. The forcing element is a pin, or rod, firmly made part of a nosepiece, or an adaptor that moves a flap or ball within a pipette away from a closed position into an open position, allowing air flow through the safety pipette. Kits comprise modified nosepieces or replacement elements thereof with safety pipettes per se, or with safety pipette inserts, and kits comprise pipette adaptors with safety pipettes or safety pipette inserts.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B01L/021
5209920,11-May-93,1993,5,11,Evaluative means for detecting inflammatory reactivity,"Inbred Lewis (LEW/N) female rats develop an arthritis in response to Group A streptococcal cell wall peptidoglycanpolysaccharide (SCW) which mimics human rheumatoid arthritis. Histocompatible Fischer (F344/N) rats, on the other hand, do not develop arthritis in response to the same SCW stimulus. To evaluate this difference in inflammatory reactivity between the two strains, the function of the hypothalamic-pituitary-adrenal axis and its ability to modulate the development of the inflammatory response was studied. It has been found that, in contrast to F344/N rats, LEW/N rats had markedly impaired plasma ACTH and corticosterone responses to SCW, recombinant human Interleukin-1 alpha (IL-1 alpha), the serotonin agonist, quipazine, and synthetic rat corticotropin-releasing hormone (CRH). In addition, LEW/N rats compared to F344/N rats had smaller adrenal glands and larger thymuses. Treatment of LEW/N rats with replacement doses of dexamethasone decreased the severity of their SCW-induced arthritis. Conversely, treatment of F344/N rats with the glucocorticoid receptor antagonist, RU 486, or the serotonin (5-HT.sub.2) antagonist, LY53857, was associated with development of severe inflammatory disease, including arthritis, in response to SCW. These findings support the concept that susceptibility of LEW/N rats to SCW arthritis is related to abnormal hypothalamic-pituitary-adrenal (HPA) axis responsiveness to inflammatory and other stress mediators and that resistance of F344/N rats to SCW arthritis is regulated by an intact HPA axis-immune system feedback loop.",41,The United States of America as represented by the United States Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/135
5210414,11-May-93,1993,5,11,Differential surface composition analysis by multiple-voltage electron beam X-ray spectroscopy,"A method of differential surface composition analysis which allows non-destructive compositional analysis with depths below a solid surface is used to analyze respirable dust particles to determine the presence of hazardous components in the surface of the dust particles. A method of incubating respirable particles in a surrogate pulmonary surfactant system used in combination with the differential surface composition analysis allows determination of surface components which survive or are exposed on the respiratory particles after incubation in the surrogate pulmonary surfactant, representing modification of the partical surface upon deposition in the lung.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/02
5211657,18-May-93,1993,5,18,"Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides","The present invention relates to peptides and derivatives thereof having laminin-like activity. The invention further relates to pharmaceutical compositions containing these peptides, to antibodies effective against these peptides, and to vectors containing a DNA sequence of cDNA coding for the A chain of laminin. The peptides of the invention may be used to treat diseases such as cancer.",17,The United States Government as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Biotechnology,Medical technology,,,,A61L/10
5212084,18-May-93,1993,5,18,Retrovirus and related method used for producing a model for evaluating the antiretroviral effects of drugs and vaccines,"A retrovirus and related method used in producing a model for evaluating the antiretroviral effects of drugs and vaccines includes the steps of removing T-lymphotropic retrovirus from a first simian primate which has developed disease over a first period of time, the disease being attributable to the retrovirus, and placing the retrovirus into a second simian primate to induce acute disease in the second simian primate over a second period of time which is shorter than the first period.",1,Emory University,Centers for Disease Control,,,,,,,,,,2,Biotechnology,,,,,,C12N/00
5212204,18-May-93,1993,5,18,Antihypertensive compositions and use thereof,"This invention concerns antihypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein J is an organic or inorganic moiety, M.sup.+x is a pharmaceutically acceptable cation and the compound decomposes under physiological conditions to release nitric oxide (NO).",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/02
5214133,25-May-93,1993,5,25,SCL: a hematopoietic growth and differentiation factor,"We have identified a new human gene, SCL. We discovered this gene because of its involvement in a chromosomal translocation associated with the occurrence of a stem cell leukemia manifesting myeloid and lymphoid differentiation capabilities. Here we report the sequence of a cDNA for the normal SCL transcript, as well as for an aberrant fusion transcript produced in the leukemic cells. Although different at their 3' untranslated regions, both cDNAs predict a protein with primary amino acid sequence homology to the previously described amphipathic helix-loop-helix DNA binding and dimerization motif of the Lyl-1, myc, MyoD, Ig enhancer binding, daughterless, and achaete-scute families of genes. For these cDNAs, two forms of the SCL protein (greater than 20 and 30 kD) are predicted, both of which retain this putative DNA binding domain. The pattern of expression of SCL mRNA is primarily predominant in early hematopoietic tissues. Taken together, these studies lead to the speculation that SCL plays a role in differentiation and/or commitment events during hematopoiesis.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5215664,1-Jun-93,1993,6,1,Separation of rare earth elements with high-speed countercurrent chromatography,A method of separating rare earth elements and compounds from mixtures containing the same which comprises separating the rare earth elements and compounds by means of rotational high speed countercurrent chromatography.,15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,"Materials, metallurgy",,,,,B01D/1807
5215916,1-Jun-93,1993,6,1,Super glucocorticoid receptors: receptors with increased affinity and specificity for glucocorticoid steriods,"The present invention relates to novel glucocorticoid receptors that have greater affinity and specifity for glucocorticoid steroids than the naturally occurring receptors. More particularly, the invention relates to the altering of the equivalent of cysteine-656 of the rat glucocorticoid receptor to either serine or glycine for the production of super glucocorticoid receptors which retain full biological activity in intact cells and have higher affinity and specificity for glucocorticoid steroid binding than the original receptor. The invention further relates to the recombinant expression of such altered receptors in host cells.",8,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/721
5217690,8-Jun-93,1993,6,8,All tantallum stopped flow microcalorimeter,"A highly sensitive, quick recovery differential microcalorimeter includes two matchingly formed and cooperatingly disposed flow channels. Each flow channel has two inlets, at least one mixing assembly connected to each fluid inlet, a fluid outlet connected to each mixing assembly, at least one heater element surrounding at least a portion of each fluid outlet, and a plurality of sensors surrounding at least a portion of each fluid outlet. Each of the mixing assemblies includes a mixing chamber and at least one entry manifold connected to a fluid inlet and having a plurality of ports which connect to the mixing chamber.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/4893
5217715,8-Jun-93,1993,6,8,Carbohydrate receptor for bacteria and method for use thereof,"The invention is a carbohydrate receptor for pathogenic bacteria. The receptor is a purified carbohydrate compound that is a member selected from the group consisting of fucosyl-asialo GM1, asialo GM1, and asialo GM2. The invented receptor can be included in a composition having a pharmaceutically acceptable carrier. The invention includes methods for purifying, detecting, or removing bacteria from diseased tissue. The applicants have discovered a carbohydrate receptor for a variety of different species of disease-producing bacteria. The structure of the receptor is N-acetylgalactosamine-beta-1-4-galactose-beta-1-4-glucose, abreviated GalNAc.beta.1-4Gal.beta.1-4Glc. The receptor is present in human and animal tissues as complex molecules and can serve as the attachment site for bacterial infection. For example, fucosyl-asialo GM1, asialo GM1, and asialo GM2 are three biological molecules which occur in cell membranes and contain the carbohydrate receptor.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,,,,,G01N/56911
5217865,8-Jun-93,1993,6,8,Screening for Tay-Sachs disease with cloned DNA for beta-hexosaminidase,Methods are disclosed of detecting mutations in the alpha chain gene that makes pre-natal diagnosis of Tay-Sachs disease possible. Screening for carrier heterozygotes of Tay-Sachs is made feasible by this invention.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5217872,8-Jun-93,1993,6,8,Method for detection of Borrelia burgdorferi antigens,"The invention relates to novel antigens associated with Borrelia burgdorferi which are exported (or shed) in vivo and whose detection is a means of diagnosing Lyme disease. The antigens are extracellular membrane vesicles and other bioproducts including the major extracellular protein. The invention further provides antibodies, monoclonal and/or polyclonal, labeled and/or unlabeled, that react with the antigens. The invention is also directed to a method of diagnosing Lyme disease by detecting the antigens in a biological sample taken from a host using the antibodies in conventional immunoassay formats. The invention further relates to kits, for the diagnosis of Lyme disease, comprising the antibodies and ancillary reagents. The advantage of the antibodies used in the invention is that they react with the antigens from geographically diverse strains of Borrelia burgdorferi, but do not react with antigens from related Borrelia spirochetes.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1207
5217898,8-Jun-93,1993,6,8,Expression of the P. falciparum transmission-blocking antigen in yeast,The present invention relates to transmission-blocking vaccines against malaria. Vaccines of the present invention contain a recombinant Pfs25 Plasmodium falciparum protein produced by yeast cells and to yeast cells producing the protein. Mice and monkeys inoculated with the yeast-expressed Pfs25 of the present invention have developed antibodies with transmission-blocking activity. The present invention also relates to methods of preventing or treating malarial infections using the vaccines of the present invention.,5,The United States of America as represented by the Secretary of Health and Human Services,Chiron Corporation,,,,,,,,,,2,Biotechnology,,,,,,C07K/445
5217953,8-Jun-93,1993,6,8,Vasoactive intestinal peptide antagonist,The present invention relates to a peptide encoding an antagonist of VIP. The invention also relates to a method of using said peptide to antagonize VIP function. The invention further relates to a pharmaceutical composition.,3,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/083
5218099,8-Jun-93,1993,6,8,"Post-transfusion, non-A, non-B hepatitis virus polynucleotides","Purified virus particles, antigens, antibodies reactive with viral antigens, and a viral genetic material associated with non-A, non-B hepatitis are provided by the present invention. Cloned genetic material useful both in identifying intact virus particles of the invention and for use in diagnostic techniques and/or production of antigens is also disclosed.",11,The United States of America as represented by the Department of Health and Human Services,Genelabs Incorporated,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,G01N/5767
5219991,15-Jun-93,1993,6,15,Macrophage stimulating protein,The present invention relates to a method of purifying macrophage stimulating protein (MSP) and to the highly purified MSP. The present invention further relates to antibodies to MSP. The highly purified MSP may be used for fighting pathogen infections.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/24
5220006,15-Jun-93,1993,6,15,Identification of a suppressor of atherogenic apolipoprotein,A region in the apolipoprotein B gene has been identified that suppresses the transcription of apolipoprotein B. Polypeptides that bind to the suppressor region have been isolated.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/775
5220014,15-Jun-93,1993,6,15,RRNA specific oligonucleotides,The present invention relates to a method of inhibiting protein synthesis comprising contacting 28S rRNA of a protein synthesizing system with a protein synthesis inhibitory amount of an oligonucleotide that hybridizes to the -sarcin recognition domain loop of said 28S rRNA under condition such that hybridization occurs. The invention also relates to oligonucleotides suitable for use in such a method.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Organic fine chemistry,,,,C12N/113
5221669,22-Jun-93,1993,6,22,Antiviral compositions containing .alpha.-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections,The present invention is directed to antiviral compositions containing .alpha.-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections.,13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/715
5221693,22-Jun-93,1993,6,22,Antimicrobial and antiviral bis-adamantanamine compounds,"Several bis-adamantanamine compounds have been found to have a broad range of antiviral and antibacterial activities. Demonstrated activity against enveloped viruses, yeasts, fungi, gram positive and gram negative bacteria is shown.",26,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07C/265
5221732,22-Jun-93,1993,6,22,Antimicrobial magainin modified peptides,"Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser.sup.8, Gly.sup.13 and Gly.sup.18 are modified with Ala which is known to have high propensity. Amidation of Ser.sup.23, and acylation of Gly.sup.1 with acetyl or beta-alanyl and substitution of Gly.sup.1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helical structure for antimicrobial activity. The modified peptide analogues exhibit an increase of up to two orders of magnitude in antimicrobial activity and, in the most favorable case, no appreciable increase in hemolytic activity over magainin 1.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/46
5225330,6-Jul-93,1993,7,6,Diagnostic kit and diagnostic method utilizing carbohydrate receptors,"A diagnostic kit for detecting the presence of microorganisms, comprising an insoluble substrate; and a carbohydrate receptor immobilized on the insoluble substrate, the carbohydrate receptor being capable of adsorbing microorganisms; and a labelled reagent useful for detecting the presence of microorganisms bound to the carbohydrate receptors and a method for detecting the presence of specified microorganisms in a sample, which comprises contacting a sample to be tested with carbohydrate receptors immobilized on an insoluble substrate; and determining the extent of binding of microorganisms in the sample to the carbohydrate receptors by use of a labelled reagent.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/56933
5225440,6-Jul-93,1993,7,6,Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase,"A method of attenuating the symptoms of opioid withdrawal in a human or animal subject comprises administering to the subject an effective opioid withdrawal symptom attenuating amount of an inhibitor of nitric oxide synthase (NOS) for a period of time effective to attenuate such symptoms upon opioid withdrawal. NOS inhibitors useful in the present method include, for example, L-N.sup.G -nitroarginine, esters of L-N.sup.G -nitroarginine, L-N.sup.G -monomethylarginine, L-N.sup.G -benzylarginine, L-N.sup.G -aminoarginine, iminoethylornithine, and pharmaceutically acceptable salts thereof. These compounds can be used alone or in combination, in conjunction with conventional drugs, such as .alpha..sub.2 -adrenoceptor agonists, mixed agonist-antagonist opioids, and NMDA antagonists, to attenuate the symptoms of opioid withdrawal. Effective doses of NOS inhibitors range from about 1 .mu.g/kg/day to about 30 mg/kg/day, administered over the course of about 1 hour to about six days, followed by opioid withdrawal.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/415
5230997,27-Jul-93,1993,7,27,Methods of detecting the presence of human herpesvirus-7 infection,"The present invention relates to a new human herpesvirus-7, proteins encoded in the genome of the virus, and antibodies specific for the virus and proteins. The virus was isolated from human peripheral blood mononuclear cells following incubation of the cells under conditions promoting T cell activation. Cultures of lymphocytes infected with the virus exhibited a cytopathic effect and electron microscopic analyses revealed a characteristic herpesvirus structure. The new virus is distinct from previously characterized human herpesviruses. The invention also relates to bioassays for the diagnosis of human herpesvirus-7 and the detection of human herpesvirus-7 in a biological sample. It further relates to a vaccine for humans against human herpesvirus-7.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5231001,27-Jul-93,1993,7,27,TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor,The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further relates to methods that may be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting NGF-trk receptor pairs.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/564
5231025,27-Jul-93,1993,7,27,Anti-platelet monoclonal antibody,"A unique anti-platelet monoclonal antibody which binds to human platelet glycoprotein IV, and various utilities of the monoclonal antibody are described.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/36
5231580,27-Jul-93,1993,7,27,Automated method and apparatus for determining characteristics of nerve fibers,"An automated method and apparatus determines characteristics of nerve fibers. The apparatus includes an imaging unit that creates a digital image data representative of an image of a cross-section of a nerve fiber to be tested; a control unit, including image processing capability, is coupled to the imaging unit and analyzes the digital image data created by the imaging unit to identify particular characteristics of the nerve fibers including axon area, the myelin sheath area, the fiber area, the myelin sheath thickness, the fiber perimeter and the fiber eccentricity.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06K/0014
5232684,3-Aug-93,1993,8,3,"Labelled resiniferatoxin, compositions thereof, and methods for using the same","The present invention relates to labelled resiniferatoxin and congeners thereof. Preferably, the labelled compounds of the invention are radio or fluorescently labelled. The invention is further directed to compositions comprising these labelled compounds, as well as to methods of using these compounds.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,,A61K/0021
5234815,10-Aug-93,1993,8,10,Monoclonal antibodies against cytosolic thyroid hormone binding protein,"Antibodies having specific binding affinity for substantially pure, isolated, thyroid hormone binding protein (p58) are described.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/26
5235416,10-Aug-93,1993,8,10,System and method for preforming simultaneous bilateral measurements on a subject in motion,"A system is provided for performing simultaneous bilateral measurements on a subject in motion at a test location. The system employs a plurality of observed targets attached to the moving subject, the targets being viewed simultaneously by each of two cameras disposed on opposite sides of the subject. Each of the cameras has associated therewith a light source emitting a light of a selected wavelength, the wavelengths for the two cameras being deliberately selected to be different enough to enable each camera to image the light source of the other without corruption of the observed data. The simultaneously operating two camera units may be computer controlled in preprogrammed manner or may be controlled by the operation of a manual control panel. In either case, the overall intensity of the two light sources providing illumination at the two selected different wavelengths facilitates the provision of illumination which avoids confusion by reflectance from the subject at other than the selected targets.",26,The Government of the United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Measurement,,,,,,G01S/875
5236584,17-Aug-93,1993,8,17,Vacuum filtration apparatus,"A filtration apparatus provides for semiautomatic operation by including a filter element dispenser located at a filtration station. In order to effect removal of a used filter element from the filtration station, a tilting mechanism allows for tilting of a filtration stage which breaks or interrupts a vacuum which is otherwise continuously applied to the filtration station. In operation, the filter dispenser is manually rotated about a support to dispense a filter element in a filtration port at the filtration station. Next, a filtration cup which includes a filtration well is manually rotated about the support and positioned to be seated in the filtration port. After the filtration cup is seated in the filtration port a liquid to be filtered can be dispensed into the filtration well.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B01D/04
5238683,24-Aug-93,1993,8,24,Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs,"An aerosol preparation of reduced glutathione (GSH) is provided to augment the level of GSH in the lungs. Treatment of pulmonary conditions, where reduced level of GSH is found, by the aerosol preparation of the present invention is taught.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0078
5239998,31-Aug-93,1993,8,31,Apparatus and method for fluorescent excitation and detection from potentiometric dyes with a single-ended optical fiber,A method of detecting and recording action-potential-related fluorescent changes from a remote tissue situs which has been treated with a voltage-sensitivity dye. The method utilizes a single optical fiber to both direct excitation light to the remote tissue situs and receive emitted fluorescence from the remote tissue situs. The emitted fluorescence from the remote tissue situs is directed to a photomultiplier or photodiode which produces a resulting fluorescence-related signal which is analyzed. The method and related apparatus eliminates signal noise and allows accurate recording and analysis of action-potential-related fluorescent changes.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/64
5242800,7-Sep-93,1993,9,7,Receptor for pathogenic fungi,A glycolipid receptor that specifically binds pathogenic fungi has been identified. Various properties and utilities of the receptor have been described.,6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56961
5242813,7-Sep-93,1993,9,7,"Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors","The subject invention relates to monoclonal antibodies and uses thereof. In particular, the invention relates to three monoclonal antibodies, referred to as B1, B3, and B5, which are useful in the treatment and diagnosis of many forms of cancer.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,Pharmaceuticals,,,,C07K/30
5244460,14-Sep-93,1993,9,14,Method to foster myocardial blood vessel growth and improve blood flow to the heart,"A method for facilitating in a damaged heart or a heart in need of improved circulation the growth of cardiac blood vessels while reducing the risk of undesired vascularization in other areas of the body comprises: PA0 (a) inserting a catheter into a coronary artery and providing an infusion port of said catheter accessible to the administration of coronary drug injections; PA0 (b) injecting an effective amount into the heart of a blood vessel growth promoting peptide through said infusion port of said catheter; and PA0 (c) repeating periodically on subsequent days the step of injecting said blood vessel growth factor via said catheter, with said periodic injections being continued until improved cardiac blood flow has been obtained. The invention may be applied to a method for treating atherosclerosis of the coronary arteries, which comprise as part of the treatment steps the above method for improving cardiac blood flow via the growth of cardiac blood vessels.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/00
5244656,14-Sep-93,1993,9,14,Antigen specific plasmacytomas and antibodies derived therefrom,Disclosed herein is a method for producing antibodies against an antigen of interest. Animal cells are exposed to both the antigen of interest and a recombinant retroviral vector. The vector contains a combination of oncogenes capable of inducing plasmacytomas. Plasmacytoma formation takes place rapidly and takes place in the presence of the antigen. A very high proportion of the plasmacytomas that are recovered are antigen specific.,1,Wisconsin Alumni Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
5244884,14-Sep-93,1993,9,14,Thionated analogues of thyrotropin releasing hormone,"There are disclosed thionated analogues of thyrotropin releasing hormone, having the formula: ##STR1## wherein, Q, W, X and Y, same or different, are oxygen or sulfur, with the proviso that at least one of Q, W, X and Y is always sulfur; PA1 Z is lower alkyl or (4-imidazolyl)methyl; and the pharmaceutically acceptable salts thereof. The disclosed compounds highly and selectively bind to TRH binding sites in animal tissues, and their utility in treating a variety of diverse physical conditions is disclosed. Pharmaceutical compositions containing the compounds are also disclosed.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/0821
5246692,21-Sep-93,1993,9,21,Backbone polysubstituted chelates for forming a metal chelate-protein conjugate,New polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates of the same are described together with the methods of preparing such compounds. A method of delivering radiolabelled compound of the present invention to a target site while minimizing the distribution of the compound to non-targeted organs or tissues is also disclosed.,7,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07C/24
5246833,21-Sep-93,1993,9,21,Kit for diagnosis of P. carninii and method thereof,Hybridomas producing antibodies having specific binding affinity against Pneumocystis carinii have been obtained and a method and kit for detecting P. carinii infection in humans have been described.,19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/14
5248594,28-Sep-93,1993,9,28,Immunodiagnostic reagent specific for legionella,"A set of three unique monoclonal antibodies have been produced which recognize Legionella with particular specificity, without substantial cross-reactivity with non-Legionella bacteria. These monoclonal antibodies are useful as immunodiagnostic reagents for detecting Legionella.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/126
5248667,28-Sep-93,1993,9,28,Method of treating psoriasis using synthetic peptide compositions,Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in patients who lack antibodies against HIV.,7,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/08
5248770,28-Sep-93,1993,9,28,Molecular probes for adenosine receptors,"This application discloses probes for adenosine receptors which are functionalized congeners of the following compound: ##STR1## wherein R is --CH.sub.2 --C(O)--R' or ##STR2## These probes bind to A.sub.2 and A.sub.3 adenosine receptors and aid in quantifying and characterizing the receptors. The compounds may be labeled, for example with fluorescent compounds or radioactive compounds, or unlabeled.",14,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07D/08
5250550,5-Oct-93,1993,10,5,Complexes of nitric oxide with polyamines,"There are disclosed novel complexes of nitric oxide and polyamines which are useful in treating cardiovascular disorders, including hypertension. The disclosed compounds release nitric oxide (endothelium-derived relaxing factor) under physiological conditions in a sustained and controllable fashion, and possess long mechanisms of action.",13,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,"Materials, metallurgy",,,,,C07C/06
5252477,12-Oct-93,1993,10,12,Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation,"HIV protease necessary for the natural synthesis of HIV has been identified and sequenced. Rabbit antiserum against the C-terminal portion of HIV protease has been produced and used to isolate natural HIV protease and characterize its activity. In addition, a method for producing synthetic HIV protease having the correct stereospecific conformation and specific HIV proteolytic activity has been achieved.",6,The United States of America as represented by the United States Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/506
5254457,19-Oct-93,1993,10,19,Monoclonal antibodies and method for identifying different aids-related viruses,"Novel hybridoma cell lines and monoclonal antibodies are provided which can differentiate between HIV-1, HIV-2 and SIV retrovirus isolates. A synthetic peptide which is useful as a universal diagnostic reagent for detecting retroviral infection is also described.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1045
5254539,19-Oct-93,1993,10,19,"Method of treating HIV with 2',3'-dideoxyinosine","A method for tearing retroviral infections including acquired immune deficiency syndrome (AIDS) with 2',3'-dideoxyinosine or 2',3'-dideoxyadenosine is disclosed. This antiviral effect is irreversible with 2',3'-dideoxyinosine and 2',3'-dideoxyadenosine but reversible with 2',3'-dideoxyguanosine.",7,"U.S. Government, Dept. of Health and Human Services, c/o National Institutes of Health",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
5255675,26-Oct-93,1993,10,26,Device for intratracheal ventilation and intratracheal pulmonary ventilation,"A method and apparatus for intratracheal ventilation (ITV) and intratracheal pulmonary ventilation (ITPV) in which a catheter positioned in a patient's trachea at the carina supplies a constant supply of fresh oxygen containing gas to flush anatomical dead space. By positioning the catheter in the patient's trachea, the dead space of the trachea is bypassed and the trachea is only utilized for expiration. By providing a timed expiratory valve in the ITPV mode, lower pressures and fresh oxygen flow rates may be utilized with respiratory rates from 10 to 120 breaths per minute or higher. The catheter has a diffuser tip, and the patient is ventilated at a flow rate between 0.54 to 4 times the anatomical dead space per breath.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/04
5256534,26-Oct-93,1993,10,26,"CD4.sup.+, latently HIV-1-infected hematopoietic progenitor cells","The present invention relates to a unique physiologic model of chronic human immunodeficiency virus type-1 (HIV-1) infection. In particular, the present invention relates to a chronically infected promyelocyte cell line harboring a single integrated provirus. Unlike other models of chronic infection, the cell line of the present invention remain CD4.sup.+ under normal culture conditions during which <10% of the cells constitutively express HIV-1 proteins. However, when treated with tumor necrosis factor-alpha (TNF-.alpha.), the cell line dramatically increased (>35-fold) HIV-1 expression and rapidly down-modulated surface CD4, as >95% of the cells became HIV-1.sup.+. These results with the new OM-10.1 cell line demonstrate that CD4 surface expression can be maintained during chronic infection and is critically dependent upon the state of viral activation; that CD4-gp160/120 intracellular complexing is responsible for CD4 down-modulation; and that protein kinase pathways function not only in the primary induction of latent HIV-1 but are also involved in maintaining the state of viral activation.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5258627,2-Nov-93,1993,11,2,Semiconductor structure using protein as its active element,A method and apparatus of testing semiconductor properties of a protein. Mercury electrodes are formed in an aqueous solution of protein and protein is adsorbed of the surface of the mercury electrodes. The electrical properties of the protein adsorbed thereon can be determined by applying current and voltage thereto.,31,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Measurement,Micro-structural and nano-technology,Semiconductors,,,,G01R/2648
5261793,16-Nov-93,1993,11,16,Miniature mechanical vacuum pump,"A miniature mechanical vacuum pump capable of producing intermediate vacuums on the order of about 10.sup.-1 to 10.sup.-2 Torr is provided by a peristaltic pump. In order to dissipate heat in the pump tubing, a cooling fan provides direct a continuously flow of air onto the pump tubing and pump parts contacting the tubing. The pump produces pressures in the range of about 10.sup.-1 to 10.sup.-2 Torr while consuming only about 17 Watts.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,"Engines, pumps, turbines",,,,,,F04B/1253
5262128,16-Nov-93,1993,11,16,Array-type multiple cell injector,"An injection device injects small amounts of injectate into each of a plurality of cells. A first plate, which may be made from a silicon chip, includes a large number of evenly spaced cell wells, in a regular array. Each well includes a through hole in the chip. A top plate, also formed from a silicon chip, includes a plurality of injection needles, arranged in a regular array corresponding to the position of the cell wells. A suspension of cells is washed over the first plate and individual cells are retained by the individual wells. A vacuum may be applied to the cell wells through a manifold beneath the first plate, thus to retain the cells in place. Excess cells and suspension are removed by washing the plate. The second plate, including the injection needles, is positioned on the first plate so that the needles pierce the plurality of cells retained in the wells, thus simultaneously introducing the injectate into a large number of individual cells.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Chemical engineering,,,,,C12N/87
5262359,16-Nov-93,1993,11,16,Method of propagating human paramyxoviruses using continuous cell lines,"A method of propagating human paramyxoviruses using a continuous cell line such as NCI-H292 (HuT-292), provides a suitable alternative to MK cells for the isolation and propagation of the human paramyxoviruses.",3,"The United States of America, as represented by the Secretary, Dept. of HHS",,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
5262945,16-Nov-93,1993,11,16,Method for quantification of brain volume from magnetic resonance images,"A simple, rapid and semi-automated method of MRI analysis based on mathematical modelling of MRI pixel intensity histograms. The method is accurate and reliable for regional analysis of brain, central and subarachnoid CSF volumes. The method can be used to reveal significant age-related changes in regional brain volumes which cannot be determined utilizing traced central CSF volumes or subarachnoid CSF volumes. The method can be used to quantify brain structure in healthy aging and brain disease.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/60
5264423,23-Nov-93,1993,11,23,Inhibitors for replication of retroviruses and for the expression of oncogene products,"Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.",48,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,Biotechnology,,,,A61K/70
5264557,23-Nov-93,1993,11,23,"Polypeptide of a human cripto-related gene, CR-3","The present invention relates, in general, to a human CRIPTO-related gene. In particular, the present invention relates to a DNA segment encoding a human CRIPTO-related gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a human CRIPTO-related polypeptide; a DNA segment encoding a genomic clone of the human CRIPTO gene (CR-1); antibodies specific to CR-3; and a method of measuring the amount of CR-3 in a sample.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5264607,23-Nov-93,1993,11,23,"Process of making benzylic .alpha.,.alpha.-diflurophosphonates from benzylic .alpha.-ketophosphorates","The disclosure is concerned with providing phosphonic acid-containing derivatives of phenylalanine and optically active isomers thereof, which are functionalized in a manner which makes them suitable for facile incorporation into peptides using standard solid-phase or solution-phase techniques. The disclosure is also concerned with providing an advantageous one-step reaction method for preparing benzylic .alpha.,.alpha.-difluorophosphonates from corresponding benzylic ketophosphonates.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/4056
5266313,30-Nov-93,1993,11,30,Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms,"Raccoon poxvirus, an organism that may be indigenous in nature, is established as a suitable substrate for insertion and expression of nucleotide coding sequence of heterolgous organisms. Two infectious raccoon poxvirus recombinants for expressing rabies virus surface spike glycoprotein (G) were produced by homologous recombination between raccoon poxvirus DNA and chimeric plasmids previously used for production of vaccinia virus recombinants by thymidine kinase insertional inactivation. Raccoons that were fed polyurethane baits loaded with raccoon poxvirus recombinant quickly developed high levels of rabies virus neutralizing antibodies and were protected when challenged with an otherwise lethal dose of raccoon rabies street virus. Dogs developed rabies virus neutralizing antibodies after feeding a vectored raccoon poxvirus recombinant in contrast to feeding a vaccinia: G recombinant that induced no rabies neutralizing antibodies. Cotton rats, skunks, mice and rabbits that were fed recombinant raccoon poxvirus developed variable levels of rabies neutralizing antibodies. All vaccinated cotton rats were protected from otherwise lethal rabies challenge.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5266562,30-Nov-93,1993,11,30,Anti-inflammatory agents,Synthetic oligopeptides having potent anti-inflammatory and phospholipase A.sub.2 inhibiting properties are described. A method of controlling inflammation of body tissue is also described.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/06
5270447,14-Dec-93,1993,12,14,Metalloproteinase peptides: role in diagnosis and therapy,"A family of metalloproteinases exist which cleave extracellular matrix molecules. These metalloproteinases are secreted in a latent inactive form and require activation in order to specifically cleave the preferred substrate. A series of peptides have been prepared based on the complete sequence analysis of type IV Procollagenase. Peptide inhibitors were synthesized which correspond to cysteine repeat regions and histidine containing regions; the mechanism of action of these peptides involves inhibition of binding of the enzyme to the substrate. Peptide inhibitors were synthesized which correspond to the peptide cleaved off during activation, and constitute a novel class of metalloproteinase inhibitors. These inhibitors are members of a series of peptides which contain the core amino acid sequence PRCG. The cysteine residue is required for activity. Affinity purified antibodies directed against specific peptides can be used to a) detect any general metalloproteinase enzyme with the sequence in part VAAHE or PRCGNPD, and distinguish it from other known members of the metalloproteinase family, b) block functional domains resulting in the inhibition of enzyme activity, and c) distinguish latent from activated forms of the enzyme.",3,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/8146
5272146,21-Dec-93,1993,12,21,"1,2-dihydroellipticines with activity against CNS specific cancer cell lines","Certain new 1,2-dihydroellipticine compounds having activity against CNS specific cancer cell lines because of their ease of passage across the blood-brain barrier are disclosed along with formulations and methods for treating CNS cancers employing these compounds.",10,The United States of America as represented by the United States Department of Health and Human Services,Purdue Research Foundation,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/04
5274121,28-Dec-93,1993,12,28,N-methyl-N-[4-(1-pyrrolidinyl)-2-butynyl]amide congeners as muscarinic agents,"Compounds, which are muscarinic agents, having the formula ##STR1## wherein Am is --N(R).sub.a).sub.2, --N(R.sub.a).sub.3.sup.+ I.sup.-, --N (CH.sub.2).sub.n', or ##STR2## n' is an integer from 2 to 7 and R.sub.a is an alkyl having 1 to 4 carbon atoms, and each R.sub.a may be the same or different wherein the other substituents are defined hereinbelow.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/125
5276016,4-Jan-94,1994,1,4,Small peptides which inhibit binding to T-4 receptors and act as immunogens,"Short peptide of the formula: EQU R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.b (I) where R.sup.a represents an amino terminal residue Ala- or D-Ala and R.sup.b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II): EQU R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II) where PA1 R.sup.1 is an amino terminal residue Thr-, Ser-, Asn-,Leu-,Ile-,Arg- or Glu- PA1 R.sup.2 is Thr, Ser or Asp PA1 R.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp PA1 R.sup.4 is Tyr and PA1 R.sup.5 is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals, or a physiologically acceptable salt thereof. Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors. These peptides are believed to act as competitive blocking agents.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5276019,4-Jan-94,1994,1,4,Inhibitors for replication of retroviruses and for the expression of oncogene products,"Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.",43,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,Biotechnology,,,,A61K/70
5276059,4-Jan-94,1994,1,4,Inhibition of diseases associated with amyloid formation,"The invention provides a method of treating a mammal having a condition associated with formation of amyloidogenic protein without deposition of amyloid plaques. This treatment includes administering to the mammal a pharmacologically effective amount of Congo Red or a pharmaceutically acceptable salt or derivative thereof to interfere with amyloidogenic protein formation or to destabilize amyloidogenic protein structures already formed in said mammal. The invention also provides a method of treating a mammal having a condition associated with deposition of amyloidogenic protein in plaques, and a method of inhibiting the transformation of PrP-sen to PrP-res in a tissue culture sample containing PrP-sen.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/655
5276170,4-Jan-94,1994,1,4,Azido-substituted aromatic amino acids,"Azido-substituted aromatic amino acids represented by the following formula I are synthesized through the use of tyrosine phenol-lyase. The azido derivatives are suitable for use as photoaffinity labels and inhibitors; ##STR1## wherein R.sup.1 represents a lower alkyl, a lower alkoxy, or an hydroxy group; R.sup.2 and R.sup.3 each independently represent a hydrogen or a lower alkyl group; X represents a hydrogen, a lower alkyl, an alkali metal, or an ammonium group; n is an integer of 0 to 3.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12P/04
5277196,11-Jan-94,1994,1,11,Portable spirometer with improved accuracy,"A spirometric measurement device includes an arrangement for computation of a dynamic correction factor to compensate for temperature-related volume changes in time varying raw forced expiratory volume (FEV) data due to cooling of expired gas. The correction factor, which compensates for body-temperature-pressure-saturated (BTPS) changes, varies in time according to variation of temperature of a flow sensor. The temperature of the flow sensor is accurately established by positioning a temperature sensor downstream of the flow sensor.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/0878
5278042,11-Jan-94,1994,1,11,Method for detecting inhibitors of tat protein,A method for evaluating the inhibitory effect of a substance on tat-protein TAR RNA binding is described. A test system for determining the association of tat-protein with TAR RNA is also included within the scope of the invention.,3,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5278145,11-Jan-94,1994,1,11,Method for protecting bone marrow against chemotherapeutic drugs using transforming growth factor beta 1,"The present invention relates to a method for protecting hematopoietic stem cells from the myelotoxicity of chemotherapeutic drugs or radiation therapy, which comprises, administering to a subject a therapeutically effective amount of transforming growth factor beta 1 for protecting bone marrow from the myelotoxicity of chemotherapeutic drugs or radiation therapy. The TGF.beta.1 may be administered prior (e.g. 24 hours) to the administration of the chemotherapeutic drugs or radiation therapy. Preferably, the TGF.beta.1 is administered to the subject in an amount of about 5 .mu.g to 25 .mu.g per kg body weight. The patient or subject of the present invention may be a mammal (e.g. human, domestic animal such as horse, cow, dog, cat or pig) and is preferably a human being. The mode of administration is either by interfemoral arterial, interperitoneally or subcutaneously, and preferably is by injection.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1841
5279938,18-Jan-94,1994,1,18,Sensitive diagnostic test for lyme disease,"The nucleotide sequence of a recombinant clone containing a specific segment of Borrelia burgdorferi DNA which enables the identification of the spirochetes causing Lyme disease has been provided. A diagnostic kit containing oligonucleotide primers derived from this sequence, suitable for the detection of Borrelia burgdoferi in a PCR assay, as well as the cloned DNA of the present invention, allows the detection of Lyme disease with sensitivity and specificity not heretofore attained by any other test.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
5280015,18-Jan-94,1994,1,18,2-substituted adenosines and 2-substituted adenosine 5'-carboxamides,The present invention is directed to compounds useful as probes for characterizing and studying the adenosine A.sub.2 receptor. The present invention is also directed to methods of treating central nervous system disorders and cardiovascular disorders which include treating hypertension and thrombosis by administering said compounds.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/70
5281519,25-Jan-94,1994,1,25,"Simple, rapid and reliable method for detecting thalassemia","A simple, rapid and reliable method for diagnosis of thalassemia is described. The method comprises amplification of the cDNA by polymerase chain reaction and determining the ratio between .alpha. and .beta. hemoglobin chain mRNAs.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5282404,1-Feb-94,1994,2,1,Microtome with micro-plane and electric contact reference,"A microtome for cutting thin sample sections utilizes an electrical contact or sole plate for guiding the section cutting knife during sectioning. The sole plate floats across the surface of the sample thereby ensuring that uniformly thin sections are cut regardless of movement of the sample or expansion or contraction thereof. An electrical contact may be used to detect and reference contact between the sample surface and the section cutting knife. After contact between the sample surface and section cutting knife is referenced, the relative position between the sample surface and section cutting knife may be adjusted to achieve a desired section thinness.",17,The Government of the United States of America as represented by the Secretary of the Dept. of Health & Human Services,,,,,,,,,,,1,Measurement,Control,,,,,G01N/06
5283196,1-Feb-94,1994,2,1,Polyacrylamide gels with improved detection of protein,"Amine-acryloyl and -methacryloyl derivatives and 1,6-heptadiene-4-ol can be used to provide crosslinked polyacrylamide gels which are useful in protein and nucleic acid separation and detection. The gels crosslinked with the compounds of the present invention exhibit much less background silver staining than previously known acrylamide gels.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,"Macromolecular chemistry, polymers",Biotechnology,,,,C07D/185
5283323,1-Feb-94,1994,2,1,Method of producing immune response,The present invention discloses a process for enhancing antibody response to an antigen. A novel step in the process is the preparation of a conjugate of the antigen with an anti-immunoglobulin. The conjugate thus prepared is then administered to a host for in vivo effect or presented to T and B cells in a suitable culture system for in vitro response. The present invention by increasing immunogenicity makes it possible to produce antibodies against very low doses of antigens and otherwise weak or insufficient antigens or synthetic vaccines.,15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4283
5283383,1-Feb-94,1994,2,1,"Antitumor compound, compositions and method of use","The present invention relates to a new antitumor compound, a method for isolating same from a red alga, antitumor compositions containing same and methods of using same for treating patients with cancer. The compound of the present invention is 6(R)-bromo-3(S)-bromomethyl-7-methyl-2,3,7-trichloro-1-octene.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/14
5284144,8-Feb-94,1994,2,8,Apparatus for hyperthermia treatment of cancer,"A hyperthermia applicator/MRI probe assembly for hyperthermia treatment of a subject. The assembly includes a hyperthermia applicator for heating target regions of a subject and a MRI probe which is utilized to monitor temperatures within the heating region. The hyperthermia applicator and MRI probe are coupled to a control system which receives information from the MRI probe and utilizes the information to control the hyperthermia applicator so as to maintain constant, desired temperatures within the heating region. The hyperthermia applicator/MRI probe assembly of the present invention allows for temperature control within about 0.5.degree. C.",19,The United States of America as represented by the Secretary of the Dept. of Health & Human Services,,,,,,,,,,,1,Measurement,Medical technology,,,,,A61B/055
5284654,8-Feb-94,1994,2,8,Method for the treatment of Parkinson's disease,The present invention is directed to a method for the treatment of Parkinson's disease which affect the dopaminergic system by implanting into the brain of a host in need thereof an anti-neurodegenerative effective amount of activated leukocytes.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
5284774,8-Feb-94,1994,2,8,"Antineoplastic, system-L specific amino acid nitrogen mustards","New antineoplastic, system - L specific amino acid nitrogen mustards with reduced myelosuppressive effect are disclosed. A method for identifying and isolating the cellular component comprising the L - amino acid transport system is also described.",2,The United States of America as represented by the Secy. of the Dept. of Health & Human Resources,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/02
5284834,8-Feb-94,1994,2,8,Adenosine functionalized congeners as cardiovascular treating agents for animals and methods for using same,"This invention comprises a series of N.sup.6 -substituted adenosine analogues bearing functionalized chains for the covalent attachment to probes or solid supports. In these compounds coronary vasodilation in the open thorax dog model, typical of A.sub.2 -adenosine receptor agonists, is shown. The potency is modulated by distal structural changes in the chain, with the highest A.sub.2 -potency observed for two methylamides, a primary amine congener, and a biotin conjugate. These compounds have antihypertensive activity and certain components are charged and are excluded from crossing the blood-brain barrier.",43,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
5286717,15-Feb-94,1994,2,15,Inhibitors for replication of retroviruses and for the expression of oncogene products,"Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,Biotechnology,,,,A61K/70
5286846,15-Feb-94,1994,2,15,"Amino acid derivative and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides","A new amino derivative, N.sup..alpha. -tert-butoxycarbonyl-N.sup..epsilon. -(N-bromoacetyl-.beta.-alanyl)-L-lysine (BBAL), has been synthesized as a reagent to be used in solid-phase peptide synthesis for introducing a side-chain bromoacetyl group at any desired position in a peptide sequence. The bromoacetyl group subsequently serves as a sulfhydryl-selective cross-linking function for the preparation of cyclic peptides, peptide conjugates and polymers. BBAL residues are stable to final HF deprotection/cleavage. BBAL peptides can be directly coupled to other molecules or surfaces which possess free sulfhydryl groups by forming stable thioether linkages. Peptides containing both BBAL and cysteine residues can be self-coupled to produce either cyclic molecules or linear peptide polymers. Such peptide derivatives are useful in preparing potential peptide immunogens, vaccines and therapeutics, and for substances such as peptides linked to polymers, plastics, enamels and ceramics.",20,The Government of the United States of America as represented by the Dept. of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Organic fine chemistry,,,,C07K/1077
5286850,15-Feb-94,1994,2,15,Antibody DTPA-type ligand conjugates,The subject matter of the present invention relates to bifunctional cyclohexyl DPTA ligands and methods for utilizing these compounds. Antibody DTPA-type ligand conjugates are also provided.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,,G01N/534
5289003,22-Feb-94,1994,2,22,Probe for thermospray mass spectrometry,A thermospray probe assembly which allows for easy replacement or exchange the central capillary tube without requiring replacement of the entire probe assembly when the capillary tube becomes degraded and/or clogged. The replaceable capillary tube is secured at a tip end to a tip of the outer tubular member of the probe assembly by a set screw. The other end of the replaceable capillary tube is sealingly secured by a compression fitting in an adapter connected to the outer tubular member.,20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,"Electrical machinery, apparatus, energy",,,,,G01N/7253
5290677,1-Mar-94,1994,3,1,Rapid and sensitive test for detecting hepatitis A virus,"Provided are methods for detecting hepatitis A virus (HAV) and HAV genotypes I and III by capturing whole hepatitis A virus with antibodies specific to hepatitis A virus, generating a cDNA copy of the RNA by reverse transcription in the presence of a negative strand primer having the sequence defined by SEQ ID NO:1, amplifying the cDNA by polymerase chain reaction with both the negative strand primer and a labelled or unlabelled positive strand primer having the sequence defined by SEQ ID NO: 2, and detecting the amplified cDNA by hybridization with either or both of the probes defined by SEQ ID NO:3 and SEQ ID NO:4 or by detection of label, wherein the presence of detectable hybridization or amplification indicates the presence of hepatitis A virus. Also provided are DNA primers and probes from the amino-terminal portion of the VPI region of the HAV genome that selectively hybridize with HAV, HAV genotype I and HAV genotype III and can amplify the amino-terminal portion of the VP1 region of HAV.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/706
5290686,1-Mar-94,1994,3,1,Expression of influenza a M2 protein in baculovirus,"The present invention relates to baculovirus-expressed influenza antigens, in particular, to the influenza A membrane protein, M2, expressed from Autographa Californica nuclear polyhedrosis virus (AcNPV). The present invention further relates to a method to increase the yield of baculovirus-expressed M2 proteins in host cells by culturing the recombinant baculovirus infected host cells with an amantadine-like drug. Other aspect of the present invention relate to the use of baculovirus-expressed M2 proteins in reproducible and routine assays for the seradiagnosis of influenza A virus infections as an alternative to the more burdensome complement fixation and hemagglutination tests.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5290816,1-Mar-94,1994,3,1,Composition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitization,"The present invention relates to a method for desensitizing a subject animal, which comprises administering to the subject animal a therapeutically effective desensitizing amount of resiniferatoxin for desensitizing the subject animal to neurogenic inflammation, to chemically and thermally induced pain and to responses involving sensory afferent pathways sensitive to capsaicin and to responses involving the hypothalamic temperature control region, and a pharmaceutically acceptable carrier therefor.",1,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/335
5292665,8-Mar-94,1994,3,8,Catalyst for preparing polyacrylamide gel which improves the detection of biomaterials by silver staining,"A polyacrylamide gel comprising acrylamide and diacrylylpiperazine. A method for providing a polyacrylamide gel comprising employing a catalyst system which comprises dimethylpiperazine, sodium thiosulfate or a mixture thereof and ammonium or potassium persulfate. The use of the gel as the matrix in a silver staining procedure for the detection of biomaterials, provides for the obtainment of reduced background staining.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/44747
5293833,15-Mar-94,1994,3,15,Splash containment testing device for emegency eye wash units,Apparatus and methods for periodically testing emergency wash units which involve the use of a transparent splash containment device which is positioned over an emergency wash unit and optionally attached thereto. The transparent splash containment device diverts and directs water flow to the drain of the emergency wash unit. An alignment indicator including sighting marks is provided to determine the alignment of the water flow. The sighting marks are provided with grid scales which can be used to estimate the velocity of the water flow.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61H/02
5294541,15-Mar-94,1994,3,15,Real-time monitoring of oxidative products from in vitro cell-biomaterial interaction using chemiluminescence,"A chemiluminescence method for continuously monitoring in real time the generation of oxidative products such as hydrogen peroxide and superoxide from in vitro cell-biomaterial interactions using cell lines such as Human Leukemic cells (HL-60); tumor cell line hybridomas; cells lacking the respiratory burst such as Chronic Granulomatous Disease cells as controls; Monocytic cell lines; Primary Human cells such as monocytes, pmns, fibroblasts, endothelial cells; and whole and isolated blood cells. The oxidative products have the potential for the degradation of the biomaterial and thus this information can be used to aid in predicting the functional lifetime of the biomaterial when it is used to fabricate an implanted medical device. Further, this method may be used to determine the amount of activation of biological cells which is inferred from the amount of oxidative products. This activation level aids in the determination of the degree of the inflammatory response and thus influences the degree of acceptance of the biomaterial. Thus, toxicity and biocompatability tests could be supported by these measurements.",21,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5008
5294604,15-Mar-94,1994,3,15,Method of treating ocular diseases by periocular administration of cyclosporine A or G,The present invention provides a method of treating ocular diseases by the administration of cyclosporine A or G by periocular injection in a pharmaceutically acceptable carrier.,16,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/13
5295746,22-Mar-94,1994,3,22,High resolution digital thermometer,A high resolution digital thermometer capable of measuring temperature differences on the order of several micro-degrees centigrade. The device includes a bridge circuit having two thermistors in series. An output of the bridge circuit feeds a signal to an analog-to-digital convertor via a high gain amplifier. A computer maintains the balance of the bridge circuit to avoid a situation wherein the range of the analog-to-digital convertor would be exceeded.,13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01K/14
5296353,22-Mar-94,1994,3,22,Evaluation and treatment of patients with progessive immunosuppression,"A method of determining the level of immunosuppression in a mammal involves determining the level of expression of at least one selected TCR subunit protein, or protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in healthy individuals. The method is useful to identify patients having T lymphocytes capable of activation for autologous adoptive immunotherapy and for identifying agents which cause or reverse immunosuppression.",6,The United States of America as represented by the Department of Health and Human Services,Regents of the University of Minnesota,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/18
5296382,22-Mar-94,1994,3,22,Recombinant DNA clone containing a genomic fragment of PfHRP-II gene from Plasmodium falciparum,"The present invention resides, in part, in cloned DNA fragments encoding a histidine-rich protein of Plasmodium falciparum (PfHRP-II). PfHRP-II is a malarial antigen that is secreted by the parasite into erythrocytes. The protein is characterized by tandem repeats of high histidine, alanine and aspartate content. The protein is found to have high affinity for divalent cations. Cloning and characterization of the PfHRP-II gene are described, as are antibodies against PfHRP-II.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
5298508,29-Mar-94,1994,3,29,Irreversible inhibitors of adenosine receptors,"Irreversible ligands for adenosine receptors are derived from agonist and antagonist functionalized congeners which contain electrophilic acylating and alkylating groups for reaction at nucleophilic residues of adenosine receptors. The ligands are based on 8-aryl-substituted xanthines as antagonists and on N.sup.6 -substituted adenosine as agonists, wherein the electrophlic group may be, for example, isothiocyanate and N-hydroxysuccinimide esters.",18,The United States of America as represented by the Department of Health and Human Services,Duke University,,,,,,,,,,2,Organic fine chemistry,,,,,,C07H/16
5298742,29-Mar-94,1994,3,29,Light sensor for photo-dynamic therapy having a transparent housing,"A light sensor constructed from a commercial photodiode packaged in a transparent housing of sufficient thickness to set the photodetector away from the underlying surface, thereby reducing the shadowing effects of the photodetector and allowing incident light to pass through the housing to the tissue below. Electrical connections are made directly on the photodiode which is sealed within the transparent housing, thus avoiding electrical shock or short circuit hazards. The transparent package is equipped with four hooks which are well suited for attachment to tissue structure, either directly or with the aid of sutures. In a second embodiment, the light sensor includes a second photodiode mounted within the sealed housing to measure light reflected from the underlying tissue. The light sensor is well suited for use with photodynamic therapy.",8,The United States of America as represented by Department of Health & Human Services,,,,,,,,,,,1,Semiconductors,Medical technology,,,,,H01L/0203
5299138,29-Mar-94,1994,3,29,Desk top spectrum analyzer,"A control system emulates an X-ray spectrum generation and analyzing system on a computer by emulating the experimental apparatus, emulating the experimental geometry between elements of the experimental apparatus and emulating a material sample within the experimental apparatus including the emulated material sample's physical properties. The control system allows an operator generate theoretical spectra of material samples based on the emulated experimental apparatus and the physical characteristics of the emulated material sample. The control system also allows the operator to compare the generated theoretical spectrum to a real spectrum acquired from the experimental system and sample which have been emulated. Thus, the operator can easily determine the sufficiency of the emulation of the experimental set-up. The control system further allows the operator to analyze the generated theoretical spectra. Thus, the operator can determine the sufficiency of the experimental set-up in determining the character and composition of the real material sample.",22,The United States of America as represented by the Secretary of Commerce,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Measurement,,,,,,G01N/20091
5300886,5-Apr-94,1994,4,5,Method to enhance the sensitivity of MRI for magnetic susceptibility effects,A method for enhancing the sensitivity of gradient-recalled echo imaging for T2* effects in dynamic magnetic resonance imaging which involves the step of delaying gradient-recalled echoes so that the gradient-recalled echoes are subjected to magnetic susceptibility effects for an extended period of time. The gradient-recalled echoes are delayed beyond a subsequent radio frequency pulse by applying an additional gradient which dephases any gradient-recalled echo of spins that are excited in the radio frequency repetition time period in which said gradient-recalled echoes are produced.,20,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/561
5301671,12-Apr-94,1994,4,12,Two- and three-dimensional autoradiographic imaging utilizing charge coupled devices,"A two- and three-dimensional autoradiographical imaging system is provided which includes a charge coupled device for detecting the emission of radioactively labeled substances from materials such as tissue samples, brains of humans or animals, or substances used in electrophoresis applications. In a first aspect, a radioactively labeled substance is included in a tissue sample. The tissue sample is sequentially imaged by a charge coupled device and a sectioning tool such as a microtome to produce a plurality of two-dimensional images. A three-dimensional image of the tissue sample is generated by further processing of the plurality of two-dimensional images derived from the charge coupled device. In a further aspect of the invention, a charge coupled device is utilized to provide realtime imaging of metabolic or physiological parameters involved in brain activity. A charge coupled device is positioned adjacent a portion of brain tissue desired to be examined, the brain tissue having a radioactively labeled substance therein for detection by the charge coupled device. A two-dimensional realtime image is produced using the charge coupled device for use in clinical or behavioral studies.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Environmental technology,Measurement,,,,G01T/161
5302151,12-Apr-94,1994,4,12,Variable air flow eddy control,"Methods and apparatus for controlling the flow of fluid around an object which include means to periodically vary or fluctuate the direction, speed or magnitude of the fluid flow. The fluid flow is particularly controlled to control eddy formation. The fluid is preferably a gas or vapor.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B08B/02
5302511,12-Apr-94,1994,4,12,Antibodies to peptides unique to specific keratin proteins,"By cloning the gene for particular keratin proteins, it has been possible to determine amino acid sequences of specific keratins. This has made possible selection of sequences which are unique to a given keratin. The production of antibodies that respond to selected sequences provides means of selectively identifying specific keratins. These diagnostic tools provide means of identifying cell source of malignancies.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/18
5305740,26-Apr-94,1994,4,26,Sealing means for endotracheal tubes,"A sealing element for a tubular member such as an endotracheal tube which includes a circular collar portion and a pliable flange or gill. One or more of the sealing elements are positioned on a tubular member such as an endotracheal tube. When the tubular member is inserted into a lumen such as a trachea, the pliable flange(s) or gill(s) forms a seal between the outer wall of the tubular member and the inner wall of the lumen. In the case of endotracheal tubes the sealing elements replace conventional inflatable cuffs and allow for tubes having diameters less than 5 mm.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,Medical technology,,,,,B29C/36
5306627,26-Apr-94,1994,4,26,Process for producing a human neutrophil chemotactic factor peptide and a recombinant expression vector for the said polypeptide,"An expression vector in which a DNA encoding a human neutrophil chemotactic factor polypeptide is inserted, a transformant (a host cell transformed with the expression vector), and a process for production of the said polypeptide by using the said transformant.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/5421
5308753,3-May-94,1994,5,3,Methods for purifying and detecting IGM antibodies,"Methods for purifying and detecting IgM antibodies employ binding substances which are Borellia burgdorferi cells, or cellular or extracellular components obtained or derived therefrom and which bind to this class of antibodies. The binding substances may be attached to a solid substrate and then the substrate contacted with a solution containing IgM antibodies under conditions such that the antibodies bind to the binding substance on the substrate. The substrate is then contacted with a solution that releases the IgM antibodies from the substrate and the antibodies are recovered or detected. Applications of these methods include, for example, assays for diagnosing diseases which elicit primary and/or secondary IgM antibody-mediated immunity.",15,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services STA MD COD 06,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/065
5309912,10-May-94,1994,5,10,Multidimensional imaging using a single point detector for a phase encoded modulated optical carrier,"Optical imaging of an object utilizes a plurality of amplitude modulated light rays propagating through the object, either sequentially or simultaneously, for detection by a single photodetector. The light rays may propagate geometrically (i.e., directly) or diffusively. Each of the rays is encoded with a different phase to provide sufficient information for decoding the light intensity detected by the photodetector. The rays may be applied simultaneously in an array, in which case different carrier frequencies as well as different phases are applied to the different rays by any of a number of modulators. Alternatively, the rays may be individually applied to the object in a sequence of phase encoded rays. In either case, the single photodetector receives sufficient information to image each of the voxels of interest in the object being imaged. Information may be obtained for different voxels selected for imaging without mechanical scanning.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/4795
5310916,10-May-94,1994,5,10,Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors,"Trifunctional agents useful as inhibitors of A.sub.1 -Adenosine receptors may be formulated into pharmaceutical compositions. These agents are represented by formula (I): ##STR1## wherein X is CH or N, R is an isothiocyanate group, an amino group or --NHCO.sub.2 C(CH.sub.3).sub.3 and R.sup.1 is hydrogen, carboxyl, lower alkoxycarbonyl, aminocarbonyl, ##STR2## lower alkyl, optionally substituted with: --OH, --COOH, lower ester of COOH, carboxamide, NHCOCH.sub.3, NHCOCH.sub.2 Br, halo, dimethylamino, triethylammonium, NHCONH.sub.2, SO.sub.2 NH.sub.2, --SO.sub.3 H, or a reporter group, particularly a spectroscopic reporter group such as a fluorescent dye, photoaffinity probe, or spin label probe, coupled through an amide, sulfonamide, amine or thiourea linkage, biotinylamino- (optionally containing an .epsilon.-aminocaproyl spacer chain or similar spacer chain) or; R.sup.1 is CONH--R.sup.2 or NHCSNH--R.sup.2, wherein R.sup.2 is lower alkyl, optionally substituted with: --OH, --COOH, lower ester of COOH, carboxamide, NHCOCH.sub.3, NHCOCH.sub.2 Br, halo, dimethylamino, triethylammonium, NHCONH.sub.2, SO.sub.2 NH.sub.2, --SO.sub.3 H, or a reporter group, particularly a spectroscopic reporter group such as a fluorescent dye, photoaffinity probe, or spin label probe, coupled through an amide, sulfonamide, amine, or thiourea linkage, biotinylamino- (optionally containing an .epsilon.-aminocaproyl spacer chain or similar spacer chain).",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/06
5312734,17-May-94,1994,5,17,CDNA encoding a dopamine transporter,"The invention described in this disclosure relates to a cloned cDNA encoding the dopamine transporter protein usually found in certain neural cells. The invention is further directed to the purified dopamine transporter protein and its use as a biosensor material and immunogen for the production of anti-DAT1 antibodies. The disclosure also discusses methods for use of the cDNA for diagnostic and treatment applications, and methods for use of permanent cell lines transformed with the dopamine transporter cDNA for pharmaceutical screening. The use of anti-DAT1 antibodies as a diagnostic tool is also addressed.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5314899,24-May-94,1994,5,24,"Epibatidine and derivatives, compositions and methods of treating pain","The present invention is directed to compounds, compositions and methods of treating pain, and derivatives that have potent analgetic activity. The compounds have the formula: ##STR1## wherein R.sup.1 is selected from H, lower alkyl, C.sub.3 -C.sub.9 cycloalkyl, acyl, and C.sub.3 -C.sub.9 cycloalkylalkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, or C.sub.3 -C.sub.8 cycloalkenyl or C.sub.3 -C.sub.8 cycloalkynyl; and wherein R is selected from cycloalkyl, aryl, heteroaryls (selected from the group consisting of pyridyl, thienyl, furanyl, imidazolyl, pyrazinyl, and pyrimidyl) or phenoxy and wherein said R groups can be substituted with hydroxyl, C.sub.1 -C.sub.6 lower alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.1 -C.sub.6 lower alkoxyl, halo, C.sub.1 -C.sub.6 haloalkyl, amino, C.sub.1 -C.sub.6 alkylamino and C.sub.2 -C.sub.10 dialkylamino, and sulfonamido or a pharmaceutically acceptable salt thereof.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/08
5316763,31-May-94,1994,5,31,Short-term anti-CD3 stimulation of lymphocytes to increase their in vivo acitivity,"The present invention is directed to a method of increasing the in vivo immune response of lymphocytes by stimulating the lymphocytes in vitro in the presence of an anti-CD3 monoclonal antibody for less than about 24 hours to form stimulated lymphocytes; infusing the stimulated lymphocytes into a tumor-bearing mammal; and administering IL-2 to the mammal. As a result of this method, the anti-CD3 stimulated lymphocytes display enhanced immunotherapeutic, e.g., cytotoxicity or lymphokine production, in vivo as represented by a decrease in the number of tumors by at least about 20%.",16,The United States of America as represented by the Department of Health and Human Services,Regents of the University of Minnesota,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C12N/0636
5316910,31-May-94,1994,5,31,Bioassay for influenza A and B nucleoprotein,"The present invention relates to nucleoprotein (NP) genes of the influenza A and B viruses which were constructed from virion RNA and subsequently expressed in Spodoptera frugiperda (S19) cells using the baculovirus vector, Autographa californica nuclear polyhedrosis virus (AcNPV). Western blot analysis of lysates prepared from S19 cells infected with the recombinant viruses confirmed that the baculovirus-expressed NP antigens were reactive with monoclonal antibodies specific for either type A or B NP and with anti-NP antibodies in human serum samples. Electrophoretic analysis indicated that the expressed influenza NP antigens comigrated with NP purified from influenza A or B virions and that the recombinant NP antigens represented greater than 10% of total protein in infected cells. Dilutions of clarified S19 cell lysates were used as antigens in a standard enzyme immunoassay format to detect serum antibody specific for influenza A or B viruses. The results from assays using the baculovirus-expressed NP antigens showed good correlation with the results obtained using bacterially-expressed NP antigen as well as complement fixation. Therefore, baculovirus-expressed NP antigens can be used in reproducible and routine assays for the serodiagnosis of influenza virus infections as an alternative to the more burdensome complement fixation or hemagglutination tests.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5317009,31-May-94,1994,5,31,"Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof","New proteins, termed GAP 31, obtainable from the seeds of Gelonium multiflorum, and DAP 30 and DAP 32, obtainable from the leaves or seeds of Dianthus caryophyllus, or the above proteins produced by recombinant means, are useful for treating HIV infections. In treating HIV infections, the protein is administered alone or in conjunction with other anti-HIV therapeutics. Also provided are processes for purifying the proteins, DNA sequences encoding the proteins, hosts expressing the proteins, recombinant DNA methods for expressing the proteins, and antibodies specific for the proteins.",3,New York University,"American Biosciences, Inc.",National Institutes of Health,,,,,,,,,3,Pharmaceuticals,Biotechnology,,,,,C07K/415
5317262,31-May-94,1994,5,31,"Single shot magnetic resonance method to measure diffusion, flow and/or motion","A method of obtaining an attenuation curve, and corresponding diffusion constant, from a single-shot procedure. In contrast to the conventional pulsed field-gradient spin echo (PGSE) procedures used to determine the diffusion attenuation curve of a body undergoing magnetic resonance imaging, the method uses a single-shot procedure. The procedure uses application of a single shot pulse sequence to initiate a spin-echo procedure. This procedure creates a number of gradient recalled echoes by alternating the diffusion gradient. Each subsequent gradient-recalled echo is attenuated by an additional pair of gradient pulses. This successive attenuation by the gradient pulses allows the diffusional attenuation curve to be determined accurately in a single procedure. Ratios of time symmetric echo pulses yield a value proportional to the diffusion constant.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56341
5318957,7-Jun-94,1994,6,7,Method of stimulating angiogenesis,"A method of stimulating angiogenesis in a mammal by administering to a mammal a haptoglobin in an amount effective to stimulate angiogenesis, and a pharmaceutical composition containing a haptoglobin and a pharmaceutically acceptable carrier.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4717
5319073,7-Jun-94,1994,6,7,Method of purifying cholecystokinin receptor protein,"An unconventional approach to purifying CCK receptor protein to sequenceable-grade homogeneity has been discovered. By this approach, CCK receptor protein can be obtained and sequenced routinely from a variety sources, and from the sequence information thus obtained it is possible to prepare oligonucleotides suitable for cloning CCK receptor genes. ""CCK receptor"" in this context denotes any from a group of proteins that displays a characteristic CCK binding affinity and that is encoded by a nucleotide sequence which hybridizes a oligonucleotide probe designed in accordance with the criteria elaborated herein.",3,"The United States of America, as represented by the Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
5320811,14-Jun-94,1994,6,14,Thin layer chromatography direct sample application manifold,An apparatus and method for directly applying a liquid sample matrix containing analytes and possible endogenous compounds to selected areas of a thin layer chromatographic sheet. The apparatus comprises a manifold made from an upper and lower filter block which are fastened together and supported on a support member. The thin layer chromatographic sheet is held between the upper and lower filter block. Samples are applied to the thin layer chromatographic sheet through aligned through-bores in the upper and lower filter block by connecting a syringe to the through-bores of the upper filter block. The method involves initially wetting areas of the thin layer chromatographic sheet where the sample is subsequently applied. Analytes retained on the thin layer chromatographic sheet are subsequently analyzed and may be further extracted from the thin layer chromatographic sheet for analysis.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/92
5320956,14-Jun-94,1994,6,14,Monoclonal antibody useful for the diagnosis of cancer,"The invention provides novel monoclonal antibodies and the hybridomas that secrete them. The antibodies can be used for the diagnosis of a number of cancers, such as ovarian, esophageal and cervical carcinomas. A preferred antibody is secreted by a hybridoma deposited with the ATCC and has Accession No. HB 10570.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1045
5321014,14-Jun-94,1994,6,14,"Molecular encapsulation and delivery of alkenes alkynes and long chain alkanes, to living mammalian cells","A complex of a cyclodextrin and an alkane, alkene, alkyne, aromatic compound, etc. can be prepared according to the method of the present invention. These complexes can be delivered to prokaryotic and eukaryotic cells, tissues, and organs in vitro and in vivo. In this manner, the toxic, genotoxic, and mitogenic effects of these compounds can be determined. Ternary complexes further including one or more biologically active molecules in addition to an alkane, etc. can be employed to determine the modulatory effects of such biologically active molecules on these alkanes, etc.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Micro-structural and nano-technology,Pharmaceuticals,,,,,B82Y/00
5322933,21-Jun-94,1994,6,21,Crystal structure of TGF-.beta.-2,A composition of crystalline TGF-.beta.2 is described. The tertiary structure of the protein homodimer determined by X-ray crystallography to 2.1 angstrom resolution is shown. This structure provides data useful in the rational design of drugs to mimic the physiologic properties of proteins of the TGF-.beta. family.,3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/495
5324831,28-Jun-94,1994,6,28,Phosphoramidite reagent for chemical synthesis of modified DNA,"5,6-dihydro-5-azacytidine phosphoramidite is useful in the synthesis of oligonucleotides and DNA containing dihydro-5-aza- and 5-azacytosine bases. The modified oligonucleotides which contain 5-azacytosine residues at specific sites can be used to determine the mechanism of selective gene activation and the relationship existing between the presence of the triazine base and inhibition of DNA methylation.",5,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/04
5324832,28-Jun-94,1994,6,28,Muscarinic antagonists,"Muscarinic antagonists formed by substitution of the distal N-methyl group of pirenzepine or telenzepine. The group used for substitution can be, for example, a propargyl group, a benzyl group, a substituted benzyl group, a hydroxyethyl group, a chloroethyl group, an aminoethyl group, an .omega.-amino alkyl group, or an N-substituted .omega.-amino alkyl group.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5325295,28-Jun-94,1994,6,28,Adaptation of microtiter plate technology to measurement of platelet aggregation,"A rapid method for the simultaneous measurement of aggregation or agglutination in plurality of microtest wells or other sample-holding vessels comprises providing a plurality of light beams having discrete focal points adapted to be focused on the contents of a plurality of wells or other vessels and a plurality of photodetectors therefor, directing the light beams through the wells or other vessels and contents thereof, continuously agitating the wells or other vessels and contents thereof with a circular movement effective to permit aggregation or agglutination while preserving the integrity of the material, producing a plurality of output signals from the detectors are proportional to the light absorbencies of the beams as they pass through the wells or other vessels and contents thereof, repeatedly sampling the signals at a predetermined time interval and determining changes in optical densities from the signals obtained after each predetermined time interval by comparing each signal sampled after each predetermined time interval with the first signal sampled for the same microtest well or vessel, whereby any change in optical density which is greater than about 0.05 units is said to indicate that aggregation or agglutination occurred in the well or other vessel. The present method is suitably applied to the measurement of aggregation in platelets.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/82
5327446,5-Jul-94,1994,7,5,Method of exciting laser action and delivering laser energy for medical and scientific applications,"A laser energy excitation and delivery device which includes a coaxial system of tubes having an annular space therebetween. A lasing or pumping gas is provided in the annular space and subjected to radio frequency discharge which results in the generation of laser radiation. The resulting laser radiation is propagated through and delivered from a section of the device which includes an extension of the innermost tube or an extension of each of the tubes. One embodiment of the device includes a central passageway though which various materials, including a guide wire, can pass. The device has particular utility for medical and surgical procedures.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Optics,Medical technology,,,,,H01S/06708
5328984,12-Jul-94,1994,7,12,Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells,"Proteins that are impermeable and foreign to the eukaryotic cells can now be delivered across cellular membranes into the cytosol of target cells by making a chimeric protein having specific attributes. A method of making such chimeric proteins is disclosed. As an example, a chimeric protein PE-Bar with dual enzymatic activity has been made. The chimeric proteins can be used for cytotoxic, diagnostic or therapeutic purposes, such as for compensating the deficiency or defect of an enzyme or a protein which may be causative of a disease or an abnormality.",13,The United States as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/21
5328990,12-Jul-94,1994,7,12,Isolation of macrophage migration inhibition factor from ocular lens,"Macrophage Migration Inhibition Factor (MIF) can be obtained from ocular lens of various birds and mammals. The amino acid sequences of lens MIF from mice, chickens and humans has been determined and the corresponding cDNA has been cloned.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/52
5332504,26-Jul-94,1994,7,26,pH-zone-refining countercurrent chromatography,"It has now been discovered that acidic or basic compounds may be purified using a new countercurrent chromatography technique. This technique utilizes two immiscible solvent phases, one being acidic and one being basic. The solutes partition between the phases and elute in contiguous, well-resolved, rectangularly shaped peaks in order of their partition coefficients. The fractions within any single peak have a substantially constant concentration. In addition to differing partition coefficients, the peaks also differ in pH, successively increasing in the case of a basic mobile phase and successively decreasing in the case of an acidic mobile phase. For this reason, the technique may be referred to as ""pH-zone-refining countercurrent chromatography."" The method of this invention provides certain advantages over previously known countercurrent chromatography techniques. First, the method permits one to load a sample as a suspension into the separation column. Additionally, the minimal degree of elution peak overlap permits one to separate mixtures of greater volume than before in any given column without loss of resolution. Thus, columns which are otherwise recommended for separations of mixtures up to a certain maximum size can be used in the method of this invention for separating mixtures up to ten times that size or greater.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
5332670,26-Jul-94,1994,7,26,Monoclonal antibody against human platelets,"A novel anti-platelet monoclonal antibody which is without effect on inactivated platelets, but which augments platelet aggregation after minimal perturbation of the platelets, and various applications of the monoclonal antibody are described.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/2854
5334522,2-Aug-94,1994,8,2,"System for isolating and producing new genes, gene products and DNA sequences","A method of producing plasmids with heteroduplex DNA sequences, in which probe plasmids containing DNA inserts that correspond to probe sequences and test plasmids containing DNA inserts that correspond to a population of test sequences are first constructed. The vector portions of the plasmids used in these constructions have similar sequences. When test and probe plasmids are cleaved with appropriate restriction enzymes and then denatured to separate strands, complementary regions of the linear strands which correspond to vector sequences can anneal. The molecules that harbor test and probe inserts that are related by sequence complementarity form non-covalently closed circular molecules. These molecules can replicate after transformation into an appropriate host organism. There is a replication bias against plasmids which anneal through vector sequences, but which do not contain homologous probe and test inserts.",9,United States/National Institutes of Health,,,,,,,,,,,1,Biotechnology,,,,,,C12N/10
5336483,9-Aug-94,1994,8,9,"Radiolabeled n-substituted-6-iodo-3,14-dihydroxy-4, 5.alpha.-epoxymorphinans, intermediates for producing the same, and a process for the preparation and methods of detecting opioid receptors","The present invention is directed to radiolabeled N-substituted-6-iodo-3,14-dihydroxy-4,5.alpha.-epoxymorphinans, intermediates for producing the same, and a process for the preparation and methods of detecting opioid receptors. The radioimaging agent of the present invention has the following formula: ##STR1## wherein I is selected from the group consisting of .sup.123 L and .sup.125 ; and where R is alkyl, cycloalkylloweralkyl or allyl.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Organic fine chemistry,,,,,G01N/534
5336758,9-Aug-94,1994,8,9,Peptides stimulating cytotoxic T cells immune to HIV RT,"The subject invention relates to a peptide having the amino acid sequence Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro or portions thereof. This peptide is derived from, or based upon, a region of a relatively conserved epitope of HIV-1 reverse transcriptase. The peptide may be utilized in the treatment of patients having human immunodeficiency virus or in the prevention of infection of those individuals who have been exposed to the disease, yet have not become sero-positive. The preparation containing the peptide may be administered either subcutaneously, intramuscularly or intravenously.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5336764,9-Aug-94,1994,8,9,2'-fluorofuranosyl derivatives and novel method of preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides,"A compound has the formula ##STR1## wherein R is selected from the group consisting of (C.sub.7 -C.sub.20)aroyl, (C.sub.6 -C.sub.20)aryl, aralkyl and alkylaryl, and (C.sub.1 -C.sub.10)alkyl-di(C.sub.6 -C.sub.20)aryl Si, R' is selected from the group consisting of (C.sub.1 -C.sub.10)alkyl, (C.sub.7 -C.sub.20)aroyl and (C.sub.2 -C.sub.12)acyl, all of which may be further substituted with O, S, N or alkyl, and R'"" is selected from the group consisting of halogen, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)acyloxy, O-methane-sulfonyl and O-p-toluenesulfonyl. A composition of matter comprises 0.001 to 99.999 wt % of the above compound.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07H/00
5338670,16-Aug-94,1994,8,16,Production of bordetella pertussis toxin with a low concentration of iron,A fermentation level cultivation of Bordetella pertussis bacteria on commercial scale is described. The critical factors in large scale cultivation of the bacteria are the presence of an antifoam agent and maintaining proper oxygen level and iron content in the culture medium. Pertussis toxin produced by the bacteria parallels the rate of growth of the bacteria.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/235
5340934,23-Aug-94,1994,8,23,CDNA sequences of human bone matrix proteins,Amino acid and cDNA sequences of a plurality of human bone matrix proteins and their uses have been described.,1,The United States of Americas as represented by the Secretary of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/51
5342777,30-Aug-94,1994,8,30,Cell culture medium for human liver epithelial cell line,"The present invention relates to cell medium developed to support long term multiplication and permanent establishment of a cell line of human liver epithelial cells. The medium may contain an effective cell growth promoting amount of calcium ions; an effective cell growth promoting amount of glucose; an effective amount of insulin to aid cells in glucose uptake; an effective cell growth promoting amount of hydrocortisone; an effective amount of epidermal growth factor to bind epidermal growth factor receptors on cells; an effective amount of transferrin to increase DNA synthesis in cells; an effective amount of cholera toxin to increase DNA synthesis in cells; an effective amount of triiodothyronine to increase DNA synthesis in cells; and an effective growth promoting amount of mammalian hormones and mitogenic factors, including lipoprotein, cholesterol, phospholipids and fatty acids.",15,The United States of America as represented by the Secretary of the Dept. of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/5017
5344755,6-Sep-94,1994,9,6,"Method for detecting immune system dysfunction in asymptomatic, HIV-scropositive individuals","A sensitive and accurate tissue culture system and kit for detecting subtle changes in immune function is provided. The system is based on the comparison of IL-2 production by T helper cells in response to recall antigens including influenza A virus, tatanus toxoid, alloantigens, mouse xenogeneic antigens and the like or combinations thereof. Different stages of immune dysfunction can be differentiated and organ graft rejection can be predicted by the method of the present invention.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56988
5344776,6-Sep-94,1994,9,6,DNA encoding an insect octopamine receptor,"The present invention pertains in general to invertebrate octopamine receptor proteins and to polynucleotides encoding such receptors. The present invention also relates to insect for example, Drosophila octopamine receptors that are recombinantly expressed in mammalian cells where the receptor mediates the attenuation of adenylate cyclase activity and exhibits a pharmacological profile that is unique but closely related to mammalian adrenergic receptors. The present invention further relates to drug screening methods for the development of specific human pharmacological drugs and insecticides targeted for the octopamine receptor system.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/43581
5344846,6-Sep-94,1994,9,6,Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells,"Compositions and methods for the treatment of mammalian cells to inhibit cell growth, especially for inhibiting the proliferative cell growth associated with malignant and non-malignant disease, are provided. More particularly, a deoxyhypusine synthase inhibitor, typically, a mono- or bisguanyl diamine or polyamine, is administered to the cells. Also provided by this invention are diagnostic methods and kits for screening the cells of a patient to determine the effect of the deoxyhypusine synthase inhibitor on proliferation of the cells.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/155
5345787,13-Sep-94,1994,9,13,Miniature cryosorption vacuum pump,"A miniature cryosorption vacuum pump capable of producing intermediate vacuums on the order of about 10.sup.-2 to 10.sup.-4 torr is provided which includes a closed cycle Stirling cycle refrigerator. The overall weight of the miniature cryosorption vacuum pump (including the refrigerator) is less than about 2.5 kg, making the miniature cryosorption vacuum pump particularly suitable for portable or field use. The miniature cryosorption vacuum pump may be used as a roughing pump in various applications which require intermediate vacuum rough pumping or as a high vacuum pump where low pumping rates are required at pressures down to 5.times.10.sup.-5 torr.",38,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Engines, pumps, turbines",,,,,,F04B/08
5345943,13-Sep-94,1994,9,13,Apparatus for determining in vivo response to thermal stimulation in an unrestrained subject,"An apparatus for determining in vivo hyperalgesia to thermal stimulation in an unrestrained subject within a predetermined space permitting the selective application of radiant heat to a site of the subject comprises a timer, a movable light source, a light detector and a stopper for the timer, the light source and the detector, the stopper being electrically connected thereto and automatically activated by the light detector upon site withdrawal, and a starter for the timer and the light source and for activating the light detector that is electrically connected thereto. When the light source is aimed at the site and positioned at a distance effective to locally provide radiant heat thereto and the starter is activated, after a latency time period the light beam elicits a spontaneous withdrawal response from the subject that is detected by the detector. The timer, the light source and detector, the stopper and the starter are part of an electrical circuit which is to be connected to a power source prior to use.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/4824
5346473,13-Sep-94,1994,9,13,Oxy-hydrogen propelled torpedo for introducing angioplasty guide wire,"A torpedo device which is attached to the end of a guide wire to provide a local driving force to the end thereof. The torpedo includes a telescopic structure having a combustion chamber therein. In operation, a combustible fuel is fed to the combustion chamber and an explosion is created by igniting the combustible fuel. Upon explosion, the torpedo expands axially to drive a projectile portion thorough an obstructed or constricted vessel lumen. Fins can be included on the exterior of the torpedo to prevent backward movement. The fins can also be used to scrape or cut an obstruction by engaging the obstruction and subsequently applying rearward movement to the torpedo.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/09041
5346908,13-Sep-94,1994,9,13,Nitrogen-containing cyclohetero cycloheteroaminoaryl derivatives for CNS disorders,"Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower alkyl, benzyl, and haloloweralkyl; wherein each of R.sup.2, R.sup.3 and R.sup.8 through R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is an integer of from four to six; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.",12,National Institutes of Health,Brown University,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/06
5348729,20-Sep-94,1994,9,20,Evaluative means for detecting inflammatory reactivity,"The present invention is directed to a method for testing the susceptibility of a mammal to inflammatory diseases which comprises the steps of: PA1 administering to a mammal a compound selected from the group consisting of Type 1 mineralocorticoid receptor antagonists, opiate antagonists, estrogen antagonists or mixed estrogen agonists/antagonists, progesterone agonists; or a combination of an estrogen antagonist with one or a combination of a Type I glucocorticoid receptor antagonist, a Type II glucocorticoid agonist or a progesterone agonist which is effective in stimulating the hypothalamic-pituitary-adrenal (HPA) axis; and PA1 measuring the level of at least one hormone secreted by the hypothalamus, pituitary or adrenal glands of said mammal. The present invention is also directed to methods of treating inflammatory diseases.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/40
5348741,20-Sep-94,1994,9,20,Vector for recombinant poxvirus expressing rabies virus glycoprotein,A plasmid vector has been constructed for producing unique vaccinia virus recombinant expressing the gene for rabiesvirus glycoprotein in cells. The recombinant induces production of glycoprotein in substantial amounts for immunization against rabies. Such recombinant could be applied for the production of anti-rabies vaccine and of G antigen antibody and related immunological reagents for research or diagnostic purposes.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5350864,27-Sep-94,1994,9,27,Aminoalkylcarbamyl derivatives of forskolin as intermediates for the synthesis of useful forskolin derivatives,"The subject matter of the present invention relates to aminoalkylcarbamates of forskolin and the methods of using these compounds. Specifically, the aminoalkylcarbamates may be utilized in the synthesis of forskolin derivatives. The final derivatives may, in turn, be used in the development of in vivo and in vitro assays designed to study different proteins.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Organic fine chemistry,,,,,G01N/566
5352447,4-Oct-94,1994,10,4,Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy,"A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are tumor specific and lack the nonspecific toxicity produced by the binding activity of the native toxin. The immunotoxin is useful in treating primary brain tumors, metastatic tumors to the brain, CSF-borne tumors, leptomeningeal leukemia and leptomeningeal carcinomatosis.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/34
5352581,4-Oct-94,1994,10,4,Sensitive yeast genetic system for identifying agents causing double-stranded DNA damage,"A sensitive, yeast-based genetic system for identifying agents causing double-strand DNA damage is described. The system comprises a yeast strain containing either chromosomes having divergent (homeologous) DNA sequences, a single nonhomologous chromosome or a single artificial chromosome with suitable genetic markers so that double-strand damage leading to the loss of such chromosome due to the inability to undergo recombinational repair with a homolog is detected.",4,United States/National Institutes of Health,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/18
5352669,4-Oct-94,1994,10,4,"O.sup.6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O.sup.6 -alkylguanine-DNA alkyltransferase depleting activity","O.sup.6 -Benzylated guanine guanosine and 2'-deoxyguanosine compounds of the formula ##STR1## wherein Z is hydrogen, ##STR2## and R is a benzyl group or a substituted benzyl group, cause a depletion of O.sup.6 -alkylguanine-DNA alkyltransferase (AGT) activity in mammalian cells. These compounds may be administered to a host so as to reduce AGT levels in tumor cells of the host in order to increase host responsiveness to anti-neoplastic alkylating agents, including chloroethylating agents, such as chloroethylnitrosoureas, for chemotherapeutic treatment of a number of neoplasms.",10,The of the United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07H/16
5354473,11-Oct-94,1994,10,11,Method for concentrating a solute by countercurrent chromatography,"A method for concentrating a solute from a mixture by countercurrent chromatography, by introducing a stationary phase into a countercurrent chromatographic centrifuge, introducing a sample of a mixture containing a solute into the centrifuge, introducing a sufficient quantity of an elution peak sharpening agent into the centrifuge, introducing a mobile phase into the centrifuge, and performing countercurrent chromatographic centrifugation. The eluting fractions containing the concentrated solute are identified and collected.",19,The United States of America as represented by the Departent of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
5354660,11-Oct-94,1994,10,11,"Isolation of diagnostic glycoproteins to taenia solium, immunoblot-assay and method for the detection of human cysticercosis","The present invention is directed to a method and a kit for diagnosing active human neurocysticercosis utilizing an immunoblot assay which comprises: PA1 detecting the presence of antibodies in the serum or cerebrospinal fluid of a human to be diagnosed, wherein the antibodies are reacted with Taenia solium larval antigens which have been isolated by lentil lectin affinity. The larval antigens are designated GP50, GP42, GP24, GP21, GP18, GP14, and GP13, wherein GP indicates that said antigen is a glycoprotein and the number indicates the molecular weight in K daltons, as determined by SDS-PAGE.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56905
5354683,11-Oct-94,1994,10,11,Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation,"HIV protease necessary for the natural synthesis of HIV has been identified and sequenced. This antibody cross reacts with the protease of HIV-2. In addition, a method for producing synthetic HIV-1 and HIV-2 protease having the correct stereospecific conformation and specific HIV proteolytic activity has been achieved. Assays for the synthetic proteases using synthetic peptide substrates have been developed.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/506
5354689,11-Oct-94,1994,10,11,Method of detecting isocyanates,The present invention provides for a method for detecting the presence of isocyanate in a sample by (a) contacting an isocyanate derivatizing reagent having the formula I EQU R--R' (I) wherein R is 9-anthracenylmethyl or a derivative thereof and R' is a radical having a single isocyanate-derivatizing functionality comprising a radical derived from a cyclic secondary amine with a sample under conditions suitable to the formation of a reaction product capable of detection and (b) detecting the presence or absence of the reaction product as an indication of the presence or absence of isocyanate in said sample. The present invention also provides a method of quantifying the total isocyanate presence by quantifying the reaction product.,18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/22
5356795,18-Oct-94,1994,10,18,Cloning cDNAs for the human interleukin-2 receptor (55 RD protein),"The cDNA encoding the human interleukin-2 receptor has been produced, sequenced, and developed for diagnosis of certain T-cell leukemias, in particular the virus associated with adult T-cell leukemia.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/7155
5356806,18-Oct-94,1994,10,18,Immortalized human cell lines containing exogenous cytochrome P450,"Non-tumorigenic, human bronchial epithelial cell lines are provided wherein the cell lines are capable of expressing cytochrome P450 genes which have been inserted into the cell lines. Also provided are methods and kits for identifying potential mutagens, cytotoxins, carcinogens, and chemotherapeutic agents utilizing these cell lines.",3,The United States of America as represented by the Department of Health and Human Services,"Nestec, S.A.",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12N/0071
5357041,18-Oct-94,1994,10,18,Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin,"The present invention relates to peptides from the three type I repeats of human endothelial cell thrombospondin, which bind to sulfated glycoconjugates including heparin and sulfatide. Such peptides are useful in glycoconjugate binding pharmaceutical compositions and in a method for binding glycoconjugates in a subject.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/10
5358866,25-Oct-94,1994,10,25,Cytosine deaminase negative selection system for gene transfer techniques and therapies,"The present invention relates to a system comprising a modified bacterial gene for cytosine deaminase that has been engineered into a eukaryotic expression vector and the expression of the gene by mammalian cells. The present invention further relates to methods, gene therapies and vaccines that employ the negative selectable marker, cytosine deaminase, which has the ability to produce a toxic antimetabolite 5-fluorouracil from 5-fluorocytosine.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/00
5358952,25-Oct-94,1994,10,25,O.sup.6 -substituted guanine compounds and methods for depleting O.sup.6 -alkylguanine-DNA alkyltransferase levels,"O.sup.6 -substituted guanine compounds of the formula ##STR1## wherein R is a benzyl group or a substituted benzyl group, cause a depletion of O.sup.6 -alkylguanine-DNA alkyltransferase (AGT) activity in mammalian cells. These compounds may be administered to a host so as to reduce AGT levels in tumor cells of the host in order to increase host responsiveness to anti-neoplastic alkylating agents, including chloroethylating agents, such as chloroethylnitrosoureas, for chemotherapeutic treatment of a number of neoplasms.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,The Penn State Research Foundation,,,,,,,,,,2,Organic fine chemistry,,,,,,C07H/16
5359078,25-Oct-94,1994,10,25,Signal transduction inhibitor compounds,"A compound having the formula: EQU Y--(CH.sub.2).sub.p --Ar.sup.11 --X--Ar.sup.12 wherein: PA0 p is an integer of from 0 to 4; PA0 Ar.sup.11 and Ar.sup.12 are each aromatic moieties independently selected from the group consisting of phenyl, naphthyl, and substituted versions thereof in which the substituents are members selected from the group consisting of halogen, nitro, carboxyl and alkoxy; PA0 X is a linking moiety selected from the group consisting of O, S, SO.sub.2, CO, CHCN, straight chain alkyl, alkoxy, and alkoxyalkyl; and PA0 Y is a nitrogen-containing heterocyclic moiety.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4164
5359685,25-Oct-94,1994,10,25,Focusing tips for optical fibers,Optical fiber devices for medical purposes and a method of making optical fiber devices. In one embodiment particularly suitable for laser surgery an optical fiber device is provided which includes an capsule which secures a lens element adjacent to an end of an optical fiber. The capsule includes fluid passageways which extend along the length thereof through which a temperature controlled fluid may be caused to flow. In another embodiment particularly suitable for providing a wide area of illumination an optical fiber device is provided which includes a main optical fiber element and a plurality of auxiliary optical fiber elements which are optically coupled thereto. The auxiliary optical fiber elements have terminal ends which project light that is transmitted through the main optical fiber.,18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/22
5362716,8-Nov-94,1994,11,8,Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines,"The present invention relates to a complex comprising hepatocyte growth factor (HGF) and met proto-oncogene protein. The present invention also relates to methods for detecting the presence of HGF ligand, met proto-oncogene receptor and methods for isolating either the ligand or receptor or complex comprising both. The present invention further relates to methods of diagnostic proliferative disorders and diseases such as hepatitis or hepatocarcinogenesis by detecting these ligand-receptor pairs.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/71
5364619,15-Nov-94,1994,11,15,Oncoimmunins,"The present invention relates, in general, to oncoimmunins. In particular, the present invention relates to oncoimmunin-lymphoid factor and oncoimmunin-myeloid factor, pharmaceutical compositions of said factors, and methods of use of said factors.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/515
5364793,15-Nov-94,1994,11,15,Methods for the diagnosis of peripheral nerve damage,"Methods of diagnosing peripheral nerve damage, including diagnosing and monitoring chronic back and cervical pain are disclosed. The methods involve subjecting a body fluid sample from a patient suspected of having chronic lumbar or cervical pain and peripheral nerve damage to two-dimensional electrophoresis or an immunoassay and measuring relative amounts of protein or proteins which increase or decrease in concentration as compared to a standard control. A preferred method employs an Apo-E variant as a marker of peripheral nerve damage. Also disclosed are kits for use with the diagnostic methods.",4,"Monoclonetics International, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/6896
5366865,22-Nov-94,1994,11,22,Anti-platelet monoclonal antibody,A method for producing novel monoclonal antibodies against purified platelets are provided. A monoclonal antibodies which inhibits platelet reactions with collagen or collagenous surfaces is described. A new method of detecting and treating tumor metastatis is described.,6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/28
5366977,22-Nov-94,1994,11,22,"Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners","A method of treating cells having a reduced apical Cl.sup.- conductance, such as that characteristic of cystic fibrosis cells, by contacting cells having a reduced apical Cl.sup.- conductance with a therapeutically effective quantity of a compound that antagonizes the A.sub.1 -adenosine cell receptor and does not antagonize the A.sub.2 -adenosine cell receptor. Suitable compounds include 8-cyclopentyl-1,3-dipropylxanthine (CPX), xanthine amino congener (XAC), and therapeutically effective derivatives thereof.",14,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,Biotechnology,,,,C07D/04
5366997,22-Nov-94,1994,11,22,Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs,"There are disclosed cardiovascularly active compounds possessing antihypertensive properties, and pharmaceutical compositions containing these agents and a method of treating cardiovascular disorders with the compounds. The active components of the pharmaceutical compositions are compounds of formula I ##STR1## wherein R.sub.1 and R.sub.2 are independently chosen from straight chain and branched chain alkyl and olefinic groups, which may be unsubstituted or substituted; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a heterocyclic group; and R.sub.3 is a pharmaceutically acceptable organic group selected from alkyl and olefinic groups which may be unsubstituted or substituted, acyl, a sulfonyl, sulfinyl, sulfenyl, carbonate, or carbamate derivative; or R.sub.3 is a group of the formula--(CH.sub.2).sub.n ONN(O)NR.sub.1 R.sub.2, wherein n is 2-8, and R.sub.1 and R.sub.2 are as described above. Novel compounds are disclosed wherein at least one of R.sub.1, R.sub.2 and R.sub.3 is an olefinic group or heteroatom-substituted straight or branched chain alkyl or olefinic group. Novel methods of synthesizing the compounds are also disclosed.",25,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/30
5368853,29-Nov-94,1994,11,29,Leukoregulin anti-viral therapy,The present invention relates to a method of treating a viral infection in an animal. The method comprises administering to said animal leukoregulin alone or in combination with an anti-viral chemotherapeutic agent. The invention further relates to a pharmaceutical composition suitable for use in such a method.,8,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/19
5369004,29-Nov-94,1994,11,29,Five highly informative microsatellite repeat polymorphic DNA markers,"The invention relates to polymorphic markers (two tetranucleotide, one dinucleotide repeat polymorphisms, 27 markers characterized by primer pairs 1A-27A, and five markers characterized by primer pairs 1B-5B that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers are characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences. The assay according to the invention is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours. Accordingly, the invention also relates to an improved PCR procedure and a PCR assay kit which comprise nucleotides according to the invention.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
5372809,13-Dec-94,1994,12,13,Antigenic matrix metalloproteinase peptides,"A family of metalloproteinases exist which cleave extracellular matrix molecules. These metalloproteinases are secreted in a latent inactive form and require activation in order to specifically cleave the preferred substrate. A series of peptides have been prepared based on the complete sequence analysis of type IV procollagenase. Peptide inhibitors were synthesized which correspond to cysteine repeat regions and histidine containing regions; the mechanism of action of these peptides involves inhibition of binding of the enzyme to the substrate. Peptide inhibitors were synthesized which correspond to the peptide cleaved off during activation, and constitute a novel class of metalloproteinase inhibitors. These inhibitors are members of a series of peptides which contain the core amino acid sequence RKPRC or analogs thereof. The cysteine residue is required for activity. Affinity purified antibodies directed against specific peptides can be used to a) detect any general metalloproteinase enzyme with the sequence in part VAAHE or PRCGNPD, and distinguish it from other known members of the metalloproteinase family, b) block functional domains resulting in the inhibition of enzyme activity, and c) distinguish latent from activated forms of the enzyme.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/8146
5374506,20-Dec-94,1994,12,20,Amino acid sequence for a functional human interleukin-8 receptor,"A cDNA clone from HL60 neutrophils, designated p2, which encodes a human interleukin-8 receptor. This IL-8 receptor can be expressed in oocytes or transfected host cells. This receptor has 77% amino acid identity with a second human neutrophil receptor isotype that also binds IL-8. It also exhibits 69% amino acid identity with a protein reported to be an N-formyl peptide receptor from rabbit neutrophils.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/715
5374717,20-Dec-94,1994,12,20,Sequences of the hemagglutinins of recent strains of influenza type B virus,The invention provides sequence analyses for recent strains of Influenza Type B Virus.,8,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5376525,27-Dec-94,1994,12,27,Method for detection of mycoplasma,"A method for detecting mycoplasma infection in a sample by contacting the sample with labeled oligonucleotides, then measuring incorporation (if any) of the label into mycoplasma RNA.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
5376642,27-Dec-94,1994,12,27,"Treatment of retroviral induced dementia by administration of 2',3'-dideoxyinosine","A preferred method and dosages for treatment of retrovirus-induced dementia by the administration of 2',3'-dideoxyinosine(ddI) is disclosed.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
5377003,27-Dec-94,1994,12,27,Spectroscopic imaging device employing imaging quality spectral filters,"Techniques for providing spectroscopic imaging integrates an acousto-optic tunable filter (AOTF), or a step-scan interferometer, and a focal plane array detector. In operation, wavelength selectivity is provided by the AOTF or the step-scan interferometer. A focal plane array detector is used as the imaging detector in both cases. Operation within the ultraviolet, visible, near-infrared (NIR) spectral regions, and into the infrared spectral region, is achieved. The techniques can be used in absorption spectroscopy and emission spectroscopy. Spectroscopic images with a spectral resolution of a few nanometers and a spatial resolution of about a micron, are collected rapidly using the AOTF. Higher spectral resolution images are recorded at lower speeds using the interferometer. The AOTF technique uses entirely solid-state components and requires no moving parts.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Optics,,,,,G01J/2823
5378602,3-Jan-95,1995,1,3,Highly informative microsatellite repeat polymorphic DNA markers twenty-[seven]six,"The invention relates to polymorphic markers (two tetranucleotide, one dinucleotide repeat polymorphisms and 27 markers characterized by primer pairs 1A-27A) that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers are characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences. The assay according to the invention is easy to perform and results can be obtained within 24 hours. It is not uncommon results to be available within 3-4 hours. Accordingly, the invention also relates to an improved PCR procedure and a PCR assay kit which comprise nucleotides according to the invention.",4,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
5378723,3-Jan-95,1995,1,3,Carbamate analogs of thiaphysovenine and method for inhibiting cholinesterases,"Substituted carbamates of tricyclic compounds which have a cyclic sulfer atom, provide highly potent and selective cholinergic agonist and blocking activity are useful as pharmaceutical agents. Cholinergic disease are treated with these compounds such as glaucoma, Myasthenia Gravis, Alzheimer's disease. Methods for inhibiting esterases, acetylcholinesterase and butyrylcholinesterase are also provided.",14,The United States of America as represented by the Secretary of the Dept. of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
5378809,3-Jan-95,1995,1,3,Polynucleotides and substrate for the epidermal growth factor receptor kinase (eps8),"A new substrate of epidermal growth factor receptor and other tyrosine kinase receptors denominated eps8, polynucleotide encoding eps8, antisense eps8 polynucleotide, antibodies to eps8, and assays for determining eps8.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
5380429,10-Jan-95,1995,1,10,Variable-position cross-axis synchronous coil planet centrifuge for countercurrent chromatography,A cross-axis synchronous flow-through coil planet centrifuge is disclosed which provides changeability in the position of the coils relative to the axis of rotation of the centrifuge. The advantage of such a feature is to allow adjustment of the centrifugal force operating on the coils to accommodate different types of separations. The coils are arranged in columns which are mounted to column holders that in turn can be engaged to the rotary frame of the centrifuge in positions in which the column holders intersect and do not intersect the rotary frame axis.,5,The United States of America as represented by the Deparment of Health and Human Services,,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/42
5380830,10-Jan-95,1995,1,10,Molecular clones of bovine immunodeficiency-like virus,Biologically active proviral molecular clones of bovine immunodeficiency-like virus and cell lines infected with the same have been prepared. Various utilities of the clones are described.,3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5380848,10-Jan-95,1995,1,10,Cocaine receptor binding ligands,"Novel compounds show high affinity for specific cocaine receptors in the brain, particularly dopamine transporter sites, and have the formula ##STR1## Wherein Y=CH.sub.2 R.sub.3, CO.sub.2 R.sub.2 or ##STR2## R.sub.1 =hydrogen, C.sub.1-5 alkyl, R.sub.2 =hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkynyl, halogen or amine, PA1 R.sub.3 =OH, hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, Cl Br, I, CN, NH.sub.2, NHC.sub.1-6 alkyl, NC.sub.1-6 alkyl, OCOC.sub.1-6 alkyl, OCOC.sub.1-3 alkylaryl, PA1 A=S, 0 or NH PA1 X=H, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkynyl, halogen, amino, acylamido, and PA1 Z=H, I, Br, Cl, F, CN, CF.sub.3 NO.sub.2, N.sub.3, OR.sub.1, CO.sub.2 NH.sub.2, CO.sub.2 R.sub.1, C.sub.1-6 alkyl , NR.sub.4 R.sub.5, NHCOR.sub.5, NHCO.sub.2 R.sub.6, wherein R.sub.4 -R.sub.6 are each C.sub.1-6 alkyl.",4,Research Triangle Institute,The United States of America as represented by the Department of Health and Human Servies,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/02
5382514,17-Jan-95,1995,1,17,In vivo angiogenesis assay,"A method of performing in vivo angiogenesis assays which involves the use of a matrix material which can be maintained in an injectable solution form at a temperature below that of a host and which forms a gel matrix when injected into a host. The matrix material is an extract of murine basement membrane. Angiogenic factors, including inducers and inhibitors can be added to the matrix material prior to injection into a host. After a period of time within the host, the gel matrix is recovered and angiogenesis of the recovered matrix gel is quantitated. The procedure can be used to induce vascularization or inhibit vascularization at a tissue situs as desired.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0004
5384243,24-Jan-95,1995,1,24,Method for screening an agent for its ability to prevent cell transformation,"The present invention relates, in general, to a method of screening agents. In particular, the present invention relates to a method of testing the cancer preventing activity of a drug and of testing an agent for its ability to prevent cell transformation.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5011
5385933,31-Jan-95,1995,1,31,Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof,"A composition and a method for inhibiting cellular proliferation, such as the abnormal cellular proliferation characteristic of cancer cells. The method comprises the administration to a mammal, in particular a human, of an effective amount of S-(methylthio)-DL-homocysteine or S-(methylthio)-L-homocysteine, either simultaneously or sequentially, with an effective amount of a copper chelate such that an effective amount of an inhibitory complex forms in the mammal between the S-(methylthio)-homocysteine and the copper of the cooper chelate. The inhibitory complex is capable of inhibiting the proliferation of cells contacted by the inhibitory complex.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/30
5385936,31-Jan-95,1995,1,31,Gossypol acetic acid for the treatment of cancer,"A method for treating cancer in a human, which comprises administering to the human subject an anti-cancer effective amount gossypol acetic acid. Also included is a method for treating cancer in a human which comprises administering to the human subject an anti-cancer effective amount of gossypol acetic acid in combination with an anti-cancer effective amount of other conventional chemotherapeutic agents. Finally, the invention also encompasses a pharmaceutical composition comprising an anti-cancer effective amount of gossypol acetic acid, and an anti-cancer effective amount of a conventional chemotherapeutic agent, or combinations of the latter.",7,The United States of America as represented by the Secretary of the Department of the Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/11
5386021,31-Jan-95,1995,1,31,Mammalian guanine nucleotide binding protein with an ADP-rybosylation factor domain,"The invention provides a method for detecting the presence of ARD 1 protein in a sample. The method includes the steps of providing labeled or immobilized anti-ARD 1 antibody in a reaction zone, introducing sample into the reaction zone such that ARD 1 protein in the sample, if present, will react with said antibody to form an immunological complex, and detecting the formation of said immunological complex. Cells, nucleotide and amino acid sequences and vectors associated with ARD 1 are also described.",5,"The United States of America, as represented by the Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5386027,31-Jan-95,1995,1,31,Carbohydrate receptor for bacteria and method for use thereof,"A carbohydrate receptor for pathogenic bacteria is a purified carbohydrate compound that is a member selected from the group consisting of fucosyl-asialo GM1, asialo GM1, and asialo GM2. The receptor can be included in a composition having a pharmaceutically acceptable carrier. The receptor may be used for purifying, detecting, or removing bacteria from diseased tissue. The structure of the receptor is N-acetylagalctosamine-beta-1-4-galactose-beta-1-4-glucose, abbreviated GalNAc.beta.1-4Gal.beta.1-4Glc. The receptor is present in human and animal tissues as complex molecule and can serve as the attachment site for bacterial infection. For example, fucosyl-asialo GM1, asialo GM1, and asialo GM2 are three biological molecules which occur in cell membranes and contain the carbohydrate receptor.",4,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,,,,,G01N/56911
5387867,7-Feb-95,1995,2,7,Pulsed low frequency EPR spectrometer and imager,An EPR imager and spectrometer includes pulse generating system for generating broadband pulses having an RF carrier frequency that is not highly absorbed by biological samples. The pulse generating system includes up and down chirp convertors for frequency modulating a carrier frequency pulse and compressing the frequency modulated pulse to form a broadband excitation pulse of high energy. Such a machine could form the basis of a clinical imaging device capable of high sensitivity to free radical species in human patients.,10,The United States of America as represented by the Dept. of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/60
5388580,14-Feb-95,1995,2,14,Head holder for magnetic resonance imaging/spectroscopy system,"A head holder with the following characteristics: it is compatible with MR (no metallic parts); it is adjustable for use with adults and children; it does not produce any degradation of imaging or spectroscopy raw data; it does not induce claustrophobia; it can be used as a fixation device for cervical spine MR examinations; and it can operate with any MR unit. A strap is placed around the head of the patient at the forehead, is tightened, and then the head with band attached is positioned for optimal comfort and examining advantage. Lock screws are then tightened, holding the head comfortably in three-dimensional space. Only a single band is placed over the forehead of the person and the rest of the fixation is provided by adjusting and locking screws located in the base and along the sides of the holder. This prevents the patient from being able to rotate his or her head from side to side or up and down. The holder is designed to fit into the MR table. This is a major improvement over existing devices in that it provides for patient comfort while providing adequate head support and fixation.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Medical technology,,,,,A61B/0555
5389521,14-Feb-95,1995,2,14,Carbohydrate receptor for bacteria and method for use thereof,"The invention is a method for detecting pathogenic bacteria by specific binding of the bacteria to GalNAc.beta.1-4Gal sequences found in fucosyl-asialo GM1, asialo GM1 and asialo GM2. An agglutination reaction is disclosed comprising contacting a culture suspected of containing the bacteria with a suspension of a purified carbohydrate compound bound to an insoluble carrier and detecting the presence of perceptible agglutination of the carrier as an indication of the presence of the bacteria. Bacteria which can be detected using the claimed method include Pseudomonas, Haemophilus, Staphylococcus, Klebsiella and Streptococcus pneumoniae.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,,,,,G01N/56911
5389675,14-Feb-95,1995,2,14,Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents,"Mixed ligand metal complexes of nitric oxide-nucleophile adducts, useful as cardiovascular agents of the formula KA, wherein A is EQU [(M).sub.x.sup.x' (L).sub.y (R.sup.1 R.sup.2 N-N.sub.2 O.sub.2).sub.x ], and K is a pharmaceutically acceptable counterion present in the composition when the overall charge of A is not zero, counterion K being present only in an amount to neutralize A. Methods of treating mammals with such compounds are provided. Pharmaceutical compositions containing such compounds are also provided.",41,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07F/005
5397696,14-Mar-95,1995,3,14,Papua New Guinea human T-lymphotropic virus,"The present invention relates to a human T-cell line (PNG-1) persistently infected with a Papua New Guinea (PNG) HTLV-I variant and to the infecting virus (PNG-1 variant). Cells of the present invention express viral antigens, type C particles and have a low level of reverse transcriptase activity. The establishment of this cell line, the first of its kind from an individual from Papua New Guinea, makes possible the screening of Melanesian populations using a local virus strain. The present invention also relates to vaccines for use in humans against infection with and diseases caused by HTLV-I and related viruses. The invention further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-I and related viruses.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5399346,21-Mar-95,1995,3,21,Gene therapy,Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/525
5401643,28-Mar-95,1995,3,28,Method of preparing an active human neutrophil chemotactic factor polypeptide,"A simple and efficient method of preparing active recombinant human neutrophil chemotactic factor. The human neutrophil chemotactic factor (NCF) is solubilized from a transformant cell homogenate using urea or guanidine hydrochloride. The polypeptide is further purified from the solution using conventional protocols such as CM-Sepharose CL-6B, HW-55 column, etc.. By using this method, large amounts of active human NCF can be recovered and purified.",10,"Dainippon Pharmaceutical Co., Ltd.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/5421
5401755,28-Mar-95,1995,3,28,N-(1-thienylcycloalkyl)alkenylamines for treatment of neurotoxic injury,"Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an N-(1-thienylcycloalkyl)alkenylamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites. Compounds of most interest are those of the formula ##STR1## wherein R.sup.1, R.sup.2, and R.sup.5 are defined in specification.",13,G. D. Searle & Co.,National Institutes of Health,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/06
5402522,28-Mar-95,1995,3,28,Dynamically stable associative learning neural system,"A dynamically stable associative learning neural network system include a plurality of synapses (122,22-28), a non-linear function circuit (30) and an adaptive weight circuit (150) for adjusting the weight of each synapse based upon the present signal and the prior history of signals applied to the input of the particular synapse and the present signal and the prior history of signals applied to the input of a predetermined set of other synapses. An embodiment of a conditional-signal neuron circuit (100) receives input signals from conditional stimuli and an unconditional-signal neuron circuit (110) receives input signals from unconditional stimuli. A neural network (200) is formed by a set of conditional-signal and unconditional-signal neuron circuits connected by flow-through synapses to form separate paths between each input (215) and a corresponding output (245). In one embodiment, the neural network (200) is initialized by varying the weight of the input signals from conditional stimuli, until a dynamic equilibrium is reached.",2,The United States of America as represented by the Department of Health and Human Services,Environmental Research Institute of Michigan,,,,,,,,,,2,Computer technology,,,,,,G06N/04
5403925,4-Apr-95,1995,4,4,Nucleic acids encoding mammalian H-2RIIBP or RXR.sub..beta. and uses thereof,"The present invention relates generally to the identification and characterization of new genes and proteins. More particularly, the present invention relates to the discovery of novel members of the nuclear hormone receptor superfamily and cDNA clones thereof. The family members are designated as H-2RIIBP (or RXR.sub..beta., retinoid x receptors). These proteins bind selectively only to the native region II sequence of the conserved major histocompatibility complex class I regulatory element (MHC CRE). Sequences homologous to the H-2RIIBP gene are found in the nuclear receptor family including: retinoic acid receptors (RAR), estrogen receptors (ER), thyroid hormone receptors (TR), (COUP-TF), and other RXR isoformes. This invention also provides for a diagnostic test which determines the nature and progression of a human tumor by measuring the quantity and quality of H-2RIIBP gene dosage or expression.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70567
5403926,4-Apr-95,1995,4,4,Hepatocellular carcinoma oncogene,The present invention relates to an oncoprotein specific for hepatocellular carcinomas and to a nucleotide sequence that codes for such a protein. The invention further relates to screening and diagnostic methodologies (and kits based thereon) that make use of the oncoprotein (or antibodies specific for same) and the nucleotide sequence.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/32
5405782,11-Apr-95,1995,4,11,Detection and quantitation method for therapeutic agents in blood,"The present invention relates to an improved method for the determination of therapeutic agents in blood. This method utilizes a solid phase extraction of the solute from plasma followed by reverse phase high performance liquid chromatography on a column of irregularly shaped C-18 modified silica. Comparison of the produced chromatogram with a standard curve provides a precise and accurate quantification of the amount of the solute in blood. Additionally, the extraction and chromatography steps can be readily automated for the rapid determination of multiple samples.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/94
5405875,11-Apr-95,1995,4,11,Method of inhibiting neoplasia and tumor promotion,"The present invention provides a method of inhibiting neoplasia and tumor promotion. The method comprises administering to a mammal, particularly a human, in need thereof an effective amount of a 12-deoxyphorbol ester, particularly a 12-deoxyphorbol 13-monoester such as 12-deoxyphorbol 13-acetate (prostratin) and 12-deoxyphorbol 13-phenylacetate (dPP).",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/216
5405919,11-Apr-95,1995,4,11,"Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders","A polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.",22,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
5409938,25-Apr-95,1995,4,25,Antimalarial korupensamines and pharmaceutical compositions and medical uses thereof,"The present invention provides new antimalarial compounds called korupensamines, korupensamine derivatives, and pharmacologically acceptable salts thereof, methods for isolating such antimalarial korupensamines from the plant Ancistrocladus korupensis, methods for obtaining new korupensamine derivatives, antimalarial compositions containing such antimalarial korupensamines or derivatives thereof or pharmacologically acceptable salts thereof, and methods of using such antimalarial compounds for the prevention of malaria infections or for treating mammals with malarial infections. The antimalarial compounds of the present invention inhibit the reproduction and cytopathicity of Plasmodium sp. parasites in vitro and in vivo.",41,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/02
5409948,25-Apr-95,1995,4,25,Method for treating cognitive disorders with phenserine,An improved method of cholinomimetic therapy for cognitive impairments associated with aging and Alzheimer's disease comprising treating a patient with an effective amount of phenserine or a pharmaceutically acceptable salt and derivatives.,6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/40
5413779,9-May-95,1995,5,9,Cocaine receptor binding ligands,"3.beta.-[4-iodophenyl]-tropan-2.beta.-carboxylic acid methyl ester tartrate is a high affinity binding ligand for cocaine receptors in mammalian brains. It and its congeners may be employed for imaging and other brain scanning techniques that allow the determination of the presence of cocaine receptors, such as dopamine and serotonin transporters and the like.",17,Research Triangle Institute,The United States of America represented by the Secretary of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/02
5415873,16-May-95,1995,5,16,Use of purinergic receptor agonists as antineoplastic agents,"The instant invention is directed to the use of a pharmaceutical composition containing an effective amount of adenosine or an adenosine analog or derivative as an agent useful in the treatment of hormone-independent cancers, such as prostate cancer. The invention is also directed to diagnostic uses of these compounds to determine effective treatment regimes for specific tumors, a process for screening for new, therapeutically useful analogs of these compounds, and the use of these compounds in facilitating the extraction of intracellular components.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/70
5416582,16-May-95,1995,5,16,Method and apparatus for localization and spectroscopy of objects using optical frequency modulation of diffusion waves,An apparatus and method for using frequency modulated diffusive photon-density waves propagating through a turbid medium such as tissue for detecting optical properties of objects and for imaging objects within the turbid medium. Frequency modulation enables real time differential measurement of the interaction of different colors with the object when the different colors are chosen such that they react the same with the medium but differently with the object. The method greatly simplifies optical imaging and increases the amount of information which may be obtained about the object.,21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/4795
5418160,23-May-95,1995,5,23,Cloned cell line expressing rat .beta..sub.3A adrenergic receptor,The present invention relates to a fat cell specific rat .beta.-adrenergic receptor that mediates lipolysis in rats. The invention further relates to cloned cells which code for the specific .beta.-adrenergic receptor that mediates lipolysis. Another aspect of the present invention relates to a diagnostic test method for determining decreased levels of fat cell .beta.-adrenergic receptors that mediate lipotysis in order to diagnosis obesity caused by less active lipolysis.,1,The United States as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
5419900,30-May-95,1995,5,30,Immunologic enhancement with intermittent interleukin-2 therapy,"A method for activating a mammalian immune system entails a series of continuous IL-2 infusions that are effected intermittently over an extended period. For example, IL-2 can be administered continuously for a period that is on the order of 5 days in length, and successive infusions of this nature can be separated by a period of at least 4 weeks. Sustained beneficial effects, including elevated CD4 cell counts, restoration of lymphocyte function and an increase in the number of IL-2 receptors, are achieved with such intermittent IL-2 therapy, which can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha.",5,The United States of America as represented by the Department of of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
5420011,30-May-95,1995,5,30,Cell bioassay for neurotoxins,"An inventive bioassay method can be used to determine the presence in a fluid sample of a toxin having sodium channel-affecting activity. The method includes the steps of incubating a plurality of cultures of cells which are responsive in a dose-dependent manner to sodium channel-affecting toxins with (i) a medium comprising a solution of ouabain and veratridine and (ii) a portion of the fluid sample, each culture being incubated with a different concentration of the fluid sample; removing the medium and fluid sample from the cultures; incubating the cultures with a medium comprising an indicator which is acted upon by living cells to form a measurable product; measuring the amounts of product formed during the preceding step; and relating the amounts of product measured to a standard calibration curve to determine the presence of the toxin in the sample. The method is readily embodied in kit form and is amenable to automation.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/025
5420030,30-May-95,1995,5,30,Molecular clones of HIV-1 viral strains MN-ST1 and BA-L and uses thereof,"The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5420033,30-May-95,1995,5,30,Epithelial cell line expressing a cystic fibrosis phenotype,"An airway epithelial cell line (CF/T43) was developed by infecting cultured cystic fibrosis (CF) airway epithelial cells with the pZIPneoSV(X)1/SV40T retrovirus and selecting for Genetian (G418) resistance and ion transport properties. The distinctive chloride secretory phenotype of CF/T43 [an apical membrane chloride permeability (P.sub.cl -) activated by calcium-mediated, but not by adenosine 3',5'-monophosphate (cAMP)-dependent agonists] was not perturbed by SV40T-induced cell transformation. Epithelial cell lines generated from CF cells with the SV40T gene can be used to test candidate CF genes, to evaluate the molecular mechanisms responsible for the CF phenotype and to test putative therapeutic CF drugs.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0688
5420162,30-May-95,1995,5,30,Phorbol ester pharmaceutical compositions and their use for treating inflammation,"The present invention relates to a method of inhibiting the protein kinase C-mediated biological response inflammation. The method comprises administering to a mammal a non-tumor promoting 12-deoxyphorbol ester. Phorbol esters suitable for use in the method include 12-deoxyphorbol 13-monoesters wherein the ester is a formate, acetate, propionate, butyrate, pentanoate, hexanote, benzoate or phenylacetate ester. The invention also relates to novel 12-deoxyphorbol 13-monoesters, wherein the ester can be a formate, propionate, butyrate or pentanoate ester, and to pharmaceutical compositions comprising same.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/216
5420244,30-May-95,1995,5,30,Methods and compositions for diagnosing HTLV-I associated myelopathy and adult T-cell leukemia,"The invention provides antigenic peptides derived from immunodominant epitopes of the HTLV-I tax or rex proteins that are immunoreactive with antibodies associated with disease in HTLV-I infected subjects. More specifically, the invention provides antigenic peptides consisting essentially of the amino acid sequences defined in the sequence listing by SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7 and 8 and antigenic fragments thereof. The invention provides a method of diagnosing HTLV-I associated myelopathy (HAM) or a predisposition thereto, comprising the steps of: (a) contacting an antibody containing sample from the subject with a detectable amount of a peptide of the invention or an antigenic fragment thereof; and (b) detecting the reaction of the peptide with an antibody in the sample, the reaction indicating HTLV-I associated myelopathy or a predisposition thereto. The invention also provides a method of diagnosing adult T-cell leukemia or a predisposition thereto in a subject, comprising the steps of: (a) contacting an antibody containing sample from the subject with a detectable amount of the peptide of SEQ ID NO: 1; and (b) detecting the reaction of the peptide with an antibody in the sample, the reaction indicating adult T-cell leukemia or predisposition thereto.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5422240,6-Jun-95,1995,6,6,Apparatus and method for testing condoms as barriers to virus penetration,"A method for testing a condom for viral penetration includes the steps of positioning a condom to be tested in a restraining device so that expansion of the condom is restricted to a size corresponding to the device anthropomorphic dimensions of a penis; pressurizing the condom via a liquid containing viral particles in suspension, and monitoring for passage of viral particles through the condom. The method which simulates conditions of human sexual intercourse while using a viral particle to test condom integrity can be effected using an apparatus with elements that are commonly found in a microbiology lab. The apparatus includes a conduit over which the open end of the condom to be tested is secured; a restrainer for restricting the expansion of the condom to a size corresponding to the mean anthropomorphic dimensions of a penis; a liquid containing viral particles in suspension, the liquid filling the condom; a pressurizing device for pressurizing the condom via the liquid; and a container filled with a collecting fluid wherein the condom and the restrainer are positioned so that the viral particles that have passed through the condom can be monitored.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01M/227
5422270,6-Jun-95,1995,6,6,One-step tray test for release of soluble mediators and apparatus therefore,"A microculture tray comprising a plurality of pairs of wells, each pair of wells connected by a trough which extends downwardly approximately 2/3 of the depth of the well so that the wells in the pair are connected so as to allow free passage of supernatant but not of cells between the wells. The tray can be used for rapid testing of animal cells or non-motile microorganisms for the release of soluble mediators.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Chemical engineering,,,,,B01L/5025
5422344,6-Jun-95,1995,6,6,Method of treating retroviral infections in mammals,"The present invention is directed to the use of pharmaceutical compositions, containing an effective amount of topoisomerase I inhibitor such as camptothecin, useful in blocking both the initiation of infection and replication of retroviruses in host cells, thus reducing and eliminating retroviral production in infected cells. Use of such inhibitors provides as means of reducing or eliminating retroviral infections and their deleterious consequences in infected humans and animals.",8,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/00
5422427,6-Jun-95,1995,6,6,Pneumococcal fimbrial protein A,"The present invention relates, in general, to pneumococcal fimbrial protein A. In particular, the present invention relates to a DNA segment encoding a pneumococcal fimbrial protein A gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a pneumococcal fimbrial protein A polypeptide; antibodies specific to pneumococcal fimbrial protein A; and a method of measuring the amount of pneumococcal fimbrial protein A in a sample.",4,The United States of America as represented by the United States Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/3156
5424191,13-Jun-95,1995,6,13,Epithelial cell specific differentiation marker,"A full length cDNA clone from a normal human mammary epithelial cell (strain 184) encoding a 25 kDa protein, HME1, was isolated. Expression of HME1 RNA appears to be limited to epithelial cells. The HME1 sequence shares strong sequence homology with bovine 14-3-3 protein, which is an activator of tyrosine and tryptophan hydroxylase, but the tissue distribution of HME1 differs from that of 14-3-3. Compared with normal mammary epithelial cells, expression of HME1 RNA is dramatically low in cells derived from human mammary carcinoma and in normal mammary epithelial cells transformed by oncogenes. HME1 therefore appears to be a cellular differentiation marker that is down-regulated during neoplastic transformation.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5426184,20-Jun-95,1995,6,20,Cyclodextrin glycosides and processes for their preparation,The invention relates to cyclodextrin glycosides and processes for their preparation. The cyclodextrin glycosides according to the invention are cyclodextrins substituted by 2-acetamido-2-deoxyaldoses. These cyclodextrin glycosides are prepared by a process which is characterized in that cyclodextrins are reacted with 2-acetamido-2-deoxyaldoses in an anhydrous acid medium and the reaction products are then treated with a mild base. The cyclodextrin glycosides can be used for solubilization of substances which are sparingly soluble or insoluble in water.,17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Macromolecular chemistry, polymers",,,,,,C08B/0012
5426719,20-Jun-95,1995,6,20,Ear based hearing protector/communication system,"A combination hearing protector and communication device may be incorporated into a set of earmuffs or earplugs, meeting the needs of workers who must work in hazardous noise environments and who must be able to communicate with each other as well as with persons outside the hazardous noise environment. Each unit of the system has two channels, one to transmit speech and one to receive speech. While each wearer will have an independent transmission channel, all wearers can use the same receiving channel. The system is designed to be incorporated into earmuffs or earplugs in such a way that their noise-reducing characteristics are not diminished. The system incorporated into the earmuff is no more difficult to use than a conventional pair of noise-reducing earmuffs in that nothing additional need be fitted into or onto the ears. Likewise, the system incorporated into the earplugs is as easy to use as custom-molded noise-reducing earplugs which are corded to keep them together.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Audio-visual technology,,,,,,H04R/1083
5428069,27-Jun-95,1995,6,27,"Treating cognition with, aminocyclopropanecarboxylic derivatives","The use of a compound possessing functional antagonist properties at the NMDA receptor complex through a specific action at the associated strychnine-insensitive glycine site to improve cognition in normal humans and to treat cognitive deficits resulting from chronic neuronal degeneration, acute brain injury, hypoxia, or other neurological disorders is provided. The compounds possessing functional antagonist properties comprise 1-aminocyclopropanecarboxylic acid, and its pharmaceutically acceptable esters, salts, and acid addition salts or 7-chlorokynurenic acid, and its pharmaceutically acceptable esters, amides, salts, ethers, and acid addition salts.",2,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/195
5428134,27-Jun-95,1995,6,27,Antibody reagents that specifically bind to the carboxyl-terminal decaptide of specific GTP-binding proteins,"Antibodies which bind to a peptide having the sequence KENLKDCGLF, which represents the C-terminal decapeptide of the GTP-binding protein transducin-.alpha., are described. Binding to transducin-.alpha. by peptide-specific antiserum AS/7 is not affected by pertussis toxin-catalyzed ADP-ribosylation.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/18
5428154,27-Jun-95,1995,6,27,"Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions","The invention is a chelate of formula I: ##STR1## wherein R.sub.1-4 is --CH.sub.2 COOH; PA0 n is 1 to 5; PA0 X is a member selected from the group consisting of PA1 --NO.sub.2, PA1 --NH.sub.2, PA1 --NCS, PA1 --NHCOCH.sub.2 --Z, with Z being a member selected from the group consisting of Br and I, PA1 --COOH; and PA1 --OCH.sub.2 OOCH; PA0 and M is a metal ion selected from the group of elements consisting of PA1 Bi, Pb, Y, Cd, Hg, Al, Th, Sr, and Lanthanides. The invention also includes a chelate, wherein M is a copper ion and n is an integer from 2 to 5. The invention includes chelate conjugates of formula I and ligand conjugates of formula II: ##STR2## The invention also includes methods to use these compounds for treatment of cellular disorders and for diagnostic tests.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Organic fine chemistry,,,,G01N/534
5429127,4-Jul-95,1995,7,4,Thin wall endotracheal tube,"An ultra-thin wire reinforced endotracheal tube which includes a novel sealing design adapted to fit in a complementary manner in a subject's larynx. The endotracheal tube includes a laryngeal section which has a cross sectional shape and size that are complementary to a subject's glottis. Preferably, the laryngeal section has an oval or egg-shaped cross section. A plurality of thin, pliable sealing ""gills"" are provided on the surface of the laryngeal section. The gills provide a fluid tight seal which does not harm a subject's larynx. The endotracheal tube is reinforced with a metallic spring material. In a preferred embodiment, the metallic spring material is a shape memory alloy. The use of a shape memory alloy prevents damage to the endotracheal tube caused by distortion, such as kinking, crushing, etc.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,Medical technology,,,,,B29C/042
5430135,4-Jul-95,1995,7,4,DNA sequence encoding a cynomolgus monkey hepatitis A virus capsid protein,"The present invention relates, in general, to substantially pure preparations of the cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55; cDNAs of the genomic RNAs of cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55; a method of preventing hepatitis A in an animal; and vaccines comprising the cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5430169,4-Jul-95,1995,7,4,Method for preparation of sphingoid bases,"The present invention provides a series of non-toxic compounds which function to inhibit the activity of S-1-P aldolase in respect to its cleavage of S-1-P. These inhibitors are described by the compounds of formula I ##STR1## wherein R is a radical containing 1 to 15 carbon atoms, a halogen, or hydrocarbon, R' is an organic radical or hydrogen, and R"" is --NH.sub.3.sup.+ or --NH--NH .sup.+, with the proviso that, when R is CH.sub.3 (CH).sub.12 (CH.dbd.CH) and R' is hydrogen, R"" is --NH--NH.sub.3.sup.+. A method for preparing such compounds, which may generally be described as 1-phosphate derivatives of compounds which include a 2-amino-1,3-alcohol radical is also disclosed.",20,The United States of America represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/091
5432060,11-Jul-95,1995,7,11,Immortalized human bronchial epithelial cell line,Human bronchial epithelial cell lines permanently transformed by human papilloma viruses have been obtained. These cell lines are useful for the study of growth and differentiation in bronchial carcinoma and the identification of chemical and biological agents that may be useful in the therapy of human lung cancer.,8,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/0688
5434079,18-Jul-95,1995,7,18,Apparatus and process for continuous in vitro synthesis of proteins,"An apparatus and process for continuous, cell-free, in vitro synthesis of peptides, particularly peptide-MHC complexes make use of a novel bioreactor flow cell which allows for the reproducible, systematic variation of single parameters in order to optimize translation processes. The bioreactor flow cell includes a pair of substantially parallel membranes positioned within a chamber to define therebetween a space, the ratio of total membrane surface area to chamber volume being at least 5 units.sup.-1, which permits high perfusion rates through the system with lower flux rate per membrane area. The apparatus also may include a novel countercurrent flow dialysis cell and other components.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12M/04
5434287,18-Jul-95,1995,7,18,Bifunctional DTPA-type ligand,The subject matter of the present invention relates to bifunctional cyclohexyl DPTA ligands and methods for utilizing these compounds.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,,G01N/534
5435307,25-Jul-95,1995,7,25,Surface fluorescent monitor,A method of optimizing photodynamic therapy in which retained concentrations of photosensitizers administered are measured on a real time basis by percutaneous measurements of fluorescence. A light weight hand held fluorometer is used to percutaneously measure fluorescence emitted by photosensitizers in a tissue situs that is subject to photodynamic therapy. The use of real time determinations of the concentration of photosensitizers allow optimization of illumination intensity and duration.,5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/0059
5436320,25-Jul-95,1995,7,25,Antibody reagents that identify the carboxy-terminal peptide of the GTP-binding protein G.sub.o,"Antibodies having binding specificity for a peptide having the sequence ANNLRGCGLY have been prepared. The antibodies bind to the GTP-binding protein G.sub.o and are useful for identifying, isolating and distinguishing between different GTP binding proteins.",3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/18
5437638,1-Aug-95,1995,8,1,Multifinger topocatheter tip for multilumen catheter for angioplasty and manipulation,"A tip design for a multilumen catheter which includes a plurality of inflatable tubes each of which is attached to a lumen at the distal end of the multilumen catheter. The inflatable tubes are normally inverted in their respective lumens, but can be individually everted, inflated, deflated and retracted or inverted back into their lumen by the application of fluid pressure and vacuums at the proximal end of the multilumen catheter. In a procedure to open a constricted passageway one or more of the inflatable tubes can be inverted into the constriction and thereafter inflated to open the passageway. Thereafter, addition inflatable tubes can be inverted into the constriction and inflated to effect further opening of the passageway. In another embodiment, the inflatable tubes are provided with gripping surfaces and are manipulated by appropriate fluid pressures like fingers to grasp and recover target objects in a blocked passageway.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/0068
5437951,1-Aug-95,1995,8,1,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5439899,8-Aug-95,1995,8,8,Cosalane and related compounds having activity against aids and aids-related infections,Novel compounds having anti-HIV activity are disclosed along with formulations and methods for treating human immunodeficiency viral infections employing these compounds.,9,Purdue Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,,,,,,C07J/00
5441530,15-Aug-95,1995,8,15,Photochemotherapy dosimeter,"A photochemotherapy dosimeter for monitoring cumulative photochemotherapy radiation dosage. The photochemotherapy dosimeter includes an optical fiber having a chemical cell attached at one end thereof. The chemical cell contains a photobleachable chemical which can be in a solution or incorporated into a matrix material. Changes in the absorption of the photobleachable chemical are used to monitor the cumulative photochemotherapy radiation dosage. In use, the chemical cell of the photochemotherapy dosimeter is positioned near an abnormal tissue which is subjected to photochemotherapy treatment.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,,,,,A61N/062
5441941,15-Aug-95,1995,8,15,"1,2-dihydroellipticines with activity against CNS specific cancer","Certain new 1,2-dihydroellipticine compounds having activity against CNS specific cancer cell lines because of their ease of passage across the blood-brain barrier are disclosed along with formulations and methods for treating CNS cancers employing these compounds.",24,The United States of America as represented by the Secretary of DHHS,Purdue Research Foundation,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/04
5443954,22-Aug-95,1995,8,22,Immortalized non-tumorigenic human bronchial epithelial cell lines,Immortalized human bronchial epithelial and human mesothelial cell lines have been obtained. Various uses of these cell lines have been described.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/0071
5444150,22-Aug-95,1995,8,22,"Amino acid derivative and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides","A new amino acid derivative, N.sup..alpha. -tert-butoxycarbonyl-N.sup.e -(N-bromoacetyl-.beta.-alanyl)-L-lysine (BBAL), has been synthesized as a reagent to be used in solid-phase peptide synthesis for introducing a side-chain bromoacetyl group at any desired position in a peptide sequence. The bromoacetyl group subsequently serves as a sulfhydryl-selective cross-linking function for the preparation of cyclic peptides, peptide conjugates and polymers. BBAL residues are stable to final HF deprotection/cleavage. BBAL peptides can be directly coupled to other molecules or surfaces which possess free sulfhydryl groups by forming stable thioether linkages. Peptides containing both BBAL and cysteine residues can be self-coupled to produce either cyclic molecules or linear peptide polymers. Such peptide derivatives are useful in preparing potential peptide immunogens, vaccines and therapeutics, and for substances such as peptides linked to polymers, plastics, enamels and ceramics.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Organic fine chemistry,,,,C07K/1077
5445932,29-Aug-95,1995,8,29,Method for detection of a new marker associated with hepatitis delta virus infection,Reagents and methods for the detection of a marker which is associated with severe forms of hepatitis delta virus infection are described. A vaccine comprising immunogenically active HDAg' polypeptides is also described.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5445968,29-Aug-95,1995,8,29,Purification of human chorionic gonadotropin .beta.-core molecule and preparation of antibodies with specificity for same,"The present invention relates to the purification of the human chorionic gonadotropin .beta.-core molecule which can then be used as the antigen in the preparation of antibodies to the .beta.-core molecule. The combination of the purified .beta.-core molecule and the antibodies can be used in an immunoassay kit to measure .beta.-core molecules in the presence of structurally similar molecules, i.e., hCG, LH, hCG.beta.-subunit and LH.beta.-subunit. Measurement of the .beta.-core molecule is particularly useful in testing for pregnancy and many malignancies.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/26
5446829,29-Aug-95,1995,8,29,Artificial network for temporal sequence processing,"A computer-based artificial network is presented that is capable of learning, recognizing, and generating temporal-spatial sequences. The network system includes time-delays and artificial neural subnetworks. The system generally includes three parts: (1) comparator units, (2) a parallel array of subnetworks and (3) delayed feedback lines from the output of the system to the neural subnetwork layer.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06K/72
5449461,12-Sep-95,1995,9,12,Displacement countercurrent chromatography,"The present invention provides a new method of pH-zone-refining countercurrent chromatography that can be operated in a manner analogous to displacement chromatography. The method uses a retainer base (acid) in the stationary phase to retain analytes in the column and a displacer acid (base) to elute the analytes in the decreasing (or increasing) order of pK.sub.a and hydrophobicity. The elution produces a train of highly concentrated rectangular solute peaks with minimum overlap. To use pH-zone refining CCC in a displacement mode, the mobile and stationary phases are switched. Thus, the original eluent becomes a retainer to retain analytes in the stationary phase, and the original retainer acid becomes a displacer to displace the analytes from the stationary phase to the mobile phase at the back of the solute bands. The present method provides a distinct advantage over the pH-zone-refining countercurrent chromatography in the normal mode in that the eluted compound is provided as a salt-free acid or base in an organic solvent which can easily be evaporated. Additionally, the displacement mode of pH-zone-refining countercurrent chromatography is amenable to a ligand-affinity separation which may cover a broader range of analytes including nonionizable compounds. As with the normal mode, the present method can be used on a preparative scale.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
5449608,12-Sep-95,1995,9,12,Parvovirus B19 receptor and parvovirus B19 detection,"The invention provides a method of detecting the presence of a parvovirus in a sample comprising contacting the sample with a purified receptor for a parvovirus, and detecting the presence of binding of parvovirus to the receptor, the presence of binding indicating the presence of parvovirus in the sample. The present invention also provides methods of purifying and removing parvoviruses from samples. The invention further provides a composition comprising a globoside, or the parvovirus B19 binding domain of globoside, in a pharmaceutically acceptable carrier. Also provided are methods of preventing or treating parvovirus B19 infection in a human subject by preventing the binding of parvovirus B19 to P antigen and methods of gene therapy utilizing parvovirus B19 and the parvovirus B19 cellular receptor.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/86
5449669,12-Sep-95,1995,9,12,IgE-binding epitopes of a major heat-stable crustacean allergen derived from shrimp,"A major heat-stable shrimp allergen is characterized as a 34 kDa protein corresponding to shrimp tropomyosin. Two IgE binding epitopes of this allergen have the sequences FLAEEADRK (SEQ ID NO: 1) and MQQLENDLDQVQESLLK (SEQ ID NO: 2), respectively. Surprisingly, both antigenic and allergenic activities of the allergen were found to be associated with these two peptide fractions. A-a-id antibodies recognized this allergen as well as a homologous 34 kDa allergen from lobster, prawn and crab, indicating that these antibodies recognize major cross-reacting IgE binding epitopes common to crustacea. The two epitopes are useful in the diagnosis and/or treatment of allergies, particularly in the desensitization of individuals that are allergic to shrimp and other crustacea. Variants and subfragments of the two epitopes display allergenicity, as assessed by reaction with allergen-specific IgE obtained from shrimp-sensitive patients.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/43509
5449688,12-Sep-95,1995,9,12,Method of treating chronic inflammatory diseases,"The present invention provides a method for treating chronic inflammatory conditions, including autoimmune diseases by administering an effective amount of an agent, such as a nitric oxide synthase inhibitor, a nitric oxide scavenger, or an inhibitor of tetrahydrobiopterin synthesis, to decrease the amount of nitric oxide present at the site of inflammation.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/223
5449753,12-Sep-95,1995,9,12,Autotaxin: motility stimulating protein useful in cancer diagnosis,"The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; and antibodies to autotaxin.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/52
5453426,26-Sep-95,1995,9,26,Sulfur-containing xanthine derivatives as adenosine antagonists,"The present invention provides sulfur-containing xanthine derivatives which are 1,3-disubstituted with a C.sub.1 -C.sub.12 alkyl, which may be further substituted with a hydroxy, amino, or halo group, and are 8-substituted with either a cycloalkyl, furyl, thienyl, or substituted phenyl group. These derivatives possess increased selectivity or potency at adenosine receptors.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/22
5455032,3-Oct-95,1995,10,3,Use of phosphocholine hapten conjugates in vaccines,"This invention relates to compositions useful for inducing immunoprotection against infections by pathogenic organisms containing phosphocholine antigens, including Streptococcus pneumoniae and other microorganisms that have a phosphocholine antigen component of their membranes or capsids. This invention also relates to vaccines and methods for inducing immunoprotection against infection by these pathogenic organisms.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/385
5455251,3-Oct-95,1995,10,3,"Michellamine antiviral agents, compositions, and treatment methods","The present invention provides new antiviral compounds, i.e., michellamines and derivatives and pharmacologically acceptable salts thereof, methods for isolating such antiviral compounds from a plant species of the genus Ancistrocladus, antiviral compositions containing such antiviral compounds, and methods of using such antiviral compounds for treating patients with viral infections. The antiviral compounds of the present invention inhibit the reproduction and cytopathicity of human acquired immunodeficiency viruses.",36,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
5458878,17-Oct-95,1995,10,17,P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity,"A target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described. Such toxins are made by inserting specific recognition molecules at specific cloning sites in at least domain III near the carboxyl terminus of the PE molecule. Various modifications of the carboxyl terminus of the PE molecule to increase cytotoxicity are set forth. Multifunctional, recombinant, cytotoxic fusion proteins containing at least two different recognition molecules are provided for killing cells expressing receptors to which the recognition molecules bind with specificity. Methods for producing novel recombinant PE molecules with specific properties are described.",29,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70514
5459056,17-Oct-95,1995,10,17,Human T cell line chronically infected with HIV,"A human T cell clone containing an integrated copy of HIV in a latent state, but inducible to productive replication by an activating agent is provided. The clone of the present invention allows in vitro screening of anti-HIV drugs.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
5459256,17-Oct-95,1995,10,17,"Lipophilic, aminohydrolase-activated prodrugs","The present invention relates, in general, to prodrugs. In particular, the present invention relates to lipophilic, aminohydrolase-activated, anti-viral nucleoside prodrug compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds.",18,The Government of the United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
5459400,17-Oct-95,1995,10,17,Method to enhance the sensitivity of MRI for magnetic susceptibility effects,A method for enhancing the sensitivity of gradient-recalled echo imaging for T2* effects in dynamic magnetic resonance imaging which involves the step of delaying gradient-recalled echoes so that the gradient-recalled echoes are subjected to magnetic susceptibility effects for an extended period of time. The gradient-recalled echoes are delayed beyond a subsequent radio frequency pulse by applying an additional gradient which dephases any gradient-recalled echo of spins that are excited in the radio frequency repetition time period in which said gradient-recalled echoes are produced.,23,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/561
5460801,24-Oct-95,1995,10,24,Inhibition of small cell lung cancer cell growth in vivo using monoclonal antibody,The present invention discloses anti-bombesin monoclonal antibody and a method of detecting autocrine growth factor. A method and kit for screening and controlling growth of human SCLC has also been disclosed.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/086
5460941,24-Oct-95,1995,10,24,Method of targeting DNA,"The present invention relates to a method of forming a three-stranded DNA molecule wherein each strand of the three-stranded DNA molecule is hybridized (that is, non-covalently bound) to at least one other strand of the three-stranded DNA molecule. The method comprises: contacting a recombination protein with a double-stranded DNA molecule and with a single-stranded DNA molecule sufficiently complementary to one strand of the double-stranded DNA molecule to hybridize therewith, which contacting is effected under conditions such that the single-stranded DNA molecule hybridizes to the double-stranded molecule so that the three stranded DNA molecule is formed.",18,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
5460942,24-Oct-95,1995,10,24,The catalytic moiety of the glucose-6-phosphatase system: the gene and protein and related mutations,"This invention relates to nucleic acid sequences and methods useful for producing recombinant glucose-6-phosphate (G-6-Pase). In addition, the invention relates to specific mutations in the gene encoding human G-6-Pase and methods for detecting the mutations and thus diagnosing the genetic disease that causes glycogen storage disease type 1A.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
5462852,31-Oct-95,1995,10,31,HIV Nucleocapsid protein capture assay and method of use,"An antigen capture method, and an antigen capture assay diagnostic kit, for detecting the presence or concentration of HIV in a biological sample without interference from antigen-antibody immune complexes is provided. The lysate of a biological sample obtained from an animal is contacted with a detectable amount of an antibody specifically reactive with the nucleocapsid p7 antigen or an immunoreactive fragment of the p7 antigen for a time and under conditions sufficient for p7 antigen contained in the lysate to form a p7-antibody complex. The presence or concentration of this p7-antibody complex is determined to detect or quantitate the presence of HIV in the biological sample. Uses of this assay and method include detecting the presence of HIV infection in an infant born to an HIV-infected mother, monitoring the progression of HIV infection, and evaluating the effectiveness of an anti-HIV treatment administered to an animal, such as a human. Purified antibodies specifically reactive with an immunoreactive epitope specific to p7 or an immunoreactive fragment of p7 are also provided as well as an antigen capture method for detecting the presence of a lentivirus in a biological sample involving the nucleocapsid protein of the lentivirus.",12,"The Government of the United States of America, as Represented by the Secretary, DHHS",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5462873,31-Oct-95,1995,10,31,DNA for use in a simple method for detecting inhibitors of retrotransposition,"The present invention relates, in general, to a DNA segment. In particular, the present invention relates to a DNA segment comprising a selectable marker gene, a DNA segment comprising a selectable marker gene inserted into a retrotransposon, cells containing these DNA segments, and methods of using these DNA segments and cells.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/81
5462946,31-Oct-95,1995,10,31,Nitroxides as protectors against oxidative stress,"The instant invention is directed to the use of a biologically compatible composition, containing an effective amount of a metal independent nitroxide compound which is preferably represented by the formula ##STR1## wherein R.sub.1 is --CH.sub.3 ; R.sub.2 is --C.sub.2 H.sub.5, --C.sub.3 H.sub.7, --C.sub.4 H.sub.9, --C.sub.5 H.sub.11, --C.sub.6 H.sub.13, --CH.sub.2 --CH(CH.sub.3).sub.2, --CHCH.sub.3 C.sub.2 H.sub.5, or --(CH.sub.2).sub.7 --CH.sub.3, or wherein R.sub.1 and R.sub.2 together form spirocyclopentane, spirocyclohexane, spirocycloheptane, spirocyclooctane, 5-cholestane, or norbornane, R.sub.3 is --O. or --OH, or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, as antioxidants capable of protecting cells, tissues, organs, and whole organisms against the deleterious effects of harmful oxygen-derived species generated during oxidative stress.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/445
5462956,31-Oct-95,1995,10,31,"Epibatidine and derivatives, compositions and methods of treating pain","The present invention is directed to compounds, compositions and methods of treating pain, and derivatives that have potent analgetic activity. The compounds have the formula: ##STR1## wherein R.sup.1 is selected from H, lower alkyl, C.sub.3 -C.sub.9 cycloalkyl, acyl, C.sub.3 -C.sub.9 cycloalkylalkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, C.sub.3 -C.sub.8 cycloalkenyl C.sub.3 -C.sub.8 cycloalkynyl and phenyl; and wherein R is selected from cycloalkyl, aryl, heteroaryls (selected from the group consisting of pyridyl, thienyl, furanyl, imidazolyl, pyrazinyl, and pyrimidyl) or phenoxy and wherein said R groups can be substituted with hydroxyl, C.sub.1 -C.sub.6 lower alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.1 -C.sub.6 lower alkoxyl, halo, C.sub.1 -C.sub.6 haloalkyl, amino, C.sub.1 -C.sub.6 alkylamino and C.sub.2 -C.sub.10 dialkylamino, and sulfonamido or a pharmaceutically acceptable salt thereof.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/08
5465013,7-Nov-95,1995,11,7,Electric field shielding system for AC electrically powered device with a two-blade plug,"An electric field shield for non-grounded AC powered appliances is connected to a neutral return terminal of the AC power distribution system. A polarized two prong connector assures connection of the shield to neutral. By eliminating a requirement for connection of the shield to ground, shields are made available for appliances precluded from ground connection such as bedding heaters. A double pole control switch is included to eliminate E-field generation in an OFF state caused by improper wiring or the use of unpolarized intermediate connectors. The shield is insulated and a current limiting device is series connected between the shield and neutral to reduce electrical hazards.",30,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,"Electrical machinery, apparatus, energy",Audio-visual technology,,,,,H01R/648
5468468,21-Nov-95,1995,11,21,"Method for making a monoclonal antibody, monoclonal antibodies to .alpha. P D","Potent neutralizing monoclonal antibodies to the human .alpha. PDGF receptor (.alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on .alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind .beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing .alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of .alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.",15,"The United States of America, as represented by the Secretary of the Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/71
5468469,21-Nov-95,1995,11,21,Methods of using azo dyes and their derivatives,"Pharmaceutical compositions containing the azo dyes Direct Orange 26, Direct Red 23, Direct Red 24, Direct Red 26, and similar dyes, as well as the use of such azo dyes to inhibit the binding of a virus to the CD4 glycoprotein, in detecting or quantitating CD4-positive T4 lymphocytes, and in the protection against or treatment of viral infections.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,,,,,G01N/5094
5468610,21-Nov-95,1995,11,21,Three highly informative microsatellite repeat polymorphic DNA markers,"The invention relates to polymorphic markers (two tetranucleotide and one dinucleotide repeat polymorphisms) that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers are characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences. The assay according to the invention is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours. Accordingly, the invention also relates to an improved PCR procedure and a PCR assay kit which comprise nucleotides according to the invention.",12,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
5468643,21-Nov-95,1995,11,21,Switching valve system for direct biological sample injection for LC analysis,"A valving arrangement and a method are provided by which a biological sample is mixed with a reactant, such as a solvent or a precipitating agent, as it is injected through a multi-position injection valve. A multi-position switching valve is connected to the injection valve, and one or more filters attached to the switching valve remove precipitates of predetermined size from the reacted sample. The sample the flows to conventional analytical columns for liquid chromatography analysis of analytes of interest. Proteins and/or peptides are thus quickly and efficiently removed from the sample as precipitates collected in the filters. The injection valve and the switching valve are then placed in respective cooperating positions to flow a carrier fluid through the injection valve and the switching valve directly to the analysis columns, while a back-flow of a suitable surfactant is pumped through the filters to purge them of collected precipitates. This quickly purges the system and puts it in condition for a repeat of the procedure. The apparatus and method may be used both when samples are provided manually under the direct control of an operator and when an autoinjector or autosampler of known type is employed for repeated sampling.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/16
5470726,28-Nov-95,1995,11,28,Retrovirus packaging and producer cell lines based on gibbon ape leukemia virus,"Retrovirus packaging cell lines PG13 (ATCC No. CRL 10686) and PG13/LNc8 (ATCC No. CRL 10685), and retroviruses packaged by said cells.",4,Fred Hutchinson Cancer Research Center,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
5472693,5-Dec-95,1995,12,5,Family of anti-carcinoembryonic antigen chimeric antibodies,"The present invention discloses novel chimeric monoclonal antibodies directed against human carcinoembryonic antigen, having antigen-specific variable regions. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are also disclosed. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also described.",10,The Dow Chemical Company,National Institutes of Health,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/3007
5474089,12-Dec-95,1995,12,12,Method and device for reversible sterilization,"A blocking device is non-surgically inserted in a duct of a reproductive system of either a male or female subject. The device may be in the form of a stent including an expandable section for sealingly engaging the duct to effect sterilization by preventing passage of gametes therethrough. The stent preferably includes a predetermined portion which is ablatable by application of a known intensity of laser irradiation. When desired, a laser beam may be used to ablate the portion of the blocking device in order to reopen the duct and to re-establish fertility of the subject. One embodiment of the device includes a guiding segment for guiding a fiber optic device to a position adjacent the ablatable portion and for accurate application of the laser beam thereto, thereby reducing potential organic damage from a misdirected laser beam. In another embodiment, the stent includes a collapsible frame structure compressed by a spring, and a central ablatable blocking portion. Upon release of the spring, the frame expands to engage the duct.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61F/20
5474898,12-Dec-95,1995,12,12,Octopamine receptor,"The present invention pertains in general to invertebrate octopamine receptor proteins and to polynucleotides encoding such receptors. The present invention also relates to insect for example, Drosophila octopamine receptors that are recombinantly expressed in mammalian cells where the receptor mediates the attenuation of adenylate cyclase activity and exhibits a pharmacological profile that is unique but closely related to mammalian adrenergic receptors. The present invention further relates to drug screening methods for the development of specific human pharmacological drugs and insecticides targeted for the octopamine receptor system.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/43581
5474935,12-Dec-95,1995,12,12,Adeno-associated virus (AAV)-based eucaryotic vectors,"The present invention relates to adeno-associated virus (AAV)-based eucaryotic vectors and uses thereof. Such vectors may, for example, be used to down regulate any targeted viral or cellular gene whose sequence is known. Furthermore, the vectors may also be used to cause the expression of proteins.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1132
5475095,12-Dec-95,1995,12,12,Nucleic acid compositions for the alpha chain of beta-hexosaminidase,Methods are disclosed of detecting mutations in the alpha chain gene that makes pre-natal diagnosis of Tay-Sachs disease possible. Screening for carrier heterozygotes of Tay-Sachs is made feasible by this invention.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5475098,12-Dec-95,1995,12,12,"Distinctive DNA sequence of E. coli 0157:H7 and its use for the rapid, sensitive and specific detection of 0157:H7 and other enterohemorrhagic E. coli","The present invention provides isolated nucleic acid sequences corresponding to the hlyA gene, the hlyB gene and the intergenic region between the hlyA gene and the hlyB gene which are present in enterohemorrhagic E. coli. In addition, the present invention provides methods for detecting enterohemorrhagic E. coli by targeting the hlyA gene, the hlyB gene, the intergenic region between the hlyA and the hlyB genes, combinations thereof, or fragments thereof. Such methods rely on nucleic acid probes and amplification primers specific for subsequences of the hlyA gene, the hlyB gene, the intergenic region between the hlyA and the hlyB genes, combination thereof or, fragments thereof. As such, the present provides nucleic acid probes and amplification primers which can be used for the rapid, sensitive and specific amplification and detection of enterohemorrhagic E. coli. In addition, the present invention provides kits embracing the above aspects.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
5475129,12-Dec-95,1995,12,12,Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis,"The disclosure is concerned with providing phosphonic acid-containing derivatives of phenylalanine and optically active isomers thereof, which are functionalized in a manner which makes them suitable for facile incorporation into peptides using standard solid-phase or solution-phase techniques.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/4056
5476658,19-Dec-95,1995,12,19,Vaccine against hepatitis a comprising simian HAV isolate AGM-27,"The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
5476785,19-Dec-95,1995,12,19,Recombinant DNA clone containing a genomic fragment of PfHRP-II gene from Plasmodium falciparum,"The invention relates to isolated clones of DNA from Plasmodium falciparum that encode a histidine-rich protein from that organism. The PfHRPII protein is expressed in P. falciparum-infected erythrocytes. The cloned gene segment includes an intron-exon boundary near the amino-terminus of the coding sequence. The PfHRPII protein has a Mr of 60-80 kDa as determined by SDS-PAGE. This is substantially higher than the molecular weight of about 35 kDa as estimated from the predicted amino acid sequence of PfHRPII. The PfHRPII amino acid sequence includes a hydrophobic leader sequence, consistent with secretion of PfHRPII observed in vivo and in vivo. The amino acid sequence of PfHRPII is also characterized by a number of tandem repeats having a high content of histidine, alanine and aspartic acid.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
5478746,26-Dec-95,1995,12,26,cDNA encoding attenuated cell culture adapted hepatitis A virus genome,"A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5480968,2-Jan-96,1996,1,2,"Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto","A DNA fragment distinct from the epidermal growth factor receptor (EGFR) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA. Characterization of the cloned DNA fragment mapped the region of v-erbB homology to three exons with closest homology of 64% and 67% to a contiguous region within the tyrosine kinase domains of the EGFR and erbB-2 proteins, respectively. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was mapped to human chromosome 12 ql 11-13 and was shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGFR and erbB-2, plays a role in some human malignancies. Using erbB-3 specific antibodies (polyclonal or monoclonal), the erbB-3 protein was identified as a 180 kDa glycoprotein, gp180.sup.EGFR/erbB-3. The intrinsic catalytic function of gp180.sup.erbB-3 was uncovered by its ability to autophosphorylate in vitro. Ligand-dependent signaling of its cytoplasmic domain was established employing transfectants which express a chimeric EGFR/erbB-3 protein, gp180.sup.EGFR/erbB-3. EGF induced tyrosine phosphorylation of the chimera and promoted soft agar colony formation of such transfectants. These findings, combined with the detection of constitutive tyrosine phosphorylation of gp180.sup.erbB-3 in 4 out of 12 human mammary tumor cell lines, implicate the activated erbB-3 product in the pathogenesis of some human malignancies.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/32
5482954,9-Jan-96,1996,1,9,Signal transduction inhibitor triazole and diazole compounds,A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the in vivo treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4164
5483163,9-Jan-96,1996,1,9,MRI coil using inductively coupled individually tuned elements arranged as free-pivoting components,An MRI probe/transmitter coil has a pair of concentric cylinders with a plurality of inductively coupled freely rotating resonant elements radially mounted between the two cylinders. The coil can be tuned both symmetrically by pivoting all the resonant elements uniformly or asymmetrically by tuning them individually. The coil is driven in quadrature by a quad-hybrid circuit. A substantial part of the electromagnetic energy is stored in the resonant elements outside of the loading region of the coil to reduce perturbation in the coil operation due to the characteristics of the test subject.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/3453
5483958,16-Jan-96,1996,1,16,Fluorescent-tipped dosimeter probe,"A solid-state fluorescent dosimeter for monitoring therapy irradiation dosage during a photodynamic therapy procedure. The solid-state fluorescent dosimeter includes an optical fiber -having a distal end and a proximal end, and a solid-state fluorescent tip attached to the proximal end of the optical fiber. The solid-state fluorescent tip includes a fluorescent material which emits fluorescence when exposed to non-ionizing radiation in the visible or near infrared range. The solid-state fluorescent tip has a sufficient length so as ensure isotropic response characteristics to the non-ionizing radiation regardless of the orientation or alignment of the solid-state fluorescent tip relative to the irradiation source.",11,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,,,,,A61N/062
5484889,16-Jan-96,1996,1,16,Plant protein useful for treating tumors and HIV infection,"A protein, in particular MAP 30, obtainable from both the fruit and seeds of Momordica charantia or produced by recombinant means useful for treating tumors and HIV infections is disclosed. In treating HIV infections, the protein is administered alone or in conjunction with conventional AIDS therapies. Also provided are processes for purifying the protein, DNA sequences encoding the protein, and recombinant DNA methods for expressing the protein.",1,New York University,"American Biosciences, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,C07K/415
5486361,23-Jan-96,1996,1,23,Hybridomas and monoclonal antibodies that speifically bind to GPIB on platelets and inhibit the binding of thrombin to platelets,"Monoclonal antibodies which specifically bind to glycoprotein Ib are described. These antibodies completely inhibit the binding of thrombin to platelets, thereby totally inhibiting the activation of platelets by thrombin. The antibodies also completely inhibit platelet aggregation and also significantly inhibit adhesion of platelets to a subendothelial arterial surface in an ex vivo model system.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/2896
5487979,30-Jan-96,1996,1,30,"DNA encoding human and murine eps15, a substrate for the epidermal growth factor receptor","A new substrate of epidermal growth factor receptor and certain other tyrosine kinase receptors denominated eps15 is disclosed, as well as, polynucleotides encoding eps15, antisense eps15 polynucleotide, triple helix eps15 polynucleotide, antibodies to eps15, and assays for determining eps15.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
5487998,30-Jan-96,1996,1,30,Trapping of aflatoxins and phytoestrogens,"Halo, azido, and amino cyclodextrin/epichlorohydrin copolymers, methods of preparing the copolymers, and the use of the copolymers for removing aflatoxins and phytoestrogens from a sample, for detecting the presence of aflatoxins and phytoestrogens, and for quantifying aflatoxin and phytoestrogen levels.",16,The United States of America as represented by the Secreatry of the Department of Health and Human Services,,,,,,,,,,,1,"Macromolecular chemistry, polymers",Food chemistry,Chemical engineering,,,,C08B/0012
5489511,6-Feb-96,1996,2,6,Specific and sensitive diagnostic test for Lyme disease,"A sensitive DNA probe for detecting infection by Borrelia burgdorferi, the causative agent of Lyme disease, is provided.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
5489524,6-Feb-96,1996,2,6,Chimeric protein that has a human Rho motif and deoxyribonuclease activity,"The present invention relates, in general, to endo-exonucleases. In particular, the present invention relates to DNA segments encoding for a polypeptide having an amino acid sequence corresponding to mammalian endo-exonuclease, a polypeptide having an amino acid sequence corresponding to mammalian endo-exonuclease, antibodies to mammalian endo-exonuclease, a recombinant DNA molecule, mutant cells substantially lacking endo-exonuclease activity, a cell containing mammalian endo-exonuclease, and methods of producing and using the polypeptide, DNA segment and mutants.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5008
5489525,6-Feb-96,1996,2,6,Monoclonal antibodies to prostate cells,"Monoclonal antibodies are provided which bind to an antigen associated with prostate cells, including prostate cancers. The monoclonal antibodies and recombinant forms thereof are used individually or conjugated radioisotopes to target the compounds to cancerous prostate cells, and thus are useful in a variety of diagnostic procedures.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/28
5491064,13-Feb-96,1996,2,13,"HTS-1 gene, a human tumor suppressor gene","A gene which is associated with tumor suppression and is localized on chromosome 11 has now been identified. The identification, localization and sequence of a gene which demonstrates differential expression in a manner that correlates with tumorigenicity suggests that this gene could potentially be used for gene therapy in cancers deleted or altered in their expression of the gene. Furthermore, a gene which is localized on chromosome 11p15, with identified polymorphisms, could be used for analysis of tumor DNA for loss of heterozygosity at chromosome 11p15. This region of chromosome 11 shows frequent loss of heterozygosity (LOH) in many human malignancies. Thus, the determination of LOH at chromosome 11p15 may be useful in predicting the prognosis of that tumor.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
5491130,13-Feb-96,1996,2,13,Peptide inhibitors of fibronectin and related collagen-binding proteins,Peptides derived from the second type 1 repeat of human endothelial cell thrombospondin which bind to the gelatin-binding domain of fibronectin have been isolated and synthetically produced. The peptides can be used to bind to fibronectin or other related collagen-binding proteins to inhibit fibronectin-dependent cell adhesion to collagen matrices and to inhibit interactions with collagen of other proteins that share homologies with the gelatin-binding domain of fibronectin.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/78
5492907,20-Feb-96,1996,2,20,Antipsychotic composition and method of treatment,"A method for treating a serious psychotic mental illness includes the step of administering to a patient in need of such treatment a combination of (i) an .alpha..sub.2 -adrenergic receptor antagonist and (ii) a D.sub.2 dopamine receptor antagonist, A pharmaceutical composition useful in the novel method includes an effective amount of the combination of the foregoing two ingredients together with a pharmaceutically acceptable carrier.",5,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
5494671,27-Feb-96,1996,2,27,C-terminally truncated dengue and Japanese encephalitis virus envelope proteins,"The present invention relates to C-terminally truncated flavivirus envelope proteins 80-81% in size which are more immunogenic than their counterpart full-length proteins. The present invention further relates to recombinant viruses which encode the truncated protein and to host cells infected therewith. Host cells express the truncated protein on their outer membrane and secrete it into the medium. The present invention further relates to vaccines for use against flavivirus infection. The vaccines include either a recombinant vaccinia virus expressing the truncated envelope protein of the present invention, and the truncated envelope protein produced by a recombinant baculovinis.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5495010,27-Feb-96,1996,2,27,Acid stable purine dideoxynucleosides,Purine nucleosides active against human immunodeficiency virus which are substituted at the 2'-position by a strong electronegative group such as fluorine are stable in an acid environment and thus can be used for oral administration.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
5496804,5-Mar-96,1996,3,5,Method for treating taxol side-effects with G-CSF,"A method of treating a host using taxol comprising administering granulocyte colony-stimulating factor to the host being treated with taxol. The present inventive method allows for increased levels of taxol to be administered to the host in the treatment of various conditions, particularly with respect to ovarian tumors.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/193
5496846,5-Mar-96,1996,3,5,Taxol treatment of breast cancer,"The present invention is a method of treatment for a patient with cancer. In particular, it is a method of treating patients having breast cancer using the microtubule agent, Taxol. The present method of administration, serves to prevent or retard the adverse side effects associated with Taxol and reduces the chances of a patient developing mdr Taxol resistance. The novel method of treatment provides a low-dose, longterm exposure to Taxol in a patient.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/335
5498605,12-Mar-96,1996,3,12,Sulfo-derivatives of adenosine,"The adenosine derivatives which contain a sulfohydrocarbon substituent, as depicted in the formula: ##STR1## wherein at least one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 is a sulfohydrocarbon radical and W is --OCH.sub.2 --, --NHCH.sub.2 --, --SCH.sub.2 --, or --NH(C.dbd.O)--. Methods of preparing such compounds, as well as methods of using such compounds to treat ischemia or hypoxia in mammals and pharmaceutical compositions containing such compounds as the active ingredients, are also described.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
5498620,12-Mar-96,1996,3,12,"Signal transduction inhibitor 1,2,3-triazolo compounds",A compound having the formula: ##STR1## and pharmaceutically acceptable salts thereof.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/12
5498719,12-Mar-96,1996,3,12,Diastereoselective process leading to a key intermediate for the preparation of fluorinated reverse transcriptase inhibitors,"The present invention provides a novel synthetic route to a key precursor, i.e., an (S,S)-.alpha.-fluoro-2,2-dimethyl-1,3-dioxolane-4-propanoic acid ester useful in the preparation of FddA and FddC. The instant diastereoselective process utilizes a novel intermediate which contains a chiral auxiliary. The chiral auxiliary can be any chiral auxiliary moiety such as for example an auxiliary containing a substituted oxazolidinone group. The intermediate containing the chiral auxiliary is fluorinated utilizing a fluorination method applied for the first time in the synthesis of fluorinated sugars to give a fluorinated intermediate which after removal of the chiral group provides the desired key intermediate. In summary, in the instant process, a fluorine is introduced diastereoselectively into an intermediate via the reaction of a chiral enolate with an electrophilic fluorinating agent and the intermediate which is fluorinated is derived from mannitol.",4,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/06
5500344,19-Mar-96,1996,3,19,Serine protease and uses thereof,"The present invention provides a purified and isolated nucleic acid molecule encoding serine protease (Met-ase) having Met-ase activity but not Asp-ase activity and a molecular weight of about 30,000 daltons on SDS PAGE under reducing and non-reducing conditions. The present invention also provides a vector comprising this nucleic acid molecule, a prokaryotic or eukaryotic host cell stably transformed or transfected with the vector, as well as a method for detecting this nucleic acid in a sample.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/6467
5502386,26-Mar-96,1996,3,26,Pulsed low frequency EPR spectrometer and imager,An EPR imager and spectrometer includes pulse generating system for generating broadband pulses having an RF carrier frequency that is not highly absorbed by biological samples. The pulse generating system includes up and down chirp convertors for frequency modulating a carrier frequency pulse and compressing the frequency modulated pulse to form a broadband excitation pulse of high energy. Such a machine could form the basis of a clinical imaging device capable of high sensitivity to free radical species in human patients.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/60
5503995,2-Apr-96,1996,4,2,Exchangeable template reaction,"The invention provides a method for the synthesis of DNA based on a cyclic mechanism of combining deoxyoligonucleotides comprising combining: (a) a series of unique single-stranded deoxypolynucleotides, each having a 5' sequence which, when in double-stranded form, can be enzymatically treated to form a unique 3' single-stranded protrusion for selective cyclic hybridization with another unique single-stranded deoxypolynucleotide of the series; (b) a unique deoxypolynucleotide having a 3' sequence which can selectively hybridize with one of the unique single-stranded deoxypolynucleotides of (a); (c) a polymerase which can direct the formation of double-stranded deoxypolynucleotides from the single-stranded deoxypolynucleotides; and (d) an enzyme which can form a unique single-stranded 3' protrusion from the double-stranded deoxypolynucleotides; under conditions which hybridize the unique single-stranded deoxypolynucleotides in a cyclic manner to form the DNA. Also provided is a kit comprising a series of unique synthesized single-stranded deoxypolynucleotides, each having a 5' sequence which, when in double-stranded form, can be enzymatically treated to form a unique 3' single-stranded protrusion for selective cyclic hybridization with another unique single-stranded deoxypolynucleotide of the series.",26,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/10
5505687,9-Apr-96,1996,4,9,Device for measuring incident light in a body cavity,An obturator for measuring incident light in a remote situs such as a body cavity which includes a treatment tubular member through which light is delivered to the remote situs and one or more auxiliary tubular members through which incident light in the remote situs is transmitted to an external light detector. The treatment and auxiliary tubular members are attached to a connector element which is in turn connected to a cystoscope lens port. The treatment and auxiliary tubular members are aligned off-center with respect to the central axis of the obturator so that a cystoscope lens can be inserted in the lens port and pass through the axial center of the obturator. Each auxiliary tubular member receives incident light from a different portion of the remote situs. The apparatus is particularly useful for conducting phototherapy in body cavities and has been demonstrated in the phototherapy treatment of superficial cancer in the bladder.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/24
5506131,9-Apr-96,1996,4,9,Immortalized human cell lines containing exogenous cytochrome P450 genes,"Non-tumorigenic, stable, human bronchial and liver epithelial cell lines are provided wherein the cell lines are capable of expressing human cytochrome P450 genes which have been inserted into the cell lines. Also provided are methods and kits for identifying potential mutagens, cytotoxins, carcinogens, chemotherapeutic and chemo-preventive agents utilizing these cell lines.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/0071
5506138,9-Apr-96,1996,4,9,Recombinant vaccinia virus encoding cytochromes P-450,The present invention is related to the construction and application of vaccinia virus containing DNA sequences for encoding and efficient expression of enzymatically active cytochrome P-450 polypeptides in mammalian cells. Preparation and use of pure P1-450 and P3-450 cytochromes have been described.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5508186,16-Apr-96,1996,4,16,B19 parvovirus capsids,The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.,4,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
5508199,16-Apr-96,1996,4,16,P450db1 clones for identifying humans with genetic defect in drug metabolism,"A cloned cDNA encoding debrisoquine 4-hydroxylase gene and a probe for identifying humans having a genetic defect in the metabolism of a certain class of drugs of which debrisoquine is a model, have been prepared. Testing of new drugs and of humans by a simple assay has also been described.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0071
5508289,16-Apr-96,1996,4,16,Bis-acridone chemotherapeutic derivatives,"The present invention provides an anticancer compound having the structure: ##STR1## wherein R is --H, --CH.sub.3, or --C.sub.2 H.sub.5 ; R1 and R2 are independently --H, --OH, --NH.sub.2, --OCH.sub.3, --C(CH.sub.3).sub.3, or a halogen atom; n is 2 to 6; X and X' are independently --N or --NO.sub.2 ; Y and Y' are independently --N, --CH, or --H; and the double-slash represents a double bond or no bond; such that when X or X' is --N, Y or Y' is --CH or --N, and the double-slash is a double bond, and when X or X' is --NO.sub.2, Y or Y' is --H, and the double-slash is no bond. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier.",28,The United States America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/0026
5510238,23-Apr-96,1996,4,23,Production of human T-cell leukemia (lymphotropic) retrovirus (HTLV-I) envelope protein fragments in bacteria and use in seroepidemiological studies,Antigenic proteins may be expressed in bacteria by use of vectors having inserted therein DNA fragments from an envelope gene. The DNA fragments employed in the example are coding sequences found in the HTLV-I envelope gene. The bacteria used was E. coli. The antigenic proteins are useful in identifying antibodies to the organisms from which the DNA fragments were originally obtained.,15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5510473,23-Apr-96,1996,4,23,Cloning of the recA gene from thermus aquaticus YT-1,"The present invention includes the isolation of an oligonucleotide encoding Thermus aquaticus recA protein, and to the purified protein. The invention also includes methods of use of the protein, particularly, methods for hybridizing a primer to a complementary template with increased binding affinity at a temperature above 45.degree. C.",6,The United States of American as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
5512434,30-Apr-96,1996,4,30,Expression cloning of a human phosphatase,"A method for the identification of related polypeptides, using an function-based selection criterion, is disclosed. A novel human phosphatase, and nucleotide sequences coding therefor, identified by the aforementioned method and designated VHR, is also disclosed.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1086
5512443,30-Apr-96,1996,4,30,Second generation monoclonal antibodies having binding specificity to TAG-72 and human carcinomas and methods for employing the same,"The present invention relates to second generation monoclonal antibodies having binding specificity to a tumor associated glycoprotein having an approximate molecular weight of >10.sup.6 d (""TAG-72"") and human carcinomas and methods for employing the same. Hybridomas producing such antibodies have been prepared.",44,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/30
5512453,30-Apr-96,1996,4,30,Activated killer monocytes and tumoricidal activity and pharmaceutical compositions,"The present invention discloses substantially pure, functional, human, clinical grade, activated killer monocytes (AKM) produced in suspension in polypropylene ware in a serum-free medium and a pharmaceutical composition for immunotherapy of humans, comprising an immonotherapeutic amount of the AKM of the present invention and a sterile pharmaceutically acceptable carrier.",8,"The United States of America as represented by the Secretary, Dept. of Health & Human Services",,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/57446
5512658,30-Apr-96,1996,4,30,Pseudomonas exotoxins (PE) and conjugates thereof having lower animal toxicity with high cytocidal activity through substitution of positively charged amino acids,Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive charge provides markedly changed exotoxins. Conjugation of the new exotoxins with suitable targeting agents provides cytocidal specificity for killing desired cellular entities.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70514
5514539,7-May-96,1996,5,7,Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines,"The nucleotide and deduced amino acid sequences of 51 cDNAs are disclosed where each cDNA encodes the envelope 1 gene of an isolate of hepatitis C virus (HCV). The invention relates to the oligonucleotides, peptides and recombinant envelope 1 proteins derived from these sequences and their use in diagnostic methods and vaccines.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5514556,7-May-96,1996,5,7,Method for detecting immune dysfunction in asymptomatic aids patients and for predicting organ transplant rejection,"A sensitive and accurate tissue culture system and kit fop detecting subtle changes in immune function is provided. The system is based on the comparison of IL-2 production by T helper cells in response to recall antigens including influenza A virus, tatanus toxoid, alloantigens, mouse xenogeneic antigens and the like or combinations thereof. Different stages of immune dysfunction can be differentiated and organ graft rejection can be predicted by the method of the present invention.",1,The United States of America as represented by The Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56988
5514600,7-May-96,1996,5,7,Mammalian guanine nucleotide binding protein with an ADP-ribosylation factor domain,"The invention provides a method for detecting the presence of ARD 1 protein in a sample. The method includes the steps of providing labeled or immobilized anti-ARD 1 antibody in a reaction zone, introducing sample into the reaction zone such that ARD 1 protein in the sample, if present, will react with said antibody to form an immunological complex, and detecting the formation of said immunological complex. Cells, nucleotide and amino acid sequences and vectors associated with ARD 1 are also described.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5516630,14-May-96,1996,5,14,Methods of detecting hepatitis A virus,"Methods for producing HAV cDNA, products thereof, and uses thereof, are described. HAV cDNA is produced, for example, by reverse transcribing HAV RNA and subsequently inserting the HAV cDNA into bacterial plasmids by genetic-engineering techniques. Transformed bacteria are then cloned and cultured to produce replicated chimetic plasmids containing the HAV cDNA. Such HAV cDNA is useful in assaying for the presence of HAV and in the production of HAV antigen and in the production of antibodies against HAV.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5516911,14-May-96,1996,5,14,Fluorescent intracellular calcium indicators,"A new class of calcium-specific, NMR-active and/or fluorescent indicators having a high dissociation constant is described. Methods of determining intracellular calcium ion concentration using .sup.19 F NMR spectroscopy or optical methods are also provided.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5518880,21-May-96,1996,5,21,Methods for diagnosis of XSCID and kits thereof,"The present invention provides a method for diagnosing XSCID in a male subject or determining whether a female subject is a carrier of XSCID which comprises determining whether the male or female subject possesses a mutated IL-2R.gamma. gene, the presence of the mutated IL-2R.gamma. gene being indicative that the male subject has XSCID or the female subject is a carrier of XSCID. The present invention also provides a method for diagnosing XSCID in a subject which comprises determining whether the subject possesses a truncated IL-2R.gamma. protein, the presence of the truncated IL-2R.gamma. protein being indicative of XSCID. The present invention further provides kits for diagnosing XSCID in a male subject or determining whether a female subject is a carrier of XSCID. The present invention still further provides methods for treating XSCID and a method for monitoring therapy. Lastly, the present invention provides a promoter which regulates expression of IL-2R.gamma., a vector comprising a DNA molecule operably linked to the promoter, a prokaryotic or eukaryotic cell host stably transformed or transfected with the vector, and a transgenic animal comprising a gene regulated by the promoter or a transgenic animal comprising a mutant IL-2R.gamma. gene.",44,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5518885,21-May-96,1996,5,21,ERBB2 promoter binding protein in neoplastic disease,"The present invention provides a purified and isolated DNA-binding protein, HPBF, which specifically binds to the promoter region of the Her-2/neu (ERBB2/c-erbB-2) gene sequence, the presence of which provides an early indication of transition to a cancerous state has been found. The present invention also provides bioassays for screening substances for the ability to inhibit HPBF activity, the ability to inhibit the mitogenic activity of HPBF and the ability to inhibit HPBF production. The present invention further provides methods of inhibiting the biological activity mediated by HPBF comprising preventing the HPBF from binding to the promoter region of the ERBB2 gene sequence.",14,The United States of America as represented by the Department of Health & Human Services,Wayne State University,,,,,,,,,,2,Biotechnology,,,,,,C07K/4705
5518999,21-May-96,1996,5,21,Method for treating Kaposi's sarcoma and blocking or inhibiting vascular permeability,"The present invention is directed to a method for arresting or inhibiting the growth of cells in Kaposi's Sarcoma lesions and a method for arresting or inhibiting the growth of the Kaposi's Sarcoma lesions, said methods comprising contacting the cells in the lesions with an effective amount of SP-PG, a naturally occurring sulfated polysaccharide-peptidoglycan produced by a specific species of the bacterium Arthrobacter, AT-25. The invention is also directed to blocking or inhibiting the activity of cellular vascular permeability factor(s), which comprises contacting vascular cells with an effective amount of SP-PG. In one embodiment, there is provided a method for blocking or inhibiting increased vascular permeability (and resulting edema) in diseases and disorders in which the increased vascular permeability contributes to the pathology, for example, in Kaposi's Sarcoma, tumorigenesis, inflammation, diabetic retinopathy, etc. Increased effectiveness is obtained when SP-PG is combined with cortisone or a cortisone derivative, such as hydrocortisone or tetrahydrocortisone.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Daiichi Pharmaceutical Co., Ltd.",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/164
5519534,21-May-96,1996,5,21,Irradiance attachment for an optical fiber to provide a uniform level of illumination across a plane,"A irradiation attachment for an optical fiber which provides an output of light that has a highly uniform intensity. The device includes a hollow spherical shell having a diffusive reflective surface or target supported therein. Light is directed into the hollow spherical shell so that it reflects off the diffusive reflective surface or target. The reflected light is internally reflected off the inner surface of the hollow spherical shell several times before passing through an output aperture. As a result of the internal reflection within the hollow spherical shell, the light leaving the device has a highly uniform intensity. The device is particularly useful for photodynamic therapy.",18,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Optics,,,,,A61N/062
5520182,28-May-96,1996,5,28,Method and apparatus for producing an image of a substance using a radioactively tagged material,"A two- and three-dimensional autoradiographical imaging system is provided which includes a charge coupled device for detecting the emission of radioactively labeled substances from materials such as tissue samples, brains of humans or animals, or substances used in electrophoresis applications. In a first aspect, a radioactively labeled substance is included in a tissue sample. The tissue sample is sequentially imaged by a charge coupled device and a sectioning tool such as a microtome to produce a plurality of two-dimensional images. A three-dimensional image of the tissue sample is generated by further processing of the plurality of two-dimensional images derived from the charge coupled device. In a further aspect of the invention, a charge coupled device is utilized to provide realtime imaging of metabolic or physiological parameters involved in brain activity. A charge coupled device is positioned adjacent a portion of brain tissue desired to be examined, the brain tissue having a radioactively labeled substance therein for detection by the charge coupled device. A two-dimensional realtime image is produced using the charge coupled device for use in clinical or behavioral studies. In another aspect of the invention, a charge coupled device is utilized in electrophoresis applications to monitor radioactively labeled or tagged substances during electrophoresis. In this application, use of the charge coupled device permits small sample volumes of material to be used during electrophoresis, as well as automatic end point detection.",32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Environmental technology,Measurement,,,,G01T/161
5523232,4-Jun-96,1996,6,4,"Use of restriction endonucleases against viruses, including HIV","Restriction endonucleases are administered to a patient topically or internally to prevent or ameliorate viral infection. The endonucleases are also useful to treat products, such as blood and blood derived products, to eliminate viral transmission when the products are administered to a patient. In addition, the endonucleases may be used in the manner of a disinfectant to inactivate viral contamination on objects. The endonucleases are used in their native form, modified to provide decreased immunoreactivity or increased ability to target a site of infection or both, and alone or in combination with a suitable excipient. In addition to methods of treatment and disinfection, the invention provides related products, such as pharmaceutical compositions.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/22
5525337,11-Jun-96,1996,6,11,Monoclonal antibody binding cell surface antigens for diagnosing cancer,"Monoclonal antibody K1 binds to an epitope on the surface of cells of some human tumors, but not to many important normal tissues. Unlike similar antigenic sites such as CA125, this epitope is not shed into the plasma of patients with mesothelioma, e.g. with ovarian cancer. Since the K1 monoclonal antibody is therefore not neutralized by circulating antigen immediately upon injection into the bloodstream, and since K1 allows efficient entry of coupled toxins into cells, the K1 monoclonal antibody can be used in the diagnosis of mesotheliomas.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1045
5525357,11-Jun-96,1996,6,11,"Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same","A polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
5525471,11-Jun-96,1996,6,11,Enzymatic degrading subtraction hybridization,"A method for subtractive hybridization of desired DNA sequences from two cell or tissue populations. cDNA from experimental cells or tissues is modified by incorporation of nucleoside analogs to prevent subsequent exonuclease attack. Hybridization of the experimental and control cDNA is performed using the phenol-emulsion reassociation technique. The hybridized DNA is incubated with exonucleases, resulting in degradation of all but the desired duplex DNA which may then be amplified. This technique may be used to isolate differentially expressed genes or gene fragments and will contribute to our understanding of pathological conditions and developmental regulation.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6809
5525606,11-Jun-96,1996,6,11,Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines,"The present invention provides 8-substituted O.sup.6 -benzylguanines of the formula ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3 are as defined in the specification, and 4(6)-substituted 2-amino-5-nitro-6(4)-benzyloxypyrimidine, and 4(6)-substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidine derivatives which have been found to be effective AGT inactivators, as well as pharmaceutical compositions comprising such derivatives along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine, by administering to a mammal an effective amount of one of the aforesaid derivatives, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O.sup.6 -benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine.",23,The United States of America as represented by the Department of Health and Human Services,ARCH Development Corporation,"Penn State Research Foundation, Inc.",,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
5525711,11-Jun-96,1996,6,11,Pteridine nucleotide analogs as fluorescent DNA probes,The invention provides novel pteridine nucleotides which are highly fluorescent under physiological conditions and which may be used in the chemical synthesis of fluorescent oligonucleotidcs. The invention further provides for fluorescent oligonucleotides comprising one or more pteridine nucleotides. In addition the invention provides for pteridine nucleotide triphosphates which may be used as the constituent monomers in DNA amplification procedures.,85,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
5526395,11-Jun-96,1996,6,11,System and method for simulating a two-dimensional radiation intensity distribution of photon or electron beams,"To simulate radiation intensity distribution of a radiation beam having a field region, a penumbra region, and a scatter tail region changes in radiation intensity distribution of a reference radiation beam in the penumbra region at a reference distance from the radiation source are determined. Next, radiation intensity distribution, at the reference distance, of a radiation beam of arbitrary shape, in the field and tail regions is determined. The radiation intensity distribution of the radiation beam of arbitrary shape is simulated by superimposing the changes in radiation intensity of the reference radiation beam in the penumbra region on to the radiation intensity of the radiation beam of arbitrary shape in the field region and the tail region.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61N/103
5527349,18-Jun-96,1996,6,18,Photochemotherapy dosimeter,"A photochemotherapy dosimeter for monitoring cumulative photochemotherapy radiation dosage. The photochemotherapy dosimeter includes an optical fiber having a chemical cell attached at one end thereof. The chemical cell contains a photobleachable chemical which can be in a solution or incorporated into a matrix material. Changes in the absorption of the photobleachable chemical are used to monitor the cumulative photochemotherapy radiation dosage. In use, the chemical cell of the photochemotherapy dosimeter is positioned near an abnormal tissue which is subjected to photochemotherapy treatment.",4,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,,,,,A61N/062
5527685,18-Jun-96,1996,6,18,"Antibodies to macrophage stimulating protein, bioassay and immunopurification method",A method of purifying macrophage stimulating protein. Antibodies to macrophage stimulating protein and a bioassay for the detection of antibodies which bind macrophage stimulating protein.,8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/24
5527700,18-Jun-96,1996,6,18,Target antigens of transmission blocking antibodies for malaria parasites,"The present invention relates novel methods and compositions for blocking transmission of Plasmodium spp. which cause malaria. In particular, P28 proteins are disclosed which, when administered to a susceptible organism, induce an immune response against a 28 kD protein on the surface of Plasmodium ookinetes and block transmission of malaria.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
5528368,18-Jun-96,1996,6,18,Spectroscopic imaging device employing imaging quality spectral filters,"Techniques for providing spectroscopic imaging integrates an acousto-optic tunable filter (AOTF), or an interferometer, and a focal plane array detector. In operation, wavelength selectivity is provided by the AOTF or the interferometer. A focal plane array detector is used as the imaging detector in both cases. Operation within the ultraviolet, visible, near-infrared (NIR) spectral regions, and into the infrared spectral region, is achieved. The techniques can be used in absorption spectroscopy and emission spectroscopy. Spectroscopic images with a spectral resolution of a few nanometers and a spatial resolution of about a micron, are collected rapidly using the AOTF. Higher spectral resolution images are recorded at lower speeds using the interferometer. The AOTF technique uses entirely solid-state components and requires no moving parts. Alternatively, the interferometer technique employs either a step-scan interferometer or a continuously modulated interferometer.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Optics,Measurement,,,,,G02B/33
5529765,25-Jun-96,1996,6,25,Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids,"A rabbit model for testing anti-AIDS therapeutic agents, vaccines, and HIV-1 infection is described.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56988
5529771,25-Jun-96,1996,6,25,Leukoregulin anti-herpes treatment,The present invention relates to a method of treating a viral infection in an animal. The method comprises administering to said animal leukoregulin alone or in combination with an anti-viral chemotherapeutic agent. Herpes virus and herpes simplex virus infections are tested. The invention further relates to a pharmaceutical composition suitable for use in such a method.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/19
5529904,25-Jun-96,1996,6,25,Diagnostic kit and diagnostic method for mycoplasma utilizing carbohydrate receptors,"A diagnostic kit for detecting the presence of microorganisms, comprising an insoluble substrate; and a carbohydrate receptor immobilized on the insoluble substrate, the carbohydrate receptor being capable of adsorbing microorganisms; and a labelled reagent useful for detecting the presence of microorganisms bound to the carbohydrate receptors and a method for detecting the presence of specified microorganisms in a sample, which comprises contacting a sample to be tested with carbohydrate receptors immobilized on an insoluble substrate; and determining the extent of binding of microorganisms in the sample to the carbohydrate receptors by use of a labelled reagent.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/56933
5529920,25-Jun-96,1996,6,25,Human liver epithelial cell line and culture media therefor,"The present invention relates to long term multiplication and permanent establishment of a cell line of human liver epithelial cells(hepatocytes). The human liver epithelial cell line is capable of mitotically proliferating and continuously growing in vitro under suitable environmental conditions in suitable culture media. A method of producing an immortalized human liver epithelial cell line is also disclosed. The invention also relates to serum-free cell medium developed to support long term multiplication and permanent establishment of a cell line of human liver epithelial cells. The medium may contain an effective cell growth promoting amount of calcium ions; an effective cell growth promoting amount of glucose; an effective amount of insulin to aid cells in glucose uptake; an effective cell growth promoting amount of hydrocortisone; an effective amount of epidermal growth factor to bind epidermal growth factor receptors on cells; an effective amount of transferrin to increase DNA synthesis in cells; an effective amount of cholera toxin to increase DNA synthesis in cells; an effective amount of triiodothyronine to increase DNA synthesis in cells; and an effective growth promoting amount of mammalian hormones and mitogenic factors, including lipoprotein, cholesterol, phospholipids and fatty acids.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/067
5529983,25-Jun-96,1996,6,25,Use of small peptides in the treatment of psoriasis,"The treatment of human patients suffering from Acquired Immune Deficiency Syndrome (AIDS) with therapeutic amounts of certain small peptides which specifically utilizes peptide T (Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr), vasoactive intestinal polypeptide (VIP), or a core pentapeptide selected from a peptide of the following formula: EQU Thr-X-Y-Tyr-Thr where PA1 X and Y=any amino acid PA1 .gamma.=preferably Asp PA1 Thr.sub.1 may be repalced by D-Ala A preferred regimen for utilization of peptide T, a preferred peptide treating agent, is 1 mg twice daily for one week followed by 2 mg twice daily for three weeks, constituting an initial dosage regimen which may be repeated. This regimen has resulted in substantial increase in total white cell count assay, thus combatting the deleterious effect of the AIDS virus.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5532144,2-Jul-96,1996,7,2,Process for preparing human derived monocyte attracting purified peptide products useful in a method of treating infection and neoplasms in a human body,"Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with the peptide products are additionally provided, as well as pharmaceutical compositions for the peptide products.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/523
5532157,2-Jul-96,1996,7,2,"Host cell line LVIP2.0Zc, useful in assays to identify ligands and ant agonists of G protein-coupled receptors","The present invention relates, in general, to a method of identifying ligands and antagonists of ligands. In particular, the present invention relates to a method of identifying ligands and antagonists of ligands which bind to cloned G.sub.s - or G.sub.i -coupled receptors. The present invention also relates to a cell that comprises a recombinant cyclic AMP sensitive reporter construct.",1,"The United States of America as represented by the Secretary, Department of Health and Human Resources",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6897
5532214,2-Jul-96,1996,7,2,"Anti-HIV protein, TAP 29, from tricosanthes, DNA coding therefor and therapeutic uses thereof","A new protein, termed TAP 29, obtainable from the root tuber of the plant Trichosanthes kirilowii or produced by recombinant means is useful for treating HIV infections or tumors. In treating HIV infections, the protein is administered alone or in conjunction with conventional AIDS therapies. Also provided are processes for purifying the protein, DNA sequences encoding the protein, hosts expressing the protein, recombinant DNA methods for expressing the protein, and antibodies specific for the protein.",1,New York University,"American Biosciences, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Biotechnology,Biotechnology,,,,,C07K/16
5534121,9-Jul-96,1996,7,9,Preparative two dimensional gel electrophoresis system,"A preparative two dimensional gel electrophoresis system which serves as a single procedure for separation and isolation of preparative amounts of proteins from complex biological preparations. The system includes sized-up isoelectric focusing tube gels and slab gel molds which allow for sample loads of between about 0.5 and 2 mg or greater. Increased protein loads, resolution and electrotransfer allow for subsequent sequencing of separated proteins by conventional methods.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/44795
5537729,23-Jul-96,1996,7,23,Method of making ultra thin walled wire reinforced endotracheal tubing,"An ultra thin walled wire reinforced endotracheal tubing includes a thin walled tubing comprising a polymeric material having a spring material incorporated therewith. Utilization of the spring wire material in combination with polymeric material results in a reduced wall thickness which results in a significant decrease in resistance to air flow through the endotracheal tubing. The endotracheal tubing of the present invention is made by depositing a dissolvable polymeric material on a rotating mandrel in. successive layers. A spring material is also applied around the mandrel to produce the ultra thin walled wire reinforced endotracheal tubing. By controlling the rate of deposition of polymeric material along the length of the mandrel, different wall thicknesses of tubing may be achieved.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,Medical technology,,,,,B29C/36
5539310,23-Jul-96,1996,7,23,Method and system for measuring the diffusion tensor and for diffusion tensor imaging,"A method and system for measuring the effective diffusion tensor for spin labeled particles, and generating images therefrom. The effective diffusion tensor is related to the echo intensity in an NMR spin-echo experiment. This relationship is used to design experiments from which the diffusion tensor components are estimated. Estimation of Deff provides the theoretical basis for a new MRI modality, diffusion tensor imaging. Diffusion ellipsoids may be used for generating images representative of physical characteristics of the observed object. Scalar invariants of the diffusion tensor are also used for imaging.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56341
5541292,30-Jul-96,1996,7,30,Plasmodium vivax and Plasmodium knowlesi Duffy receptor,"The present invention relates to DNA segments encoding the Duffy receptor of a Plasmodium parasite, the recombinant DNA and to recombinantly produced Duffy receptor. The Duffy receptor can be utilized as a vaccine for humans against malaria.",3,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
5543509,6-Aug-96,1996,8,6,Method for quantifying laminin and .beta.-actin messenger RNA,"A method for the quantifying of human and murine laminin mRNA transcripts of the A, B1 and B2 chains, and of human and murine .beta.-actin mRNA, entails utilizing particular types of PCR primers and control cRNA.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/78
5544652,13-Aug-96,1996,8,13,Ultrafast burst imaging using shifting of excited regions,"An ultrafast BURST imaging method in which burst RF pulses are repeatedly used to excite equally spaced, narrow section strips in an object. The location of the excited section strips of the object is shifted between successive repetitions of the burst RF pulses by at least one strip width. This shifting avoids saturation effects and allows for three dimensional imaging and averaging a repeated series of scans.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/5615
5545620,13-Aug-96,1996,8,13,Synthetic fibronectin fragments as inhibitors of retroviral infection,The invention includes methods for inhibiting retroviral infections such as HIV. The methods of this invention involve the use of certain fragments of fibronectin and such fragments conjugated to carrier molecules such as ovalbumin to inhibit retroviral infections. The invention also includes novel proteins which comprise fibronectin fragments covalently linked to carrier proteins.,3,The United States of America as represented by the Department of Health and Human Services,Reagents of the University of Minnesota,,,,,,,,,,2,Biotechnology,,,,,,C07K/78
5545627,13-Aug-96,1996,8,13,Irreversible inhibitors of adenosine receptors,Irreversible ligands for adenosine receptors are derived from agonist and antagonist functionalized congeners which contain electrophilic acylating and alkylating groups for reaction at nucleophilic residues of adenosine receptors. The ligands are based on 8-aryl-substituted xanthines as antagonists and on N.sup.6 -substituted adenosine as agonists.,22,The United States of America as represented by the Department of Health and Human Services,Duke University,,,,,,,,,,2,Organic fine chemistry,,,,,,C07H/16
5545639,13-Aug-96,1996,8,13,Method of inhibiting transformed cells,"The present invention relates to a method for the inhibition of transformed cells, comprising the application of an effective amount of at least one of the group consisting of 2,9-bis(halomethyl)-1,10-phenanthroline and structural congeners thereof.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4745
5547351,20-Aug-96,1996,8,20,Low pressure low volume liquid pump,A diaphragm pump which provides a low internal volume and minimizes volume contributions for applications which require the transfer of fluid volumes on the order of one to several microliters. The pump includes a plunger which reciprocates within a bore and applies fluid pressure to a diaphragm of a head cavity that is connected to the cylinder bore. Hydraulic feed and vent passages connect to the cylinder bore at a point where the end of the plunger passes during reciprocal movement to ensure that the amount of hydraulic fluid within the cylinder bore is consistent during each stroke of the plunger. The pump is particularly useful for supplying receptor media to a Franz cell.,2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,"Engines, pumps, turbines",,,,,G01N/1095
5549884,27-Aug-96,1996,8,27,Rat or mouse exhibiting behaviors associated with human schizophrenia,"This invention provides a unique and surprisingly accurate animal model for human schizophrenia. The animals are brain damaged while prepubescent. The brain damage consists of a ventral hippocampus lesion induced by exposure of the hippocampus region to a neurotoxin. When the animal reaches puberty, abnormal behavior and a number of biological phenomena associated with schizophrenic symptoms emerge. These animals are useful for assaying pharmaceutical compounds for anti-schizophrenic activity.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,Pharmaceuticals,,,,,A01K/027
5550018,27-Aug-96,1996,8,27,Test for virulent genomic nucleotide 472 revertants in attenuated live poliovirus type 3 vaccines,"The present invention comprises the method of evaluation of the safety of live attenuated vaccines based on detection and measurement of the incidence of genetic changes associated with reversion to virulence in vaccine microorganisms. The method based on PCR and restriction enzyme analysis was developed and used for determination of the proportion of mutants contributing to neurovirulence of type 3 live oral poliovirus vaccine. The correlation between the neurovirulence of OPV lots revealed by the monkey test and the abundance of mutant virus containing cytidine in the position 472 was discovered. The amount of these mutants increases upon passages of the virus in cell cultures at a rate dependent on the cell type, cultivation conditions and the seed virus stock. The present invention can be applied for the safety test of lots of live vaccines and in-process control of vaccine manufacturing as well as the approach for optimization of conditions for manufacturing of safe vaccine and selection of the seed virus and cell substrate.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/683
5552143,3-Sep-96,1996,9,3,Recombinant cytomegalovirus vaccine,"The present invention provides a non-defective adenovirus recombinant expression system for the expression of the HCMV gB subunit, an immunogenic fragment of the gB subunit, and for the expression of non-structural immediate-early exon 4 proteins, said recombinant HCMV-expressing adenovirus being useful as a vaccine.",19,The Wistar Institute of Anatomy & Biology,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
5552308,3-Sep-96,1996,9,3,CDNA clone of a rat serotonin transporter and protein encoded thereby,"The invention described in this disclosure relates to a cloned cDNA encoding the serotonin transporter protein (5HTT) usually found in cells of part of the central nervous system, gut, adrenal gland and in platelets. The invention is further directed to the purified serotonin transporter protein and its use and immunogen for the production of anti-5HTT antibodies. The disclosure also discussses methods for use of the cDNA for diagnostic and treatment applications, and methods for use of permanent cell lines transformed with the serotonin transporter cDNA for pharmaceutical screening. The use of anti-5HTT antibodies as a diagnostic tool is also addressed.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
5552550,3-Sep-96,1996,9,3,Monomeric Naphthylisoquinoline alkaloids and synthesis methods thereof,"The present invention provides methods of preparing monomeric naphthylisoquinoline alkaloids, including the antiparasitic korupensamines and related compounds, as well as non-korupensamines and other monomeric naphthylisoquinoline alkaloids. The invention also provides new, medically useful naphthylisoquinoline compounds and derivatives thereof.",22,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/02
5554500,10-Sep-96,1996,9,10,Cloned genes for human dopamine D2 receptors and cell lines expressing same,"Disclosed herein is an isolated or essentially pure DNA sequence encoding a human Dopamine D2 receptor, the protein comprising the receptor, vectors for transforming or transfecting host cells with such DNA so that the cells express the DNA, methods of obtaining the DNA and preparing the transformed or transfected cells and cell lines, and methods of using the cells and cell lines in assays for the determination of human dopamine D2 receptor antagonists or agonists.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
5554603,10-Sep-96,1996,9,10,"Orally active derivatives of 1,3,5(10)-estratriene","The invention presents 17.beta.-nitro and 11.beta., 17.beta.-dinitro esters of estradiol which are made from 3-acyloxy-17-keto- or 3,17-dihydroxy-1,3,5-estratrienes by processes known in the art. The compounds exhibit estrogenic activity.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07J/0072
5556754,17-Sep-96,1996,9,17,Methods for assessing the ability of a candidate drug to suppress MHC class I expression,The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of MHC Class I molecules. In particular the use of the drug methimazole to suppress expression of MHC Class I molecules in the treatment of autoimmune diseases and the prevention or treatment of rejection in a transplant recipient is disclosed. In addition in vivo and in vitro assays are provided for the assessment and development of drugs capable of suppressing MHC Class I molecules.,17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,G01N/56977
5556763,17-Sep-96,1996,9,17,Evaluation and treatment of patients with progressive immunosuppression,"A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.",11,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/18
5556947,17-Sep-96,1996,9,17,Monoclonal antibody recognizing a surface molecule on a subset of antigen-stimulated T cells and on certain malignancies of T and B cell origin,"This invention provides an IL-6 dependent B-cell lymphoma cell line designated DS-1 deposited with the American Type Culture Collection, wherein the cell line is reactive with a monoclonal antibody produced by a hybridoma cell line designated 10D2F6 deposited with the American Type Culture Collection. The invention also provides a purified antigen reactive with a monoclonal antibody produced by 10D2F6. The antigen also exists on DS-1. Also provided is a method of detecting the presence of an antigen-stimulated T-cell comprising detecting the presence of the antigen on a lymphocyte. In addition, the invention provides a method of detecting the presence of a neoplastic cell comprising detecting the presence of the antigen on a cell which is not normal a T-cell.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/3061
5557199,17-Sep-96,1996,9,17,Magnetic resonance monitor,"A magnetic resonance monitor measures static and extremely low frequency magnetic fields in order to determine the degree of magnetic resonance with the magnetic moments of a biological substrate, more particularly resonance with the magnetic moments of a human body. A digital bandpass filter varies in response to the magnitude of the static magnetic field so that it selects frequencies of the oscillating magnetic field in accordance with the gyromagnetic equation. A spatial analyzer determines the three spatial components of the filtered signals representing the magnetic field oscillating parallel to the static magnetic field vector and the two circularly-polarized components rotating perpendicular to the static field with helicities opposite to each other. A resonance analyzer evaluates accurately the resonance yield which is the change in biochemical processes due to magnetic field exposures. The magnetic resonance monitor can measure from magnetic fields in residential and workplace environments, either for research studies or for the routine evaluations of health hazards.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/443
5560936,1-Oct-96,1996,10,1,Intrinsic inhibitors of aldose reductase,"An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4703
5562101,8-Oct-96,1996,10,8,Portable spirometer with improved accuracy,"A spirometric measurement device includes an arrangement for computation of a dynamic BTPS correction factor, to compensate for temperature-related volume changes due to cooling of expired gas. The correction factor varies in time according to variation of temperature of a flow sensor. The temperature of the flow sensor is accurately established by positioning a temperature sensor downstream of the flow sensor. Autozeroing drift compensation is provided by addition of a PWM signal having an adjusted DC value. Resolution accuracy is increased beyond the capacity of an analog-to-digital converter used in the circuit by implementing a dithering procedure, wherein zero average noise is superimposed on the signal, or by implementing a modified dithering procedure wherein a sawtooth waveform is added to the flow signal, and oversampling the resultant signal.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/0878
5563032,8-Oct-96,1996,10,8,Mosaic polypeptide and methods for detecting the hepatitis E virus,"A nucleic acid encoding a mosaic hepatitis E virus (HEV) polypeptide, consisting of the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. A nucleic acid encoding epitopes 5, 6, 22, 23, 28 and 29 of hepatitis E virus and substantially lacking the nucleic acids intervening the epitope-coding nucleic acids in the native hepatitis E virus is also provided. An isolated nucleic acid that selectively hybridizes under stringent conditions with the mosaic polypeptide-encoding nucleic acid and has at least 70% sequence identity with SEQ ID NO:1 is provided. Also provided are such nucleic acids having at least 80%, 90% and 95% sequence identity. A polypeptide consisting essentially of the amino acid sequence defined in the Sequence Listing as SEQ ID NO:2 is provided. Polypeptides encoded by the present selectively hybridizing nucleic acids, and nucleic acids encoding epitopes 5, 6, 22, 23, 28 and 29 of HEV and substantially lacking the nucleic acids intervening the epitope-coding nucleic acids are also provided.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5565437,15-Oct-96,1996,10,15,"2',3'-dideoxy-2'-fluoro-purine nucleosides and methods for using same","Methods of treating a human infected with human immunodeficiency virus (HIV), such as a human with AIDS, with the purina nucleotides 2',3'-dideoxy-2'-beta-fluoroadenosine (FddA) and 2',3'-dideoxy-2'-beta-fluoroinosine (FddI) are disclosed. These nucleotides are stable in an acid environment and thus can be used for oral administration. Methods of inhibiting human immunodeficiency virus replication in a human T cell using these purina nucleotides are also disclosed.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
5565478,15-Oct-96,1996,10,15,Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs,The present invention provides compositions and methods for the treatment of cancer in a subject wherein compounds of formula I defined herein in combination with paclitaxel or other modified taxane analogs provide enhanced anticancer effects over the effects achieved with the individual compounds.,14,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/40
5567681,22-Oct-96,1996,10,22,PGLa and XPF peptides and uses therefor,"The present invention relates to a method of producing antimicrobial effect by contacting a subject susceptible to microbial invasion or contamination, with antimicrobial amount of XPF and PGLa polypeptides.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/46
5569074,29-Oct-96,1996,10,29,Ventilated workstation with turntable,"A workstation for cleaning or machining workpieces such as foundry castings includes a rotatable workpiece support positioned above a ventilated surface of the workstation. In operation, a workpiece is mounted to the rotatable support and rotated as necessary during a cleaning process to enable a user to conveniently access various surfaces of the workpiece. The cleaning process can include chipping, grinding, sanding and polishing steps. The rotatable workpiece support can include a mechanical clamp or a turntable which can be operatively locked in a desired position. Positioning of the workpiece relative to cleaning tools will reduce worker exposure to respirable particulates.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Materials, metallurgy",Chemical engineering,,,,,B22D/002
5569447,29-Oct-96,1996,10,29,Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives,"The present invention provides stannylated 3-quinuclidinyl benzilate compounds and a method of synthesizing *AQNB by iodinating such stannylated 3-quinuclidinyl benzilate compounds. The iodination of these stannylated 3-quinuclidinyl benzilates proceeds in as little as five minutes; thus, the stannylated 3-quinuclidinyl benzilates may be converted to *AQNB in situ for immediate use. Using this method, radiolabelling yields as high as 80% have been observed. The present invention also is directed towards a method of synthesis of the stannylated 3-quinuclidinyl benzilate compounds. The method comprises providing a 4'-halo-3-quinuclidinyl benzilate and reacting the 4'-halo-3-quinuclidinyl benzilate with a compound having the formula (SnR.sub.3).sub.2, wherein R is an alkyl.",35,The United States of America represented by the Secretary Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/02
5569602,29-Oct-96,1996,10,29,First immortalized Kaposi's sarcoma cell line,"The present invention is related to immortalized cell lines. More particularly, the present invention is related to an immortalized Kaposi's sarcoma (KS) cell line derived from cells isolated from the pleural effusion of AIDS patients with KS. Monoclonal antibodies against KS cells are also provided, as are methods for evaluating antimalignancy therapies.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0693
5569755,29-Oct-96,1996,10,29,Colon mucosa gene having down regulated expression in colon adenomas and adenocarcinomas,"A new down-regulated gene called DRA, for down regulated in adenoma, maps to chromosome 7 and is believed to encode a tumor suppressor. The DRA gene encodes a highly hydrophobic protein with charged clusters located primarily in the carboxyl terminus. Additionally, the expression of the mRNA product appears to be strictly limited to the mucosa of normal colon and it is down-regulated early in colon tumorigenesis. Absence of the DRA polypeptide in tissue that usually expresses it can be used as an indicator of tissue abnormality. The DRA gene and cDNA may also have therapeutic capabilities as well.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
5570019,29-Oct-96,1996,10,29,Method for magnetic resonance spectroscopic imaging with multiple spin-echoes,"A nuclear magnetic resonance pulse sequence to provide spectral encoding so that the resulting series of spin-echoes each include both spatial and spectral information for spectroscopic imaging. Atoms within the object are excited and may then be spatially encoded, as by a phase encoding gradient. A series of refocusing pulses is then applied, inducing a respective series of spin-echoes. Spectral information is directly encoded in the spin-echo signals. The multiple spin-echoes may be used for sampling different points of k-space, and/or for increasing the signal-to-noise ratio by averaging. In an alternative embodiment, the present invention produces compound weighted spectroscopic images by selecting the period between refocussing pulses according to the coupling constant of a group contained in the compound; thereby, the signal of the selected compounds modulate with a known frequency different for compounds with different coupling constants.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/5615
5571156,5-Nov-96,1996,11,5,Switched implantable electrical stimulator leads,"A pacemaker includes apparatus and method for testing the integrity of an insulated pacemaker lead to detect lead degradation at an early stage and warn the user. An electronic switch is placed between two ends of an insulated pacemaker lead that couples a pacemaker housing to the heart of a pacemaker user. The pacemaker electronics circuit asserts a control signal to the switch, opening the switch and interrupting the continuity of the insulated pacemaker lead. After the switch interrupts continuity of the lead, an onboard lead integrity tester tests for insulation leakage of the insulated pacemaker leads by measuring a quality factor, Q, of the insulated lead.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61N/3706
5571832,5-Nov-96,1996,11,5,Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS disorders,Compounds comprising a pyrrolidinyl ring are disclosed for use in the treatment of cerebral ischemia.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/22
5571919,5-Nov-96,1996,11,5,Dimeric naphthylisoquinoline alkaloids and synthesis methods thereof,"The present invention provides methods of preparing dimeric naphthylisoquinoline alkaloids by coupling together two monomeric naphthylisoquinoline alkaloids, each of which may be the same or different, and one, both, or neither of which may possess a C-8' to C-5 naphthalene/isoquinoline linkage, to form homodimers or heterodimers, including the antiviral michellamines. The present invention also provides new, medically useful homodimeric and heterodimeric naphthylisoquinoline compounds and derivatives thereof.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5571929,5-Nov-96,1996,11,5,Resolution and reduction of physostigmine intermediates and derivatives,"One aspect of the present invention provides for the separation of a racemic mixture or a mixture enriched with one or other enantiomer, said mixture comprising the enantiomers of the compound of the formula: ##STR1## wherein R is CN or CONHR' where R' is a C.sub.1 -C.sub.6 alkyl, hydrogen, or benzyl, and R.sub.1 is C.sub.1 -C.sub.6 alkyl or benzyl. Another aspect of the present invention provides a method of preparing a compound of the formula: ##STR2## wherein R is H, C.sub.1 -C.sub.6 alkyl or benzyl, and wherein R.sub.2, R.sub.3, and R.sub.4 are C.sub.1 -C.sub.6 alkyl or benzyl.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5573935,12-Nov-96,1996,11,12,Protein tyrosine kinase A6,A novel protein tyrosine kinase (A6) exhibiting no significant similarity to any known kinase. This protein in widely expressed throughout the body and is present in a variety of vertebrates. The cDNA was expressed in bacteria as a fusion protein which was both autophosphorylated and exhibited kinase activity toward exogenous substrates. Potential uses of this invention include immunodiagnostics and antiproliferative therapeutics.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
5574060,12-Nov-96,1996,11,12,Selective inhibitors of biogenic amine transporters,"The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2, N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3, and (CH.sub.2).sub.n, if present, may be substituted with OH, OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease.",36,The United States of America as represented by the Department of Health and Human Services,Office of Technology Transfer,Research Triangle Institue,,,,,,,,,3,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
5575751,19-Nov-96,1996,11,19,Device for measuring incident light in a body cavity,A device for measuring incident light in a remote situs such as a body cavity which includes a central tubular member through which light is delivered to the remote situs and one or more auxiliary tubular members through which incident light in the remote situs is transmitted to a light detector. Each auxiliary tubular member receives incident light from a different portion of the remote situs. The apparatus is particularly useful for conducting phototherapy in body cavities and has been demonstrated in the phototherapy treatment of superficial cancer in a bladder.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/24
5576000,19-Nov-96,1996,11,19,"Molecular clones of HIV-1 viral strains MH-ST1 and BA-L, and uses thereof","The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST 1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
5578448,26-Nov-96,1996,11,26,Nucleic acids encoding wild-type measles virus consensus hemagglutinin and fusion polypeptides and methods of detection,The present invention provides nucleic acids encoding consensus hemagglutinin and consensus fusion polypeptides which contain at least one amino acid substitution relative to the Moraten vaccine strain that is found in at least one strain of wild-type measles virus. Nucleic acid reagents useful for detecting and differentiating wild-type measles strains by polymerase chain reaction and a method utilizing the same are provided. Recombinant vectors comprising nucleic acids encoding the consensus hemagglutinin and/or the consensus fusion polypeptides are also provided.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5578566,26-Nov-96,1996,11,26,KGF receptor-derived antagonists of KGF binding,The invention provides KGFR peptides which inhibit binding between keratinocyte growth factor (KGF) and its receptor. The sequence of the peptides is derived from regions in the receptor which specifically bind the growth factor. Also provided are pharmaceutical compositions and methods of inhibiting the interaction of KGF and the receptor in a patient to treat various carcinomas.,16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/71
5578729,26-Nov-96,1996,11,26,Dimeric arylisoquinoline alkaloid compounds,"The present invention provides a method of preparing dimeric arylisoquinoline alkaloids by coupling two isoquinoline building blocks, each of which may be the same or different, together with a symmetrical or nonsymmetrical biaryl building block to form homodimers or heterodimers, including the antiviral michellamines. The present invention also provides new, medically useful homodimeric and heterodimeric arylisoquinoline compounds and derivatives thereof.",5,The United States of America as represented by the Department of Health and Human Services,The Trustees of Boston College,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/02
5580738,3-Dec-96,1996,12,3,Delta-like gene expressed in neuroendocrine tumors,"A polynucleotide molecule dlk is expressed in neuroendocrine tumors, including small cell lung carcinoma. A Dlk polypeptide encoded by dlk polynucleotide molecule can be used in detecting the existence of a primary or secondary neuroendocrine tumor. Monoclonal antibodies are produced against Dlk which are useful for detection and therapy of a neuroendocrine tumor.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
5580748,3-Dec-96,1996,12,3,Diagnostic tests for alzheimers disease,"The present invention is a method for the diagnosis of Alzheimer's disease using human cells. Specifically, the method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/6872
5580760,3-Dec-96,1996,12,3,FUSE binding protein and cDNA therefor,"The Far Upstream Element (FUSE) of the human c-myc gene, stimulates expression in undifferentiated cells. A FUSE binding protein (FBP), also referred to as DROME (DNA-binding regulator of c-myc expression), is active in undifferentiated but not differentiated cell extracts. Cloned FBP exhibits the same DNA-binding specificity as the purified human protein and can trans-activate in a FUSE dependent manner. Sequence-specific binding to the FUSE oligonucleotide required at least two copies of a repeat-helix unit which defines a new DNA-binding motif. Expression of FBP mRNA declined in parallel with decreased FUSE binding activity upon differentiation suggesting transcriptional regulation of FBP. Features were identified in clones which suggested FBP is also regulated by RNA processing, translation and post-translational mechanisms.",50,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4705
5582185,10-Dec-96,1996,12,10,Device for evaluating optical elements by reflected images,"A method and apparatus for evaluating optical elements which utilizes reflected images. The method allows determination of the optical effects contributed by individual surfaces of a single optical alone or in a multiple element optical system. The method is particularly useful for evaluating corneas after transplant, grafting and reshaping procedures.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/107
5582973,10-Dec-96,1996,12,10,Sensitive method for localizing chromosomal breakpoints,"A sensitive method for identifying chromosomal breakpoints flanked by repeat sequences, through amplification by polymerase chain reaction, is described. The application of the method to the detection of Burkitt's lymphoma cells is demonstrated.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5583002,10-Dec-96,1996,12,10,Evaluation and treatment of patients with progressive immunosuppression,"A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels and T-lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, or a protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.",18,Regents of the University of Minnesota,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/18
5583032,10-Dec-96,1996,12,10,Method of cleaving specific strands of RNA,"A method of using a chimeric molecule made up of an antisense oligonucleotide attached to a 2',5'-oligoadenylate molecule to specifically cleave a sense strand of RNA, wherein the antisense oligonucleotide of the chimeric molecule is hybridized to the sense strand of RNA in the presence of 2',5'-dependent RNase.",21,The Cleveland Clinic Foundation and National Institutes of Health,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12N/113
5583201,10-Dec-96,1996,12,10,Methods for diagnosis of peripheral nerve damage,"Methods of diagnosing peripheral nerve damage, including diagnosing and monitoring chronic back and cervical pain are disclosed. The methods involve subjecting a body fluid sample from a patient suspected of having chronic lumbar or cervical pain and peripheral nerve damage to two-dimensional electrophoresis or an immunoassay and measuring relative amounts of protein or proteins which increase or decrease in concentration as compared to a standard control. A preferred method employs an Apo-E variant as a marker of peripheral nerve damage. Also disclosed are kits for use with the diagnostic methods.",1,"Monoclonetics International, Inc.",United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/6896
5585250,17-Dec-96,1996,12,17,"Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies","The present invention provides a composition that can be administered to a mammal to cause immunoprotection in the mammal against a pathogenic organism that has an immunodominant epitope. The composition includes a modified form of the antigen in which the immunodominant epitope is located. In this modified form, the immunodominant epitope is immunodampened by any of a number of techniques. Examples of immunodampening techniques include addition of N-linked glycosylation sites, change of the net charge on the epitope, and substitution with a tolerated sequence. The composition also includes a pharmacologically acceptable carrier.",12,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5585346,17-Dec-96,1996,12,17,Peptide derivatives of cytochrome b.sub.558 and their use as medicaments,Peptide derivatives with inhibitory activity on the enzyme systems involved in the oxidative burst of human phagocytic cells comprise a certain sequence of a number of carboxyl-terminal amino acids of human cytochrome b.sub.558. The derivatives may be used in medicaments for the treatment of inflammatory diseases.,17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/80
5587308,24-Dec-96,1996,12,24,Modified adeno-associated virus vector capable of expression from a novel promoter,"Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.",10,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5587309,24-Dec-96,1996,12,24,Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo,"A method of inducing the proliferation and/or differentiation of human fetal pancreatic cells entails contacting such cells in primary culture with Hepatocyte Growth Factor/Scatter Factor, thereby inducing a proliferation of .beta.-epithelial cells, an increase in the number of .beta.-epithelial cells which form islet-like cell clusters, and an increase in insulin production per cell. The method provides increased numbers of functional islet-like cell clusters for transplantation, for example, into Type 1 diabetic patients. The method can be scaled up so as to provide clinically useful numbers of cells for transplantation.",6,The United States of America as represented by the Department of Health and Human Services,Whittler Institute for Diabetes and Endocrinology,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/0676
5587455,24-Dec-96,1996,12,24,Cytotoxic agent against specific virus infection,A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70514
5589331,31-Dec-96,1996,12,31,Method for detecting abnormal serotonergic function,"A method of detecting abnormal serotonergic function in an impulsive human subject is disclosed. The method comprises detecting an L allele of a gene encoding tryptophan hydroxylase. The invention also includes an isolated nucleic acid having a sequence specific to an L allele of a gene encoding tryptophan hydroxylase. The nucleic acid may migrate in a denaturing gel at the same rate as a second nucleic acid specific to a corresponding region of a U allele of a gene encoding tryptophan hydroxylase, and migrate in a nondenaturing gel at a rate about 1.02 times the migration rate of the second nucleic acid.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5589397,31-Dec-96,1996,12,31,Method for monitoring the performance of an amino acid sequencer,"The present invention further provides novel synthetic control peptides containing from about 3 to 100 natural amino acid residues that are designed for use in monitoring the proper operation of amino acid sequencers and to monitor peptide or protein cleavage reactions. The control peptide, or mixture of control peptides, are designed to obtain data for many or all common, uncommon and difficult to measure amino acids within 15 sequencer cycles and to provide cleavage sites for at least 4 different amino acid cleavage reactants.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/4717
5591631,7-Jan-97,1997,1,7,"Anthrax toxin fusion proteins, nucleic acid encoding same","The present invention provides a nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the protective antigen (PA) binding domain of the native lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein, comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided. A composition comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety is further provided. A method for delivering an activity to a cell is provided. The steps of the method include administering to the cell a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain, and administering to the cell a product comprising the PA binding domain of the native LF protein and a non-LF activity inducing moiety, whereby the product administered is internalized into the cell and performs the activity within the cell.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5591719,7-Jan-97,1997,1,7,Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity,A method for treating acute or chronic inflammatory or autoimmune disorders using polypeptides with fibronectin or related activity is provided. The method involves (administering an amount of) one or more polypeptides corresponding to isolated amino acid residue sequences of the 33 kD carboxy terminal heparin-binding region located on the A chain of fibronectin to effectively suppress inflammation and impairment of tissue function in a patient.,17,Regents of the University of Minnesota,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/78
5591770,7-Jan-97,1997,1,7,"Calanolide and related antiretroviral compounds, compositions, and uses thereof","The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.",24,The United States of America as represented by the Department of Health and Human Services,The Board of Trustees of the University of Illinois,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/14
5591977,7-Jan-97,1997,1,7,Variable axial aperture positron emission tomography scanner,"An imaging device includes a means for defining an imaging target space and at least two scintillation cameras which are positioned on opposite sides of the imaging target space so as to define one or more matched pairs of scintillation cameras. Each of the scintillation cameras includes a scintillation crystal. Means are provided for tilting the scintillation cameras of the one or more matched pairs of scintillation cameras and their respective scintillation crystals, so as to maximize coincidence detection sensitivity by adjusting an axial field of view to match an axial extent of a target located in the imaging target space. Means for processing signals generated by the scintillation cameras are also provided. Each pair of cameras is configured to detect paired gamma rays, emitted simultaneously and in opposite directions from a point of annihilation of a positron in the target within the target space, to thereby define endpoints of a coincidence line passing through the target and connecting the pair of cameras. Each pair of cameras generates electrical signals, responsive to substantially simultaneous absorption of each of the paired gamma rays by a respective one of the pair of cameras, indicative of the paired gamma rays emanating from a single positron annihilation in the target.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Environmental technology,,,,,G01T/2985
5592572,7-Jan-97,1997,1,7,Automated portrait/landscape mode detection on a binary image,"A process for determining an orientation of a binary image includes segmentation of the image into many square regions. Orientations of the individual regions that are determined to be textual squares allow local variations of the binary image to establish an overall orientation for the binary image. The process iteratively groups and consolidates the individual regions into successively larger and larger regions. An orientation for particular ones of the larger regions is determined by a single mode of the various composite modes of the particular one regions having the greatest weight. After all the regions have been consolidated in this fashion, the process uses the orientation of the single consolidated region as the orientation of the binary image.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Telecommunications,,,,,G06K/3283
5593966,14-Jan-97,1997,1,14,Peptide derivatives of cytochrome b.sub.558 and their use as medicaments,Peptide derivatives with inhibitory activity on the enzyme systems involved in the oxidative burst of human phagocytic cells comprise six and seven amino acid peptide sequences from human cytochrome b.sub.558. The derivatives may be used in medicaments for the treatment of inflammatory diseases.,13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/80
5595885,21-Jan-97,1997,1,21,Matrix metalloproteinase inhibitor peptides,"The present invention is an isolated protein of 21,600 Da which binds to both latent and activated type IV collagenase with high affinity at 1:1 molar stoichiometry, thereby abolishing enzyme activity. The protein is purified by affinity chromatography on solid phase metalloproteinase, or solid phase metalloproteinase substrates which bind the enzyme-inhibitor complex. The complete primary structure of this protein (initially called CSC-21K), as determined by sequencing overlapping peptides spanning the entire protein, reveals homology with a protein called TIMP, Tissue Inhibitor of Metalloproteinases. In addition, a cDNA for this novel inhibitor, now designated TIMP-2, was cloned from a melanoma cell and its sequence was compared with that of human TIMP-1. Northern blots of melanoma cell mRNA showed two distinct transcripts of 0.9 kb and 3.5 kb which are down-regulated by transforming growth factor-.beta., and are unchanged by phorbol ester treatment. The inhibitor of the present invention may be used for treatment of pathologic conditions resulting from inappropriate degradation of extracellular matrix molecules by matrix metalloproteinases, such as metastatic neoplasia, myocardial infarction, and arthritis. Therapeutic treatments using this inhibitor may include formulations for inhalation and inclusion complexes adapted for buccal or sublingual administration, or administration of a recombinant DNA molecule which expresses a DNA segment that encodes the matrix metalloproteinase inhibitor of this invention.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/8146
5595895,21-Jan-97,1997,1,21,Efficient directional genetic cloning system,"A highly efficient genetic cloning system is disclosed which is particularly useful for cloning cDNA copies of eukaryotic mRNAs and can direct the orientation of inserts in .lambda.-plasmid composite vectors with large cloning capacities. Cleavage of such vector DNA, by the restriction enzyme SfiI, for example, creates two different non-symmetrical 3' extensions at the ends of vector DNA. Using a linker-primer and an adaptor, cDNA is prepared to have two different sticky ends which can be ligated to those of the vector. When the cDNA fragments and the vector DNAs are mixed, both the molecules can assemble without self-circularization due to base-pairing specificity. This system provides (1) high cloning efficiency (10.sup.7 -10.sup.8 clones/.mu.g poly(A).sup.+ RNA), (2) low background (more than 90% of the clones contain inserts), (3) directional insertion of cDNA fragments into the vectors, (4) presence of a single insert in each clone, (5) accommodation of long inserts (up to 10 kb), (6) a mechanism for rescue of the plasmid part from a .lambda. genome, and (7) a straightforward protocol for library preparation.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/71
5597567,28-Jan-97,1997,1,28,Blocking cell adhesion molecules and treating animals with ocular inflammation,"The present invention relates, in general, to a method of blocking of cell adhesion molecules. In particular, the present invention relates to a method of blocking cell adhesion molecules with monoclonal antibodies or synthesized substances.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/2854
5599839,4-Feb-97,1997,2,4,Antiviral composition,"The present invention relates to an antiviral composition and to methods of treating patients with viral infections. The antiviral composition of the present invention comprises prostratin, a phorbol ester derivative, and a pharmaceutically acceptable carrier. The present composition while having antiviral activity does not have substantial tumor promoting activity and does not have other substantial adverse toxicological properties that would preclude its use in antiviral therapy.",6,The United States of America as represented by the Department of Health and Human Services,Brigham Young University,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/22
5601826,11-Feb-97,1997,2,11,Peptide which produces protective immunity against tetanus,"The invention provides an immunogen against tetanus toxin including a peptide having a single, linear, antigenic, tetanus-toxin-specific epitope. The epitope is derived from the heavy chain C fragment of the toxin. In a preferred embodiment, the immunogen includes the last 20 amino acids of the toxin, including the carboxy terminus. Antibodies, including antipeptide antibodies, are also provided as well as methods of vaccination.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1282
5602095,11-Feb-97,1997,2,11,Recombinant pseudomonas exotoxin with increased activity,"This invention relates to the production and use of recombinant Pseudomonas-derived toxins modified to increase their toxicity and potency in therapy. More particularly, the invention relates to certain deletions in domain II of the amino acid sequence of Pseudomonas exotoxin the domain which relates to the toxin's natural proteolytic processing.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/30
5602156,11-Feb-97,1997,2,11,Method for inhibiting metalloproteinase expression,"Calcium homeostasis is an important regulator of MMP-2 transcription, activation and activity. Disclosed herein are compounds which inhibit the expression of matrix metalloproteinases in cells. Pharmaceutical application of these compounds to inhibit the expression of MMPs offers a new approach to cancer treatment as well as treatment for nerve healing, degenerative cartilagenous diseases, decubitus ulcers, arthritis, Alzheimer's disease, wound healing, proliferative retinopathy, proliferative renal diseases, corneal ulcers and fertility problems.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/415
5602184,11-Feb-97,1997,2,11,"Monoterpenes, sesquiterpenes and diterpenes as cancer therapy","The invention provides methods of treating cancer including administering an effective amount of selected terpenes to a mammal having the cancer when the cancer is prostate cancer, colon cancer, astrocytoma, or sarcoma. The terpene is selected from the group consisting of a cyclic monoterpene, a noncyclic monoterpene, a noncyclic sesquiterpene and a noncyclic diterpene. The invention also provides a method of sensitizing a cancer to radiation including administering an effective amount of a terpene to a mammal having the cancer wherein the terpene is selected from the group noted above. Additionally, the invention provides methods of inhibiting the growth of cancer cells including applying an effective amount of a selected terpene to the cancer cells which are cells of prostate cancer, colon cancer, osteosarcoma, or glioblastoma.",19,The United States of America as represented by Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/01
5603820,18-Feb-97,1997,2,18,Nitric oxide sensor,"An electrode sensor which may be used to specifically and quantitatively measure nitric oxide is provided, as well as a method of preparing and using such an electrode sensor to measure nitric oxide concentration in solution. A nitric oxide (NO) microsensor based on catalytic oxidation of NO comprises a thermally-sharpened carbon fiber with a tip diameter of about 0.5-0.7 .mu.m coated with several layers of p-type semiconducting polymeric porphyrin and cationic exchanger deposited thereon. The microsensor, which can be operated in either the amperometric, voltammetric or coulometric mode utilizing a two or three electrode system, is characterized by a linear response up to about 300 .mu.M, a response time better than 10 msec and a detection limit of about 10 nM. The sensor of the present invention also discriminates against nitrite, the most problematic interferant in NO measurements. The amount of NO released from a single cell can thus be selectively measured in situ by a porphyrinic microsensor of the invention. A larger scale sensor utilizing porphyrin and cationic exchanger deposited on larger fibers or wires, platinum mesh or tin indium oxide layered on glass, can also be employed when measurement of NO concentration in chemical media, tissue or cell culture is desired.",66,The United States of America as represented by the Department of Health and Human Services,The University of North Carolina at Chapel Hill,,,,,,,,,,2,Chemical engineering,Measurement,,,,,B01J/1815
5604093,18-Feb-97,1997,2,18,Human herpesvirus-6(HHV-6)Isolution and Products,"A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.",8,"The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5604118,18-Feb-97,1997,2,18,Eukaryotic expression vector system,"The present invention relates to two plasmid vectors and eucaryotic expression vector created therefrom. The present invention further relates to a method of cloning a gene in a eucaryotic cell the expression of which is affected by drug treatment, a method of constructing a subtracted cDNA library and a method of identifying a eucaryotic gene the product of which inhibits cell growth.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
5604255,18-Feb-97,1997,2,18,N-(1-thienylcycloalkyl)alkenylamines for treatment of neurotoxic injury,"Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an N-(1-thienylcycloalkyl)alkenylamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites. Compounds of most interest are those of the formula ##STR1## wherein R.sup.1 is one or more groups selected from hydrido, alkyl of one to about five carbon atoms, cycloalkyl of three to about five carbon atoms, alkenyl of two to about five carbon atoms, hydroxyl and alkoxy; wherein each of R.sup.2 is one or more groups selected from hydrido, alkyl of one to about five carbon atoms, cycloalkyl of three to about five carbon atoms, alkenyl of two to about five carbon atoms, hydroxyl, oxo and alkoxy; wherein R.sup.5 is one or more groups selected from hydrido, alkyl of one to about five carbon atoms, cycloalkyl of three to about five carbon atoms, alkenyl of two to about five carbon atoms, hydroxyl and alkoxy; and wherein the broken line within the N-containing ring represents a double bond between any two adjacent carbon atoms",8,The United States of America as represented by the Department of Health and Human Services,G. D. Searle & Co.,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/06
5604976,25-Feb-97,1997,2,25,Method of making percutaneous connector for multi-conductor electrical cables,A biologically implantable percutaneous connector for providing optionally separable interconnection of a large number of small electrical conductors of an externally located electrical cable includes a mating face incorporating an array of exposed end surfaces of tiny conductive rods sealed in a supporting matrix of dielectric material which is supported in a connector body. Elastomeric anisotropic connector material is located between corresponding arrays of contacts to provide for repeated reliable electrical connection and disconnection. External surfaces of the implantable body of the percutaneous connector are coated with a bioactive material promoting integration of surrounding tissue into the surfaces of the implanted percutaneous connector. A contact block including the mating face and a terminal face to which the conductors of a cable are individually connected is made by shaping an array of conductive rods and supporting dielectric material to form a smooth surface including dielectric matrix material and the ends of the electrically conductive rods.,34,PI Medical Corporation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Medical technology,"Electrical machinery, apparatus, energy",,,,,H01R/2414
5605930,25-Feb-97,1997,2,25,Compositions and methods for treating and preventing pathologies including cancer,"Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents including retinoids, hydroxyurea, and flavonoids. Intravesicle methods of treatment of cancers phenylacetate. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention. A product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonid (or other mevalonate pathway inhibitor) for simultaneous, separate, or sequential use in treating a neoplastic condition in a subject. Methods of modulating lipid metabolism and/or reducing serum triglycerides in a subject using phenylacetate.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/35
5606060,25-Feb-97,1997,2,25,Topoisomerase II inhibitors and therapeutic uses therefor,"Azatoxin and derivatives thereof are illustrative of a new class of antitumor drugs that are topoisomerase II (top 2) inhibitors. The pharmacophore inhibits the catalytic activity of the purified enzyme but does not unwind relaxed or supercoiled DNA. It is nonintercalative and has at least two domains: a quasiplanar polycyclic ring system, which may bind between DNA base pairs, and a pendant substituent thought to interact with the enzyme, with the DNA grooves or with both. In SV40 and c-myc DNA, azatoxin induces numerous double-strand breaks according to a cleavage pattern which differs from those of known top 2 inhibitors. Azatoxin also is a potent inhibitor of tubulin polymerization.",7,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5607831,4-Mar-97,1997,3,4,In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death,Calpain has been identified as a component of the biochemical pathway in programmed cell death. Calpain inhibitors are effective in preventing the progression to cell death and can restore cell function. T lymphocytes from HIV infected individuals undergo T cell receptor-triggered programmed cell death which can be treated by calpain inhibitors and immune function can be restored in affected cells. Methods for diagnosing cell populations or individuals susceptible to programmed cell death and for monitoring therapeutic effectiveness are provided.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,A61K/55
5608039,4-Mar-97,1997,3,4,Single chain B3 antibody fusion proteins and their uses,"This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,G01N/57492
5610018,11-Mar-97,1997,3,11,"Substrate for the epidermal growth factor receptor kinase, antibodies thereto and methods of use thereof","A new substrate of epidermal growth factor receptor and other tyrosine kinase receptors denominated eps8, polynucleotide encoding eps8, antisense eps8 polynucleotide, antibodies to eps8, and assays for determining eps8.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
5610043,11-Mar-97,1997,3,11,Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus,"Immortalized non-tumorigenic or tumorigenic human prostatic epithelial and fibroblast cell lines and derivatives thereof, containing DNA of a hybrid virus between adenovirus 12 and simian virus 40. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5011
5610053,11-Mar-97,1997,3,11,DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells,"A newly-characterized chromatin insulator element isolated from the DNA of a higher eukaryotic organism and contained in vector constructs is described. The insulator element of the invention comprises a DNA sequence which contains a 5' constitutive hypersensitive site whose functional activity and biochemical characterization as a pure insulator were previously unknown. A core DNA sequence having strong insulator activity is described. The insulator element, including the core sequence, have been demonstrated for the first time in mammalian cells to function to buffer or insulate an expressed gene from the activity of cis-acting regulatory elements, such as enhancers, in the surrounding chromatin or DNA.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/465
5610060,11-Mar-97,1997,3,11,Isolated Helicobacter hepaticus,"An isolated bacterium of the genus Helicobacter, characterized by the 16S ribosomal RNA encoding nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. An isolated nucleic acid having the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. Such a nucleic acid can be used for diagnosis of infection with H. hepaticus. A nucleic acid of the present invention in a vector suitable for expression of the nucleic acid is also provided. The vector can be in a host suitable for expressing the nucleic acid. A purified antigen specific for H. hepaticus is provided. A method of making an animal model for chronic Helicobacter infection is also provided.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/205
5610185,11-Mar-97,1997,3,11,Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds,"The present invention relates to a method of treating hyperproliferative epithelial lesions by topical administration. The method prevents growth and actively cross-links these aberrant cells, thereby killing the cells. The present invention is useful in control and prevention of hyperproliferative epithelial disorders, such as HPV-infected cell lesions, actinic keratosis, melanomas, and malignant and pre-malignant carcinomas.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/472
5610198,11-Mar-97,1997,3,11,Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases,"Compounds, pharmaceutical compositions, and methods for the treatment of mycobacterial diseases, such as tuberculosis and leprosy, are provided. Use of the compounds for promoting an antiseptic condition of a surface are also included. Some of the preferred compounds include thiatetracosanoic acids, esters, and fluorinated analogs.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/22
5610282,11-Mar-97,1997,3,11,cDNA encoding a rat D.sub.1 dopamine receptor linked to adenylyl cyclase activation and expression of the receptor protein in plasmid-transfected cell lines,"The present invention relates to the molecular cloning and expression of the D.sub.1 dopamine receptor protein that is linked to the activation of adenylyl cyclase activity. By constructing cell lines that express the D.sub.1 receptor, the affinities and efficacies of agonist and antagonist drugs with the receptor can be assessed. The present invention further relates to a recombinant DNA construct that includes a vector and a DNA fragment encoding the D.sub.1 receptor. The present invention also relates to a host cell transformed with a recombinant DNA construct, so that the DNA fragment is expressed and the D.sub.1 receptor is produced. Suitable expression systems include eukaryotic and procaryotic cells, especially mammalian cells such as rat or human. The present invention further relates to the antibody to the D.sub.1 receptor protein. For diagnostic purposes, antibodies to this receptor can be prepared by producing all or a portion of the receptor protein and injecting these into various types of mammals. Using the resulting antibodies, expression of the D.sub.1 receptor cDNA in cells can be measured.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
5612032,18-Mar-97,1997,3,18,Method for diagnosing tumors using mouse monoclonal antibodies,"The subject invention relates to monoclonal antibodies and uses thereof. In particular, the invention relates to three monoclonal antibodies, referred to as B1, B3, and B5, which are useful in the treatment and diagnosis of many forms of cancer.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,Pharmaceuticals,,,,C07K/30
5612468,18-Mar-97,1997,3,18,Pteridine nucletide analogs as fluorescent DNA probes,The invention provides novel pteridine nucleotides which are highly fluorescent under physiological conditions and which may be used in the chemical synthesis of fluorescent oligonucleotides. The invention further provides for fluorescent oligonucleotides comprising one or more pteridine nucleotides. In addition the invention provides for pteridine nucleotide triphosphates which may be used as the constituent monomers in DNA amplification procedures.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
5614187,25-Mar-97,1997,3,25,Specific tolerance in transplantation,"In general, the invention features, a method of inducing tolerance in a recipient mammal, e.g., a human, of a first species to a tissue obtained from a mammal, e.g., a swine, e.g., a miniature swine, of a second species, which tissue expresses an MHC antigen, including inserting DNA encoding an MHC antigen of the second species into a bone marrow hematopoietic stem cell from the recipient mammal, and allowing the MHC antigen encoding DNA to be expressed in the recipient.",15,The General Hospital Corporation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/26
5614191,25-Mar-97,1997,3,25,IL-13 receptor specific chimeric proteins and uses thereof,The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule that comprises an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule.,21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/2866
5616463,1-Apr-97,1997,4,1,Methods for determining the presence of functional p53 in mammalian cells,The dependence of ionizing radiation-induced GADD45 mRNA expression on the presence of functional p53 in mammalian cells is disclosed. First and second oligonucleotide sequences are provided which can form a double-stranded oligomer capable of binding to functional p53 protein. The present invention demonstrates that the dependence of ionizing radiation-induced GADD45 mRNA expression on the presence of functional p53 and the binding of functional p53 to a double-stranded oligomer binding sequence can serve as the basis for methods for determining the presence of functional p53 in mammalian cell lines and tumors.,12,The United States of America as represented by the Secretary Department of Health and Human Services,Johns Hopkins University,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/18
5616471,1-Apr-97,1997,4,1,Effects of growth factors on hair follicle cell proliferation and release of collagenolytic factors,"The present invention relates to methods for detecting the effects of selected growth factors and pharmaceuticals on the growth and development of hair follicles by assaying hair follicle cell proliferation and cellular collagenolytic factor secretion. In particular, isolated hair follicle cells maintained as intact functioning folliculoids are embedded in a three-dimensional culture system, and exposed to the chemical agent of choice. The effect of this agent can then be determined with respect to its ability to modify cellular proliferation or secretion of proteolytic factors. Each determination involves the use of a separate assay.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5008
5616500,1-Apr-97,1997,4,1,Trichohyalin and transglutaminase-3 and methods of using same,"The sequences of a pair of human proteins, trichohyalin and transglutaminase-3, in addition to the sequence of the mouse transglutaminase-3 protein, have been discovered. The enzyme transglutaminase-3 is used to cross-link the structural protein trichohyalin in order to form a gel.",12,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Medical technology,Organic fine chemistry,Food chemistry,,,C12N/1044
5616566,1-Apr-97,1997,4,1,"Method of inhibiting HIV replication with 2',3'-dideoxyadenosine","A method for inhibiting intracellular replication of HIV in an HIV-infected individual comprising contacting the HIV reverse transcriptase in the HIV-infected cells with 2',3'-dideoxyadenosine-5'-triphosphate whose source is 2',3'-dideoxyadenosine or a pharmaceutically acceptable salt or prodrug thereof.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
5616608,1-Apr-97,1997,4,1,Method of treating atherosclerosis or restenosis using microtubule stabilizing agent,"The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,,,,,A61K/337
5618536,8-Apr-97,1997,4,8,Chimeric papillomavirus-like particles,"The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5618670,8-Apr-97,1997,4,8,Detection method for c-raf-1 genes,"The present invention relates to (1) a method of identifying an individual at an increased risk for developing cancer, (2) a method for determining a prognosis in patients afflicted with cancer, and (3) a method for determining the proper course of treatment for a patient afflicted with cancer; comprising: amplifying a region of the c-raf-1 gene.",15,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/001162
5618786,8-Apr-97,1997,4,8,Aerosolization of protein therapeutic agent,Aerosolization of therapeutic proteins is demonstrated using recombinant .alpha..sub.1 -antitrypsin for treatment of emphysema as paradigmatic.,10,"Cooper Laboratories, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/0078
5620676,15-Apr-97,1997,4,15,Biologically active ATP analogs,"The present invention provides certain novel adenosine triphosphate (ATP) analogs, pharmaceutical compositions, and methods of using such analogs in the treatment of septic shock and other disease conditions. Examples of the ATP analogs include the mono-, di- and triphosphates of adenosines with various selected substituents at the 2, 6, 8, and 9-positions, such as alkyl, alkylphenyl, phenylalkyl, S-alkyl, S-alkenyl, S-alkylcyano, S-phenyl, S-alkylphenyl, S-alkylamino, S-alkylthioalkyl, S-alkylthiocyanato, S-alkylaminophenyl, S-alkylnitrophenyl, hydroxy, bromo, fluoro, chloro, and aminoalkylamino. The present invention also provides pharmaceutical compositions of and methods of using certain xanthine and uracil derivatives for the above disease conditions. Examples of the xanthine derivatives include xanthines having alkyl or alkyltriphosphate substituents at the 1, 3, and 7-positions. Examples of the uracil derivatives include 5-fluoro- and 5-bromo uracil triphosphates. Also provided are assays for assessing the binding of the ATP analogs.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/0491
5620866,15-Apr-97,1997,4,15,Human cripto-related gene,"The present invention relates, in general, to a human CRIPTO-related gene. In particular, the present invention relates to a DNA segment encoding a human CRIPTO-related gene; polypeptides encoded by that DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a human CRIPTO-related polypeptide; a DNA segment encoding a genomic clone of the human CRIPTO gene (CR-1); antibodies specific to CR-3; and a method of measuring the amount of CR-3 in a sample.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5621667,15-Apr-97,1997,4,15,Lift task analysis system,"A lift task analysis system includes a sensor having a retractable cable grasped by the hands of a participant. The participant moves in accordance with a selected lifting task and, in doing so, move the cable end correspondingly. The sensor generates an output indicative of a location of the mid-point of the participant's hands holding the cable end with respect to that sensor, i.e., a position of the end of the extended cable. The sensor is attached to the housing of an analysis device which includes an input for receiving user/selected parameters. The housing also includes a control processor with means for determining a recommended weight limit and means for determining a lifting index. These determinations are made based upon user-selected input and NIOSH equation multipliers automatically determined through the use of the sensor. The system also includes a memory for storing the lifting index and the recommended weight limit for a plurality of different lifting tasks, as well as other data relevant to those lifting tasks.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Medical technology,,,,,G01G/00
5622703,22-Apr-97,1997,4,22,Immunodominant sites of HTLV-I envelope protein,"The invention relates to peptides representing CTL epitopes from the HTLV-I envelope protein. The invention further relates to compositions, comprising the peptides, for priming a T-cell response in a subject. Furthermore, methods for priming a T-cell response by administration of the compositions to a subject and methods for evaluating the T-cell function of a patient are described.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5622861,22-Apr-97,1997,4,22,Recombinant DNA encoding hepatitis A virus receptor,"Provided is the discovery and isolation of a cellular receptor for hepatitis A virus. Also provided is an isolated nucleic acid molecule comprising a nucleic acid encoding a polypeptide having the biological activity of a hepatitis A virus receptor. Also provided are vectors comprising the isolated nucleic acids encoding a hepatitis A virus receptor in host suitable for expression of the nucleic acids encoding the hepatitis receptor, fragments of the hepatitis A virus receptor, or homologs of the hepatitis A virus receptor. Further provided is a nonhuman transgenic animal which expresses a hepatitis A virus receptor, but does not express an endogenous, active hepatitis A virus receptor. Also provided is a method for screening drugs or vaccines utilizing the transgenic animal expressing a hepatitis A virus receptor. Also provided are methods for use of the purified hepatitis A virus receptor, such as separating hepatitis A virus from blood or other samples, detecting the presence of hepatitis A virus in a sample, determining the anti-hepatitis A virus binding of a compound, preventing hepatitis A virus infection in a subject, or treating a subject infected with hepatitis A virus. Also provided are nucleic acids which selectively hybridize with the nucleic encoding the hepatitis A virus receptor of the present invention.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
5622959,22-Apr-97,1997,4,22,Method of treating retroviral infections in mammals,"The present invention is directed to the use of pharmaceutical compositions, containing an effective amount of topoisomerase I inhibitor such as camptothecin, useful in blocking both the initiation of infection and replication of retroviruses in host cells, thus reducing and eliminating retroviral production in infected cells. Use of such inhibitors provides as means of reducing or eliminating retroviral infections and their deleterious consequences in infected humans and animals.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/00
5622960,22-Apr-97,1997,4,22,Topoisomerase II inhibitors and therapeutic uses therefor,"Azatoxin and derivatives thereof are illustrative of a new class of antitumor drugs that are topoisomerase II (top 2) inhibitors. The pharmacophore inhibits the catalytic activity of the purified enzyme but does not unwind relaxed or supercoiled DNA. It is nonintercalative and has at least two domains: a quasi-planar polycyclic ring system, which may bind between DNA base pairs, and a pendant substituent thought to interact with the enzyme, with the DNA grooves or with both. In SV40 and c-myc DNA, azatoxin induces numerous double-strand breaks according to a cleavage pattern which differs from those of known top 2 inhibitors. Azatoxin also is a potent inhibitor of tubulin polymerization.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5624830,29-Apr-97,1997,4,29,Cytosine deaminase negative selection system for gene transfer techniques and therapies,"The present invention relates to a system comprising a modified bacterial gene for cytosine deaminase that has been engineered into a eukaryotic expression vector and the expression of the gene by mammalian cells. The present invention further relates to methods, gene therapies and vaccines that employ the negative selectable marker, cytosine deaminase, which has the ability to produce a toxic antimetabolic 5-fluorouracil from 5-fluorocytosine.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/00
5626846,6-May-97,1997,5,6,Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides,"The present invention relates to contraceptive vaccines based on cloned zona pellucida genes and the strategy of alloimmunization with zona pellucida polypeptides. In particular, the present invention relates to a contraceptive vaccine for use in a mammalian female comprising a polypeptide which displays at least one epitope for binding of an antibody that inhibits fertilization of an oocyte by a sperm. This epitope is from a zona pellucida protein of the species in which the said vaccine is used. This invention relates, more particularly, to such vaccines wherein the zona pellucida protein is either the ZP3 or the ZP2 or the ZP1 protein or the mouse or homologues of these proteins in some other mammalian species. Further, this invention comprehends vaccines comprising a synthetic peptide that displays an epitope for such an antibody that inhibits fertilization. In addition, this invention relates to cloned DNA segments variously encoding the mouse ZP3 or ZP2 proteins or the human ZP3 or ZP2 protein.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/28
5627047,6-May-97,1997,5,6,Astrocyte-specific transcription of human genes,"Three unique control DNA sequences of the glial fibrillary acidic (gfa) protein gene have been identified upstream of its basal promoter that are capable of regulating astrocyte-specific transcription of the human gene for glial fibrillary acidic protein (GFAP). One or more of those three regions alone or together with the SV40 early promoter and SV40 enhancer control expression of endogenous or heterologous protein in astrocytes. Transgenic animals expressing amyloid protein can be prepared and used as a model for evaluating Alzheimer's disease. Many heterologous proteins can be expressed in the astrocytes so as to take advantage of the growing list of astrocyte functions. Such proteins include hormones, growth factors, and their receptors. Examples include basic fibroblast growth factor (bFGF), acidic FGF (aFGF), platelet derived growth factor (PDGF), insulin like growth factors 1 and 2 (IGF-1, IGF-2), epidermal growth factor (EGF), transforming growth factors .beta.-1 and .beta.-2 (TGF.beta.1, TGF.beta.2), and S100.beta.; other examples totalled proteins encoded by oncogenes like myc, fos, and erb-a, ion channels, like the calcium channel and the potassium channel, and metabolic enzymes, especially ones involved in processing drugs or neurotransmitters; e.g., glutamine synthetase. Additionally, in each case, a dominant dysfunctional protein, an antisense RNA, or a ribozyme, all of which can inhibit the function or production of the protein, can be expressed in astrocytes.",37,United States of America Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/85
5629192,13-May-97,1997,5,13,ETS1 gene: a human tumor suppressor gene,"The present invention relates, in general, to methods for reducing cell tumorigenicity. More particularly, the present invention provides a method for reducing cell tumorigenicity comprising transfecting a tumor cell with an ETS1 gene, the tumor cell not endogenously expressing the ETS1 gene. In addition, the present invention provides a method for reducing cell tumorigenicity comprising contacting a tumor cell with a peptide expressed by an ETS1 gene, the tumor cell not endogenously expressing the ETSI gene. The methods of the present invention are particularly useful for reducing tumorigenicity in epithelial tumor cells.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/82
5629454,13-May-97,1997,5,13,Conformationally locked nucleoside analogues,"Conformationally locked 4',6'-cyclopropane-fused carbocyclic nucleoside analogues. The compounds are prepared by condensing a cyclopropane-fused carbocyclic allylic alcohol with substituted purine or pyrimidine bases. The condensation products are then modified to produce the adenosine, guanosine, cytidine, thymidine and uracil nucleoside analogues. The compounds are therapeutically useful as antimetabolites, or in the preparation of anti-metabolic agents.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
5631132,20-May-97,1997,5,20,Nucleic acid probes and methods for detecting Candida glabrata DNA in blood,"Provided is an isolated double-stranded nucleic acid consisting essentially of the nucleotide sequences defined in the Sequence Listing by SEQ ID NOs: 5-9. These are the ITS2 sequences for C. albicans, C. parapsilosis, C. tropicalis, C. glabrata and C. krusei. A method of diagnosing systemic candidiasis in a subject is also provided. The method comprises the steps of: (a) collecting blood from the subject into tubes containing detergent, polypropylene glycol, sodium poyantholesulfonate, and sodium ethylene diamine tetraacetic acid; (b) lysing Candida cells using ZYMOLYASE.RTM.-100T with agitation; (c) extracting and precipitating the DNA from the lysed cells; (d) amplifying the precipitated DNA using universal fungal primer pairs derived from the internal transcribed spacer regions of the Candida ribosomal DNA; and (e) detecting amplified DNA from Candida by hybridizing the amplified DNA with a probe that selectively hybridizes with Candida DNA, the presence of amplified DNA indicating systemic candidiasis.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
5632981,27-May-97,1997,5,27,"Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same","A polymeric composition capable of releasing nitric oxide under physiological conditions which includes a biopolymer, such as a peptide, polypeptide, protein, oligonucleotide or nucleic acid, to which is bound a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group; pharmaceutical compositions comprising the polymeric composition; and methods of treating biological disorders in which dosage with nitric oxide is therapeutic.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/785
5635353,3-Jun-97,1997,6,3,Nucleic acid probes and methods for detecting Candida krusei cells in blood,"Provided is an isolated double-stranded nucleic acid consisting essentially of the nucleotide sequences defined in the Sequence Listing by SEQ ID Nos:5-9. These are the ITS2 sequences for C. albicans, C. parapsilosis, C. tropicalis, C. glabrata and C. krusei. A method of diagnosing systemic candidiasis in a subject is also provided. The method comprises the steps of: (a) collecting blood from the subject into tubes containing detergent, polypropylene glycol, sodium poyantholesulfonate, and sodium ethylene diamine tetraacetic acid; (b) lysing Candida cells using ZYMOLYASE.RTM.-100T with agitation; (c) extracting and precipitating the DNA from the lysed cells; (d) amplifying the precipitated DNA using universal fungal primer pairs derived from the internal transcribed spacer regions of the Candida ribosomal DNA; and (e) detecting amplified DNA from Candida by hybridizing the amplified DNA with a probe that selectively hybridizes with Candida DNA, the presence of amplified DNA indicating systemic candidiasis.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
5635356,3-Jun-97,1997,6,3,Anti-oncoimmunin-M antibodies and uses thereof,"The present invention relates, in general, to oncoimmunins. In particular, the present invention relates to antibodies that specifically bind to a tumor-derived Oncoimmunin-myeloid (OI-M) factor that induces differentiation of myeloid cells. The invention also provides methods of detecting OI-M factors utilizing OI-M specific antibodies and immunodetection kits.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4702
5635532,3-Jun-97,1997,6,3,"Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia","Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",60,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5635533,3-Jun-97,1997,6,3,Methods for inducing differentiation of a cell using phenyacetic acid and derivatives,"Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5635599,3-Jun-97,1997,6,3,Fusion proteins comprising circularly permuted ligands,The present invention provides for circularly permuted ligands which possess specificity and binding affinity comparable to or greater than the specificity and binding affinity of the original (unpermuted) ligand. The invention further provides for novel fusion proteins comprising a circularly permuted ligand fused to one or more proteins of interest.,17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
5637323,10-Jun-97,1997,6,10,Method of mobilizing pluripotential hematopoietic stem cells with IL-7,"This invention provides a method of isolating an increased number of hematopoietic stem cells from a subject comprising a) administering interleukin-7 to the subject in an amount that mobilizes the hematopoietic stem cells to the peripheral blood; and, b) isolating a population of leukocytes enriched for hematopoietic stem cells from the peripheral blood. Also provided is a method of transplanting an increased number of hematopoietic stem cells from a donor to a recipient to enhance repopulation of the recipient's hematopoietic and immune cells comprising a) administering interleukin-7 to the donor in an amount that mobilizes the hematopoietic stem cells to the peripheral blood; b) isolating a population of leukocytes enriched for hematopoietic stem cells from the donor's peripheral blood; and, c) transplanting the isolated population of leukocytes enriched for hematopoietic stem cells to the recipient, thereby enhancing the repopulation of the recipient's hematopoietic and immune cells. Finally, the invention provides a method of improving engraftment of a bone marrow transplant or a peripheral blood leukocyte transplant from a donor to a recipient comprising administering interleukin-7 to the recipient following transplantation in an amount that enhances engraftment.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0647
5637488,10-Jun-97,1997,6,10,HIV protease gene and method for its expression,"The invention is a synthetic DNA sequence for encoding a specific enzyme or protease. The protease is essential for the completion (replication) of an infective human immunodeficiency virus (HIV). The invented gene is desirable for the expression of the protease by recombinant methodology in prokaryotic and/or eukaryotic cells and the production of a commercially desirable amount of the protease for biochemical and physical characterization, necessary to find effective inhibitor of the protease, and thereby to block the production of infectious human immunodeficiency virus (HIVs).",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/506
5639660,17-Jun-97,1997,6,17,Polypeptide and DNA sequence corresponding to the human receptor with high affinity for IgE,"A Polypeptide and DNA Sequence corresponding to the human receptor high affinity receptor for IgE as well as replicable microbial expression vehicles, transformed microorganisms, and cultures of microbial cells which produce this polypeptide.",7,Hoffmann-La Roche Inc.,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/70535
5639761,17-Jun-97,1997,6,17,Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof,"The present invention provides antimalarial pharmaceutical compositions containing antimalarial naphthylisoquinoline alkaloids or antimalarial derivatives thereof, useful new antimalarial naphthylisoquinoline alkaloid derivatives, methods for obtaining such derivatives, and methods of using such antimalarial compounds for the prevention of malaria infections in mammals and for treating mammals with malarial infections. The antimalarial compounds of the present invention inhibit the reproduction and cytopathicity of Plasmodium sp. parasites in vitro and in vivo.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/47
5639906,17-Jun-97,1997,6,17,Fluorescent and NMR sensitive pH indicators,"This invention relates to compositions and methods useful for measuring pH generally, and intracellular pH specifically, and, more particularly, to a new class of fluorescent and fluorinated (NMR sensitive) aromatic compounds having excitation emission wavelengths in the ultraviolet or or visible portions of the electromagnetic spectrum, useful as pH indicators, as well as fluorine containing analogs useful in NMR spectroscopic determinations.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07C/76
5641487,24-Jun-97,1997,6,24,Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides,"The present invention relates to contraceptive vaccines based on cloned zona pellucida genes and the strategy of alloimmunization with zona pellucida polypeptides. In particular, the present invention relates to a contraceptive vaccine for use in a mammalian female comprising a polypeptide which displays at least one epitope for binding of an antibody that inhibits fertilization of an oocyte by a sperm. This epitope is from a zona pellucida protein of the species in which the said vaccine is used. This invention relates, more particularly, to such vaccines wherein the zona pellucida protein is the ZP3 protein or the mouse or homologues of the protein in some other mammalian species. Further, this invention comprehends vaccines comprising a synthetic peptide that displays an epitope for such an antibody that inhibits fertilization. In addition, this invention relates to cloned DNA segments variously encoding the mouse ZP3 protein or the human ZP3 protein.",6,The Government of the United States of America as represented by the Secretary Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/28
5641500,24-Jun-97,1997,6,24,Use of purinergic receptor agonists as antineoplastic agents,"The instant invention is directed to the use of a pharmaceutical composition containing an effective amount of adenosine or an adenosine analog or derivative as an agent useful in the treatment of hormone-independent cancers, such as prostate cancer. The invention is also directed to diagnostic uses of these compounds to determine effective treatment regimes for specific tumors, a process for screening for new, therapeutically useful analogs of these compounds, and the use of these compounds in facilitating the extraction of intracellular components.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/70
5643786,1-Jul-97,1997,7,1,Method for isolating dendritic cells,A method of isolating dendritic cells is described. This method involves elutriating peripheral blood samples in at least four flow rates from an elutriation rotor. Calcium ionophore is used to stimulate monocytes isolated during the process into dendritic cells. Treatments for diseases involving re-introduction of activated dentritic cells are also described.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/15
5643876,1-Jul-97,1997,7,1,Biologically active synthetic magainin peptides,"A class of broad spectrum bioactive polypeptides termed ""Magainin"" have been described. These peptides have a molecular weight of about 2500 or less, are highly water soluble, amphiphilic and non-hemolytic.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/46
5643892,1-Jul-97,1997,7,1,Method of treating chronic progressive vascular diseases,"A method of treating a mammalian patient suffering from a chronic progressive vascular disease (CPVD) characterized by scarring and/or fibrosis to halt the progress of the disease and cause resolution of already-formed scarring or fibrotic lesions. The method consists of the administration to the patient of a pharmaceutical composition containing an effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof. The oral route of administration is preferred, with total daily dosage of PPS or PPS salt ranging from about 50 to 1200 mg per day.",14,"Baker Norton Pharmaceuticals, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/737
5644031,1-Jul-97,1997,7,1,Delta-like gene expressed in neuroendocrine tumors,"A polynucleotide molecule dlk is expressed in neuroendocrine tumors, including small cell lung carcinoma. A Dlk polypeptide encoded by dlk polynucleotide molecule can be used in detecting the existence of a primary or secondary neuroendocrine tumor. Monoclonal antibodies are produced against Dlk which are useful for detection and therapy of a neuroendocrine tumor.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
5644047,1-Jul-97,1997,7,1,Compositions for diagnosing rochalimaea henselae and rochalimaea quintana infection,A method of diagnosing cat scratch disease and a method of diagnosing bacillary angiomatosis in a subject by detecting the presence of Rochalimaea henselae or an immunogenically specific determinant thereof in the subject is provided. Also provided is a vaccine comprising an immunogenic amount of a nonpathogenic Rochalimaea henselae or an immunogenically specific determinant thereof and a pharmaceutically acceptable carrier. A method of diagnosing Rochalimaea quintana infection in a subject by detecting the presence of a nucleic acid specific to Rochalimaea quintana in a sample from the subject is provided. A purified heat shock protein of Rochalimaea is provided.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/0233
5645988,8-Jul-97,1997,7,8,Methods of identifying drugs with selective effects against cancer cells,"The present invention involves a method of identifying drugs which selectively inhibit the growth of particular cancer cells, which method comprises: (a) contacting with the drug at least two cancer cells derived from the same type of biological material, wherein the cancer cells differ as to the presence of a particular DNA sequence, (b) measuring the effect of the drug on the growth of the cancer cells, and (c) determining whether there is a correlation between the effect of the drug on the cancer cells and the presence or absence of the DNA sequence in the cancer cells. The present invention further involves the use of such drugs.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/335
5645992,8-Jul-97,1997,7,8,Nucleic acid sequences and methods for detecting candida tropicalis in blood,"Provided is an isolated double-stranded nucleic acid consisting essentially of the nucleotide sequences defined in the Sequence Listing by SEQ ID Nos: 5-9. These are the ITS2 sequences for C. albicans, C. parapsilosis, C. tropicalis, C. glabrata and C. krusei. A method of diagnosing systemic candidiasis in a subject is also provided. The method comprises the steps of: (a) collecting blood from the subject into tubes containing detergent, polypropylene glycol, sodium poyantholesulfonate, and sodium ethylene diamine tetraacetic acid; (b) lysing Candida cells using ZYMOLYASE.RTM.-100T with agitation; (c) extracting and precipitating the DNA from the lysed cells; (d) amplifying the precipitated DNA using universal fungal primer pairs derived from the internal transcribed spacer regions of the Candida ribosomal DNA; and (e) detecting amplified DNA from Candida by hybridizing the amplified DNA with a probe that selectively hybridizes with Candida DNA, the presence of amplified DNA indicating systemic candidiasis.",9,The United States of America As Represented By The Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
5646033,8-Jul-97,1997,7,8,African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines,A novel African Green Monkey Kidney (AGMK) cell line is taught as well as a method for the preparation thereof. The cell line which is free of viable adventitious microbial agents is useful as a substrate for viruses and for the preparation of viral vaccines.,1,Dyncorp,National Institutes of Health,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
5646249,8-Jul-97,1997,7,8,Isolation and characterization of a novel chaperone protein,"This invention relates to the identification and molecular characterization of the human and rat STCH chaperone protein including the corresponding gene sequence, gene fragments and protein fragments. The invention also relates antibodies to STCH and to assays to detect the presence of STCH genes, transcripts and protein in a sample.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5648273,15-Jul-97,1997,7,15,Hepatic growth factor receptor is the MET proto-oncogene,"The present invention relates to a complex comprising hepatocyte growth factor (HGF) and met proto-oncogene protein. The present invention also relates to methods for detecting the presence of HGF ligand, met proto-oncogene receptor and methods for isolating either the ligand or receptor or complex comprising both. The present invention further relates to methods of diagnostic proliferative disorders and diseases such as hepatitis or hepatocarcinogenesis by detecting these ligand-receptor pairs.",2,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,G01N/6872
5650285,22-Jul-97,1997,7,22,Human CRIPTO-related gene and method of measuring CR-3,"The present invention relates, in general, to a human CRIPTO-related gene. In particular, the present invention relates to a DNA segment encoding a human CRIPTO-related gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a human CRIPTO-related polypeptide; a DNA segment encoding a genomic clone of the human CRIPTO gene (CR-1); antibodies specific to CR-3; and a method of measuring the amount of CR-3 in a sample.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5650441,22-Jul-97,1997,7,22,Method of assaying CD4 glycoproteins by using certain azo dyes,Antiviral compositions useful for the inhibition of HIV include various azo dye compounds which have the ability of inhibiting the binding of HIV rgp120 to CD4 cells on peripheral blood lymphocytes and affecting HIV replication. Also disclosed are methods for treating HIV viral infections with these compositions.,21,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/655
5650442,22-Jul-97,1997,7,22,Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers,"The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
5650447,22-Jul-97,1997,7,22,Nitric oxide-releasing polymers to treat restenosis and related disorders,"Methods of amelioration, treatment and prevention for restenosis and related disorders are provided. Methods involve the administration of nitric oxide by a nitric oxide delivery means comprising a restenosis-ameliorating or therapeutically/prophylactically effective amount of either a polymer to which is bound a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group a compound comprising a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group. Also provided are nitric oxide delivery means comprising such nitric oxide-releasing polymers or compounds for use in such methods. Preferably, the delivery means is coated with a nitric oxide-releasing polymer, which may be biodegradable, and enables the controllable and predictable release of NO to a given site in such a manner that effective ameliorating, prophylactic or therapeutic dosing is realized.",42,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Comedicus, Incorporated",,,,,,,,,,2,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
5650550,22-Jul-97,1997,7,22,Mutant mice having a deficit of functional estrogen receptors,"The present invention provides a mutant non-human vertebrate, in which all or some of the germ and somatic cells contain a mutation in at least one steroid hormone receptor allele, which mutation is introduced into the vertebrate, or an ancestor of the vertebrate, at an embryonic stage, and which mutation produces a phenotype in the vertebrate characterized by a deficit of functional steroid hormone receptors encoded by the allele. Also disclosed are related methods and constructs.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Other special machines,,,,,C12N/8509
5650627,22-Jul-97,1997,7,22,Sensitive assay method for measuring gallium levels in body tissues and fluids,"A sensitive assay method for measuring the quantity of elemental gallium present in a test sample comprising a body tissue or a body fluid, the method comprising: PA1 diluting a test sample with nitric acid, PA1 introducing the diluted test sample into an atomic absorption spectrometer having a Zeeman-effect background correction calculating capability, PA1 determining the test sample's absorption at a desired wavelength while subjecting the test sample to an atomization and a burning in the atomic absorption spectrometer, PA1 performing a Zeeman-effect background correction on the determined absorption for the test sample to give a corrected absorption for the test sample, and PA1 comparing the corrected absorption for the test sample with a standard curve.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Measurement,,,,,G01N/52
5652106,29-Jul-97,1997,7,29,Rapid amplification-based subtyping of mycobacterium tuberculosis,"The present invention provides methods of detecting or distinguishing the DNA of an individual strain of Mycobacterium tuberculosis utilizing the polymerase chain reaction (PCR). Reproducible, unique patterns can be produced allowing the identification of unknown M. tuberculosis DNA by performing this reaction and comparing the pattern produced to the known reproducible, unique patterns. The invention further provides a kit useful to detect or distinguish the DNA of an individual strain of M. tuberculosis in a sample, comprising specific primers for use in PCR. The present invention also provides a method of determining the presence of a multidrug-resistant M. tuberculosis by detecting the presence of a specific arrangement of genomic DNA. Such detection can be done using PCR or a ligase chain reaction (LCR). The present invention provides nucleic acid sequences useful in detecting multidrug-resistant M. tuberculosis.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
5652133,29-Jul-97,1997,7,29,Cloning and expression of the human macrophage inflammatory protein-1.alpha . .alpha.) /rantes receptor,This invention provides for the cloning and expression of the human Macrophage Inflammatory Protein-1.alpha. (MIP-1.alpha.)/RANTES Receptor. This receptor binds two cytokines MIP-1.alpha. and RANTES which are pro-inflammatory cytokines. The receptor is useful for assaying the levels of these cytokines in biological specimens. These cytokines play key roles in the inflammatory processes afflicting man.,12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/715
5652223,29-Jul-97,1997,7,29,DNA encoding CAI resistance proteins and uses thereof,This invention provides for nucleotide sequences that encode CAIR proteins correlated with cellular resistance to carboxyamido-triazole (CAI) and functionally equivalent compounds. The invention further provides for methods of detecting CAI resistance in biological samples and for cell lines that grow and proliferate in the presence of CAI and functionally equivalent compounds.,5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
5652338,29-Jul-97,1997,7,29,Neutrophil chemotactic factor,"An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/5421
5654138,5-Aug-97,1997,8,5,Von hippel-lindau (VHL) disease gene and corresponding cDNA and methods for detecting carriers of the VHL disease gene,The invention is the Yon Hippel-Lindau (VHL) disease gene and its corresponding cDNA. Methods for detecting carriers of the VHL disease gene using probes derived from the cDNAs are described.,27,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
5654139,5-Aug-97,1997,8,5,Allelic variation of the serotonin 5HT.sub.2c receptor,"We describe identification of a non-conservative amino acid substitution in the 5-HT.sub.2C receptor gene. The variant was found using single strand conformational polymorphism (SSCP) analysis. By typing this polymorphism in CEPH families, the gene was genetically mapped on the long arm of the X chromosome. Since this polymorphism was not detectable as a conventional RFLP, we also developed a PCR-RFLP based method which allows rapid genotyping in populations and families.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
5654140,5-Aug-97,1997,8,5,Cloned human cripto gene and applications thereof,"A new human gene designated as ""CRIPTO"" gene has been identified and cloned. CRIPTO gene products and derivatives thereof have been obtained and various utilities of the same have been described. Association of CRIPTO gene with cancers, such as colorectal cancer and breast carcinoma, has been indicated.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/18
5654187,5-Aug-97,1997,8,5,MDR1 retroviral plasmid,"Existing plasmids, such as pHaMDR/A (available from NIH) are large and cumbersome. The size may limit the known utility of MDR1 as an effective selectable marker in gene transfer experiments. The invention provides novel plasmids including heterologous promoters and cDNA sequences positioned between the retroviral LTRs.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5654333,5-Aug-97,1997,8,5,Methods for prevention of cancer using phenylacetic acids and derivatives thereof,"Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5654405,5-Aug-97,1997,8,5,Antbodies to human kerctinocyte growth factor (KGF) and related pharmaceuticals,"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6876
5654406,5-Aug-97,1997,8,5,Antibody to ERBB2 promoter binding factor,"The present invention provides a purified and isolated DNA-binding protein, HPBF, which specifically binds to the promoter region of the Her-2/neu (ERBB2/c-erbB-2) gene sequence, the presence of which provides an early indication of transition to a cancerous state has been found. The present invention also provides bioassays for screening substances for the ability to inhibit HPBF activity, the ability to inhibit the mitogenic activity of HPBF and the ability to inhibit HPBF production. The present invention further provides methods of inhibiting the biological activity mediated by HPBF comprising preventing the HPBF from binding to the promoter region of the ERBB2 gene sequence.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4705
5654432,5-Aug-97,1997,8,5,Process of preparing michellamine compounds,"The present invention provides new antiviral compounds, i.e., michellamines and derivatives and pharmacologically acceptable salts thereof, methods for isolating such antiviral compounds from a plant species of the genus Ancistrocladus, antiviral compositions containing such antiviral compounds, and methods of using such antiviral compounds for treating patients with viral infections. The antiviral compounds of the present invention inhibit the reproduction and cytopathicity of human acquired immunodeficiency viruses.",5,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
5656587,12-Aug-97,1997,8,12,Promotion of cell proliferation by use of transforming growth factor beta (TGF-.beta.),A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-.beta. which is activated by either a TGF-.alpha. or an EGF or both; and methods for administration. As another embodiment these active ingredients can be admixed with other (secondary) growth factors.,6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/495
5656625,12-Aug-97,1997,8,12,Nitrogen-containing cyclohetero cycloheteroaminoaryl derivatives for CNS disorders,"Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower alkyl, benzyl, and haloloweralkyl; wherein each of R.sup.2, R.sup.3 and R.sup.8 through R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is an integer of from four to six; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.",29,The United States of America as represented by the Department of Health and Human Services,Brown University Research Foundation,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/06
5656737,12-Aug-97,1997,8,12,DNA encoding macrophage migration inhibition factor from ocular lens,"Macrophage Migration Inhibition Factor (MIF) can be obtained from ocular lens of various birds and mammals. The amino acid sequences of lens MIF from mice, chickens and humans has been determined and the corresponding cDNA has been cloned.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/52
5657758,19-Aug-97,1997,8,19,Method and system for multidimensional localization and for rapid magnetic resonance spectroscopic imaging,"A method and system for providing prelocalization of a volume of interest and for rapidly acquiring a data set for generating spectroscopic images. Spatial prelocalization of a volume of interest is achieved by providing a presuppression sequence before a stimulated echo (STE) sequence and a suppression sequence during the mixing time (TM) interval of the STE sequence. The presuppression sequence includes a spatial suppression sequence to selectively saturate slices that intersect the plane selected by the STE sequence in order to define a boundary for the volume of interest, and this spatial suppression sequence is substantially repeated during the TM interval of the STE sequence. Spectroscopic imaging data is acquired by an oversampled echo planar spatial-spectral imaging sequence in which the gradient reversal frequency is a integer factor of n greater than the gradient reversal frequency required to sample the spectral width. Each RF pulse of the STE sequence excites spins in substantially the same plane, and an adaptation of this STE sequence provides for acquiring multiple echoes at different effective echo times without compromising spatial localization of the different echoes.",16,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/4833
5658146,19-Aug-97,1997,8,19,Dental implant,"A device for securing a dental prothesis to a base implanted into body tissue of a patient has a stud which is secured to the base and has a cylindrical body and a threaded free end. A tubular spacer surrounds the stud, is supported on the base, and terminates short of the free stud end. A tubular cup is supported on the spacer and has a through hole defining a first hole section of a first diameter about equal to an inner diameter of the tubular spacer and a second hole section of a diameter larger than the inner diameter of the tubular spacer. An annular ledge is positioned between the first and second hole sections, extends radially inwardly to proximate the threaded free end of the stud, and defines a bearing surface facing away from the tubular space. A retaining nut is threaded onto the threaded free end of the stud and has an under side in engagement with the bearing surface which, upon tightening of the nut on the stud, firmly presses the cup against the tubular spacer. The nut can be turned relative to the stud to increase the force with which the cup and the spacer are pressed against the base. The nut and the bearing surface and/or the threaded free end of the stud are constructed to inhibit relative rotation of the nut, and a resulting loosening of the dental prosthesis on the base, by increasing friction between them.",27,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61C/0048
5658744,19-Aug-97,1997,8,19,Methods of identifying patients having an altered immune status,"Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM). In addition, the ratio of a TH-1-type BRM to a TH-2-type BRM, the ratio of cytoplasmic to nuclear levels of polynucleotide binding proteins, the pattern of protein binding to an oligonucleotide probe that comprises the protein binding region of a gene for a BRM, or the pattern of distribution of T lymphocytes in a density gradient following density gradient centrifugation are also suitable as an immune status index. The methods are useful in identifying patients exhibiting immunosuppression, hyperimmunity and autoimmunity, as well as in assessing the immune status of a patient undergoing organ transplant.",2,The United States of America as represented by the Department of Health and Human Services,Biomira USA Inc.,,,,,,,,,,2,Analysis of biological materials,Computer technology,,,,,G01N/68
5658792,19-Aug-97,1997,8,19,Antiproliferative protein,"The subject invention relates to a novel mammalian antiproliferative protein, prohibitin, and uses thereof. For example, prohibitin may be utilized in the treatment of diseases involving excess cellular replication, such as cancer, or in the treatment of conditions involving an insufficient amount of cellular replication, such as impaired tissue regeneration.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4703
5660812,26-Aug-97,1997,8,26,Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system,"The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.",1,"Exponential Biotherapies, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
5661179,26-Aug-97,1997,8,26,Methods for treating neoplastic conditions using phenylacetic acid and derivatives thereof,"Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5663066,2-Sep-97,1997,9,2,Assay using recombinant histidyl-tRNA synthetase,"Recombinant Histidyl tRNA synthetase produced by non-mammalian host cells is used in a sensitive assay to determine the presence of autoimmune diseases in mammals. Methods for isolating, cloning and expressing rHRS are described. In addition, a kit for determining the presence of an autoimmune disease is provided.",2,The United States of America as represented by the Department of Health and Human Services,National Institutes of Health,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12N/93
5663167,2-Sep-97,1997,9,2,Antipsychotic composition and method of treatment,A method for treating a serious psychotic mental illness includes the step of administering to a patient in need of such treatment a combination of (i) an .alpha..sub.2 -adrenergic receptor antagonist and (ii) a D.sub.2 dopamine receptor antagonist. A pharmaceutical composition useful in the novel method includes an effective amount of the combination of the foregoing two ingredients together with a pharmaceutically acceptable carrier.,15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/415
5665345,9-Sep-97,1997,9,9,Methods of inhibiting viral replication using IL-10,"The present invention provides a method of inhibiting the replication of human immunodeficiency virus in cells which are infected with HIV comprising administering to the cells a replication inhibiting amount of interleukin-10. Also provided is a parenteral method of the administration of interleukin-10 administration. Further provided is a method of inhibiting retroviral replication in a human subject infected by a retrovirus, comprising administering to the subject an inhibiting amount of interleukin-10, including the retrovirus is. Finally, a method of treating Kaposi's sarcoma in a human subject comprising administering to the subject an effective amount of interleukin-10 to the subject is provided.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2066
5665589,9-Sep-97,1997,9,9,Human liver epithelial cell lines,Immortalized cell lines derived from normal adult human liver are described which express phenotypic characteristics of normal adult liver epithelial cells.,15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5014
5665870,9-Sep-97,1997,9,9,Method of purifying keratinocyte growth factor (KGF),"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6876
5668149,16-Sep-97,1997,9,16,Inhibition of human immunodeficiency virus-1 infectivity in human cells,"Methods are disclosed for inhibiting the infectivity of HIV-1 in human cells. The methods comprise contacting human cells infected with HIV-1, with certain quinolinyl and acridinyl derivatives, including amodiaquin, chloroquine, hydroxychloroquine, primoquine, quinacrine and compounds having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each hydrogen, or join to form a cyclic structure of the formula: ##STR2## and R.sup.3 and R.sup.4, same or different, are hydrogen, C.sub.1 -C.sub.8 lower alkyl or hydroxy substituted C.sub.1 -C.sub.8 lower alkyl, and the pharmaceutically acceptable salts thereof.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/47
5668285,16-Sep-97,1997,9,16,"Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates","The invention involves a method of making key intermediates useful in the synthesis of many opiate narcotics and antagonists and agonists; and the non-opiate enantiomers thereof which have potent antitussive properties. The synthesis starts from either the natural or unnatural enantiomer of nordihydrocodeinone and produces 8, 14-dihydronorthebaine, the diketal of 7-bromonordihydrocodeinone, northebaine, norcodeinone diketal and 14-hydroxynorcodeinone intermediates without the necessity of leaving the N-nor structure. The syntheses have fewer steps than previous methods, and also have high yields.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5670310,23-Sep-97,1997,9,23,Methods and compositions for differential diagnosis of acute and chronic hepatitis c virus infection,"The present invention provides antigenic peptides which bind anti-HCV antibodies for the differential diagnosis of acute and chronic HCV infection. The invention further provides a method of differentiating acute and chronic hepatitis C virus infection in a subject comprising: a) contacting an antibody-containing sample from the subject with one or more of the peptides selected from the group consisting of peptide 59, comprising the amino acids AFASRGNHVSPTHYVPESDA (SEQ ID NO:1), peptide 137, comprising the amino acids MNRLIAFASRGNHVSPTHYV (SEQ ID NO:2) and peptide 138, comprising the amino acids SRGNHVSPTHYVPESDAAAR (SEQ ID NO:3) under conditions that permit binding between the peptide and the antibodies; b) detecting the presence of binding between the peptide and the antibodies; c) contacting the antibody-containing sample from the subject with an amount of peptide 139, comprising the amino acids NHVSPTHYVPESDAAARVTA (SEQ ID NO:4) under conditions that permit binding between the peptide and the antibodies; d) detecting the presence of binding between the peptide and the antibodies; and comparing the strength of the antibody binding of step b) with the strength of the antibody binding of step d), a stronger binding in step b) as compared to the binding in step d) indicating acute hepatitis C virus infection and an equivalent binding in both steps b) and d) indicating chronic hepatitis C virus infection. The present invention further provides a method of diagnosing a hepatitis C virus infection in a subject comprising contacting an antibody containing sample from the subject with a peptide comprising the amino acids SPTHYV (SEQ ID NO:5) and determining the presence of binding between the peptide and the antibodies from the sample, the presence of binding between the peptide and the antibodies indicating a hepatitis C virus infection.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5671754,30-Sep-97,1997,9,30,Viral-proofing a protective barrier,"A method of preventing charged particles from passing through holes in a barrier material which involves surface treating a barrier material with an ionic surfactant to impart a charge to the barrier material. In a preferred embodiment, prophylactics such as condoms and surgical gloves can be treated with an anionic surfactant. Tests have confirmed that such surface treated articles can repel virus particles such as human immunodeficiency (HIV) virus, hepatitis B virus and herpes simplex virus (HSV). Ionic surfactant treated articles include prophylactics such as condoms and diaphragms, gloves, including surgical gloves, surgical masks, respiratory masks and filters, filters, including membrane, and wound dressings, including bandages.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61F/04
5672354,30-Sep-97,1997,9,30,Treated bird seed preferentially palatable to birds but not palatable to animals having capsaicin sensitive receptors,"The present invention is directed to preparations of birdseed treated with capsaicin or capsaicin derivatives or analogues thereof in an amount sufficient to be unpalatable to animals having capsaicin sensitive receptors, and more specifically to mammals such as rodents. These ""hot"" compounds, extracts or whole plant material containing these compounds may be coated on, impregnated in or combined (e.g., mixed) with birdseed to repel troublesome mammals which recognize these compounds as ""hot"". These ""hot"" compounds, in contrast, will not repel birds because birds do not recognize these compounds as ""hot"" since they do not have capsaicin sensitive receptors. The invention is further directed to a method of selectively repelling animals having capsaicin sensitive receptors, which comprises feeding the treated birdseed of the invention to birds, in an amount effective for repelling animals having capsaicin sensitive receptors, thereby discouraging said animals from eating the treated birdseed.",16,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Food chemistry,,,,,,A23K/70
5672488,30-Sep-97,1997,9,30,Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides,"The present invention relates to contraceptive vaccines based on cloned zona pellucida genes and the strategy of alloimmunization with zona pellucida polypeptides. In particular, the present invention relates to a contraceptive vaccine for use in a mammalian female comprising a polypeptide which displays at least one epitope for binding of an antibody that inhibits fertilization of an oocyte by a sperm. This epitope is from a zona pellucida protein of the species in which the said vaccine is used. This invention relates, more particularly, to such vaccines wherein the zona pellucida protein is either the ZP3 or the ZP2 or the ZP1 protein or the mouse or homologues of these proteins in some other mammalian species. Further, this invention comprehends vaccines comprising a synthetic peptide that displays an epitope for such an antibody that inhibits fertilization. In addition, this invention relates to cloned DNA segments variously encoding the mouse ZP3 or ZP2 proteins or the human ZP3 or ZP2 protein.",6,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/28
5672510,30-Sep-97,1997,9,30,Retroviral vectors,"A retroviral vector including a multiple cloning site having no greater than about 70 base pairs, and which includes at least four different enzyme restriction sites, wherein at least two of the sites have an average frequency of appearance in eukaryotic genes of less than one in 10,000 base pairs. Such vector may be employed in conjunction with a shuttle cloning vector having complementary cloning sites to accomplish transfers of genes and/or promoters between the shuttle cloning vector and the retroviral vector. Such a system provides for efficient transfer of genes and/or promoters to a retroviral vector without necessitating reconstruction of the entire retroviral vector. Also contemplated within the scope of the present invention is a retroviral vector having a 3' LTR wherein at least the promoter sequence of the 3' LTR is mutated such that the promoter sequence becomes nonfunctional.",27,"Genetic Therapy, Inc.",The United States of America as represented by the Secretary Deptartment of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
5672593,30-Sep-97,1997,9,30,Bistriazenes as chemotherapeutic agents,"The present invention is directed to bistriazene compounds, pharmaceutical compositions containing effective anti-cancer amounts of these compounds, a method for treating cancer comprising administering to affected subjects an anti-cancer effective amount of a bistriazene compound, and the use of bistriazene compounds as crosslinking reagents applicable to the synthesis and manipulation of polymeric macromolecules.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07C/24
5672607,30-Sep-97,1997,9,30,"Antiviral naphthoquinone compounds, compositions and uses thereof","The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/92
5674492,7-Oct-97,1997,10,7,Method of preventing or treating disease characterized by neoplastic cells expressing CD40,"There is disclosed a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40, in individuals at risk for such disease.",18,Immunex Corporation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/28
5674705,7-Oct-97,1997,10,7,Productive of human T-cell leukemia (lymphotropic) retrovirus (HTLV-1) envelope protein fragments in bacteria and use in seroepidemiological studies,Antigenic proteins may be expressed in bacteria by use of vectors having inserted therein DNA fragments from an envelope gene. The DNA fragments employed in the example are coding sequences found in the HTLV-I envelope gene. The bacteria used was E. coli. The antigenic proteins are useful in identifying antibodies to the organisms from which the DNA fragments were originally obtained.,28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5674835,7-Oct-97,1997,10,7,Papillomaviral expression inhibitors,"A method of inhibiting the growth of a virus, the DNA of the virus including the nucleic acid sequence 5' ACCXNNNPyCGGTXY3', wherein each N, X, and Y is, independently, any nucleotide, and Py is C or T, the nucleic acid sequence being capable of binding to a protein encoded by the DNA of the virus, the protein, upon binding to the nucleic acid sequence, being capable of causing the enhancement of the transcription of DNA of the virus, the method including inhibiting the protein from binding to the nucleic acid sequence to repress the transcription of DNA of said virus to inhibit the growth of the virus.",11,"New England Medical Center Hospitals, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/70
5674902,7-Oct-97,1997,10,7,Method of inhibiting hyperplasia to a mammal in need thereof,"The present invention relates to a method of inhibiting a protein kinase C-mediated biological response, such as, hyperplasia. The method comprises administering to a mammal a non-tumor promoting 12-deoxyphorbol ester. Phorbol esters suitable for use in the method include 12-deoxyphorbol 13-monoesters wherein the ester is a formate, acetate, propionate, butyrate, pentanoate, hexanoate, benzoate or phenylacetate ester.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/216
5674983,7-Oct-97,1997,10,7,Natural human chorionic gonadotropin .beta.-core molecule,"The present invention relates to the purification of the human chorionic gonadotropin .beta.-core molecule which can then be used as the antigen in the preparation of antibodies to the .beta.-core molecule. The combination of the purified .beta.-core molecule and the antibodies can be used in an immunoassay kit to measure .beta.-core molecules in the presence of structurally similar molecules, i.e., hCG, LH, hCG.beta.-subunit and LH.beta.-subunit. Measurement of the .beta.-core molecule is particularly useful in testing for pregnancy and many malignancies.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/26
5676963,14-Oct-97,1997,10,14,"Implants, prostheses, and stents comprising polymer-bound nitric oxide/nucleophile adducts capable of releasing nitric oxide","Implants, prostheses, and stents comprising a polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
5677274,14-Oct-97,1997,10,14,Anthrax toxin fusion proteins and related methods,"The present invention provides a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native anthrax PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided. A composition comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety is further provided. A method for delivering an activity to a cell is provided. The steps of the method include a) administering to the cell a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain, and b) administering to the cell a product comprising the PA binding domain of the native LF protein and a non-LF activity inducing moiety, whereby the product administered in step b) is internalized into the cell and performs the activity within the cell. The invention also provides proteins including an anthrax protective antigen which has been mutated to replace the trypsin cleavage site with residues recognized specifically by the HIV-1 protease.",12,The Government of the United States as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5677275,14-Oct-97,1997,10,14,Treatment of cancer with human chorionic gonadotropin,"Methods useful for treating cancers are disclosed. The methods involve administering human chorionic gonadotropin (hCG) or human luteinizing hormone (hLH) to patients having cancers. Articles of manufacture that are useful for carrying out the described methods are also described. The claimed methods are effective against breast, prostate, ovary, and stomach carcinomas, as well as neuroblastomas, and Kaposi's sarcoma, among others.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/24
5678548,21-Oct-97,1997,10,21,System and method for performing in vivo imaging and oxymetry and FT microscopy by pulsed radiofrequency electron paramagnetic resonance,"A system for performing pulsed RF FT EPR spectroscopy and imaging includes an ultra-fast excitation subsystem and an ultra-fast data acquisition subsystem. Additionally, method for measuring and imaging in vivo oxygen and free radicals or for performing RF FT EPR spectroscopy utilizes short RF excitations pulses and ultra-fast sampling, digitizing, and summing steps.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/60
5678550,21-Oct-97,1997,10,21,Apparatus and method for in situ detection of areas of cardiac electrical activity,"An apparatus and method for detecting electrical activity in areas of tissue. The apparatus (1) includes a main catheter (5), multifibered endoscope (10), light filtering means (30, 42, 52), photodetectors (40, 50) and a signal processor (60). The apparatus is used to detect electrical activity by first infusing both an electrically sensitive dye and an electrically insensitive reference dye into the subject tissue and then detecting the intensity of light emitted from both dyes. The wavelength of light emitted from each dye is different. The intensity of light emitted from each dye is similar for non-electrically active tissue and moving tissue but different for electrically active tissue. The intensity of light from the two dyes as separately recorded by the photodetectors is compared by a signal processor to eliminate noise attributable to movement within the area of tissue and arrive at a accurate calculation of electrical activity within the area of tissue.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/0084
5679673,21-Oct-97,1997,10,21,Aralkyl bridged diazabicycloalkane derivatives for CNS disorders,"Certain aralkyl diazabicycloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R, R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower-alkyl, benzyl, and haloloweralkyl; wherein each of R.sup.2, R.sup.3 and R.sup.10 through R.sup.13 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein each of R.sup.8 and R.sup.9 is selected from hydrido, loweralkyl, benzyl and haloloweralkyl; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothiophenyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.",21,"The United States of America, represented by the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/08
5679679,21-Oct-97,1997,10,21,Aralkyl diazabicycloalkane derivatives for CNS disorders,"Certain aralkyl diazabicyloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein: each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from the group consisting of hydrido, loweralkyl, benzyl and haloloweralkyl; PA1 each of R.sup.2, R.sup.3, and R.sup.8 through R.sup.11 is independently selected from the group consisting of hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; PA1 n is an integer of from three to four; PA1 m is an integer of two; PA1 A is selected from the group consisting of phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl and wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from the group consisting of hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; PA0 or a pharmaceutically acceptable salt thereof.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
5681832,28-Oct-97,1997,10,28,"Aroylaniline compounds, pharmaceutical compositions, and methods of using same to inhibit viral activity","Aroylaniline compounds which exhibit anti-retroviral activity, pharmaceutical compositions containing such aroylaniline compounds, and methods for treating a retroviral-infected host comprising administering an antiviral effective amount of an aroylaniline compound to a host.",31,The United States of America as represented by the Department of Health and Human Services,Georgia Tech Research Corporation,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/38
5683668,4-Nov-97,1997,11,4,Method of generating nitric oxide gas using nitric oxide complexes,"The present invention provides a method for the generation of NO gas by exposing zwitterionic polyamine-nitric oxide adducts of the formula RNN(O)NO.sup.- !(CH.sub.2).sub.x NH.sub.2.sup.+ R', wherein R=C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 aminoalkyl, or cyclohexy, R'=hydrogen or C.sub.1 -C.sub.6 alkyl, and x=2-6, to suitable conditions to effect the release of NO, such as by contact with a mildly acidic solvent or water of neutral or slightly alkaline pH.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Materials, metallurgy",,,,,,C01B/24
5683902,4-Nov-97,1997,11,4,Human papilloma virus inhibition by a hairpin ribozyme,"Synthetic catalytic RNAs, i.e. ribozyme, including a hairpin portion, binding sites for binding to a human papilloma virus after viral base 419 and 434, respectively, and cleavage sites for cleaving the virus at the binding sites have been constructed.",8,Northern Illinois University,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/1131
5685305,11-Nov-97,1997,11,11,Method and system for MRI detection of abnormal blood flow,"A magnetic resonance imaging system and method for detecting blood flow abnormalities according to the time delay for the arrival of a bolus of a MR contrast agent into localized regions as observed in a temporal series magnetic resonance signals or images obtained subsequent to bolus injection. A rapid series of imaging pulse sequences acquires the time development of the signal from localized regions within the imaged field of view of a body. During the imaging period, a bolus of a MR contrast agent is injected into the cardiovascular system of the body. As the MR contrast material circulates through the imaged region, the associated field gradient which extends into the surrounding tissue results in signal losses in the acquired signal from these regions. The arrival time for the bolus into a given localized region is determined from the acquired time data, and the relative arrival time among regions in the imaged field of view indicates whether there is decreased blood flow to certain areas.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Medical technology,,,,,G01R/56366
5687714,18-Nov-97,1997,11,18,Self-cleaning endotracheal tube apparatus,"An endotracheal tube apparatus (10) which can efficiently impart air to the lungs of a human or animal while preventing the harmful build up of mucus deposits on critical parts of the apparatus. This endotracheal tube apparatus features an endotracheal tube (12) and a catheter (14) which are together inserted into the trachea (16) of a human or animal to a point slightly above the carina (28) of the lungs. Humidified air entrained with water or saline droplets from reservoir (56) is pumped into and through the catheter. The catheter features a reverse thrust catheter (RTC) tip (60, 62, 64, 80) at its distal end (24) which reverses the direction of humidified air flow away from the lungs. The RTC tip serves to protect the lungs from accumulation of water or saline droplets while the water or saline droplets continually clean both the catheter and endotracheal tube by dissolving and expelling any mucus which might otherwise accumulate.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/0463
5688501,18-Nov-97,1997,11,18,Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system,"The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.",16,"Exponential Biotherapies, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
5688774,18-Nov-97,1997,11,18,A.sub.3 adenosine receptor agonists,"The present invention provides A.sub.3 selective agonists, particularly, adenine compounds having selected substituents at the 2, 6, and 9 positions, and related substituted compounds, particularly those containing substituents on the benzyl and/or uronamide groups, as well as pharmaceutical compositions containing such compounds. The present invention also provides a method of selectively activating an A.sub.3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A.sub.3 adenosine receptor a therapeutically or prophylactically effective amount of a compound which binds with the A.sub.3 receptor so as to stimulate an A.sub.3 receptor-dependent response.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
5688992,18-Nov-97,1997,11,18,"O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof","The present invention relates to non-phosphorus containing O-malonyltryrosyl compounds, derivatives thereof, uses of the O-malonyltryrosyl compounds in the synthesis of peptides, and O-malonyltryrosyl compound-containing peptides. The O-malonyltyrosyl malonyltyrosyl compounds and O-malonyltryrosyl compound-containing peptides of the present invention are uniquely stable to phosphotases, capable of crossing cell membranes, suitable for application to peptide synthesis of O-malonyltryrosyl compound-containing peptides, and amenable to prodrag defivatization for delivery into cells. The present invention also provides for O-malonyltryrosyl compound-containing peptides which exhibit inhibitory potency against binding interactions of receptor domains with phosphotyrosyl-containing peptide ligands.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Pharmaceuticals,,,,C07C/22
5690927,25-Nov-97,1997,11,25,Use of neuro-glial fetal cell lines for transplantation therapy,Human fetal neuro-derived cell lines are implanted into host tissues. The methods allow for treatment of a variety of neurological disorders and other diseases. A preferred cell line is SVG.,21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0071
5691134,25-Nov-97,1997,11,25,Poliovirus specific primers and methods of detection utilizing the same,"The ability to rapidly detect wild polioviruses in clinical specimens is a major concern for the world-wide eradication of polioviruses. Provided is a method of detecting polioviruses of all three serotypes from viral isolates of clinical specimens using a pair of degenerate PCR primers. This primer set, which uses deoxyinosine residues to compensate for third position mismatches at specific positions, recognizes nucleotide sequences near the receptor binding site of polioviruses. These sequences are unique to polioviruses and are absolutely conserved at the amino acid level. As a result, these PCR primers do not recognize nonpoliovirus enteroviruses. All poliovirus serotypes (40 poliovaccine related genotypes and 120 wild poliovirus genotypes from around the world) tested positive. All 14 prototype strains of nonpoliovirus enteroviruses tested negative. Also provided is a series of degenerate PCR primers that differentiates between the three wild poliovirus serotypes and a method of detecting the presence of the three serotypes utilizing a nucleic acid amplification technique.",11,"The United States of America as represented by Secretary, Dept. HHS, NTH, OTT",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
5691307,25-Nov-97,1997,11,25,O.sup.6 -substituted guanine compositions and methods for depleting O.sup.6,Novel O.sup.6 -substituted guanine compounds and pharmaceutical compositions thereof are useful for effectively reducing O.sup.6 -alkylguanine-DNA alkyltransferase (AGT). The novel compounds are useful for treating tumors and when used with anti-neoplastic alkylating agents enhance the chemotherapeutic treatment of tumor cells in a host.,76,The United States of America as represented by the Department of Health and Human Services,The Penn State Research Foundation,Arch Development Corporation,,,,,,,,,3,Organic fine chemistry,,,,,,C07H/16
5691423,25-Nov-97,1997,11,25,Polysaccharide-bound nitric oxide-nucleophile adducts,"A polymeric composition capable of releasing nitric oxide comprises a polysaccharide including a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
5693322,2-Dec-97,1997,12,2,Enhanced intercellular interaction by associational antibody molecules,A method to enhance intercellular association between two or more cells through the linking of attachment molecules on the cellular surfaces of the cells is described. Appropriate attachment molecules include antibodies having an IgG.sub.3 isotype that can cross-associate with antibodies on other cells to bring the cells into proximity with one another. An enhanced method to kill tumor cells with effector cells is also provided.,28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/468
5693531,2-Dec-97,1997,12,2,Vector systems for the generation of adeno-associated virus particles,"A vector system comprising a first vector, which is an adeno-associated viral vector, and which includes an adeno-associated virus 5'ITR, an adeno-associated virus 3'ITR, and at least one heterologous DNA sequence. The vector system also includes a second vector which includes an inducible origin of replication, such as an SV40 origin of replication, which is capable of being induced or activated by an agent, such as the SV40 T-antigen. The second vector also includes DNA sequences encoding the adeno-associated virus rep and cap proteins. When induced by an agent, the second vector may replicate to a high copy number, and thereby increased numbers of infectious adeno-associated viral particles may be generated.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5693776,2-Dec-97,1997,12,2,Nucleic acids specific for Rochalimaea quintana,A method of diagnosing cat scratch disease and a method of diagnosing bacillary angiomatosis in a subject by detecting the presence of Rochalimaea henselae or an immunogenically specific determinant thereof in the subject is provided. Also provided is a vaccine comprising an immunogenic amount of a nonpathogenic Rochalimaea henselae or an immunogenically specific determinant thereof and a pharmaceutically acceptable carrier. A method of diagnosing Rochalimaea quintana infection in a subject by detecting the presence of a nucleic acid specific to Rochalimaea quintana in a sample from the subject is provided. A purified heat shock protein of Rochalimaea is provided.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/0233
5693778,2-Dec-97,1997,12,2,Arg a human gene related to but distinct from abl proto-oncogene,"The invention concerns the isolation and sequencing of a new gene, arg, related to the abl proto-oncogene. The gene gets transcripted to two mRNA's; which in turn form two proteins. Antibodies, oligonucleotide probes and assays of detecting the arg gene, its mRNA and its protein products are also objects of the invention.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
5693779,2-Dec-97,1997,12,2,Production and use of anti-dorsalizing morphogenetic protein,"An isolated polynucleotide of anti-dorsalizing morphogenetic protein (ADMP-1) is obtained from Xenopus. The protein is most closely related to human BMP-3. ADMP-1 functions as a modulator for dorsalizing influences, and prevents syndromes involving inappropriate proliferation of tissues.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/475
5695762,9-Dec-97,1997,12,9,Immunodominant sites of HTLV-I envelope protein,"The invention resides in various peptides derived from the envelope glycoprotein of HTLV-1 and conjugates of the peptides. Compositions including the peptides are also included in the invention. The peptides, their conjugates and compositions thereof have use in diagnostic and immunization methods, especially those that are based upon T-helper and/or cytotoxic T lymphocyte function.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5695996,9-Dec-97,1997,12,9,Artificial organ culture system,"The present invention provides an artificial organ system comprising an endothelial cell layer, an epithelial cell layer and an artificial microporous membrane disposed between and indirect contact with the endothelial cell layer and epithelial cell layer such that the membrane has an endothelial side and an epithelial side. Also provided is a method of constructing an artificial organ system, comprising the steps of placing an artificial microporous membrane into a tissue culture well and supporting the membrane a selected distance from a bottom of the well to create an upper and lower chamber in the well such that the membrane has an endothelial side facing the bottom of the well and an opposite epithelial side; placing endothelial cells into the upper chamber of the well under conditions such that the endothelial cells form a confluent layer of cells on the epithelial side of the membrane; and placing epithelial cells into the upper chamber of the well under conditions such that the endothelial cells migrate through pores in the membrane and attach to the endothelial side of the membrane to form a confluent layer of endothelial cells on the endothelial side of the membrane and the epithelial cells form a confluent layer of epithelial cells on the epithelial side of the membrane.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12M/08
5696079,9-Dec-97,1997,12,9,Immunologic enhancement with intermittent interleukin-2 therapy,"A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retrovital vector directly to the patient.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
5696154,9-Dec-97,1997,12,9,Brefeldin A derivatives and their utility in the treatment of cancer,"Provided are brefeldin A derivatives of the formula: ##STR1## wherein one of R.sub.1 and R.sub.2 is H and the other of R.sub.1 and R.sub.2 is a substituent group having 1 to 12 carbon atoms containing a basic nitrogen atom or a quaternary ammonium group, or a salt thereof. These derivatives exhibit good antitumor activity, and are administrable to human patients without the problems associated with brefeldin A.",26,The United States of America as represented by the Department of Health and Human Services,"Starks Associates, Inc.",,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/00
5696237,9-Dec-97,1997,12,9,Recombinant antibody-toxin fusion protein,The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/62
5697076,9-Dec-97,1997,12,9,Suspended carrier modulation of high-Q transmitters,"A method for on-off modulation of a transmitter coil current of a high-Q resonant circuit transmitter comprising the steps of sensing a zero-crossing of the transmitter coil current and substantially instantaneously interrupting the transmitter coil current, and a high-Q resonant circuit transmitter for carrying out said method.",14,Illinois Institute of Technology,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Telecommunications,Digital communication,,,,,H01Q/00
5698196,16-Dec-97,1997,12,16,Antibodies specific for neutrophic chemotactic factor,"The present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.",11,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/5421
5698413,16-Dec-97,1997,12,16,Method of evaluating chemotherapeutic agents in vivo,"The present invention relates to a method of screening chemotherapeutic agents in vivo. The method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing a target cell-line, treating the laboratory animal with a test agent, then evaluating the target cells for reaction to the test agent.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0004
5698530,16-Dec-97,1997,12,16,Recombinant virus expressing human carcinoembryonic antigen and methods of use thereof,"The present invention relates to a recombinant carcinoembryonic antigen (CEA)/vaccinia virus or other viral vector which expresses CEA on the surface of infected cells and which elicits an immune response in vivo directed against CEA or cells expressing CEA and a pharmaceutical composition containing same. The invention also relates to methods of treating patients having tumors in which CEA is expressed and methods of stimulating the immune system against CEA,",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70503
5698593,16-Dec-97,1997,12,16,Method for treating acne,Nodulocystic and conglobate acne in humans can be alleviated by the oral administration of 13-cis-retinoic acid or a derivative thereof. The active ingredient is administered in a dosage of from about 1.5 to about 3 mg/kg of body weight per day for a period of from about two to about four weeks.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/203
5698671,16-Dec-97,1997,12,16,Metalloproteinase peptides,"Inappropriate degradation of extracellular matrix molecules by metalloproteinases plays an important role in a wide variety of pathologic conditions including neoplasia and arthritis. The present invention is an isolated protein of approximately 23,000 daltons in size which binds to metalloproteinases with high affinity, can be purified using affinity chromatography on solid phase metalloproteinases, and is potentially useful for therapy of pathologic conditions involving the inappropriate production of metalloproteinases. This protein is characterized by the presence of the following amino acid sequences: PA0 CSCSPVHPQQAFCNADVVIRAKAVSEKEVDSGNPIYGNNI PA0 KDIEFIYTAPSEAVCGVELDVEGK PA0 KRHITLCDFIVPWDTLSTTQKKSLNHRYQQGCEECKITRCPMIPCYISSPDECLWTDTVV PA0 KFFACIKRHITLCDFIVPWSQIADXLSS With the positions of the cysteine residues and associated disulfide bridges required for biologic activity.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/8146
5698693,16-Dec-97,1997,12,16,"Process of separating the diastereomers of (6R,6S) -5,6,7,8-tetrahydrofolic acid derivatives","A method for resolving 5,6,7,8-tetrahydrofolic acid derivatives into diastereomerically pure 6R and 6S forms. The method comprises (1) alpha esterification of the tetrahydrofolic acid derivative; (2) resolution of the alpha monoester into pure diastereomer; and (3) deprotecting the resolved alpha monoester to thereby produce the pure diastereomer of the original 5,6,7,8 tetrahydrofolic acid derivative. The resolution step can be carried out by any conventional means including chromatography or fractional crystallization. The method results in absolute diastereomeric purity even when an achiral stationary phase is used for the resolution.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5698764,16-Dec-97,1997,12,16,Transgenic mice expressing HPV early region oncogene develop progressive epithelial neoplasia,"The present invention relates to improved models for progressive epithelial neoplasias and methods for their use. In particular, the invention provides transgenic mice comprising a human papilloma virus early region oncogene operably linked to a promoter which directs expression of the oncogene in a transient amplifying cell in the mice.",12,The Regents of the University of California,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,2,Biotechnology,Other special machines,,,,,C07K/005
5700830,23-Dec-97,1997,12,23,Use of nitric oxide-releasing agents for reducing metastasis risk,"A method for inhibiting the adherence between cancerous cells and noncancerous structures in a mammal, comprising the administration to the mammal of a nitric oxide-releasing compound containing a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group. The compound is capable of releasing an adherence-inhibiting effective amount of nitric oxide to the mammal.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/14
5701898,30-Dec-97,1997,12,30,Method and system for Doppler ultrasound measurement of blood flow,"A method and system for providing Doppler data that is corrected for misalignment between the flow direction within a vessel and the beam orientation of the ultrasound probe. A conventional ultrasonic Doppler color mapping system is adapted to include a system to measure and record the free space position and orientation of the ultrasonic probe, as well as a system to generate and record the experiment time. A set of 2D image planes is acquired, each plane labelled with time, position, and orientation data. A structural representation according to the acquired data is used to determine the flow direction for the imaged vessel structure. Based on this identified flow direction, and the orientation and position information for each acquired 2D slice, the 2D Doppler signals are appropriately transformed into corrected velocity values. These corrected velocity values may then be used to construct a 3D flow field as a function of time.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,,,,,A61B/483
5702892,30-Dec-97,1997,12,30,Phage-display of immunoglobulin heavy chain libraries,"One aspect of the invention relates to a phage-display library that expresses single-chain recombinant binding proteins. Inserts in the library comprise immunoglobulin heavy chain framework regions flanking highly divergent, synthetically produced hypervariable regions. A second aspect of the invention relates to the use of single-chain recombinant binding proteins to inhibit the activity of an intracellular constituent. In the exemplary case presented, the activity of intracellular glucose-6-phosphate dehydrogenase was inhibited by intracellular expression of a cloned single-chain recombinant binding protein.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Analysis of biological materials,,,,C40B/02
5702907,30-Dec-97,1997,12,30,Antibodies to the hepatocellular carcinoma oncogene and immunoassays using the same,The present invention relates to an oncoprotein specific for hepatocellular carcinomas and to a nucleotide sequence that codes for such a protein. The invention further relates to screening and diagnostic methodologies (and kits based thereon) that make use of the oncoprotein (or antibodies specific for same) and the nucleotide sequence.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/32
5705150,6-Jan-98,1998,1,6,Antigen specific plasmacytomas and antibodies derived therefrom,Disclosed herein is a method for producing antibodies against an antigen of interest. Animal cells are exposed to both the antigen of interest and a recombinant retroviral vector. The vector contains a combination of oncogenes capable of inducing plasmacytomas. Plasmacytoma formation takes place rapidly and takes place in the presence of the antigen. A very high proportion of the plasmacytomas that are recovered are antigen specific.,8,The United States of America as represented by the Department of Health and Human Services,Wisconsin Alumni Research Foundation,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
5705153,6-Jan-98,1998,1,6,Glycolipid enzyme-polymer conjugates,"Conjugates containing glucocerebrosidase and non-antigenic polymers such as polyethylene glycol are disclosed. The conjugates circulate for extended times and have prolonged activity in vivo when compared to unmodified enzymes. The conjugates are useful in the treatment of Gaucher's Disease and have improved enzyme activity at the pH ranges associated with lysosomal, arterial and capillary regions.",10,"The United States of America, as represented by The Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/2402
5705156,6-Jan-98,1998,1,6,Psuedomonas exotoxins of low animal toxicity and high cytocidal activity,Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive charge provides markedly changed exotoxins. Conjugation of the new exotoxins with suitable targeting agents provides cytocidal specificity for killing desired cellular entities.,13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70514
5705163,6-Jan-98,1998,1,6,"Target-specific, cytotoxic, recombinant pseudomonas exotoxin","A target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described. Such toxins are made by inserting specific recognition molecules at specific cloning sites in at least domain III near the carboxyl terminus of the PE molecule. Various modifications of the carboxyl terminus of the PE molecule to increase cytotoxicity are set forth. Multifunctional, recombinant, cytotoxic fusion proteins containing at least two different recognition molecules are provided for killing cells expressing receptors to which the recognition molecules bind with specificity. Methods for producing novel recombinant PE molecules with specific properties are described.",21,"The United States of America as represented by the Department of Health and Human Services, National Institutes of Health",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70514
5705331,6-Jan-98,1998,1,6,HIV nucleocapsid protein capture assay and method of use,"An antigen capture method, and an antigen capture assay diagnostic kit, for detecting the presence or concentration of HIV in a biological sample without interference from antigen-antibody immune complexes is provided. The lysate of a biological sample obtained from an animal is contacted with a detectable mount of an antibody specifically reactive with the nucleocapsid p7 antigen or an immunoreactive fragment of the p7 antigen for a time and under conditions sufficient for p7 antigen contained in the lysate to form a p7-antibody complex. The presence or concentration of this p7-antibody complex is determined to detect or quantitate the presence of HIV in the biological sample. Uses of this assay and method include detecting the presence of HIV infection in an infant born to an HIV-infected mother, monitoring the progression of HIV infection, and evaluating the effectiveness of an anti-HIV treatment administered to an animal, such as a human. Purified antibodies specifically reactive with an immunoreactive epitope specific to p7 or an immunoreactive fragment of p7 are also provided as well as an antigen capture method for detecting the presence of a lentivirus in a biological sample involving the nucleocapsid protein of the lentivirus.",13,The United States of America as represented by the Secretary Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5705336,6-Jan-98,1998,1,6,Assay for sensitivity of tumors to DNA-platinating chemotherapy,"Assay of the mRNA levels of ERCC1 and XPAC, two genes whose products are involved in DNA repair, provides a method for determining the sensitivity of tumors to treatment by platinum-based chemotherapy. Tumors that are resistant to cisplatin tend to express high levels of the mRNA for ERCC1 which includes exon VIII. In some tumor types, concurrent expression of ERCC1 and XPAC mRNAs is also an indicator of cisplatin resistance.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5705477,6-Jan-98,1998,1,6,Compositions of transforming growth factor .beta.(TGF-.beta.) which promotes wound healing and methods for their use,A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-.beta. which is activated by either a TGF-.alpha. or an EGF or both; and methods for administration. As another embodiment these active ingredients can be admixed with other (secondary) growth factors.,27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/495
5705514,6-Jan-98,1998,1,6,Signal transduction inhibitor compounds,"A method of inhibiting the invasion and metastasis of malignant solid tumors in mammals, said method comprising administering to said mammal an anti-proliferative, anti-invasive and anti-metastasis effective amount of a compound selected from the group of formulas consisting of: ##STR1## wherein: p is an integer of from 0 to 4; Ar.sup.1 is a moiety selected from the group consisting of --Ar.sup.2 --X--Ar.sup.3, phenyl, trioxaadamantyl, anthracenyl, anthraquinonyl, naphthyl, phenanthryl, and substituted versions thereof; Ar.sup.2 and Ar.sup.3 are each aromatic moieties independently selected from the group consisting of phenyl, naphthyl, and substituted versions thereof; X is a linking moiety selected from the group consisting of O, S, SO.sub.2 2, CO, CHCN, straight chain alkyl, alkoxy, and alkoxyalkyl; and Z is a nitrogen-containing heterocyclic moiety selected from the group consisting of imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl and substituted versions thereof, said heterocyclic moieties being attached to the --(CH.sub.2).sub.p -- portion of the molecule at the N1 position of the heterocycle.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4164
5706520,13-Jan-98,1998,1,13,Hand puncture protector,"A hand puncture protector (10) including a pivoting shell which covers susceptible areas on the back and sides of the wearer's thumb (53), index finger (52) and thenar web space to reduce the risk of injury or infection from accidental punctures from needles and other sharp instruments (""SHARPS""). The pivoting shell is formed of a SHARP impervious material, such as thermoplastic, and has separate thumb (11) and index finger (12) components which are preferably fastened together by a single rivet (30) placed above the thenar web space region. VELCRO straps (20, 21) are affixed to the thumb and index finger regions of the molded shell at about the interphalange joint of the thumb and middle phalanx of the index finger to secure the hand protector to the user's hand. A method of protecting health care professionals from injury or infection by accidental punctures is also disclosed.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Other consumer goods,,,,,,A41D/01517
5707805,13-Jan-98,1998,1,13,Assay for detecting keratinocyte growth factor (KGF) and its activity,"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6876
5707811,13-Jan-98,1998,1,13,Reca-assisted cloning of DNA,"DNA is cloned and labeled in a sequence-specific manner. The DNA is digested with one or more restriction enzymes which produce 3' recessed ends. A desired fragment is protected from elongation by DNA polymerase by addition of E. coli RecA protein and oligonucleotides about 30 to 60 bases in length complementary to the 3' recessed ends of the digested fragment. RecA and DNA polymerase are then inactivated, leaving only the desired fragment with 3' recessed ends which is then ligated into a vector containing complementary 3' recessed ends.",26,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6853
5708025,13-Jan-98,1998,1,13,Methods for promoting wound healing,"Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5709208,20-Jan-98,1998,1,20,Method and system for multidimensional localization and for rapid magnetic resonance spectroscopic imaging,"A method and system for providing prelocalization of a volume of interest and for rapidly acquiring a data set for generating spectroscopic images. Spatial prelocalization of a volume of interest is achieved by providing a presuppression sequence before a stimulated echo (STE) sequence and a suppression sequence during the mixing time (TM) interval of the STE sequence. The presuppression sequence includes a spatial suppression sequence to selectively saturate slices that intersect the plane selected by the STE sequence in order to define a boundary for the volume of interest, and this spatial suppression sequence is substantially repeated during the TM interval of the STE sequence. Spectroscopic imaging data is acquired by an oversampled echo planar spatial-spectral imaging sequence in which the gradient reversal frequency is a integer factor of n greater than the gradient reversal frequency required to sample the spectral width.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/4833
5709996,20-Jan-98,1998,1,20,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5710001,20-Jan-98,1998,1,20,17q-linked breast and ovarian cancer susceptibility gene,"The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.",35,"Myriad Genetics, Inc.",University of Utah Research Foundation,"The United States of America as represented by the Secretary of Health and Human Services, Technology Transfer Office",,,,,,,,,3,Biotechnology,,,,,,C07K/4703
5710014,20-Jan-98,1998,1,20,Cloned cDNA for human procathepsin l.,"A cloned cDNA containing complete coding sequence for the expression of a protein with all properties of the precursor to human procathepsin L is described. All of the protein's major domains, including the pre, pro, and carboxyterminal extensions are represented in the full length cDNA sequence of the present invention.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/6472
5710037,20-Jan-98,1998,1,20,Retroviral vector particles,"A retroviral vector which includes a nucleic acid sequence encoding a retroviral envelope. The nucleic acid sequence encoding a retroviral envelope includes a first nucleic acid sequence encoding a first envelope portion which is a portion of MCF viral gp 70 protein, a nucleic acid sequence which encodes xenotropic envelope, a nucleic acid sequence which encodes an amphotropic envelope portion, and a nucleic acid sequence which encodes p15E protein. Such retroviral envelopes encoded by such nucleic acid sequence may be included in infectious viral particles. The infectious viral particles also may include gene(s) encoding therapeutic agents, and thus may be used in gene therapy.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5710178,20-Jan-98,1998,1,20,"Compositions and methods for therapy and prevention of pathologies including cancer, AIDS, and anemia","Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",63,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5711296,27-Jan-98,1998,1,27,Continuous positive airway pressure system,A passive continuous positive airway intratracheal pulmonary ventilation system which includes an inspiration limb and an expiration limb which are pressure balanced by inflatable bags. An intratracheal pulmonary ventilation system is provided which includes a catheter having a tip which is positioned through a low resistance endotracheal tube at or near a patient's carina. A constant source of an oxygen-containing gas flows through the catheter. The catheter has a tip which deflects and reverses the flow direction of the oxygen-containing gas.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Other special machines,,,,,A61M/0009
5711947,27-Jan-98,1998,1,27,Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides,"The instant invention describes the synthesis of short peptides, corresponding to the amino acid residues of the V3 loop of the gp160 envelope glycoprotein of HIV-1 numbered 315 to 329 by Ratner (Ratner, L. et al., Nature 313, 277 (1985)) in the strain IIIB, wherein the residue corresponding to number 325 in HIV-1 IIIB is substituted by the homologous residue from another clinical isolate or strain. The invention further describes the use of said peptides in pharmaceutical compositions and an immunization protocol which elicits cytotoxic T cells reactive to a broad range of isolates of HIV-1.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5712307,27-Jan-98,1998,1,27,Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof,"Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",40,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5714313,3-Feb-98,1998,2,3,Simple method for detecting inhibitors of retroviral replication,"The present invention relates, in general, to a DNA segment. In particular, the present invention relates to a DNA segment comprising a selectable marker gene, a DNA segment comprising a selectable marker gene inserted into a retrotransposon, cells containing these DNA segments, and methods of using these DNA segments and cells. The present invention further relates to a vector comprising a selectable marker gene inserted into a retrotransposon, wherein the retrotransposon comprises a retroviral reverse transcriptase/RNase H gene domain and wherein the selectable marker gene contains an intron inserted into a coding sequence of the marker gene and the intron is in antisense orientation relative to transcription of the marker gene and in sense orientation relative to transcription of the retrotransposon.",21,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/81
5714511,3-Feb-98,1998,2,3,Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs,A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically effective amount of nitric oxide sufficient to protect the tissue from sepsis- or shock-induced injury.,27,The United States of America as represented by the Secretary of the Department of Health and Human Services,The University of Pittsburgh,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/445
5714578,3-Feb-98,1998,2,3,Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body,"Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/523
5716620,10-Feb-98,1998,2,10,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5716788,10-Feb-98,1998,2,10,Antibodies to human reduced folate carrier protein,"One shortcoming of methotrexate chemotherapy is that previously responsive tumors can become refractory to methotrexate after continued exposure. Such methotrexate resistance may be due to underexpression of reduced folate carrier (RFC) protein. The present invention provides DNA molecules encoding human RFC. The present invention also relates to expression vectors comprising RFC-encoding DNA molecules, and to the use of such vectors to restore methotrexate sensitivity in mammalian cells. The present invention further relates to antibodies that bind with human RFC protein, and to methods of detecting human RFC protein using such antibodies.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5716816,10-Feb-98,1998,2,10,Clones encoding mammalian ADP-ribosylarginine hydrolases,The present invention relates to the production of mammalian ADP-ribosylarginine hydrolases. These enzymes can be manufactured using recombinant DNA technology and are useful in regulation of proteins involved in key metabolic pathways.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Y/02019
5716830,10-Feb-98,1998,2,10,Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus,"Immortalized non-tumorigenic or tumorigenic human prostatic epithelial and fibroblast cell lines and derivatives thereof, containing DNA of a hybrid virus between adenovirus 12 and simian virus 40. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.",11,Board of Trustees operating Michigan State University,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/5011
5717067,10-Feb-98,1998,2,10,Substrate for the epidermal growth factor receptor kinase,"A new substrate of epidermal growth factor receptor and certain other tyrosine kinase receptors denominated eps15, polynucleotides encoding epsl5, antisense eps15 polynucleotide, triple helix eps15 polynucleotide, antibodies to eps15, and assays for determining eps15.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
5718892,17-Feb-98,1998,2,17,"Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same","A polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
5720720,24-Feb-98,1998,2,24,Convection-enhanced drug delivery,"A method of high-flow microinfusion which provides convection-enhanced delivery of agents into the brain and other solid tissue structures. The method involves positioning the tip of an infusion catheter within a tissue structure and supplying an agent through the catheter while maintaining a pressure gradient from the tip of the catheter during infusion. Agent delivery rates of 0.5 to 15.0 .mu.l/min have been used experimentally with infusion distances greater than 1 cm from the delivery source. The method can be used to delivery various drugs, protein toxins, antibodies for treatment or imaging, proteins in enzyme replacement therapy, growth factors in the treatment of various neurodegenerative disorders and viruses and gene therapy. An infusion catheter developed for the high-flow microinfusion includes a plurality of elongated slits adjacent a tapered portion of the catheter which are parallel to the axis of the catheter and spaced symmetrically about the circumference thereof. The infusion catheter is used in a convention-enhanced delivery system in which, after the infusion catheter is positioned in a tissue situs, it is connected to a pump which delivers a desired agent and maintains a desired pressure gradient throughout delivery of the agent.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/0075
5721100,24-Feb-98,1998,2,24,Three highly informative microsatellite repeat polymorphic DNA markers,"The invention relates to polymorphic markers (two tetranucleotide and one dinucleotide repeat polymorphisms) that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers are characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences. The assay according to the invention is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours. Accordingly, the invention also relates to an improved PCR procedure and a PCR assay kit which comprise nucleotides according to the invention.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
5722395,3-Mar-98,1998,3,3,Ultra thin walled wire reinforced endotracheal tubing,"An ultra thin walled wire reinforced endotracheal tubing includes a thin walled tubing comprising a polymeric material having a spring material incorporated therewith. Utilization of the spring wire material in combination with polymeric material results in a reduced wall thickness which results in a significant decrease in resistance to air flow through the endotracheal tubing. The endotracheal tubing of the present invention is made by depositing a dissolvable polymeric material on a rotating mandrel in successive layers. A spring material is also applied around the mandrel to produce the ultra thin walled wire reinforced endotracheal tubing. By controlling the rate of deposition of polymeric material along the length of the mandrel, different wall thicknesses of tubing may be achieved.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,Medical technology,,,,,B29C/36
5725855,10-Mar-98,1998,3,10,Method of treating tumors with CD8.sup.+ -depleted or CD4.sup.+ T cell subpopulations,"The present invention provides a method for enhancing the immunotherapeutic activity, e.g., antitumor activity, of immune cells by depleting immune cells of a cell subset that down-regulates the immune response, such as either CD4.sup.+ or CD8.sup.+ lymphocytes. The remaining depleted immune cell population or the separated immune cell subsets then are cultured in the presence of an antibody to a lymphocyte surface receptor, preferably an anti-CD3 monoclonal antibody (MoAb), optionally in the presence of a relatively minor amount of interleukin-2 (IL-2). These stimulated cells then are optionally additionally cultured in the presence of IL-2 without an antibody to a lymphocyte surface receptor. The present invention also provides a method of treating a mammal having tumors or immunizing a mammal against tumors by administering the stimulated depleted immune cell population or a stimulated immune cell subset to a mammal, advantageously together with an immunosuppressant, and with liposomal IL-2. The invention further provides a method of transferring the immunity of mammals that are treated or immunized in accordance with the invention by extracting splenocytes from these mammals and administering these splenocytes to a second mammal.",4,The United States of America as represented by the Department of Health and Human Services,Regents of the Univ. of Minnesota,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C12N/0636
5725857,10-Mar-98,1998,3,10,Immunotoxin with in vivo T cell suppressant activity and methods of use,"In one embodiment, the invention provides a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-CRM9 conjugate which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In another embodiment, the invention provides an anti-V.beta.-CRM9 immunoconjugate. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-CRM9 conjugate which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/6849
5726041,10-Mar-98,1998,3,10,Method for detecting a receptor-ligand complex using a cytochrome P450 reporter gene,An improved method for measuring the activity of a promoter sequence in a mammalian cell using a reporter gene is provided. The improvement involves using a reporter cassette containing a DNA sequence encoding a cytochrome P450 with a polyadenylation signal sequence as the reporter gene. Compositions containing the cytochrome P450 reporter cassette also are provided.,5,Gentest Corporation,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12Q/6897
5726189,10-Mar-98,1998,3,10,Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes,"The present invention is directed to radiolabeled epibatidine analogues, specifically FPH labeled with radioisotopes of fluorine and/or carbon. These radiolabeled epibatidine compounds are used to noninvasively image and quantify nicotinic cholinergic receptors in the living brain for both research studies and the diagnosis of neurodegenerative diseases.",22,"The United States of America, represented by The Secretary, Department of Health and Human Services",Johns Hopkins University School of Medicine,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/439
5728383,17-Mar-98,1998,3,17,Treatment of tumors of the central nervous system with immunotoxins,"Potent and specific immunotoxins are prepared by conjugation of moieties binding to receptors on the surface of tumor cells to a mutant diphtheria toxin having A-chain translocation activity, but lacking membrane-binding activity. The immunotoxins are used to treat primary tumors of neurologic origin, metastatic tumors of small cell lung carcinoma or breast carcinoma origin, leptomeningeal leukemia and leptomeningeal carcinomatosis. The preferred route of administration of the immunotoxin is to a compartment of the body containing cerebrospinal fluid.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/34
5728519,17-Mar-98,1998,3,17,Assay for virulent revertants of attenuated live vaccines and kits therefor,"The present invention provides a method of classifying an unclassified live poliovirus vaccine as having an acceptable or unacceptable level of neurovirulence, comprising, prior to vaccine administration, the steps of: a) selectively amplifying a region of an unclassified poliovirus vaccine genome containing a nucleotide position predictive for increased neurovirulence using selectively mismatched primers, whereby a restriction endonuclease site in the selectively amplified region is created by introducing a site-specific mutation into the amplified region; b) digesting an amount of the amplified region with a restriction endonuclease that specifically cleaves the amplified sequences in revertant viruses which contain a reversion at the nucleotide position predictive for increased neurovirulence; c) digesting an amount of the amplified region with a restriction endonuclease that specifically cleaves the amplified sequences in nonrevertant viruses which contain the nucleotide position predictive for increased neurovirulence; d) quantifying the percentage of revertant viruses in the unclassified vaccine; and e) comparing the percentage of revertant viruses in the unclassified vaccine to the percentage of revertant viruses in an accepted reference vaccine, and unclassified vaccine with a highter percentage of revertant viruses than in the reference vaccine being classified as unacceptable or an unclassified vaccine with an equal or lower percentage of revertant viruses than in the reference vaccine being classified as acceptable. Related methods and kits are also provided.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
5728718,17-Mar-98,1998,3,17,"2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same","The present invention provides 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane (DAD) isosteres comprising benzamide, sulfonamide and anthranilamide subunits, a pharmaceutical composition comprising such compounds, a method of using such compounds to treat retroviral, specifically HIV and more specifically HIV-1 and HIV-2, infections in mammals, particularly humans, a method of synthesizing asymmetric DAD isosteres comprising benzamide, sulfonamide and anthranilamide subunits, and a method of using such compounds to assay new compounds for antiretroviral activity.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/82
5730700,24-Mar-98,1998,3,24,Method for measuring incident light in a body cavity,An obturator for measuring incident light in a remote situs such as a body cavity which includes a treatment tubular member through which light is delivered to the remote situs and one or more auxiliary tubular members through which incident light in the remote situs is transmitted to an external light detector. The treatment and auxiliary tubular members are attached to a connector element which is in turn connected to a cystoscope lens port. The treatment and auxiliary tubular members are aligned off-center with respect to the central axis of the obturator so that a cystoscope lens can be inserted in the lens port and pass through the axial center of the obturator. Each auxiliary tubular member receives incident light from a different portion of the remote situs. The apparatus is particularly useful for conducting phototherapy in body cavities and has been demonstrated in the phototherapy treatment of superficial cancer in the bladder.,11,The United States of America as represented by the Department of Health and Human Service,,,,,,,,,,,1,Medical technology,,,,,,A61B/24
5731151,24-Mar-98,1998,3,24,Regulator of contact-mediated hemolysin,The present invention relates to a nucleic acid that encodes a hemolysin protein and to a nucleic acid that encodes a positive regulator of hemolysis. The nucleic acid can be the basis of a vaccine against tuberculosis. The nucleic acid can be inserted into an avirulent vaccine strain such as M. bovis BCG.,15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/35
5731167,24-Mar-98,1998,3,24,Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy,"The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Micro-structural and nano-technology,Biotechnology,,,,,B82Y/00
5731170,24-Mar-98,1998,3,24,DNA encoding a growth factor specific for epithelial cells,"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments .introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6876
5731301,24-Mar-98,1998,3,24,Bistriazenes as chemotherapeutic agents,"The present invention is directed to bistriazene compounds, pharmaceutical compositions containing effective anti-cancer amounts of these compounds, a method for treating cancer comprising administering to affected subjects an anti-cancer effective amount of a bistriazene compound, and the use of bistriazene compounds as crosslinking reagents applicable to the synthesis and manipulation of polymeric macromolecules.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/24
5731305,24-Mar-98,1998,3,24,Anti-hypertension compositions of secondary amine-nitric oxide adducts and use thereof,"There are disclosed anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component in the anti-hypertensive compositions is a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl group; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a heterocyclic ring; M.sup.+x is a pharmaceutically acceptable cation, wherein x is the valence of the cation.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/30
5731411,24-Mar-98,1998,3,24,Promotion of homologous DNA pairing by RecA-derived peptides,A peptide having at least 15 consecutive amino acids of the amino acid sequence shown in SEQ ID NO:1 or conservative amino acid substitutions thereof. The peptide is capable of promoting pairing of a single-stranded DNA molecule and a double-stranded DNA molecule. The single-stranded DNA molecule is homologous to at least a portion of the double-stranded DNA molecule. The single-stranded DNA molecule and the double-stranded DNA molecule form a three-stranded DNA molecule.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/245
5733548,31-Mar-98,1998,3,31,"Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments","Immunogenic chimeric proteins comprising an endoplasmic reticulum signal sequence and at least one other peptide are disclosed. The invention relates to the design of vaccinia virus constructs capable of directing host organism synthesis of immunogenic chimeric proteins which can be used as immunogens, as vaccines, or in methods of treatment for cancer, infectious diseases, or autoimmune diseases.",16,"The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/205
5733772,31-Mar-98,1998,3,31,"Cloning and expression of Plasmodium falciparum transmission blocking target antigen, Pfs230",Compositions comprising biologically pure Pfs230 and nucleic acids which encode them are provided. The proteins can be used induce transmission blocking immune responses in susceptible hosts.,13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
5734016,31-Mar-98,1998,3,31,Fuse binding protein and method for inhibiting expression of fuse binding protein,"The Far Upstream Element (FUSE) of the human c-myc gene stimulates expression in undifferentiated cells. A FUSE binding protein (FBP), also referred to as DROME (DNA-binding regulator of c-myc expression), is active in undifferentiated but not differentiated cell extracts. Cloned FBP exhibits the same DNA-binding specificity as the purified human protein and can trans-activate in a FUSE dependent manner. Sequence-specific binding to the FUSE oligonucleotide requires at least two copies of a repeat-helix unit which defines a new DNA-binding motif. Expression of FBP mRNA declined in parallel with decreased FUSE binding activity upon differentiation suggesting transcriptional regulation of FBP.",30,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4705
5736315,7-Apr-98,1998,4,7,Methods and compositions for detecting anti-hepatitis E virus activity,The present invention provides antigenic peptides and polypeptides of hepatitis E virus. Also provided are mixtures of conjugated and unconjugated peptides of the present invention. Methods of detecting hepatitis E viral infection in a subject using the peptides and peptide mixtures of the present invention are also contemplated.,19,National Institute of Health,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5738855,14-Apr-98,1998,4,14,Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide,"The present invention is a modified plant, fruit or synthetic oligo- or polysaccharide which has been structurally altered so as to render the modified saccharide antigenically similar to the Vi of Salmonella typhi. The modified saccharide may be conjugated to a carrier to form a conjugate that is immunogenic against S. typhi. Antibodies produced in response to the immunogenic conjugate are protective against typhoid fever. Methods are provided for making the modified saccharide and the immunogenic conjugate.",49,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/385
5738878,14-Apr-98,1998,4,14,Process for making intrinsic inhibitors of aldose reductase,"An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4703
5739158,14-Apr-98,1998,4,14,Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS disorders,"Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders, convulsions and parkinsonism. Compounds of particular interest are of the formula ##STR1## wherein R.sup.1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms and loweralkenylloweralkyl; wherein each of R.sup.2 and R.sup.3 is independently selected from hydrido and loweralkyl; wherein each of R.sup.4 through R.sup.7, R.sup.10 and R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is a number selected from four through six; wherein p is a number selected from zero through four; wherein q is a number selected from three through five; wherein A is selected from phenyl, naphthyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/135
5741642,21-Apr-98,1998,4,21,Assay for detecting the expression of a gene encoding human keratinocyte growth factor (KGF),"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6876
5744142,28-Apr-98,1998,4,28,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5747261,5-May-98,1998,5,5,Protein related to but distinct from EGF receptor and antibodies reactive therewith,"The isolation, cloning and characterization of a human gene related to but distinct from EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of the nucleic acid probes and antibodies having specific binding affinity with said polypeptide for diagnostic and therapeutic purposes have also been described.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/71
5747282,5-May-98,1998,5,5,17Q-linked breast and ovarian cancer susceptibility gene,"The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.",20,"Myraid Genetics, Inc.",University of Utah Research Foundation,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,3,Biotechnology,,,,,,C07K/4703
5747336,5-May-98,1998,5,5,Cloned human genes for muscarinic acetylcholine receptors and cells lines expressing same,Clones of human genes for a plurality of different muscarinic acetylcholine receptors and stable cell lines homogeneously expressing a specific subtype of the receptors have been prepared. A method for screening muscarinic drugs has been described.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
5747503,5-May-98,1998,5,5,Selective inhibitors of biogenic amine transporters,"The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2, N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3, and (CH.sub.2).sub.n, if present, may be substituted with OH, OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease.",70,The United States of America as represented by the Department of Health and Human Services,Research Triangle Institute,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
5747654,5-May-98,1998,5,5,Recombinant disulfide-stabilized polypeptide fragments having binding specificity,"The present invention relates to disulfide-stabilized recombinant polypeptide molecules which have the binding ability and specificity for another peptide, such as the variable region of an antibody molecule. Methods of producing these molecules and nucleic acid sequences encoding these molecules are also described. In particular, the invention discloses Fv antibody fragments stabilized by a disulfide bond connecting the V.sub.H and V.sub.L regions of the Fv fragment. The .alpha. and .beta. chains of T cell receptors may be similarly stabilized by means described in the invention.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/7051
5750329,12-May-98,1998,5,12,Methods and compositions for an artificial lung organ culture system,"The present invention provides an artificial organ system comprising an endothelial cell layer, an epithelial cell layer and an artificial microporous membrane, having pores therein, disposed between and in direct contact with the endothelial cell layer and the epithelial cell layer such that the membrane has an endothelial side and an epithelial side. The present invention also provides an artificial organ system contained in a vessel comprising an upper chamber into which the epithelial side faces and containing the epithelial cell layer, and a lower chamber into which the endothelial side faces and containing the endothelial cells. The present invention also provides an artificial lung system comprising an endothelial cell layer, an alveolar epithelial cell layer and an artificial microporous membrane, having pores therein, disposed between and in direct contact with the endothelial cell layer and the alveolar epithelial cell layer such that the membrane has an endothelial side and an epithelial side. A method is also provided for constructing an artificial lung system, comprising placing an artificial microporous membrane, having pores therein, into a vessel having a bottom and supporting the membrane a distance from the bottom of the vessel to create an upper and lower chamber in the vessel such that the membrane has an endothelial side facing into the lower chamber of the vessel and an opposite epithelial side facing into the upper chamber of the vessel; placing endothelial cells into the upper chamber of the vessel under conditions such that the endothelial cells form a confluent layer of cells on the epithelial side of the membrane; and placing alveolar epithelial cells into the upper chamber of the vessel under conditions such that the endothelial cells migrate through the pores in the membrane and attach to the endothelial side of the membrane to form a confluent layer of the endothelial cells on the endothelial side of the membrane in the lower chamber and the alveolar epithelial cells form a confluent layer of the epithelial cells on the epithelial side of the membrane in the upper chamber.",24,Centers for Disease Control and Prevention,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12M/08
5750332,12-May-98,1998,5,12,Peptomers with enhanced immunogenicity,"The present invention relates to synthetic peptide analogues useful as therapeutic agents, immunogens or for the diagnosis of disease. In particular, it relates to peptide multimers which maintain the conformation of the native proteins from which they are derived. Peptomers constructed from peptides derived from gp120 of the human immunodeficiency virus are exemplified.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5753238,19-May-98,1998,5,19,Target antigens of transmission blocking antibodies for malaria parasites,"The present invention relates novel methods and compositions for blocking transmission of Plasmodium spp. which cause malaria. In particular, P28 proteins are disclosed which, when administered to a susceptible organism, induce an immune response against a 28 kD protein on the surface of Plasmodium ookinetes and block transmission of malaria.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/445
5753437,19-May-98,1998,5,19,Method of diagnosing cancer susceptibility or metastatic potential,"The present invention relates, in general, to a method for diagnosing cancer susceptibility based on alterations in the nm23 gene. In particular, the present invention relates to a method of identifying individuals at risk for developing a primary cancer or at risk for suffering treatment failure, morbidity, or mortality associated with cancer. The invention further relates to a means of using genetic methods to predict individuals at increased risk for developing distant metastases.",3,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
5753441,19-May-98,1998,5,19,170-linked breast and ovarian cancer susceptibility gene,"The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.",37,"Myriad Genetics, Inc.",University of Utah Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Biotechnology,,,,,,C07K/82
5753668,19-May-98,1998,5,19,Substituted benzyloxypyrimidines and their inactivation of O.sup.6 -alkylguanine-DNA alkyltransferase,"The present invention provides certain novel nitro or nitroso substituted benzyloxy pyrimidines useful as AGT inactivators. An example of such a pyrimidine is a compound of the formula ##STR1## wherein R.sub.1, is NO.sub.2 or NO, and R.sub.2 is hydrogen, halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 hydroxyalkyl, thiol, C.sub.1 -C.sub.4 alkythio, trifluoromethoxy, oxymethanesulfonyl, oxytrifluoromethanesulfonyl, or C.sub.1 -C.sub.4 oxyacyl. The present invention further provides pharmaceutical compositions comprising these compounds, and a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine.",18,The United States of America as represented by the Department of Health and Human Services,Penn State Research Foundation,Arch Development Corporation,,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
5756284,26-May-98,1998,5,26,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5756293,26-May-98,1998,5,26,"Rapid, sensitive and specific detection of 0157:H7 and other enterohemorrhagic E. coli","The present invention provides isolated nucleic acid sequences corresponding to the hlyA gene, the hlyB gene and the intergenic region between the hlyA gene and the hlyB gene which are present in enterohemorrhagic E. coli. In addition, the present invention provides methods for detecting enterohemorrhagic E. coli by targeting the hlyA gene, the hlyB gene, the intergenic region between the hlyA and the hlyB genes, combinations thereof, or fragments thereof. Such methods rely on nucleic acid probes and amplification primers specific for subsequences of the hlyA gene, the hlyB gene, the intergenic region between the hlyA and the hlyB genes, combination thereof or, fragments thereof. As such, the present provides nucleic acid probes and amplification primers which can be used for the rapid, sensitive and specific amplification and detection of enterohemorrhagic E. coli. In addition, the present invention provides kits embracing the above aspects.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
5756307,26-May-98,1998,5,26,Sequence of human dopamine transporter cDNA,The cloning and characterization of a human dopamine transporter (HUDAT) cDNA is described. RFLP analysis is used to determine the distribution of HUDAT alleles in two ethic backgrounds. The means by which the association between HUDAT alleles and behavioral disorders which have altered HUDAT expression as a basis for their etiology is discussed. Methods for evaluating the expression of HUDAT are described.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5756343,26-May-98,1998,5,26,Cell stress transcriptional factors,"The present invention relates to DNA sequence coding for part or all of the heat shock transcription factor or heat shock factor (HSF) proteins derived from humans and Drosophila, and the proteins encoded by these sequences. The present invention also includes methods for detecting HSF in a biological sample. The presence of HSF in the nucleus of a cell can be detected with specific anti-HSF antibody reagents. The presence of such HSF proteins in the nucleus indicates a stressed condition including diseases. Furthermore, the presence of multimeric HSF in the crude or fractionated cell extract is indicative of a stressed state.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
5756476,26-May-98,1998,5,26,Inhibition of cell proliferation using antisense oligonucleotides,"The present invention provides a method of inhibiting restenosis of a blood vessel in a mammal after mechanical treatment of the vessel to reduce a stenosis. The method includes contacting proliferating smooth muscle cells in the vessel with an antisense oligonucleotide directed against a cellular division cycle gene product. This gene product can be one of the following: c-myc, PCNA, and cyclin B.sub.1. The antisense oligonucleotide is used in an amount effective to inhibit translation of the cellular division cycle gene product in the cell.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
5759765,2-Jun-98,1998,6,2,Human liver epithelial cell lines,Immortalized cell lines derived from normal adult human liver are described which express phenotypic characteristics of normal adult liver epithelial cells. The invention further provides methods of using the immortalized cells to evaluate the cytotoxicity or carcinogenicity of a compound.,4,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5014
5759790,2-Jun-98,1998,6,2,Von Hippel - Lindau (VHL) disease gene and corresponding cDNA and methods for detecting carriers of the VHL disease gene,"The invention is the Von Hippel-Lindau (VHL) disease gene and its corresponding cDNA protein product, and antibodies therefore. Methods for detecting carriers of the VHL disease gene using probes derived from the cDNAs are described. Antibodies and methods of detecting the Von-Hippel-Lindau protein are also described.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
5763166,9-Jun-98,1998,6,9,Gene associated with X linked Kallmann syndrome and diagnostic applications therefrom,"The invention relates to a fragment of nucleic acid characterized in that it comprises a nucleotide sequence selected from: (A) the sequence SEQ ID No. 1; (B) the sequences of one or more bases; (C) fragments of the said sequences (A) and (B); (D) sequences complementary to the said sequences (A), (B), and (C); and (E) the sequences which hybridize with the sequences (A),(B), and (C). The corresponding peptide sequences are also disclosed. A nucleic acid fragment of the invention may be used as a primer or probe, particularly in a method for diagnosing a genetic anomaly linked to the Kallmann syndrome.",16,Institut Pasteur,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12Q/6883
5763183,9-Jun-98,1998,6,9,Allelic variation of the serotonin 5HT7 receptor,"An allelic variant of the 5HT7 serotonin receptor was discovered. Family study data indicate that this variant can be correlated to alchoholic offerders. DNA encoding the variant protein, the protein itself, vectors containing the variant gene and cell lines carrying a vector with the variant gene are part of the invention.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5763216,9-Jun-98,1998,6,9,Gene encoding a human reduced folate carrier (RFC),"One shortcoming of methotrexate chemotherapy is that previously responsive tumors can become refractory to methotrexate after continued exposure. Such methotrexate resistance may be due to underexpression of reduced folate carrier (RFC) protein. The present invention provides DNA molecules encoding human RFC. The present invention also relates to expression vectors comprising RFC-encoding DNA molecules, and to the use of such vectors to restore methotrexate sensitivity in mammalian cells. The present invention further relates to antibodies that bind with human RFC protein, and to methods of detecting human RFC protein using such antibodies.",7,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5763464,9-Jun-98,1998,6,9,"Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same","The present invention provides novel retroviral agents containing anthranilamide, substituted benzamide, amino acid, and other subunits, a pharmaceutical composition comprising such compound, and a method of using such compounds to treat retroviral infections in mammals, specifically HIV and more specifically HIV-1 and HIV-2, in humans.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/30
5763613,9-Jun-98,1998,6,9,Monomeric naphthylisoquinoline alkaloids and synthesis methods thereof,"The present invention provides methods of preparing monomeric naphthylisoquinoline alkaloids, including the antiparasitic korupensamines and related compounds, as well as non-korupensamines and other monomeric naphthylisoquinoline alkaloids. The invention also provides new, medically useful naphthylisoquinoline compounds and derivatives thereof.",20,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/02
5766892,16-Jun-98,1998,6,16,Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic,"The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.",1,"Exponential Biotherapies, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
5767240,16-Jun-98,1998,6,16,Activity-dependent neurotrophic factor,"The present invention relates to a purified non-neuronal activity-dependent neurotrophic factor (ADNF) protein that increase the survival of spinal cord neuron cells, cerebral cortical cells and hippocampal neuron cells which has a molecular weight of 16,000 to 18,000 Daltons as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and a basic pI of about 8.1.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/475
5770083,23-Jun-98,1998,6,23,Separation of polar compounds by affinity countercurrent chromatography,Separations of very hydrophilic organic compounds has now been achieved using countercurrent chromatography in which a ligand for the analytes of interest is used to enhance the partitioning of the polar species into the organic layer of an aqueous/organic solvent mixture. The compounds are separated according to their affinity for the ligand in the stationary organic phase. This method of affinity countercurrent chromatography can also be conducted in a pH-zone refining mode.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
5770210,23-Jun-98,1998,6,23,Recombinant vaccinia virus expressing human retrovirus gene,"A recombinant vaccinia virus capable of expressing HTLV-III envelope protein (env) has been constructed. The expressed env protein is recognized by sera obtained from AIDS patients. The synthesized env protein also produces antibodies when administered to a suitable host, such antibodies having specific binding affinity with the env protein.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5770386,23-Jun-98,1998,6,23,Methods and compositions for increasing the sensitivity of a cell to a DNA damaging agent,The invention provides a method of increasing the sensitivity of a cell to a DNA damaging agent comprising increasing the amount of an NM23 in the cell. The method is especially useful for increasing the sensitivity of tumor cells to chemotherapy and radiation.,17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/12
5770396,23-Jun-98,1998,6,23,"Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E","The present invention relates to nucleic acid sequences, encoding amino acid sequences of the .alpha., .beta., and .gamma. subunits of the high affinity receptor for immunoglobulin E, and for amino acid sequences of the subunits. The invention further relates to a method of producing the receptor by expressing cDNA for its .alpha., .beta., and .gamma. subunits in a host cell simultaneously. Aspects of the invention are methods and compositions to inhibit the function of the human beta subunit, thereby treating or preventing allergic reactions.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70535
5770563,23-Jun-98,1998,6,23,Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof,"This invention identifies a biologically active group of peptide sequences from Type I repeat units of the extracellular matrix protein, human thrombospondin-1, identical or homologous to the sequence, KRFKQDGGWSHWSPWSSC (SEQ ID NO:30). The biological activities residing with the full sequences, portions thereof, and variants of the full or partial sequences are disclosed. The invention describes how biological activity may be enhanced by covalently linking these peptides to suitable carriers, preferably a branched, water-soluble polymer of low (or absent) toxicity and immunogenicity, such as polysucrose (Ficoll.TM.). The invention describes (1) a method for preparing such conjugates, (2) the use of the defined peptides or their conjugates in blocking or modifying the action on cellular processes of heparin (e.g., proliferation, adhesion, motility, extravasation and neovascularization), sulfatides, related sulfated glycoconjugates, fibronectin, and basic fibroblast growth factor, involving malignant cell lines and normal endothelial cells. Use of the defined peptides, analogs or peptidomimetics and their conjugates for treatment of metastatic tumors, breast carcinomas, melanomas, Kaposi's sarcomas, hemangiomas, diabetic retinopathies, and various pathological conditions dependent upon neovascularization is also disclosed.",41,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/10
5770689,23-Jun-98,1998,6,23,Hepatitis E virus ORF Z peptides,An antigen composition hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reading frames of the HEV genome.,1,"Genelabs Technologies, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/005
5773009,30-Jun-98,1998,6,30,Rotavirus strain G9P11,"Provided is an isolated rotavirus of the strain G9P11, an isolated nucleic acid encoding the rotavirus of strain G9P11 and a purified antigen specific for the rotavirus. An isolated nucleic acid encoding the antigen of the rotavirus is also provided, as is an isolated nucleic acid that selectively hybridizes under high stringency conditions with the nucleic acid encoding te virus. A purified antibody which selectively binds the virus of strain G9P11 is provided. The G9P11 rotavirus in a pharmaceutically acceptable carrier for administration in an immunization protocol is provided. Also provided is an isolated rotavirus of strain G9P11, wherein the G9 gene is substituted. Further provided is an isolated rotavirus of strain G9P11, wherein the P11 gene is substituted.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5773210,30-Jun-98,1998,6,30,Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS,An envelope protein of the etiologic agent of acquired immune deficiency syndrome (AIDS) and a method for its preparation are disclosed. Proviral DNA is transferred into a host cell after engineering into an expression vector which produces the envelope protein. A method of testing human blood for the presence of antibodies to the AIDS virus using the AIDS envelope protein is disclosed.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5773219,30-Jun-98,1998,6,30,Process for detecting Alzheimer disease using cultured cells,"A process for aiding in the diagnosis of Alzheimer disease is disclosed in which the frequency of chromatid breaks and gaps is calculated in G.sub.1 -phase fluorescent-light-irradiated skin fibroblasts or stimulated peripheral blood lymphocytes after the addition of the DNA repair inhibitor caffeine or in G.sub.2 -phase fluorescent-light-irradiated skin fibroblasts or stimulated peripheral blood lymphocytes after the addition of the DNA repair inhibitor 1.beta.-D-arabinofuranosylcytosine (ara-C). In the G.sub.1 -phase test, the presence of Alzheimer disease is indicated when the total frequency of breaks and gaps caused by caffeine in the cells being examined is higher than the total frequency caused by caffeine in the normal cells. In the G.sub.2 -phase test, the presence of Alzheimer disease is indicated when the total frequency of breaks and gaps in the presence of ara-C is much less in the cells being examined than in normal cells.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5091
5773423,30-Jun-98,1998,6,30,A3 adenosine receptor agonists,"The present invention provides N.sup.6 -benzyladenosine-5'-N-uronamide and related substituted compounds, particularly those containing substituents on the benzyl and/or uronamide groups, and modified xanthine ribosides, as well as pharmaceutical compositions containing such compounds. The present invention also provides a method of selectively activating an A.sub.3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A.sub.3 adenosine receptor a therapeutically effective amount of a compound which binds with the A.sub.3 receptor so as to stimulate an A.sub.3 receptor-dependent response.",50,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/70
5776676,7-Jul-98,1998,7,7,HME1 nucleic acids and probes,"A full length cDNA clone from a normal human mammary epithelial cell (strain 184) encoding a 25 kDa protein, HME1, was isolated. Expression of HME1 RNA appears to be limited to epithelial cells. The HME1 sequence shares strong sequence homology with bovine 14-3-3 protein, which is an activator of tyrosine and tryptophan hydroxylase, but the tissue distribution of HME1 differs from that of 14-3-3. Compared with normal mammary epithelial cells, expression of HME1 RNA is dramatically low in cells derived from human mammary carcinoma and in normal mammary epithelial cells transformed by oncogenes. HME1 therefore appears to be a cellular differentiation marker that is down-regulated during neoplastic transformation.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5780041,14-Jul-98,1998,7,14,39-kilodalton antigen specific to Borrelia burgdorferi,"The present invention relates to antigenic proteins specific to Borrelia burgdorferi which have a molecular weight of 28 kDa or 39 kDa as determined by SDS-PAGE and are reactivity with Lyme borreliosis serum or fragments thereof and to the corresponding DNA. The proteins, especially the 39 kDa proteins (.alpha. and .beta.) can be used to diagnosis mammals previously or currently infected with the Lyme borreliosis causing agent.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/20
5780589,14-Jul-98,1998,7,14,Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof,"Novel opioidmimetic dipeptides, tripeptides and cyclic peptides exhibit enhanced affinity and selectivity for .delta. opioid receptors. The peptides are represented by the formulas L/D-Dmt-L-/D-Tic-R', L/D-Dmt-L-/D-Tic-R-R' and cyclic (L/D-Dmt-L/D-Tic) wherein Dmt is 2',6',-dimethyl-L/D-tyrosine Tic is L-/D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, R is a natural or unusual aliphatic amino residue and R' is a functional group at the carboxyl terminus of the peptide. Pharmacological and therapeutic and compositions are also provided.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70
5782645,21-Jul-98,1998,7,21,Percutaneous connector for multi-conductor electrical cables,"A biologically implantable percutaneous connector (20) for providing optionally separable interconnection between an implanted connector (21) attached to bone tissue and a removable connector (40). The connectors each include a supporting matrix of dielectric material (86, 94) within which an array of tiny conductive rods (90, 88) are sealed with ends (112, 110) of the rods exposed as contacts at mating faces (94, 92) and the other ends (102, 100) joined to conductors (33, 43) of cables (32, 42). Elastomeric anisotropic connector material (44) is located between corresponding arrays of contacts to provide for repeated reliable electrical connection and disconnection of corresponding contacts. External surfaces of the implantable body (21) of the percutaneous connector may be coated with a bioactive material promoting integration of surrounding tissue into the surfaces of the implanted percutaneous connector. A contact block (22, 62) including the mating face (94, 92) and a terminal face (98, 96) to which the conductors of a cable are individually connected is made by shaping an array of conductive rods (90, 88) and supporting dielectric material to form a smooth surface including dielectric matrix material and the ends of the electrically conductive rods.",21,PI Medical Corporation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Medical technology,"Electrical machinery, apparatus, energy",,,,,H01R/2414
5783402,21-Jul-98,1998,7,21,Method of identifying ligands and anatgonists of G-protein coupled receptor,"The present invention relates, in general, to a method of identifying ligands and antagonists of ligands. In particular, the present invention relates to a method of identifying ligands and antagonists of ligands which bind to cloned G.sub.8 - or G.sub.1 -coupled receptors. The present invention also relates to a cell that comprises a recombinant cyclic AMP sensitive reporter construct.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6897
5783598,21-Jul-98,1998,7,21,Antiretroviral naphthoquinone compounds compositions and uses thereof,"The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",21,The United States of America as represented by the Secretary of the Department of Health and Human Sevices,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/92
5785998,28-Jul-98,1998,7,28,Apparatus for making ultra thin walled wire reinforced endotracheal tubing,"An ultra thin walled wire reinforced endotracheal tubing includes a thin walled tubing comprising a polymeric material having a spring material incorporated therewith. Utilization of the spring wire material in combination with polymeric material results in a reduced wall thickness which results in a significant decrease in resistance to air flow through the endotracheal tubing. The endotracheal tubing of the present invention is made by depositing a dissolvable polymeric material on a rotating mandrel in successive layers. A spring material is also applied around the mandrel to produce the ultra thin walled wire reinforced endotracheal tubing. By controlling the rate of deposition of polymeric material along the length of the mandrel, different wall thicknesses of tubing may be achieved.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,Medical technology,,,,,B29C/36
5786482,28-Jul-98,1998,7,28,Dimeric arylisoquinoline alkaloids and synthesis method thereof,"The present invention provides a method of preparing dimeric arylisoquinoline alkaloids by coupling two isoquinoline building blocks, which may be the same or different, together with a symmetrical or nonsymmetrical biaryl building block to form homodimers or heterodimers, including the antiviral michellamines. The present invention also provides new, medically useful homodimeric and heterodimeric arylisoquinoline compounds and derivatives thereof.",18,The United States of America as represented by the Department of Health and Human Services,The Trustees of Boston College,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/02
5789176,4-Aug-98,1998,8,4,Identification of a new Ehrlichia species from a patient suffering from Ehrlichiosis,"A new isolate of Ehrlichia species has been obtained from a patient suffering from ehrlichiosis. The new isolate has been found to be similar, but distinctly different from E. canis. A diagnostic kit and methods for diagnosing ehrlichiosis in humans and for screening drugs toxic to the new isolate have been described.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12R/01
5789447,4-Aug-98,1998,8,4,Nitric oxide releasing compounds as protective agents in ischemia reperfusion injury,"The present invention provides a method for treating oxygen free radical induced tissue damage associated with ischemia reperfusion injury, wherein nitric oxide is delivered to target cells/tissues through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen.",6,The United States of America as represented by the Department of Health and Human Services,The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/198
5789594,4-Aug-98,1998,8,4,Dimeric naphthylisoquinoline alkaloids and synthesis methods thereof,"The present invention provides methods of preparing dimeric naphthylisoquinoline alkaloids by coupling together two monomeric naphthylisoquinoline alkaloids, each of which may be the same or different, and one, both, or neither of which may possess a C-8' to C-5 naphthalene/isoquinoline linkage, to form homodimers or heterodimers, including the antiviral michellamines. The present invention also provides new, medically useful homodimeric and heterodimeric naphthylisoquinoline compounds and derivatives thereof.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
5792458,11-Aug-98,1998,8,11,Mutant diphtheria toxin conjugates,"A potent and specific immunotoxin is prepared by coupling an inactivated diphtheria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.",39,The United States of America as represented by the Department of Health and Human Services,Cetus Corporation,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/34
5792638,11-Aug-98,1998,8,11,Human ras-related oncogenes unmasked by expression cDNA cloning,"The oncogene of the present invention, isolated by expression cloning from a human ovarian cancer is a mutant of TC21. The present invention teaches that ras-related genes not thought to have transforming potential can contribute importantly to cancers which have been refractory to oncogene detection. The present invention teaches that another ras relative gene, R-ras, which was previously reported to lack transforming potential, has transforming capacity as well. Thus, these and other genes similarly related to prototype and activated by analogous mechanisms may be important in the diagnosis and prognosis of certain cancers, as well as be critical in the design of rational approaches to therapy of cancers in which they play a role.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
5792657,11-Aug-98,1998,8,11,Steroid secreting human adrenocortical carcinoma cell lines,"Continuous cell lines have been established from adrenocortical corcinomas. The cell lines are maintained in fully defined serum-free, steroid-free mediums. The cells of the invention, as exemplified by NCI-H295 cells, express all of the major pathways of steroid-ogenesis, including formation of corticosteroids, mineralocorticoids and androgens.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0693
5792752,11-Aug-98,1998,8,11,8-chloro camp and related camp compounds as antineoplastic agents,Site 1- and site 2-selective derivatives of cAMP have been found to inhibit the growth of a variety of cancer and leukemic cells. The compounds have been found to have a synergistic effect in cancer and leukemic cell growth inhibition when a site 1-selective compound is used in combination with a site 2-selective compound.,24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/70
5792775,11-Aug-98,1998,8,11,"""4' and 4', 4""""-substituted-3-.alpha.-(diphenylmethoxy) tropane analogs as cocaine therapeutics""","The present invention provides a family of tropane analogs. More particularly, the present invention provides a family of 4' and 4',4""-substituted-3.alpha.-(diphenylmethoxy)tropane analogs having the formula ##STR1## in which R is a functional group including, but not limited to, hydrogen, alkyl, alkoxy, arylalkyl, aryloxyalkyl, cinnamyl and acyl; and R.sup.1 and R.sup.2 are independently selected and are functional groups including, but not limited to, hydrogen, alkyl, alkoxy, hydroxy, halogen, cyano, amino and nitro. The benztropine analogs of the present invention have a high affinity for the dopamine transporter and inhibit dopamine uptake, but they do not exhibit a cocaine-like behavioral profile. Moreover, the present invention provides methods of using such benztropine analogs to treat cocaine abuse, to image dopamine transporter/cocaine binding sites, and to diagnose and/or monitor neurodegenerative disorders (e.g., Parkinson's disease). In addition, the present invention provides pharmaceutical compositions comprising a benztropine analog of the present invention and a pharmaceutically acceptable carrier or excipient.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/06
5795866,18-Aug-98,1998,8,18,ETS1 gene: a human tumor suppressor gene,"The present invention relates, in general, to methods for reducing cell tumorigenicity. More particularly, the present invention provides a method for reducing cell tumorigenicity comprising transfecting a tumor cell with an ETS1 gene, the tumor cell not endogenously expressing the ETS1 gene. In addition, the present invention provides a method for reducing cell tumorigenicity comprising contacting a tumor cell with a peptide expressed by an ETS1 gene, the tumor cell not endogenously expressing the ETS1 gene. The methods of the present invention are particularly useful for reducing tumorigenicity in epithelial tumor cells.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/82
5801056,1-Sep-98,1998,9,1,Nucleic acid encoding HIV-1 tat protein,"Nucleic acid encoding a functional HTLV-III/LAV (HIV-1) protein having trans-activating ability, and expression vectors comprising this nucleic acid are described.",13,Dana-Farber Cancer Institute,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
5807988,15-Sep-98,1998,9,15,"Isolation, characterization, and use of the human and subunit of the high affinity receptor for immunoglobulin E","The present invention relates to nucleic acid sequences, encoding amino acid sequences of the .beta., and subunit of the human high affinity receptor for immunoglobulin E, and for amino acid sequences of the subunit. A segment of the amino acid sequence containing an antigen recognition activation motif (ARAM) that exhibits different functions than other ARAMS, including that of the ARAM-.gamma. subunit of Fc.epsilon.RI. The invention further relates to a method of producing the receptor by expressing cDNA for its a, .beta., and .gamma. subunits in a host cell simultaneously. Aspects of the invention are methods and compositions to inhibit the function of the human beta subunit, thereby treating or preventing allergic reactions.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70535
5808028,15-Sep-98,1998,9,15,Molecular clone of a P58 receptor protein and uses thereof,"The present invention provides a purified and isolated nucleic acid molecule encoding the p58 receptor protein. The present invention also provides vectors encoding this nucleic acid molecule, a host cell stably transformed or transfected with the vector, as well as the p58 receptor protein produced by this host cell. The present invention further provides methods for detecting nucleic acid encoding the p58 receptor as well as the p58 receptor protein in biological samples, methods for identifying a ligand capable of binding to the p58 receptor protein, and methods for screening for drugs capable of acting as agonists or antagonists to the p58 receptor protein. The present invention also provides the agonists and antagonists identified by the screening methods, as well as their use. Lastly, the present invention provides chimeric protein comprising the cytoplasmic region of a p58 receptor protein.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70503
5808038,15-Sep-98,1998,9,15,Bistriazenes as chemotherapeutic agents,"The present invention is directed to bistriazene compounds, pharmaceutical compositions containing effective anti-cancer amounts of these compounds, a method for treating cancer comprising administering to affected subjects an anti-cancer effective amount of a bistriazene compound, and the use of bistriazene compounds as crosslinking reagents applicable to the synthesis and manipulation of polymeric macromolecules.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/77
5810773,22-Sep-98,1998,9,22,Mixing arrangement and method,"An arrangement for mixing together two fluids includes a base and first, second, and third holding members each secured to the base. The first holding member is constructed and arranged to hold a first fluid holding device, such as a syringe, relative to a second fluid holding device, such as a syringe, and a connector. The second holding member is constructed and arranged to hold the second fluid holding device relative to the first fluid holding device and the connector. The third holding member is constructed and arranged to hold the connector relative to the first fluid holding device and second fluid holding device. The third holding member is positioned on the base in axial alignment with both the first holding member and the second holding member. A method for mixing two fluids includes connecting first and second syringes with a three-way stopcock. The connected syringes are positioned on a base containing three holding members. The fluids are pumped back and forth between the two syringes in order to mix the fluids.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61J/2096
5811093,22-Sep-98,1998,9,22,Bacteriophage genotypically modified to delay inactivations by the host defense system,"The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging of a bacteriophage, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.",4,"Exponential Biotherapies, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
5811262,22-Sep-98,1998,9,22,Hepatocellular carcinoma oncogene,The present invention relates to an oncoprotein specific for hepatocellular carcinomas and to a nucleotide sequence that codes for such a protein. The invention further relates to screening and diagnostic methodologies (and kits based thereon) that make use of the oncoprotein (or antibodies specific for same) and the nucleotide sequence.,3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/32
5811282,22-Sep-98,1998,9,22,Cell lines useful for detection of human immunodeficiency virus,"The present invention relates to a method for AIDS diagnosis and monitoring of anti-AIDS drug therapy, and more particularly to a method of assaying for human immunodeficiency virus. The present invention uses a focal immunoassay (FIA) which utilizes HIV-specific antibodies and indirect immunoassay techniques to detect local areas of HIV infection in susceptible target cells growing in monolayers on plastic dishes. The present invention further relates to specific cell lines used as the susceptible target cells in the disclosed methods.",8,The Unites States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5811396,22-Sep-98,1998,9,22,TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor,The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further relates to methods that can be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting NGF-trk receptor pairs and the phosphorylation of trk protein.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/71
5814452,29-Sep-98,1998,9,29,Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus,"Immortalized non-tumorigenic or tumorigenic human prostatic epithelial and fibroblast cell lines and derivatives thereof, containing DNA of a hybrid virus between adenovirus 12 and simian virus 40. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.",8,Board of Trustees operating Michigan State University,The United State of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/5011
5814656,29-Sep-98,1998,9,29,Selective prevention of organ injury is sepsis and shock using selective release of nitric oxide vulnerable organs,A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically effective amount of nitric oxide sufficient to protect the tissue from sepsis- or shock-induced injury.,9,"The United States Of America, as represented by the Department Of Health And Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/445
5814666,29-Sep-98,1998,9,29,Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents,"This invention relates to compositions capable of releasing nitric oxide and therapeutic methods of use thereof for the treatment of microorganism-related disease states. The composition comprises one or more nitric oxide generators, preferably encapsulated in vesicles, such as liposomes. The compositions are used therapeutically by administration to humans and animals via different routes for the treatment of infectious diseases caused by pathogenic microbes.",26,The United States as represented by the Department of Health and Human Services,"Entremed, Inc.",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/495
5814667,29-Sep-98,1998,9,29,Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers,"The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.",6,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
5817313,6-Oct-98,1998,10,6,Monoclonal antibodies and conjugates thereof useful for the treatment of cancer,"The invention provides a novel treatment of cancer using a monoclonal antibody that recognizes cell surface antigens present on a number of tumor cells, including ovarian, esophageal and cervical carcinomas. A preferred monoclonal antibody is secreted by a hybridoma deposited with the ATCC and has Accession NO. HB 10570.",4,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1045
5817471,6-Oct-98,1998,10,6,Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor,The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further relates to methods that can be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting NGF-trk receptor pairs and the phosphorylation of trk protein.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/71
5817797,6-Oct-98,1998,10,6,Sequencing DNA; a modification of the polymerase chain reaction,The invention provides a process wherein a biotinylated oligonucleotide primer and an oligonucleotide primer which has not undergone biotinylation are used when amplifying a DNA sequence to facilitate separation of the DNA strands following the polymerase chain reaction process. The biotinylation/PCR product is then exposed to a support which will selectively bind the biotinylated strand to allow selective elution of the product.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12Q/6844
5817799,6-Oct-98,1998,10,6,2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides,"A method of preparing a 2'-fluoro compound of the formula ##STR1## where B is selected from the group consisting of purines and pyrimidines, both of which may be substituted, comprises reacting a compound of the formula II(a) or II(b) ##STR2## where R and R' are as defined in the specification with an acid halide under conditions effective to obtain a halide of the formula ##STR3## where X is a halogen. A silane of the formula B-Si (R"").sub.3 where R"" is as defined in the specification, is added to this product (III) under conditions effective to obtain a compound of the formula (IV) ##STR4## The compound of formula (IV) is reacted with a reagent selected from the group consisting of ammonia, BCl.sub.3 and ((C.sub.1 -C.sub.10)alkyl).sub.4 NF, under conditions effective to obtain the compound of formula (I). The compounds of formula (I) resulting from these methods exhibit anti-HIV activities and are useful for therapy against the HIV virus.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07H/00
5820859,13-Oct-98,1998,10,13,Method of targeting a therapeutic agent to cells expressing the erb B-3 receptor,"A DNA fragment distinct from the epidermal growth factor receptor (EGFR) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was mapped to human chromosome 12q11-13 and was shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGFR and erbB-2, plays a role in some human malignancies. Using erbB-3 specific antibodies (polyclonal or monoclonal), the erbB-3 protein was identified as a 180 kDa glycoprotein, gp180.sup.erbB-3. The intrinsic catalytic function of gp180.sup.erbB-3 was uncovered by its ability to autophosphorylate in vitro. Ligand-dependent signaling of its cytoplasmic domain was established employing transfectants which express a chimeric EGFR/erbB-3 protein, gp180.sup.EGFR/erbB-3. EGF induced tyrosine phosphorylation of the chimera and promoted soft agar colony formation of such transfectants. These findings, combined with the detection of constitutive tyrosine phosphorylation of gp180.sup.erbB-3 in 4 out of 12 human mammary tumor cell lines, implicate the activated erbB-3 product in the pathogenesis of some human malignancies. Thus, this invention also relates to procedures for targeting a therapeutic drug to cells having a high level of the receptor protein.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/32
5820865,13-Oct-98,1998,10,13,Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides,"The instant invention describes the synthesis of short peptides, corresponding to the amino acid residues of the V3 loop of the gpl6O envelope glycoprotein of HIV-1 numbered 315 to 329 by Ratner (Ratner, L. et al., Nature 313, 277 (1985)) in the strain IIIB, wherein the residue corresponding to number 325 in HIV-1 IIIB is substituted by the homologous residue from another clinical isolate or strain. The invention further describes the use of said peptides in pharmaceutical compositions and an immunization protocol which elicits cytotoxic T cells reactive to a broad range of isolates of HIV-1.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5821081,13-Oct-98,1998,10,13,"Nucleic acids encoding antiviral proteins and peptides, vectors and host cells comprising same, and methods of producing the antiviral proteins and peptides","The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.",14,The United States of Americaa as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
5821223,13-Oct-98,1998,10,13,Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen,"The present invention relates to a potent mitogenic growth factor called plasminogen-like growth factor (PLGF) isolated from conditioned medium of human lung fibroblasts. The protein has an apparent molecular weight under reducing conditions of 87 kDa and is structurally related to hepatocyte growth factor (HGF); however unlike HGF, which was reported to be specific for hepatic cells, PLGF stimulates a wide spectrum of target cells including melanocytes, endothelial cells and epithelial cells but excludes fibroblast cells. The present invention further relates to recombinant cloned DNA fragments and expression cell systems expressing biologically active PLGF. The availability of purified PLGF as well as immunological and molecular probes should facilitate the study of proliferative disorders in which the factor plays an important role.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4753
5821238,13-Oct-98,1998,10,13,Recombinant pseudomonas exotoxin with increased activity,"This invention relates to the production and use of recombinant Pseudomonas-derived toxins modified to increase their toxicity and potency in therapy. More particularly, the invention relates to certain deletions in domain II of the amino acid sequence of Pseudomonas exotoxin the domain which relates to the toxin's natural proteolytic processing.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/30
5821254,13-Oct-98,1998,10,13,Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer,"This invention relates to methods and compositions for preventing or treating cancer. Specifically this invention relates to the use of 9-cis-retinoic acid or derivatives thereof in preventing or treating cancers, in particular breast cancer. The invention also relates to compositions of 9-cis-retinoic acid or derivatives thereof and at least one other antineoplastic agent and to the use of such compositions in the prevention or treatment of cancer, in particular breast cancer.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/20
5821269,13-Oct-98,1998,10,13,Treated bird seed preferentially palatable to birds but not palatable to animals having capsaicin sensitive receptors,"The present invention is directed to preparations of birdseed treated with capsaicin or capsaicin derivatives or analogs thereof in an amount sufficient to be unpalatable to animals having capsaicin sensitive receptors, and more specifically to mammals such as rodents. These ""hot"" compounds, extracts or whole plant material containing these compounds may be coated on, impregnated in or combined (e.g., mixed) with birdseed to repel troublesome mammals which recognize these compounds as ""hot"". These ""hot"" compounds, in contrast, will not repel birds because birds do not recognize these compounds as ""hot"" since they do not have capsaicin sensitive receptors. The invention is further directed to a method of selectively repelling animals having capsaicin sensitive receptors, which comprises feeding the treated birdseed of the invention to birds, in an amount effective for repelling animals having capsaicin sensitive receptors, thereby discouraging said animals from eating the treated birdseed.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Food chemistry,,,,,,A23K/70
5822742,13-Oct-98,1998,10,13,Dynamically stable associative learning neural network system,"A dynamically stable associative learning neural system includes a plurality of neural network architectural units. A neural network architectural unit has as input both condition stimuli and unconditioned stimulus, an output neuron for accepting the input, and patch elements interposed between each input and the output neuron. The patches in the architectural unit can be modified and added. A neural network can be formed from a single unit, a layer of units, or multiple layers of units.",51,The United States of America as represented by the Secretary of Health & Human Services,"ERIM International, Inc.",,,,,,,,,,2,Computer technology,,,,,,G06N/04
5824310,20-Oct-98,1998,10,20,Lipopplysaccharide conjugate vaccines,"The present invention relates to lipopolysaccharides from Brucella abortus and their use as carriers in vaccines for humans and animals. In particular, the present invention relates to conjugate molecules having a carrier molecule of purified lipopolysaccharide from B. abortus coupled to an antigenic component of an infectious organism.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/385
5824488,20-Oct-98,1998,10,20,Immortalized and malignant human prostatic cell lines,"Immortalized malignant human prostatic epithelial and fibroblast cell lines are described containing DNA of a human papillomavirus (HPV) and similar cell lines containing DNA of a human papillomavirus and an activated viral ras oncogene, such as v-Ki-ras. The cell lines are useful for research on drugs for treatment of prostatic cancer and other diseases. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.",20,Board of Trustees operating Michigan State University,The United States of America as represented by the Deparmtent of Health and Human Services,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12N/0683
5824520,20-Oct-98,1998,10,20,Phage-display of immunoglobulin heavy chain libraries for identification of inhibitors of intracellular constituents,"One aspect of the invention relates to a phage-display library that expresses single-chain recombinant binding proteins. Inserts in the library comprise immunoglobulin heavy chain framework regions flanking highly divergent, synthetically produced hypervariable regions. A second aspect of the invention relates to the use of single-chain recombinant binding proteins to inhibit the activity of an intracellular constituent. In the exemplary case presented, the activity of intracellular glucose-6-phosphate dehydrogenase was inhibited by intracellular expression of a cloned single-chain recombinant binding protein.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Analysis of biological materials,,,,C40B/02
5824664,20-Oct-98,1998,10,20,Suppression of HIV expression by organic thiophosphate,"Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.",24,"U.S. Bioscience, Inc.","National Institutes of Health, The National Cancer Institute",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/66
5824674,20-Oct-98,1998,10,20,Brefeldin A derivatives and their utility in the treatment of cancer,"Provided are brefeldin A derivatives of the formula: ##STR1## wherein one of R.sub.1 and R.sub.2 is H and the other of R.sub.1 and R.sub.2 is a substituent group having 1 to 12 carbon atoms containing a basic nitrogen atom or a quaternary ammonium group, or a salt thereof. These derivatives exhibit good antitumor activity, and are administrable to human patients without the problems associated with brefeldin A.",2,The United States of America as represented by the Department of Health and Human Services,Starks Associates,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/00
5827647,27-Oct-98,1998,10,27,Parvovirus capsids,The present invention relates to a method of producing non-infectious-parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
5827658,27-Oct-98,1998,10,27,Isolation of amplified genes via cDNA subtractive hybridization,"A method of analyzing an amplified gene, including determining its copy number, involves subtractive hybridization of two cDNA libraries, one from the tissue of interest and the other containing biotinylated cDNA from normal tissue, where the annealed cDNA is removed by means of magnetic beads coated with streptavidin or avidin. The cDNA isolated after subtractive hybridization represents amplified DNA, and it is analyzed to determine what gene(s) were amplified. Furthermore, the copy number of the gene(s) can be estimated. The copy number thus determined can be correlated to the severity of a pathogenic state, to its prognosis, or to treatment efficacy.",7,The United States of America as reprsented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1072
5828216,27-Oct-98,1998,10,27,Gated RF preamplifier for use in pulsed radiofrequency electron paramagnetic resonance and MRI,A gated RF preamplifier used in system for performing pulsed RF FT EPR spectroscopy and imaging or MRI. The RF preamplifier does not overload during a transmit cycle so that recovery is very fast to provide for ultra-fast data acquisition in an ultra-fast excitation subsystem. The preamplifier includes multiple low-gain amplification stages with high-speed RF gates inserted between stages that are switched off to prevent each stage from overloading during the transmit cycle.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Basic communication processes,,,,,G01R/3621
5830755,3-Nov-98,1998,11,3,T-cell receptors and their use in therapeutic and diagnostic methods,"The present invention provides nucleic acid sequences for T-cell receptors which recognize tumor associated antigens. In particular, T-cell receptors which recognize melanoma antigens. This invention also provides T-cells expressing the antigen specific T-cell receptors. In addition, this invention provides stem cells expressing the antigen specific T-cell receptors or chimeric receptors. This invention further relates to therapeutic and diagnostic compositions and methods employing the T-cell receptors and chimeric receptors provided herein.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/7051
5831015,3-Nov-98,1998,11,3,Colon mucosa gene having down-regulated expression in colon adenumas and adenocarcinomas,"A new down-regulated gene called DRA, for down regulated in adenoma, maps to chromosome 7 and is believed to encode a tumor suppressor. The DRA gene encodes a highly hydrophobic protein with charged clusters located primarily in the carboxyl terminus. Additionally, the expression of the mRNA product appears to be strictly limited to the mucosa of normal colon and it is down-regulated early in colon tumorigenesis. Absence of the DRA polypeptide in tissue that usually expresses it can be used as an indicator of tissue abnormality. The DRA gene and cDNA may also have therapeutic capabilities as well.",2,The United State of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
5831016,3-Nov-98,1998,11,3,Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes,The infusion of TIL586 along with interleukin-2 (IL-2) into the autologous patient with metastatic melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen recognized by TIL586 was previously isolated and shown to encode gp75 or TRP-1. The present invention relates to the identification of a second tumor antigen recognized by a HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP-2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Modified peptides were also recognized by the CTL clone.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0059
5831141,3-Nov-98,1998,11,3,Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter,Heterologous polypeptides are produced in the milk of transgenic non-human mammals by the expression of a stably integrated DNA sequence containing the long whey acidic protein promoter operably linked to a DNA sequence encoding a heterologous polypeptide and a signal sequence. The transgenic non-human mammals of the present invention are produced by introducing this DNA sequence such that the DNA sequence is stably integrated into the DNA of germ line cells of the mature mammal and inherited in normal Mendelian fashion. A representative heterologous polypeptide is protein C.,20,United States of America as represented by the Department of Health and Human Services,American Red Cross,,,,,,,,,,2,Biotechnology,Other special machines,Biotechnology,,,,C12N/8509
5833983,10-Nov-98,1998,11,10,Interleukin 2 receptor and applications thereof,"The present invention is related to the field of receptor molecules and complexes. More particularly, the present invention is related to a new polypeptide receptor for interleukin-2 having a molecular weight of about 70-75,000, which is a component of the high affinity IL-2 receptor, antibodies against this new polypeptide, and recombinant interleukins capable of binding to the new receptor. Various applications of the p70-75 receptor, the anti-p70-75 antibodies and IL-2W.sub.1 and IL2W.sub.2 have also been described.",2,The United States of America as represented by the Secretary of Dept. of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/7155
5833986,10-Nov-98,1998,11,10,Methods of inhibiting the growth of neoplasia using a monoclonal antibody against .alpha. platelet derived growth factor receptor,"Potent neutralizing monoclonal antibodies to the human .alpha. PDGF receptor (.alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on .alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind .beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing .alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of .alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/71
5834310,10-Nov-98,1998,11,10,Mammalian muscle NAD: arginine ADP-ribosyltransferase,This invention relates to the identification and molecular characterization of NAD:arginine ADP-ribosyltransferases. Sequences from the rabbit skeletal muscle NAD:arginine ADP-ribosyltransferase and the human NAD:arginine ADP-ribosyltransferase are provided herein. Recombinant protein is expressed from a recombinant gene vector containing at least 15 continuous bases of genes encoding these sequences.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
5834429,10-Nov-98,1998,11,10,Small peptides which inhibit binding to T-4 receptors and act as immunogens,"Short peptide of the formula: EQU R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.b (I) where R.sup.a represents an amino terminal residue Ala- or D-Ala and R.sup.b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II): EQU R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II) where R.sup.1 is an amino terminal residue Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu- PA1 R.sup.2 is Thr, Ser or Asp PA1 R.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp PA1 R.sup.4 is Tyr and R.sup.5 is a carboxy terminal amnio group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals, or a physiologically acceptable salt thereof. Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors. These peptides are believed to act as competitive blocking agents.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5837247,17-Nov-98,1998,11,17,Chemotactic agents for t-cells,Chemotactic activity of defensins and CAP37 is disclosed. Methods of treatment associated with such activity and compositions for such treatment are also provided.,7,United States of America as represented by the Public Health Service National Institutes of Health,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1709
5837260,17-Nov-98,1998,11,17,Chimeric hepatitis A vaccine,"A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.",6,The United of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5837477,17-Nov-98,1998,11,17,T cell receptor ligands and methods of using same,"The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/80
5837536,17-Nov-98,1998,11,17,Expression of human multidrug resistance genes and improved selection of cells transduced with such genes,"A DNA sequence for a human mdr1 gene, which encodes p-glycoprotein, wherein at least one base in a splice region of the DNA encoding p-glycoprotein is changed. Such a mutation prevents truncation of the p-glycoprotein upon expression thereof. There is also provided a method of identifying cells which express the human mdr1 gene in a cell population that has been transduced with an expression vehicle including a human mdr1 gene. The method comprises contacting the cell population with a staining material, such as rhodamine 123, and identifying cells which express the human mdr1 gene based on differentiation in color among the cells of the cell population. This method has allowed identification of retroviral producer clones facilitate mdr gene transfer into primary cells. Repopulating hematopoietic stem cells have been genetically engineered with the human mdr1 gene.",21,"Genetic Therapy, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/00
5837736,17-Nov-98,1998,11,17,Nitric oxide-releasing compounds to sensitive cancerous cells to chemotherapeutic agents,"The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
5840686,24-Nov-98,1998,11,24,Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use,"Nucleic acids encoding the neurotrophic protein known as pigment epithelium-derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF -BP, -BX and BA, and the PEDF protein produced by recombinant methods Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/811
5840728,24-Nov-98,1998,11,24,Conformationally locked nucleoside analogs as antiherpetic agents,A method for treatment of herpes virus infection by administering an effective virus-inhibiting amount of a cyclopropanated carbocyclic 2'-deoxynucleoside to an individual in need thereof. The nucleoside analogs are effective against herpes simplex virus types 1 and 2; Epstein-Barr Virus and human cytomegalovirus.,5,United States of America as represented by the Department of Health and Human services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/44
5840759,24-Nov-98,1998,11,24,Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents,"The present invention provides a method for sensitizing hypoxic cells in a tumor to radiation, wherein nitric oxide is delivered to target hypoxic cells through the administration of a nitric oxide-containing compound that spontaneously releases nitric oxide under physiological conditions without requiring the presence of oxygen. Also provided are methods of protecting noncancerous cells or tissues in a mammal from radiation, sensitizing cancerous cells in a mammal to chemotherapeutic agents, and protecting noncancerous cells or tissues in a mammal from chemotherapeutic agents, all by administration of the same compounds.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/13
5840839,24-Nov-98,1998,11,24,Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein,"The present invention discloses that the normal melanogenic gene, gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3, which is processed to an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The products of this gene are promising candidates for immunotherapeutic strategies for the treatment and diagnosis of patients with cancer.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0059
5840840,24-Nov-98,1998,11,24,Selective RNase cytotoxic reagents,"The present invention relates to a selective cytotoxic RNase reagent. The reagent comprises a toxic moiety that is an RNase linked to a recognition moiety that binds a specific cell surface marker. Binding of the recognition moiety to a surface marker on a cell allows the toxic moiety to selectively kill the cell. To reduce immunogenicity, preferably the toxic moiety and the recognition moiety of the conjugate are endogenous to the species in which the reagent is intended for use. Cytotoxic reagents intended for use in humans preferably have as the toxic moiety a human ribonuclease, such as angiogenin, and as the recognition moiety as humanized chimeric antibody. The human ribonuclease and chimeric antibody preferably form a fused protein. The present invention also relates to pharmaceutical compositions including the cytotoxic reagent as well as treatment methods involving the use of the cytotoxic reagent.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/79
5843644,1-Dec-98,1998,12,1,Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe,"A method of direct extraction of cellular material from a tissue sample which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extracted zone(s) of cells is subjected to analysis. The overall process of identifying, extracting, transporting, and analyzing the extracted zones(s) of cells can be fully automated.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Optics,Analysis of biological materials,,,,G02B/32
5843648,1-Dec-98,1998,12,1,P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated p15. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the p15 melanoma antigen and a second melanoma antigen designated tyrosinase. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",14,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5843657,1-Dec-98,1998,12,1,Isolation of cellular material under microscopic visualization,"A method of microdissection which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes an activatable adhesive layer which provides chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated the transfer surface and tissue sample are separated. During separation the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Optics,Biotechnology,Analysis of biological materials,,,G02B/32
5843882,1-Dec-98,1998,12,1,Antiviral proteins and peptides,"The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",21,The United States of America as Represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
5843916,1-Dec-98,1998,12,1,"Cyclic amp analogues, individually and in pairs, to inhibit neoplastic cell growth","A method of inhibiting the proliferation of cells, particularly cancerous cells, by contacting the cells with a phosphorothioate derivative of a cAMP modified at either or both the C-6 and C-8 positions of the adenine moiety, and pharmaceutical compositions therefor.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5843994,1-Dec-98,1998,12,1,Compositions and methods for treating and preventing pathologies including cancer,"Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents including retinoids, hydroxyurea, and flavonoids. Intravesicle methods of treatment of cancers phenylacetate. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention. A product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonid (or other mevalonate pathway inhibitor) for simultaneous, separate, or sequential use in treating a neoplastic condition in a subject. Methods of modulating lipid metabolism and/or reducing serum triglycerides in a subject using phenylacetate.",48,The United States of America as represeneted by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/35
5844075,1-Dec-98,1998,12,1,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
5846535,8-Dec-98,1998,12,8,Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity,"The subject invention relates to methods for reducing tumor cell growth in a mammal by administering compositions which include an antibody having the binding specificity of a monoclonal antibody selected from the group comprising one of those referred to as B1, B3 or B5 conjugated to a toxin, radionuclide or drug.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/3046
5846540,8-Dec-98,1998,12,8,"Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments","Immunogenic chimeric proteins comprising an endoplasmic reticulum signal sequence and at least one other peptide are disclosed. The invention relates to the design of vaccinia virus constructs capable of directing host organism synthesis of immunogenic chimeric proteins which can be used as immunogens, as vaccines, or in methods of treatment for cancer, infectious diseases, or autoimmune diseases.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/205
5847096,8-Dec-98,1998,12,8,DNA constructs encoding CD4 fusion proteins,"The subject invention relates to defective, interfering HIV particles and uses thereof. In particular, these particles encode a membrane bound receptor protein, as well as multitarget ribozymes, which together interfere with the production of infectious HIV by a host cell by downregulating the amount of HIV envelope protein on the surface of the cell as well as the amount of HIV genomic RNA.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1132
5849304,15-Dec-98,1998,12,15,Recombinant vaccinia virus expressing human retrovirus gene,"A recombinant vaccinia virus capable of expressing HTLV-III envelope protein (env) has been constructed. The expressed env protein is recognized by sera obtained from AIDS patients. The synthesized env protein also produces antibodies when administered to a suitable host, such antibodies having specific binding affinity with the env protein.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5849306,15-Dec-98,1998,12,15,Binding domains from Plasmodium vivax and Plasmodium falciparum erythrocyte binding proteins,"The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
5849494,15-Dec-98,1998,12,15,Methods for sensitive detection of reverse transcriptase,"The present invention provides a method for detecting the presence of a retrovirus in a biological sample comprising the steps of: a) contacting the biological sample with an RNA template and a complementary DNA primer under conditions whereby the RNA template and the DNA primer will anneal and a DNA strand will be synthesized as an extension from the DNA primer if reverse transcriptase is present in the sample; b) amplifying the synthesized DNA; and c) detecting the amplification of the synthesized DNA, the amplification of the synthesized DNA indicating the presence of reverse transcriptase in the biological sample, thus indicating the presence of a retrovirus in the biological sample.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/702
5849562,15-Dec-98,1998,12,15,Production of complementary DNA representing hepatitis A viral sequences by recombinant DNA methods and uses therefor,"Methods for producing HAV cDNA, products thereof, and uses thereof, are described. HAV cDNA is produced, for example, by reverse transcribing HAV RNA and subsequently inserting the HAV cDNA into bacterial plasmids by genetic-engineering techniques. Transformed bacteria are then cloned and cultured to produce replicated chimeric plasmids containing the HAV cDNA. Such HAV cDNA is useful in assaying for the presence of HAV and in the production of HAV antigen and in the production of antibodies against HAV.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5849691,15-Dec-98,1998,12,15,Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II,The present invention relates to the design and synthesis of linear and cyclic inhibitors of cathepsin D and plasmepsins I and II. The present invention also relates to the uses of these inhibitors for inhibiting invasion and metastasis of cancerous cells. The present invention further relates to the use of cathepsin D and plasmepsin I and II inhibitors for the prevention and treatment of Alzheimer's disease and malaria.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/0205
5849701,15-Dec-98,1998,12,15,Peptide inhibitors of fibronectin and related collagen-binding proteins,Peptides derived from the second type 1 repeat of human endothelial cell thrombospondin which bind to the gelatin-binding domain of fibronectin have been isolated and synthetically produced. The peptides can be used to bind to fibronectin or other related collagen-binding proteins to inhibit fibronectin-dependent cell adhesion to collagen matrices and to inhibit interactions with collagen of other proteins that share homologies with the gelatin-binding domain of fibronectin.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/78
5851819,22-Dec-98,1998,12,22,Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells,The present invention provides for vectors carrying a cDNA containing the entire coding region of the human multidrug resistance gene (MDR1) and for a method for introducing MDR1 cDNA into cells thereby inducing a multidrug resistant phenotype.,8,National Institutes of Health,,,,,,,,,,,1,Other special machines,Biotechnology,,,,,A01K/0271
5852056,22-Dec-98,1998,12,22,Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders,Methods of inhibiting IL-6 in a cell by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/35
5853697,29-Dec-98,1998,12,29,Methods of treating established colitis using antibodies against IL-12,"The present invention provides a method for treating the inflammatory response of an established colitis in a subject with inflammatory bowel disease (IBD), comprising administering to a subject diagnosed with an established colitis from an IBD an amount of an antibody to interleukin-12 effective in reducing the colitis-inducing effect of interleukin-12. Also provided is a method for screening a substance for its effectiveness in reducing the inflammatory response of an established colitis comprising obtaining an animal having an established colitis; administering the substance to an animal; and assaying the animal for an effect on interleukin-12 which results in the reduction of the inflammatory response of the colitis, an amount of reduction of the inflammatory response greater than the amount of reduction produced by the administration of antibodies against interferon-gamma or tumor necrosis factor-alpha indicating an effective substance. Additionally, the present invention provides a method for screening a substance for its effectiveness in preventing inflammatory bowel disease comprising administering the substance to an animal susceptible to colitis; subjecting the animal to a treatment that will induce a colitis; assaying the animal for the development of a colitis; and comparing the effectiveness of the substance in preventing development of a colitis to the effectiveness of antibodies to interferon-gamma or tumor necrosis factor-alpha in preventing development of a colitis, a substance more effective in preventing the development of a colitis than antibodies to interferon-gamma or tumor necrosis factor-alpha indicating an effective substance.",11,"The United States of America, as represented by the Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/244
5853724,29-Dec-98,1998,12,29,"Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies","The present invention provides a vaccine that can be administered to a mammal to cause immunoprotection in the mammal against a pathogenic organism that has an immunodominant epitope. The vaccine includes a modified form of the antigen in which the immunodominant epitope is located. In this modified form, the immunodominant epitope is immunodampened by any of a number of techniques. Examples of immunodampening techniques include addition of N-linked glycosylation sites, change of the net charge on the epitope, and substitution with a tolerated sequence. The vaccine also includes a pharmacologically acceptable carrier.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5853739,29-Dec-98,1998,12,29,Transmission-blocking vaccine against malaria,The present invention relates to transmission-blocking vaccines against malaria. Vaccines of the present invention contain a recombinant Pfs25 Plasmodium falciparum protein produced by yeast cells and to yeast cells producing the protein. Mice and monkeys inoculated with the yeast-expressed Pfs25 of the present invention have developed antibodies with transmission-blocking activity. The present invention also relates to methods of preventing or treating malarial infections using the vaccines of the present invention.,13,The United States of America as represented by the Department of Health and Human Services,Chiron Corporation,,,,,,,,,,2,Biotechnology,,,,,,C07K/445
5853980,29-Dec-98,1998,12,29,Black creek canal hantavirus and related methods,"The present invention relates to the discovery and isolation of a novel hantavirus designated the Black Creek Canal hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents (primers and probes), purified polypeptides and antibodies for use in methods of detection and prevention of infection by the virus. A vaccine or purified immunogenic polypeptide of the Black Creek Canal hantavirus in a pharmaceutically acceptable carrier is provided. A vector comprising the nucleic acids of the invention is provided. A method of detecting the presence of a hantavirus in a subject comprising contacting an antibody-containing sample from the subject with a purified polypeptide of the invention and detecting the reaction of the polypeptide and the antibody is provided. A method of detecting the presence of the Black Creek Canal hantavirus is provided comprising reverse transcribing viral RNA to synthesize a complementary DNA sequence followed by amplifying the DNA using primers which are selective for the Black Creek Canal hantavirus and detecting the presence of amplification, thereby indicating presence of the Black Creek Canal hantavirus in the sample.",4,The United States of America as represented by the Department of Health and Human Services,National Institutes of Health Office of Technology Transfer,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12N/00
5854044,29-Dec-98,1998,12,29,Recombinant pseudomonas exotoxin with increased activity,"This invention relates to the production and use of recombinant Pseudomonas-derived toxins modified to increase their toxicity and potency in therapy. More particularly, the invention relates to certain deletions in domain II of the amino acid sequence of Pseudomonas exotoxin the domain which relates to the toxin's natural proteolytic processing.",13,National Institutes of Health,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/30
5854399,29-Dec-98,1998,12,29,Antibodies specific for human cripto-related polypeptide CR-3,"The present invention relates, in general, to a human CRIPTO-related gene. In particular, the present invention relates to a DNA segment encoding a human CRIPTO-related gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a human CRIPTO-related polypeptide; a DNA segment encoding a genomic clone of the human CRIPTO gene (CR-1); antibodies specific to CR-3; and a method of measuring the amount of CR-3 in a sample.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5854416,29-Dec-98,1998,12,29,Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor,"The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Further provided is a method of detecting the presence of Streptococcus pneumoniae in a sample comprising the steps of contacting a sample suspected of containing Streptococcus pneumoniae with nucleic acid primers capable of hybridizing to a nucleic acid comprising a portion of the nucleic acid encoding the 37-kDa protein, amplifying the nucleic acid and detecting the presence of an amplification product, the presence of the amplification product indicating the presence of Streptococcus pneumoniae in the sample. Further provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens, methods of preventing and treating Streptococcus pneumoniae infection in a subject.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/3156
5855841,5-Jan-99,1999,1,5,Process for producing dense ceramic product,"A process for the production of dense polycrystalline silicon carbide shaped articles, includes the steps: (a) heating a powder compact containing silicon carbide and alumina or a precursor thereof together with a secondary sintering assist, to an intermediate temperature for an extended dwell, and then (b) heating the product of step (a) to a higher temperature for sufficient time to produce a dense polycrystalline silicon carbide product. The secondary sintering assist includes one or more rare earths or their precursors, for example scandia, yttria or dysprosia.",29,Commonwealth Scientific and Industrial Research Organisation,,,,,,,,,,,1,"Materials, metallurgy",,,,,,C04B/64
5855891,5-Jan-99,1999,1,5,Ichimeric papillomavirus-like particles,"The present invention provides a papillomavirus-like particle having conformational epitopes comprising a papillomavirus L1 fusion product and, optionally, a papillomavirus L2 product; and related DNA molecules, host cells, and methods.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5856125,5-Jan-99,1999,1,5,ETS2 repressor factor (ERF) genetic locus and its products,"The present invention relates, inter alia, to the ERF gene and to the products encoded by this gene. More particularly, the present invention relates to DNA sequences encoding ERF and AERF; polypeptides encoded by such DNA sequences; ERF chimeric molecules; and methods of using ERF and ERF chimeric molecules to reduce tumorigenicity in a tumor cell.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4703
5856187,5-Jan-99,1999,1,5,"Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments","Immunogenic chimeric proteins comprising an endoplasmic reticulum signal sequence and at least one other peptide are disclosed. The invention relates to the design of vaccinia virus constructs capable of directing host organism synthesis of immunogenic chimeric proteins which can be used as immunogens, as vaccines, or in methods of treatment for cancer, infectious diseases, or autoimmune diseases.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/205
5856318,5-Jan-99,1999,1,5,Nitrogen-containing cyclohetero cyclo-heteroaminoaryl derivatives for CNS disorders,"Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower alkyl, benzyl, and haloloweralkyl; PA1 wherein each of R.sup.2, R.sup.3 and R.sup.8 through R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is an integer of from four to six; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/06
5856454,5-Jan-99,1999,1,5,CDNA for human and pig dihydropyrimidine dehydrogenase,"The invention relates to methods and compositions that are useful for detecting deficiencies in dihydropyrimidine dehydrogenase (DPD) levels in mammals including humans. Cancer patients having a DPD deficiency are at risk of a severe toxic reaction to the commonly used anticancer agent 5-fluorouracil (5-FU). Claimed are DPD genes from human and pig, methods for detecting the level of nucleic acids that encode DPD in a patient, and nucleic acids that are useful as probes for this purpose. Also claimed are methods for expressing DPD in heterologous organisms. Expression vectors that employ a DPD nucleic acid as a selectable marker are also claimed. This selectable marker functions in both prokaryotes and eukaryotes.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/001
5858687,12-Jan-99,1999,1,12,Cell bioassay of neurotoxins,"A cell bioassay is provided for determining the presence in a fluid sample of a sodium channel-activating toxin wherein (a) a fluid sample is incubated in the presence of a culture of cells which express voltage-gated sodium channels and which are responsive in a dose-dependent manner to sodium channel-activating toxins and a medium comprising an agent which causes persistent activation of the voltage-gated sodium channel; (b) the culture is incubated with a medium comprising an indicator which is acted upon by living cells to generate a discernable result, (c) the culture is observed for an incidence of the result, and an observation of the result is correlated with the presence of the toxin in the sample. A simplified assay where steps (a) and (b) are effected together also is provided, as is a cell bioassay for determining the sodium channel affect of a toxin in a fluid sample. A competitive assay for sodium channel-blocking toxins also is provided wherein the fluid sample and culture of cells are incubated with a medium comprising (i) an agent which causes persistent activation of the voltage-gated sodium channel and (ii) a sodium channel-activating toxin. Kits for performing the assays also are provided.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/025
5859019,12-Jan-99,1999,1,12,Methods for protecting against cardiac ischemia by administering adenosine A.sub.2a receptor antagonists,"Methods for reducing or preventing ischemic damage of the heart are disclosed. A preferred embodiment of the invention comprises the administration of a specific A.sub.2a receptor antagonist, 8-(3-chlorostyryl) caffeine, to patients suffering from ischemic damage or at risk for the same.",20,Trustees of the University of Pennsylvania,National Institute of Health,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/53
5859049,12-Jan-99,1999,1,12,"Calanolide and related antiviral compounds, compositions, and uses thereof","The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.",12,The United States of America as represented by the Department of Health and Human Services,The Board of Trustees of the University of Illinois,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/14
5861156,19-Jan-99,1999,1,19,Methods of delivering agents to target cells,"Methods of delivering agents to target cells including methods of immunotherapy, are disclosed in which monospecific binding proteins are administered to a host and bind to target cells followed by administration of multivalent antibodies to direct the agents to the target cells.",22,Creative BioMolecules,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/1093
5861158,19-Jan-99,1999,1,19,Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor,"This invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic cell tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's hematopoietic cell tumor, and transplanting the donor's immunized hematopoietic cells to the recipient. Also provided is a composition comprising purified hematopoietic cells primed to produce an immunological response to foreign tumor specific antigen. Also provided is a method of treating a tumor by the transplantation of hematopoietic cells from a donor to a recipient to treat the tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's tumor, and transplanting the donor's immunized hematopoietic cells to the recipient.",17,The United States of America as represented by the Deptartment of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/28
5861405,19-Jan-99,1999,1,19,"S-substituted 1,3,7-trialkyl-xanthine derivatives","The present invention provides 8-substituted 1,3,7-trialkylxanthines useful as A.sub.2 -selective adenosine receptor antagonists and compositions comprising such compounds. Examples of the 8-substituted 1,3,7-trialkyl xanthines include: ##STR1## In compound (a), R.sub.1, R.sub.3, and R.sub.7 are methyl and X is one to three substituents, which may be the same or different and selected from the group consisting of amino, C.sub.1 -C.sub.4 alkylcarbonylamino, carboxy C.sub.2 -C.sub.4 alkylcarbonylamino, halo, C.sub.1 -C.sub.3 alkyloxy, amino C.sub.1 -C.sub.4 alkyloxy, C.sub.1 -C.sub.4 alkyloxy carbonylamino, amino C.sub.1 -C.sub.4 alkenyloxy, isothiocyanato, and diazonium tetrafluoroborate. In compound (b), R.sub.1, R.sub.3, and R.sub.7 are methyl, R.sub..beta. is hydrogen or methyl, and X is selected from the group consisting of R, C(.dbd.O)OR, and C(.dbd.O)NH--R, wherein R is a C.sub.1 -C.sub.6 alkyl.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/06
5861504,19-Jan-99,1999,1,19,Eleven highly informative microsatelite repeat polymorphic DNA markers,"The invention relates to polymorphic markers (two tetranucleotide, one dinucleotide repeat polymorphisms, 27 markers characterized by primer pairs 1A-27A, and eleven markers characterized by primer pairs 1B-11B that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers are characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences. The assay according to the invention is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours. Accordingly, the invention also relates to an improved PCR procedure and a PCR assay kit which comprise nucleotides according to the invention.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
5863718,26-Jan-99,1999,1,26,Small peptides which inhibit to T-4 receptors and act as immunogens,"Short peptide of the formula: EQU R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.b (I) where R.sup.a represents an amino terminal residue Ala- or D-Ala and R.sup.b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II): EQU R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II) where R.sup.l is an amino terminal residue Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu- PA1 R.sup.2 is Thr, Ser or Asp PA1 R.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp PA1 R.sup.4 is Tyr and R.sup.5 is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals, or a physiologically acceptable salt thereof. Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors. These peptides are believed to act as completitive blocking agents.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5863739,26-Jan-99,1999,1,26,Assay and kit for the detection of .alpha. platelet derived growth factor receptor,"Potent neutralizing monoclonal antibodies to the human .alpha. PDGF receptor (.alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on .alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind .beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing .alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of .alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/71
5863745,26-Jan-99,1999,1,26,Recombinant antibody-toxin fusion protein,The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/495
5865746,2-Feb-99,1999,2,2,In vivo imaging and oxymetry by pulsed radiofrequency paramagnetic resonance,"A system for performing pulsed RF FT EPR spectroscopy and imaging includes an ultra-fast excitation subsystem and an ultra-fast data acquisition subsystem. Additionally, method for measuring and imaging in vivo oxygen and free radicals or for performing RF FT EPR spectroscopy utilizes short RF excitations pulses and ultra-fast sampling, digitizing, and summing steps.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/60
5866347,2-Feb-99,1999,2,2,Method of identifying persons susceptible to autoimmune neuropsychiatric disorders,"A method of identifying individuals who have, or who are at risk of developing, autoimmune neuropsychiatric disorders is disclosed. The invented method relies on detection of the B lymphocyte antigen, D8/17. The invented method can conveniently be carried out as a simple blood test.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56944
5866383,2-Feb-99,1999,2,2,In vitro ligation of foreign DNA into large eukaryotic viruses,"In a preferred embodiment of the invention, methods are provided for the production of viral vectors from large viral genomes (greater than 50 kbp) that incorporate nucleic acid insertions by direct in vitro ligation. In another preferred embodiment of this invention, viral vectors are provided from large viral genomes. These viral vectors accommodate nucleic acid inserts by direct in vitro ligation and facilitate the expression of foreign protein in eukaryotic cell systems.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5866696,2-Feb-99,1999,2,2,Modified adeno-associated virus vector capable of expression from a novel promoter,"Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5867402,2-Feb-99,1999,2,2,Computational analysis of nucleic acid information defines binding sites,"In accordance with the present invention, binding sites are defined based upon the individual information content of a particular site of interest. Substitutions within the binding site sequences can be analyzed to determine whether the substitution will cause a deleterious mutation or a benign polymorphism. In addition, new binding sites can be identified using individual information content. Further a computer system is described for determining and displaying individual information content of a binding site sequence.",57,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Biotechnology,,,,,G06T/0012
5869266,9-Feb-99,1999,2,9,Human olfactory neuron cultures to diagnose Alzheimer's disease,"The present invention relates to a culture of human olfactory neurons. The neurons may display a normal neuronal pathology or a pathology characteristic of a generalized central nervous system disease. The cultured neurons can be used for neurotoxicity tests, screening for therapeutic drugs and anti-viral agents, and diagnosing Alzheimer's disease.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/70
5869308,9-Feb-99,1999,2,9,Detection method for C-RAF-1 genes,"The present invention relates to (1) a method of identifying an individual at an increased risk for developing cancer, (2) a method for determining a prognosis in patients afflicted with cancer, and (3) a method for determining the proper course of treatment for a patient afflicted with cancer; comprising: amplifying a region of the c-raf-1 gene.",8,The United States of America as represented by the Department of the Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/001162
5869313,9-Feb-99,1999,2,9,"Molecular clones of HIV-1 viral strains MN-ST1 and BA-L, and uses thereof","The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
5869463,9-Feb-99,1999,2,9,Use of neuro-glial cell lines for transplantation therapy,Human fetal neuro-derived cell lines are implanted into host tissues. The methods allow for treatment of a variety of neurological disorders and other diseases. A preferred cell line is SVG.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0071
5869522,9-Feb-99,1999,2,9,"Antiviral naphthoquinone compounds, compositions and uses thereof","The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",33,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/92
5869608,9-Feb-99,1999,2,9,Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis,The nucleotide and deduced amino acid sequences of the four variable domains of the major outer membrane proteins of the 15 serovars of Chlamydia trachomatis are disclosed together with sequence and immunogenic analysis of these domains.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/295
5869666,9-Feb-99,1999,2,9,Conformationally locked nucleoside analogues,"Conformationally locked 4',6'-cyclopropane-fused carboxylic nucleoside analogues. The compounds are prepared by condensing a cyclopropane-fused carbocyclic allylic alcohol with substituted purine or pyrimidine bases. The condensation products are then modified to produce the adenosine, guanosine, cytidine, thymidine, and uracil nucleoside analogues. The compounds are therapeutically useful as antimetabolites, or in the preparation of anti-metabolic agents.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
5870493,9-Feb-99,1999,2,9,Top down preprocessor for a machine vision system,"An image recognition and classification system includes a preprocessor in which a ""top-down"" method is used to extract features from an image; an associative learning neural network system, which groups the features into patterns and classifies the patterns: and a feedback mechanism which improves system performance by tuning preprocessor scale, feature detection, and feature selection.",17,The United States of America as represented by the Department of Health and Human Services,"ERIM, International, Inc.",,,,,,,,,,2,Computer technology,,,,,,G06K/4628
5871959,16-Feb-99,1999,2,16,Method of producing hepatocycte growth factor/scatter factor and related cell lines,"A method of preventing tumor cell metastasis by inhibiting the binding of hepatocyte growth factor/scatter factor (""HGF/SF"") with met proto-oncogene protein is described. A method of producing HGF/SF and a cell line for the production of HGF/SF are also described. The met proto-oncogene tyrosine kinase receptor (Met) and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), ordinarily constitute a paracrine signalling system in which cells of mesenchymal origin produce the ligand, which binds to the receptor that is predominantly expressed in cells of epithelial origin. The method of the present invention disrupts the Met-HGF/SF autocrine signaling that contributes to the tumorigenic process in tumors of mesenchymal origin, such as sarcomas.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4753
5871962,16-Feb-99,1999,2,16,Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods,"The nucleotide and deduced amino acid sequences of 51 cDNAs are disclosed where each cDNA encodes the envelope 1 gene of an isolate of hepatitis C virus (HCV). The invention relates to the oligonucleotides, peptides and recombinant envelope 1 proteins derived from these sequences and their use in diagnostic methods and vaccines.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5871998,16-Feb-99,1999,2,16,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5872210,16-Feb-99,1999,2,16,Transframe peptide inhibitor of viral protease,"The present invention describes small, water soluble peptides isolated from a native virus inhibitory sequence that blocks maturation of the virally encoded protease and inhibits the mature protease as well. The peptides may be used in the treatment of virally infected cells, in the preparation of vaccine formulations, in the generation of clinically relevant antibodies and anti-idiotypic antibodies and in the generation of a screening assay or kit that can be used to identify other similarly acting protease inhibitors.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5872219,16-Feb-99,1999,2,16,Antibodies drawn to the eps15 substrate for epidermal growth factor receptor kinase,"A new substrate of epidermal growth factor receptor and certain other tyrosine kinase receptors denominated eps15, polynucleotides encoding eps15, antisense eps15 polynucleotide, triple helix eps15 polynucleotide, antibodies to eps15, and assays for determining eps15.",11,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
5874464,23-Feb-99,1999,2,23,Conformationally constrained diacylglycerol analogues,"Conformationally constrained diacylglycerol analogues, pharmaceutical compositions comprising such analogues, and methods of using such analogues as agonists and antagonists of protein kinase C.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/58
5874560,23-Feb-99,1999,2,23,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
5877148,2-Mar-99,1999,3,2,Treatment of cancer with human chorionic gonadotropin,"Methods useful for treating cancers are disclosed. The methods involve administering human chorionic gonadotropin (hCG) or human luteinizing hormone (hLH) to patients having cancers. Articles of manufacture that are useful for carrying out the described methods are also described. The claimed methods are effective against breast, prostate, ovary, and stomach carcinomas, as well as neuroblastomas, and Kaposi's sarcoma, among others.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/24
5877179,2-Mar-99,1999,3,2,Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells,"The present invention provides novel compounds and pharmaceutical compositions comprising such compounds useful for treating cystic fibrosis cells, wherein such compounds have the formula ##STR1## wherein (a) R.sub.1 and R.sub.3 are methyl, R.sub.7 is ethyl or cyclopropylmethyl, and R.sub.8 is cyclohexyl; (b) R.sub.1 and R.sub.3 are allyl, R.sub.7 is hydrogen and R.sub.8 is cyclohexyl, cyclohexylmethyl, or cycloheptyl; (c) R.sub.1 is allyl and R.sub.3 is methyl, R.sub.7 is hydrogen, and R.sub.8 is cyclohexyl; or (d) R.sub.1 is methyl, R.sub.3 is allyl, R.sub.7 is cyclopropylmethyl or ethyl, and R.sub.8 is cyclohexyl.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/52
5877213,2-Mar-99,1999,3,2,"Compositions and methods for therapy and prevention of cancer, AIDS, and anemia","Compositions and methods of treating anemia, cancer, AIDS, or severs .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
5879299,9-Mar-99,1999,3,9,Method and system for multidimensional localization and for rapid magnetic resonance spectroscopic imaging,"A method and system for providing prelocalization of a volume of interest and for rapidly acquiring a data set for generating spectroscopic images. Spatial prelocalization of a volume of interest is achieved by providing a presuppression sequence before a stimulated echo (STE) sequence and a suppression sequence during the mixing time (TM) interval of the STE sequence. The presuppression sequence includes a spatial suppression sequence to selectively saturate slices that intersect the plane selected by the STE sequence in order to define a boundary for the volume of interest, and this spatial suppression sequence is substantially repeated during the TM interval of the STE sequence. Spectroscopic imaging data is acquired by an oversampled echo planar spatial-spectral imaging sequence in which the gradient reversal frequency is a integer factor of n greater than the gradient reversal frequency required to sample the spectral width.",10,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/4833
5879680,9-Mar-99,1999,3,9,Cloned DNA for synthesizing unique glucocerebrosidase,The invention is directed to a pharmaceutical composition comprising a therapeutic amount of a glycosylated recombinantly-produced human glucocerebrosidase protein in a pharmaceutically acceptable carrier. The invention is further directed to a method of treating Gaucher's disease comprising administering to a subject afflicted with Gaucher's disease a therapeutic amount of a pharmaceutical composition comprising a therapeutic amount of a glycosylated recombinantly-produced human glucocerebrosidase protein in a pharmaceutically acceptable carrier.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Y/01045
5879696,9-Mar-99,1999,3,9,Treated bird seed preferentially palatable to birds but not to animals,"The present invention is directed to preparations of birdseed treated with capsaicin or capsaicin derivatives or analogues thereof in an amount sufficient to be unpalatable to animals having capsaicin sensitive receptors, and more specifically to mammals such as rodents. These ""hot"" compounds, extracts or whole plant material containing these compounds may be coated on, impregnated in or combined (e.g., mixed) with birdseed to repel troublesome mammals which recognize these compounds as ""hot"". These ""hot"" compounds, in contrast, will not repel birds because birds do not recognize these compounds as ""hot"" since they do not have capsaicin sensitive receptors. The invention is further directed to a method of selectively repelling animals having capsaicin sensitive receptors, which comprises feeding the treated birdseed of the invention to birds, in an amount effective for repelling animals having capsaicin sensitive receptors, thereby discouraging said animals from eating the treated birdseed.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Food chemistry,,,,,,A23K/70
5879882,9-Mar-99,1999,3,9,RNA probe for detecting c-fes MRNA,A recombinant plasmid and an RNA sequence expressed by said plasmid are described. The RNA sequence hybridizes specifically with human c-fes mRNA.,6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
5880129,9-Mar-99,1999,3,9,Methods of inhibiting invasion and metastasis of malignant solid tumors,A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the in vivo treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/12
5880161,9-Mar-99,1999,3,9,Therapeutic polyamines,"Therapeutic polyamines useful as a cancer chemotherapeutic agents, including molecules having a formula R.sub.1 --NH--(CH.sub.2).sub.x --NH-- (CH.sub.2).sub.x --NH-- (CH.sub.2).sub.y --NH--(CH.sub.2).sub.z --NH--R, wherein R.sub.1 and R.sub.2 are hydrocarbon chains having 1 to 5 carbons and w, x, y and z are integer of 1 to 10, are disclosed. One such molecule is N.sup.1, N.sup.19 -bis(ethylamino)-5,10,15-triazanonadecane, which is longer than spermine. This preferred compound may be used alone or in combination with other therapeutic agents, such as 1,3-bis(2-chloroethyl)-1-nitrosourea or cis-Pt.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07C/14
5882852,16-Mar-99,1999,3,16,Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates,"The nucleotide and deduced amino acid sequences of cDNAs encoding the envelope 1 genes and core genes of isolates of hepatitis C virus (HCV) are disclosed. The invention relates to the oligonucleotides, peptides and recombinant envelope 1 and core proteins derived from these sequences and their use in diagnostic methods and vaccines.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5882853,16-Mar-99,1999,3,16,Method of evaluating HTLV-I-specific T cell responses,The invention relates to the use of peptides representing a portion of the HTLV-I envelope protein in diagnostic assays for exposure to HTLV-I. The peptides are also useful as components of compositions for eliciting a T-cell response to HTLV-I in an immunized subject.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5882912,16-Mar-99,1999,3,16,Retrovirus isolated from humans,"The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies.",4,Center For Disease Control And Prevention,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/86
5883124,16-Mar-99,1999,3,16,Compositions and methods for treating and preventing pathologies including cancer,"Compositions and methods of treating various disorders by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents including retinoids, hydroxyurea, and flavonoids. Intravesicle methods of treatment of cancers phenylacetate. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention. A product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonid (or other mevalonate pathway inhibitor) for simultaneous, separate, or sequential use in treating a neoplastic condition in a subject. Methods of modulating lipid metabolism and/or reducing serum triglycerides in a subject using phenylacetate.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/35
5885768,23-Mar-99,1999,3,23,Hepatitis E virus peptide antigen and antibodies,"Immunogenic peptides derived from the ORF1, ORF2, and ORF3 regions of hepatitis E virus (HEV), diagnostic reagents containing the peptide antigens, vaccine compositions containing the antigens, and antibodies which are immunoreactive with the antigens are disclosed.",8,The United States of America as Represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
5885828,23-Mar-99,1999,3,23,SecA gene of mycobacterium tuberculosis and related methods and compositions,An isolated nucleic acid encoding a SecA protein of M. tuberculosis is provided. This nucleic acid can be a native coding sequence for the SecA protein of M. tuberculosis. A specific example of the isolated nucleic acid is one that encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2. An isolated fragment of the secA gene that is specific for M. tuberculosis is provided. A purified SecA protein of Mycobacterium tuberculosis is provided. The purified SecA protein of Mycobacterium tuberculosis comprises the polypeptide having the sequence set forth in the Sequence Listing as SEQ ID NO:2. Fragments of the M. tuberculosis SecA protein are provided. A purified mutant SecA protein of Mycobacterium tuberculosis is provided. The invention provides purified mutant M. tuberculosis expressing the mutant SecA protein of the invention. The invention also provides methods of screening for putative M. tuberculosis virulence factors translocated by the SecA protein.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/35
5888705,30-Mar-99,1999,3,30,Compositions and method of stimulating the proliferation and differentiation of human fetal and adult pancreatic cells ex vivo,"A method of inducing the proliferation and/or differentiation of human adult pancreatic cells entails contacting primary cultures of such cells with Hepatocyte Growth Factor/Scatter Factor (HGF/SF), thereby inducing a proliferation of .beta.-epithelial cells, an increase in the number of .beta.-epithelial cells which form islet-like cell clusters, and an increase in insulin production per cell. The method is improved by culturing the cells on an extracellular matrix such as 804G in the presence of HGF/SF, and is further improved by reaggregating thus-treated cells and contacting said cells with an insulin gene upregulating agent such as a poly(ADP-ribose) synthetase inhibitor such as a nicotinamide or benzamide. The method provides increased numbers of functional islet-like cell clusters for transplantation.",25,The United States of America as represented by the Department of Health and Human Services,The Whittier Institute for Diabetes and Endocrinology,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/0676
5888773,30-Mar-99,1999,3,30,Method of producing single-chain Fv molecules,"The invention relates to a method of producing single-chain Fv molecules in eukaryotic cells, and to secretable sFv proteins having at least one non-naturally occurring glycosylation site. The single-chain Fv molecules produced by this method are biologically active and capable of being secreted from eukaryotic cells into the cell culture medium.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/44
5888965,30-Mar-99,1999,3,30,Method of stimulating bone marrow regeneration,"The present invention relates to a complex comprising hepatocyte growth factor (HGF) and met proto-oncogene protein. The present invention also relates to methods for detecting the presence of HGF ligand, met proto-oncogene receptor and methods for isolating either the ligand or receptor or complex comprising both. The present invention further relates to methods of diagnostic proliferative disorders and diseases such as hepatitis or hepatocarcinogenesis by detecting these ligand-receptor pairs.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/71
5889143,30-Mar-99,1999,3,30,Evaluation and treatment of patients with progressive immunosuppression,"A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/18
5889157,30-Mar-99,1999,3,30,"Humanized B3 antibody fragments, fusion proteins, and uses thereof","This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for humanized chain Fv regions of the monoclonal antibodies B1, B3 and B5 and fusion proteins incorporating these humanized antibodies. The antibodies may comprise humanized variable heavy (V.sub.H) chains, humanized variable light (V.sub.L) chains, or both. The invention also provides for DNA sequences encoding the various humanized antibodies. In addition, the invention provides for methods of detecting cells bearing a Lewis.sup.Y antigen in a patient and for methods of killing or inhibiting the growth of cells bearing a Lewis.sup.Y antigen in a patient.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,G01N/57419
5891633,6-Apr-99,1999,4,6,Defects in drug metabolism,"The invention relates to genetic material, and specifically portions of DNA, for identifying the presence or absence of a mutation in the drug metabolism gene CYP2C9 and CYP2A6. Further, the invention comprises a method for determining such mutations and a kit incorporating the genetic material of the invention for performing the said methods so as to determine the presence or absence of mutations in the drug metabolizing gene CYP2C9 and CYP2A6.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5891723,6-Apr-99,1999,4,6,Large granular lymphocyte leukemia associated virus,"A large granular lymphocyte (LGL) leukemia related virus has been isolated and characterized from patients having LGL leukemia. The virus appears to be related to the family of retroviruses including HTLV-I, HTLV-I and Bovine Leukemia Virus. Nucleic acid sequences of the virus are presented.",8,The Research Foundation of State University of New York,The United States of America as represented by The Department of Health and Human Services,Central New York Research Corporation,,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,C07K/005
5892019,6-Apr-99,1999,4,6,Production of a single-gene-encoded immunoglobulin,"Construction of a single gene encoding a signal-chain immunoglobulin-like molecule is described. This single-gene approach circumvents inefficiencies inherent in delivering two genes into a mammalian cell and in the assembly of a functional immunoglobulin molecule. It also facilitates ex vivo transfection of cells for gene-therapy protocols. The single-chain protein comprises the heavy- and light-chain variable (V.sub.H and V.sub.L) domains of a monoclonal antibody covalently joined through a short linker peptide, while the carboxyl end of a V domain is linked to the amino terminus of a human constant region such as .gamma.1 Fc, through the hinge region. The single-chain protein assembles into a dimeric molecule of .apprxeq.120 kDa and is secreted into the culture fluid. The single-chain immunoglobulin-like protein shows similar antigen binding affinity to that of chimeric or parental antibody and mediates ADCC. This single-gene construct approach provides a way of generating an immunoglobulin-like molecule which retains the specificity, binding properties, and cytolytic activity of a parental monoclonal antibody, and thus is a useful therapeutic and diagnostic reagent against a range of antigens, such as human carcinomas.",28,"The United States of America, as represented by The Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
5902794,11-May-99,1999,5,11,8-CI cAMP as anti-cancer drug,Site 1- and site 2-selective derivatives of cAMP have been found to inhibit the of a variety of cancer and leukemic cells. The compounds have been found to have a synergistic effect in cancer and leukemic cell growth inhibition when a site 1-selective compounds is used in combination with a site 2-selective compound.,16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/70
5908635,1-Jun-99,1999,6,1,Method for the liposomal delivery of nucleic acids,"The present invention is directed to a liposomal preparation which is based on specific lipid components. The liposomal compounds are also combined with nucleic acids, forming nucleic acid-liposomal compounds. These compounds are useful in drug delivery, where specific therapeutic nucleic acids are used in the liposomes. The specific lipid components of the present invention provide a highly efficient and stable delivery system for nucleic acids. Consequently, the liposomal preparations are suitable for use in gene therapy.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/88
5910316,8-Jun-99,1999,6,8,Use of nitric oxide-releasing agents to treat impotency,A method of treatment for impotency is provided. The method involves the administration of nitric oxide by a nitric oxide-releasing agent capable of providing a penile erection-inducing amount of nitric oxide to the corpus cavernosum of the penis of an impotent male animal. Also provided is a nitric oxide delivery means for use in the method.,11,"The United States of America, as represented by the Department of Health and Human Services","Vivus, Inc.",,,,,,,,,,2,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
5910443,8-Jun-99,1999,6,8,Medium for culturing human olfactory neurons,"The present invention relates to a culture of human olfactory neurons. The neurons may display a normal neuronal pathology or a pathology characteristic of a generalized central nervous system disease. The cultured neurons can be used for neurotoxicity tests, screening for therapeutic drugs and anti-viral agents.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/5091
5911998,15-Jun-99,1999,6,15,Method of producing a virus vaccine from an African green monkey kidney cell line,A method for producing novel African Green Monkey Kidney (AGMK) cell lines is taught. These cell lines which are free of viable adventitious microbial agents are useful as substrates for viruses and for the preparation of viral vaccines.,4,Dyncorp,National Institutes of Health,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
5912120,15-Jun-99,1999,6,15,"Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism","The invention provides two novel members of the cytochrome P450 2C subfamily of enzymes, designated 2C18 and 2C19. DNA segments encoding these enzymes are also provided. The 2C19 polypeptide represents the principal human determinant of human S-mephenytoin 4'-hydroxylase activity. The invention also provides methods of identifying drugs metabolized by S-mephenytoin 4'-hydroxylase activity. Drugs shown to be metabolized by this activity should in general not be administered to individuals having, or belong to an ethnic group at risk of, a polymorphic deficiency in S-mephenytoin 4'-hydroxylase activity. The invention also provides methods of diagnosing individuals having a polymorphic deficiency.",37,"The United States of America as represented by the Department of Health and Human Services,",,,,,,,,,,,1,Biotechnology,,,,,,C12N/0077
5912173,15-Jun-99,1999,6,15,Transgenic murine model for XSCID,"The present invention provides an isolated nucleic acid sequence encoding murine IL-2R.gamma.. The present invention also provides a vector comprising a mutated IL-2R.gamma. nucleic acid which is capable of homologous recombination in at least some cells to which the vector is introduced. The present invention also provides an embryonic stem cell comprising a mutated IL-2R.gamma. nucleic acid integrated into the cell by homologous recombination following transfection with the vector above. The present invention further provides a blastocyst cell comprising the embryonic stem cell above. In addition, the present invention provides a transgenic animal comprising a mutated IL-2R.gamma. gene. In particular, the animal is a non-human mammal whose germ and somatic cells contain a mutated IL-2R.gamma. gene sequence introduced into said mammal, or an ancestor thereof, at an embryonic stage. The present invention also provides a method of producing a non-human mammal with XSCID which comprises introducing into at least some cells of the recipient animal a mutated IL-2R.gamma. gene. Lastly, the present invention provides a non-human animal produced by the method above, and progeny thereof, wherein at least some cells retain a mutated IL-2R.gamma. gene.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
5914121,22-Jun-99,1999,6,22,Formation of human bone in vivo using ceramic powder and human marrow stromal fibroblasts,"An in vivo model for human bone metabolism. Human marrow stromal fibroblasts are isolated, expanded in culture, combined with ceramic powder (hydroxyapatite) delivery vehicles with or without fibrin glue and implanted into a mammal. This protocol results in the formation of self-maintained human bone which supports hematopoiesis. This model system can be used to screen compounds which inhibit or stimulate bone formation. The marrow stromal fibroblast delivery vehicles can be implanted into humans to augment bone implants or to repair bone defects.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Biotechnology,,,,,A61L/3804
5914265,22-Jun-99,1999,6,22,Keratin K1 expression vectors and methods of use,"A keratin K1 vector for expression of a nucleic acid sequence in an epidermal cell. The vector includes a 5' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a keratin K1 3' flanking region which regulates expression of a nucleic acid sequence, predominantly in the epidermis, and a linker which connects the 5' flanking region to a nucleic acid. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. That is, the linker is not the normal gene associated with the 5' and 3' regions.",34,Baylor College of Medicine,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Other special machines,Pharmaceuticals,,,,C12N/85
5914389,22-Jun-99,1999,6,22,E6 associated protein,The present invention provides compositions of isolated and purified E6 Associated Protein and fragments thereof. Also provided are nucleic acid constructs encoding E6 Associated Protein. These compositions may be employed to identify compounds which inhibit binding of high risk HPV E6 to p53. The compositions of the present invention may also be used in methods to detect the presence of high risk HPV in biological samples.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
5916754,29-Jun-99,1999,6,29,Bayou hantavirus and related methods,"The present invention relates to the discovery and isolation of a novel hantavirus designated the Bayou hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents (primers and probes), purified polypeptides and antibodies for use in methods of detection and prevention of infection by the virus. A vaccine or purified immunogenic polypeptide of the Bayou hantavirus in a pharmaceutically acceptable carrier is provided. A vector comprising the nucleic acids of the invention is provided. A method of detecting the presence of a hantavirus in a subject comprising contacting an antibody-containing sample from the subject with a purified polypeptide of the invention and detecting the reaction of the polypeptide and the antibody is provided. A method of detecting the presence of the Bayou hantavirus is provided comprising reverse transcribing viral RNA to synthesize a complementary DNA sequence followed by amplifying the DNA using primers which are selective for the Bayou hantavirus and detecting the presence of amplification, thereby indicating presence of the Bayou hantavirus in the sample.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
5916755,29-Jun-99,1999,6,29,"Methods of characterizing ligands for the erbB-3 receptor, methods of influencing erbB-3 activities and methods of diagnosing erbB-3-related neoplasm","A DNA fragment distinct from the epidermal growth factor receptor (EGFR) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGFR and erbB-2, plays a role in some human malignancies. Using erbB-3 specific antibodies (polyclonal or monoclonal), the erbB-3 protein was identified as a 180 kDa glycoprotein, gp180.sup.erbB-3. The intrinsic catalytic function of gp180.sup.erbB-3 was uncovered by its ability to autophosphorylate in vitro. These findings, combined with the detection of constitutive tyrosine phosphorylation of gp180.sup.erbB-3 in 4 out of 12 human mammary tumor cell lines, implicate the activated erbB-3 product in the pathogenesis of some human malignancies. Thus, this invention also relates to a method for detecting a receptor ligand capable of either activating or down-regulating the receptor protein, as well as procedures for purifying the resultant ligand; and a method of screening potential ligand analogs for their ability to activate the receptor protein.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/32
5916768,29-Jun-99,1999,6,29,Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides,"The present invention relates to contraceptive vaccines based on cloned zona pellucida genes and the strategy of alloimmunization with zona pellucida polypeptides. In particular, the present invention relates to a contraceptive vaccine for use in a mammalian female comprising a polypeptide which displays at least one epitope for binding of an antibody that inhibits fertilization of an oocyte by a sperm. This epitope is from a zona pellucida procein of the species in which the said vaccine is used. This invention relates, more particularly, to such vaccines wherein the zona pellucida protein is either the ZP3 or the ZP2 or the ZP1 protein or the mouse or homologues of these proteins in some other mammalian species. Further, this invention comprehends vaccines comprising a synthetic peptide that displays an epitope for such an antibody that inhibits fertilization. In addition, this invention relates to cloned DNA segments variously encoding the mouse ZP3 or ZP2 proteins or the human ZP3 or ZP2 protein.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/28
5916894,29-Jun-99,1999,6,29,Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines,"The present invention provides 8-substituted O.sup.6 -benzylguanine derivatives which have been found to be effective AGT inactivators, as well as pharmaceutical compositions comprising such derivatives along with a pharmaceutically acceptable carrier. Thus, for example, the present invention provides a compound of the formula ##STR1## wherein R.sub.1 is a substituent selected from the group consisting of amino, hydroxy, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, and C.sub.1 -C.sub.4 acylamino, R.sub.2 is a substituent selected from the group consisting of C.sub.1 -C.sub.4 aminoalkyl, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 dialkylamino alkyl, and C.sub.1 -C.sub.4 pivaloylalkyl, and R.sub.3 is a C.sub.1 -C.sub.4 alkyl. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lessons at the O.sup.6 -position of guanine by administering to a mammal an effective amount of one of the aforesaid derivatives and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine.",16,The United States of America as represented by the Department of Health and Human Services,The Penn State Research Foundation,Arch Development Corporation,,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
5919456,6-Jul-99,1999,7,6,IL-13 receptor specific chimeric proteins,This invention provides chimeric molecules useful for killing tumor cells bearing IL13 receptor(s) (IL-13R). The molecules comprise a cytotoxic molecule attached to a targeting molecule that specifically binds an IL-13 receptor. Preferred targeting molecules include IL-13 and anti-IL-13R antibodies.,14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/2866
5919624,6-Jul-99,1999,7,6,Methods for detecting cervical cancer,"The invention provides a method of detecting the presence of invasive cervical carcinoma in a subject comprising detecting in a cervical cell from the subject the presence of a chromosome abnormality which is associated with invasive cervical carcinoma; the presence of the cervical cell containing the chromosome abnormality indicating the presence of invasive cervical carcinoma in the subject. The invention also provides a method of detecting the presence of advanced-stage cervical carcinoma in a subject comprising detecting in a cervical cell from the subject the presence of a chromosome abnormality associated with advanced-stage cervical carcinoma; the presence of the cervical cell containing the chromosome abnormality indicating the presence of advanced-stage cervical carcinoma in the subject. The invention also provides a method of classifying the progression of dysplastic cervical cells from a non-invasive cervical carcinoma to an invasive cervical carcinoma comprising analyzing the dysplastic cervical cells for the presence of a chromosome abnormality which is associated with invasive cervical carcinoma, and classifying the dysplastic cervical cells having the chromosome abnormality as having progressed from a non-invasive cervical carcinoma cells to an invasive cervical carcinoma. The invention further provides kits comprising nucleic acids that specifically hybridize to chromosome 3q and specifically hybridize to another chromosome, and to compositions comprising nucleic acids.",7,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
5919709,6-Jul-99,1999,7,6,Amino acid sequencing peptides and methods for their use,"The present invention provides a novel internal standard for amino acid sequencing which contains a peptide consisting of unnatural amino acid residues, such as ornithine, norvaline, norleucine and .alpha.-aminobutyric acid, that is capable of being sequenced simultaneously with an unknown peptide or protein without interfering with the analysis. The internal standard peptide has an amino acid sequence containing at least two different unnatural amino acid residues having retention times distinct from the corresponding retention times for natural amino acid residues. Information derived from the sequencing of the internal standard allows determination of repetitive yield, lag, N-terminal blockage and discrimination between blank cycles caused by missed injection and blank cycles caused by faulty delivery of chemicals during the sequencer reactions. The present invention further provides novel synthetic control peptides containing from about 3 to 100 natural amino acid residues that are designed for use in monitoring the proper operation of amino acid sequencers and to monitor peptide or protein cleavage reactions. The control peptide, or mixture of control peptides, are designed to obtain data for many or all common, uncommon and difficult to measure amino acids within 15 sequencer cycles and to provide cleavage sites for at least 4 different amino acid cleavage reactants.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/4717
5922326,13-Jul-99,1999,7,13,Attenuated respiratory syncytial virus vaccine compositions,"The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.",26,"The United States of America, as represented by the Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
5925345,20-Jul-99,1999,7,20,Vectors including foreign genes and negative selective markers,"A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.",14,"Genetic Therapy, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
5925352,20-Jul-99,1999,7,20,Method of treating inflammation with antibodies to neutrophil chemotactic factor,"An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/5421
5925780,20-Jul-99,1999,7,20,"2, 5-diamino-3, 4-disubstituted-1, 6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same","The present invention provides 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane (DAD) isosteres comprising benzamide, sulfonamide and anthranilamide subunits, a pharmaceutical composition comprising such compounds, a method of using such compounds to treat retroviral, specifically HIV and more specifically HIV-1 and HIV-2, infections in mammals, particularly humans, a method of synthesizing asymmetric DAD isosteres comprising benzamide, sulfonamide and anthranilamide subunits, and a method of using such compounds to assay new compounds for antiretroviral activity.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/82
5928637,27-Jul-99,1999,7,27,Methods of inducing multidrug resistance using human MDR1 cDNA,The present invention provides for vectors carrying a cDNA containing the entire coding region of the human multidrug resistance gene (MDR1) and for a method for introducing MDR1 cDNA into cells thereby inducing a multidrug resistant phenotype.,13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,Biotechnology,,,,,A01K/0271
5928670,27-Jul-99,1999,7,27,Method of inhibiting aldose reductase in vivo with intrinsic inhibitors of aldose reductase,"An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.",4,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4703
5928944,27-Jul-99,1999,7,27,Method of adenoviral-medicated cell transfection,"The present invention provides an adenoviral-mediated method of transfection with nucleic acids which can be augmented through incubation of the nucleic acids with cationic agents. Specifically, the present inventive method of introducing a nucleic acid into a eukaryotic cell comprises contacting the cell with, in any order or simultaneously, the nucleic acid and an adenovirus, wherein the nucleic acid is not bound to any molecule capable of effecting its entry into the cell. The cell is preferably additionally contacted with a cationic agent, such as a monocationic or polycationic liposome, such that the nucleic acid is not bound to any molecule capable of effecting its entry into the cell other than, optionally, the cationic agent.",50,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
5929262,27-Jul-99,1999,7,27,"Method for preparing 17.alpha.-acetoxy-11.beta.-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates","Methods for the preparation of the 19-norprogesterone of formula I ##STR1## and its intermediates, in crystalline and amorphous forms are disclosed. The process is performed by (1) protecting the hydroxyl group of a compound of formula II ##STR2## (2) reacting the protected compound with an alkali or alkaline earth metal anion radical, (3) hydrolyzing the resulting compound, (4) ketalizing the carbonyl groups, (5) epoxidizing the compound, (6) opening the epoxide ring and introducing an N,N,dimethylamino-phenyl functional group into the axial position of C.sub.11, (7) deketalizing and dehydrating the resulting compound, and (8) acetylating to provide 17.alpha.-acetoxy-11.beta.-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-di ene-3,20-dione (I).",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07J/0045
5932218,3-Aug-99,1999,8,3,"Multideterminant peptides eliciting helper T-lymphocyte, cytotoxic T-lymphocyte, and neutralizing antibody responses against HIV-1","This invention is directed toward a multideterminant human immunodeficiency virus type 1 (HIV-1) peptide which comprises a covalently linked T-helper (Th) lymphocyte epitope, cytotoxic T-lymphocyte (CTL) epitope, and an epitope capable of eliciting a neutralizing antibody response (AbN), wherein said peptide has the following amino acid sequence: KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN. This peptide has the further characteristic of evoking all three of these immune responses in hosts having a broad range of major histocompatibility complex (MHC) types. This peptide is useful as an immunogen to generate broad immune responses in a host, to assess immune responses in virally infected hosts, and as a diagnostic reagent to detect viral infection.",2,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
5935575,10-Aug-99,1999,8,10,Interleukin-4 stimulated T lymphocyte cell death for the treatment of allergic disorders,"This invention discloses a method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders and graft rejection. Specifically, it provides a means of killing a specific sub-population of T lymphocytes while leaving the majority of other T lymphocytes in the population unaffected. The sub-population of T lymphocytes are killed by repeatedly challenging the population with an antigen in conjunction with administration of interleukin-4.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/001
5937083,10-Aug-99,1999,8,10,Image registration using closest corresponding voxels with an iterative registration process,"A robust, automatic volume registration process based on intensity gradients successfully performs registrations under conditions of unrelated intervolume voxel intensities, significant object displacements and/or significant amounts of missing data. The process allows a user to visualize the registration convergence, clearly illustrating any source of registration errors. The process includes steps of matching, based on iteratively finding a correspondence of the closest voxels containing a high three-dimensional (3D) intensity gradient magnitude. The process is a powerful method of sequence-independent MR volume registration which is simple to both use and understand.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/0068
5939074,17-Aug-99,1999,8,17,Multideterminant peptide antigens,"This invention relates to the selection and preparation of synthetic peptides which stimulate helper T lymphocyte response to HIV in a wide range of human subjects. These multideterminant peptides are, therefore, useful for the production of vaccines against HIV infection and for diagnostic procedures to test for HIV seroconversion.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5939530,17-Aug-99,1999,8,17,Inhibitory and non-inhibitory antigen binding polypeptides against human P450 enzymes,"Antigen binding polypeptides that specifically bind human cytochrome P450 3A3, 3A4, and 3A5 and that specifically inhibit the enzyme activity of human cytochrome P450 3A3, 3A4, and 3A5 are described. Antigen binding polypeptides that specifically bind to human cytochrome P450 3A3 and 3A4 are also described. Antigen binding polypeptides which specifically bind to human cytochrome P450 2E1 and which specifically inhibit the enzyme activity of human cytochrome P450 2E1 are described. Antigen binding polypeptides which specifically bind to human cytochrome P450 2E1 are also described. Methods of determining the contribution of human cytochrome P450s to the metabolism of compounds, using the antigen binding polypeptides of the invention, are also described.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0077
5942230,24-Aug-99,1999,8,24,Composition of immunotoxins and retinoids and use thereof,"RACT) ""Retinoic Acid Alters Cellular Traffic and Potentiates Immunotoxins"" (1994) Proc. of the American Association for Cancer Research, Vol. 35:503, Abstract #2996. LREP FRM Morgan & Finnegan, L.L.P.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,G01N/5014
5942433,24-Aug-99,1999,8,24,Extension of a protein-protein interaction surface to inactivate the function of a cellular protein,"Acidic amino acid extensions to multimeric nucleic acid (e.g., DNA or RNA) binding proteins provide novel nucleic acid binding proteins which can inhibit the function of cellular proteins, thereby regulating and controlling cell growth. The nucleic acid binding proteins are engineered to contain a plurality of acidic amino acids appended to the proteins, generally as extensions of the multimerization or dimerization domain at the amino terminus. The acidically extended nucleic acid binding proteins act as potent dominant negatives which were demonstrated to inhibit the activation of endogenous transactivators, such as AP1. The invention provides novel methods to create DNA binding proteins which can specifically and stably heterodimerize with cellular regulatory proteins and control cell growth. Suitable nucleic acid binding proteins for acidic extensions include members of transcription regulatory protein families, e.g., bZIP and HLH proteins, having characteristic leucine zipper motifs and helix-loop-helix motifs, respectively. The amino terminal extensions of the basic regions of nucleic acid binding proteins are comprised of a sequence of amino acid residues, all or some of which are acidic in nature, and produce robust dominant negatives to the native counterpart proteins in the cell. The acidic amino terminal extension affords a unique protein-protein interaction surface and allows stable multimerization or dimerization between a native protein and the acidically extended protein, thereby controlling, via inhibition or inactivation, the functions of cellular protein products of diverse species, including plants, animals, microorganisms, and viruses.",49,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/11
5945277,31-Aug-99,1999,8,31,"Strain of hantavirus nucleotide sequences thereof related probes, primers and vectors, and methods for detection","The present invention relates to the discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the virus.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
5948409,7-Sep-99,1999,9,7,T cell receptor ligands and methods of using same,"The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/80
5948613,7-Sep-99,1999,9,7,Methods of screening for risk of cancer using human lactoferrin DNA probe or primer,The present invention relates to a human lactoferrin cDNA obtained from human breast tissue and the protein encoded therefrom. The present invention further relates to methods for detecting malignancy arising from tissues that normally secrete lactoferrin using the cDNA gene probe of the present invention. Another aspect of the present invention relates to the promotor region that regulates the human lactoferrin gene.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/79
5952454,14-Sep-99,1999,9,14,Linking compounds useful for coupling carbohydrates to amine-containing carriers,"The present invention provides a method to couple a glycosyl donor to an amine-containing carrier or substrate material using as a spacer a compound of the general formula I: ##STR1## in which n and m are each independently an integer of from 1 to 12, R.sub.1 and R.sub.2 are each independently H, lower alkyl, a hydroxyl group, or a substituent which does not interfere with the linking reactions, R.sub.4 and R.sub.5 are each independently H, lower alkyl, a hydroxyl group, or a substituent which does not interfere with the linking reactions, R.sub.3 and R'.sub.3 are each independently an optionally substituted lower alkyl or R.sub.3 and R'.sub.3 can be joined to form an optionally substituted cyclic moiety having from 2 to 5 carbon atoms.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07H/12
5955073,21-Sep-99,1999,9,21,Selective RNase cytotoxic reagents,"The present invention relates to a selective cytotoxic RNase reagent. The reagent comprises a toxic moiety that is an RNase linked to a recognition moiety that binds a specific cell surface marker. Binding of the recognition moiety to a surface marker on a cell allows the toxic moiety to selectively kill the cell. To reduce immunogenicity, preferably the toxic moiety and the recognition moiety of the conjugate are endogenous to the species in which the reagent is intended for use. Cytotoxic reagents intended for use in humans preferably have as the toxic moiety a human ribonuclease, such as angiogenin, and as the recognition moiety as humanized chimeric antibody. The human ribonuclease and chimeric antibody preferably form a fused protein. The present invention also relates to pharmaceutical compositions including the cytotoxic reagent as well as treatment methods involving the use of the cytotoxic reagent.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/79
5958414,28-Sep-99,1999,9,28,Composition to protect a mammal against Bartonella henselae infection,The present invention relates to a therapeutic composition to protect a mammal from B. henselae infection that includes an isolated B. henselae antigen and an adjuvant comprising a phosphazene polymer. Also included is a method to use such a therapeutic composition to protect a mammal from B. henselae infection. One embodiment is a method to protect a human from cat scratch disease by administering such a therapeutic composition to a domestic cat in contact with the human. The present invention also includes a method to produce such a therapeutic composition.,36,Heska Corporation,"Avant Immunotherapeutics, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/0233
5958712,28-Sep-99,1999,9,28,T-cell receptor ligands and methods of using same,"The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/80
5958752,28-Sep-99,1999,9,28,Nucleic acid molecules encoding human trichohyalin and use thereof,"The sequences of a pair of human proteins, trichohyalin and transglutaminase-3, in addition to the sequence of the mouse transglutaminase-3 protein, have been discovered. The enzyme transglutaminase-3 is used to cross-link the structural protein trichohyalin in order to form a gel.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Medical technology,Organic fine chemistry,Food chemistry,,,C12N/1044
5958778,28-Sep-99,1999,9,28,"Container for drying biological samples, method of making such container, and method of using same","A container suitable for high speed centrifugation is provided with a cap carrying a microbe-impermeable filter means. The filter means permits gas flow into and out of the container but prevents microbes from entering the container. A method of making such a container is also described. A preferred embodiment is for a container that can be used as a microcentrifuge tube. A method of drying, e.g., lyophilizing, a biological sample using the container is also provided.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Handling,,,,,B01L/5021
5958920,28-Sep-99,1999,9,28,Aralkyl diazabicycloalkane derivatives for CNS disorders,"Certain aralkyl diazabicycloalkyl compounds are disclosed for treatment of CNS disorders, such as cerebral ischemia, psychosis and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein m is three or four; wherein z is selected from the group consisting of ##STR2## wherein when Z is ##STR3## n and p are integers of from one to four, with a sum of four or five, and when Z is ##STR4## n and p are integers of from one to three, with a sum of three or four; wherein A is selected from the group consisting of aryl, heteroaryl, aryloxy, heteroaryloxy, aralkoxy, heteroaralkoxy, arylamino, heteroarylamino, aralkylamino, heteroaralkylamino, arylthio, heteroarylthio, aralkylthio, and heteroaralkylthio; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from the group consisting of hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aryloxy, aralkoxy, alkoxyalkyl, halo, haloalkyl, hydroxyalkyl, cyano, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, alkanoyl, alkenyl and alkynyl; or a pharmaceutically acceptable salt thereof.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
5958932,28-Sep-99,1999,9,28,"Substitutes O.sup.6 -benzylguanines, compositions, and methods of using same","The present invention provides AGT inactivating compounds such as substituted O.sup.6 -benzylguanines of the formula ##STR1## wherein, for example, R.sub.1 is amino, hydroxy, or alkylamino, R.sub.2 is aminoalkyl, hydroxyalkyl, or alkylaminoalkyl, and R.sub.3 is halo, hydroxyalkyl, thiol or alkylthio, as well as pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine comprising administering to a mammal an effective amount of one of the aforesaid compounds and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine.",31,The United States of America as represented by the Secretary of the Department of Health and Human Services,Arch Development Corporation,Penn State Research Foundation,,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
5961977,5-Oct-99,1999,10,5,Method of treating or preventing autoimmune uveoretinitis in mammals,"The present invention provides a method of treating or preventing the clinical manifestation of an autoimmune disease having the symptoms of uveoretinitis in a mammal in need of such treatment comprising orally administering to said mammal an effective amount of an autoantigen, e.g., S antigen (S-Ag), and/or biologically active fragments, or analogs thereof specific for uveoretinitis. Also provided is a pharmaceutical formulation useful for treating or preventing uveoretinitis in mammals comprising an effective amount of one or more of the foregoing autoantigen, fragments or analogs.",9,AutoImmune Inc.,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/0008
5962653,5-Oct-99,1999,10,5,Methods of obtaining antiviral proteins and antiviral peptides from Nostoc ellipsosporum,"The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
5962668,5-Oct-99,1999,10,5,Nucleic acids encoding antiviral proteins and peptides fused to effector proteins,"The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/6817
5965359,12-Oct-99,1999,10,12,Method of detecting the expression of alpha platelet-derived growth factor receptor gene,"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/103
5965366,12-Oct-99,1999,10,12,Methods of identifying patients having an altered immune status,"Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM). In addition, the ratio of a TH-1-type BRM to a TH-2-type BRM, the ratio of cytoplasmic to nuclear levels of polynucleotide binding proteins, the pattern of protein binding to an oligonucleotide probe that comprises the protein binding region of a gene for a BRM, or the pattern of distribution of T lymphocytes in a density gradient following density gradient centrifugation are also suitable as an immune status index. The methods are useful in identifying patients exhibiting immunosuppression, hyperimmunity and autoimmunity, as well as in assessing the immune status of a patient undergoing organ transplant.",10,"The United States of America as represented by the Secretary, Department of Health and Human Services",Biormia USA Inc.,,,,,,,,,,2,Analysis of biological materials,Computer technology,,,,,G01N/68
5965531,12-Oct-99,1999,10,12,Method of reducing perivascular lesions using insulin-like growth factor I,"A disease or disorder associated with myelin injury, such as multiple sclerosis, is treated by administering to a patient in need thereof an effective amount of insulin-like growth factor I (IGF-I). The method reduces blood brain and blood nerve barrier permeability defects. It also decreases the size and number of perivascular lesions (often associated with myelin breakdown) and reduces the formation of sclerotic plaques in the central nervous system. IGF-I administration also reverses the clinical deficits associated with myelin injury, including visual defects, unsteadiness, poor coordination, muscular weakness and paralysis.",16,National Institutes of Health,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/30
5965726,12-Oct-99,1999,10,12,Method of eliminating inhibitory/ instability regions of mRNA,A method of locating an inhibitory/instability sequence or sequences within the coding region of an mRNA and modifying the gene encoding that mRNA to remove these inhibitory/instability sequences by making clustered nucleotide substitutions without altering the coding capacity of the gene is disclosed. Constructs containing these mutated genes and host cells containing these constructs are also disclosed. The method and constructs are exemplified by the mutation of a Human Immunodeficiency Virus-1 Rev-dependent gag gene to a Rev-independent gag gene. Constructs useful in locating inhibitory/instability sequences within either the coding region or the 3' untranslated region of an mRNA are also disclosed. The exemplified constructs of the invention may also be useful in HIV-1 immunotherapy and immunoprophylaxis.,36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
5969144,19-Oct-99,1999,10,19,"Radiolabeled pyridyl-7-azabicyclo[2,2,1]heptanes","The present invention is directed to radiolabeled epibatidine analogues, specifically FPH labeled with radioisotopes of fluorine and/or carbon. These radiolabeled epibatidine compounds are used to noninvasively image and quantify nicotinic cholinergic receptors in the living brain for both research studies and the diagnosis of neurodegenerative diseases.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/439
5969524,19-Oct-99,1999,10,19,Method to significantly reduce bias and variance of diffusion anisotrophy measurements,"A method for quantitatively assessing diffusion anisotropy according to an invariant anisotropy index that accounts for orientational coherence of the measured principal directions between different localized regions of an object to counteract the bias and increased variance effects of noise inherent in the diffusion measurement. A diffusion weighted imaging sequence is performed on a two-dimensional slice of an object to provide raw diffusion weighted image signals, which are processed by conventional Fourier transform and magnitude reconstruction to provide diffusion weighted images, from which a diffusion tensor is estimated for each voxel of the imaged slice. In each voxel a lattice anisotropy index is calculated as a function of both the eigenvalues and eigenvectors of neighboring voxels such that intervoxel orientational coherence compensates noise-induced bias effects. The orientational coherence measure between two voxels is calculated according to an intervoxel deviatoric tensor dot product. The intervoxel lattice index for a given voxel is locally averaged over a group of adjacent voxel to provide a resulting lattice index for the given voxel. Lattice index images for visual observation of diffusion anisotropy are generated according to the lattice index in each voxel. Monte Carlo simulations are used to assess the noise immunity of lattice index functions formulated according to the present invention.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56341
5972596,26-Oct-99,1999,10,26,Nucleic acid constructs containing HIV genes with mutated inhibitory/instability regions and methods of using same,A method of locating an inhibitory/instability sequence or sequences within the coding region of an mRNA and modifying the gene encoding that mRNA to remove these inhibitory/instability sequences by making clustered nucleotide substitutions without altering the coding capacity of the gene is disclosed. Constructs containing these mutated genes and host cells containing these constructs are also disclosed. The method and constructs are exemplified by the mutation of a Human Immunodeficiency Virus-1 Rev-dependent gag gene to a Rev-independent gag gene. Constructs useful in locating inhibitory/instability sequences within either the coding region or the 3' untranslated region of an mRNA are also disclosed. The exemplified constructs of the invention may also be useful in HIV-1 immunotherapy and immunoprophylaxis.,22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
5976541,2-Nov-99,1999,11,2,Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope,Peptides having high activity in the eliciting of a cytotoxic T lymphocyte response to the HIV-1 envelope glycoprotein gpl60 are described. The activation of 12-15 residue peptides by proteolytic degradation to shorter peptides is shown as are general techniques for characterizing such activation processes.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
5976816,2-Nov-99,1999,11,2,Cell tests for alzheimer's disease,"The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5091
5980895,9-Nov-99,1999,11,9,Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation,"This invention provides for immunotoxins comprising a Pseudomonas exotoxin (PE) that does not require proteolytic activation for cytotoxic activity attached to an Fv antibody fragment having a variable heavy chain region bound through at least one disulfide bond to a variable light chain region. The combination of a ""disulfide-stabilized"" binding agent fused to a PE that does not require proteolytic activation provides an immunotoxin having surprising cytotoxic activity.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/30
5980899,9-Nov-99,1999,11,9,Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells,"The cytotoxic T cell response to the protein encoded by the NS5 region of hepatitis C virus was determined using 28 peptides from NS5 which were selected by an amphipathicity algorithm as candidates for T cell epitopes. In BALB/c mice, a single relatively conserved epitope represented by a 16-residue synthetic peptide was presented by D.sup.d class I major histocompatibility complex (MHC) molecules to conventional CD4.sup.- CD8.sup.+ CTL. An exemplary peptide, which represents amino acid residues 2422-2437 of the polyprotein of the Chiron HCV1 isolate, had the amino acid sequence MSYSWTGALVTPCAAE [SEQ ID NO: 1]. A CTL line specific for this peptide recognized the two known natural variants of this NS5 sequence, each with conservative substitutions. Thus, CTL can recognize the product of the HCV NS5 gene, the probable RNA polymerase, in association with class I MHC molecules on model target cells and may recognize the same epitope on hepatocytes or any other cells infected with the virus.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5981712,9-Nov-99,1999,11,9,DNA encoding CAI resistance proteins and uses thereof,This invention provides for nucleotide sequences that encode CAIR proteins correlated with cellular resistance to carboxyamido-triazole (CAI) and functionally equivalent compounds. The invention further provides for methods of detecting CAI resistance in biological samples and for cell lines that grow and proliferate in the presence of CAI and functionally equivalent compounds.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
5981726,9-Nov-99,1999,11,9,"Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof","This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibodies B1 and B5. The invention also provides for a number of stabilizing mutations of the Lewis.sup.Y -binding monoclonal antibody B3. In addition, the invention provides for methods of detecting cells bearing a Lewis.sup.Y antigen in a patient and for methods of killing or inhibiting the growth of cells bearing a Lewis.sup.Y antigen in a patient.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,G01N/57492
5985553,16-Nov-99,1999,11,16,"erbB-2 gene segments, probes, recombinant DNA and kits for detection","The isolation, cloning and characterization of a human gene related to but distinct from the EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of the nucleic acid probes and antibodies having specific binding affinity with said polypeptide for diagnostic and therapeutic purposes has also been described.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/71
5985610,16-Nov-99,1999,11,16,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self-assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high-titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
5985829,16-Nov-99,1999,11,16,Screening assays for compounds that cause apoptosis and related compounds,"This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1709
5988875,23-Nov-99,1999,11,23,Calorimeter and method for simultaneous measurement of thermal conductivity and specific heat of fluids,"A method of simultaneously measuring thermal conductivity and heat capacity of a fluid, using a heat conduction calorimeter having a reference fluid in a first cell and a sample fluid in a second cell includes the steps of calibrating the calorimeter using a standard fluid having known thermal conductivity and heat capacity over a range of temperatures and the reference fluid to determine a set of sensitivity parameters, {a.sub.n.sup.ij }, of the calorimeter, wherein the a.sub.n.sup.ij are functions of the calorimeter, temperature and the reference fluid; applying a square wave heat pulse to the calorimeter containing said sample fluid and said reference fluid; measuring the thermal response curve to the square wave heat pulse, wherein the thermal response curve is a function of time, temperature of the measurement, thermal properties of the sample fluid, and thermal properties of the reference fluid; reducing the response curve to a set of discrete characteristic parameters, {p.sub.n } wherein each pn is a function of time, temperature of the measurement, thermal properties of the sample fluid and thermal properties of the reference fluid; calculating the thermal conductivity and heat capacity of the sample fluid from the {p.sub.n } for the sample fluid and the {a.sub.n.sup.ij } for the calorimeter.",17,The United States of America as respresented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/4866
5989521,23-Nov-99,1999,11,23,Method for augmenting a decreased level of reduced glutathione in the lung,"The present invention relates, in general, to a method for augmenting reduced glutathione level in the lungs of patients. In particular, the present invention relates to a method for augmenting reduced glutathione level in the lungs of patients with cystic fibrosis (CF), acquired immunodeficiency syndrome (AIDS), or idiopathic pulmonary fibrosis (IPF).",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0078
5989540,23-Nov-99,1999,11,23,Modified adeno-associated virus vector capable of expression from a novel promoter,"Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.",7,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5989546,23-Nov-99,1999,11,23,Interleukin-2 stimulated T lymphocyte cell death for the treatment of allergic responses,"A method for the treatment or prevention of allergic disorders is provided, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing such diseases, while leaving substantially unaffected the majority of other T lymphocytes. Cell death is achieved by cycle(s) comprising challenging via immunization these T cells with antigenic substance at short time intervals, or by immunization followed by administering interleukin-2 (IL-2) when these T cells are expressing high levels of IL-2 receptor so as to cause these T cells to undergo apoptosis upon re-immunization with the antigenic peptide or protein. These methods are applicable to the treatment of allergic disorders such as hay fever, extrinsic asthma, or insect bite and sting allergies, and food and drug allergies.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
5989551,23-Nov-99,1999,11,23,Materials and methods for detection and treatment of insulin-dependent diabetes,"The method and compositions of this invention provide an effective and reliable substitute for the currently employed ICA assay for diabetes. By providing a method for detecting autoantibodies to GAD.sub.65, IA-2 and a previously unidentified antigen termed IA-2.beta. herein, the method provides a chemical assay which has improved reliability. In addition, these antigens may be employed in therapeutic regimens aimed at achieving amelioration of the clinical condition.",6,The United States of America as represented by the Department of Health and Human Services,The University of Florida,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/4713
5989848,23-Nov-99,1999,11,23,Use of human immortalized endothelial cells to isolate and propagate Ehrlichia chaffeensis and Ehrlichia canis,"This invention provides a purified immortalized human endothelial cell infected with Ehrlichia chaffeensis or Ehrlichia canis. Also provided is a method of simultaneously screening a sample from a human subject for the presence of E. chaffeensis and Rickettsia rickettsii comprising contacting the sample with immortalized human endothelial cells under conditions which allow infection of the cells and detecting the presence of infection, the presence of infection indicating the presence of E. chaffeensis and/or R. rickettsii. The invention also provides a method of screening a sample from a human subject for the presence of E. chaffeensis comprising contacting the sample with endothelial cells under conditions which allow infection of the cells by E. chaffeensis and detecting the presence of infection by E. chaffeensis, the presence of infection by E. chaffeensis indicating the presence of E. chaffeensis in the sample. Finally, the invention provides a method of culturing E. chaffeensis or E. canis comprising contacting E. chaffeensis or E. canis with immortalized human endothelial cells under conditions which allow the propagation of E. chaffeensis or E. canis.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12R/01
5990088,23-Nov-99,1999,11,23,Method for treating kaposi's sarcoma with antisense oligonucleotides,"The present invention relates to a method to treat Kaposi's sarcoma (KS), and particularly, human immunodeficiency virus associated KS through the administration of antisense oligonucleotides complementary to basic fibroblast growth factor RNA.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/70
5990279,23-Nov-99,1999,11,23,Amino-terminally truncated cystic fibrosis transmembrane conductance regulator,"Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
5990296,23-Nov-99,1999,11,23,Single chain B3 antibody fusion proteins and their uses,"This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,G01N/57492
5993824,30-Nov-99,1999,11,30,Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences,"Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. Alternatively, recombinant RSV and vaccine compositions thereof incorporate attenuating and other mutations specifying desired structural and or phenotypic characteristics in an infectious RSV. Recombinant RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of a selected nucleotide sequence, gene, or gene segment in an infectious RSV clone. The immune system of an individual is stimulated to induce protection against natural RSV infection, or multivalently against infection by RSV and another pathogen, such as PIV, by administration of attenuated, biologically derived or recombinant RSV.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
5993827,30-Nov-99,1999,11,30,Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins,"The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the DBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.",20,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/445
5994062,30-Nov-99,1999,11,30,Epithelial protein and DNA thereof for use in early cancer detection,"The present invention is a purified and isolated epithelial protein, peptide and variants thereof whose increased presence in an epithelial cell is at indicative of precancer. One epithelial protein which is an early detection marked for lung cancer was purified from two human lung cancer cell lines, NCI-H720 and NCI-H157. Using a six-step procedure, the epithelial protein was purified using a Western blot detection system under both non-reducing and reducing conditions. Purification steps included anion exchange chromatography, preparative isoelectric focusing, polymer-based C.sub.18 HPLC and analytic C.sub.4 HPLC. After an approximately 25,000 fold purification the immunostaining protein was >90% pure as judged by coomassie blue staining after reducing SDS-PAGE. The primary epithelial protein share some sequence homology with the heterogeneous nuclear ribonucleoprotein (hnRNP) A2. A minor co-purifying epithelial protein shares some sequence homology with the splice variant hnRNP-B1. Molecular analysis of primary normal bronchial epithelial cell cultures demonstrated a low level the epithelial protein expression, consistent with immunohistochemical staining of clinical samples, and an increased level of expression in most lung cancer cells. The epithelial protein is a marker of epithelial transformation in lung, breast, bone, ovary, prostate, kidney, melanoma and myeloma and may be casual in the process of carcinogenesis. Methods are provided for monitoring the expression of the epithelial protein, peptides and variants using molecular and immunological techniques as a screen for precancer and cancer in mammals.",15,The United States of America as represented by the Department of Health and Human Services,The Johns Hopkins University,,,,,,,,,,2,Biotechnology,,,,,,C07K/4747
5994292,30-Nov-99,1999,11,30,Interferon-inducible protein 10 is a potent inhibitor of angiogenesis,"The present invention is interferon-inducible protein 10 and fragments and analogs of interferon-inducible protein 10 as inhibitors of angiogenesis. The present invention is also the use of interferon-inducible protein 10 (IP-10) as well as fragments and analogs of IP-10 as potent inhibitors of angiogenesis. IP-10 profoundly inhibited basic fibroblast growth factor (bFGF)-induced neovascularization in immunocompromised mammals. In addition, IP-10, is useful in a dose-dependent fashion in suppressing endothelial cell differentiation into tubular capillary structures.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/522
5994523,30-Nov-99,1999,11,30,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
5997869,7-Dec-99,1999,12,7,Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens,A method of immunizing a mammal against a tumor cell by exposing splenic or peripheral blood mononuclear cells to a peptide that encompasses a fusion joint of a fusion protein encoded by DNA spanning a human chromosomal translocation associated with Ewing's sarcoma (t(11;22)(q24;q12)) or alveolar rhabdomyosarcoma (t(2:13)(q35;q14)) is provided.,22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/02
5998149,7-Dec-99,1999,12,7,Method of detecting transmissible spongiform encephalopathies,"This invention provides an improved assays for the detection of transmissible spongiform encephalopathies (TSEs) in humans and non-human mammals. The methods involve detecting the presence or absence of 14-3-3 proteins in cerebrospinal fluid from the tested organism. Elevated levels of 14-3-3 are indicative of transmissible spongiform encephalopathies, in particular Creutzfeldt-Jacob disease in humans or mad cow disease in bovines).",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6896
5998151,7-Dec-99,1999,12,7,Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase,"Methods for determining whether a chemotherapeutic treatment is appropriate for patients afflicted with gastrointestinal cancers, comprising; PA1 (a) obtaining a solid tumor tissue sample from the patient; PA1 (b) measuring a thymidylate synthase expression level in the tissue sample; and PA1 (c) comparing the thymidylate synthase expression level with a group of standard tumor tissue samples, the standards having known thymidylate synthase expression levels and known responses to the chemotherapeutic treatment, to determine if that chemotherapeutic treatment is appropriate for the patient.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/1229
5998382,7-Dec-99,1999,12,7,Targeting gene expression to living tissue using jet injection,"The present invention provides a method of targeting transient gene expression and stable gene expression from the exogenous administration of a DNA sequence, which sequence is less than a complete genome, wherein said DNA sequence encodes RNA and protein, or RNA only, to differentiate tissue of living organisms wherein said DNA sequence through a jet injector technique, and said DNA sequence of less than a complete genome is expressed in a living organism. The present invention further provides a flexible multi-nozzle injector device with a wide surface area to allow molding of the injector nozzle to the surface contours of the tissue. Another aspect of the present invention provides an injection device having a long nozzle for injection of DNA deep into the host tissue. Also, in a further aspect the present invention provides an injector device modified to be used with and/or inject through an endoscopic device.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/89
5998460,7-Dec-99,1999,12,7,"Phenylcarbamates of (-)-eseroline, (-)-N1-noreseroline and (-)-N1-benzylnoreseroline: selective inhibitors of acetyl and butyrylcholinesterase, pharmaceutical compositions and method of use thereof","The present invention relates to eseroline, N.sup.1 -noreseroline, and N.sup.1 -benzylnoreseroline phenyl carbamate analogues which provide highly potent and selective cholinergic agonist and blocking activity and their use as pharmaceutical agents. The invention further relates to improvements in therapeutic methods related to diseases such as glaucoma, myasthenia gravis, alzheimer's disease and to improvements in therapy related to organophosphate poisoning. The invention further provides for selective acetyl-cholinesterase and butyrylcholinesterase agents and a method for inhibiting these esterases.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
5998587,7-Dec-99,1999,12,7,Anti-cyanovirin antibody,"The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences ending such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.",2,"The United States of America, represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
5998596,7-Dec-99,1999,12,7,Inhibition of protein kinase activity by aptameric action of oligonucleotides,"The present invention are oligonucleotides that specifically bind to and directly inhibit the biological function of target molecules such as proteins, peptides or derivatives. The direct or aptameric interaction of oligonucleotides of the present invention with proteins, peptides and derivatives represents a non-antisense mediated effect. The oligonucleotides have been shown to bind to isolated target molecules and to inhibit biological function of the target molecule within cells. In particular, the oligonucleotides have been shown to directly inhibit the kinase activity of protein-tyrosine kinase. The oligonucleotides of the present invention have significant beneficial effects against a chronic myelogenous leukemia derived cell line as demonstrated using cellular phosphotyrosine content as well as cellular growth in soft agar.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12N/115
5998598,7-Dec-99,1999,12,7,Immunoadhesins and methods of production and use thereof,"The invention is directed toward a compound comprising a recombinant nucleic acid encoding an immunoadhesin inserted within an adenoviral nucleic acid, wherein the recombinant nucleic acid can be packaged in an adenovirus particle and wherein expression of the recombinant nucleic acid encoding the immunoadhesin results in production of the immunoadhesin protein. The recombinant nucleic acid encoding the immunoadhesin can be within an adenovirus. The invention further provides methods for delivering an immunoadhesin to a cell or a subject comprising administering to the cell or the subject an adenovirus comprising a recombinant nucleic acid encoding an immunoadhesin; producing an immunoadhesin comprising administering to a cell an adenovirus comprising a recombinant nucleic acid encoding an immunoadhesin inserted within an adenoviral nucleic acid, whereby the cell expresses the recombinant nucleic acid encoding the immunoadhesin, thereby producing the immunoadhesin; treating an inflammatory condition in a subject comprising administering to the subject an adenovirus comprising a recombinant nucleic acid encoding an immunoadhesin inserted within an adenoviral nucleic acid or a recombinant nucleic acid encoding an immunoadhesin inserted within an adenoviral nucleic acid, whereby a cell in the subject expresses the recombinant nucleic acid encoding the immunoadhesin and produces the immunoadhesin, thereby treating the inflammatory condition or administering to the subject a recombinant nucleic acid encoding an immunoadhesin, or an immunoadhesin, wherein the immunoadhesin is selected from the group consisting of vIL-10-IgG, IL-13-IgG, LFA-IgG, IL-2ra-IgG, IL-1ra-IgG, mutant IL-4-IgG, VLA4-IgG, IL-2-IgG, TGF-.beta.1-IgG, TGF-.beta.1.sup.223,225 -IgG, and VCAM-IgG; and methods of screening an immunoadhesin for bioactivity.",2,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70525
6001349,14-Dec-99,1999,12,14,Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof,"We have discovered that by using a recombinant DNA viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding the carcinoma self-associated antigen, or a cytotoxic T-cell eliciting epitope thereof, operably linked to a promoter capable of expression in the host, human cytotoxic T-cells specific for the carcinoma self-associated antigens can be produced. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate production of cytotoxic T-cells, and contacting the host with additional antigen at periodic intervals thereafter. The additional antigen may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional antigen is added by contacting the host with antigen. The antigen may be formulated with an adjuvant or in a liposomal formulation. The T-cells can be isolated. The number of T-cells can be expanded by contacting the isolated cytotoxic T-cells alternately with the carcinoma self-associated antigen or an epitope thereof and IL-2. The isolated T-cells can be used in a method for treating a host having a tumor expressing a carcinoma self-associated antigen comprising introducing cytotoxic T-cells specific for the antigen to the host and at at least one periodic interval thereafter introducing to the host a T-cell eliciting epitope of the carcinoma self-associated antigen.",12,Therion Biologics Corporation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/705
6001371,14-Dec-99,1999,12,14,Parvovirus capsids,The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.,16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6001555,14-Dec-99,1999,12,14,Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein,"The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds that can react with CCHC zinc fingers of the nucleocapsid proteins of a large number of different retroviruses have also been developed. The kits of the present invention describe a set of specific tests and reagents that can be used to screen and identify compounds based on their ability to react with and disrupt retroviral zinc fingers in the viral NC proteins and, in turn, inactivate the retrovirus of interest.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12Q/18
6001853,14-Dec-99,1999,12,14,Hydroxylamine compositions for the prevention or retardation of cataracts,"A pharmaceutical composition and treatment to inhibit the development of cataracts in the crystalline lens of the eye by administering a hydroxylamine to a subject at risk of developing a cataract. The pharmaceutical composition comprises a hydroxylamine compound in a therapeutically sufficient amount to prevent or retard the development of the cataract. A reducing agent can also be administered in combination with the hydroxylamine. Particular examples of the hydroxylamine are TEMPOL-H, TEMPO-H and OXANO-H, while particular examples of the reducing agent are a sulfhydryl compound, such as N-(2-mercaptopropionyl)glycine (MPG), N-acetyl cysteine, .beta.-mercaptopropionyl glycine, and glutathione. In particular embodiments, the composition comprises TEMPOL-H in an amount that is sufficient to provide a concentration of about 1 .mu.M to 1 mM in the aqueous humor of the eye, and mercaptopropionyl glycine in an amount sufficient to provide an aqueous humor concentrations of about 0.1 to 5 mM.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/20
6001977,14-Dec-99,1999,12,14,Cloning and expression of HTLV-III DNA,"The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant,DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/702
6010888,4-Jan-00,2000,1,4,Isolation of cellular material under microscopic visualization,"A method of microdissection which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes an activatable adhesive layer which provides chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated the transfer surface and tissue sample are separated. During separation the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Optics,Biotechnology,Analysis of biological materials,,,G02B/32
6010905,4-Jan-00,2000,1,4,Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells,"The present invention relates to methods of increasing the antigen presenting ability of monocytes by contacting them with an agent which increases the intracellular calcium level. Methods of obtaining the monocytes are also disclosed. In addition, the present invention relates to methods of inducing bone marrow progenitor cells and endothelial cells to express molecules involved in generating immune responses. Methods of modulating the expression of molecules involved in generating immune responses are also disclosed, as are methods of treating cancer and leukemia.",32,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0694
6011002,4-Jan-00,2000,1,4,Circularly permuted ligands and circularly permuted chimeric molecules,The present invention provides for circularly permuted ligands which possess specificity and binding affinity comparable to or greater than the specificity and binding affinity of the original (unpermuted) ligand. The invention further provides for novel chimeric molecules comprising a circularly permuted ligand joined to one or more molecules of interest.,50,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
6013433,11-Jan-00,2000,1,11,Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus,"Novel baculovirus expression vectors and recombinant antigens for detecting, type-specific herpes simplex virus (HSV) infection have been made. Diagnostic kits and assays for detecting type-specific HSV infection have been described. High level production of foreign proteins in substantially pure form are now made possible by the novel baculoviruses of the present invention.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/86
6013449,11-Jan-00,2000,1,11,Probe-based analysis of heterozygous mutations using two-color labelling,"The invention provides methods of analyzing a nucleic acid in a target sample for variant alleles. In such methods, a first-labelled control sample and a second-labelled target sample are hybridized to at least one set of probes. The control sample comprises a homozygous reference allele. The target sample comprises the homozygous reference allele, or variant alleles differing from the reference allele at a locus, or one variant allele differing from the reference allele at the locus and one reference allele. The probes in the probe set span the locus and are complementary to the reference allele. After hybridization the intensity of first and second label bound to each probe in the set is measured. This information is then used to indicate the presence of one variant allele and one reference allele, or the presence of two variant alleles in the target sample.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6827
6013638,11-Jan-00,2000,1,11,"Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung","The present invention relates, in general, to a adenovirus mediated transfer of genes to the lung. In particular, the present invention relates to a method of recombinant, replication-deficient adenovirus mediated transfer of desired genes to the lung whereby desired proteins of interest are produced for local and/or systemic use.",14,The United States of America as represented by the Department of Health and Human Services,Transgene S.A.,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
6015543,18-Jan-00,2000,1,18,Benzamide compounds containing a heterocyclic ring for tumor imaging and therapy,"The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.",89,"Research Corporation Technologies, Inc.",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/79
6015673,18-Jan-00,2000,1,18,Cloning and expression of cDNA for human dihydropyrimidine dehydrogenase,"The invention relates to methods and compositions that are useful for detecting deficiencies in dihydropyrimidine dehydrogenase (DPD) levels in mammals including humans. Cancer patients having a DPD deficiency are at risk of a severe toxic reaction to the commonly used anticancer agent 5-fluorouracil (5-FU). Claimed are DPD genes from human and pig, methods for detecting the level of nucleic acids that encode DPD in a patient, and nucleic acids that are useful as probes for this purpose. Also claimed are methods for expressing DPD in heterologous organisms. Expression vectors that employ a DPD nucleic acid as a selectable marker are also claimed. This selectable marker functions in both prokaryotes and eukaryotes.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/001
6015876,18-Jan-00,2000,1,18,Method of using cyanovirins,"The present invention provides antiviral proteins, peptides and conjugates as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
6017706,25-Jan-00,2000,1,25,Process for identifying compounds which protect against the formation of fluorescent light induced DNA lesions and x-ray-induced lesions,"Processes for detecting compounds which protect against fluorescent light-induced DNA lesions, in particular DNA lesions which are induced by oxygen free radicals, are disclosed. The methods of the present invention encompass modifying G.sub.1 -phase test and/or G.sub.2 -phase tests so that a compound which is suspected of being capable of protecting against the formation of fluorescent light-induced DNA lesions (i.e., a suspected ""DNA protectant""), such as an anti-oxidant or free-radical scavenger, is added to the cell cultures prior to irradiation of the cell cultures with fluorescent light or x-rays. Addition of a DNA protectant to cultures of human skin fibroblasts or PHA-stimulated blood lymphocytes significantly reduces the frequency of radiation-induced chromatid breaks so that there is a small, preferably no, statistical difference in the frequency of radiation-induced chromatid breaks in Alzheimer disease cells in the presence or absence of caffeine in the G.sub.1 -phase test using fluorescent light, or in normal cells in the presence or absence of ara-C in the G.sub.2 -phase test using fluorescent light or x-rays.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5091
6017721,25-Jan-00,2000,1,25,Chromatographic method and device for preparing blood serum for compatibility testing,"The invention provides a new method for antiglobulin testing from serum of a potential blood transfusion recipient in which warm autoantibodies are removed from serum so as to allow identification of alloantibodies present. The method involves contacting serum from a patient with one or more ligands that bind warm autoantibodies but do not bind alloantibodies, separating the non-bound serum components from the bound warm autoantibodies, and using the warm autoantibody-depleted serum in antiglobulin testing. Suitable ligands include phospholipids, the polar head groups of phosphoglycerides, and naturally occurring and synthetic analogues of these molecules.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6854
6017880,25-Jan-00,2000,1,25,Inhibition of retrovirus infection,"Methods and pharmaceutical compositions are provided to prevent retroviral infections of host cells. More particularly, the invention relates to prevention of HIV infection of human cells by serine leukocyte protease inhibitor (SLPI).",25,Amgen Inc.,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/06
6017957,25-Jan-00,2000,1,25,Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents,"A method is disclosed for the treatment of neuropsychopharmacological disorders which are associated with or result from excessive activation of the N-methyl-D-aspartate receptor complex, which method comprises administering an effective neuropsychopharmacological disorder-treating amount of a compound possessing partial agonist properties for the strychnine insensitive glycine modulatory sites of N-methyl-D-aspartate receptors. Exemplary of partial agonists which are useful in the method of the invention are 1-aminocyclopropanecarboxylic acid, and associated derivates thereof. Novel injectable pharmaceutical compositions are also disclosed.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/195
6018027,25-Jan-00,2000,1,25,Human herpesvirus-6 (HHV-6) isolation and products,"A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6020128,1-Feb-00,2000,2,1,DNA polymerase from Treponema pallidum,"The nucleic acid sequence encoding the gene for the DNA polymerase I enzyme of Treponema pallidum, the organism causing syphilis. Nucleic acid molecules useful as probes for detecting Treponema pallidum are described. Isolated, recombinant, and synthetic DNA polymerase I enzyme of Treponema pallidum, and the amino acid sequence of the enzyme, are also described. Antibodies to DNA polymerase I from Treponema pallidum are further provided. The nucleic acid molecules are useful in methods for the detection and diagnosis of Treponema pallidum infection in a sample or subject.",17,United States of Ameria,,,,,,,,,,,1,Biotechnology,,,,,,C07K/20
6022950,8-Feb-00,2000,2,8,Hybrid molecules having translocation region and cell-binding region,"Disclosed is a hybrid molecule comprising a first part, a second part, and a third part connected by covalent bonds, PA1 (a) wherein said first part comprises a portion of the binding domain of a cell-binding polypeptide ligand effective to cause said hybrid protein to bind to a cell of an animal; PA1 (b) wherein said second part comprises a portion of a translocation domain of naturally occurring protein which translocates said third part across the cytoplasmic membrane into the cytosol of the cell; and PA1 (c) wherein said third part comprises a chemical entity to be introduced into the cell, wherein each of said first part and said third part is non-native with respect to said naturally occurring protein, and further wherein said covalent bond connecting said second part and said third part is a cleavable bond, provided that when said second part comprises a portion of a translocation domain of Pseudomonas exotoxin, said third part is not a polypeptide.",51,"Seragen, Inc.",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6025154,15-Feb-00,2000,2,15,Polynucleotides encoding human G-protein chemokine receptor HDGNR10,"Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.",19,"Human Genome Sciences, Inc.",,,,,,,,,,,1,Biotechnology,,,,,,C07K/7158
6025182,15-Feb-00,2000,2,15,Method for producing a virus from an african green monkey kidney cell line,A method for producing novel African Green Monkey Kidney (AGMK) cell lines is taught. These cell lines which are free of viable adventitious microbial agents are useful as substrates for viruses and for the preparation of viral vaccines.,8,Dyncorp,National Institutes of Health,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
6027516,22-Feb-00,2000,2,22,"Highly elastic, adjustable helical coil stent","A highly elastic, adjustable helical coil stent (10) has a helical coil (20) which can be contracted around a small diameter catheter (12) for percutaneous insertion into a human body and then can be remotely expanded back to its original shape when positioned at the desired location within the human body. The helical coil is preferably formed of a metal alloy (25) with high elasticity, such as superelastic Nitinol, encased within an elastomer (26). The helical coil is affixed at its distal end to a catheter and affixed at its proximal end to a control tube (30). By rotating the control tube in one direction relative to the catheter (e.g., clockwise), the helical coil contracts and by rotating the control tube in the opposite direction (e.g., counterclockwise), the helical coil expands. The adjustable helical coil stent of the present invention is particularly useful for total or partial heart assist during heart bypass procedures. It can also be used, for example, as a stent for damaged blood vessels or other body conduits in either humans or animals.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61F/88
6027881,22-Feb-00,2000,2,22,Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence,"The present invention is directed to mutants of the jellyfish Aequorea victoria green fluorescent protein (GFP) having at least 5 and preferably greater than 20 times the specific green fluorescence of the wild type protein. In other embodiments, the invention comprises mutant blue fluorescent proteins (BFPs) that emit an enhanced blue fluorescence. The invention also encompasses the expression of nucleic acids that encode a mutant GFP or BFP in a wide variety of engineered host cells, and the isolation of engineered proteins having increased fluorescent activity. The novel mutants of the present invention allow for a significantly more sensitive detection of fluorescence in engineered host cells than is possible with GFP or with its known mutants. Thus, the mutant fluorescent proteins provided herein can be used as sensitive reporter molecules to detect the cell and tissue-specific expression and subcellular compartmentalization of GFP or BFP mutants, or of chimeric proteins comprising GFP or BFP mutants fused to a regulatory sequence or to a second protein sequence.",21,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/43595
6030771,29-Feb-00,2000,2,29,Mosaic protein and restriction endonuclease assisted ligation method for making the same,"A mosaic protein comprising a variety of immunoreactive antigenic epitopes from several genotypes of hepatitis C virus. The mosaic protein provides a sensitive and specific immunological hepatitis detection assay. A restriction enzyme assisted ligation method of making an artificial gene permits controlled construction of mosaic proteins, and allows confirmatory expression of the intermediate gene products.",8,Centers for Disease Control and Prevention,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6031074,29-Feb-00,2000,2,29,Automated Peptide design and synthesis,"An automated peptide design and synthesis method is provided, wherein peptides are synthesized on interior, inward facing surfaces of reservoirs formed in a solvent resistant substrate. Novel substrates, as well as novel solutions for storing protected carboxyl terminal amino acids, are also provided.",7,National Institutes of Health,,,,,,,,,,,1,Biotechnology,Chemical engineering,Biotechnology,,,,C07K/04
6031374,29-Feb-00,2000,2,29,Method for extracting deformations from velocity-encoded magnetic resonance images of the heart,"An MRI scan is conducted in which velocity encoded NMR data is acquired for a slice through the heart. Velocity images and magnitude images are reconstructed at multiple cardiac phases and masks are formed using the magnitude images. The masks are applied to the velocity images to isolate the left ventricle, and rigid body motion is calculated and subtracted from the masked velocity images to indicate deformation of the left ventricle.",12,,,,,,,,,,,,,Medical technology,Measurement,,,,,A61B/7207
6033905,7-Mar-00,2000,3,7,Gibbon ape leukemia virus-based retroviral vectors,"The present invention provides replication-defective hybrid retroviral vectors comprising GaLV components and methods for preparing and using such vectors. The vectors comprise a envelope component, a core component and a defective genome, at least one of which is derived from GaLV. The vectors can comprise the minimal cis acting sequences from GaLV that allow packaging of the defective genome in a hybrid virion.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6037376,14-Mar-00,2000,3,14,Methods for therapy of cancer,"Compositions and methods of treating anemia, cancer, AIDS, or severs .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.",41,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
6039957,21-Mar-00,2000,3,21,Oligomeric HIV-1 envelope glycoproteins,"The present invention relates to methods for producing recombinant HIV-1 envelope (env) oligomers for use as immunogens. When gp140 oligomeric glycoproteins were purified by sucrose velocity gradient sedimentation, and then used to immunize mice, the resulting humoral immune response was skewed toward the production of antibodies that recognize conformation-dependent epitopes on the HIV-1 env protein. Assays for HIV-1 infections are described, as well as immonogens for vaccinating against HIV-1 infection.",5,"United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6040334,21-Mar-00,2000,3,21,Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy,"Methods of treating various cancers, such as prostatic adenocarcinoma, with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG Co-A), such as lovastatin, are provided. Dosing ranges, schedules and toxicities are included.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/366
6043345,28-Mar-00,2000,3,28,IgE isoforms and methods of use,"Methods and compositions are provided relating to novel IgE isoforms and their use in immune hypersensitivity diagnosis and treatment. The compositions include transcription and translation products of the immunoglobulin epsilon locus, specific probes for epsilon transcription products, and compounds that specifically bind epitopes of epsilon translation products. Novel products of the epsilon locus include the following transcription products and translation products thereof: CH4-M2"", CH4'-CH5-M1'-M2, CH4'-CH5-M2', CH4'-CH5-M2.increment. and CH4-M2'. Such epsilon products, specific probes and binding compounds find use in methods and kits for immune hypersensitivity diagnosis and treatment.",4,The Regents of the University of California,,,,,,,,,,,1,Biotechnology,,,,,,C07K/00
6045789,4-Apr-00,2000,4,4,Bystander effect tumoricidal therapy by expressing an HSV-tk gene,"A method for treating an tumor involves the initial identification of the tumor as one displaying a ""bystander effect,"" whereby in vivo transfer of a gene conferring sensitivity to chemotherapeutic agent affects both transformed and non-transformed tumor cells. Into a tumor thus characterized is introduced in situ a retroviral vector containing the sensitizing gene. The retroviral vector, which may replication-defective or replication-competent, can be introduced directly (if it is replication-competent) or can be provided by means of a packaging cell line. Treatment of the patient with the chemotherapeutic agent thereafter effects tumor regression when as few as 10% of tumor cells are transformed, while normal tissue is not damaged. The anti-tumor impact of the treatment can be increased when the transducing vector also encodes an immune response-enhance substance such as IL-2 or another cytokine.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/00
6045793,4-Apr-00,2000,4,4,Recombinant ribonuclease proteins,The invention relates to ribonucleases derived from a native ribonuclease found in the oocytes of Rana pipiens. Various humanized and recombinant forms of these molecules are described as well as uses for them.,31,,,,,,,,,,,,,Biotechnology,Biotechnology,,,,,C12N/22
6045802,4-Apr-00,2000,4,4,Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule,The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.,24,The United States of America as represented by the Secretary of the Department Of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70532
6046175,4-Apr-00,2000,4,4,Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis,"A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/708
6046200,4-Apr-00,2000,4,4,Compositions having neuroprotective and analgesic activity,"Compounds of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are alkyl of 1-8 carbons have been shown to have both neuroprotective and analgesic activities. The compounds of the invention may be used in treatment of conditions that would normally result in neuronal damage, including those arising on account of cerebral ischemia/hypoxia or increase in intracranial pressure such as neoplasms, stroke, meningitis or trauma. Compositions of the invention can also be useful for treatment of toxin-related damage such as drug over-dose or exposure to toxins in the environment.",6,The United States of America as represented by the Secretary of the Army,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/4965
6046228,4-Apr-00,2000,4,4,"Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof","The present invention is directed to pharmaceutical compositions including a saturated 1,2-dithiaheterocyclic compound having antiviral activity. The present invention also provides a kit containing the pharmaceutical composition and methods of treating or preventing viral disease using the composition, as well as methods for inactivating retrovirus in a body fluid.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
6051225,18-Apr-00,2000,4,18,"Family of high affinity, modified antibodies for cancer treatment","This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H .alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.",9,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/462
6051405,18-Apr-00,2000,4,18,Constructs encoding recombinant antibody-toxin fusion proteins,The present invention describes constructs encoding recombinant scFv-toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Protein Design Labs, Inc.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/495
6051410,18-Apr-00,2000,4,18,"Self-assembled, defective, nonself-propagating viral particles",Recombinant viral vectors which coexpress heterologous polypeptides capable of assembling into defective nonself-propagating viral particles are disclosed. The viral vectors as well as the viral particles can be used as immunogens and for targeted delivery of heterologous gene products and drugs.,7,"Therion Biologics, Corp.",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C12N/86
6051549,18-Apr-00,2000,4,18,Heparin and sulfatide binding peptides from the type-I repeats of human thrombospondin and conjugates thereof,"This invention identifies a biologically active group of peptide sequences from Type I repeat units of the extracellular matrix protein, human thrombospondin-1, identical or homologous to the sequence, KRFKQDGGWSHWSPWSSC (SEQ ID NO.30). The biological activities residing with the full sequences, portions thereof, and variants of the full or partial sequences are disclosed. The invention describes how biological activity may be enhanced by covalently linking these peptides to suitable carriers, preferably a branched, water-soluble polymer of low (or absent) toxicity and immunogenicity, such as polysucrose (Ficoll.TM.). The invention describes (1) a method for preparing such conjugates, (2) the use of the defined peptides or their conjugates in blocking or modifying the action on cellular processes of heparin (e.g., proliferation, adhesion, motility, extravasation and neovascularization), sulfatides, related sulfated glycoconjugates, fibronectin, and basic fibroblast growth factor, involving malignant cell lines and normal endothelial cells. Use of the defined peptides, analogs or peptidomimetics and their conjugates for treatment of metastatic tumors, breast carcinomas, melanomas, Kaposi's sarcomas, hemangiomas, diabetic retinopathies, and various pathological conditions dependent upon neovascularization is also disclosed.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/10
6054283,25-Apr-00,2000,4,25,Antibodies against human herpesvirus-6(HHV-6) and method of use,"A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.",3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6054567,25-Apr-00,2000,4,25,Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines,The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.,9,The United States of America as represented by the Department of Health and Human Services,"Novavax, Inc.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
6056952,2-May-00,2000,5,2,Selective elimination of T cells that recognize specific preselected targets,"This invention provides compositions and methods for the elimination of T cells that recognize specific preselected targets. The methods involve providing killer cells (e.g. natural killer cells or cytotoxic T lymphocytes) having a T cell receptor in which the zeta chain is joined to the antigen target of the T cell population it is desired to eliminate. Recognition of the antigen target activates the killer cell thereby inhibiting or destroying the T cell. Where the antigen target is the extracellular domain of a major histocompatibility complex, the method provides a means of mitigating graft rejection or an autoimmune response.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0636
6057298,2-May-00,2000,5,2,Keratin K1 expression vectors and methods of use,"A keratin K1 vector for expression of a nucleic acid sequence in an epidermal cell. The vector includes a 5' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a keratin K1 3' flanking region which regulates expression of a nucleic acid sequence, predominantly in the epidermis, and a linker which connects the 5' flanking region to a nucleic acid. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. That is, the linker is not the normal gene associated with the 5' and 3' regions.",23,Baylor College of Medicine,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Other special machines,Pharmaceuticals,,,,C12N/85
6057346,2-May-00,2000,5,2,Inhibition of retroviral LTR promoters by calcium response modifiers,"A class of calcium-response modification compounds is disclosed which inhibits the activation of retroviral LTR promoters, including the HIV-LTR. This class of compounds are used to delay or suppress the transition of a retroviral infection from a latent to a virulent condition, thereby ameliorating retrovirally caused diseases such as AIDS. The compounds are also useful in cancer treatment, allowing for coordinated therapeutic approaches to retroviral diseases and related cancers such as AIDS and Kaposi's Sarcoma. The compounds are also useful in standardizing in vitro assays of clinical and experimental importance.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4174
6060253,9-May-00,2000,5,9,Agents that bind to and inhibit human cytochrome P450 2D6,"The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2D6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2D6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful in methods for screening drugs for metabolism by cytochrome P450 2D6, and in methods of screening individuals for a poor metabolizing human P450 2D6 phenotype.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/40
6060310,9-May-00,2000,5,9,Transcription factor decoy and tumor growth inhibitor,"The present invention provides compositions with high affinity for a target transcription factor, that can be introduced into cells as decoy cis-elements to bind the factor and alter gene expression. Specifically, the present invention provides nucleic acid molecules that compete with cAMP response element (CRE) enhancers for binding to transcription factors.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/711
6060317,9-May-00,2000,5,9,"Method of transducing mammalian cells, and products related thereto","In accordance with the present invention, there are provided methods of transducing cells comprising providing a flexible closed culture container having cells therein and contacting said cells with a viral-vector in the presence of a multi-functional chemical moiety. Also provided are methods of delivering a functional protein to a subject in need thereof, comprising transducing mammalian cells according to the invention method and introducing said cells into a subject in need thereof. Also provided are cell-culture systems for transducing cells, comprising a flexible closed culture container and a multi-functional chemical moiety therein.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/87
6060458,9-May-00,2000,5,9,Oligodeoxyribonucleotides comprising O.sup.6 -benzylguanine and their use,"The present invention provides a single-stranded oligodeoxyribonucleotide, which (i) comprises from about 5 to 11 bases, at least one of which is a substituted or an unsubstituted O.sup.6 -benzylguanine, and (ii) inactivates human AGT. The present invention also provides a single-stranded oligodeoxyribonucleotide, which can inactivate a mutant human AGT, which either is not inactivated by O.sup.6 -benzylguanine or is less inactivated by O.sup.6 -benzylguanine than by said single-stranded oligodeoxyribonucleotide. A phosphate of the single-stranded oligodeoxyribonucleotide can be replaced by a methylphosphonate or a phosphorothioate. The present invention also provides a composition comprising such an oligodeoxyribonucleotide. In addition, the present invention provides a method of enhancing the effect of an antineoplastic alkylating agent, which alkylates the O.sup.6 position of guanine residues in DNA, in the chemotherapeutic treatment of cancer in a mammal, which method comprises the co-administration to the mammal of a cancer-treatment effective amount of an antineoplastic alkylating agent and a chemotherapeutic treatment-enhancing amount of a present inventive oligodeoxyribonucleotide or composition thereof.",61,The United States of America as represented by the Department of Health and Human Services,The Penn State Research Foundation,Arch Development Corporation,,,,,,,,,3,Organic fine chemistry,Pharmaceuticals,,,,,C07H/00
6060505,9-May-00,2000,5,9,Method of treating cancer using C-26 modified bryostatin,Disclosed are modified bryostatins and their use as anticancer drugs.,40,The United States of America as represented by the Department of Health and Human Services,Arizona Board of Regents of Arizona State University,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/365
6063905,16-May-00,2000,5,16,Recombinant human IGA-J. chain dimer,"Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.",102,"Board of Regents, The University of Texas System",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/1063
6066642,23-May-00,2000,5,23,"Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists","The present invention provides certain novel compounds, compositions, and a method of treating a mammal by blocking its adenosine receptors comprising administering at least one compound of the present invention. Examples of the present inventive compounds include certain flavonoids of formulae (I) and (II), wherein R.sub.1 to R.sub.4 are as defined in the description, and M is --CH(OH)--CH(R.sub.2)-- or --C(OH).dbd.C(R.sub.2)-- and R.sub.1, R.sub.2 are as defined in the description; or dihydropyridines of formula (III), wherein R.sub.2 to R.sub.6 are as defined in the description; or pyridines of formula (IV), wherein R.sub.2 to R.sub.6 are as defined in the description, or triazoloquinazolines of formula (V), wherein R.sub.1 and R.sub.2 are as defined in the description; and their derivatives, or pharmaceutically acceptable salts thereof.",33,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
6066656,23-May-00,2000,5,23,"2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same","The present invention provides 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane (DAD) isosteres comprising benzamide, sulfonamide and anthranilamide subunits, a pharmaceutical composition comprising such compounds, a method of using such compounds to treat retroviral, specifically HIV and more specifically HIV-1 and HIV-2, infections in mammals, particularly humans, a method of synthesizing asymmetric DAD isosteres comprising benzamide, sulfonamide and anthranilamide subunits, and a method of using such compounds to assay new compounds for antiretroviral activity.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/82
6068844,30-May-00,2000,5,30,Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof,"The present invention relates to a method of inducing oral tolerance to ischemic injury which has the objective of minimizing the severity and size of injured regions in the brain that arise as a result of ischemia. The method responds rapidly to the onset of infarction, with treatment that is short in duration. The procedure is specifically focused on the injured area of the infarct by virtue of being targeted immunologically to the ischemic site. The method therefore avoids the possibility of inducing systemic side effects affecting other organs of the patient. The present invention involves administering myelin or a component thereof such as myelin basic protein or proteolipid protein to a subject either orally or by inhalation. The amount administered and the duration of the treatment are effective to minimize the size and severity of the infarct in the brain of the subject. The method is intended for acute conditions related either to an actual recent cerebral ischemic event or to a potential ischemic event that might arise as a result of medical or surgical treatment planned for the subject.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1709
6071515,6-Jun-00,2000,6,6,Dimer and multimer forms of single chain polypeptides,The present invention discloses novel proteins which are dimers and multimers of single chain polypeptides. The single chain polypeptides having two domains derived from the immunoglobulin superfamily which are joined by a peptide linker. The dimers and multimers being formed by non-covalent linking of the single chain polypeptides.,5,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/10
6071709,6-Jun-00,2000,6,6,Nerve growth factor/receptor complex,"The present invention relates to a complex comprising nerve growth factor (NGF) and trk proto-oncogene protein and a complex comprising neurotrophic factors, NT-3 or BDNF, and trkB proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF, NT-3 or BDNF neurotrophic factors and trk and trk-related proto-oncogene receptors. The present invention further relates to methods that may be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting complexes comprising NGF or NGF related neurotrophic factors bound to the product of the tyrosine kinase trk or related trk proto-oncogene family member.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/564
6071949,6-Jun-00,2000,6,6,Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents,"The present method provides a method for treating an epithelial cell-derived cancer in a subject in need of such treatment which comprises administering to the subject an amount of a 5-lipoxygenase inhibitor or derivative thereof effective to treat the epithelial cell-derived cancer. The present invention also provides a method for preventing an epithelial cell-derived cancer in a subject in need of such prevention which comprises administering to the subject an amount of a 5-lipoxygenase inhibitor effective to prevent the epithelial cell-derived cancer. Suitable 5-lipoxygenase inhibitors useful for the methods of the present invention preferably include 2-(12-Hydroxydodeca-5,10-dinyl)-3,5,6-trimethyl-1,4-benzoquinone and derivatives thereof; Nordihydroguaiaretic acid and derivatives; and 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-t-isopropyl-indol-2-yl]-2-2-dimethylp ropanoic acid and derivatives thereof. Also intended to be encompassed by this invention are hydroxyurea derivatives as inhibitors of 5-lipoxygenase inhibitors for use in the prevention and treatment of epithelial cell-derived cancers.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/40
6072031,6-Jun-00,2000,6,6,Cellular apoptosis susceptibility protein (CSP),The cDNA and amino acid sequences for a cellular apoptosis susceptibility (CAS) protein are used to detect expression and amplification of the CAS gene in normal and cancer cells. An antisense CAS gene sequence introduced into living cells inhibits CAS protein activity and thus prevents or inhibits apoptosis in the cells.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/18
6073039,6-Jun-00,2000,6,6,Device and method for real-time monitoring of an electrocardiogram during magnetic resonance imaging,"An electrode assembly for monitoring bioelectric signals includes a first electrode member and a second electrode member disposed around the first electrode member. When the electrode assembly is placed on a body of a person, a bioelectric signal is monitored by measuring the electrical potential between the first and second electrode members with the measurement device. The first and second electrode members may be single electrodes or two or more electrodes connected by conductors. Alternatively, the first and second electrodes can be formed from an array of electrodes by connecting the electrodes in a desired configuration either electrically or by use of a software algorithm.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/04085
6074644,13-Jun-00,2000,6,13,"Nucleic acids encoding immunotoxins containing a disulfide-stabilized antibody fragment replacing half or more of domain IB of pseudomonas exotoxin, and methods of use of the encoded immunotoxins","This invention provides for nucleic acids encoding immunotoxins comprising a Pseudomonas exotoxin (PE) that does not require proteolytic activation for cytotoxic activity attached to an Fv antibody fragment having a variable heavy chain region bound through at least one disulfide bond to a variable light chain region. The combination of a ""disulfide-stabilized"" binding agent fused to a PE that does not require proteolytic activation provides an immunotoxin having surprising cytotoxic activity.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/30
6074842,13-Jun-00,2000,6,13,Cloning of perilipin proteins,"The present invention provides isolated nucleic acid sequences, i.e., polynucleotides, which encode a family of perilipin proteins. The present invention also provides isolated, substantially purified perilipin proteins which are useful as markers for differentiating true adipocytes from non-adipocyte cells which, as a result of pathophysiological conditions, assume adipocyte characteristics and become lipid-laden. The present invention further provides methods for producing a substantially purified perilipin protein and methods for detecting the presence of such perilipin proteins in a biological samples.",14,The United States of America as represented by the Department of Health,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
6074864,13-Jun-00,2000,6,13,Cloned DNA for synthesizing unique glucocerebrosidase,Glucocerebrosidase produced by recombinant methods and having use for treatment of Gaucher's disease is disclosed. A cDNA for encoding the specific protein is taught along with the method of preparing the construct used to produce the protein.,15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Y/01045
6077694,20-Jun-00,2000,6,20,Method for over-expression and rapid purification of biosynthetic proteins,The subject invention relates to a method of producing and purifying large quantities of a biosynthetic protein. The gene which codes for the protease is placed between the binding domain of a gene which codes for a binding protein and a gene coding for the target protein of interest. The fused gene construct is inserted in an expression vector which is then introduced into a host cell.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6077935,20-Jun-00,2000,6,20,Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS,An envelope protein of the etiologic agent of acquired immune deficiency syndrome (AIDS) and a method for its preparation are disclosed. Proviral DNA is transferred into a host cell after engineering into an expression vector which produces the envelope protein. A method of testing human blood for the presence of antibodies to the AIDS virus using the AIDS envelope protein is disclosed.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6080582,27-Jun-00,2000,6,27,Cell tests for Alzheimer's disease,"The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5091
6083502,4-Jul-00,2000,7,4,Mesothelium antigen and methods and kits for targeting it,"This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1072
6083503,4-Jul-00,2000,7,4,"Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection","A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T lymphocytes that is capable of causing such diseases, while leaving substantially unaffected the majority of other T lymphocytes. Cell death is achieved by cycle(s) comprising challenging via immunization these T cells with antigenic substance at short time intervals, or by immunization followed by administering interleukin-2 (IL-2) when these T cells are expressing high levels of IL-2 receptor so as to cause these T cells to undergo apoptosis upon re-immunization with the antigenic peptide or protein. These methods are applicable to the treatment of autoimmune diseases such as, for example, multiple sclerosis, uveitis, arthritis, Type I insulin-dependent diabetes, Hashimoto's thyroiditis, Grave's thyroiditis, autoimmune myocarditis, etc., allergic disorders such as hay fever, extrinsic asthma, or insect bite and sting allergies, food and drug allergies, as well as for the treatment or prevention of graft rejection.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
6083703,4-Jul-00,2000,7,4,Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes,The infusion of TIL586 along with interleukin-2 (IL-2) into the autologous patient with metastatic melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen recognized by TIL586 was previously isolated and shown to encode gp75 or TRP-1. The present invention relates to the identification of a second tumor antigen recognized by a HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP-2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Modified peptides were also recognized by the CTL clone.,27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0059
6083954,4-Jul-00,2000,7,4,Method of treating cystic fibrosis,"The present invention provides a method of identifying CFTR-binding compounds for treating cells having a reduced apical Cl.sup.- conductance, such as cystic fibrosis cells. This identification method involves the use of polypeptide I.alpha., which constitutes a portion of the CFTR protein. The present invention also provides a method of treating CF cells by contacting cells having a reduced apical Cl.sup.- conductance with a therapeutically effective quantity of a compound selected by the present inventive identification method. Preferred compounds for such treatment have little or no affinity for adenosine cell receptors. The present invention provides novel compounds useful in practicing the present inventive method, as well as pharmaceutical compositions containing such compounds.",11,,,,,,,,,,,,,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/52
6084063,4-Jul-00,2000,7,4,Signal transduction inhibitors of allergic reactions,"The present invention provides an isolated polypeptide consisting of amino acids 1-66 of the human tyrosine kinase, Lyn A, in a pharmaceutically acceptable carrier and an isolated polypeptide consisting of amino acids 1-45 of the human tyrosine kinase, Lyn B, in a pharmaceutically acceptable carrier. The present invention also provides isolated nucleic acids encoding the above-described amino acid sequences, as well as vectors comprising the nucleic acids and cells comprising the vectors. The present invention further provides a method of treating or preventing an allergic disorder in a subject, comprising administering any of the above nucleic acids to a cell of the subject under conditions whereby the nucleic acid is expressed in the subject's cells, thereby treating the allergic disorder. Additionally provided in this invention is a fusion protein comprising either a polypeptide consisting of amino acids 1-66 of the human tyrosine kinase, Lyn A or a polypeptide consisting of amino acids 1-45 of the human tyrosine kinase, Lyn B and a ligand which binds to and is internalized by cells which express a high affinity receptor for IgE on the surface. A method of treating or preventing an allergic disorder in a subject is also provided, comprising administering an effective amount of the above fusion protein to a cell of the subject, whereby the fusion protein treats the subject's allergic disorder.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
6084069,4-Jul-00,2000,7,4,Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy,"The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Micro-structural and nano-technology,Biotechnology,,,,,B82Y/00
6084090,4-Jul-00,2000,7,4,Human papilloma virus anti-sense oligonucleotides,Antisense oligonucleotides having phosphorothioate backbone structure and sequences complementary to nucleotides contained with residues 415 to 445 of human papilloma virus 16 (HPV-16) are disclosed. Methods of treatment using antisense oligonucleotides having phosphorothioate backbone structure and nucleotide sequences complementary to nucleotides contained with residues 415 to 445 of HPV-16 are disclosed.,1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Organic fine chemistry,,,,C12N/1131
6086881,11-Jul-00,2000,7,11,Spatially aligned conjugated composition having a thioether bond linkage,"The present invention is a spatially aligned conjugated composition which comprises at least one chemically modified substance which is immunologically representative of a prechosen infectious agent and provides a chemical constituent for entering into and forming a thioether bond; a plurality of chemically substituted metallic oxide particles which range from about 10-10,000 nanometers and are able to enter into a thioether bond and covalent linkage; and at least one thioether bond and linkage joining the metallic oxide particles in a controlled and spatially aligned manner to the antigen or hapten. The conjugated composition may be alternatively employed as an immunogen; as a vaccine; as a diagnostic tool and reactant; and as an analytical material suitable for testing the pharmacological activity of new compounds.",11,Children's Medical Center Corp.,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6087110,11-Jul-00,2000,7,11,Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein,"The present invention discloses that the normal melanogenic gene, gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3, which is processed to an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The products of this gene are promising candidates for immunotherapeutic strategies for the treatment and diagnosis of patients with cancer.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0059
6087117,11-Jul-00,2000,7,11,Production and use of human nm23 protein and antibodies therefor,Human nm23 DNA and protein is disclosed as well as antibodies which recognize human nm23 protein. The DNA and antibodies may be used to detect nm23 in human tumors to predict the malignancy potential of such tumors.,29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/12
6090414,18-Jul-00,2000,7,18,Method and composition to reduce cancer incidence,"The five component composition consisting essentially of: PA1 (1) Water soluble antioxidant vitamin C or ascorbic acid, or any of its forms or derivatives, or mixtures thereof. PA1 (2) Oil soluble antioxidant vitamin E or Alpha-tocophorol, or any of its forms or derivatives, or mixtures thereof. PA1 (3) The element selenium, or a chemical (or composition) containing it, or mixtures thereof. The most preferred chemical containing selenium is dimethyl selenide and mixtures thereof. The words ""dimethyl selenide"" here and hereinafter mean dimethyl selenide and/or it's oxidation products, including dimethyl selenoxide. PA1 (4) A sulfur amino acid, in any form, or a sulfur peptide, or a sulfur protein, or any of their derivatives, or mixtures thereof. The mixture of methionine and cysteine, which contains as impurities some seleno-methionine and some selenocysteine, is preferred,--the tripeptide glutathione containing cysteine is also preferred. PA1 (5) Another antioxidant, other than vitamin C and other than vitamin E, which is synthetic or natural and water soluble or oil soluble, or a mixture of such antioxidants, or a combination of such forms thereof. The mixtures of butylated hydroxyanisole and ethoxyquin is preferred.",116,"Life Science Labs, Inc.",,,,,,,,,,,1,Food chemistry,Pharmaceuticals,,,,,A61K/621
6090554,18-Jul-00,2000,7,18,Efficient construction of gene targeting vectors,The present invention is directed to methods for producing or obtaining gene targeting constructs by way of homologous recombination in host cells and to targeting constructs produced by those methods. The invention is also directed to transgenic animals having targeted mutations introduced in to the cells of the animal using the targeting constructs of the invention.,26,"Amgen, Inc.",,,,,,,,,,,1,Biotechnology,Other special machines,,,,,A01K/0276
6090795,18-Jul-00,2000,7,18,Human derived monocyte attracting purified peptide products useful in a method of treating infection and neoplasms in a human body,"Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with the peptide products are additionally provided, as well as pharmaceutical compositions for the peptide products.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/523
6093539,25-Jul-00,2000,7,25,DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS,"This invention provides an isolated single-stranded nucleic acid which encodes an aqueous-soluble polypeptide comprising at least a portion of a human T4 glycoprotein, which portion specifically forms a complex with a human immunodeficiency virus envelope glycoprotein.",28,The Trustees of Columbia University in the City of New York,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70514
6093702,25-Jul-00,2000,7,25,Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread,A method and composition for inhibiting the spread of a retrovirus such as HIV in a human cell population in which a retrovirus such as HIV is present has been found. The spread of the retrovirus is inhibited by treatment of the cells with a synergistic combination mixture of a dideoxy-ribonucleoside excluding AZT and hydroxycarbamide.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
6096534,1-Aug-00,2000,8,1,Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells,"Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an envelope gene from a virus capable of infecting both mammalian and avian cells. The resulting recombinant ASLV-derived retroviral vectors can replicate efficiently in avian cells, infect both avian and mammalian cells in high titer, and are replication-defective in mammalian cells. Thus, they are quite safe and advantageous for use in gene therapy and vaccines.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6099842,8-Aug-00,2000,8,8,Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin,"Single chain immunotoxins directed at the human transferrin receptor using PCR based methods are described. Anti-TFR(Fv)-PE40 contains DNA for the antigen binding portion (Fv) of a monoclonal antibody directed at the human transferrin receptor fused to the DNA for a 40,000 molecular weight fragment of Pseudomonas exotoxin (PE40). In another fusion protein, DT388-anti-TFR(Fv), DNA for the antigen binding portions of the anti-TFR antibody has been fused to the DNA encoding a truncated form of Diphtheria toxin. In anti-TFR(Fv)-PE40, the single chain antibody precedes the toxin whereas in DT388-anti-TFR(Fv) the single chain antibody is at the carboxyl end of toxin. The proteins encoded by these gene fusions were expressed in E.coli and purified by conventional chromatographic techniques to near homogeneity.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/34
6099847,8-Aug-00,2000,8,8,Chimeric Gag pseudovirions,"The present invention provides, inter alia, recombinant chimeric nucleic acids encoding a Gag-fs-fusion partner fusion protein; a pseudovirion comprising a retroviral Gag protein and a fusion partner, wherein the fusion partner is present in a Gag-fs-fusion partner fusion protein; an immunogenic composition comprising a pseudovirion; a Gag-fs-fusion partner fusion protein; and a method of making the pseudovirions of the present invention.",43,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6100051,8-Aug-00,2000,8,8,Method utilizing convex geometry for laser capture microdissection,"A process of microdissection where a tissue sample is conventionally visualized in a microscope. A selectively activatable convex surface is provided, preferably on the periphery at the distal end of a rod. This selectively activatable convex surface when locally activated, typically with a laser through an optic light path in the microscope, provides the activated region with adhesive properties. The tissue sample has at least one portion, which is to be extracted is identified. This identified portion is contacted with a portion of the selectively activatable convex surface on the periphery of the rod. When the convex surface is locally activated, typically by exposure to laser light in the footprint of the desired portion, an adhesive transfer surface on the selectively activatable convex surface is activated which adheres to the desired cells in the footprint of the desired portion. Thereafter, the adhesive transfer surface is separated from the remainder of the tissue sample while maintaining adhesion with the portion of the sample. Thus the desired portion of the tissue sample is extracted. The disclosed selectively activatable convex surface is preferably utilized to collect desired tissue samples at more than one location on the same slide or from different slides. A rod having a convex surface with the selectively activatable material is set forth as a staple for use with the apparatus and process. Preferred shapes for the convex surface are disclosed as well as a method for coating rods.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Optics,Measurement,,,,,G02B/34
6103235,15-Aug-00,2000,8,15,Methods of inducing immune tolerance using immunotoxins,"Provided is a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease. Also provided is a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign mammalian donor tissue or cells, comprising the steps of: a) exposing the recipient to an immunotoxin so as to reduce the recipients's peripheral blood T-cell lymphocyte population by at least 80%, wherein the immunotoxin is anti-CD3 antibody linked to a diphtheria protein toxin, wherein the protein has a binding site mutation; and b) transplanting the donor cells into the recipient, whereby a rejection response by the recipient to the donor organ cell is inhibited, and the host is tolerized to the donor cell.",8,The United States of America as represented by the Department of Health and Human Services,The UAB Research Foundation,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/2809
6103694,15-Aug-00,2000,8,15,Method of decreasing radiation of radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment,"The present invention provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiation, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiation; and (c) transplanting the donor hematopoietic pluripotent cells into the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiation. The invention also provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiomimetic compound, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiomimetic compound; and (c) transplanting the hematopoietic pluripotent cells into the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiomimetic compound.",40,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/193
6107050,22-Aug-00,2000,8,22,Diagnostic test for alzheimers disease,"The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells. Another method utilizes the differential effects of .beta.-amyloid protein on levels of the protein kinase C isoenzymes PKC.alpha. and PKC.gamma. in Alzheimer's and normal cells. Yet another method detects Eu-TTA fluorescence differences between Alzheimer's and normal cells treated with an activator of a receptor-mediated metabolic pathway. In addition a diagnostic index for improved assessment between Alzheimer's and non Alzheimer's cells is provided.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/4711
6110453,29-Aug-00,2000,8,29,"Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same","A polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.",18,The United States of America as represented by the Department of Health and Human Services,"ICN Pharmaceuticals, Inc.",,,,,,,,,,2,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
6110465,29-Aug-00,2000,8,29,Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines,The nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of 49 isolates of hepatitis C are disclosed. The invention relates to the use of these sequences to design proteins and nucleic acid sequences useful in diagnostic methods and vaccines.,16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6110490,29-Aug-00,2000,8,29,Liposomal delivery system for biologically active agents,"The present invention is directed to a liposomal preparation which is based on specific lipid components. The liposomal compounds are also combined with a biologically active agent, forming liposomal compounds. These compounds are useful in drug delivery, where specific therapeutic compounds are provided in the liposomes. The specific lipid components of the present invention provide a highly efficient and stable delivery system for nucleic acids. Consequently, one embodiment of the invention provide the liposomal preparations which are suitable for use in gene therapy.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/88
6110710,29-Aug-00,2000,8,29,Sequence modification of oligonucleotide primers to manipulate non-templated nucleotide addition,The present invention is directed to methods for resisting or promoting template independent nucleotide addition to the 3' terminus of a DNA duplex. The process comprises amplifying a target nucleic acid using primers which comprise a 5' terminal sequence which resists or promotes non-templated nucleotide addition to the 3' terminus of the complementary nucleic acid strand. The invention is also directed to a kit for cloning 3' nucleotidylated duplex DNA.,25,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12P/34
6113912,5-Sep-00,2000,9,5,Hepatitis A virus vaccines,"A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6114397,5-Sep-00,2000,9,5,Gossypol for the treatment of cancer,"A method for treating cancer in a human, which comprises administering to the human subject an anti-cancer effective amount of a compound selected from gossypol, gossypol acetic acid, gossypolone, metabolites thereof, or physiologically acceptable salts thereof. Also included is a method for treating cancer in a human which comprises administering to the human subject an anti-cancer effective amount of any of the compounds listed above in combination with an anti-cancer effective amount of other conventional chemotherapeutic agents. Finally, the invention also encompasses a pharmaceutical composition comprising an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone, and an anti-cancer effective amount of a conventional chemotherapeutic agent, or combinations of the latter.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/11
6117667,12-Sep-00,2000,9,12,Method for producing an adapted virus population from an African green monkey kidney cell line,"The invention described herein provides a method for selecting a novel African Green monkey kidney (AGMK) cell substrate, its cultivation and serial passage and its subsequent characterization. The invention provides a method for the use of the cell substrate in the isolation, growth and serial passage of a large number of viruses, particularly rotaviruses, enteroviruses, respiratory viruses and hepatitis A virus. The invention provides a method for the utilization of this AGMK cell substrate for the production of live and killed virus vaccines.",12,Dyncorp,National Institutes of Health,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
6117991,12-Sep-00,2000,9,12,Biologically active synthetic thyrotropin and cloned gene producing same,Substantially pure recombinant TSH has been prepared from a clone comprising complete nucleotide sequence for the expression of the TSH. Diagnostic and therapeutic applications of the synthetic TSH are described.,1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57407
6120988,19-Sep-00,2000,9,19,Method of detecting hev infection,"Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.",6,"Genelabs Technologies, Inc.",The United States of America,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/005
6126944,3-Oct-00,2000,10,3,Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus,"Novel baculovirus expression vectors and recombinant antigens for detecting, type-specific herpes simplex virus (HSV) infection have been made. Diagnostic kits and assays for detecting type-specific HSV infection have been described. High level production of foreign proteins in substantially pure form are now made possible by the novel baculoviruses of the present invention.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/86
6130042,10-Oct-00,2000,10,10,Compositions and methods for diagnosing periodontal disease,"Compositions and methods are described for diagnosing periodontal disease, and in particular, early-onset periodontal disease. Nucleic acid-based testing is described which permits the detection of a high risk haplotype.",40,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
6132732,17-Oct-00,2000,10,17,Parvovirus capsids,The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6132954,17-Oct-00,2000,10,17,Methods of screening for agents that delay a cell cycle and compositions comprising era and an analogue of wild-type era,"The present invention provides for methods of screening for agents which delay the cell cycle and methods of delaying the cell cycle. Analogues of Era having arginine, histidine, or lysine at amino acid codon 17 are embodied by the present invention. Human and other homologs of bacterial Era amino acid and nucleic acid sequences are provided in the present invention. Vectors, host cells, protein preparations, cell cultures, and compositions comprising said analogue are also set forth in the present invention.",25,Baylor College of Medicine,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12Q/34
6132980,17-Oct-00,2000,10,17,Antibodies specific for TRP-2 a human tumor antigen recognized by cytotoxic T lymphocytes,The infusion of TIL586 along with interleukin-2 (IL-2) into the autologous patient with metastatic melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen recognized by TIL586 was previously isolated and shown to encode gp75 or TRP-1. The present invention relates to the identification of a second tumor antigen recognized by a HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP-2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Modified peptides were also recognized by the CTL clone.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0059
6136534,24-Oct-00,2000,10,24,Methods for sensitive detection of reverse transcriptase,"The present invention provides a method for detecting the presence of a retrovirus in a biological sample comprising the steps of: a) contacting the biological sample with an RNA template and a complementary DNA primer under conditions whereby the RNA template and the DNA primer will anneal and a DNA strand will be synthesized as an extension from the DNA primer if reverse transcriptase is present in the sample; b) amplifying the synthesized DNA; and c) detecting the amplification of the synthesized DNA, the amplification of the synthesized DNA indicating the presence of reverse transcriptase in the biological sample, thus indicating the presence of a retrovirus in the biological sample.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/702
6136594,24-Oct-00,2000,10,24,Replication deficient recombinant adenovirus vector,"The present invention relates to a replication deficient recombinant adenovirus vector in the genome of which is inserted an expression cassette comprising the DNA fragment coding for the human CFTR protein, said DNA fragment being placed under the control of the elements for the expression thereof. The present invention also concerns a vector according to claim 1 wherein in the expression cassette the human CFTR gene is under the control of the endogenous human CFTR promoter.",15,Transgene S.A.,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6136992,24-Oct-00,2000,10,24,2-alkoxy estradiols and derivatives thereof,"Compounds represented by the following structural formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification. The compounds are disclosed as useful in the treatment of various forms of cancer.",3,The United States of America as represented by the Department of Health and Human Services,"Pharm-Eco Laboratories, Incorporated",,,,,,,,,,2,Organic fine chemistry,,,,,,C07J/00
6140339,31-Oct-00,2000,10,31,Monomeric and dimeric arylisoquinoline alkaloids and derivatives thereof,"The present invention provides new monomeric derivatives of the C-8'-7 linked naphthylisoquinoline alkaloid dioncophylline D. The invention also provides new C-4 substituted monomeric arylisoquinoline alkaloid derivatives. The present invention furthermore provides novel dimeric arylisoquinoline alkaloids comprised of coupled first and second arylisoquinoline monomers, wherein either or both of said monomer(s) is (are) monomeric compound(s) of the present invention. Monomeric and dimeric compounds of the present invention have medically useful properties, such as antimicrobial properties, more specifically such as antimalarial and antiviral properties. Monomeric compounds of the present invention are also useful as building blocks or intermediates for synthesis of novel dimeric arylisoquinoline alkaloids. Monomeric and dimeric compounds of the present invention may be obtained in substantially pure form by total synthesis, partial synthesis, or derivatization from known synthetic or naturally occurring compounds, and by isolation and purification from plants of the Dioncophyllaceae and Ancistrocladaceae families.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
6143494,7-Nov-00,2000,11,7,Poliovirus specific primers and methods of detection utilizing the same,"The ability to rapidly detect wild polioviruses in clinical specimens is a major concern for the world-wide eradication of polioviruses. Provided is a method of detecting polioviruses of all three serotypes from viral isolates of clinical specimens using a pair of degenerate PCR primers. This primer set, which uses deoxyinosine residues to compensate for third position mismatches at specific positions, recognizes nucleotide sequences near the receptor binding site of polioviruses. These sequences are unique to polioviruses and are absolutely conserved at the amino acid level. As a result, these PCR primers do not recognize nonpoliovirus enteroviruses. All poliovirus serotypes (40 poliovaccine related genotypes and 120 wild poliovirus genotypes from around the world) tested positive. All 14 prototype strains of nonpoliovirus enteroviruses tested negative. Also provided is a series of degenerate PCR primers that differentiates between the three wild poliovirus serotypes and a method of detecting the presence of the three serotypes utilizing a nucleic acid amplification technique.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
6143496,7-Nov-00,2000,11,7,"Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly",Methods of detecting and quantifying genomic nucleic acid molecule sequences are provided using the simultaneous amplification of a plurality of discrete nanoliter-sized samples. A miniaturized closed assembly is also provided for carrying out amplification of a nucleic acid molecule by polymerase chain reaction in multiple nanoliter-sized samples. Methods of filling miniaturized sample chambers are also provided as are methods for determining the number of template molecules in a sample by conducting replicate nucleic acid sequence amplification reactions on a set of terminally diluted samples and counting the number of positive amplification reactions. The methods can be used to detect a single starting nucleic acid target molecule.,17,Cytonix Corporation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
6144877,7-Nov-00,2000,11,7,Determining the hurst exponent for time series data,Statistical information is determined for time series data of a measurable activity. The time series data of the measurable activity is obtained and comprises data elements representative of the measurable activity. A Hurst exponent is determined from the time series data and is the statistical information of the time series data.,45,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Medical technology,,,,,G06F/10
6146643,14-Nov-00,2000,11,14,Human/simian chimeric hepatitis A virus vaccine,"The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6147203,14-Nov-00,2000,11,14,Recombinant disulfide-stabilized polypeptide fragments having binding specificity,"The present invention relates to disulfide-stabilized recombinant polypeptide molecules which have the binding ability and specificity for another peptide, such as the variable region of an antibody molecule. Methods of producing these molecules and nucleic acid sequences encoding these molecules are also described. In particular, the invention discloses Fv antibody fragments stabilized by a disulfide bond connecting the V.sub.H and V.sub.L regions of the Fv fragment. The .alpha. and .beta. chains of T cell receptors may be similarly stabilized by means described in the invention.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/7051
6150398,21-Nov-00,2000,11,21,Methods for the treatment of cancer,"A pharmaceutical composition comprising an effective cancerous cell growth inhibiting amount of paclitaxel, or a paclitaxel derivative, and an effective cancerous cell growth inhibiting amount of an active agent which inhibits cancerous cell growth by exerting an effect on mammalian cell cycle during G.sub.1 or S-phase of the cell division cycle to inhibit said cancerous cell growth and methods of using same.",40,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,G01N/5011
6150415,21-Nov-00,2000,11,21,Epoxide hydrolase complexes and methods therewith,"Biologically stable inhibitors of soluble epoxide hydrolases are provided. The inhibitors can be used, for example, to selectively inhibit epoxide hydrolase in therapeutic applications such as treating inflammation, for use in affinity separations of the epoxide hydrolases, and in agricultural applications. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 ##STR1## wherein X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R.sub.1 -R.sub.4 is hydrogen, R.sub.2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R.sub.4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R.sub.1 and R.sub.3 are each independently a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, acyl, or heterocyclic, or being a metabolite or degradation product thereof.",26,The Regents of the University of California,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/155
6153421,28-Nov-00,2000,11,28,Cloned genomes of infectious hepatitis C viruses and uses thereof,"The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6153430,28-Nov-00,2000,11,28,"Nucleic acid encoding mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers","This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1072
6153589,28-Nov-00,2000,11,28,"2,3-epoxy alcohols, acids and derivatives as anti retroviral chemotherapeutic agents","The present invention is related to compounds, compositions and methods of treating viral infections. Compounds of the present invention have the following general formula: ##STR1## wherein R is selected from --CH.sub.2 OH, --CO.sub.2 R.sup.2, --CONR.sup.3 R.sup.4, or COR.sup.5, wherein R.sup.2 is hydrogen or a lower alkyl group, R.sup.3 and R.sup.4 are each independently hydrogen or a lower alkyl group, R.sup.5 is an amino acid residue bound via a terminal nitrogen or peptide having at least two amino acid residues; and wherein R.sup.1 is C.sub.5 -C.sub.13 alkyl, aryl, aralkyl, aralkyl(lower alkyl)ether, or C.sub.5 -C.sub.13 alkyl(lower alkyl)ether.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,Biotechnology,,,,C07D/22
6154706,28-Nov-00,2000,11,28,Apparatus and method for kinetic analysis of the intraoperative assay for parathyroid hormone,"An apparatus for predicting a residual hormone concentration in a patient after a removal of a portion of the patient's glandular tissue which secretes the hormone, includes an input device constructed to receive a plurality of measured hormone concentrations corresponding to a plurality of human fluid samples taken from a patient at a plurality of sample times, respectively; and further includes a computer processor configured to iteratively calculate a residual hormone concentration. In accordance with one feature of the present invention, the computer processor is configured to generate data denoting a residual amount of glandular tissue that will remain in the patient after the removal of the portion of the patient's glandular tissue; and the apparatus further comprises an output device constructed to output the generated data denoting the residual amount of glandular tissue. The computer processor is further configured to iteratively calculate a half-life value of the hormone concentration in the patient.",78,,,,,,,,,,,,,Analysis of biological materials,Computer technology,,,,,G01N/78
6156499,5-Dec-00,2000,12,5,Methods for detecting antibodies to HAV 3C proteinase,The present invention discloses methods for detecting antibodies to HAV 3C proteinase. These methods can distinguish an individual with a natural infection from one who has been vaccinated with an inactivated vaccine and are thus of utility in the diagnosis of hepatitis A in situations in which vaccination is widespread.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5768
6156564,5-Dec-00,2000,12,5,Cellular apoptosis susceptibility protein (CSP) and antisense CSP,The cDNA and amino acid sequences for a cellular apoptosis susceptibility (CAS) protein are used to detect expression and amplification of CAS gene in normal and cancer cells. An antisense CAS gene sequence introduced into living cells inhibits CAS protein activity and thus prevents or inhibits apoptosis in the cells.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/18
6156765,5-Dec-00,2000,12,5,Method of treating and preventing vasospasm,The present invention is drawn to a method of preventing or treating vasospasm by administering to a patient an effective amount of an iron chelator which preferentially chelates ferrous iron over ferric iron. The iron chelators to be use in the present invention are small compounds which can penetrate the blood-brain barrier and act intracellularly to chelate ferrous iron. The present invention further encompasses a kit to be used for the prevention and treatment of vasospasm with the method of the invention.,16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4745
6162897,19-Dec-00,2000,12,19,17q-linked breast and ovarian cancer susceptibility gene,"The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.",3,"Myriad Genetics, Inc.",University of Utah Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Biotechnology,,,,,,C07K/4703
6165460,26-Dec-00,2000,12,26,Generation of immune responses to prostate-specific antigen (PSA),"We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cellular immune response to PSA can be generated. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate the immune response, and contacting the host with additional PSA at periodic intervals thereafter. The additional PSA may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional PSA can be added by contacting the host with PSA by a variety of other methods, including in one preferred embodiment adding PSA. The PSA may be formulated with an adjuvant or in a liposomal formulation.",17,Therion Biologics Corporation,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/4748
6165744,26-Dec-00,2000,12,26,"Isolation and characterization of cDNAs coding for the .alpha., .beta., and .gamma. subunits of the high-affinity receptor for immunoglobulin E","The present invention relates to DNA segments encoding the .alpha., .beta., and .gamma. subunits of the high affinity receptor for immunoglobulin E (IgE). The invention further relates to a method of producing the receptor by expressing cDNA for its .alpha., .beta., and .gamma. subunits in a host cell simultaneously.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70535
6165781,26-Dec-00,2000,12,26,Modified adeno-associated virus vector capable of expression from a novel promoter,"Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6168917,2-Jan-01,2001,1,2,Detection and identification of non-polio enteroviruses,This invention provides sensitive nucleic acid hybridization assay methods for the detection of non-polio enterovirus nucleic acids. The methods are particularly useful in detecting the presence of enterovirus nucleic acids in a biological sample and for ascertaining the serotype of enteroviruses present in a sample.,13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6844
6169173,2-Jan-01,2001,1,2,Cloning and functional expression of cholecystokinin/gastrin receptor-encoding DNA,"An unconventional approach to purifying CCK receptor protein to sequenceable-grade homogeneity has been discovered. By this approach, CCK receptor protein can be obtained and sequenced routinely from a variety sources, and from the sequence information thus obtained it is possible to prepare oligonucleotides suitable for cloning CCK receptor genes. ""CCK receptor"" in this context denotes, any from a group of proteins that displays a characteristic CCK binding affinity and that is encoded by a nucleotide sequence which hybridizes a oligonucleotide probe designed in accordance with the criteria elaborated herein.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
6169175,2-Jan-01,2001,1,2,Preparation and use of recombinant influenza A virus M2 construct vaccines,"The present invention provides a method of increasing the recombinant expression and solubility of influenza A virus M2 polypeptide comprising nucleic acids encoding variants of the M2 protein of influenza A virus in which transmembrane and other hydrophobic domains have been deleted. The present invention also provides purified polypeptides encoded by the nucleic acids, which polypeptides are immunogenic and are less hydrophobic than full-length M2. Also provided are vaccines comprising variants of M2 expressed in prokaryotic hosts. Further provided are methods of preventing influenza A infection using vaccines comprised of variants of M2. Also provided are antibodies raised against the variants of M2, and use of such antibodies in diagnosis and treatment of influenza A infections.",8,Centers For Disease Control and Prevention,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6171596,9-Jan-01,2001,1,9,Oligomeric HIV-1 envelope glycoproteins,"Immunogenic compositions and methods of stimulating an immune response against the envelope protein of HIV-1. Immunogenic compositions include a purified oligomeric structure that comprises a C-terminally truncated form of HIV-1 gp160 protein that is missing the gp41 transmembrane domain. The gp120-gp41 proteolytic processing site is retained in one form of the composition and is deleted in a different form of the composition. In one embodiment, the engineered env protein is proteolytically cleaved, but the gp120 and gp41 components of the complex remain noncovalently associated. Immunization with these compositions advantageously stimulates the production of conformation-dependent antibodies.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6171803,9-Jan-01,2001,1,9,"Isolation, characterization, and use of the human .beta. subunit of the high affinity receptor for immunoglobulin E","The present invention relates to nucleic acid sequences, encoding amino acid sequences of the .alpha., .beta., and .gamma. subunits of the high affinity receptor for immunoglobulin E, and for amino acid sequences of the subunits. The invention further relates to a method of producing the receptor by expressing cDNA for its .alpha., .beta., and .gamma. subunits in a host cell simultaneously. Aspects of the invention are methods and compositions to inhibit the function of the human beta subunit, thereby treating or preventing allergic reactions.",4,The United States Government as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70535
6172070,9-Jan-01,2001,1,9,Substituted O6-benzyl-8-aza-guanines and 6(4)-benzyloxypyrimidines,"The present invention provides 8-substituted O.sup.6 -benzylguanine, 4(6)-substituted 2-amino-5-nitro-6(4)-benzyloxypyrimidine, and 4(6)-substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidine derivatives which have been found to be effective AGT inactivators, as well as pharmaceutical compositions comprising such derivatives along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine, by administering to a mammal an effective amount of one of the aforesaid derivatives, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O.sup.6 -benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine.",8,The United States of America as represented by the Department of Health and Human Services,The Penn State Research Foundation,Arch Development Corporation,,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
6173618,16-Jan-01,2001,1,16,Ore pass level and blockage locator device,"A method of, and apparatus for, detecting level and blockages in an ore pass or other near-vertical shaft is described. The level and blockage detector includes a flexible metal strip in which a plurality of strain gages have been located, spaced apart from one another, preferably at known distances. A plurality of anchors secure the metal strip to the interior surface of the shaft such that the metal strip is displaced a fixed distance from the interior surface. The anchors are located intermediate the strain gages. When the ore pass fills up with bulk material, the bulk material causes the metal strip to deflect toward the interior surface of the shaft. This causes the resistance of the strain gage in the region of the deflection to change. To detect the location of the blockage, a microcontroller cycles through each strain gage, placing it as the fourth arm of a bridge circuit. When a change in the output voltage across the bridge circuit is detected, the location of the strain gage causing the change in output voltage is an indication of the presence of bulk material (ore). A series of LEDs, one for each strain gage, may be used to indicate which strain gage senses the presence of bulk material and which strain gage does not.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Civil engineering,,,,,,E21F/04
6174666,16-Jan-01,2001,1,16,Method of eliminating inhibitory/instability regions from mRNA,A method of locating an inhibitory/instability sequence or sequences within the coding region of an mRNA and modifying the gene encoding that mRNA to remove these inhibitory/instability sequences by making clustered nucleotide substitutions without altering the coding capacity of the gene is disclosed. Constructs containing these mutated genes and host cells containing these constructs are also disclosed. The method and constructs are exemplified by the mutation of a Human Immunodeficiency Virus-1 Rev-dependent gag gene to a Rev-independent gag gene. Constructs useful in locating inhibitory/instability sequences within either the coding region or the 3' untranslated region of an mRNA are also disclosed.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6174690,16-Jan-01,2001,1,16,Cell bioassay of neurotoxins,"A cell bioassay is provided for determining the presence in a fluid sample of a sodium channel-activating toxin wherein (a) a fluid sample is incubated in the presence of a culture of cells which express voltage-gated sodium channels and which are responsive in a dose-dependent manner to sodium channel-activating toxins and a medium comprising an agent which causes persistent activation of the voltage-gated sodium channel; (b) the culture is incubated with a medium comprising an indicator which is acted upon by living cells to generate a discernable result, (c) the culture is observed for an incidence of the result, and an observation of the result is correlated with the presence of the toxin in the sample. A simplified assay where steps (a) and (b) are effected together also is provided, as is a cell bioassay for determining the sodium channel affect of a toxin in a fluid sample. A competitive assay for sodium channel-blocking toxins also is provided wherein the fluid sample and culture of cells are incubated with a medium comprising (i) an agent which causes persistent activation of the voltage-gated sodium channel and (ii) a sodium channel-activating toxin. Kits for performing the assays also are provided.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/025
6174862,16-Jan-01,2001,1,16,Neurotrophic peptides of activity dependent neurotrophic factor,"The present invention relates generally to Activity Dependent Neurotrophic Factor (ADNF). More particularly, the present invention relates to a family of polypeptides derived from ADNF that exhibit neuroprotective/neurotrophic action on neurons originating in the central nervous system and to uses thereof for the treatment of neurological deficiencies and for the prevention of cell death. The present invention also relates to pharmaceutical compositions designed to prevent neuronal cell death.",35,"Ramot University Authority for Applied Research and Industrial Development, Ltd.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/22
6177534,23-Jan-01,2001,1,23,Silylated resins and the synthesis thereof,"A silylated resin suitable for use as an adhesive binder for composites and in sealant and adhesive dental applications is represented by the general formula (I): ##STR1## in which: PA1 R.sub.1 is an aliphatic, cycloaliphatic, aryl, hydrocarbon, or fluorocarbon group; PA1 R.sub.2 is the same as R.sub.1 or a different aliphatic, cycloaliphatic, aryl, hydrocarbon, or fluorocarbon group; ##STR2## M.sub.2 is the same as M.sub.1 or a different functional or nonfunctional group selected from the group consisting of: ##STR3## PA1 n is 1-3; PA1 x is 1-20; and PA1 y is 1-20; PA1 which comprises the reaction product of the exchange reaction of a hydroxylated, aminated, or carboxylated acrylic resin represented by the general formula (II): ##STR4## in which: PA1 R.sub.4 is an aliphatic, cycloaliphatic, aryl, hydrocarbon, or fluorocarbon group with one or more protic functional groups selected from the group consisting of: EQU OH, N--H, and CO.sub.2 H PA1 R.sub.5 is H or CH.sub.3 ; and PA1 R.sub.6 is H or CH.sub.3 ; with a trialkoxyorganosilane or triacyloxyorganosilane represented by the general formula (III): ##STR5## in which: PA1 R.sub.7, R.sub.8, and R.sub.9 each is: ##STR6## PA1 R.sub.10 is an aliphatic, or aryl group which can optionally be substituted with a group from the group of an acrylic group, a methacrylic group, an epoxy group, and a substituted amino, hydroxyl, or carboxylic acid group such as an ester or an amide.",24,The United States of America as represented by the Secretary of Commerce,,,,,,,,,,,1,"Macromolecular chemistry, polymers",Pharmaceuticals,Basic materials chemistry,,,,A61K/30
6180110,30-Jan-01,2001,1,30,Attenuated hepatitis a virus vaccine which grows in MRC-5 cells,"A live hepatitis A virus (HAV) adapted to grow in MRC-5 cells is described, the HAV preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation. Methods for adapting HAV to grow in MRC-5 cells, vaccine compositions comprising the attenuated HAV, and methods of vaccinating humans against HAV infection are also described.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6183752,6-Feb-01,2001,2,6,"Restenosis/atherosclerosis diagnosis, prophylaxis and therapy","Disclosed and claimed are compositions and methods for therapy and/or prevention of restenosis and/or atherosclerosis. The compositions can include an agent for decreasing viral load of cytomegalovirus, such as an immunological composition or vaccine against cytomegalovirus (CMV) containing at least one epitope of interest of CMV and/or an expression system which expresses at least one epitope of interest of CMV. Such compositions can include at least one epitope of p53. Alternatively, the compositions can include at least one epitope of p53 and/or an expression system which expresses the epitope. The methods can include administering the compositions to a patient in need of such therapy and/or prevention. Additionally, compositions and methods for diagnosing atherosclerosis and/or restenosis, or susceptibility thereto, including screening a sample from a patient for antibodies to CMV and/or CMV proteins and/or screening a sample from a patient for specific viral proteins that predict whether the virus has been reactivated and/or antibodies thereto and/or detecting whether CMV nucleic acid, e.g., mRNA is present in peripheral blood monocytes (PBMCs) and/or detecting a cellular-mediated immune response to CMV peptides or proteins is present and/or HLA phenotyping and/or HLA genotyping. Embodiements can include a skin test.",22,Pasteur Merieux Serums et Vaccins,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12Q/6883
6184024,6-Feb-01,2001,2,6,Chimeric and/or growth-restricted flaviviruses,"The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a. The invention further includes a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes the Japanese B encephalitis virus capsid protein, pre-matrix protein, envelope glycoprotein and non-structural proteins NS1 and NS2a. The invention further includes a vaccine and a method to produce that vaccine.",52,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6184353,6-Feb-01,2001,2,6,Method for modulating processes mediated by farnesoid activated receptors,"Farnesyl pyrophosphate, the metabolically active form of farnesol, is a key precursor in the synthesis of cholesterol, carotenoids, steroid hormones, bile acids and other molecules involved in cellular growth and metabolism. A nuclear receptor has been identified that is transcriptionally activated by farnesol and related molecules. This novel signaling pathway can be modulated by the use of key metabolic intermediates (or analogs and/or derivatives thereof) as transcriptional regulatory signals.",8,The Salk Institute for Biological Studies,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/045
6187306,13-Feb-01,2001,2,13,Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same,"The invention pertains to a method of treating or protecting against melanoma that comprises (a) obtaining a melanoma cell line that expresses one or more shared immunodominant melanoma antigens, (b) modifying the melanoma cell line to render it capable of producing an increased level of a cytokine relative to the unmodified cell line, and (c) administering the melanoma cell line to a mammalian host that has melanoma or is at risk for developing melanoma. Preferably the melanoma cell line is allogeneic and is not MHC-matched to the host.",17,The Johns Hopkins Universtiy,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/00119
6187745,13-Feb-01,2001,2,13,Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus,"A method of preventing, reducing or reversing nephrotoxicity or renal dysfunction induced by administration of a cyclosporin or tacrolimus to a mammalian patient. The method comprises the co-administration to the patient, either before, together with or after cyclosporin or tacrolimus administration, of a pharmaceutical composition containing an effective amount of pentosan polysulfate (PPS) or a pharmaceutically acceptable salt thereof. The oral route of administration is preferred. The total daily dosage of PPS or PPS salt ranges from about 2 to about 50 mg/kg of patient body weight, or about 140 to about 3,500 mg per day in adult human patients. Also disclosed are a method of providing immunosuppressive therapy to a patient while avoiding cyclosporin or tacrolimus-induced nephrotoxicity, and combination pharmaceutical compositions to be used in such therapy.",42,"Baker Norton Pharmaceuticals, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/13
6187775,13-Feb-01,2001,2,13,Acridone-derived compounds useful as antineoplastic and antiretroviral agents,"The present invention relates to several novel acridone-derived compounds of of formula (I) or (II). These compounds are potent anti-viral agents, useful in the treatment of viral diseases, such as Human Immunodeficiency Virus. In addition, these compounds are anti-neoplastic agents useful in the treatment of various forms of cancer. ##STR1## wherein R1 and R2 are independently --H, --OH, amino, alkylamino, dialkylamino, alkoxy, alkyl, haloalkyl or halogen; n is 2 to 6, X and X' are independently --N or --NO.sub.2 ; Y and Y' are independently --N or --CH, or --H; and the double-slash represents a double bond or no bond.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
6189479,20-Feb-01,2001,2,20,Method and apparatus for detecting a temperature increase in an electrical insulator,"The present invention provides a heat-sensitive warning device and a related method for visually detecting an increase in the temperature of the outer surface of an electrical insulator, which may indicate the unsafe flow of leakage electrical current through the electrical insulator, prior to a fire, an explosion or some other unsafe event. When the temperature of the outer surface of the electrical insulator increases to a preselected temperature, a visual indication of this rise in temperature will be provided by the ejection of a spool from a heat-sensitive warning device which has been attached to the outside of the electrical insulator. The temperature at which this visual indication of electrical insulator temperature increase occurs is preferably well below an unsafe temperature for the particular electrical insulator being used under the particular conditions of use, such as the autoignition temperature of coal or coal dust, so that the electrical insulator may be replaced prior to reaching this unsafe temperature.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01K/06
6190656,20-Feb-01,2001,2,20,Immunologic enhancement with intermittent interleukin-2 therapy,"A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
6190693,20-Feb-01,2001,2,20,Pharmaceutical methods of delivering folic acid,"This invention provides folic acid-containing pharmaceutical compositions comprising either an oral contraceptive or a hormone replacement composition. This invention also provides methods of administering folic acid to a subject using the instant pharmaceutical compositions. Finally, this invention provides a drug delivery system useful for administering the instant pharmaceutical compositions.",8,"Ortho-McNeil Pharamceutical, Inc.",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/565
6192264,20-Feb-01,2001,2,20,Method and system for MRI venography including arterial and venous discrimination,"A system and method for arterial and venous discrimination in MR venography is disclosed. By setting a noise level in the phase image (that is proportional to the velocity encoding value) at a threshold level between that of the arterial signals and the venous signals during the diastole portion of the cardiac cycle and acquiring a phase contrast MR image during the diastole portion, the arterial signals are effectively suppressed and a venous only image can be reconstructed. Post-processing steps are disclosed which can alternatively provide an arterial only image. By separately reconstructing a magnitude image and a phase image map to produce a magnitude image and a phase image, a masking module can create an output displaying venous only or arterial only images based on a user selection. The present invention allows for a complete noninvasive angiography exam to be completed within approximately 30 minutes.",24,General Electric Company,Uniformed Services University of Health Sciences,,,,,,,,,,2,Medical technology,,,,,,A61B/055
6193982,27-Feb-01,2001,2,27,"Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120","The present invention provides an anti-cyanovirin antibody with an internal image of gp120, a method of using an anti-cyanovirin antibody with an internal image of gp120 to induce an immune response to gp120 so as to prevent or treat a viral infection in an animal, and a method of using a cyanovirin to induce an immune response to gp120 so as to prevent or treat a viral infection in an animal.",10,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Medical technology,,,,A61K/164
6194142,27-Feb-01,2001,2,27,"Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2, and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruse","The present invention relates to polypeptides encoded by a nucleotide sequence from an HIV-1, HIV-2, or SIV viral genome, in which the nucleotide sequence is amplified from the viral genome using a pair of primers that contain sequences that are conserved between different HIV and SIV strains. The primers are insensitive to variations in the genomes of different HIV and SIV isolates and, therefore, can be used to amplify nucleotide sequences from HIV-1, HIV-2, and SIV strains. The invention also relates to antibodies directed against these polypeptides and methods and kits for diagnosing viral infection.",7,Institut Pasteur,Institut National de la Sante et de la Recherche Medicale,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
6194388,27-Feb-01,2001,2,27,Immunomodulatory oligonucleotides,"Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.",22,The University of Iowa Research Foundation,The United States of America,Coley Pharmaceutical Group,,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/70
6194390,27-Feb-01,2001,2,27,Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis,"A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/708
6194547,27-Feb-01,2001,2,27,ETS2 repressor factor (ERF),"The present invention relates, inter alia, to the ERF gene and to the products encoded by this gene. More particularly, the present invention relates to DNA sequences encoding ERF and AERF; polypeptides encoded by such DNA sequences; ERF chimeric molecules; and methods of using ERF and ERF chimeric molecules to reduce tumorigenicity in a tumor cell.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4703
6197499,6-Mar-01,2001,3,6,Method for the fluorescent detection of a DNA sequence in real time,The present invention relates to a method of detecting a DNA sequence by means of a DNA:DNA hybrid in real time using fluorescence. The present invention eliminates the need to use radioactive probes to detect the DNA and eliminates the delay needed for autoradiographic exposure of the X-ray to the radioactive label.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6844
6197528,6-Mar-01,2001,3,6,Composition of immunotoxins and retinoids and use thereof,The present invention relates to compositions of retinoids plus immunotoxins. More particularly this invention relates to the use of retinoids to potentiate the activity of immunotoxins for treatment of mammalian diseases.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,G01N/5014
6197578,6-Mar-01,2001,3,6,Cells expressing both human CD4 and a human fusion accessory factor associated with HIV infection,The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (CXCR4). CXCR4 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CXCR4 plays an essential role in the membrane fusion step of HIV infection. The establishment of stable cell lines that coexpress human CD4 and CXCR4 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/7158
6197751,6-Mar-01,2001,3,6,"Thymosin .alpha.1 promotes tissue repair, angiogenesis and cell migration","The present invention relates to methods for promoting tissue repair, angiogenesis and cell migration. The method of the invention utilizes thymosin a1 (T.alpha.1) peptide to promote tissue repair, angiogenesis and cell migration. The invention further relates to modulating T.alpha.1 activity in tissues.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1841
6200558,13-Mar-01,2001,3,13,"Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same","A polymeric composition capable of releasing nitric oxide under physiological conditions which includes a biopolymer, such as a peptide, polypeptide, protein, oligonucleotide or nucleic acid, to which is bound a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group; pharmaceutical compositions comprising the polymeric composition; and methods of treating biological disorders in which dosage with nitric oxide is therapeutic.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/655
6200806,13-Mar-01,2001,3,13,Primate embryonic stem cells,"A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (-); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.",11,Wisconsin Alumni Research Foundation,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0605
6204000,20-Mar-01,2001,3,20,Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1,The isolation and characterization of a metastasis tumor suppressor gene KAI1 is disclosed and diagnostic methods and gene therapy approaches utilizing reagents derived from the nucleotide and deduced amino acid sequences of the KAI1 gene are provided.,7,The United States of America as represented by the Department of Health and Human Services,Johns Hopkins University,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,G01N/574
6204030,20-Mar-01,2001,3,20,Isolation of cellular material under microscopic visualization,"A method of microdissection which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes an activatable adhesive layer which provides chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated the transfer surface and tissue sample are separated. During separation the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Optics,Biotechnology,Analysis of biological materials,,,G02B/32
6204044,20-Mar-01,2001,3,20,"Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines","The invention relates to the coat proteins VP1 and VP2 of the human parvovirus B19 and virus-like particles consisting of VP2 or of VP1 and VP2. The invention further comprises genetic information in the form of recombinant expression vectors which contain the genes coding for said proteins, and organisms which through genetic manipulation using such vectors have acquired the ability to produce such proteins and/or particles. The invention further comprises uses of such proteins and virus-like particles for diagnostics or vaccination.",1,,,,,,,,,,,,,Biotechnology,,,,,,C07K/005
6207157,27-Mar-01,2001,3,27,Conjugate vaccine for nontypeable Haemophilus influenzae,A conjugate vaccine for Nontypeable Haemophilus influenzae comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/102
6207416,27-Mar-01,2001,3,27,Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines,"A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C07H/00
6207646,27-Mar-01,2001,3,27,Immunostimulatory nucleic acid molecules,Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed.,39,University of Iowa Research Foundation,"Coley Pharmaceutical Group, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
6207815,27-Mar-01,2001,3,27,"Family of high affinity, modified antibodies for cancer treatment","This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H.alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.",7,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/462
6210887,3-Apr-01,2001,4,3,Methods for evaluating colon tissue for expression of the DRA (down regulated in adenoma) gene,"A new down-regulated gene called DRA, for down regulated in adenoma, maps to chromosome 7 and is believed to encode a tumor suppressor. The DRA gene encodes a highly hydrophobic protein with charged clusters located primarily in the carboxyl terminus. Additionally, the expression of the mRNA product appears to be strictly limited to the mucosa of normal colon and it is down-regulated early in colon tumorigenesis. Absence of the DRA polypeptide in tissue that usually expresses it can be used as an indicator of tissue abnormality. The DRA gene and cDNA may also have therapeutic capabilities as well.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
6211149,3-Apr-01,2001,4,3,Inhibitors of formation of protease resistant prion protein,"Peptides are disclosed that inhibit the conversion of protease sensitive prion protein (PrPsen) to the protease resistant isoform (PrPres). These peptides comprise discrete fragments of prion proteins, and are shown to inhibit the in vitro conversion of PrPsen to PrPres in a cell-free system. Numerous peptides are disclosed that include at least two amino acid residues from the highly amyloidogenic region P113-120 of the PrP protein. None of these peptides conferred protease-resistance to the PrPsen molecules. The presence of residues 119 and 120 from the highly hydrophobic sequence AGAAAAGA (position 113 to 120) produced a particular inhibitory effect. The inhibition occurred with a high degree of specificity (e.g. with an IC.sub.50 of less than about 1000 .mu.M).",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
6211165,3-Apr-01,2001,4,3,Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists,"Compositions and methods for reducing or preventing ischemic damage of the heart are disclosed. A preferred embodiment of the invention comprises the simultaneous administration of specific A3/A1 receptor agonists, to patients suffering from ischemic damage or at risk for the same. In yet another embodiment of the invention, a binary conjugate which acts as an agonist for the A3 receptor and an antagonist at the A2a receptor, is administered to reduce or prevent ischemic damage to the heart.",60,The Trustees of the University of Pennsylvania,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/7076
6211336,3-Apr-01,2001,4,3,Ataxia-telangiectasia gene,There is provided a purified amino acid sequence selected from the group of Sequence ID No.: 3 and analogs thereof and mutations of Sequence ID No.: 3 which cause ataxia-telangiectasia. Also provided is a purified amino acid sequence as set forth in Sequence ID No.: 3 and analogs thereof.,5,The United States of America as represented by the Department of Health and Human Services,Ramot University Authority for Applied Research and Industrial Dev.,,,,,,,,,,2,Biotechnology,,,,,,C07K/47
6214347,10-Apr-01,2001,4,10,"Multideterminant peptides that elicit helper T-lymphocyte, cytotoxic T lymphocyte and neutralizing antibody responses against HIV-1","The invention is directed to peptides of the HIV-1 envelope protein presenting multiple immune determinants. The peptide elicits both humoral and cell-mediated immune responses in mice having a variety of MHC types. In other embodiments, the invention is directed to immunogens composed of the peptides and methods for immunization employing them.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
6214542,10-Apr-01,2001,4,10,Quantification of indicators of fibrosis,"The state of the extracellular matrix of discrete tissue subsegments can be determined via an approach that combines microdissection, reverse transcription and polymerase chain reaction. Using this approach, a positive correlation between a fibrotic condition and alterations in messenger RNA levels of matrix components provides the basis for (i) the diagnosis of a fibrotic disease and (ii) the monitoring of the efficacy of a therapeutic regimen.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
6214615,10-Apr-01,2001,4,10,Cloned genes for human dopamine D2 receptors and cell lines expressing same,"Disclosed herein is an isolated or essentially pure DNA sequence encoding a human Dopamine D2 receptor, the protein comprising the receptor, vectors for transforming or transfecting host cells with such DNA so that the cells express the DNA, methods of obtaining the DNA and preparing the transformed or transfected cells and cell lines, and methods of using the cells and cell lines in assays for the determination of human dopamine D2 receptor antagonists or agonists.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
6214805,10-Apr-01,2001,4,10,RNase L activators and antisense oligonucleotides effective to treat RSV infections,"The present invention relates to methods of inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a negative strand RNA virus to specifically cleave the genomic or antigenomic RNA strand of the virus. In accordance with the present invention, the methods and complexes of the invention may be applied to target any negative strand RNA virus. The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an ""antisense oligonucleotide"") coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.",15,The United States of America as represented by the Department of Health and Human Services,The Cleveland Clinic Foundation,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Organic fine chemistry,,,,C12N/1131
6214970,10-Apr-01,2001,4,10,Hepatitis E virus antigens and uses therefor,"Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.",1,"Genelabs Technologies, Inc.",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6217884,17-Apr-01,2001,4,17,Streptococcus pneumoniae 37-kDa surface adhesin a protein,"The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Further provided is a method of detecting the presence of Streptococcus pneumoniae in a sample comprising the steps of contacting a sample suspected of containing Streptococcus pneumoniae with nucleic acid primers capable of hybridizing to a nucleic acid comprising a portion of the nucleic acid encoding the 37-kDa protein, amplifying the nucleic acid and detecting the presence of an amplification product, the presence of the amplification product indicating the presence of Streptococcus pneumoniae in the sample. Further provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens, methods of preventing and treating Streptococcus pneumoniae infection in a subject.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/3156
6218596,17-Apr-01,2001,4,17,Enhancement of musculature in non-human mammals expressing c-ski,"The present invention relates to DNA segments encoding chicken c-ski protein, to DNA constructs comprising the DNA segments and to cells transformed therewith. The present invention further relates to non-human transgenic mammals having increased muscle size and/or reduced fat. In addition, the present invention relates to methods of stimulating muscle growth and preventing degeneration of muscle, and to methods of treating muscle degenerative diseases and obesity.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Other special machines,,,,,C12N/8509
6221620,24-Apr-01,2001,4,24,Monoclonal antibodies specific for human thymidylate synthase,"The present invention relates to monoclonal antibodies that are specific for the protein thymidylate synthase, and hybridomas producing these monoclonal antibodies. The invention further relates to methods of detection and diagnostic kits to test for the presence of thymidylate synthase. The invention also relates to the use of the monoclonal antibodies in determining the presence of colon carcinoma cells.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
6225049,1-May-01,2001,5,1,Human insulinoma-associated cDNA,"A novel insulinoma-associated, neuroendocrine tumor-associated cDNA sequence is disclosed. The sequence and fragments thereof are useful for the diagnosis and identification of insulinoma and neuroendocrine tumors. The invention relates to a method for identifying a cancer employing the insulinoma-associated nucleic acid, polypeptide and antibody generated thereto.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
6225080,1-May-01,2001,5,1,Mu-subtype opioid receptor,Isolated DNA encoding mu-subtype opioid receptor polypeptides is provided. Recombinant cloning vectors which include this DNA and cells that incorporate these vectors are also provided. Methods for producing these receptors and purifying them from native and heterologous sources are also disclosed.,6,,,,,,,,,,,,,Biotechnology,,,,,,C07K/705
6225088,1-May-01,2001,5,1,DNA encoding plasminogen-like growth factor (PLGF) and related embodiments,"The present invention relates to a potent mitogenic growth factor called plasminogen-like growth factor (PLGF) isolated from conditioned medium of human lung fibroblasts. The protein has an apparent molecular weight under reducing conditioning of 87 kDa and is structurally related to hepatocyte growth factor (HGF); however unlike HGF, which appears to be specific for hepatic cells, PLGF stimulates a wide spectrum of target cells including melanocytes, endothelial cells and epithelial cells but excludes fibroblast cells. The present invention further relates to recombinant cloned DNA fragments and expression cell systems expressing biologically active PLGF. The availability of purified PLGF as well as immunological and molecular probes should facilitate the study of proliferative disorders in which the factor plays an important role.",7,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4753
6228600,8-May-01,2001,5,8,Immunoassays for the alpha platelet-derived growth factor receptor,Recombinant DNA technology was used to clone encoding nucleic acids for the human alpha platelet-derived growth factor receptor (PDGF-R type alpha). Peptides corresponding to the predicted sequence of this type and of the PDGF-R type beta were used to elicit antibodies specific for either type of the PDGF-R. Immunoassays are described for determining the level of PDGF-R type alpha in biological samples with the PDGF-R type alpha-specific antibodies.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/71
6229005,8-May-01,2001,5,8,DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent,"Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.",6,The United States of America as represented by the Department of Health and Human Services,"Genelabs Technologies, Inc.",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/005
6232069,15-May-01,2001,5,15,RNA probe for detecting c-fes mRNA,A recombinant plasmid and an RNA sequence expressed by said plasmid are described. The RNA sequence hybridize specifically with human c-fes mRNA.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/82
6232086,15-May-01,2001,5,15,Method for detecting cancer cells,The cDNA and amino acid sequences for a cellular apoptosis susceptibility (CAS) protein are used to detect expression and amplification of the CAS gene in normal and cancer cells. An antisense CAS gene sequence introduced into living cells inhibits CAS protein activity and thus prevents or inhibits apoptosis in the cells.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/18
6232336,15-May-01,2001,5,15,"Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same","The present invention relates to nitric oxide-releasing amidine- and enamide-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, a method for the preparation of nitric oxide-releasing amidine- and enamide-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamides, and a method of converting amines into such compounds.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/023
6235761,22-May-01,2001,5,22,"Compound, composition and method for treating cancer","Substantially pure 3,5-dichloro-2-nethoxy-4-hydroxy-6-(trichloromethyl)pyridine or 4-demethylpenclomedine (formula I), acid addition salts thereof, pharmaceutical compositions containing the aforesaid compound, and a method of using the compound in the treatment of cancer in a mammal are disclosed. ##STR1##",17,,,,,,,,,,,,,Organic fine chemistry,,,,,,C07D/69
6235890,22-May-01,2001,5,22,Methods and compositions for the detection of Candida spp.,"The present invention provides a rapid method for identifying species of Candida. Identification is through the use of a non-conserved regions of the ITS2 region flanked by highly conserved functional domains. Detection of members of the Candida and Aspergillus genera is enhanced by the detection of genus-specific regions of the 5.8S rRNA gene. The present invention provides isolated nucleic acids that selectively hybridize to the fungal genus-specific 5.8S rRNA region, and to the species-specific ITS2 region. The invention provides for nucleic acid sequences for use as selective probes for fungal genus-specific probes and as Candida species-specific probes. The present invention provides methods for the use of the Candida species-specific probes that allow the detection and identification of the individual species in biological samples.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
6238858,29-May-01,2001,5,29,Transgenomic viruses,"The present invention provides chimeric primary viruses, which are capable of producing secondary viruses in a producer host cell, and methods of making the same.",39,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
6239116,29-May-01,2001,5,29,Immunostimulatory nucleic acid molecules,"Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant.",49,University of Iowa Research Foundation,"Coley Pharmaceutical Group, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
6241989,5-Jun-01,2001,6,5,Recombinant multivalent viral vaccine,"The present invention relates to multivalent recombinant raccoon poxviruses, containing more than one exogenous gene inserted into either the thymidine kinase gene, the hemagglutinin gene, or a combination thereof. Disclosed is the use of the multivalent recombinant raccoon poxviruses as vaccines to immunize felines against subsequent challenge by feline pathogens. Also disclosed is a method of making a a multivalent recombinant raccoon poxvirus by a recombination process involving the construction of an insertion vector into which the exogenous genes are inserted, and flanking the inserted genes are sequences which can recombine into the raccoon poxvirus thymidine kinase gene, or the hemagglutinin gene, or a combination thereof; introducing both the insertion vector containing the exogenous genes, and raccoon poxvirus into susceptible host cells; and selecting the recombinant raccoon poxvirus from the resultant plaques.",21,"Cornell Research Foundation, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
6242178,5-Jun-01,2001,6,5,Nucleic acid probes for detecting Candida species,"The nucleic acid sequence encoding the internal transcribed spacer 2 region of Candida, the organism causing candidiasis, for various Candida species. Nucleic acid molecules useful as probes for detecting Candida species are described. The nucleic acid molecules are useful in methods for the detection and diagnosis of Candida infection in a sample or subject.",50,Centers for Disease Control and Prevention,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
6245517,12-Jun-01,2001,6,12,Ratio-based decisions and the quantitative analysis of cDNA micro-array images,"Gene expression can be quantitatively analyzed by hybridizing fluor-tagged mRNA to targets on a cDNA micro-array. Comparison of gene expression levels arising from co-hybridized samples is achieved by taking ratios of average expression levels for individual genes. In an image-processing phase, a method of image segmentation identifies cDNA target sites in a cDNA micro-array image. The resulting cDNA target sites are analyzed based on a hypothesis test and confidence interval to quantify the significance of observed differences in expression ratios. In particular, the probability density of the ratio and the maximum-likelihood estimator for the distribution are derived, and an iterative procedure for signal calibration is developed.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G16B/00
6245560,12-Jun-01,2001,6,12,Vector with multiple target response elements affecting gene expression,"The present invention relates to viral inhibition, particularly HIV inhibition, by DNA sequences including multiple target response elements. The DNA construct of the present invention comprises a vector and a promoter operably linked to at least one target response element and, optionally, to other viral inhibitory elements, so that the elements are transcribed in tandem. The DNA construct can be used in the treatment of viral infections, HIV in particular, by obtaining cells from an HIV-infected patient, transforming the cells with the construct and administering the transformed cells to the patient. The protective gene product will only be expressed if the cell becomes infected and a viral protein is made.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1132
6245737,12-Jun-01,2001,6,12,Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins,"The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
6246784,12-Jun-01,2001,6,12,Method for segmenting medical images and detecting surface anomalies in anatomical structures,"A region growing method segments three-dimensional image data of an anatomical structure using a tortuous path length limit to constrain voxel growth. The path length limit constrains the number of successive generations of voxel growth from a seed point to prevent leakage of voxels outside the boundary of the anatomical structure. Once segmented, a process for detecting surface anomalies performs a curvature analysis on a computer model of the surface of the structure. This process detects surface anomalies automatically by traversing the vertices in the surface model, computing partial derivatives of the surface at the vertices, and computing curvature characteristics from the partial derivatives. To identify possible anomalies, the process compares the curvature characteristics with predetermined curvature characteristics of anomalies and classifies the vertices. The process further refines potential anomalies by segmenting neighboring vertices that are classified as being part of an anomaly using curvature characteristics. Finally, the process colorizes the anomalies and computes a camera position and direction for each one to assist the user in viewing 2D renderings of the computer model.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/0012
6248593,19-Jun-01,2001,6,19,Handwipe disclosing method for the presence of lead,"A method of detecting lead contamination of a surface is disclosed. A handwipe issued to collect any lead contamination on the surface. The lead is solubilized with an aqueous acid solution and treated with rhodizonate or sulfide anions. A change in color from pink to red, where rhodizonate anions are used, or brown to black, where sulfide anions are used, is indicative of the presence of lead. The method is suitable for testing surfaces such as floors, walls, windowsills, and human skin.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/22
6251467,26-Jun-01,2001,6,26,Isolation of cellular material under microscopic visualization,"A method of microdissection which involves forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes a selectively activatable adhesive layer which provides, for example, chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated, the transfer surface and tissue sample are separated. During separation, the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample, the zone of cells of interest may then be molecularly analyzed.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Analysis of biological materials,Optics,,,,G01N/2813
6251516,26-Jun-01,2001,6,26,Isolation of cellular material under microscopic visualization,"A method of microdissection which involves forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes a selectively activatable adhesive layer which provides, for example, chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated, the transfer surface and tissue sample are separated. During separation, the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample, the zone of cells of interest may then be molecularly analyzed.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Analysis of biological materials,Optics,,,,G01N/2813
6251586,26-Jun-01,2001,6,26,Epithelial protein and DNA thereof for use in early cancer detection,"The present invention is a purified and isolated epithelial protein, peptide and variants thereof whose increased presence in an epithelial cell is indicative of precancer. One epithelial protein which is an early detection marked for lung cancer was purified from two human lung cancer cell lines, NCI-H720 and NCI-H157. Using a six-step procedure, the epithelial protein was purified using a Western blot detection system under both non-reducing and reducing conditions. Purification steps included anion exchange chromatography, preparative isoelectric focusing, polymer-based C.sub.18 HPLC and analytic C.sub.4 HPLC. After an approximately 25,000 fold purification the immunostaining protein was >90% pure as judged by coomassie blue staining after reducing SDS-PAGE. The primary epithelial protein share some sequence homology with the heterogeneous nuclear ribonucleoprotein (hnRNP) A2. A minor co-purifying epithelial protein shares some sequence homology with the splice variant hnRNP-B1. Molecular analysis of primary normal bronchial epithelial cell cultures demonstrated a low level the epithelial protein expression, consistent with immunohistochemical staining of clinical samples, and an increased level of expression in most lung cancer cells. The epithelial protein is a marker of epithelial transformation in lung, breast, bone, ovary, prostate, kidney, melanoma and myeloma and may be casual in the process of carcinogenesis. Methods are provided for monitoring the expression of the epithelial protein, peptides and variants using molecular and immunological techniques as a screen for precancer and cancer in mammals. A method of computerized diagnoses of cancer and precancer is provided which detects levels of hnRNP messenger RNA.",35,The United States of America as represented by the Department of Health and Human Services,The Johns Hopkins University,,,,,,,,,,2,Biotechnology,,,,,,C12Q/6809
6255058,3-Jul-01,2001,7,3,Immortalized and malignant human prostatic cell lines,"Immortalized malignant human prostatic epithelial and fibroblast cell lines containing DNA of a human papillomavirus (HPV) and similar cell lines containing DNA of a human papillomavirus and an activated viral ras oncogene, such as v-Ki-ras. The cell lines are useful for research on drugs for treatment of prostatic cancer and other diseases. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.",3,Board of Trustees operating Michigan State University,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12N/0683
6255105,3-Jul-01,2001,7,3,Nucleotide and deduced amino acid sequences of tumor gene Int6,"The present invention discloses the isolation of the human and murine wild-type Int6 gene and the cDNAs corresponding to these genes. The invention further describes the use of reagents derived from the nucleic acid and amino acid sequences of the Int6 gene in diagnostic methods, immunotherapy, gene therapy and as vaccines.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/82
6255281,3-Jul-01,2001,7,3,Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions,"Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are also provided.",10,"Claragen, Inc. and U.S. Government",,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Pharmaceuticals,Other special machines,,,C12N/8509
6255292,3-Jul-01,2001,7,3,"Purine nucleotide analogues, pharmaceutical compositions thereof, and methods of improving cardiac functions","The specification discloses purine nucleotide analogues which modulate cardiac muscle contractility and possess vasodilator activity. In addition, related methods of administration and the identity of receptors that bind these compounds are disclosed.",26,The Trustees of the University of Pennsylvania,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/20
6258556,10-Jul-01,2001,7,10,cDNA and genomic clones encoding human .mu. opiate receptor and the purified gene product,"A human .mu. opiate receptor cDNA has been identified from a cerebral cortical CDNA library using sequences from the rat .mu. opiate receptor CDNA. The human .mu. opiate receptor (h.mu.OR1) shares 95% amino acid identity with the rat sequence. The expressed .mu.OR1 recognizes tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat .mu. opiate receptor. Effects on cyclic AMP are similar to those noted for the rat .mu. opiate receptor. Overlapping genomic clones spanning 50 kilobasepairs and hybridizing with the h.mu.OR1 cDNA contains exon sequences encoding the entire open reading frame of the human A opiate receptor are described. Analysis of hybridization to DNA prepared from human rodent hybrid cell lines and chromosomal in situ hybridization studies indicate localization to 6q24-25. An MspI polymorphism, producing a 3.7 kb band, is being used to assess this gene's involvement in neuropsychiatric disorders involving opiatergic systems.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
6261564,17-Jul-01,2001,7,17,Peptides of human immunodeficiency virus type 1 (HIV-1),"This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.",2,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
6262336,17-Jul-01,2001,7,17,Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter,"An isolated DNA sequence which regulates the expression of a heterologous gene composed of a mouse whey acidic protein promoter having a length of greater than about 2.4 kb extending upstream from the unique KpnI site in the mouse whey acidic protein gene is disclosed. Specifically a mouse whey acidic protein promoter of about 4.1-4.2 kb in length extending upstream from the unique KpnI site is preferred. This mouse whey acid protein promoter is operably linked to a DNA sequence encoding a heterologous polypeptide and used to prepare transgenic non-human mammals expressing the heterologous polypeptide in their milk. Particularly efficient expression of both cDNAs and genomic DNAs encoding heterologous polypeptides was obtained in transgenic non-human mammals using this promoter, known as the long whey acidic protein promoter.",29,American Red Cross,"Virginia Tech Intellectual Properties, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Biotechnology,Other special machines,,,,,C12N/8509
6264957,24-Jul-01,2001,7,24,Product of infectious respiratory syncytial virus from cloned nucleotide sequences,"Isolated polynucleotide molecules provide RSV genome and antigenomes, including that of human, bovine or murine RSV or RSV-like viruses, and chimera thereof. The recombinant genome or antigenome can be expressed with a nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large (L) polymerase protein, and an RNA polymerase elongation factor to produce isolated infectious RSV particles. The recombinant RSV genome and antigenome can be modified to produce desired phenotypic changes, such as attenuated viruses for vaccine use.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6264958,24-Jul-01,2001,7,24,Genes of kaposi's sarcoma associated herpesvirus,"A human gamma herpesviris genome known as Kaposi sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV-8) is present in virtually all AIDS and non-AIDS Kaposi's sarcoma (KS) lesions, as well as in body cavity based lymphomas (BCBL), Multiple myeloma, and in multicentric Casdeman's disease. Isolation and DNA sequencing of a 17-kb segment encompassing a HHV-8 divergent locus (DL-B) between ORF11 and ORF17 revealed the presence of nine viral ORFs with gene products related to cellular proteins. These include the complete thymidylate synthase (TS) gene and a dihydrofolate reductase (DHFR) gene, four cytokine genes (vIL6, vMIP-1A, vMIP-1B and BCK) that have not previously been found to be encoded by a virus, and a Bcl2 homologue. This region in HHV-8 also contains the T1.1 abundant lytic cycle nuclear RNA gene and encompasses two genes (or exons) encoding proteins with C4HC3 zinc finger domains of the PHD/LAP subtype. The latter are related to the spliced immediatelady IE1 protein of the bovine gamma-2 class herpesvirus BHV-4 and a similar motif found in HVS ORF12. Transcripts form the IE-1A, IE-1B, DHFR, and MIP-1B genes were all detected by Northern blot hybridization analysis in a BCBL cell line at 12-h after induction with butyrate, but were not present before induction, indicating that these are all primarily lytic cycle genes.",10,The Johns Hopkins University,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6265160,24-Jul-01,2001,7,24,Method of identifying inhibitors of the Jak-Stat signal transduction pathway,"Agents which inhibit the Jak-Stat signal transduction pathway are identified in order to identify candidate drugs for treatment of proliferative disorders. Identification methods are alternatively based on inhibiting the interaction of: (1) the activated Stat3 and Stat5 transcription factors with an electrophoretic mobility shift assay probe, or (2) the Stat3 or Stat5 proteins with the IL-2R.beta. chain of the IL-2 receptor.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5041
6265548,24-Jul-01,2001,7,24,Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence,"The present invention is directed to mutants of the jellyfish Aequorea victoria green fluorescent protein (GFP) having at least 5 and preferably greater than 20 times the specific green fluorescence of the wild type protein. In other embodiments, the invention comprises mutant blue fluorescent proteins (BFPs) that emit an enhanced blue fluorescence. The invention also encompasses the expression of nucleic acids that encode a mutant GFP or BFP in a wide variety of engineered host cells, and the isolation of engineered proteins having increased fluorescent activity. The novel mutants of the present invention allow for a significantly more sensitive detection of fluorescence in engineered host cells than is possible with GFP or with its known mutants. Thus, the mutant fluorescent proteins provided herein can be used as sensitive reporter molecules to detect the cell and tissue-specific expression and subcellular compartmentalization of GFP or BFP mutants, or of chimeric proteins comprising GFP or BFP mutants fused to a regulatory sequence or to a second protein sequence.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/43595
6268213,31-Jul-01,2001,7,31,Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy,The subject invention concerns a recombinant adeno-associated virus vector characterized as being capable of delivering and expressing at least one mammalian gene into a genome of a mammalian host cell such that the expression of the gene is regulated in a tissue specific manner by cis-acting regulatory and promoter elements of the gene. A method of using this recombinant adeno-associated virus vector for therapeutic purposes is also provided.,8,,,,,,,,,,,,,Biotechnology,,,,,,C12N/86
6270778,7-Aug-01,2001,8,7,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
6270779,7-Aug-01,2001,8,7,Nitric oxide-releasing metallic medical devices,"Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.",14,United States of America,,,,,,,,,,,1,Medical technology,Pharmaceuticals,,,,,A61L/04
6270958,7-Aug-01,2001,8,7,Detection of negative-strand RNA viruses,A diagnostic assay for detecting a negative-strand RNA virus in a sample and a genetically engineered cell for use in the assay are disclosed. The cell expresses a heterologous DNA-dependent RNA polymerase that synthesizes a minigenome or miniantigenome of the RNA virus from a cDNA template present in the cell. The cell also expresses the nucleocapsid proteins of the negative-strand virus that are necessary for replication of the minigenome or miniantigenome. Infection of the cell by the negative-strand virus results in expression of a reporter gene product encoded by the miniantigenome.,21,Washington University,National Institute of Health,Rush Presbyterian St. Luke's Medical Center,,,,,,,,,3,Biotechnology,,,,,,C12Q/6897
6270966,7-Aug-01,2001,8,7,Restriction display (RD-PCR) of differentially expressed mRNAs,"A method for detecting gene expression in cells by reverse transcribing mRNA molecules into cDNA, cutting the cDNA with at least one restriction endonuclease, adding adaptor sequences to the cDNA fragments and selectively amplifying a subset of the cDNA by a polymerase chain reaction (PCR) to present a two-dimensional display of the DNA fragments or for cloning the DNA fragments into a vector is disclosed. In one embodiment, cDNA corresponding to the 3' end of the mRNA is amplified and displayed or cloned, whereas in another embodiment, cDNA corresponding to the entire mRNA molecule is amplified and displayed or cloned.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1096
6271369,7-Aug-01,2001,8,7,Chimeric molecules targeted to viral RNAs,Chimeric molecules comprising a virus targeting antisense oligonucleotide moiety attached to an activator of 2-5A-dependent RNase.,9,The United States of America as represented by the Department of Health and Human Services,The Cleveland Clinic Foundation,,,,,,,,,,2,Biotechnology,Organic fine chemistry,,,,,C12N/113
6274134,14-Aug-01,2001,8,14,Human cell adhesion protein AAMP-1 and uses thereof,"The present invention relates, in general, to AAMP-1, and to a peptide derived from the amino-terminal region of AAMP, P189. In particular, the present invention relates to a DNA segment encoding AAMP-1, P189 or fragments thereof; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a AAMP-1, and P189 polypeptide or fragments thereof; antibodies specific to AAMP-1; and a method of measuring the amount of AAMP-1 in a sample. The present invention further relates to methods of using AAMP, P189 or fragments thereof in promoting cell-cell or cell-substrate adhesion, wound healing in patients, prosthetic acceptance, concentrating heparin in tissues, and inhibiting metastases and invasion of malignant cells.",4,National Institutes of Health,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/2803
6274611,14-Aug-01,2001,8,14,Methods and compositions for inhibition of viral replication,"The present invention comprises methods and compositions for treating viral infection by inhibiting the activity of host cellular enzymes. More specifically, methods and compositions comprising casein kinase II inhibitors and various related compounds such as precursors, analogs, metabolites and hydrolysis products that inhibit cellular proteins and thus viral replication are provided.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/352
6277980,21-Aug-01,2001,8,21,Human papilloma virus inhibition by anti-sense oligonucleotides,Antisense oligonucleotides having phosphorothioate backbone structure and sequences complementary to nucleotides contained with residues 415 to 445 of human papilloma virus 16 (HPV-16) are disclosed. Methods of treatment using antisense oligonucleotides having phosphorothioate backbone structure and nucleotide sequences complementary to nucleotides contained with residues 415 to 445 of HPV-16 are disclosed.,1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Organic fine chemistry,,,,C12N/1131
6280734,28-Aug-01,2001,8,28,Simian-human HAV having a chimeric 2C protein,The present invention discloses simian-human hepatitis A virus chimeric genomes which encode a hepatitis A virus having a chimeric 2C protein. The invention further discloses the use of these viruses or the nucleic acid sequence encoding them as vaccines.,33,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6284254,4-Sep-01,2001,9,4,Immunogenic compositions comprising cold-adapted attenuated respiratory syncytial virus mutants,"The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and children throughout the world. RSV is a major cause of pneumonia and bronchiolitis in infants under one year of age, and is a major cause of fatal respiratory tract disease in these infants. The treatment and prevention of RSV infection has been problematic. However, the present invention addresses some of these concerns by providing attenuated RSV strains that are suitable for inclusion in immunizing compositions. Specifically, the present invention is directed toward the introduction of growth restriction mutations into incompletely attenuated host range-restricted cold-passaged respiratory syncytial virus (cpRSV) strains by further passage of the strains at increasingly reduced temperatures to produce derivative strains which are more satisfactorily attenuated. These cold-adaptation (ca) approaches were used to introduce further attenuation in the parental RSV virus cpRSV-3131, which is incompletely attenuated in seronegative children. Mutants of the parental strain were obtained by selecting for large plaque production at reduced temperatures. An RSV cp-3131 derivative, designated D1, was isolated that produces large plaques at 25.degree. C. Biologically cloned virus D1 produces distinctly and uniformly larger plaques at 25.degree. C. as compared to the parental attenuated strain cpRSV-3131 or wild-type strain A2. Thus, D1 is an attenuated cold-adapted, but not temperature-sensitive, RSV mutant. The invention also provides methods for stimulating RSV-specific immune responses in an individual through the administration of said mutants.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
6284454,4-Sep-01,2001,9,4,Variant of LAV viruses,"A variant of a LAV virus, designated LAV.sub.MAL and capable of causing AIDS. The cDNA and antigens of the LAV.sub.MAL virus can be used for the diagnosis of AIDS and pre-AIDS.",3,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/702
6284491,4-Sep-01,2001,9,4,Biologically active synthetic thyrotropin and cloned gene for producing same,Substantially pure recombinant TSH has been prepared from a clone comprising complete nucleotide sequence for the expression of the TSH. Diagnostic and therapeutic applications of the synthetic TSH are described.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57407
6287562,11-Sep-01,2001,9,11,"Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates","The invention provides methods for inhibiting the growth of a cell bearing a Lewis.sup.Y antigen. The methods involve contacting the cell with a composition comprising an Fv region of a light chain of a monoclonal antibody selected from B1, B3, and B5, and the Fv region of a humanized heavy chain of a monoclonal antibody independently selected from B1, B3, and B5, provided that if the heavy and the light chains are from the same antibody, the residue at position 95 of the heavy chain is a serine, and, if the antibody chain is from B3, the residue at position 4 of the light chain can be a leucine and the residue at position 82b of the heavy chain can be an arginine. The Fv regions are joined to an effector molecule selected from a chemotherapeutic agent, a toxin, a radioisotope, and a liposome loaded with a chemotherapeutic agent. In preferred embodiments, the heavy chain and the light chain are recombinantly fused, and the Fv regions are recombinantly fused to a toxin.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,G01N/57419
6287759,11-Sep-01,2001,9,11,Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines,"A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C07K/005
6287815,11-Sep-01,2001,9,11,"Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines","The invention relates to the coat proteins VP1 and VP2 of the human parvovirus B19 and virus-like particles consisting of VP2 or of VP1 and VP2. The invention further comprises genetic information in the form of recombinant expression vectors which contain the genes coding for said proteins, and organisms which through genetic manipulation using such vectors have acquired the ability to produce such proteins and/or particles. The invention further comprises uses of such proteins and virus-like particles for diagnostics or vaccination.",13,Rijksuniversiteit te Leiden,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6288042,11-Sep-01,2001,9,11,Anti-viral guanosine-rich tetrad forming oligonucleotides,"Guanosine-rich oligonucleotides having sequences that favor the formation under physiological conditions of a stable four-stranded structure containing two stacked guanosine quartets (G4s) are disclosed. These oligonucleotides demonstrate enhanced nuclease resistance, cellular uptake and biological efficacy. Methods and composition for treating viral infection using these guanosine-rich oligonucleotides are also disclosed. Certain embodiments of the new oligonucleotides are 16-17 nucleotides long and contain at least one C-5 propynyl dU substitution. A method for designing anti-viral oligonucleotides is also disclosed.",26,"Aronex Pharmaceuticals, Inc.",Baylor College of Medicine,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/70
6289753,18-Sep-01,2001,9,18,Method for measuring mechanical properties of the collagen network in cartilage,"A method for measuring the mechanical integrity of a collagen network in cartilage and of other extracellular matrices according to applying a known mechanical stress to the sample; measuring a quantity representing hydration of the sample; and providing the extracellular network recoil pressure according to the known applied mechanical stress and the independently determined proteoglycan osmotic pressure corresponding to the hydration. In accordance with an embodiment of the present invention, an in vitro mechanowsmotic titration method for determining the collagen network tension (i.e., recoil pressure) for a given collagen network hydration is used. In accordance with a further embodiment of the present invention, the method may be used for diagnosing and/or monitoring the progression of diseases, such as osteoarthritis, preferably according to the collagen network stiffness, which for example, is shown to be reduced in osteoardritic cartilage compared with normal cartilage.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Analysis of biological materials,,,,,G01N/04
6290963,18-Sep-01,2001,9,18,Anti-HIV compositions containing native and recombinant peptides,Native and recombinant peptides which elicit anti-HIV immune response are provided.,8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6290981,18-Sep-01,2001,9,18,Use of nitric oxide-releasing agents to treat impotency,A method of treatment for impotency is provided. The method involves the administration of nitric oxide by a nitric oxide-releasing agent capable of providing a penile erection-inducing amount of nitric oxide to the corpus cavernosum of the penis of an impotent male animal. Also provided is a nitric oxide delivery means for use in the method.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/655
6291641,18-Sep-01,2001,9,18,Hepatitis E virus antigens and uses therefor,"Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, a soluble 62 kDa species of the capsid protein encoded by ORF2, are immunoreactive with sera from individuals infected with HEV. The 62K antigen may be produced by a baculovirus expression vector and forms virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.",1,"Genelabs Technologies, Inc.",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6291664,18-Sep-01,2001,9,18,Method of eliminating inhibitory/instability regions of mRNA,A method of locating an inhibitory/instability sequence or sequences within the coding region of an mRNA and modifying the gene encoding that mRNA to remove these inhibitory/instability sequences by making clustered nucleotide substitutions without altering the coding capacity of the gene is disclosed. Constructs containing these mutated genes and host cells containing these constructs are also disclosed. The method and constructs are exemplified by the mutation of a Human Immunodeficiency Virus-1 Rev-dependent gag gene to a Rev independent gag gene. Constructs useful in locating inhibitory/instability sequences within either the coding region or the 3' untranslated region of an mRNA are also disclosed. The exemplified constructs of the invention may also be useful in HIV-1 immunotherapy and immunoprophylaxis.,48,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6291675,18-Sep-01,2001,9,18,Methods of o-demethylation and n-deprotection,"The present invention provides a method for N-deprotecting an opioid compound, a method for N-deprotecting and O-demethylating an opioid compound, a method for O-demethylating an opioid compound, and a method for O-demethylating a nonpeptidic delta agonist compound or an opioid compound having a tertiary amide with no significant reaction at amide groups.",18,The United States as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/02
6294322,25-Sep-01,2001,9,25,Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1,"Peptide constructs comprised of multideterminant T helper peptides from the envelope glycoprotein of HIV previously identified to induce proliferative responses in four different haplotypes of mice and IL-2 responses in 52-73% of HIV positive, flu positive patients (cluster peptides), were co-linearly synthesized with the peptide 18 of the V3 loop of HIV-1 gp 160, corresponding to the principal neutralizing determinant of HIV-IIIB and also shown to contain a dominant CTL epitope. Cognate help for peptide 18 antibody was elicited following a single immunization in all strains of mice which had previously responded to a T cell epitope encompassed by the peptides. In two strains of mice, the level of neutralizing antibody achieved was comparable to levels adequate for protection from homologous viral challenge in chimpanzees. After a single boost, much higher antibody titers for 90% neutralization in the range of 1:1000 to 1:16,000 were achieved. Spleen cells from mice of three distinct MHC haplotypes sharing the D.sup.d class I MHC molecule but with different class II molecules, immunized with the compound peptides, exhibited enhanced gp160-specific CTL activity.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
6294331,25-Sep-01,2001,9,25,Methods for assessing genetic and phenotypic markers by simultaneous multicolor visualization of chromogenic dyes using brightfield microscopy and spectral imaging,"The present invention is directed to an improved method for detecting a genetic marker in a biological sample comprising contacting the biological sample with a nucleic acid probe linked to a detectable moiety, whereby the detectable moiety can be detected by the presence of a chromogenic dye associated with the detectable moiety, obtaining a spectral image of the biological sample using brightfield microscopy, and detecting the presence of the chromogenic dye, thereby detecting the genetic marker in the biological sample. The present invention also provides an improved method for detecting a phenotypic marker in a biological sample comprising contacting the biological sample with a compound comprising a detectable moiety, whereby the compound associates with the phenotypic marker and whereby the detectable moiety can be detected by the presence of a chromogenic dye associated with the detectable moiety, obtaining a spectral image of the biological sample using brightfield microscopy, and detecting the presence of the chromogenic dye, thereby detecting the phenotypic marker in the biological sample.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6841
6300056,9-Oct-01,2001,10,9,HIV probes for use in solution phase sandwich hybridization assays,Novel DNA probe sequences for detection of HIV in a sample in a solution phase sandwich hybridization assay are described. Amplified nucleic acid hybridization assays using the probes are exemplified.,20,Chiron Corporation,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
6300085,9-Oct-01,2001,10,9,Diagnostic method for Alzheimer's disease,"The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells. In addition a diagnostic index for improved assessment between Alzheimer's and non Alzheimer's cells is provided.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/4711
6303604,16-Oct-01,2001,10,16,"Pharmaceutical composition comprising 2,4-diamino-6-benzyloxy-s-triazine and inactivation of O6-alkylguanine-DNA-alkyltransferase","The present invention provides 8-substituted O.sup.6 -benzylguanine, 4(6)-substituted 2-amino-5-nitro-6(4)-benzyloxypyrimidine, and 4(6)-substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidine derivatives which have been found to be effective AGT inactivators, as well as pharmaceutical compositions comprising such derivatives along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of quanine, by administering to a mammal an effective amount of one of the aforesaid derivatives, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O.sup.6 -benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine.",3,The United States of America as represented by the Department of Health and Human Services,The Penn State Research Foundation,Arch Development Corporation,,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
6306651,23-Oct-01,2001,10,23,Specific tolerance in transplantation,"In general, the invention features, a method of inducing tolerance in a recipient mammal, e.g., a human, of a first species to a tissue obtained from a mammal, e.g., a swine, e.g., a miniature swine, of a second species, which tissue expresses an MHC antigen, including inserting DNA encoding an MHC antigen of the second species into a bone marrow hematopoietic stem cell from the recipient mammal, and allowing the MHC antigen encoding DNA to be expressed in the recipient.",40,The General Hospital Corporation,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/26
6307090,23-Oct-01,2001,10,23,Acylated oligopeptide derivatives having cell signal inhibiting activity,"The invention relates to an acylated peptide, namely a compound of formula (I), ##STR1## wherein PA1 n is 0 to 15, PA1 X is oxalyl PA1 PTI is the bivalent radical of tyrosine or (preferably) the bivalent radical of phosphotyrosine or a phosphotyrosine mimetic, AA stands for a bivalent radical of a natural or unnatural amino acid, and Y is secondary amino group, or a salt thereof, said compound being useful for the treatment of diseases that respond to inhibition of the interaction of (a) protein(s) comprising (an) SH2 domain(s) and a protein tyrosine kinase or a modified version thereof.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/3882
6309818,30-Oct-01,2001,10,30,Scratch wound assay device,"An apparatus having at least one template opening for causing a substantially reproducible injury to a cell, organ or tissue layer. The apparatus is useful in determining the effects of cell growth and migration agents in model wounds produced in the cell, organ or tissue layer. Also provided are methods of using the apparatus including juxtapositioning the apparatus to cells on a cell growth substrate and disrupting cells thereon.",21,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/50
6309863,30-Oct-01,2001,10,30,Methods for generating phosphorylation site-specific immunological reagents,"The present invention provides methods for generating phosphorylation site-specific immunological reagents. More specifically, a phosphopeptide mimetic is incorporated into a polypeptide in place of a phosphorylated amino acid. The polypeptide is used as antigen by standard methods to generate either monoclonal or polyclonal antibodies which cross-react with the naturally phosphorylated polypeptide. The phosphopeptide mimetic preferably contains a non-hydrolyzable linkage from the appropriate carbon atom of the amino acid residue to a phosphate group. A preferred linkage is a CF.sub.2 group. Such a linkage is used to generate the phosphoserine mimetic F.sub.2 Pab, which is incorporated into a polypeptide sequence derived from p53 to produce antibodies which recognize a specific phosphorylation state of p53. A CF.sub.2 group linkage is also used to produce the phosphothreonine mimetic F.sub.2 Pmb, and to produce the phosphotyrosine mimetic, F.sub.2 Pmp.",32,Brookhaven Science Associates,,,,,,,,,,,1,Biotechnology,,,,,,C07K/32
6310064,30-Oct-01,2001,10,30,Aralkyl diazabicycloalkane derivatives for CNS disorders,"Certain aralkyl diazabicycloalkyl compounds are disclosed for treatment of CNS disorders, such as cerebral ischemia, psychosis, and convulsions. For example, compounds of interest are of the formula: ##STR1##",21,The United States of America as represented by the of Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
6311564,6-Nov-01,2001,11,6,Support apparatus with stress measuring capability,"Apparatus for providing support to, and/or measuring the stress present in a potentially unstable structure, such as the roof of a coal or other underground mine, or a rock mass. The apparatus is an instrumented cable that has a center wire having a plurality of stress measuring devices attached along its length. Forming material is placed around the center wire and the stress measuring devices in order to provide protection and support. A plurality of noncenter wires extend generally longitudinally around the center wire, the stress measuring devices, and the forming material. Advantageously, the apparatus measures the stress placed thereon when inserted into the potentially unstable structure at more than one location along the length thereof, may be spun into a rock mass without damaging the stress measuring devices (or other components of the apparatus) and may be grouted into the potentially unstable structure with a variety of different grouts.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01L/101
6312648,6-Nov-01,2001,11,6,Applicator system,"The present invention relates to an applicator system including an applicator, an applicator tube, an applicator tube system, and a cap system.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,,,,,,B01L/50825
6312718,6-Nov-01,2001,11,6,Vaccine for B-cell malignancies,"A vaccine comprising a liposome preparation including at least one B-cell malignancy-associated antigen, IL-2, alone or in combination with at least one other cytokine, and at least one type of lipid molecule, is useful in a method of inducing humoral and cellular immune responses against malignant B-cells in a mammal.",17,"Biomira USA, Inc.",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/127
6312890,6-Nov-01,2001,11,6,Partial intron sequence of von hippel-lindau (VHL) disease gene and its use in diagnosis of disease,The Von Hippel-Lindau (VHL) disease gene and its corresponding cDNA are disclosed. Methods for detecting carriers of the VHL disease gene using probes derived from the VHL disease gene sequence are described. Pharmaceutical compositions and methods of treating diseases related to the VHL gene are also disclosed.,24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/5748
6312944,6-Nov-01,2001,11,6,Pneumococcal fimbrial protein A,"The present invention relates, in general, to pneumococcal fimbrial protein A. In particular, the present invention relates to a DNA segment encoding a pneumococcal fimbrial protein A gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a pneumococcal fimbrial protein A polypeptide; antibodies specific to pneumococcal fimbrial protein A; and a method of measuring the amount of pneumococcal fimbrial protein A in a sample.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1275
6313090,6-Nov-01,2001,11,6,Methods for treating parasitic infection using thiopeptides,"The present invention provides a method for treating a parasitic infection in a subject infected with a parasite having a plastid-like organelle, comprising administering to the subject an infection treating amount of a thiopeptide in a pharmaceutically acceptable carrier. Methods for treating Cryptospordium, Toxoplasma or Plasmodium infection in a subject are also provided, each method comprising administering to the subject an infection treating amount of a thiopeptide in a pharmaceutically acceptable carrier.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/04
6313098,6-Nov-01,2001,11,6,Methods of neuroendocrine regulation of affective disorders,"Methods of treating an affective disorder in an individual are disclosed. Affective disorders include major depression, melancholic and atypical subtypes, and dysthymia.",6,"Beth Israel Deaconess Medical Center, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/2264
6315997,13-Nov-01,2001,11,13,Use of modified antibodies with human milk fat globule specificity,"An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the analogue peptide, and a hybrid vector carrying the nucleotides and transfected cells express the peptides and a method produces the analogue peptide. An anti-idiotype polypeptide comprises polyclonal antibodies raised against an anti-carcinoma antibody or the analogue peptide of this invention, monoclonal antibodies thereof, Fab, Fab', (Fab').sub.2, CDR, variable region, or analogues or fragments thereof, combinations thereof with an oligopeptide comprising a TRP trimer, tandem repeats thereof, or combination or mixtures thereof. An anti-idiotype hybrid polypeptide with an effector agent and the anti-idiotype polypeptide, an anti-carcinoma vaccine, an anti-carcinoma vaccination kit, a method of vaccinating against carcinoma and a method of lowering the serum concentration of a circulating antibody or polypeptide are provided.",65,Cancer Research Fund,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/465
6316000,13-Nov-01,2001,11,13,"Cloning and expression of plasmodium falciparum transmission-blocking target antigen, PFS230",Compositions comprising biologically pure Pfs230 and nucleic acids which encode them are provided. The proteins can be used induce transmission blocking immune responses in susceptible hosts.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/445
6316190,13-Nov-01,2001,11,13,Oligonucleotides which specifically bind retroviral nucleocapsid proteins,"The invention provides oligonucleotides which bind to retroviral nucleocapsid proteins with high affinity, molecular decoys for retroviral nucleocapsid proteins which inhibit viral replication, targeted molecules comprising high affinity oligonucleotides, assays for selecting test compounds, and related kits.",37,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/56988
6316423,13-Nov-01,2001,11,13,"Method of treating ischemic, hypoxic and anoxic brain damage","The present invention provides a method of treating ischemic, hypoxic or anoxic brain damage in an animal comprising administering to an animal afflicted with ischemic, hypoxic, or anoxic brain damage, or an animal in imminent danger of suffering ischemic, hypoxic, or anoxic brain damage, a therapeutically effective amount of ADAC, or an analogue thereof.",21,The United States of America as represented by the Departmant of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
6319496,20-Nov-01,2001,11,20,Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof,"We have discovered that by using a recombinant DNA viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding the carcinoma self-associated antigen, or a cytotoxic T-cell eliciting epitope thereof, operably linked to a promoter capable of expression in the host, human cytotoxic T-cells specific for the carcinoma self-associated antigens can be produced. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate production of cytotoxic T-cells, and contacting the host with additional antigen at periodic intervals thereafter. The additional antigen may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional antigen is added by contacting the host with antigen. The antigen may be formulated with an adjuvant or in a liposomal formulation. The T-cells can be isolated. The number of T-cells can be expanded by contacting the isolated cytotoxic T-cells alternately with the carcinoma self-associated antigen or an epitope thereof and IL-2. The isolated T-cells can be used in a method for treating a host having a tumor expressing a carcinoma self-associated antigen comprising introducing cytotoxic T-cells specific for the antigen to the host and at at least one periodic interval thereafter introducing to the host a T-cell eliciting epitope of the carcinoma self-associated antigen.",16,Therion Biologics Corporation,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/705
6319687,20-Nov-01,2001,11,20,"Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene","Nucleic acids encoding the neurotrophic protein known as pigment epithelium-derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/811
6319707,20-Nov-01,2001,11,20,Cap-independent multicistronic retroviral vectors,"Retroviral vectors for producing coordinately expressed polycistronic mRNA in transfected host cells. A representative retroviral construct capable of forming a proviral genome in a host cell contains a first nucleotide coding sequence, a second nucleotide coding sequence, and a third nucleotide sequence capable of hybridizing under stringent conditions to a 5' nontranslated region (NTR) of a picornavirus RNA or its complementary RNA strand. The first, second, and third nucleotide sequences are operably linked such that transcription of the proviral genome gives rise to a messenger RNA molecule containing transcripts of the first, second, and third nucleotide sequences. The transcript of the third nucleotide sequence in the messenger RNA molecule contains a nucleic acid capable of forming a regulatory stem-loop nucleic acid structure followed by at least one operable AUG start codon. The regulatory stem-loop nucleic acid structure is capable of operably binding a translation initiation complex in a host cell such that the transcripts of the first and second nucleotide sequences in the messenger RNA molecule are coordinately expressed in the host cell.",16,Fred Hutchinson Cancer Research Center Board Regents of the University of Washington,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6320022,20-Nov-01,2001,11,20,Adrenomedullin peptides,"The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/26
6322981,27-Nov-01,2001,11,27,Rapid method for diagnosing the various forms of alpha-thalassemia,"The present invention relates to the simultaneous and specific identification of the variant forms of .alpha.-thalassemia. This invention utilizes simple and readily available equipment to rapidly identify, diagnose and differentiate the different forms of .alpha.-thalassemia. Specifically, the present invention relates to a simple and rapid non-radioisotopic technique for the diagnosis and differentiation of the common forms of .alpha.-thalassemia has been developed. This approach works on any biological tissue including blood, wherein the assay works equally well with fresh blood and dried blood samples stored on filter paper.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
6323185,27-Nov-01,2001,11,27,Anti-viral guanosine-rich oligonucleotides and method of treating HIV,"A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotide. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity and integrase inhibition activity.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Organic fine chemistry,Semiconductors,,,A61K/70
6323316,27-Nov-01,2001,11,27,Fibroblast growth factor receptor activating gene 1 and related compositions and methods,"A novel gene designated as FRAG 1 and its encoded protein are disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies.",35,The United States of America as represented by the Secretary of the Department of and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4702
6323325,27-Nov-01,2001,11,27,Agents that bind to and inhibit human cytochrome P450 2A6,"The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2A6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2A6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in an individual relative to p450 2A6 levels in a control population.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/40
6326466,4-Dec-01,2001,12,4,Double-stranded RNA dependent protein kinase derived peptides to promote proliferation of cells and tissues in a controlled manner,"This invention relates to double-stranded RNA dependent protein kinase (PKR) peptide antagonists. More specifically, the invention relates to compositions and methods for antagonizing activation of double-stranded RNA dependent protein kinase (PKR) to stimulate eukaryotic cell proliferation. The invention relates to compositions and methods to inhibit activation of double-stranded RNA dependent protein kinase (PKR) to stimulate cell proliferation under conditions of cell cycle arrest, quiescence, reduced growth or cell death. The invention also relates to methods of protecting cells from HIV-1 pathogenesis using inhibitors of PKR.",47,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
6329198,11-Dec-01,2001,12,11,Production and use of human nm23 protein and antibodies therefor,Human nm23 DNA and protein is disclosed as well as antibodies which recognize human nm23 protein. The DNA and antibodies may be used to detect nm23 in human tumors to predict the malignancy potential of such tumors.,4,The United States of America as represented by the Department of Secretary Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/12
6329349,11-Dec-01,2001,12,11,Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents,Materials and methods for reducing or preventing ischemic damage of the heart are disclosed. A preferred embodiment of the invention comprises methods of sequential administration of a plurality of cardioprotective agents to patients suffering from ischernic damage or at risk for the same.,30,Trustees of the University of Pennsylvania,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/06
6329507,11-Dec-01,2001,12,11,Dimer and multimer forms of single chain polypeptides,The present invention discloses novel proteins which are dimers and multimers of single chain polypeptides. The single chain polypeptides having two domains derived from the immunoglobulin superfamily which are joined by a peptide linker. The dimers and multimers being formed by non-covalent linking of the single chain polypeptides.,18,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/10
6331630,18-Dec-01,2001,12,18,Dimeric arylisoquinoline alkaloids and derivatives thereof,"The present invention provides new naphthylisoquinoline derivatives. In particular, the present invention furthermore provides novel dimeric arylisoquinoline alkaloids comprised of coupled first and second arylisoquinoline monomers. Monomeric and dimeric compounds of the present invention have medically useful properties, such as antimicrobial properties, more specifically such as antimalarial and antiviral properties. Monomeric compounds of the present invention are also useful as building blocks or intermediates for synthesis of novel dimeric arylisoquinoline alkaloids. Monomeric and dimeric compounds of the present invention may be obtained in substantially pure form by total synthesis, partial synthesis, or derivatization from known synthetic or naturally occurring compounds, and by isolation and purification from plants of the Dioncophyllaceae and Ancistrocladaceae families.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
6333331,25-Dec-01,2001,12,25,Substituted O6-benzylguanines,"The present invention provides AGT inactivating compounds such as substituted O.sup.6 -benzylguanines of the formula ##STR1## 7- or 9-substituted 8-aza-O.sup.6 -benzylguanines, 7,8-disubstituted O.sup.6 -benzylguanines, 7,9-disubstituted O.sup.6 -benzylguanines, 4(6)-substituted 2-amino-5-nitro-6(4)-benzyloxypyrimidines, and 4(6)-substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidines, as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O.sup.6 -benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O.sup.6 -position of guanine.",15,The United States of America as represented by the Department of Health and Human Services,The Penn State Research Foundation,ARCH Development Corporation,,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
6335428,1-Jan-02,2002,1,1,Agents that bind to and inhibit human cytochrome P450 1A2,"The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 1A2 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 1A2 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 1A2, and in methods of measuring p450 1A2 levels in individuals relative to p450 1A2 levels in a control population.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/40
6337021,8-Jan-02,2002,1,8,Chiral separation of enantiomers by high-speed countercurrent chromatography,"Preparative-scale separations of chiral compounds were achieved by high-speed countercurrent chromatography (HSCCC) using a multilayer coil planet centrifuge equipped with a 325 mL capacity column. The separations were performed by two different procedures both utilizing a set of N-(3,5-dintrobenzoyl)-D,L-amino acids as test samples with N-dodecanoyl-L-proline-3,5-dimethylanilide as a chiral selector (Cs). The HSCCC separations were carried out with a two-phase solvent system composed of hexane/ethyl acetate/methanol/water where the chiral selector was added to the organic stationary phase. A second procedure using pH-zone-refining CCC yielded characteristic fused rectangular peaks in which the two isomers were resolved with less than 5% of overlap.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
6337179,8-Jan-02,2002,1,8,Methods and kits for detecting antibodies against an HIV variant,"Methods and kits for the in vitro detection of antibodies of an HIV variant are disclosed. In particular, the detection of HIV-1 variants, such as LAVBRU, LAVELI, LAVMAL, are taught by using an immunologically distinct antigen of these HIV variants to detect the antibodies of these variants. Moreover, the immunological characteristics of the HIV-1 variants of the invention are disclosed.",8,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6342355,29-Jan-02,2002,1,29,Probe-based analysis of heterozygous mutations using two-color labelling,"The invention provides methods of analyzing a nucleic acid in a target sample for variant alleles. In such methods, a first-labelled control sample and a second-labelled target sample are hybridized to at least one set of probes. The control sample comprises a homozygous reference allele. The target sample comprises the homozygous reference allele, or variant alleles differing from the reference allele at a locus, or one variant allele differing from the reference allele at the locus and one reference allele. The probes in the probe set span the locus and are complementary to the reference allele. After hybridization the intensity of first and second label bound to each probe in the set is measured. This information is then used to indicate the presence of one variant allele and one reference allele, or the presence of two variant alleles in the target sample.",20,The United States of America as represented by the Department of Health & Human Services,"Affymetrix, Inc.",,,,,,,,,,2,Biotechnology,,,,,,C12Q/6827
6342390,29-Jan-02,2002,1,29,Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy,"A composition for delivering at least one DNA sequence encoding a desired protein or polypeptide (such as a therapeutic agent) to a cell. The composition comprises an adeno-associated virus rep protein (or a nucleic acid sequence encoding an adeno-associated virus rep protein) and a genetic construct including at least one DNA sequence encoding a protein or polypeptide or genetic transcript of interest and a promoter controlling the at least one DNA sequence. The genetic construct also includes a first adeno-associated virus ITR or protein or derivative thereof and a second adeno-associated virus ITR or a portion or derivative thereof. The first and second adeno-associated virus ITRs or portions or derivatives thereof flank the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest and the promoter controlling the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest. Such a composition provides for integration of genetic material at a specific locus in the human chromosome, while minimizing the possibility of inadvertent inactivation of host genes and minimizing the possibility of viral contamination.",18,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
6342392,29-Jan-02,2002,1,29,Nucleotide and deduced amino acid sequences of tumor gene Int6,"The present invention discloses the isolation of the human and murine wild-type Int6 gene and the cDNAs corresponding to these genes. The invention further describes the use of reagents derived from the nucleic acid and amino acid sequences of the Int6 gene in diagnostic methods, immunotherapy, gene therapy and as vaccines",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/82
6345112,5-Feb-02,2002,2,5,Method for segmenting medical images and detecting surface anomalies in anatomical structures,"A region growing method segments three-dimensional image data of an anatomical structure using a tortuous path length limit to constrain voxel growth. The path length limit constrains the number of successive generations of voxel growth from a seed point to prevent leakage of voxels outside the boundary of the anatomical structure. Once segmented, a process for detecting surface anomalies performs a curvature analysis on a computer model of the surface of the structure. This process detects surface anomalies automatically by traversing the vertices in the surface model, computing partial derivatives of the surface at the vertices, and computing curvature characteristics from the partial derivatives. To identify possible anomalies, the process compares the curvature characteristics with predetermined curvature characteristics of anomalies and classifies the vertices. The process further refines potential anomalies by segmenting neighboring vertices that are classified as being part of an anomaly using curvature characteristics. Finally, the process colorizes the anomalies and computes a camera position and direction for each one to assist the user in viewing 2D renderings of the computer model.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/0012
6348581,19-Feb-02,2002,2,19,High affinity humanized anti-TAG-72 monoclonalantibodies,"Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.",6,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
6353019,5-Mar-02,2002,3,5,"Macrocyclic lactones, compositions, and methods of use","The present invention provides compound of the formula: wherein R1 and R2 are the same or different and are independently H, C1-C6 straight-chain or branched saturated or unsaturated alkyl, aryl, R6CH2&#8212;, R6CO&#8212;, or R6SO2&#8212;, wherein R6 is H, C1-C6 straight-chain or branched saturated or unsaturated alkyl, or aryl; R3 is H, C1&#8594;C6 straight-chain or branched-chain saturated alkyl, aryl, an oxime, or an oxime methyl ether; at least one aromatic ring position is optionally substituted with a substituent selected from the group consisting of halo, nitro, amino, hydroxyl, thio, acyl, C1-C6 alkyl, and cyano; and Z is a contiguous linker comprising a chain of 7-10 atoms (including heteroatoms) which atoms, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR1 and ending with the carbon directly attached to the alkyl oxygen of the lactone, which carbons are covalently bonded to either end of linker Z, integrally form a 12-15 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof.The present invention further provides a pharmaceutical composition, and a method of preventing or treating cancer, using at least one compound of the present invention, optionally in conjunction with an additional compound other than a compound of the present invention.",21,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/00
6353097,5-Mar-02,2002,3,5,Nucleic acids encoding signal transduction inhibitors of allergic reactions,"The present invention provides an isolated polypeptide consisting of amino acids 1-66 of the human tyrosine kinase, Lyn A, in a pharmaceutically acceptable carrier and an isolated polypeptide consisting of amino acids 1-45 of the human tyrosine kinase, Lyn B, in a pharmaceutically acceptable carrier. The present invention also provides isolated nucleic acids encoding the above-described amino acid sequences, as well as vectors comprising the nucleic acids and cells comprising the vectors. The present invention further provides a method of treating or preventing an allergic disorder in a subject, comprising administering any of the above nucleic acids to a cell of the subject under conditions whereby the nucleic acid is expressed in the subject's cells, thereby treating the allergic disorder. Additionally provided in this invention is a fusion protein comprising either a polypeptide consisting of amino acids 1-66 of the human tyrosine kinase, Lyn A or a polypeptide consisting of amino acids 1-45 of the human tyrosine kinase, Lyn B and a ligand which binds to and is internalized by cells which express a high affinity receptor for IgE on the surface. A method of treating or preventing an allergic disorder in a subject is also provided, comprising administering an effective amount of the above fusion protein to a cell of the subject, whereby the fusion protein treats the subject's allergic disorder.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
6355610,12-Mar-02,2002,3,12,Inhibitors of formation of protease resistant prion protein,"Peptides are disclosed that inhibit the conversion of protease sensitive prion protein (PrPsen) to the protease resistant isoform (PrPres). These peptides comprise discrete fragments of prion proteins, and are shown to inhibit the in vitro conversion of PrPsen to PrPres in a cell-free system. Numerous peptides are disclosed that include at least two amino acid residues from the highly amyloidogenic region P113-120 of the PrP protein. None of these peptides conferred protease-resistance to the PrPsen molecules. The presence of residues 119 and 120 from the highly hydrophobic sequence AGAAAAGA (position 113 to 120) produced a particular inhibitory effect. The inhibition occurred with a high degree of specificity (e.g. with an IC50 of less than about 1000 &mgr;M).",33,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
6358736,19-Mar-02,2002,3,19,Method for increasing the antigen presenting ability of leukemia cells,The present invention relates to methods of increasing the antigen presenting ability of leukemia cells by contacting them with an agent which increases the intracellular calcium level. Methods of treating leukemia are also disclosed.,31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Pharmaceuticals,,,,,G06T/001
6361968,26-Mar-02,2002,3,26,Extension of a protein-protein interaction surface to inactive the function of a cellular protein,"Acidic amino acid extensions to multimeric proteins, particularly nucleic acid (e.g., DNA or RNA) binding proteins, provide novel acidically modified proteins which can inhibit the function of cellular proteins, thereby regulating and controlling cell growth. The acidically modified nucleic acid binding proteins are engineered to contain a plurality of acidic amino acids appended to the proteins, generally as extensions of the multimerization or dimerization domain at the amino terminus, and can replace the basic region DNA binding domain of a DNA binding protein. The acidically extended nucleic acid binding proteins act as potent dominant negatives which were demonstrated to inhibit the activation of endogenous transactivators, such as AP1. The invention provides novel methods to create such acidically modified DNA binding proteins which can specifically and stably heterodimerize with cellular regulatory proteins and control cell growth. Suitable nucleic acid binding proteins for acidic extensions include members of transcription regulatory protein families, e.g., bZIP and HLH proteins, having characteristic leucine zipper motifs and helix-loop-helix motifs, respectively. The amino terminal extensions of the basic regions of acidically modified nucleic acid binding proteins are comprised of a sequence of amino acid residues, all or some of which are acidic in nature, and produce robust dominant negatives to the native counterpart proteins in the cell. The acidic amino terminal extension affords a unique protein-protein interaction surface and allows stable multimerization or dimerization between a native protein and the acidically extended protein, thereby controlling, via inhibition or inactivation, the functions of cellular protein products of diverse species, including plants, animals, microorganisms, and viruses.",69,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/11
6361991,26-Mar-02,2002,3,26,Targeting gene expression to living tissue using jet injection,"The present invention provides a method of targeting transient gene expression and stable gene expression from the exogenous administration of a DNA sequence, which sequence is less than a complete genome, wherein said DNA sequence encodes RNA and protein, or RNA only, to differentiate tissue of living organisms wherein said DNA sequence through a jet injector technique, and said DNA sequence of less than a complete genome is expressed in a living organism. The present invention further provides a flexible multi-nozzle injector device with a wide surface area to allow molding of the injector nozzle to the surface contours of the tissue. Another aspect of the present invention provides an injection device having a long nozzle for injection of DNA deep into the host tissue. Also, in a further aspect the present invention provides an injector device modified to be used with and/or inject through an endoscopic device.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/89
6361992,26-Mar-02,2002,3,26,Thyroid stimulating hormone superagonists,"The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the &agr;-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the &bgr;-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone. The invention is also directed to a method of constructing superactive nonchimeric analogs of human hormones comprising comparing the amino acid sequence of a more active homolog from another species to the human hormone, and selecting superactive analogs from the substituted human hormones. The invention is also directed to nucleic acids encoding the modified human glycoprotein hormones, vectors containing those nucleic acids, and host cells containing those vectors.",60,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/59
6362160,26-Mar-02,2002,3,26,Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases,"Immunophilin-binding agents inhibit the phosphatase calcineurin, leading to the increased phosphorylation of certain brain proteins, including nitric oxide synthase. The increased levels of phosphorylation of nitric oxide synthase inhibits the enzymatic production of nitric oxide. Thus the neurotoxic effects of glutamate, which are ordinarily the result of vascular strokes and other neurodegenerative diseases, are minimized, because the neurotoxic effects are at least partially mediated by nitric oxide. Thus immunophilin-binding drugs can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease.",18,The Johns Hopkins University School of Medicine,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/13
6362218,26-Mar-02,2002,3,26,Brefeldin A derivatives,Cytotoxic Michael addition derivatives of brefeldin A are described. Oxidation of thiol addition products of brefeldin A provides the corresponding sulfoxides and sulfones. The sulfoxides exhibited more cytotoxic activity than the corresponding sulfides and sulfones in a variety of human cancer cell lines. Pharmaceutical formulations of the disclosed cytotoxic derivatives are also described.,8,Purdue Research Foundation,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/00
6362317,26-Mar-02,2002,3,26,"Anti-&ggr;-H2A antibody, fusion proteins thereof and method and kit for determining DNA double-stranded breaks",The present invention provides an isolated or purified antibody or antigenically-reactive fragment thereof that specifically binds to a C-terminal phosphorylated serine in an H2A histone protein and a product comprising the same. The present invention further provides fusion proteins comprising the isolated or purified antibody or antigenically-reactive fragment thereof. Also provided by the present invention are a method and a kit for determining double-stranded breaks in DNA. The method comprises contacting a sample comprising H2A histone proteins with the isolated or purified antibody or antigenically-reactive fragment thereof and detecting binding of the antibody or fragment thereof to an H2A histone protein in the sample. The detection of the binding of the antibody or fragment thereof to the H2A histone protein indicates the presence of a DNA double-stranded break in DNA.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/6875
6365616,2-Apr-02,2002,4,2,Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases,"The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. These methods utilize specifically-defined methimazole derivatives and tautomeric cyclic thione compounds, as well as pharmaceutical compositions containing those compounds. These compounds and compositions have been found to be at least as effective as methimazole in terms of pharmaceutical activity, while having less of an adverse affect on thyroid function. They are also more soluble in conventional pharmaceutical vehicles than methimazole. An assay for screening the activity of compounds useful against autoimmune diseases (ability to suppress expression of MHC Class I and II molecules) is also taught.",44,"Sentron Medical, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,C07D/92
6365712,2-Apr-02,2002,4,2,Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 &agr; subunit,"Isolated proteins comprising the T-cell surface antigen CD97 &agr; are provided. Compositions and methods for making and detecting CD97 &agr; are also provided. Further, the invention provides diagnostic and therapeutic methods and compositions for medical conditions involving CD97.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/2896
6368828,9-Apr-02,2002,4,9,Attenuated and dominant negative variant cDNAs of Stat6: Stat6b and Stat6c,"The present invention provides an isolated nucleic acid encoding the polypeptide Stat6b, having an amino acid sequence of Stat6 wherein a deletion in the nucleic acid is present, encompassing the last base pair of codon 39 of Stat6 and continuing through to and including codon 86 of Stat6 and an isolated polypeptide, Stat6b, having an amino acid sequence of Stat6 wherein amino acids 39-86 are deleted at the amino terminus. Also provided is an isolated nucleic acid encoding the polypeptide Stat6c, having an amino acid sequence of Stat6 wherein amino acids 537-564 are deleted and an isolated polypeptide, Stat6c, having an amino acid sequence of Stat6 wherein amino acids 537-564 are deleted. Methods of producing the polypeptide Stat6b and polypeptide Stat6c are also provided, comprising culturing cells comprising nucleic acid encoding the polypeptide Stat6b or the polypeptide Stat6c under conditions whereby the polypeptide Stat6b or the polypeptide Stat6c is produced.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4705
6369235,9-Apr-02,2002,4,9,"Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection","The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside inhibitors of RT. In preferred embodiments, the present invention provides a novel class of substituted benzimidazoles, effective in the inhibition of human immunodeficiency virus (HIV) RT.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/06
6372430,16-Apr-02,2002,4,16,Nucleic acids for detecting Aspergillus species and other filamentous fungi,"Nucleic acids for detecting Aspergillus species and other filamentous fungi are provided. Unique internal transcribed space 2 coding regions permit the development of nucleic acid probes specific for five different species of Aspergillus, three species of Fusarium, four species of Mucor, two species of Penecillium, five species of Rhizopus, one species of Rhizomucor, as well as probes for Absidia corymbifer, Cunninghamella elagans, Pseudallescheria boydii, and Sporothrix schenkii. Methods are disclosed for the species-specific detection and diagnosis of infection by Aspergillus, Fusarium, Mucor, Penecillium, Rhizomucor, absidia, Cunninghaemella, Pseudallescheria or Sporthrix in a subject. Furthermore, genus-specific probes are also provided for Aspergillus, Fusarium and Mucor, in addition to an all-fungus nucleic acid probe.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
6376521,23-Apr-02,2002,4,23,A3 adenosine receptor antagonists,"Disclosed are pyridine and dihydropyridine derivatives, pharmaceutical compositions comprising one or more of these derivatives, and a method of selectively blocking an A3 adenosine receptor of a mammal by the use of one or more of these derivatives. An example of the pyridine derivative is of the formula (I): wherein R2 is ethyl, R3 is ethylsulfanyl; R4 is ethyl, propyl, or hydroxypropyl; R5 is ethyl, propyl, fluoroethyl, or fluoropropyl; and R6 is phenyl or fluorophenyl. The derivatives of the present invention can be used for inhibiting binding of ligands to an adenosine receptor. The derivatives also can be used for characterizing an adenosine receptor.",40,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/80
6376659,23-Apr-02,2002,4,23,Nucleic acids encoding a novel neutrophil chemotactic factor,"An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.",6,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/5421
6379660,30-Apr-02,2002,4,30,"Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same","A polymeric composition capable of releasing nitric oxide under physiological conditions which includes a biopolymer, such as a peptide, polypeptide, protein, oligonucleotide or nucleic acid, to which is bound a nitric oxide-releasing N2O2&#8722; functional group; pharmaceutical compositions comprising the polymeric composition; and methods of treating biological disorders in which dosage with nitric oxide is therapeutic.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/655
6379885,30-Apr-02,2002,4,30,"Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines","The invention relates to the coat proteins VP1 and VP2 of the human parvovirus B19 and virus-like particles consisting of VP2 or of VP1 and VP2. The invention further comprises genetic information in the form of recombinant expression vectors which contain the genes coding for said proteins, and organisms which through genetic manipulation using such vectors have acquired the ability to produce such proteins and/or particles. The invention further comprises uses of such proteins and virus-like particles for diagnostics or vaccination.",3,Rijksuniversiteit te Leiden,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6379891,30-Apr-02,2002,4,30,Method of detecting HEV infection,"Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.",5,The United States of America as represented by the Department of Health and Human Services,"Genelabs Technologies, Inc.,",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/005
6379906,30-Apr-02,2002,4,30,Compositions and methods for detecting adult Taenia solium,"Compositions and methods for the detection of adult Taenia solium and the diagnosis and treatment of T. solium infection are described. The compositions contain one or more adult T. solium polypeptides. The polypeptides are useful as diagnostic agents for the detection of adult tapeworm infection. More preferably, the polypeptides are T. solium glycoprotein antigens referred to herein as T. solium excretory/secretory (TS/ES) polypeptides. The most preferred TS/ES polypeptide has a molecular weight of approximately 33 kDa, 38 kDa, or 42 kDa as determined by SDS-PAGE analysis.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/43554
6379973,30-Apr-02,2002,4,30,Chromatographic separation apparatus and method,A fractionation apparatus comprises two channels coupled through a semipermeable membrane. A time and position dependent concentration of precipitation reagent is produced in one of the channels. Sample entities such as macromolecules or cells introduced into this channel are eluted therefrom at different times depending on their solubility or mobility in the presence of the precipitation reagent.,28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0005
6383746,7-May-02,2002,5,7,Functional promoter for CCR5,A functional promoter for the chemokine receptor CCR5 is provided. The invention provides a nucleic acid sequence for the promoter and methods of reducing inflammation and susceptibility to HIV infection by suppressing the activity of the promoter.,30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/7158
6383761,7-May-02,2002,5,7,Methods and compositions for identifying modulators of G-protein-coupled receptors,The present invention provides methods and compositions that can be used to identify modulators of G-protein-coupled receptors.,78,The Regents of the University of California,National Institutes of Health,,,,,,,,,,2,Biotechnology,,,,,,C07K/4722
6384189,7-May-02,2002,5,7,Compositions for stimulating TGF-&bgr; activity,"The invention provides a method of stimulating TGF-&bgr; activity, comprising contacting latent TGF-&bgr; with an amount of an activating peptide from TSP effective to convert latent TGF-&bgr; to active TGF-&bgr;. Also provided is a method of inhibiting the stimulation of TGF-&bgr; activity, comprising contacting latent TGF-&bgr; with an amount of an inhibiting peptide from TSP effective to inhibit conversion of latent of TGF-&bgr; to active TGF-&bgr;. The invention also provides a method of enhancing wound healing, comprising the step of administering to the wound site an amount of an activating peptide from TSP effective to convert latent TGF-&bgr; to active TGF-&bgr;, the activation of TGF-&bgr; resulting in enhanced wound healing. A method of preventing excessive fibrosis stimulated by TGF-&bgr; in pathology is also provided, comprising administering to a site of potential fibrosis an amount of inhibiting peptide from TSP effective to inhibit conversion of latent TGF-&bgr; to active TGF-&bgr;, resulting in reduced fibrosis. The invention also provides a method of blocking TGF-&bgr;-mediated inhibition of endothelial cell proliferation comprising contacting the endothelial cells with an inhibiting peptide effective to inhibit conversion of latent TGF-&bgr; to active TGF-&bgr;, resulting in proliferation of endothelial cells.",18,,,,,,,,,,,,,Biotechnology,Biotechnology,,,,,C07K/78
6384206,7-May-02,2002,5,7,Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis,The nucleotide and deduced amino acid sequences of the four variable domains of the major outer membrane proteins of the 15 serovars of Chlamydia trachomatis are disclosed together with sequence and immunogenic analysis of these domains.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/295
6384601,7-May-02,2002,5,7,Local magnetization spoiling using a gradient insert for reducing the field of view in magnetic resonance imaging,"A method, and related apparatus, for suppressing the magnetic resonance signal to an experimentally adjustable depth by applying a spatially inhomogeneous field between the slice-select pulse and the data acquisition. Eliminating the signal from near surface regions allows one to shrink the field of view of an image without introducing aliasing artifacts, thereby improving the image's resolution or decreasing imaging time. Experimental tests on a phantom and a human subject indicate that the depth of signal suppression may be continuously varied to depths of over 80 millimeters with modest requirements on power supplies, pulse sequences, and materials.",10,The United States of America as represented by the Secretary of Department of Health & Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/4838
6387389,14-May-02,2002,5,14,Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use,"The present invention provides sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines, pharmaceutical compositions comprising the same, and a method of using such sustained-release derivatives to bind the dopamine transporter to achieve a desired effect, such as antagonism of dopamine reuptake inhibitors, such as cocaine, or dopamine releasers or norepinephrine and/or serotonin reuptake inhibitors, such as methamphetamine.",34,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/088
6387662,14-May-02,2002,5,14,Synthesis and purification of hepatitis C virus-like particles,"Production of enveloped RNA virus-like particles intracellularly in vitro in insect cells using a recombinant baculovirus vector containing a cDNA coding for viral structural proteins is disclosed. In vitro production and purification of hepatitis C virus (HCV)-like particles containing HCV core protein, E1 protein and E2 protein is disclosed. Production of antibodies in vivo to the purified HCV-like particles is disclosed.",11,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6391559,21-May-02,2002,5,21,"Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly",Methods of detecting and quantifying genomic nucliec acid molecule sequences are provided using the simultaneous amplification of a plurality of discrete nanoliter-sized samples. A miniaturized closed assembly is also provided for carrying out amplification of a nucleic acid molecule by polymerase chain reaction in multiple nanoliter-sized samples. Methods of filling miniaturized sample chambers are also provided as are methods for determining the number of template molecules in a sample by conducting replicate nucleic acid sequence amplification reactions on a set of terminally diluted samples and counting the number of positive amplification reactions. The methods can be used to detect a single starting nucleic acid target molecule.,22,Cytonix Corporation,,,,,,,,,,,1,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
6391642,21-May-02,2002,5,21,Transformation-associated recombination cloning,"The invention is directed to a method of making a yeast artificial chromosome (YAC) comprising introducing into yeast cells a population of nucleic acids and a vector, wherein the vector comprises a yeast centromere, a selectable marker, a yeast telomere, and a sequence which can recombine with a region of a nucleic acid within the population of nucleic acids, whereby in vivo recombination makes the YAC. The invention is also directed to a method of making a YAC using two vectors and a method of making a circular YAC. The invention is also directed toward methods of making YACs with a selected nucleic acid insert from a mixed population of nucleic acids using transformation-associated recombination. The invention is further directed toward a method of cloning a selected nucleic acid from a population of nucleic acids into a vector comprising introducing into yeast cells a population of nucleic acids and the vector, wherein the vector comprises a specific sequence which can recombine with a region of the selected nucleic acid within the population of nucleic acids and a non-specific sequence which can recombine with the selected nucleic acid within the population of nucleic acids; whereby in vivo recombination makes a clone of the vector selected nucleic within the vector. The invention is also directed toward the products made by, and the vectors and reagents used in these methods. The invention is also directed toward a method of TAR cloning in E. coli.",120,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/81
6391651,21-May-02,2002,5,21,Materials and methods for detection of insulin dependent diabetes,"The method and compositions of this invention provide an effective and reliable substitute for the currently employed ICA assay for diabetes. By providing a method for detecting autoantibodies to both GAD65 and IA-2 auto-antigens, the method provides a chemical assay which has improved reliability. In addition, these antigens may be employed in therapeutic regimens aimed at achieving immune tolerance and therefore amelioration of the clinical condition.",11,The United States of America as represented by the Secretary of the Department of Health & Human Services,University of Florida,,,,,,,,,,2,Biotechnology,,,,,,C07K/4713
6392026,21-May-02,2002,5,21,Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins,"The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
6395276,28-May-02,2002,5,28,Immunotoxins directed against malignant cells,"The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a Rana pipiens protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.",8,"Immunomedics, Inc.",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/463
6395495,28-May-02,2002,5,28,Methods and kits for detecting antibodies against an HIV variant,"The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.",14,Institut Pasteur,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
6395900,28-May-02,2002,5,28,Methods of O-demethylation and N-deprotection,"The present invention provides a method for N-deprotecting an opioid compound, a method for N-deprotecting and O-demethylating an opioid compound, a method for O-demethylating an opioid compound, and a method for O-demethylating a nonpeptidic delta agonist compound or an opioid compound having a tertiary amide with no significant reaction at amide groups.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/02
6399294,4-Jun-02,2002,6,4,Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens,"An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.",11,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6401520,11-Jun-02,2002,6,11,Dust detector tube,A personal sampling method and apparatus for real time respirable dust dosimetry for dust exposure assessment is provided to aid in assuring the respiratory health of workers. An embodiment uses a low flow-rate gas sampling pump for differential pressure measurements across a glass fiber collection filter in a disposable detector tube (12) or dust detecting device coupled to the pump inlet. The dust detecting device includes an elongated tubular element (12) having the filter (30) positioned between proximal and distal ends of the tube (12) for trapping dust mass. A pressure transducer (16) at the proximal end (36) measures the pressure from the flow of gas. The pump draws the flow of gas through the dust detecting device from the distal end (38) towards the proximal end (36) trapping the dust mass at the filter (30). A differential pressure across the filter (30) determined using the pressure from the flow of the gas in the proximal end (36) of the tubular element measured by the pressure transducer (16) is indicative of cumulative dust mass trapped at the filter (30).,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0618
6403100,11-Jun-02,2002,6,11,Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated,This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by eliminating or by downregulating the expression of the &agr;-crystallin heat shock protein gene (&#8220;acr gene&#8221;). The invention provides for vaccines and methods of vaccinating mammals for protection against Mycobacterium sp. that cause tuberculosis.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12R/32
6403300,11-Jun-02,2002,6,11,Monoclonal antibodies for detection of friend murine leukemia virus,"The present invention relates to Friend murine leukemia virus (F-MuLV) specific monoclonal antibodies, or binding fragments thereof, specific for an antigenic determinant of a gp85 envelope precursor protein characteristic of a methanol-fixed F-MuLV infected cell. The invention also relates to hybridomas resulting from the fusion of myeloma cells and spleen cells, which hybridomas produce a Friend murine leukemia virus (F-MuLV) specific monoclonal antibody specific for an antigenic determinant of a gp85 envelope precursor protein characteristic of a methanol-fixed F-MuLV infected cell. The invention further relates to kits containing the above-described monoclonal antibodies.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56983
6403635,11-Jun-02,2002,6,11,Method of treating atherosclerosis or restenosis using microtubule stabilizing agent,"The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,,,,,A61K/337
6403769,11-Jun-02,2002,6,11,Fusion proteins that include antibody and nonantibody portions,"The high affinity which is characteristic of homodimers of IgG heavy chains is achieved, along with favorable secretion and flexibility/adaptability properties, in a fusion protein that has a nonantibody portion, comprised of an effector domain, joined to the aminoterminal end of an IgG-derived sequence consisting of a hinge:CH2:CH3 segment which lacks a CH1 domain, with a heterologous signal peptide preferably provided upstream of the nonantibody portion. Chimeric molecules of this structure can be secreted readily in stable form by mammalian cells transfected with DNA encoding the molecule, and are amenable to rapid, efficient purification to homogeneity, for example, using protein A. These molecules are effective substitutes for monoclonal antibodies in contexts such as flow cytometry, immunohistochemistry, immunoprecipitation and ELISAs. A fusion protein as described also can be used in screening for agonists and antagonists to the cognate binding partner of the nonantibody portion of the fusion protein. Moreover, chimeric molecules in which the nonantibody portion contains a growth factor domain are internalized, essentially like the natural growth factor, in contrast to the situation that generally pertains with respect to antibodies which are directed to external receptor domains.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/71
6406860,18-Jun-02,2002,6,18,Method of detecting transmissible spongiform encephalopathies,"This invention provides an improved assays for the detection of transmissable spongiform encephalopathies (TSEs) in humans and non-human mammals. The methods involve detecting the presence or absence of 14-3-3 proteins in cerebrospinal fluid from the tested organism. Elevated levels of 14-3-3 are indicative of transmissable spongiform encephalopathies, in particular Cretzfeldt-Jacob disease in humans or mad cow disease in bovines).",6,The United States of America as represented by the Department of Health and Human Services,California Institute of Technology,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/6896
6406887,18-Jun-02,2002,6,18,Compositions for diagnosing Rochalimaea henselae and Rochalmaea quintana infection,Fusion protein compositions containing the sequence of a 17 kilodalton antigenic polypeptide of Rochalimaea (SEQ ID NO:12) are disclosed for diagnosis of cat scratch disease and bacillary angiomatosis by detection of antibodies specifically binding to the polypeptide.,7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/0233
6407079,18-Jun-02,2002,6,18,Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation,Pharmaceutical compositions comprising inclusion compounds of sparingly water-soluble or water-instable drugs with &bgr;-cyclodextrin ethers or &bgr;-cyclodextrin esters and process for the preparation thereof.,35,Janssen Pharmaceutica N.V.,,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,,,,,B82Y/00
6410023,25-Jun-02,2002,6,25,Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene,"Recombinant parainfluenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C, D and/or V ORF(s) is reduced or ablated by modifying a recombinant PIV genome or antigenome, for example by introduction of a stop codon, by a mutation in an RNA editing site, by a mutation that alters the amino acid specified by an initiation codon, or by a frame shift mutation in the targeted ORF(s). Alternatively, the C, D and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby partially or entirely non-functional or to disrupt protein expression altogether. C, D and/or V ORF(s) deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These deletion and knock out mutations changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in viral growth characteristics, attenuation, plaque size, and/or a change in cytopathogenicity, among other novel phenotypes. A variety of additional mutations and nucleotide modifications are provided within the C, D and/or V ORF(s) deletion or ablation mutant PIV of the invention to yield desired phenotypic and structural effects.",53,United States of America,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/00
6410537,25-Jun-02,2002,6,25,Compositions having neuroprotective and analgesic activity,"Compounds of the formula: wherein R1 and R2 are alkyl of 1-8 carbons have been shown to have both neuroprotective and analgesic activities. The compounds of the invention may be used in treatment of conditions that would normally result in neuronal damage, including those arising on account of cerebral ischemia/hypoxia or increase in intracranial pressure such as neoplasms, stroke, meningitis or trauma and for treatment of pain. Compositions of the invention can also be useful for treatment of toxin-related damage such as drug over-dose or exposure to toxins in the environment.",8,The United States of America as represented by the Secretary of the Army,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4965
6410747,25-Jun-02,2002,6,25,Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias,A method for preventing or treating cognitive impairments associated with aging or Alzheimer's disease which comprises treating a patient at risk for having the cognitive impairment with an effective amount of a highly selective butyrylcholinesterase inhibitor.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/40
6413544,2-Jul-02,2002,7,2,Liposome complexes for increased systemic delivery,"Highly efficient cationic liposomes have been developed as an improved delivery system for biologically active reagents. A novel structure, the sandwich liposome, is formed and comprises one or more biologically active agents sandwiched (and thus sequestered) between the lipid bilayers. This structure protects the incoming agent and accounts for the high efficiency of in vivo delivery and for the broad tissue distribution of the sandwich liposome complexes.These novel liposomes are also highly efficient carriers of nucleic acids. By using extruded DOTAP:cholesterol liposomes to form complexes with DNA encoding specific proteins, expression has been improved dramatically. Highest expression was achieved in the lung, while increased expression was detected in several organs and tissues.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,Biotechnology,,,,B82Y/00
6414132,2-Jul-02,2002,7,2,Method of eliminating inhibitory/instability regions of mRNA,A method of locating an inhibitory/instability sequence or sequences within the coding region of an mRNA and modifying the gene encoding that mRNA to remove these inhibitory/instability sequences by making clustered nucleotide substitutions without altering the coding capacity of the gene is disclosed. Constructs containing these mutated genes and host cells containing these constructs are also disclosed. The method and constructs are exemplified by the mutation of a Human Immunodeficiency Virus-1 Rev-dependent gag gene to a Rev-independent gag gene. Constructs useful in locating inhibitory/instability sequences within either the coding region or the 3&#8242; untranslated region of an mRNA are also disclosed. The exemplified constructs of the invention may also be useful in HIV-1 immunotherapy and immunoprophylaxis.,27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6416957,9-Jul-02,2002,7,9,Method for modulating process mediated by farnesoid activated receptors,"Farnesyl pyrophosphate, the metabolically active form of farnesol, is a key precursor in the synthesis of cholesterol, carotenoids, steroid hormones, bile acids and other molecules involved in cellular growth and metabolism. A nuclear receptor has been identified that is transcriptionally activated by farnesol and related molecules. This novel signaling pathway can be modulated by the use of key metabolic intermediates (or analogs and/or derivatives thereof) as transcriptional regulatory signals.",24,The Salk Institute for Biological Studies,"Ligand Pharmaceuticals, Inc.",The Government of the United States of America,,,,,,,,,3,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/045
6417338,9-Jul-02,2002,7,9,Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy,"The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Micro-structural and nano-technology,Biotechnology,,,,,B82Y/00
6419639,16-Jul-02,2002,7,16,Laparoscopic SAC holder assembly,"This invention relates to a surgical device and methods for accessing and retrieving a tissue mass from a body cavity through a minimally invasive laparoscopic procedure. The device consists of a handle comprising an inner rod, which is rotatably engaged within a tubular member, and a loop adapted to hold a surgical bag. The loop comprises first and second bowed leaf elements, wherein the first bowed leaf element is attached to the inner rod and the second bowed leaf element is attached to the tubular member. The device further has a rotatable articulation, such as a hinge, joining the first and second bowed leaf elements, wherein rotation of the inner rod causes the first bowed leaf element to rotate about the articulation, such that the surgical bag may be opened and closed by rotation of the inner rod.",14,National Institute of Health,,,,,,,,,,,1,Medical technology,,,,,,A61B/00234
6420132,16-Jul-02,2002,7,16,Precision laser capture microdissection utilizing short pulse length,"Laser capture microdissection occurs where the transfer polymer film is placed on a substrate overlying visualized and selected cellular material from a sample for extraction. The transfer polymer film is focally activated (melted) with a pulse brief enough to allow the melted volume to be confined to that polymer directly irradiated. This invention uses brief pulses to reduce the thermal diffusion into surrounding non-irradiated polymer, preventing it from being heated hot enough to melt while providing sufficient heat by direct absorption in the small focal volume directly irradiated by the focused laser beam. This method can be used both in previously disclosed contact LCM, non contact LCM, using either condenser-side (or beam passes through polymer before tissue) or epi-irradiation (or laser passes through tissue before polymer). It can be used in configuration in which laser passes through tissue before polymer with and without an additional rigid substrate. In its preferred configuration it uses the inertial confinement of the surrounding unmelted thermoplastic polymer (and the overlying rigid substrate) to force expansion of the melted polymer into the underlying tissue target. Utilizing the short pulse protocol, the targeted and extracted material can have a diameter equal to or smaller than the exciting beam.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/2813
6420336,16-Jul-02,2002,7,16,Methods of using cyanovirins topically to inhibit viral infection,"The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",42,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
6420531,16-Jul-02,2002,7,16,"Epithelial cell specific growth factor, keratinocyte growth factor (KGF)","Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",44,The United States as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6876
6423308,23-Jul-02,2002,7,23,Treatment of Kaposi's sarcoma with IL-12,"Methods are provided for using IL-12 to treat Kaposi's sarcoma (KS), particularly AIDS-associated KS.",12,Wyeth,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/208
6423311,23-Jul-02,2002,7,23,Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment,"The present invention provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiation, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiation; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiation. The invention also provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiomimetic compound, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiomimetic compound; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiomimetic compound.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/193
6423318,23-Jul-02,2002,7,23,Hepatitis A virus vaccines,"A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.",7,The United States of America as represented by the Department of Health and Human Services,SmithKline Beecham Biologicals,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
6423513,23-Jul-02,2002,7,23,Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins,"This invention provides protease-activatable Pseudomonas exotoxin A-like (&#8220;PE-like&#8221;) proproteins. The proproteins comprise (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a modified PE translocation domain comprising an amino acid sequence sufficiently homologous to domain II of PE to effect translocation to a cell cytosol upon proteolytic cleavage, wherein the translocation domain comprises a cysteine-cysteine loop that comprises a protease activatable sequence cleavable by a protease and wherein the cysteine-cysteine loop is substantially un-activatable by furin; (3) optionally, a PE Ib-like domain comprising an amino acid sequence up to 1500 amino acids; (4) a cytotoxicity domain comprising an amino acid sequence substantially homologous to domain m of PE, the cytotoxicity domain having ADP-ribosylating activity; and (5) an endoplasmic reticulum (&#8220;ER&#8221;) retention sequence. The invention also provides methods of using these proproteins for killing target cells.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/21
6423696,23-Jul-02,2002,7,23,Inhibition of arylamine N-acetyl transferase,"The present invention is directed to a method of inhibiting arylamine N-acetyl transferase (NAT) from acetylating an arylamine group in a substrate. The method comprises contacting NAT with an inhibitor that interacts with NAT and thereby inhibits NAT from acetylating said arylamine group in said substrate. Preferably, NAT is in vivo, such as in a mammal, and the substrate is a drug. Preferably, the method inhibits acetylation of arylamine substrates which are inhaled, ingested, or absorbed through the skin, wherein acetylation of the substrate predisposes a mammal to a biological disorder or a disease. The present invention also provides a composition comprising a compound comprising an arylamine group and an inhibitor, wherein the inhibitor interacts with NAT to inhibit NAT from acetylating the arylamine group in the compound.",36,"The United States of America, as represented by the Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/606
6423835,23-Jul-02,2002,7,23,"Nucleotide deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins","The present invention relates to novel polypeptides comprising a unique &#8220;chlamydial-specific&#8221; primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokaryotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/295
6423836,23-Jul-02,2002,7,23,Production and use of human nm23 protein and antibodies therefor,Human nm23 DNA and protein is disclosed as well as antiodies which recognize human nm23 protein. The DNA and antibodies may be used to detect nm23 in human tumors to predict the malignancy potential of such tumors.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/12
6425864,30-Jul-02,2002,7,30,Method and apparatus for optimal imaging of the peripheral vasculature,"A system and method for optimally imaging the peripheral vasculature is disclosed which includes defining a given number of scan stations along a patient's peripheral vasculature and initially injecting a relatively small amount of contrast agent into the patient to pass a test bolus through the patient's peripheral vasculature, and thereafter tracking the test bolus through the patient and adjusting the patient on a moveable table within the MR imaging device from one scan station to a next station to determine a maximum travel time that the test bolus takes to travel through each of the given number of scan stations. Additional contrast agent is then injected into the patient to pass an exam bolus through the patient's peripheral vasculature, and using the test bolus travel time, MR data can be acquired from each scan station while it is known that the exam bolus is present in that station to optimize image resolution. Initially, central k-space data is acquired for each scan station, and if time permits, the higher spatial frequency k-space data can be acquired. Otherwise, once the central k-space data is acquired for each station, the patient table is adjusted to the scan stations that require additional data acquisition. Similarly, if there is time remaining after all MR data is acquired for a particular scan station, the patient table can be moved to a previous scan station to acquire additional data in that station before moving to a subsequent scan station to acquire the central k-space data when the exam bolus arrives in that particular scan station.",29,General Electric Company,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Measurement,,,,,,G01R/563
6426070,30-Jul-02,2002,7,30,Methods for inactivating enveloped RNA virus particles and compositions for use therewith,"A method for inactivating a virion of an enveloped RNA virus comprising contacting the virion with an eosinophil-derived ribonuclease, such as eosinophil-derived neurotoxin (EDN) or eosinophil cationic protein (ECP). The invention also provides methods for treating a subject infected by an enveloped RNA virus and for preventing infection by an enveloped RNA virus comprising administering an effective amount of an eosinophil-derived ribonuclease, such as EDN or ECP. The invention also provides a composition comprising an effective amount of an eosinophil-derived ribonuclease and an acceptable carrier.",15,The United States as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/465
6426073,30-Jul-02,2002,7,30,Variant of LAV viruses,"The present invention relates to a novel human immunodeficiency virus (HIV) capable of inducing lymphadenopathies (LAS) and acquired immune deficiency syndromes (AIDS) in patients which has been designated the lymphadenopathy associated virus strain MAL (LAVMAL). Although the overall genomic organization of LAVMAL is similar to other known HIV-1 isolates such as LAVBRU and HTLV-III, nevertheless, this virus also displays considerable genotypic and phenotypic diversity as compared to these isolates. A proviral molecular clone of the virus was obtained and characterized. The complete nucleotide sequence of this clone was ascertained and putative regulatory regions (e.g., U3, R, U5,), regulatory elements (e.g., the TATA box, AATAAA polyadenylation signal, primer binding site), and open reading frames (e.g., Gag, Pol, Env, Vif, Vpr, Tat, Rev, Nef) identified. Of particular interest are unique polypeptides derived from the viral envelope. The claimed invention is directed toward isolated LAVMAL Env polypeptides consisting of 5-150 amino acids wherein said peptides contain a LAVMAL-specific epitope. These peptides will prove useful, inter alia, as diagnostic reagents and in the generation of immunological reagents for the detection of the virus.",5,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/702
6426075,30-Jul-02,2002,7,30,Protease-activatable pseudomonas exotoxin A-like proproteins,"This invention provides protease-activatable Pseudomonas exotoxin A-like (&#8220;PE-like&#8221;) proproteins. The proproteins comprise (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a modified PE translocation domain comprising an amino acid sequence sufficiently homologous to domain II of PE to effect translocation to a cell cytosol upon proteolytic cleavage, wherein the translocation domain comprises a cysteine-cysteine loop that comprises a protease activatable sequence cleavable by a protease and wherein the cysteine-cysteine loop is substantially un-activatable by furin; (3) optionally, a PE Ib-like domain comprising an amino acid sequence up to 1500 amino acids; (4) a cytotoxicity domain comprising an amino acid sequence substantially homologous to domain III of PE, the cytotoxicity domain having ADP-ribosylating activity; and (5) an endoplasmic reticulum (&#8220;ER&#8221;) retention sequence. The invention also provides methods of using these proproteins for killing target cells.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/21
6426198,30-Jul-02,2002,7,30,Genes for Niemann-Pick type C disease,"A gene for type C Niemann-Pick disease (NP-C) is disclosed, along with the amino acid sequence of the encoded peptide. Applications which are made possible by the present invention include detection of NP-C carriers and diagnosis of NP-C sufferers. The murine ortholog of the human gene is also disclosed.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
6428788,6-Aug-02,2002,8,6,Compositions and methods for specifically targeting tumors,The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule comprising an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule in the presence of an interleukin-4 receptor (IL-4R) blocker.,53,Penn State University,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/2866
6428790,6-Aug-02,2002,8,6,Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use,"The present invention provides, among other things, methods of removing virus from a sample, a composition comprising a solid support matrix to which is attached a cyanovirin, a conjugate comprising a cyanovirin coupled to at least one effector component, a composition comprising such a conjugate, methods of inhibiting prophylactically or therapeutically a viral infection of a host, and a matrix-anchored anti-cyanovirin antibody.",47,The United States of America as represented by the Secretary Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Pharmaceuticals,Biotechnology,,,,A61K/164
6428952,6-Aug-02,2002,8,6,Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies,"Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.",7,Institut Pasteur,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/1045
6429232,6-Aug-02,2002,8,6,Method of treating atherosclerosis or restenosis using microtubule stabilizing agent,"The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.",40,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,,,,,A61K/337
6432408,13-Aug-02,2002,8,13,Swine hepatitis E virus and uses thereof,"The present invention discloses the isolation and chaterization of a novel swine hepatitis E virus and the use of the virus, the proteins and its nucleic acid sequence as diagnostic reagents and vaccines.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6436057,20-Aug-02,2002,8,20,Method and apparatus for cough sound analysis,"A fast, simple, and reliable method and apparatus for recording cough sounds for diagnosing pulmonary disorders and diseases is provided. This method uses signal analysis techniques to extract quantitative information from recorded cough sound pressure waves. The generated data can be used to diagnose pulmonary disorders and diseases as well as track the effectiveness of treatment regimes over time. The method can also be used to quickly and reliably screen individuals at risk of pulmonary disorders and diseases. A system according to one embodiment includes a mouthpiece connected to the proximal end of a tube. The distal end of the tube is connected to a flexible tube. A microphone is attached to the tube between the distal and proximal ends therof for recording sound pressure waves. A calculated cough sound index (CSI) can be used in diagnostic applications.",26,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Medical technology,,,,,,A61B/0806
6436945,20-Aug-02,2002,8,20,Substituted O6-benzyl-8-aza-guanines,"The present invention provides AGT inactivating compounds, for example, substituted O6-benzyl-8-aza-guanines of the formula wherein R, for example, is pivaloyloxymethyl as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O6-position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O6-position of guanine.",22,The United States of America as represented by the of Health and Human Services,The Penn State Research Foundation,Arch Development Corporation,,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/47
6441156,27-Aug-02,2002,8,27,Calcium channel compositions and methods of use thereof,"The present invention relates to calcium channel compositions and methods of making and using same. In particular, the invention relates to calcium channel alpha2delta (&agr;2&dgr;) subunits and nucleic acid sequences encoding them. These compositions are useful in methods for identifying compounds that modulate the activity of calcium channels and for identifying compounds as therapeutic for disease.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
6444421,3-Sep-02,2002,9,3,Methods for detecting intermolecular interactions in vivo and in vitro,"Methods for assessing intermolecular interactions in vivo and in vitro are provided. Methods are provided for detecting protein-DNA interactions in vivo, in which a cell having a chimeric guide endonuclease molecule and a target nucleic acid is provided, and cleavage of the target nucleic acid by the chimeric guide endonuclease molecule is monitored. Cleavage by the chimeric guide molecule corresponds to binding of the guide domain to the target nucleic acid, or to a protein associated with the nucleic acid. The methods of the invention are adapted to cleavage of target nucleic acids, amplification of target nucleic acids, detection of target nucleic acids, screening of genomic target nucleic acid sequences for guide binding domains, and screening for modulators of chimeric guide binding domain activity. Also provided are methods for detecting interactions between other molecules, including hormones and receptors, enzymes and substrates, and the like.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/542
6447748,10-Sep-02,2002,9,10,Benzamide compounds for cancer imaging and therapy,"The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.",24,"Research Corporation Technologies, Inc.",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/79
6448245,10-Sep-02,2002,9,10,Methods of and compounds for inhibiting calpains,"A method is disclosed for inhibiting calpain by contacting calpain with one or more HIV protease inhibitors or analogs. Included are embodiments for identifying subjects at risk of suffering calpain-mediated physiological damage and administering to them the HIV protease inhibitors or analogs. Alternatively, a compound may be administered to a subject following an actual event implicating activation of calpain. Also included are methods of treating or preventing calpain-mediated physiological damage in a subject by administering to the subject a therapeutically effective amount of a pharmaceutical composition which includes at least one HIV protease inhibitor or analog. The pharmaceutical compositions can be used in the treatment of a variety of conditions or diseases implicated by or associated with calpain activation, including cardiovascular diseases.",48,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
6449603,10-Sep-02,2002,9,10,System and method for combining multiple learning agents to produce a prediction method,"System and method for improving the performance of learning agents such as neural networks, genetic algorithms and decision trees that derive prediction methods from a training set of data. In part of the method, a population of learning agents of different classes is trained on the data set, each agent producing in response a prediction method based on the agent's input representation. Feature combinations are extracted from the prediction methods produced by the learning agents. The input representations of the learning agents are then modified by including therein a feature combination extracted from another learning agent. In another part of a method, the parameter values of the learning agents are changed to improve the accuracy of the prediction method. A fitness measure is determined for each learning agent based on the prediction method the agent produces. Parameter values of a learning agent are then selected based on the agent's fitness measure. Variation is introduced into the selected parameter values, and another learning agent of the same class is defined using the varied parameter values. The learning agents are then again trained on the data set to cause a learning agent to produce a prediction method based on the derived feature combinations and varied parameter values.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06K/6229
6451530,17-Sep-02,2002,9,17,Fluorescent nucleotide analog hairpin formation for detection of nucleic acid hybridization,"This invention provides methods and compositions for the detection of nucleic acid interactions with other nucleic acids or with proteins. The methods generally utilize a nucleic acid (e.g., an oligonucleotide) that contains one or more fluorescent nucleotide analogues. The fluorescence of the nucleotide analogues is quenched (reduced) when they are incorporated into the oligonucleotide. Alteration of the normal conformation of the oligonucleotide by hybridization (e.g. to form a loop) or by protein binding reduces and/or eliminates the quench thereby causing a detectable increase in fluorescence.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6816
6451763,17-Sep-02,2002,9,17,Retinal pigmented epithelium derived neurotrophic factor and methods of use,"The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule.In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/811
6455249,24-Sep-02,2002,9,24,Method of amplifying DNA and RNA mismatch cleavage products,"Detection of probe fragment products of basepair mismatch cleavage indicate the presence and sequence of target DNA. Detection of the target is enhanced by amplification through recycling targets by maintaining an assay temperature between the melting point of the target/probe DNA duplex and that of the target/product complex, in the presence of an amplifier comprising ammonium acetate or an amine derivative (for example, diethylamine, piperidine or ammonium carbonate). Cleavage reduces the size of the duplex, and thus lowering its melting point. The amplifier releases the target from the complex, thereby permitting further catalysis of cleavage and effectively amplifying the signal to be detected.",25,National Institutes of Health,University of Maryland Baltimore,,,,,,,,,,2,Biotechnology,,,,,,C12Q/6827
6455300,24-Sep-02,2002,9,24,Method and compositions for monitoring DNA binding molecules in living cells,"The present invention provides a method of screening for a compound that binds to a selected nuclei acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nuclei acid can be directly detected when bound by fluorescently labeled compound; and directly detecting the location of fluorescence within the cell, fluorescence aggregated at the site of the nuclei acid array indicating a compound that binds to the selected nucleic acid. In particular compounds such a transcription factors can be screened. Reagents for such method are provided including a mammalian cell having a plurality of steroid receptor response elements in an array such that the response element can be directly detected when bound by fluorescently labeled steroid receptor and a chimeric protein comprising a fluorescent protein fused to a steroid receptor.",1,Han Htun,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/721
6455492,24-Sep-02,2002,9,24,Hepatitis E virus vaccine and method,Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reasing frames of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.,5,"Genelabs Technologies, Inc.",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6458527,1-Oct-02,2002,10,1,HIV immunoassays using gag polypeptides,"Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",33,Chiron Corporation,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6458532,1-Oct-02,2002,10,1,Polynucleotides encoding IMP.18p myo-inositol monophosphatase and methods of detecting said polynucleotides,Methods and compositions are provided for determining a genotype associated with increased susceptibility to manic-depressive illness. The genotype is determined using markers for a region of chromosome 18 exhibiting linkage disequilibrium with manic-depressive illness. The invention also provides for a novel myo-inositol monophosphatase protein encoded for on chromosome 18.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/16
6458562,1-Oct-02,2002,10,1,Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines,The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.,24,The United States of America as represented by the Secretary of Health and Human Services,"Novavax, Inc.",,,,,,,,,,2,Biotechnology,,,,,,C07K/005
6458590,1-Oct-02,2002,10,1,Methods and compositions for treatment of restenosis,"The present invention provides sequences capable of inhibiting osteopontin (OPN) expression. In particular, the sequences provided herein are antisense osteopontin oligonucleotide sequences. The present invention further provides methods for treating restenosis using antisense osteopontin oligonucleotide sequences. In particular, methods for treating restenosis following vascular surgery (e.g., percutaneous transluminal coronary angioplasty (PCTA) and directional coronary atherectomy (DCA)) by using antisense osteopontin oligonucleotide sequences are provided.",7,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/1136
6461676,8-Oct-02,2002,10,8,Semi-finished wood simulating product and method,"A semi-finished wood simulating product and method is disclosed. The product is manufactured by providing a substrate having at least one surface to be finished. A liquid basecoat is applied on the substrate and dried. A wood grain pattern is deposited, in liquid form, on the basecoat. Some of the pattern is transferred from the originally deposited position on the basecoat to a subsequent position. The pattern is then cured. A polymerizable protective coating is applied onto the substrate overlying the basecoat and the pattern. The protective coating seals the substrate and is adapted for accepting a colorant to be applied by an end user. The protective coating is then polymerized. Additionally, if a porous substrate is provided, a sealer is applied prior to the liquid basecoat and is then cured.",16,"Premdor, Inc.",,,,,,,,,,,1,"Surface technology, coating",Other consumer goods,,,,,B05D/061
6468524,22-Oct-02,2002,10,22,AAV4 vector and uses thereof,"The present invention relates to AAV4 vectors for methods of delivering nucleic acids to cells. Specifically, the present invention provides methods of delivering nucleic acids to specific regions and cells of the brain, particularly ependymal cells.",12,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
6468983,22-Oct-02,2002,10,22,RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies,"The present invention relates to chimeric molecules comprising an oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of RNase L (&#8220;activator-antisense complex&#8221;) which specifically cleaves the ribonucleotide portion of a telomerase enzyme. The present invention relates to methods of inhibiting telomerase enzymatic activity with activator-antisense complexes targeted to the RNA component of telomerase. The present invention further relates to methods of treating malignant neoplastic disease, wherein the malignant cells contain a telomerase activity that is necessary for the growth of the malignant cells.",29,The Cleveland Clinic Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/1137
6469156,22-Oct-02,2002,10,22,Rapid and sensitive method for detecting histoplasma capsulatum,"Oligonucleotides are provided which are useful as primers to initiate the amplification of a segment of Histoplasma capsulatum DNA that is specific to H. capsulatum, using the polymerase chain reaction. A method of detecting the presence of H. capsulatum in a sample using a nested, or two-stage, PCR assay is also provided. The outer pair of primers, for use in the first stage of the assay, are fungal-specific oligonucleotides; the inner pair of primers, for use in the second stage, are oligonucleotides specific for H. capsulatum.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
6469619,22-Oct-02,2002,10,22,Intrinsically-safe roof hazard alert module,"A light weight, self-contained, portable, intrinsically-safe warning device for providing warning to personnel of an unsafe condition is provided. This warning device is especially adapted for attachment to the roof of a mine to indicate unsupported roof conditions or other unsafe conditions. This intrinsically-safe warning device has (a) a case having side walls, a first end wall, and second end wall wherein the case has an internal cavity formed by the side walls and first and second end walls; (b) a low-voltage power supply within the case comprising one or more direct current batteries; (c) a switch in electrical contact with the low-voltage power supply to activate the module; (d) a light-emitting diode in electrical contact with the switch and the low-voltage power supply, and (e) a means to attach the module in close proximity to or in a hazard area having a potential hazard such that the light is directed towards the area from which personnel are likely to enter the hazard area, wherein the module is lightweight, portable, and intrinsically-safe; whereby, when the module is activated, the light-emitting diode emits a light to warn personnel in the area of the potential hazard and direct their attention to the potential hazard. This device is especially useful in underground mining operations in order to discourage miners from going into unsupported mine roof areas by rendering the attendant hazard more evident, directing the miner's attention to an appropriate warning message on the device, and thus avoiding the hazard beyond the device.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Civil engineering,Control,,,,,E21F/18
6472518,29-Oct-02,2002,10,29,Invasion associated genes from Neisseria meningitidis serogroup B,"Genes isolated from Neisseria memingitidis, as well as isolated nucleic acids, probes, expression cassettes, polypeptides, antibodies, immunogenic compositions, antisense nucleic acids, amplification mixtures, and new invasion deficient swains of Neisseria meningitidis are provided Methods of detecting Neisseria meningitidis and Neisseria meningitidis nucleic acids, and methods of inhibiting the invasion of mammalian cells by Neisseria meningitidis are also provided.",7,"Centers for Disease Control and Prevention, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/22
6475741,5-Nov-02,2002,11,5,Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto,"An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/5421
6475747,5-Nov-02,2002,11,5,Method for detecting Cryptosporidium parvum oocysts,"Methods for detecting parasites, such as Cryptosporidium parvum, in turbid and non-turbid samples by solubilizing molecular markers or antigens of the parasite. The molecular markers are solubilized by incubating a sample containing the parasite with a solubilization buffer and detecting the solubilized antigens by electrochemiluminescence. The solubilization buffer contains one or more detergents alone or in combination with one or more denaturing agents in a buffered solution. The methods are an improvement over existing immunofluorescence assays for C. parvum because the methods described herein are quantitative, reproducible, have high sensitivity, are not labor-intensive, require only minimal sample processing, and avoid being adversely affected by sample turbidity. In addition, by using a electrochemiluminescence assay, microscopy is not required.",28,The United States of America as represented by the Department of Health and Human Services,Centers for Disease Control and Prevention,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12Q/04
6479255,12-Nov-02,2002,11,12,Polynucleotides encoding human FRP and fragments thereof,"The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.",49,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
6479286,12-Nov-02,2002,11,12,Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells,"Methods of generating IL-3 expanded populations of monocytes and differentiating the cells into dendritic cells are provided. The methods include use of the dendritic cells to activate T-cells, in vitro and in vivo, and for ex vivo and other therapeutic methods.",53,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0639
6479465,12-Nov-02,2002,11,12,Methods of treating colitis using STAT-4 anti-sense oligonucleotides,"The present invention provides a method of treating or preventing the inflammatory response of an inflammatory bowel disease in a subject, comprising administering to the subject an amount of a STAT-4 antisense oligonucleotide effective in treating or preventing the inflammatory response of the inflammatory bowel disease.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
6483112,19-Nov-02,2002,11,19,High-throughput infrared spectroscopy,"A spectrometer includes an infrared source, a spectrally selective element, and a cell array. The cell array includes walls that define a number of cavities. The spectrometer also includes an infrared spatial detector responsive to infrared radiation travelling from the infrared source through contents of at least two of the cavities as well as through the spectrally selective element.",75,,,,,,,,,,,,,Measurement,,,,,,G01J/42
6485925,26-Nov-02,2002,11,26,Anthrax lethal factor is a MAPK kinase protease,"The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
6489167,3-Dec-02,2002,12,3,Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors,"This invention provides a Togavirus-amplified retrovirus vector and a novel method for packaging a retrovirus cassette that contains a heterologous nucleic acid, which is amplified in a packaging cell cytoplasm by a Togavirus vector. The retroviral cassette is packaged into infectious retrovirus particles by retroviral packaging cells. These retroviral particles carrying the retroviral packaging cassette are then used to infect host cells.",13,The Government of the United States as represented by the Secretary of the Department of Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6490527,3-Dec-02,2002,12,3,Method for characterization of rock strata in drilling operations,"A method and system for determining the relative strength and classification of rock strata in near real-time during drilling operations is provided for use in underground mines. Neural network technology is used to classify mine roof strata in terms of, for example, relative strength or strength index as the roof bolt hole is being drilled (i.e., in near real-time). Measurements taken while a layer of the rock strata is being drilled are used to compute the specific energy input and convert these data to suitably scaled features. A neural network is then used to classify the strength of the layer. The neural network can be trained using data of known rock strata classifications prior to using it to classify new measurements. The present system allows for detection of unsafe conditions within the rock strata being drilled, and allows appropriate warnings to be issued in near real-time so that appropriate actions can be taken.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Civil engineering,Measurement,,,,,G01V/00
6491908,10-Dec-02,2002,12,10,Selective elimination of T cells that recognize specific preselected targets,"This invention provides compositions and methods for the elimination of T cells that recognize specific preselected targets. The methods involve providing killer cells (e.g. natural killer cells or cytotoxic T lymphocytes) having a T cell receptor in which the zeta chain is joined to the antigen target of the T cell population it is desired to eliminate. Recognition of the antigen target activates the killer cell thereby inhibiting or destroying the T cell. Where the antigen target is the extracellular domain of a major histocompatibility complex, the method provides a means of mitigating graft rejection or an autoimmune response.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0636
6492165,10-Dec-02,2002,12,10,Retrovirus isolated from humans,"The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6492166,10-Dec-02,2002,12,10,Use of constitutive transport elements for host range control,"An Avian-derived retroviral vector from which the Constitutive Transport Element (CTE) has been removed and replaced with a genetic fragment from a mammalian virus in order to produce a vector that is replication competent in at least one non-native cell type without the need for a &#8220;helper&#8221; virus, and that is unlikely to recombine with endogenous mammalian viruses, making it both safe and simple to use in research and gene-therapy applications.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6495137,17-Dec-02,2002,12,17,Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains,"Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.",20,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
6497884,24-Dec-02,2002,12,24,Chimeric vaccine against tick-borne encephalitis virus,"A live, attenuated chimeric virus vaccine against tick-borne encephalitis virus comprising the preM and E structural genes of the tick-borne encephalitis Langat virus and the non-structural genes of the mosquito-borne dengue virus. The live chimeric vaccine was administered intraperitoneally and exhibited complete attenuation in mice while at the same time providing protection against subsequent challenge with the virulent parental Langat virus.",9,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6498148,24-Dec-02,2002,12,24,Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype,"The invention relates to methods for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation in tissue of an antigen-sensitized mammal host by delivering an immunostimulatory oligonucleotide to the host. In addition, methods for using the immunostimulatory oligonucleotides to boost a mammal host's immune responsiveness to a sensitizing antigen (without immunization of the host by the antigen) and shifting the host's immune responsiveness to a Th1 phenotype to achieve various therapeutic ends are provided. Kits for practicing the methods of the invention are also provided.",19,The Regents of the University of California,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/35
6500625,31-Dec-02,2002,12,31,Methods for diagnosing cancer or precancer based upon hnRNP protein expression,"The present invention is a purified and isolated epithelial protein, peptide and variants thereof whose increased presence in an epithelial cell is indicative of precancer. One epithelial protein which is an early detection marker for lung cancer was purified from two human lung cancer cell lines, NCI-H720 and NCI-H157. Using a six-step procedure, the epithelial protein was purified using a Western blot detection system under both non-reducing and reducing conditions. Purification steps included anion exchange chromatography, preparative isoelectric focusing, polymer-based C18 HPLC and analytic C4 HPLC. After an approximately 25,000 fold purification the immunostaining protein was >90% pure as judged by Coomassie blue staining after reducing SDS-PAGE. The primary epithelial protein shares some sequence homology with the heterogeneous nuclear ribonucleoprotein (hnRNP) A2. A minor co-purifying epithelial protein shares some sequence homology with the splice variant hnRNP-B1. Molecular analysis of primary normal bronchial epithelial cell cultures demonstrated low levels of epithelial protein expression, consistent with immunohistochemical staining of clinical samples, and an increased level of expression in most lung cancer cells. The epithelial protein is a marker of epithelial transformation in lung, breast, bone, ovary, prostate, kidney, melanoma and myeloma and may be casual in the process of carcinogenesis. Methods are provided for monitoring the expression of the epithelial protein, peptides and variants using molecular and immunological techniques as a screen for precancer and cancer in mammals.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4747
6500859,31-Dec-02,2002,12,31,Method for treating atherosclerosis or restenosis using microtubule stabilizing agent,"The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.",4,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,,,,,A61K/337
6500919,31-Dec-02,2002,12,31,"Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma","A melanoma associated antigen known as gp100. Furthermore, peptides derived from the antigen are described. Gp100 and its peptides can be used in vaccines for the treatment of melanoma. Another aspect of the invention is host cells capable of expressing gp100 for the gp100-derived peptides. Furthermore, tumor infiltrating lymphocytes (TIL's) specifically recognizing gp100 are described, as are vaccines with these TIL's. Also disclosed are diagnostics for the detection of melanoma and for the monitoring of vaccination.",6,IntroGene B.V.,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
6503398,7-Jan-03,2003,1,7,Chiral separation of enantiomers by high-speed countercurrent chromatography,"Preparative-scale separations of chiral compounds were achieved by high-speed countercurrent chromatography (HSCCC) using a multilayer coil planet centrifuge equipped with a 325 mL capacity column. The separations were performed by two different procedures both utilizing a set of N-(3,5-introbenzoyl)-D,L-amino acids as test samples with N-dodecanoyl-L-proline-3,5-dimethylanilide as a chiral selector (Cs). The HSCCC separations were carried out with a two-phase solvent system composed of hexane/ethyl acetate/methanol/water where the chiral selector was added to the organic stationary phase. A second procedure using pH-zone-refining CCC yielded characteristic fused rectangular peaks in which the two isomers were resolved with less than 5% of overlap.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/42
6503455,7-Jan-03,2003,1,7,"Container for dying biological samples, method of making such container, and method of using same","A container suitable for high speed centrifugation is provided with a cap carrying a microbe-impermeable filter means. The filter means permits gas flow into and out of the container but prevents microbes from entering the container. A method of making such a container is also described. A preferred embodiment is for a container that can be used as a microcentrifuge tube. A method of drying, e.g., lyophilizing, a biological sample using the container is also provided.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Handling,,,,,B01L/5021
6503501,7-Jan-03,2003,1,7,Targetable vector particles,"A vector particle (eg., a retroviral vector particle) containing a chimeric envelope includes a receptor binding region that binds to a receptor of a target cell. The receptor of the target cell is other than the amphotropic cell receptor. The receptor binding region may be a receptor binding region of a human virus. A portion of the envelope gene may be deleted and the deleted portion is replaced with another receptor binding region or ligand. Such vector particles are targetable to a desired target cell or tissue, and may be administered directly to the desired target cell or tissue as part of a gene therapy procedure, or administered directly into the patient.",12,,,,,,,,,,,,,Biotechnology,,,,,,C07K/005
6509018,21-Jan-03,2003,1,21,"Non-M non-O HIV strains, fragments and uses","The invention provides peptides which are expressed by the env gene of a non-M, non-O HIV-1 virus, in particular a strain designated YBF30. The invention also provides fragments of the peptides that including the V3 loop region and their corresponding nucleotide sequences. The invention further provides kits including diagnostic reagents containing these molecules or immunogenic compositions containing these peptides, as well as methods for screening and typing non-M, non-O HIV-1 viruses and HIV-1 viruses expressing these peptide and/or nucleotide sequences.",10,Institute National de la Sante et de la Recherche Medicale-Inserm,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6509321,21-Jan-03,2003,1,21,Treatment of Kaposi's sarcoma with IL-12,"Methods are provided for using IL-12 to treat Kaposi's sarcoma (KS), particularly AIDS-associated KS.",12,"Genetics Institute, Inc.",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/208
6509344,21-Jan-03,2003,1,21,Indenoisoquinolines as antineoplastic agents,"A number of indenoisoquinolines were prepared and evaluated for cytotoxicity in human cancer cell cultures and for activity versus topoisomerase I. The two most cytotoxic indenoisoquinolines proved to be cis-6-ethyl-5,6,12,13-tetrahydro-2,3-dimethoxy-8,9(methylenedioxy)-5,11-dioxo-11H-indeno[1,2-c]isoquinoline and cis-6-allyl-5,6,12,13-tetrahydro-2,3-dimethoxy-8,9-(methylenedioxy)-5,11-dioxo-(11H)indeno[1,2-c]isoquinoline. Two of the most potent topoisomerase I inhibitors were 6-(3-carboxy-1-propyl)-5,6-dihydro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (26) and 6-ethyl-2,3-dimethoxy-8,9-(methylenedioxy)-11H-indeno[1,2-c]isoquinolinium chloride (27). Two additional potent topoisomerase I inhibitors, 6-allyl-5,6-dihydro-2,3-dimethoxy-8,9-(methylenedioxy)-5,11-dioxo-11H-indeno[1,2-c]isoquinoline (13c) and 5,6-dihydro-6-(4-hydoxybut-1-yl)-2,3-dimethoxy-8,9-methylenedioxy-5,11 dioxo-(11H)-indeno[1,2-c]isoquinoline (19a), did not unwind DNA and did not affect topoisomerase II.",54,The United States of America as represented by the Department of Health and Human Services,Office of Technology Transfer National Institute of Health,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/18
6511991,28-Jan-03,2003,1,28,"Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same","The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine and enamine derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/023
6517811,11-Feb-03,2003,2,11,Compounds for cancer imaging and therapy,"The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.",36,"Research Corporation Technologies, Inc.",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07B/00
6518061,11-Feb-03,2003,2,11,IL-13 receptor specific chimeric proteins and uses thereof,The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell bearing an IL-13 receptor. The method involves providing a chimeric molecule that comprises an effector molecule attached to a circularly permuted IL-13 (&#8220;cpIL-13&#8221;) that specifically binds an IL-13 receptor and contacting the tumor cell with the chimeric molecule. The compositions include chimeric molecules comprising effector molecules such as modified Pseudomonas exotoxin attached to a cpIL-13. The invention further provides vectors encoding the chimeric molecules.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/21
6518399,11-Feb-03,2003,2,11,Receptor,"The present invention relates to the novel GABAB receptor subtypes GABAB-R1c and GABAB-R2 as well as to a novel, functional GABAB receptor which comprises a heterodimer of GABAB-R1 and GABAB-R2 receptor subunits. The present invention also relates to variants of the receptors, nucleotide sequences encoding the receptors and variants thereof and novel vectors, stable cell lines, antibodies, screening methods, methods of treatment and methods of receptor production.",3,Smithkline Beecham Corporation,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/70571
6520911,18-Feb-03,2003,2,18,Ultrasound-hall effect imaging system and method,"A system and method of imaging based on the interaction of ultrasonic pulses with a magnetic field. A static magnetic field is applied to an object having conductive properties. An ultrasound pulse is propagated into the object, and an electrical signal is detected which is related to the interaction of the ultrasound pulse local displacement of the conductive object and the magnetic field. Alternatively, and equivalently, an electrical pulse is propagated into the object, and an ultrasound signal is detected which is related to the interaction of the electrical pulse generated in the conductive object and the magnetic field. The acquired acoustic signals or the acquired electrical signals are processed to provide an image of the object. The acquired signals are dependent on local conductivity as well as local acoustic properties.",39,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Medical technology,,,,,G01V/082
6521635,18-Feb-03,2003,2,18,Inhibition of MXR transport by acridine derivatives,"This invention provides methods that are useful for inhibiting a MXR transporter in a cell overexpressing a MXR gene but not overexpressing a Pgp gene by contacting the cell with an acridine derivative. The invention also provides for a method of treating a mammal suffering from a cancer, which overexpressing a MXR gene but not overexpress a Pgp gene, by the co-administration of a chemotherapeutic and an acridine derivative.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,G01N/5011
6524590,25-Feb-03,2003,2,25,Identification of a new ehrlichia species from a patient suffering from ehrlichiosis,"A new isolate of Ehrlichia species has been obtained from a patient suffering from ehrlichiosis. The new isolate has been found to be similar, but distinctly different from E. canis. A diagnostic kit and methods for diagnosing ehrlichiosis in humans and for screening drugs toxic to the new isolate have been described.",3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12R/01
6528516,4-Mar-03,2003,3,4,Methods for reducing intraocular pressure using A3 adenosine receptor antagonists,"This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen.",17,"Trustees of the University of Pennsylvania, The Center for Technology Transfer",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/5415
6529892,4-Mar-03,2003,3,4,"Apparatus, method and product for multi-attribute drug comparison","A computer-implemented apparatus or method, or a software product, for generating a composite quantitative comparison of drug products based on multiple attributes of them. A set of name-attribute similarity scores are generated based on similarities among the names of selected target and reference drugs. A set of product-attribute similarity scores are generated based on similarities among product attributes of the selected target and reference drugs. A target drug confusability score is generated based on the confusability of the target drug as compared to a population of other drugs. The composite quantitative comparison is generated based on a composite of the name-attribute and product-attribute similarity scores, and the target confusability score.",90,"Illinois, University of",,,,,,,,,,,1,Computer technology,,,,,,G06F/284
6531131,11-Mar-03,2003,3,11,Conjugate vaccine for Neisseria meningitidis,A conjugate vaccine for Neisseria meningitidis comprising lipooligosaccharide which does not contain a lacto-N-tetraose antigen from which at least one primary O-linked fatty acid has been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of meningitis and septic shock in mammals.,30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/095
6531276,11-Mar-03,2003,3,11,Methods for detecting human immunodeficiency virus nucleic acid,"Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",45,Chiron Corporation,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6531506,11-Mar-03,2003,3,11,Inhibitors of epoxide hydrolases for the treatment of hypertension,"The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula I wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.",11,Regents of the University of California,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7088
6534626,18-Mar-03,2003,3,18,Chemokine variants,"The present invention provide the nucleotide and amino acid sequence of truncated RANTES (3-68) which has the same amino acid sequence as the wild-type RANTES, but with a serine/proline truncation at positions 1 and 2 from the N-terminus, respectively.",7,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/48
6535754,18-Mar-03,2003,3,18,Lever coil sensor for respiratory and cardiac motion,"The invention includes a device for detection of respiratory motion of a subject during acquisition of an magnetic resonance image that includes a lever having a proximal and a distal end, a counterweight on the proximal end of the lever, a fulcrum, a pickup coil attached to the distal end of the lever, and a MRI machine that has a radio frequency resonator, a gradient coil, and a magnetic field, wherein the lever, fulcrum, counterweight, and pickup coil are positioned so that the lever moves as the subject breathes, the pickup coil is also positioned so that it does not cause artifacts in the MRI image, and the device as a whole generates an electrical signal that can be used to detect and monitor the respiratory motion of the subject. The invention also includes a device for respiratory gating of a magnetic resonance imaging experiment including a lever having a proximal and a distal end, a counterweight on the proximal end of the lever, a fulcrum, a pickup coil attached to the distal end of the lever, and a MRI machine that has a radio frequency resonator, a gradient coil, and a magnetic field, wherein the lever, fulcrum, counterweight, and pickup coil are positioned so that the lever moves as the subject breathes, the pickup coil is also positioned so that it does not cause artifacts in the MRI image, and the device as a whole generates an electrical signal that can be used to detect and monitor the respiratory motion of the subject and the threshold detector is used to trigger the acquisition of the individual scans of the magnetic resonance image.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/055
6537560,25-Mar-03,2003,3,25,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
6541199,1-Apr-03,2003,4,1,Identification of a new ehrlichia species from a patient suffering from ehrlichiosis,"A new isolate of Ehrlichia species has been obtained from a patient suffering from ehrlichiosis. The new isolate has been found to be similar, but distinctly different from E. canis. A diagnostic kit and methods for diagnosing ehrlichiosis in humans and for screening drugs toxic to the new isolate have been described.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12R/01
6541483,1-Apr-03,2003,4,1,Acridone-derived compounds useful as antineoplastic and antiretroviral agents,"The present invention relates to several novel acridone-derived compounds of of formula (I) or (II). These compounds are potent anti-viral agents, useful in the treatment of viral diseases, such as Human Immunodeficiency Virus. In addition, these compounds are anti-neoplastic agents useful in the treatment of various forms of cancer. wherein R1 and R2 are independently &#8212;H, &#8212;OH, amino, alkylamino, dialkylamino, alkoxy, alkyl, haloalkyl or halogen; n is 2 to 6, X and X&#8242; are independently &#8212;N or &#8212;NO2; Y and Y&#8242; are independently &#8212;N or &#8212;CH, or &#8212;H; and the double-slash represents a double bond or no bond.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
6545002,8-Apr-03,2003,4,8,Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors,"The present invention provides compounds having the formula I: X is (C1-C8)alkylene, (C2-C8)alkenylene, (C2-C8)alkynylene, wherein one of the carbon atoms in the alkylene, alkenylene or alkynylene groups is optionally replaced with a group having the formula &#8212;O&#8212;, &#8212;N(R4)C(O)&#8212;, &#8212;OC(O&#8212;, S&#8212;, &#8212;S(O)&#8212;or &#8212;SO2&#8212;, or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising compounds having the formula I. The compounds of the invention are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents for treatment of diseases that are mediated by A2B adenosine receptors.",27,University of Virginia Patent Foundation,National Institutes of Health,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
6548055,15-Apr-03,2003,4,15,Immunologic enhancement with intermittent interleukin-2 therapy,"A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2013
6548068,15-Apr-03,2003,4,15,Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule,The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/705
6551585,22-Apr-03,2003,4,22,Use of tumor necrosis factor as an adjuvant,"Tumor necrosis factors, alone or together with cytokines such as IL-1 or IFN-&ggr;, are capable of serving as non-toxic vaccine adjuvants.",4,"Genentech, Inc.",National Institutes of Health,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/001138
6552053,22-Apr-03,2003,4,22,Controlling attention and memory by altering neuronal carbonic anhydrase activity,"The invention provides a method for modulating attentive cognition comprising administering a compound that alters intraneuronal carbonic anhydrase activity thereby affecting establishment of a theta rhythm. The metabolic pathway of the compound preferably involves bicarbonate-mediated GABAergic depolarization. The term &#8220;attentive cognition&#8221; is meant to encompass memory formation, learning, spatial memory, and attention. The modulating may be stimulating, or the compound may have the multiple effects of inhibiting intraneuronal carbonic anhydrase activity, establishment of a theta rhythm, and memory acquisition. The invention further provides a method of modulating memory and attention comprising switching theta rhythm on and off, the switching comprising potentiating or inhibiting intraneuronal carbonic anhydrase activity.",26,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/00
6552181,22-Apr-03,2003,4,22,Basal cell carcinoma tumor supressor gene,This invention provides for a tumor suppressor gene inactivation of which is a causal factor in nevoid basal cell carcinoma syndrome and various sporadic basal cell carcinomas. The NBCCS gene is a homologue of the Drosophila patched (ptc) gene.,21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/705
6555112,29-Apr-03,2003,4,29,Peptides derived from the lymphadenopathy-associated virus (LAV) envelope coding region,"The molecular cloning and characterization of a novel human retrovirus, designated lymphadenopathy-associated virus, or LAV, is disclosed. LAV was originally isolated from a patient with acquired immune deficiency syndrome (AIDS). A cloned LAV complementary DNA (cDNA) was used to screen a library of recombinant phages constructed from the genomic DNA of LAV-infected T lymphocytes. The nucleotide sequence of an insert obtained from the recombinant phage clone &lgr;J19 was ascertained through M13 shotgun cloning and the dideoxy chain termination sequencing method. The env coding region was identified and peptides obtained therefrom. These peptides correspond to amino acids 239-294, 273-317, 300-327, 334-381, 397-424, and 466-500 of the LAV env. These peptides provide suitable diagnostic reagents for the detection LAV-specific antibodies and for the generation of LAV-specific immunological reagents.",10,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/162
6555367,29-Apr-03,2003,4,29,Complex of biotinylated viral vector and ligand for targeted gene delivery,"The present invention provides a composition for targeted delivery of a nucleic acid to a cell comprising a biotinylated recombinant adenovirus, wherein biotin is covalently linked to the recombinant adenovirus, wherein the recombinant adenovirus comprises the nucleic acid, and wherein the recombinant adenovirus is linked via streptavidin to a biotinylated targeting moiety. Also provided by this invention is a method for targeted delivery of a nucleic acid to a selected cell in a subject comprising administering to the subject a composition comprising a biotinylated recombinant adenovirus, wherein biotin is covalently linked to the recombinant adenovirus, wherein the recombinant adenovirus comprises the nucleic acid, and wherein the recombinant virus is linked via streptavidin to a biotinylated targeting moiety that specifically targets the selected cell.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
6556009,29-Apr-03,2003,4,29,Accelerated magnetic resonance imaging using a parallel spatial filter,"An apparatus and method for accelerating magnetic resonance imaging by decreasing the number of sequential phase encodes (undersampling). Image reconstruction of undersampled k-space data can cause ghost artifacts to be produced in the resulting sequence of images. A combination of temporal and spatial filters are used to substantially suppress the ghost artifacts. Additionally, the spatial filter receives spatial filter coefficients used in the filtering process. The spatial filter coefficients are adaptively or dynamically generated so that the coefficients are provided to the spatial filter while generating the sequence of images.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/5611
6556696,29-Apr-03,2003,4,29,Method for segmenting medical images and detecting surface anomalies in anatomical structures,"A region growing method segments three-dimensional image data of an anatomical structure using a tortuous path length limit to constrain voxel growth. The path length limit constrains the number of successive generations of voxel growth from a seed point to prevent leakage of voxels outside the boundary of the anatomical structure. Once segmented, a process for detecting surface anomalies performs a curvature analysis on a computer model of the surface of the structure. This process detects surface anomalies automatically by traversing the vertices in the surface model, computing partial derivatives of the surface at the vertices, and computing curvature characteristics from the partial derivatives. To identify possible anomalies, the process compares the curvature characteristics with predetermined curvature characteristics of anomalies and classifies the vertices. The process further refines potential anomalies by segmenting neighboring vertices that are classified as being part of an anomaly using curvature characteristics. Finally, the process colorizes the anomalies and computes a camera position and direction for each one to assist the user in viewing 2D renderings of the computer model.",40,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/0012
6556951,29-Apr-03,2003,4,29,System and method for intelligent quality control of a process,"A method and system for detecting errors in a process such as laboratory analysis of patient specimens and generation of test results is described. The steps of the method include collecting data elements having a range of values from the process. The number of data elements having values within predetermined intervals of the range are then counted. The counts of the data elements are applied as inputs to nodes of a neural network, each count being applied to a node representing the predetermined interval corresponding to the count. Output is then generated from the neural network based on the inputs, the output indicative of whether an error in the process (such as bias error or a precision error) has occurred. If the technology is used with a laboratory instrument, the output is generated in real time and available immediately for automatic or manual correction of the instrument.",33,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G16H/20
6558672,6-May-03,2003,5,6,Methods of making recombinant disulfide-stabilized polypeptide fragments having binding specificity,"The present invention relates to disulfide-stabilized recombinant polypeptide molecules which have the binding ability and specificity for another peptide, such as the variable region of an antibody molecule. Methods of producing these molecules and nucleic acid sequences encoding these molecules are also described. In particular, the invention discloses Fv antibody fragments stabilized by a disulfide bond connecting the VH and VL regions of the Fv fragment. The &agr; and &bgr; chains of T cell receptors may be similarly stabilized by means described in the invention.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/7051
6558676,6-May-03,2003,5,6,Parvovirus capsids,The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6558910,6-May-03,2003,5,6,"SF, a novel family of taste receptors","The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors.",19,The Regents of the University of California,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
6562347,13-May-03,2003,5,13,Chemokine-tumor antigen fusion proteins as cancer vaccines,The present invention provides a fusion polypeptide comprising a chemokine and either a tumor or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing HIV infection.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4727
6562589,13-May-03,2003,5,13,"AIB1, a novel steroid receptor co-activator","The invention features a substantially pure DNA which includes a sequence encoding a novel steroid receptor co-activator which is overexpressed in breast cancer cells, diagnostic assays for steroid hormone-responsive cancers, and screening assays to identify compounds which inhibit an interaction of the co-activator with the steroid hormone.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/4705
6562805,13-May-03,2003,5,13,Cosalane compounds and methods for their use,"The present invention relates to methods, compounds and compositions for inhibiting effective binding of a chemokine to its cellular receptor. In one form of the invention, a method includes contacting a cellular population with an effective amount of cosalane or an analog thereof. The invention further relates to methods, compounds and compositions for treating inflammatory diseases. In one form, a method includes administering to a patient a therapeutically effective amount of cosalane or an analog thereof.",6,Purdue Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,,,,,,C07J/00
6562859,13-May-03,2003,5,13,Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation,"A method of using a ureido derivative of a poly-4-amino-2-carboxy-1-methyl pyrrole or a pharmaceutically acceptable salt thereof to inhibit inflammation, particularly non-TNF-&agr; dependent inflammation, in a mammal.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/00
6566061,20-May-03,2003,5,20,Identification of polymorphisms in the PCTG4 region of Xq13,"Nucleic acid sequences within the q13 region of the X chromosome having polymorphisms associated with neuropsychiatric disorders and associated conditions are disclosed herein. One polymorphism occurs within the coding region of the HOPA gene and introduces a four amino acid insertion into a putative OPA domain, a domain which has been shown to be involved in tissue specific expression. Compositions including nucleic acids having these polymorphisms and antibodies to polymorphic regions within proteins encoded in the PCTG4 region are provided. Methods of using the information and nucleic acid sequences disclosed herein for the diagnosis and assessment of pathologies associated with neuropsychiatric disorders and associated conditions are also provided.",8,"The University of Iowa, as represented by the University of Iowa Research Foundation",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12Q/6883
6566098,20-May-03,2003,5,20,DNA encoding truncated hepatocyte growth factor variants,"The present invention relates to a novel truncated forms of hepatocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions. The present invention further relates to the utilization of the small HGF variants to either inhibit HGF mitogenesis or stimulate HGF mitogenesis in cells expressing the receptor for HGF.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/193
6566102,20-May-03,2003,5,20,Methods and devices for detection of xenogeneic graft persistence and infectious agents,"Compositions, methods and diagnostic devices for monitoring graft integrity in xenotransplantation and for detecting infectious agents transmitted by the xenograft are described. In particular, the compositions, methods and devices are useful for determining porcine xenograft integrity and persistence and can detect the presence of PERV (porcine endogenous retrovirus) in a biological sample. The compositions, methods and devices are useful for determining or monitoring graft survival and rejection in recipients of xenografts and are useful for detecting the presence of pig cell and PERV infection in a xenotransplant recipient or donor. In addition, the compositions, methods and devices are useful for screening therapeutic products to be administered to humans to ensure that the products are free of pig cells, and thus free of PERV contamination, prior to administration.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6888
6569639,27-May-03,2003,5,27,Isolation of cellular material under microscopic visualization,"A method of microdissection which involves: forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes an activatable adhesive layer which provides chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated the transfer surface and tissue sample are separated. During separation the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Optics,Biotechnology,Analysis of biological materials,,,G02B/32
6569897,27-May-03,2003,5,27,Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors,"Alkenyldiarylmethane (ADAM) compounds have been found effective as anti-HIV agents. Novel ADAM compounds, their pharmaceutical formulations and a method of using same to treat viral infections are described.",6,Purdue Research Foundation,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07C/94
6570000,27-May-03,2003,5,27,DNA encoding the T cell surface protein CD4 and use of fragments of CD4 in the treatment of AIDS,"A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, which are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution may be administered to a subject infected with a human immunodeficiency virus so as to block the human immunodeficiency virus from binding to T4+ cells.Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.",10,The Trustees of Columbia University in the City of New York,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/703
6572864,3-Jun-03,2003,6,3,Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines,"The nucleotide and deduced amino acid sequences of 51 cDNAs are disclosed where each cDNA encodes the envelope 1 gene of an isolate of hepatitis C virus (HCV). The invention relates to the oligonucleotides, peptides and recombinant envelope 1 proteins derived from these sequences and their use in diagnostic methods and vaccines.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6573720,3-Jun-03,2003,6,3,Resonant structure for spatial and spectral-spatial imaging of free radical spin probes using radiofrequency time domain electron paramagnetic resonance spectroscopy,"A radiofrequency (RF) coil design, suitable for detecting time domain electron paramagnetic resonance (EPR) responses from spin probes after pulsed excitation using radiofrequency irradiation (60-400 MHz), is configured in an array of numerous surface coils of appropriate diameters connected in a parallel or axial configuration with appropriate spacing between individual surface coils to form a volume type resonator.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/3671
6579848,17-Jun-03,2003,6,17,Depigmenting activity of agouti signal protein and peptides thereof,The invention is an agouti signaling protein and peptides as well as pharmaceutical compositions thereof and their use in methods of inhibiting melanin production by melanocytes. The agouti signaling protein and peptides thereof are useful in cosmetics and in clinical prevention and treatment of hyperpigmentary conditions. Methods for screening peptides for melanogenesis inhibiting activity are also provided.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/4703
6582583,24-Jun-03,2003,6,24,Amperometric biomimetic enzyme sensors based on modified cyclodextrin as electrocatalysts,"The present invention provides a novel biosensor for the detection of chemicals of interest. The novel biosensor of the present invention comprises an electrode having a catalytically active cyclodextrin attached thereto. The present invention will be useful for the detection of materials in a wide variety of samples. In particular, the present invention will permit the detection of nitrophenyl esters.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Micro-structural and nano-technology,Biotechnology,,,,,B82Y/00
6586392,1-Jul-03,2003,7,1,Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins,"The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
6586413,1-Jul-03,2003,7,1,Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists,"Compositions and methods for reducing or preventing ischemic damage of the heart are disclosed. A preferred embodiment of the invention comprises the simultaneous administration of specific A3/A1 receptor agonists, to patients suffering from ischemic damage or at risk for the same. In yet another embodiment of the invention, a binary conjugate which acts as an agonist for the A3 receptor and an antagonist at the A2a receptor, is administered to reduce or prevent ischemic damage to the heart.",73,The United States of America as represented by the Department of Health and Human Services,The Trustees of the University of Pennsylvania,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/7076
6589966,8-Jul-03,2003,7,8,Cytotoxic metal chelators and methods for making and using same,"A family of hexadentate Fe(II) chelators having marked antiproliferative activity against tumor cells is disclosed. The cytotoxic metal chelators and complexes of the present invention are represented by the general formula below: wherein:X1, X3, and X5 are N, O or S, wherein the X1, X3, and X5 atoms are at the 1, 3, and 5 positions of a cyclohexyl group and are in a cis, cis disposition;B, B&#8242;, and B&#8243; are aliphatic, branched aliphatic, or aryl groups, or any combination thereof, wherein the number of atoms between X and Y is about 2 to about 4;Y, Y&#8242; and Y&#8243; contain N, O, or S atoms that originate from either aliphatic, branched aliphatic, aryl, or heterocyclic groups, or any combination thereof, and/or Y, Y&#8242; and Y&#8243; are NH2 or NHR, OH, or SH, CO2H, P(O)(OH)2, RP(O)OH, ROP(O)OH groups or a combination thereof, and R is H, aliphatic, branched aliphatic, or aryl groups, or any combination thereof that may or may not be identical in Y, Y&#8242; and Y&#8243;;s, s&#8242;, and s&#8243; are 0 to about 2; andt, t&#8242;, and t&#8243; are 0 to about 2. Application of the metal chelators of the present invention as chemotherapeutic agents is also disclosed.",35,Wake Forest University Health Sciences,University of New Hampshile,National Institutes of Health,,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/53
6592872,15-Jul-03,2003,7,15,Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein,"The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of Bacillus anthracis and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6596269,22-Jul-03,2003,7,22,Methods of treating chronic pain,"This invention pertains to the surprising discovery of novel compositions and methods which selectively treat chronic pain while not significantly affecting basal nociceptive, acute pain, responses. The invention provides for compositions and methods of treating chronic pain by administering beta-endorphin-expressing recombinant expression systems such as adenovirus or adeno-associated virus into a subarachnoid or epidural space. The recombinant virus infects the pia mater connectve tissue cells and the infected cells express the fusion protein, wherein the fusion protein is secreted into the spinal cord parenchymal tissue in an amount effective to treat the chronic pain but not significantly affecting basal nociceptive responses.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/6755
6596279,22-Jul-03,2003,7,22,Immunodeficiency recombinant poxvirus,"Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL etpitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. DNA from the recombinant viruses are useful as probes or, for generating PCR primers or for immunization. Also disclosed and claimed are HIV immunogens and modified gp160 and gp120.",23,Virogenetics Corporation,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6596478,22-Jul-03,2003,7,22,Method and composition to detect C-type retroviral infection,"The present invention comprises methods, devices and compositions for detection of endogenous retroviruses found in xenotransplant materials. The methods and compositions are suited for detection of endogenous type-C retroviruses and in particular, for porcine endogenous retrovirus, PERV.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56983
6596690,22-Jul-03,2003,7,22,Vasostatin as marrow protectant,"Specific fragments of vasostatin are disclosed. Also disclosed is a method of stimulating the proliferation or survival of a hematopoietic cell exposed to a chemotherapeutic agent or irradiation using these fragments. A method of stimulating the proliferation or survival of a hematopoietic cell is also disclosed. In one embodiment, the method is disclosed for stimulating the growth or survival of a hematopoietic stem cell with a fragment of vasostatin, in the presence of a growth factor.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4725
6599739,29-Jul-03,2003,7,29,Infectious papillomavirus pseudoviral particles,"The invention provides an infectious papillomavirus pseudoviral particle useful in gene transfer comprising: (a) a papillomavirus vector DNA which comprises an E2 binding site and an expression cassette comprising a gene and a sequence controlling expression of said gene; and (b) a papillomavirus capsid which comprises L1 and L2 structural proteins, such that said capsid encapsidates said vector DNA, wherein said gene is derived from a first biological species and said L1 structural protein is derived from a second biological species and said first biological species is different from said second biological species.",8,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/00
6600018,29-Jul-03,2003,7,29,"Secreted frizzled related protein, sFRP, fragments and methods of use thereof","The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
6600023,29-Jul-03,2003,7,29,Antibody directed against HIV-1 P25 antigen,"Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.",2,Institut Pasteur,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/1045
6600030,29-Jul-03,2003,7,29,Delayed progression to aids by a missense allele of the CCR2 gene,"The present invention relates to a CCR2 deletion mutant, designated &#8220;CCR2-64I.&#8221; CCR2 is a C&#8212;C chemokine receptor and has been implicated as a co-receptor for HIV-1. It has been discovered that the presence of the CCR2-64I allele correlates with a postponement of AIDS outcomes, and that infected individuals who have the CCR2-64I allele are at a reduced risk for progression from HIV-1 infection to the development of clinical AIDS and death. Isolated nucleic acid molecule encoding CCR2-64I and the establishment of cell lines that express CCR2-64I provides valuable tools for continuing research on HIV infection. Diagnostic methods for analysis of the allelic frequency of CCR2 wild-type and 64I genes are provided. In addition, antibodies which bind to CCR2-64I, CCR2-64I variants, and CCR2 binding agents represent potential anti-HIV agents.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12Q/703
6600426,29-Jul-03,2003,7,29,Alarm system for detecting hazards due to power transmission lines,"An alarm system for detecting and warning of the risk of shock and electrocution is provided. The alarm system is adapted for use with mobile construction equipment, e.g., cranes, trucks, etc., that can be used around overhead power transmission lines. The present alarm system has a sensor that detects the presence of outside power at the equipment where current is flowing therethrough to ground. The sensor preferably includes a conductor and an inductive sensor such as a current transformer which limits the output signal on its low side that is sent to an alarm unit. In this manner, the system herein continues to properly function despite the presence of large voltages at the equipment such as when the equipment contacts a high voltage power transmission line. The sensor can include a cable that provides a path of least resistance for current flowing through the equipment which can be detected by the sensor. Preferably, the cable is attached across a moving joint of the equipment where potential differences readily can be found. Alternatively, the conductor can be a portion of the equipment itself through which current flows with the sensor detecting the flow through the equipment portion.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Transport,Handling,,,,,B60P/00
6602661,5-Aug-03,2003,8,5,Methods and arrays for detecting biomolecules,"The present invention is directed to a device and a method for detecting biomolecules in a tissue section or other two-dimensional sample by creating &#8220;carbon copies&#8221; of the biomolecules eluted from the sample and visualizing the biomolecules on the copies using antibodies or DNA probes having specific affinity for the biomolecules of interest. Thin membranes in a stacked or layered configuration are applied to the sample, such as a tissue section, and reagents and reaction conditions are provided so that the biomolecules are eluted from the sample and transferred onto each of the stacked membranes thereby producing multiple replicas of the biomolecular content of the sample.",32,"20/20 GeneSystems, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,Biotechnology,Organic fine chemistry,,,,G01N/6803
6602979,5-Aug-03,2003,8,5,Screening assays for compounds that cause apoptosis,"This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1709
6602983,5-Aug-03,2003,8,5,Polypeptide and DNA sequence corresponding to human receptor with high affinity for IgE,"A Polypeptide and DNA Sequence corresponding to the human receptor high affinity receptor for IgE as well as replicable microbial expression vehicles, transformed microorganisms, and cultures of microbial cells which produce this polypeptide.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70535
6605619,12-Aug-03,2003,8,12,Nitroxides as protectors against oxidatives stress,"The instant invention is directed to the use of a biologically compatible composition, containing an effective amount of a metal-independent nitroxide compound which is preferably represented by the formula wherein R1 is &#8212;CH3; R2 is &#8212;C2H5, &#8212;C3H7, &#8212;C4H9, &#8212;C5H11, &#8212;C6H13, &#8212;CH2&#8212;CH(CH3)2, &#8212;CHCH3C2H5, or &#8212;(CH2)7&#8212;CH3, or wherein R1 and R2 together form spirocyclopentane, spirocyclohexane, spirocycloheptane, spirocyclooctane, 5-cholestane, or norbornane, R3 is &#8212;O. or &#8212;OH, or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, as antioxidants capable of protecting cells, tissues, organs, and whole organisms against the deleterious effects of harmful free radical species generated during oxidative stress.",4,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/45
6607725,19-Aug-03,2003,8,19,Conjugate vaccine for nontypeable Haemophilus influenzae,A conjugate vaccine for Nontypeable Haemophilus influenzae comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/102
6608181,19-Aug-03,2003,8,19,Fibroblast growth factor receptor activating gene I and related compositions and methods,"A novel gene designated as FRAG1 and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.",75,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4702
6610476,26-Aug-03,2003,8,26,Detection of HIV-1 DNA,"The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant,DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.",10,The United States of America as represented by the Department of Health and Human Services,"Centocor, Inc.",,,,,,,,,,2,Biotechnology,,,,,,C12Q/702
6610540,26-Aug-03,2003,8,26,Low oxygen culturing of central nervous system progenitor cells,"The present invention relates to the growth of cells in culture under conditions that promote cell survival, proliferation, and/or cellular differentiation. The present inventors have found that proliferation was promoted and apoptosis reduced when cells were grown in lowered oxygen as compared to environmental oxygen conditions traditionally employed in cell culture techniques. Further, the inventors found that differentiation of precursor cells to specific fates also was enhanced in lowered oxygen where a much greater number and fraction of dopaminergic neurons were obtained when mesencephalic precursors were expanded and differentiated in lowered oxygen conditions. Thus at more physiological oxygen levels the proliferation and differentiation of CNS precursors is enhanced, and lowered oxygen is a useful adjunct for ex vivo generation of specific neuron types. Methods and compositions exploiting these findings are described.",11,California Institute of Technology,National Institutes of Health,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/0658
6610660,26-Aug-03,2003,8,26,"O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates","Diazeniumdiolates, wherein the N1 position is substituted by an inorganic or organic moiety and the O2-oxygen is bound to a substituted or unsubstituted aromatic group, are provided. Also provided are O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O2-glycosylated diazeniumdiolates) and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates (1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates). The O2-aryl diazeniumdiolates are stable with respect to the hydrolytic generation of nitric oxide in neutral to acidic solutions and generate nitric oxide in basic or nucleophilic environments or microenvironments. Also provided are compositions, including pharmaceutical compositions, comprising such compounds and methods of using such compounds.",39,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/64
6610684,26-Aug-03,2003,8,26,Fused azepinone cyclin dependent kinase inhibitors,"A new class of cyclin dependent kinase inhibitors that also have antiproliferative activity in human tumor cell line assays are described. Most of these compounds satisfy the formula wherein A is oxygen or sulfur coupled to the right by a single or double bond; R2 is selected from the group consisting of hydrogen, aryl, lower aliphatic substituents, particularly alkyl and lower alkyl ester; R4-R7 are independently selected from the group consisting of alkoxy, amino, acyl, aliphatic substituents, particularly alkyl, alkenyl and alkinyl substituents, aliphatic alcohols, particularly alkyl alcohols, aliphatic nitriles, particularly alkyl nitriles, cyano, nitro, carboxyl, halogen, hydrogen, hydroxyl, imino, and &agr;, &bgr;, unsaturated ketones; R8-R11 are independently selected from the group consisting of aliphatic substituents, particularly alkyl, alkenyl and alkinyl substituents, particularly lower aliphatic substituents, alipahatic alcohols, particularly alkyl alcohols, alkoxy, acyl, cyano, nitro, epoxy, haloalkyl groups, halogen, hydrogen and hydroxyl; R12 is selected from the group consisting of aliphatic groups, particularly lower alkyl groups, aliphatic alcohols, particularly alkyl alcohols, carboxylic acids and hydrogen. Compositions comprising effective amounts of such compounds also are described. These compounds and compositions can be used in a method for inhibiting the proliferation of living cells in a subject comprising administering an effective amount of the compound(s), or composition(s) comprising the compound(s), to a subject to inhibit the proliferation of living cells, such as neoplastic cells.",39,The United States of America as represented by the Department of Health and Human Services,Centre National de la Recherche Scientifique,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
6613318,2-Sep-03,2003,9,2,"Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity","The present invention is directed to novel methods for assaying for modulators of GADD45 polypeptide activity. The invention also provides means to sensitize a proliferating cell to a DNA base-damaging agent by administration of novel inhibitors of GADD45 polypeptide activity. The invention further provides polypeptides which interfere with the ability of Cdc2/cyclin B1 complexes to cause a pause at the G2/M stage of the cell cycle in response to GADD45, and nucleic acids which encode such polypeptides.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5008
6613740,2-Sep-03,2003,9,2,Activity dependent neurotrophic factor III (ADNF III),"The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) &bgr;-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.",16,Ramot University Authority for Applied Research and Industrial Development Ltd.,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/475
6613764,2-Sep-03,2003,9,2,Aspartic protease inhibitors,"The present invention provides a compound of formula (I) wherein a, b, c, d, and e, are R7, OR7, SR7, NR7R8, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen. R7 and R8 are H or alkyl, R1 and R2 are H or alkyl, and R3 is a non-aromatic substituent. Substituent A is OH, NH2, or SH. Substituents B and B1 include amide and sulfonamide groups, which can be cyclic, acyclic, or amino acid derivatives. Alternatively, B and R&#8242; together with the nitrogen to which they are bonded, and/or B&#8242; and R2 together with the nitrogen to which they are bonded, define a heterocycle. The present invention further provides a pharmaceutical composition that includes a carrier and a therapeutically effective amount of at least one compound of the present invention. The present invention further provides therapeutic methods that include administering a therapeutically effective amount of at least one compound of the present invention",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/27
6613883,2-Sep-03,2003,9,2,Screening assays for compounds that cause apoptosis and related compounds,"This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1709
6617103,9-Sep-03,2003,9,9,Identification of a transforming fragment of herpes simplex type 2 and detection thereof in clinical specimens,"The present invention relates to oligonucleotide probes derived from HSV-2, capable of selectively hybridizing thereto and to a subsequence of HSV-2 BglII N from which the oligonucleotide probes were derived. Further, the invention relates to an optimized assay of nudeic acid amplification permitting the sensitive and specific detection in clinical specimens of HSV-2 as well as a specific typing of the HSV in the sample. The present invention further relates to kits for the detection and typing of the HSV in a sample. In addition, the invention provides the nucleic acid and amino acid sequence of a subsequence of HSV-2 BglII N having transforming activity. Further, the invention teaches diagnostic and therapeutic methods for genital cancer comprising the use of these sequences or ligands directed thereto.",8,The United States of America as represented by the Department of Health and Human Services,Universite de Montreal,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,G01N/56994
6617161,9-Sep-03,2003,9,9,Serum-free cell growth medium,"A chemically defined-serum free growth medium for the in vitro and ex vivo of cells and cell lines. The medium consists of about a one to one ratio (v/v) of two basal growth media containing &agr;-ketoglutarate, insulin, transferrin, selenium, bovine serum albumin, linoleic acid, ceruloplasmin, cholesterol, phosphatidyl-ethanolamine, &agr;-tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, &bgr;-glycerophosphate, PDGF, EGF and FGF. Chondrocytes, when cultured in this medium in the presence of a cartilage derived morphogenetic protein or bone morphogenetic protein, retain their cartilaginous phenotype.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0655
6620913,16-Sep-03,2003,9,16,Polypeptides of a novel hantavirus,"The present invention relates to the discovery of a novel Hantavirus. In particular, the present invention relates to nucleic acids of the newly discovered virus and to nucleic acid reagents and antibodies for use in methods of detection and prevention of infection by the virus.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6623952,23-Sep-03,2003,9,23,Spumavirus isolated from humans,"The present invention comprises a spumavirus isolated from a human. More specifically, the spumavirus of the present invention was isolated from a human who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
6623960,23-Sep-03,2003,9,23,"Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19","The invention provides monoclonal antibodies to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/40
6626267,30-Sep-03,2003,9,30,Apparatus and method for generating power onboard a hoist conveyance,"An onboard power generation apparatus for a hoist conveyance includes a drive wheel carried by the conveyance. The drive wheel is positioned to engage the surface of a stationary structure adjacent the conveyance, such as a shaft guide, so that movement of the conveyance relative to the structure causes rotation of the drive wheel. A charging generator coupled to the drive wheel is operable to produce an electric current upon rotation of the drive wheel. A battery may be electrically connected to the generator so that the generator provides an electric current to recharge the battery. The drive wheel may be mounted for movement relative to the conveyance with biasing mechanism for resiliently biasing the drive wheel toward the surface of the adjacent structure.",38,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Handling,,,,,,B66B/34
6627191,30-Sep-03,2003,9,30,Anti-transforming growth factor Beta (TGF-&bgr;) treated stem cell composition and method,The invention relates to stem cell compositions comprising anti-TGF-&bgr; treated stem cells which are viable for at least 14 days in culture without replication or differentiation and methods for rapid and long term in vitro hematopoiesis and in vivo hematopoietic reconstitution using such anti-TGF-&bgr; treated stem cells.,3,Seattle Biomedical Research Institute,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0647
6627395,30-Sep-03,2003,9,30,"Methods for the propagation, isolation, identification, and preparation of human immunodeficiency virus type 1 (HIV-1)","The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.",6,Institut Pasteur,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/1045
6627641,30-Sep-03,2003,9,30,Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof,"The present invention provides antimalarial pharmaceutical compositions containing antimalarial naphthylisoquinoline alkaloids or antimalarial derivatives thereof, useful new antimalarial naphthylisoquinoline alkaloid derivatives, methods for obtaining such derivatives, and methods of using such antimalarial compounds for the prevention of malaria infections in mammals and for treating mammals with malarial infections. The antimalarial compounds of the present invention inhibit the reproduction and cytopathicity of Plasmodium sp. parasites in vitro and in vivo.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/47
6627745,30-Sep-03,2003,9,30,"Pyrin gene and mutants thereof, which cause familial Mediterranean fever","The invention provides the nucleic acid sequence encoding the protein associated with familial Mediterranean fever (FMF). The cDNA sequence is designated as MEFV. The invention is also directed towards fragments of the DNA sequence, as well as the corresponding sequence for the RNA transcript and fragments thereof. Another aspect of the invention provides the amino acid sequence for a protein (pyrin) associated with FMF. The invention is directed towards both the full length amino acid sequence, fusion proteins containing the amino acid sequence and fragments thereof. The invention is also directed towards mutants of the nucleic acid and amino acid sequences associated with FMF. In particular, the invention discloses three missense mutations, clustered in within about 40 to 50 amino acids, in the highly conserved rfp (B30.2) domain at the C-terminal of the protein. These mutants include M6801, M694V, K695R, and V726A. Additionally, the invention includes methods for diagnosing a patient at risk for having FMF and kits therefor.",3,The United States of America as represented by the Department of Health and Human Services,Cedars-Sinai Medical Center,University of California,University of Michigan,Women's and Children's Hospital,Heller Institute for Medical Research,,,,,,6,Biotechnology,,,,,,C07K/47
6630124,7-Oct-03,2003,10,7,Combination therapy with VIP antagonist,The present invention relates to combination therapy using a pharmaceutical composition comprising a polypeptide which is an antagonist of the vasoactive intestinal polypeptide (VIP) and a chemotherapeutic agent. Methods of using the pharmaceutical composition are also disclosed.,47,Ramot-University Authority for Applied Research and Industrial Development Ltd.,Yeda Research and Development Co. Ltd.,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/427
6630464,7-Oct-03,2003,10,7,Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer,Certain derivatives of acridones and benzothiadiazines have been found to have anti-cancer properties by virtue of their specific inhibition of the cyclin D dependant kinase CDK4. These molecules inhibit CDK4 activity more than they inhibit the activity of other such kinases (e.g. CDC2 and CDK2). This specificity results in an improved therapeutic index when used as drugs to treat susceptible cancers.,12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/433
6630507,7-Oct-03,2003,10,7,Cannabinoids as antioxidants and neuroprotectants,"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/35
6632437,14-Oct-03,2003,10,14,"Immunogenic polysaccharide-protein conjugates containing poly &agr;(2&#8594;8), &agr;(2&#8594;9) NeuNAc capsular polysaccharides",The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a polysaccharide-protein conjugate.,38,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/1203
6632808,14-Oct-03,2003,10,14,Inhibitors of amyloid formation,"Methods, compounds and compositions are disclosed for treating amyloidogenic diseases, like Alzheimer's disease and type 2 diabetes, and particularly prion diseases associated with conversion of protease sensitive PrP (PrP-sen) to protease resistant PrP (PrP-res), by administering therapeutically effective amounts of a tetrapyrrole. Particular disclosed tetrapyrroles having this activity include phthalocyanines, deuteroporphyrins, and meso-substituted porphines. Complexes of certain of the pyrroles with metals or metal ions produce compounds that are particularly effective in converting the conversion of PrP-sen to PrP-sen. The treatment of the present invention is particularly suited for preventing or inhibiting the progression of prion related diseases, such as transmissible spongiform encephalopathies.",70,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/409
6632928,14-Oct-03,2003,10,14,Immunotoxins and methods of inducing immune tolerance,"Provided are novel DT- and ETA-based immunotoxins and a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease. Also provided is a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign mammalian donor tissue or cells, comprising the steps of: a) exposing the recipient to an immunotoxin so as to reduce the recipients' peripheral blood T-cell lymphocyte population by at least 80%, wherein the immunotoxin is anti-CD3 antibody linked to a diphtheria protein toxin, wherein the protein has a binding site mutation; and b) transplanting the donor cells into the recipient, whereby a rejection response by the recipient to the donor organ cell is inhibited, and the host is tolerized to the donor cell.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/2809
6635614,21-Oct-03,2003,10,21,Use of lecithin-cholesterol acyltransferase (LCAT) to reduce accumulation of cholesterol,This invention provides methods for treating atherosclerosis in a mammalian subject by increasing the activity of LCAT in the serum of the subject to a level effective to decrease the accumulation of cholesterol in the subject. Pharmaceutical dosage forms containing LCAT also are provided.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Other special machines,,,,,C12N/8509
6635752,21-Oct-03,2003,10,21,Variant of LAV viruses,"A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.",2,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/702
6639060,28-Oct-03,2003,10,28,erbB-3 nucleic acids,"A DNA fragment distinct from the epidermal growth factor receptor (EGFR) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA. Characterization of the cloned DNA fragment mapped the region of v-erbB homology to three exons with closest homology of 64% and 67% to a contiguous region within the tyrosine kinase domains of the EGFR and erbB-2 proteins, respectively. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was mapped to human chromosome 12q11-13 and was shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGFR and erbB-2, plays a role in some human malignancies. Using erbB-3 specific antibodies (polyclonal or monoclonal), the erbB-3 protein was identified as a 180 kDa glycoprotein, gp180erbB-3.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/32
6641999,4-Nov-03,2003,11,4,Probing method for identifying antibodies specific for selected antigens,"This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VH&agr;TAG VH, CC46 VH, CC49VH, CC83 VH, and CC92 VH, and CC49VL, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.",17,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
6643534,4-Nov-03,2003,11,4,Optimal imaging of the peripheral vasculature with test bolus tracking,"A system and method for optimally imaging the peripheral vasculature is disclosed which includes defining a given number of scan stations along a patient's peripheral vasculature and initially injecting a relatively small amount of contrast agent into the patient to pass a test bolus through the patient's peripheral vasculature, and thereafter tracking the test bolus through the patient and adjusting the patient on a moveable table within the MR imaging device from one scan station to a next station to determine a maximum travel time that the test bolus takes to travel through each of the given number of scan stations. Additional contrast agent is then injected into the patient to pass an exam bolus through the patient's peripheral vasculature, and using the test bolus travel time, MR data can be acquired from each scan station while it is known that the exam bolus is present in that station to optimize image resolution. Initially, central k-space data is acquired for each scan station, and if time permits, the higher spatial frequency k-space data can be acquired. Otherwise, once the central k-space data is acquired for each station, the patient table is adjusted to the scan stations that require additional data acquisition. Similarly, if there is time remaining after all MR data is acquired for a particular scan station, the patient table can be moved to a previous scan station to acquire additional data in that station before moving to a subsequent scan station to acquire the central k-space data when the exam bolus arrives in that particular scan station.",26,General Electric Company,Uniform Services University of Health Sciences,The United States of America as represented by the Secretary of Defense,,,,,,,,,3,Measurement,,,,,,G01R/563
6645144,11-Nov-03,2003,11,11,Electroacoustic imaging methods and apparatus,"Methods are disclosed for obtaining electroacoustic images of specimens. One method includes applying an acoustic wave to a specimen and forming an image based on an electroacoustically induced electric field or voltage. In another method, an electric field or voltage is applied to a specimen and an electroacoustically induced acoustic wave is measured to form an image. Apparatus suitable for obtaining electroacoustc images are disclosed as well as methods for distinguishing image contributions from the electroacoustic, thermoacoustic, and Hall effects.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0654
6649392,18-Nov-03,2003,11,18,Mutant form of a cytotoxic ribonucleolytic protein which allows production by recombinant methods,The present invention provides recombinant Onc (rOnc) compositions and methods. Recombinant Onc proteins of the invention have an amino terminal methionine and comprise an Onc polypeptide. The amino terminal methionine of the protein allows for recombinant production in a bacterial host cell. Cleaving the amino terminal methionine exposes the amino terminal glutamine of the polypeptide. The Onc polypeptide has an amino terminal glutamine. Cyclization of the amino terminal glutamine of the polypeptide to a pyroglutamyl residue provides rOnc polypeptides and proteins have anti-cancer and anti-viral activity.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/22
6649393,18-Nov-03,2003,11,18,Mutant form of cytotoxic ribonucleolytic protein which allows production by recombinant methods,The present invention provides recombinant Onc (rOnc) compositions and methods. Recombinant Onc proteins of the invention have an amino terminal methionine and comprise an Onc polypeptide. The amino terminal methionine of the protein allows for recombinant production in a bacterial host cell. Cleaving the amino terminal methionine exposes the amino terminal glutamine of the polypeptide. The Onc polypeptide has an amino terminal glutamine. Cyclization of the amino terminal glutamine of the polypeptide to a pyroglutamyl residue provides rOnc polypeptides and proteins have anti-cancer and anti-viral activity.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/22
6649411,18-Nov-03,2003,11,18,Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides,The present invention provides methods of using antisense ADNF III oligonucleotides to inhibit the growth of pathologically proliferating cells. The invention also provides methods and kits for using ADNF III nucleic acid probes to detect the presence of pathologically proliferating cells in human tissues.,13,The United States of America as represented by the Department of Health and Human Services,Ramot at Tel-Aviv University Ltd.,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/1136
6649651,18-Nov-03,2003,11,18,"Hexahydrofuro[2,3-B]furan-3-yl-n{3[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor","Novel bis-tetrahydrofuran benzodioxolyl sulfonamide compounds which are surprisingly effective protease inhibitors. The invention also relates to pharmaceutical compositions, methods of inhibiting retrovirus proteases, in particular multidrug resistant retrovirus proteases, methods of treating or combating infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication.",17,Tibotec Pharmaceuticals LTD,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
6653084,25-Nov-03,2003,11,25,Anti-erbB-2 antibodies to human receptor related to but distinct from EGF receptor,"The isolation, cloning and characterization of a human gene related to but distinct from the EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of the nucleic acid probes and antibodies having specific binding affinity with said polypeptide for diagnostic and therapeutic purposes has also been described.",87,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/71
6653104,25-Nov-03,2003,11,25,"Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells","The present invention relates to immunotoxins that effectively kill malignant cells having a given marker. The immunotoxins are reagents that comprise internalizing antibodies conjugated to cytotoxic ribonucleases or fragments thereof. The internalizing antibodies are capable of binding with a chosen tumor cell, and thereby confer little non-specific toxicity to the immunotoxin in a host. The immunotoxins exhibit up to 2000-fold higher toxicity against malignant B cells than did the ribonuclease counterparts alone.",140,"Immunomedics, Inc.",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/5443
6653292,25-Nov-03,2003,11,25,Method of treating cancer using immunostimulatory oligonucleotides,"Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant.",57,University of Iowa Research Foundation,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
6655382,2-Dec-03,2003,12,2,Spontaneous breathing apparatus and method,"A spontaneous breathing apparatus and method. The apparatus includes: a source of oxygen containing gas (7); a catheter (5) in flow communication with the source of oxygen containing gas (7) and configured to be introduced into a subject's trachea (1) through a tracheostomy for delivering oxygen containing gas therein; a tracheostomy tube (9) disposed adjacent the catheter (5) and having one end configured to be disposed in the subject's trachea (1); and a pressure actuated threshold valve (32) connected to another end of the tracheostomy tube (9), the valve (32) being configured for venting a gas existing within the subject's trachea (1) at the one end of the tracheostomy tube (9) when the gas exceeds a threshold pressure of the valve (32), the valve (32) thereby being effective for reducing pressure within the subject's trachea 1) when the pressure within the subject's trachea (1) exceeds the threshold pressure.",8,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/04
6656706,2-Dec-03,2003,12,2,"Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes","Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV env genes which have been mutated to remove or reduce inhibitory/instability sequences are disclosed. Viral particles and host cells containing these constructs and/or viral particles are also disclosed. The exemplified constructs and viral particles of the invention may be useful in gene therapy for numerous disorders, including HIV infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6656737,2-Dec-03,2003,12,2,Isocynate derivatizing agent and methods of production and use,"An organic compound useful for detecting the total quantity of isocyanate in an environmental sample is provided. The compound is 9-anthrcenylmethyl-1-piperazinecarboxylate (PAC), an isocyanate derivatizing agent. A process for producing PAC and methods for detecting a particular isocyanate monomer or the total isocyanate in environmental samples using PAC & related isocyanate derivatizing agents are also provided.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/205
6656930,2-Dec-03,2003,12,2,Aralkyl diazabicycloalkane derivatives for CNS disorders,"Certain aralkyl diazabicycloalkyl compounds are disclosed for treatment of CNS disorders, such as cerebral ischemia, psychosis, and convulsions. For example, compounds of interest are of the formula:",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
6660273,9-Dec-03,2003,12,9,Chimeric vaccine against tick-borne encephalitis virus,"A live, attenuated chimeric virus vaccine against tick-borne encephalitis virus comprising the preM and E structural genes of the tick-borne encephalitis Langat virus and the non-structural genes of the mosquito-borne dengue virus. The live chimeric vaccine was administered intraperitoneally and exhibited complete attenuation in mice while at the same time providing protection against subsequent challenge with the virulent parental Langat virus.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6660276,9-Dec-03,2003,12,9,"Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor","The instant disclosure identifies and synthesizes peptide residues initially isolated from a melanoma cell line. The peptides are capable of reconstituting an epitope recognized by tumor specific CTL. Some of the sequences are homologous with proteins identified as pMEL17, tyrosinase and cofilin. The present invention provides for the treatment of melanoma patients using synthetic peptides that reconstitute epitopes for melanoma specific CTL. In another embodiment the peptides are used as vaccines for imparting immunity. Alternatively, in one embodiment the peptides may be used to bind to antigen presenting cells in a method for providing specific antigenic stimulation of CTL. The instant invention provides CTL cell lines capable of recognizing reconstituted HLA-A2.1 epitopes and their use in methods of adoptive immunotherapy. The invention additionally provides for genes encoding for peptides capable of reconstituting epitopes recognized by tumor specific CTL and their use as vaccines in the prevention and management of melanoma. A splitter is also disclosed to identify active peptides.",12,The University of Virginia Patent Foundation,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Y/03001
6660297,9-Dec-03,2003,12,9,Nutritional supplement to treat macular degeneration,"A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.",21,Bausch & Lomb Incorporated,,,,,,,,,,,1,Food chemistry,Pharmaceuticals,,,,,A61K/34
6660488,9-Dec-03,2003,12,9,Antibodies for the alpha platelet-derived growth factor receptor,"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.",12,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/71
6660750,9-Dec-03,2003,12,9,Flavopiridol methods and compositions for HIV therapy,"Disclosed is the unexpected discovery that flavopiridol binds tightly to the transcription elongation factor, P-TEFb and dramatically inhibits its activity. As P-TEFb is required for HIV propagation and replication, this invention provides new methods, compositions and kits for the effective treatment of HIV infections and AIDS using flavopiridol, both alone and combination with other therapies.",11,University of Iowa Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/453
6664053,16-Dec-03,2003,12,16,Identification of a region of the major surface glycoprotein (MSG) gene of human Pneumocystis carinii,"Particularly sensitive techniques for the detection of P. carinii in clinical samples are disclosed. These techniques relate to the PCR amplification and/or detection of human-P. carinii major surface glycoprotein (MSG) gene sequences. Also disclosed are seven novel genes encoding human-P. carinii MSG, and the proteins encoded for by these genes. These genes provide proof that human-P. carinii MSG is encoded for by a highly conserved gene family, and that the conesponding proteins have a very highly conserved region of about 100 amino acids near their C-terminal end. This highly conserved carboxy-terminal region has a significantly different sequence than that found in rat-derived MSG.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
6664227,16-Dec-03,2003,12,16,Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains,"Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.",32,"Genetics Institute, LLC",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/7155
6664263,16-Dec-03,2003,12,16,"1,8-naphthalimide imidazo{4,5,1-de}acridones with anti-tumor activity","The invention provides imidazoacridone compounds of general formula (1) which have cytotoxic and anti-tumor activity. The invention also provides methods of preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirably high levels of cell proliferation. The compounds of the invention are also expected to have utility as research tools.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/06
6664374,16-Dec-03,2003,12,16,Polypeptides comprising IL-6 ligand-binding receptor domains,"The present invention provides, among other things, a polypeptide, and a pharmaceutically acceptable salt. thereof, that inhibits the binding of IL-6 ligand with IL-6 receptor under physiological conditions, a nucleic acid that encodes such a polypeptide and can be expressed in a cell, a nucleic acid that comprises or encodes an antisense nucleic acid molecule or a ribozyme that is specific for such a polypeptide, an antibody that is specific to such a polypeptide, an anti-antibody thereto, a composition comprising such a polypeptide, nucleic acid, antibody or an anti-body and a carrier therefor, a composition comprising a solid support matrix to which is attached an above-described polypeptide or an anti-antibody to a specified polypeptide sequence, a method of prophylactically or therapeutically inhibiting IL-6 signaling in a mammal in need thereof, a mammal in need thereof, and a method of removing IL-6 ligand from a bodily fluid of an animal.",1,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/7155
6667801,23-Dec-03,2003,12,23,Method and apparatus for safety testing optical systems for hazardous locations,"A method of determining the ignition characteristics of an optical source emitting optical power into a hazardous environment includes providing a chamber and a tapered optical fiber having an input end and an output end, wherein the output end has a smaller diameter than the input end. The output end of the tapered fiber is disposed within the chamber and the input end of the tapered fiber is optically coupled to the optical source for receiving optical power therefrom. Power is first applied to the tapered fiber and the power output at the tapered fiber output end measured. Then a target is applied to the tapered fiber output end, and the chamber is filled with the desired gas/air mixture and the same power applied to the tapered fiber. After power is applied for a period of time, a determination is made whether or not the gas/air mixture ignited.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Other special machines,Measurement,,,,,G01M/30
6669935,30-Dec-03,2003,12,30,Delivery of therapeutic agents by gene therapy,"A process for treating a disease or disorder of a host by delivery of a therapeutic agent to the brain of the host, which comprises transducing endothelial cells of blood vessels located in the brain of a host in vivo with a vector including a polynucleotide encoding a therapeutic agent. The vector is administered intravascularly to the host, and the vector produces the therapeutic agent in the endothelial cells.",4,The United States of America as represented by the Department of Health and Human Services,"Genetic Therapy, Inc.",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C12N/902
6670176,30-Dec-03,2003,12,30,Adeno-associated virus capable of expressing factor IX protein and cells comprising the same,The subject invention concerns a recombinant adeno-associated virus vector characterized as being capable of delivering and expressing at least one mammalian gene into a genome of a mammalian host cell such that the expression of the gene is regulated in a tissue specific manner by cis-acting regulatory and promoter elements of the gene. A method of using this recombinant adeno-associated virus vector for therapeutic purposes is also provided.,8,National Institutes of Health,University of Pittsburgh,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
6672673,6-Jan-04,2004,1,6,Ore pass inspection system,"The present invention discloses an apparatus and method for imaging and clearing an ore pass hang-up. The apparatus includes: a platform that is movable along generally a longitudinal direction of an ore pass; a controllable propulsion unit capable of propelling the platform within the ore pass and to the location of the hang-up; an imaging unit capable of generating an image of the ore pass as the apparatus is moved trough the ore pass, wherein the image is transmittable to a remove viewer; extensible, remotely controllable immobilizing units affixed to the platform; and a remotely controllable unit for clearing the ore pass hang-up. Once in place the apparatus is used to break up or clear the hang-up by, for example, directing blows to the hang-up, directing high pressure fluids to the hang-up, and using an explosive charge.",39,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Civil engineering,,,,,,E21C/16
6673338,6-Jan-04,2004,1,6,"Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same","The invention provides NO&#8212; or NO&#8722;-releasing imidate, thioimidate, and amide diazeniumdiolates, in which the N2O2&#8722; functional group is bonded to a carbon atom. The invention also provides compositions comprising such diazeniumdiolate compounds, and methods of using such compounds and compositions. The invention further provides a method of preparing NO&#8212; or NO&#8722;-releasing imidate, thioimidate, and amide diazeniumdiolates.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07C/06
6673342,6-Jan-04,2004,1,6,Recombinant human IgA-J chain dimer,"Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.",5,"Bond of Regents, The University of Texas System",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/1063
6673559,6-Jan-04,2004,1,6,Met proto-oncogene and a method for predicting breast cancer progression,A method for predicting breast tumor metastasis entails determining the amount of met protein in tumor tissue relative to normal breast duct tissue.,4,The Government of the United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,G01N/6872
6673830,6-Jan-04,2004,1,6,"Calanolide and related antiviral compounds, compositions, and uses thereof","The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.",32,The United States of America as represented by the Secretary of Health and Human Services,The Board of Trustees of the University of Illinois,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/14
6673896,6-Jan-04,2004,1,6,Derivatives of soluble T-4,"This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus. The method comprises administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of a therapeutic agent of the invention and a pharmaceutically acceptable carrier.",2,The Trustees of Columbia University in the City of New York,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
6673905,6-Jan-04,2004,1,6,Conjugation of biomolecules using Diels-Alder cycloaddition,"A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,"Macromolecular chemistry, polymers",,,,A61K/385
6676657,13-Jan-04,2004,1,13,Endoluminal radiofrequency cauterization system,"Disclosed are methods and devices for occluding the lumen of a hollow organ by delivering radiofrequency energy to the inner wall of a hollow organ. The disclosure includes radiofrequency electrodes that expand, in a deployed condition, to contact the walls of the organ. In some embodiments, the electrodes substantially conform to the inner wall to enhance therapeutic contact. Methods are also disclosed for using these electrodes to totally or partially occlude a lumen, or remove or reduce a total or partial occlusion of a lumen.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/1492
6676936,13-Jan-04,2004,1,13,Chimeric and/or growth-restricted flaviviruses,"The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a. The invention further includes a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes the Japanese B encephalitis virus capsid protein, pre-matrix protein, envelope glycoprotein and non-structural proteins NS1 and NS2a. The invention further includes a vaccine and a method to produce that vaccine.",5,The United States of America as represented by the Department of Health and Human Services.,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6676973,13-Jan-04,2004,1,13,Method of treating ovarian cancers with cadmium,"A method is provided for treating an ovarian cancer in a human or other mammalian patient suffering from the ovarian cancer, the method comprises administering to the human or the other mammalian patient an effective ovarian cancer treating amount of cadmium, preferably in the form of cadmium chloride.Pharmaceutical compositions and pharmaceutical kits which are useful in practicing the described method of treating ovarian cancer in the human or other mammalian patient suffering from the ovarian cancer are also provided for in the disclosure.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/28
6677314,13-Jan-04,2004,1,13,Nucleosides for imaging and treatment applications,"Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
6677315,13-Jan-04,2004,1,13,Nucleosides for imaging and treatment applications,"Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
6678541,13-Jan-04,2004,1,13,Optical fiber probe and methods for measuring optical properties,"A probe for the characterization of optical properties, including scattering and absorption properties of a sample, such as medical and industrial samples, includes an illumination fiber to radiate light toward an object and at least two collection fibers to receive light diffusely reflected from the object. At least two of the collection fibers are spaced at different distances from the illumination fiber. A region of the sample is illuminated with light from the illumination fiber. A portion of the light is diffusely reflected by the region. A portion of the diffusely reflected light is received by the two or more collection fibers. The region is characterized based on an amount of light received by each of the collection fibers. When the method is used for medical purposes, the characterization of the region may be used to make a diagnosis.",46,The Governmemt of the United States of America,,,,,,,,,,,1,Measurement,,,,,,G01N/474
6680055,20-Jan-04,2004,1,20,"Mycolactone and related compounds, compositions and methods of use","The present invention provides, inter alia, polyketide macrolides including a polyketide macrolide of the structure wherein R1-R5 are the same or different and each is independently selected from the group consisting of hydrogen, R6, a C(O)R7, a C(S)R7, a C(O)NHR7, and a C(S)NHR7, each occurrence of R6 is independently selected from the group consisting of a C1-C6 alkyl, a C5-C12 aryl, and a sugar, each occurrence of R7 is independently selected from the group consisting of hydrogen, a C1-C6 alkyl, and a C5-C12 aryl, and wherein R1 and R2, R2 and R3, and/or R4 and R5 can be taken together to form a ketal ring. Also provided are asceptic mixtures of polyketide macrolides isolated from M. ulcerans in a pharmaceutically acceptable carrier, methods of using the polyketide macrolides and aseptic mixtures to inhibit cancer and suppress an inflammatory response in a mammal, a method of inducing an immune response to Mycobacteria ulcerans without inducing a buruli ulcer, and a composition comprising M. ulcerans.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12R/32
6680060,20-Jan-04,2004,1,20,Hepatitus A virus vaccines,"A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6680176,20-Jan-04,2004,1,20,Identification of candidate ligands which modulate antigen presenting cells,"The present invention relates to the identification of candidate ligands which modulate antigen presenting cells. Specifically, ligands which superactivate antigen presenting cells are identified.",6,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/2812
6682715,27-Jan-04,2004,1,27,Nucleosides for imaging and treatment applications,"Methods of diagnosing and/or of treating tumors by administering a nucleoside analog which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analog compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.",12,The United States of Americas as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
6682728,27-Jan-04,2004,1,27,Efficient and selective adenoviral-mediated gene transfer into vascular neointima,"The present invention provides a method of selectively expressing DNA in neointimal cells in an injured blood vessel of a subject comprising administering a replication-deficient recombinant adenovirus which functionally encodes the DNA to the blood vessel at the site of injury, such that the adenovirus remains at the site of injury for a time sufficient for the adenovirus to selectively infect neointimal cells and thereby selectively express the DNA in neointimal cells. In particular, the invention provides administering a replication-deficient recombinant adenovirus which functionally encodes a DNA encoding a protein or an antisense ribonucleic acid. This method can be used to treat restenosis and, relatedly, prevent neointimal cell proliferation.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
6682741,27-Jan-04,2004,1,27,&bgr;2 microglobulin fusion proteins and high affinity variants,"&bgr;2-microglobulin fusion proteins and modified forms of &bgr;2-microglobulin are disclosed. The fusion proteins are shown to incorporate onto the surface of MHC I expressing mammalian cells and to cause an increased cytotoxic T-cell response to antigens presented by such cells. The fusion proteins are useful in methods of tumor therapy. Modified forms of human &bgr;2-microglobulin, particularly a form having a serine to valine transition at amino acid position 55 of the mature protein are shown to have an enhanced affinity for MHC I heavy chain, and are useful both in the disclosed fusion proteins and as a vaccine adjuvant where enhanced cytotoxic T-cell response is desired.",64,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70528
6682758,27-Jan-04,2004,1,27,Water-insoluble drug delivery system,"The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.",33,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4196
6683045,27-Jan-04,2004,1,27,Nucleosides for imaging and treatment applications,"Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
6683105,27-Jan-04,2004,1,27,Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias,"A method for treating cognitive impairments associated with aging or Alzheimer's disease which comprises treating a patient at risk for having the cognitive impairment with an effective amount of a highly selective butyrylcholinesterase inhibitor which is N8-benzylnorcymserine, N1-phenethylnorcymserine, N1, N8-bisnorcymserine, N1-N8-bisbenzylnorphysostigmine, N1, N8-bisbenzylnorphenserine, N1, N8-bisbenzylnorcymserine, or pharmaceutical acceptable salts thereof.",7,"Axonyx, Inc.",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/40
6685933,3-Feb-04,2004,2,3,Interferon &agr; hybrids,"Hybrid human interferon-&agr; polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these peptides, and the use of these polypeptides to treat viral disease and regulate cell growth are also provided.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/56
6685942,3-Feb-04,2004,2,3,Human neutralizing monoclonal antibodies to respiratory syncytial virus,"A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.",16,The Scripps Research Institute,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1006
6685944,3-Feb-04,2004,2,3,Modified HCV peptide vaccines,"The present invention provides 1) an isolated peptide having the amino acid sequence DLMGYIPAV, (SEQ ID NO: 1); 2) an isolated HCV core polypeptide comprising an L&#8594;A substitution at amino acid position 139; 3) an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2; and 4) a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence SEQ ID NO: 1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. The present invention further provides methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
6685948,3-Feb-04,2004,2,3,Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines,"The present invention is directed toward vector stage replication-defective flaviviruses that are replication-defective in mosquito vectors that transmit them to humans. Such mutant flaviviruses may be useful as vaccines. The replication-defective flaviviruses of the present invention demonstrate a limited ability to replicate in the vector organisms that transmit flaviviruses from one host to another. More specifically, the present invention is directed toward the construction and propagation of flaviviruses that possess 3&#8242;-noncoding regions altered in such a way as to prevent or severely limit viral reproduction in a vector organism. In one embodiment of the present invention, a replication-defective dengue virus that is replication-defective in arthropods is contemplated for use as a vaccine. In another embodiment, a replication-defective dengue virus that is replication-defective in mosquitoes is contemplated for use as a vaccine. The present invention also contemplates methods of producing such mutant flaviviruses for use as vaccines as well as methods that induce a protective immunity against flavivirus infection or disease in an immunized subject.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
6685949,3-Feb-04,2004,2,3,Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans,"A conjugate vaccine for Moraxella (Branhamella) catarrhalis comprising isolated lipooligosaccharide from which esterified fatty acids have been removed, to produce a detoxified lipooligosaccharide (dLOS), or from which lipid A has been removed, to produce a detoxified oligosaccharide (OS), which is linked to an immunogenic carrier. The vaccine is useful for preventing otitis media and respiratory infections caused by M. catarrhalis in mammals, including humans.",12,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12P/04
6686333,3-Feb-04,2004,2,3,Inhibition of HIV replication using soluble Tat peptide analogs,"Methods and compositions for inhibiting replication of HIV in a mammalian cell. The compositions can be a peptide, or a nucleic acids encoding a peptide, which inhibits transactivation of the HIV long terminal repeat.",8,The United States of America as represented by the Department of Health and Human Resources,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6689367,10-Feb-04,2004,2,10,Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences,"Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV backround of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.",51,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6689560,10-Feb-04,2004,2,10,Raf protein kinase therapeutics,It is a general object of this invention to provide a DNA segment comprising a Raf gene in an antisense orientation downstream of a promoter. It is a specific object of this invention to provide a method of inhibiting Raf expression comprising expressing an antisense Raf gene in a cell such that said Raf expression is inhibited. It is a further object of the invention to provide a method of inhibiting Raf kinase activity comprising replacement of a serine or threonine amino acid within the Raf gene for a non-phosphorylated amino acid.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1135
6690464,10-Feb-04,2004,2,10,High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units,"Disclosed are pharmaceutical dosage unit manufacturing process control apparatus and methods. These can include acquiring a plurality of multi-pixel images of a flow of pharmaceutical dosage units at different wavelengths along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing.",69,"Spectral Dimensions, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Measurement,,,,,,G01N/31
6693130,17-Feb-04,2004,2,17,Inhibitors of epoxide hydrolases for the treatment of hypertension,"The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by wherein R is alkyl or aryl, the compound is trans-across the epoxide ring, OX is a carbonyl (&boxH;O) or hydroxy group (OH) and R&#8242; is a H, alkyl or aryl group. The invention further provides methods of identifying patients at increased risk for hypertension, comprising assaying for epoxide hydrolase activity in a urine sample from the patient. In particular, the assays comprise determining the amount of dihydroxyeicosatrienoic acids (DHETs), determining the amount of epoxyeicosatrienoic acids (EETs) in said sample, or determining the amount of both DHETs and EETs in said sample.",8,Regents of the University of California,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/325
6696064,24-Feb-04,2004,2,24,Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy,"Vascular damage has proven to be dose limiting in administering immunotoxins into the brain to treat brain tumors. Vascular toxicity of immunotoxins which rely in part on exposure to lowered pH in cellular endosomes and lysosomes can be avoided by administering an endosome pH-raising agent systemically during some or all of the time that the immunotoxin is present in the brain of the organism. Suitable endosome pH-raising agents include lysosomotrophic amines, proton ionophores, and vacuolar H+ ATPase inhibitors. The invention increases the therapeutic window of the immunotoxins and increases the likelihood the treatment will have an effect on the course of the tumor.",48,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/365
6696242,24-Feb-04,2004,2,24,Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines,"A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C07K/005
6696436,24-Feb-04,2004,2,24,"B-homoestra-1,3,5(10)-trienes as modulators of tubulin polymerization","The invention provides B-ring expanded estra-1,3,5(10)-triene compounds of general formula (1) which modulate the polymerization of tubulin and/or the depolymerization of microtubules. The compounds have anti-angiogenic and anti-tumor activity. The invention also provides methods of preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirable angiogenesis. The compounds of the invention are also expected to have utility as research tools.",39,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07J/004
6696551,24-Feb-04,2004,2,24,"225Ac-HEHA and related compounds, methods of synthesis and methods of use","The present invention provides an &agr;-particle-emitting radioisotope chelation complex comprising 225Actinium (225Ac) and 1,4,7,10,13,16-hexaazacyclohexadecane-N,N&#8242;,N&#8243;,N&#8242;&#8243;,N&#8243;&#8243;,N&#8242;&#8243;&#8243;-hexaacetic acid (HEHA) (225Ac-HEHA). Also provided is a bifunctional HEHA, and a bifunctional 225Ac-HEHA. The bifunctional HEHA and the bifunctional 225Ac-HEHA can be conjugated to a targeting agent. In view of the above, the present invention provides a method of making HEHA and methods of making a bifunctional HEHA, including a conjugate thereof. Also provided are a method of treating disease, a method of treating cancer, a method of decontaminating a sample from 225Ac, a method of decontaminating a person who has been externally contaminated with 225Ac, and a method of detoxifying a person who has internalized 225Ac.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/00
6697739,24-Feb-04,2004,2,24,Test for linkage and association in general pedigrees: the pedigree disequilibrium test,"The present invention provides a method for the analysis of linkage disequilibrium between at least one marker locus and a disease or trait locus of interest. The method comprises the steps of: (a) providing a data set comprising a marker locus with at least two alleles for a plurality of extended pedigrees (e.g., plant pedigrees, animal pedigrees), where N is the number of unrelated extended pedigrees, at least one of said extended pedigrees containing at least one informative nuclear family or informative discordant sibship; then (b) determining a random variable XT for each triad within an informative nuclear family for each allele Mi; (c) determining a random variable XS for each DSP within an informative discordant sibship for each allele Mi; (d) determining a summary random variable D from XS and XT for each of said extended pedigrees for each allele Mi; and then (e) determining a statistic T from each of said summary random variables D from each of said N unrelated extended pedigrees for each allele Mi. An extreme (large or small) value for T indicates greater linkage disequilibrium.",44,Duke University,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Computer technology,,,,,,G16B/00
6699475,2-Mar-04,2004,3,2,Recombinant pox virus for immunization against tumor-associated antigens,"Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.",7,Therion Biologics Corporation,Whitehead Institute for Biomedical Research,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
6699476,2-Mar-04,2004,3,2,Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules,"Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.",78,,,,,,,,,,,,,Biotechnology,,,,,,C07K/005
6699710,2-Mar-04,2004,3,2,Tumor tissue microarrays for rapid molecular profiling,"An array-based technology facilitates rapid correlated gene copy number and expression profiling of very large numbers of human tumors. Hundreds of cylindrical tissue biopsies (diameter 0.6 mm) from morphologically representative regions of individual tumors can be arrayed in a single paraffin block. Consecutive sections from such arrays provide targets for parallel in situ visualization and quantitation of DNA, RNA or protein targets. For example, amplifications of six loci (mybL2, erbB2, Cyclin-D1, myc, 17q23 and 20q13) were rapidly determined by fluorescence in situ hybridization from 372 ethanol-fixed breast cancers. Stratification of tumors by estrogen receptor and p53 expression data revealed distinct patterns of gene amplification in the various subgroups of breast cancer that may have prognostic utility. The tissue array technology is useful in the rapid molecular profiling of hundreds of normal and pathological tissue specimens or cultured cells.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Chemical engineering,Biotechnology,Measurement,Optics,,B01L/5085
6699721,2-Mar-04,2004,3,2,Surface coatings for hot-melt adhesive film,"A low temperature melt film such as EVA is prepared for laser capture microdissection by having a thin specimen non-adhering coating in the range of 0.1% to 10% of the total film thickness placed on the sample exposed side of the film. When the film is brought into contact with the specimen, the specimen non-adhering coating prevents non-specific transfer due to sticky adherence of portions of the sample. At the same time, the non-adhering coating on the low temperature melt film surface can stabilize and protect the low temperature melt film against variations in performance due to ambient humidity and temperature variation. Upon appropriate heating for laser capture microdissection, the barrier of the thin coating allows conventional film melting with otherwise uninhibited adhesion of selected cell areas to the film. Coatings on the low temperature melt film (EVA) surface in selected locations is made by applying film-forming material from a volatile solvent-based solution, followed by evaporation of the solvent. The coating solution can be applied by spraying, dipping, or adding exact volumes to a surface with a micropipet. Spreading a measured volume of solution over the surfaces can coat flat surfaces. The coating thickness can be controlled by the volume and concentration of coating solids added to a known area.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/718
6699835,2-Mar-04,2004,3,2,Formulation of boronic acid compounds,"The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of the invention.",92,The United States of America as represented by the Department of Health and Human Services,"Millennium Pharmaceuticals, Inc.",,,,,,,,,,2,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C07K/0827
6699842,2-Mar-04,2004,3,2,Dominant negative deletion mutants of C-jun and their use in the prevention and treatment of cancer,"The inhibition of AP-1 activity by dominant negative deletion mutants of c-jun is disclosed. This inhibition of AP-1 activity is shown to be associated with inhibition of tumor promoter-induced neoplastic transformation. Therefore, the invention relates to the utilization of dominant negative deletion mutants of c-jun which are inhibitory to tumor promotor-induced neoplastic transformation as therapeutic agents in the prevention and treatment of cancer in mammals.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/711
6703046,9-Mar-04,2004,3,9,"Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use",Extremely hydrophobic nitric oxide (NO) releasing polymers are disclosed. The extremely hydrophobic NO-releasing polymers provided are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. These polymers can be loaded with extremely high NO levels and designed to release NO in manners than mimic natural biological systems. The NO-releasing extremely hydrophobic polymers provided can maintain a sustained NO release for periods exceeding nine months. Also provided are related medical devices made using these NO-releasing extremely hydrophobic polymers.,25,Medtronic AVE Inc.,United States of America,,,,,,,,,,2,Medical technology,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,C08F/30
6703374,9-Mar-04,2004,3,9,Nucleosides for imaging and treatment applications,"Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
6706268,16-Mar-04,2004,3,16,Human deficiency virus type-1 (HIV-1) peptide encoded by the VIF gene,"This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.",2,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
6706475,16-Mar-04,2004,3,16,Oligonucleotide probes for detecting Enterobacteriaceae and quinolone-resistant Enterobacteriaceae,"Oligonucleotide probes for detecting Enterobacteriaceae species. Unique gyrA coding regions permit the development of probes specific for eight different species: Escherichia coli, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Providencia stuartii, and Serratia marcescens. The invention thereby provides methods for the species-specific identification of these Enterobacteriaceae in a sample, and detection and diagnosis of Enterobacteriaceae infection in a subject. Further, nucleic acids are provided for determining quinolone-resistant status of these Enterobacteriaceae.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12Q/6827
6706493,16-Mar-04,2004,3,16,DNA encoding a cholecystokinin receptor,"An unconventional approach to purifying CCK receptor protein to sequenceable-grade homogeneity has been discovered. By this approach, CCK receptor protein can be obtained and sequenced, routinely from a variety sources, and from the sequence information thus obtained it is possible to prepare oligonucleotides suitable for cloning CCK receptor genes. &#8220;CCK receptor&#8221; in this context denotes any from a group of proteins that displays a characteristic CCK binding affinity and that is encoded by a nucleotide sequence which hybridizes a oligonucleotide probe designed in accordance with the criteria elaborated herein.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
6706528,16-Mar-04,2004,3,16,Fluorescent magnesium indicators,"The present invention generally relates to analytical elements and methods for the selective determination of magnesium. In particular, the present invention is further directed to carboxy-quinolizine suitable for use as magnesium indicators, and more particularly, to 4-oxo-4H-quinolizine-3-carboxylic acid derivatives for use as novel fluorescent magnesium indicators.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/22
6706729,16-Mar-04,2004,3,16,Thiolesters and uses thereof,This invention pertains to the discovery of a novel family of thiolesters and uses thereof. Also provided for are viricidal compounds and pharmaceutical formulations comprising these novel thiolesters. The invention also provides thiolester-inactivated viruses and thiolester-complexed viral proteins.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/76
6706867,16-Mar-04,2004,3,16,DNA array sequence selection,"The present invention provides methods and compositions for the construction of custom cDNA microarrays. In particular, the methods involve the selection of relevant clusters based on knowledge and expression patterns using public database information and the identification of the best representative cDNA clones within the selected cluster. The methods facilitate the construction of custom microarrays suitable for use in any biotechnological art. In preferred embodiments, the present invention provides the the ImmunoChip.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
6706873,16-Mar-04,2004,3,16,Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines,"A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C07K/005
6709811,23-Mar-04,2004,3,23,Versatile reagent for detecting murine leukemia viruses,"A method for detecting broad spectrum of murine leukemia viruses belonging to any or all of the ecotropic, xenotropic, polytropic and amphotropic groups, has been described. The method utilizes a monoclonal antibody designated 83A25 which identifies almost all classes or groups of the murine leukemia virus with only a few exceptions.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/1036
6709842,23-Mar-04,2004,3,23,DNA encoding a growth factor specific for epithelial cells,"Disccoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",79,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6876
6713066,30-Mar-04,2004,3,30,Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2,"Recombinant respiratory syncytial virus (RSV) are provided in which expression of the second translational open reading frame encoded by the M2 gene (M2ORF2) is reduced or ablated to yield novel RSV vaccine candidates. Expression of M2 ORF2 is reduced or ablated by modifying a recombinant RSV genome or antigenome to incorporate a frame shift mutation, or one or more stop codons in M2 ORF2. Alternatively, M2 ORF2 is deleted in whole or in part to render the M2-2 protein partially or entirely non-functional or to disrupt its expression altogether. M2 ORF2 deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in mRNA transcription, genomic or antigenomic RNA replication, viral growth characteristics, viral antigen expression, viral plaque size, and/or a change in cytopathogenicity. In addition, M2-2 knock out or deletion virus exhibits increased levels of synthesis of viral proteins in cell culture, providing an enriched source of viral antigen or protein for purification and use as a noninfectious subunit vaccine.",63,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6713081,30-Mar-04,2004,3,30,Ocular therapeutic agent delivery devices and methods for making and using such devices,Ocular implant devices for the delivery of a therapeutic agent to an eye in a controlled and sustained manner. Dual mode and single mode drug delivery devices are illustrated and described. Implants suitable for subconjunctival placement are described. Implants suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices that are presented herein.,18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Other special machines,,,,A61K/0051
6713300,30-Mar-04,2004,3,30,Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter,The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.,18,University of Utah Research Foundation,Baylor College of Medicine,Johns Hopkins University,The United States of America as represented by the Department of Health and Human Services,,,,,,,,4,Biotechnology,,,,,,C07K/705
6713446,30-Mar-04,2004,3,30,Formulation of boronic acid compounds,The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): in which Z1 and Z2 are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.,92,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C07K/0827
6716971,6-Apr-04,2004,4,6,Pteridine nucleotide analogs,The invention provides pteridine nucleotides of formula (I) which are highly fluorescent and which can be used in the chemical synthesis of fluorescent oligonucleotide. The invention further provides for fluorescent oligonucleotide comprising one or more pteridine nucleotides. In addition the invention provides for pteridine nucleotide triphosphates which may be used as the constituent monomers in DNA amplification procedures. The pteridine nucleotides are more stable and possess higher quantum yields than structurally similar pteridine nucleotides.,30,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/00
6719978,13-Apr-04,2004,4,13,Virus-like particles for the induction of autoantibodies,"The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
6720191,13-Apr-04,2004,4,13,Mechanical handling systems for laser capture microdissection,"A method and apparatus of gathering by LCM identified cellular material from randorn locations on a tissue sample to designated locations on a transporting substrate enables convenient further processing. A transporting substrate has an identified mapped location for receiving identified cellular material. At least a segment of a selectively activatable coating is placed on the side of the transporting substrate in apposition to the tissue sample at the mapped location. The transporting substrate and sample are relatively moved to place the selectively activated coating at the mapped location in apposition to identified cellular material of the tissue sample which is to be extracted. Thereafter, the selectively activatable coating is activated and impressed or impressed and activated to form an adhesive region on the transporting substrate for adhering to the identified cellular material. Upon removal of the transporting substrate from the tissue sample, identified cellular material adheres to the transporting substrate at the mapped location.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/2813
6721583,13-Apr-04,2004,4,13,Method for non-invasive identification of individuals at risk for diabetes,"The invention provides methods for the use of Raman spectroscopy to non-invasively detect molecular characteristics of the constituents of the aqueous humor, vitreous humor, lens or retina. The method can be employed for the detection of molecular changes underlying ocular pathologies. In one embodiment of the invention, the method involves the steps of introducing light into the eye of the subject using a laser; collecting Raman spectra emitted from the eye; dispersing the collected Raman spectra onto a detector; and analyzing detected Raman spectral data to identify a molecular change related to an ocular pathology. The non-invasive method provided by the invention makes use of techniques and equipment that enable detection of Raman spectra with light intensities that fall within acceptable safety standards.",53,The United States of America,,,,,,,,,,,1,Medical technology,,,,,,A61B/1455
6723551,20-Apr-04,2004,4,20,Production of adeno-associated virus in insect cells,"A method of producing an adeno-associated virus (AAV) in an insect cell comprising (i) providing at least one insect cell-compatible vector comprising a first nucleotide sequence comprising at least one AAV ITR nucleotide sequence, a second nucleotide sequence containing an open reading frame encoding AAV VP1, VP2, and VP3 capsid proteins, a third nucleotide sequence comprising a Rep52 or a Rep40 coding sequence, and a fourth nucleotide sequence comprising a Rep78 or a Rep68 coding sequence, (ii) introducing the at least one insect cell-compatible vector into an insect cell, and (iii) maintaining the insect cell under conditions such that AAV is produced. Also provided are recombinant AAV made in accordance with the method, insect cell-compatible vectors, and insect cells comprising nucleotide sequences for production of AAV in an insect cell.",36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6727079,27-Apr-04,2004,4,27,cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product,"Nucleic acids that encode novel polypeptides, designated in the present application as &#8220;BOG&#8221; (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-&bgr;1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4738
6727405,27-Apr-04,2004,4,27,Transgenic animals secreting desired proteins into milk,"A DNA sequence containing a gene encoding a protein, the gene being under the transcriptional control in the DNA sequence of a mammalian milk protein promoter which does not naturally control the transcription of the gene, such DNA sequence including DNA enabling secretion of the protein.",5,Genzyme Corporation,,,,,,,,,,,1,Biotechnology,,,,,,C12N/8509
6730304,4-May-04,2004,5,4,Variant of LAV viruses,"A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.",8,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/702
6730663,4-May-04,2004,5,4,Targeting gene expression to living tissue using jet injection,"The present invention provides a method of targeting transient gene expression and stable gene expression from the exogenous administration of a DNA sequence, which sequence is less than a complete genome, wherein said DNA sequence encodes RNA and protein, or RNA only, to differentiate tissue of living organisms wherein said DNA sequence through a jet injector technique, and said DNA sequence of less than a complete genome is expressed in a living organism. The present invention further provides a flexible multi-nozzle injector device with a wide surface area to allow molding of the injector nozzle to the surface contours of the tissue. Another aspect of the present invention provides an injection device having a long nozzle for injection of DNA deep into the host tissue. Also, in a further aspect the present invention provides an injector device modified to be used with and/or inject through an endoscopic device.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/89
6734014,11-May-04,2004,5,11,Methods and compositions for transforming dendritic cells and activating T cells,"Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0639
6736225,18-May-04,2004,5,18,Guide for attachment to a roof bolter to allow for core drilling,"The present disclosure provides a coring guide for converting a mine roof bolter into apparatus suitable for guiding a coring rod, or drill, into a mine roof, as well as a method for obtaining a geological core from the mine roof using the guide. The guide includes a pair of jaws, wherein each jaw has an adapter end and a pivotable end. The adapter end of each jaw includes a cavity that faces a cavity included in the adapter end of the other jaw, such that the closed jaws form at least a major portion of a cylindrical coring cavity that accommodates a coring rod. Each jaw includes means for fixing the rod guide within a mine roof bolter apparatus such that when the coring guide is positioned between the jaws and the jaws are partially closed such that they enclose the coring rod, the roof bolter causes the coring rod to penetrate the mine roof and obtain a core sample. The method of obtaining the geological core includes installing the rod guide into the roof bolter apparatus, introducing a cylindrical coring rod, driving the coring rod into the mine roof sufficiently to accumulate a core therein, and withdrawing the rod.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Civil engineering,,,,,,E21B/24
6737060,18-May-04,2004,5,18,High affinity humanized anti-TAG-72 monoclonal antibodies,"Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.",3,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
6737061,18-May-04,2004,5,18,High affinity humanized anti-TAG-72 monoclonal antibodies,"Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.",4,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
6737251,18-May-04,2004,5,18,Nucleotide and deduced amino acid sequences of tumor gene Int6,"The present invention discloses the isolation of the human and murine wild-type Int6 gene and the cDNAs corresponding to these genes. The invention further describes the use of reagents derived from the nucleic acid and amino acid sequences of the Int6 gene in diagnostic methods, immunotherapy, gene therapy and as vaccines.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/82
6737511,18-May-04,2004,5,18,Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis,"Apoptosis-modifying fusion polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these polypeptides, and the use of these polypeptides to modify apoptosis are also provided.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/34
6740492,25-May-04,2004,5,25,High sensitivity phage display biomolecule detection,"The invention relates to a biomolecular complex comprising a target biomolecule; a phage having a phage-expressed binding protein that can bind to the target biomolecule or having joined thereto a linked or un-linked protein or nucleic acid that can bind to the target biomolecule, wherein the phage-expressed binding protein or the linked or unlinked protein or nucleic acid is bound to the target biomolecule to provide a bound phage; and a host bacterial cell that is a host for the phage under conditions that permit the bound phage to infect the host.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/54306
6741884,25-May-04,2004,5,25,Infrared endoscopic balloon probes,"Balloon probes, adapted for use in endoscopy and other medical procedures, are useful to obtain spectroscopic information reflected or emitted from a tissue of interest in the infrared spectral region. The information collected by the probe is useful in the diagnosis and treatment of disease. The invention also relates to methods utilizing these probes to analyze a surface of interest, in a minimally invasive manner, in connection with the diagnosis and treatment of disease.",52,"HyperMed, Inc.",,,,,,,,,,,1,Medical technology,,,,,,A61B/6885
6742909,1-Jun-04,2004,6,1,Lighted line,A lighted line having an elongate flexible wire-formed bulbless light source is encased in a supportive covering which may include a surrounding rope and tubular sheathing. An electrical power source operatively connected to the wire-formed light source is adapted to energize it to produce light which radiates laterally of the line and emanates through the rope and tubular sheathing.,33,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,"Electrical machinery, apparatus, energy",Other consumer goods,,,,,F21S/26
6743577,1-Jun-04,2004,6,1,Methods of using cyanovirins to inhibit viral infection,"The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/195
6743601,1-Jun-04,2004,6,1,Non-contact laser capture microdissection,"An apparatus and process for the micro juxtaposition is set forth where a selectively activatable surface is maintained spaced apart from the tissue sample and juxtaposed to the tissue sample by activation. In the typical case, activation occurs by laser radiation with the material of the activatable surface thermally expanding and bringing about the desired micro juxtaposition. The disclosed micro juxtapositioning can cause locally and microscopically pressure on tissue sample, insertion to the tissue sample, or contact of an activated or prepared surface to the tissue sample.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/2813
6743626,1-Jun-04,2004,6,1,Artificial salivary gland,"The present invention generally relates to the field of oral prosthetics and tissue engineering. More specifically, a novel, artificial fluid secreting prosthesis for non-invasive insertion is disclosed. Further, methods of use of the foregoing are provided.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Pharmaceuticals,Biotechnology,,,,A61L/3839
6743797,1-Jun-04,2004,6,1,Methods for treating cardiac arrhythmia,"Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.",9,"ChanTest, Inc.",United States of America,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/495
6747055,8-Jun-04,2004,6,8,Water-soluble drugs and methods for their production,"The present invention provides water-soluble drugs, in particular, water-soluble analogues of geldanamycin, and compositions comprising the same. This invention also provides a method of rendering water-soluble drugs soluble in water through derivatization with a bifunctional linking molecule and subsequent conjugation to a polar moiety through a thio ether. The present invention ether provides a method of treating cancer in a mammal.",44,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/416
6749856,15-Jun-04,2004,6,15,Mucosal cytotoxic T lymphocyte responses,"The invention provides methods for induction of an antigen-specific, mucosal cytotoxic T lymphocyte response useful in preventing and treating infections with pathogens that gain entry via a mucosal surface.",40,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
6750254,15-Jun-04,2004,6,15,"Nitric oxide-releasing amidine&#8212;and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same","The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/023
6752990,22-Jun-04,2004,6,22,High affinity humanized anti-TAG-72 monoclonal antibodies,"Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.",3,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
6753152,22-Jun-04,2004,6,22,High affinity humanized anti-tag-72 monoclonalantibodies,"Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.",5,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
6753309,22-Jun-04,2004,6,22,Nucleosides for imaging and treatment applications,"Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
6753317,22-Jun-04,2004,6,22,Dmt-Tic di- and tri-peptide derivatives and related compositions and methods of use,"A compound of formula: comprising the Dmt-Tic pharmacophore and related compositions and methods of use in the inhibition of the binding of an opioid receptor-binding compound with a P-glycoprotein, specifically hMDR-1, are provided.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07D/12
6753420,22-Jun-04,2004,6,22,High affinity humanized anti-Tag-72 monoclonal antibodies,"Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.",4,The Dow Chemical Company,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
6756038,29-Jun-04,2004,6,29,Agonist and antagonist peptides of carcinoembryonic antigen (CEA),"The present invention relates to the preparation and use of peptides that act as agonists and antagonists of human carcinoembryonic antigen (CEA). Agonists of the CEA peptide, CAP1, are disclosed and their utility in enhancing immune responses against CEA demonstrated.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70503
6756043,29-Jun-04,2004,6,29,Compositions and methods for detecting adult Taenia solium,"Compositions and methods for the detection of adult Taenia solium and the diagnosis and treatment of T. solium infection are described. The compositions contain one or more adult T. solium polypeptides. The polypeptides are useful as diagnostic agents for the detection of adult tapeworm infection. More preferably, the polypeptides are T. solium glycoprotein antigens referred to herein as T. solium excretory/secretory (TS/ES) polypeptides. The most preferred TS/ES polypeptide has a molecular weight of approximately 33 kDa, 38 kDa, or 42 kDa as determined by SDS-PAGE analysis.",13,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/43554
6756201,29-Jun-04,2004,6,29,Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1,The isolation and characterization of a metastasis tumor suppressor gene KAI1 is disclosed and diagnostic methods and gene therapy approaches utilizing reagents derived from the nucleotide and deduced amino acid sequences of the KAI1 gene are provided.,12,The United States of America as represented by the Department of Health and Services,John Hopkins University,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,G01N/574
6756215,29-Jun-04,2004,6,29,Functionalized TGF-&bgr; fusion proteins,"This disclosure relates to TGF-&bgr; family protein fusions that display substantial native TGF-&bgr; family protein function while also having an additional functionality conveyed by the addition of a functionalizing peptide domain. Such functionalizing peptide domain can be a tag peptide (e.g., an epitope tag, a purification tag, a molecular size differentiation tag, etc.) or a passenger or targeting protein. Also provided are methods of making these fusions, as well as methods of using them for diagnosis and diagnosis of various conditions, in measuring and monitoring levels of the fusion molecule in experimental systems and subjects, and in measuring and detecting receptor proteins.",24,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/495
6756399,29-Jun-04,2004,6,29,Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents,"The present invention provides a method for treating and preventing an epithelial cell-derived cancer in a subject in need thereof, comprising administering to the subject an amount of a 5-lipoxygenase inhibitor and PPAR ligand or derivatives thereof, effective to treat or prevent the epithelial cell-derived cancer. Also encompassed by the invention are inhibitors of enzymes that metabolize arachidonic acid.",55,The United States of America as represented by the Department of Health and Human Services,The United States of America as represented by the Secretary of the Army,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/405
6759525,6-Jul-04,2004,7,6,Protein kinase A and carney complex,"The present invention provides compositions and methods useful in the diagnosis and prognosis of Carney complex (CNC), as well as methods and compositions for the identification of compounds useful in the treatment and/or prevention of CNC. In addition, the present invention provides compositions and methods useful in the diagnosis and treatment of conditions associated with skin pigmentation defects, including but not limited to freckling, as well as endocrine tumors including, but not limited to adrenal and pituitary tumors. In addition, the present invention provides methods and compositions for the diagnosis and treatment of various types of cancers associated with abnormal activity of protein kinase A. In particular, the present invention provides genetic and other sequence information, as well as assay systems that will find use in these and related areas.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
6761884,13-Jul-04,2004,7,13,Vectors including foreign genes and negative selective markers,"A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6762294,13-Jul-04,2004,7,13,Polynucleotides encoding polymorphic human GABAA receptor &agr;-6 subunit,"Compositions and methods based on a polymorphism in the gene encoding the &agr;6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the &agr;6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
6762298,13-Jul-04,2004,7,13,"Thermolabile phosphorus protecting groups, associated intermediates and methods of use","The invention provides a method of thermally deprotecting the internucleosidic phosphorus linkage of an oligonucleotide, which method comprises heating a protected oligonucleotide in a fluid medium at a substantially neutral pH, so as to deprotect the oligonucleotide.The present invention further provides a method of synthesizing an oligonucleotide using the thermal deprotection method described above, and novel oligonucleotides and intermediates that incorporate the thermolabile protecting group used in accordance with the present invention.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
6765104,20-Jul-04,2004,7,20,"Transition metal complexes of n, n',n&#8243;trialkyl-cis-1,3,5-triaminocyclohexane and related compositions and methods of synthesis and use","The present invention provides transition metal complexes of N,N&#8242;,N&#8243;-trialkyl-cis,cis-1,3,5-triaminocyclohexane and related compositions and methods of synthesis and use in vitro and in vivo, such as a therapeutic agent or a delivery/imaging agent.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07F/005
6768014,27-Jul-04,2004,7,27,"PROCESS FOR PREPARING 17&agr;-ACETOXY-11&bgr;-[4-N,N(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS , AND PROCESSES FOR PREPARING SUCH INTERMEDIATES","A compound having general formula (I) in which R1 is a member selected from the group consisting of &#8212;OCH3, &#8212;SCH3, &#8212;N(CH3)2, &#8212;NHCH3, &#8212;CHO, &#8212;COCH3 and &#8212;CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of &#8212;O and &#8212;N&#8212;OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl. In addition to providing the compounds of formula (I), the present invention provides methods wherein the compounds of formula (I) are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07J/00
6770291,3-Aug-04,2004,8,3,Liposome complexes for increased systemic delivery,"Highly efficient cationic liposomes have been developed as an improved delivery system for biologically-active reagents. A novel structure, the sandwich liposome, is formed and comprises one or more biologically active agents internalized between two bilomellar liposomes. This structure protects the incoming agent and accounts for the high efficiency of in vivo delivery and for the broad tissue distribution of the sandwich liposome complexes.These novel liposomes are also highly efficient carriers of nucleic acids. By using extruded DOTAP:cholesterol liposomes to form complexes with DNA encoding specific proteins, expression has been improved dramatically. Highest expression was achieved in the lung, while increased expression was detected in several organs and tissues.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/88
6771067,3-Aug-04,2004,8,3,Ghost artifact cancellation using phased array processing,"A ghost artifact cancellation technique is disclosed. Phased array combining is used to cancel ghosts caused by a variety of distortion mechanisms, including space-variant distortions, such as local flow or off-resonance. The technique uses a constrained optimization that optimizes signal-to-noise ratio (SNR) subject to the constraint of nulling ghost artifacts at known locations. In one aspect multi-coil, k-space data is passed through a converter to convert the k-space data to image domain. After the conversion, the images contain ghost artifacts. The images are then passed through one or more phased array combiners. Each phased array combiner separates the superimposed ghosts to produce an image without ghosts. These images may then be aligned by means of shifting and combined by a variety of means to improve the final image quality. In another aspect, the phase encode order is varied in time to produce ghosts with time varying phase. The series of images are then used to adaptively compute the phased array combiner and output combiner coefficients. The developed technique may be used with phase encode orders which reduce image distortion.",32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/565
6773880,10-Aug-04,2004,8,10,Streptococcus pneumoniale 37-kDa surface adhesion A protein,"The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Further provided is a method of detecting the presence of Streptococcus pneumoniae in a sample comprising the steps of contacting a sample suspected of containing Streptococcus pneumoniae with nucleic acid primers capable of hybridizing to a nucleic acid comprising a portion of the nucleic acid encoding the 37-kDa protein, amplifying the nucleic acid and detecting the presence of an amplification product, the presence of the amplification product indicating the presence of Streptococcus pneumoniae in the sample. Further provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens, methods of preventing and treating Streptococcus pneumoniae infection in a subject.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/3156
6774141,10-Aug-04,2004,8,10,"Calanolide and related antiviral compounds, compositions, and uses thereof","The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.",28,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/14
6774222,10-Aug-04,2004,8,10,"Molecular computing elements, gates and flip-flops","This invention relates to novel molecular constructs that act as various logic elements, i.e., gates and flip-flops. The constructs are useful in a wide variety of contexts including, but not limited to, computation and control systems. The basic functional unit of the construct comprises a nucleic acid having at least two protein binding sites that cannot be simultaneously occupied by their cognate binding protein. This basic unit can be assembled in any number of formats providing molecular constructs that act like traditional digital logic elements (flips-flops, gates, inverters, etc.).",65,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Micro-structural and nano-technology,Computer technology,,,,B82Y/00
6780413,24-Aug-04,2004,8,24,Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders,Compositions and methods for treatment of focal muscle spasms. Immunotoxin conjugates comprise a toxin conjugated to an antibody reactive to a muscle specific antigen.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/286
6780417,24-Aug-04,2004,8,24,Transmission blocking immunogen from malaria,"The present invention relates to transmission blocking vaccines against malaria. Vaccines of the present invention contain a recombinant virus encoding all, or a unique portion, of the 25 kDa sexual stage surface protein of Plasmodium falciparum, Pfs25, or the Pfs25 protein purified from host cells infected with the above-described recombinant virus. Mice inoculated with the recombinant virus developed antibodies with transmission blocking activity. The present invention also relates to recombinant viruses used in the vaccines of the present invention, host cells infected with the recombinant viruses of the present invention and methods of preventing or treating malarial infections using the vaccines of the present invention.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
6780847,24-Aug-04,2004,8,24,"Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins","An isolated and purified nucleic acid molecule that encodes a protein or peptide comprising at least nine contiguous amino acids of SEQ ID NO:2, wherein the at least nine contiguous amino acids comprise amino acids 30-32 of SEQ ID NO: 2 which have been rendered glycosylation resistant and wherein the at least nine contiguous amino acids have antiviral activity, a vector comprising such an isolated and purified nucleic acid molecule, a host cell or organism comprising the vector, a method of producing an antiviral protein or antiviral peptide, the antiviral protein or antiviral peptide itself, a conjugate comprising the antiviral protein or antiviral peptide, and compositions comprising an effective amount of the antiviral protein, antiviral peptide, antiviral protein conjugate or antiviral peptide conjugate. Further provided is a method of inhibiting prophylactically or therapeutically a viral infection, specifically an influenza viral infection, of a host.",57,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Pharmaceuticals,Biotechnology,,,,A61K/164
6783734,31-Aug-04,2004,8,31,Convex geometry adhesive film system for laser capture microdissection,"A tissue sample is conventionally visualized in a microscope. A selectively activated convex surface is provided, preferably at the distal end of a rod. This selectively activated convex surface when activated, typically with a laser through an optic light path in the microscope, provides the activated region with adhesive properties. At least one portion of the tissue sample which is to be extracted is identified. This identified portion is contacted with a portion of the selectively activated convex surface on the end of the rod. When the convex surface is activated, typically by exposure to laser light in the footprint of the desired sample, an adhesive transfer surface on the selectively activated convex surface is provided which adheres to the desired cells in the footprint of the desired sample. Thereafter, the adhesive transfer surface is separated from the remainder of the tissue sample while maintaining adhesion with the desired cells. Thus the desired portion of the tissue sample is extracted. The disclosed selectively activated convex surface is preferably utilized to collect desired tissue samples at more than one location on the same slide or from different slides. The collected tissue samples can thereafter be inspected if desired, as collected on the convex surface, and then liberated&#8212;as by dissolving the proteins of the samples. This can effectively concentrate rarely occurring cells in order to obtain enough pure material for analysis. A rod having a convex surface with the selectively activated material is set forth as a staple for use with the apparatus and process. Preferred shapes for the convex surface are disclosed as well as a method for coating rods with a resultant rod article.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Optics,Measurement,,,,,G02B/34
6787126,7-Sep-04,2004,9,7,Method and kit for detecting resistance to antiviral drugs,An assay and kit for the detection of phenotypic resistance of a retrovirus to a reverse transcriptase inhibitor drug in a biological sample. The assay is based on the direct analysis of the susceptibility of retroviral reverse transcriptase to inhibition by a reverse transcriptase inhibitor drug. The enzymatic activity of the reverse transcriptase is determined by measuring the DNA product produced when an RNA template and a first complementary DNA primer from a suitable region of the encephalomyocarditis virus genome are incubated with a biological sample containing reverse transcriptase in the presence of the drug to which resistance is being determined.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/702
6787145,7-Sep-04,2004,9,7,Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines,"A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12N/1131
6787306,7-Sep-04,2004,9,7,Methods and compositions for detecting dihydropyrimidine dehydrogenase splicing mutations,"The present invention provides compositions, methods and kits for the detection of genetic polymorphisms or mutations related to dihydropyrimidine dehydrogenase deficiency (DPDD). The polymorphism or mutations generally occur in the dihydropyrimidine dehydrogenase DPD gene in chromosome 1. Also provided are mutant forms of DPD.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
6787333,7-Sep-04,2004,9,7,Retrovirus isolated from humans,"The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6787356,7-Sep-04,2004,9,7,Cell expansion system for use in neural transplantation,"The invention provides a method of culturing cells which includes a proliferating step in which the number of precursor cells is expanded and a differentiating step in which the expanded precursor cells develop into neuronal cells. The proliferating step includes the step of incubating the precursor cells in proliferating medium which includes basic fibroblast growth factor (bFGF). The differentiating step includes incubating the precursor cells in differentiation media in a manner effective to form a cellular aggregate that is not adhered to any surface of the incubation vessel. In a preferred embodiment, the cells arc incubated in a roller tube. The differentiation media can also include at least one differentiating agent. The invention also provides a method for treating a neurological disorder, such as Parkinson's disease, a method of introducing a gene product into a brain of a patient, an assay for neurologically active substances, and a cell culture.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0619
6790449,14-Sep-04,2004,9,14,"Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins","RNA synthesis by the paramyxovirus respiratory syncytial virus (RSV), a ubiquitous human pathogen, was found to be more complex than previously appreciated for the nonsegmented negative-strand RNA viruses. Intracellular RNA replication of a plasmid-encoded &#8220;minigenome&#8221; analog of viral genomic RNA was directed by coexpression of the nucleocapsid (N) protein, nucleocapsid phosphoprotein (P), and the large polymerase (L) protein. But, under these conditions, it appeared that the greater part of mRNA synthesis terminated prematurely. However, coexpression of the M2 (ORF1) gene resulted in the efficient production of full-length mRNA. Thus, these results demonstrate that expression of the upstream ORF1, which encoded the previously described 22-kDa M2 protein, was associated with transcription elongation. Accordingly, the claimed invention is directed toward infectious recombinant RSV particles which comprise a recombinant genome or antigenome, as well as the RSV proteins N, P, L, and the RNA polymerase elongation factor M2. This system will permit the introduction of defined changes into infectious RSV which will prove useful in a variety of applications, such as the analysis of RSV molecular biology and pathogenesis, the development of attenuated RSV immunogenic compositions for the preparation of RSV-specific immunological reagents, and the expression of foreign antigens.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6790636,14-Sep-04,2004,9,14,Rapid fluorescent labeling of tissue for microdissection using fluorescent specific binding agents,Methods are disclosed for rapid and specific fluorescent staining of biological tissue samples that substantially preserve biological molecules such as mRNA. Methods for microdissecting tissue to obtain pure populations of cells or tissue structures based upon identifying and excising cells or tissue structures that are labeled with fluorescent specific binding agents are also included. A laser capture microdissection apparatus useful for identifying and isolating cells and tissue structures following rapid immunofluorescent staining is also disclosed.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Measurement,,,,,G01N/533
6790657,14-Sep-04,2004,9,14,Lentivirus vector system,"A method is disclosed for improving encapsidation of transgene RNA using retroviral packaging and transfer vectors. An HIV-2 transfer vector, which includes the transgene, is introduced into a packaging cell that is also transfected with (or stably expresses) an HIV-2 derived packaging vector or a combination of packaging vectors. The packaging vector has mutations in packaging signal sequences that are both upstream and downstream of the 5&#8242; splice donor site. It can also be composed of a combination of two or more partial vectors. A transfer vector, which is introduced into the packaging cell line, has a mutation that renders its splice donor site non-functional. Transgene RNA expression and encapsidation from these cells is markedly increased, but with little or no levels of infectious viral RNA encapsidation.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6790936,14-Sep-04,2004,9,14,CAI resistance proteins and uses thereof,"The invention provides for proteins correlated with cellular resistance to carboxyamido-triazole (CAI) which have at least one Src homology 3 (SH3) binding domain, and functionally equivalent compounds.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/52
6790948,14-Sep-04,2004,9,14,Tumor suppressor gene p33ING2,"The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/02
6794174,21-Sep-04,2004,9,21,Full-length infectious cDNA clones of tick borne flavivirus,Embodiments described herein include full-length infectious cDNA clones of Langat tick-borne flavivirus.,20,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6794188,21-Sep-04,2004,9,21,Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of genes into mammalian cells and therapeutic uses thereof,"Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an envelope gene from a virus capable of infecting both mammalian and avian cells. The resulting recombinant ASLV-derived retroviral vectors can replicate efficiently in avian cells, infect both avian and mammalian cells in high titer, and are replication-defective in mammalian cells. Thus, they are quite safe and advantageous for use in gene therapy and vaccines.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6794498,21-Sep-04,2004,9,21,Method of eliminating inhibitory/instability regions of mRNA,A method of locating an inhibitory/instability sequence or sequences within the coding region of an mRNA and modifying the gene encoding that mRNA to remove these inhibitory/instability sequences by making clustered nucleotide substitutions without altering the coding capacity of the gene is disclosed. Constructs containing these mutated genes and host cells containing these constructs are also disclosed. The method and constructs are exemplified by the mutation of a Human Immunodeficiency Virus-1 Rev-dependent gag gene to a Rev-independent gag gene. Constructs useful in locating inhibitory/instability sequences within either the coding region or the 3&#8242; untranslated region of an mRNA are also disclosed. The exemplified constructs of the invention may also be useful in HIV-1 immunotherapy and immunoprophylaxis.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
6797275,28-Sep-04,2004,9,28,Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine,"This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0275
6797485,28-Sep-04,2004,9,28,Mass spectrometry of colonization factors,"Disclosed herein are methods for identifying at least one bacterial colonization factor of enterotoxigenic E. coil which comprise the following steps in the following order: 1) obtaining the colonization factor; 2) solubilizing the colonization factor by dissolving the colonization factor in 1,1,1,3,3,3-hexafluoro-2-propanol; 3) adding a solution of volatile acid to the solubilized colonization factor of step 2 to obtain a product; 4) subjecting the product of step 3 to mass spectrometry to determine the mass of the colonization factor; and 5) comparing the mass determined in step 4 with the mass of at least one known colonization factor.",11,The United States of America as represented by the Secretary of the Army,,,,,,,,,,,1,Biotechnology,,,,,,C07K/245
6797492,28-Sep-04,2004,9,28,Method for reducing the immunogenicity of antibody variable domains,A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.,3,"Merck & Co., Inc.",United States of America,,,,,,,,,,2,Biotechnology,,,,,,C07K/467
6800475,5-Oct-04,2004,10,5,Isolation of a human retrovirus,"The present invention comprises compositions and methods comprising a spumavirus isolated from a human. More specifically, the spumavirus of the present invention was isolated from a human who had exposure to nonhuman primates. Importantly, the methods and compositions of the present invention comprising the spumavirus and including antibodies to the spumavirus, can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The present invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6802967,12-Oct-04,2004,10,12,Multi-dimension liquid chromatography separation system,"Liquid chromatography based on the difference of two or more kinds of separation modes, (e.g., chemical or physical properties of analytes) may improve separations when samples contain complex mixtures. In this invention, the analytes separated on the 1st analysis system (consisting of the 1st column and the 1st mobile phase) will be trapped onto individual trapping columns. Then the trapped analytes will be loaded onto the 2nd analysis system consisting of the 2nd column and the 2nd mobile phase. This invention has the trapping and loading mechanism consisting of a combination of switching valves necessary to produce the serial separations. Also this invention has the capability to affect online desalting when it is needed depending on a detector or the nature of the analyte mixture.",4,Shimadzu Corporation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Measurement,,,,,,G01N/463
6808877,26-Oct-04,2004,10,26,Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection,"The present invention relates to the discovery of molecules that inhibit viral infection and promote a host immune response to a pathogen. More specifically, the invention disclosed herein concerns molecules that interact with a FPR class receptor, inhibit HIV infection, and stimulate an inflammatory response in a subject. Embodiments of the invention include biotechnological tools, prophylactics, therapeutics, and methods of use of the foregoing, for the study, treatment, and prevention of HIV infection and the induction of an inflammatory response in a subject.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/06
6808931,26-Oct-04,2004,10,26,Method for the determination of hexavalent chromium using ultrasonication and strong anion exchange solid phase extraction,"A method for the determination of hexavalent chromium (CrVI) in environmental and industrial hygiene samples is provided. Based on the chemical properties of chromium species in aqueous solutions, a simple, fast, sensitive, and economical field method has been developed and evaluated for the determination of hexavalent chromium (CrVI). Using ultrasonic extraction in combination with a strong anion exchange solid phase extraction (SAE-SPE) technique, the filtration, preconcentration, and isolation of CrVI in the presence of other chromium species and interferents was achieved. The method generally involves: (1) ultrasonication in basic buffer solution to extract CrVI from environmental matrices; (2) strong anionic exchange solid phase extraction to separate CrVI from other chromium species and potential interferents; (3) acidification of the eluate containing the CrVI ions; (4) complexation of CrVI with a complexing agent to form a soluble, colored CrVI-complex; and (5) spectrophotometric determination of the colored CrVI-complex. Preferably, the ultrasonication step is carried out in the presence of a slightly basic ammonium buffer and the complexing agent is 1,5-diphenylcarbazide.",19,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/22
6809184,26-Oct-04,2004,10,26,"Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use","Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.",52,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/57492
6810353,26-Oct-04,2004,10,26,Non-directional magnet field based proximity receiver with multiple warning and machine shutdown capability,"A hazardous area warning system with a non-directional magnetic field based proximity receiver for warning personnel of an attendant hazard. The receiver includes a x-axis receiver with an antenna directed in a x direction, a y-axis receiver with an antenna directed in a y direction and a z-axis receiver with an antenna directed in a z direction. The antennas may be a wire loop wrapped around a ferrite core. The output from each of the three receivers are combined in an adder. The combined result from the adder is representative of the distance between the receiver and a warning transmitter antenna. A comparator determines whether the received signal indicates an attendant hazard, i.e., the receiver is too close to the warning transmitter. The receiver wearer is warned of the attendant hazard, visually and/or tactilly, e.g., with warning lights and/or vibrations. An encoder encodes the signal indication and a transmitter transmits the encoded signal. A data link receiver (located, for example, at a potentially hazardous machine) receives the encoded signal from the proximity receiver. The data link receiver decodes the encoded signal and activates a safety indicator light in response to the decoded information, a green light indicating normal operation, a yellow light indicating a caution or potentially hazardous condition, and a red light indicating danger. The data link receiver may shutdown and/or disable the machinery in a caution or dangerous condition.",26,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control",,,,,,,,,,,1,Control,Mechanical elements,,,,,G08B/0213
6812246,2-Nov-04,2004,11,2,"Aminoflavone compounds, compositions, and methods of use thereof","The invention provides an aminoflavone having formula (I), wherein each of R1 and R2 is H, COCH2&#8212;R7, wherein R7 is amino alkylamino, dialkylamino, or alkyl- or dialkylaminoalkyl, or an &agr;-amino acid residue, provided that at least one of R1 or R2 is other than H, and R3 is H, branched or straight-chain alkyl, hydroxyalkyl, alkanoyloxyalkyl, alkanoyloxy, alkoxy, or alkoxyalkyl, or pharmaceutically acceptable salts thereof. The present invention also provides a pharmaceutical composition comprising an aminoflavone as described above, and a method of inhibiting the growth of a tumor in a host by administering a tumor growth-inhibiting amount of an aminoflavone compound having the formula as described above.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/30
6815172,9-Nov-04,2004,11,9,Methods and compositions for opsonophagocytic assays,"Methods and compositions comprising immunoassays for the detection of functional antibodies and the analysis of vaccine efficacy are described. In particular, the present invention provides opsonophagocytic assays. The assays are useful for the rapid and simultaneous detection of multiple different functional antibodies. In preferred embodiments, the assays include fluorescent labels of multiple colors and/or intensities.",33,The United States of America as represented by the Department of Health and Human Services,"Flow Applications, Inc.",,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/56911
6815173,9-Nov-04,2004,11,9,Method for detecting syphilis using synthetic antigents,An antigen composition and method for the detection of antibodies to Treponema pallidum and the diagnosis of syphilis are described. The antigen composition contains synthetic cardiolipin and synthetic lecithin. The antigen composition may additionally contain cholesterol and an alcohol. The antigen composition is useful as an immunoreagent in immunoassays for the detection of antibodies associated with T. pallidum infection. The methods are sensitive and specific for T. pallidum infection.,23,The United States of America as represented by the Department of Health and Human Services,Centers for Disease Control & Prevention,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/92
6818749,16-Nov-04,2004,11,16,Variants of humanized anti carcinoma monoclonal antibody cc49,The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.,47,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/0002
6821511,23-Nov-04,2004,11,23,Methods of using adeno-associated virus rep protein,"A composition for delivering at least one DNA sequence encoding a desired protein or polypeptide (such as a therapeutic agent) to a cell. The composition comprises an adeno-associated virus rep protein (or a nucleic acid sequence encoding an adeno-associated virus rep protein) and a genetic construct including at least one DNA sequence encoding a protein or polypeptide or genetic transcript of interest and a promoter controlling the at least one DNA sequence. The genetic construct also includes a first adeno-associated virus ITR or protein or derivative thereof and a second adeno-associated virus ITR or a portion or derivative thereof. The first and second adeno-associated virus ITRs or portions or derivatives thereof flank the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest and the promoter controlling the at least one DNA sequence encoding the protein or polypeptide or genetic transcript of interest. Such a composition provides for integration of genetic material at a specific locus in the human chromosome, while minimizing the possibility of inadvertent inactivation of host genes and minimizing the possibility of viral contamination.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
6825206,30-Nov-04,2004,11,30,Camptothecin compounds with a thioether group,Camptothecin compounds which are effective anti-tumor compounds are disclosed. These conjugates inhibit the enzyme topoisomerase I and enhance the stability of the topoisomerase I-DNA cleavable complex.,8,Research Triangle Institute,Duke University,National Institutes of Health,,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,C07D/22
6828309,7-Dec-04,2004,12,7,Use of pentosan polysulfate to treat certain conditions of the prostate,"The invention relates to the field of pharmacology. More particularly, the invention relates to the treatment of prostate conditions, such as BPH. The invention provides new therapeutic compositions and methods for treating BPH, as well as chronic prostatitis, prostadynia, and irritative bladder conditions, other than interstitial cystitis. The compositions and methods according to the invention, which may be administered orally, efficaciously and safely treat the designated conditions by causing regression of established lesions and reduction of bladder irritation. In particular, the compositions and methods of the invention treat BPH by reducing the size of the prostate gland and decreasing the associated obstructive symptoms.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/715
6828416,7-Dec-04,2004,12,7,Recombinant multivalent malarial vaccine against Plasmodium falciparum,"A recombinant protein is provided which comprises peptides derived from different stages in the life cycle of parasite Plasmodium falciparum. The protein is useful as a reagent and, when combined with a pharmaceutically-acceptable vehicle or carrier, is useful as a vaccine against the material parasite Plasmodium falciparum. A genetic construct used to produce this recombinant protein vaccine is also described. In addition, antibodies to this recombinant protein are provided which are useful for the detection and measurement of peptides derived from different stages in the life cycle of the parasite Plasmodium falciparum.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
6830893,14-Dec-04,2004,12,14,T20/DP178 is an activator of human phagocyte formyl peptide receptors,"The present invention relates to the discovery that T20/DP178, T21/DP107, and fragments thereof interact with members of the formyl peptide receptor family and thereby modulate cell migration and activation. Novel biological tools, prophylactics, therapeutics and methods of use of the foregoing for modulating an inflammatory response are disclosed.",5,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
6831170,14-Dec-04,2004,12,14,Fibroblast growth factor receptor activating gene I and related compositions and methods,"A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4702
6833128,21-Dec-04,2004,12,21,Method for monitoring local reaction associated with injections,"A method is disclosed for monitoring local reactions, such as inflammatory responses, associated with injection sites. The method is performed using a temporary tattoo, which is transferred from a substrate to the skin of a subject, to measure the local reaction to an injection. A kit is also disclosed that can be used to perform the disclosed method. One example of the method includes transferring from the substrate to the subject's skin a temporary tattoo having a plurality of concentric rings and using the rings to measure the local reaction. For example, if the local reaction exceeds the boundary of the largest ring, the local reaction is considered clinically significant and additional medical interventions may be sought.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0006
6833132,21-Dec-04,2004,12,21,Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity,"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",121,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6876
6838090,4-Jan-05,2005,1,4,Water-insoluble drug delivery system,"The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4196
6838237,4-Jan-05,2005,1,4,Antigenically reactive regions of the hepatitis a virus polyprotein,"Antigenically reactive regions of the Hepatitis A virus polyprotein are provided. These antigenically reactive regions, and polypeptides and proteins comprising these antigenically reactive regions, provide a sensitive and specific immunological hepatitis A virus detection assay. The specific use of regions derived from the nonstructural regions of the polypeptide provides the basis for determining immunity derived from prior or present infection by the Hepatitis A virus and allows one to distinguish between an immunological response derived from infection and that derived from immunization.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6838580,4-Jan-05,2005,1,4,Opioid derivative,"1. A peptide derivative represented by the following formula (1) or a salt thereof; wherein R1 is hydrogen atom or methyl group, R2 is hydrogen atom or hydroxy group and n is an integer of 1-8, provided that R1 is hydrogen atom when R2 is hydrogen atom, which has specific and high binding affinity with the μ-opioid receptor.",6,"Teikoku Seiyaku Co., Ltd.",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/20
6844190,18-Jan-05,2005,1,18,St-B17 serotonin receptor,"Genes encoding the St-B17 serotonin receptor protein were cloned and characterized from a rat striatum mRNA and a human genomic library. The St-B17 receptor has nucleotide and amino acid homology with previously described 5-HT genes and can bind ligands that are known to interact with serotonin receptors. In addition, the levels of intracellular cAMP in cells transfected with the receptor gene respond in a dose dependent manner to introduction of serotonin in the media.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70571
6845342,18-Jan-05,2005,1,18,Determination of an empirical statistical distribution of the diffusion tensor in MRI,"Diffusion tensor magnetic resonance signals are analyzed. Diffusion weighted, signals are acquired, each signal having a plurality of voxels (10). The diffusion weighted signals are sampled to obtain at least one set of resampled diffusion weighted signals (11). A diffusion tensor for each voxel is determined from each set of the resampled diffusion weighted signals (12). An empirical statistical distribution is determined for a quantity associated with the diffusion tensor from the diffusion tensors determined from the at least one set of the resampled diffusion weighted signals (13).",44,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56341
6846621,25-Jan-05,2005,1,25,Typing of human enteroviruses,"The present invention discloses a method for detecting the presence of an enterovirus in a clinical sample. The invention additionally discloses a method for typing an enterovirus in a clinical sample. Both methods employ a set of primer oligonucleotides for reverse transcription and amplification that hybridize to conserved regions of the enterovirus genome, and that provide amplicons that include significant portions of the VP1 region that are characteristic of the various serotypes. In the typing method, the invention further provides a database consisting of nucleotide sequences from prototypical enteroviral serotypes, which is used to type the clinical sample by comparing the sequence of its amplicon with each prototypical sequence in the database. The invention additionally provides mixtures of primer oligonucleotides, and a kit for use in conducting the typing method that includes a mixture of the primer oligonucleotides.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12Q/701
6846636,25-Jan-05,2005,1,25,Methods and compositions for HDL holoparticle uptake receptor,"The present invention provides an isolated mammalian receptor which specifically binds a high density lipoprotein holoparticle, comprising a subunit of approximately 45-600 kDa molecular weight and one or more subunits selected from the group consisting of a subunit of approximately 40-50 kDa molecular weight, a subunit of approximately 120 kDa molecular weight and a subunit of approximately 400 kDa molecular weight. In addition, the present invention provides a method of screening a substance for the ability to modulate the HDL holoparticle binding and/or internalization activity of the receptor of this invention, comprising: a) contacting the substance with a cell producing a functional HDL receptor; and b) assaying the cell for a modulation of the HDL holoparticle binding and/or internalization activity of the receptor, whereby a modulation of the HDL holoparticle binding and/or internalization activity of the receptor identifies a substance with the ability to modulate the HDL holoparticle binding and/or internalization activity of the ADL receptor.",3,American National Red Cross,The United States of America as represented by the Department of Health and Human Services,MUSC Foundation for Research Development,,,,,,,,,3,Biotechnology,,,,,,C07K/705
6846911,25-Jan-05,2005,1,25,Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit,"Isolated proteins comprising the T-cell surface antigen CD97 α are provided. Compositions and methods for making and detecting CD97 α are also provided. Further, the invention provides diagnostic and therapeutic methods and compositions for medical conditions involving CD97. The inventions also provides antibody compositions that bind specifically to CD97 α subunits.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/2896
6849266,1-Feb-05,2005,2,1,Control of arthropod vectors of parasitic diseases,"The present invention provides a method for controlling ectoparasites of small rodents, thereby preventing the transmission of diseases by arthropod vectors. The invention further provides an enclosure having openings for entry of rodents, and having arranged therein one or more applicators which are configured to contact rodents entering the chamber and having an ectoparasiticide on the applicator for application to the rodents.",31,Centers for Disease Control & Prevention,,,,,,,,,,,1,Pharmaceuticals,Other special machines,,,,,A61K/4439
6849417,1-Feb-05,2005,2,1,Mammalian selenoprotein differentially expressed in tumor cells,"A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
6852324,8-Feb-05,2005,2,8,Immunization for ebola virus infection,"Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the nucleic acid molecule encodes the viral nucleoprotein (NP). Methods for immunizing a subject against disease caused by infection with Ebola virus are also provided.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6852686,8-Feb-05,2005,2,8,Methods for ameliorating icthyosiform skin diseases,"The present invention relates to the discovery of a method to provide stabilized transglutaminase 1 enzyme, involucrin, and other molecules necessary for the assembly of the cell envelope to skin cells. Novel biological tools, prophylactics, therapeutics, cosmetics, and methods of use of the foregoing for study, prevention, and treatment of skin disorders are also disclosed.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1044
6852842,8-Feb-05,2005,2,8,Methods for functional kidney imaging using small dendrimer contrast agents,"Small dendrimer-based MRI contrast agents are disclosed to accumulate in renal tubules. The accumulation enables visualization of renal structure and function, permitting assessment of structural and functional damage to the kidneys. In a disclosed embodiment, six, small dendrimer-based MRI contrast agents were synthesized, and their pharmacokinetics, whole body retention, and renal MRI images were evaluated in mice. Surprisingly, despite having unequal renal clearance properties, all of the dendrimer agents clearly visualized the renal anatomy and proximal straight tubules of the mice better than Gd-[DTPA]-dimeglumine. Dendrimer conjugate contrast agents prepared from PAMAM-G2D, DAB-G3D, and DAB-G2D dendrimers were excreted rapidly and may be acceptable for use in clinical applications.",49,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,,,,,A61K/124
6855314,15-Feb-05,2005,2,15,AAV5 vector for transducing brain cells and lung cells,"The present invention provides methods of delivering nucleic acids to specific regions, tissues and cell types of the CNS. More particularly the invention provides methods of delivering nucleic acids to cells of the CNS such as cerebellar cells and ependymal cells. The invention also provides methods of delivering nucleic acids to cells of the lung such as alveolar cells using AAV5 vectors and particles.",9,The United States of America as represented by the Department of Health and Human Services,University of Iowa Research Foundation,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
6855323,15-Feb-05,2005,2,15,Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A,"The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/445
6858211,22-Feb-05,2005,2,22,Vaccines against Escherichia coli O157 infection,"This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-D-GalpNAc-(1→2)-α-D-PerpNAc-(1→3)-α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide of E. coli O157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0258
6858712,22-Feb-05,2005,2,22,Cloning and expression of HTLV-III DNA,"The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.",16,The United States of America as represented by the Department of Health and Human Services,"Centocor, Inc.",,,,,,,,,,2,Biotechnology,,,,,,C12Q/702
6861415,1-Mar-05,2005,3,1,21-substituted progesterone derivatives as new antiprogestational agents,"A compound having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.",36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07J/00
6863885,8-Mar-05,2005,3,8,Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment,"The present invention provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiation, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiation; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiation. The invention also provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiomimetic compound, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiomimetic compound; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiomimetic compound.",4,The United States of America as represented by the Department of Health and Human Servies,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/193
6867017,15-Mar-05,2005,3,15,ATP-binding transporter (ABC7) and methods for detection of anemia and ataxia,"Disclosed is a novel ATP-binding cassette gene (ABC7), polypeptide and methods of detecting mutations therein. Further, the disclosure provides methods of detecting ABC7 associated disease and treatments thereof. In particular, the disclosure provides methods of detecting X-linked Sideroblastic Anemia and Ataxia associated with a mutation in the ABC7 polypeptide.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/04
6867038,15-Mar-05,2005,3,15,Isolation of cellular material under microscopic visualization,"A method of microdissection which involves forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes a selectively activatable adhesive layer which provides, for example, chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated, the transfer surface and tissue sample are separated. During separation, the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample, the zone of cells of interest may then be molecularly analyzed.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Analysis of biological materials,Optics,,,,G01N/2813
6867180,15-Mar-05,2005,3,15,"Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth","Methods for inhibiting endothelial cell growth and angiogenesis, and suppressing tumor growth using calreticulin, fragments of calreticulin and variants of calreticulin are provided. Such methods are useful for the treatment of cancer and diseases associated with unwanted angiogenesis, for example chronic retinal detachment.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4725
6869604,22-Mar-05,2005,3,22,Recombinant anti-tumor RNAse,"This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermore, these proteins are more active than ribonucleases currently available even though the proteins of this invention lack an N-terminal pyroglutamic acid, which has been found to be necessary for ribonucleolytic activity. Because these proteins are recombinant proteins, mutations which increase cytotoxicity can be engineered.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/22
6869924,22-Mar-05,2005,3,22,"Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof","Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. The cloning of full length cDNA for the peptide products is also provided, as well as recombinant methods for the production of monocyte chemoattractant products. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/523
6869925,22-Mar-05,2005,3,22,Inhibition of retrovirus infection,"Methods and pharmaceutical compositions are provided to prevent retroviral infections of host cells. More particularly, the invention relates to prevention of HIV infection of human cells by serine leukocyte protease inhibitor (SLPI).",22,Amgen Inc.,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/811
6875855,5-Apr-05,2005,4,5,NUCLEIC ACID AND AMINO ACID SEQUENCES OF HEMOGLOBIN-RESPONSE GENES IN CANDIDA ALBICANS AND THE USE OF REAGENTS DERIVED FROM THESE SEQUENCES IN THE DIAGNOSIS OF DISSEMINATED CANDIDA ALBICANS INFECTION,"Three hemoglobin-response genes in the pathogenic yeast Candida albicans are disclosed. The expression of these genes is specifically induced when the organism is exposed to hemoglobin during disseminated infections. The invention relates to the nucleic acid and amino acid sequences of these hemoglobin-response genes. The invention also relates to diagnostic methods, kits and compositions which employ the nucleic acid and amino acid sequences of the invention.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/40
6881718,19-Apr-05,2005,4,19,Disulfide conjugated cell toxins and methods of making and using them,The invention pertains to the discovery of novel disulfide linked cell toxins which can ablate NK-1 receptor expressing cells. These toxins are used as pharmaceutical compositions for the ablation of NK1 receptor expressing cells and comprise a substance P (SP)-Pseudomonas exotoxin disulfide linked conjugate. The invention also includes methods of making and using these toxins and pharmaceutical compositions.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/22
6884413,26-Apr-05,2005,4,26,Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (GCS),"The present invention concerns methods of specifically inhibiting an immune response of a subject to one or more selected antigens using an immunosuppressive composition derived from a glioblastoma cell line. The method steps include obtaining a population of antigen presenting cells (APCs); loading the APC population with specific antigens (in auto-immune diseases) or using donor APCs (for transplantation); incubating the APC population with the immunosuppressive composition; and introducing the incubated cells into the subject being treated. The APCs can be monocytes, macrophages, or dendritic cells. This method causes specific inhibition of the immune response because it induces apoptosis and/or anergy in the subject's T cells specific for antigens present on the APCs, but does not affect the immune response to antigens not present on the APC surfaces. One particular embodiment of the present method is the specific inhibition of a transplant recipient's immune reaction to antigens present on the allogenic graft. A second particular embodiment of the present method is the specific inhibition of the immune response to an autoantigenic protein by a subject suffering from an autoimmune disease.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/13
6884414,26-Apr-05,2005,4,26,Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents,"The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.",2,Mount Sinai School of Medicine of New York University,The United State of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
6884871,26-Apr-05,2005,4,26,Isolation and use of tissue growth-inducing Frzb protein,"An isolated cDNA encoding a growth-inducing protein, Frzb, capable of stimulating bone, cartilage, muscle and nerve tissue formation. The CDNA and protein sequences of human and bovine frzb are provided. Production and purification of recombinant Frzb are also described.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/71
6884873,26-Apr-05,2005,4,26,Kit for determining DNA double-stranded breaks with anti-γ-H2A antibodies,The present invention provides an isolated or purified antibody or antigenically-reactive fragment thereof that specifically binds to a C-terminal phosphorylated serine in an H2A histone protein and a product comprising the same. The present invention further provides fusion proteins comprising the isolated or purified antibody or antigenically-reactive fragment thereof. Also provided by the present invention are a method and a kit for determining double-stranded breaks in DNA. The method comprises contacting a sample comprising H2A histone proteins with the isolated or purified antibody or antigenically-reactive fragment thereof and detecting binding of the antibody or fragment thereof to an H2A histone protein in the sample. The detection of the binding of the antibody or fragment thereof to the H2A histone protein indicates the presence of a DNA double-stranded break in DNA.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/6875
6887485,3-May-05,2005,5,3,Nitric oxide-releasing metallic medical devices,"Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.",4,"Medtronic Vascular, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Medical technology,Pharmaceuticals,,,,,A61L/04
6890917,10-May-05,2005,5,10,Geldanamycin derivative and method of treating cancer using same,"A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
6893835,17-May-05,2005,5,17,Anthrax lethal factor is a MAPK kinase protease,"The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
6893841,17-May-05,2005,5,17,"Nucleic acids of the human ABCC11 gene, vectors containing such nucleic acids and uses thereof","The present invention relates to nucleic acids corresponding to various exons of the ABCC11 gene as well as the cDNA encoding the novel full length of ABCC11 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABCC11 gene or in the corresponding protein produced by the allelic form of the ABCC11 gene.",10,Aventis Pharma S.A.,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6883
6893869,17-May-05,2005,5,17,Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule,The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.,15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/705
6894068,17-May-05,2005,5,17,Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase,"The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside inhibitors of RT. In preferred embodiments, the present invention provides a novel class of substituted benzimidazoles, effective in the inhibition of human immunodeficiency virus (HIV) RT.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/06
6894152,17-May-05,2005,5,17,Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA,"This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments of the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.",36,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,,,,,,C12Q/703
6896892,24-May-05,2005,5,24,Insecticide-impregnated fabric and method of production,"An insecticide-impregnated fabric that remains sufficiently effective at killing and repelling disease vector insects after repeated washings with detergent and water is described. The fabric is impregnated with an insecticide composition containing an insecticide, a cyclodextrin, and a binding agent. The resulting fabric is useful for providing personal protection against disease-carrying insect vectors, particularly when assembled as a bednet in regions of the world where malaria is prevalent, and will remain effective for a longer period of time before re-impregnation is necessary.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Basic materials chemistry,Textile and paper machines,,,,,A01N/34
6897018,24-May-05,2005,5,24,DLC-1 gene deleted in cancers,"A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4703
6897022,24-May-05,2005,5,24,Susceptability and resistance genes for bipolar affective disorder,"Chromosomal regions comprising loci associated with susceptibility and resistance to bipolar affective disorder have been identified. Methods and compositions are provided for determining the contribution of these chromosomal regions to bipolar affective disorder in an affected family, for determining in an affected family a genotype associated with increased or decreased susceptibility or resistance to bipolar illness, and for assessing an increased or decreased risk of developing bipolar illness for a tested individual from an affected family.",12,University of Miami,The United States of America as represented by the Secretary of Health & Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12Q/6883
6897038,24-May-05,2005,5,24,Method of laser capture microdissection from a sample utilizing short pulse length,"Laser capture microdissection occurs where the transfer polymer film is placed on a substrate overlying visualized and selected cellular material from a sample for extraction. The transfer polymer film is focally activated (melted) with a pulse brief enough to allow the melted volume to be confined to that polymer directly irradiated. This invention uses brief pulses to reduce the thermal diffusion into surrounding non-irradiated polymer, preventing it from being heated hot enough to melt while providing sufficient heat by direct absorption in the small focal volume directly irradiated by the focused laser beam. This method can be used both in previously disclosed contact LCM, non contact LCM, using either condenser-side (or beam passes through polymer before tissue) or epi-irradiation (or laser passes through tissue before polymer). It can be used in configuration in which laser passes through tissue before polymer with and without an additional rigid substrate. In its preferred configuration it uses the inertial confinement of the surrounding unmelted thermoplastic polymer (and the overlying rigid substrate) to force expansion of the melted polymer into the underlying tissue target. Utilizing the short pulse protocol, the targeted and extracted material can have a diameter equal to or smaller than the exciting beam.",3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/2813
6897783,24-May-05,2005,5,24,Electrical injury protection system using radio frequency transmission,"A personal electrical injury protection system is provided which can be worn by electricians, construction workers, or other individuals working around or with low-voltage lines (i.e. generally less than about 600 volts). The personal electrical injury protection system has both a proximity warning component which provides a warning of potential electrical hazards upon close approach to the low-voltage power line and an electrical contact protection component which turns off the power upon actual electrical contact with the power line. The present personal electrical protection system relies on a radio frequency transmitter attached to the worker or person to be protected and a radio receiver/controller connected to the power line. The radio frequency transmitter has a low frequency generator which is used for electrical-contact protection and a high frequency generator which is used for proximity warning.",33,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Electrical machinery, apparatus, energy",,,,,,H02H/12
6898533,24-May-05,2005,5,24,"Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties","Methods are disclosed for establishing a quantitative relationship between spectral properties of molecules and a biological, chemical, or physical endpoint of the molecules. Spectral data including data from nuclear magnetic resonance, mass spectrometric, infrared, and ultraviolet-visible techniques are used along with endpoint data to train a pattern-recognition program. The training yields a spectral data-activity relationship that may be used to predict the endpoint value of a molecule from its spectral data alone. Methods for rapidly screening isolated compounds or mixtures of compounds based upon their spectral data are included.",74,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Electrical machinery, apparatus, energy",Measurement,,,,,H01J/0036
6900024,31-May-05,2005,5,31,T cell receptor ligands and methods of using same,"The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.",4,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/80
6900193,31-May-05,2005,5,31,Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents,"The present invention relates, inter alia, to compounds having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —NC4H8, —NC5H10, —NC4H8O, —CHO, —CH(OH)CH3, —C(O)CH3, —O(CH2)2N(CH3)2, and —O(CH2)2NC5H10; R2 is a member selected from the group consisting of hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy (e.g., methoxy, ethoxy, vinyloxy, ethynyloxy, cyclopropyloxy, etc.), acyloxy (e.g., acetoxy, glycinate, etc.), alkylcarbonate, cypionyloxy, S-alkyl, —SCN, S-acyl and —OC(O)R6, wherein R6 is a functional group including, but not limited to, alkyl (e.g., methyl, ethyl, etc.), alkoxy ester (e.g., —CH2OCH3) and alkoxy (—OCH3); R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception.",56,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07J/0083
6903184,7-Jun-05,2005,6,7,Multiple antigenic peptides immunogenic against Streptococcus pneumonia,"The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention. Also provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens and methods of preventing and treating Streptococcus pneumoniae infection in a subject.",1,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/08
6905822,14-Jun-05,2005,6,14,Methods of diagnosing multidrug resistant tuberculosis,"The invention relates to the discovery that a putative gene of Mycobacterium tuberculosis with no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. Since M. tuberculosis has a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854c and now termed “EtaA,” are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0071
6905823,14-Jun-05,2005,6,14,Cellular arrays and methods of detecting and using genetic disorder markers,"A method is disclosed for rapid molecular profiling of tissue or other cellular specimens by placing a donor specimen in an assigned location in a recipient array, providing copies of the array, and performing a different biological analysis of each copy. The results of the different biological analyses are compared to determine if there are correlations between the results of the different biological analyses at each assigned location. In some embodiments, the specimens may be tissue specimens from different tumors, which are subjected to multiple parallel molecular (including genetic and immunological) analyses. The results of the parallel analyses are then used to detect common molecular characteristics of the genetic disorder type, which can subsequently be used in the diagnosis or treatment of the disease. The biological characteristics of the tissue can be correlated with clinical or other information, to detect characteristics associated with the tissue, such as susceptibility or resistance to particular types of drug treatment. Other examples of suitable tissues which can be placed in the matrix include tissue from transgenic or model organisms, or cellular suspensions (such as cytological preparations or specimens of liquid malignancies or cell lines).",4,Abbott Laboratories,,,,,,,,,,,1,Biotechnology,Measurement,Analysis of biological materials,Chemical engineering,Optics,,C12Q/6886
6908738,21-Jun-05,2005,6,21,Agents that bind to and inhibit human cytochrome P450 2C19,"The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.",14,National Institute of Health,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/573
6911203,28-Jun-05,2005,6,28,Anthrax lethal factor is a MAPK kinase protease,"The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
6911433,28-Jun-05,2005,6,28,"O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates","Provided are O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O2-glycosylated diazeniumdiolates) having the formula: in which R is a saccharide, which is attached to the O2 of the compound by the anomeric carbon of a pyranose ring or a furanose ring.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/64
6911478,28-Jun-05,2005,6,28,"Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same","The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions comprising such compounds, methods of using such compounds and compositions, and to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amines into such compounds.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/023
6911527,28-Jun-05,2005,6,28,HIV related peptides,This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.,7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6916843,12-Jul-05,2005,7,12,Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids,Epoxyeicosatrienoic acids (EETs) are products of cytocrome P450 epoxygenases that have vasodilatory properties similar to endotheilum-derived hyperpolarizing factor (EDHF). The cytochrome P450 isoform CYP2J2 was cloned and identified as a source of EETs in human endothelial cells. Physiological concentrations of EETs or overexpression of CYP2J2 decreased cytolcine-induced endothelial cell adhesion molecule expression and prevented subsequent leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-κB and IκB kinase (IKK). The inhibitory effects of EETs were independent of their membrane hyporpolarizing effects suggesting that these molecules play an important non-vasodilatory role in vascular inflammation.,25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/559
6916905,12-Jul-05,2005,7,12,Dmt-Tic di-and tri-peptidic derivatives and related compositions and methods of use,A compound of formula: wherein X is a spacer comprising one or more amino acid residues and Y comprises an aromatic group and related compositions and methods of use.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C07K/0812
6919442,19-Jul-05,2005,7,19,Nucleic acids comprising a post-transcriptional regulatory element (PRE) and their uses,"The invention provides a novel post-transcriptional regulatory element that can function as an RNA nucleo-cytoplasmic transport element. The invention also provides for an attenuated HIV-1 hybrid virus for use as a vaccine and a kit incorporating the hybrid virus. The kit also includes instructional material teaching the use of the vaccine, where the instructional material indicates that the vaccine is used for the prophylaxis or amelioration of HIV-1 infection in a mammal; that the vaccine is to be administered to a mammal in a therapeutically effective amount sufficient to express a viral protein; where the vaccine will not cause clinically significant CD4+ cell depletion; and, the expression of the viral protein elicits an immune response to the attenuated HIV-1 virus. The invention further provides for a method for screening for post-transcriptional RNA nucleo-cytoplasmic transport element (NCTE) binding proteins.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
6923971,2-Aug-05,2005,8,2,Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes,"Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful for eliciting an anti-RSV immune response. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene. In one embodiment, expression of RSV glycoproteins is upregulated by shifting one or more glycoprotein-encoding genes to a more promoter-proximal position. Genes of interest for manipulation to create gene position-shifted RSV include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment that may be part of a gene or extragenic. Additional mutations and nucleotide modifications are provided within gene position-shifted RSV to yield desired phenotypic and structural effects.",81,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
6924362,2-Aug-05,2005,8,2,"Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C virus and their use in the diagnosis, treatment, and prevention of hepatitis C","The present invention describes the identification and characterization of five human HC E1-specific monoclonal antibodies isolated from a phage display library and their use in the diagnosis, treatment, and prevention of HCV in mammals, preferably humans.",16,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/6878
6924367,2-Aug-05,2005,8,2,Method of modulating tissue growth using Frzb Protein,"An isolated cDNA encoding a growth-inducing protein, Frzb, capable of stimulating bone, cartilage, muscle, and nerve tissue formation. Frzb binds to and modulates the activity of Wnt growth factors which play a role in various developmental and neoplastic processes. The cDNA and protein sequences of human, bovine and Xenopus Frzb are provided. Production and purification of recombinant Frzb are also described.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/71
6925389,2-Aug-05,2005,8,2,Process for discriminating between biological states based on hidden patterns from biological data,"The invention describes a process for determining a biological state through the discovery and analysis of hidden or non-obvious, discriminatory biological data patterns. The biological data can be from health data, clinical data, or from a biological sample, (e.g., a biological sample from a human, e.g., serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate.), etc. which is analyzed to determine the biological state of the donor. The biological state can be a pathologic diagnosis, toxicity state, efficacy of a drug, prognosis of a disease, etc. Specifically, the invention concerns processes that discover hidden discriminatory biological data patterns (e.g., patterns of protein expression in a serum sample that classify the biological state of an organ) that describe biological states.",48,"Correlogic Systems, Inc.,",The United States of America as Represented by the Department of Health and Human Services,,,,,,,,,,2,Computer technology,,,,,,G16H/40
6930176,16-Aug-05,2005,8,16,Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus,"The invention describes the identification of major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isolation and characterization of neutralizing chimpanzee monoclonal antibodies reactive to the neutralization site and the use of these antibodies in the diagnosis, treatment and prevention of HEV.",6,The United States of America as represented by the Secretary of the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6932814,23-Aug-05,2005,8,23,Radiofrequency probes for tissue treatment and methods of use,"A device and method for radiofrequency treatment of tissue is disclosed. The device includes an introducer, a plurality of RF electrodes positionable in a nondeployed state within the introducer, and an electrode advancement element. In the nondeployed state, the RF electrodes are contained within the introducer, and separated from the subject's tissue by a plug which substantially occludes the distal end of the introducer. In the method for RF tissue treatment, the introducer is introduced into the tissue of a subject. The RF electrodes are then positioned in the deployed state when the electrode advancement element advances the RF electrodes through the distal end of the introducer, thereby displacing the plug. The electrode advancement element may be a spring-loaded element, and may be actuated by a triggering device on the introducer. The introducer and the RF electrodes may be scored to enhance their visibility in medical imaging studies such as ultrasound, thereby helping to ensure optimal placement of the introducer and the RF electrodes.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/1477
6933277,23-Aug-05,2005,8,23,Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides,"This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.",16,The United States of America as represented by the Department of Health and Human Services,"Ramot University Authority for Applied Research and Industrial Development, Ltd.",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/18
6936311,30-Aug-05,2005,8,30,Generation of biomaterial microarrays by laser transfer,"A method for creating a microarray of biomaterial uses a source of laser energy, a receiving substrate, and a target substrate. The target substrate comprises a laser-transparent support having a laser-facing surface and a support surface. The target substrate also comprises a composite material having a back surface in contact with the support surface and a front surface. The composite material comprises a mixture of the biomaterial to be deposited and a matrix material. The matrix material is a material that has the property that, when it is exposed to laser energy, it desorbs from the laser-transparent support. The source of laser energy is positioned in relation to the target substrate so that laser energy is directed through the laser-facing surface of the target substrate and through the laser-transparent support to strike the composite material at a defined target location. The receiving substrate is positioned in a spaced relation to the target substrate. The source of laser energy has sufficient energy to desorb the composite material at the defined target location, causing the composite material to desorb from the defined target location and be lifted from the support surface of the laser-transparent support. The composite material is deposited at a defined receiving location on the receiving substrate. The steps are repeated at successive defined target locations and successive defined receiving locations such that the composite material is deposited in a microarray of deposited composite material. The method is useful for creating, for example, a gene recognition array,",42,The United States of America as represented by the Secretary of the Navy,,,,,,,,,,,1,"Surface technology, coating",Chemical engineering,Micro-structural and nano-technology,Audio-visual technology,,,B01J/0046
6936639,30-Aug-05,2005,8,30,Nitroxyl progenitors in the treatment of heart failure,"Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,The Regents of the University of California,Johns Hopkins University,"The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Louisiana State University Health Sciences Center",,,,,,,,4,Pharmaceuticals,,,,,,A61K/655
6936706,30-Aug-05,2005,8,30,Modified antibodies with human milk fat globule specificity and uses,"An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the analogue peptide, and a hybrid vector carrying the nucleotides and transfected cells express the peptides and a method produces the analogue peptide. An anti-idiotype polypeptide comprises polyclonal antibodies raised against an anti-carcinoma antibody or the analogue peptide of this invention, monoclonal antibodies thereof, Fab, Fab′, (Fab′)2, CDR, variable region, or analogues or fragments thereof, combinations thereof with an oligopeptide comprising a TRP trimer, tandem repeats thereof, or combination or mixtures thereof. An anti-idiotype hybrid polypeptide with an effector agent and the anti-idiotype polypeptide, an anti-carcinoma vaccine, an anti-carcinoma vaccination kit, a method of vaccinating against carcinoma and a method of lowering the serum concentration of a circulating antibody or polypeptide are provided.",73,,,,,,,,,,,,,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/465
6937885,30-Aug-05,2005,8,30,Multispectral/hyperspectral medical instrument,A medical instrument that comprises: a first-stage optic responsive to a tissue surface of a patient; a spectral separator optically responsive to the first stage optic and having a control input; an imaging sensor optically responsive to the spectral separator and having an image data output; and a diagnostic processor having an image acquisition interface with an input responsive to the imaging sensor and a filter control interface having a control output provided to the control input of the spectral separator.,87,"HyperMed, Inc.",,,,,,,,,,,1,Medical technology,,,,,,A61B/0064
6939547,6-Sep-05,2005,9,6,Specific binding agents for KSHV vIL-6 that neutralize a biological activity,"A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56994
6943191,13-Sep-05,2005,9,13,Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs,"Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the disclosure, without limitation, satisfy either Formula 1 or Formula 2. The present disclosure also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs and potentially comprising other active ingredients, other materials conventionally used in the formulation of pharmaceutical compositions, and mixtures thereof. The compounds and compositions of the disclosure can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07C/60
6946133,20-Sep-05,2005,9,20,Prostate specific antigen oligo-epitope peptide,"The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/001194
6949530,27-Sep-05,2005,9,27,"Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same","The present invention relates to nitric oxide-releasing amidine diazeniumdiolates, compositions comprising same, methods of using same, and a method for preparing same from imidate diazeniumdiolates and primary or secondary amines.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/655
6949624,27-Sep-05,2005,9,27,Cloning of the human nuclear receptor co-repressor gene,"The present invention relates to the discovery of the human nuclear receptor co-repressor gene and the human nuclear receptor co-repressor protein, a molecule that recruits a complex of proteins that alters chromatin structure and mediates transcriptional repression. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/04
6951648,4-Oct-05,2005,10,4,Variant of LAV viruses,"A variant of a LAV virus, designated LAVELI and capable of causing AIDS. The cDNA and antigens of the LAVELI virus can be used for the diagnosis of AIDS and pre-AIDS.",8,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
6951761,4-Oct-05,2005,10,4,Measurements of multiple molecules using a CryoArray,"This disclosure relates to CryoArrays, which permit the analysis of samples (such as protein, nucleic acid, virus, or cell samples) in arrays that are prepared at low temperatures. Because CryoArrays are constructed as a block of substantially columnar samples, the block can be sliced to provide a plurality of identical or substantially identical individual arrays. The individual arrays can be used for parallel analysis of the same array feature set, for instance with different probes or under different conditions. Also provided are methods of making CryoArrays, devices for making CryoArrays, and kits.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Basic materials chemistry,Chemical engineering,Organic fine chemistry,Biotechnology,Measurement,Analysis of biological materials,C40B/04
6951915,4-Oct-05,2005,10,4,"Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use","A compound of formula: in which L is sulfur, sulfoxide, oxygen or methylene, and a compound of formula: in which (i) aa1 is Adi and aa4 is Glu or (ii) each of aa1 and aa4 is Adi, L is sulfur, sulfoxide, oxygen or methylene, which compounds (and their conjugates) bind to an SH2 domain in a protein comprising an SH2 domain, are non-phosphorylated, are redox-stable in vivo, are characterized by an IC50 in vivo of less than about 4.0 μM with respect to the SH2 domain in Grb2, and, upon binding to the SH2 domain of Grb2, have a turn conformation. A conjugate comprising a compound as described above and a carrier agent, a composition comprising (i) a compound or a conjugate as described above and (ii) a carrier, a method of inhibiting binding of an SH2 domain in a protein comprising an SH2 domain to a target protein in an animal, wherein the SH2 domain is contacted with a target protein-binding inhibiting effective amount of a compound or a conjugate as described above, and a method of synthesizing such conjugates.",5,The United States of America as represented by the Department of Health and Human Services,Georgetown University,,,,,,,,,,2,Biotechnology,,,,,,C07K/06
6951917,4-Oct-05,2005,10,4,MHC-class II restricted melanoma antigens and their use in therapeutic methods,"The present invention provides MHC Class II restricted melanoma antigens recognized by CD4+ T cells. This invention further provides prophylactic and therapeutic applications for the Class II restricted melanoma antigens. In particular, this invention provides tyrosinase Class II restricted melanoma antigens, as well as tyrosinase immunogenic peptides which have been modified to enhance their immunogenicity. These antigens can serve as an immunogens or vaccines to prevent or treat melanoma. In addition a method for isolating Class II restricted melanoma antigens or identifying new Class II restricted melanoma antigens is provided.",61,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0059
6951961,4-Oct-05,2005,10,4,Methods of use and compositions for the diagnosis and treatment of infectious disease,"Methods and compositions for treating disease caused by microorganisms, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.",79,,,,,,,,,,,,,Organic fine chemistry,Pharmaceuticals,,,,,C07C/25
6953687,11-Oct-05,2005,10,11,Vectors for delivering viral and oncogenic inhibitors,"Cell transformation vectors for inhibiting HIV and tumor growth are provided. Optionally, the vectors encode RNAses such as EDN. Cells transduced by the vectors and methods of transforming cells (in vitro and in vivo) using the vectors are also provided.",36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12N/86
6955895,18-Oct-05,2005,10,18,Thymic stromal lymphopoietin receptor molecules and uses thereof,"The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.",15,Whitehead Institute for Biomedical Research,Government of the United States of America,Health Research Inc. Rosewell Park Division,,,,,,,,,3,Biotechnology,,,,,,C07K/7155
6957166,18-Oct-05,2005,10,18,Method and apparatus for load rate monitoring,"A system for real-time monitoring of the dynamic loading rate on support systems used in underground mines and other situations is provided. The load rate monitoring apparatus uses a programmable microcontroller to monitor and calculate the loading rates on the support system from pressure transducers or welded strain gauge instrumentation installed on the support systems. The apparatus is programmed to sequentially activate different color lights and/or audio alarms as the loading rate increases on the support systems. The apparatus is intended for installation with numerous underground support systems used in underground mining to alert miners of dangerous loading conditions, which support systems include longwall shields, mobile roof support (MRS) machines, hydraulic jacks, rock bolts, steel sets, and roof trusses. Intrinsically safe hand-held computers and displays may be used for programming the microcontroller subsystem and optimal load weight indicators include multicolor strobes, light-emitting diodes (LEDs), fluorescent visual indicators and audio alarms.",43,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Civil engineering,,,,,G01G/23
6957653,25-Oct-05,2005,10,25,Flushed-seal respirator,"Improved full-face, flushed-seal respirators are provided having a primary sealing element adjacent to a breathing space and a secondary sealing element. Exhaled air (i.e., clean air obtained by passage through a filtering element or elements) is passed from the breathing space into a flushing channel formed between the primary and secondary seals. If there is leakage in the primary seal, air from this flushing channel leaks into the breathing space rather than ambient air. Air within the flushing channel will predominately be air that has already passed through the filtering elements. The present invention provides, therefore, an inexpensive respirator which provides significantly more protection than conventional negative-pressure respirators.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Other consumer goods,,,,,,A62B/04
6958319,25-Oct-05,2005,10,25,Formulation of boronic acid compounds,The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): in which Z1 and Z2 are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.,105,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C07K/0827
6960659,1-Nov-05,2005,11,1,Mosaic protein and restriction endonuclease assisted ligation method for making the same,"A mosaic protein comprising a variety of immunoreactive antigenic epitopes from several genotypes of hepatitis C virus. The mosaic protein provides a sensitive and specific immunological hepatitis detection assay. A restriction enzyme assisted ligation method of making an artificial gene permits controlled construction of mosaic proteins, and allows confirmatory expression of the intermediate gene products.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
6962987,8-Nov-05,2005,11,8,Binding domains from Plasmodium vivax and Plasmodium falciparum erythrocyte binding proteins,"The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
6963769,8-Nov-05,2005,11,8,Method for enhancing contrast produced by MRI,"A method for obtaining an image by MRI, comprising: administering at least one contrast agent to a subject in amounts effective to perform CEDST MRI analysis; and performing CEDST MRI analysis to produce an image of the subject. A number of different contast agents can be used to practice the present method including, without limitation, sugars, animo acids, nitrogen-containing heterocycles, purines and pyrimidines, nucleosides; imidazole and derivatives thereof, imino acids, barbituric acid and analogs thereof, and miscellaneous materials, such as guanidine hydantoin, parabanic acid, and biologically active salts thereof.",50,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Pharmaceuticals,Measurement,,,,A61B/055
6965017,15-Nov-05,2005,11,15,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
6965041,15-Nov-05,2005,11,15,N-acylphosphoramidites and their use in oligonucleotide synthesis,"The present invention provides a compound of formula (I), (II), or (III), wherein R1, R2, R2′, R3, and R3′ are the same or different and each is H an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl, or an aralkyl. Alternatively, either of R2 or R2′ combined with either of R3 or R3′ comprises a ring. R4 is a protecting group or a solid support R5 is H or an alkyl. R6 is a protecting group, an amidoalkyl, an alkyl, an alkyl ketone, an alkenyl, an alkynyl, a cycloalkyl, an aryl, or an aralkyl. R15 is H or a protecting group. Q and Q1 are the same or different and each is a nucleoside, an oligonucleotide comprising a nucleoside, or an oligomer comprising a nucleoside, which is of formula (a) or (b), wherein B is a labeling group, an alkyl, an alkenyl, an alkynyl, a cyclic group optionally containing one or more heteroatoms, or an amino; and, E is H, a halogen, a hydroxy, an alkoxy, an ester, an amino or a protecting group. X and X1 are independently O, S, or Se, and n is an integer from 1 to about 300. Each Q in each monomeric unit defined by n can be the same or different. The present invention further provides a method of preparing a polymer using the N-acylphosphoramidite of formula (I) or (II).",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/00
6965240,15-Nov-05,2005,11,15,Apparatus and methods for analyzing particles using light-scattering sensors and ionization sensors,"Apparatus and methods are disclosed for analyzing particles, such as coarse particulates, fine particulates (e.g., diesel particulate matter), and combustion aerosols, using light-scattering sensors and/or ionization-type sensors. In one disclosed embodiment, a particle monitor includes an ionization module and a controller adapted to receive an output signal from the ionization module. The controller is operable to translate the output signal into the mass concentration of particulate matter within the ionization chamber. In another embodiment, a particle monitor includes a light-scattering sensor and an ionization sensor. The monitor is configured to measure separate mass concentrations of sub-micrometer particles and larger dust particles in an atmosphere having both types of particles.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0656
6969609,29-Nov-05,2005,11,29,Recombinant vector expressing multiple costimulatory molecules and uses thereof,"The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of them costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater that the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+and CD8+T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced and antigen-presenting functions.",32,The United States of America as represented by the Department of Health and Human Serivces,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6969614,29-Nov-05,2005,11,29,Methods for the isolation and analysis of cellular protein content,"The present invention describes devices and methods for performing protein analysis on laser capture microdissected cells, which permits proteomic analysis on cells of different populations. Particular disclosed examples are analysis of normal versus malignant cells, or a comparison of differential protein expression in cells that are progressing from normal to malignant. The protein content of the microdissected cells may be analyzed using techniques such as immunoassays, 1D and 2D gel electrophoresis characterization, Western blotting, liquid chromatography quadrapole ion trap electrospray (LCQ-MS), Matrix Assisted Laser Desorption Ionization/Time of Flight (MALDI/TOF), and Surface Enhanced Laser Desorption Ionization Spectroscopy (SELDI). In addition to permitting direct comparison of qualitative and quantitative protein content of tumor cells and normal cells from the same tissue sample, the methods also allow for investigation of protein characteristics of tumor cells, such as binding ability and amino acid sequence, and differential expression of proteins in particular cell populations in response to drug treatment. The present methods also provide, through the use of protein fingerprinting, a rapid and reliable way to identify the source tissue of a tumor metastasis.",77,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6803
6969615,29-Nov-05,2005,11,29,"Methods, devices, arrays and kits for detecting and analyzing biomolecules","The present disclosure is directed to devices, arrays, kits and methods for detecting biomolecules in a tissue section (such as a fresh or archival sample, tissue microarray, or cells harvested by an LCM procedure) or other substantially two-dimensional sample (such as an electrophoretic gel or cDNA microarray) by creating “carbon copies” of the biomolecules eluted from the sample and visualizing the biomolecules on the copies using one or more detector molecules (e.g., antibodies or DNA probes) having specific affinity for the biomolecules of interest. Specific methods are provided for identifying the pattern of biomolecules (e.g., proteins and nucleic acids) in the samples. Other specific methods are provided for the identification and analysis of proteins and other biological molecules produced by cells and/or tissue, especially human cells and/or tissue. The disclosure also provides a plurality of differentially prepared and/or processed membranes that can be used in described methods, and which permit the identification and analysis of biomolecules.",26,"20/20 GeneSystems, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Measurement,Chemical engineering,Analysis of biological materials,,,,B01L/5023
6974698,13-Dec-05,2005,12,13,Methods for delivering biologically active molecules into cells,"Methods for delivering a biologically active molecule into a cell by linking a molecule to the cell surface, wherein the molecule can act as a surface receptor, then complexing the biologically active molecule with a ligand for the surface receptor, and finally contacting the biologically active molecule-ligand complex with the cell surface are disclosed. Delivery of any biologically active molecule, e.g. proteins, enzymes, nucleic acids, hormones, nucleic acids, and oligonucleotides, is contemplated. The use of biotin or biotinylated antibodies as the surface receptor is disclosed. The use of PEI and PEI-avidin conjugates complexed with oligonucleotides for delivery into a directly or indirectly biotinylated cell surface, along with the PEI-avidin-nucleic acid compositions, are disclosed. Primary and cultured cells with a covalently linked surface receptor molecule, such as biotin, on their surfaces are also disclosed.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0041
6977241,20-Dec-05,2005,12,20,SH2 domain binding inhibitors,"Disclosed are compounds for SH2 domain binding inhibition. For example, disclosed is a compound of formula (I) wherein R1 is a lipophile; R2, in combination with the phenyl ring, forms a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R6 is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. Also disclosed are a pharmaceutical composition, a method for inhibiting an SH2 domain from binding with a phosphoprotein and a method of treating breast cancer.",47,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/06078
6977245,20-Dec-05,2005,12,20,Oligodeoxynucleotide and its use to induce an immune response,"D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula:5′X1X2X3Pu1 Py2 CpG Pu3 Py4 X4X5X6(W)M(G)N-3′wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10. Methods of using these oligodeoxynucleotides to induce an immune response are provided.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/008
6979724,27-Dec-05,2005,12,27,Calcium channel proteins,"The present invention relates to calcium channel compositions and methods of making and using same. In particular, the invention relates to calcium channel alpha2delta (α2δ) subunits and nucleic acid sequences encoding them. These compositions are useful in methods for identifying compounds that modulate the activity of calcium channels and for identifying compounds as therapeutic for disease.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,The Board of Regents of the University of Texas System,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
6982146,3-Jan-06,2006,1,3,High speed parallel molecular nucleic acid sequencing,"A method and device is disclosed for high speed, automated sequencing of nucleic acid molecules. A nucleic acid molecule to be sequenced is exposed to a polymerase in the presence of nucleotides which are to be incorporated into a complementary nucleic acid strand. The polymerase carries a donor fluorophore, and each type of nucleotide (e.g. A, T/U, C and G) carries a distinguishable acceptor fluorophore characteristic of the particular type of nucleotide. As the polymerase incorporates individual nucleic acid molecules into a complementary strand, a laser continuously irradiates the donor fluorophore, at a wavelength that causes it to emit an emission signal (but the laser wavelength does not stimulate the acceptor fluorophore). In particular embodiments, no laser is needed if the donor fluorophore is a luminescent molecule or is stimulated by one. The emission signal from the polymerase is capable of stimulating any of the donor fluorophores (but not acceptor fluorophores), so that as a nucleotide is added by the polymerase, the acceptor fluorophore emits a signal associated with the type of nucleotide added to the complementary strand. The series of emission signals from the acceptor fluorophores is detected, and correlated with a sequence of nucleotides that correspond to the sequence of emission signals.",38,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6869
6982168,3-Jan-06,2006,1,3,Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer,"The present invention relates to immortalized, malignant, human, adult prostate epithelial cell lines or cell lines derived therefrom useful in the diagnosis and treatment of prostate cancer. More particularly, the present invention relates to cloned, immortalized, malignant, human, adult prostate epithelial cell lines and uses of these cell lines for the diagnosis and treatment of cancer. Furthermore, the present invention provides for the characterization of said cell lines through the analysis of specific chromosomal deletions.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/85
6984379,10-Jan-06,2006,1,10,Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood,A method of providing a therapeutic effect in a human patient which comprises administering to the patient CD34+ cells obtained from cord blood. The CD34+ cells have been engineered with at least one nucleic acid sequence encoding a therapeutic agent. Such CD34+ cells may be engineered by transducing the cells with a retroviral vector including the nucleic acid sequence encoding the therapeutic agent. This method has been applied in treating newborn infants suffering from ADA deficiency.,16,Children's Hospital of LosAngeles,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/50
6984517,10-Jan-06,2006,1,10,AAV5 vector and uses thereof,"The present invention provides an adeno-associated virus 5 (AAV5) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV5 vectors and particles.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
6987096,17-Jan-06,2006,1,17,"Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof","The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,A61K/164
6987266,17-Jan-06,2006,1,17,Structure determination of materials using electron microscopy,"The invention includes methods for automating acquisition of electron microscopic images. Methods use in the invention include development of search algorithms, including spiral search algorithms for the automated determination of areas suitable for imaging in vitrified specimens at liquid nitrogen temperatures, development of criteria to image areas that meet user-specific needs for the thickness of vitreous ice in which the proteins are embedded, automated setting of key imaging parameters such as extent of defocus and magnification required for recording images, automated assessment of most suitable conditions such as thermal and mechanical stability of specimen stage immediately before recording of the image, recording a “low-dose” image of radiation sensitive biological specimens by carrying out all of the setting and assessment steps on an area immediately adjacent to the area of interest, thereby avoiding pre-exposure of the final imaged area to electrons, creation of a seamless interface to transfer the images recorded on a CCD camera directly to computers capable of processing the recorded images, and carrying out the entire process of data collection from a remote computer either within the network, or connected to the network through a telephone modem from any remote location.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,"Electrical machinery, apparatus, energy",,,,,G01N/2251
6989263,24-Jan-06,2006,1,24,Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein,"The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds that can react with CCHC zinc fingers of the nucleocapsid proteins of a large number of different retroviruses have also been developed. The kits of the present invention describe a set of specific tests and reagents that can be used to screen and identify compounds based on their ability to react with and disrupt retroviral zinc fingers in the viral NC proteins and, in turn, inactivate the retrovirus of interest.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
6990369,24-Jan-06,2006,1,24,Probe using diffuse-reflectance spectroscopy,"The invention provides a device and method for monitoring inflammation of the epithelium. The device consists of a head region, a handle region and an optical bundle. At least two of the optical fibers in the bundle are utilized as a source of radiation, these two fibers are at two different angles from normal. At least one of the other optical fibers is utilized as a detector for the reflected radiation, or alternatively an image guide can be used as the detector. The device of the invention can be part of an external or internal system that can include a light source, the device, a multiplexer, a spectrometer, and a computer for data analysis. The method of the invention allows for the detection and monitoring of general inflammation of the oral epithelium. The inflammation of the epithelium can be detected or monitored to diagnose diseases of the oral epithelium, monitor such diseases, monitor treatment of such diseases, or pre-screen for and monitor preventative treatments of such diseases.",24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/682
6993959,7-Feb-06,2006,2,7,System and method for the analysis of atomic force microscopy data,"A system and method for the analysis of AFM data is provided. The system and method can be used in conjunction with an atomic force microscopy (AFM) system including a cantilever with a tip used to analyze a sample, the AFM outputting an AFM data file. An exemplary embodiment of the invention includes a computer readable medium storing computer readable program code for causing a computer to receive user input regarding an analysis to be performed and analysis parameters; parse the AFM data file based on the user input to obtain a deflection of the cantilever; determine an indentation depth of the tip into the sample based at least in part on the deflection; select a model of contact mechanics based on the user input; solve the selected model of contact mechanics based on the input analysis using the determined indentation depth; and determine a residual error.",25,National Institutes of Health,,,,,,,,,,,1,Measurement,Micro-structural and nano-technology,,,,,G01Q/04
6995018,7-Feb-06,2006,2,7,Complex formed by N-linked glycoproteins (SIBLINGS)and Factor H,"The invention provides methods and compositions for exploiting the discovery that members of the small integrin-binding ligand, n-linked glycoproteins family termed SIBLINGS bind to complement Factor H, and moreover that SIBLINGS proteins, such as BSP, exist in relatively acidic forms. The methods provided can be used to detect SIBLINGS proteins in samples from subjects that are suspected of having tumors or abnormal bone turnover. The invention also provides methods of using SIBLINGS proteins to protect cells from complement mediated lysis. Finally, the discovery allows for the creation of specific binding agents that facilitate the detection of SIBLINGS proteins when they are associated with Factor H.",31,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/57484
6995247,7-Feb-06,2006,2,7,"Ac-HEHA and related compounds, methods of synthesis and methods of use","The present invention provides an α-particle-emitting radioisotope chelation complex comprising 225Actinium (225Ac) and 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N′,N′,N′,N′-hexaacetic acid (HEHA) (225Ac-HEHA). Also provided is a bifunctional HEHA, and a bifunctional 225Ac-HEHA. The bifunctional HEHA and the bifunctional 225Ac-HEHA can be conjugated to a targeting agent. In view of the above, the present invention provides a method of making HEHA and methods of making a bifunctional HEHA, including a conjugate thereof. Also provided are a method of treating disease, a method of treating cancer, a method of decontaminating a sample from 225Ac, a method of decontaminating a person who has been externally contaminated with 225Ac, and a method of detoxifying a person who has internalized 225Ac.",38,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/00
6996472,7-Feb-06,2006,2,7,Drift compensation method for fingerprint spectra,"Methods of compensating for drift in fingerprint spectra of microorganisms caused by changes in their environment are disclosed. These methods of compensating for drift permit identification of microorganisms from their fingerprint spectra regardless of the environment from which the microorganisms are obtained. Furthermore, the disclosed methods may be used to construct coherent databases of fingerprint spectra that may be expanded even though the standard database conditions are no longer experimentally achievable. In particular embodiments, methods of compensating for drift in pyrolysis mass spectra, constructing coherent pyrolysis mass spectral databases, and identifying bacteria from their pyrolysis mass spectra are disclosed.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6848
6998252,14-Feb-06,2006,2,14,Recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences,"Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses also are provided.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
7001600,21-Feb-06,2006,2,21,Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes,The infusion of TIL586 along with interleukin-2 (IL-2) into the autologous patient with metastatic melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen recognized by TIL586 was previously isolated and shown to encode gp75 or TRP-1. The present invention relates to the identification of a second tumor antigen recognized by a HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP-2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Modified peptides were also recognized by the CTL clone.,74,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/001156
7001614,21-Feb-06,2006,2,21,Liposome complexes for increased systemic delivery,"Highly efficient cationic liposomes have been developed as an improved delivery system for biologically-active reagents. A novel structure, the sandwich liposome, is formed and comprises one or more biologically active agents internalized between two bilomellar liposomes. This structure protects the incoming agent and accounts for the high efficiency of in vivo delivery and for the broad tissue distribution of the sandwich liposome complexes.These novel liposomes are also highly efficient carriers of nucleic acids. By using extruded DOTAP:cholesterol liposomes to form complexes with DNA encoding specific proteins, expression has been improved dramatically. Highest expression was achieved in the lung, while increased expression was detected in several organs and tissues.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/00
7001720,21-Feb-06,2006,2,21,Cloning of a gene mutation for parkinson's disease,"Parkinson's disease (PD) is a common neurodegenrative disorder with a lifetime incidence of approximately 2 percent. It was recently reported that a PD susceptibility gene is located on the long arm of human chromosome four. The present invention reports the subsequent identification of a mutation in the alpha synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity. The finding of a specific molecular alteration which is causative for PD will permit the detailed understanding of the pathophysiology of the disorder, which will lead to potential therapetuic interventions, as well as a means for diagnosing individuals having an increased risk of developing the disease.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
7003144,21-Feb-06,2006,2,21,Vessel delineation in magnetic resonance angiographic images,"Delineating vessels in an angiogram involves two methods: graph generation and skeletonization. Generating a graph includes obtaining a digital image of an angiogram, recognizing a first growth point within the image, and identifying region boundary points around the growth point. The region boundary points are connected to the first growth point, thereby creating edges of a graph. The boundary point that has the greatest intensity is then selected as a second growth point, and additional region boundary points around the second growth point are identified. The additional region growth points are connected to the second growth point. The region boundary point with the greatest intensity in the image is then selected as a third growth point, and the method repeats until each point in the image is connected to another point in the graph. The skeletonization of the graph begins with recognizing a point in the graph as an endpoint of a vessel. This may be done explicitly through manual or automatic selection of specific points. It may also be done implicitly through a trimming process whereby graph branches of fewer than a certain number of connected points are discarded. The endpoints in the remaining branches are recognized as vessel endpoints. The skeletonization concludes with display of the delineated vessels. This may be done by superimposing the vessels in two or three dimensions over a conventional two-dimensional angiographic image such as a maximum intensity projection (MIP).",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06K/342
7003403,21-Feb-06,2006,2,21,Quantifying gene relatedness via nonlinear prediction of gene,"Relatedness between genes is quantified by constructing nonlinear models predicting gene expression. Effectiveness of the model is evaluated to provide a measurement of the relatedness of genes associated with the model. Various types of models, including full-logic or neural networks can be constructed. A graphical user interface presents results of the analysis to allow evaluation by a user. Each gene's contribution to the measurement of relatedness can be shown on a graph, and graphical representations of models used to predict gene expression can be displayed.",81,The United States of America as represented by the Department of Health and Human Services,The Texas A & M University System,,,,,,,,,,2,Computer technology,,,,,,G16B/00
7005252,28-Feb-06,2006,2,28,Serum free cultivation of primate embryonic stem cells,Disclosed herein are methods for culturing primate embryonic stem cells. These cells are cultured on a prolonged and stable basis in the presence of exogenously supplied fibroblast growth factor and in the absence of animal serum. Preferably there is also a fibroblast feeder layer. Also disclosed is a culture media containing fibroblast feeder layer and the fibroblast growth factor.,14,Wisconsin Alumni Research Foundation,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0606
7005270,28-Feb-06,2006,2,28,Compositions and methods for detecting Treponema pallidum,"Methods for the specific and highly sensitive detection of Treponema pallidum infection comprising the use of specific antigenic proteins and peptides unique to Treponema pallidum are provided. In particular, detection assays based recognition of acidic repeat protein are provided. The methods of the present invention are useful for detection of primary syphilis at early stages of infection. In addition, the methods and compositions disclosed herein are directed to the differential detection of specific Treponema infections enabling the identification of causative agents for specific Treponema disease states: syphilis (Treponema pallidum subspecies pallidum), yaws (Treponema pallidum subspecies pertenue CDC-1 or CDC-2 strain), and bejel (Treponema pallidum subspecies endemicum).",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/20
7005419,28-Feb-06,2006,2,28,Methods for identifying inhibitors of GADD45 polypeptide activity and inhibitors of such activity,"The present invention is directed to novel methods for assaying for modulators of GADD45 polypeptide activity. The invention also provides means to sensitize a proliferating cell to a DNA base-damaging agent by administration of novel inhibitors of GADD45 polypeptide activity. The invention further provides polypeptides which interfere with the ability of Cdc2/cyclin B1 complexes to cause a pause at the G2/M stage of the cell cycle in response to GADD45, and nucleic acids which encode such polypeptides.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5008
7008768,7-Mar-06,2006,3,7,Method for detecting radiation exposure,"A method is disclosed for detecting exposure of organisms to biologically significant or hazardous amounts of ionizing radiation. The method uses nucleic acid microarray hybridization to evaluate biological effects, such as patterns of expression of genes after radiation exposure. Numerous genes are provided which have been found to be responsive to radiation exposure in a variety of cell lines. These genes are incorporated into probe sets, which are exposed to a labeled nucleic acid composition from a test cell, such as cDNA reverse transcribed from mRNA in the test cell, which specifically hybridizes to members of the probe set when the cell has been exposed to a biologically significant amount of ionizing radiation. Whether the nucleic acid composition hybridizes to the nucleic acid molecules representing genes that are differentially expressed is determined. The invention also includes methods for determining a dose response relationship between radiation exposure and differential expression of one or more genes, for example to determine a probable radiation dose in cells that have actually or potentially been exposed to the ionizing radiation. The invention also includes probe sets and microarrays used in this method.",58,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
7009044,7-Mar-06,2006,3,7,HCV/BVDV chimeric genomes and uses thereof,"The present invention relates to molecular approaches to the production of nucleic acid sequences which comprise the genomes of chimeric hepatitis C virus-bovine viral diarrhea viruses (HCV/BVDV). The invention also relates to the use of these chimeric nucleic acid sequences to produce chimeric virions in cells and the use of these chimeric virions in HCV antibody neutralization assays, and for the development of vaccines and therapeutics for HCV.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7009050,7-Mar-06,2006,3,7,5-Substituted pyrimidine derivatives of conformationally locked nucleoside analogues,"The embodiments described herein concern 5-substituted pyrimidine derivatives of conformationally locked nucleoside analogues and to the use of these derivatives as anti-viral and anti-cancer agents. The compounds are of the formula: wherein B is uracil-1-yl or cytosin-1-yl having a 5-substituent selected from halogen, alkyl, alkenyl, and alkynyl, with the proviso that where B is uracil-1-yl, the 5-substituent is not methyl. The compounds are useful in the treatment of Herpes simplex virus (HSV).",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/54
7014816,21-Mar-06,2006,3,21,Food quality indicator device,"A food quality indicator device an indicator compound provided on a substrate. The indicator compound changes color due to the presence of volatile compounds, such as volatile bases, in spoiled food, even when the food is frozen. Alternatively, the indicator compound detects the presence of an unwanted amine-producing biological agent, such as bacteria or fungi. The indicator compound is typically contained within a polymeric matrix disposed on the substrate. Examples of suitable indicator compounds include halogenated azo dyes, sulfonated xanthene dyes, and sulfonated hydroxy-functional triphenylmethane dyes.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Measurement,,,,,G01N/02
7015024,21-Mar-06,2006,3,21,Compositions containing recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences,"Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses, also are provided.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
7015212,21-Mar-06,2006,3,21,Thiazepine inhibitors of HIV-1 integrase,"The present invention discloses non-catechol compounds, such as thiazolothiazepines, and analogs and derivatives thereof, which are anti-integrase inhibitors. The compounds, which are useful as treatments for HIV disease, include compounds (I), (II), (III), or pharmaceutically acceptable salts thereof wherein A is thiazole, benzene, naphthalene, pyridine, pyrimidine, pyrazine, or quinoline; R is one or more of H, halogen, lower alkyl, lower alkoxy, NO2, lower ester or carboxylic acid; X—Y is CH2—S, S—CH2, CH2—O, CH2—S(O). S(O)—CH2, CH2—CH2, CH2—CH2—CH2, or CH2—CH2—CH2—CH2; R4 is H or hydroxy; R5 is H, phenyl, or alkylamine; W is S or O; and R6 is H, substituted or unsubstituted alkyl or amine; and Z is S, O, CH2, CH2CH2, or C═O.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
7015312,21-Mar-06,2006,3,21,Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof,"The present invention discloses that the normal melanogenic gene, gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3, which is processed to an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The products of this gene are promising candidates for immunotherapeutic strategies for the treatment and diagnosis of patients with cancer.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0011
7022321,4-Apr-06,2006,4,4,Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system,"The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell.The disclosure also relates to a method for delivery of therapeutic protein molecules into the brain of a mammal, by administering to a mammal an effective amount of bone marrow-derived progenitor cells which contain a gene having a nucleic acid sequence that encodes a functional therapeutic protein.Isolated recombinant cells and a pharmaceutical composition are also provided.",8,,,,,,,,,,,,,Biotechnology,Pharmaceuticals,,,,,C12N/0647
7022814,4-Apr-06,2006,4,4,"Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses","The present invention relates to polypeptides encoded by a nucleotide sequence from an HIV-1, HIV-2, or SIV viral genome, in which the nucleotide sequence is amplified from the viral genome using a pair of primers that contain sequences that are conserved between different HIV and SIV strains. The primers are insensitive to variations in the genomes of different HIV and SIV isolates and, therefore, can be used to amplify nucleotide sequences from HIV-1, HIV-2, and SIV strains. The invention also relates to antibodies directed against these polypeptides and methods and kits for diagnosing viral infection.",14,Institut Pasteur and Institut National de la Sante et de la Recherche Medicale,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7024736,11-Apr-06,2006,4,11,Apparatus and method for manufacture of multilayer metal products,"Apparatus for manufacturing multi-layer metal feedstock material for stamping shaped parts eliminates the need for rolls of metal at the stamping site. Multilayer metal feedstock material is assembled from multiple rolls of metal stock, then folded in a zig zag fashion, or “Z-fold” configuration, whereby the multilayer metal assembly is stacked vertically, usually on conventional pallets, for ease of moving with a forklift or otherwise. The multilayer metal z-fold stack of material is then transported to a parts stamping operation where the material is used as it unfolds as a continuous feed to machines to produce shaped multilayer metal parts. This invention is most useful in making multilayer metal foil z-fold feedstock material and using the z-fold material as continuous feed to processes for making shaped multilayer metal foil parts. The layers may have non-metal layers of material, such as fiber, between the metal layers or on the outside of the metal layers. At the location of making the shaped parts from the feedstock material, the layers of the z-fold feedstock material may be separated and one or more of the layers treated, textured, embossed, etc., then reassembled into the stack which is fed to the stamping operation, all on a continuous basis. This enables the z-fold feedstock material to be made from smooth metal layers, which increases the density of the material and reduces the volume space required for storage of the z-fold material.",22,ATD Corporation,,,,,,,,,,,1,"Surface technology, coating",Machine tools,Handling,,,,B32B/14
7025961,11-Apr-06,2006,4,11,Anti-plasmodium composition and methods of use,"Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes are provided. More particularly, antibodies specific for Plasmodium falciparum binding proteins and blocking peptides that prevent the binding of Plasmodium falciparum are included in the present invention. The methods provided utilize the antibody and peptide compositions provided herein and include methods for the diagnosis, prevention, and treatment of Plasmodium falciparum diseases such as malaria as well as methods for the detection of Plasmodium falciparum in biological samples and culture media.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/205
7026291,11-Apr-06,2006,4,11,"Epithelial cell specific growth factor, keratinocyte growth factor (KGF)","Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.",44,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/74
7026350,11-Apr-06,2006,4,11,Water-soluble drugs and methods for their production,"The present invention relates to water-soluble drugs, compositions containing same, and, in particular, a water-soluble analogue of geldanamycin. This invention also relates to a method of producing water-soluble analogues of water-insoluble drugs through derivatization and conjugation with a polar moiety via a thiol ether bond with a heterobifunctional linking molecule.",40,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/416
7027628,11-Apr-06,2006,4,11,"Automated microscopic image acquisition, compositing, and display","An automated microscope and computer system captures a set of images for a capture area in a plurality of focal planes. The images can then be integrated into composite images for browsing to simulate viewing an item, such as a biological sample, under a microscope. A corrective filter can be constructed from the images to avoid an effect called “tiling.” Before capture, variable focal plane error can be avoided by collecting z locations for a set of points in the capture area. During image browsing, entire composite images can be loaded into memory in compressed form. Compressed image portions can be pre-decompressed to avoid delay as a browsing user navigates throughout the composite images. Pre-decompression can be done by a thread separate from the thread performing navigation operations.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Measurement,,,,,G06T/50
7029679,18-Apr-06,2006,4,18,Variant of LAV viruses,"A variant of a LAV virus, designated LAVELI and capable of causing AIDS. The cDNA and antigens of the LAVELI virus can be used for the diagnosis of AIDS and pre-AIDS.",5,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
7029899,18-Apr-06,2006,4,18,Selective toxicity of amino-terminal modified rnase a superfamily polypeptides,"This invention provides RNase A superfamily polypeptides with modified amino terminal which can be used to selectively kill target Kaposi's sarcoma cells, neoplastic endothelial cells, and non-neoplastic endothelial cells. In certain embodiments of the invention, the amino terminal modification consists of an addition of 4 amino acid sequence consisting of the SLHV sequence at position −4 to −1 to the eosinophil derived neurotoxin protein. The amino terminal addition is capable of directing the claimed RNase A superfamily polypeptides to proliferating endothelial cells, such as Kaposi's sarcoma cells, and selectively killing these cells.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Y/27005
7030234,18-Apr-06,2006,4,18,"Non-M, non-O HIV-1 strains, fragments and uses","Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent.The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics:",11,Institute National de la Sante et de la Recherche Medicale-Inserm,Assistance Publique-Hopitaux de Paris,Institute Pasteur,,,,,,,,,3,Biotechnology,Analysis of biological materials,,,,,C07K/005
7030236,18-Apr-06,2006,4,18,"Antisense oligonucleotides tarageting folate receptor alpha, and the use thereof","The invention relates to treatment of cancers and cancerous cells which over-express α folate receptor (FRα) compared to the normal cells of the same tissue. The invention is directed to antisense oligonucleotides which are complimentary to the coding region of FRα, as well as the pharmaceutical compositions made thereof, and the methods of using the same for treatment of cancers, e.g. cancers of ovary, cervix, uterus, and brain.",11,,,,,,,,,,,,,Biotechnology,,,,,,C12N/1138
7041296,9-May-06,2006,5,9,Methods of treating inflammatory bowel disease using cholera toxin B subunit,"The present invention provides a method of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. The present invention also provides a method of decreasing the activity of interferon gamma in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Further provided is a method of decreasing the activity of IL-12 in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Additionally, the present invention provides a method of treating or preventing a Th1 T-cell mediated autoimmune disorder in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4886
7041441,9-May-06,2006,5,9,Phage display of intact domains at high copy number,"Disclosed is a phage display system in which the molecules to be displayed (i.e., molecules of interest) are bound to dispensable capsid polypeptides such as SOC (small outer capsid) and HOC (highly antigenic outer capsid) polypeptides that are, in turn, bound to a surface lattice protein, such as those on the surface of a virion or polyhead. Also disclosed are methods of displaying a molecule of interest, methods of immunizing a patient by administering a displayed antigen, and methods of treating a patient who has a disorder associated with aberrent expression or activity of a biological molecule. In the latter instance, the method includes administering a displayed polypeptide, such as an immunoglobulin molecule or an enzyme, that is capable of specifically interacting with the aberrent biological molecule.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12N/1037
7041448,9-May-06,2006,5,9,Gene encoding a new TRP channel is mutated in mucolipidosis IV,"The present invention relates to identification of a gene that is inactivated in a mucolipidosis condition. In particular, the invention concerns mutations that disrupt a mucolipin, preferably MCOLN1, in mucolipidosis IV. Recombinant nucleic acids encoding mutant forms of MCOLN1, oligonucleotides specific for such mutations, and diagnostic and therapeutic applications related to these discoveries, are also contemplated.",46,The ML4 Foundation,The General Hospital Corporation,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7041503,9-May-06,2006,5,9,Modified myelin basic protein molecules,"Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.",19,The United States of America as represented by the Department of Health and Human Services,"Alexion Pharmaceuticals, Inc.",,,,,,,,,,2,Biotechnology,,,,,,C07K/4713
7045130,16-May-06,2006,5,16,Antibodies against antigens of human immunodeficiency virus (HIV-1),"This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.",10,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,,,,,,C07K/1063
7045132,16-May-06,2006,5,16,Streptococcus pneumoniae 37-kDa surface adhesin a protein,"The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Further provided is a method of detecting the presence of Streptococcus pneumoniae in a sample comprising the steps of contacting a sample suspected of containing Streptococcus pneumoniae with nucleic acid primers capable of hybridizing to a nucleic acid comprising a portion of the nucleic acid encoding the 37-kDa protein, amplifying the nucleic acid and detecting the presence of an amplification product, the presence of the amplification product indicating the presence of Streptococcus pneumoniae in the sample. Further provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens, methods of preventing and treating Streptococcus pneumoniae infection in a subject.",2,"The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, c/o Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/3156
7045136,16-May-06,2006,5,16,Methods of immunization using recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences,"Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses also are provided.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
7045313,16-May-06,2006,5,16,Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA,"Methods and compositions are provided for the use of vaccinia virus or other poxviruses as vectors for expression of foreign genes. Expression of foreign genes is obtained by combining vaccinia virus transcriptional regulatory sequence with uninterrupted foreign protein coding sequences in vitro to form a chimeric gene. The chimeric gene is flanked by DNA from a non-essential region of the vaccinia virus genome to provide sites for in vivo homologous recombination. These steps are facilitated by the construction of plasmids that contain multiple restriction endonuclease sites, next to the vaccinia transcriptional regulatory sequences, for insertion of any foreign protein coding sequence. Transfection procedures are used to introduce the DNA into cells where homologous recombination results in the insertion of the chimeric gene into a non-essential region of the vaccinia virus genome. Infectious vaccinia virus recombinants are distinguished or selected by expression of the foreign gene, loss of activity of a vaccinia virus gene, or by DNA—DNA hybridization. Expression of the foreign gene is obtained by infecting cells or animals with the recombinant vaccinia virus. Examples are provided to show expression of prokaryotic, RNA virus and other DNA virus genes in vaccinia recombinants.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
7045675,16-May-06,2006,5,16,Genes for Niemann-Pick type C disease,"A gene for type C Niemann-Pick disease (NP-C) is disclosed, along with the amino acid sequence of the encoded peptide. Applications which are made possible by the present invention include detection of NP-C carriers and diagnosis of NP-C sufferers. The murine ortholog of the human gene is also disclosed.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
7048935,23-May-06,2006,5,23,Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use,"The present invention provides, among other things, methods of removing virus from a sample, a composition comprising a solid support matrix to which is attached a cyanovirin, a conjugate comprising a cyanovirin coupled to at least one effector component, a composition comprising such a conjugate, methods of inhibiting prophylactically or therapeutically a viral infection of a host, and a matrix-anchored anti-cyanovirin antibody.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,A61K/164
7049291,23-May-06,2006,5,23,Isolation and method of using tissue growth-inducing Frzb protein,"An isolated cDNA encoding a growth-inducing protein, Frzb, capable of stimulating bone, cartilage, muscle and nerve tissue formation. Frzb binds to and modulates the activity of Wnt growth factors which play a role in various developmental and neoplastic processes. The cDNA and protein sequences of human, bovine and Xenopus Frzb are provided. Production and purification of recombinant Frzb are also described.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/71
7051737,30-May-06,2006,5,30,Mucus shaving apparatus for endotracheal tubes,"An endotracheal tube cleaning apparatus 10 which can be periodically inserted into the inside of an endotracheal tube 30 to shave away mucus deposits. In a preferred embodiment, this cleaning apparatus 10 comprises a flexible central tube 12 with an inflatable balloon 40 at its distal end. Affixed to the inflatable balloon are one or more shaving rings 70, each having a squared leading edge 72, to shave away mucus accumulations 60. In operation, the uninflated cleaning apparatus 10 is inserted into the endotracheal tube. The balloon 40 is then inflated by a suitable inflation device, such as a syringe 14, until the balloon's shaving rings are pressed against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube to shave off mucus deposits.",19,The United States of America as represented by the Department of Health and Human Sevices,,,,,,,,,,,1,Medical technology,,,,,,A61M/0488
7052696,30-May-06,2006,5,30,Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins,"Antigenic epitopes of hepatitis C virus (HCV) and mosaic HCV polypeptides useful as reagents in assays for the diagnosis or monitoring of HCV in a biological sample. The antigenic epitopes and mosaic polypeptides are also useful for the construction of immunogenic pharmaceutical compositions, such as vaccines. The mosaic polypeptides are artificial composite proteins constructed from diagnostically relevant antigenic regions derived from different HCV proteins. Preferably, the mosaic polypeptides contain antigenic epitopes from the core protein, NS3 protein, and NS4 protein. The preferred mosaic polypeptides optionally contain an additional antigenic epitope from either the NS4 protein or the NS5a protein or both.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7052703,30-May-06,2006,5,30,"T-cell receptorγ alternate reading frame protein, (TARP) and uses thereof","This invention provides nucleic acids containing sequences from a TCRγ transcript from prostate epithelial cells and many breast cancer cells and a T-cell receptor gamma Alternate Reading frame Protein (“TARP”) expressed from the translation of those sequences. Vaccines made from TARP are useful in raising immune responses to cells in which the protein is expressed, including prostate cancer cells and cells of many breast cancers. The invention also provides methods for diagnosing the presence of prostate cancer and TARP-expressing breast cancers, as well as methods of administering TARP and nucleic acids encoding TARP to subjects.",31,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
7052836,30-May-06,2006,5,30,Nucleic acids for detecting fusarium species,"Nucleic acids for detecting Aspergillus species and other filamentous fungi are provided. Unique internal transcribed space 2 coding regions permit the development of nucleic acid probes specific for five different species of Aspergillus, three species of Fusarium, four species of Mucor, two species of Penecillium, five species of Rhizopus, one species of Rhizomucor, as well as probes for Absidia corymbifer, Cunninghamella elagans, Pseudallescheria boydii, and Sporothrix schenkii. Methods are disclosed for the species-specific detection and diagnosis of infection by Aspergillus, Fusarium, Mucor, Penecillium, Rhizomucor, absidia, Cunninghaemella, Pseudallescheria or Sporthrix in a subject. Furthermore, genus-specific probes are also provided for Aspergillus, Fusarium and Mucor, in addition to an all-fungus nucleic acid probe.",20,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
7052904,30-May-06,2006,5,30,Hybrid adeno-retroviral vector for the transfection of cells,"An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.",38,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/86
7052907,30-May-06,2006,5,30,Adult human dental pulp stem cells in vitro and in vivo,The present invention provides a culture of isolated adult human dental pulp stem cells that can differentiate into dentin/pulp tissue that can be used to produce a tooth in a human being. The present invention further provides a method of regenerating human dentin/pulp tissue.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/0664
7056693,6-Jun-06,2006,6,6,Anthrax lethal factor is a mapk kinase protease,"The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
7056734,6-Jun-06,2006,6,6,Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof,"The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragmets thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.",40,"The United States of America as represented by the Department of Health and Human Services, NIH",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0676
7056908,6-Jun-06,2006,6,6,Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors,"Pharmaceutical compositions and methods for treating epithelial cancers and precancerous lesions employ indole carbazole compounds, such as staurosporine. Compositions containing these compounds are administered to a patient in an effective amount and may be administered topically.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/70
7067635,27-Jun-06,2006,6,27,Nucleotide and deduced amino acid sequences of tumor gene Int6,"The present invention discloses the isolation of the human and murine wild-type Int6 gene and the cDNAs sorresponding to these genes. The invention further describes the use of reagents derived from the nucleic acid and amino acid sequences of the Int6 gene in diagnostic methods, immunotherapy, gene therapy and as vaccines.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/82
7070788,4-Jul-06,2006,7,4,Follicle stimulating hormone superagonists,"The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The inventions is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the β-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone. The invention is also directed to a method of constructing superactive nonchimeric analogs of human hormones comprising comparing the amino acid sequence of a more active homolog from another species to the human hormone, and selecting superactive analogs from the substituted human hormones. The invention is also directed to nucleic acids encoding the modified human glycoprotein hormones, vectors containing those nucleic acids, and host cells containing those vectors.",45,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/59
7070790,4-Jul-06,2006,7,4,Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines,"The nucleotide and deduced amino acid sequences of cDNAs encoding the envelope 1 genes and core genes of isolates of hepatitis C virus (HCV) are disclosed. The invention relates to the oligonucleotides, peptides and recombinant envelope 1 and core proteins derived from these sequences and their use in diagnostic methods and vaccines.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
7070972,4-Jul-06,2006,7,4,Janus family kinases and identification of immune modulators,"An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
7074410,11-Jul-06,2006,7,11,Modified HCV peptide vaccines,"Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
7074413,11-Jul-06,2006,7,11,Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife,"Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity against rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.",16,Thomas Jefferson University,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7078176,18-Jul-06,2006,7,18,Detection and quantification of Cripto-1,"The present invention provides methods and compositions for the detection and quantification of Cripto-1. In particular, the present invention provides methods and compositions for the detection and quantification of Cripto-1 in samples such as milk, plasma, serum, and other biological fluids. In particularly preferred embodiments, the present invention finds use in the detection and/or quantification of Cripto-1 in human milk, plasma, serum, and other biological fluids.",25,The United States of America as represented by the Department of Health and Human Serivices,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6872
7078507,18-Jul-06,2006,7,18,Synthetic genes for malarial proteins and methods of use,"Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into the DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both.",3,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/445
7078508,18-Jul-06,2006,7,18,Ixodes scapularis tissue factor pathway inhibitor,"Ixolaris, a novel protein with anticoagulant activity is described. Ixolaris can be isolated from the salivary glands of ticks or made by recombinant methods using various DNA expression techniques.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/8114
7078516,18-Jul-06,2006,7,18,"NUCLEOTIDE SEQUENCES DERIVED FROM THE GENOME OF RETROVIRUSES OF THE HIV-1, HIV-2 AND SIV TYPE, AND THEIR USES IN PARTICULAR FOR THE AMPLIFICATION OF THE GENOMES OF THESE RETROVIRUSES AND FOR THE IN VITRO DIAGNOSIS OF THE DISEASES DUE TO THESE VIRUSES","The invention provides oligonucleotide primers selected from the group consisting of a nucleotide sequence of the gag, vpr, and pol genes of HIV-1 Bru, HIV-1 Mal, HIV-1 Eli, HIV-2 ROD, and SIV MAC; the nef, vif, and vpx genes of HIV-2 ROD and SIV MAC; and the env, nef, vif, and vpu genes of HIV-1 Bru, HIV-1 Mal and HIV-1 Eli and nucleotide sequences complementary thereto.",3,Institut Pasteur,Institut National de la Sante et de la Recherche Medicale,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
7081452,25-Jul-06,2006,7,25,"Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same","Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.",63,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/02
7081518,25-Jul-06,2006,7,25,Anti-mesothelin antibodies having high binding affinity,"Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
7081524,25-Jul-06,2006,7,25,"O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates","The present invention provides O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates (1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates) of the formulain which R and R22are as described herein. Also provided is a composition comprising such a compound and a carrier. The 1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates compounds release nitric oxide under physiological conditions and are useful for treating biological disorders.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/64
7084239,1-Aug-06,2006,8,1,Cancer peptides of NY-ESO-1/CAG-3,"The present invention discloses the identification, isolation and cloning of a gene encoding a novel cancer antigen NY ESO-1CAG-3 and peptides thereof derived from various open reading frames from the NY ESO-1 gene. The novel cancer antigen and peptides are recognized by cytotoxic T lymphocytes in an HLA restricted manner. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.",41,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4748
7084266,1-Aug-06,2006,8,1,Cloned genome of infectious hepatitus C virus of genotype 2A and uses thereof,"The present invention discloses nucleic acid sequence which encodes infectious hepatitis C virus of strain HC-J6CH, gentotype 2a, and the use of the sequence, and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7087234,8-Aug-06,2006,8,8,Recombinant multivalent viral vaccine,"The present invention relates to multivalent recombinant raccoon poxviruses, containing more than one exogenous gene inserted into either the thymidine kinase gene, the hemagglutinin gene, or a combination thereof. Disclosed is the use of the multivalent recombinant raccoon poxviruses as vaccines to immunize felines against subsequent challenge by feline pathogens. Also disclosed is a method of making a multivalent recombinant raccoon poxvirus by a recombination process involving the construction of an insertion vector into which the exogenous genes are inserted, and flanking the inserted genes are sequences which can recombine into the raccoon poxvirus thymidine kinase gene, or the hemagglutinin gene, or a combination thereof; introducing both the insertion vector containing the exogenous genes, and raccoon poxvirus into susceptible host cells; and selecting the recombinant raccoon poxvirus from the resultant plaques.",10,"Cornell Research Foundation, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
7087589,8-Aug-06,2006,8,8,Methanocarba cycloakyl nucleoside analogues,"The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloakyl group. The compounds of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A2B, A3, P2Y2 receptors), cancer (through A3, P2 receptors), cardiac arrhythmias (through A1 receptors), cardiac ischemia (through A1, A3 receptors), epilepsy (through A1, P2X receptors), and Huntington's Disease (through A2A receptors).",47,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
7087591,8-Aug-06,2006,8,8,21-substituted progesterone derivatives as new antiprogestational agents,"A compound having the general formula:in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07J/00
7087736,8-Aug-06,2006,8,8,Tyrosine DNA phosphodiesterases (TDP) and related polypeptides nucleic acids vectors TDP producing host cells antibodies and methods of use,"The present invention provides a nucleic acid molecule encoding a tyrosine-DNA phosphodiesterase (TDP), and a related vector, host cell, polypeptide, antibody, antisense nucleic acid molecule, and ribozyme. Also provided are a method of altering the level of TDP in a cell, tissue, organ or organism, as well as the resulting cell, tissue, organ or non-human organism, as well as a method of identifying a TDP-resistant compound, a method of assessing TDP1 activity in an animal, and a method of assessing the efficacy of a topoisomerase I inhibitor.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/16
7091035,15-Aug-06,2006,8,15,"Cell culturing and storage systems, devices and methods","Featured is a long-term cell culture system being configured and arranged so as to be capable of monitoring the dynamic processes that occur during proliferation and differentiation of stem cells such as central nervous system (CNS) stem cells/embryonic stem cells. In particular aspects, the system allows monitoring of such dynamic processes continually and to focally manipulate the cells by focal application of growth factors such as BMP, CNTF and other growth factors. Preferred systems are capable of electrical recording from the cells.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Chemical engineering,Measurement,Optics,,,B01L/508
7094404,22-Aug-06,2006,8,22,Method for treating malignancy and autoimmune disorders in humans using tac antibodies,"The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1033
7094405,22-Aug-06,2006,8,22,"Peptides which elicit a high neutralizing antibody titer, cytotoxic T lymphocyte response and T helper cell response in a broad range of MHC type recipients","Peptide constructs comprised of multideterminant T helper peptides from the envelope glycoprotein of HIV previously identified to induce proliferative responses in four different haplotypes of mice and IL-2 responses in 52-73% of HIV positive, flu positive patients (cluster peptides), were co-linearly synthesized with the peptide 18 of the V3 loop of HIV-1 gp 160, corresponding to the principal neutralizing determinant of HIV-IIIB and also shown to contain a dominant CTL epitope. Cognate help for peptide 18 antibody was elicited following a single immunization in all strains of mice which had previously responded to a T cell epitope encompassed by the peptides. In two strains of mice, the level of neutralizing antibody achieved was comparable to levels adequate for protection from homologous viral challenge in chimpanzees. After a single boost, much higher antibody titers for 90% neutralization in the range of 1:1000 to 1:16,000 were achieved. Spleen cells from mice of three distinct MHC haplotypes sharing the Dd class I MHC molecule but with different class II molecules, immunized with the compound peptides, exhibited enhanced gp160-specific CTL activity.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
7094406,22-Aug-06,2006,8,22,Enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof,"Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.",16,"The United States of America as represented by the Secretary of the Department of Health and Human Services and Genelabs Technologies, Inc.",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
7094408,22-Aug-06,2006,8,22,Immunogenicity using a combination of DNA and vaccinia virus vector vaccines,"This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7094411,22-Aug-06,2006,8,22,"Avirulent, immunogenic flavivirus chimeras",Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
7094576,22-Aug-06,2006,8,22,Methods and compositions for detecting larval Taenia solium with a cloned diagnostic antigen,"Compositions and methods for the detection of Taenia solium and the diagnosis of T. solium infection are described. The nucleotide and amino acid sequences of the antigenic T. solium polypeptides gp50a, gp50b and gp50c are provided. The compositions contain synthetic antigenic polypeptides of larval origin prepared using the sequences described herein. Probes and primers for the detection or amplification of T. solium nucleic acid molecules are also described. The polypeptides can be administered to a human or animal to protect against T. solium infection. In addition, the polypeptides are useful as research tools for studying T. solium and as reagents in assays for the detection of T. solium antibodies in a biological sample. The methods are sensitive and specific assays that utilize the stable recombinant or synthetic antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/56905
7094593,22-Aug-06,2006,8,22,Method for improving the function of heterologous G protein-coupled receptors,"This invention relates to mutant G protein-coupled receptors with improved G-protein coupling and receptor response, yeast cells expressing such receptors, vectors useful for making such cells, and methods of making and using same.",11,BASF Aktiengesellschaft,The United States of America as represented by the Department of Health,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/566
7094598,22-Aug-06,2006,8,22,Development of a preventive vaccine for filovirus infection in primates,"The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7096206,22-Aug-06,2006,8,22,Heuristic method of classification,"The invention concerns heuristic algorithms for the classification of Objects. A first learning algorithm comprises a genetic algorithm that is used to abstract a data stream associated with each Object and a pattern recognition algorithm that is used to classify the Objects and measure the fitness of the chromosomes of the genetic algorithm. The learning algorithm is applied to a training data set. The learning algorithm generates a classifying algorithm, which is used to classify or categorize unknown Objects. The invention is useful in the areas of classifying texts and medical samples, predicting the behavior of one financial market based on price changes in others and in monitoring the state of complex process facilities to detect impending failures.",10,"Correlogic Systems, Inc.",,,,,,,,,,,1,Computer technology,,,,,,G06K/6217
7097965,29-Aug-06,2006,8,29,Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein,"The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary toxin protective antigen and the antigen, which is bound to a binary toxin protective antigen binding protein. In one embodiment the vaccine is comprised of an anthrax protective antigen and the antigen bound to anthrax protective antigen binding protein. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7099857,29-Aug-06,2006,8,29,Multi-attribute drug comparison,"A computer-implemented apparatus or method, or a software product, for generating a composite quantitative comparison of drug products based on multiple attributes of them. A set of name-attribute similarity scores are generated based on similarities among the names of selected target and reference drugs. A set of product-attribute similarity scores are generated based on similarities among product attributes of the selected target and reference drugs. A target drug confusability score is generated based on the confusability of the target drug as compared to a population of other drugs. The composite quantitative comparison is generated based on a composite of the name-attribute and product-attribute similarity scores, and the target confusability score. A set of one or more severity of confusion scores may also be included in the composite quantitative comparison. These scores are based on one or more indicators of the severity of the consequences to a patient of confusing the target and reference drugs so that, for example, the wrong drug is administered to the patient, or the correct drug is incorrectly administered. The name-attribute similarity scores may be generated based on orthographic, phonetic, and/or phonological analysis. The product-attribute similarity scores may be generated based on the drugs'strengths, indications, dosages, administration routes, manufacturers, pharmacological categories, storage requirements, colors, shapes, legal standing, trademark description, and/or other attributes. The composite quantitative comparison may include severity-weighted similarity scores or both similarity scores and severity of confusion scores. The severity of confusion indicators may include a therapeutic index and/or a contraindication index.",47,"BLL Consulting, Inc.",,,,,,,,,,,1,Computer technology,,,,,,G06F/284
7101541,5-Sep-06,2006,9,5,Utilization of non-viral sequences for minus-strand DNA transfer and gene reconstitution,"A retroviral vector for gene reconstitution is provided that includes a 3′ portion of a heterologous nucleic acid sequence 5′ of a first att site and a 5′ portion of the heterologous nucleic acid sequence 3′ of a second att site. A sub-portion of the 3′ portion of the heterologous nucleic acid sequence and a sub-portion the 5′ portion of the heterologous nucleic acid sequence are direct repeats. A retroviral vector for gene reconstitution is also provided that includes a 3′ portion of a heterologous nucleic acid sequence inserted into or adjacent to a 5′ retroviral terminal repeat of the retroviral vector, and a 5′ portion of the heterologous nucleic acid sequence inserted into or adjacent to a 3′ retroviral terminal repeat of the retroviral vector, wherein the 3′ and the 5′ retroviral terminal repeats each comprise an att site. Methods and kits are also provided.",49,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7101547,5-Sep-06,2006,9,5,Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies,"The present invention provides methods for preventing or treating a disease in a subject which is caused by an inflammatory response to a disease or syndrome which is mediated by endogenous substance P. These methods comprise the administration to the subject of a pharmaceutically-effective amount of anti-substance P antibodies, or anti-substance P antibody fragments, such as F(ab)2 fragments, thereby inhibiting the activity of endogenous substance P in the subject. By inhibiting the activity of endogenous substance P in the subject, the levels of cytokines produced by T lymphocytes present in the subject are reduced, the signals which direct the inflammatory response to the infection become altered, and the amount of cytokine-induced inflammation becomes reduced. Respiratory syncytial virus is one example of an agent which causes an infection which often results in a disease caused by an inflammatory response to the infection mediated by endogenous substance P. Generally, from about 0.001 mg to about 10 g of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day are administered to a mammalian subject, with from about 1 mg to about 1000 mg of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day being preferred.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/26
7101548,5-Sep-06,2006,9,5,Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology,"The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/26
7101558,5-Sep-06,2006,9,5,High yield pertussis vaccine production strain and method for making same,"The present invention provides a vaccine production strain of Bordetella bronchiseptica that produces a pertussis toxin in high yield. The present invention provides a method for creating a Bordetella bronchiseptica cell line which produces a Bordetella pertussis toxin comprising the steps of introducing a plasmid containing a DNA encoding antibiotic resistance into a Bordetella bronchiseptica strain, selecting for isolates in which the DNA encoding antibiotic resistance is recombinantly incorporated into the chromosome in place of the Bordetella bronchiseptica toxin gene, introducing a plasmid containing DNA encoding subunits of the Bordetella pertussis toxins into the Bordetella bronchiseptica isolates; and, selecting for isolates in which DNA encoding Bordetella pertussis toxin subunit is recombinantly incorporated into the chromosome, the resulting cells producing the Bordetella pertussis toxin. The present invention further provides a method for creating a Bordetella bronchiseptica cell line which produces a Bordetella pertussis toxin and does not express filamentous hemagglutinin.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/20
7105169,12-Sep-06,2006,9,12,Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use,"The present invention provides, among other things, methods of removing virus from a sample, a composition comprising a solid support matrix to which is attached a cyanovirin, a conjugate comprising a cyanovirin coupled to at least one effector component, a composition comprising such a conjugate, methods of inhibiting prophylactically or therapeutically a viral infection of a host, and a matrix-anchored anti-cyanovirin antibody.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Pharmaceuticals,Biotechnology,,,,A61K/164
7105170,12-Sep-06,2006,9,12,"Latent human tuberculosis model, diagnostic antigens, and methods of use","Provided herein is an in vitro granuloma model and methods of its use. Methods of detecting and/or diagnosing latent tuberculosis in a subject are also provided, as are latency-specific antigens (and antibodies thereto), such as α-crystallin, and methods of identifying and using such molecules. Also provided are immunostimulatory compositions, for instance for use in eliciting an immune response in a subject, such as an immune response to a latent tuberculosis infection. Kits for carrying out the provided methods are also described.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5695
7105488,12-Sep-06,2006,9,12,G protein-coupled receptor antagonists,"G-protein coupled receptors (GPCR) generally contain seven transmembrane helices. The present invention provides synthetic peptides derived from these transmembrane helices. The peptides inhibit GPCR function by disrupting GPCR structure. In certain embodiments, charged residues are added at one terminus to promote correct orientation of the peptide in the membrane.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/08
7105502,12-Sep-06,2006,9,12,Nitric oxide-releasing imidate and thioimidate diazeniumdiolates,"The invention provides NO- or NO−-releasing imidate; and thioimidate, diazeniumdiolates, in which the N2O2− functional group is bonded to a carbon atom. The imidate and thioimidate diazeniumdiolates are bound to a polymer or a substrate.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07C/06
7107991,19-Sep-06,2006,9,19,Endotracheal tube using leak hole to lower dead space,"A tracheal tube ventilation apparatus to more effectively remove expired gases. In one preferred embodiment, one or more leak holes are created in the side walls of an endotracheal tube so that expired gases can leak out of the endotracheal tube above the larynx, such as into the back of the mouth (i.e., oropharynx). Each leak hole might advantageously have a diameter between 0.5 and 4.0 mm. In another preferred embodiment, a tube is attached to a proportionately larger leak hole (e.g., up to 8.0 mm) so that the expired gases can be directed away from the leak hole to a specific location, such as directed out of the mouth. In the case of mechanically controlled ventilation, a positive end expiratory pressure can be applied to this tube to mechanically assist with the process of exhaling. In each of these embodiments, it is preferred, but not required, that the endotracheal tube be an ultra-thin walled, two stage tube so as to further assist in the reduction of resistance to the flow of oxygen/air.",10,The United States of America as represented by the Department of Health & Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/04
7108981,19-Sep-06,2006,9,19,Specific binding agents for KSHV vIL-6 that neutralize a biological activity,"A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56994
7109245,19-Sep-06,2006,9,19,Vasoconstrictor cannabinoid analogs,"Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising:wherein dashed lines independently represent either a single or a double bond, R1 is a lower alkyl, R2 is a lower alkyl, R3 is a lower alkyl or halogen, R4 is a lower alkyl or hydrogen, R5 is a lower alkyl or hydrogen, R6 is a hydrogen, lower alkyl or halogen, and R7 is a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,Organix Inc.,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07C/215
7109323,19-Sep-06,2006,9,19,Formulation of boronic acid compounds,"The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of the invention.",12,The United States of America as represented by the Department of Health and Human Services,"Millennium Pharmaceutical, Inc.",,,,,,,,,,2,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C07K/0827
7115262,3-Oct-06,2006,10,3,Chimeric protein for prevention and treatment of HIV infection,"This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1045
7118738,10-Oct-06,2006,10,10,Recombinant pox virus for immunization against MUC1 tumor-associated antigen,"Recombinant pox viruses capable of expressing an immunogenic fragment of the MUC1 tumor-associated antigen are disclosed. The recombinant viruses can be used as vaccines to prevent the establishment of or treat tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The vaccines can be provided as an admixture comprising: (1) a recombinant pox virus encoding the immunogenic fragment of the MUC1 tumor-associated antigen, and (2) a recombinant pox virus encoding a T-cell co-stimulatory factor. The vaccine admixture can be used, e.g., to prevent establishment of tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The MUC1 specific cytotoxic T-cells can be isolated and expanded and used in a method for treating a host having a tumor expressing MCU1 positive tumor cells.",37,Therion Biologics Corporation,Dana-Farber Cancer Institute,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Biotechnology,,,,,,C12Q/6897
7118889,10-Oct-06,2006,10,10,Protein tyrosine kinase substrate LAT and its use in the indentification of (ant)agonists of the kinase,"The invention generally relates to compositions and methods for identifying and testing tyrosine kinase signaling pathway agonists and antagonists, and more particularly, methods and compositions for screening compounds and identifying compounds that will modulate the interaction of protein tyrosine kinase substrates with their intracellular ligands, as well as between their intracellular ligands and other members of the signaling pathway.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/40
7119181,10-Oct-06,2006,10,10,DNA sequences and peptides of human immunodeficiency virus (HIV-1),"This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.",13,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
7119193,10-Oct-06,2006,10,10,Identification of new small RNAs and ORFs of E. coli as mediators of cell and intercell regulation,The invention relates to new small RNAs and ORFs of E. coli as mediators of cell and intercell regulation.,1,The United States of America as represented by the Department of Health and Human Services,"Affymetrix, Inc.",,,,,,,,,,2,Biotechnology,,,,,,C12N/11
7122033,17-Oct-06,2006,10,17,Endoluminal radiofrequency cauterization system,"Disclosed are methods and devices for occluding the lumen of a hollow organ by delivering radiofrequency energy to the inner wall of a hollow organ. The disclosure includes radiofrequency electrodes that expand, in a deployed condition, to contact the walls of the organ. In some embodiments, the electrodes substantially conform to the inner wall to enhance therapeutic contact. Methods are also disclosed for using these electrodes to totally or partially occlude a lumen, or remove or reduce a total or partial occlusion of a lumen.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/1492
7122188,17-Oct-06,2006,10,17,"Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1","This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1, mixtures of antibodies which bind with immune complexes comprising the HIV-1 proteins, immune complexes comprising p12 or p18 proteins of HIV-1, and methods for production of antibodies against p2 or p18 proteins of HIV-1.",7,Institut Pasteur,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7122344,17-Oct-06,2006,10,17,Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions,"The present invention relates generally to the production of recombinant human uteroglobin (rhUG) for use as a therapeutic in the treatment of inflammation and fibrotic diseases. More particularly, the invention provides processes, including broadly the steps of bacterial expression and protein purification, for the scaled-up production of rhUG according to current Good Manufacturing Practices (cGMP). The invention further provides analytical assays for evaluating the relative strength of in vivo biological activity of rhUG produced via the scaled-up cGMP processes.",16,"Claragen, Inc.",,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Other special machines,Pharmaceuticals,,,C07K/4721
7122624,17-Oct-06,2006,10,17,Parathyroid hormone receptor ligands,An isolated or purified PTH2 receptor ligand or PTH1 receptor ligand is disclosed.,1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/635
7124838,24-Oct-06,2006,10,24,Gripping assembly for impact hammer,"A gripping assembly mounted on an impact hammer having a longitudinally extending impact axis, the gripping assembly including a pair of opposed elongate gripping arms, having gripping end portions which may be extended and swung toward each other to grip material in the region of the working end of the impact hammer. When retracted, the gripping arms rest to opposite sides of the impact hammer to permit free operation of the impact hammer.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Civil engineering,Machine tools,,,,,E02F/966
7125553,24-Oct-06,2006,10,24,Methods of inducing immune tolerance using immunotoxins,"Provided is a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease. Also provided is a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign mammalian donor tissue or cells, comprising the steps of: a) exposing the recipient to an immunotoxin so as to reduce the recipients's peripheral blood T-cell lymphocyte population by at least 80%, wherein the immunotoxin is anti-CD3 antibody linked to a diphtheria protein toxin, wherein the protein has a binding site mutation; and b) transplanting the donor cells into the recipient, whereby a rejection response by the recipient to the donor organ cell is inhibited, and the host is tolerized to the donor cell.",15,The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention,The UAB Research Foundation,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/2809
7125850,24-Oct-06,2006,10,24,"Methods of identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity","The present invention is directed to novel methods for assaying for modulators of GADD45 polypeptide activity. The invention also provides means to sensitize a proliferating cell to a DNA base-damaging agent by administration of novel inhibitors of GADD45 polypeptide activity. The invention further provides polypeptides which interfere with the ability of Cdc2/cyclin B1 complexes to cause a pause at the G2/M stage of the cell cycle in response to GADD45, and nucleic acids which encode such polypeptides.",8,The United States of America as represented by the Department of Health and Human Sevices,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5008
7129052,31-Oct-06,2006,10,31,Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins,"The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention. The invention also relates to a method of inhibiting adhesion of a cell expressing α3β1 integrin to an cellular matrix, inhibiting α3β1-integrin-mediated cell motility, inhibiting α3β1-integrin mediated cell proliferation, promoting α3β1-integrin mediated cell proliferation and inhibiting angiogenesis utilizing the peptides of the invention.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/06
7129271,31-Oct-06,2006,10,31,Compounds for pest control and methods for their use,"Compounds, compositions, and methods that employ an eremophilane sesguiterpene are presented for controlling an arthropod pest population. The compounds have minimal adverse or toxic effects on humans, non-human animals, and the natural environment. The compounds may be isolated from natural sources, semi-synthesized from naturally occurring compounds, or completely synthesized. The compounds may be applied directly to a pest or the locus of a pest, and function as topical or ingestible toxins. Eremophilane sesguiterpenes 13-hydroxy-valencene, valencene-11,12-epoxide, valencene-13-aldehyde, and nootkatone-1,10-11,12-diepoxide are exemplary compounds.",47,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Basic materials chemistry,,,,,C07D/32
7129332,31-Oct-06,2006,10,31,"Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof","The invention provides antibodies to a mutant form of the epidermal growth factor receptor known as EGFRvIII found only or primarily on the surface of glioblastoma cells, and on cells of breast, ovarian and non-small cell lung carcinomas. The antibodies provided by the invention have the complementarity determining regions (“CDRs”) of the scFv designated MR1, but with mutations at positions 98 and 99 in the CDR3 of the heavy chain variable region and, optionally, in other CDRs. In particular, the invention provides an antibody, designated MR1-1, which mutates MR1 in the CDR3 of the VH and VL chains. The invention provides additional antibodies in which MR1 is mutated in the CDR1 and 2 of VH or VL, or both.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/2863
7129342,31-Oct-06,2006,10,31,Infectious cDNA clone of GB virus B and uses thereof,"The present invention relates to nucleic acid sequence which comprises the genome of an infectious GB virus B clone. The invention also relates to the use of the nucleic acid sequence of the infectious GB virus B clone to indirectly study the molecular properties of HCV, and in the production of HCV/GBV-B chimeras. The invention further relates to the use of the infectious nucleic acid sequence of GB virus B clone and the HCV/GBV-B chimeras in the development of vaccines and therapeutics for HCV.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7132392,7-Nov-06,2006,11,7,Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain,"Disclosed are methods of inhibiting cell motility, for example, by inhibiting the binding between an intracellular transducer and a receptor protein tyrosine kinase, and more particularly by inhibiting hepatocyte growth factor (HGF) induced cell motility. The present invention also provides a method of inhibiting angiogenesis. The methods of the present invention employ peptides such as phosphotyrosyl mimetics. The present invention further provides methods of preventing and/or treating diseases, disorders, states, or conditions such as cancer, particularly metastatic cancer comprising administering to a mammal of interest one or more peptides of the present invention. Also disclosed are methods of blocking HGF, VEGF, or bFGF-stimulated migration, cell proliferation, and formation of capillary-like structures",36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/07
7132420,7-Nov-06,2006,11,7,Aspartic protease inhibitors,"The present invention provides an aspartic proteinase-inhibiting compound of the formula:wherein a, b, c, d, and e, can be the same or different and each are R7, OR7, SR7, NR7R8, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen, wherein R7 and R8 are independently H or an alkyl. Substituents R1 or R2 are each H or an alkyl. Substituent R3 is a straight chain or branched alkyl, alkenyl, or alkynyl substituent, or is a cycloalkyl. Substituent A is OH, NH2, or SH.Further provided are pharmaceutical compositions, which include a therapeutically effective amount of at least one of the foregoing compounds, and therapeutic methods of using the foregoing compounds.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/27
7135303,14-Nov-06,2006,11,14,Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding,"The present invention provides compositions and methods for the regulation of cytokine signaling through the Tumor Necrosis Factor (TNF) pathway. Specifically, the invention provides a novel gene, polypeptide and related compositions and methods for the regulation of ectodomain shedding. In preferred embodiments, methods and compositions for the regulation of TNF Type-1 Receptor ectodomain shedding are provided. The present invention finds use in therapeutics, diagnostics, and drug screening applications.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C07H/04
7138493,21-Nov-06,2006,11,21,ATP-binding cassette protein responsible for cytotoxin resistance,This invention provides for a novel ATP-binding cassette protein which is responsible for cytotoxin resistance. The invention also provides for methods of expressing the protein and assays for identification of inhibitors of the protein.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
7141234,28-Nov-06,2006,11,28,Imaging of drug accumulation as a guide to antitumor therapy,"The present invention describes the use of radio-labeled antitumor drugs in the treatment of solid tumors by the method of administering a radio-labelled anticancer drug to a patient and imaging at least a part of the patient using Positron Emission Tomography imaging. The method is used to monitor delivery of antitumor drugs to tumors and may be used to predict the effectiveness of therapy with a particular antitumor drug or combination of antitumor drugs, to assess the effectiveness of modulators of cellular accumulation, to individualize therapy and to evaluate the effectiveness of antitumor drugs with respect to particular cancers. Particularly preferred drugs are labeled taxanes, e.g., 11C-paclitaxel and 11C-docetaxel, labeled anthracyclines, e.g., 11C-doxorubicin and 11C-epirubicin, and other radio-labeled drug, e.g. 11C-topotecan and 11C-mitoxantrone. The invention further describes antitumor drugs labeled with the radioactive label 11C and methods of preparing radio-labeled drugs.",45,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0491
7141420,28-Nov-06,2006,11,28,Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter,The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.,5,University of Utah Research Foundation,Baylor College of Medicine,John Hopkins University,The United States of America as represented by the Department of Health and Human Services,,,,,,,,4,Biotechnology,,,,,,C07K/705
7141589,28-Nov-06,2006,11,28,Methods of inhibiting formation of vascular channels and methods of inhibiting proliferation,"A method of inhibiting formation of vascular channels in tissues and a method of inhibiting proliferation of a cell of a non-vascularized intraepithelial neoplasia, both of which methods comprise administering to the tissues or the cell a compound.",67,The United States of America as represented by the Department of Health and Human Services,University of Medicine and Dentistry of New Jersey,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/16
7141661,28-Nov-06,2006,11,28,Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties,The present invention provides methods and compositions for drug screens to identify and characterize agents that are agonistic or antagonistic to activation of the promoter region of the NAG-1 gene. Activation of the NAG-1 gene is associated with the apoptotic elimination of cancer cells both in vitro and in vivo. The invention also provides novel promoter region sequences of the NAG-1 gene.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/5082
7144734,5-Dec-06,2006,12,5,Enhanced homologous recombination mediated by lambda recombination proteins,"Disclosed herein are methods for generating recombinant DNA molecules in cells using homologous recombination mediated by recombinases and similar proteins. The methods promote high efficiency homologous recombination in bacterial cells, and in eukaryotic cells such as mammalian cells. The methods are useful for cloning, the generation of transgenic and knockout animals, and gene replacement. The methods are also useful for subcloning large DNA fragments without the need for restriction enzymes. The methods are also useful for repairing single or multiple base mutations to wild type or creating specific mutations in the genome. Also disclosed are bacterial strains and vectors which are useful for high-efficiency homologous recombination.",36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Other special machines,,,,,A01K/0275
7144918,5-Dec-06,2006,12,5,"Biologically active macrolides, compositions, and uses thereof","The present invention provides a compound of the formula (I).The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/395
7144986,5-Dec-06,2006,12,5,Polypeptides comprising IL-6 ligand binding receptor domains,"The present invention provides, among other things, a polypeptide, and a pharmaceutically acceptable salt thereof, that inhibits the binding of IL-6 ligand with IL-6 receptor under physiological conditions, a nucleic acid that encodes such a polypeptide and can be expressed in a cell, a nucleic acid that comprises or encodes an antisense nucleic acid molecule or a ribozyme that is specific for such a polypeptide, an antibody that is specific to such a polypeptide, an anti-antibody thereto, a composition comprising such a polypeptide, nucleic acid, antibody or an anti-body and a carrier therefor, a composition comprising a solid support matrix to which is attached an above-described polypeptide or an anti-antibody to a specified polypeptide sequence, a method of prophylactically or therapeutically inhibiting IL-6 signaling in a mammal in need thereof, a mammal in need thereof, and a method of removing IL-6 ligand from a bodily fluid of an animal.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/7155
7148017,12-Dec-06,2006,12,12,High sensitivity mechanical resonant sensor,"A system and method for detecting mass based on a frequency differential of a resonating micromachined structure, such as a cantilever beam. A high aspect ratio cantilever beam is coated with an immobilized binding partner that couples to a predetermined cell or molecule. A first resonant frequency is determined for the cantilever having the immobilized binding partner. Upon exposure of the cantilever to a solution that binds with the binding partner, the mass of the cantilever beam increases. A second resonant frequency is determined and the differential resonant frequency provides the basis for detecting the target cell or molecule. The cantilever may be driven externally or by ambient noise. The frequency response of the beam can be determined optically using reflected light and two photodetectors or by interference using a single photodetector.",23,"Cornell Research Foundation, Inc.",,,,,,,,,,,1,Measurement,Analysis of biological materials,,,,,G01N/022
7148036,12-Dec-06,2006,12,12,DNA molecules encoding cartilage-derived morphogenetic proteins,The present invention is a purified cartilage extract that stimulates local cartilage formation when combined with a matrix and implanted into a mammal. This extract can conveniently be produced by a method which includes the steps of: obtaining cartilage tissue; homogenizing the cartilage tissue in the presence of chaotropic agents under conditions that permit separation of proteins from proteoglycans; separating the proteins from the proteoglycans and then obtaining the proteins. The step for separating the proteins from the proteoglycans can be carried out using a sepharose column. The extract can also be obtained by additionally including the steps of separating the proteins on a molecular sieve and then collecting the proteins having molecular weights in the 30 kDa to 60 kDa size range. Articular cartilage or epiphyseal cartilage can be used in the preparation of this purified extract.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/1875
7148061,12-Dec-06,2006,12,12,Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function,"The present invention provides a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD) of a TNF-like receptor. Also provided by this invention is a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD), wherein the PLAD is selected from the group consisting of: the PLAD of a TNF-R, the PLAD of p60, the PLAD of p80, the PLAD of Fas (CD95/APO-1), the PLAD of TRAIL receptors, the PLAD of LTβR, the PLAD of CD40, the PLAD of CD30, the PLAD of CD27, the PLAD of HVEM, the PLAD of OX40 and the PLAD of DR4. TNF-R, p60, p80, Fas, TRAIL receptor, LTβR, CD40, CD30, CD27, HVEM, OX40, DR4, TROY, EDAR, XEDAR, DCR3, AITR, 4-1BB, DR3, RANK, TACI, BCMA, DR6, DPG, DR5, DCR1 AND DCR2 are all members of the TNF receptor superfamily or the TNF-like receptor family. The invention also provides the PLAD for other members of the TNF receptor superfamily. The polypeptides of the present invention can be utilized to inhibit oligomerization of members of the TNF receptor superfamily. These polypeptides can also be utilized to inhibit ligand binding to members of the TNF receptor superfamily. The present invention also provides a composition comprising an inhibitor of TNF receptor oligomerization. Further provided by this invention are members of the TNF receptor superfamily that are lacking a PLAD.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/7151
7148323,12-Dec-06,2006,12,12,Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus,"The invention describes the identification of a major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isolation and characterization of neutralizing chimpanzee monoclonal antibodies reactive to the neutralization site and the use of these antibodies in the diagnosis, treatment and prevention of HEV.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7150984,19-Dec-06,2006,12,19,Attenuated human rotavirus vaccine,"The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.",49,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
7151087,19-Dec-06,2006,12,19,"CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection","The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.",8,The United States of America as represented by the Department of Health and Human Resources,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/7158
7152919,26-Dec-06,2006,12,26,Wearable kneel-sit support device,"A wearable kneel-sit support device includes a U-shaped body that is pivotally connected to both a seat member and a base member. A linking member connects the seat member and the base member, such that moving one of the seat member and the base member causes both the seat member and the base member to rotate from a folded position adjacent the leg of the user to an unfolded position. In the unfolded position, the base member can rest on a horizontal surface and the seat member is substantially parallel to the base member, so that the wearer can sit on the seat while kneeling. The device may be worn on the lower leg of a user in a folded position to allow unhindered ambulation.",24,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,"Furniture, games",,,,,,A47C/027
7153866,26-Dec-06,2006,12,26,Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia,"The present invention provides a method for the prophylactic and therapeutic treatment of cancer. The method comprises administering to an animal, preferably a mammal, more preferably a human, at risk for developing a cancer or having a cancer a nitroxide or a prodrug thereof, wherein the nitroxide or prodrug thereof preferably is alicyclic or heterocyclic and more preferably is a compound of Formula (I) or Formula (II): in an amount sufficient to prevent or treat said cancer, wherein said cancer is susceptible to prevention or treatment by said nitroxide or prodrug thereof. Also provided is a composition for use in the method",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/42
7153882,26-Dec-06,2006,12,26,Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof,The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.,157,The United States of America as represented by the Department of Health and Human Services,"The National Institutes of Health and Axonyx, Inc.",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
7153947,26-Dec-06,2006,12,26,Ixodes salivary anticomplement protein,"Isac, a novel protein with anticomplement activity is disclosed. Isac can be isolated from the salivary glands of ticks or made by recombinant methods using various DNA expression techniques.",7,The United States of America as represented by the Department of Health and Human Services,University of Rhode Island,,,,,,,,,,2,Biotechnology,Organic fine chemistry,,,,,C07K/43527
7154268,26-Dec-06,2006,12,26,Method and apparatus to improve an MRI image using regularization,"An MRI imaging system includes at least one processor and a plurality of coils to acquire a plurality of k-space samples of a target to image. The system includes a machine-readable media comprising instructions which, when executed by the processor, result in determining a plurality of different regularization matrices for a plurality of different regions of an image of the target. The regularization matrices are applied in the determination of a plurality of unmixing matrices for the regions. The unmixing matrices are applied to produce the image without ghost artifacts, from a plurality of MRI images produced from the plurality of k-space samples and each comprising ghost artifacts.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56554
7156052,2-Jan-07,2007,1,2,Apparatus for applying chemicals to rodents,An enclosure is provided having openings for allowing entry of rodents into the enclosure. There is arranged one or more applicators in the form of a suspended flexible web configured to contact rodents entering the chamber and having a chemical on the web for application to the rodents.,18,Bayer Crop Science SA,Center for Disease Control and Prevention,Band G Equipment Company,,,,,,,,,3,Other special machines,,,,,,A01K/003
7157225,2-Jan-07,2007,1,2,Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens,"An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.",3,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
7157495,2-Jan-07,2007,1,2,"Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor","Compositions comprising bis-tetrahydrofuran benzodioxyolyl sulfonamide compounds that are surprisingly effective protease inhibitors and a second antiretroviral compound are disclosed. Methods of inhibiting retrovirus proteases, in particular multi-drug resistant retrovirus proteases, methods of treating or preventing infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication are also disclosed.",51,"Tibotec Pharmaceuticals, Ltd.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
7163818,16-Jan-07,2007,1,16,Bacteriophage having multiple host range,The present invention discloses compositions and methods for the prophylaxis and treatment of bacterial infections by the use of polyvalent bacteriophage having multiple host range.,3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/76
7163935,16-Jan-07,2007,1,16,"Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same","Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.",38,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/02
7166294,23-Jan-07,2007,1,23,Control of arthropods in rodents,"The present invention provides a method for controlling ectoparasites of small rodents, thereby preventing the transmission of diseases by arthropod vectors.",22,Centers for Disease Control and Prevention,Aventis CropScience S.A.,,,,,,,,,,2,Basic materials chemistry,,,,,,A01N/02
7166433,23-Jan-07,2007,1,23,Transductin-1 and transductin-2 and applications to hereditary deafness,"The invention provides an isolated or purified nucleic acid molecule consisting essentially of the nucleotide sequence encoding transductin-2 (TDC2), related and derivative nucleic acid molecules, vectors comprising the isolated or purified nucleic acid sequences, cells comprising such vectors, polypeptides encoded by the nucleic acid molecules, monoclonal antibodies and cell lines producing the monoclonal antibodies. The invention also provides methods of treating, prognosticating and monitoring hearing loss.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
7169819,30-Jan-07,2007,1,30,Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same,"A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.",7,Childrens Hospital Los Angeles,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/16
7175830,13-Feb-07,2007,2,13,Imaging of drug accumulation as a guide to antitumor therapy,"The use of radio-labeled antitumor drugs in the treatment of solid tumors by the method of administering a radio-labeled anticancer drug to a patient and imaging at least a part of the patient using Positron Emission Tomography imaging is described. The method can be used to monitor delivery of antitumor drugs to tumors, to predict the effectiveness of therapy with a particular antitumor drug or combination of antitumor drugs, to assess the effectiveness of modulators of cellular accumulation, to individualize therapy and to evaluate the effectiveness of antitumor drugs with respect to particular cancers. Particularly preferred drugs are labeled taxanes, e.g., 11C-paclitaxel and 11C-docetaxel, labeled anthracyclines, e.g., 11C-doxorubicin and 11C-epirubicin, and other radiolabeled drugs, e.g. 11C-topotecan, 11C-SN-38, and 11C-imatinib. The invention further describes antitumor drugs labeled with the radioactive label 11C and methods of preparing radio-labeled drugs.",23,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0491
7175838,13-Feb-07,2007,2,13,Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state,"The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer of CD40 stimulation are administered in synergistically effective amounts to treat or prevent the pathologic state in the mammal. The invention also provides a method of assessing the effectiveness of treatment of a pathologic state in a mammal, wherein the mammal has been administered a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The method comprises measuring the level of at least one antibody in a test sample obtained from the mammal, which at least one antibody is specific for an antigen that is known to be associated with the pathologic state, and wherein the level of the at least one antibody is indicative of the effectiveness of treatment of the pathologic state in the mammal.",14,The United States of America represented by the Department of Health and Human Services,University of Minnesota,Chiron Corporation,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/2013
7179621,20-Feb-07,2007,2,20,Pigment epithelium-derived factor: sequence of the PEDF gene,"Nucleic acids encoding the neurotrophic protein known as pigment epithelium derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.",52,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/811
7179899,20-Feb-07,2007,2,20,Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72,"Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
7182944,27-Feb-07,2007,2,27,Methods of increasing distribution of nucleic acids,"This invention provides a method of increasing the volume of distribution of a nucleic acid encoding a therapeutic agent in a tissue in a subject during localized delivery, comprising administering to the tissue in the subject a nucleic acid encoding a therapeutic agent and a facilitating agent, whereby the inclusion of the facilitating agent increases the volume of distribution of the nucleic acid encoding a therapeutic agent in the tissue.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7183071,27-Feb-07,2007,2,27,Anthrax lethal factor is a MAPK kinase protease,"The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
7183254,27-Feb-07,2007,2,27,Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment,"Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.",30,"Amgen, Inc.",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/2264
7183377,27-Feb-07,2007,2,27,Human FRP and fragments thereof including methods for using them,"The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
7186698,6-Mar-07,2007,3,6,Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat,"The invention provides methods for using local heat to control gene expression. The heat shock protein (hsp) gene promoter is recombined with a selected therapeutic gene and expressed in selected cells. Local controlled heating is used to activate the hsp promoter, for example by using focused ultrasound controlled by MRI.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
7189393,13-Mar-07,2007,3,13,Recombinant anti-tumor RNAse,"This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermore, these proteins are more active than ribonucleases currently available even though the proteins of this invention lack an N-terminal pyroglutamic acid, which has been found to be necessary for ribonucleolytic activity. Because these proteins are recombinant proteins, mutations which increase cytotoxicity can be engineered.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/22
7189511,13-Mar-07,2007,3,13,Methods of screening and diagnostics using ATP-binding cassette transporter,The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.,23,Baylor College of Medicine,The United States of America as represented by the Department of Health and Human Services,University of Utah Research Foundation,John Hopkins University,,,,,,,,4,Biotechnology,,,,,,C07K/705
7189513,13-Mar-07,2007,3,13,Human papilloma virus immunoreactive peptides,"This invention provides immunogenic peptides from the HPV-18E6 protein that comprise class I restricted T cell epitopes and discloses methods of administering these peptides to individuals, and a method for monitoring or evaluating an immune response to HPV with these peptides.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
7189812,13-Mar-07,2007,3,13,Human gene critical to fertility,"Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater genomic, cDNA and protein sequences are provided, as are fragments and variants thereof. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for using Mater molecules in diagnoses, prognosis, and treatment of infertility and reduced fertility, and kits related to such methods. Also provided are methods for using MATER as a contraceptive agent. The disclosure also describes compounds involved in such methods, and the identification of such compounds.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Analysis of biological materials,,,,C07H/04
7191097,13-Mar-07,2007,3,13,"Method, apparatus, and system for assessing conditions",Real-time condition data indicative of conditions is collected from at least one sensor at a particular location or from a plurality of sensors at different locations over time. The data collected from different locations is time-synchronized to produce data indicative of conditions at the different locations at one or more times. Real-time position data indicative of the location(s) of the sensor(s) are also collected over time. The collected real-time condition data are correlated with the collected real-time position data to produce correlated data indicative of conditions at the one or more locations over time. At least a portion of the collected and correlated data is analyzed to determine conditions at the one or more locations over time.,6,United States of America,,,,,,,,,,,1,IT methods for management,,,,,,G06Q/06
7192579,20-Mar-07,2007,3,20,Methods of gene therapy using nucleic acid sequences for ATP-binding cassette transporter,The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.,6,Baylor College of Medicine,Johns Hopkins University,University of Utah Research Foundation,"United States of America, Represented by the Secretary, Department of Health and Human Services, c/o National Institute of Health",,,,,,,,4,Biotechnology,,,,,,C07K/705
7192593,20-Mar-07,2007,3,20,Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens,"Chimeric parainfluenza viruses (PIVs) incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric Ply genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen.",43,"The United States of America, Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7192705,20-Mar-07,2007,3,20,Transductin-1 and applications to hereditary deafness,"The invention provides methods of detecting hearing loss or a predisposition to hearing loss in an animal, which comprises detecting at least one mutation in a gene encoding transduction-1 (TDC1) in a test sample obtained from the animal. The invention also provides a method of determining the level of nucleic acid comprising a wild-type TDC1 gene and/or a mutant TDC1 gene in a test sample obtained from an animal.",9,"United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6883
7192934,20-Mar-07,2007,3,20,Vaccines for blocking transmission of Plasmodium vivax,"The present invention relates to novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/70
7193053,20-Mar-07,2007,3,20,Hypoxia-inducible factor 1alpha variants and methods of use,This invention relates to unique variant forms of HIF-1 alpha polypeptide that are stable under hypoxic and nonhypoxic conditions and their use in the treatment of disorders involving oxygen homeostasis.,17,"United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/4702
7194978,27-Mar-07,2007,3,27,Inducing sterility in fish by disrupting the development of the GnRH system,"The present invention provides for a method for inducing sterility in fish by administering at least one compound that disrupts the establishment of the gonadotropin-releasing hormone system during early development thereby inhibiting sexual maturity in the treated fish. Effective compounds include GABA, GABA receptor agonists, or GABA receptor antagonists.",18,University of Maryland Biotechnology Institute,Ramot at Tel Aviv University,United States of America,,,,,,,,,3,Biotechnology,,,,,,C07K/575
7195756,27-Mar-07,2007,3,27,Control of arthropod vectors of parasitic diseases,"The present invention provides a method for controlling ectoparasites of small rodents, thereby preventing the transmission of diseases by arthropod vectors. The invention further provides an enclosure having openings for entry of rodents, and having arranged therein one or more applicators which are configured to contact rodents entering the chamber and having an ectoparasiticide on the applicator for application to the rodents.",5,Centers for Disease Control and Prevention,,,,,,,,,,,1,Pharmaceuticals,Other special machines,,,,,A61K/4439
7196074,27-Mar-07,2007,3,27,"Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof","Methods of using 7α,11β-dimethyl-17β-hydroxyestra-4,14-dien-3-one (III)and 17 esters thereof for various hormonal therapies, oral and parenteral dosage forms comprising these actives, and processes for their preparation.",96,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07J/00
7199127,3-Apr-07,2007,4,3,Purine nucleosides,"Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof:wherein X is sulfur or oxygen; R1 is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R2 is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R3 and R3′ are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocarbonyl, whereas R3 and R3′ do not have identical substituents simultaneously; and R4 is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a method for preventing or treating various diseases, state, or condition, including asthma, inflammation, cerebral ischemia, heart diseases, and cancer.",11,"United States of America, Represented by the Secretary, Department of Health and Human Services",Ewha Womans University,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07H/10
7201907,10-Apr-07,2007,4,10,Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines,Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response or as vectors for introducing heterologous genes into a host. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.,46,"The United States of America, Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
7201911,10-Apr-07,2007,4,10,Cloned genomes of infectious hepatitis C viruses and uses thereof,"The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.",8,"United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7202333,10-Apr-07,2007,4,10,DNA encoding IgE Receptor α-subunit or fragment thereof,A cDNA sequence encoding the α-subunit of human mast cell IgE surface receptor or an IgE binding fragment thereof.,1,President and Fellows of Harvard College,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70535
7205101,17-Apr-07,2007,4,17,"Human immunodeficiency virus (HIV) nucleotide sequences, recombinant polypeptides, and applications thereof","Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",19,"Novartis Vaccines and Diagnostics, Inc.",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7205102,17-Apr-07,2007,4,17,Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA,"This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.",3,Institut Pasteur,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12Q/703
7205334,17-Apr-07,2007,4,17,"Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof","A substantially purified compound of the formula: a composition comprising a therapeutically effective amount of at least one compound of the formula, alone or in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.",10,"United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
7206701,17-Apr-07,2007,4,17,Systems and methods for automated quantitative analysis of digitized spectra,A variety of methods and systems related to automated quantitative analyses via digital spectroscopy techniques can be used to determine the quantity of one or more analytes in a sample. A parameter file can be used to control automated analysis. Suspect conditions related to parameters can be identified and-appropriate advisories provided. Suspect conditions related to analysis can be identified and appropriate warnings provided. Various algorithmic techniques are supported and can be selected by a user by modifying parameters via a parameter-editing user interface presented by software.,46,"United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Measurement,,,,,,G01J/28
7208161,24-Apr-07,2007,4,24,Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences,"Isolated polynucleotide molecules provide recombinant PIV genomes and antigenomes for production of recombinant PIV vaccines. The recombinant genome or antigenome can be expressed with a nucleoprotein (N), phosphoprotein (P), and a large (L) polymerase protein to produce isolated infectious PIV particles. The recombinant PIV genome and antigenome can be modified to produce desired changes, for example to incorporate attenuating mutations from biologically derived PIV mutants or to create chimeric PIV clones, to generate attenuated, immunogenic viruses for vaccine use.",70,"The United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/1027
7208313,24-Apr-07,2007,4,24,Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector,A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.,23,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7209796,24-Apr-07,2007,4,24,Auscultatory training system,"According to a disclosed embodiment, an auscultatory training apparatus includes a database of pre-recorded physiological sounds stored on a computer for playing on a playback system. A user-friendly, graphical user interface software program is stored on the computer for use with a conventional computer mouse. The program allows a user to select one of the pre-recorded sounds for playback. In addition, the program is operable to generate an inverse model of the playback system in the form of a digital filter. If employed by the user, the inverse model processes the selected sound to cancel the distortions of the playback system so that the sound is accurately reproduced in the playback system. The program also permits the extraction of a specific sound component from a pre-recorded sound so that only the extracted sound component is audible during playback.",9,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Medical technology,Control,,,,,A61B/04
7211432,1-May-07,2007,5,1,Recombinant vector expressing multiple costimulatory molecules and uses thereof,"The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced antigen-presenting functions.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7211445,1-May-07,2007,5,1,Conjugation of biomolecules using diels-alder cycloaddition,"A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.",13,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,"Macromolecular chemistry, polymers",,,,A61K/385
7211696,1-May-07,2007,5,1,Antileishmanial dinitroaniline sulfanomides with activity against parasite tubulin,"Dinitroaniline compounds useful for the treatment of diseases caused by parasitic protozoa in subjects in need of such treatment. The compounds are particularly useful in the treatment of leishmaniasis. The compounds are preferably less cytotoxic to normal cells than oryzalin. Also provided are methods of treating subjects having diseases caused by parasitic protozoa, preferably humans. The method comprising administering a therapeutically effective amount of a dinitroaniline compound of the present invention to a subject in need of such treatment",20,The Ohio State University,National Institutes of Health,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/096
7214477,8-May-07,2007,5,8,Layered device with capture regions for cellular analysis,"The present invention involves methods, systems, and devices for analyzing a biological material, such as a cellular or other specimen. The method includes placing the specimen on a substrate having different capture regions, such as contiguous layers, wherein the different capture regions of the substrate contain different identification molecules, and transferring components of the specimen through the capture regions under conditions that allow the components to interact with different identification molecules in the different regions of the substrate. The components of the specimen can be transferred through the different layers (or other regions) of the substrate by capillary action of a solution moving through the cellular specimen or by electrophoresis. The transfer of components of the specimen through the substrate may occur while maintaining a geometric correspondence to the specimen, such as the cytoarchitecture of a cellular specimen, for example by moving the components through parallel layers having positions that correspond to positions within the specimen. When the cellular architecture of the specimen is maintained, a correlation between the different identification molecules and the components of the cellular specimens may be made. The analysis can occur with one or more different discrete (for example cellular) specimens on a surface of the substrate. Examples of cellular specimens include, but are not limited to tissue sections, particularly tumor tissue sections. The cellular specimen can also include cultured cells or a cytology sample. Cytostat tissue sections cut slightly thicker than usual, that is about 25 to about 50 μm, improves the ability to detect molecules of moderate and low level abundance.",57,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/54386
7214488,8-May-07,2007,5,8,Detection of MECT1-MAML2 fusion products,"The present invention provides methods and compositions for the diagnosis and treatment of cancer, including cancers involving the NOTCH pathway. In particular, the present invention provides methods and compositions for the diagnosis of mucoepidermoid carcinoma, the most common malignant salivary gland tumor. The present invention further provides methods and compositions for the diagnosis of other tumors associated with the t(11;19)(q14–21;12–13) translocation.",12,"United States of America, Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57496
7217508,15-May-07,2007,5,15,Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1),"This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.",10,Institut Pasteur,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
7217811,15-May-07,2007,5,15,Human gene critical to fertility,"Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater cDNA and protein sequences are provided. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for using Mater molecules in diagnoses, prognosis, and treatment of infertility and reduced fertility. Also provided are methods for using MATER as a contraceptive agent. The disclosure also describes compounds involved in such methods, and the identification of such compounds.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Analysis of biological materials,,,,C07H/04
7220419,22-May-07,2007,5,22,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7220558,22-May-07,2007,5,22,Cartilage-derived morphogenetic proteins,Nucleotide and amino acid sequences of cartilage-derived morphogenetic proteins (CDMP-1 and CDMP-2) from human and bovine cartilage extracts. These proteins exhibit chondrogenic activity and can be used to repair cartilage defects in a mammal.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/32
7220582,22-May-07,2007,5,22,Stem cells that transform to beating cardiomyocytes,"Disclosed herein is a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are also provided herein to utilize spoc cells in therapeutic applications for the treatment of myocardial defects, such as areas of ischemic or traumatic damage.",17,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,G01N/5073
7220718,22-May-07,2007,5,22,Oral treatment of hemophilia,"Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.",28,United States of America as represented by the Secretary of the Department of Health and Human Services,"Virginia Tech Intellectual Properties, Inc.",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/36
7220852,22-May-07,2007,5,22,Coronavirus isolated from humans,"Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.",1,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7223535,29-May-07,2007,5,29,Synthetic peptides immunoreactive with hepatitis A virus antibodies,"Synthetic peptides immunoreactive with hepatitis A virus (HAV) antibodies are provided. The peptides are useful as laboratory reagents to detect or quantify HAV antibodies in biological samples in clinical or research-based assays and for inducing an immune response to HAV when administered to a human or animal. The peptides contain antigenic epitopes, modified antigenic epitopes or combinations of epitopes of the major structural capsid polypeptides or non-structural polypeptides of HAV and contain one or more molecules of the amino acid glutamine (Q) at the carboxyl end of the peptide, which enhances immunoreactivity and immunogenicity, particularly IgM antibody reactivity.",7,Centers for Disease Control,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
7223836,29-May-07,2007,5,29,Peptides for chlamydophila pneumoniae vaccine and diagnosis,"Peptides are disclosed that include SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, or a conservative variant or mimic thereof, wherein the conservative variant or mimic specifically binds an antibody that specifically binds SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID or NO:6. These peptides are of use in generating an immune response against C. pneumoniae, or in preventing infection with against C. pneumoniae.",16,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C07K/295
7223844,29-May-07,2007,5,29,Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes,"The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.",27,"United States of America, Represented by the Secretary, Department of Health and Human Services",Scripps Research Institute,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/1063
7223853,29-May-07,2007,5,29,Secreted frizzled related protein fragments,"The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services.,The University of Massachusetts,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/47
7225807,5-Jun-07,2007,6,5,Systems and methods for aerosol delivery of agents,"Aerosol delivery systems and methods for delivering an agent to a patient are described herein. The present invention includes embodiments comprising an insulated receptacle connected to a body to hold a vial of an agent to be delivered to a patient. The vial is located in an inverted position within the receptacle and connected to the housing. One or more reusable thermal packs can be located on the inner sides of the receptacle, to maintain a selected temperature surrounding the vial. The agent is administered to a patient by placing a prong into one of the patient's orifices and then activating an aerosol delivery system. Such systems comprise jet aerosolization and pneumatic and ultrasonic nebulizers and preferably are portable.",33,Creare Incorporated,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,2,Medical technology,,,,,,A61M/005
7226586,5-Jun-07,2007,6,5,"Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use",Extremely hydrophobic nitric oxide (NO) releasing polymers are disclosed. The extremely hydrophobic NO-releasing polymers provided are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. These polymers can be loaded with extremely high NO levels and designed to release NO in manners than mimic natural biological systems. The NO-releasing extremely hydrophobic polymers provided can maintain a sustained NO release for periods exceeding nine months. Also provided are related medical devices made using these NO-releasing extremely hydrophobic polymers.,13,"Medtronic Vascular, Inc.",,,,,,,,,,,1,Medical technology,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,C08F/30
7226602,5-Jun-07,2007,6,5,Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses,A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.,13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
7226731,5-Jun-07,2007,6,5,"PB 39, a gene dysregulated in prostate cancer, and uses thereof","A novel gene, PB39, that is up-regulated, or over-expressed, in prostate cancer has been identified. The gene has been identified by means of its cDNA obtained by reverse transcription of the corresponding mRNA. Microdissection of prostate glands that had been surgically removed from prostate cancer patients revealed a novel up-regulated transcript in an aggressive prostate carcinoma. Differential analysis for the presence of this gene was carried out from the same glands by comparing transcription in microdissected normal prostatic epithelium versus that in microdissected invasive tumor. The transcript was over-expressed in 5 of 10 prostate carcinomas examined. A variant transcript was over-expressed in 4 of 4 prostate carcinomas, and was found in 1 of 4 normal samples. The invention provides a purified and isolated nucleic acid that includes the sequence of PB39 or its complement, the sequence of a variant of PB39 or its complement, and a primer or probe, that includes a sequence that is a fragment of these sequences. Additionally, the polypeptide encoded by these genes, an antibody to the polypeptide, and methods of detection of PB39 or its gene product are provided.",13,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
7226779,5-Jun-07,2007,6,5,Hybrid adenoviral vector,"An adenoviral vector is disclosed that includes two adenoviral ITRs, wherein the two adenoviral ITRs flank a packaging signal and a single retroviral LTR operably linked to a nucleic acid sequence of interest, wherein the adenoviral vector does not include a nucleic acid sequence encoding the retroviral structural proteins and wherein the adenoviral vector does not include a second retroviral LTR. In one embodiment, a method for transforming a cell is disclosed. In another embodiment, a method is disclosed for introducing a transgene into a cell with a single viral vector. In a further embodiment, a method is provided for preventing or treating disorder in a subject. A pharmaceutical composition is also provided.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7226780,5-Jun-07,2007,6,5,Lentivirus vector system,"A method is disclosed for improving encapsidation of transgene RNA using retroviral packaging and transfer vectors. An HIV-2 transfer vector, which includes the transgene, is introduced into a packaging cell that is also transfected with (or stably expresses) an HIV-2 derived packaging vector or a combination of packaging vectors. The packaging vector has mutations in packaging signal sequences that are both upstream and downstream of the 5′ splice donor site. The upstream mutation can be a functional deletion of a signal sequence located between the 5′ LTR and the 5′ splice donor site, while the downstream mutation can be a functional deletion of a signal sequence located between the 5′ splice donor site and an initiation codon of the gag gene on the HIV-2 genome. It can also be composed of a combination of two or more partial vectors. A transfer vector, which is introduced into the packaging cell line, has a mutation that renders its splice donor site non-functional. Transgene RNA expression and encapsidation from these cells is markedly increased, but with little or no levels of infectious viral RNA encapsidation. In particular embodiments, the packaging vector is an HIV-2(ROD) clone, such as pROD(SD36) or pROD(SD36/EM) plus pCM-ENV(ROD), the transfer vector is an HIV-2 clone, such as pSGT-5(SDM), and the packaging cell is a 293T cell. The invention also includes vectors used in this method, cells transformed with the vector or vectors, the supernatant of the packaging cells with the encapsidated vector RNA, as well as the encapsidated RNA itself.",20,United States of America as Represented by the Secretary of the Department of Health and Human Resources,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7226991,5-Jun-07,2007,6,5,Phenylalanine derivatives,"Disclosed herein are phenylalanine derivative compounds of the following formulaW—Y—(AA)n—Zwherein Y is a phenylalanyl radical, AA is an amino acid, n is an integer of 1 to 15, and substituent variables W and Z are as described herein. The compounds can be used to inhibit SH2 binding with phosphoproteins, and to inhibit proliferation of tumor cells.",49,"United States of America, represented by the Secretary, Department of Health and Human Services",Georgetown University,,,,,,,,,,2,Biotechnology,,,,,,C07K/0812
7227011,5-Jun-07,2007,6,5,Nucleic acid vaccines for prevention of flavivirus infection,"The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.",20,"United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
7229754,12-Jun-07,2007,6,12,Sensing phage-triggered ion cascade (SEPTIC),The present invention provides a method for detecting bacteria and a nano-well device having one or more input/output connections about a gap and one or more bacteriophages at or about the gap that trigger a detectable electrical field fluctuation when the one or more bacteriophages contact a cognate target within a liquid sample.,23,,,,,,,,,,,,,Biotechnology,Analysis of biological materials,Micro-structural and nano-technology,,,,B82Y/00
7229963,12-Jun-07,2007,6,12,Methods of using deacetylase inhibitors to promote cell differentiation and regeneration,"A method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis, and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of progenitor cell differentiation, or can be part of an organsism, such as a human or other mammal. Contacting the progenitor cell with a DI can lead to enhancement of expression of terminal cell-type specific genes in the progenitor cell, such as enhancing expression of muscle-specific genes in myoblasts. Administering a DI to a subject also can provide some prophylactic or therapeutic effect for inhibiting, preventing, or treating associated with a degeneration or loss of tissue. The DI can be administered to a subject as part of a pharmaceutical composition.",10,"United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health",The Salk Institute for Biological Study,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/165
7230033,12-Jun-07,2007,6,12,Pest control compositions and methods for their use,"Compositions and methods for controlling an arthropod pest population that include an eremophilane sesquiterpene pest control agent (such as, nootkatone or 13-hydroxy-valencene) and a dialkyl-substituted phenol pest control agent (such as, carvacrol) are disclosed. The compounds present in the compositions may be isolated from natural sources, semi-synthesized from naturally occurring compounds, or completely synthesized. The pest control compositions may be applied directly to a pest or the locus of a pest, and function as topical or ingestible pest toxins.",23,"United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention",State of Oregon Acting by and Through the State Board of Higher Education on Behalf of Oregon State University,,,,,,,,,,2,Organic fine chemistry,Basic materials chemistry,,,,,C07D/32
7232654,19-Jun-07,2007,6,19,DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1),"This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.",21,Institut Pasteur,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12Q/703
7232671,19-Jun-07,2007,6,19,Pertussis toxin gene: cloning and expression of protective antigen,A cloned gene encoding the expression of an antigenic mutant pertussis toxin with substantially reduced enzymatic activity has been described.,1,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/1077
7232887,19-Jun-07,2007,6,19,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",15,"United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
7232890,19-Jun-07,2007,6,19,"AIB1, a novel steroid receptor co-activator","The invention features a substantially pure DNA which includes a sequence encoding a novel steroid receptor co-activator which is overexpressed in breast cancer cells, diagnostic assays for steroid hormone-responsive cancers, and screening assays to identify compounds which inhibit an interaction of the co-activator with the steroid hormone.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/4705
7233818,19-Jun-07,2007,6,19,Methods and apparatus for mapping internal and bulk motion of an object with phase labeling in magnetic resonance imaging,"Magnetic resonance imaging method and apparatus are provided for mapping the internal or bulk motion of an object by labeling the phase of a specimen magnetization with a selected spatial function and measuring changes in the phase of the magnetization. The spatial function is selectable to provide magnetization phase modulation corresponding to displacements in a selected direction, such as a radial or azimuthal direction. Methods and apparatus for producing images based on magnetization phase modulation acquire image data based on stimulated echos and stimulated anti-echos. In an embodiment, a series of 180 degree pulses produces alternating stimulated and stimulated anti-echos that are measured and assigned to respective images.",30,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56308
7235232,26-Jun-07,2007,6,26,Interferon alpha hybrids,"Hybrid human interferon-α polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these peptides, and the use of these polypeptides to treat viral disease and regulate cell growth are also provided.",23,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/56
7235365,26-Jun-07,2007,6,26,Specific binding agents for KSHV vIL-6 that neutralize a biological activity,"A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.",11,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56994
7238473,3-Jul-07,2007,7,3,TTP-related zinc finger domains and methods of use,"The present invention provides methods of regulating the destruction of mRNA molecules containing an AU-rich element (ARE), for example, methods of stimulating the degradation of an mRNA molecule encoding TNF-α, and methods of inhibiting the degradation of an mRNA molecule encoding GM-CSF. Also provided are methods for identifying compounds that regulate the destruction of mRNA molecules containing AREs.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/566
7244558,17-Jul-07,2007,7,17,Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines,"The present invention concerns cDNAs for making attentuated, infectious Newcastle disease virus (NDV). Another aspect of the invention relates to methods of making the cDNAs. Another aspect of the invention is a vector containing the cDNA optionally linked to an operable promoter. Within the scope of the invention are vaccines comprising the attenuated, infectious NDV. Also disclosed are methods of making the vaccines and methods of using the vaccines to prevent or treat Newcastle disease in an avian host. The present invention also concerns the nucleotide sequences of the entire genome of NDV, the leading region, the trailing region, and the NP region, as well as proteins encoded by these nucleotide sequences.",10,University of Maryland,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/17
7244584,17-Jul-07,2007,7,17,"T2R, a novel family of taste receptors","The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.",7,The Regents of the University of California,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7244724,17-Jul-07,2007,7,17,Pyrrolobenzodiazepines,"A compound of formula I:or solvate thereof, wherein n is 1 to 10, and M and M′ are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.",14,"United States of America, Represented by the Secretary, Department of Health and Human Services","Spirogen, Ltd.",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
7247307,24-Jul-07,2007,7,24,Vaccines against Escherichia coli O157 infection,"This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-DGalpNAc-(1→2)-α-D-PerpNAc-(1→3)-α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide of E. coli O157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0258
7247457,24-Jul-07,2007,7,24,Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein,Disclosed are methods of using enterovirus-specific primers for the detection and identification of enterovirus infection. Also provided are isolated nucleic acid molecules and kits useful for detection and diagnostic testing of enterovirus infection in a subject.,11,"United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
7247615,24-Jul-07,2007,7,24,Peptide agonists of prostate-specific antigen and uses therefor,"This invention relates to isolated peptides comprising agonist epitopes of prostate-specific antigen (PSA). In various aspects, the invention relates to peptides comprising agonist epitopes of the PSA-3 cytotoxic T lymphocyte epitope, and nucleic acids encoding peptides that comprise PSA-3 agonist epitopes. Also related are probes, primers, and vectors comprising these nucleic acids, as well as host cells comprising these vectors, and antibodies that bind to the PSA-3 agonist peptides. This invention further relates to diagnostic reagents and methods utilizing the disclosed nucleic acids or antibodies. The invention also relates to pharmaceutical compositions comprising the nucleic acids, host cells, and peptides of the invention, as well as methods of treatment or prevention of prostate cancer employing such compositions, for example, for peptide-mediated, cell-mediated, and vector-mediated immunotherapies.",23,"United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/6445
7250097,31-Jul-07,2007,7,31,Device for sequential protein transfer from a gel,"An apparatus and method for the sequential electroelution of biomolecules is described, the apparatus comprising a separation medium having an outlet, and a collector having at least a first receptacle and a second receptacle that can be sequentially brought into contact with the outlet of the separation medium by translating the first receptacle and the second receptacle in relation to the outlet of the separation medium, and the method comprising the steps of receiving a first substantially separated molecule in the first receptacle and translating the first receptacle and the second receptacle such that the second receptacle is brought into in contact with the outlet of the separation medium, receiving a second substantially separated molecule in the second receptacle, and repeating said steps to sequentially receive a desired number of substantially separated molecules.",51,"The United States of America, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01N/44704
7250171,31-Jul-07,2007,7,31,Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein,"Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic domains, fragments, or epitopes of a second, antigenically distinct HPIV. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, and, optionally against respiratory syncytial virus (RSV). Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a HPIV vector genome or antigenome combined or integrated with one or more heterologous genome segment(s) encoding one or more antigenic determinant(s) of a heterologous PIV to encode a chimeric glycoprotein. In preferred aspects of the invention, the chimeric virus is attenuated for use as a vaccine agent by additional mutations or nucleotide modifications introduced into the chimeric genome or antigenome.",70,United States of America as Represented by the Dept. of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7252929,7-Aug-07,2007,8,7,Methods for identifying alpha PDGFR agonists and antagonists,"Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.",7,"United States of America, as represented by the Secretary, Dept of Health & Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/74
7253620,7-Aug-07,2007,8,7,Spectrally selective suppression with steady-state free precession,"A method that exploits the intrinsic selectivity of steady-state free precession (SSFP) to perform spectral suppression is disclosed. Such a method avoids the need to incorporate additional spectrally selective pulse sequence elements. The scheme is based on breaking the FISP imaging sequence into short trains having, for example, 8–64 RF pulses. At the moment of echo formation (i.e., TE=TR/2) after the last full RF pulse of the train, water signal is z-stored. Residual transverse magnetization, which include isochromats phase-opposed to the on-resonance water, is gradient crushed and RF spoiled. The stored magnetization is subsequently re-excited with little disturbance to the on-resonance steady-state water signal. The additional time required to perform the steady-state interruption is typically as little as a single TR, minimally affecting the efficiency of the imaging process. The sequence can be employed repetitively, greatly reducing the amplitude of fat signals throughout a real-time or cine imaging process.",16,"United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/5613
7255993,14-Aug-07,2007,8,14,Detection of mutational frequency and related methods,"Methods are provided herein for measuring the mutational frequency of a DNA molecule in cells, for example stem cells or hematopoietic cells such as CD34+ cells or granulocytes. The method includes sequencing corresponding regions of mtDNA from a set of hematopoietic cells, or a set of clonal populations of hematopoietic cells, and comparing the sequence of the corresponding regions of mtDNA from the cells, or clonal populations of cells. The method also includes the comparison of mtDNA sequences with genomic DNA sequences. Also provided are methods for screening for an agent that has a mutagenic effect on a cell. The method includes contacting, or treating, clonal populations of cells with an agent and comparing the sequence of the mtDNA obtained from the treated clonal populations of cells, with the sequence of the corresponding region of mtDNA obtained from a control clonal populations of cells.",32,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
7256004,14-Aug-07,2007,8,14,Variants of humanized anti-carcinoma monoclonal antibody CC49,The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.,19,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/0002
7256256,14-Aug-07,2007,8,14,CDK4 binding peptide,"The invention provides a CDK4 binding peptide, and a nucleic acid sequence coding therefore, that is capable of specifically binding cyclin dependent kinase (CDK4) to inhibit CDK4 activity and cell growth. The invention also includes variants of the CDK4 binding peptide which comprise polypeptides which have at least about 80% amino acid sequence identity with the amino acid sequence of the CDK4 binding peptide. In another embodiment, the invention provides chimeric molecules comprising a CDK4 binding peptide fused to a heterologous peptide or amino acid sequence, preferably a nuclear localization signal. Therapeutic and diagnostic methods are also provided.",5,"United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/10
7256260,14-Aug-07,2007,8,14,Human p53 mutations and a genetic system in yeast for functional identification of human p53 mutations,"The present invention provides isolated polypeptides of human p53 that contain mutations. These mutations can be toxic mutations, supertransactivating mutations or tox-suppressor mutations. Further provided by the invention are methods of identifying toxic, supertransactivating, weak transactivating and tox-suppressor mutations as well as methods of identifying compounds that mimic the toxic, supertransactivating and tox-suppressor mutations in human p53. Also provided are methods of inducing toxicity in a cell by administering a polypeptide comprising a supertransactivating or a toxic mutation.",2,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services, NIH",,,,,,,,,,,1,Biotechnology,,,,,,C07K/4746
7258859,21-Aug-07,2007,8,21,Method for the treatment of multiple sclerosis,"A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/2866
7259142,21-Aug-07,2007,8,21,"Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use",A compound of formula:,7,"The United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/06
7260250,21-Aug-07,2007,8,21,Computer-aided classification of anomalies in anatomical structures,"Candidate anomalies in an anatomical structure are processed for classification. For example, false positives can be reduced by techniques related to the anomaly's neck, wall thickness associated with the anomaly, template matching performed for the anomaly, or some combination thereof. The various techniques can be combined for use in a classifier, which can determine whether the anomaly is of interest. For example, a computed tomography scan of a colon can be analyzed to determine whether a candidate anomaly is a polyp. The technologies can be applied to a variety of other scenarios involving other anatomical structures.",44,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,G16H/00
7261896,28-Aug-07,2007,8,28,Methods for preventing strokes by inducing tolerance to e-selectin,"The present invention provides a method for reducing stroke-related tissue damage by treating a mammal with E-selectin. Preferably, this treatment induces E-selectin tolerance in the mammal. Another aspect of the invention is a method for inducing E-selectin tolerance in a mammal through intranasal administration of E-selectin, preferably including booster administrations. The present methods are especially adapted for use in patients at increased risk of stroke or who may become at increased risk of stroke.",6,United States of America as represented by the Secretary of the Department of Health and Human Services National Institutes of Health,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0043
7261900,28-Aug-07,2007,8,28,Recombinant modified Bacillus anthracis protective antigen for use in vaccines,"The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/32
7262018,28-Aug-07,2007,8,28,Agents that bind to and inhibit human cytochrome P450 2C19,"The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.",15,National Institutes of Health,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5735
7264947,4-Sep-07,2007,9,4,Activity dependent neurotrophic factor III (ADNF III),"The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) β-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.",12,"United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/475
7267941,11-Sep-07,2007,9,11,Cyanovirin variant-polymer conjugates,"The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.",45,"The Government of the United States of America as represented by The Secretary of The Department of Health and Human Services, The National Institutes of Health",Nektar Therapeutics AL,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/195
7268118,11-Sep-07,2007,9,11,Thymosin β4 compositions,"A composition with a polypeptide including amino acid sequence LKKTET [SEQ ID NO:1] or a conservative variant thereof, the composition further including a carrier for application to a surface of a body.",13,United States of America as represented by The Secretary of Health,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2292
7271002,18-Sep-07,2007,9,18,Production of adeno-associated virus in insect cells,"A method of producing an adeno-associated virus (AAV) in an insect cell comprising (i) providing at least one insect cell-compatible vector comprising a first nucleotide sequence comprising at least one AAV ITR nucleotide sequence, a second nucleotide sequence containing an open reading frame encoding AAV VP1, VP2, and VP3 capsid proteins, a third nucleotide sequence comprising a Rep52 or a Rep40 coding sequence, and a fourth nucleotide sequence comprising a Rep78 or a Rep68 coding sequence, (ii) introducing the at least one insect cell-compatible vector into an insect cell, and (iii) maintaining the insect cell under conditions such that AAV is produced. Also provided are recombinant AAV made in accordance with the method, insect cell-compatible vectors, and insect cells comprising nucleotide sequences for production of AAV in an insect cell.",52,"United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7271150,18-Sep-07,2007,9,18,Modified growth hormone,"The invention provides a growth hormone (GH) in which amino acids within the regulated secretory pathway (RSP) sorting signal have been mutated as well as a GH in which the three-dimensional conformation of the RSP sorting signal has been altered, and a composition comprising an effective amount of such a GH in an excipient.",11,"United States of America, Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/61
7271781,18-Sep-07,2007,9,18,Multiplex hybridization system for identification of pathogenic mycobacterium  and method of use,"A method for species-specific identification of a Mycobacterium species is provided. Also disclosed is a method for identifying the species of Mycobacterium present in a sample. A device is disclosed for the detection of Mycobacterium. Mycobacterium-specific oligonucleotides are also disclosed, as are kits.",14,The United States of America as Represented by the Secretary of the Department of Health and Human Services,"Beckman Coulter, Inc.",,,,,,,,,,2,Biotechnology,,,,,,C12Q/689
7273695,25-Sep-07,2007,9,25,HIV immunoassays using synthetic envelope polypeptides,"Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",10,"Novartis Vaccines and Diagnostics, Inc.",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7273699,25-Sep-07,2007,9,25,Methods for detecting nucleic acid sequence variation,"Sequence variations, such as polymorphisms, are detected by detecting differences between or among melting profiles of plural nucleic acids. Melting profiles are produced by observing the nucleic acids during a temperature change over a period of time. If the nucleic acids are diluted into solutions for analysis, the nucleic acid concentrations between or among the solutions can be substantially the same. The melting profiles and sequence variation can be used to identify changes in a wild-type nucleic acid sequence, such as a single-nucleotide polymorphism (SNP), a small insertion or deletion, or a small inversion.",44,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6827
7276227,2-Oct-07,2007,10,2,Obligate domain-swapped dimer of cyanovirin with enhanced anti-viral activity,The present invention relates to a purified or isolated obligate domain-swapped dimer of CVN and a composition comprising the same.,6,"United States of America, repesented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/195
7276367,2-Oct-07,2007,10,2,Method of etching islands of cells in a grid pattern,"An apparatus and process for monitoring migratory cell proliferation with restricted migration on a substrate includes providing a substrate, coating the substrate with extracellular matrix, plating cells suspended in cell culture media on extracellular matrix, and placing intersecting channels across the extracellular matrix components by removing the extracellular matrix components from the channels to isolate islands of the extracellular matrix components on the substrate. When the cells are immersed with a fluid, migration of the cells is confined to the isolated islands of the extracellular matrix components, permitting long-term observation of a migratory population.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12M/36
7279294,9-Oct-07,2007,10,9,Tumor markers in ovarian cancer,"The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.",4,"The United States of America as represented by the Secretary, Dept. of Health and Human Services, NIH",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6809
7282205,16-Oct-07,2007,10,16,Anti-hepatitis A virus antibodies,"Chimpanzee monoclonal antibodies and antigen binding fragments including a γ1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1009
7282206,16-Oct-07,2007,10,16,Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains,"Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.",34,Wyeth,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/7155
7285954,23-Oct-07,2007,10,23,Imaging and reconstruction of partial field of view in phase contrast MRI,"Phase contrast magnetic resonance images are produced using interleaved spiral k-space scanning with a bipolar phase contrast gradient. Spiral scanning is configured so that acquisition impulse response defines a central alias free portion in a partial field of view, and signal acquisition is arranged so that moving spins are contained with this central alias free portion. First and second signals are acquired with alternate phase encodings, and a complex difference of the acquired signals is obtained. The complex difference is substantially free of aliasing artifacts within the central portion.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56308
7288254,30-Oct-07,2007,10,30,Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation,"The invention provides a method of treating diabetes in a subject, comprising administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population, and administering to the subject pancreatic islet cells from a donor. The immune tolerance inducing treatment regimen, used optionally with adjunct immunosuppressive agents, prevents pancreatic islet cell rejection while maintaining long term islet cell function following xenogeneic and allogeneic pancreatic islet cell transplantation. Thus, the methods of the present invention provide a means for treating diabetes, wherein the need for exogenous insulin or immunosuppressive agents is decreased or eliminated. Also provided is a method of inhibiting a rejection response of a transplant recipient, comprising administering an immunotoxin during the peritransplant period, thereby transiently reducing the number of T-cell lymphocytes and promoting long-term survival of the transplant.",8,"The United States of America as represented by the Secretary, Department of Health and Human Services, NIH",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/2809
7288266,30-Oct-07,2007,10,30,Liposome complexes for increased systemic delivery,"Highly efficient cationic liposomes have been developed as an improved delivery system for biologically-active reagents. A novel structure, the sandwich liposome, is formed and comprises one or more biologically active agents internalized between two bilomellar liposomes. This structure protects the incoming agent and accounts for the high efficiency of in vivo delivery and for the broad tissue distribution of the sandwich liposome complexes.These novel liposomes are also highly efficient carriers of nucleic acids. By using extruded DOTAP:cholesterol liposomes to form complexes with DNA encoding specific proteins, expression has been improved dramatically. Highest expression was achieved in the lung, while increased expression was detected in several organs and tissues.",3,"United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1272
7297492,20-Nov-07,2007,11,20,LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis,"Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,"The Progeria Research Foundation, Inc.","Research Foundation for Mental Hygiene, Inc.",,,,,,,,,3,Biotechnology,,,,,,C07K/47
7297493,20-Nov-07,2007,11,20,Fibroblast growth factor receptor activating gene 1 and related compositions and methods,"A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.",20,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4702
7300940,27-Nov-07,2007,11,27,Integrin α-v β-3 antagonists for use in imaging and therapy,Integrin receptor antagonists whose molecular structure includes a tetrahydropyridimidinylaminoethyloxybenzoyl group on a sulfonylamino-β-alanine nucleus exhibit increased binding affinity for the αvβ3 receptor when further substituted on the sulfonyl moiety with an N-amino alkycarbamyl group or a butyloxycarbonylamino alkylcarbamoyl group or similar groups.,48,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/14
7302287,27-Nov-07,2007,11,27,Methods of detecting inflammation of an epithelium layer in the oral region with a probe using diffuse-reflectance spectroscopy,"The invention provides a device and method for monitoring inflammation of the epithelium. The device consists of a head region, a handle region and an optical bundle. At least two of the optical fibers in the bundle are utilized as a source of radiation, these two fibers are at two different angles from normal. At least one of the other optical fibers is utilized as a detector for the reflected radiation, or alternatively an image guide can be used as the detector. The device of the invention can be part of an external or internal system that can include a light source, the device, a multiplexer, a spectrometer, and a computer for data analysis. The method of the invention allows for the detection and monitoring of general inflammation of the oral epithelium. The inflammation of the epithelium can be detected or monitored to diagnose diseases of the oral epithelium, monitor such diseases, monitor treatment of such diseases, or pre-screen for and monitor preventative treatments of such diseases.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/682
7303751,4-Dec-07,2007,12,4,Anti-plasmodium compositions and methods of use,"Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins (EBPs). The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that also prevent the binding of P. falciparum are also included. Methods of the invention utilize the paralogues, antibodies thereof and peptide compositions for the diagnosis, prevention, and treatment of P. falciparum diseases such as malaria, as well as methods for the detection of P. falciparum in biological samples and culture media.",8,"The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
7303754,4-Dec-07,2007,12,4,"MVA expressing modified HIV envelope, gag, and pol genes","The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.",14,"The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services","Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.","The United States of America, as represented by the Secretary, Department of the Army",,,,,,,,,3,Biotechnology,,,,,,C12N/86
7304127,4-Dec-07,2007,12,4,"Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use","The present invention provides, among other things, a polypeptide that binds with the gp120 envelope protein of HIV, in particular HIV-1, under physiological conditions, a nucleic acid that encodes such a polypeptide and can be expressed in a cell, a composition comprising such a polypeptide or nucleic acid or an antibody and a carrier therefor, a composition comprising a solid support matrix to which is attached an above-described polypeptide or an anti-antibody to a specified polypeptide sequence, a method of making an antibody to gp120, and a method of removing HIV from a bodily fluid.",18,"United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/531
7305109,4-Dec-07,2007,12,4,"Automated microscopic image acquisition compositing, and display","An automated microscope and computer system captures a set of images for a capture area in a plurality of focal planes. The images can then be integrated into composite images for browsing to simulate viewing an item, such as a biological sample, under a microscope. A corrective filter can be constructed from the images to avoid an effect called “tiling.” Before capture, variable focal plane error can be avoided by collecting z locations for a set of points in the capture area. During image browsing, entire composite images can be loaded into memory in compressed form. Compressed image portions can be pre-decompressed to avoid delay as a browsing user navigates throughout the composite images. Pre-decompression can be done by a thread separate from the thread performing navigation operations.",15,"The Government of the United States of America as represented by the Secretary of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Computer technology,Measurement,,,,,G06T/50
7311916,25-Dec-07,2007,12,25,Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41,"The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.",16,"The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services","Panacos Pharmaceuticals, Inc.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
7312032,25-Dec-07,2007,12,25,Methods for screening ligands that activate the translocation of a steroid receptor to the nucleus in mammalian cells,"The present invention provides a method of screening for a compound that binds to a selected nucleic acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nucleic acid can be directly detected when bound by fluorescently labeled compound; and directly detecting the location of fluorescence within the cell, fluorescence aggregated at the site of the nucleic acid array indicating a compound that binds to the selected nucleic acid. In particular compounds such a transcription factors can be screened. Reagents for such method are provided including a mammalian cell having a plurality of steroid receptor response elements in an array such that the response element can be directly detected when bound by fluorescently labeled steroid receptor and a chimeric protein comprising a fluorescent protein fused to a steroid receptor.",3,Han Htun,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/721
7312228,25-Dec-07,2007,12,25,Cytotoxic indeno and isoindoloisoquinolones,The synthesis and biological activity of benzoisoindoloisoquinolone compounds are described. The synthesis and biological activity of C-11-substituted indenoisoquinolones are also described. Indenoisoquinolones substituted at C-11 are prepared by McMurry reactions of 11-ketoindenoisoquinolones with aldehydes.,19,Purdue Research Foundation,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
7314625,1-Jan-08,2008,1,1,Chimeric protein comprising non-toxic Pseudomonas exotoxin A and Type IV pilin sequences,"The invention provides chimeric proteins comprising a non-toxic Pseudomonas exotoxin A sequence and a Type IV pilin loop sequence, wherein the Type IV loop sequence is inserted within the non-toxic Pseudomonas exotoxin A. The invention also provides polynucleotides encoding the chimeric proteins, and compositions comprising the polynucleotides or the chimeric proteins. The invention also provides methods for using the chimeric proteins, polynucleotides and compositions of the invention.",13,The United States as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/21
7314631,1-Jan-08,2008,1,1,Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV),"Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting and immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.",33,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/86
7314632,1-Jan-08,2008,1,1,Pseudomonas  exotoxin A-like chimeric immunogens,This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using these immunogens also are provided.,12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/385
7314712,1-Jan-08,2008,1,1,Systems for in vivo site-directed mutagenesis using oligonucleotides,"This disclosure provides several methods to generate nucleic acid mutations in vivo, for instance in such a way that no heterologous sequence is retained after the mutagenesis is complete. The methods employ integrative recombinant oligonucleotides (IROs). Specific examples of the described mutagenesis methods enable site-specific point mutations, deletions, and insertions. Also provided are methods that enable multiple rounds of mutation and random mutagenesis in a localized region. The described methods are applicable to any organism that has a homologous recombination system.",78,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/102
7314725,1-Jan-08,2008,1,1,Phenylthiocarbamide (PTC) taste receptor,"The invention provides isolated nucleic and amino acid sequences of a taste cell receptor that serves as a sensor for the bitter taste of phenylthiocarbamide (PTC), antibodies to such PTC taste receptor, methods of detecting such nucleic and amino acid sequences, and methods of screening for modulators of such PTC taste receptor.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
7316903,8-Jan-08,2008,1,8,Detection of nucleic acid sequence variations using phase Mu transposase,"The present invention relates, e.g., to a method of detecting a mismatch in a double stranded nucleic acid target, comprising (a) contacting the target with (i) a Mu-end nucleic acid, and (ii) a phage Mu transposase, under conditions effective for the Mu-end nucleic acid to transpose into the target at about the site of a mismatch, if the target comprises a mismatch, and (b) detecting transposition of the Mu-end DNA into the target, wherein transposition of the Mu-end nucleic acid into the target at a predominant site indicates the presence of a mismatch at that site.",31,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6827
7317086,8-Jan-08,2008,1,8,Basal cell carcinoma tumor suppressor protein,This invention provides for a tumor suppressor gene inactivation of which is a causal factor in nevoid basal cell carcinoma syndrome and various sporadic basal cell carcinomas. The NBCCS gene is a homologue of the Drosophila patched (ptc) gene.,7,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/705
7319091,15-Jan-08,2008,1,15,"Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof","Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. The cloning of full length cDNA for the peptide products is also provided, as well as recombinant methods for the production of monocyte chemoattractant products. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.",7,The United States of America as represented by the Secretary Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/523
7320881,22-Jan-08,2008,1,22,Rapid identification of Nocardia farcinica,"Provided are Nocardia farcinica-specific primers comprising the nucleotide sequence of SEQ ID NO:1-39. Provided is a polynucleotide represented by SEQ ID NO:41 and SEQ ID NO:40. Further provided is a method of identifying a Nocardia farcinica infection in a subject with the primer identified by SEQ ID NO:1-39, or detecting the presence of a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO:40 or SEQ ID NO:41. Also provided is a method of identifying Nocardia farcinica infection in a subject by amplifying DNA from the subject using a Nocardia farcinica-specific primer comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1-39. Further provided is a kit for identifying Nocardia farcinica comprising a Nocardia farcinica-specific primer comprising SEQ ID: NO:1-39 and a kit for identifying Nocardia farcinica comprising a Nocardia farcinica specific primer capable of amplifying SEQ ID NO:41.",3,"The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
7320991,22-Jan-08,2008,1,22,Analogs of thalidomide as potential angiogenesis inhibitors,"A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.",9,"The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/48
7324007,29-Jan-08,2008,1,29,"Instrumented rock bolt, data logger and user interface system","A rock bolt includes a hollow body and a gap along a length of the hollow body. At least one strain gauge is affixed to an inner surface of the rock bolt and is accessible from the gap. The rock bolt may include a data logger within the hollow body and coupled to receive signals from one or more strain gauges, and to record these signals in a memory. The data logger may comprise a data port adapted to be accessible from the outside of a bore hole into which the rock bolt is inserted. The data logger also may include at least one of a visual and auditory alarm. A graphic user interface software program can be used to download data from the data logger and set certain operating parameters of the data logger.",38,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Civil engineering,,,,,,E21D/02
7329502,12-Feb-08,2008,2,12,ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),"It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57426
7330748,12-Feb-08,2008,2,12,Method for determining in vivo concentration of a metabolite,"Method for determining in vivo concentration of a metabolite that includes administering a contrast agent to a subject, allowing the contrast agent to disperse to tissue of interest, performing CEDST MRI analysis of the subject, and comparing the results to known in vitro results to determine metabolite concentration.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Pharmaceuticals,Measurement,,,,A61B/055
7332167,19-Feb-08,2008,2,19,Nucleic acid and amino acid sequences of hemoglobin-response genes in Candida albicans and the use of reagents derived from these sequences in the diagnosis of disseminated Candida albicans infection,"Three hemoglobin-response genes in the pathogenic yeast Candida albicans are disclosed. The expression of these genes is specifically induced when the organism is exposed to hemoglobin during disseminated infections. The invention relates to the nucleic acid and amino acid sequences of these hemoglobin-response genes. The invention also relates to diagnostic methods, kits and compositions which employ the nucleic acid and amino acid sequences of the invention.",2,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/40
7332307,19-Feb-08,2008,2,19,Antibacterial therapy with bacteriophage physico-chemically altered by pegylation to delay inactivation by the host defense system,"The present invention is directed to bacteriophage therapy, using methods which enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects. The HDS normally reduces the number of bacteriophage in an animal, which decreases the efficiency of the bacteriophage in killing the host bacteria present during an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes by physico-chemical alteration of the bacteriophage surface proteins, so that the altered bacteriophage remain active in the body for longer periods of time than the unmodified bacteriophage.",2,The United States of America as represented by the Department of Health and Human Services,"Exponential Biotherapies, Inc.",,,,,,,,,,2,Biotechnology,,,,,,C12N/00
7332590,19-Feb-08,2008,2,19,Molecular characteristics of non-small cell lung cancer,"We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation. The messages of two p53-regulated genes, p21WAF1/CIP1 and 14-3-3σ, were consistently under-expressed in the adenocarcinomas, suggesting that the p53 pathway itself might be compromised in this cancer type. Gene expression observed by SAGE were consistent with the results obtained by quantitative real-time PCR or cDNA array analyses using 43 additional lung tumor and normal samples. Thus, although derived from only a few tissue libraries, molecular signatures of non-small cell lung cancer derived from SAGE most likely represent an unbiased yet distinctive molecular signature for human lung cancer.",23,The United States of America as Represented by the Department of Health and Human Services,Genzyme Corporation,The Johns Hopkins University of Medicine,,,,,,,,,3,Biotechnology,Biotechnology,,,,,C12Q/6886
7332645,19-Feb-08,2008,2,19,IL-21 as a regulator of immunoglobin production,"A transgenic mouse is disclosed herein whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit the production of IL-4 or the binding of IL-4 to the IL-4 receptor. A mouse homozygous for the disrupted IL-21 receptor gene and homozygous for the disrupted IL-4 gene has diminished B cell function. A method is disclosed for altering a B cell activity. The method includes administering a therapeutically effective amount of an agent that interferes with the interaction of IL-21 with an IL-21 receptor, thereby altering the B cell activity. A method is also disclosed for of treating a subject with Job's disorder or atopic disease. A method is also disclosed for treating or preventing an allergic reaction in a subject. A method is also disclosed for treating a subject with an autoimmune or antibody mediated disorder.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Other special machines,Biotechnology,,,,C07K/7155
7333896,19-Feb-08,2008,2,19,Quality assurance/quality control for high throughput bioassay process,"The present invention relates to a method of quality assurance/quality control for high-throughput bioassay processes. The method includes generating a bioassay process model, and then comparing spectral data based on a combination of a biochip and a test serum to the bioassay process model to determine if the test sample and the bioassay process are producing acceptable data. Alternatively, the method may include comparing spectral data based on a combination of serum and diluents used in an electrospray process to the bioassay process model. If the bioassay process and test sample fall within the model, then the spectrum produced may be further analyzed.",27,"Correlogic Systems, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,Organic fine chemistry,Computer technology,,,,G01N/6848
7335736,26-Feb-08,2008,2,26,Compositions and methods for detecting Treponema palidum,"Methods for the specific and highly sensitive detection of Treponema pallidum infection comprising the use of specific antigenic proteins and peptides unique to Treponema pallidum are provided. In particular, detection assays based on recognition of acidic repeat protein are provided. The methods of the present invention are useful for detection of primary syphilis at early stages of infection. In addition, the methods and compositions disclosed herein are directed to the differential detection of specific Treponema infections enabling the identification of causative agents for specific Treponema disease states: syphilis (Treponema pallidum subspecies pallidum), yaws (Treponema pallidum subspecies pertenue CDC-1 or CDC-2 strain), and bejel (Treponema pallidum subspecies endemicum).",1,The United State of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/20
7335749,26-Feb-08,2008,2,26,"Tumor suppressor gene, p47Ing3","The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6886
7338807,4-Mar-08,2008,3,4,Screening assays for compounds that cause apoptosis,"This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1709
7339037,4-Mar-08,2008,3,4,"Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins","The invention provides a method of inhibiting prophylactically or therapeutically an influenza viral infection in a host. The method comprises instilling into or onto a host a cell producing an antiviral protein, antiviral peptide, or antiviral conjugate comprising at least nine contiguous amino acids of SEQ ID NO: 2, wherein the at least nine contiguous amino acids are nonglycosylated and have antiviral activity, whereupon the influenza viral infection is inhibited.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/195
7341726,11-Mar-08,2008,3,11,Modified HCV peptide immunogens,"Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.",9,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
7342099,11-Mar-08,2008,3,11,cDNA encoding a gene BOG (B5T over-expressed gene) and its protein product,"Nucleic acids that encode novel polypeptides, designated in the present application as “BOG” (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-β1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided.",20,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/4738
7344555,18-Mar-08,2008,3,18,Light promotes regeneration and functional recovery after spinal cord injury,"The present invention relates generally to the treatment of SCI by stimulating axon regeneration within the central nerve system. One aspect of the present invention provides methods of treating SCI with low power laser irradiation (LPLI). Another aspect of the present invention provides methods of treating SCI by modulating a gene activity to stimulate axon regeneration. In this regard, the present invention also provides compositions that modulate genes expression relating to the neuron-regeneration after SCI. Another aspect of the present invention provides methods for evaluating the effectiveness of a treatment for SCI.",21,The United States of America as represented by the Department of Health and Human Services,Uniformed Services University of Health Services,,,,,,,,,,2,Medical technology,,,,,,A61N/0613
7348315,25-Mar-08,2008,3,25,"Methods of treating heart failure with modified ATP, ADP and AMP compounds","Disclosed herein are methods of using an adenosine analog or derivative for treating heart failure, increasing cardiac muscle contractility, increasing cardiac diastolic relaxation, and increasing vasodilation. Exemplary adenosine analogs/derivatives include compounds of the following formulawherein",46,The University of Connecticut,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07F/65586
7348319,25-Mar-08,2008,3,25,"Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same","The present invention relates to nitric oxide-releasing amidine diazeniundiolates, compositions comprising same, methods of using same, and a method for preparing same from imidate diazeniumdiolates and primary or secondary amines.",31,United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/655
7349834,25-Mar-08,2008,3,25,Molecular motor,"A molecular motor in which multiple concentric cylinders (or nested cones) rotate around a common longitudinal axis. Opposing complementary surfaces of the cylinders or cones are coated with complementary motor protein pairs (such as actin and myosin). The actin and myosin interact with one another in the presence of ATP to rotate the cylinders or cones relative to one another, and this rotational energy is harnessed to produce work. The concentration of ATP and the number of nested cylinders or cones can be used to control the rotational speed of the motor. The length of the cylinders can also be used to control the power generated by the motor. In another embodiment, the molecular motor includes at least two annular substrates wherein one annular substrate is coated with a first motor protein and the other annular substrate is coated with a second motor protein. The first and second motor proteins interact with each other to move the second annular relative to the first annular substrate.",60,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Micro-structural and nano-technology,Biotechnology,"Electrical machinery, apparatus, energy",,,,C12M/00
7351412,1-Apr-08,2008,4,1,Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA,"This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus (HIV). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.",7,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/21
7351580,1-Apr-08,2008,4,1,Use of a transgene encoding a vertebrate phytase to increase capacity to utilize phytic acid in livestock feed,"The present invention provides an isolated animal cell comprising an exogenous nucleic acid encoding a mutated phytase, wherein the cell produces phytase and secretes the phytase from the cell. The present invention also provides an animal having a phenotype not naturally occurring, characterized by secretion of phytase into the lumen of the gastrointestinal tract of the animal, the phenotype being conferred by a transgene contained in the cells of the animal, the transgene comprising a nucleic acid sequence encoding phytase and methods of making said animal.",8,North Carolina State University,"The United States of America, as represented by the Department of Health and Human Services, N.I.H.",University of Rochester,,,,,,,,,3,Biotechnology,,,,,,C12N/8509
7354909,8-Apr-08,2008,4,8,Method for rapid generation of mature dendritic cells,"Novel methods for rapidly generating dendritic cells are disclosed herein. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one specific, non/limiting example, the method includes contacting the dendritic cell precursor or the mature dendritic cell with an antigen. The methods are of use both in vitro and in vivo.",53,The United States of America as represented by Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0639
7355012,8-Apr-08,2008,4,8,Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells,Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.,28,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/2803
7355037,8-Apr-08,2008,4,8,Thermolabile hydroxyl protecting groups and methods of use,"Provided is a hydroxyl-protected alcohol of the formula R—O—Pg, wherein Pg is a protecting group of the formula:",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/06
7355697,8-Apr-08,2008,4,8,"Flow-through, thermal-expansion-compensated cell for light spectroscopy",Optical cells are non-actively compensated to ensure that a sample gap of a sample space remains nearly constant upon a change in temperature. Fluids can be flowed through the sample space of the optical cells.,48,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0332
7358090,15-Apr-08,2008,4,15,Establishment of cellular manipulations which enhance oligo-mediated gene targeting,"The invention relates to improved methods for the modification, including recombination, of genes in cells. More specifically, the invention relates to the increased efficiency of modification, including recombination, by introduction of a DNA-modifying molecule into a cell cycle synchronized cell. Additionally, the invention relates to target DNA that has been modified, mutated or marked by the approaches disclosed herein. The invention also relates to cells, tissue, and organisms which have been modified by the invention's methods.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
7358347,15-Apr-08,2008,4,15,"MEN1, the gene associated with multiple endocrine neoplasia type 1, menin polypeptides and uses thereof",The invention relates to the discovery of a novel tumor suppressor gene which is associated with multiple endocrine neoplasia type 1. The gene has been designated MEN1 and the gene product is menin. The absence of this protein and associated mutations in the corresponding gene have been identified in individuals suffering from multiple endocrine neoplasia type 1. The identification of this marker for multiple endocrine neoplasia type 1 has diagnostic uses as well as for gene therapy.,17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
7358377,15-Apr-08,2008,4,15,Schweinfurthin analogues,"Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.",22,University of Iowa Research Foundation,The United States of America,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/80
7361356,22-Apr-08,2008,4,22,Self-assembling recombinant papillomavirus capsid proteins,"Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.",23,The United States of America as represented by the Department of Health and Human Services,"Deutsches Krebsforschungszentrum, The German Cancer Research Center",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
7361664,22-Apr-08,2008,4,22,Vitamin D receptor antagonists and related compositions and methods of use,A compound of formula:,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07F/022
7361739,22-Apr-08,2008,4,22,Methods and apparatus for creating particle derivatives of HDL with reduced lipid content,"The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.",33,"Lipid Sciences, Inc.",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,G01N/92
7363169,22-Apr-08,2008,4,22,Simulating microarrays using a parameterized model,"Simulating a microarray includes defining a number of parameters. A microarray is generated according to the parameters using an imaging procedure. The microarray is compared to a known value, and the imaging procedure is evaluated in response to the comparison. A simulated microarray image can be generated based on parameters. The simulated microarray can be associated with known values. An imaging procedure is applied to the simulated microarray image to generate observed values. The known values (e.g., intensities) can be compared to the observed values to evaluate the imaging procedure.",33,United States of America as represented by the Secretary of the Department of Health and Human Services,The Texas A&M University System,,,,,,,,,,2,Computer technology,,,,,,G06T/0012
7364719,29-Apr-08,2008,4,29,Vasoregulating compounds and methods of their use,"Methods and compounds are described for regulating blood pressure in a subject. Specific embodiments are methods for reversing vasodilation of blood vessels, by administering to a subject a therapeutically effective amount peptide AM(11-22). The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock. Other specific embodiments are methods for reversing vasoconstriction of blood vessels, by administering to a subject a therapeutically effect amount of an inhibitor of AM(11-22), sufficient to reduce hypertension in the subject. Compounds and pharmaceutical compositions are also provided, as are kits.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/22
7365047,29-Apr-08,2008,4,29,Use of pentagastrin to inhibit gastric acid secretion or as a diuretic,"This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.",20,The Regents of the University of California,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2207
7365160,29-Apr-08,2008,4,29,Mutated constitutively active nuclear orphan receptor,"Disclosed are constitutively active nuclear orphan receptors (CAR), which include one or more mutations which decrease the constitutive nature of CAR in vitro. The resulting non-constitutively active nuclear orphan receptors can be used to screen for agents that metabolize xenochemicals and/or steroids.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/70567
7365289,29-Apr-08,2008,4,29,Production of nanostructures by curie point induction heating,"An apparatus for synthesizing nanostructures. In one embodiment, the apparatus includes a heating device that defines a reaction zone therein and a susceptor made of a ferromagnetic material with a Curie temperature and placed in the reaction zone, where the Curie temperature substantially corresponds to a temperature at which the growth of desired nanostructures occurs and the heating device is capable of heating the susceptor substantially at the Curie temperature.",17,The United States of America as represented by the Department of Health and Human Services,Board of Trustees of the University of Arkansas,,,,,,,,,,2,Chemical engineering,Micro-structural and nano-technology,"Electrical machinery, apparatus, energy","Materials, metallurgy","Surface technology, coating",,H05B/108
7368100,6-May-08,2008,5,6,"Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same","Backbone-substituted 1,4,7,10-tetraaza cyclododecane-N,N′,N″,N′″-tetraacetic acid compounds, metal complexes thereof, compositions thereof, conjugates thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.",22,"The United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/1051
7368106,6-May-08,2008,5,6,Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state,"The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer of CD40 stimulation are administered in synergistically effective amounts to treat or prevent the pathologic state in the mammal. The invention also provides a method of assessing the effectiveness of treatment of a pathologic state in a mammal, wherein the mammal has been administered a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The method comprises measuring the level of at least one antibody in a test sample obtained from the mammal, which at least one antibody is specific for an antigen that is known to be associated with the pathologic state, and wherein the level of the at least one antibody is indicative of the effectiveness of treatment of the pathologic state in the mammal.",14,The United States of America as represented by the Department of Health and Human Services,University of Minnesota,Chiron Corporation,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/2013
7368110,6-May-08,2008,5,6,"Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use","Mesothelin ins a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/57492
7368114,6-May-08,2008,5,6,Fusion protein including of CD4,Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.,16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70514
7368116,6-May-08,2008,5,6,Method of enhancing a targeted immune response against tumors,The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.,28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/705
7368256,6-May-08,2008,5,6,Antibodies against Stachybotrys chartarum and methods for their use,"Antibodies to various fungal antigens are disclosed, including monoclonal antibody 9B4 that selectively binds an antigen of Stachybotrys chartarum spores not found in Stachybotrys chartarum mycelium. The antibodies may be used in a variety of methods, such as detecting the presence of fungal antigens in the environment or within a sample obtained from an animal or plant, or testing the effectiveness of an agent in binding an antigen.",19,"United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56961
7370543,13-May-08,2008,5,13,Air-sampling device and method of use,"The present disclosure concerns embodiments of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere. In one representative embodiment, the sampling apparatus includes a collection-vessel retaining member that is adapted to be removably coupled to a collection vessel. The retaining member has an air-inlet conduit for permitting air to flow through the open end of the collection vessel and an air-outlet conduit for permitting air to exit the open end of the collection vessel. The airinlet conduit and the air-outlet conduit are configured to cause air flowing into the collection vessel to establishes a cyclonic flow path, which causes airborne particles to separate out from the air stream and collect in the collection vessel.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0606
7371225,13-May-08,2008,5,13,Method for convection enhanced delivery of therapeutic agents,"A method for monitoring and controlling convection enhanced delivery of a therapeutic agent to a target tissue is disclosed. A tracer that is detectable, for example, by magnetic resonance imaging (MRI) and/or by X-ray computed tomography (CT) is co-infused with the therapeutic agent and used to monitor the distribution of the therapeutic agent as it moves through the target tissue. The images obtained during delivery are used to confirm delivery of the therapeutic agent to the target tissue and to avoid exposure of tissue outside of the targeted area to the therapeutic agent. In addition, the signal intensity of the images may be used to confirm that the therapeutic agent has been delivered to the target tissue at a desired concentration.",29,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Measurement,,,,,G01R/5601
7371392,13-May-08,2008,5,13,Cd40 ligand adjuvant for respiratory syncytial virus,"The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/39
7371572,13-May-08,2008,5,13,Mouse titers after two immunizations with VLPs alone,"The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.",6,The United States of America as represented by the Department of Health of Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7374756,20-May-08,2008,5,20,Specific binding agents for KSHV vIL-6 that neutralize a biological activity,"A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56994
7374872,20-May-08,2008,5,20,"CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection","The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/7158
7375183,20-May-08,2008,5,20,"Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof","This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4748
7375185,20-May-08,2008,5,20,"Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use","The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/1205
7375191,20-May-08,2008,5,20,Methods and apparatus for creating particle derivatives of HDL with reduced lipid content,"The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.",23,"Lipid Science, Inc.",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,G01N/92
7375206,20-May-08,2008,5,20,Brother of the regulator of imprinted sites (BORIS),"An isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence that is complementary to a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; a vector comprising such an isolated or purified nucleic acid molecule; a cell comprising such a vector; an isolated or purified polypeptide molecule consisting essentially of an amino acid sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; a cell line that produces a monoclonal antibody that is specific for an aforementioned isolated or purified polypeptide molecule; and the monoclonal antibody produced by the cell line; methods of diagnosing a cancer or a predisposition to a cancer in a male or female mammal; a method of prognosticating a cancer in a mammal; a method of assessing the effectiveness of treatment of a cancer in a mammal; a method of treating a mammal prophylactically or therapeutically for a cancer, and a composition comprising a carrier and an inhibitor of BORIS.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/47
7375520,20-May-08,2008,5,20,Method for spectrally selective B1 insensitive T2 preparation contrast enhancement for high field magnetic resonance imaging,"A T2 preparation sequence uses a segmented BIR-4 adiabatic pulse with two substantially equal delays and is insensitive to B1 field variations and can simultaneously suppress fat signals with low specific absorption rate (SAR). An adiabatic reverse half passage pulse is applied followed by a predetermined delay. An adiabatic full passage pulse is applied followed by a substantially equal delay, followed by an adiabatic half passage pulse. Fat signal suppression is achieved by increasing or decreasing either the first delay or the second delay.",23,The United States of America as represented by the Department of Health,Johns Hopkins University,,,,,,,,,,2,Measurement,Medical technology,,,,,G01R/5635
7378093,27-May-08,2008,5,27,Broadly cross-reactive neutralizing antibodies against Human Immunodeficiency Virus selected by Env-CD4-co-receptor complexes,"The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.",15,The United States of America as represented by the Department of Health and Human Services,The Scripps Research Institute,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/1063
7378274,27-May-08,2008,5,27,"Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses","The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.",11,Aventis Pharma S.A.,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/705
7378276,27-May-08,2008,5,27,Method of inducing memory B cell development and terminal differentiation,"A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. In one embodiment, the B cell progenitor is an immature B cell. A method is also disclosed for enhancing an immune response. The method includes contacting a population of cells including a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. The memory B cells and/or the plasma cell are then introduced into the subject to enhance the immune response. A method is also disclosed for treating a subject with a condition comprising a specific deficiency of at least one of memory B cells and plasma cells. A method is disclosed for identifying an agent with a physiological effect on one or more of a memory B cell and a plasma cell differentiation. A method is also disclosed for identifying agents that inhibit an activity of IL-21. Methods are also disclosed for inducing apoptosis of a B cell and for decreasing the number of B cells. A method is also described for producing a B cell hybridoma.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,G01N/5052
7378277,27-May-08,2008,5,27,Methods and compositions for transforming dendritic cells and activating T cells,"Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0639
7378403,27-May-08,2008,5,27,"Akt inhibitors, pharmaceutical compositions, and uses thereof","Disclosed are inhibitors of the serine/threonine kinase Akt, pharmaceutical compositions comprising such inhibitors, and a method of preventing or treating a disease or condition in an animal by the use of such inhibitors. The Akt inhibitors have the formula (I) wherein X and Y are independently selected from the group consisting of O, CF2, CH2, and CHF; wherein A is independently selected from the group consisting of P(O)OH, CH2000H, and CH(COOH)2; R2 is selected from the group consisting of H, OH, isosteres of OH, C1-C25 alkyloxy, C6-C10 aryloxy, C3-C8 cycloalkyloxy, C3-C8 cycloalkyl C1-C6 alkoxy, C2-C22 alkenyloxy, C3-C8 cycloalkenyloxy, C7-C32 aralkyloxy, C7-C32 alkylaryloxy, C9-C32 aralkenyloxy, and C9-C32 alkenylaryloxy; R3-R6 are independently selected from the group consisting of H, OH, isosteres of OH; and R1 and R7 are independently selected from the group consisting of C1-C25 alkyl, C6-C10 aryl, C3-C8 cycloalkyl, C2-C22 alkenyl, C3-C8 cycloalkenyl, C7-C32 aralkyl, C7-C32 alkylaryl, C9-C32 aralkenyl, and C9-C32 alkenylaryl; with the provisos that (i) when X is O, Y is O or CH2, and R3 is H, at least one of R2 and R4-R6 is not OH; (ii) when A is CH2COOH or CH(COOH)2, X and Y cannot be simultaneously O; and (iii) all of R2-R6 are not simultaneously H. The inhibitors can be in the form of a salt also",54,The United States of America as represented by the Department of Health and Human Services,Georgetown University,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07C/196
7380477,3-Jun-08,2008,6,3,Method for tissue osmometry,"A measurement system including a staging unit including a substrate having piezoelectric properties and a conductive electrode formed on the substrate, the conductive electrode including an area adapted to receive a sample, and an oscillator coupled to the conductive electrode. A method including in a tissue sample having a mass of less than about one microgram and that exerts a high osmotic pressure, calculating an osmotic pressure value for the tissue sample from a plurality of measurements of changes in the mass due to swelling.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01G/13
7381405,3-Jun-08,2008,6,3,Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer,"The invention provides methods of preparing autologous T-lymphocytes for re-introduction into a patient having cancer, which method comprises obtaining peripheral blood mononuclear cells (PBMCs) from a patient immunized with an antigen of the cancer, stimulating the PBMCs with the antigen of the cancer in vitro, transducing the PBMCs with a retroviral vector, which (a) comprises and expresses a human interleukin-2 (IL-2) coding sequence operably linked to a retroviral promoter, (b) does not comprise an exogenously introduced gene that enables phenotypic selection, and (c) comprises a viral envelope that efficiently transduces CD8+ T-lymphocytes; compositions comprising cells obtained in accordance with such methods; and methods of treating a patient having cancer by administering to the patient cells obtained in accordance with such methods or compositions comprising same.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0011
7381744,3-Jun-08,2008,6,3,Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds,"The present invention provides vacuolar-type (H+)-ATPase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of the present invention comprises a compound of the present invention and a carrier. The method of the present invention includes administering a vacuolar-type (H+)-ATPase inhibiting-effective amount of a compound of the present invention. The compound of the present invention has formula (I) wherein R1 and R2 are H, saturated or unsaturated alkyl, aryl, R6CH2—, R6CO—, or R6SO2—, wherein R6 is H, saturated or unsaturated alkyl, or aryl; R3 is H, alkyl, aryl, an oxime, or an oxime methyl ether; the aromatic ring is unsubstituted or substituted; and Z is a contiguous linker comprising a chain of 0-10 atoms which, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR1 and ending with the carbon directly attached to the alkyl oxygen of the lactone, integrally form a 5-17 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/366
7384741,10-Jun-08,2008,6,10,Molecular identification of Aspergillus species,"Novel techniques for the detection of Aspergillus in samples are disclosed. These techniques relate to PCR amplification and/or detection of Aspergillus ITS1 rDNA sequences, and the identification of particular species of Aspergillus by detecting differences in the ITS1-V1, ITS-V2, ITS-V3, ITS-V4, and ITS-V5 nucleic acid sequences of Aspergillus. The highly variable regions of the ITS1 rDNA sequences are particularly useful in distinguishing, for example, Aspergillus clavatus, Aspergillus granulosus, Aspergillus sydowii, Aspergillus flavipes, Aspergillus restrictus, Aspergillus versicolor, Aspergillus wentii, and Aspergillus chevalieri. In particular embodiments, the sequence differences are also able to distinguish among variants of particular species, such as Aspergillus granulosus CBS 119.5A, Aspergillus granulosus strain NRRL 1932, Aspergillus sydowii strain NRRL 250, Aspergillus sydowii strain NRRL 4768, Aspergillus sydowii strain CUHI, Aspergillus sydowii strain CUH2, Aspergillus sydowii strain CUH7, and Aspergillus sydowii strain CUH8.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
7384908,10-Jun-08,2008,6,10,Orally active peptides that prevent cell damage and death,"This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.",12,National Institute of Health,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/04
7388089,17-Jun-08,2008,6,17,Anti-arthropod vector vaccines method of selecting and uses thereof,The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0003
7391025,24-Jun-08,2008,6,24,High-throughput infrared spectroscopy,"A spectrometer includes an infrared source, a spectrally selective element, and a cell array. The cell array includes walls that define a number of cavities. The spectrometer also includes an infrared spatial detector responsive to infrared radiation travelling from the infrared source through contents of at least two of the cavities as well as through the spectrally selective element.",43,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,Measurement,,,,,G01N/253
7393826,1-Jul-08,2008,7,1,Methods and apparatus for creating particle derivatives of HDL with reduced lipid content,"The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.",21,"Lipid Sciences, Inc.",,,,,,,,,,,1,Pharmaceuticals,Chemical engineering,Biotechnology,Analysis of biological materials,,,C07K/775
7393949,1-Jul-08,2008,7,1,Human immunodeficiency virus (HIV) nucleotide sequences,"Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",24,"Novartis Vaccines and Diagnostics, Inc.",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/1063
7399753,15-Jul-08,2008,7,15,Trans-splicing mediated photodynamic therapy,The present invention provides methods and compositions for conferring selective death on cells expressing a specific target precursor messenger RNA (selective target pre-mRNA). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) expressed within a cell and mediate a trans-splicing reaction resulting in the generation of a novel chimeric mRNA molecule (chimeric mRNA) capable of encoding a light producing protein or enzyme. Cell death is further mediated by the presence of a photosensitizer which upon photoactivation produces cytotoxicity.,15,Virxsys Corporation,,,,,,,,,,,1,Biotechnology,,,,,,C12N/10
7399827,15-Jul-08,2008,7,15,"Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor","PAGE-4 is a gene preferentially expressed in normal male and female reproductive tissues, prostate, testis, fallopian tube, uterus and placenta, as well as in prostate cancer, testicular cancer and uterine cancer. This expression pattern makes it a target for diagnosis and for vaccine based therapy of neoplasms of prostate, testis and uterus. The invention provides immunogenic compositions comprising PAGE-4 protein or immunogenic peptides thereof, methods of inhibiting the growth of malignant cells expressing PAGE-4, and methods of inducing an enhanced immune response to PAGE-4-expressing cancers.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
7399968,15-Jul-08,2008,7,15,Spectroscopic instruments and methods employing array detector and variable filtering,"Disclosed are pharmaceutical dosage unit manufacturing process control apparatus and methods. These can include acquiring a plurality of multi-pixel images of a flow of pharmaceutical dosage units at different wavelengths along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing.",28,Malvern Instruments Incorporated,,,,,,,,,,,1,Measurement,,,,,,G01N/31
7401519,22-Jul-08,2008,7,22,System for monitoring exposure to impulse noise,"In one embodiment, a system for monitoring exposure to impulse noise includes a sound-sensing device, such as a microphone or other type of pressure transducer, operable to sense impulse noise, and a storage module operable to store the waveform of the impulse noise sensed by the sound-sensing device. The sound-sensing device desirably is operable to sense impulses that are greater than 146 dB, such as impulses created by construction machinery and firearms. The system also can include a processor operable to calculate one or more noise parameters of the impulse noise from the waveform, and a user interface program operable to display said one or more noise parameters selected by a user.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01H/10
7402387,22-Jul-08,2008,7,22,Methods and compositions for detecting dihydropyrimidine dehydrogenase splicing mutations,"The present invention provides compositions, methods, and kits for the detection of genetic polymorphisms or mutations of the dihydropyrimidine dehydrogenase deficiency (DPDD). The polymorphisms or mutations generally occur in the dihydropyrimidine dehydrogenase (DPD) gene in chromosome 1. Also provided are mutant forms of DPD.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
7402400,22-Jul-08,2008,7,22,Mammalian sweet taste receptors,"The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet taste receptors.",13,Regents of the University of California,The United States of America Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7402659,22-Jul-08,2008,7,22,Thymic stromal lymphopoietin receptor molecules and uses thereof,"The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.",19,Whitehead Institute for Biomedical Research,The Government of the United States of America,"Health Research Inc., Roswell Park Division",University of Washington,,,,,,,,4,Biotechnology,,,,,,C07K/7155
7407478,5-Aug-08,2008,8,5,Coil for magnetic stimulation,"A magnetic stimulator, which may be used as a transcranial magnetic stimulation (TMS) device, and a method for its use are disclosed. The stimulator comprises a frame and an electrically conductive coil having a partially toroidal or ovate base and an outwardly projecting extension portion. The frame may be a flexible or malleable material and may be non-conductive. The electrically conductive coil may comprise one or more windings of electrically conductive material (such as a wire) coupled to the frame. The coil is electrically connected to a power supply. The device may be placed adjacent to or in contact with the body of a subject, such as on the head of a subject. The device may be used on humans for treating certain physiological conditions, such as cardiovascular or neurophysiological conditions, or for studying the physiology of the body. This device is useful in studying or treating neurophysiological conditions associated with the deep regions of the brain, such as drug addiction and depression.",71,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61N/006
7407658,5-Aug-08,2008,8,5,Vaccines for blocking transmission of plasmodium vivax,"The present invention relates novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/015
7407664,5-Aug-08,2008,8,5,Peptide vaccines against group A streptococci,"This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.",32,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/092
7407801,5-Aug-08,2008,8,5,Truncated CMV promoters and vectors containing same,"The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by such vectors. The nucleic acid molecules, vectors and transformed host cells of the present invention are useful for treating a variety of genetic, metabolic and acquired diseases, including inter alia cystic fibrosis (CF) airway disease.",16,University of Iowa Research Foundation,National Institutes of Health (NIH),,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/86
7408053,5-Aug-08,2008,8,5,Recombinant DNA constructs for GAG polypeptides and polypeptides produced thereby,"Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",21,"Novartis Vaccines and Diagnostics, Inc.",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7408075,5-Aug-08,2008,8,5,Synthesis of phosphocholine ester derivatives and conjugates thereof,Aspects of the present invention include methods of synthesizing phosphocholine analogues and the phosphocholine conjugates formed therefrom and their use in preventing infections caused by microorganisms.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07F/091
7410644,12-Aug-08,2008,8,12,Recombinant pox virus for immunization against tumor-associated antigens,"Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/86
7410771,12-Aug-08,2008,8,12,Reagent and method for detecting a Cryptosporidium parvum sporozoite antigen,"A reagent and method for the specific and highly sensitive detection of C. parvum in which the reagent is an antibody for a soluble C. parvum sporozoite antigen and the method is an immunoassay in which the antibody is used to detect or quantify C. parvum sporozoite antigen in a sample. The sample is treated to cause excystation of C. parvum oocytes, thereby releasing a C. parvum sporozoite antigen, and combined with antibodies specific for the sporozoite antigen under conditions to form an antibody-antigen complex. Detection of the complex indicates the presence of C. parvum in the sample. The assay allows recognition and detection of C. parvum in turbid samples, and due to a lack of crossreactivity with other Cryptosporidium species, is specific for C. parvum contamination or infection. The assay is highly sensitive, allowing for the detection of less than 100 oocysts per milliliter of sample.",17,"The United States of America as represented by the Department of Health and Human Services, Center for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/20
7410801,12-Aug-08,2008,8,12,Lambda phage display system and the process,"The present invention relates to a process of obtaining recombinant lambdoid bacteriophage with high density display of functional peptides and proteins on surface of said phage comprising of: constructing a donor plasmid having a nucleotide sequence that defines the elements for replication of the vector in bacteria, a selectable marker, a nucleotide sequence flanked by two non-compatible recombination sequences, and an inducible cistron for expression of a capsid protein and a fusion protein; constructing a recipient phage having a nucleotide sequence that defines the lambdoid elements for replication and packaging of the vector into an assembled bacteriophage and encodes an inducible cistron for expression of a selectable marker flanked by two non-compatible recombination sequences; transferring the said donor plasmid to said recipient plasmid to obtain cointegrates; growing said cointegrates in selective liquid medium; harvesting phages displaying protein encoded by the foreign DNA encapsulated in said harvested phage particle.",7,University of Delhi Department of Biochemistry,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C40B/02
7417136,26-Aug-08,2008,8,26,Nucleic acid vaccines for prevention of flavivirus infection,"The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention.",21,"The United States of America as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
7419817,2-Sep-08,2008,9,2,"Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography","The present invention provides methods of purifying adeno-associated virus (AAV) particles. These AAV particles include AAV2, AAV4 and AAV5 particles. The present invention also provides AAV particles purified by the methods of the present invention.",55,"The United States of America as represented by the Secretary Department of Health and Human Services, NIH.",,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
7419957,2-Sep-08,2008,9,2,"Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods","Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/4748
7420032,2-Sep-08,2008,9,2,Dominant B cell epitopes and methods of making and using thereof,"Disclosed are methods for obtaining at least one epitope suitable for detecting the presence of an antibody against a tumor associated antigen of a cancer in a sample. Kits, assays, and substrates employing the epitopes of the present invention are disclosed. Also disclosed are epitopes of NY-ESO-1 and XAGE-1b and methods of using thereof.",13,The Regents of the University of California,National Institutes of Health,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/57484
7422755,9-Sep-08,2008,9,9,Antimultiorganism glycoconjugate vaccine,"The present invention relates, e.g., to a glycoconjugate composition comprising one or more polysaccharide types from a cell wall polysaccharide preparation from B. pumilus Sh 18, or variants thereof. Also disclosed are antibodies generated against the glycoconjugates, and methods of using the glycoconjugates and antibodies. An antimultiorganism vaccine which reacts against at least Haemophilus influenzae type a, Haemophilus influenzae type b, Staphylococcus aureus, and Staphylococcus epidermidis, is disclosed.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/07
7425218,16-Sep-08,2008,9,16,Nitric oxide-releasing medical devices,An implant or intravascular stent comprising a polymeric composition capable of releasing nitric oxide under physiological conditions. The polymeric composition comprises a polymer and at least one nitric oxide-releasing N2O2− functional group bound to the polymer.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/655
7425428,16-Sep-08,2008,9,16,Recombinant DNA construct for HIV envelope polypeptides and polypeptides produced thereby,"Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",14,"Novartis Vaccines and Diagnostics, Inc.",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7425537,16-Sep-08,2008,9,16,SH2 domain binding inhibitors,"Disclosed are compounds for SH2 domain binding inhibition, for example, a compound of formula (I), wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R6 is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. The conformationally compounds provide enhanced binding affinity with SH2 domain protein. Also disclosed are a pharmaceutical compositions and a method for inhibiting an SH2 domain from binding with a phosphoprotein.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C07F/6515
7425611,16-Sep-08,2008,9,16,"Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use","Described herein are nucleic acid molecules which encode multiple highly conserved epitopes from HIV-1 proteins, and optionally also epitopes from CCR5; usually also included sequences that encode spacers between two or more of the epitopes. Some of the provided nucleic acid molecules further include sequences that encode targeting domains, useful for targeting the encoded protein into a pathway for enhancing epitope presentation in a vertebrate immune system. Also described are multivalent proteins encoded for by these nucleic acid molecules. The disclosure also encompasses immunogenic compositions that comprise one or more of the nucleic acid molecules, and/or one or more of the proteins encoded thereby, as well as methods of inducing an immune response against HIV-1 in a subject by administering to the subject an effective amount of a composition containing one or more of these molecules. Also provided are cultured host cells containing within them one or more of the described nucleic acid molecules.",10,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
7427472,23-Sep-08,2008,9,23,Methods for the differentiation and identification of medically important endemic fungi,"Methods of detecting a dimorphic fungus, including differentiating a dimorphic fungus from other fungi are disclosed. A sample suspected of containing a nucleic acid of a fungus, such as an internal transcribed spacer-2 (ITS2) nucleic acid sequence of a dimorphic fungal rDNA, is screened for the presence or absence of that nucleic acid. The presence of the nucleic acid indicates the sample was contacted by the fungus. Determining whether the nucleic acid sequence is present in the sample can be accomplished by detecting hybridization between a dimorphic probe, species-specific probe, and/or microbe-specific probe and a nucleic acid sequence corresponding to the ITS2 region of fungal rDNA. Kits and arrays for carrying out these methods also are disclosed.",34,"United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
7427590,23-Sep-08,2008,9,23,Neurothrophic components of the ADNF I complex,"This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Ramot at Tel-Aviv University, Ltd.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/475
7427598,23-Sep-08,2008,9,23,Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory,"The present invention provides methods for improving performance (e.g. learning and/or memory) using (ADNF) polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.",22,The United States of Americas as represented by the Secretary of the Department of Health and Human Services,"Ramot at Tel-Aviv University, Ltd.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/475
7427671,23-Sep-08,2008,9,23,Compositions of alpha platelet derived growth factor receptor nucleic acid and protein and method of making,"A DNA sequence which encodes a human type α platelet derived growth factor receptor protein which preferentially binds to the AA homodimer and AB heterodimer forms of platelet derived growth factor and also binds the BB homodimer at high affinity, is described. Substantially pure human a platelet derived growth factor receptor protein and methods for recombinantly producing human α platelet derived growth factor receptor protein are also described.",15,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/103
7431926,7-Oct-08,2008,10,7,Tumor supressor gene p33ING2,"The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/02
7431931,7-Oct-08,2008,10,7,Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions,"The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x rhesus reassortant rotavirus compositions were made which when administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactogenicity of the composition when administered as a second vaccine dose at or after 2 months of age. Administration of the immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of intussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
7432067,7-Oct-08,2008,10,7,Methods of detection of MATER protein autoantibodies,"Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater cDNA and protein sequences are provided. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for detecting an autoimmune response to MATER in a subject by detecting autoantibodies that recognize an epitope of a MATER protein. Also provided are methods for diagnosis of infertility or reduced fertility by detecting presence of MATER protein autoantibodies in a subject. The disclosure also describes kits for detecting MATER autoantibodies comprising MATER protein.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services & The National Institutes of Health,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Analysis of biological materials,,,,C07H/04
7432236,7-Oct-08,2008,10,7,Vasostatin as marrow protectant,"Specific fragments of vasostatin are disclosed. Also disclosed is a method of stimulating the proliferation or survival of a hematopoietic cell exposed to a chemotherapeutic agent or irradiation using these fragments. A method of stimulating the proliferation or survival of a hematopoietic cell is also disclosed. In one embodiment, the method is disclosed for stimulating the growth or survival of a hematopoietic stem cell with a fragment of vasostatin, in the presence of a growth factor.",31,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4725
7432349,7-Oct-08,2008,10,7,"Tumor suppressor gene, p28ING5","This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0693
7435539,14-Oct-08,2008,10,14,Typing of human enteroviruses,"The present invention discloses a method for detecting the presence of an enterovirus in a clinical sample. The invention additionally discloses a method for typing an enterovirus in a clinical sample. Both methods employ a set of primer oligonucleotides for reverse transcription and amplification that hybridize to conserved regions of the enterovirus genome, and that provide amplicons that include significant portions of the VP1 region that are characteristic of the various serotypes. In the typing method, the invention further provides a database consisting of nucleotide sequences from prototypical enteroviral serotypes, which is used to type the clinical sample by comparing the sequence of its amplicon with each prototypical sequence in the database. The invention additionally provides mixtures of primer oligonucleotides, and a kit for use in conducting the typing method that includes a mixture of the primer oligonucleotides.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12Q/701
7435801,14-Oct-08,2008,10,14,Antibodies and other ligands directed against KIR2DL4 receptor for production of interferon gamma,The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC.,17,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/2803
7438892,21-Oct-08,2008,10,21,"Method of identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity","The present invention is directed to novel methods for assaying for modulators of GADD45 polypeptide activity. The invention also provides means to sensitize a proliferating cell to a DNA base-damaging agent by administration of novel inhibitors of GADD45 polypeptide activity. The invention further provides polypeptides which interfere with the ability of Cdc2/cyclin B1 complexes to cause a pause at the G2/M stage of the cell cycle in response to GADD45, and nucleic acids which encode such polypeptides.",6,The United States of Americas as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5008
7439226,21-Oct-08,2008,10,21,Serine protease inhibitors,The present disclosure concerns peptides and peptidomimetics having inhibitory activity against serine proteases. The disclosed peptides and peptidomimetics are particularly useful as selective inhibitors of matriptase and MTSP1. Pharmaceutical compositions comprising serine protease inhibitors and methods for administering the compositions also are disclosed.,20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/64
7440601,21-Oct-08,2008,10,21,Automated identification of ileocecal valve,"Portions of a virtual colon can be analyzed to identify a normal structure, such as an ileocecal valve. Paradigmatic characteristics of ileocecal valves can be used to identify a digital representation as an ileocecal valve. Upon determination that a digital representation has the characteristics of an ileocecal valve, action can be taken. For example, the digital representation can be removed from a list of polyp candidates.",41,The United States of America as represented by the Department of Health and Human Services,Mayo Foundation for Medical Education and Research,,,,,,,,,,2,Computer technology,,,,,,G06K/00201
7442212,28-Oct-08,2008,10,28,Decoding algorithm for neuronal responses,"A device and method for decoding neuronal responses wherein sequences of potentials from neurons are monitored while specific motor tasks are carried out, and these sequences are characterized using order statistics and subsequently the order statistics are used to decode action potentials representing unidentified motor tasks to determine the desired motor task. The method of the invention comprises the steps of monitoring action potentials caused by a motor task being requested by the brain, calculating a spike density function and order tasks for each distinct motor task, to relate action potentials to their specific motor task. The invention also offers methods of formulating instructions for a prosthetic device. This method comprises the steps of learning the neuronal responses of distinct motor tasks by monitoring action potentials caused by a motor task being requested by the brain, calculating a cumulative density function for each distinct motor task, and using order statistics to relate action potentials to their respective motor tasks; monitoring action potentials from at least one neuron of said user wherein the action potentials are caused by the request for an unknown motor task; using said learned neuronal responses to determine which motor task is being requested by the monitored neuron; and formulating instructions on how to carry out the requested motor task. The device of the invention comprises a prosthetic limb, a device capable of making said prosthetic limb carry out motor tasks, a device capable of recording action potentials from neurons, and a device containing instructions for monitoring neurons, calculating cumulative density functions, utilizing order statistics, and determining instructions for various motor tasks.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61F/72
7442543,28-Oct-08,2008,10,28,Mammalian selenoprotein differentially expressed in tumor cells,"A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.",11,The United States of America as represented by the Department of Health and Human Services,The Board of Trustees of the University of Illinois,,,,,,,,,,2,Biotechnology,,,,,,C07K/47
7449190,11-Nov-08,2008,11,11,Assays for assembly of Ebola virus nucleocapsids,"The present invention relates to assays for the identification of compounds that inhibit assembly of NP, VP35, and VP24, or inhibit the glycosylation of NP, required for nucleocapsid formation, for use as anti-viral agents. The invention also relates to assays for the identification of compounds that block glycosylation of proteins having a glycosylation domain that is substantially homologous to a glycosylation domain of NP required for polymerization. The invention further relates to pseudoparticles for presentation of antigens or antigenic epitopes for immunogenic or vaccination purposes.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56983
7452694,18-Nov-08,2008,11,18,Nucleic acids encoding T2R of taste receptors,"The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors.",8,The Regents of the University of California,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7454045,18-Nov-08,2008,11,18,Determination of feature boundaries in a digital representation of an anatomical structure,"A virtual anatomical structure can be analyzed to determine enclosing three-dimensional boundaries of features therein. Various techniques can be used to determine tissue types in the virtual anatomical structure. For example, tissue types can be determined via an iso-boundary between lumen and air in the virtual anatomical structure and a fuzzy clustering approach. Based on the tissue type determination, a deformable model approach can be used to determine an enclosing three-dimensional boundary of a feature in the virtual anatomical structure. The enclosing three-dimensional boundary can be used to determine characteristics of the feature and classify it as of interest or not of interest.",46,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06K/00201
7456222,25-Nov-08,2008,11,25,Anti tubercular drug: compositions and methods,"Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.",27,"Sequella, Inc.","The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/132
7456260,25-Nov-08,2008,11,25,Humanized antibody,The current invention provides new human variable chain framework regions and humanized antibodies comprising the framework regions. The invention also provides a new method of identifying framework acceptor regions in framework sequences for backmutation to graft a donor sequence to the human framework.,40,The United States of America as represented by the Secretary of the Department of Health and Human Services,The University of Reading,,,,,,,,,,2,Biotechnology,,,,,,C07K/2803
7456268,25-Nov-08,2008,11,25,Materials and methods for inhibiting Wip1,"Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/82
7459277,2-Dec-08,2008,12,2,Mammalian T1R3 sweet taste receptors,"The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors, the receptors comprising consisting of a monomer or homodimer of a T1R3 G-protein coupled receptor polypeptide, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.",19,The Regents of the University of California,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7459315,2-Dec-08,2008,12,2,Miniaturized assembly and method of filling assembly,A miniaturized assembly is provided whereby a fluid sample can be divided into a plurality of sample portions in retaining wells and the sample fluid can be displaced from open ends of the wells while simultaneously being sealed in the wells. A method of dividing a fluid sample using the assembly is also provided.,24,Cytonix Corporation,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
7459536,2-Dec-08,2008,12,2,HGF-SF monoclonal antibody combinations,"The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.",8,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/22
7462356,9-Dec-08,2008,12,9,Chimeric papillomavirus-like particles,"The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines.",6,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
7462593,9-Dec-08,2008,12,9,Compositions and methods for promoting angiogenesis,"The present disclosure concerns the use of peptides and compositions, such as pharmaceutical compositions, to influence angiogenesis. Particular methods are useful for promoting angiogenesis, while others are particularly useful for inhibiting angiogenesis.",10,,,,,,,,,,,,,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,G01N/74
7465550,16-Dec-08,2008,12,16,Method for screening taste-modulating compounds,"The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.",23,The Regents of the University of California,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/74
7465794,16-Dec-08,2008,12,16,Polynucleotides encoding recombinant respiratory syncytial viruses expressing immune modulatory molecules,"Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.",63,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7468352,23-Dec-08,2008,12,23,Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors,"The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Micro-structural and nano-technology,,,,C07K/06
7468435,23-Dec-08,2008,12,23,"Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same","The present invention provides compound of the formula (I):in which at least two of R1, R2, R3, R4, R5, and R6 are N2O2M and related compounds substrates, compositions, and methods of using such compounds and compositions to treat biological disorders in which a polyphasic release of nitric oxide would be beneficial.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/00
7469186,23-Dec-08,2008,12,23,Finding usable portion of sigmoid curve,"Various technologies are described by which the usable portion or threshold value of a sigmoid curve is found. Such techniques can be useful, for example, when determining the concentration or presence of a substance in a test sample. Various techniques can avoid variability in results.",30,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Computer technology,Measurement,,,,,G01N/5907
7470430,30-Dec-08,2008,12,30,"Modifications of HIV, ENV, GAG, and POL enhance immunogenicity for genetic immunization","Modified HIV Env, Gag, Pol, or Nef DNA with improved ability to elicit antibody and CTL responses to HIV antigens have been identified as prototype immunogens for the treatment and prevention of HIV infections. Modifications to Env glycoprotein include deletions in the cleavage site, fusogenic domain, and spacing of heptad repeats 1 and 2 and different COOH-terminal deletions. Other modifications entail expression of Gag-Pol and Gag-Pol-Nef as fusion proteins.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
7470506,30-Dec-08,2008,12,30,Fitness assay and associated methods,"The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R1, R2, R3, R5 or R6 is H, or an optionally substituted and/or heteroatom-bearing alkyl, alkenyl, alkynyl, or cyclic group; Y and/or Z are CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivatives thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n is from 1 to 5; X is a bond, an optionally substituted methylene or ethylene, an amino, O or S; Q is C(O), C(S), or SO2; m is from 0 to 6; R4 is OH, ═O (keto), NH2, or alkylamino, including esters, amides, and salts thereof; and W is C(O), C(S), S(O), or SO2. Optionally, R5 and R6, together with the N—W bond of formula (I), comprises a macrocyclic ring.",9,The United States of America as represented by the Department of Health and Human Services,Board of Trustees of the University of Illinois,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/341
7470775,30-Dec-08,2008,12,30,Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins,"CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv (“dsFv”)-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/2878
7476535,13-Jan-09,2009,1,13,TRP2 isoform TRP2-6b containing HLA-A2 restricted epitopes,"The present invention relates to a new and potent tumor antigen capable of causing T cells to elicit an immune response and methods of its use in the detection, prevention, and treatment of cancer, preferably melanoma, in mammals. More specifically, this invention relates to the identification of a novel tyrosinase-related protein 2(TRP2), specifically TRP2-6b protein, and peptides derived from said protein. The present invention therefore also relates to nucleic acid seciuences that encode the TRP2-6b protein or peptide fragments thereof.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/705
7476692,13-Jan-09,2009,1,13,Pharmaceutical compositions of safingol and methods of using the same,"The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0.1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0.2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.",27,Childrens Hospital Los Angeles,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/133
7476733,13-Jan-09,2009,1,13,Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease,Disclosed are compositions and methods for detecting a specific sequence of the psaA gene using real-time PCR for diagnosis of Pneumococcal Disease.,19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
7479280,20-Jan-09,2009,1,20,Virus-like particles for the induction of autoantibodies,"The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7479373,20-Jan-09,2009,1,20,Method for identifying compounds modulating taste transduction,"The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors.",14,The Regents of the University of California,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7479554,20-Jan-09,2009,1,20,AAV5 nucleic acids,"The present invention provides an adeno-associated virus 5 (AAV5) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV5 vectors and particles.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7482133,27-Jan-09,2009,1,27,"Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use","Disclosed are methods and compositions that can be used to synthesize oligosaccharides; mutants of galactosyltransferases having altered donor and acceptor specificity; methods for increasing the immunogenicity of an antigen; and polypeptide stem regions that can be used to promote in vitro folding of polypeptides, such as the catalytic domain from a galactosyltransferase.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Y/01133
7485306,3-Feb-09,2009,2,3,Lutzomyia longipalpis polypeptides and methods of use,"Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,Fundacao Oswaldo Cruz,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/008
7485415,3-Feb-09,2009,2,3,Sequence analysis of the tetravalent rotavirus vaccine,"Isolated nucleic acid molecules comprising a gene segment from a rhesus rotavirus (RRV) or from one of three rhesus: human reassortant viruses are disclosed, including isolated nucleic acid molecules having a sequence selected from the group consisting of: SEQ ID NO: 1-14, inclusive, and isolated nucleic acid molecules encoding a protein having a sequence selected from the group consisting of SEQ ID NO: 15-28, inclusive, as well as variants of the isolated nucleic acid molecules.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
7485440,3-Feb-09,2009,2,3,Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2,"Recombinant respiratory syncytial virus (RSV) are provided in which expression of the second translational open reading frame encoded by the M2 gene (M2ORF2) is reduced or ablated to yield novel RSV vaccine candidates. Expression of M2 ORF2 is reduced or ablated by modifying a recombinant RSV genome or antigenome to incorporate a frame shift mutation, or one or more stop codons in M2 ORF2. Alternatively, M2 ORF2 is deleted in whole or in part to render the M2-2 protein partially or entirely non-functional or to disrupt its expression altogether. M2 ORF2 deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in mRNA transcription, genomic or antigenomic RNA replication, viral growth characteristics, viral antigen expression, viral plaque size, and/or a change in cytopathogenicity. In addition, M2-2 knock out or deletion virus exhibits increased levels of synthesis of viral proteins in cell culture, providing an enriched source of viral antigen or protein for purification and use as a noninfectious subunit vaccine.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/155
7485709,3-Feb-09,2009,2,3,Identification of a novel BHD gene,"The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating BHD skin lesions.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
7488477,10-Feb-09,2009,2,10,Neutralizing monoclonal antibodies to respiratory syncytial virus,"The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.",1,Intracel Resources LLC,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/1027
7488710,10-Feb-09,2009,2,10,SFRP and peptide motifs that interact with SFRP and methods of their use,"This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also includes methods of regulating the interaction of sFRP-1 with proteins containing the motif.",33,The United States of America as represented by the Department of Health and Human Services,St. Vincent's Institute of Medical Research,,,,,,,,,,2,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C12N/0643
7488711,10-Feb-09,2009,2,10,"Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth","Methods for inhibiting endothelial cell growth and angiogenesis, and suppressing tumor growth using calreticulin, fragments of calreticulin and variants of calreticulin are provided. Such methods are useful for the treatment of cancer and diseases associated with unwanted angiogenesis, for example chronic retinal detachment.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4725
7488808,10-Feb-09,2009,2,10,Janus family kinases and identification of immune modulators,"An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.",2,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
7491798,17-Feb-09,2009,2,17,"Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins","An isolated or purified antiviral protein of SEQ ID NO: 1, nucleic acids encoding the antiviral protein, cells comprising the nucleic acids, and methods of inhibiting viral infection comprising contacting the virus with the antiviral protein.",46,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/195
7493854,24-Feb-09,2009,2,24,Jam detection and safety device for jamming machinery,"The present disclosure concerns a jam detection and safety system for machines prone to jamming, such as a baler. In particular embodiments, the system is implemented in a horizontal baler having a shear bar and a hydraulic ram that advances material being baled past the shear bar into a compression chamber. The system includes a strain gage mounted on the shear bar and a controller that is electrically connected to the strain gage. The controller receives strain signals from the stage gage and compares the strain of the shear bar to a predetermined strain threshold corresponding to a jamming condition. If the strain exceeds the predetermined threshold, the controller automatically deactivates the ram, such as by disconnecting line power from the baler and/or by turning off the control power of the baler.",7,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,West Virginia University,,,,,,,,,,2,Machine tools,,,,,,B30B/0047
7494813,24-Feb-09,2009,2,24,VAC-BAC shuttle vector system,The invention relates to a VAC-BAC shuttle vector system for creation of recombinant poxviruses from DNA cloned in a bacterial artificial chromosome.,41,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7495100,24-Feb-09,2009,2,24,Synthesis of indenoisoquinolines,"Indenoisoquinolines and dihydroindenoisoquinolines are described. In particular, such compounds possessing one or more electron withdrawing substituents are described. The in vitro anticancer activities of these molecules tested in the National Cancer Institute's screen of 55 cell lines is described. The compounds tested for topoisomerase I (top1) inhibition is described.",10,Purdue Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/18
7498336,3-Mar-09,2009,3,3,Deazaflavin compounds and methods of use thereof,"The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.",22,"The United States of America as represented by the Secretary, Department of Health and Human Services",BioVeris Corporation,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
7501132,10-Mar-09,2009,3,10,Multiple antigenic peptides immunogenic against Streptococcus pneumonia,"The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention further provides monoclonal antibodies which selectively bind PsaA. In addition, peptides are provided that immunospecifically bind to the monoclonal antibodies of the invention, and that are immunogenic against Streptococcus pneumoniae infection. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention. Also provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens and methods of preventing and treating Streptococcus pneumoniae infection in a subject. In addition, a method of identifying the sequence of a peptide potentially capable of eliciting protective immunity against a pathogenic microorganism is provided.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/08
7501501,10-Mar-09,2009,3,10,MHC-Class II restricted melanoma antigens and their use in therapeutic methods,"The present invention provides MHC Class II restricted melanoma antigens recognized by CD4+ T cells. This invention further provides prophylactic and therapeutic applications for the Class II restricted melanoma antigens. In particular, this invention provides tyrosinase Class II restricted melanoma antigens, as well as tyrosinase immunogenic peptides which have been modified to enhance their immunogenicity. These antigens can serve as an immunogens or vaccines to prevent or treat melanoma. In addition a method for isolating Class II restricted melanoma antigens or identifying new Class II restricted melanoma antigens is provided.",20,The United States of America as represented by the Secretary Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12N/0059
7503328,17-Mar-09,2009,3,17,Mucus slurping endotracheal tube,"An endotracheal tube assembly (10) is disclosed which suctions away bacteria multiplying mucus before such mucus can accumulate on the inside walls of the endotracheal tube (14). In the preferred embodiment, one or more suctioning tubes (20, 21) are formed into the walls of an endotracheal tube so that they extend along length of the endotracheal tube. A plurality of mucus slurping holes (34) are then formed at or near the distal end of the endotracheal tube and connected to the suctioning tubes. In operation, suctioning through the mucus slurping holes is preferably performed intermittently during patient expiration. By timing this intermittent suctioning with patient expiration, the suctioning flow will be in the same direction as patient breathing. While the mucus slurper of the present invention has been found to be effective at keeping the inner walls of the endotracheal tube free of mucus deposits, it can nonetheless be combined with other cleaning and disinfectant techniques for greater assurance of cleanliness.",3,The United States of America as represented by the Secretary of The Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/0463
7504096,17-Mar-09,2009,3,17,Methods for in vitro fertilization,"Compositions and methods are described to enhance embryo implantation. Cytokines capable of binding to a receptor complex (the complex comprising a member of the hematopoietic cytokine receptor family) are utilized to treat female mammals, and in particular, females receiving in vitro fertilized embryos.",3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/54
7504109,17-Mar-09,2009,3,17,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.",16,"MedImmune, LLC","The United States of America as Represented by The Department of Health Services, National Institute of Health",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
7504202,17-Mar-09,2009,3,17,Rapid immunoassay of anthrax protective antigen in vaccine cultures and bodily fluids by fluorescence polarization,"The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a Bacillus anthracis protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of Fluorescence Polarization, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0.1 to 10.0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including B. anthracis by fluorescent methods.",11,The United States of America as represented by the Secretary of the Navy,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56911
7504243,17-Mar-09,2009,3,17,Methods for the production of biliverdin,"The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12P/165
7504430,17-Mar-09,2009,3,17,Maleiimide anti-tumor phosphatase inhibitors,"The present invention features maleiimide compounds, pharmaceutical compositions of maleiimide compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more maleiimide compounds of the invention.",41,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/456
7507538,24-Mar-09,2009,3,24,Human papilloma virus immunoreactive peptides,"This invention provides immunogenic peptides from the HPV-18E6 protein that comprise class I restricted T cell epitopes and discloses methods of administering these peptides to individuals, and a method for monitoring or evaluating an immune response to HPV with these peptides.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
7507793,24-Mar-09,2009,3,24,Mammalian sweet taste receptors t1r3,"The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet taste receptors.",10,The Regents of the University of California,United States of America Dept. of Health and Human Services National Institutes of Health-OTT,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7509702,31-Mar-09,2009,3,31,Barricade system and barricade bracket for use therein,"A protective barricade system to prevent persons from accidentally falling through holes in roofs or floors or from the edges of stairwells, balconies, or pitched roofs. The barricade system comprises a plurality of barricade brackets that are spaced apart and can be releasably attached to the underlying surface.",45,"The United States of America as represented by the Secretary of the Department of Health and Human Services, c/o Centers for Disease Control and Prevention",,,,,,,,,,,1,Civil engineering,,,,,,E04G/26
7510715,31-Mar-09,2009,3,31,Protozoan derived compositions and methods of use thereof,"The instant invention relates to methods for treating a subject suffering from or susceptible to an autoimmune disease or disorder, or a disease or disorder having an autoimmune component, comprising administering to the subject an effective amount of cyclophilin or a biologically active fragment thereof.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/16
7511009,31-Mar-09,2009,3,31,Retinal pigmented epithelium derived neurotrophic factor,"The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule.In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.",13,The National Institutes of Health,,,,,,,,,,,1,Biotechnology,,,,,,C07K/811
7511015,31-Mar-09,2009,3,31,Modified defensins and their use,"This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method is provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/1709
7511032,31-Mar-09,2009,3,31,"Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto","Disclosed are compounds of Formula (I) wherein X, Y, Ri-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula (I) and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula (I); a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula (I); a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula (I); and a method of preparing a compound of Formula (I) as described herein.",39,"The United States of America as represented by the Secretary, Department of Health and Human Services","Starks Associates, Inc.",Midwest Research Institute,"Spirogen, Ltd.",,,,,,,,4,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
7514414,7-Apr-09,2009,4,7,Suppressors of CpG oligonucleotides and methods of use,"The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
7514415,7-Apr-09,2009,4,7,Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides,The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
7514529,7-Apr-09,2009,4,7,Peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines,The present invention relates to peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines.,17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/102
7517527,14-Apr-09,2009,4,14,Immunotoxin with in vivo T cell suppressant activity and methods of use,"Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/2809
7517531,14-Apr-09,2009,4,14,"Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4","The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.",42,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7517849,14-Apr-09,2009,4,14,Inhibition of ABC transporters by transmembrane domain analogs,"ATP-binding cassette (ABC) transporters generally contain a number of transmembrane helices. The present invention provides synthetic peptides derived from these transmembrane helices. The peptides inhibit ABC transporter function, presumably by disrupting the structure of the ABC transporter. Negatively charged residues are added at the extracellular terminus to promote correct orientation of the peptide in the membrane, and residues considered to aid solubility may be added at that terminus to increase solubility. Exemplary ABC transporters that can be inhibited by these peptides include MDR1, MRP1, MRP2 and BCRP. The invention further provides nucleic acids encoding the peptides, expression cassettes comprising the nucleic acids, and host cells expressing the expression cassettes. The invention further provides a simple and inexpensive assay for determining whether a potential chemotherapeutic agent can inhibit the activity of P-gly-coprotein.",39,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
7521054,21-Apr-09,2009,4,21,Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point,"The invention provides recombinant immunotoxins that have been modified from a parental immunotoxin to lower liver toxicity. The immunotoxins are created by specifically mutating charged residues in the framework regions of the heavy chain, the light chain, or both, of the antibody portion or antigen-binding fragment thereof of the parental immunotoxin to reduce the pI of the antibody or fragment. In preferred forms, the antibody portion of the parental is an anti-Tac, anti-mesothelin, or anti-LewisY antigen antibody or antigen-binding fragment, and in particularly preferred forms the antibody portion is an M16 dsFv, a St6 dsFv or a Mt9 dsFv, or a sequence that has at least 90% sequence identity to one of these molecules but retain the particular mutations that lower pI without affecting antibody activity. The invention further provides nucleic acids encoding the recombinant immunotoxins of the invention, expression cassettes comprising the nucleic acids, and host cells comprising the expression cassettes. The invention also provides a method for killing a cell comprising an antigen on the surface of the cell, the method comprising contacting the cell with a recombinant immunotoxin of the invention that has an antibody or antigen-binding fragment thereof that binds specifically to the antigen on the surface of the cell, and uses of immunotoxins of the invention for the manufacture of medicaments.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/28
7521063,21-Apr-09,2009,4,21,Multiple CPG oligodeoxynucleotides and their use to induce an immune response,Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
7521177,21-Apr-09,2009,4,21,Flavivirus detection methods employing recombinant antigens comprising a Japanese encephalitis (JEV) signal sequence,"The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
7521242,21-Apr-09,2009,4,21,Host cells deficient for mismatch repair and their use in methods for inducing homologous recombination using single-stranded nucleic acids,"Methods are disclosed herein for inducing homologous recombination in a host cell comprising a target nucleic acid, using a single-stranded nucleic acid molecule. The single-stranded nucleic acid molecule has a sufficient number of nucleotides homologous to the target nucleic acid to enable homologous recombination with the target nucleic acid. The host cell includes a de-repressible promoter operably linked to a nucleic acid encoding a single-stranded binding protein and is deficient for mismatch repair. Isolated host cells of use in this method are also disclosed.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/20
7521475,21-Apr-09,2009,4,21,"Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof","A composition comprising a substantially purified compound of the formula:in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
7521479,21-Apr-09,2009,4,21,Methods of treating prion disease in mammals,The invention is related to the treatment of prion-related diseases such as the transmissible spongiform encephalopathies (TSEs) in mammals by administering chaotropic agents to or inducing a hyperthermia state in the affected mammals.,14,"Panacea Pharmaceuticals, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/17
7524508,28-Apr-09,2009,4,28,Subgenomic replicons of the flavivirus dengue,"The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.",18,The United states of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/21
7524939,28-Apr-09,2009,4,28,"Antibodies that bind to and inhibit human cytochrome P450 2C9*1, 2C9*2, and 2C9*3","The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.",18,United States of America as represented by Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/40
7527797,5-May-09,2009,5,5,Vibrio cholerae 0139 conjugate vaccines,"The invention pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present invention also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/107
7527800,5-May-09,2009,5,5,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.",29,"MedImmune, LLC",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7527925,5-May-09,2009,5,5,"Purified pol DNA, a recombinant DNA construct for expression of HIV pol polypeptide sequences and a cell containing such construct","Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",16,"Novartis Vaccines and Diagnostics, Inc.",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7527970,5-May-09,2009,5,5,Method of identifying active chromatin domains,"The invention provides a method of mapping DNA-protein interactions within a genome by fixing living cells to cross-link DNA and proteins, lysing the cells, and isolating chromatin by immunoprecipitation. DNA is purified and a SAGE protocol is performed on the purified DNA to produce GMAT-tag sequences, which are compared to a genomic sequence of the living cells to map DNA-protein interactions. The invention further provides a method of identifying an active chromatin domain and a method of identifying aberrant chromatin acetylation, wherein chromatin immunoprecipitation is performed using an antibody recognizing acetylated histone protein.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5308
7528274,5-May-09,2009,5,5,Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents,"Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/20
7531352,12-May-09,2009,5,12,Inducible plasmid vector encoding TGF-β and use thereof,"The present invention provides alternatives to traditional drug and surgical treatments for IBD. In particular, the present invention provides compositions and methods for the treatment of autoimmune diseases such as IBD in humans using TGF-β therapy. The compositions of the present invention provide vectors containing TGF-β under the control of an inducible promoter. In particularly preferred embodiments, the present invention provides regulated plasmid constructs capable of inducing TGF-β production. In preferred embodiments, the methods of the present invention utilize the vectors described for assaying the expression of a gene in a cell. In some preferred embodiments, the methods of the present invention utilize the administration of TGF-β containing vectors to treat IBD. In alternative preferred embodiments, the present invention provides methods and compositions for the induction of high-level interleukin (e.g., IL-10) production.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Other special machines,,,,A01K/027
7531635,12-May-09,2009,5,12,MATER-protein specific antibodies and methods of use,"Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater cDNA and protein sequences are provided. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. MATER-protein specific binding agents, such as antibodies, are described. Methods are described for detecting MATER protein in a subject, including methods for determining whether a subject has a biological condition associated with abnormal Mater expression. Also provided are kits for detecting MATER protein in a subject.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Analysis of biological materials,,,,C07H/04
7534565,19-May-09,2009,5,19,DLC-1 gene deleted in cancers,"A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4703
7534877,19-May-09,2009,5,19,"Non-M, non-O HIV-1 strains, fragments and uses","Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBE30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent.The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics:",10,Institute National de la Sante et de la Recherche Medicale-Inserm,Assitance Publique-Hopitaux de Paris,Institut Pasteur,,,,,,,,,3,Biotechnology,Analysis of biological materials,,,,,C07K/005
7537765,26-May-09,2009,5,26,Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein,"Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.",40,"Panacos Pharmaceuticals, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/215
7541034,2-Jun-09,2009,6,2,Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors,"Methods and compositions relating to recombinant anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as a Pseudomonas exotoxin or a detectable label. The invention provides diagnostic methods, and means to inhibit the growth of malignant B cells.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/48561
7541035,2-Jun-09,2009,6,2,Immunogenic peptides for the treatment of prostate and breast cancer,"Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1. Several specific, non-limiting examples of these polypeptides are set forth as SEQ ID NOs: 3-7. Nucleic acids encoding these polypeptides, and host cells transfected with these nucleic acids, are also disclosed. Methods of using these polypeptides, and polynucleotides encoding these polypeptides, for the treatment of breast and prostate cancer are also disclosed.",25,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
7541040,2-Jun-09,2009,6,2,Chimeric molecule for the treatment of th2-like cytokine mediated disorders,"The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.",18,The United States of America as represented by the Department of Health and Human Serivces,"The Regents of the University of Michigan, Office of Technology Transfer",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/6849
7541043,2-Jun-09,2009,6,2,Vaccine for protection against Shigella sonnei disease,Compositions and methods for protecting a susceptable host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.,24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
7541139,2-Jun-09,2009,6,2,Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins,"A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine residue is capable of being ADP-ribosylated. In another embodiment, methods are disclosed for modifying an immune response in a subject.",18,The United States of America as represented by the Department of Health and Human Services,University of Massachusetts,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Organic fine chemistry,,,,A61K/1709
7541182,2-Jun-09,2009,6,2,In vitro test to detect risk of preeclampsia,"The present invention provides methods for identifying patients at risk of developing preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.",7,Yale University,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/5091
7544932,9-Jun-09,2009,6,9,Contiguous capillary electrospray sources and analytical devices,"Contiguous capillaries useful for separating and electrospraying a fluid comprising analyte and electrolyte are provided. The contiguous capillaries have spray tips at one end of the capillaries and electrically conductive portions in proximity to the spray tips. Methods for making the contiguous capillaries and their use as electrospray sources are also disclosed. Apparatus and methods for conveying analyte ions from the capillaries into analytical instruments, such as a mass spectrometer, are also disclosed. The disclosed contiguous capillaries may be used to carryout electrophoresis separation and electrospray ionization of analytes. Methods for obtaining the mass spectra of macromolecular analytes at concentrations lower than previously possibly are provided using the apparatus and procedures described herein.",44,"The United States of America, as represented by the Secretary, of the Department of Health and Human Services",,,,,,,,,,,1,"Electrical machinery, apparatus, energy",Chemical engineering,Measurement,,,,H01J/04
7547509,16-Jun-09,2009,6,16,Cyanovirin variant-polymer conjugates,"The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof, and methods of preparing such conjugates. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.",10,"Nektar Therapeutics AL, Corporation",National Institute of Heatlh,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/195
7547519,16-Jun-09,2009,6,16,Methods of diagnosing multidrug resistant tuberculosis,"The invention relates to the discovery that a putative gene of Mycobacterium tuberculosis with no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. Since M. tuberculosis has a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854c and now termed “EtaA,” are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/0071
7547712,16-Jun-09,2009,6,16,Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women,The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.,20,Nabi Biopharmaceuticals,"United States of America as Represented by the Secretary, DHHS Office of Technology Transfer, National Institutes of Health",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/0013
7547762,16-Jun-09,2009,6,16,T24 antigen for immunodiagnosis of Taenia solium cysticercosis,"The present disclosure relates to T24 nucleic acid sequences, amino acid sequences, and antibodies. Methods for detecting and diagnosing Taenia solium infection in a subject using the T24 sequences and specific binding agents are also disclosed. The T24 sequences disclosed herein can be formulated into a pharmaceutical composition for administration to a subject. For example, the disclosed T24 polypeptides can also be administered to a subject to stimulate an immune response in the subject, thereby protecting the subject against T. solium infection.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/43554
7547773,16-Jun-09,2009,6,16,Nucleic acid molecules encoding prostate specific antigen oligo epitope peptides,"The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/001194
7553490,30-Jun-09,2009,6,30,Vaccines against Escherichia coli O157 infection,"This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-DGalpNAc-(1→2)-α-D-PerpNAc-(1→3) -α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide of E. coli O157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0258
7553822,30-Jun-09,2009,6,30,Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene,"Composition for the inhibition of the translation of a Mect1-MAML2 chimeric gene consisting essentially of: (a) a fragment of the nucleic acid encoding the chimeric gene, and (b) a nucleic acid complementary to the fragment, and a method of inhibiting the translation of a Mect1-MAML2 chimeric gene comprising contacting a cell expressing the chimeric gene with the composition, whereupon the translation of the chimeric gene is inhibited.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
7553936,30-Jun-09,2009,6,30,Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions,"The present invention relates to methods and compositions for modulating platelet activity, and methods and compositions for treating a disease or disorder associated with platelet activity in a subject, comprising administering a single chain anti-TREM-like transcript-1 (TLT-1) antibody or a functional fragment or variant thereof in an amount effective to modulate platelet activity.",6,The United States of America as represented by Secretary Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/6893
7554090,30-Jun-09,2009,6,30,Apparatus and process for dose-guided radiotherapy,A method and an apparatus for dose-guided radiotherapy for a patient (P) having an identified radiotherapy target utilizes a radiation detecting array (R) of radiation-sensitive dosimeters for the real-time remote measurement of radiotherapy at the radiation detecting array (R). The radiation detecting array is positioned within the patient's (P) body along the treatment path before or after the identified radiotherapy target or the device may be positioned beyond the patient (P) to measure transit dose. A radiation source (A) for emitting radiation for radiotherapy along a treatment path through the patient (P) to the identified radiotherapy target is utilized. The method includes generating a predicted dose pattern of radiation at the placed radiation detecting array (R). The predicted dose pattern assumes an on-target radiation source (A) emitting the radiotherapy beam along the treatment path through the patient (P) to the identified radiotherapy target. Gating of the radiation source (A) can occur responsive to the comparing of the predicted dose pattern of radiation to the real-time dose pattern at the radiation detecting array (R). Radiation intensity can vary between low levels to a treatment level responsive to coincidence of the predicted dose pattern of radiation to the real-time dose pattern at the radiation detecting array (R).,28,The United States of America as represented by the Department of Health and Human Services,The United States of America as represent by the Secretary of the Navy,,,,,,,,,,2,Medical technology,,,,,,A61N/1048
7557196,7-Jul-09,2009,7,7,"hGC-1, a gene encoding a member of the olfactomedin-related protein family","An isolated acid having the sequence of a) SEQ ID NO: 1; b) the sequence of SEQ ID NO: 2; c) the sequence of SEQ ID NO: 3; d) a sequence complementary to any of a), b), or c); or e) a sequence of at least 10 contiguous nucleotides specific for any of a)-d). The invention relates to the identification and characterization of a hitherto unidentified human gene, hGC-1. The protein encoded by hGC-1 appears to be a member of the olfactomedin-related proteins. The invention relates generally to the gene (hGC-1), nucleic acids, cDNA, vectors, polypeptides, protein, antibodies, cells, transgenic animal, and other compositions related to hGC-1. Additionally, primers are provided for identifying hGC-1. The invention further relates to methods of using these compositions, such as diagnosis and treatment of various cancers, and kits comprising these compositions.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
7560116,14-Jul-09,2009,7,14,"Compositions, methods and kits relating to poxvirus subunit vaccines","The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.",18,The Trustees of the University of Pennsylvania,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7560118,14-Jul-09,2009,7,14,Attenuated dengue virus comprising mutations in the NS3 gene,A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.,16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
7561909,14-Jul-09,2009,7,14,MRI navigator methods and systems,"Navigator methods are disclosed that are based on detecting a flow-sensitive signal within a subject, and using the position of the signal to track subject motion between imaging sequences. In a disclosed embodiment, the fast-moving blood volume in the left ventricle of the heart is detected and used as a reference point to correct for cardiac motion that results from respiratory motion in a subject. The navigator based on the position of the fast-moving blood volume in the left ventricle may be applied prospectively to shift a subsequent imaging slice to compensate for subject motion, and thereby provide MRI images with increased clarity and resolution.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Measurement,,,,,A61B/055
7563573,21-Jul-09,2009,7,21,Method for detecting radiation exposure,"A method is disclosed for detecting exposure of organisms to biologically significant or hazardous amounts of ionizing radiation. The method uses nucleic acid microarray hybridization to evaluate biological effects, such as patterns of expression of genes after radiation exposure. Numerous genes are provided which have been found to be responsive to radiation exposure in a variety of cell lines. These genes are incorporated into probe sets, which are exposed to a labeled nucleic acid composition from a test cell, such as cDNA reverse transcribed from mRNA in the test cell, which specifically hybridizes to members of the probe set when the cell has been exposed to a biologically significant amount of ionizing radiation. Whether the nucleic acid composition hybridizes to the nucleic acid molecules representing genes that are differentially expressed is determined. The invention also includes methods for determining a dose response relationship between radiation exposure and differential expression of one or more genes, for example to determine a probable radiation dose in cells that have actually or potentially been exposed to the ionizing radiation. The invention also includes probe sets and microarrays used in this method.",52,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
7563596,21-Jul-09,2009,7,21,Method of modulating tissue growth using Frzb protein,"An isolated cDNA encoding a growth-inducing protein, Frzb, capable of stimulating bone, cartilage, muscle and nerve tissue formation. Frzb binds to and modulates the activity of Wnt growth factors which play a role in various developmental and neoplastic processes. The cDNA and protein sequences of human, bovine and Xenopus Frzb are provided. Production and purification of recombinant Frzb are also described.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/71
7563766,21-Jul-09,2009,7,21,Methods and compositions for the promotion of a hair growth utilizing actin binding peptides,"Disclosed herein are methods and compositions suitable for the promotion of hair growth on humans and other animals. Disclosed embodiments include compositions comprising actin-binding peptides. In some embodiments, the actin-binding peptides comprise fragments of thymosin β4. In other embodiments, the disclosure provides compositions comprising fragments of thymosin β4 and/or other actin-binding peptides that are suitable for the treatment of alopecia and other conditions associated with hair loss. In still further embodiments, the disclosure provides compositions comprising the sequence of approximately six or seven amino acids of the thymosin β4 sequence that bind actin.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/64
7566451,28-Jul-09,2009,7,28,Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency,"The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/21
7569673,4-Aug-09,2009,8,4,Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors,"The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.",49,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
7570802,4-Aug-09,2009,8,4,Automated centerline detection algorithm for colon-like 3D surfaces,"A three dimensional image of the colon like surface is processed to determine at least its ring structure. The image is composed of vertex points, each vertex point having a discrete point identifier and three dimensional position information. The three dimensional position information is averaged in a shrinking procedure to contract the three dimensional image proximate to a major axis of the colon-like surface. Evenly spaced points are taken through the shrunken colon like surface and connected to form a curve. Planes are generated at intervals normal to the curve to split the shrunken colon like surface into image segments. By mapping these image segments back to the original image through their discrete point identifiers, an accurate ring profile of the colon like surface can be generated.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/00
7570986,4-Aug-09,2009,8,4,Teniae coli guided navigation and registration for virtual colonoscopy,A computer-assisted method for detecting surface features in a virtual colonoscopy. The method includes providing a three-dimensional construction of a computed tomography colonography surface; creating a path along the teniae coli from the proximal ascending colon to the distal descending colon on the colonography surface; forming an indexed computed tomography colonography surface using the created path; and registering the supine and prone scans of the computed tomography colonography surface using the indexed computed tomography colonography surface. The method also includes navigating the internal surface of the computed tomography colonography using the indexed computed tomography colonography surface.,20,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G06T/0012
7572771,11-Aug-09,2009,8,11,Multi-domain amphipathic helical peptides and methods of their use,Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.,21,The United States of America as represented by the Departments of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/775
7572828,11-Aug-09,2009,8,11,Identification of anti-HIV compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid,"The invention provides methods and pharmaceutical compositions for inhibiting viral replication, particularly retroviral replication. The methods comprise administration of stibonic acid or diphenyl compounds that disrupt viral nucleocapsid binding to nucleic acids.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/194
7572887,11-Aug-09,2009,8,11,"Gene expressed in prostate cancer, methods and use thereof","A polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Splice Variant-Novel Gene Expressed in Prostate (SV-NGEP). Polynucleotides encoding SV-NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies and immunoconjugages are disclosed that specifically bind SV-NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds SV-NGEP, or a polynucleotide encoding SV-NGEP. Assays are disclosed for the detection of prostate cancer. Pharmaceutical compositions including an SV-NGEP polypeptide, an antibody that specifically binds SV-NEGP, or a polynucleotide encoding SV-NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/168
7574340,11-Aug-09,2009,8,11,Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof,"Disclosed herein is a pharmacophore model for inhibiting Botulinum neurotoxin A metalloprotease activity which comprises a first plane A, a second plane B, a first hydrophobic moiety C, a second hydrophobic moiety D and a positive ionizable substituent E. The pharmacophore model may further comprise a heteroatom in the first plane A. In some embodiments, the distance between the center of the first plane A and the center of the second plane B is about 6.5 to about 9.5 Å. In some embodiments, the distance between the center of the first hydrophobic moiety C and the center of the second hydrophobic moiety D is about 8.0 to about 16.0 Å. In some embodiments, the distance between the center of the first plane to the center of the first hydrophobic moiety C is about 3.0 to about 5.0 Å. In some embodiments, the distance between the center of the second plane to the center of the second hydrophobic moiety C is about 3.0 to about 5.0 Å. In some embodiments, the distance between the center of the first plane to the center of the positive ionizable substituent is about 6.5 to about 9.5 Å.",17,The United States of America as represented by the Secretary of the Army,,,,,,,,,,,1,Pharmaceuticals,Computer technology,,,,,A61K/635
7575742,18-Aug-09,2009,8,18,Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist,"Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/2866
7576050,18-Aug-09,2009,8,18,GLP-1 exendin-4 peptide analogs and uses thereof,"The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/575
7579453,25-Aug-09,2009,8,25,Variants of human taste receptor genes,"Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.",25,The United States of America as represented by the Secretary of the Dapartment of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/705
7585619,8-Sep-09,2009,9,8,Method for detecting human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity,This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method of detecting lymphadenopathy associated virus or related viruses or DNA pro-viruses with cloned DNA sequences which are hybridizable to genomic RNA and DNA of lymphadenopathy associated virus. It further relates to the cloned DNA sequences and a process for their preparation.,3,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
7585667,8-Sep-09,2009,9,8,Negative strand RNA virus replicon,"The present invention relates to non-cytopathic negative-strand RNA virus replicons, and methods of making and using the replicons and replicon systems.",18,The United States of America as represented by The Department of Health and Human Services,Rush University Medical Center,,,,,,,,,,2,Biotechnology,,,,,,C12N/00
7585841,8-Sep-09,2009,9,8,Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src,"The present invention describes methods for modulating angiogenesis in tissues using Src protein, modified Src protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Src protein, or nucleic acids encoding therefor, or for potentiating angiogenesis using an active Src protein, or nucleic acids encoding therefor. The invention also describes the use of gene delivery systems for providing nucleic acids encoding for the Src protein, or modified forms thereof.",10,The Scripps Research Institute,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/12
7588900,15-Sep-09,2009,9,15,Mammalian sweet and amino acid heterodimeric taste receptors,"The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.",29,The Regents of the University of California,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/5076
7589181,15-Sep-09,2009,9,15,Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use,"Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28′ CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.",36,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/465
7595059,29-Sep-09,2009,9,29,Methods and compositions for detecting larval Taenia solium with a cloned diagnostic antigen,"Compositions and methods for the detection of Taenia solium and the diagnosis of T. solium infection are described. The nucleotide and amino acid sequences of the antigenic T. solium polypeptides gp50a, gp50b and gp50c are provided. The compositions contain synthetic antigenic polypeptides of larval origin prepared using the sequences described herein. Probes and primers for the detection or amplification of T. solium nucleic acid molecules are also described. The polypeptides can be administered to a human or animal to protect against T. solium infection. In addition, the polypeptides are useful as research tools for studying T. solium and as reagents in assays for the detection of T. solium antibodies in a biological sample. The methods are sensitive and specific assays that utilize the stable recombinant or synthetic antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.",11,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/56905
7595166,29-Sep-09,2009,9,29,Methods of screening modulators of T2R taste receptors,"The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.",21,The Regents of the University of California,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/74
7598071,6-Oct-09,2009,10,6,Infectious clone of human parvovirus B19 and methods,"The invention relates to infectious clones of parvovirus B19, methods of cloning infectious B19 clones, and methods of cloning viral genomes that have secondary DNA structures that are unstable in bacterial cells. A B19 infectious clone and methods of producing B19 infectious clones are useful for producing infectious virus. Infectious virus is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B19 infections.",9,The United States of America as represented by the Department of Health and Human Services,Institut National de Recherche Scientifique,,,,,,,,,,2,Biotechnology,,,,,,C12Q/701
7598077,6-Oct-09,2009,10,6,Compositions and methods for enhancing differential expression,"Artificial TERT promoters, which are useful for enhancing the differential expression of operably linked heterologous nucleic acid sequences, such as polypeptide cytotoxins, are disclosed herein. Methods for treating disease cells, such as cancer cells, while minimizing effects on normal, somatic cells by administering therapeutically effective amounts of heterologous nucleic acid sequences operably linked to artificial TERT promoters are provided. Kits containing artificial TERT promoters for enhancing differential expression are also provided.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/04
7598225,6-Oct-09,2009,10,6,Generation of immune response to prostate-specific antigen (PSA),"We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cellular immune response to PSA can be generated. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate the immune response, and contacting the host with additional PSA at periodic intervals thereafter. The additional PSA may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional PSA can be added by contacting the host with PSA by a variety of other methods, including in one preferred embodiment adding PSA. The PSA may be formulated with an adjuvant or in a liposomal formulation.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
7600410,13-Oct-09,2009,10,13,Optical techniques and system for 3-D characterization of ultrasound beams,"A system for optically characterizing an acoustic beam generally includes an immersant, which is an immersion medium seeded with a plurality of seed particles that respond to illumination with fluorescence indicative of at least one parameter of the immersant such as flow or temperature. Optical transmitters illuminate the immersant slicewise, and optical receptors receive the fluorescence in order to generate a three-dimensional map of the parameter over time. A processor back-calculates one or more characteristics of an acoustic beam that results in the map. The processor initially generates a behavior model of an acoustic beam propagating in the immersant by utilizing initial guesses for the characteristics. The initial guess model is compared to the map, and an optimization routine is used to refine the initial guesses. The process repeats iteratively with refined guesses until the difference between the model and the map is minimized.",52,"St. Jude Medical, Atrial Fibrillation Division, Inc.",The United States of America as represented by the Secretary Department of Health and Human Services,The University of Cincinnati,,,,,,,,,3,Measurement,,,,,,G01H/00
7604997,20-Oct-09,2009,10,20,Wipes and methods for removal of metal contamination from surfaces,"Wipes, methods and kits useful for testing and/or removal of metal from surfaces (such as, dermal surfaces) are disclosed. Exemplar wipes, including the combination of a three-dimensionally textured absorbent support, a cationic surfactant, and a weak acid, are disclosed. In some examples, the cationic surfactant is isostearamidopropyl morpholine lactate (ISML), and the weak acid is citric acid.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Basic materials chemistry,,,,,,C11D/049
7605125,20-Oct-09,2009,10,20,DNA-binding polyamide drug conjugates,"A conjugate of formula: V—(Y)a—Z-T: (I), T-X—B—(Y)a—Z-T′: (II), V—(Y)a Z—(Y′)a V′: (III), T-X—B—(Y)a—Z—(Y′)a—X′—B′-T′: (IV), V—(Y)a—Z—(Y′)a—X—B-T: (V), V—(Y)a—Z—X—B—Z′—(Y′)a—(V′)b: (VI), or (W)a—(Y)b—[(Z)c—(Y′)d—(X—B)e—(Y″)f—(Z′)g]h—(Y . . . )i—(W′)j: (VII), in which W and W′ are independently a DNA intercalator or terminal subunit, V and V′ are independently a DNA intercalator, X and X′ are independently a DNA alkylator, B and B′ are the same or different and each is a heteoaromatic residue that is attached to the Nterminus of an alkylator subunit (X or X′), Y, Y′, Y″ and Y′″ are independently a linker, T and T′ are independently terminal subunits, Z and Z′ are independently a polyamide group that binds to the minor groove of DNA, a, b, c, d, f, g, i, and j are independently 0 to 5, and e and h are independently 1 to 5, a composition comprising a conjugate of any of formulae (I)-(VII) and a carrier, and a method for treating cancer in a mammal comprising administering an effective amount of a conjugate of any of formulae (I)-(VII) or a composition comprising same.",32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/645
7605127,20-Oct-09,2009,10,20,Truncated hepatocyte growth factor variant protein HGF/NK2,"The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions. The present invention further relates to the utilization of the small HGF variants to either inhibit HGF mitogenesis or stimulate HGF mitogenesis in cells expressing the receptor for HGF.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/193
7605259,20-Oct-09,2009,10,20,Structurally rigid dopamine d3 receptor selective ligands and process for making them,"A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.",8,University of North Texas Health Science Center at Fort Worth,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/70
7606623,20-Oct-09,2009,10,20,Methods and devices for intramuscular stimulation of upper airway and swallowing muscle groups,"Devices and methods were discovered that successfully provided patient autonomous control of both hyolaryngeal elevation, anterior hyoid motion and opening of the upper esophageal sphincter for swallowing by intramuscular stimulation of two muscles. The technology allows patient self stimulation of swallowing and can return oral feeding to dysphagia patients. Indwelling electrode stimulation of only two muscles generated as much as 80 % of normal synergistic movement leading to swallowing. The devices and methods also are useful for control of other upper respiratory muscle groups involved in speech and voice. Calibration techniques may be used in combination for greater freedom in setting and using electrodes over extended implantation time periods. These methods and devices can control complex movements of body solids such as bone and cartilage and tissues by electro stimulation of a minimum set of muscles simultaneously.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61N/36007
7608240,27-Oct-09,2009,10,27,Nanotubes for cancer therapy and diagnostics,"The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.",13,Board of Trustees of the University of Arkansas,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Micro-structural and nano-technology,,,,C07K/30
7608422,27-Oct-09,2009,10,27,Simian immunodeficiency virus (SIV) molecular clone encoding mutant gag gene lacking inhibitory/instability regions,"Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV env genes which have been mutated to remove or reduce inhibitory/instability sequences are disclosed. Viral particles and host cells containing these constructs and/or viral particles are also disclosed. The exemplified constructs and viral particles of the invention may be useful in gene therapy for numerous disorders, including HIV infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7608594,27-Oct-09,2009,10,27,Novobiocin analogues as anticancer agents,"Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.",34,University of Kansas,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07H/075
7611702,3-Nov-09,2009,11,3,TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy,"The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.",20,"Medarex, Inc.",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/39558
7611856,3-Nov-09,2009,11,3,Mass spectrometry-based methods for detection and differentiation of botulinum neurotoxins,"The present invention is directed to a method for detecting the presence of clostridial neurotoxins in a sample by mixing a sample with a peptide that can serve as a substrate for proteolytic activity of a clostridial neurotoxin; and measuring for proteolytic activity of a clostridial neurotoxin by a mass spectroscopy technique. In one embodiment, the peptide can have an affinity tag attached at two or more sites.",13,"Los Alamos National Security, LLC",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/37
7612035,3-Nov-09,2009,11,3,Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma,"Inhibitors of the MAPK pathway, including MEK-directed proteases and small molecule inhibitors, are cytotoxic to human melanoma cells in vitro and in vivo via apoptotic mechanisms. These compounds are used to kill melanoma cells and to treat subjects with melanoma, either alone or in combination with other therapeutic modalities.",9,Van Andel Research Institute,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4886
7612044,3-Nov-09,2009,11,3,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
7612197,3-Nov-09,2009,11,3,Thermolabile hydroxyl protecting groups and methods of use,"Provided is a hydroxyl-protected alcohol comprising a thermolabile hydroxyl-protecting group comprising a 2-pyridyl substituent and a precursor of the thermolabile hydroxyl-protected alcohol. An exemplary thermolabile hydroxyl-protected alcohol is represented by the formula Pg-O—R, wherein Pg is a protecting group of the formula: (Formula) wherein: A is a 2-pyridyl; Z is CH2 or NR1; R1, R2, R2′, R3 and R3′ are the same or different and each can be, e.g., H, alkyl, or alkyl comprising an aryl substituent; W is CO, CS, or SO; and R is the organic residue of the hydroxyl-protected alcohol. Also provided is a method of producing an alcohol, which method comprises heating the hydroxyl-protected alcohol, which optionally may be obtained from a precursor, at a temperature effective to cleave the hydroxyl-protecting group. The method can be used to produce oligonucleotides.",27,The United States of America as repesented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Food chemistry,,,,,C07H/20
7615227,10-Nov-09,2009,11,10,Use of CpG oligodeoxynucleotides to induce angiogenesis,"This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This method includes comprising introducing a CpG oligodeoxynucleotide into an area of the tissue wherein the formation of new blood vessels is desired, thereby inducing neovascularization in the area of the tissue.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
7618623,17-Nov-09,2009,11,17,Hybrid adeno-retroviral vector for the transfection of cells,"An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.",14,The United of States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/86
7618632,17-Nov-09,2009,11,17,Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies,"The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.",4,Wyeth,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/47
7618789,17-Nov-09,2009,11,17,"Use of semenogelin in the diagnosis, prognosis and treatment of cancer",Method of diagnosing cancer in a male mammal comprising obtaining and assaying a test sample for an increased level of semenogelin; method of diagnosing cancer in a female mammal comprising obtaining and assaying a test sample for the presence of semenogelin; methods of prognosticating and assessing the effectiveness of treatment of a cancer in a mammal comprising measuring the level of semenogelin in a test sample; method of inducing an immune response to a cancer in a mammal comprising administering to the mammal a composition comprising (a) an immune-response inducing effective amount of (i) semenogelin or (ii) antibody thereto or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii); and composition comprising a carrier and (a) an immune-response inducing effective amount of (i) a polypeptide of any of SEQ ID NOS:1-27 or (ii) antibody thereto or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii).,16,The United States of America as represented by the Secretary of Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57423
7619057,17-Nov-09,2009,11,17,"MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1","The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.",12,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/17
7622113,24-Nov-09,2009,11,24,Monoclonal antibodies that bind or neutralize dengue virus,"The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/10
7622123,24-Nov-09,2009,11,24,Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines,Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.,36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7622272,24-Nov-09,2009,11,24,Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology,"The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/26
7622451,24-Nov-09,2009,11,24,Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders,Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.,24,University of Kansas,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/14
7625736,1-Dec-09,2009,12,1,Methods for preparing immunogenic conjugates,"Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/32
7625917,1-Dec-09,2009,12,1,Thiolesters and uses thereof,This invention pertains to the discovery of a novel family of thiolesters and uses thereof. Also provided for are viricidal compounds and pharmaceutical formulations comprising these novel thiolesters. The invention also provides thiolester-inactivated viruses and thiolester-complexed viral proteins.,8,,,,,,,,,,,,,Organic fine chemistry,,,,,,C07D/76
7626013,1-Dec-09,2009,12,1,HIV-1 DNA fragments that hybridize to genomic HIV-1DNA,"The inventors have isolated cloned cDNA encoding the RNA genome of Human Immunodeficiency Virus type 1 (HIV-1). Various clones are described, which encode different regions of the genome, including those regions encoding viral antigens or proteins. Hybridization results indicate the difference between the HIV-1 clones and those of HTLV-I and HTLV-II. The inventors have also produced a restriction map of the entire cloned genomic sequence in order to facilitate further subcloning and using the restriction fragments in other hybridization tests and in methods to express encoded sequences.",16,Institut-Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
7629387,8-Dec-09,2009,12,8,Compounds for pest control and methods for their use,"Compounds, compositions, and methods for controlling an arthropod pest population that employ an eremophilane sesquiterpene parent structure are presented. The compounds have minimal adverse or toxic effects on humans, non-human animals, and the natural environment. The compounds may be isolated from natural sources, semi-synthesized from naturally occurring compounds, or completely synthesized. The compounds may be applied directly to a pest, or the locus of a pest, and function as topical or ingestible toxins. Eremophilane sesquiterpenes 13-hydroxy-valencene, valencene-11,12-epoxide, valencene-13-aldehyde, and nootkatone-1,10-11,12-diepoxide are exemplary compounds.",27,The United States of America as represented by the Secretary of the Department of Health and Human Services,State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon State University,,,,,,,,,,2,Organic fine chemistry,Basic materials chemistry,,,,,C07D/32
7632508,15-Dec-09,2009,12,15,Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines,"Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an immune response to PIV or other pathogens. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different pathogen, including different PIV virus to form the human-bovine chimeric PIV genome or antigenome.",21,The United States of America,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
7632510,15-Dec-09,2009,12,15,Methods of inducing flavivirus immune responses through the administration of recombinant flaviviruses comprising an engineered japanese encephalitis virus signal sequence,"The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.",21,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
7635476,22-Dec-09,2009,12,22,Anti-hepatitis a virus antibodies,"Chimpanzee monoclonal antibodies and antigen binding fragments including a γ1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/1009
7635485,22-Dec-09,2009,12,22,Method of accelerated vaccination against Ebola viruses,"The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7635486,22-Dec-09,2009,12,22,"Recombinant lipidated PsaA protein, methods of preparation and use","The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene of Borrelia burgdorferi, which leader sequence is joined in translational reading frame with the psaA structural gene. The invention also provides methods of preparation of lipidated PsaA proteins and use of such proteins in immunological compositions. Also provided are vaccines comprising immunogenic lipidated PsaA proteins and methods of use of such vaccines in the prevention and treatment of S. pneumoniae infection.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/3156
7635688,22-Dec-09,2009,12,22,Development of a preventive vaccine for filovirus infection in primates,"The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7638134,29-Dec-09,2009,12,29,Insertion sites in fowlpox vectors,The present invention provides novel insertion sites for introducing DNA into pox vectors.,13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
7641906,5-Jan-10,2010,1,5,Intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis,The invention relates to intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis.,25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/102
7641907,5-Jan-10,2010,1,5,Dengue serotype 1 attenuated strain,The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.,10,Sanofi Pasteur,Center for Disease Control and Prevention,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
7641908,5-Jan-10,2010,1,5,Dengue serotype 2 attenuated strain,The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.,10,Sanofi Pasteur,Center for Disease Control and Prevention,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
7641909,5-Jan-10,2010,1,5,"Avirulent, immunogenic flavivirus chimeras",Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.,11,"The United States of America as represented by the Secretary, Department of Health and Human Services, Certers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
7642068,5-Jan-10,2010,1,5,Multiple-valent opsonophagocytic assay selection panel arrays and uses therefor,"This application discloses a multivalent opsonophagocytosis assay that does not rely on counting of bacterial colonies to determine bacteria viability following opsonophagocytosis. Instead, the method uses a metabolic colorimetric indicator to determine if viable bacteria are present. Also disclosed are arrays that can be used to determine the viability of bacteria following opsonophagocytosis.",18,"The United States of America as represented by the Department of Health and Human Services, Center for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/04
7642280,5-Jan-10,2010,1,5,Inhibitors of acyl glucosaminyl inositol amidase and methods of use,"The present invention provides compounds with activity as inhibitors of acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. Certain of the invention compounds are naturally occurring compounds obtained from marine sponges and other organisms. The invention further provides methods for using the compounds to inhibit virulence and reduce antibiotic resistance of mycothiol-producing bacteria.",3,The Regents of the University of California,National Institutes of Health,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/06
7643863,5-Jan-10,2010,1,5,Diffusion tensor and q-space MRI specimen characterization,"Magnetic resonance methods include modeling magnetic resonance signals obtained from specimens at low and high q-values to obtain parameters associated with specimen structure and orientation. In evaluation of brain white matter specimens, diffusion within axons can be modeled based on hindered diffusion parallel to an axis of the axon and restricted diffusion perpendicular to the axis. Diffusion exterior to axons can be modeled as hindered diffusion with differing diffusivities parallel to and perpendicular to the axis. Based on extracted parameters and associated model functions, specimen properties such as intra and extra-axonal principal diffusivities and the corresponding principal directions can be estimated.",42,,,,,,,,,,,,,Measurement,,,,,,G01R/56341
7646904,12-Jan-10,2010,1,12,Computer-aided classification of anomalies in anatomical structures,"Candidate anomalies in an anatomical structure are processed for classification. For example, false positives can be reduced by techniques related to the anomaly's neck, wall thickness associated with the anomaly, template matching performed for the anomaly, or some combination thereof. The various techniques can be combined for use in a classifier, which can determine whether the anomaly is of interest. For example, a computed tomography scan of a colon can be analyzed to determine whether a candidate anomaly is a polyp. The technologies can be applied to a variety of other scenarios involving other anatomical structures.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,G16H/00
7655397,2-Feb-10,2010,2,2,Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers,A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for diagnosing a cancer.,10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,,,,,,G16B/00
7655694,2-Feb-10,2010,2,2,"Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury","The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4′,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Food chemistry,Organic fine chemistry,,,,A61K/48
7655752,2-Feb-10,2010,2,2,TNF-α converting enzyme inhibitory agents and method of using same,"The invention provides peptides, variants of peptides, peptide fragments, and peptidomimetics that can inhibit the protease activity of tumor necrosis factor alpha converting enzyme. The invention also provides coupled proteins containing a partner protein coupled to a peptide, peptide fragment, or peptidomimetic. The invention also provides polyproteins containing at least two peptides, peptide fragments, or coupled proteins that are connected through a linker. Isolated nucleic acid segments, expression cassettes, and nucleic acid constructs are also provided by the invention. The invention also provides antibodies and aptamers. Pharmaceutical compositions are provided by the invention. Methods to lower or increase levels of active tumor necrosis factor alpha in a mammal are also provided.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/6489
7658364,9-Feb-10,2010,2,9,Ocular therapeutic agent delivery devices and methods for making and using such devices,"Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121, 10, 20) suitable for intravitreal placement also are described. The invention also includes fabrication and implementation techniques associated with the unique ocular implant devices (10, 20, 121) that are presented herein.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Other special machines,,,,A61K/0051
7659081,9-Feb-10,2010,2,9,Determination of AM-binding proteins and the association of adrenomedullin (AM) therewith,"The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the present invention provides a newly identified complex between AM and a specific AM-binding protein 1 (AMBP-1); which has been isolated and identified herein as factor H (fH). The invention also provides AM/AMBP complexes, particularly AM/FH complexes, and antibodies specifically reactive with this complexes. Further provided are methods for identifying and purifying complexes of AM and an AM binding protein using anti-AM/fH antibodies, and methods for treating conditions such as cancer or diabetes utilizing compositions comprising these antibodies. The present invention additionally provides methods for identifying antagonists agents that inhibit the function of AM, factor H, or the AM/factor H complex. The invention also provides methods for treating conditions such as cancer or diabetes using these antagonist agents.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/18
7659085,9-Feb-10,2010,2,9,Methods and compositions for the simultaneous detection of multiple analytes,"Methods and compositions comprising immunoassays for the detection of antigens and antibodies in a sample are described. In particular, the present invention provides assays that are useful for the rapid and simultaneous detection of multiple different antigens and antibodies. In preferred embodiments, the assays include fluorescent labels of multiple wavelengths or intensities, which are used to label the antigens and antibodies directly and to label beads coated with molecules specific for the antigen or antibody. The detection of a fluorescence shift indicates the presence or identity of the antigen or antibody in the sample.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/54313
7659115,9-Feb-10,2010,2,9,Nucleic acid encoding human transductin-1 polypeptide,"The invention provides isolated or purified nucleic molecules consisting of a nucleotide sequence encoding human transductin-1 (TDC1), such as SEQ ID NO: 1. The invention also provides vectors comprising the isolated or purified nucleic acid sequences and cells comprising such vectors.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6883
7662394,16-Feb-10,2010,2,16,Nucleic acids encoding chimeric Flavivirus immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence,"The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus antigen comprising sequence from more than one flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.",47,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
7662395,16-Feb-10,2010,2,16,Method of enhancing a targeted immune response against tumors,The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.,8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70532
7662397,16-Feb-10,2010,2,16,Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes,"Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are infectious and attenuated in humans and other mammals. Gene shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant RSV genome or antigenome wherein a gene or gene segment is shifted to a more promoter-proximal or promoter-distal position within the genome or antigenome compared to a wild type position of the gene in the RSV gene map. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene, depending on the nature and degree of the positional shift.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7662573,16-Feb-10,2010,2,16,Methods for evaluating osteoarthritis risk,"Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/54366
7662619,16-Feb-10,2010,2,16,Sol-fusin: use of GP64-6His to catalyze membrane fusion,"The present invention provides an isolated nucleic acid comprising the nucleotides set forth in the Sequence Listing as SEQ ID NO: 1. SEQ ID NO: 1 is an example of GP64-6His nucleic acid. The invention further provides polypeptides encoded by GP64-6His nucleic acids as well as the polypeptide encoded by SEQ ID NO: 2. The invention also provides liposomes comprising GP64-6His polypeptides as well as liposomes comprising GP64-6His polypeptides and biological molecules. The invention further provides a method of increasing the solubility of polypeptides comprising linking a 6His tag to a polypeptide and measuring the solubility of the 6His-tagged polypeptide, whereby an increase in solubility of the 6His-tagged polypeptide can be detected. The invention also provides a method of solubilizing a viral fusion polypeptide comprising linking a 6His tag to a viral fusion polypeptide. Further provided is a method of delivering a biological molecule to a cell comprising, administering the liposome comprising a GP64-6His polypeptide to a cell. This invention also provides a method of delivering a viral vaccine to a cell comprising administering the liposome comprising a GP64-6His polypeptide to a cell. Also provided is a method of delivering a DNA vaccine to a cell comprising administering the liposome comprising a GP64-6His polypeptide to a cell. Further provided is a GP64-6His polypeptide further comprising a binding site for a cell surface molecule. Also provided by this invention are chimeric proteins comprising GP64-6His.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Organic fine chemistry,,,,A61K/127
7666411,23-Feb-10,2010,2,23,Methods of treating and preventing colitis involving IL-13 and NK-T cells,Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.,5,The United States of America as represented by the Department of Health and Human Services,"The Brigham & Women's Hospital, Inc.",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/2833
7666427,23-Feb-10,2010,2,23,HIV vaccines based on Env of multiple clades of HIV,"In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.",42,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/21
7666601,23-Feb-10,2010,2,23,Phenylthiocarbamide (PTC) taste receptor,"The invention provides isolated nucleic and amino acid sequences of a taste cell receptor that serves as a sensor for the bitter taste of phenylthiocarbamide (PTC), antibodies to such PTC taste receptor, methods of detecting such nucleic and amino acid sequences, and methods of screening for modulators of such PTC taste receptor.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,The University of Utah Research Foundation,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7666674,23-Feb-10,2010,2,23,Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo,"Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.",25,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1272
7666846,23-Feb-10,2010,2,23,Cholesterol-containing compounds and their use as immunogens against Borrelia burgdorferi,"Unique compounds that can be used for inducing an immune response to Borrelia burgdorferi in a subject by administering a therapeutically effective amount of the glycolipid to the subject. Such administration is particularly useful for preventing or treating Lyme disease in a subject. The compounds(s), and therapeutically acceptable salts thereof, may be formulated into pharmaceutical or immunogenic compositions.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/0225
7667210,23-Feb-10,2010,2,23,Wide-area fluorescence detection system for multi-photon microscopy,"A multi-photon microscope has an illumination source, an objective lens unit arranged in an optical path of the illumination source, a first light collection system arranged to collect a first portion of light emitted from a sample when the sample is illuminated by light from the illumination source, and a second light collection system arranged to collect a second portion of light emitted from the sample when the sample is illuminated by light from the illumination source. The first portion of light when collected by the first light collection system and the second portion of light when collected by the second light collection system, together provide a means of collecting as much light from as many angles as possible emanating from an emitting point source. This collection scheme has the potential to approach the total emission collection of light from an emitting point source depending on the optical properties of the sample being imaged.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Optics,,,,,,G02B/06
7670806,2-Mar-10,2010,3,2,ADP-ribosyl acceptor hydrolase 3 (ARH3) polypeptides and methods of use,"This disclosure provides methods for catalyzing the release of ADP-ribose from poly(ADP-ribose) or O-acetyl-ADP-ribose. Also provided are methods for modifying DNA repair or chromatin structure by introducing into the cell an agent that modifies the activity of an ARH3 polypeptide, or variant or fragment thereof. Further provided are methods for screening molecules involved in the poly(ADP-ribosyl)ation of proteins or O-acetyl-ADP-ribose content, and method for treating disorders by altering activity of an ARH3 protein.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12Y/01143
7674621,9-Mar-10,2010,3,9,Plasmids and phages for homologous recombination and methods of use,"Lambda phages that can be used to introduce recombineering functions into host cells are disclosed. Also disclosed are plasmids that can be used to confer recombineering functions to a variety of strains of E. coli and to other bacteria, including Salmonella, Pseudomonas, Cyanobacteria, Spirochaetes. These plasmids and phages can be isolated in vitro and can be used to transform bacterial cells, such as gram negative bacteria.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/74
7674777,9-Mar-10,2010,3,9,Immunostimulatory nucleic acid molecules,"Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.",6,University of Iowa Research Foundation,The United States of America as represented by the Department of Health and Human Services,"Coley Pharmaceutical Group, Inc.",,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
7678569,16-Mar-10,2010,3,16,Cloned genome of infectious hepatitis C virus strain HC-TN and uses thereof,"Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,G01N/5767
7682800,23-Mar-10,2010,3,23,Agents that bind to and inhibit human cytochrome P450 2C19,"The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5735
7684934,23-Mar-10,2010,3,23,Pattern recognition of whole cell mass spectra,A method for reproducibly analyzing mass spectra from different sample sources is provided. The method deconvolutes the complex spectra by collapsing multiple peaks of different molecular mass that originate from the same molecular fragment into a single peak. The differences in molecular mass are apparent differences caused by different charge states of the fragment and/or different metal ion adducts and/or reactant products of one or more of the charge states. The deconvoluted spectrum is compared to a library of mass spectra acquired from samples of known identity to unambiguously determine the identity of one or more components of the sample undergoing analysis.,32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,"Electrical machinery, apparatus, energy",,,,,,H01J/04
7687610,30-Mar-10,2010,3,30,Human chorionic gonadotropin superagonists,"The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the β-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone. The invention is also directed to a method of constructing superactive nonchimeric analogs of human hormones comprising comparing the amino acid sequence of a more active homolog from another species to the human hormone, and selecting superactive analogs from the substituted human hormones. The invention is also directed to nucleic acids encoding the modified human glycoprotein hormones, vectors containing those nucleic acids, and host cells containing those vectors.",50,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/59
7691386,6-Apr-10,2010,4,6,Chimeric papillomavirus-like particles,"The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines.",1,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7691572,6-Apr-10,2010,4,6,Method and kit for detecting resistance to antiviral drugs,Assays and kits for the detection of phenotypic resistance of a retrovirus to reverse transcriptase inhibitor-drugs in a biological sample. The assays are based on the direct analysis of the susceptibility of retroviral reverse transcriptase to inhibition by a reverse transcriptase inhibitor drug. The enzymatic activity of the reverse transcriptase is determined by measuring the DNA product produced when an RNA template and a first complementary DNA primer from a suitable region of the encephalomyocarditis virus genome are incubated with a biological sample containing reverse transcriptase in the presence of the drug to which resistance is being determined. The DNA product is amplified and detection of the amplified DNA indicates resistance to the drug employed in the assay. Detection of relatively greater amounts of amplified DNA when certain drugs are used indicates the presence of multiple nucleoside analog resistant strains or mutations.,15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/702
7691579,6-Apr-10,2010,4,6,Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen,The present invention relates to novel methods for producing an enhanced immune response to an immunogen in a subject via the co-administration of a CD40 agonist and a GM-CSF agent.,20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/39
7691583,6-Apr-10,2010,4,6,High sensitivity mechanical resonant sensor,"A system and method for detecting mass based on a frequency differential of a resonating micromachined structure, such as a cantilever beam. A high aspect ratio cantilever beam is coated with an immobilized binding partner that couples to a predetermined cell or molecule. A first resonant frequency is determined for the cantilever having the immobilized binding partner. Upon exposure of the cantilever to a solution that binds with the binding partner, the mass of the cantilever beam increases. A second resonant frequency is determined and the differential resonant frequency provides the basis for detecting the target cell or molecule. The cantilever may be driven externally or by ambient noise. The frequency response of the beam can be determined optically using reflected light and two photodetectors or by interference using a single photodetector.",32,"Cornell Research Foundation, Inc.",,,,,,,,,,,1,Measurement,Analysis of biological materials,,,,,G01N/022
7695504,13-Apr-10,2010,4,13,Method for regeneration and functional recovery after spinal cord injury using phototherapy,A method of treating spinal cord injury (SCI) includes transcutaneously irradiating at least a portion of a spinal environment of the patient with light having a power density of at least about 0.01 mW/cm2 at the portion of the spinal environment.,9,The United States of America as represented by the Department of Health and Human Services,Henry M. Jackson Foundation for the Advancement of Military Medicine,,,,,,,,,,2,Medical technology,,,,,,A61N/0613
7695752,13-Apr-10,2010,4,13,Target activated microtransfer,"A device for performing target activated transfer that includes a mounting surface for mounting a tissue sample; and a light source positioned to substantially uniformly irradiate both stained and unstained regions of the tissue sample with light energy that activates the reagent to selectively adhere the stained regions to a transfer surface. Also described is an automated system for transferring tissue from a tissue sample to a transfer substrate. The system includes means for holding a tissue section that includes targets specifically stained with an absorptive stain thereby resulting in a stained tissue surface, and a flexible transfer film that includes a lower thermoplastic layer in sufficient thermal contact with the stained tissue surface; an irradiating assembly configured to provide a predetermined uniform light dose to the entire tissue section; and means for applying a constant pressure to the transfer film during irradiation.",28,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/543
7696338,13-Apr-10,2010,4,13,Immunotoxin fusion proteins and means for expression thereof,"The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.",2,The United States of America as represented by the Department of Health and Human Services,Novartis AG,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/00
7700273,20-Apr-10,2010,4,20,Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor,"The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/2866
7700600,20-Apr-10,2010,4,20,Methods for treating cardiac arrhythmia,"Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.",5,"ChanTest, Inc.",United States of America,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/495
7704491,27-Apr-10,2010,4,27,Recombinant human metapneumovirus and its use,"Recombinant HMPV (rHMPV) and related immunogenic compositions and methods are provided. The rHMPVs, including chimeric and chimeric HMPV vectors viruses, provided according to the current disclosure are infectious and attenuated in permissive mammalian subjects, including humans. The rHMPVs are useful in immunogenic compositions for eliciting an immune response against HPIV, against one or more non-HMPV pathogens, or against a HMPV and a non-HMPV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HMPV genome or antigenome.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/155
7704509,27-Apr-10,2010,4,27,Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens,"Recombinant human parainfluenza virus type 1 (HPIV1) compostions, formulations and methods are provided. The recombinant HPIV1 viruses and HPIV1 chimeric and chimeric vector viruses provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic composition s for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV1 genome or antigenome.",270,United States of America,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
7706857,27-Apr-10,2010,4,27,Methods and apparatus for mapping internal and bulk motion of an object with phase labeling in magnetic resonance imaging,"Magnetic resonance imaging method and apparatus are provided for mapping the internal or bulk motion of an object by labeling the phase of a specimen magnetization with a selected spatial function and measuring changes in the phase of the magnetization. The spatial function is selectable to provide magnetization phase modulation corresponding to displacements in a selected direction, such as a radial or azimuthal direction. Methods and apparatus for producing images based on magnetization phase modulation acquire image data based on stimulated echos and stimulated anti-echos. In an embodiment, a series of 180 degree pulses produces alternating stimulated and stimulated anti-echos that are measured and assigned to respective images.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56308
7708977,4-May-10,2010,5,4,Method for diagnosis and treatment of vascular disease,"A method for diagnosing decreased vascular function is disclosed. The method includes assaying the number of endothelial progenitor cells. A method for detecting increased cardiovascular risk is also disclosed, as is a method for diagnosing atherosclerosis. In one example, the methods include assaying the number of endothelial progenitor cells. A method for treating a subject with decreased vascular function is disclosed. The method includes administering a therapeutically effective amount of endothelial progenitor cells to the subject. In one embodiment, the subject has atherosclerosis.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56966
7709002,4-May-10,2010,5,4,Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes,"Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in-vivo-primed CD8+ CTL precursors.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/06
7709007,4-May-10,2010,5,4,Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences,"Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. Alternatively, recombinant RSV and vaccine compositions thereof incorporate attenuating and other mutations specifying desired structural and or phenotypic characteristics in an infectious RSV. Recombinant RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of a selected nucleotide sequence, gene, or gene segment in an infectious RSV clone. The immune system of an individual is stimulated to induce protection against natural RSV infection, or multivalently against infection by RSV and another pathogen, such as PIV, by administration of attenuated, biologically derived or recombinant RSV.",46,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/005
7709047,4-May-10,2010,5,4,Target activated microtransfer,"A method of removing a target from a biological sample which involves placing a transfer surface in contact with the biological sample, and then focally altering the transfer surface to allow selective separation of the target from the biological sample. In disclosed embodiments, the target is a cell or cellular component of a tissue section and the transfer surface is a film that can be focally altered to adhere the target to the transfer surface. Subsequent separation of the film from the tissue section selectively removes the adhered target from the tissue section. The transfer surface is activated from within the target to adhere the target to the transfer surface, for example by heating the target to adhere it to a thermoplastic transfer surface. Such in situ activation can be achieved by exposing the biological sample to an immunoreagent that specifically binds to the target (or a component of the target). The immunoreagent can alter the transfer surface directly (for example with a heat generating enzyme carried by the immunoreagent), or indirectly (for example by changing a characteristic of the target). In some embodiments, the immunoreagent deposits a precipitate in the target that increases its light absorption relative to surrounding tissue, such that the biological specimen can be exposed to light to selectively heat the target. Alternatively, the immunoreagent is an immunofluorescent agent that carries a fluorophore that absorbs light and emits heat.",47,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56966
7709202,4-May-10,2010,5,4,Molecular characteristics of non-small cell lung cancer,"We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation. The messages of two p53-regulated genes, p21WAF1/CIP1 and 14-3-3σ, were consistently under-expressed in the adenocarcinomas, suggesting that the p53 pathway itself might be compromised in this cancer type. Gene expression observed by SAGE were consistent with the results obtained by quantitative real-time PCR or cDNA array analyses using 43 additional lung tumor and normal samples. Thus, although derived from only a few tissue libraries, molecular signatures of non-small cell lung cancer derived from SAGE most likely represent an unbiased yet distinctive molecular signature for human lung cancer.",23,The Johns Hopkins University,Genzyne Corporation,The U.S.A. as represented by the Secretary of the HHS,,,,,,,,,3,Biotechnology,Biotechnology,,,,,C12Q/6886
7709252,4-May-10,2010,5,4,"Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use","Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/57492
7709609,4-May-10,2010,5,4,"Tumor suppressor gene, p47ING3","The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",28,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6886
7709626,4-May-10,2010,5,4,Primer for nucleic acid detection,"This application provides universal labeled primers for detection and amplification of nucleic acid molecules. These universal primers can be attached to the 5′-end of a target sequence-specific primer. In particular examples, the universal primer includes a labeled nucleotide flanked on both sides a nucleotide whose complement nucleotides changes a detectable signal from the label when the universal primer hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using the universal primer in nucleic acid amplification, such as real-time PCR.",25,"The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6818
7711171,4-May-10,2010,5,4,Estimation of the average propagator from magnetic resonance data,An average propagator is estimated from diffusion-weighted magnetic resonance data. Diffusion-weighted signal attenuation data is determined from the diffusion-weighted magnetic resonance data. Estimated average propagator data is determined from the diffusion-weighted signal attenuation data based on at least one of a priori information of the diffusion-weighted signal attenuation data or a priori information of the average propagator.,33,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56341
7711492,4-May-10,2010,5,4,Methods for diagnosing lymphoma types,"Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.",29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Biotechnology,,,,,C12Q/6886
7713529,11-May-10,2010,5,11,Methods for treating and preventing infectious disease,"Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.",13,University of Iowa Research Foundation,"Coley Pharmaceutical Group, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
7714122,11-May-10,2010,5,11,"Nucleic acid molecules and kits including VP1 and VP3 nucleic acid molecules, useful for detecting and identifying enteroviruses",Disclosed are methods of using enterovirus-specific primers for the detection and identification of enterovirus infection. Also provided are isolated nucleic acid molecules and kits useful for detection and diagnostic testing of enterovirus infection in a subject.,14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
7718196,18-May-10,2010,5,18,Rapamycin-resistant T cells and therapeutic uses thereof,"Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.",17,"The United States of America, as represented by the Department of Health and Human Services",The Trustees of the University of Pennsylvania,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/17
7718424,18-May-10,2010,5,18,AAV4 vector and uses thereof,"The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7719668,18-May-10,2010,5,18,Confocal fiber-optic laser device and method for intraocular lens power measurements,"A lens power measuring system has a light source and a fiber-optic light delivery system optically coupled to the light source to receive illumination light from the light source. The fiber-optic light delivery system has a transmit/receive end. The lens power measurement system also has a microscope objective optically coupled to the fiber-optic light delivery system through the transmit/receive end of the fiber-optic light delivery system, a movable mirror arranged to intercept at least a portion of light after having passed through the microscope objective, and an optical detection system optically coupled to the fiber-optic light delivery system to receive light after having been reflected from said movable mirror. The optical detection system is constructed to be able to determine a substantially maximum signal of light reflected from the movable mirror in correspondence with a relative position of the movable mirror to a lens to be measured. Methods of measurement include methods using such a lens system.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01M/0228
7722565,25-May-10,2010,5,25,Access system,"The invention provides systems and methods for providing access to a target site. Example systems may include a needle, a grid to guide the needle, a plate with an aperture, a member coupled to the plate and including a semispherical surface, and a hub slideably coupled to the plate by a guide. The system may also include a needle coupled to the hub, the needle including a magnetically trackable sensor positioned in a tip of the needle. The semispherical surface can be positioned against skin of a body and the hub slid relative to the plate along the guide to insert the needle through the aperture in the plate into the body until the tip reaches a target site. The hub can be locked by a lock mechanism when the tip of the needle reaches the target site, and an action performed on the target site through the needle.",23,"Traxtal, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Medical technology,,,,,,A61B/3403
7723022,25-May-10,2010,5,25,Immunostimulatory nucleic acid molecules,"Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.",7,University of Iowa Research Foundation,"Coley Pharmaceutical Group, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
7723096,25-May-10,2010,5,25,Agonist peptides of carcinoembryonic antigen (CEA) and nucleic acid sequences encoding the agonist peptides,"A nucleic acid molecule encoding an amino acid sequence consisting of an agonist of a MHC class I binding native sequence of CEA having an amino acid substitution and enhanced immunogenicity compared to the native sequence is described. A vector comprising the nucleic acid molecule, host cell comprising the vector and a kit comprising the encoded agonist peptide are also described.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70503
7723111,25-May-10,2010,5,25,Activated dual specificity lymphocytes and their methods of use,"The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0636
7723500,25-May-10,2010,5,25,Immunostimulatory nucleic acid molecules,"Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.",27,University of Iowa Research Foundation,The United States of America as represented by the Department of Health and Human Services,"Coley Pharmaceutical Group, Inc.",,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
7727532,1-Jun-10,2010,6,1,Human antibodies against rabies and uses thereof,"Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.",26,University of Massachusetts,Centers for Disease Control and Prevention,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/005
7727765,1-Jun-10,2010,6,1,Method for leak testing an environmental enclosure,"Methods and apparatus are disclosed for leak testing the ventilation system of an environmental enclosure using a gas that is naturally present in ambient air, such as nitrogen, oxygen, argon, or carbon dioxide, as a tracer gas. In one embodiment, a gas filter capable of filtering all of the tracer gas from the air flowing through the filter is installed in the ventilation system. Testing is performed by operating the ventilation system to cause outside air to flow through the filter and into the enclosure so as to establish positive pressurization inside the enclosure. A gas monitor placed inside the enclosure is used to detect for the presence of leaks in the ventilation system by monitoring the concentration of the tracer gas inside the enclosure.",15,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Measurement,,,,,,G01M/226
7728001,1-Jun-10,2010,6,1,Opioid receptor ligands and methods for their preparation,The invention provides novel compounds of formula I:that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. The invention also provides an improved method for isolating intermediate materials useful for obtaining compounds of formula I.,19,University of Iowa Research Foundation,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
7728123,1-Jun-10,2010,6,1,Internal control nucleic acid molecule for nucleic acid amplification systems,"The invention provides an internal control nucleic acid molecule including at least one forward primer binding site, at least one reverse primer binding site, and at least one amplifiable region, wherein the forward primer binding site, the reverse primer binding site, and the amplifiable region are all randomly generated. The invention also provides a kit that includes at least one internal control nucleic acid molecule of the invention, at least one forward primer, configured to be complementary to the forward primer binding site of the internal control nucleic acid molecule, and at least one reverse primer, configured to be complementary to the reverse primer binding site of the internal control nucleic acid molecule. The invention also provides methods of using the internal control nucleic acid molecules and kits of the invention.",35,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12Q/6851
7731953,8-Jun-10,2010,6,8,Methods for use of TSLP and agonists and antagonists thereof,"Methods are disclosed herein for specifically inducing proliferation of CD4+ T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with an effective amount of a thymic stromal derived lymphopoietin (TSLP) polypeptide or a therapeutically effective amount of nucleic acid encoding the TSLP polypeptide, thereby inducing proliferation of the T cells. Methods are also disclosed for treating an IgE mediated disorder, such as asthma. The methods include administering to a subject a therapeutically effective amount of a TSLP antagonist. Transgenic mice are also disclosed herein. The somatic and germ cells of these mice include a disrupted thymic stromal lymphopoietin receptor (TSLP) gene, the disruption being sufficient to inhibit the interaction of TSLP with its receptor, and a disrupted γc gene, the disruption being sufficient to reduce signaling through the γc. The mice exhibit diminished thymic cellularity. Methods of using these mice for drug screening are also disclosed.",9,The United States of America as represented by the Department of Health and Human Services,Whitehead Institute of Biomedical Research,,,,,,,,,,2,Pharmaceuticals,Biotechnology,Other special machines,,,,A61K/17
7731971,8-Jun-10,2010,6,8,Enhanced CTL epitope-containing HIV-1 reverse transcriptase polypeptides,The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.,27,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/1276
7732126,8-Jun-10,2010,6,8,Integrin CD18 is a novel stromal stem cell marker and functions to promote osteogenesis,"The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the HMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.",20,"University of Maryland, Baltimore",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C12N/0663
7734351,8-Jun-10,2010,6,8,Method and apparatus for assisting deglutition,"Methods and systems for artificially stimulating user deglutition without substantial aspiration are provided. Methods and systems include artificially stimulating user deglutition according to various specialized programs, including passive user secretion maintenance programs, active feeding programs, proprioceptive feedback programs, and others.",8,"Medtronic Xomed, Inc.",,,,,,,,,,,1,Medical technology,,,,,,A61N/36007
7741437,22-Jun-10,2010,6,22,"P. ariasi polypeptides, p. perniciosus polypeptides and methods of use","Substantially purified salivary P. ariasi and P. perniciosus polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the P. ariasi and P. perniciosus polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating or preventing Leishmaniasis are disclosed.",10,The United States of America as represented by the Department of Health and Human Services,Merial Limited,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/0003
7741465,22-Jun-10,2010,6,22,Chimeric receptor genes and cells transformed therewith,"Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.",20,Zelig Eshhar,Tova Waks,Gideon Gross,,,,,,,,,3,Biotechnology,Biotechnology,,,,,C07K/32
7744901,29-Jun-10,2010,6,29,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.",17,"MedImmune, LLC",National Institute of Health,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
7744902,29-Jun-10,2010,6,29,Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes,"Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are infectious and attenuated in humans and other mammals. Gene shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant RSV genome or antigenome wherein a gene or gene segment is shifted to a more promoter-proximal or promoter-distal position within the genome or antigenome compared to a wild type position of the gene in the RSV gene map. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene, depending on the nature and degree of the positional shift. In one embodiment, RSV glycoproteins are upregulated by shifting one or more glycoprotein-encoding genes to a more promoter-proximal position. Genes of interest for manipulation to create gene position-shifted RSV include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment that may be part of a gene or extragenic. A variety of additional mutations and nucleotide modifications are provided within the gene position-shifted RSV of the invention to yield desired phenotypic and structural effects.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C07K/005
7745144,29-Jun-10,2010,6,29,Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins,"The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X1 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention. The invention also relates to a method of inhibiting adhesion of a cell expressing α3β1 integrin to an extracellular matrix, inhibiting α3β1-integrin-mediated cell motility, inhibiting α3β1-integrin mediated cell proliferation, promoting α3β1-integrin mediated cell proliferation and inhibiting angiogenesis utilizing the peptides of the invention.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/06
7745188,29-Jun-10,2010,6,29,Thermostable Y-family polymerases and chimeras,"The present disclosure is related to thermostable Y-family polymerases, in particular several novel Y-family polymerases and chimeras made therefrom, as well as methods of identifying other Y-family polymerases, methods of generating other chimeric Y-family polymerases, methods of amplifying ancient or damaged DNA, and methods of incorporating fluorescent or modified nucleotides into a DNA molecule.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12P/34
7745212,29-Jun-10,2010,6,29,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
7745601,29-Jun-10,2010,6,29,"Nucleic acids encoding T2R, a novel family of taste receptors","The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors.",7,The Regents of the University of California,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7749700,6-Jul-10,2010,7,6,Differential expression of molecules associated with acute stroke,"Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
7749719,6-Jul-10,2010,7,6,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
7749967,6-Jul-10,2010,7,6,"Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods","Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.",15,The United States of America as represented by the Department of Health and Human Services.,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/4748
7749984,6-Jul-10,2010,7,6,Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors,A computer readable medium holding data of a molecular model of a ligand-gated ion channel receptor and/or a computer system for modeling said receptor are provided by the instant invention. The molecular model can be used to design novel compounds having activity as non-competitive inhibitors of the ion channel. A preferred embodiment of the invention relates to nicotinic acetylcholine receptors. Compounds having activity as non-competitive inhibitors of ligand-gated ion channel receptors and methods for inhibiting the receptor and treating diseases or disorders mediated by function of the receptor are also disclosed.,5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Computer technology,,,,A61K/43
7754227,13-Jul-10,2010,7,13,Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine,"This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0275
7754420,13-Jul-10,2010,7,13,Methods of using cyanovirins to inhibit viral infection,The present invention provides methods of treating a viral infection of a host using antiviral proteins (collectively referred to as cyanovirins).,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,A61K/164
7754676,13-Jul-10,2010,7,13,Defensin-antigen fusion proteins,"The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
7758855,20-Jul-10,2010,7,20,DNA promoters and anthrax vaccines,The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.,21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/32
7758876,20-Jul-10,2010,7,20,Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides,"The present disclosure relates to a method of preventing or treating an infection caused by a bioterrorism agent, specifically to a method of increasing an immune response to a bioterrorism agent using an oligodeoxynucleotide including a CpG motif, and a method of enhancing the immunogenicity of a vaccine against a bioterrorism agent using an oligodeoxynucleotide including a CpG motif.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/39
7759330,20-Jul-10,2010,7,20,21-substituted progesterone derivatives as new antiprogestational agents,"A compound having the general formula:in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.",38,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07J/00
7759477,20-Jul-10,2010,7,20,"HIV-1, HIV-2, and SIV pol nucleotide fragments","The invention relates to polypeptide fragments of HIV-1, HIV-2, and SIV, antibodies that bind to the polypeptides of the invention, methods of using the antibodies, and kits containing the antibodies. The invention also relates to polynucleotides that encode the polypeptide fragments of the invention.",20,Institut Pasteur,Institut National de la Sante et de la Recherche Medicale,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
7759643,20-Jul-10,2010,7,20,Single electrode corona discharge electrochemical/electrospray ionization,"A single electrode electrochemical/electrospray ionization source using a corona discharge and a method of analyzing a sample using a corona discharge single electrode electrochemical/electrospray ionization source are provided. In the corona discharge single electrode electrochemical/electrospray ionization technique electrons are removed from the metal tip of the device through gases present in the electrospray ion source resulting in electrochemical ionization of the sample of interest. The resulting odd electron sample cation (positive ion mode) or anion (negative ion mode) can then be analyzed by an appropriate technique, such as, for example, a mass spectrometer.",38,California Institute of Technology,The United States of America,,,,,,,,,,2,"Electrical machinery, apparatus, energy",,,,,,H01J/165
7763451,27-Jul-10,2010,7,27,Methods for preparing Bacillus anthracis protective antigen for use in vaccines,"The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.",30,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Pharmaceuticals,,,,C07H/04
7763586,27-Jul-10,2010,7,27,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
7763719,27-Jul-10,2010,7,27,Variants of humanized anti-carcinoma MAb CC49,The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.,23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/0002
7767645,3-Aug-10,2010,8,3,SH2 domain binding inhibitors,"Disclosed are compounds represented by the formula:or a pharmaceutically acceptable salt or isomer thereof, wherein R1-R6 are as defined in the specification. These compounds are targeted for use as inhibitors of SH2 domain binding with a phosphoprotein, and are contemplated for use in a number of diseases including cancer. Also disclosed are pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable carrier.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/021
7767800,3-Aug-10,2010,8,3,"Nucleic acids obtained from LAVMAL, a variant African AIDS virus","A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.",11,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/702
7771715,10-Aug-10,2010,8,10,Recombinant vector expressing multiple costimulatory molecules and uses thereof,"The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced antigen-presenting functions.",32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
7771729,10-Aug-10,2010,8,10,Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors,"This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7774143,10-Aug-10,2010,8,10,"Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states","A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.",35,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Computer technology,Biotechnology,,,,,G16B/00
7776292,17-Aug-10,2010,8,17,Method and apparatus for bioweapon decontamination,"The present disclosure relates to the decontamination of articles contaminated (or thought to be contaminated) with bioweapons, such as methods and apparatus for decontaminating articles contaminated with sporualated bioweapons. In some embodiments, the methods are methods of decontaminating an environment, for example a room or building contaminated with a bioweapon.",33,"CDIC, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,CDG Research Corporation,,,,,,,,,3,Medical technology,,,,,,A61L/20
7776521,17-Aug-10,2010,8,17,Coronavirus isolated from humans,"Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.",7,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7776607,17-Aug-10,2010,8,17,Mammalian selenoprotein differentially expressed in tumor cells,"A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.",7,The United States of America as represented by the Department of Health and Human Services,The Board of Trustees of the University of Illinois,,,,,,,,,,2,Biotechnology,,,,,,C07K/47
7776883,17-Aug-10,2010,8,17,"Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and AIDS related complex (ARC)","Novel quinoline inhibitors of retroviral integrase, particularly HIV-1 integrase. The quinoline inhibitors are oxoquinolines that can be used for preventing or treating AIDS or HIV infection in a subject.",42,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Analysis of biological materials,,,,C07D/04
7777019,17-Aug-10,2010,8,17,Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells,Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.,24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/2803
7777020,17-Aug-10,2010,8,17,Nucleotide sequences derived from the env gene of HIV-1,This invention encompasses an env nucleic acid product produced by a process comprising providing a sample containing HIV-1 nucleic acid and amplifying the nucleic acid using primer pairs.,9,Institut Pasteur,Institut National de la Sante et de la Recherche Medicale,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
7781183,24-Aug-10,2010,8,24,Inhibition of anthrax lethal factor protease,"Disclosed herein is a pharmacophore model for inhibiting anthrax lethal factor protease activity which comprises a first aromatic center A, a second aromatic center B, a first polar center C, a second polar center D, a third polar center E, and a neutral linker F. Also disclosed are small molecules fitting the pharmacophore model and compositions and methods of using thereof.",6,The United States of America as represented by the Secretary of the Army,,,,,,,,,,,1,Biotechnology,Computer technology,,,,,C12Q/18
7781413,24-Aug-10,2010,8,24,SEMA3B inhibits tumor growth and induces apoptosis in cancer cells,"The present invention identifies the semaphorin polypeptide SEMA3B as a tumor suppressor. This molecule can inhibit tumor growth and induce apoptosis of tumor cells when produced internally in a cancer cell via gene transfer, or when applied extracellularly. These observations permit new methods for treatment and diagnosis of cancer.",11,"Board of Regents, The University of Texas System",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/1709
7783431,24-Aug-10,2010,8,24,"Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states","A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Biotechnology,,,,,G16B/00
7785565,31-Aug-10,2010,8,31,Metal chelators and methods of their use,"Metal chelators of Formula I and Formula II are disclosed:    Also disclosed are metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of their preparation and use in diagnosis and/or treatment of diseases and conditions, including, inter alia, cancer and thrombosis.",1,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/22
7785814,31-Aug-10,2010,8,31,Method of detecting cancer based on immune reaction to BORIS,"The invention provides a method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising detecting antibodies to BORIS in a sample obtained from the mammal. The invention also provides BORIS polypeptides as well as compositions and kits comprising the BORIS polypeptides and methods of using the same. The invention further provides a method of inducing an immune response in a mammal using BORIS polypeptides.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/57407
7786162,31-Aug-10,2010,8,31,Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof,The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.,21,Raptor Pharmaceutical Corp.,National Institutes of Health (NIH),,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
7787106,31-Aug-10,2010,8,31,Particle image velocimetry system having an improved hollow-waveguide-based laser illumination system,"An illumination system for a particle image velocimetry system has an illumination source, a hollow tapered optical funnel arranged to receive illumination light from the illumination source, a hollow optical waveguide optically coupled to an output end of the hollow tapered optical funnel, and a beam shaping optical system optically coupled to an output end of the hollow optical waveguide. The illumination system is constructed to provide a light sheet to illuminate particles within a fluid under observation. A particle image velocimetry system has such an illumination system.",32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01P/20
7787930,31-Aug-10,2010,8,31,Adiabatic T2 preparation sequence for magnetic resonance imaging with reduced B1 sensitivity,"Adiabatic pulses that define an amplitude modulation and a frequency modulation are applied in a sequence of pulses to obtain a T2 weighted magnetic resonance image. Such an adiabatic T2 prep sequence typically includes a first 90° pulse, an even number of adiabatic pulses, and a second 90° pulse. Adiabatic pulses can be selected based on function pairs, or can be defined numerically. A magnetic resonance imaging (MRI) system includes a library of adiabatic pulse waveforms, and is configured to select a waveform and apply an RF magnetic field based on the selected pulse waveform.",30,The United States of America as represented by the Department of Health and Human Services,The Johns Hopkins University,,,,,,,,,,2,Measurement,Medical technology,,,,,G01R/5635
7790182,7-Sep-10,2010,9,7,Protein vaccines against poxviruses,"The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity. The invention also entails a vaccine protocol against poxvirus whereby a vaccine is vaccinated with a first vaccine made up of a nucleic acid vaccine of three or more poxvirus virus genes, and subsequently vaccinated with at least one other booster vaccine made up of two or more poxvirus virus proteins.",14,The United States of America as represented by the Secretary of the Army,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0019
7790463,7-Sep-10,2010,9,7,Methods of determining whether a pregnant woman is at risk of developing preeclampsia,"The present invention provides methods and compositions related to biomarker profiles for each trimester of pregnancy. The present invention also provides methods for identifying patients at risk of developing a complication of pregnancy, such as preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.",22,Yale University,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/689
7790473,7-Sep-10,2010,9,7,Biofunctionalized quantum dots for biological imaging,Novel biofunctionalized quantum dots include a mercaptoalkanoic acid linked to the surface of a nanocrystalline core and a bio-functional group linked to the surface. Biofunctionalized quantum dots are made by a novel synthesis method. Biofunctionalized quantum dots can be used in imaging or therapy applications.,4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,,,,,A61K/0052
7790735,7-Sep-10,2010,9,7,Methanocarba cycloalkyl nucleoside analogues,"The present invention provides novel nucleoside and nucleotide derivatives that are useful agonist or antagonists of P1 and P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloalkyl group. The compounds of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A2B, A3, P2Y2 receptors), cancer (through A3, P2 receptors), cardiac arrhythmias (through A1 receptors), cardiac ischemia (through A1, A3 receptors), epilepsy (through A1, P2X receptors), and Huntington's Disease (through A2A receptors).",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
7790764,7-Sep-10,2010,9,7,"Biologically active macrolides, compositions, and uses thereof","The present invention provides a compound of formula (II).The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/395
7794998,14-Sep-10,2010,9,14,Primate T-lymphotropic viruses,"Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.",23,Johns Hopkins University,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12Q/701
7795017,14-Sep-10,2010,9,14,DNA expression vectors and methods of use,"The present invention relates to novel plasmid constructs useful for the delivery of DNA vaccines. The present invention provides novel plasmids having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The present invention, however, is particularly useful for inducing in a patient an immune response against pathogenic viruses such as HIV, measles or influenza. Immunodeficiency virus vaccine inserts of the present invention express non-infectious HIV virus-like particles (VLP) bearing multiple viral epitopes. VLPs allow presentation of the epitopes to multiple histocompatability types, thereby reducing the possibility of the targeted virus escaping the immune response. Also described are methods for immunizing a patient by delivery of a novel plasmid of the present invention to the patient for expression of the vaccine insert therein. Optionally, the immunization protocol may include a booster vaccination that may be a live vector vaccine such as a recombinant pox virus or modified vaccinia Arbora vector. The booster live vaccine vector includes a transcription cassette expressing the same vaccine insert as the primary immunizing vector.",10,Emory University,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7795033,14-Sep-10,2010,9,14,Methods to predict the outcome of treatment with antidepressant medication,"The invention provides a method for determining the outcome of treatment with an antidepressant medication in a patient. In particular, the invention provides a method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication by obtaining a sample of genetic material from the patients, and then assaying the sample for the presence of a genotype which is associated with a decreased risk of non-response to treatment with antidepressant medication. The genotype is characterized by a polymorphism in the genes HTR2A, GRIK4, BCL2, and a combination thereof.",25,The United States of America as represented by the Department of Health and Human Services,"Board of Regents, The University of Texas System",,,,,,,,,,2,Biotechnology,,,,,,C12Q/6883
7795208,14-Sep-10,2010,9,14,Methods of using deacetylase inhibitors to promote cell differentiation and regeneration,"A method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis, and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of progenitor cell differentiation, or can be part of an organism, such as a human or other mammal. Contacting the progenitor cell with a DI can lead to enhancement of expression of terminal cell-type specific genes in the progenitor cell, such as enhancing expression of muscle-specific genes in myoblasts. Administering a DI to a subject also can provide some prophylactic or therapeutic effect for inhibiting, preventing, or treating associated with a degeneration or loss of tissue. The DI can be administered to a subject as part of a pharmaceutical composition.",45,The Salk Institute for Biological Study,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/165
7803380,28-Sep-10,2010,9,28,Compositions and methods for diagnosis and treatment of tumors,"Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.",63,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/2848
7803386,28-Sep-10,2010,9,28,Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli,"Immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacilli are provided that include immunogenic conjugates of a poly-γ-glutamic acid (γPGA) polypeptide of B. anthracis, or of another Bacillus that expresses a γPGA polypeptide. The γPGA conjugates elicit an effective immune response against B. anthracis, or against another Bacillus, in mammalian hosts to which the conjugates are administered.",42,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/32
7803565,28-Sep-10,2010,9,28,Use of lymphocytes to measure anthrax lethal toxin activity,"It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.",32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5047
7803614,28-Sep-10,2010,9,28,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MRT-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
7803913,28-Sep-10,2010,9,28,Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries,"The present invention provides a method of identifying novel broadly crossreactive neutralizing monoclonal antibodies using sequential antigen panning of phage display libraries, antibodies obtained in accordance with such a method, as well as fusion proteins and conjugates comprising same, and related isolated or purified nucleic acid molecules, vectors, host cells, compositions, and methods of use to inhibit an infection, reduce the severity of an infection, treat an infection, and inhibit cancer.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/1037
7805269,28-Sep-10,2010,9,28,Device and method for ensuring the accuracy of a tracking device in a volume,"The invention provides a system and method for testing and correcting the accuracy of a tracking device in a volume using an accuracy device. The invention may include placing a rigid object into an experimental volume and sampling position and orientation information regarding one or more position indicating elements at known positions relative to a frame of reference of the tracking device. The position and orientation information may then be compared to known baseline position and orientation information. If a difference between the experimental position and orientation information and the baseline position and orientation information exceeds a predetermined threshold, a correction map enabling adjustment of the tracking device to correct for the distortion in the experimental volume may be generated, and the tracking device may be adjusted accordingly.",32,Philips Electronics Ltd,,,,,,,,,,,1,Medical technology,Medical technology,,,,,A61B/36
7807472,5-Oct-10,2010,10,5,Methods for separation and detection of ketosteroids and other carbonyl-containing compounds,"Methods for enhancing detection by mass spectroscopy (MS) and/or chromatographic separability of carbonyl-containing compounds such as steroids are disclosed. Reaction of a carbonyl compound with a sulfonhydrazide compound provides a sulfonhydrazone with enhanced ionization efficiency during the electrospray ionization process. In a particularly disclosed embodiment, derivatization of catechol estrogens with p-toluenesulfonhydrazide enhances both detection by atmospheric pressure ionization-MS (API-MS), such as electron spray ionization-MS (ESI-MS) and separation by liquid chromatography (such as HPLC) under reverse phase conditions. In yet other embodiments, the sulfonhydrazone is further reacted with a sulfonyl halide under alkaline conditions to derivatize hydroxyl groups in the compound. Prior formation of the sulfonhydrazide derivative protects the carbonyl bond of the compound during subsequent alkaline reaction with the sulfonyl halide.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/743
7807805,5-Oct-10,2010,10,5,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/47
7811439,12-Oct-10,2010,10,12,Concentration and separation of biological organisms by ultrafiltration and dielectrophoresis,"Disclosed is a method for monitoring sources of public water supply for a variety of pathogens by using a combination of ultrafiltration techniques together dielectrophoretic separation techniques. Because water-borne pathogens, whether present due to “natural” contamination or intentional introduction, would likely be present in drinking water at low concentrations when samples are collected for monitoring or outbreak investigations, an approach is needed to quickly and efficiently concentrate and separate particles such as viruses, bacteria, and parasites in large volumes of water (e.g., 100 L or more) while simultaneously reducing the sample volume to levels sufficient for detecting low concentrations of microbes (e.g., <10 mL). The technique is also designed to screen the separated microbes based on specific conductivity and size.",11,Sandia Corporation,,,,,,,,,,,1,Chemical engineering,,,,,,B01D/145
7811998,12-Oct-10,2010,10,12,Novobiocin analogues as anticancer agents,"Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.",18,University of Kansas,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07H/075
7812117,12-Oct-10,2010,10,12,Vasostatin as marrow protectant,"Specific fragments of vasostatin are disclosed. These fragments are of use in methods of stimulating the proliferation or survival of a hematopoietic cell exposed to a chemotherapeutic agent or irradiation. Methods of stimulating the proliferation or survival of a hematopoietic cell using these fragments are also disclosed. In one embodiment, methods are disclosed for stimulating the growth or survival of a hematopoietic stem cell with a fragment of vasostatin, in the presence of a growth factor.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4725
7815916,19-Oct-10,2010,10,19,Cloning and expression of HTLV-III DNA,"The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.",78,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/702
7816087,19-Oct-10,2010,10,19,Gene expressed in prostate cancer and methods of use,"A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specfically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharamaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
7820174,26-Oct-10,2010,10,26,T cell receptors and related materials and methods of use,"The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/70503
7820181,26-Oct-10,2010,10,26,Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens,"Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7820182,26-Oct-10,2010,10,26,"Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions","Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in immunogenic compositions for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete “background” RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. Genes of interest include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment including a protein or portion thereof. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
7820385,26-Oct-10,2010,10,26,Method for retaining methylation pattern in globally amplified DNA,"A method for preserving information about cytosine methylation status in amplified nucleic acid molecules is disclosed. The method includes contacting a sample that contains nucleic acid molecules, such as nucleic acid molecules having or suspected of having methylated cytosines, with a modifying agent that converts the unmethylated cytosines to produce converted nucleic acid molecules. The converted nucleic acid molecule retains information about cytosine methylation. The method further involves contacting the sample with a DNA polymerase to amplify the converted nucleic acid molecules by multiple strand displacement amplification. The sample is not contacted with a nucleic acid ligase or an RNA polymerase. Also disclosed are methods for detecting cytosine methylation in a sample. Such methods include detecting the presence of the signature of cytosine methylation in a bisulfite treated DNA sample that has been amplified by multiple strand displacement.",32,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/686
7820642,26-Oct-10,2010,10,26,Nandrolone 17β-carbonates,"Disclosed are compounds of the formula (I)wherein R is C1-C30 alkyl, which may be optionally further substituted with one or more of C5-C8 cycloalkyl groups, or a C5-C12 cycloalkyl, which may be optionally substituted with one or more C1-C30 alkyl groups, R′ is hydrogen or lower alkyl, R″ is a C1-C30 alkyl or halo, and the bond between C14 and C15 can be a single bond or double bond. Also disclosed are pharmaceutical compositions comprising such compounds and methods of use thereof. These compounds can find use in treating a number of diseases or conditions such as hypogonadism, osteoporosis, and anemia, in providing hormonal therapy and contraception, as an anabolic agent, and in suppressing the release of hormones such as the luteinizing hormone.",62,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07J/0074
7824660,2-Nov-10,2010,11,2,Nanotubes for cancer therapy and diagnostics,"The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.",8,,,,,,,,,,,,,Pharmaceuticals,Micro-structural and nano-technology,,,,,A61K/0095
7824681,2-Nov-10,2010,11,2,Human monoclonal antibodies that specifically bind IGF-II,"Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation constant (Kd) of 1 mM or greater. The antibodies inhibit phosphorylation of the insulin-like growth factor receptor. Nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and isolated host cells that express the nucleic acids are also disclosed. The antibodies can be used to detect human IGF-II in a sample. Methods of diagnosing a tumor are disclosed herein that utilize these antibodies. Methods of treating a subject with a tumor are also disclosed.",31,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57484
7824682,2-Nov-10,2010,11,2,Cardiac myosin light chain kinase-specific antibodies and methods of detecting,"The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.",32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/1205
7824695,2-Nov-10,2010,11,2,Delivery of proteins across polar epithelial cell layers,"This invention provides bioactive conjugates. The bioactive conjugates include: (1) a cell recognition moiety that binds to α2 macroglobulin receptor α2-MR and (2) a bioactive moiety which: (a) has a biological activity, (b) does not function solely as an immunogen to invoke an immune response and (c) does not have ADP ribosylating activity. The bioactive conjugates of this invention are useful in methods of transporting the bioactive moiety across a polar epithelial membrane. Thus, this invention provides methods for parenteral administration of proteins without injection.",30,The United States of America as represented by the Department of Health and Human Services,"Genentech, Inc.",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/6425
7825096,2-Nov-10,2010,11,2,O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs,"Disclosed are prodrugs of inactivators of O6-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the β-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrugs are represented by the formula A-B-C, wherein A is a glucuronosyl residue linked through its 1-oxygen to the phenyl ring of B; B is a benzyloxycarbonyl group, optionally ring-substituted with one or more electron withdrawing groups; and C is an inactivator of AGT, e.g., a substituted or unsubstituted O6-benzylguanine or O6-benzyl-2′-deoxyguanosine. Also disclosed are additional inactivators of AGT, pharmaceutical compositions comprising an inactivator or prodrug and a pharmaceutically acceptable carrier, and a method of use of the inactivator or prodrug in enhancing the chemotherapeutic treatment of tumor cells in a mammal, e.g., a human, with an antineoplastic alkylating agent that causes cytotoxic lesions at the O6-position of guanine.",6,The United States of America as represented by the Department of Health and Human Services,The Penn State Research Foundation,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/18
7825126,2-Nov-10,2010,11,2,Purine derivatives as A3 and A1 adenosine receptor agonists,"Disclosed are (N)-methanocarba adenine nucleosides of the formula:as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.",57,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/00
7825154,2-Nov-10,2010,11,2,Small molecule inhibitors of botulinum neurotoxins,"Disclosed herein are methods of inhibiting the activity of Botulinum neurotoxin A metalloprotease with the compounds disclosed herein. Also disclosed are methods of treating, inhibiting or preventing intoxication caused by bacteria of at least one bacterial strain in a subject, and pharmaceutical and cosmetic compositions comprising the compounds disclosed herein.",13,The United States of America as represented by the Secretary of the Army,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/4184
7825216,2-Nov-10,2010,11,2,Phenylanine derivatives,"The present invention provides phenylalanine derivatives that inhibit SH2 domain binding with a phosphoprotein. These derivatives include compounds of the formula: W—Y-(AA)n-Z wherein n is 0 to 15; Y is a phenylalanyl radical having a phenyl ring, an amine end, and a carboxyl end, the phenyl ring having one or more substituents, e.g., hydroxyl, carboxyl, formyl, carboxyalkyl, carboxyalkyloxy, dicarboxyalkyl, dicarboxyalkyloxy, dicarboxyhaloalkyl, dicarboxyhaloalkyloxy, and phosphonoalkyl, or phosphonohaloalkyl; W is a moiety attached to the nitrogen of Y and is, e.g., alkylcarbonyl, oxalyl, alkylaminooxalyl, arylaminooxalyl, arylalkylaminooxalyl, or alkoxyoxalyl; AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and Z is an arylalkylamino or arylheterocyclyl alkylamino; or a salt thereof; with the proviso that W is not arylalkylamino when the phenyl ring of phenylalanyl contains a phosphonoalkyl or phosphonohaloalkyl substituent at a position para to the alkylamido group and the ortho and meta positions are unsubstituted. The present invention further provides precursors suitable for preparing the phenylalanine derivatives and a method for the preparation of the precursors. The present invention further provides conjugates comprising a precursor and a conjugant that are covalently linked. These conjugates have biological and/or pharmacological properties.",15,The United States of America as represented by the Department of Health and Human Services,Georgetown University,,,,,,,,,,2,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C07K/0819
7829102,9-Nov-10,2010,11,9,"Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines",Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete “background” RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome.,7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7833754,16-Nov-10,2010,11,16,IL-12 for expression in mammalian cell,The present invention provides for nucleic acids improved for the expression of interleukin-12 (IL-12) in mammalian cells. The invention further provides for methods of expressing IL-12 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-12 sequence.,18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/5434
7834005,16-Nov-10,2010,11,16,"Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto","Disclosed are compounds of Formula Iwherein X, Y, R1-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula I and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula I; a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula I; a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula I; and a method of preparing a compound of Formula I as described herein.",25,The United States of America as represented by the Department of Health and Human Services,"Starks Associates, Inc.",Midwest Research Institute,"Spirogen, Ltd.",,,,,,,,4,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
7835783,16-Nov-10,2010,11,16,Magnetic resonance imaging methods and apparatus for time-series motion tracking with inversion recovery compensation,"Image contributions produced by an untagged specimen magnetization component in magnetic resonance imaging are controlled by applying one or more radiofrequency (RF) pulses that invert at least a portion of the untagged specimen magnetization. In an example, a specimen is tagged with a spatially modulated magnetization that is used to produce an image signal that includes a contribution associated with the tagged magnetization and an untagged magnetization. The untagged magnetization is substantially along an axial direction defined by an applied axial magnetic field. The untagged magnetization increases in magnitude because of so-called T1 relaxation. A contribution to the image signal increases for a predetermined time or to a predetermined magnitude, and a 180-degree pulse is applied to invert at least a portion of the untagged magnetization. The untagged magnetization is then antiparallel with respect to the applied axial magnetic field. Additional inversion recovery causes the untagged magnetization to increase from a negative value to zero and then becomes positive. As a result, signal contributions associated with the untagged magnetization are reduced. Additional 180-degree pulses can be applied whenever the untagged magnetization becomes larger than a predetermined value so that image contrast can be maintained. When the tagged magnetization decreases to a predetermined level, an initial specimen magnetization is reestablished for subsequent imaging.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56333
7838216,23-Nov-10,2010,11,23,Human gene related to but distinct from EGF receptor gene,"The isolation, cloning and characterization of a human gene related to but distinct from EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of the nucleic acid probes and antibodies having specific binding affinity with said polypeptide for diagnostic and therapeutic purposes have also been described.",15,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/71
7838222,23-Nov-10,2010,11,23,"Methods, devices and kits for multiplex blotting of biological samples from multi-well plates","The present disclosure provides methods, devices and kits that permit large numbers of target biomolecules to be detected simultaneously in samples originating from a multi-sample holder, such as a multi-well plate. One specific example method is a method of making multiple substantial replicas of a biomolecular content of a multi-well sample holder. Devices and kits for carrying out the described methods are also provided.",25,United States of America/ NIH,"20/20 Genesystems, Inc.",,,,,,,,,,2,Analysis of biological materials,Chemical engineering,,,,,G01N/6845
7838305,23-Nov-10,2010,11,23,Autoantibody detection for cancer diagnostics,"The present invention relates to compositions and methods for the detection of anti-ECPKA autoantibodies in a biological sample, and to the use of such compositions and methods in the diagnosis of cancer in humans and non-human mammals.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/574
7838531,23-Nov-10,2010,11,23,"Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis","Although it can be farnesylated, the mutant lamin A protein expressed in Hutchison Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors.",11,The United States of America as represented by the Department of Health and Human Services,The Regents of the University of Michiga,"Progeria Research Foundation, Inc.",The University of North Carolina at Chapel Hill,,,,,,,,4,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/4545
7838645,23-Nov-10,2010,11,23,Function of autophagy genes in cell death,"The present invention relates to a new molecular pathway in which activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy. Further, autophagic death is induced by caspase 8 inhibition and expression of the mammalian genes ATG7 and beclin.",2,University of Maryland College Park,National Institutes of Health,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/1137
7842729,30-Nov-10,2010,11,30,Anti tubercular drug: compositions and methods,"Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.",24,The United States of America as represented by the Department of Health and Human Services,"Sequella, Inc.",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07C/25
7842786,30-Nov-10,2010,11,30,Mammalian sweet and amino acid heterodimeric taste receptors comprising T1R3 and T1R1,"The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising T1R3 and T1R1, two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.",28,Regents of the University of California,"United States of America, NIH",,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/5076
7842798,30-Nov-10,2010,11,30,"Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines","Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. In preferred aspects of the invention, chimeric RSV incorporate a partial or complete bovine RSV background genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a human RSV. A variety of additional mutations and nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.",15,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7846450,7-Dec-10,2010,12,7,Melanoma associated peptide analogues and vaccines against melanoma,"The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.",3,"United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
7846454,7-Dec-10,2010,12,7,Cloned genomes of infectious hepatitis C viruses and uses thereof,"The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7846455,7-Dec-10,2010,12,7,Attenuated chimeric respiratory syncytial virus,"Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV backround of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.",11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
7847078,7-Dec-10,2010,12,7,PDE11A mutations in adrenal disease,"The invention provides previously uncharacterized variants of PDE11A that are correlated with a newly discovered form of Cushing Syndrome that presents at a young age. The invention also provides methods useful to research, screen for, treat, or prevent diagnose the disease using the PDE11A variants, as well as other methods relating thereto.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6893
7851143,14-Dec-10,2010,12,14,Assays for diagnosing and evaluating treatment options for Fabry disease,Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.,10,"Amicus Therapeutics, Inc.",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,,A61K/445
7851194,14-Dec-10,2010,12,14,West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines,"The invention provides West Nile (WN) viruses and chimeric WN viruses having one or more mutations in the 3′ terminal stem loop secondary structure (3′SL) that results in decreased neurovirulence, methods of making such WN viruses, and methods for using these WN viruses to prevent or treat WN virus infection.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/12
7854899,21-Dec-10,2010,12,21,Template methods and devices for preparing sample arrays,"A method for preparing a microarray that includes placing at least one template over a first surface of the recipient block, wherein the template defines an array of openings and the recipient block has a plurality of receptacle holes, such that the array of openings are aligned with the plurality of receptacle holes. A needle or punch that contains a sample is inserted through the openings of the template. The sample then is inserted into the receptacle hole in the recipient block. A device is also disclosed that includes a platform defining (i) a first surface, and (ii) a first region configured to retain at least one recipient block; and a raised template defining an array of openings, secured to the first surface of the platform and positioned above the first region configured to retain the recipient block.",16,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Organic fine chemistry,,,,,B01J/0046
7855076,21-Dec-10,2010,12,21,Use of discoidin domain receptor 1 (DDR1) and agents that affect the DDR1/collagen pathway,"The disclosure provides methods of modulating the activity of DDR1. Methods for screening for agents that activate DDR1 are disclosed. Methods for inducing the maturation of immature macrophages and immature dendritic cells are also disclosed. In addition, methods for increasing neutrophil activation using a DDR1 activating agent, and methods for increasing leukocyte migration using a DDR1 activating agent, are provided.",26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/001102
7855276,21-Dec-10,2010,12,21,Framework residue substituted humanized COL-1 antibodies and their use,"The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.",47,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/3007
7862815,4-Jan-11,2011,1,4,Methods for inhibiting angiogenesis with inhibitors of proadrenomedullin N-terminal 20 peptide (PAMP),"The present disclosure concerns the use of peptides and compositions, such as pharmaceutical compositions, to influence angiogenesis. Particular methods are useful for promoting angiogenesis, while others are particularly useful for inhibiting angiogenesis.",13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,G01N/74
7863041,4-Jan-11,2011,1,4,Rabies virus vector systems and compositions and methods thereof,"Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.",19,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7863247,4-Jan-11,2011,1,4,Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides,"The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.",21,Ramot-University Authority for Applied Research and Development Ltd.,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/18
7863262,4-Jan-11,2011,1,4,Nitroxyl progenitors in the treatment of heart failure,"Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.",18,Johns Hopkins University,The United States of America as represented by the Department of Health and Human Services,The Regents of the University of California,The Board of Supervisors of Louisiana State University and Agriculture and Mechanical College,,,,,,,,4,Pharmaceuticals,,,,,,A61K/655
7867245,11-Jan-11,2011,1,11,Venous filters,"Venous filters having at least two struts (110) each having a connected end and a non-connected end, wherein each of the struts includes a strut portion and an anchor portion (116), and wherein the strut portion and the anchor portion are attached via an electrolytically active thread (221, 222); and a head (118) that connects the connected ends of the struts, wherein the strut portion can be separated from the anchor portion at least in part by the application of an electrical current. The invention also includes a venous filter having at least two struts, wherein each of the struts includes a temperature sensitive portion and an anchor portion; wherein the anchor portion is separated from the temperature sensitive portion at least in part by changing the temperature around at least the temperature sensitive portion. Also included is a venous filter having a web (650) of dissolvable material; and at least two anchors (618), wherein the at least two anchors are configured to retain the web within a mammalian blood vessel.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61F/01
7867500,11-Jan-11,2011,1,11,Cofactor that modulates steroid receptor activities,"The invention provides a new glucocorticoid receptor coactivator named STAMP (Steroid receptor coactivator-1 and Transcription intermediary factor-2 Associated Modulatory Protein) that can modulate transcription of glucocorticoid-, progesterone-, mineralocorticoid- and androgen-responsive genes. The invention also provides antibodies that can bind STAMP and modulate its activity. In addition, the invention provides antisense, ribozyme and siRNA STAMP nucleic acids that can modulate the expression of STAMP. Also provided are compositions and methods for modulating glucocorticoid-responsive gene expression and for treating a variety of diseases and conditions.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4702
7867974,11-Jan-11,2011,1,11,Induction of tolerance by oral administration of factor VIII and treatment of hemophilia,"Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.",20,The United States of America as represented by the Department of Health and Human Services,"Virginia Tech Intellectual Properties, Inc.",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/36
7867977,11-Jan-11,2011,1,11,Immunogenic peptides and methods of use for treating and preventing cancer,"Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4+ and CD8+ T cells, and methods of treating or preventing cancer are further provided herein.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70539
7867982,11-Jan-11,2011,1,11,"MVA expressing modified HIV envelope, gag, and pol genes","The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.",2,Emory University,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/21
7868150,11-Jan-11,2011,1,11,Nucleic acids encoding T2R taste receptors,"The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.",18,The Regents of the University of California,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/74
7871777,18-Jan-11,2011,1,18,Probe for nucleic acid sequencing and methods of use,"A nanoprobe for sequencing of nucleic acid molecules is provided, as well as methods for using the nanoprobe. In particular examples, the probe includes a polymerizing agent and one or more molecular linkers that carry a chemical moiety capable of reversibly binding to the template strand of a nucleic acid molecule, without being detached from the linker, by specifically binding with a complementary nucleotide in the target nucleic acid molecule. The reversible binding of the chemical moiety on the linker with a complementary nucleotide in the target nucleic acid molecule is indicated by emission of a characteristic signal that indicates pairing of the chemical moiety on the linker with its complementary nucleotide. An example of such a chemical moiety is a nonhydrolyzable nucleotide analog. In particular examples, the polymerizing agent and the chemical moiety are associated with a tag, such as a donor fluorophore and acceptor fluorophore characteristic of the particular type of chemical moiety.",69,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/542
7871779,18-Jan-11,2011,1,18,Molecular identification of Aspergillus species,"Novel techniques for the detection of Aspergillus in samples are disclosed. These techniques relate to PCR amplification and/or detection of Aspergillus ITS1 rDNA sequences, and the identification of particular species of Aspergillus by detecting differences in the ITS1-V1, ITS-V2, ITS-V3, ITS-V4, and ITS-V5 nucleic acid sequences of Aspergillus. The highly variable regions of the ITS1 rDNA sequences are particularly useful in distinguishing, for example, Aspergillus clavatus, Aspergillus granulosus, Aspergillus sydowii, Aspergillus flavipes, Aspergillus restrictus, Aspergillus versicolor, Aspergillus wentii, and Aspergillus chevalieri. In particular embodiments, the sequence differences are also able to distinguish among variants of particular species, such as Aspergillus granulosus CBS 119.5A, Aspergillus granulosus strain NRRL 1932, Aspergillus sydowii strain NRRL 250, Aspergillus sydowii strain NRRL 4768, Aspergillus sydowii strain CUHI, Aspergillus sydowii strain CUH2, Aspergillus sydowii strain CUH7, and Aspergillus sydowii strain CUH8.",19,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
7871790,18-Jan-11,2011,1,18,Anthrax bioassays and methods of treating and diagnosing anthrax infection,"Based on the observation that exposure of cells or animals to anthrax lethal toxin results in activation of the intracellular enzyme caspase-1/IL-1 converting enzyme (ICE), which, in turn, leads to production and extracellular release of the cytokine substrates of ICE: interleukin 1 beta (IL-1β) and interleukin 18 (IL-18), disclosed herein are bioassays that can be used to determine the efficacy of a potential anthrax therapeutic agent and for screening test agents to identify anthrax therapeutic agents. Also disclosed herein are methods of diagnosing and treating anthrax infection.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/18
7871981,18-Jan-11,2011,1,18,"Inhibition of cell motility, angiogenesis, and metastasis","Disclosed are methods of inhibiting cell motility, for example, by inhibiting the binding between an intracellular transducer and a receptor protein tyrosine kinase, and more particularly by inhibiting hepatocyte growth factor (HGF) induced cell motility. The present invention also provides a method of inhibiting angiogenesis. The methods of the present invention employ peptides such as phosphotyrosyl mimetics. Also disclosed are methods of preventing and/or treating diseases, disorders, states, or conditions such as cancer, particularly metastatic cancer, for example, melanoma or prostate cancer, comprising administering to a mammal of interest one or more peptides of the present invention. Also disclosed are methods of blocking blocks HGF, VEGF, or bFGF-stimulated migration, cell proliferation, and formation of capillary-like structures.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/0819
7871986,18-Jan-11,2011,1,18,Methods of stimulating an immune response against prostate specific antigen,"The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus.",38,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/001194
7875450,25-Jan-11,2011,1,25,Virus-like particles for the induction of autoantibodies,"The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7879551,1-Feb-11,2011,2,1,"Methods and materials for identifying polymorphic variants, diagnosing susceptibilities, and treating disease","The invention is directed to materials and methods associated with polymorphic variants in two enzymes involved in folate-dependent and one-carbon metabolic pathways: MTHFD1 (5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase, 10-formyltetrahydrofolate synthetase) and methylenetetrahydrofolate dehydrogenase (NADP+dependent) 1-like (MTHFD1L). Diagnostic and therapeutic methods are provided involving the correlation of polymorphic variants in MTHFD1, MTHFD1, and other genes with relative susceptibility for various pregnancy-related and other complications.",2,The United States of America as represented by the Department of Health and Human Services,The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin,The Health Research Board,,,,,,,,,3,Analysis of biological materials,Biotechnology,,,,,G01N/689
7880466,1-Feb-11,2011,2,1,Spectrally selective suppression with steady-state free precession,"A method for fat-suppressed imaging is disclosed. Such a method may include storing a first spectral component of an echo signal formed at TR/2 from a sample, suppressing a second spectral component of the echo signal at TR/2, re-exciting the stored spectral component after suppressing the second spectral component, and producing an image of the sample based on the re-excited stored spectral component.",18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/5613
7883710,8-Feb-11,2011,2,8,Peptide vaccines against Group A streptococci,"This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/092
7884178,8-Feb-11,2011,2,8,"Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use","An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral polypeptide or conjugate or fusion protein thereof. Further provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host.",6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/14
7887812,15-Feb-11,2011,2,15,Live attenuated Leishmania vaccines,"Targeted disruption of the centrin gene leads to attenuation of growth in Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of immunological and diagnostic reagents. Other preferred embodiments provide related immunogenic compositions, methods of generating an immune response, methods for producing a vaccine, and methods of forming attenuated strains of Leishmania.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/008
7888003,15-Feb-11,2011,2,15,Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein,"This invention relates to compositions and methods for the detection of HIV-1 antibodies employing polypeptides obtained from the Gag-p6 protein, the method comprising the steps of: (a) contacting a biological sample with a peptide having an epitope that is recognized by the anti-HIV-1 antibody where the contacting is under conditions sufficient to permit anti-HIV-1 present in the sample to bind to the epitope and form a peptide-anti-HIV-1 antibody complex; (b) contacting the formed peptide-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule under conditions sufficient to permit the anti-HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed peptide-anti-HIV-1 antibody complex and form an extended complex; said extended complex being immobilized on a solid support; and (c) removing unbound antibody from said extended complex; and (d) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentration of the formed extended complex.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/6854
7888043,15-Feb-11,2011,2,15,Modified cardiolipin and uses therefor,"Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies in subjects, for example, when used in lateral flow devices. Lateral flow devices are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.",16,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/571
7888045,15-Feb-11,2011,2,15,Methods for identifying modulators of SF taste receptor signaling,"The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors.",13,The Regents of the University of California,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
7888070,15-Feb-11,2011,2,15,Nucleic acids encoding growth hormone with a modified RSP sorting signal,"The invention provides a nucleic acid molecule encoding a growth hormone (GH) in which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides a nucleic acid molecule encoding a GH in which the three-dimensional conformation of the RSP sorting signal has been altered such that the GH can be constitutively secreted by the NRSP in a mammalian cell.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/61
7888116,15-Feb-11,2011,2,15,"Uses of notch receptors, notch ligands, and notch modulators in methods related to metabolic diseases","Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic B-cell. Further, disclosed are methods of improving pancreatic B-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or preventing a metabolic disease in a subject, and to compositions for treating or preventing a metabolic disease in a subject in need of such treatment or prevention.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6893
7888327,15-Feb-11,2011,2,15,Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions,"Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.",9,University of Iowa Research Foundation,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
7889954,15-Feb-11,2011,2,15,Optical fiber-mounted porous photonic crystals and sensors,"An embodiment of the invention is a remote sensor that has an optical fiber terminating in a tip. A thin film porous particle having a characteristic optical response that changes in the presence of an analyte is optically coupled and physically attached to the tip of the optical fiber. The optical response of the particle changes in the presence of analyte, and the particle also serves to concentrate analyte. The thin film porous particle can be functionalized toward sensitivity for a predetermined analyte or analytes. A method of remote sensing exposes the remote sensor to an environment to be monitored for analyte. The thin film porous particle is probed with a beam of light. Reflected light is monitored through the optical fiber for a shift in frequency or intensity.",17,The Regents of the University of California,,,,,,,,,,,1,Measurement,,,,,,G01N/7703
7892569,22-Feb-11,2011,2,22,Methods of altering an immune response induced by CpG oligodeoxynucleotides,It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided.,26,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
7892738,22-Feb-11,2011,2,22,Pot1 alternative splicing variants,The present invention provides methods an compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk of developing a colorectal carcinoma.,9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
7892786,22-Feb-11,2011,2,22,Methods for expression and purification of immunotoxins,"The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.",37,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/18
7892847,22-Feb-11,2011,2,22,Method and apparatus for countercurrent chromatography,"A countercurrent chromatography apparatus includes a plurality of plates, at least one plate (16) having first and second interleaved spiral flow channels (52, 54, 56, 58) therein. Each spiral flow channels (52, 54, 56, 58) has a first end (I1, I2, I3, I4) near the central axis and a second ends (O1, O2, O3, O4) near the periphery. The outlet of the first channel (O1) is connected to the inlet of the second channel (I2) by a connecting channel (72). Septa may be provided between the plates to connect the spiral channels of one plate to the spiral channels of the next plate.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Chemical engineering,Measurement,,,,,B01D/1892
7893094,22-Feb-11,2011,2,22,"Amphiphilic pyridinium compounds, method of making and use thereof","The present invention is directed to the amphiphilic pyridinium compounds, such as for suppressing IL-8 secretion and production. The present invention further provides methods of making and using such compounds for the treatment of the IL-8 related diseases, such as cystic fibrosis.",14,"The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.",National Institutes of Health (NIH),,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/20
7894055,22-Feb-11,2011,2,22,"Flow-through, inlet-gas-temperature-controlled, solvent-resistant, thermal-expansion compensated cell for light spectroscopy","Optical cells include a spacer formed of a hydrocarbon-resistant polymer, so that fluids such as hydrocarbons and alcohols can be introduced to a sample space, or include a fluid inlet and a heated inlet tube, so that a humid gas can be introduced to the sample space without condensation occurring. Optical cells can be used with, for example, solid, gel, and liquid samples. Measurements can be performed with various selected sample gaps of an optical cell.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/05
7897152,1-Mar-11,2011,3,1,Viral chemokine-antigen fusion proteins,"The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.",32,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/521
7897355,1-Mar-11,2011,3,1,Gene expressed in prostate cancer and methods of use,"A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
7897575,1-Mar-11,2011,3,1,Treatment and prevention of vascular dementia,The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.,18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0043
7901881,8-Mar-11,2011,3,8,Diagnostic tool for diagnosing benign versus malignant thyroid lesions,The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.,36,The United States of America as represented by the Department of Health and Human Services,The John Hopkins University,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/57407
7902228,8-Mar-11,2011,3,8,Schweinfurthin analogues,"Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.",21,University of Iowa Research Foundation,"The United States of America, National Institute of Health",,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/80
7902348,8-Mar-11,2011,3,8,Janus family kinases and identification of immune modulators,"An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1205
7902441,8-Mar-11,2011,3,8,Chromosome 3p21.3 genes are tumor suppressors,"Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.",35,"Board of Regents, The University of Texas",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Other special machines,Pharmaceuticals,,,,C12N/86
7906283,15-Mar-11,2011,3,15,Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication,"The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.",4,The United States of America as represented by the Department of Health and Human Services,"Board of Regents, the University of Texas System",,,,,,,,,,2,Biotechnology,,,,,,C12Q/6883
7906292,15-Mar-11,2011,3,15,Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use,"Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glyco-protein cross-reactive epitopes and flavivirus E-glycoprotein crossreactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.",10,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
7906965,15-Mar-11,2011,3,15,Methods and apparatuses for estimating the elliptical cone of uncertainty,A magnetic resonance imaging scanner acquires diffusion-weighted imaging data. A reconstruction engine reconstructs the acquired diffusion-weighted imaging data into diffusion-weighted image representations. A diffusion tensor engine constructs a diffusion tensor map of an area of an interest of a subject. An eigenvalue/eigenvector ordering engine obtains and orders eigenvectors and eigenvalues at each voxel. A covariance matrix determining engine constructs a covariance matrix of a major eigenvector of each voxel. A first normalized measure determining engine computes a first normalized measure. A second normalized measure determining engine computes a second normalized measure. A rendering engine generates a human-viewable display of an image representation.,18,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01R/56341
7907999,15-Mar-11,2011,3,15,Apparatus and method for measuring physiological characteristics of an intact trachea in vitro,"Apparatus and methods for measuring smooth muscles responses (relaxation and contraction), transepithelial potential difference, and/or transepithelial impedance of an intact trachea in vitro. In particular embodiments, the apparatus includes a perfusion device on which an extracted, intact trachea is mounted. The perfusion device and the trachea are immersed in an extraluminal bath, which is isolated from the perfusion liquid flowing through the trachea. A set of voltage-sensing electrodes is provided for measuring the transepithelial potential difference across the trachea wall. A set of current electrodes is provided for inducing an electrical current to flow across the trachea wall in order to determine transepithelial impedance.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,East Carolina University,Centers for Disease Control and Prevention,,,,,,,,,3,Medical technology,,,,,,A61B/0421
7910105,22-Mar-11,2011,3,22,Methods for treating and preventing fibrosis,"The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).",8,Wyeth LLC,The United States of America as represented by the Department of Health and Human Services,President and Fellows of Harvard College,,,,,,,,,3,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,G01N/6869
7910692,22-Mar-11,2011,3,22,Immunogenic peptides and methods of use,"The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.",39,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
7914788,29-Mar-11,2011,3,29,Monoclonal antibodies against orthopoxviruses,"The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",15,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/081
7915036,29-Mar-11,2011,3,29,Compositions comprising T cell receptors and methods of use thereof,"Nucleic acids encoding antitumor TCRs recognizing MART-1, NY-ESO-1, and melanoma gp100 peptides; vectors and cells comprising the same; and methods of using the foregoing.",11,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/7051
7915040,29-Mar-11,2011,3,29,Defensin-antigen fusion proteins,"The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
7915396,29-Mar-11,2011,3,29,Nucleic acid molecules encoding minimally immunogenic variants of SDR-grafted humanized antibody CC49,"Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28′ CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/465
7918819,5-Apr-11,2011,4,5,Variable curve catheter,"Disclosed is a deflectable tip guiding device, such as a catheter, that enables a physician, or other health care personnel, to vary the radius of curvature of the tip of the device. In one embodiment, a guiding device includes an elongate body and a deflectable distal tip. An elongate stiffener tube is coupled to the body for longitudinal movement relative thereto and has a distal end spaced a variable distance from the distal end of the tip, thereby serving as a fulcrum for the tip. Longitudinal movement of the stiffener tube relative to the body varies the distance between the distal ends of the tip and tube, which in turn causes a corresponding increase or decrease in the radius of curvature of the tip.",44,Health & Human Services - NIH,,,,,,,,,,,1,Medical technology,,,,,,A61M/0147
7919104,5-Apr-11,2011,4,5,Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof,"Provided is a P4 peptide, which contains functional epitopes of the PsaA protein of Streptococcus pneumoniae, and related methods and compositions. P4 peptide mimetics having a conformational structure identical or similar to the conformation of P4 (e.g., SEQ ID NO: 1 and SEQ ID NO:2) are provided. An antibody that specifically binds to the epitope defined by the disclosed peptides is provided. A P4-specific antibody is PsaA-specific since P4 defines an epitope specific for PsaA. Immunogenic compositions comprising the peptide of SEQ ID NO: 1 and a pharmaceutical carrier or the peptide of SEQ ID NO:2 and a pharmaceutical carrier are also provided. Methods of using the peptides and antibodies of the invention are provided.",6,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/3156
7919301,5-Apr-11,2011,4,5,Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from CDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens,"Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.",10,"The United States of America as represented by the Secretary, Department of Health of Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
7919477,5-Apr-11,2011,4,5,Multiple CpG oligodeoxynucleotides and their use to induce an immune response,Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.,36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
7919590,5-Apr-11,2011,4,5,Tumor suppressor gene P33ING2,"The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/02
7919607,5-Apr-11,2011,4,5,Nucleic acids encoding humanized anti-tag 72 CC49 antbodies,"The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
7923535,12-Apr-11,2011,4,12,Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins,"A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine residue is capable of being ADP-ribosylated. In another embodiment, methods are disclosed for modifying an immune response in a subject.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,University of Massachusetts,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Organic fine chemistry,,,,A61K/1709
7924425,12-Apr-11,2011,4,12,"Spatially selective fixed-optics multicolor fluorescence detection system for a multichannel microfluidic device, and method for detection","A system for spatially selective, fixed-optics fluorescence detection in a multichannel polymeric microfluidic device, and a method for performing spatially selective, fixed-optics fluorescence detection.",34,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/6456
7927793,19-Apr-11,2011,4,19,Cell lines and host nucleic acid sequences related to infectious disease,"Host nucleic acids and host proteins that participate in viral infection, such as human immunodeficiency virus (HIV), influenza A, and Ebola virus, have been identified. Interfering with or disrupting the interaction between a host nucleic acid or host protein and a virus or viral protein confers an inhibition of or resistance to infection. Thus, interfering with such an interaction in a host subject can confer a therapeutic or prophylactic effect against a virus. The sequences identified can be used to identify agents that reduce or inhibit viral infection.",3,The United States of America as represented by the Department of Health and Human Services,Vanderbilt University,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/47
7928079,19-Apr-11,2011,4,19,Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates,"The invention relates to compounds capable of releasing nitric oxide wherein the compounds comprise a saccharide and at least one nitric oxide-releasing diazeniumdiolate [N2O2] functional group, which is bonded directly to a carbon atom of the saccharide, and methods for preparing the same. The invention further comprises the treatment of biological disorders treatable by the administration of nitric oxide.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/61
7928096,19-Apr-11,2011,4,19,"Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same","The present invention provides compound of the formula (I):in which at least two of R1, R2, R3, R4, R5, and R6 are N2O2M and related compounds, substrates, compositions, and methods of using such compounds and compositions to treat biological disorders in which a polyphasic release of nitric oxide would be beneficial.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/00
7932074,26-Apr-11,2011,4,26,Multivalent human-bovine rotavirus vaccine,The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.,11,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
7932721,26-Apr-11,2011,4,26,Inductive decoupling of a RF coil array,"An apparatus for imaging includes: a radio frequency (RF) coil array having a first RF coil and at least one additional RF coil, where the RF coil array is adapted to generate an image signal; a preamplifier having an input impedance, where the preamplifier is adapted to receive the image signal from the first RF coil; and a transformer to couple the first RF coil to the preamplifier, where impedance of the transformer is adapted to match the input impedance of the preamplifier.",19,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Basic communication processes,Measurement,,,,,G01R/365
7933721,26-Apr-11,2011,4,26,Multiplexed analysis for determining a serodiagnosis of viral infection,"Clinical samples can be analyzed using microparticles to determine the serodiagnosis of a viral infection from two candidate viral infections of the same viral group. Serodiagnosis can be determined via a pooled population of subsets of microparticles, with the particles in the pooled population having a bound viral group-reactive antibody and the particles in each subset having at least one characteristic classification parameter that distinguishes between subsets. Viral antigens of antibodies of interest in the same viral-class as the viral group-reactive antibody can be bound to the viral group-reactive antibody on the microparticles, and subsequently exposed to a clinical sample. Binding and labeling can be used. Automated analysis of data from multiplexed flow analysis can determine the presence or absence of antibodies of interest in the sample, thereby diagnosing for two candidate viral infections in a single assay.",43,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,IT methods for management,,,,,G01N/56983
7935351,3-May-11,2011,5,3,Use of CPG oligodeoxynucleotides to induce angiogenesis,"This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This method includes comprising introducing a CpG oligodeoxynucleotide into an area of the tissue wherein the formation of new blood vessels is desired, thereby inducing neovascularization in the area of the tissue.",24,The United States of America as represented by the Department of Health and Human Services,University of Tennessee Research Foundation,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/117
7939273,10-May-11,2011,5,10,High sensitivity mechanical resonant sensor,"A system and method for detecting mass based on a frequency differential of a resonating micromachined structure, such as a cantilever beam. A high aspect ratio cantilever beam is coated with an immobilized binding partner that couples to a predetermined cell or molecule. A first resonant frequency is determined for the cantilever having the immobilized binding partner. Upon exposure of the cantilever to a solution that binds with the binding partner, the mass of the cantilever beam increases. A second resonant frequency is determined and the differential resonant frequency provides the basis for detecting the target cell or molecule. The cantilever may be driven externally or by ambient noise. The frequency response of the beam can be determined optically using reflected light and two photodetectors or by interference using a single photodetector.",20,"Cornell Research Foundation, Inc.",,,,,,,,,,,1,Measurement,Analysis of biological materials,,,,,G01N/022
7939279,10-May-11,2011,5,10,Mammalian T1R3 sweet taste receptors,"The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors, the receptors comprising consisting of a monomer or homodimer of a T1R3 G-protein coupled receptor polypeptide, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.",25,The Regents of the University of California,The Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7939635,10-May-11,2011,5,10,Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy,"The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.",2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4705
7939639,10-May-11,2011,5,10,Functional role of adrenomedullin (AM) and the gene related product (PAMP) in human pathology and physiology,"The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.",6,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/26
7943318,17-May-11,2011,5,17,"Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer","The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provide methods of identifying anti-lung cancer agents.",22,The Ohio State University Research Foundation,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12Q/6886
7943729,17-May-11,2011,5,17,Dominant B cell epitopes and methods of making and using thereof,"Disclosed are methods for obtaining at least one epitope suitable for detecting the presence of an antibody against a tumor associated antigen of a cancer in a sample. Kits, assays, and substrates employing the epitopes of the present invention are disclosed. Also disclosed are epitopes of NY-ESO-1 and XAGE-1b and methods of using thereof.",11,The Regents of the University of California,National Institutes of Health,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/57484
7943775,17-May-11,2011,5,17,Small molecules for imaging protein-protein interactions,"A tissue is imaged to detect the presence of amyloid deposits or other target proteins prior to their aggregation into plaques, with the assistance of the administration of a labeled bifunctional compound of which one functionality binds to the target protein and the second functionality binds to a chaperone protein that is present in the tissue of interest. The two functionalities have different binding affinities, the target-binding functionality having the greater binding affinity, with the result that the bifunctional compound preferentially remains in the tissue when bound to the chaperone and then the target protein while bifunctional compound that is not bound to the target protein will leave the tissue. The inclusion of the chaperone allows the imaging process to detect the non-aggregated proteins by way of the label and the difference in kinetics of the binding to the chaperone and the target protein permits one to distinguish between binding of the bifunctional molecule to the chaperone only and binding to the chaperone and then to the target protein. Certain intermediates toward the synthesis of these bifunctional compounds are novel by themselves, and labeled bifunctional molecules in general that utilize a lysine linker are also disclosed as a novel class of compounds.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07C/40
7947289,24-May-11,2011,5,24,Multimeric protein toxins to target cells having multiple identifying characteristics,The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.,29,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Micro-structural and nano-technology,Pharmaceuticals,,,,B82Y/00
7947503,24-May-11,2011,5,24,Monitor and methods for characterizing airborne particulates,"A dust monitor is disclosed that is suitably deployed in dusty environments and capable of providing near real-time indications of exposure to airborne particulates. The monitor includes a filter and filter assembly made of materials that do not interfere with subsequent instrumental (such as spectrometric) analysis for detecting and/or quantitating an analyte. In some disclosed embodiments, the filter is made of nylon or other material that is readily subjected to thermal destruction prior to spectrometric analysis. The dust monitor also includes a humidity correction feature that permits the filter to be made of ashable organic materials even if those materials are not highly hydrophobic. Transport devices are provided for shipment of the filter and/or filter assembly to an analytical laboratory which prevent loss of particulate matter and which facilitate an accurate analysis procedure.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Measurement,,,,,,G01N/0618
7947651,24-May-11,2011,5,24,"Secreted frizzled related protein, sFRP, fragments and methods of use thereof","The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.",14,The United States of America as represented by the Department of Health and Human Services,University of Massachusetts,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/47
7947822,24-May-11,2011,5,24,HIV vaccines based on Env of multiple clades of HIV,"The invention provides a composition comprising a pharmaceutically acceptable carrier and six plasmids, each of which encodes an HIV Env, Gag, Pol, or Nef protein. The invention also provides a method of inducing an immune response in an animal using the composition.",3,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/21
7951078,31-May-11,2011,5,31,Method and apparatus for determining familial risk of disease,"Personal and family health history information can be used to assess familial risk of disease. For example, information can be collected about the disease history of a person and the person's first- and second-degree relatives and then analyzed to determine the familial risk of common diseases such as coronary heart disease, stroke, type 2 diabetes, and colorectal, breast, and ovarian cancer. Assessed familial risk of disease can then be used by researchers to better estimate the contribution of personal history and family history to the etiology and natural history of a disease of interest, and by consumers and health professionals to determine recommendations for disease management, prevention and screening that are personalized and targeted to the familial risk. Other embodiments are also described and claimed.",9,,,,,,,,,,,,,IT methods for management,Computer technology,,,,,G06Q/24
7951383,31-May-11,2011,5,31,Attenuated parainfluenza virus (PIV) vaccines,The invention provides isolated nucleic acids encoding recombinant genomes or antigenomes of Human Parainfluenza Viruses that are useful as vaccines. The recombinant genomes or antigenomes can be incorporated into expression vectors for production of recombinant viruses in vitro. The invention also provides recombinant Human Parainfluenza viruses having one or more mutations that attenuate replication of the virus in a host.,2,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/00
7951576,31-May-11,2011,5,31,Methods for preparing cells and viruses,Methods for preparing cells and viruses such as poxviruses are provided herein.,32,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
7951786,31-May-11,2011,5,31,Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides,The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.,13,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
7954486,7-Jun-11,2011,6,7,Aerosol delivery systems and methods,"Methods and systems for aerosol delivery of agents to a patient are described herein. The present system can be used to administer various types of agents, such as a vaccine or other types of pharmaceutical substances. Certain embodiments of the present system utilize an actuator coupled to a disposable aerosolizing element that aerosolizes an agent for delivery to a patient when acted upon by the actuator. The aerosolizing element prevents the agent from contacting the actuator and other non-disposable components of the system so that little or no cleaning or maintenance is required. The present system also can include an aerosolization rate monitor that monitors the rate at which an agent is being aerosolized and provides feedback to the user to ensure that the proper dose is being administered.",30,The United States of America as represented by the Secretary of the Department of Health and Human Services,Centers for Disease Control and Prevention,Creare Inc.,,,,,,,,,3,Chemical engineering,Medical technology,,,,,B05B/0638
7959929,14-Jun-11,2011,6,14,Materials and methods for respiratory disease control in canines,The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.,96,"University of Florida Research Foundation, Inc.","Cornell Research Foundation, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,Centers for Disease Control and Prevention,Intervet International B.V.,,,,,,,5,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/145
7959934,14-Jun-11,2011,6,14,Method for rapid generation of mature dendritic cells,"Novel methods of rapidly generating dendrtic cells are disclosed herein. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one specific, non-limiting example, the method includes contacting the dendritic cell precursor or the mature dendritic cell with an antigen. The methods are of use both in vitro and in vivo.",41,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0639
7960353,14-Jun-11,2011,6,14,Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders,Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.,15,University of Kansas,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07H/06
7960356,14-Jun-11,2011,6,14,Oligodeoxynucleotide and its use to induce an immune response,"D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula:5′ X1X2X3Pu1 Py2 CpG Pu3 Py4 X4X5X6(W)M (G)N-3′wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10. Methods of using these oligodeoxynucleotides to induce an immune response are provided.",42,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/008
7960535,14-Jun-11,2011,6,14,"Recombinant lipidated PsaA protein, methods of preparation and use","The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene of Borrelia burgdorferi, which leader sequence is joined in translational reading frame with the psaA structural gene. The invention also provides methods of preparation of lipidated PsaA proteins and use of such proteins in immunological compositions. Also provided are vaccines comprising immunogenic lipidated PsaA proteins and methods of use of such vaccines in the prevention and treatment of S. pneumoniae infection.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/3156
7964365,21-Jun-11,2011,6,21,Methods for diagnosing and monitoring the progression of cancer,Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.,32,"The United States of Americam as represented by the Secretary, Department of Health and Human Services","Amgen, Inc.",,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/57488
7964559,21-Jun-11,2011,6,21,"MVL, an antiviral protein from a cyanobacterium","The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1→6)Man-beta (1→4) GlcNAc-beta(1→4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/195
7964576,21-Jun-11,2011,6,21,"Anti-arthropod vector vaccines, methods of selecting and uses thereof",The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis.,14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0003
7968298,28-Jun-11,2011,6,28,"Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit CCR5-tropic HIV-1 infection and replication","It has been discovered that herpesviruses can trigger an increase in the production of HIV-suppressive chemokines, and that these chemokines block the CCR5 receptor, which is used as a co-receptor with CD4 in the CCR5-tropic forms of HIV-1 that predominate in early stage HIV-1 infection. Use of live, attenuated or killed herpesviruses, or of herpesvirus proteins which trigger an increase in production of HIV-suppressive chemokines, or of nucleic acids encoding those proteins, can likewise be used to prevent establishment of HIV-1 infection or to inhibit HIV-1 replication. The invention provides uses, methods and compositions related to these discoveries.",4,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/162
7968664,28-Jun-11,2011,6,28,"Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof","The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N2O2— group, wherein the N2O2— group is attached directly to the polyacrylonitrile backbone, to a specific location on or within the mammal in an amount effective to treat the biological disorder or promote angiogenesis.",16,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/78
7972606,5-Jul-11,2011,7,5,T24 antigen for immunodiagnosis of Taenia solium cysticercosis,"The present disclosure relates to T24 nucleic acid sequences, amino acid sequences, and antibodies. Methods for detecting and diagnosing Taenia solium infection in a subject using the T24 sequences and specific binding agents are also disclosed. The T24 sequences disclosed herein can be formulated into a pharmaceutical composition for administration to a subject. For example, the disclosed T24 polypeptides can also be administered to a subject to stimulate an immune response in the subject, thereby protecting the subject against T. solium infection.",11,The United States of America as respresented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/43554
7972778,5-Jul-11,2011,7,5,Method for detecting the presence of a single target nucleic acid in a sample,A miniaturized assembly is provided whereby a fluid sample can be divided into a plurality of sample portions in retaining wells and the sample fluid can be displaced from open ends of the wells while simultaneously being sealed in the wells. A method of dividing a fluid sample using the assembly is also provided.,35,"Applied Biosystems, LLC",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
7973057,5-Jul-11,2011,7,5,Thalidomide analogs,"Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.",11,The United States of America as represented by the Department of Health and Human Services,P2D Inc.,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/44
7976451,12-Jul-11,2011,7,12,Transcranial magnetic stimulation system and methods,"A system and methods for transcranial magnetic stimulation, the system including a helmet, a positioning portion, a stimulator and a cooling system, are disclosed. The helmet includes a coil for deep brain magnetic stimulation. The coil has a base portion, and return portions, which may include a protruding return portion and a contacting return portion. The coil is designed to minimize unintended stimulation of portions of the brain, while reducing accumulation of surface charges. The coil is stimulated at several locations and/or at different times so as to focus the electrical field on a specific deep neuronal structure.",11,The United States of America as represented by the Department of Health and Human Services,Yeda Research & Development Co. Ltd.,"Brainsway, Inc.",,,,,,,,,3,Medical technology,,,,,,A61N/02
7977060,12-Jul-11,2011,7,12,Mammalian sweet taste receptors,"The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet taste receptors.",29,Regents of the University of California,The United States of America as represented by NIH,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
7977468,12-Jul-11,2011,7,12,Chromosome 3p21.3 genes are tumor suppressors,"Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.",10,Board of Regents of the University of Texas System,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Other special machines,Pharmaceuticals,,,,C12N/86
7981429,19-Jul-11,2011,7,19,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.",29,"Medimmune, LLC",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
7981610,19-Jul-11,2011,7,19,ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL),"It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.",10,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57426
7981656,19-Jul-11,2011,7,19,Pseudotyped retrovirus with modified ebola glycoprotein,Pseudotyped retroviruses having viral glycoproteins with modified O glycosylation regions are provided. Also provided are methods for making the pseudotyped retroviruses of the present invention and for using the pseudotyped retroviruses for transduction of target cells. Cells for stably producing the pseudotyped retroviruses or the present invention are also provided.,7,Purdue Research Foundation,Centers for Disease Control and Prevention,,,,,,,,,,2,Biotechnology,,,,,,C12N/86
7982011,19-Jul-11,2011,7,19,Mutated anti-cd22 antibodies and immunoconjugates,"Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.",40,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/2803
7985548,26-Jul-11,2011,7,26,Materials and methods directed to asparagine synthetase and asparaginase therapies,"Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/1137
7985561,26-Jul-11,2011,7,26,Manganese superoxide dismutase Val16Ala polymorphism predicts resistance to chemotherapeutic drug cancer therapy,"The present invention provides, for the first time, the finding that the manganese superoxide dismutase Val16Ala polymorphism is significantly associated with prognosis for cancer patients treated with chemotherapeutic drug therapy. The alanine allele is a novel biomarker that predicts poor response and poor outcome to chemotherapeutic drug cancer therapy. Conversely, the valine allele predicts a good response and a good outcome to chemotherapeutic drug cancer therapy. Therefore, a genotype assay can be used to determine which alleles a subject is carrying, and subsequently this information can be used to determine if chemotherapeutic drug therapy is appropriate, and to customize therapy according to the patient's MnSOD genotype.",22,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
7988971,2-Aug-11,2011,8,2,Human monoclonal antibodies against Hendra and Nipah viruses,"The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",16,The United States of America as represented by the Department of Health and Human Services,"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.",,,,,,,,,,2,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1203
7989501,2-Aug-11,2011,8,2,Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde,"The present invention features methods of treating a mammalian subject having renal cancer by administration of certain dimethylsulfonate compounds, such as a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.",27,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
7989630,2-Aug-11,2011,8,2,Radiotracers for imaging P-glycoprotein function,"P-glycoprotein transporter (P-gp) acts as a pump at the blood-brain barrier to exclude a wide range of xenobiotics (e.g., toxins, drugs, etc.) from the brain and is also expressed in a tumor in response to exposure to established or prospective chemotherapeutics (a phenomenon known as multidrug resistance). This invention concerns the preparation and use of radiotracers for imaging P-gp function in vitro and in vivo. Radiotracers of the present invention are avid substrates for P-gp and have structures based on N-Desmethyl-loperamide.",2,"National Institutes of Health Represented by the Secretary of the Department of Health and Human Services, National Institutes of Health",,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Organic fine chemistry,,,,G01N/6872
7993647,9-Aug-11,2011,8,9,Monoclonal antibodies to HIV-1 and methods of using same,The present invention provides monoclonal antibodies to HIV-1 Vpr and hybridoma cell lines that produce the monoclonal antibodies to HIV-1 Vpr. Methods for use of such antibodies in the detection of HIV-1 infection are also provided.,29,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/1072
7993857,9-Aug-11,2011,8,9,Determination of AM-binding proteins and the association of adrenomedullin (AM) therewith,"The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the present invention provides a newly identified complex between AM and a specific AM-binding protein 1 (AMBP-1); which has been isolated and identified herein as factor H (fH). The invention also provides AM/AMBP complexes, particularly AM/FH complexes, and antibodies specifically reactive with this complexes. Further provided are methods for identifying and purifying complexes of AM and an AM binding protein using anti-AM/fH antibodies, and methods for treating conditions such as cancer or diabetes utilizing compositions comprising these antibodies. The present invention additionally provides methods for identifying antagonists agents that inhibit the function of AM, factor H, or the AM/factor H complex. The invention also provides methods for treating conditions such as cancer or diabetes using these antagonist agents.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/18
7993919,9-Aug-11,2011,8,9,Method of inducing memory B cell development and terminal differentiation,"A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. In one embodiment, the B cell progenitor is an immature B cell. A method is also disclosed for enhancing an immune response. The method includes contacting a population of cells including a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. The memory B cells arid/or the plasma cell are then introduced into the subject to enhance the immune response. A method is also disclosed for treating a subject with a condition comprising a specific deficiency of at least one of memory B cells and plasma cells. A method is disclosed for identifying an agent with a physiological effect on one or more of a memory B cell and a plasma cell differentiation. A method is also disclosed for identifying agents that inhibit an activity of IL-21.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,G01N/5052
7996156,9-Aug-11,2011,8,9,Methods for predicting properties of molecules,"Structure-activity methods based on molecular descriptors that are a combination of structural information about the through-space and through-bond relationships between components of a molecule's structure and spectral data attributable to those components are disclosed. In some embodiments, a molecule is described by multiple sets of such descriptors to account for flexibility in the structure of the molecule. In a particularly disclosed embodiment, predicted 13C—13C COSY data and 13C—13C distance data are used as descriptors. Models of molecular properties may be established using the disclosed spectral data-activity methods and used to predict the properties of molecules.",35,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Computer technology,,,,,G01N/48
7998682,16-Aug-11,2011,8,16,Method for assessing atherosclerosis by measuring expression of FOS or DUSP1 in monocytes,"A non-invasive method for the diagnosis of atherosclerosis is provided. In one example, the method includes assaying the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes or a cell fraction thereof, or in plasma, serum or peripheral blood from the subject. An increase the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes in the sample as compared to a control indicates that the subject has atherosclerosis. A method is also provided for determining if a pharmaceutical agent is effective for treatment of atherosclerosis in a subject. The method includes assaying the expression of FOS, DUSP1, or both FOS and DUSP1 in a monocytes treated with the pharmaceutical agent, wherein a decrease the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes in the sample as compared to a control indicates that the pharmaceutical agent is effective for the treatment of atherosclerosis. The monocytes can be contacted with the agent in vivo or in vitro.",30,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/6893
7998736,16-Aug-11,2011,8,16,Adoptive immunotherapy with enhanced T lymphocyte survival,"The invention provides for compositions, e.g., pharmaceutical compositions, comprising a T lymphocyte, or a population thereof, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response. The invention further provides an isolated T lymphocyte, or population thereof, expressing at least one recombinant polynucleotide encoding the cytokine, wherein the polynucleotide comprises a non-native coding sequence encoding the cytokine. Also provided is the use of such compositions and T lymphocytes, or populations thereof, for the treatment or prevention of a medical condition e.g., cancer. A method of preparing the a T lymphocyte with enhanced T cell survival is further provided herein.",21,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0636
7999071,16-Aug-11,2011,8,16,Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1,"Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.",45,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0011
7999077,16-Aug-11,2011,8,16,IRTA2 antibodies and methods of use,"Antibodies that specifically bind the extracellular domain of IRTA2 are disclosed herein. In one embodiment, these antibodies do not specifically bind IRTA1, IRTA3, IRTA4, or IRTA5. In one example, the antibodies are humanized antibodies. The antibodies can be conjugated to effector molecules, including detectable labels, radionucleotides, toxins and chemotherapeutic agents. The antibodies that specifically bind IRTA2 are of use to detect B cell malignancies, such as hairy cell leukemia and non-Hodgkin's lymphoma. These antibodies that specifically bind IRTA2 are also of use to treat B cell malignancies that express IRTA2, such as hairy cell leukemia and non-Hodgkin's lymphoma.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57407
8003112,23-Aug-11,2011,8,23,Meningococcal and pneumococcal conjugate vaccine and method of using same,"This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.",5,Howard University,"The United States of America as represented by the Secretary, Department of Health and Human Services; National Institutes of Health, Office of Technology Transfer",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/095
8003406,23-Aug-11,2011,8,23,Methods for detecting attention-deficit/hyperactivity disorder,"The invention provides a method of determining a susceptibility of a subject for development of ADHD. The method comprises obtaining a sample from the subject, analyzing the sample for an ADHD susceptibility haplotype of LPHN3 receptor which is associated with at least one genetic marker selected from the group consisting of rs7678046, rs1901223, rs6813183, and rs1355368, and determining if the subject has a susceptibility to develop ADHD, whereby the presence of the haplotype having one or more of the genetic markers is indicative of a susceptibility to develop ADHD. The invention also provides methods of treating ADHD.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12Q/6883
8003629,23-Aug-11,2011,8,23,21-substituted progesterone derivatives as new antiprogestational agents,"A compound having the general formula:in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.",34,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07J/00
8003764,23-Aug-11,2011,8,23,Folliculin-specific antibodies and methods of detection,"The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and antibodies that specifically bind to the BHD protein (folliculin). In addition, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, by detection of altered expression of folliculin using folliculin-specific antibodies.",23,United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
8008266,30-Aug-11,2011,8,30,Methods of treating cancer using immunostimulatory oligonucleotides,"Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.",30,University of Iowa Foundation,The United States of America as represented by the Department of Health and Human Services,"Coley Pharmaceutical Group, Inc.",,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
8008316,30-Aug-11,2011,8,30,Azonafide derived tumor and cancer targeting compounds,"An azonafide-based compound of Formula I, a composition comprising the compound, and a method of using the compound to deliver a cytotoxic azonafide derivative to a cell, as well as related compounds and methods for the use thereof to pre-pare an azonafide-based compound of Formula I.",39,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/18
8008463,30-Aug-11,2011,8,30,Compositions and methods for diagnostics and therapeutics for hydrocephalus,"The present disclosure relates to RFX4_v3 protein and nucleic acids encoding the RFX4_v3 protein. The present disclosure provides non-human transgenic animals with altered RFX4_v3 genes, and provides assays for the detection of RFX4_v3 and RFX4_v3 polymorphisms associated with disease states. The present disclosure additionally provides methods of determining a subjects' risk of developing congenital hydrocephalus, and treating or inhibiting its development.",31,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/4702
8012490,6-Sep-11,2011,9,6,Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents,"The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.",13,Mount Sinai School of Medicine,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
8012683,6-Sep-11,2011,9,6,Variants in complement regulatory genes predict age-related macular degeneration,"Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided.",10,University of Iowa Research Foundation,The Trustees of Columbia University in the City of New York,"United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,3,Organic fine chemistry,Analysis of biological materials,Biotechnology,,,,G01N/564
8017130,13-Sep-11,2011,9,13,Method of accelerated vaccination against Ebola viruses,"The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
8017578,13-Sep-11,2011,9,13,Orally active peptides that prevent cell damage and death,"This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,Ramot at Tel-Aviv University Ltd.,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/04
8017938,13-Sep-11,2011,9,13,Apparatus for microarray binding sensors having biological probe materials using carbon nanotube transistors,"A microarray apparatus is provided which contains at least one chip having source and drain electrodes positioned on an array of carbon nanotube transistors which allows for electronic detection of nucleic acid hybridizations, thereby affording both increased sensitivity and the capability of miniaturization.",28,The United States of America as represented by the Department of Health and Human Services,"University of Maryland, College Park",,,,,,,,,,2,Micro-structural and nano-technology,Analysis of biological materials,,,,,G01N/5438
8023703,20-Sep-11,2011,9,20,Hybrid segmentation of anatomical structure,"An image of an anatomical structure can be analyzed to determine an enclosing three-dimensional boundary when the anatomical structure is filled with two substances, such as air and a fluid. Various techniques can be used to determine the enclosing boundary including: analyzing the virtual structure to segment the structure into air and fluid pockets, determining if there are multiple fluid pockets whose surface touches a single air-fluid boundary, determining a separate threshold for respective fluid pockets, resegmenting the virtual anatomical structure using the separate threshold for different fluid pockets, forming a hierarchical pocket tree which represents the relationship between the fluid and air pockets, pruning the pocket tree based on various criteria which corresponds to deleting those pruned portions from the virtual anatomical structure, and resegmenting the remaining virtual anatomical structure using one or more of fuzzy connectedness, two-dimensional gap filling, and level set segmentation.",22,"The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institues of Health",,,,,,,,,,,1,Computer technology,,,,,,G06K/34
8023710,20-Sep-11,2011,9,20,Virtual colonoscopy via wavelets,"Various techniques can be used to improve classification of colon polyps candidates found via computed tomographic colonography computer aided detection (CTCCAD). A polyp candidate can be classified as a true positive or a false positive. For example, a two-dimensional projection image of the polyp can be generated from a three-dimensional representation and classified based on features of the projection image. An optimal viewpoint for the projection image can be found via techniques such as maximizing viewpoint entropy. Wavelet processing can be used to extract features from the two-dimensional projection image. Feature extraction can use a piecewise linear orthonormal floating search for locating most predictive neighbors for wavelet coefficients, and support vector machines can be employed for classification. The techniques can be useful for improving accuracy of CTCCAD techniques.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/05
8024027,20-Sep-11,2011,9,20,Infrared endoscopic balloon probes,"Balloon probes, adapted for use in endoscopy and other medical procedures, are useful to obtain spectroscopic information reflected or emitted from a tissue of interest in the infrared spectral region. The information collected by the probe is useful in the diagnosis and treatment of disease. The invention also relates to methods utilizing these probes to analyze a surface of interest, in a minimally invasive manner, in connection with the diagnosis and treatment of disease.",78,"Hyperspectral Imaging, Inc.",,,,,,,,,,,1,Medical technology,,,,,,A61B/00082
8025887,27-Sep-11,2011,9,27,"Avirulent, immunogenic flavivirus chimeras",Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.,10,"The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention",Mahidol University,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/12
8026350,27-Sep-11,2011,9,27,"Tumor suppressor gene, p28ING5","This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided.",4,The United States of America as represented by theDepartment of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0693
8028661,4-Oct-11,2011,10,4,Method for applying chemicals to rodents,An enclosure is provided having openings for entry of rodents within the enclosure. There is arranged one or more applicators in the form of a suspended flexible web configured to contact rodents entering the chamber and having a chemical on the web for application to the rodents.,8,Centers for Disease Control and Prevention,Bayer Cropscience S.A.,B & G Equipment Company,,,,,,,,,3,Other special machines,,,,,,A01K/003
8029788,4-Oct-11,2011,10,4,Variants of humanized anti-carcinoma MAb CC49,The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.,15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/0002
8030280,4-Oct-11,2011,10,4,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use.",14,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
8030281,4-Oct-11,2011,10,4,Methods and apparatus for creating particle derivatives of HDL with reduced lipid content,"The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.",10,HDL Therapeutics,,,,,,,,,,,1,Pharmaceuticals,Chemical engineering,Biotechnology,Analysis of biological materials,,,C07K/775
8030285,4-Oct-11,2011,10,4,Oligodeoxynucleotide and its use to induce an immune response,"The present invention provides a substantially pure or isolated oligodeoxynucleotide of at least about 10 nucleotides comprising a sequence represented by either the formula:5′N1N2N3T-CpG-WN4N5N63′wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are any nucleotides, or the formula:5′RY-CpG-RY3′wherein the central CpG motif is unmethylated, R is. A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host.",32,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,C07H/04
8030341,4-Oct-11,2011,10,4,Dmt-derivative compounds and related compositions and methods of use,"The present invention relates to symmetric and asymmetric dimeric Dmt (2′,6′-ditnethyl) compounds and Dmt derivative compounds with dual δ and μ opioid receptor antagonist activity. Also, the present invention provides compositions comprising these compounds and it provides methods of using these compounds.",34,The United States of America as represented by the Secretary of the Department of Health and Human Services,Kobe Gakuin University,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
8034334,11-Oct-11,2011,10,11,Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy,"A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.",18,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
8034557,11-Oct-11,2011,10,11,LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis,"Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Research Foundation for Mental Hygiene, Inc.","The Progeria Research Foundation, Inc.",,,,,,,,,3,Biotechnology,,,,,,C07K/47
8038997,18-Oct-11,2011,10,18,Anti-marinobufagenin antibodies and methods for their use,"Described herein are deposited hybridoma cell lines and the monoclonal antibodies produced by these hybridomas, and antigen binding fragments thereof. These monoclonal antibodies and antigen binding fragments specifically bind marinobufagenin. The disclosure also encompasses the use of these monoclonal antibodies or antigen binding fragments in a method for detecting the presence of marinobufagenin in a biological sample. Also provided are methods for the use of these monoclonal antibodies or antigen binding fragments as prophylactic, therapeutic, and diagnostic agents for the detection, inhibition and treatment of a cardiovascular disease, for example, essential hypertension, hypertension associated with preeclampsia, eclampsia, or renal failure, or myocardial fibrosis in a subject.",57,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/26
8039003,18-Oct-11,2011,10,18,Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis,The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.,10,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
8039585,18-Oct-11,2011,10,18,Therapeutic administration of the scrambled anti-angiogenic peptide C16Y,"Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/08
8039593,18-Oct-11,2011,10,18,Antibodies and immunotoxins that target human glycoprotein NMB,"The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.",32,Duke University,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/28
8041412,18-Oct-11,2011,10,18,System for image-guided endovascular prosthesis and method for using same,Systems and methods for obtaining position sensor space data regarding an endovascular prosthesis within an anatomical region of a patient include at least one position indicating element which is movable within an endovascular prosthesis is tracked by a tracking system. A guidance portion of the endovascular prosthesis constrains movement of position indicating elements within the endovascular prosthesis.,19,Koninklijke Philips Electronics N.V.,"The United States of America, as represented by the Secretary DHHS",,,,,,,,,,2,Medical technology,,,,,,A61B/06
8043622,25-Oct-11,2011,10,25,Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides,The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for inhibiting or treating inflammatory lung disease by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.,29,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
8043623,25-Oct-11,2011,10,25,Immunogenic peptides for the treatment of prostate and breast cancer,"Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1. Several specific, non-limiting examples of these polypeptides are set forth as SEQ ID NOs: 3-7. Nucleic acids encoding these polypeptides, and host cells transfected with these nucleic acids, are also disclosed. Methods of using these polypeptides, and polynucleotides encoding these polypeptides, for the treatment of breast and prostate cancer are also disclosed.",25,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/4748
8043809,25-Oct-11,2011,10,25,Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs,"Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.",13,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
8044057,25-Oct-11,2011,10,25,Methods for suppressing an immune response or treating a proliferative disorder,"Disclosed herein are methods for suppressing an immune response in a subject, treating a neoplasm in a subject, or treating a fibroproliferative vascular disease in a subject, that includes administering to the subject a therapeutically effective amount of a 2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compound, or a pharmaceutically acceptable salt thereof, having the structure ofwherein the presence of each of R1 and R2 is optional and R1 and R2 are each independently selected from alkyl, substituted alkyl, heteroalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, halogen, hydroxy, or amino.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/496
8044185,25-Oct-11,2011,10,25,Conformationally stabilized HIV envelope immunogens and triggering HIV-I envelope to reveal cryptic V3-loop epitopes,"Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Dana Farber Cancer Institute, Inc.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
8044187,25-Oct-11,2011,10,25,Human luteinizing hormone superagonists,"The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the β-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone. The invention is also directed to a method of constructing superactive nonchimeric analogs of human hormones comprising comparing the amino acid sequence of a more active homolog from another species to the human hormone, and selecting superactive analogs from the substituted human hormones. The invention is also directed to nucleic acids encoding the modified human glycoprotein hormones, vectors containing those nucleic acids, and host cells containing those vectors.",42,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/59
8044189,25-Oct-11,2011,10,25,Bacillus anthracis protective antigen nucleic acid sequences,"The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Pharmaceuticals,,,,C07H/04
8048427,1-Nov-11,2011,11,1,Subgenomic replicons of the flavivirus dengue,"The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.",31,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/21
8048432,1-Nov-11,2011,11,1,Polysaccharide-protein conjugate vaccines,"Abstract of the Disclosure Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/08
8048630,1-Nov-11,2011,11,1,Methods and agents for detecting Parechovirus,"The present disclosure provides methods that permit detection of all known species of Parechovirus, including Human parechovirus and Ljungan virus (LV). In particular examples the method includes amplifying at least a portion of the 5′NTR of parechovirus nucleic acid molecules obtained from a sample, and detecting the resulting amplicons, but does not require culturing of the virus. The present disclosure also provides methods for determining which particular species or serotype of parechovirus is present in a biological sample. Also provided are oligonucleotide primers and probes that can be used in the disclosed methods.",29,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
8048641,1-Nov-11,2011,11,1,Micropatterning of biological molecules using laser ablation,"The present invention employs the natural hydrophilic properties of a macromolecular film such as a hydrogel and in combination with localized photo-ablation of monolayers created with the hydrogel using multi-photon laser excitation, provides a stampless, versatile method of micropattern fabrication.",10,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Other special machines,,,,,,B29C/16
8053422,8-Nov-11,2011,11,8,Anti-cancer oligodeoxynucleotides,"It is disclosed herein that suppressive ODNs are of use for preventing or delaying the formation of a tumor, reducing the risk of developing a tumor, treating a tumor, preventing conversion of a benign to a malignant lesion, or preventing metastasis. In some embodiments, methods are disclosed herein for treating, preventing or reducing the risk of developing a tumor, such as esophageal, gastrointestinal, liver, lung, skin and colon tumors or a mesothelioma. Generally, the methods disclosed herein include selecting a subject for treatment and administering to the subject a therapeutically effective amount of one or more suppressive ODN. In some examples, additional agents can also be administered to the subject of interest.",20,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7088
8053443,8-Nov-11,2011,11,8,N-substituted indenoisoquinolines and syntheses thereof,"N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.",25,Purdue Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/005
8058249,15-Nov-11,2011,11,15,Immunostimulatory nucleic acid molecules,"Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.",19,University of Iowa Research Foundation,United States of America as represented by the Department of Health and Human Services,"Coley Pharmaceutical Group, Inc.",,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
8058395,15-Nov-11,2011,11,15,Chimeric protein comprising a green fluorescent ptotein fused to a transcription factor,"The present invention provides a method of screening for a compound that binds to a selected nucleic acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nucleic acid can be directly detected when bound by fluorescently labeled compound; and directly detecting the location of fluorescence within the cell, fluorescence aggregated at the site of the nucleic acid array indicating a compound that binds to the selected nucleic acid. In particular compounds such a transcription factors can be screened. Reagents for such method are provided including a mammalian cell having a plurality of steroid receptor response elements in an array such that the response element can be directly detected when bound by fluorescently labeled steroid receptor and a chimeric protein comprising a fluorescent protein fused to a steroid receptor.",8,Han Htun,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/721
8065092,22-Nov-11,2011,11,22,"Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states","A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.",27,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Biotechnology,,,,,G16B/00
8067159,29-Nov-11,2011,11,29,Methods of detecting amplified product,"A microfluidic device comprising a first surface portion and a first sample retaining element, which have differing affinities to a fluid, and a method comprising supplying a sample to such a device. In some embodiments, the differing affinity is a result of plasma, ion embedding, surface charging, chemical, optical, electronic and/or electromagnetic treatment. Also, a microfluidic device comprising at least one microcapillary device having a sample retaining element, at least one surface of which exhibits hydrophobicity, hydrophilicity, electromagnetic force exertion and electrostatic force exertion. Also, a microfluidic device comprising a first element having a hydrophilic pattern comprising at least a first sample retaining element. Also, a method comprising supplying a sample to a channel between a first element and a second element, and inducing in the first element at least one hydrophilic pattern by electrets or by internal or external electrodes to provide a charged surface.",15,"Applied Biosystems, LLC",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
8067530,29-Nov-11,2011,11,29,Scytovirin domain 1 related polypeptides,"A scytovirin domain 1 (SD1) polypeptide, a nucleic acid encoding the polypeptide, and related fusion proteins, conjugates, isolated cells, vectors, and antibodies, as well as a method of inhibiting a viral infection using the same.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/195
8067563,29-Nov-11,2011,11,29,"Tumor suppressor gene, p471NG3","The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6886
8067565,29-Nov-11,2011,11,29,Dengue serotype 1 attenuated strain,The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.,4,Sanofi Pasteur,Centers For Disease Control and Prevention,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
8067566,29-Nov-11,2011,11,29,Dengue serotype 2 attenuated strain,The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.,4,Sanofi Pasteur,Centers for Disease Control and Prevention,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
8068893,29-Nov-11,2011,11,29,"Real-time, interactive volumetric magnetic resonance imaging",A method of producing volume renderings from magnetic resonance image data in real time with user interactivity. The method comprises collecting raw magnetic resonance image (MRI) data representative of shapes within an image volume; transferring the raw MRI data to a computer; and continuously producing volume renderings from the raw MRI data in real time with respect to the act of collecting raw MRI data representative of shapes within the image volume.,17,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Computer technology,Measurement,,,,,G06T/08
8069947,6-Dec-11,2011,12,6,Sound attenuation canopy,"A sound attenuation canopy for reducing levels of sound passing through an opening comprises a sound absorbing member. The sound absorbing member is comprised of a flexible sound absorbing material and has a first end, a second end and an intermediate portion extending between the first end and the second end. The first end is configured to attach to a periphery of the opening at a first location, the second end is configured to attach to a periphery of the opening at a second location and the intermediate portion is configured to be spaced apart from the opening. When the first end and the second end of the sound absorbing member are attached to the periphery of the opening, at least one side opening is at least partially defined by the intermediate portion and the perimeter of the opening, and a sound transmission flow path through open space between the opening and the side opening comprises at least one change of direction greater than 45 degrees.",26,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Civil engineering,,,,,,E04B/001
8071084,6-Dec-11,2011,12,6,Vaccine for protection against Shigella sonnei disease,Compositions and methods for protecting a susceptible host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
8071100,6-Dec-11,2011,12,6,Monoclonal antibodies that neutralize anthrax toxins,"The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",7,The Unites States of America as represented by the Secretary of Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1278
8071113,6-Dec-11,2011,12,6,"Live, oral vaccine for protection against Shigella dysenteriae serotype 1","The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.",25,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
8071323,6-Dec-11,2011,12,6,Human monoclonal antibodies that bind human insulin like growth factors and their use,Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.,52,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,C07K/22
8071746,6-Dec-11,2011,12,6,Isolated nucleic acid molecule encoding a peptide or peptide analog comprising the SEQ ID No. 3,Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.,5,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/775
8075900,13-Dec-11,2011,12,13,Melanoma associated peptide analogues and vaccines against melanoma,"The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof; vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.",3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
8075903,13-Dec-11,2011,12,13,"Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4","The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.",36,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
8075921,13-Dec-11,2011,12,13,Rapamycin-resistant T cells and therapeutic uses thereof,"Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.",7,The United States of America as represented by the Secretary of the Deparment of Health and Human Services,The Trustees of the University of Pennsylvania,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/17
8076100,13-Dec-11,2011,12,13,"Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes","Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV env genes which have been mutated to remove or reduce inhibitory/instability sequences are disclosed. Viral particles and host cells containing these constructs and/or viral particles are also disclosed. The exemplified constructs and viral particles of the invention may be useful in gene therapy for numerous disorders, including HIV infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
8076372,13-Dec-11,2011,12,13,Acythiols and component thiol compositions as anti-HIV and anti-retroviral agents,"Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.",17,Government of the United States,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/20
8080554,20-Dec-11,2011,12,20,Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation,A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.,34,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/39
8084199,27-Dec-11,2011,12,27,Method of diagnosing poor survival prognosis colon cancer using microRNA-21,The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. The invention also provides methods of identifying inhibitors of tumorigenesis.,9,The Ohio State University Research Foundation,"The United States of America as represented by the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8084250,27-Dec-11,2011,12,27,Defensin-antigen fusion proteins,"The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.",30,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
8084415,27-Dec-11,2011,12,27,Uteroglobin in the treatment of IGA mediated nephropathy,"Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.",7,The United States of America as represented by the Secretary of the Departmant of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/1709
8085041,27-Dec-11,2011,12,27,Three-point method and system for fast and robust field mapping for EPI geometric distortion correction,"A system and method for MR magnetic field mapping includes a computer programmed to acquire a first data point at a first location in a first phase image data set, a second data point at the first location in a second phase image data set, a third data point at the first location in a third phase image data set. The first, second, and third phase images are acquired using a first, second, and third TE, respectively. Phase wrapping does not occur among the first and second phase image data sets; however, phase wrapping does occur among the second and third phase image data sets. The computer is also programmed to determine a magnetic field inhomogeneity, wherein the determination of the magnetic field inhomogeneity is based on the first, second, and third data points.",22,General Electric Company,"The United States of America as represented by the Secretary of the Office of Technology Transfer, National Institute of Health",,,,,,,,,,2,Measurement,,,,,,G01R/5616
8086432,27-Dec-11,2011,12,27,Molecular motor,"A molecular motor in which multiple concentric cylinders (or nested cones) rotate around a common longitudinal axis. Opposing complementary surfaces of the cylinders or cones are coated with complementary motor protein pairs (such as actin and myosin). The actin and myosin interact with one another in the presence of ATP to rotate the cylinders or cones relative to one another, and this rotational energy is harnessed to produce work. The concentration of ATP and the number of nested cylinders or cones can be used to control the rotational speed of the motor. The length of the cylinders can also be used to control the power generated by the motor. In another embodiment, the molecular motor includes at least two annular substrates wherein one annular substrate is coated with a first motor protein and the other annular substrate is coated with a second motor protein. The first and second motor proteins interact with each other to move the second annular relative to the first annular substrate.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Micro-structural and nano-technology,Biotechnology,"Electrical machinery, apparatus, energy",,,,C12M/00
8088379,3-Jan-12,2012,1,3,Modified T cell receptors and related materials and methods,"The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.",31,The United States of America as represented by the Department of Health and Human Services,Immunocore Limited,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/505
8088729,3-Jan-12,2012,1,3,"Anti-viral griffithsin compounds, compositions and methods of use","A method of inhibiting a viral infection of a host comprising administering to the host an anti-viral griffithsin polypeptide comprising SEQ ID NO: 3 or a fragment thereof comprising at least eight contiguous amino acids, a nucleic acid encoding the anti-viral polypeptide, or an antibody to the anti-viral polypeptide. A method of inhibiting a virus in a sample comprising contacting the sample with an anti-viral griffithsin polypeptide or antibody thereto also is provided.",8,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/168
8088787,3-Jan-12,2012,1,3,Methods related to the treatment of neurodegenerative and inflammatory conditions,"The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.",2,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
8092809,10-Jan-12,2012,1,10,Pseudomonas exotoxin A-like chimeric immunogens,This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using these immunogens also are provided.,16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
8093343,10-Jan-12,2012,1,10,Nitric oxide-releasing diazeniumdiolated compounds,"The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N2O2− group, wherein the N2O2− group is attached directly to the polyacrylonitrile backbone, to a specific location on or within the mammal in an amount effective to treat the biological disorder or promote angiogenesis.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/78
8101380,24-Jan-12,2012,1,24,Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs,The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.,10,The United States of America as represented by the Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/705
8101739,24-Jan-12,2012,1,24,Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector,"The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.",8,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
8105598,31-Jan-12,2012,1,31,Human monoclonal antibodies that specifically bind IGF-II,"Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation constant (Kd) of 1 mM or greater. The antibodies inhibit phosphorylation of the insulin-like growth factor receptor. Nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and isolated host cells that express the nucleic acids are also disclosed. The antibodies can be used to detect human IGF-II in a sample. Methods of diagnosing a tumor are disclosed herein that utilize these antibodies. Methods of treating a subject with a tumor are also disclosed.",33,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/22
8105609,31-Jan-12,2012,1,31,Flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens,"The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention.",9,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
8106006,31-Jan-12,2012,1,31,Modified defensins and their use,"This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. Compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. Methods are provided for modulating an antimicrobial activity and for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/1709
8106026,31-Jan-12,2012,1,31,Development of a preventive vaccine for filovirus infection in primates,"The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
8106027,31-Jan-12,2012,1,31,Development of a preventive vaccine for filovirus infection in primates,"The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
8110192,7-Feb-12,2012,2,7,Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency,"The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/21
8110352,7-Feb-12,2012,2,7,Method of diagnosing and treating cancer using B-catenin splice variants,"The invention relates to method of diagnosing and treating cancer, in particular β-catenin related cancers. The invention further relates to methods of identifying CTNNB1 related cancer CTNNB1 therapeutics.",7,"The United States of America as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6886
8110681,7-Feb-12,2012,2,7,Compounds for the treatment of spinal muscular atrophy and other uses,"Compounds of Formula (I) or (II) useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced by mutation or frameshift.",15,"The United States of America as represented by the Secretary, Department of Health and Human Services","Albany Molecular Research, Inc.",Science Applications International Inc. (SAIC),,,,,,,,,3,Organic fine chemistry,Pharmaceuticals,,,,,C07D/46
8114406,14-Feb-12,2012,2,14,Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins,"The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention. The invention also relates to a method of inhibiting adhesion of a cell expressing α3β1 integrin to an extracellular matrix, inhibiting α3β1-integrin-mediated cell motility, inhibiting α3β1-integrin mediated cell proliferation, promoting β3β1-integrin mediated cell proliferation and inhibiting angiogenesis utilizing the peptides of the invention.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/06
8114653,14-Feb-12,2012,2,14,Thermostable Y-family polymerases and chimeras,"The present disclosure is related to thermostable Y-family polymerases, in particular several novel Y-family polymerases and chimeras made therefrom, as well as methods of identifying other Y-family polymerases, methods of generating other chimeric Y-family polymerases, methods of amplifying ancient or damaged DNA, and methods of incorporating fluorescent or modified nucleotides into a DNA molecule.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12P/34
8114848,14-Feb-12,2012,2,14,Immunomodulatory oligonucleotides,"Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.",10,The United States of America as represented by the Department of Health and Human Services,University of Iowa Research Foundation,"Coley Pharmaceutical Group, Inc.",,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/4706
8114975,14-Feb-12,2012,2,14,Protein tyrosine kinase substrate LAT and its use in the identification of (ANT) agonists of the kinase,"The invention generally relates to compositions and methods for identifying and testing tyrosine kinase signaling pathway agonists and antagonists, and more particularly, methods and compositions for screening compounds and identifying compounds that will modulate the interaction of protein tyrosine kinase substrates with their intracellular ligands, as well as between their intracellular ligands and other members of the signaling pathway.",20,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/40
8119642,21-Feb-12,2012,2,21,Structurally rigid dopamine D3 receptor selective ligands and process for making them,"A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,University of North Texas Health Science Center at Fort Worth,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/70
8119788,21-Feb-12,2012,2,21,Compositions and methods for the detection of Candida species,"Compositions and methods for detecting and/or differentiating among Candida organisms, including C. albicans and C. dubliniensis, are disclosed. Exemplary methods involve screening a sample suspected of containing at least one or more Candida sp. for the presence or absence of a nucleic acid sequence specific for each such fungal pathogen. Some disclosed methods permit the rapid and simultaneous detection and identification of several fungal pathogens (e.g., up to 100 fungi) in a single sample.",15,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
8124092,28-Feb-12,2012,2,28,Antibodies against H5N1 strains of influenza A virus,"Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain, and that are IgG antibodies (but not with a IgG1 heavy chain) that can neutralize a H5N1 strain of influenza A virus.",20,Institute for Research in Biomedicine,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1018
8124105,28-Feb-12,2012,2,28,"Compositions, methods and kits relating to poxvirus subunit vaccines","The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.",4,The Trustees of the University of Pennsylvania,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
8124592,28-Feb-12,2012,2,28,Development of a preventive vaccine for filovirus infection in primates,"The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.",9,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
8124753,28-Feb-12,2012,2,28,Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene,"Composition for the inhibition of the translation of a Mect1-MAML2 chimeric gene consisting essentially of: (a) a fragment of the nucleic acid encoding the chimeric gene, and (b) a nucleic acid complementary to the fragment, and a method of inhibiting the translation of a Mect1-MAML2 chimeric gene comprising contacting a cell expressing the chimeric gene with the composition, whereupon the translation of the chimeric gene is inhibited.",23,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
8125225,28-Feb-12,2012,2,28,Transmit profile control in MRI,"An apparatus for imaging includes: a main magnet to generate a substantially uniform main B0 magnetic field through an examination region; and a coil system including a first coil layer and a second coil layer disposed substantially parallel to the first coil layer with a defined air gap in a radial direction, the first coil layer including a first coil array, the second coil layer including a second coil array, the first and second coil arrays being coupled and cooperating to selectively produce a prespecified B1 magnetic field within the examination region.",23,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/245
8129351,6-Mar-12,2012,3,6,Immunostimulatory nucleic acid molecules,"Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.",18,The University of Iowa Research Foundation,"Coley Pharmaceutical Group, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
8129353,6-Mar-12,2012,3,6,Methods of gene therapy using nucleic acid sequences for ATP-binding cassette transporter,The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.,6,Baylor College of Medicine,John Hopkins University,"The United States of America as represented by the Secretary, Department of Health and Human Services",University of Utah Research Foundation,,,,,,,,4,Biotechnology,,,,,,C07K/705
8131475,6-Mar-12,2012,3,6,"Methods for identifying, diagnosing, and predicting survival of lymphomas","Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.",6,"The United States of America as represented by the Secretary, Department of Health and Human Services",Board of Regents of the University of Nebraska,University of Rochester,Arizona Board of Regents of Behalf of the University of Arizona,Universitat de Barcelona,Fundacio Clinic,Hospital Clinic,Julius-Maximilians-University of Wuerzburg,British Columbia Cancer Agency Branch,Oslo University Hospital HF,"Queen Mary and Westfield College, University of London",11,Analysis of biological materials,Biotechnology,Computer technology,,,,G01N/6842
8132911,13-Mar-12,2012,3,13,Fundus photo-stimulation system and method,"An eye examination device has a fundus observation system and an optical stimulation system. The optical stimulation system has an optical targeting subsystem and an optical stimulation subsystem, wherein the optical stimulation system is structured to be used to provide light stimulation to a portion of a fundus of an eye targeted by the optical targeting subsystem in conjunction with observations made with the fundus observation system.",28,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61B/12
8133859,13-Mar-12,2012,3,13,SCGB3A2 as a growth factor and anti-apoptotic agent,"The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents.",7,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/18
8137960,20-Mar-12,2012,3,20,Bovine adeno-associated viral (BAAV) vector and uses thereof,"The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.",17,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
8143218,27-Mar-12,2012,3,27,"Treatment of skin, and wound repair, with thymosin beta 4",Compositions and methods for treatment of skin utilizing thymosin β4.,21,"Regenerx Biopharmaceuticals, Inc.",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2292
8143252,27-Mar-12,2012,3,27,Tetrahalogenated compounds useful as inhibitors of angiogenesis,"Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof.",31,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/62
8147840,3-Apr-12,2012,4,3,"Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid","This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.",7,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/1063
8148057,3-Apr-12,2012,4,3,"Methods, immunoassays and devices for detection of anti-lipoidal antibodies","Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.",26,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/571
8148082,3-Apr-12,2012,4,3,Phenylthiocarbamide (PTC) taste receptor,"The invention provides isolated nucleic and amino acid sequences of a taste cell receptor that serves as a sensor for the bitter taste of phenylthiocarbamide (PTC), antibodies to such PTC taste receptor, methods of detecting such nucleic and amino acid sequences, and methods of screening for modulators of such PTC taste receptor.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,The University of Utah Research Foundation,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
8148302,3-Apr-12,2012,4,3,In situ assembling of protein microarrays,"The invention provides a microarray and methods for producing a protein microarray. The array comprises multiple nucleic acid molecules immobilized on a substrate, each comprising (i) a protein-binding domain and (ii) a nucleic acid sequence encoding a fusion protein comprising a polypeptide of interest and a DNA-binding protein that binds the protein-binding domain, and one or more fusion proteins produced from the multiple nucleic acid molecules. Each fusion protein is immobilized on the substrate via binding to a nucleic acid sequence comprising the protein-binding domain present on the nucleic acid molecule from which the fusion protein is produced or on the substrate. The invention also provides a method of analyzing protein interactions with, for example, other proteins, lipids and drugs.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6837
8148323,3-Apr-12,2012,4,3,Method of treating or inhibiting inflammation by multi-domain amphipathic helical peptides,Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.,8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/775
8148340,3-Apr-12,2012,4,3,Immunomodulatory oligonucleotides,"Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.",7,The United States of America as represented by the Department of Health and Human Services,University of Iowa Research Foundation,Pfizer Inc.,,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/4706
8153781,10-Apr-12,2012,4,10,Dendrimer conjugates of agonists and antagonists of the GPCR superfamily,"Disclosed are conjugates comprising a dendrimer and a ligand, which is a functionalized congener of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily, for example, wherein the functionalized congener is an A1 adenosine receptor agonist having a purine nucleoside moiety and a functional group at the N6 position of the purine nucleoside moiety, wherein the functional group has the formula (I):N6H—Ar1—CH2—C(═O)NH—R1 (I), wherein Ar1 and R1 as defined herein. Also disclosed are pharmaceutical compositions, methods of treating various diseases, and a diagnostic method employing such conjugates.",56,"The United States of America as represented by the Secretary, Department of Health and Human Services",Inserm,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/0054
8158603,17-Apr-12,2012,4,17,Fragments of secreted frizzled related protein,"The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.",36,The United States of America as represented by the Secretary of the Department of Health and Human Services,University of Massachusetts,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/47
8163542,24-Apr-12,2012,4,24,Potent combinations of mRNA transport elements,This invention provides expression vectors that comprise a combination of RNA transport elements that improve expression.,29,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
8163545,24-Apr-12,2012,4,24,Vaccine against pandemic strains of influenza viruses,"The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided.",21,"United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",Purdue Research Foundation,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
8167087,1-May-12,2012,5,1,Multimodal indicator safety device for ladder positioning,"A safety device for measuring and indicating the level of a ladder having rungs extending between a pair of elongated ladder rails, the safety device comprising a housing dimensioned to be inserted into one of the rungs of the ladder, an electronic sensor disposed in the housing, a controller disposed in the housing, which is in electronical communication with the sensor, at least one indicator, and a power supply for supplying power to the device. The electronic sensor measures the inclination of the ladder to produce a measured inclination which the controller compares to a stored predetermined level value to produce a comparison signal. The at least one indicator receives the comparison signal and indicates to the user the comparison signal.",17,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Civil engineering,,,,,,E06C/003
8168195,1-May-12,2012,5,1,Vaccines against Escherichia coli O157 infection,"This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-DGalpNAc-(1→2)-α-D-PerpNAc-(1→3)-α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide of E. coli O157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.",14,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0258
8168202,1-May-12,2012,5,1,Hexavalent bovine rotavirus reassortant composition designed for use in developing countries,The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human× bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
8168568,1-May-12,2012,5,1,Combinatorial therapy for protein signaling diseases,"A method for selecting combinations of drugs for treatment of diseases that arise from deranged signaling pathways is disclosed. The method involves measuring the activity states for signaling proteins in a diseased cell and determining whether the activity states are different from the activity states observed for a reference cell such as a normal cell. Based on the observed differences, combinations of two or more drugs are selected to reduce these differences. Treatment of a subject with the combinations restores the activity states of the signaling proteins of the deranged disease-associated signaling pathways toward the activity states observed in the reference cell. Since the diseased cell and the reference cell can both be obtained from the same subject, combinations of drugs that specifically target patient-specific signaling derangements is possible.",90,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5041
8173123,8-May-12,2012,5,8,Methods of treating colitis involving IL-13 and NK-T cells,Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.,4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Brigham & Women's Hospital,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/2833
8173131,8-May-12,2012,5,8,Compositions and methods for modulating RSV infection and immunity,"Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.",9,"PerkinElmer Health Sciences, Inc.",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/00
8173135,8-May-12,2012,5,8,Methods for preparing complex multivalent immunogenic conjugates,Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.,34,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/084
8175348,8-May-12,2012,5,8,Segmenting colon wall via level set techniques,"Various level set techniques can be used to automatically segment the colon wall, including identifying the colon wall outer boundary. A speed image can be used during level set processing. For example, the speed image can be generated via inverting the gradient perpendicular to the segmented inner boundary of the colon wall. The techniques can be useful for determining wall thickness, which can be used to classify polyp candidates, diagnose diseases of the colon, and the like.",32,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Computer technology,,,,,G06T/0012
8175688,8-May-12,2012,5,8,Multispectral/hyperspectral medical instrument,A medical instrument that comprises: a first-stage optic responsive to a tissue surface of a patient; a spectral separator optically responsive to the first stage optic and having a control input; an imaging sensor optically responsive to the spectral separator and having an image data output; and a diagnostic processor having an image acquisition interface with an input responsive to the imaging sensor and a filter control interface having a control output provided to the control input of the spectral separator.,20,"Hypermed Imaging, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Medical technology,,,,,,A61B/0064
8178508,15-May-12,2012,5,15,Methods of stimulating an immune response against prostate specific antigen,"The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus.",18,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/001194
8188055,29-May-12,2012,5,29,Inactivators of O6-alkylguanine-DNA alkyltransferase,"Disclosed are compounds that are AGT inactivators that include a folate residue, e.g., a compound of formula (I), wherein X1, X2, R1, and R2 are as described herein. Also disclosed is a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier. Also disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells and inactivating AGT in a tumor cell. The methods comprise, inter alia, administering a compound or pharmaceutically acceptable salt of formula (I).",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The Penn State Research Foundation,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07H/16
8188214,29-May-12,2012,5,29,Brachyury polypeptides and methods for use,"It is disclosed herein that Brachyury is expressed in human tumors, specifically in tumors of the small intestine, stomach, kidney, bladder, uterus, ovary, and testes, as well as in lung, colon and prostate carcinomas. Immunogenic Brachyury polypeptides are disclosed herein. These polypeptides can be used in diagnostic assays for Brachyury expression, as well as for inducing an immune response to Brachyury. Polynucleotides encoding the immunogenic Brachyury polypeptides, vectors including these polypeptides, host cells transformed with these vectors, and methods of using these polypeptides, polynucleotides, vectors, and host cells are provided. Methods of diagnosing a Brachyury-expressing cancer are also provided. Exemplary cancers include lung, colon, small intestine, stomach, kidney, bladder, uterus, ovary, and testes and prostate cancers. Methods of treating cancer are also disclosed.",42,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/113
8189890,29-May-12,2012,5,29,Computer-aided classification of anomalies in anatomical structures,"Candidate anomalies in an anatomical structure are processed for classification. For example, false positives can be reduced by techniques related to the anomaly's neck, wall thickness associated with the anomaly, template matching performed for the anomaly, or some combination thereof. The various techniques can be combined for use in a classifier, which can determine whether the anomaly is of interest. For example, a computed tomography scan of a colon can be analyzed to determine whether a candidate anomaly is a polyp. The technologies can be applied to a variety of other scenarios involving other anatomical structures.",27,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,G16H/00
8191552,5-Jun-12,2012,6,5,"Negative pressure, bi-directional nasal aerosol delivery","A method and apparatus for nasal drug delivery comprises a first tube in fluid communication with a means for generating a negative pressure and a second tube in fluid communication with an aerosol. The first tube is contacted with one nostril, the said second tube is contacted with the other nostril, and a negative pressure is applied to the first tube, producing a negative pressure within a nasal cavity and causing the aerosol to be drawn into the nasal passages and to deposit on an internal nasal surface.",25,CFD Research Corporation,Centers For Disease Control and Prevention,,,,,,,,,,2,Medical technology,,,,,,A61M/08
8198042,12-Jun-12,2012,6,12,"CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection","The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.",20,"The United States of America, represented by the Secretary, Department of Health and Human Services","The United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/7158
8198042,12-Jun-12,2012,6,12,"CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection","The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.",20,"The United States of America, represented by the Secretary, Department of Health and Human Services","The United States of America, represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/7158
8198048,12-Jun-12,2012,6,12,Mammalian sweet taste receptors,"The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet taste receptors.",23,The Regents of the University of California,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C07K/705
8198244,12-Jun-12,2012,6,12,Regulation of skin characteristics by DICKKOPF1 (DKK1),"The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/1709
8198402,12-Jun-12,2012,6,12,Smoothened polypeptides and methods of use,"Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided. Methods of inhibiting proliferation of a diseased cell, treating or preventing cancer, treating a neoplasm or psoriasis, and inhibiting the expression of genes involved in the Hedgehog signaling pathway, thereby inhibiting the Hedgehog signaling pathway, are furthermore provided by the invention.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/705
8202520,19-Jun-12,2012,6,19,Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine,"This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0275
8202551,19-Jun-12,2012,6,19,"Tissue engineered cartilage, method of making same, therapeutic and cosmetic surgical applications using same","Cartilage has been constructed using biodegradable electrospun polymeric scaffolds seeded with chondrocytes or adult mesenchymal stem cells. More particularly engineered cartilage has been prepared where the cartilage has a biodegradable and biocompatible nanofibrous polymer support prepared by electrospinning and a plurality of chondocytes or mesenchymal stem cells dispersed in the pores of the support. The tissue engineered cartilages of the invention possess compressive strength properties similar to natural cartilage. Methods of preparing engineered tissues, including tissue engineered cartilages, are provided in which an electrospun nanofibrous polymer support is provided, the support is treated with a cell solution and the polymer-cell mixture cultured in a rotating bioreactor to generate the cartilage. The invention provides for the use of the tissue engineered cartilages in the treatment of cartilage degenerative diseases, reconstructive surgery, and cosmetic surgery.",5,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Medical technology,Organic fine chemistry,"Macromolecular chemistry, polymers",,,,A61Q/00
8202910,19-Jun-12,2012,6,19,Compositions and methods for treatment of infectious disease,"Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol.",33,"Sequella, Inc.",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/132
8205511,26-Jun-12,2012,6,26,Air-sampling device and method of use,"The present disclosure concerns embodiments of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere. In one representative embodiment, the sampling apparatus includes a collection-vessel retaining member that is adapted to be removably coupled to a collection vessel. The retaining member has an air-inlet conduit for permitting air to flow through the open end of the collection vessel and an air-outlet conduit for permitting air to exit the open end of the collection vessel. The air-inlet conduit and the air-outlet conduit are configured to cause air flowing into the collection vessel to establishes a cyclonic flow path, which causes airborne particles to separate out from the air stream and collect in the collection vessel.",20,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Measurement,,,,,,G01N/0606
8206933,26-Jun-12,2012,6,26,Boris isoforms and methods of detecting and treating disease,"A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same.",8,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/574
8206937,26-Jun-12,2012,6,26,Tumor suppressor gene p33ING2,"The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",3,"The United States of America, as represented by the Secretay of the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07H/02
8207142,26-Jun-12,2012,6,26,Inhibitor of DNA methylation,"Zebularine has hypomethylating activity, and can be used to inhibit, reverse, and/or reduce DNA methylation in vivo and in vitro. Methods are provided for treating methylation-linked conditions through the application of 2-pyrimidinone derivatives, such as Zebularine. Compositions, including pharmaceutical compositions, comprising such derivatives are also provided. Also provided are kits for use in inhibiting DNA methylation, which kits include an amount of a 2-pyrimidinone derivative.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,University of Oregon,University of Miami School of Medicine,University of Sounthern California,University of Miami,,,,,,,5,Pharmaceuticals,Organic fine chemistry,,,,,A61K/7068
8211171,3-Jul-12,2012,7,3,Transcatheter coronary sinus mitral valve annuloplasty procedure and coronary artery and myocardial protection device,A protective device or bridge (20) comprising a central arch (24) is suitable to be placed between an annuplasty device placed in the coronary sinus and an underlying coronary artery to inhibit transmission of compressive force on the coronary artery by the annuplasty device.,22,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61F/2451
8211422,3-Jul-12,2012,7,3,Chimeric receptor genes and cells transformed therewith,"Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.",30,"The United States of America, as represented by the Secretary, Department of Health and Human Services","Yeda Research and Development Co., Ltd.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/7155
8211445,3-Jul-12,2012,7,3,PSM peptides as vaccine targets against methicillin-resistant Staphylococcus,"This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly methicillin-resistant Staphylococcus. In certain embodiments, the disclosure concerns immunogenic peptides, for instance PSM peptides, which can be used to induce protective immunity against methicillin-resistant Staphylococcus. Also disclosed are methods of detecting methicillin-resistant staphylococcus in a sample, and methods of diagnosing methicillin-resistant staphylococcus in a subject.",16,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56938
8212011,3-Jul-12,2012,7,3,Novobiocin analogues,"Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders, as well as cancer.",31,University of Kansas,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/14
8212012,3-Jul-12,2012,7,3,Novobiocin analogues having modified sugar moieties,"Novobiocin analogues useful as Hsp90 inhibitors in the treatment of cancer, neuroprotection, and autoimmune disorders.",27,University of Kansas,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/14
8216565,10-Jul-12,2012,7,10,GP100-specific T cell receptors and related materials and methods of use,"The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.",9,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/70503
8216783,10-Jul-12,2012,7,10,Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors,"This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR4 variants, which are linked to increased risk of tumor metastasis. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6883
8216788,10-Jul-12,2012,7,10,Detection of infectious prion protein by seeded conversion of recombinant prion protein,"The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting PrP-res (PrPSc) that allows the use of recombinant PrP-sen (rPrP-sen) as a substrate for seeded polymerization. A sample is mixed with purified rPrP-sen to make a reaction mix which is incubated to permit aggregation of the rPrP-sen with the PrP-res that may be present in the sample. Any aggregates are intermittently disaggregated by agitation (for example by sonication) and the reaction allowed to proceed to amplify target substrate. Any rPrP-res(Sc) in the reaction mix is detected to indicate the presence of PrP-res in the original sample. This assay, which is called rPrP-PMCA, is surprisingly much faster than existing PMCA methods, yet it still retains sufficient sensitivity to detect extremely low levels of PrP-res. An alternative of rPrP-PMCA is the QUIC method in which shaking of the reaction mixture is substituted for sonication. The surprising speed and efficiency of the method permits the rapid identification and diagnosis of prion disease, which can limit the transmission of prion diseases, particularly through the food supply.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6896
8217158,10-Jul-12,2012,7,10,Immunotoxin fusion proteins and means for expression thereof,"The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.",4,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/00
8217222,10-Jul-12,2012,7,10,"Methods for identifying markers for early-stage human cancer, cancer progression and recurrence",A method is described to identify secreted proteins identified with stages of malignancy of cancer. The proteins are initially identified by trapping them with a fluorescent protein containing vector that can insert in any gene. The secreted proteins are initially identified by their fluorescence. Secreted proteins identifying tumors with specific degrees of malignancy are isolated to determine if they can serve as markers of cancer progression.,6,"Anticancer, Inc.",The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12N/1051
8221759,17-Jul-12,2012,7,17,Neutralizing monoclonal antibodies to respiratory syncytial virus,"The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.",1,Intracel Resources LLC,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/1027
8221768,17-Jul-12,2012,7,17,Chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence,"The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus antigen comprising sequence from more than one flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.",30,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
8222225,17-Jul-12,2012,7,17,Method of treating pneumoconiosis with oligodeoxynucleotides,"Methods are disclosed for treating, preventing or reducing the risk of developing occupational lung diseases, such as pneumoconiosis. In several embodiments, the methods include administering a therapeutically effective amount of the suppressive ODN to a subject having or at risk of developing a pneumoconiosis, thereby treating or inhibiting the pneumoconiosis. In several examples, thee subject can have or be at risk of developing silicosis, asbestosis or berryliosis. The method can include selecting a subject exposed to, or at risk of exposure to, inorganic particles, including, but not limited to silica, asbestos, berrylium, coal dust, or bauxite.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7088
8226952,24-Jul-12,2012,7,24,Human antibodies against rabies and uses thereof,"Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.",23,University of Massachusetts,Centers for Disease Control and Prevention,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/005
8227185,24-Jul-12,2012,7,24,"Non-M, non-O HIV-1 strains, fragments and uses","Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent.The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics:",12,Institute National de la Sante et de la Recherche Medical-Inserm,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
8227417,24-Jul-12,2012,7,24,HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants,"A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.",32,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/0639
8227438,24-Jul-12,2012,7,24,Suppressors of CpG oligonucleotides and methods of use,"The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.",26,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
8227443,24-Jul-12,2012,7,24,Silencing of CSN5 gene expression using interfering RNA,"The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.",20,"Protiva Biotherapeutics, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8227446,24-Jul-12,2012,7,24,Oligodeoxynucleotide and its use to induce an immune response,"D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula:5′X1X2X3Pu1Py2CpGPu3Py4X4X5X6(W)M(G)N-3′wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10. Methods of using these oligodeoxynucleotides to induce an immune response are provided.",27,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/008
8232259,31-Jul-12,2012,7,31,Multiple CpG oligodeoxynucleotide and their use to induce an immune response,Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.,19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
8232379,31-Jul-12,2012,7,31,Nucleic acids encoding chimeric flavivirus immunogens comprising the Japanese encephalitis virus (JEV) prM signal sequence,"The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.",20,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
8236313,7-Aug-12,2012,8,7,"Prevention of tissue ischemia, related methods and compositions","Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow.",29,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",Washington University,,,,,,,,,,2,Organic fine chemistry,Chemical engineering,Pharmaceuticals,Biotechnology,Analysis of biological materials,,C07K/18
8236324,7-Aug-12,2012,8,7,Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens,"An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognized by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.",11,Institut Pasteur,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
8240202,14-Aug-12,2012,8,14,Hand dynamometer with improved configuration for grip strength assessment,A handle assembly mounted to a dynamometer measuring device including a base mounted to an input location of the measuring device. A plurality of arms extend in a lineal direction from the base and are arranged in spaced and gap defining fashion. The arms deflect inward relative to one another upon being exerted by a compressing force and concurrent with outputting a signal through at least one strain gauge wire extending from an interior of each arm to the measuring device.,16,Centers for Disease Control and Prevention,,,,,,,,,,,1,Medical technology,,,,,,A61B/225
8241853,14-Aug-12,2012,8,14,Primers and probes for detection and discrimination of types and subtypes of influenza viruses,"Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.",34,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
8242160,14-Aug-12,2012,8,14,Inhibitors of ubiquitin E1,"The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.",3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
8242778,14-Aug-12,2012,8,14,Fast electron paramagnetic resonance imaging (EPRI) in the CW EPR mode using rapid-scan in the presence of rotating gradients and direct detection with transmit/receive and data processing in a digital signal processing platform,"An electron paramagnetic resonance imaging system that includes means for continuously irradiating a sample with RF irradiation; means for imposing on the sample a sinusoidally varying magnetic field along with rotating gradients for spatial encoding; means for directly detecting signal data from the sample, without using field modulation, while irradiating the sample with RF radiation continuously, the means for directly detecting having means for sweeping the sinusoidally varying magnetic field; and means for transmitting, receiving and processing the signal data, using means including a digital signal processor.",22,"The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/60
8247183,21-Aug-12,2012,8,21,Compositions and methods for diagnosis and treatment of tumors,"Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.",17,"The United States of America, as represented by the Secretary of the Departmant of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/2848
8247225,21-Aug-12,2012,8,21,DNA promoters and anthrax vaccines,The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.,5,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/32
8247228,21-Aug-12,2012,8,21,Method of inducing memory B cell development and terminal differentiation,"The invention provides a method for promoting differentiation of a mature naïve B cell or a B cell progenitor into a memory B cell or a plasma cell. The method comprises (a) contacting a population of cells comprising a mature naïve B cell or a B cell progenitor with an agent that activates at least one of JAK1, JAK3, STAT3, STAT5A or STAT5B; wherein the population of cells optionally is contacted with an antigen, and (b) isolating the memory B cell or plasma cell.",8,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,G01N/5052
8252538,28-Aug-12,2012,8,28,MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma,"Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.",9,The Ohio State University,"The United States of America as represented by the Secretary of the Department of Health and Human Services National Institute of Health, Office of Technology Transfer","Liver Cancer Institute and Zhongshan Hospital, Fudan University",,,,,,,,,3,Biotechnology,Biotechnology,,,,,C12Q/6886
8252545,28-Aug-12,2012,8,28,"Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods","Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.",20,"The United States of America, as represented by the Secretary Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/4748
8252550,28-Aug-12,2012,8,28,Targeting poly-γ-glutamic acid to treat Staphylococcus epidermidis and related infections,"Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-γ-glutamic acid (such as γDLPGA) polypeptides of S. epidermidis, or related staphylococci that express a γPGA polypeptide. The γPGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the Staphylococcus organism which expresses γPGA from the cap genes. Further, the expression of a γPGA polypeptide by the organism can then be altered.",4,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12P/02
8257568,4-Sep-12,2012,9,4,Method for concentration and separation of biological organisms by ultrafiltration and dielectrophoresis,"Disclosed is a method for monitoring sources of public water supply for a variety of pathogens by using a combination of ultrafiltration techniques together dielectrophoretic separation techniques. Because water-borne pathogens, whether present due to “natural” contamination or intentional introduction, would likely be present in drinking water at low concentrations when samples are collected for monitoring or outbreak investigations, an approach is needed to quickly and efficiently concentrate and separate particles such as viruses, bacteria, and parasites in large volumes of water (e.g., 100 L or more) while simultaneously reducing the sample volume to levels sufficient for detecting low concentrations of microbes (e.g., <10 mL). The technique is also designed to screen the separated microbes based on specific conductivity and size.",11,Sandia Corporation,,,,,,,,,,,1,Chemical engineering,,,,,,B01D/145
8257915,4-Sep-12,2012,9,4,"Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis","Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors.",8,"Progeria Research Foundation, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,The University of North Carolina at Chapel Hill,The Regents of the University of Michigan,,,,,,,,4,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/4545
8257925,4-Sep-12,2012,9,4,Method for detecting the presence of a single target nucleic acid in a sample,A miniaturized assembly is provided whereby a fluid sample can be divided into a plurality of sample portions in retaining wells and the sample fluid can be displaced from open ends of the wells while simultaneously being sealed in the wells. A method of dividing a fluid sample using the assembly is also provided.,15,"Applied Biosystems, LLC","The United States of America, as represented Department of Health and Human Services",,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
8258106,4-Sep-12,2012,9,4,Immunostimulatory nucleic acid molecules,"Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.",26,University of Iowa Research Foundation,"Coley Pharmaceutical Group, Inc.","The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,3,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,A61K/00
8258172,4-Sep-12,2012,9,4,Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof,The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.,25,Raptor Pharmaceutical Corp,National Institutes of Health (NIH),,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
8258278,4-Sep-12,2012,9,4,Methods and compositions for the treatment and prevention of cancer,"The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3α/CCL20 or β-defensin mDF2β. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/4748
8263091,11-Sep-12,2012,9,11,Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides,"A method is disclosed herein for increasing an immune response to an opportunistic infection in an immunocompromised subject. In one embodiment, the subject is infected with a lentivirus. The method includes increasing an immune response to a pathogen using D oligodeoxynucleotides including a CpG motif.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/082
8263360,11-Sep-12,2012,9,11,"Hydrophilic IR transparent membrane, spectroscopic sample holder comprising same and method of using same","The present invention features hydrophilic IR-transparent porous membranes, particularly hydrophilic IR-transparent porous polyethylene membranes and methods of preparing the hydrophilic membranes by treatment of hydrophobic IR-transparent porous membranes with plasma. The present invention further features spectroscopic sample holders which incorporate the hydrophilic IR-transparent porous membranes and methods of identifying bacteria and other microorganisms in samples by infrared spectroscopy.",14,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Measurement,Biotechnology,,,,,C12Q/04
8263759,11-Sep-12,2012,9,11,Sets of probes and primers for the diagnosis of select cancers,A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for diagnosing a cancer.,12,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Computer technology,,,,,,G16B/00
8268323,18-Sep-12,2012,9,18,Conformationally stabilized HIV envelope immunogens,"Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Dana Farber Cancer Institute, Inc.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
8268602,18-Sep-12,2012,9,18,Cellular and viral inactivation,"The invention provides compositions of inactivated viruses, bacteria, fungi, parasites and tumor cells that can be used as vaccines. Methods for making such inactivated viruses, bacteria, fungi, parasites and tumor cells are also provided.",10,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
8268787,18-Sep-12,2012,9,18,Methods and apparatus for creating particle derivatives of HDL with reduced lipid content,"The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.",11,HDL Therapeutics,,,,,,,,,,,1,Pharmaceuticals,Chemical engineering,Biotechnology,Analysis of biological materials,,,C07K/775
8268890,18-Sep-12,2012,9,18,Method of treating ischemia/reperfusion injury with nitroxyl donors,"Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.",56,Johns Hopkins University,The United States of America as represented by the Secretary of Health and Human Services,The Regents of the University of California,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/655
8268894,18-Sep-12,2012,9,18,Compositions and methods for the treatment of infectious diseases,"Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.",21,"The United States of America as Represented by the Secretary, Department of Health and Human Services","Sequella, Inc.",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07C/25
8269496,18-Sep-12,2012,9,18,Fast electron paramagnetic resonance imaging (EPRI) using CW EPR spectrometer with sinusoidal rapid-scan and digital signal processing,"An electron paramagnetic resonance imaging system that includes means for continuously irradiating a sample with RF irradiation; means for imposing on the sample a sinusoidally varying magnetic field along with rotating gradients for spatial encoding; means for directly detecting signal data from the sample, without using field modulation, while irradiating the sample with RF radiation continuously, the means for directly detecting having means for sweeping the sinusoidally varying magnetic field; and means for processing the signal data, using means including a digital signal processor.",16,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/60
8273724,25-Sep-12,2012,9,25,Melanoma antigens and their use in diagnostic and therapeutic methods,"The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
8273797,25-Sep-12,2012,9,25,Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde,The present invention features methods of treating a mammalian subject having renal cancer by administration of 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.,20,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
8278071,2-Oct-12,2012,10,2,Method for detecting the presence of a single target nucleic acid in a sample,"A method comprising subjecting one or more sample portion(s) to a single amplification step, thereby amplifying a single molecule in the sample portion to a detectable level, and, in some embodiments, then determining whether the sample portion contains at least one molecule of the target nucleic acid. In some embodiments, the sample portion is in a porous sample structure, or in a sample chamber which comprises means for minimizing diffusion of the sample portion, or in a sample chamber which is inside a microcapillary device, or in a sample retaining means.",6,"Applied Biosystems, LLC",The United States Department of Health and Human Service,,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
8278083,2-Oct-12,2012,10,2,Inactivated influenza virus compositions,"The invention provides compositions of inactivated influenza virus that can be used as vaccines and immunological compositions useful for inhibiting, preventing and treating influenza.",5,The United States of America as represented by the Secretary of the Department of Health and Human Services,"University of Georgia Research Foundation, Inc.",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/145
8278100,2-Oct-12,2012,10,2,Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders,"The present invention is directed towards lasonolide derivatives, methods of inducing premature chromosome condensation using lasonolide derivatives, and methods of treating disorders, such as cancer, in a subject, the method comprising administering to the subject a lasonolide derivative.",8,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/18
8278272,2-Oct-12,2012,10,2,"GLP-1, exendin-4, peptide analogs and uses thereof","The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.",24,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/575
8278348,2-Oct-12,2012,10,2,"Chondropsin-class antitumor V-atpase inhibitor compounds, compositions and methods of use thereof","A composition comprising a substantially purified compound of the formula:in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.",9,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
8282926,9-Oct-12,2012,10,9,CCR5-specific antibodies with HIV neutralizing activity that recognize a linear dodecapeptide that mimics a conformational epitope in the second extracellular loop of CCR5,"The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.",7,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/2866
8283122,9-Oct-12,2012,10,9,Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma,A method of predicting the outcome of a patient with neuroblastoma that includes obtaining experimental data on gene selections. The gene selection functions to predict the outcome of a patient with neuroblastoma when the expression of that gene selection is compared to the identical selection from a non-neuroblastoma cell or a different type of neuroblastoma cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for predicting the outcome of patient with neuroblastoma.,24,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
8283151,9-Oct-12,2012,10,9,"Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes","The present invention provides new adeno-associated virus (AAV) viruses and vectors, and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV vectors and particles.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/005
8283158,9-Oct-12,2012,10,9,Method and apparatus for performing multiple simultaneous manipulations of biomolecules in a two dimensional array,"This invention relates to methods and apparati for performing multiple simultaneous manipulations of biomolecules in a two-dimensional array, such as a gel, membrane, tissue biopsy, etc. Such manipulations particularly include assays and nucleic acid amplification protocols.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6837
8287857,16-Oct-12,2012,10,16,Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy,"A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.",26,"The United States of America, as represented by the Secretary, Deparment of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
8288359,16-Oct-12,2012,10,16,Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides,The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.,20,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
8288439,16-Oct-12,2012,10,16,Methods and compositions for the inhibition of HIV-1 replication,"This invention relates to methods and compositions for the attenuation of HIV-1 replication in human cells, and especially in human macrophages. The invention particularly concerns the use of inhibitors of P21 (CDKNIA) expression to attenuate such replication. The invention particularly concerns the use of antisense P21 oligonucleotides, siRNA and/or 2-cyano-3,12-dioxooleana-1,9-dien28-oic (CDDO) to attenuate such replication.",3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/1132
8288530,16-Oct-12,2012,10,16,Method of preparing macromolecular contrast agents and uses thereof,"Disclosed are methods of preparing a macromolecular conjugated ligand and a metal complex thereof. The metal complex is targeted for use as a contrast agent, for example, in MRI. The method of preparing a macromolecular conjugated ligand comprises: (a) providing a compound of formula (I)wherein R, A, and Pg are as defined herein, (b) reacting the compound of formula (I) with a macromolecular compound (e.g., dendrimer) in an organic solvent medium which is substantially free of water to obtain a macromolecular conjugated compound, and (c) removing the carboxyl-protecting groups to obtain a carboxyl-deprotected macromolecular conjugated compound. The metal complex can be prepared by reacting the carboxyl-deprotected macromolecular conjugated compound with an ion (e.g., Gd(III)). Also disclosed are two carboxyl-protected 1B4M-DTPA intermediate compounds.",28,"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/065
8293187,23-Oct-12,2012,10,23,Device and method for direct measurement of isotopes of expired gases,"The invention provides a device including a chamber wherein the chamber including a rigid enclosure; a rigid lid for the enclosure; a gasket between the lid and the enclosure to allow for an airtight seal between the enclosure and the gasket upon closure of a latch connecting the enclosure and the lid; a port for airtight attachment of a syringe, and a port for airtight insertion of a gas sensor. The device can further include a gas sensor and one or more syringes for attachment to the device by a three-way stopcocks. The device is appropriately sized for use with the subject of interest. The invention also provides methods for use of the device.",17,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Analysis of biological materials,,,,,G01N/497
8293724,23-Oct-12,2012,10,23,Therapeutic applications of fatty acid amide hydrolase inhibitors,"Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/82
8298525,30-Oct-12,2012,10,30,Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist,"Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/2866
8298541,30-Oct-12,2012,10,30,Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae,"The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.",7,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/12
8299046,30-Oct-12,2012,10,30,Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth,"The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34.",36,Trustees of Dartmouth College,"Osteoscreen, Inc.",The Regents of the Universtiy of California,,,,,,,,,3,Pharmaceuticals,Biotechnology,,,,,A61K/4164
8299050,30-Oct-12,2012,10,30,Method for treating uterine fibroids,"The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.",9,Laboratoire HRA-Pharma,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/57
8303960,6-Nov-12,2012,11,6,Radiolabeled affibody molecules,"The invention provides a radiolabeled affibody molecule comprising a fragment of an IgG-binding domain of protein A from Staphylococcus aureus, a bifunctional linker, and a radiolabel comprising 18F or 76Br, wherein the bifunctional linker links the fragment and the radiolabel. The affibody molecule binds with high affinity to select receptors, which are over-expressed in certain cancers. Since the radionuclides emit a positron, the in vitro and in vivo binding characteristics of the radiolabeled affibody can be assessed using diagnostic imaging.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/1045
8304199,6-Nov-12,2012,11,6,Methods for diagnosing and monitoring the progression of cancer by measuring soluble c-Met ectodomain,Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.,23,"The United States of America, as represented by the Secretary, Department of Health and Human Services","Amgen, Inc.",,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/57488
8309313,13-Nov-12,2012,11,13,Glycated peptides and methods of use,"The invention provides glycated peptides and glycated fragments and glycated variants thereof, antibodies and aptamers which bind thereto, compositions and kits comprising the same, related conjugates, and a database comprising data indicating the concentration of glycated peptides present in diabetic and non-diabetic persons. The invention also provides a method of monitoring glycemic control, a method of treating or preventing diabetes, a method of preventing a complication of diabetes, a method of monitoring the status of diabetes, a method of determining the efficacy of a diabetes treatment, as well as methods of detecting diabetes or a predisposition thereto.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/6893
8309527,13-Nov-12,2012,11,13,Immunomodulatory oligonucleotides,"Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.",8,University of Iowa Research Foundation,"The United States of America, as represented by the Secretary, Department of Health and Human Services","Coley Pharmaceutical Group, Inc.",,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/4706
8309701,13-Nov-12,2012,11,13,Variants of human taste receptor genes,"Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.",18,The United States of America as represented by the Secrectary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/705
8313746,20-Nov-12,2012,11,20,Human monoclonal antibodies against hendra and nipah viruses,"The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",14,"The Henry Jackson Foundation for the Advancement of Military Medicine, Inc.","The United States of America, as Represented by the Secretary of the Department of Health and Human Services National Institutes of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1203
8316986,27-Nov-12,2012,11,27,Sound attenuation canopy,"A sound attenuation canopy for reducing levels of sound passing through an opening comprises a sound absorbing member. The member is comprised of a flexible sound absorbing material and has a first end, a second end and an intermediate portion extending therebetween. The first end is configured to attach to the opening's periphery at a first location, the second end is configured to attach to the periphery at a second location and the intermediate portion is configured to be spaced apart from the opening. When the first end and the second end are attached to the periphery of the opening, at least one side opening is at least partially defined by the intermediate portion and the perimeter of the opening, and a sound transmission flow path through open space between the opening and the side opening comprises at least one change of direction greater than 45 degrees.",20,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Civil engineering,,,,,,E04B/001
8318177,27-Nov-12,2012,11,27,Viral chemokine-antigen fusion proteins,"The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/521
8318425,27-Nov-12,2012,11,27,Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein,"Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.",1,"The United States of America, as represented by the Secretary, Department & Human Services","Myrexis, Inc.",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/06
8318428,27-Nov-12,2012,11,27,Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs,"Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.",7,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
8318666,27-Nov-12,2012,11,27,Use of leptin to treat metabolic abnormalities associated with lipoatrophy,"Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.",35,"Amgen, Inc.","The United States of America, as Represented by the Secretary, Department of Health and Human Services","Board of Regents, The University of Texas System",,,,,,,,,3,Pharmaceuticals,Analysis of biological materials,,,,,A61K/2264
8323961,4-Dec-12,2012,12,4,HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV,"The invention provides a composition comprising four adenoviral vectors, each comprising a nucleic acid sequence encoding a clade A HIV Env protein, a clade B HIV Env protein, a clade C HIV Env protein, and a clade B HIV Gag-Pol fusion protein, respectively. The invention also provides a method of inducing an immune response against HIV-1 in an animal comprising administering the composition to the animal.",2,"The United States of America, as represented by the Secretary, Department of Health and Human Services","GenVex, Inc.",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/21
8328729,11-Dec-12,2012,12,11,Acoustic plethysmograph for measuring pulmonary function,"The present disclosure concerns embodiments of an acoustic plethysmograph for measuring pulmonary function of an animal, such as a mouse. The plethysmograph in exemplary embodiments can measure thoracic tidal volume of an unrestrained animal. The plethysmograph in exemplary embodiments acoustically excites the chamber containing the animal and detects changes in the acoustic pressure in the chamber, which correlate to the thoracic tidal volume of the animal. Unlike the conventional whole-body plethysmograph, this acoustic plethysmograph provides a direct measure of thoracic tidal volume. The plethysmograph also can be configured to measure chamber flow (the flow of air into and out of the chamber). Specific airway resistance of the animal can then be determined from the thoracic tidal volume and plethysmograph flow measurements.",23,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Medical technology,,,,,,A61B/0806
8328857,11-Dec-12,2012,12,11,Method for treating a patient having a spinal cord injury using phototherapy,A method of treating spinal cord injury (SCI) includes transcutaneously irradiating at least a portion of a spinal environment of the patient with light having a power density of at least about 0.01 mW/cm2 at the portion of the spinal environment.,25,The United States of America as represented by the Department of Health and Human Services,Henry M. Jackson Foundation for the Advancement of Military Medicine,,,,,,,,,,2,Medical technology,,,,,,A61N/0613
8329396,11-Dec-12,2012,12,11,Cloned DNA sequences hybridizable with genomic RNA of lymphadenopathy associated virus (LAV),This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method of detecting lymphadenopathy associated virus or related viruses or DNA pro-viruses with cloned DNA sequences which are hybridizable to genomic RNA and DNA of lymphadenopathy associated virus. It further relates to the cloned DNA sequences and a process for their preparation.,27,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
8329885,11-Dec-12,2012,12,11,Nucleic acid encoding a T2R taste receptor,"The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.",6,The Regents of the University of California,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/74
8334260,18-Dec-12,2012,12,18,sFRP and peptide motifs that interact with sFRP and methods of their use,"This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also includes methods of regulating the interaction of sFRP-1 with proteins containing the motif.",27,The United States of America as represented by the Secretary of the Department of Health and Human Services,St. Vincent's Institute of Medical Research,,,,,,,,,,2,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C12N/0643
8337831,25-Dec-12,2012,12,25,"Live, oral vaccine for protection against Shigella dysenteriae serotype 1","The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.",6,"The United States of America, as Represented by the Secrectary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
8337832,25-Dec-12,2012,12,25,Vaccine for protection against Shigella sonnei disease,Compositions and methods for protecting a susceptible host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.,20,"The United States of America, As Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
8337853,25-Dec-12,2012,12,25,Monoclonal antibodies that bind or neutralize dengue virus,"The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",25,"The United States of America as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/10
8337854,25-Dec-12,2012,12,25,Monoclonal antibodies against dengue and other viruses with deletion in Fc region,"The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (FcγR) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.",16,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1081
8337860,25-Dec-12,2012,12,25,Development of dengue virus vaccine components,"The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.",14,"The United States of America, as represented by the Secretary of the Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/045
8338102,25-Dec-12,2012,12,25,Method of diagnosing poor survival prognosis colon cancer using miR-181b,"The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.",18,The Ohio State University Research Foundation,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institute of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8338103,25-Dec-12,2012,12,25,Method of diagnosing poor survival prognosis colon cancer using miR-106a,"The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.",18,The Ohio State University Research Foundation,"The United States of America, as represented by the Secretary of the Deparment of Health and Human Services, National Institute of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8338104,25-Dec-12,2012,12,25,Method of diagnosing poor survival prognosis colon cancer using miR-103-2,"The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.",18,The Ohio State University Research Foundation,"The United States of America, as represented by the Department of Health and Human Services, National Institute of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8338105,25-Dec-12,2012,12,25,Method of diagnosing poor survival prognosis colon cancer using miR-203,"The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.",18,The Ohio State University Research Foundation,"The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institute of Health, Office of Technology Tansfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8338106,25-Dec-12,2012,12,25,Method of diagnosing poor survival prognosis colon cancer using miR-29a,"The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.",18,The Ohio State University Research Foundation,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institute of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8338457,25-Dec-12,2012,12,25,Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist,"The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons.",14,The United States of America as represented by the Secretary of the Department of Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/357
8340381,25-Dec-12,2012,12,25,Hybrid segmentation of anatomical structure,"An image of an anatomical structure can be analyzed to determine an enclosing three-dimensional boundary when the anatomical structure is filled with two substances, such as air and a fluid. Various techniques can be used to determine the enclosing boundary including: analyzing the virtual structure to segment the structure into air and fluid pockets, determining if there are multiple fluid pockets whose surface touches a single air-fluid boundary, determining a separate threshold for respective fluid pockets, resegmenting the virtual anatomical structure using the separate threshold for different fluid pockets, forming a hierarchical pocket tree which represents the relationship between the fluid and air pockets, pruning the pocket tree based on various criteria which corresponds to deleting those pruned portions from the virtual anatomical structure, and resegmenting the remaining virtual anatomical structure using one or more of fuzzy connectedness, two-dimensional gap filling, and level set segmentation.",25,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Computer technology,,,,,,G06K/34
8343479,1-Jan-13,2013,1,1,Methods and compositions for the repair and/or regeneration of damaged myocardium,"Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of stem cells, such as adult stem cells, optionally with cytokines are disclosed and claimed.",21,New York Medical College,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Other special machines,,,,C12N/0647
8343499,1-Jan-13,2013,1,1,"Anti-arthropod vector vaccines, methods of selecting and uses thereof",The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis.,18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0003
8343725,1-Jan-13,2013,1,1,Method of diagnosing poor survival prognosis colon cancer using miR-10a,"The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.",18,The Ohio State University Research Foundation,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institute of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8344019,1-Jan-13,2013,1,1,Methods for the production of biliverdin,"The present invention relates to compositions and methods for the production of biliverdin and methods of treatment and prevention. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12P/165
8344121,1-Jan-13,2013,1,1,Nanoprobes for detection or modification of molecules,"The disclosure provides probes for one or more target molecules. In particular examples, the probes include a molecular linker and first and second functional groups linked and spaced by the molecular linker, wherein the functional groups are capable of interacting with one another or with the target biomolecule in a predetermined reaction, and wherein the molecular linker maintains the first and second functional groups sufficiently spaced from one another such that the functional groups do not substantially interact in an absence of the target biomolecule. In the presence of the target biomolecule the functional groups interact (with each other, with the target biomolecule, or both), and in some examples a detectable signal is produced. In some examples, the functional groups can detect or modify a target molecule. Also provided are methods of using the probes, for example to detect or modify a target molecule.",37,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/542
8347984,8-Jan-13,2013,1,8,Variable force/variable frequency sonic drill head,"An oscillator assembly includes a first eccentrically weighted rotor having a first eccentric weight configured to rotate about an axis, a second eccentrically weighted rotor having a second eccentric weight configured to rotate about the axis. Rotation of the first eccentrically weighted rotor is coupled to rotation of the second eccentrically weighted rotor. An actuator is configured to vary an angular separation between the first eccentric weight and the second eccentric weight.",22,"Longyear™, Inc.",,,,,,,,,,,1,Civil engineering,Chemical engineering,,,,,E21B/24
8349568,8-Jan-13,2013,1,8,Method of diagnosing poor survival prognosis colon cancer using let-7g,"The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.",18,The Ohio State University Research Foundation,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services, National Institute of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8349586,8-Jan-13,2013,1,8,Commensal strain of E. coli encoding an HIV GP41 protein,"The present invention relates, e.g., to a commensal bacterium which can colonize the genitourinary and/or gastrointestinal mucosa, and which, under suitable conditions, secretes a heterologous antimicrobial polypeptide, wherein the secreted antimicrobial polypeptide is effective to inhibit infectivity by, or a pathogenic activity of, a pathogen. In a most preferred embodiment, the antimicrobial polypeptide inhibits HIV infection (e.g., fusion) and/or pathogenesis. Also described are preventive or therapeutic compositions comprising the commensal bacteria, and methods to inhibit infectivity and/or pathogenesis, using the bacteria.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/74
8349888,8-Jan-13,2013,1,8,"Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury","The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4′,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.",20,The United States of America as represented by the Secretary Department of Health and Human Services,Henry M. Jackson Foundation for the Advancement of Military Medicine,,,,,,,,,,2,Pharmaceuticals,Food chemistry,Organic fine chemistry,,,,A61K/48
8354115,15-Jan-13,2013,1,15,CD40 ligand adjuvant for respiratory syncytial virus,"The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/39
8357089,22-Jan-13,2013,1,22,Method and apparatus for determining familial risk of disease,"Personal and family health history information can be used to assess familial risk of disease. For example, information can be collected about the disease history of a person and the person's first- and second-degree relatives and then analyzed to determine the familial risk of common diseases such as coronary heart disease, stroke, type 2 diabetes, and colorectal, breast, and ovarian cancer. Assessed familial risk of disease can then be used by researchers to better estimate the contribution of personal history and family history to the etiology and natural history of a disease of interest, and by consumers and health professionals to determine recommendations for disease management, prevention and screening that are personalized and targeted to the familial risk. Other embodiments are also described and claimed.",12,,,,,,,,,,,,,IT methods for management,Computer technology,,,,,G06Q/24
8357488,22-Jan-13,2013,1,22,Primers and probes for the detection of streptococcus pneumoniae,"Methods of detecting Streptococcus pneumoniae (S. pneumoniae), are disclosed. A sample suspected of containing a nucleic acid of S. pneumoniae is screened for the presence or absence of that nucleic acid. The presence of the S. pneumoniae nucleic acid indicates the presence of S. pneumoniae. Determining whether the S. pneumoniae nucleic acid is present in the sample can be accomplished by detecting hybridization between a S. pneumoniae probe, such as a S. pneumoniae lytA probe, a S. pneumoniae psaA probe, or a S. pneumoniae ply probe. Probes and primers for the detection of S. pneumoniae are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.",14,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
8357525,22-Jan-13,2013,1,22,Thermal inactivation of rotavirus,"Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.",11,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
8357783,22-Jan-13,2013,1,22,Human anti-mesothelin monoclonal antibodies,"Disclosed herein are isolated human monoclonal antibodies that specifically bind human mesothelin with a binding affinity of about 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human mesothelin in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/30
8361710,29-Jan-13,2013,1,29,"MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21","The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents.",17,The Ohio State University Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12Q/6886
8367074,5-Feb-13,2013,2,5,Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens,"Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.",11,The United States of America as represented by the Secretary of the Department  of Health & Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
8377637,19-Feb-13,2013,2,19,"MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P","The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents.",17,The Ohio State University Research Foundation,Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12Q/6886
8378071,19-Feb-13,2013,2,19,Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis,The disclosure provides antigenic peptides of Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)/KDR. Pharmaceutical compositions including the peptides and/or antigen presenting cells that exhibit the VEGFR-2/KDR peptides on their cell surface are also provided. Methods for eliciting an immune response and for inhibiting angiogenesis by administering such pharmaceutical compositions are provided.,10,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/71
8380280,19-Feb-13,2013,2,19,Non-invasive in vivo MRI axon diameter measurement methods,"Magnetic resonance methods include modeling magnetic resonance signals obtained from specimens at low and high q-values to obtain parameters and distributions of parameters associated with specimen structure and orientation. In evaluation of brain white matter specimens, diffusion within axons can be modeled based on hindered diffusion parallel to an axis of the axon and restricted diffusion perpendicular to the axis. Diffusion exterior to axons can be modeled as hindered diffusion with differing diffusivities parallel to and perpendicular to the axis. Based on extracted parameters and associated model functions, distributions of specimen properties such as intra and extra-axonal principal diffusivities and the corresponding principal directions can be estimated. Features of the axon diameter distribution can also be estimated using this approach.",22,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/56341
8383099,26-Feb-13,2013,2,26,Adoptive cell therapy with young T cells,"The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/0636
8383133,26-Feb-13,2013,2,26,Conjugates of Plasmodium falciparum surface proteins as malaria vaccines,"Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.",6,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
8383359,26-Feb-13,2013,2,26,Use of lymphocytes to measure anthrax lethal toxin activity,"It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/5047
8383589,26-Feb-13,2013,2,26,Aegyptin and uses thereof,"The present invention relates to the discovery of the Aegyptin gene and Aegyptin protein, a molecule that interacts with collagen and inhibits platelet adhesion, activation and aggregation. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.",7,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",Regents of the University of California,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/43563
8383817,26-Feb-13,2013,2,26,Benztropine compounds and uses thereof,"Disclosed are benztropine analogs having the formula (I) in which Ar is a C6-C20 monocyclic aryl group or a C10-C20 bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m=1 to 5; n=1 to 3; and R1 to R4 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/46
8388510,5-Mar-13,2013,3,5,Transcranial magnetic stimulation system and methods,"A system and methods for transcranial magnetic stimulation, the system including a helmet, a positioning portion, a stimulator and a cooling system, are disclosed. The helmet includes a coil for deep brain magnetic stimulation. The coil has a base portion, and return portions, which may include a protruding return portion and a contacting return portion. The coil is designed to minimize unintended stimulation of portions of the brain, while reducing accumulation of surface charges. The coil is stimulated at several locations and/or at different times so as to focus the electrical field on a specific deep neuronal structure.",16,"Brainsway, Inc.",Yeda Research & Development Co. Ltd. at the Weizmann Institute of Science,The United States of America as Represented by the Secretary Department of Health and Human Services,,,,,,,,,3,Medical technology,,,,,,A61N/02
8388561,5-Mar-13,2013,3,5,Systems and methods for recovery from motor control via stimulation to a substituted site to an affected area,"A device and methods for treating a subject with dysphagia or other neurological disease, neurological disorder, neurological injury, neurological impairment or neurodegenerative disease that affects voluntary motor control of the hyoid, pharynx, larynx, or oropharyngeal area is disclosed. A device of the invention generally comprises a vibrotactile stimulator for applying at least one stimulus to the outside surface of a subject's neck; a connector for attaching the vibrotactile stimulator to an outside surface of the subject's neck, and a switch control communicatively connected to the vibrotactile stimulator to selectively engage a manual stimulation module and/or automatic stimulation module. Stimulation of an outside surface of the throat area of a subject by a device of the invention stimulates a swallowing reflex in the subject.",36,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61H/00
8388933,5-Mar-13,2013,3,5,Multimeric protein toxins to target cells having multiple identifying characteristics,The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.,18,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Micro-structural and nano-technology,Pharmaceuticals,,,,B82Y/00
8389229,5-Mar-13,2013,3,5,"Methods, immunoassays and devices for detection of anti-lipoidal antibodies","Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.",39,"The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/92
8389495,5-Mar-13,2013,3,5,Olioodeoxynucleotide and its use to induce an immune response,"A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula:5′N1N2N3T-CpG-WN4N5N63′wherein the CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are nucleotides, or the formula:5′RY-CpG-RY3′wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. In some embodiments, the oligodeoxynucleotide includes the nucleic acid sequences set forth as SEQ ID NO: 137.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,C07H/04
8394387,12-Mar-13,2013,3,12,Recombinant modified Bacillus anthracis protective antigen for use in vaccines,"The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/32
8394411,12-Mar-13,2013,3,12,Papillomavirus pseudoviruses for detection and therapy of tumors,"Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).",9,"The United States of America as represented by the Secretary, Dept. of Health and Human Services National Institutes of Health",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Micro-structural and nano-technology,Biotechnology,,,A61K/0004
8394600,12-Mar-13,2013,3,12,"Methods, immunoassays and devices for detection of anti-lipoidal antibodies","Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.",25,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/571
8394764,12-Mar-13,2013,3,12,"Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use","An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral polypeptide or conjugate or fusion protein thereof. Further provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host.",21,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/14
8399689,19-Mar-13,2013,3,19,Chrysophaentin antimicrobial compounds that inhibit FtsZ protein,"Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from Chrysophaeum taylori. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.",36,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07C/295
8404244,26-Mar-13,2013,3,26,Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies,"The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide.",4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The Johns Hopkins University,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/01
8404818,26-Mar-13,2013,3,26,Monoclonal antibodies against orthopoxviruses,"The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/081
8409166,2-Apr-13,2013,4,2,Method for pressure mediated selective delivery of therapeutic substances and cannula,"Methods and devices are disclosed for selective delivery of therapeutic substances to specific histologic or microanatomic areas of organs. Introduction of the therapeutic substance into a hollow organ space (such as an hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume or rate allows the substance to reach a predetermined cellular layer (such as the ephithelium or sub-epithelial space). The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold level beyond which subsequent subepithelial delivery of the substance occurs. Alternatively, a lower pressure is selected that does not exceed the threshold level, so that delivery occurs substantially only to the epithelial layer. Such site specific delivery of therapeutic agents permits localized delivery of substances (for example to the interstitial tissue of an organ) in concentrations that may otherwise produce systemic toxicity. Occlusion of venous or lymphatic drainage from the organ can also help prevent systemic administration of therapeutic substances, and increase selective delivery to superficial epithelial cellular layers. Delivery of genetic vectors can also be better targeted to cells where gene expression is desired. The access device comprises a cannula with a wall piercing tracar within the lumen. Two axially spaced inflatable balloons engage the wall securing the cannula and sealing the puncture site. A catheter equipped with an occlusion balloon is guided through the cannula to the location where the therapeutic substance is to be delivered.",39,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,,,,,,A61M/1011
8409808,2-Apr-13,2013,4,2,Method for detecting risk of progression of low grade cervical dysplasia,The invention provides methods for identifying conditions of low grade cervical dysplasia and assessing the progressive potential of individual lesions to develop into high grade cervical dysplasia and cervical squamous cell cancer as well as cervical adenocarcinoma.,14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6886
8410063,2-Apr-13,2013,4,2,N-acetyl mannosamine as a therapeutic agent,The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.,20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7008
8410292,2-Apr-13,2013,4,2,Epoxy-guaiane derivatives and treatment of cancer,"Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the plant Phyllanthus engleri or produced by synthetic methods. An example of the englerin derivative is 2′-chloroenglerin A, which has the structure (II), wherein double bond ‘a’ is E, Z, or a mixture of E and Z.",40,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
8415097,9-Apr-13,2013,4,9,"Tumor suppressor gene, p47ING3","The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",3,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6886
8415456,9-Apr-13,2013,4,9,Substituted IL-15 polypeptides,"The invention provides IL-15 amino acid sequences with amino acid substitutions that reduce or eliminate deamidation of IL-15 and degradation by-products. The invention also provides DNA sequences that encode the substituted amino acid sequences, a pharmaceutical composition comprising the substituted IL-15 amino acid sequence and a pharmaceutically acceptable carrier, and a method of treating a condition in a mammalian host comprising administering to the host the substituted IL-15 amino acid sequence or the pharmaceutical composition including the substituted IL-15 amino acid sequence in an amount effective to treat the condition in the host.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/5443
8420099,16-Apr-13,2013,4,16,Chimeric protein for prevention and treatment of HIV infection,"This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1045
8420107,16-Apr-13,2013,4,16,Peptide vaccines against group A streptococci,"This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/092
8420607,16-Apr-13,2013,4,16,"Anthrax carbohydrates, synthesis and uses thereof","The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.",14,"University of Georgia Research Foundation, Inc.","The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,2,Organic fine chemistry,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,G01N/56911
8420620,16-Apr-13,2013,4,16,Induced internalization of surface receptors,"Disclosed is a hetero-bifunctional ligand for use in inducing internalization of a target receptor. The hetero-bifunctional ligand includes a target receptor-binding agent that specifically binds the target receptor linked to an internalizing receptor-binding agent that specifically binds to an internalizing receptor, where the two binding agents are non-identical. Also disclosed is a method of inducing the internalization of a target receptor on a cell. The method includes contacting a cell with a hetero-bifunctional ligand, where binding of the hetero-bifunctional ligand induces internalization of a target receptor of the cell. Also disclosed a method of treating a disease or condition associated with a target receptor using the disclosed hetero-bifunctional ligand and pharmaceutical compositions including a hetero-bifunctional ligand.",14,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Biotechnology,,,,C07K/00
8420664,16-Apr-13,2013,4,16,A3 adenosine receptor allosteric modulators,"The present invention relates to allosteric modulation of A3 adenosine receptor (A3AR) and provides for the use of an A3 adenosine receptor modulator (A3RM), for the preparation of pharmaceutical compositions for modulating the A3AR in a subject, as well as pharmaceutical compositions comprising the same and therapeutic methods comprising administering to a subject an amount of an A3RM, the amount being effective to modulate A3AR activity. The A3RM according to the invention are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. The invention also provides some of such novel 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.",7,"The United States of America, represented by the Secretary, Dept. of Health and Human Services",Universiteit Leiden,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4745
8420776,16-Apr-13,2013,4,16,Ube2g2 binding domain in the ubiquitin ligase gp78 and methods of use thereof,"The present invention features isolated nucleic acid molecules, designated G2BD nucleic acid molecules, which encode the binding site from the gp78 ubiquitin ligase that binds to the Ube2G2 ubiquitin conjugating enzyme. The invention further provides isolated G2BD proteins and fusion proteins. Still further provided are diagnostic and therapeutic methods, as well as screening assays utilizing compositions of the invention.",2,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/93
8425901,23-Apr-13,2013,4,23,Alpha 1-3 N-galactosyltransferase with altered donor specificities,The invention generally features compositions and methods based on the structure-based design of alpha 1-3 N-Acetylgalactosaminyltransferase (alpha 3 GaINAc-T) enzymes from alpha 1-3 galactosyltransferase (a3Gal-T) that can transfer 2′-modified galactose from the corresponding UDP-derivatives due to substitutions that broaden the alpha 3Gal-T donor specificity and make the enzyme a3 GaINAc-T.,16,"The United States of America, as  represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/1051
8426379,23-Apr-13,2013,4,23,POT1 alternative splicing variants,The present invention provides methods and compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk of developing a colorectal carcinoma.,4,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
8426574,23-Apr-13,2013,4,23,Identification of astrovirus VA1 associated with gastroenteritis in humans,"Provided herein is a novel human astrovirus, its nucleic acid sequence, as well as methods to detect and diagnose the presence of the astrovirus.",6,Washington University,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/56983
8427160,23-Apr-13,2013,4,23,Susceptibility-matched multi-well sample holders for high-throughput screening by magnetic analysis,"A method of performing high throughput magnetic sensing of one or more samples. The method comprises selecting a first sample having a first bulk magnetic susceptibility, selecting an assay plate having a second bulk magnetic susceptibility matched to the first bulk magnetic susceptibility, the assay plate including multiple wells, introducing the first sample into a plurality of the wells, and performing magnetic sensing on the plurality of wells containing the first sample. Assay plates, caps, kits, and other devices and methods relating to high throughput magnetic sensing are also disclosed.",27,"The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/44
8431134,30-Apr-13,2013,4,30,Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen,"Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.",6,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/164
8431137,30-Apr-13,2013,4,30,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.",22,"Medimmune, LLC",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/145
8431690,30-Apr-13,2013,4,30,T cell receptors and related materials and methods of use,"The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/70503
8433523,30-Apr-13,2013,4,30,Multiplexed analysis for determining a serodiagnosis of viral infection,"Clinical samples can be analyzed using microparticles to determine the serodiagnosis of a viral infection from two candidate viral infections of the same viral group. Serodiagnosis can be determined via a pooled population of subsets of microparticles, with the particles in the pooled population having a bound viral group-reactive antibody and the particles in each subset having at least one characteristic classification parameter that distinguishes between subsets. Viral antigens of antibodies of interest in the same viral-class as the viral group-reactive antibody can be bound to the viral group-reactive antibody on the microparticles, and subsequently exposed to a clinical sample. Binding and labeling can be used. Automated analysis of data from multiplexed flow analysis can determine the presence or absence of antibodies of interest in the sample, thereby diagnosing for two candidate viral infections in a single assay.",38,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,IT methods for management,,,,,G01N/56983
8435794,7-May-13,2013,5,7,Colorimetric test for antimalarial artemesin derivatives,A process for testing a composition as containing an artemisinin derivative is provided that includes contacting the composition with a reagent made up of a hydrogen bonding polar organic solvent and an acid having a pK value of less than 3.8 at 25° Celsius and capable of acid catalyzing a decomposition reaction of the artemisinin derivative so as to provide a reaction mixture. The reaction mixture is allowed sufficient time at a reaction temperature for the artemisinin derivative to decompose to yield a colored decomposition product discerned by a normal unaided human eye. A kit for testing a composition for an artemisinin derivative according to the process is provided together with instructions for contacting the solvent and the acid with the composition to decompose the artemisinin derivative to yield the colored decomposition.,12,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,Measurement,,,,,G01N/94
8440393,14-May-13,2013,5,14,Pro-angiogenic genes in ovarian tumor endothelial cell isolates,"A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.",7,The United States of America as Represented by the Secretary of the Department of Health and Human Services,The University of MD Anderson Cancer Center,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12Q/6886
8440411,14-May-13,2013,5,14,Differential gene expression in physiological and pathological angiogenesis,"Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIIIα1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.",8,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,Pharmaceuticals,,,,C12Q/6886
8440415,14-May-13,2013,5,14,BORIS isoforms and methods of detecting and treating disease,"A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/574
8444996,21-May-13,2013,5,21,Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia,"Disclosed are immunogenic conjugates which elicit an immune response to Plasmodium proteins. In particular examples, the Plasmodium proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to Plasmodium in a subject, comprising administering to the subject an immunogenic composition disclosed herein.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",New York University,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/00
8445216,21-May-13,2013,5,21,Antibodies and immunotoxins that target human glycoprotein NMB,"The invention provides high affinity antibodies suitable for forming Immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.",6,Duke University,"The United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health",,,,,,,,,,2,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/28
8447384,21-May-13,2013,5,21,Method and system for performing biopsies,"A method and system for performing biopsies can include an imaging system for obtaining diagnostic images of a target region; a tracking system; a probe having a deployable biopsy needle for performing a biopsy procedure where the tracking system generates tracking information for at least one of the probe and the biopsy needle; an ultrasound imaging system for obtaining ultrasound imaging of the target region; and a computer in communication with the tracking system, the imaging system and the ultrasound imaging system. The computer can register the tracking system with the imaging system. The computer transfers a marking of a biopsy site associated with the biopsy procedure from the ultrasound imaging to the diagnostic images based on the tracking information and the registration of the tracking system with the diagnostic images.",20,Koninklijke Philips Electronics N.V.,,,,,,,,,,,1,Medical technology,,,,,,A61B/4254
8449445,28-May-13,2013,5,28,Device for volitional swallowing with a substitute sensory system,"A device for volitional swallowing with a substitute sensory system comprises a band 101 wrapped around the neck with a vibrator 102 positioned over the larynx. Upon activation by a button 103 on a spoon 104 held by an operator, such as the subject 105, the vibrator 102 moves and vibrates the larynx. The patient 105 initiates the sensory stimulation immediately prior to the patient's own initiation of a swallow by viewing on a display screen 106 a movement feedback signal 107, possibly from a piezo-electric sensor 108 also contained in the band 101 which will also be displayed on the display screen 106. The signal 109 from the switch device initiating sensory stimulation will be presented on the same display screen 106 for the patient 105 and trainer to observe when the button or switch 103 is activated for sensory stimulation in relation to the onset of the swallow.",41,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61H/02
8450325,28-May-13,2013,5,28,Methods for reducing the recurrence of cardiac arrhythmia,"Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.",5,ChanRx Corp.,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/495
8454936,4-Jun-13,2013,6,4,Metal chelators and methods of their use,"Metal chelators of Formula I and Formula II are disclosed:    Also disclosed are metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of their preparation and use in diagnosis and/or treatment of diseases and conditions, including, inter alia, cancer and thrombosis.",24,"The United States of America, as represented by the Secretary, Department of Health And Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/22
8454965,4-Jun-13,2013,6,4,Method for the treatment of multiple sclerosis,"A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.",15,The United States of America as represented by The Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/2866
8454972,4-Jun-13,2013,6,4,Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen,"The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services","GenVec, Inc.",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/21
8455437,4-Jun-13,2013,6,4,Method to predict and prevent oxygen-induced inflammatory tissue injury,"Methods for modulating responsiveness to increased oxygen levels in an at-risk subject identifying an at-risk subject; and before exposing the identified at-risk subject to an increased amount of oxygen, administering to the at-risk subject an anti-inflammatory agent wherein the responsiveness of the at-risk subject to said increased amount of oxygen is modulated as compared to the responsiveness of the at-risk subject to said increased amount of oxygen in the absence of said anti-inflammatory.",9,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
8455454,4-Jun-13,2013,6,4,"miR 204, miR 211, their anti-miRs, and therapeutic uses of same","Embodiments of the invention provide methods of preventing or treating detrimental epithelial cell proliferation, loss of epithelial cell differentiation, age-related macular degeneration and/or proliferative vitreal retinopathy in an individual comprising administering to an individual in need thereof an effective amount of miR 204, an effective amount of miR 211, or an effective amount of a mixture of miR 204 and miR 211. A further embodiment of the invention provides a method of facilitating the transport of a substance across an epithelium in an individual comprising administrating to an individual an effective amount of anti-miR 204, an effective amount of anti-miR 211, or an effective amount of a mixture of anti-miR 204 and anti-miR 211. Additional embodiments of the invention include pharmaceutical compositions of miR 204 and/or miR 211 and pharmaceutical compositions of anti-miR 204 and/or anti-miR 211.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/7105
8456738,4-Jun-13,2013,6,4,Ultrahigh-resolution fiber-optic confocal microscope and method,"An ultrahigh-resolution fiber-optic confocal microscope has an illumination system; three single-mode optical fibers, each optically coupled to a fiber coupler; a sample support stage arranged to receive illumination radiation from an end of one of the single-mode optical fibers; a detector arranged to receive output radiation from one of the single-mode optical fibers; and a lock-in amplifier electrically connected to the detector and the illumination system. The illumination system is adapted to provide illumination radiation that has a time-varying strength that is correlated with the detector by the lock-in amplifier.",14,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,,,,,,G02B/0032
8459098,11-Jun-13,2013,6,11,Universal physiologic sampling pump (PSP) capable of rapid response to breathing,"The present invention discloses a physiologic sampling pump (PSP) which uses at least one valve placed near the sampling medium to modulate air sampling to follow a person's inhalation rate and to obviate the sluggishness inherent in prior art PSPs caused by varying pump speed and by the propagation time through an air tube that connects the collection medium to prior art pumps thereby also obviating limitations inherent in system response, functionality, and accuracy. Moreover, by maintaining an essentially constant air flow through a cyclone at all times and through the collection medium while sampling, the present invention operates at known collection efficiencies, and is therefore capable of size-selective sampling of particulates as opposed to prior art PSPs that by varying the magnitude of air flow, make the separation efficiencies of pre-collection devices indeterminate and the samples worthless. When used instead with an impact sampling head, the present invention may collect total particulate as well, and may collect gases and vapors with a charcoal tube sampling head. Structural features associated with the physiological sampling pump for providing rapid response to breathing include an outer housing including a thereto-resistant case, multiple and interchangeable PSP sampling heads further including collection media and a valve(s) mounted on a valve manifold with associated tubing.",13,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Measurement,,,,,,G01N/2211
8460660,11-Jun-13,2013,6,11,Anti-mesothelin antibodies,The present invention provides monoclonal anti-mesothelin antibodies and antibody fragments and methods for their use. The antibodies can be completely human.,19,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/30
8460675,11-Jun-13,2013,6,11,Viral chemokine-antigen fusion proteins,"The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a viral chemokine fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.",15,"The United States of America, as represented by the Secretary, Department of the Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/521
8460744,11-Jun-13,2013,6,11,Target activated microtransfer,"A device for performing target activated transfer that includes a mounting surface for mounting a tissue sample; and a light source positioned to substantially uniformly irradiate both stained and unstained regions of the tissue sample with light energy that activates the reagent to selectively adhere the stained regions to a transfer surface. Also described is an automated system for transferring tissue from a tissue sample to a transfer substrate. The system includes means for holding a tissue section that includes targets specifically stained with an absorptive stain thereby resulting in a stained tissue surface, and a flexible transfer film that includes a lower thermoplastic layer in sufficient thermal contact with the stained tissue surface; an irradiating assembly configured to provide a predetermined uniform light dose to the entire tissue section; and means for applying a constant pressure to the transfer film during irradiation.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/543
8465743,18-Jun-13,2013,6,18,Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer,"The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/2863
8465749,18-Jun-13,2013,6,18,Polysaccharide-protein conjugate vaccines,"Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.",8,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/08
8465917,18-Jun-13,2013,6,18,Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells,"The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells.",8,The Ohio State University Research Foundation,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12Q/6886
8466116,18-Jun-13,2013,6,18,Use of CpG oligodeoxynucleotides to induce epithelial cell growth,"This disclosure provides a method of inducing epithelial cell growth. The method includes administering an effective amount of a K-type CpG oligonucleotide, thereby inducing epithelial cell growth. The epithelial cell can be in vivo or in vitro. Methods are also provided for inducing wound healing in a subject. The methods include administering to the subject a therapeutically effective amount of at least one K-type CpG ODN.",44,The Unites States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/711
8470342,25-Jun-13,2013,6,25,Methods of altering an immune response induced by CpG oligodeoxynucleotides,It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided.,17,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
8470888,25-Jun-13,2013,6,25,Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer,"Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.",3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/277
8470970,25-Jun-13,2013,6,25,Mammalian sweet and amino acid heterodimeric taste receptors comprising T1R3 and T1R1,"The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising T1R3 and T1R1, two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.",20,The Regents of the University of California,The Government of the United States of America,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/5076
8476236,2-Jul-13,2013,7,2,Treatment of skin conditions by Dickkopf1 (DKK1),"The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/1709
8478381,2-Jul-13,2013,7,2,MRI guidewire,"A guidewire (100) for use with interventional magnetic resonance imaging has a guidewire body (102) having a distal end and a proximal end and reserving a space therein, a dipole antenna (108) disposed in the space reserved within the guidewire body, the dipole antenna being adapted to be electrically connected to a signal processing system through a first signal channel (110) through the proximal end of the guidewire body, and a loop antenna (112) disposed in the space reserved within the guidewire body toward the distal end of the guidewire body, the loop antenna (112) being adapted to be electrically connected to the signal processing system through a second signal channel (114) through the proximal end of the guidewire body. The dipole antenna and the loop antenna are each constructed to receive magnetic resonance imaging signals independently of each other and to transmit received signals through the first and second signal channels, respectively, to be received by the signal processing system. An interventional magnetic resonance imaging system includes an active guidewire.",11,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Measurement,,,,,A61M/09
8481048,9-Jul-13,2013,7,9,Methods for preparing immunogenic conjugates,"Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.",16,"The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/32
8481055,9-Jul-13,2013,7,9,Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides,"The present disclosure relates to a method of preventing or treating an infection caused by a bioterrorism agent, specifically to a method of increasing an immune response to a bioterrorism agent using an oligodeoxynucleotide including a CpG motif, and a method of enhancing the immunogenicity of a vaccine against a bioterrorism agent using an oligodeoxynucleotide including a CpG motif.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/39
8481255,9-Jul-13,2013,7,9,Scytovirin domain 1 related polypeptides,"A scytovirin domain 1 (SD1) polypeptide, a nucleic acid encoding the polypeptide, and related fusion proteins, conjugates, isolated cells, vectors, and antibodies, as well as a method of inhibiting a viral infection using the same.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/195
8497122,30-Jul-13,2013,7,30,Biomarkers for Niemann-pick C disease and related disorders,"Methods for screening or diagnosing subjects for disorders involving accumulation of one or more oxysterols such as cytotoxic oxysterol accumulation, Niemann-Pick C(NPC) disease, lysosomal storage diseases, cholesterol trafficking diseases, and neurodegenerative diseases. Also provided are methods for methods for screening or diagnosing subjects (including infants and neonatal subjects) for NPC disease, methods for monitoring the progression, remission, and clinical status of NPC disease, and methods for evaluating the efficacy of therapeutic treatment of NPC disease.",18,Washington University,,,,,,,,,,,1,Analysis of biological materials,Measurement,,,,,G01N/92
8501182,6-Aug-13,2013,8,6,Monoclonal antibodies that react with the capsule of Bacillus anthracis,"The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.",29,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/1278
8501188,6-Aug-13,2013,8,6,Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides,The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for inhibiting or treating inflammatory lung disease by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.,13,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
8501688,6-Aug-13,2013,8,6,SCGB3A2 as a growth factor and anti-apoptotic agent,"The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents.",18,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/18
8501912,6-Aug-13,2013,8,6,Filipil compositions and methods for treating cancer,"A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/4703
8501925,6-Aug-13,2013,8,6,Nucleic acid modules for expression and tagging of membrane proteins and methods of use,"Described herein are nucleic acid modules for cloning, expression and tagging of eukaryotic membrane proteins. The nucleic acid modules include a receptor for advanced glycation end products (RAGE) signal sequence, a nucleic acid sequence encoding a tag and a multiple cloning sequence (MCS). Any membrane protein of interest can be cloned into the MCS for expression in cells. The nucleic acid modules can encode any type of tag, such as an epitope tag or affinity tag. The nucleic acid modules disclosed herein can be used to express any type of membrane protein and are particularly suited to the expression and tagging of Type I and Type III membrane proteins.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Resources",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/625
8506947,13-Aug-13,2013,8,13,Vaccinia virus expression vector for selective replication in a tumor cell and introduction of exogenous nucleotide sequence into a tumor cell,A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.,20,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
8506961,13-Aug-13,2013,8,13,Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus (JEV) and their use,"Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.",33,The United States of America as Represented by the Secretary Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1081
8507196,13-Aug-13,2013,8,13,"Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1","This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method to detect the presence of DNA, RNA, or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them, and the proteins expressed.",4,Institut Pasteur,Centre National de la Recherche Scientifique,,,,,,,,,,2,Biotechnology,,,,,,C07K/005
8507267,13-Aug-13,2013,8,13,AAV4 vector and uses thereof,"The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.",35,"U.S. Dept. of Health and Human Services, National Institutes of Health",,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
8510245,13-Aug-13,2013,8,13,Bayesian clinical decision model for determining probability of transplant glomerulopathy,"An embodiment of the invention provides a method for determining a patient-specific probability of transplant glomerulopathy. The method collects clinical parameters from a plurality of patients to create a training database. A fully unsupervised Bayesian Belief Network model is created using data from the training database; and, the fully unsupervised Bayesian Belief Network is validated. Clinical parameters are collected from an individual patient; and, such clinical parameters are input into the fully unsupervised Bayesian Belief Network model via a graphical user interface. The patient-specific probability of transplant glomerulopathy is output from the fully unsupervised Bayesian Belief Network model and sent to the graphical user interface for use by a clinician in pre-operative planning. The fully unsupervised Bayesian Belief Network model is updated using the clinical parameters from the individual patient and the patient-specific probability of transplant glomerulopathy.",7,The United States of America as Represented by the Secretary of the Army,,,,,,,,,,,1,Computer technology,,,,,,G16B/00
8512991,20-Aug-13,2013,8,20,"Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use","The invention relates generally to beta (1,4)-galactosyltransferase I mutants having altered donor and acceptor specificities, and methods of use thereof. In addition, the invention relates to methods for synthesizing oligosaccharides using the beta (1,4)-galactosyltransferase I mutants and to using the beta (1,4)-galactosyltransferase I mutants to conjugate agents, such as therapeutic agents or diagnostic agents, to acceptor molecules.",7,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/1051
8513214,20-Aug-13,2013,8,20,C4′-substituted-2-deoxyadenosine analogs and methods of treating HIV,"The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4′-position provided compounds which demonstrated low cytotoxicity values in an ATP-based cytotoxicity assay.",17,The United States of America as Represented by the Secretary of the Dept. of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
8518647,27-Aug-13,2013,8,27,Method of diagnosing poor survival prognosis colon cancer using miR-16b,"The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.",18,The Ohio State University Research Foundation,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institute of Health, Office of Technology Transfer",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/113
8518957,27-Aug-13,2013,8,27,"Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure","Disclosed are (N)-methanocarba adenine nucleosides, e.g., of the formula (I): as A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein A, a, R2, and R3 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. Also disclosed are conjugates comprising a dendrimer and one or more ligands, which are functionalized congeners of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily. Such conjugates are have the potential of being used as dual agonists, dual antagonists, or agonist/antagonist combinations.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
8518968,27-Aug-13,2013,8,27,Hydrazone and diacyl hydrazine compounds and methods of use,Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.,20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/73
8524239,3-Sep-13,2013,9,3,Photosensitizing antibody-fluorophore conjugates,"The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm−2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.",25,"The United States of America as represented by the Secrectary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Biotechnology,,,,A61K/06
8524247,3-Sep-13,2013,9,3,Rabies virus-based recombinant immunocontraceptive compositions and methods of use,"Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein.",18,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/86
8524248,3-Sep-13,2013,9,3,Methods to diagnose and immunize against the virus causing human Merkel cell carcinoma,"The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecules that bind to MCV polypeptides. The invention further provides diagnostic, prophylactic, and therapeutic methods relating to the identification, prevention, and treatment of MCV-related diseases.",25,University of Pittsburgh—Of the Commonwealth System of Higher Education,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/081
8524461,3-Sep-13,2013,9,3,Multiple antigenic peptide assay for detection of HIV or SIV type retroviruses,A method for detecting at least one antibody directed against at least one primate immunodeficiency virus in a biological sample that includes contacting a biological sample with (i) at least one detection multiple antigenic peptide comprising a portion of an immunodominant region of a transmembrane protein of a primate immunodeficiency virus and (ii) at least one differentiation multiple antigenic peptide comprising a portion of a V3-loop of an envelope protein of a primate immunodeficiency virus. Also disclosed is an enzyme immunoassay that includes a first substrate to which are bound at least one of the detection multiple antigenic peptides and a second substrate to which are bound at least one of the differentiation multiple antigenic peptides.,25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56983
8530167,10-Sep-13,2013,9,10,"Diagnostic and therapeutic uses of GNPTAB, GNPTG, and NAGPA in stuttering","The allelic variants or mutations in three genes: GNPTAB, GNPTG and NAGPA, that correlate with stuttering in humans, as well as the encoded mutated polypeptides and related vectors, host cells, antibodies, antibody-producing cell lines and methods of diagnosing, prognosticating and treating stuttering are provided.",2,"The United States of America, as represented by the Secretary, Department of Health and Human Services","Centre of Excellence in Molecular Biology Together With All Allied Components, University of Punjab",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12Q/6883
8530182,10-Sep-13,2013,9,10,Viral protein quantification process and vaccine quality control therewith,A process of quantifying proteins in a complex mixture is provided. The invention has utility in quantifying proteins in a complex preparation of uni- or multivalent commercial or research vaccine preparations.,19,Centers for Disease Control and Prevention,,,,,,,,,,,1,Measurement,,,,,,G01N/7233
8535639,17-Sep-13,2013,9,17,Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging,"The present invention relates to trifunctional imaging agents that include an antibody for cell targeting, as well as a chelating moiety for sequestering radioisotopes and a fluorescing moiety for imaging. The invention also provides methods using the conjugates for medical diagnostic imaging.",22,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/00
8535881,17-Sep-13,2013,9,17,High speed parallel molecular nucleic acid sequencing,"A method and device is disclosed for sequencing of nucleic acid molecules. A nucleic acid molecule is exposed to a polymerase in the presence of nucleotides. The polymerase carries a donor fluorophore, and each type of nucleotide carries a distinguishable acceptor fluorophore characteristic of the particular type of nucleotide. As the polymerase incorporates individual nucleic acid molecules into a complementary strand, a laser continuously irradiates the donor fluorophore, at a wavelength that causes it to emit an emission signal. The emission signal from the polymerase can stimulate any of the donor fluorophores (but not acceptor fluorophores), so that as a nucleotide is added, the acceptor fluorophore emits a signal associated with the type of nucleotide added to the complementary strand. The series of emission signals from the acceptor fluorophores is detected, and correlated with a sequence of nucleotides that correspond to the sequence of emission signals.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6869
8535884,17-Sep-13,2013,9,17,LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis,"Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening.",4,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Research Foundation for Mental Hygiene, Inc.","The Progeria Research Foundation, Inc.",,,,,,,,,3,Biotechnology,,,,,,C07K/47
8535890,17-Sep-13,2013,9,17,Methods to determine immunogenicity of humanized anti-tag 72 CC49 antibodies,"The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.",19,The United of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
8536148,17-Sep-13,2013,9,17,Disabling autophagy as a treatment for lysosomal storage diseases,"Provided herein are methods of treating lysosomal storage disease, for instance Pompe disease, through inhibition of autophagy. Optionally, treatment is administered as an adjunct to enzyme replacement therapy (ERT).",16,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/113
8541221,24-Sep-13,2013,9,24,Primate T-lymphotropic viruses,"Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.",14,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",Johns Hopkins University,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12Q/701
8541229,24-Sep-13,2013,9,24,Plasmids and phages for homologous recombination and methods of use,"Lambda phages that can be used to introduce recombineering functions into host cells are disclosed. Also disclosed are plasmids that can be used to confer recombineering functions to a variety of strains of E. coli and to other bacteria, including Salmonella, Pseudomonas, Cyanobacteria, Spirochaetes. These plasmids and phages can be isolated in vitro and can be used to transform bacterial cells, such as gram negative bacteria.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/74
8544462,1-Oct-13,2013,10,1,Systems and methods for aerosol delivery of agents,"Aerosol delivery systems and methods for delivering an agent to a patient are described herein. In particular embodiments, an insulated receptacle is connected to a housing and holds a vial of an agent to be delivered to a patient. The vial is located in an inverted position within the receptacle. One or more reusable thermal packs can be located on the inner sides of the receptacle, to maintain a selected temperature surrounding the vial. The agent is administered to a patient by placing a prong into one of the patient's orifices and then activating an aerosol delivery system. Such systems can include jet aerosolization and pneumatic and ultrasonic nebulizers and preferably are portable.",49,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",Creare Incorporated,,,,,,,,,,2,Medical technology,,,,,,A61M/005
8545888,1-Oct-13,2013,10,1,Tendon stem cells,"The invention relates to tendon stem cell useful for treating a variety of diseases and conditions, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation by use of biglycan and/or fibromodulin.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0662
8546091,1-Oct-13,2013,10,1,AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy,"Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57484
8546430,1-Oct-13,2013,10,1,Thalidomide analogs,"Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.",19,"P2D, Inc.",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/44
8546524,1-Oct-13,2013,10,1,Smoothened polypeptides and methods of use,"Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided. Methods of inhibiting proliferation of a diseased cell, treating or preventing cancer, treating a neoplasm or psoriasis, and inhibiting the expression of genes involved in the Hedgehog signaling pathway, thereby inhibiting the Hedgehog signaling pathway, are furthermore provided by the invention.",46,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/705
8547533,1-Oct-13,2013,10,1,Composite probes and use thereof in super resolution methods,"Composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ) include a donor moiety and an acceptor moiety joined by a linker, wherein the acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activated quenching mechanisms and moieties could accomplish the same task by reducing donor population. Also disclosed are methods for irradiating a selected region of a target material including the composite probe, wherein the composite probe enables improved resolution by point spread function modification and/or nanoscale chemical reactions.",40,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Basic materials chemistry,Measurement,Biotechnology,,,,C07K/00
8548786,1-Oct-13,2013,10,1,Neuronal avalanche assay,"Method and system for determining a cognitive enhancement and/or anti-epileptic effect comprising: detecting synchronized neuronal activity in neuronal tissue (601), monitoring spreading of the synchronized neuronal activity (602), determining a parameter (604, 605) indicative of the closeness of the synchronized neuronal activity to the critical state and comparing (613) the parameter to a predetermined value.",27,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Medical technology,Computer technology,,,,,G06F/34
8551536,8-Oct-13,2013,10,8,Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes,"This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.",19,The United States of America as represented by the Secretary of the Department of Health and Human Services,University of Alabama at Birmingham,Wake Forest University,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/26
8551698,8-Oct-13,2013,10,8,Method of loading sample into a microfluidic device,"A method comprising loading a sample into a microfluidic device which comprises plural sample chambers, subdividing the sample into a plurality of sample portions, such that respective sample portions are positioned in each of a plurality of the sample chambers, and subjecting the sample portions loaded into the respective sample chambers to at least a first amplification step. Each of the sample chambers has a respective volume such that if a sample portion positioned in the sample chamber comprises at least one molecule of a target nucleic acid, the target nucleic acid would attain a detectable concentration in the sample chamber after a single round of amplification.",41,"Applied Biosystems, LLC",The United States Department of Health and Human Services,,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
8551936,8-Oct-13,2013,10,8,Defensin-antigen fusion proteins,"The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.",20,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
8556882,15-Oct-13,2013,10,15,Inducible interleukin-12,"The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3′ of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/5434
8557250,15-Oct-13,2013,10,15,Methods for preparing complex multivalent immunogenic conjugates,Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.,27,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/084
8557788,15-Oct-13,2013,10,15,Prevention of tissue ischemia and related compositions,"Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Chemical engineering,Pharmaceuticals,Biotechnology,Analysis of biological materials,,C07K/18
8557789,15-Oct-13,2013,10,15,Method of treating inflammatory arthropathies with supressors of CPG oligonucleotides,The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.,15,The United States of America as represented by the Secretary of the Development of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
8557844,15-Oct-13,2013,10,15,Substrate reduction therapy,The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.,13,"The Chancellor, Masters and Scholars of the University of Oxford","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,C07J/003
8563275,22-Oct-13,2013,10,22,Method and device for detecting the presence of a single target nucleic acid in a sample,"A method comprising subjecting one or more sample portion(s) to a single amplification step, thereby amplifying a single molecule in the sample portion to a detectable level, and, in some embodiments, then determining whether the sample portion contains at least one molecule of the target nucleic acid. In some embodiments, the sample portion is in a porous sample structure, or in a sample chamber which comprises means for minimizing diffusion of the sample portion, or in a sample chamber which is inside a microcapillary device, or in a sample retaining means.",7,"Applied Biosystems, LLC","The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
8568739,29-Oct-13,2013,10,29,Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses,"Disclosed herein are chimeric TBEV/DEN4 flaviviruses including a first nucleic acid molecule including a 5′ non-coding region (NCR) from a DEN4 virus, a nucleic acid encoding a C protein and non-structural proteins from a DEN4 virus, and a 3′ NCR from a DEN4 virus, wherein nonstructural protein NS4B includes a phenylalanine at amino acid position 112, nonstructural protein NS5 includes an alanine at amino acid position 654 and an alanine at amino acid position 655, and the 3′ NCR includes a deletion of nucleotides 10478-10507. The chimeric construct also includes a second nucleic acid molecule, which is operably linked to the first nucleic acid molecule, encoding a prM protein and an E protein from a TBEV, wherein the E protein includes an amino acid substitution that differs from the wild type TBEV at amino acid position 315 and a tryptophan at amino acid position 240. Also disclosed are methods of eliciting an immune response using the disclosed TBEV/DEN4 chimeric flaviviruses and immunogenic compositions including the disclosed chimeric flaviviruses and a pharmaceutically acceptable carrier.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
8568977,29-Oct-13,2013,10,29,Compositions and methods for diagnosis and treatment of tumors,"Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/2848
8568981,29-Oct-13,2013,10,29,Probe and method for detection and discrimination of types and subtypes of influenza viruses,"Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.",26,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
8569276,29-Oct-13,2013,10,29,Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents,"The present invention relates, inter alia, to compounds having the general formula:in which R1, R2, R3, R4 and X are as defined by the present specification. In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception.",52,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07J/0083
8569360,29-Oct-13,2013,10,29,Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling,"Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met obtained by virtual screening, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are provided. Methods of making derivatives and analogs of c-Met inhibitors and methods of use thereof are provided. Formula (I)",13,,,,,,,,,,,,,Organic fine chemistry,Organic fine chemistry,,,,,C07D/90
8573199,5-Nov-13,2013,11,5,Ultrasonic in situ respiratory mask testing process and mask,A respiratory mask includes a mask body with a perimeter. The mask has a use position wherein the mask body covers at least the mouth and nose and the perimeter is in contact with the face surrounding at least the mouth and nose. At least one ultrasonic sensor is supported on the mask body in detecting proximity to the perimeter. The ultrasonic sensor is operable to detect ultrasound. The ultrasonic sensor allows leakage around the perimeter of the mask body to be detected.,17,Centers for Disease Control and Prevention,,,,,,,,,,,1,Other consumer goods,Measurement,,,,,A62B/00
8574844,5-Nov-13,2013,11,5,Quantitative real-time assay for Noroviruses and Enteroviruses with built in quality control standard,"A method is provided for reverse transcription-polymerase chain reaction (RT-PCR) accomplished by: a) amplifying a reverse transcribed cDNA in a mixture containing Norovirus Genogroup I and Norovirus Genogroup II primers and probes, in which the Norovirus primers and probes can distinguish between Genogroup I and Genogroup II viruses; b) quantifying virus; and c) normalizing data based on a universal internal RNA control. Optionally, the method may also include primers and probes for Enteroviruses. The present invention also provides a reaction mixture containing Norovirus Genogroup I and Norovirus Genogroup II primers and probes, in which the Norovirus primers and probes can distinguish between Genogroup I and Genogroup II viruses and universal internal RNA control primers and probes.",32,The United States of America as represented by the Department Secretary of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
8574853,5-Nov-13,2013,11,5,Monoclonal antibodies that neutralize anthrax toxins,"The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1278
8575121,5-Nov-13,2013,11,5,"Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer",The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.,8,The United States of America as represented by the Secetary of the Department of Health and Human Services,The University of Dundee,Masaryk Memorial Cancer Institute,,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,C12N/113
8575324,5-Nov-13,2013,11,5,"Methods and reagents for molecular detection of HIV-1 groups M, N and O","Reagents and assays for detecting HIV-1 groups M and O and optionally HIV-1 group N and SIVcpz are provided. The reagents are nucleic acid primers for the hybridization to, amplification and subsequent detection of HIV-1 groups M, N and O and SIVcpz in a biological sample. The primers are oligonucleotides that selectively hybridize to the highly conserved regions of the env and pol regions of HIV-1. Due to the high sensitivity of the assays, small concentrations of HIV in a biological sample can be detected, allowing diagnosis at an early stage of infection. The assays are qualitative or quantitative and are useful for viral load determinations of HIV-1 groups M, N or O in a patient undergoing treatment for HIV-1 infection. Viral load determinations can be used to monitor the progress of the treatment regimen, the development of drug resistance, and to predict disease progression.",25,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
8575375,5-Nov-13,2013,11,5,Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties,"This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.",1,Research Triangle Institute,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/0005
8579787,12-Nov-13,2013,11,12,"Methods and systems for using therapeutic, diagnostic or prophylactic magnetic agents","Systems and methods are disclosed for directing magnetizable particles comprising therapeutic agents to a target volume, or for guiding magnetizable particles comprising therapeutic agents from a first target volume to a second target volume, at a distance using a magnetic field, to enable the treatment of diseased areas including areas deep inside a patient's body. The methods may be used to diagnose or treat diseased areas within a patient, for example tumors of the lungs, intestines, and liver, and is also useful in enhancing the permeability of solid tumors to chemotherapeutic agents.",43,University of Maryland College Park,"The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health",,,,,,,,,,2,Medical technology,Medical technology,,,,,A61N/00
8579839,12-Nov-13,2013,11,12,Methods for recovery from motor control via stimulation to a substituted site to an affected area,"Methods, devices and systems for recovering motor control of an area in the body of a patient affected by a neurological disorder. A device vibrotactilely stimulates a substitute site for the affected area thereby recovering the motor control of the affected area. The stimulation provided by the device is volitionally controlled by the patient.",38,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61H/02
8580277,12-Nov-13,2013,11,12,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.",20,"Medimmune, LLC",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/145
8580527,12-Nov-13,2013,11,12,Methods for identifying compounds which modulate T2R bitter taste receptors,"The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors.",17,The Regents of the University of California,,,,,,,,,,,1,Biotechnology,,,,,,C07K/705
8580927,12-Nov-13,2013,11,12,Engineered antibody constant domain molecules,"Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.",25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1063
8580944,12-Nov-13,2013,11,12,Suppressors of CpG oligonucleotides and methods of use,"The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
8586055,19-Nov-13,2013,11,19,DNA immunization protocols,This invention provides DNA vaccines for the treatment of patients undergoing anti-retroviral therapy. The vaccines are surprisingly effective at controlling viremia.,6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/21
8591889,26-Nov-13,2013,11,26,Human monoclonal antibodies specific for CD22,"Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/2803
8592146,26-Nov-13,2013,11,26,Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs,"Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.",9,Centers for Disease Control and Prevention,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
8597660,3-Dec-13,2013,12,3,Therapeutic approach to neurodegenerative disorders using a TFP5-peptide,"Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, wherein the Cdk5 inhibitory domain is linked to a protein transduction domain. Methods of reducing or inhibiting one or more symptoms associated with a neurodegenerative disease by administering a therapeutically effective amount of a pharmaceutical composition including one or more disclosed peptides are also provided.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4738
8597715,3-Dec-13,2013,12,3,Target activated microtransfer,"A method of removing a target from a biological sample which involves placing a transfer surface in contact with the biological sample, and then focally altering the transfer surface to allow selective separation of the target from the biological sample. In disclosed embodiments, the target is a cell or cellular component of a tissue section and the transfer surface is a film that can be focally altered to adhere the target to the transfer surface. Subsequent separation of the film from the tissue section selectively removes the adhered target from the tissue section. The transfer surface is activated from within the target to adhere the target to the transfer surface, for example by heating the target to adhere it to a thermoplastic transfer surface. Such in situ activation can be achieved by exposing the biological sample to an immunoreagent that specifically binds to the target (or a component of the target). The immunoreagent can alter the transfer surface directly (for example with a heat generating enzyme carried by the immunoreagent), or indirectly (for example by changing a characteristic of the target). In some embodiments, the immunoreagent deposits a precipitate in the target that increases its light absorption relative to surrounding tissue, such that the biological specimen can be exposed to light to selectively heat the target. Alternatively, the immunoreagent is an immunofluorescent agent that carries a fluorophore that absorbs light and emits heat.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56966
8597876,3-Dec-13,2013,12,3,Method of treating HIV infection,"Disclosed is a method of treating human immunodeficiency virus (HIV) infection in an antiretroviral treatment-experienced mammal, which involves administering to the mammal an effective amount of a compound of the formula:or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of the compound, the salt, the prodrug, or the ester thereof, wherein A, X, Q, W, m, and R2-R6 are as defined herein.",57,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Board of Trustees of the University of Illinois,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/341
8597883,3-Dec-13,2013,12,3,Biomarkers for cancer-related fatigue and use thereof,"Described herein is the identification of genes that are significantly up- or down-regulated in patients suffering from cancer-related fatigue (CRF), providing a means for the diagnosis and treatment of CRF. In particular, provided herein is a method of diagnosing a subject with CRF by detecting expression of at least one gene associated with CRF in a sample obtained from the subject; and comparing expression of the at least one gene to a control. Also described herein is a method of treating a patient with CRF by administering to the subject an agent that alters expression or activity of a gene associated with CRF. Further provided is array that includes a plurality of genes associated with CRF, such as TNFRSF25, SLC6A8, OGT, SNCA, APBA2, CASK, OR2W3, MYL4, IL7R, ARHGEF10 and ITGA6.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/574
8603468,10-Dec-13,2013,12,10,Neutralization of HCV,Aspects of the present invention concern compositions that induce and/or improve an immune response to hepatitis C virus (HCV). Methods of making and using compositions that include epitopes of the HCV E2 structural protein involved in promoting or inhibiting neutralization of HCV are provided.,9,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/109
8603522,10-Dec-13,2013,12,10,Nutritional supplement to treat macular degeneration,"A daily nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The ingredients of the daily nutritional or dietary supplement composition include vitamin C, vitamin E, lutein, zinc and copper. The ingredients are preferably provided in a tablet form suitable for oral ingestion.",20,Bausch & Lomb Incorporated,,,,,,,,,,,1,Food chemistry,Pharmaceuticals,,,,,A61K/34
8603745,10-Dec-13,2013,12,10,Artificial mutation controls for diagnostic testing,"Disclosed are artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular mutation. Also provided are methods of generating such compositions, and methods of their use.",10,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention",The Regents of the University of California,,,,,,,,,,2,Biotechnology,,,,,,C12N/102
8603784,10-Dec-13,2013,12,10,Infectious clone of human parvovirus B19 and methods,"The invention relates to infectious clones of parvovirus B19, methods of cloning infectious B19 clones, and methods of cloning viral genomes that have secondary DNA structures that are unstable in bacterial cells. A B19 infectious clone and methods of producing B19 infectious clones are useful for producing infectious virus. Infectious virus is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B19 infections.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Institut National de Rechesche Scientifique,,,,,,,,,,2,Biotechnology,,,,,,C12Q/701
8603808,10-Dec-13,2013,12,10,Leishmania vaccine using sand fly salivary immunogen,"The present invention provides vectors that contain and express in vivo or in vitro sand fly Lu. longipalpis salivary antigens that elicit an immune response in animal or human against Leishmania, vaccine compositions comprising said vectors and/or Lu. longipalpis salivary polypeptides, methods of vaccination against Leishmania, and kits for use with such methods and compositions.",12,Merial Limited,The United States of America As Represented by The Secretary of the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/43577
8603978,10-Dec-13,2013,12,10,Use of muramyl dipeptide (MDP) for treating inflammation,The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP).,8,"The United States of America, as represented by the Secretary, Department of Health and Humand Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/14
8608634,17-Dec-13,2013,12,17,Coil for magnetic stimulation and methods for using the same,"A magnetic stimulator, which may be used as a transcranial magnetic stimulation (TMS) device, and a method for its use are disclosed. The stimulator comprises a frame and an electrically conductive coil having a partially toroidal or ovate base and an outwardly projecting extension portion. The frame may be a flexible or malleable material and may be nonconductive. The electrically conductive coil may comprise one or more windings of electrically conductive material (such as a wire) coupled to the frame. The coil is electrically connected to a power supply. The device may be placed adjacent to or in contact with the body of a subject, such as on the head of a subject. The device may be used on humans for treating certain physiological conditions, such as cardiovascular or neurophysiological conditions, or for studying the physiology of the body. This device is useful in studying or treating neurophysiological conditions associated with the deep regions of the brain, such as drug addiction and depression.",41,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61N/006
8609395,17-Dec-13,2013,12,17,Agonist and antagonist peptides of carcinoembryonic antigen (CEA),"The invention provides a polypeptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention provides DNA encoding the polypeptide, as well as vectors and cells comprising the DNA and methods comprising the administration of the polypeptide.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/70503
8609607,17-Dec-13,2013,12,17,Modified defensins and their use,"This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. Compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. Methods are provided for modulating an antimicrobial activity and for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.",10,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/1709
8609716,17-Dec-13,2013,12,17,"Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof","A composition comprising a substantially purified compound of the formula:in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
8611066,17-Dec-13,2013,12,17,Non-radioactive bipolar charger for aerosol particles,"A bipolar charger includes a housing with a main chamber and positive and negative electrode chambers facing each other. The electrode chambers each have a ground electrode and a high voltage electrode that cooperate to create a cloud of ions. An aerosol flowing from an inlet passage through the main chamber and out an outlet passage mixes with the clouds of ions, thereby providing an aerosol with a steady-state electric charge distribution.",19,Centers for Disease Control and Prevention,,,,,,,,,,,1,Measurement,,,,,,G01N/0656
8613932,24-Dec-13,2013,12,24,GP100-specific T cell receptors and related materials and methods of use,"The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/70503
8613933,24-Dec-13,2013,12,24,Brachyury polypeptides and methods for use,"It is disclosed herein that Brachyury is expressed in human tumors, specifically in tumors of the small intestine, stomach, kidney, bladder, uterus, ovary, and testes, as well as in lung, colon and prostate carcinomas. Immunogenic Brachyury polypeptides are disclosed herein. These polypeptides can be used in diagnostic assays for Brachyury expression, as well as for inducing an immune response to Brachyury. Polynucleotides encoding the immunogenic Brachyury polypeptides, vectors including these polypeptides, host cells transformed with these vectors, and methods of using these polypeptides, polynucleotides, vectors, and host cells are provided. Methods of diagnosing a Brachyury-expressing cancer are also provided. Exemplary cancers include small lung, colon, intestine, stomach, kidney, bladder, uterus, ovary, and testes and prostate cancers. Methods of treating cancer are also disclosed.",29,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12N/113
8613934,24-Dec-13,2013,12,24,Cellular and viral inactivation,"The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal.",17,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/00
8613935,24-Dec-13,2013,12,24,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.",24,"Medimmune, LLC",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/145
8614091,24-Dec-13,2013,12,24,PNMT as a novel marker for progenitor cells,"In certain aspects, the present invention provides methods and compositions relating to a Pnmt-positive progenitor cell. In certain aspects, the present invention relates to methods for isolating and transplanting the subject progenitor cells, and methods for treating diseases such as myocardiac injuries and neurodegenerative disorders.",5,,,,,,,,,,,,,Pharmaceuticals,Biotechnology,Other special machines,,,,A61K/34
8614304,24-Dec-13,2013,12,24,Immunogenic peptides and methods of use for treating and preventing cancer,"Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4+ and CD8+ T cells, and methods of treating or preventing cancer are further provided herein.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Serives",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70539
8614466,24-Dec-13,2013,12,24,Semiconductor for measuring biological interactions,"An apparatus and method are disclosed for electrically directly detecting biomolecular binding in a semiconductor. The semiconductor can be based on electrical percolation of nanomaterial formed in the gate region. In one embodiment of an apparatus, a semiconductor includes first and second electrodes with a gate region there between. The gate region includes a multilayered matrix of electrically conductive material with capture molecules for binding target molecules, such as antibody, receptors, DNA, RNA, peptides and aptamer. The molecular interactions between the capture molecules and the target molecules disrupts the matrix's continuity resulting in a change in electrical resistance, capacitance or impedance. The increase in resistance, capacitance or impedance can be directly measured electronically, without the need for optical sensors or labels. The multi-layered matrix can be formed from a plurality of single-walled nanotubes, graphene, or buckeyballs or any kind of conductive nanowire, such as metal nanowires or nanowires made from conductive polymers.",30,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","University of Maryland, Baltimore County","University of Maryland, College Park",,,,,,,,,3,Analysis of biological materials,,,,,,G01N/5438
8617813,31-Dec-13,2013,12,31,Methods for modulating embryonic stem cell differentiation,"Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described. Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Other special machines,,,,,C07K/47
8617831,31-Dec-13,2013,12,31,Methods for diagnosing and monitoring the progression of cancer by measuring soluble c-Met ectodomain,Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.,16,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","Amgen, Inc.",,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/57488
8618090,31-Dec-13,2013,12,31,Inhibitors of the plasmodial surface anion channel as antimalarials,"Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/553
8620592,31-Dec-13,2013,12,31,"Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states","A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition.",10,"The United States of America Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Computer technology,Biotechnology,,,,,G16B/00
8623371,7-Jan-14,2014,1,7,Targeting poly-gama-glutamic acid to treat Staphylococcus epidermidis and related infections,"Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-γ-glutamic acid (such as γDLPGA) polypeptides of S. epidermidis, or related staphylococci that express a γPGA polypeptide. The γPGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses γPGA from the cap genes. Further, the expression of a γPGA polypeptide by the organism can then be altered.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12P/02
8623379,7-Jan-14,2014,1,7,Compositions and methods for generating an immune response,"We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).",18,Emory University,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/21
8623828,7-Jan-14,2014,1,7,Blocking mesothelin peptide fragments,"The present invention provides mesothelin peptide fragments corresponding to the CA125 binding site of mesothelin. The peptide fragments find use in disrupting the binding interaction between mesothelin and CA 125, for example, in the treatment and prevention of cancers that require the interaction of mesothelin and CA125 for growth, progression and/or metastasis.",27,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/47
8624012,7-Jan-14,2014,1,7,Nucleic acids encoding T2R bitter taste receptors,"The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.",10,The Regents of the University of California,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/74
8628780,14-Jan-14,2014,1,14,Lutzomyia longipalpis polypeptides and methods of use,"Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,Fundação Oswaldo Cruz (FIOCRUZ),,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/008
8628782,14-Jan-14,2014,1,14,Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction,"Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions. Also disclosed are uses of these variant gp120 polypeptides and nucleic acids encoding variant polypeptides, such as to induce an immune response to HIV-1.",10,"The United States of America, as Represented by the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
8628962,14-Jan-14,2014,1,14,Differentiation of stem cells into dopaminergic cells,"Methods for differentiating stem cells are disclosed herein. These methods can be used to generate neurons, including, but not limited to, dopaminergic neurons. The disclosed methods include culturing stem cells in the absence of fibroblast growth factor-2 to generate embryoid bodies and culturing the embryoid bodies in the presence of an effective amount of at least one of stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2, and ephrin B1 on an extracellular matrix for a period of time sufficient to produce dopaminergic neuronal cells. The differentiated cells can be used to study pharmaceutical agents that affect dopaminergic neurons and can be used in the treatment of neurodegenerative disorders such as Parkinson's disease.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0606
8629260,14-Jan-14,2014,1,14,"Anti-arthropod vector vaccines, methods of selecting and uses thereof",The present disclosure provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present disclosure also provides compositions for vaccines to prevent Leishmaniasis.,19,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0003
8632468,21-Jan-14,2014,1,21,"Method, system and devices for transjugular intrahepatic portosystemic shunt (TIPS) procedures","Systems and methods for assisting/performing image-guided transjugular intrahepatic portosystemic shunt (TIPS) procedures in a portion of an anatomy of a patient include a guide needle portion having a hollow tube with a bend toward its distal tip, and a puncture needle portion that includes at least one position indicating element at its tip. The puncture needle is slidably mounted within the hollow tube of the guide needle such that a distal tip of the puncture needle can be extended from an opening in the distal tip of the guide needle and used to place a shunt between the portal and hepatic veins of a patient. The position indicating element of the puncture needle is used to produce a display of the puncture needle relative to a target vessel, including a projected path of the puncture needle that can be adjusted to accurately locate a shunt.",18,Koninklijke Philips N.V.,,,,,,,,,,,1,Medical technology,,,,,,A61B/4245
8632782,21-Jan-14,2014,1,21,Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region,The invention features novel attenuated dengue virus mutants and compositions thereof.,17,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
8633177,21-Jan-14,2014,1,21,Nitroxyl (HNO) releasing compounds and uses thereof in treating diseases,"Disclosed is a compound of the formula (I) or a pharmaceutically acceptable salt thereof: (I) in which R1, R2, R3, and R4 are defined herein and pharmaceutical compositions thereof. Further provided is a method of treating various disorders, such as a disorder selected from the group consisting of a cardiovascular disorder, cancer, chronic pain, alcohol dependence, and inflammation in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt of formula (I).",34,"The United States of America, as represented by the Secretary, Department of Health and Human Services","The Arizona Board of Regents, on behalf of the University of Arizona",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/12
8636978,28-Jan-14,2014,1,28,"Cyclized NGR peptide compounds, compositions, and methods of their use",Cyclized peptide compounds containing the NGR motif of formula (I) or a pharmaceutically-acceptable salt thereof are disclosed. Compositions comprising the cyclized peptide compounds and methods of their use are also disclosed.,36,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/56
8636997,28-Jan-14,2014,1,28,Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist,"Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Medical technology,Biotechnology,,,,C07K/2866
8637036,28-Jan-14,2014,1,28,Neutralizing antibodies to HIV-1 and their use,"Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Washington,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/1063
8637050,28-Jan-14,2014,1,28,Peptide vaccines against group A streptococci,"This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/092
8637234,28-Jan-14,2014,1,28,Molecular scaffolds for HIV-1 epitopes,"Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.",13,UAB Research Foundation,The Administrators of Tulane Educational Fund,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,3,Biotechnology,Analysis of biological materials,,,,,G01N/56988
8637310,28-Jan-14,2014,1,28,Use of a rock inhibitor to sustain primary human keratinocytes in a proliferative state,"Disclosed herein is the finding that treatment with a ROCK inhibitor increases proliferation and induces immortalization of primary keratinocytes. Accordingly, provided is a method of immortalizing primary keratinocytes by exposure to a ROCK inhibitor. Also provided are immortalized primary keratinocytes produced by the described method, as well as organotypic tissue equivalents and cell cultures comprising the immortalized primary keratinocytes. Furthermore, ROCK inhibitor-treated cells show a greatly increased ability to support viral DNA replication of both “low risk” and “high risk” HPV genomes, indicating that ROCK inhibitors will be useful for studying the life cycles of a wide range of HPVs.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0629
8637560,28-Jan-14,2014,1,28,"Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment",The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.,18,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/4178
8642048,4-Feb-14,2014,2,4,Multiple antigenic peptides immunogenic against Streptococcus pneumonia,"The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention. Also provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens and methods of preventing and treating Streptococcus pneumoniae infection in a subject.",28,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/08
8642654,4-Feb-14,2014,2,4,Hydroxybutyrate ester and medical use thereof,"A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.",5,ISIS Innovation Limited,"Government of the USA, as Represented by the Sec-Retary, Department of Health and Human Services",,,,,,,,,,2,Food chemistry,Pharmaceuticals,Organic fine chemistry,,,,A23L/52
8647818,11-Feb-14,2014,2,11,Molecular scaffolds for HIV-1 immunogens,"Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided. Vaccines comprising such immunogenic compositions are also provided. Further provided are methods which employ the immunogenic compositions of the invention. Such methods include, for example, methods for eliciting an immune response in a subject, methods for generating antibodies specific for the chimeric polypeptide or the chimeric polypeptide, and methods for inhibiting or preventing infection by HIV-1 in a subject.",26,"UAB Research Foundation, University of Alabama—Birmingham","The United States of America, as represented by the Secretary, Department of Health and Human Services (Hereinafter the Government) Office of Technology Transfer, National Institutes of Health",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/21
8652458,18-Feb-14,2014,2,18,Tissue graft with non-aligned fiber matrix retains mesenchymal progenitor cells on the non-injury-facing side,"A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.",27,"The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.","The United States of America, as represented by the Secretary of the Army, U.S.A.","The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,3,Medical technology,Pharmaceuticals,Biotechnology,"Macromolecular chemistry, polymers",,,A61K/70
8652787,18-Feb-14,2014,2,18,Use of ERBB4 as a prognostic and therapeutic marker for melanoma,"It is disclosed herein that members of the protein tyrosine kinase (PTK) family are highly mutated in patients with melanoma. Described herein are novel somatic mutations in the ERBB4 gene that result in increased kinase activity, transformation ability and anchorage-independent growth. These ERBB4 mutations contribute to the tumorogenicity of melanoma. Thus, provided herein is a method of predicting the prognosis of a patient with melanoma by detecting the presence or absence of a mutation in the ERBB4 gene. In some examples, the ERBB4 mutation is selected from G949A, G1354A, G1624A, C1630T, G1687A, G2506A and G2614A (numbering based on SEQ ID NO: 1). Also provided are methods of selecting a patient as a candidate for treatment with an ERBB4 and/or PI3K/AKT pathway inhibitor, and a method of identifying a therapeutic agent for the treatment of a subject diagnosed with melanoma. Oligonucleotides that specifically hybridize with an ERBB4 nucleic acid molecule comprising a novel mutation, and arrays comprising such oligonucleotides, are also provided.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12Q/6886
8652801,18-Feb-14,2014,2,18,"Hydrophilic IR transparent membrane, spectroscopic sample holder comprising same and method of using same","The present invention features hydrophilic IR-transparent porous membranes, particularly hydrophilic IR-transparent porous polyethylene membranes and methods of preparing the hydrophilic membranes by treatment of hydrophobic IR-transparent porous membranes with plasma. The present invention further features spectroscopic sample holders which incorporate the hydrophilic IR-transparent porous membranes and methods of identifying bacteria and other microorganisms in samples by infrared spectroscopy.",6,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Measurement,Biotechnology,,,,,C12Q/04
8656908,25-Feb-14,2014,2,25,Aerosol delivery systems and methods,"Methods and systems for aerosol delivery of agents to a patient are described herein. The present system can be used to administer various types of agents, such as a vaccine or other types of pharmaceutical substances. Certain embodiments of the present system utilize an actuator coupled to a disposable aerosolizing element that aerosolizes an agent for delivery to a patient when acted upon by the actuator. The aerosolizing element prevents the agent from contacting the actuator and other non-disposable components of the system so that little or no cleaning or maintenance is required. The present system also can include an aerosolization rate monitor that monitors the rate at which an agent is being aerosolized and provides feedback to the user to ensure that the proper dose is being administered.",37,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",Creare Inc.,,,,,,,,,,2,Chemical engineering,Medical technology,,,,,B05B/0638
8658180,25-Feb-14,2014,2,25,Vaccines against influenza virus,"Disclosed are immunogenic conjugates having the general formula:M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr,were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.",22,,,,,,,,,,,,,Biotechnology,Pharmaceuticals,,,,,C07K/06
8658608,25-Feb-14,2014,2,25,Modified triple-helix forming oligonucleotides for targeted mutagenesis,"High affinity, chemically modified triplex-forming oligonucleotides (TFOs) and methods for use thereof are disclosed. TFOs are defined as triplex-forming oligonucleotides which bind as third strands to duplex DNA in a sequence specific manner. Triplex-forming oligonucleotides may be comprised of any possible combination of nucleotides and modified nucleotides. Modified nucleotides may contain chemical modifications of the heterocyclic base, sugar moiety or phosphate moiety. A high affinity oligonucleotide (Kd≦2×10−8) which forms a triple strand with a specific DNA segment of a target gene DNA is generated. It is preferable that the Kd for the high affinity oligonucleotide is below 2×10−10. The nucleotide binds or hybridizes to a target sequence within a target gene or target region of a chromosome, forming a triplex region. The binding of the oligonucleotide to the target region stimulates mutations within or adjacent to the target region using cellular DNA synthesis, recombination, and repair mechanisms. The mutation generated activates, inactivates, or alters the activity and function of the target gene.",23,Yale University,Department of Health and Human Services,,,,,,,,,,2,Biotechnology,,,,,,C12N/102
8663622,4-Mar-14,2014,3,4,Recombinant vaccine viruses expressing IL-15 and methods using the same,"The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.",16,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/39
8663926,4-Mar-14,2014,3,4,Detection of anthrax pathogenicity factors,"One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By capitalizing on the endopeptidase activity of lethal factor the present invention amplifies output signals producing reliable detection of picomolar concentrations of lethal factor. The instant invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax lethal factor in biological samples.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56911
8663968,4-Mar-14,2014,3,4,Simian T-cell lymphotropic virus,"Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which included isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed.",8,"The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",Johns Hopkins University,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/005
8664183,4-Mar-14,2014,3,4,SPANX-B polypeptides and their use,"It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
8667731,11-Mar-14,2014,3,11,Suction trap for collecting resting mosquitoes,"A method and apparatus are disclosed that can sample a wide variety of mosquitoes attempting to rest. Because all mosquitoes rest daily, biases of typical mosquito traps are avoided, such as targeted collections of host-seeking mosquitoes or gravid female mosquitoes. A particular advantage is the inclusion of blood-engorged mosquitoes in the resting collections. In one embodiment, the apparatus includes an open-sided pot designed to attract mosquitoes seeking a daytime resting location. The mosquitoes that enter a dark space of the pot are aspirated into a screened collection receptacle by means of a battery-powered fan.",19,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Other special machines,,,,,,A01M/06
8673316,18-Mar-14,2014,3,18,"Avirulent, immunogenic flavivirus chimeras",Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.,27,"The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",Mahidol University,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/12
8673333,18-Mar-14,2014,3,18,"Cross-linked polymer matrices, and methods of making and using same","Functionalized chondroitin sulfate, cross-linked polymer matrices comprising functionalized chondroitin sulfate, and methods of making and using the same are provided. Such polymer matrices may be used for tissue engineering, reconstructing cartilage, and the like. Kits are also provided for detection of cartilage degrading enzymes.",18,The Johns Hopkins University,"University of Maryland, Baltimore","The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,3,"Macromolecular chemistry, polymers",Medical technology,Pharmaceuticals,Biotechnology,Other special machines,Basic materials chemistry,C12Q/527
8673629,18-Mar-14,2014,3,18,Recombinant Rift Valley fever (RVF) viruses and methods of use,"Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.",25,The United States of America as represented by the Secretary of the Department of Health and Human Services Centers for Disease Control and Prevention,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
8673888,18-Mar-14,2014,3,18,Depsipeptide for therapy of kidney cancer,"The present invention provides a therapeutic agent of kidney cancer, which comprises FK228 of the formula (I) or a salt thereof. FK228 or a salt thereof, which is an active ingredient in the present invention, shows a superior antitumor activity in vivo against kidney cancer.",6,"The United States of America, represented by the Secretary, Department of Health and Human Services",Astellas Pharma Inc.,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/15
8675942,18-Mar-14,2014,3,18,Prior enhanced compressed sensing (PRINCE-CS) reconstruction for dynamic 2D-radial cardiac MRI,"A reconstructed image is rendered from a set of MRI data by first estimating an image with an area which does not contain artifacts or has an artifact with a relative small magnitude. Corresponding data elements in the estimated image and a trial image are processed, for instance by multiplication, to generate an intermediate data set. The intermediate data set is transformed and minimized iteratively to generate a reconstructed image that is free or substantially free of artifacts. In one embodiment a Karhunen-Loeve Transform (KLT) is used. A sparsifying transformation may be applied to generate the reconstructed image. The sparsifying transformation may be also not be applied.",18,Siemens Aktiengesellschaft,National Institutes of Health,,,,,,,,,,2,Measurement,,,,,,G01R/4824
8679836,25-Mar-14,2014,3,25,Methods of monitoring angiogenesis and metastasis in three dimensional co-cultures,"This disclosure relates to fluorescent cell lines and to the use of such cell lines in monitoring cellular activity, such as angiogenesis. This disclosure further relates to the use of such cell lines in a three-dimensional cell culture to monitor angiogenic and metastatic potential of tumor cells and selecting personalized therapeutics for treatment of cancer.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5011
8680046,25-Mar-14,2014,3,25,Inhibitors of viral integrase and methods of use,Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.,15,"Integratech Proteomics, LLC","The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,C07K/00
8680056,25-Mar-14,2014,3,25,Antiproliferative factor and methods of use,"A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services","University of Maryland, Baltimore",The United States of America as Represented by the Department of Veterans Affairs,,,,,,,,,3,Biotechnology,,,,,,C07K/005
8680065,25-Mar-14,2014,3,25,Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use,"Described herein are oligonucleotides that target the human endogenous retrovirus-9 (ERV-9) long terminal repeat (LTR). The ERV-9 LTR oligonucleotides specifically hybridize with either the coding strand or non-coding strand of ERV-9 LTR. It is disclosed herein that ERV-9 LTR oligonucleotides inhibit the proliferation of cancer cells, including breast cancer, liver cancer, prostate cancer, fibrosarcoma and myeloid cancer cells. Also described herein are methods of treating a subject diagnosed with cancer comprising administering to the subject an ERV-9 LTR oligonucleotide. In some examples, the methods further comprise administering a second therapeutic agent, such as an antisense compound or a chemotherapeutic agent.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/1135
8680129,25-Mar-14,2014,3,25,"Compounds, composition, methods, targets for cancer therapy",This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.,1,,,,,,,,,,,,,Pharmaceuticals,Biotechnology,Organic fine chemistry,,,,C12N/113
8685396,1-Apr-14,2014,4,1,Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin,"The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1278
8685416,1-Apr-14,2014,4,1,Compositions and methods for the treatment of cancer,"Methods for inducing an immune response to a tumor in a subject are disclosed herein. These methods include selecting a subject with a tumor and administering a therapeutically effective amount of apoptotic tumor cells conjugated to a CpG oligodexoynucleotide (ODN) to the subject. In some embodiments, the CpG ODN is a K-type or a D-type CpG ODN. Methods for treating a tumor in a subject are also disclosed herein. These methods include selecting a subject with a tumor and administering a therapeutically effective amount of apoptotic tumor cells conjugated to a CpG oligodexoynucleotide (ODN) to the subject. In some embodiments, the tumor cells are autologous. In additional embodiments, the tumor is a lymphoma, cervical cancer, prostate cancer, breast cancer, colon cancer or a lung cancer.",34,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/549
8685722,1-Apr-14,2014,4,1,Bovine adeno-associated viral (BAAV) vector and uses thereof,"The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.",2,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
8686016,1-Apr-14,2014,4,1,Schweinfurthins and uses thereof,"Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Iowa Research Foundation,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,C07D/78
8686146,1-Apr-14,2014,4,1,Azaindenoisoquinoline topoisomerase I inhibitors,"The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.",18,Purdue Research Foundation,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
8691501,8-Apr-14,2014,4,8,"Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis","Although it can be farnesylated, mutant lamin A expressed in Hutchinson Gilford Progeria Syndrome cannot be defarnesylated; the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (“progerin”) that alters normal lamin A function as a dominant negative, and assumes its own aberrant function through its association with the nuclear membrane. Retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) will inhibit formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with FTIs.",4,"Progeria Research Foundation, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,The Universitry of North Carolina at Chapel Hill,The Regents of the University of Michigan,,,,,,,,4,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/4545
8691859,8-Apr-14,2014,4,8,Broad spectrum antibacterial compounds,"Disclosed herein are methods of inhibiting, reducing or preventing growth of or destroying bacteria of at least one bacterial strain which comprises contacting the bacteria with the compounds disclosed herein. Also disclosed are methods of treating, inhibiting or preventing an infection or intoxication caused by bacteria of at least one bacterial strain in a subject and pharmaceutical and cosmetic compositions comprising the compounds disclosed herein.",18,The United States of America as Represented by the Secretary of the Army,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/4184
8691864,8-Apr-14,2014,4,8,Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof,The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.,25,,,,,,,,,,,,,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
8697046,15-Apr-14,2014,4,15,Methods of administering interferon gamma to absorb fluid from the subretinal space,Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space.,18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Pharmaceuticals,,,,,A61K/217
8697666,15-Apr-14,2014,4,15,Anti-cancer oligodeoxynucleotides,"It is disclosed herein that suppressive OD Ns are of use for preventing or delaying the formation of a tumor, reducing the risk of developing a tumor, treating a tumor, preventing conversion of a benign to a malignant lesion, or preventing metastasis. In some embodiments, methods are disclosed herein for treating, preventing or reducing the risk of developing a tumor, such as esophageal, gastrointestinal, liver, lung, skin and colon tumors or a mesothelioma. Generally, the methods disclosed herein include selecting a subject for treatment and administering to the subject a therapeutically effective amount of one or more suppressive ODN. In some examples, additional agents can also be administered to the subject of interest.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7088
8701597,22-Apr-14,2014,4,22,Apparatus for applying chemicals to rodents,An enclosure is provided having openings for entry of rodents within the enclosure. There is arranged one or more applicators in the form of a suspended flexible web configured to contact rodents entering the chamber and having a chemical on the web for application to the rodents.,7,Centers for Disease Control and Prevention,Bayer Cropscience S.A.,"B&G Equipment Company, Inc.",,,,,,,,,3,Other special machines,,,,,,A01K/003
8703096,22-Apr-14,2014,4,22,Beta-amyloid PET imaging agents,Novel derivatives of imidazopyridinylbenzeneamines and novel derivatives of benzothiazolylbenzeneamines are disclosed that offer improved behavior when used as imaging agents for positron emission tomography of beta-amyloids. Also disclosed is a palladium-catalyzed reaction scheme under microwave conditions for aryl thioethers in general that provides a high ratio of substitution relative to reduction and can be used for the imidazopyridinylbenzeneamine derivatives as well as other compounds of related structure.,12,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/04
8703150,22-Apr-14,2014,4,22,Methods of using Bacillus anthracis protective antigen sequences for vaccination,"The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.",10,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Pharmaceuticals,,,,C07H/04
8703459,22-Apr-14,2014,4,22,"Catalytic domains of beta(1,4)-galactosyltransferase I having altered metal ion specificity",Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.,12,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12N/1051
8703484,22-Apr-14,2014,4,22,Methods and compositions for detecting immune responses,"The invention provides a method for detecting an antigen-specific hematopoietic cell in a biological sample, wherein the method comprises (a) providing a biological sample comprising a hematopoietic cell of a first species; (b) providing a target cell of a second species, wherein the second species is different from the first species, wherein the second species is a macaque species, and wherein the target cell comprises an antigen; (c) contacting the target cell with the sample; and (d) detecting an immune activation marker or activity in the sample, wherein an increase in expression of the immune activation marker or activity in the sample, relative to a control, is an indication that the sample comprises an antigen-specific hematopoietic cell; and wherein a cell identical to the target cell but lacking the antigen does not stimulate expression of the immune activation marker or activity in hematopoietic cells of the first species.",29,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/56977
8703734,22-Apr-14,2014,4,22,Nanoprobes for detection or modification of molecules,"The disclosure provides probes for one or more target molecules. In particular examples, the probes include a molecular linker and first and second functional groups linked and spaced by the molecular linker, wherein the functional groups are capable of interacting with one another or with the target biomolecule in a predetermined reaction, and wherein the molecular linker maintains the first and second functional groups sufficiently spaced from one another such that the functional groups do not substantially interact in an absence of the target biomolecule. In the presence of the target biomolecule the functional groups interact (with each other, with the target biomolecule, or both), and in some examples a detectable signal is produced. In some examples, the functional groups can detect or modify a target molecule. Also provided are methods of using the probes, for example to detect or modify a target molecule.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Measurement,Analysis of biological materials,,,,G01N/6486
8703826,22-Apr-14,2014,4,22,"Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol analogues and their use in treating congestive heart failure","This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.",13,"The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/60
8703921,22-Apr-14,2014,4,22,Compositions and methods for delivering inhibitory oligonucleotides,"The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.",10,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/713
8704169,22-Apr-14,2014,4,22,Direct impact ionization (DII) mass spectrometry,"Disclosed is a mass spectrometer for analyzing a sample that has or is suspected of having microorganisms. The disclosed mass spectrometer has been uniquely configured to include a sample platform which functions as a counter electrode or discharge electrode and a surface to provide the sample to be analyzed. The mass spectrometer also includes an ion source positioned adjacent to the sample platform for ionizing and volatizing molecules within the sample, wherein the sample platform and the ion source are positioned such that during operation of the mass spectrometer an electrical discharge takes place between the ion source and the sample platform. Also disclosed are methods for generating a mass spectrum profile/fingerprint of a sample. The methods include positioning a sample platform having a sample adjacent to an ion source.",28,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,"Electrical machinery, apparatus, energy",,,,,,H01J/0409
8704515,22-Apr-14,2014,4,22,Magnetic resonance specimen evaluation using multiple pulsed field gradient sequences with a wavenumber magnitude local minimum and restricted compartment estimation,"Using pulsed-field-gradient (PFG) sequences, the sizes of the pores in ordered porous media can be estimated from the “diffraction” pattern that the signal attenuation curves exhibit. A different diffraction pattern is observed when the experiment is extended to a larger number (N) of diffusion gradient pulse pairs. Differences in the characteristics of attenuation curves also permit distinguishing different pore shapes and distributions using the N-PFG technique. Using an even number of PFG pairs, an approximation to the average pore size can be obtained even when the sample contains pores with a broad distribution of sizes. Multi-PFG sequences can also be used to differentiate free and multi-compartment diffusion, and to estimate compartment sizes and orientations, and to distinguish microscopic and ensemble anisotropy.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/56341
8709793,29-Apr-14,2014,4,29,"Bioreactor device, and method and system for fabricating tissues in the bioreactor device","A bioreactor device, and a method and system for fabricating tissues and growing cells and tissues in the bioreactor device, accommodates less than about 1 mL (or less than about 200 μL) of local medium volume but sample sizes of about 100 μL or greater. The bioreactor device includes a bioreactor chamber for containing a sample, where sample growth in response to mechanical, electrical, and biofactor stimulation is monitored through one or more optical ports. Embedded sensors are provided for measuring fluid pressure, pH, temperature, and oxygen tension. The bioreactor device can receive different types of mechanical loadings, including fluid shear, hydrostatic pressure, matrix compression, and clinorotation.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12M/10
8709813,29-Apr-14,2014,4,29,DNA promoters and anthrax vaccines,The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.,6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/32
8710026,29-Apr-14,2014,4,29,"MiR 204, miR 211, their anti-miRs, and therapeutic uses of same","Embodiments of the invention provide methods of preventing or treating detrimental epithelial cell proliferation, loss of epithelial cell differentiation, age-related macular degeneration and/or proliferative vitreal retinopathy in an individual comprising administering to an individual in need thereof an effective amount of miR 204, an effective amount of miR 211, or an effective amount of a mixture of miR 204 and miR 211. A further embodiment of the invention provides a method of facilitating the transport of a substance across an epithelium in an individual comprising administrating to an individual an effective amount of anti-miR 204, an effective amount of anti-miR 211, or an effective amount of a mixture of anti-miR 204 and anti-miR 211. Additional embodiments of the invention include pharmaceutical compositions of miR 204 and/or miR 211 and pharmaceutical compositions of anti-miR 204 and/or anti-miR 211.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/7105
8712499,29-Apr-14,2014,4,29,Quantitative oxygen imaging systems and methods using echo-based single point imaging,"An echo-based single point imaging (ESPI) system (10) providing high-resolution oxygen images of a sample is disclosed. The ESPI system (10) employs spin echo detection of the resonance from a spin probe and concurrent Single Point Imaging (SPI) for spatial encoding of the oxygen concentration within the sample. Images are derived by comparing spin echo intensities of two images reconstructed at two time points selected at identical time intervals on either side of a refocusing pulse, eliminating artifacts associated with sample magnetic susceptibility and field inhomogeneity effects.",16,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/60
8715686,6-May-14,2014,5,6,Conformationally stabilized HIV envelope immunogens,"Isolated immunogens including a HIV-1 gp120 polypeptide or immunogenic fragment thereof stabilized in a CD4 bound confirmation by crosslinked cysteines, and methods of their use are disclosed. The immunogens are useful, for example, for generating an immune response to HIV-1 gp120 in a subject.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services","Dana-Faber Cancer Institute, Inc.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
8715689,6-May-14,2014,5,6,Chimeric west nile/dengue viruses,"The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.",22,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
8715928,6-May-14,2014,5,6,Molecular-based method of cancer diagnosis and prognosis,"A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Also provided is a method of treating a patient diagnosed with cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed cancer survival factor-associated genes. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/6886
8715964,6-May-14,2014,5,6,Expression of IL-12 family heterodimers,"The present invention provides methods of improving the levels and stability of expression of interleukin-12 family cytokine polypeptides by expressing the alpha and beta subunits of the polypeptides at their determined relative molar ratios that increase the levels and stability of expression of the heterodimer, e.g., in comparison to heterodimer expressed at an equimolar ratio.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/5434
8716021,6-May-14,2014,5,6,Use of replicators to prevent gene silencing,"Regulatory elements, specifically replicators and transgene constructs containing replicator nucleic acid sequences, are disclosed herein. Methods of using replicators and transgene constructs including replicators to inhibit, delay, or prevent gene silencing are also disclosed herein.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/79
8716295,6-May-14,2014,5,6,Fluoroquinolone derivatives or sulfonamide moiety-containing compounds as inhibitors of tyrosyl-dnaphosphodiesterase (TDP1),"A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject. In certain embodiments, the fluoroquinolone derivative or sulfonamide moiety-containing compound is co-administered with a topoisomerase I (TopI) inhibitor.",11,,,,,,,,,,,,,Pharmaceuticals,Biotechnology,,,,,C12N/99
8716301,6-May-14,2014,5,6,Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation,A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.,22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/39
8716315,6-May-14,2014,5,6,Analogs of thalidomide as potential angiogenesis inhibitors,"A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/48
8719045,6-May-14,2014,5,6,Personal assessment including familial risk analysis for personalized disease prevention plan,"Family health history information can be used to assess familial risk for common diseases and determine early detection and prevention medical strategies. Assessed familial risk of disease can then be used to determine recommendations for disease prevention and screening that are targeted to familial risk. Other factors can be included to generate personalized disease prevention recommendations. For example, personal health history information, personal health behavior information, or both can be collected and assessed to generate personalized disease prevention recommendations based on the information collected. Recommendations for disease prevention and screening based at least on familial risk can be used to provide a personalized disease prevention plan that encourages a person to make behavior changes that will reduce the risk of disease and utilize preventive health services.",48,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,IT methods for management,Computer technology,,,,,G06F/00
8721988,13-May-14,2014,5,13,Method for direct measurement of isotopes of expired gases,"The invention provides a device including a chamber wherein the chamber including a rigid enclosure; a rigid lid for the enclosure; a gasket between the lid and the enclosure to allow for an airtight seal between the enclosure and the gasket upon closure of a latch connecting the enclosure and the lid; a port for airtight attachment of a syringe, and a port for airtight insertion of a gas sensor. The device can further include a gas sensor and one or more syringes for attachment to the device by a three-way stopcocks. The device is appropriately sized for use with the subject of interest. The invention also provides methods for use of the device.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Analysis of biological materials,,,,,G01N/497
8722046,13-May-14,2014,5,13,Human monoclonal antibodies protective against bubonic plague,"In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.",16,The United States of America as Represented by the Secretary of the Army,The United States of America as Represented by the Secretary of the Army,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/1228
8722046,13-May-14,2014,5,13,Human monoclonal antibodies protective against bubonic plague,"In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.",16,The United States of America as Represented by the Secretary of the Army,The United States of America as Represented by the Secretary of the Army,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/1228
8722324,13-May-14,2014,5,13,Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides,"This invention relates to compositions and methods or the detection of human immunodeficiency virus-1 (HIV-1) infection by conducting an immunoassay comprising the steps of: (a) contacting a biological sample containing HIV-1 antibody with a peptide, having an epitope, of one or more of SEQ ID 49-56 to form a peptide-anti-HIV-1 antibody complex; (b) contacting the formed complex with an anti-HIV-1 antibody binding molecule to permit the anti-HIV-1 antibody binding molecule to bind to the anti-HIV-1 antibody of the formed peptide-anti-HIV-1 antibody complex and form an extended complex that is immobilized on a solid support; (c) removing unbound anti-HIV-1 antibody and anti-HIV-1 antibody binding molecule from the extended complex; and (d) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample.",9,"The United States of America, as represented by the Secretary Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/6854
8722653,13-May-14,2014,5,13,Method for treating uterine fibroids,"The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.",11,Laboratoire HRA-Pharma,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/57
8728488,20-May-14,2014,5,20,Methods of inducing an immune response in a host by administering flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens,"The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
8728526,20-May-14,2014,5,20,Coacervate microparticles useful for the sustained release administration of therapeutic agents,"The present invention relates to novel microparticles formed using a coacervation process, methods of forming the microparticles, and methods of using the microparticles for the sustained release administration of therapeutic agents.",6,"The United States of America, Represented by Secretary of Department of Health and Human Services, NIH",,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,,,,,B82Y/00
8729053,20-May-14,2014,5,20,Nuclear factor kappa B pathway inhibitor composition and use of same,"An embodiment of the invention provides a pharmaceutical composition comprising a compound of formula (I) a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Another embodiment of the invention provides a method of treating or preventing a condition associated with increased expression and/or activity of an NFκB pathway using same compounds. A further embodiment of the invention provides a method of diagnosing a condition in an individual using same compounds.",20,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/66
8731264,20-May-14,2014,5,20,System and method for fusing real-time ultrasound images with pre-acquired medical images,"A method, apparatus and system for fusing real-time ultrasound images with pre-acquired medical images are described.",15,Koninklijke Philips N.V.,,,,,,,,,,,1,Medical technology,Computer technology,,,,,A61B/4254
8735082,27-May-14,2014,5,27,Gene signature for predicting prognosis of patients with solid tumors,"Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Thus, provided herein is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes in a tumor sample and comparing expression of the one or more tumor-associated genes in the tumor sample to a control. Also provided is a method of treating a patient diagnosed with HCC or breast cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed tumor-associated genes. Further provided are arrays comprising probes or antibodies specific for a plurality of tumor-associated genes or proteins.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
8735126,27-May-14,2014,5,27,Disease control with tick phospholipase A2,"The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from A. americanum saliva effective in reducing the viability of gram positive, gram negative, or acid-fast bacteria and spirochetes including B. burgdurferi is administered. The inventive protein from A. americanum saliva has utility as a therapeutic for the treatment of an organism infected with bacteria, particularly the spirochete B. burgdorferi.",4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Basic materials chemistry,Pharmaceuticals,Biotechnology,,,,A01N/46
8735355,27-May-14,2014,5,27,"Methods of use of fragments of secreted frizzled related protein, sFRP","The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,University of Massachusetts,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/47
8735407,27-May-14,2014,5,27,Purine derivatives as A3 adenosine receptor-selective agonists,"Disclosed are (N)-methanocarba adenine nucleosides, e.g., of formula (I) as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.",35,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
8741259,3-Jun-14,2014,6,3,Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists,"Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.",28,,,,,,,,,,,,,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
8741313,3-Jun-14,2014,6,3,Polypeptide vaccine and vaccination strategy against mycobacterium,"A vaccine is provided wherein a polypeptide or combination of peptides from M. tuberculosis is administered to a subject to elicit an immune response. The polypeptide vaccine is administered as part of a prime-boost strategy with BCG vaccine to increase the immunoprotection in a subject such that prevention or elimination of disease is achieved. Finally, a pharmaceutical package is provided that encompasses a polypeptide vaccine for M. tuberculosis that when administered to a subject elicits immunoprotection.",18,Emory University,"The United States of America,  as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/04
8741561,3-Jun-14,2014,6,3,Gene sets for detection of ultraviolet A exposure and methods of use thereof,"Ultraviolet radiation (UVR) has profound effects on human skin. However, its effects on the global transcriptome in vivo have not been well characterized. In addition, the contribution of the UVA component of UVR has not been previously assessed in vivo. Disclosed herein is the identification of sets of genes that are either up-regulated or down-regulated in response to UVA exposure. The gene sets described herein can be used to accurately identify skin samples that have been exposed to UVA and to assess the ability of a sun protection product to block the effects of UVA.",28,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
8741574,3-Jun-14,2014,6,3,Gene expression signature of genomic instability in breast cancer,"Methods of assessing genomic instability in breast cancer tissue by measuring the expression level of genes CDKN2A, SCYA18, STK15, NXF1, cDNA Dkfzp762M127, p28 KIAA0882, MYB, Human clone 23948, RERG, HNF3A, and ACADSB or a nucleic acid sequence comprising about 90% or greater sequence identity to SEQ ID NO: 21 in breast cancer tissue, an array suitable for use in such methods, and related methods and compositions.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",West Virginia University Research Corporation,,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/57415
8741649,3-Jun-14,2014,6,3,Methods for enhancing genome stability and telomere elongation in embryonic stem cells,"The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing the genome stability in a population of ES or iPS cells, increasing telomere length in a population of ES or iPS cells, or both, are provided, for example by selecting Zscan4+ ES or iPS cells from the population of ES or iPS cells (which can include both Zscan4+ and Zscan4− ES or iPS cells). Therapeutic methods of using ES or iPS cells expressing Zscan4 are also provided. Further provided are methods of treating cancer by administering a Zscan4 polynucleotide or Zscan4 polypeptide. Also provided are methods of inducing differentiation of isolated ES or iPS cells into germ cells.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/85
8741869,3-Jun-14,2014,6,3,Oligodeoxynucleotide and its use to induce an immune response,"A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula:5′ N1N2N3T-CpG-WN4N5N6 3′wherein the CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are nucleotides, or the formula:5′ RY-CpG-RY 3′wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. In some embodiments, the oligodeoxynucleotide includes the nucleic acid sequences set forth as SEQ ID NO: 137.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,"Uniformed Services University of the Health Sciences, an institution of higher learning within the Department of Defense",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,C07H/04
8741947,3-Jun-14,2014,6,3,"Biologically active macrolides, compositions, and uses thereof","The present invention provides a compound of the formula (I) or (II, wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or aryl, and R9 is R9a, C(O)R9a or SO2R9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(═O), OR9b, OC(O)R9b, OSO2R9b, NHR9b, NHC(O)R9b and NHSO2R9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(═O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.",15,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/395
8747863,10-Jun-14,2014,6,10,Vaccine for shigella,"Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure:Pr—Sr—O—N═C-Kdo-OSwherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure:    In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure:α-L-AltNAcA-3-β-FucNAc4N-4-.",19,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",National Research Council of Canada,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/02
8748114,10-Jun-14,2014,6,10,ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL),"It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57426
8748390,10-Jun-14,2014,6,10,Immunogenic epitopes of NGEP antigen,"The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/17
8748572,10-Jun-14,2014,6,10,"RNase a peptides, fragments and uses thereof","The present invention features isolated polypeptides that have bactericidal and angiogenic activities. The invention features isolated polypeptides comprising amino acid sequences of RNase A ribonucleases, fragments and variants thereof, pharmaceutical compositions, and methods for treatment of a subject.",4,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/22
8748608,10-Jun-14,2014,6,10,4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use,"Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved D3 receptor affinity and selectivity, as well as water solubility, is achieved. A series of linking-chain derivatives are disclosed wherein functionality such as OH or OAc groups have been introduced into the linking chain. In general, these modifications are well tolerated at D3 receptors and achieve high selectivity over D2 and D4 receptors.",18,The United States of America as Represented by the Secretary of the Department of Health and Human Services,The University of North Texas Health Science Center at Fort Worth,,,,,,,,,,2,Organic fine chemistry,Analysis of biological materials,,,,,C07D/85
8753649,17-Jun-14,2014,6,17,Polysaccharide-protein conjugate vaccines,"Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.",10,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/08
8754030,17-Jun-14,2014,6,17,Defensin-antigen fusion proteins,"The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
8754046,17-Jun-14,2014,6,17,"MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1","The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/17
8754081,17-Jun-14,2014,6,17,Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling,"Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are provided. Methods of making derivatives and analogs of c-Met inhibitors and methods of use thereof are provided.",17,"The United States of America as represented by the Secretary, Departmnet of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/90
8759014,24-Jun-14,2014,6,24,Methods of obtaining antigen-specific T cell populations,"The invention provides a method of obtaining a population of antigen-specific T cells from peripheral blood of a host. An embodiment of the method of the invention comprises (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs with an antigen and IL-2; (iii) obtaining a sample of PBMCs from each sub-population; (iv) identifying an antigen-reactive sub-population by determining by high throughput quantitative PCR the expression of a factor produced by the PBMCs of each sample; (v) dividing the antigen-reactive sub-population into microcultures; (vi) identifying the antigen-reactive microculture; and (vii) expanding the microculture, thereby obtaining a population of T cells specific for the antigen. The invention also provides a population of T cells obtained by the inventive method, a pharmaceutical composition comprising the same, and a method of treating a disease in a host using the pharmaceutical composition. Related isolating and screening methods are further provided.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/0011
8759792,24-Jun-14,2014,6,24,Non-contact total emission detection method and system for multi-photon microscopy,"A multi-photon microscope having an illumination source that transmits an illumination light into a housing having an objective lens arrangement for illuminating a sample disposed outside the housing and directing a first portion of emission light emitted from the sample to a detection system is disclosed. A light collection system is disposed proximate the objective lens arrangement for directing a second portion of emission light in a coaxial relationship with the first portion of emission light to the detection system such that substantially all of the emission light on, around and above the illumination region is detected.",19,"The United States of America, as Represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Optics,Measurement,,,,,G01N/64
8765136,1-Jul-14,2014,7,1,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.",12,"MedImmune, LLC",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
8765802,1-Jul-14,2014,7,1,"Kinase inhibitors, compositions thereof, and methods of use therewith",Provided herein are Compounds having the following structure:,3,"Provid Pharmaceuticals, Inc.",United States of America as represented by the Department of Health and Human Resources NIH,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/42
8771163,8-Jul-14,2014,7,8,Transcranial magnetic stimulation system and methods,"A system and methods for transcranial magnetic stimulation, the system including a helmet, a positioning portion, a stimulator and a cooling system, are disclosed. The helmet includes a coil for deep brain magnetic stimulation. The coil has a base portion, and return portions, which may include a protruding return portion and a contacting return portion. The coil is designed to minimize unintended stimulation of portions of the brain, while reducing accumulation of surface charges. The coil is stimulated at several locations and/or at different times so as to focus the electrical field on a specific deep neuronal structure.",28,"Brainsway, Ltd.",Yeda Research & Development Co. Ltd. at the Weizmann Institute of Science,"The United States of America as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,3,Medical technology,,,,,,A61N/02
8771706,8-Jul-14,2014,7,8,Anti-RSV immunogens and methods of immunization,"Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogs thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogs thereof.",10,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/135
8772238,8-Jul-14,2014,7,8,"Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer","The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease. The invention also features kits.",21,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/57
8772256,8-Jul-14,2014,7,8,Codon modified immunogenic compositions and methods of use,"The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.",17,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/005
8778354,15-Jul-14,2014,7,15,Compositions and methods for modulating RSV infection and immunity,"Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/00
8778619,15-Jul-14,2014,7,15,Oxidized cardiolipin and uses to detect cardiolipin antibodies,"Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies (such as IgG and IgM antibodies) in subjects, for example, when used in ELISA plates. ELISA plates are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,Arlington Scientific Inc.,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/571
8778671,15-Jul-14,2014,7,15,Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus,"The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.",6,"The United States of America, as represented by the Secretary of the Department of Health & Human Services",The Walter Reed Army Institute of Research,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/12
8778847,15-Jul-14,2014,7,15,Immunogenic peptides of influenza virus,"Peptides and polypeptides that elicit immunogenic responses in a mammal; especially neutralizing antibodies, against human and avian influenza strains H1N1, H3N2, H5N1 and H7N7 are disclosed Immunogenic compositions including these peptides, and polypeptides are also provided. Compositions including these peptides and polypeptides with or without adjuvants are disclosed. Nucleic acids and expression cassettes encoding these peptides and polypeptides are also disclosed. Methods of inhibiting infection by influenza, with or without cell entry, are also disclosed using these peptides and polypeptides.",6,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,G01N/56983
8779095,15-Jul-14,2014,7,15,LAT adapter molecule for enhanced T-cell signaling and method of use,"LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention further provides use for a LAT protein including mutations at ubiquitylation sites for therapeutic and laboratory methods.",3,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/17
8779312,15-Jul-14,2014,7,15,Method and device for analyzing biomolecules with track-etched polymeric layers,"The present disclosure provides methods, devices and kits that permit large numbers of target biomolecules to be detected simultaneously in samples originating from a multi-sample holder, such as a multi-well plate. One specific example method is a method of making multiple substantial replicas of a biomolecular content of a multi-well sample holder. Devices and kits for carrying out the described methods are also provided.",6,United States of America/NIH,"20/20 Genesystems, Inc.",,,,,,,,,,2,Analysis of biological materials,Chemical engineering,,,,,G01N/6845
8785193,22-Jul-14,2014,7,22,Dissection tool and methods of use,"The present disclosure provides cutting tools which include a handle coupled to a rotatable shaft having shallow grooves that extend substantially entirely across the surface of the rotatable shaft. The grooves define sharp cutting edges. In particular examples, the cutting edges are continuous, such as being defined by helical threads. The present disclosure also provides methods of dissecting a substrate of cultured cells. The substrate of cultured cells is separated into separated portions with a cutting tool. The cutting tool includes a rotatable shaft having a cutting blade which extends around the shaft. The cutting blade is rolled through the substrate to cut the substrate into portions. The portions are separated from one another to dissect the substrate.",14,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Machine tools,Machine tools,,,,,B26B/008
8785414,22-Jul-14,2014,7,22,Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome,"The identification of differentially expressed microRNAs in patients with Sjögren's syndrome is disclosed herein. Provided is a method of diagnosing a subject as having Sjögren's syndrome by measuring the level of at least one differentially expressed miR gene product identified herein. An alteration in the level of the at least one miR gene product in the biological sample of the subject relative to a control indicates the subject has Sjögren's syndrome. Also provided is a method of treating a patient with Sjögren's syndrome by administering to the patient a therapeutically effective amount of an agent that inhibits expression of a miR gene product that is up-regulated in the patient with Sjögren's syndrome relative to a control, or by administering to the patient a therapeutically effective amount of an isolated miR gene product that is down-regulated in the patient with Sjögren's syndrome relative to a control. A method of restoring salivary flow in a patient with Sjögren's syndrome is also provided.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/113
8785500,22-Jul-14,2014,7,22,Intranasal administration of ketamine to treat depression,"Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).",18,Icahn School of Medicine at Mount Sinai,Yale University,National Institute of Health,,,,,,,,,3,Pharmaceuticals,Medical technology,,,,,A61K/135
8785601,22-Jul-14,2014,7,22,T cell receptors and related materials and methods of use,"The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/70503
8785609,22-Jul-14,2014,7,22,Cloning and expression of HTLV-III DNA,"The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.",21,"United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/702
8790597,29-Jul-14,2014,7,29,Selective access to cryopreserved samples,"Methods and apparatus for selectively accessing a portion of a sterile cryopreserved sample are disclosed. The apparatus may include a container configured to receive the cryopreserved sample and having a first portion and a second portion, a heat sink chamber surrounding the first portion of the container, and a heat source adjacent to the second portion of the container. The chamber may be configured to maintain a non-accessed portion of the sample in a cryopreserved state. The heat source may be configured to separating an accessed portion of the sample from the non-accessed portion of the sample while maintaining the viability of the accessed portion while the non-accessed portion is maintained in the cryopreserved state.",20,"The United States of Americas, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Other special machines,Basic materials chemistry,Measurement,Medical technology,,,B65B/00
8790635,29-Jul-14,2014,7,29,"Live, oral vaccine for protection against Shigella dysenteriae serotype 1","The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.",3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
8790869,29-Jul-14,2014,7,29,Renal cell carcinoma biomarkers,"Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/50
8791074,29-Jul-14,2014,7,29,Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors,"The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.",17,"The United States of America as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Micro-structural and nano-technology,,,,C07K/06
8795674,5-Aug-14,2014,8,5,Methods and compositions for modulating immune tolerance,"The instant invention provides methods and compositions for modulation of the immune system. Specifically, the invention provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.",16,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/465
8795680,5-Aug-14,2014,8,5,Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-D-manno-octulsonic acid,Methods for preparing an oligosaccharide-protein carrier immunogenic conjugate or a polysaccharide-protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier.,16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",National Research Council of Canada,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/0283
8795688,5-Aug-14,2014,8,5,Dengue serotype 2 attenuated strain,The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.,7,Sanofi Pasteur,Centers for Disease Control and Prevention,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
8795964,5-Aug-14,2014,8,5,GRM3 mutations and use thereof for the diagnosis and treatment of melanoma,"Described herein is a G-protein coupled receptor (GPCR)-directed mutational analysis of tumor DNA obtained from melanoma tissue samples. The GPCR gene glutamate receptor, metabotropic 3 (GRM3) was identified as the most highly mutated GPCR gene in this screen. Functional characterization of GRM3 mutants revealed that these mutants promote activation of MEK, anchorage-independent cell growth and metastasis. Thus, provided herein are methods of diagnosing a subject as having melanoma, or susceptible to developing melanoma, by detecting the presence of at least one mutation in GRM3. Also provided are methods of treating a subject with melanoma by detecting the presence of at least one mutation in GRM3 and administering an appropriate therapy. Further provided are methods of selecting a subject diagnosed with melanoma as a candidate for treatment with a GRM3 inhibitor, an MEK inhibitor, or both, by detecting the presence of at least one mutation in GRM3.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C12Q/6886
8796291,5-Aug-14,2014,8,5,A3 adenosine receptor antagonists and partial agonists,"Disclosed are A3 adenosine receptor antagonists and/or partial agonists of formula (I): wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The antagonists or partial agonists find use in treating a number of diseases including cancer, glaucoma, inflammatory diseases, asthma, stroke, myocardial infarction, allergic reactions, rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis, brain arteriole diameter constriction, bronchoconstriction, and myocardial ischemia, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
8796302,5-Aug-14,2014,8,5,Methods related to the treatment of neurodegenerative and inflammatory conditions,"The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.",6,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
8796441,5-Aug-14,2014,8,5,Human sweet and umami taste receptor variants,"Identified herein are different forms of sweet and umami receptor encoding sequences that occur in different human populations. In particular, there are provided several single nucleotide polymorphisms (SNPs) that occur within the exons/coding sequence (and are therefore coding SNPs, cSNPs) of one of the three T1R genes. Some SNPs cause amino acid substitutions, while others introduce a chain termination codon, rendering a truncated product. Differences in these genes are believed to affect the sense of taste of individuals, such that individuals with different SNPs (or different haplotypes) are believed to perceive the taste of sweet or umami (e.g., glutamate) substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define groups and populations who perceive tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
8798980,5-Aug-14,2014,8,5,Molecular motor,"A molecular motor in which multiple concentric cylinders (or nested cones) rotate around a common longitudinal axis. Opposing complementary surfaces of the cylinders or cones are coated with complementary motor protein pairs (such as actin and myosin). The actin and myosin interact with one another in the presence of ATP to rotate the cylinders or cones relative to one another, and this rotational energy is harnessed to produce work. The length of the cylinders can also be used to control the power generated by the motor. In another embodiment, the molecular motor includes at least two annular substrates wherein one annular substrate is coated with a first motor protein and the other annular substrate is coated with a second motor protein. The first and second motor proteins interact with each other to move the second annular relative to the first annular substrate.",10,,,,,,,,,,,,,Micro-structural and nano-technology,Biotechnology,"Electrical machinery, apparatus, energy",,,,C12M/00
8808207,19-Aug-14,2014,8,19,Systems and methods for recovery from motor control via stimulation to a substituted site to an affected area,"A device and methods for treating a subject with dysphagia or other neurological disease, neurological disorder, neurological injury, neurological impairment or neurodegenerative disease that affects voluntary motor control of the hyoid, pharynx, larynx, or oropharyngeal area is disclosed. A device of the invention generally comprises a vibrotactile stimulator for applying at least one stimulus to the outside surface of a subject's neck; a connector for attaching the vibrotactile stimulator to an outside surface of the subject's neck, and a switch control communicatively connected to the vibrotactile stimulator to selectively engage a manual stimulation module and/or automatic stimulation module. Stimulation of an outside surface of the throat area of a subject by a device of the invention stimulates a swallowing reflex in the subject.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61H/00
8808684,19-Aug-14,2014,8,19,Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction,"Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Biotechnology,,,,A61K/005
8809502,19-Aug-14,2014,8,19,Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells,Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.,18,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/2803
8815229,26-Aug-14,2014,8,26,Granulysin in immunotherapy,"Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/39
8816059,26-Aug-14,2014,8,26,Method for predicting and detecting tumor metastasis,"The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-ΔN, and inhibitors of CPE-ΔN and compositions thereof.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C12Q/6886
8821409,2-Sep-14,2014,9,2,Lung aerosol collection device,A device for collecting material from lung aerosols. The device functions by collecting aerosols from the lower airway separated from material in the by collecting air from the upper airway in a chamber that when full causes the remaining exhaled aerosols from the lungs to be captured by a filter. The filter collects sample of material from the separated lung aerosols.,14,"The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",Georgia Tech Research Corporation,,,,,,,,,,2,Medical technology,Analysis of biological materials,,,,,A61B/097
8821866,2-Sep-14,2014,9,2,Methods of treating and preventing colitis involving IL-13 and NK-T cells,Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.,3,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/2833
8822192,2-Sep-14,2014,9,2,Human rotavirus vaccine strains and diagnostics,"A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/15
8822196,2-Sep-14,2014,9,2,Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer,"The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/2863
8822434,2-Sep-14,2014,9,2,Compositions and methods to treat cardiac diseases,"Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogs of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life in vivo due to the stability of the C—P bond. When administered to calsequestrin-overexpressing mice (a genetic model of heart failure) via a mini-osmotic pump (Alzet), some analogs significantly increased intact heart contractile function in vivo, as assessed by echocardiography-derived fractional shortening (FS) as compared to vehicle-infused mice. The range of carbocyclic nucleotide analogs for treatment of heart failure has been expanded.",9,The University of Connecticut,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/675
8822540,2-Sep-14,2014,9,2,Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation,"A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/122
8828356,9-Sep-14,2014,9,9,"Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis","Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors.",14,"Progeria Research Foundation, Inc.",The United States of America as represented by the Secretary of the Department of Health and Human Services,The University of North Carolina at Chapel Hill,The Regents of the University of Michigan,,,,,,,,4,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/4545
8828380,9-Sep-14,2014,9,9,Method for the treatment of pulmonary disease and method of producing proteins of use therein,"Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD). In some embodiments, the polypeptide and/or NAD is administered via inhalation. Also disclosed is a pharmaceutical composition including at least one polypeptide (such as HNP-1) and NAD. The disclosure also provides in vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase (for example, ART1) to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide. Methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a modified polypeptide (such as HNP-1) including at least one ornithine residue in place of an arginine residue are also disclosed.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/4712
8828667,9-Sep-14,2014,9,9,Methods and compositions relating to isocyanate conjugates,Compositions are provided according to embodiments of the present invention which include an isolated antibody or antigen binding antibody fragment characterized by binding specificity for a conjugate which is a reaction product of a protein moiety and an isocyanate moiety. Methods of detecting diisocyanate-protein conjugates in a sample are provided according to embodiments of the present invention which include contacting a sample with one or more isolated antibodies or antigen binding antibody fragments characterized by binding specificity for corresponding diisocyanate-protein conjugate antigens.,5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/44
8828717,9-Sep-14,2014,9,9,Framework residue substituted humanized COL-1 antibodies and their use,"The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.",30,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/3007
8828936,9-Sep-14,2014,9,9,Therapeutic use of SCGB3A2,"The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents.",9,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/18
8829022,9-Sep-14,2014,9,9,N-substituted indenoisoquinolines and syntheses thereof,"N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.",9,Purdue Research Foundation,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/005
8835115,16-Sep-14,2014,9,16,ABCB1 genotyping to predict microtubule-stabilizing-agent-induced toxicity,"The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.",14,"The United States of America as represented by the Secretary, Department of Health and Human Services",Universitätsklinikum Freiburg,,,,,,,,,,2,Biotechnology,,,,,,C12Q/6883
8835117,16-Sep-14,2014,9,16,Nucleic acids for detection and discrimination of genotypes of Chlamydophila psittaci,"Methods of detecting Chlamydophila, including differentiating between species of Chlamydophila and/or strains of Chlamydophila psittaci are disclosed, for example to detect and genotype a Chlamydophila psittaci infection. A sample suspected of containing a nucleic acid of a Chlamydophila, is screened for the presence of that nucleic acid. The presence of the Chlamydophila nucleic acid indicates the presence of the Chlamydophila bacterium. Determining whether a Chlamydophila nucleic acid is present in a sample can be accomplished by detecting hybridization between a Chlamydophila specific primer, a Chlamydophila psittaci specific primer, and/or a Chlamydophila psittaci genotype-specific primer and the Chlamydophila nucleic acid containing sample. Thus, primers for the detection, species-specific and/or genotype-specific identification of Chlamydophila psittaci are disclosed. Kits that contain the disclosed primers also are disclosed.",9,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
8835167,16-Sep-14,2014,9,16,Humanized anti-tag 72 CC49 for diagnosis and therapy of human tumors,"The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/30
8835360,16-Sep-14,2014,9,16,Combinatorial therapy for protein signaling diseases,"A method for selecting combinations of drugs for treatment of diseases that arise from deranged signaling pathways is disclosed. The method involves measuring the activity states for signaling proteins in a diseased cell and determining whether the activity states are different from the activity states observed for a reference cell such as a normal cell. Based on the observed differences, combinations of two or more drugs are selected to reduce these differences. Treatment of a subject with the combinations restores the activity states of the signaling proteins of the deranged disease-associated signaling pathways toward the activity states observed in the reference cell. Since the diseased cell and the reference cell can both be obtained from the same subject, combinations of drugs that specifically target patient-specific signaling derangements is possible.",60,The United States of America as represented by the Secretary of the Department of HHS,,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/5041
8835378,16-Sep-14,2014,9,16,Multi-domain amphipathic helical peptides and methods of their use,Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.,29,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/775
8835613,16-Sep-14,2014,9,16,β-mannosylceramide and stimulation of NKT cell anti-tumor immunity,"β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services","The University of Birmingham, of Edgbaston",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/7032
8841266,23-Sep-14,2014,9,23,Pharmaceutical composition and method for regulating abnormal cellular proliferation,"A method of treating a disease associated with a cell population which proliferates abnormally in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one modulator capable of modulating in the cell population a level and/or activity of a polypeptide having an amino acid sequence at least 60 percent similar to SEQ ID NO: 5, as determined using the Standard protein-protein BLAST [blastp] software of the NCBI.",10,Tel Hashomer Medical Research Infrastructure and Services Ltd.,The United States of America as represented by the Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/1135
8841305,23-Sep-14,2014,9,23,Activators of the human pyruvate kinase M2 receptor,"Disclosed are pyruvate kinase M2 activators, which are bis sulfonamide piperazinyl and piperidinyl compounds of Formula (I), 2,4-disubstituted 4H-thieno[3,2-c]pyrrole-2-(substituted benzyl)pyridazin-3(2H)-ones of Formula (II) and 6-(3,4-dimethylphenylaminosulfonyl)-3,4-dihydro-1H-quinolin-2-one of formula (III), wherein L, R1, R2, R11 to R16, R21 and R22 are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/496
8846051,30-Sep-14,2014,9,30,Modulation of replicative fitness by deoptimization of synonymous codons,"Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.",29,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0258
8846056,30-Sep-14,2014,9,30,Anti-RSV immunogens and methods of immunization,"Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.",10,"The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/135
8846341,30-Sep-14,2014,9,30,Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation,The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.,16,University of Pittsburgh—of the Commonwealth System of Higher Education,The University of Chicago,Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas—D.F.,,,,,,,,,3,Analysis of biological materials,Biotechnology,,,,,G01N/573
8846389,30-Sep-14,2014,9,30,AAV4 vector and uses thereof,"The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/86
8852074,7-Oct-14,2014,10,7,Device for volitional swallowing with a substitute sensory system,"A device for volitional swallowing with a substitute sensory system comprises a band wrapped around the neck with a vibrator positioned over the larynx. Upon activation by a button on a spoon held by an operator, such as the subject, the vibrator moves and vibrates the larynx. The patient initiates the sensory stimulation immediately prior to the patient's own initiation of a swallow by viewing on a display screen a movement feedback signal, possibly from a piezo-electric sensor also contained in the band which will also be displayed on the display screen. The signal from the switch device initiating sensory stimulation will be presented on the same display screen for the patient and trainer to observe when the button or switch is activated for sensory stimulation in relation to the onset of the swallow.",19,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61H/02
8852605,7-Oct-14,2014,10,7,Vibrio cholerae O139 conjugate vaccines,"The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/107
8852861,7-Oct-14,2014,10,7,Composition for detecting the response of rectal adenocarcinomas to radiochemotherapy,A cDNA array (9984 genes) was used for expression profiling in rectal adenocarcinoma. The expression data were correlated to responsiveness to chemotherapy followed by radiotherapy. A set of 54 genes was found that were differentially expressed in responders vs. non-responders. The genes may be used as prognostic markers for determining whether a rectal adenocarcinoma is responsive to radiochemotherapy.,15,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
8853160,7-Oct-14,2014,10,7,"GLP-1, exendin-4, peptide analogs and uses thereof","The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.",20,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/575
8853253,7-Oct-14,2014,10,7,Thalidomide analogs,"Thalidomide analogs that modulate tumor necrosis factor alpha (TNFα) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.",15,"P2D, Inc.",,,,,,,,,,,1,Computer technology,Telecommunications,Organic fine chemistry,,,,H04M/72522
8853277,7-Oct-14,2014,10,7,Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC),"The invention provides therapeutic methods that include administering a stable nitroxide to a subject that has, is suspected to have, or is at risk for having a condition associated with reduced VHL or elevated HIF-2α.",36,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/40
8858938,14-Oct-14,2014,10,14,Human monoclonal antibodies against Hendra and Nipah viruses,"The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",2,"The United States of America, as represented by the Secretary, Department of Health and Human Services","The Henry M. Jackson Foundation of the Advancement of Military Medicine, Inc.",,,,,,,,,,2,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1203
8859204,14-Oct-14,2014,10,14,Method for detecting the presence of a target nucleic acid sequence in a sample,"A method comprises loading a sample portion into a sample chamber which comprises means for minimizing diffusion of the sample portion, subjecting the sample portion to an amplification step, and determining whether the sample portion contains at least one molecule of a target nucleic acid. If the sample portion contains a single molecule of the target nucleic acid, the sample portion would attain a detectable concentration of the target nucleic acid after a single round of amplification. Also, a microfluidic device comprising a sample portion and a sample chamber comprising means for minimizing diffusion of the sample portion. Also, a microfluidic device comprising a sample chamber and an amplification targeting reagent positioned in the first sample chamber.",16,"Applied Biosystems, LLC","The United States of America, As Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
8859207,14-Oct-14,2014,10,14,Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same,"Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.",1,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Texas at El Paso,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4741
8859277,14-Oct-14,2014,10,14,Plasmids and phages for homologous recombination and methods of use,"Lambda phages that can be used to introduce recombineering functions into host cells are disclosed. Also disclosed are plasmids that can be used to confer recombineering functions to a variety of strains of E. coli and to other bacteria, including Salmonella, Pseudomonas, Cyanobacteria, Spirochaetes. These plasmids and phages can be isolated in vitro and can be used to transform bacterial cells, such as gram negative bacteria.",21,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/74
8859585,14-Oct-14,2014,10,14,Scopolamine for the treatment of depression and anxiety,"Provided are methods and compositions for the treatment of depression and anxiety. The compositions contain scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler containing scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.",18,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/46
8859742,14-Oct-14,2014,10,14,Diagnostic assays for chordopoxviruses,"This disclosure relates to compositions and methods of their use in detection and identification of a chordopoxvirus in a sample, such as diagnosis of an infection in a subject. The compositions and methods allow for detection and identification of all non-avian low-GC content chordopoxviruses, identification of most known high-GC content chordopoxvirus, and species-specific detection of Canarypox virus, Fowlpox virus, and Sealpox virus.",15,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
8865461,21-Oct-14,2014,10,21,Rabies virus vector systems and compositions and methods thereof,"Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.",20,"The United States of America as represtented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
8865672,21-Oct-14,2014,10,21,Prevention of tissue ischemia and related methods,"Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.",31,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Chemical engineering,Pharmaceuticals,Biotechnology,Analysis of biological materials,,C07K/18
8865686,21-Oct-14,2014,10,21,Tetracycline compounds as tyrosyl-DNA phosphodiesterase I inhibitors,"The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.",8,"The United States of America, as Represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/65
8865880,21-Oct-14,2014,10,21,Identification of a novel BHD gene,"The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating BHD skin lesions.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/47
8871191,28-Oct-14,2014,10,28,Use of IL-15 preparations to treat lymphopenia,"The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.",15,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/5443
8871206,28-Oct-14,2014,10,28,Anti-human folate receptor beta antibodies and methods of use,"Human anti-human folate receptor beta (FRβ) antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ.",17,Purdue Research Foundation,"The United States of America, as Represented by the Secretary Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/28
8871443,28-Oct-14,2014,10,28,Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs,The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia and response to therapy.,5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/6883
8871789,28-Oct-14,2014,10,28,Method of preventing or treating viral infection,"Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I):wherein R1, R2, R3, R4, and R5 are as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/551
8871902,28-Oct-14,2014,10,28,Immunogenic POTE peptides and methods of use,"POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.",31,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
8871906,28-Oct-14,2014,10,28,Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes,"The invention provides mutated, cytotoxic forms of Pseudomonas exotoxin A (PE) comprising a furin cleavage sequence conjugated or fused directly to residues 395-613 of PE or variants of that sequence. These minimal forms of PE are smaller than previous cytotoxic forms of PE, reduce non-specific toxicity, and reduce immunogenicity due to domain II or domain Ib of PE. The invention further provides nucleic acids encoding said PEs, chimeric molecules containing them, and methods of use thereof.",41,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/21
8875702,4-Nov-14,2014,11,4,Aerosol generator,A sonic aerosol generator is provided that provides a constant concentration of particulate aerosol over a long exposure time to an animal. The concentration of aerosols is maintainable for greater than 30 hours at concentrations of 15 mg/m3 or more. The aerosol generator is used to expose subject to high concentrations of aerosols that more accurately represents the levels that may be seen in a workplace environment.,25,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Medical technology,,,,,,A61M/005
8875851,4-Nov-14,2014,11,4,Electromechanical vehicle brake,"A combined electromechanical vehicle brake has a hydraulically activated operating brake and an electromechanically activated parking brake apparatus. A hydraulic operating pressure chamber in a brake housing is delimited by a brake piston that can be loaded by hydraulic pressure to carry out operating braking actions. The brake piston can be activated along a longitudinal piston axis to achieve a braking effect. The parking brake apparatus acts upon the brake piston by a gear unit because the gear unit converts the rotational movement of an electromechanical actuator into a translational movement, causing the brake piston to be activated to carry out parking brake processes and remain in the activated position. The gear unit has a threaded spindle and a threaded nut that contact one another via a plurality of rolling elements. A spring element allows the rolling elements to slip when the gear unit is activated in the unloaded state.",8,Continental Teves AG & Co. oHG,,,,,,,,,,,1,Mechanical elements,,,,,,F16D/18
8877199,4-Nov-14,2014,11,4,B cell surface reactive antibodies,"The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.",17,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
8877213,4-Nov-14,2014,11,4,Live attenuated Leishmania vaccines,"Targeted disruption of the centrin gene leads to attenuation of growth in the Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of immunological and diagnostic reagents. Other preferred embodiments provide related immunogenic compositions, methods of generating an immune response, methods for producing a vaccine, and methods of forming attenuated strains of Leishmania.",6,The United States of America as Represented by the Secretary of the Department of Health and Human Services,Indian Council of Medical Research,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/008
8877765,4-Nov-14,2014,11,4,Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer,"The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention.",21,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
8877914,4-Nov-14,2014,11,4,Compositions comprising nucleic acids encoding HIV-1 reverse transcriptase CTL epitopes,"The present invention provides compositions comprising a vector including a nucleic acid comprising a nucleotide sequence encoding a peptide having the sequence X1LYQYMDDV, wherein X1 is any hydrophobic amino acid. The compositions are used to induce an immune response against human immunodeficiency virus (HIV).",2,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/1276
8880354,4-Nov-14,2014,11,4,System for magnetic resonance spectroscopy of brain tissue for pattern-based diagnostics,"A system and method for preprocessing magnetic resonance spectroscopy (MRS) data of brain tissue for pattern-based diagnostics is disclosed. The MRS preprocessing system includes an MRS preprocessing module that executes an operation that normalizes MRS spectrum data, recalibrates and scales the normalized MRS spectrum data, and then renormalizes the scaled MRS spectrum data. The resulting preprocessed MRS data is used to assist in identifying abnormalities in tissues shown in MRS scans.",8,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Medical technology,Computer technology,,,,A61B/055
8883448,11-Nov-14,2014,11,11,Mutated ras peptides for generation of CD8+ cytotoxic T lymphocytes,"Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in vivo-primed CD8+ CTL precursors.",2,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/82
8889101,18-Nov-14,2014,11,18,Dendrimer based nanodevices for therapeutic and imaging purposes,"A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.",21,Wayne State University,,,,,,,,,,,1,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/65
8895521,25-Nov-14,2014,11,25,Methods and compositions for the treatment of uveitis,"Pharmaceutical compositions are disclosed that are of use for the treatment of uveitis. These compositions include a suppressive oligonucleotide. These compositions including an immunosuppressive oligonucleotide can be used for the treatment of uveitis, including anterior, posterior, and diffuse uveitis.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
8900599,2-Dec-14,2014,12,2,Conjugates of Plasmodium falciparum surface proteins as malaria vaccines,"Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/445
8900807,2-Dec-14,2014,12,2,Composition and methods for rapid detection of HIV by loop-mediated isothermal amplification (LAMP),"Methods and compositions for detection of HIV nucleic acids in a sample, such as a biological sample obtained from a human subject, are provided according to embodiments of the present invention which include providing a reaction mixture including at least one LAMP, accelerated LAMP, RT-LAMP or RT-accelerated LAMP assay primer set specific for HIV-I or HIV-2 nucleic acids and the biological sample to be tested for presence of HIV-I and/or HIV-2 nucleic acids; incubating the reaction mixture under conditions suitable to produce a LAMP assay reaction product; and detecting the reaction product. Primers and primer sets for use in LAMP assays of HIV-I or HIV-2 nucleic acids are provided.",20,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
8901093,2-Dec-14,2014,12,2,Custom vectors for treating and preventing pancreatic cancer,"The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).",24,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
8906603,9-Dec-14,2014,12,9,Modified cardiolipin and uses therefor,"Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies in subjects, for example, when used in lateral flow devices. Lateral flow devices are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.",19,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/571
8907060,9-Dec-14,2014,12,9,Mutated Pseudomonas exotoxins with reduced antigenicity,"The invention provides mutated Pseudomonas exotoxins (PE) that have reduced immunogenicity compared to PEs containing the native sequence. The PEs of the invention have one or more individual mutations of positions of the native sequence of PE that reduce antibody binding to one or more PE epitopes. Nucleic acids encoding the mutated PEs, chimeric molecules comprising them, compositions comprising the chimeric molecules and methods of using them, are also provided.",105,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/6829
8911728,16-Dec-14,2014,12,16,"High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins","The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also are provided.",17,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/1063
8912146,16-Dec-14,2014,12,16,Derivatives of APF and methods of use,"Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid.",7,"University of Maryland, Baltimore",The Department of Health and Human Services,The United States of America as Represented by the Department of Veterans Affairs,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/14
8912214,16-Dec-14,2014,12,16,Use of Chk2 kinase inhibitors for cancer treatment,"Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.",20,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/17
8916159,23-Dec-14,2014,12,23,Selenocysteine mediated hybrid antibody molecules,"The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier. The invention further provides for methods of making the hybrid molecules, and methods of using the hybrid molecule described above to inhibit cell surface receptor binding.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Micro-structural and nano-technology,,,,,A61K/10
8916172,23-Dec-14,2014,12,23,"MVA expressing modified HIV envelope, gag, and pol genes","The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.",4,Emory University,National Institute of Allergy and Infectious Diseases (NIAID),"The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,3,Pharmaceuticals,Biotechnology,,,,,A61K/21
8916175,23-Dec-14,2014,12,23,Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection,"Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the varicella zoster virus. Deletion of a significant portion from both copies of the varicella zoster gene ORF63 was shown to inhibit establishment of a latent infection from a live vaccine form of the virus. Insertion of an additional ORF62 gene which is partially truncated with the ORF63 deletion inhibited establishment of latency and allowed normal growth of the virus. Other desirable viral antigen encoding sequence(s) and/or cytokine genes advantageously may replace deleted genetic material to enhance a desired immunological response. Aspects of the discovery pertain to live vaccines of other viruses, and can provide a variety of vaccines having greater safety.",7,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/25
8916570,23-Dec-14,2014,12,23,A3 adenosine receptor agonists and antagonists,"Disclosed are (N)-methanocarba adenine nucleosides of formulas (I)-(V), for example, of formula (V):as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
8916596,23-Dec-14,2014,12,23,"Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor","An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5.",7,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/1137
8921050,30-Dec-14,2014,12,30,Methods of diagnosing renal cell carcinoma,"Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.",2,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/0638
8921071,30-Dec-14,2014,12,30,Targeting poly-gamma-glutamic acid to treat Staphylococcus epidermidis and related infections,"Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-γ-glutamic acid (such as γDLPGA) polypeptides of S. epidermidis, or related staphylococci that express a γPGA polypeptide. The γPGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the Staphylococcus organism which expresses γPGA from the cap genes. Further, the expression of a γPGA polypeptide by the organism can then be altered.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12P/02
8921097,30-Dec-14,2014,12,30,Methods for expression and purification of immunotoxins,"The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.",10,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/18
8921323,30-Dec-14,2014,12,30,Methods and compositions for modulating BCL-2 family polypeptides,"The present invention is based, at least in part, on the identification of a novel active site on BCL-2 family polypeptide such as BAX, which when bound by a compound, modifies the activity of the BCL-2 family polypeptide.",2,"Dana Farber Cancer Institute, Inc.","The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/5079
8921340,30-Dec-14,2014,12,30,Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions,The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions.,2,Trustees of Dartmouth College,"Rutgers, The State University of New Jersey","The United States of America, as represented by the Secretary Department of Health and Human Services",,,,,,,,,3,Pharmaceuticals,Biotechnology,,,,,A61K/28
8926986,6-Jan-15,2015,1,6,Use of saccharides cross-reactive with Bacillus anthracis spore glycoprotein as a vaccine against anthrax,Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.,4,National Research Council of Canada,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/07
8926987,6-Jan-15,2015,1,6,Replication-competent adenoviral vectors,"This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.",23,The Government of The United States of America as represented by the Secretary of the Department of Health and Human Services,Istituto Superiore di Sanita,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/21
8926989,6-Jan-15,2015,1,6,Compositions and methods for screening for Lyme disease,"The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56911
8927030,6-Jan-15,2015,1,6,Use of nitrite salts for the treatment of cardiovascular conditions,"It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.",17,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/00
8927269,6-Jan-15,2015,1,6,Avian adenoassociated virus and uses thereof,"The present invention provides an Avian adeno-associated virus (AAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAAV vectors and particles. Methods of isolating the AAAV are provided.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
8927725,6-Jan-15,2015,1,6,Thio compounds,"A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/454
8933041,13-Jan-15,2015,1,13,System for treating and preventing breast cancer,"The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
8936787,20-Jan-15,2015,1,20,Peptides promoting lipid efflux,"Disclosed herein are peptides and peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway, as well as peptides that activate lipoprotein lipase, and compositions comprising such peptides or combinations thereof. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells and activate lipoprotein lipase within cells are also disclosed herein.",20,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/775
8936792,20-Jan-15,2015,1,20,Pseudomonas exotoxin a with reduced immunogenicity,"The present invention provides improved Pseudomonas Exotoxin A (PE) molecules with high cytotoxicity and reduced immunogenicity, compositions containing the improved (PE), and methods of use.",37,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/21
8937067,20-Jan-15,2015,1,20,Activators of human pyruvate kinase,"Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R1 to R16 are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia,",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/496
8940700,27-Jan-15,2015,1,27,E-selectin compositions and use thereof for inducing E-selectin tolerance,The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.,8,"The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0043
8941057,27-Jan-15,2015,1,27,Probe and method for obtaining three-dimensional compositional maps of a biological sample,"The invention provides a probe and a method of obtaining a three-dimensional compositional map of one or more targets in a biological sample, or a portion thereof, comprising: (a) milling a surface layer of a biological sample with a focused ion beam, thereby creating a newly exposed surface layer of the biological sample; (b) imaging the newly exposed surface layer of the biological sample; (c) identifying the chemical composition of the newly exposed surface layer of the biological sample, or a portion thereof, with a mass spectrometer; and (d) repeating (a) to (c) until a three-dimensional compositional map of one or more targets in the biological sample, or portion thereof, is obtained. Uses of the three-dimensional map obtained from the inventive method are further provided.",1,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,"Electrical machinery, apparatus, energy",,,,,G01N/6848
8942454,27-Jan-15,2015,1,27,Signal to-noise enhancement in imaging applications using a time-series of images,"An apparatus and method are disclosed for improving imaging based on a time-series of images. In one embodiment, a time-series of images are acquired using a same imaging protocol of the same subject area, but the images are spaced in time by one or more time intervals (e.g, 1, 2, 3 . . . seconds apart). A sub-region is projected across all of the images to perform a localized analysis (corresponding X-Y pixels or X-Y-Z voxels are analyzed across all images) that identifies temporal components within each sub-region. In some of the sub-regions, the temporal components are removed when the amplitude of the component is below a predetermined amplitude threshold. The images are then combined using the sub-regions with reduced components in order to obtain a single image with reduced noise.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Computer technology,,,,,,G06T/50
8942662,27-Jan-15,2015,1,27,System and method to predict and avoid musculoskeletal injuries,"A miniaturized, ruggedized, field-deployable Portable Exposure Assessment System (PEAS) is used to remotely monitor workers and provide real-time warning of exposure to musculoskeletal injury conditions via alarm and smart-phone transmission. The PEAS unit wirelessly acquires exposure data from sensors; conducts initial data analysis; triggers proximal and remote alarms; sends out text messages with abnormal data, GPS locations, and time stamps to a safety office; and saves data for more extensive assessment. Sensor technology is used in this field-deployable system to simultaneously measure and collect the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibration exposures. Wireless technology is used to set up wireless communication links between the sensors and a data logger and between the data logger and a smart phone with GPS, date/time stamp and text messaging capabilities.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services, Center for Disease Control and Prevention",,,,,,,,,,,1,Medical technology,Control,Computer technology,,,,G08B/02
8946243,3-Feb-15,2015,2,3,Compounds and methods for the treatment of viral infection,"The invention relates to compounds and methods for treating or preventing a viral infection, by administering a monophosphorylated prodrug of acyclovir or monophosphorylated derivative of an acyclovir prodrug to a subject suffering from or susceptible (to a viral infection, such as HIV infection.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Katholieke Universiteit Leuven,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07F/65616
8946291,3-Feb-15,2015,2,3,Compositions and methods for treating pigmentary conditions and melanoma,A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating a hyperpigmentary condition in a subject comprising administering an amount of inhibitor of SOX9 activity sufficient to treat the condition is disclosed. A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering an amount of prostaglandin D2 and retinoic acid sufficient to treat cancer is disclosed. A method of sensitizing a melanoma cell to RA comprising administering an amount of SOX9 sufficient to decrease PRAME expression is disclosed.,6,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/1709
8946382,3-Feb-15,2015,2,3,Apelin peptides and methods of use,"The present disclosure concerns the use of biologically active apelin peptides and compositions that are processed from larger precursor proteins and further post-translationally modified to influence cell growth. Particular methods are useful for promoting cell growth, while others are particularly useful for inhibiting cell growth.",3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/26
8946398,3-Feb-15,2015,2,3,Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof,"The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.",14,Hvidovre Hospital,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12Q/18
8948845,3-Feb-15,2015,2,3,"System, methods, and instrumentation for image guided prostate treatment","The invention provides systems, methods, and instrumentation for aiding the performance of an image guided procedure of the anatomy of a patient such as, for example, the prostate. The invention includes a plurality of lumens therein and a balloon portion or other fixating portion. In some embodiments, the catheter includes a lumen for introducing a contrast agent visible to an imaging modality external to the anatomy of the patient. Image space data of the catheter within the anatomy of the patient may be obtained using the imaging modality. The catheter also includes at least a lumen for inserting a registration device for obtaining patient space data regarding the anatomy of the patient. Other lumens and/or other elements visible to the imaging modality may be used. The image space data may be registered to the patient space data for use during an image guided procedure to the anatomy of the patient.",38,Koninklijke Philips N.V.,"The United States of America as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,2,Medical technology,,,,,,A61B/20
8951527,10-Feb-15,2015,2,10,Radioprotectants targeting thrombospondin-1 and CD47,"Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, peptides, and antibodies, which can now be used as radioprotectant agents. These agents find application in minimizing, reducing and/or preventing tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage and by increasing tumor ablation following radiation treatment.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Biotechnology,,,,A61K/39
8951723,10-Feb-15,2015,2,10,Serological screening for HHV-8 infection using antigen mixtures,"The invention provides compositions, methods, and kits for the diagnosis or detection of active, latent, or prior infection with human herpesvirus 8 in a subject sample.",17,"The United States of America as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56994
8951793,10-Feb-15,2015,2,10,Method of making an isolated population of FOXP3+ regulatory T cells,"Disclosed are methods of isolating and using a population of FOXP3+ regulatory T cells in a variety of preventative and therapeutic approaches to autoimmune diseases, graft-versus-host disease and transplant rejection.",17,"The United States of America, as represented by The Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0636
8957015,17-Feb-15,2015,2,17,Tumor suppressor gene p47ING3,"The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6886
8957027,17-Feb-15,2015,2,17,Deacetylase inhibitor therapy,"The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.",22,Celgene Corporation,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/15
8957188,17-Feb-15,2015,2,17,"Antibodies that bind GalNAc1-3Gal, pharmaceutical compositions and methods of using same","Monoclonal antibodies to carbohydrate antigens containing a terminal GalNAcα1-3Gal are provided. The antibodies of the present invention are found to specifically recognize GalNAcα1-3Gal with little cross-reactivity to other structurally similar antigens such as GalNAcα1-6Gal, blood group A, Forssman antigen and the Tn antigen on both solution assays and human tissue. Compositions comprising the monoclonal antibodies, as well as methods of diagnosis, treatment and prognostication are also provided.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/1045
8957192,17-Feb-15,2015,2,17,Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1,"Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.",22,"The United States of America, as represented by the Secretary Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0011
8961975,24-Feb-15,2015,2,24,Monoclonal antibodies that neutralize anthrax toxins,"The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1278
8968719,3-Mar-15,2015,3,3,"Live, oral vaccine for protection against Shigella dysenteriae serotype 1","The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.",2,"The United States of America, as represented by the Secretary, Department of Health and Human Sevices",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
8970840,3-Mar-15,2015,3,3,Method and apparatus for aerosol analysis using optical spectroscopy,"Particles of a flow of aerosol are collected and analyzed by passing them through a housing having an inlet area, an outlet area, and a collection and analysis area interconnecting the inlet and outlet areas. A collection electrode has a tip disposed in the collection and analysis area and particles are collected thereon. After collection, the particles are ablated and atomic emissions are collected for analysis of the particles.",23,"The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Measurement,,,,,,G01N/67
8980546,17-Mar-15,2015,3,17,Method for the detection of HIV-1-specific antibodies utilizing a Vpu polypeptide,"This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56988
8980859,17-Mar-15,2015,3,17,Aegyptin and uses thereof,"The present invention relates to the discovery of the Aegyptin gene and Aegyptin protein, a molecule that interacts with collagen and inhibits platelet adhesion, activation and aggregation. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.",7,"The United States of America, as represented by the Secretary, Department of Health & Human Services",The Regents of the University of California,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/43563
8980871,17-Mar-15,2015,3,17,Methods of treatment for hemolysis,"Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.",17,Wake Forest University Health Sciences,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/58
8986933,24-Mar-15,2015,3,24,Selective detection of human rhinovirus,"A process for detecting human rhinovirus nucleic acid in a biological sample, includes producing an amplification product by amplifying an human bocavirus nucleotide sequence using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and measuring said amplification product to detect human rhinovirus in said biological sample. Also provided are reagents and methods for detecting and distinguishing human rhinovirus from other viruses. A kit is provided for detecting and quantifying human rhinovirus in a biological sample.",13,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
8987246,24-Mar-15,2015,3,24,Methods for treatment of autism spectrum disorder,"The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorder. Accordingly, in one aspect, the present invention provides methods for treating patients with autism spectrum disorder. In one embodiment, a method for treating an autism spectrum disorder (ASD) in a patient comprises the step of administering a therapeutically effective amount of cholesterol to the patient. In more specific embodiments, the ASD is autism, Asperger's disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS), Rett's syndrome and childhood disintegrative disorder. In one embodiment, the patient has autism.",14,The Johns Hopkins University,"Kennedy Krieger Institute, Inc.",National Institutes of Health,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/575
8987426,24-Mar-15,2015,3,24,Immunotoxin fusion proteins and means for expression thereof,"The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.",9,"The United States of America, as represented by the Secretary, Department of Health & Human Services",Novartis AG,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/00
8992943,31-Mar-15,2015,3,31,Vaccine for protection against Shigella sonnei disease,Compositions and methods for protecting a susceptable host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.,16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
8993626,31-Mar-15,2015,3,31,Methods of treatment using sterculic acid,"The use of sterculic acid, and the pharmaceutically acceptable salt forms thereof, described for the treatment of inflammation, in particular, 7-ketocholesterol induced inflammation, 7-ketocholesterol toxicity, and unregulated angiogenesis.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/201
8993768,31-Mar-15,2015,3,31,Tropolone compounds for treating or preventing retroviral infection,"Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/4453
8999290,7-Apr-15,2015,4,7,Papillomavirus pseudoviruses for detection and therapy of tumors,"Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Micro-structural and nano-technology,Biotechnology,,,A61K/0004
8999336,7-Apr-15,2015,4,7,Monoclonal antibodies against Orthopoxviruses,"The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/081
8999927,7-Apr-15,2015,4,7,Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof,"Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/47
9000011,7-Apr-15,2015,4,7,Methods for treatment of Fabry disease,Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.,11,"Amicus Therapeutics, Inc.",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,,A61K/445
9000141,7-Apr-15,2015,4,7,Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use,"Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.",21,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
9005631,14-Apr-15,2015,4,14,Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine,"Disclosed herein are isolated immunogens including variant hepatitis B surface antigens (HBsAgs). In an example, a variant HBsAg includes a HBsAg with one or more transmembrane domains of the HBsAg replaced with a gp41 antigenic insert. The antigenic insert can include an antigenic polypeptide fragment of gp41 including the membrane proximal region of gp41 and a transmembrane membrane region of gp41. The replacement of a membrane spanning domain of HBsAg with a membrane spanning domain of gp41 anchors gp41 into HBsAg in virtually the identical orientation as on HIV virions and correctly orients the nearby MPR on the lipid layer. Thus, the disclosed variant HBsAgs display the neutralization-sensitive MPR in association with a lipid layer, while presenting it at the most immunogenic site on HBsAg. Also disclosed are uses of these variant HBsAgs, and nucleic acids encoding variant HBsAgs, such as to induce an immune response to HIV-1.",12,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/292
9006203,14-Apr-15,2015,4,14,Method of reducing inflammatory infiltration in subjects with inflammatory lung disease,The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for reducing neutrophil infiltration in subjects with inflammatory lung disease-by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.,21,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/117
9008751,14-Apr-15,2015,4,14,"Real time, interactive volumetric magnetic resonance imaging",A method of producing volume renderings from magnetic resonance image data in real time with user interactivity. The method comprises collecting raw magnetic resonance image (MRI) data representative of shapes within an image volume; transferring the raw MRI data to a computer; and continuously producing volume renderings from the raw MRI data in real time with respect to the act of collecting raw MRI data representative of shapes within the image volume.,16,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Computer technology,Measurement,,,,,G06T/08
9012216,21-Apr-15,2015,4,21,Methods of determining efficacy of cyclodextrin therapy,"Disclosed are methods for determining efficacy of a cyclodextrin therapy in a subject afflicted with a disorder involving oxysterol accumulation. These methods comprise: obtaining a first body fluid sample from the subject prior to cyclodextrin administration; administering cyclodextrin; obtaining at least one second body fluid sample after the cyclodextrin administration; subjecting the body fluid samples to chromatography-mass spectroscopy analysis to determine concentration of 24-hydroxycholesterol and/or cholestane-3β,5α,6β-triol; and determining magnitude of difference between the 24-hydroxycholesterol and/or cholestane-3β,5α,6β-triol concentration of the body fluid samples, whereby an increase or stabilization of 24-hydroxycholesterol concentration, or a reduction of cholestane-3β,5α,6β-triol concentration in the at least one second sample compared to the first sample, indicates efficacy of the cyclodextrin therapy.",20,Washington University,US National Institutes of Health,,,,,,,,,,2,Analysis of biological materials,Measurement,,,,,G01N/92
9012223,21-Apr-15,2015,4,21,Methods for enhancing genome stability and telomere elongation in embryonic stem cells,"The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing genome stability or increasing telomere length in a population of ES or iPS cells are provided, for example by selecting Zscan4+ ES or iPS cells from the population of ES or iPS cells (which can include both Zscan4+ and Zscan4− ES or iPS cells). Therapeutic methods of using ES or iPS cells expressing Zscan4 are also provided. Further provided are methods of treating cancer by administering a Zscan4 polynucleotide or Zscan4 polypeptide. Also provided are methods of inducing differentiation of isolated ES or iPS cells into germ cells.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/85
9012618,21-Apr-15,2015,4,21,Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures,"The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.",8,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
9012647,21-Apr-15,2015,4,21,Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders,"Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof:in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.",8,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",Wake Forest University,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/12
9018011,28-Apr-15,2015,4,28,Gamma satellite insulator sequences and their use in preventing gene silencing,"Regulatory elements, specifically insulators and transgene constructs containing insulator nucleic acid sequences, are disclosed herein. Methods of using insulators and transgene constructs including insulators to inhibit, delay, or prevent gene silencing are also disclosed herein.",14,The United States as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12N/85
9018227,28-Apr-15,2015,4,28,Nicotinic acetylcholine receptor agonists,"The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula (I). Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine for agonists.",6,Indiana State University,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Analysis of biological materials,Basic materials chemistry,Pharmaceuticals,,,C07D/16
9018371,28-Apr-15,2015,4,28,"Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient","Disclosed are adenosine derivatives, methods for the synthesis thereof, and pharmaceutical compositions for the prevention and treatment of inflammatory diseases, comprising the same as an active ingredient. The adenosine derivatives have high binding affinity and selectivity for adenosine receptors, especially for A3 adenosine receptors and act as A3 adenosine receptor antagonists, and exhibit anti-inflammatory activity. Thus, the adenosine derivatives are useful in the prevention and treatment of inflammatory diseases.",14,"FM Therapeutics Co., Ltd.","The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
9028693,12-May-15,2015,5,12,Apparatus for countercurrent chromatography,"A plate apparatus for use in countercurrent chromatography is disclosed which comprises a disk shaped tube support (60) having a tube support pattern form in an upper surface (63) of the support and configured to accommodate at least one layer of fluid flow tubing (70), wherein the pattern comprises at least one spiral groove (62) and at least one return path (72).",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Chemical engineering,,,,,G01N/42
9028838,12-May-15,2015,5,12,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.",18,"MedImmune, LLC",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/145
9029344,12-May-15,2015,5,12,Linked purine pterin HPPK inhibitors useful as antibacterial agents,"The disclosure provides linked purine pterin compounds and analogs thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula IThe variables, e.g. A1 to A3, R1 to R4, L1, L2, B1, and B2 are described herein. Compounds and salts of Formula I bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing an HPPK inhibitor of Formula I and methods of treating a bacterial infection in a patient by providing one or more HPPK inhibitors of Formula I to the patient are also provided. Processes and intermediates useful for preparing compounds of Formula I are also provided. Methods of using the disclosed compounds to guide the development of additional novel anti-bacterial agents are also provided.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Computer technology,,,,,C07H/16
9034343,19-May-15,2015,5,19,"Attenuated human parainfluenza virus, methods and uses thereof","The invention provides self replicating infectious recombinant paramyxoviruses. The recombinant paramyxovirus preferably have one or more attenuating mutations. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein. In some embodiments, recombinant paramyxovirus have at least one temperature sensitive mutation and one non-temperature sensitive mutation. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
9034613,19-May-15,2015,5,19,Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing Lactobacillus brevis alcohol dehydrogenase,"A process for producing a compound which is (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) which process comprises submitting, to enantioselective reduction, a compound of the following formula (II), (III) or (IV).",17,ISIS Innovation Limited,"The United States of America, as Represented by the Secretary, Department of Health & Human Services",,,,,,,,,,2,Biotechnology,Organic fine chemistry,,,,,C12P/62
9034870,19-May-15,2015,5,19,Azaindenoisoquinoline topoisomerase I inhibitors,"The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.",18,Purdue Research Foundation,"United States Government National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resources (DEITR)",,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/04
9040244,26-May-15,2015,5,26,HIV-1 genotyping assay for global surveillance of HIV-1 drug resistance,"Provided herein are new methods, primers, and kits for genotyping HIV-1, including group M viral strains. The methods can be used for HIV-1 drug resistance surveillance and monitoring, for example in resource-poor countries. The disclosed methods can detected more mixed HIV-1 population than previous methods. Given the high efficiency in genotyping diverse HIV-1 group M viral strains from plasma and dried blood spot (DBS) samples and substantial reagent cost saving, the disclosed methods can be used for HIV-1 drug resistance genotyping in both antiretroviral therapy (ART)-naive and -experienced populations for surveillance purposes and patient monitoring.",18,"The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
9040248,26-May-15,2015,5,26,Kits for detecting and monitoring endocrine disrupting chemicals (EDCs),"Described herein are compositions, a system, and kits for detection of endocrine disruptor chemicals (EDCs) in environmental samples, such as samples of water including but not limited to waste water treatment plant effluent, using a live-cell fluorescence-based nuclear translocation reporter system. Upon binding of a ligand to a fluorescent-labeled reporter protein, the protein (and therefore the fluorescence) is translocated in a ligand level-dependent manner from the cytoplasm to the nucleus of live mammalian cells; this translocation is detectable as diffuse (cytoplasmic) fluorescence converting to localized, brightly fluorescent nuclei. The described kits can be used to reliably detect very low levels of EDC contamination, including in high throughput analysis systems as described.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,Measurement,,,,G01N/5035
9044451,2-Jun-15,2015,6,2,Use of delta tocopherol for the treatment of lysosomal storage disorders,"This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol in combination with cyclodextrin to a patient in need thereof.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/355
9044457,2-Jun-15,2015,6,2,Anti-DR4 agonist antibodies,The present invention provides antibodies and antibody fragments that specifically recognize and agonize the death receptor 4 (DR4). Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.,21,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/3955
9044509,2-Jun-15,2015,6,2,Inhibition of HIV infection through chemoprophylaxis,A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.,18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/675
9046520,2-Jun-15,2015,6,2,Serologic correlates of protection against Bacillis anthracis infection,Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.,8,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/07
9051392,9-Jun-15,2015,6,9,Inhibitors of pre-ligand assembly doman and function of the tumor necrosis factor receptor family,"The present invention provides a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD) of a TNF-like receptor. Also provided by this invention is a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD), wherein the PLAD is selected from the group consisting of: the PLAD of a TNF-R, the PLAD of p60, the PLAD of p80, the PLAD of Fas (CD95/APO-1), the PLAD of TRAIL receptors, the PLAD of LTβR, the PLAD of CD40, the PLAD of CD30, the PLAD of CD27, the PLAD of HVEM, the PLAD of OX40 and the PLAD of DR4. TNF-R, p60, p80, Fas, TRAIL receptor, LTβR, CD40, CD30, CD27, HVEM, OX40, DR4, TROY, EDAR, XEDAR, DCR3, AITR, 4-1BB, DR3, RANK, TACI, BCMA, DR6, DPG, DR5, DCR1 AND DCR2 are all members of the TNF receptor superfamily or the TNF-like receptor family. The invention also provides the PLAD for other members of the TNF receptor superfamily. The polypeptides of the present invention can be utilized to inhibit oligomerization of members of the TNF receptor superfamily. These polypeptides can also be utilized to inhibit ligand binding to members of the TNF receptor superfamily. The present invention also provides a composition comprising an inhibitor of TNF receptor oligomerization. Further provided by this invention are members of the TNF receptor superfamily that are lacking a PLAD.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/7151
9051573,9-Jun-15,2015,6,9,Newly discovered bacterium in the family acetobacteraceae,"Provided is an isolated novel Gram-negative bacterium, wherein the bacterium is an aerobic, facultative methylotroph that produces colonies that are yellow pigmented, wherein the bacterium can use methanol as a sole carbon source and can oxidize glucose and ethanol into acid. Also provided are novel purified polypeptides and isolated nucleic acids from the bacterium. Further provided are methods of using the bacterium and the purified polypeptides to degrade organic material and for use in biofuel cells.",76,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,"Electrical machinery, apparatus, energy",,,,,C12N/52
9052321,9-Jun-15,2015,6,9,Flavivirus-based system for production of hepatitis C virus (HCV),"Provided herein is a mammalian cell transformed to contain a plasmid encoding a T7 or SP6 promoter operably linked to one or more HCV genes, a subgenomic replicon from a flavivirus and a cytoplasmic T7 and SP6 RNA amplification system. Also provided herein are isolated replication-competent HCV particles produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the replication-competent HCV particles from the cell culture. Provided herein are isolated HCV structural proteins produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the HCV structural proteins from the cell culture. Further provided herein is a system for assaying HCV entry into a cell comprising a first plasmid encoding a T7 or SP6 promoter operably linked to an HCV polynucleotide comprising at least the 5′-UTR to NS2 operably linked to an EMCV IRES in frame with an SP6 or T7 polymerase gene, respectively, a first host cell line expressing a replicon from a flavivirus and comprising a cytoplasmic T7 and SP6 RNA amplification system, a second plasmid encoding a reporter gene operably linked to both T7 and SP6 promoters in tandem, and a second host cell line comprising a cytoplasmic T7 polymerase or SP6 polymerase RNA amplification system.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",INSERM (Institut National de la Sante et de la Recherche Medicale),,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/5767
9056068,16-Jun-15,2015,6,16,Vaccine and methods of use against Strongyloide stercoralis infection,"The polynucleotide encoding the SSIR gene from the nematode Strongyloides stercoralis is provided, along with the polypeptide encoded by the SSIR gene. It was found that when mice were immunized with the SSIR polypeptide vaccine, it provided immunity to mice which were implanted with Strongyloides stercoralis L3 implants. Methods for making the SSIR protein, recombinant vectors encoding the SSIR gene, a vaccine made from the SSIR protein, and methods of use are also provided.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Thomas Jefferson University,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/0003
9056891,16-Jun-15,2015,6,16,Synthetic peptide inhibitors of Wnt pathway,"A peptide or peptidomimetic comprising the amino acid sequence KKRLSVXLTSSLFR (SEQ ID NO: 1) or the inverse thereof, or comprising at least eight contiguous amino acids of helix C of β-catenin (SEQ ID NO: 41) or inverse thereof, wherein the peptide or peptidomimetic comprises a total of about 50 or fewer amino acids and inhibits the Wnt pathway, as well as a method of inhibiting the Wnt pathway in a cell, a method of treating or preventing a disease mediated by the Wnt pathway, and related compounds, compositions, and methods.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/08
9056907,16-Jun-15,2015,6,16,Human domain antibodies against components of the human insulin-like growth factor (IGF) system,"The invention provides antibodies or antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as method of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer. The invention also provides a method of detecting the presence of IGF-1R or IGF-2 in a sample using the inventive antibodies and antibody fragments.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/22
9063124,23-Jun-15,2015,6,23,Method for identifying compounds that modulate a T2R taste receptor,"The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.",12,The Regents of the University of California,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/74
9063139,23-Jun-15,2015,6,23,Variants in complement regulatory genes predict age-related macular degeneration,"Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided.",8,The Trustees of Columbia University in the City of New York,University of Iowa Research Foundation,"The United States of America, As Represented By the Secretary of the Department of Health and Human Services",,,,,,,,,3,Organic fine chemistry,Analysis of biological materials,Biotechnology,,,,G01N/564
9063150,23-Jun-15,2015,6,23,Method for detection of antigen-specific antibodies in biological samples,"Disclosed herein is a rapid and universal assay for the detection of antigen-specific antibodies in biological samples. The assay allows for the detection of antigen-specific antibodies in any species, including species for which secondary antibodies or antisera have not been developed or are not available. Biological samples to be tested are directly labeled, such as with biotin, and contacted with antigen-bound microparticles. The presence of antigen-specific antibodies in the biological samples is detected using a binding partner for the label, such as a biotin binding partner, conjugated to a detectable label, such as a fluorophore. This improved test provides a total antibody assay that is capable of detecting all classes of antibodies simultaneously.",25,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/6854
9066948,30-Jun-15,2015,6,30,"Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines","The present invention relates to compounds of formula P-1 and related compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of A, Y, R1, R2, Ra, Ra′, Rb, Rb′, Rc, Rc′, Rd, Rd′, Re, and Re′ are provided herein. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.",6,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",THE ROCKEFELLER UNIVERSITY,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,,,,,A61K/519
9068003,30-Jun-15,2015,6,30,Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies,"Provided are methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).",13,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/2875
9068165,30-Jun-15,2015,6,30,"Therapeutic applications of P53 isoforms in regenerative medicine, aging and cancer",The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,The University of Dundee,Masaryk Memorial Cancer Institute,,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,C12N/113
9068993,30-Jun-15,2015,6,30,Diagnostic assays and methods of use for detection of filarial infection,"The polynucleotide encoding the antigen Wb123 from the filarial nematode Wuchereria bancrofti, the major causative organism of lymphatic filariasis is provided, along with the polypeptide encoded by the polynucleotide. Methods for making the WM23 antigen, recombinant vectors encoding the Wb123 polynucleotide, and methods of detection of the Wb123 antigen through luciferase immunoprecipitation, ELISA and other detection systems are also provided.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/6893
9072716,7-Jul-15,2015,7,7,Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells,The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells.,10,"The United States of America, as represented by the Secretary Department of Health by Human Servies",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/2086
9074185,7-Jul-15,2015,7,7,Adoptive cell therapy with young T cells,"The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/0636
9075062,7-Jul-15,2015,7,7,Identification of biomarkers by serum protein profiling,The present invention relates to methods of determining colorectal cancer status in a subject. The invention further relates to kits for determining colorectal cancer status in a subject. The invention further related to methods of identifying biomarker for determining colorectal cancer status in a subject.,14,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/57419
9075796,7-Jul-15,2015,7,7,Text mining for large medical text datasets and corresponding medical text classification using informative feature selection,"Techniques include performing text mining on a set of case reports in text format to determine a set of grammar rules to be used to determine whether case reports meet a medical condition. The text mining includes performing feature selection, used to determine the set of grammar rules, that combines standardized case definitions with experience of medical officers for the medical condition and outputting the set of grammar rules. Another technique includes applying grammar rule(s) to new case report(s), the grammar rule(s) previously determined at least by performing text mining comprised of performing feature selection, used to determine the set of grammar rules, that combines standardized case definitions with experience of medical officers for the medical condition. Indication(s) are output of whether the new case report(s) meet or do not meet the medical condition. The techniques may be performed by a method, an apparatus, and a program product.",20,International Business Machines Corporation,"The National Institutes of Health, A Component of the US Department of Health and Human Services",,,,,,,,,,2,Computer technology,,,,,,G06F/40
9079936,14-Jul-15,2015,7,14,Derivatives of APF and methods of use,"Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline.",4,"University of Maryland, Baltimore",The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,The United States of America as Represented by the Department of Veterans Affairs,,,,,,,,,3,Biotechnology,,,,,,C07K/005
9081009,14-Jul-15,2015,7,14,Oxidized cardiolipin and uses to detect cardiolipin antibodies,"Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies (such as IgG and IgM antibodies) in subjects, for example, when used in ELISA plates. ELISA plates are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.",22,The United States of America as represented by the Secretary of the Department of Health and Human Services,Arlington Scientific Inc.,,,,,,,,,,2,Analysis of biological materials,,,,,,G01N/571
9084783,21-Jul-15,2015,7,21,Thio compounds,"A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.",10,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/454
9084819,21-Jul-15,2015,7,21,Magnetic microstructures for magnetic resonance imaging,The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T2* contrast agents that have a significantly higher magnetic moment compared to similarly-sized existing MRI contrast agents.,7,"The United States of America, as Represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health","THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF COMMERCE",,,,,,,,,,2,Measurement,Pharmaceuticals,Micro-structural and nano-technology,Medical technology,,,A61K/1818
9084820,21-Jul-15,2015,7,21,Magnetic microstructures for magnetic resonance imaging,"A magnetic resonance contrast agent has a medium, and a contrast structure dispersed in the medium. The contrast structure comprises a magnetic material arranged to create a local region of a local magnetic field such that nuclear magnetic moments of a material when arranged within the local region precess at a characteristic Larmor frequency about a total magnetic field in the local region while in use, the characteristic Larmor frequency being identifiable with the contrast structure, and the total magnetic field in the local region being a substantially spatially uniform magnetic field.",13,"The United States of America, as Represented by the Secretary, Department of Health and Human Services Office of Technology Transfer, National Institutes of Health","The United States of America, Represented by the Secretary of Commerce",,,,,,,,,,2,Measurement,Pharmaceuticals,Medical technology,"Electrical machinery, apparatus, energy",,,A61K/1818
9085604,21-Jul-15,2015,7,21,Antiproliferative factor and methods of use,"A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.",26,"University of Maryland, Baltimore",The United States of America as represented by the Secretary of the Department of Health and Human Services,The United Sates of America as Represented by the Department of Veterans Affairs,,,,,,,,,3,Biotechnology,,,,,,C07K/005
9086509,21-Jul-15,2015,7,21,Azicon beam polarization devices,Polarizers and polarizing beam splitter include one or more pairs of axicons that are configured to separate an input beam into a radially polarized component and a tangentially (or azimuthally) polarized component. A second axicon pair can be provided to recombine the tangentially polarized component so as to provide a more uniform beam intensity. The radially polarized component can be reflected or otherwise directed so that one or both the radial and tangential components are available for use.,24,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,,,,,,G02B/001
9090873,28-Jul-15,2015,7,28,Development of dengue virus vaccine components,"The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′direction as far as the 5′boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.",19,"The United States of America, as represented by the Secretary of the Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/045
9091597,28-Jul-15,2015,7,28,Electrode-assisted microwave-induced plasma spectroscopy,"Particles of a flow of aerosol are collected and analyzed by passing them through a housing having an inlet area, an outlet area, and a collection and analysis area. A collection electrode has a tip disposed in the flow path in the collection and analysis area. Particles are collected on the tip of the collection electrode. A microwave pulse is applied to the collection and analysis area such that a plasma is created. Atomic emissions produced during at least part of the microwave step are collected for analysis of the ablated particles.",14,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Measurement,,,,,,G01J/443
9093649,28-Jul-15,2015,7,28,"Organic compound, light-emitting element, light-emitting device, electronic appliance, and lighting device",An organic compound that emits blue light with high color purity and has a long lifetime is provided as a novel substance. The organic compound is a fluorescent organic compound having a structure in which benzonaphthofuranylamine is bonded to the 1-position and the 6-position of a pyrene skeleton.,20,"Semiconductor Energy Laboratory Co., Ltd.",,,,,,,,,,,1,Semiconductors,Organic fine chemistry,Basic materials chemistry,,,,H01L/006
9095597,4-Aug-15,2015,8,4,N-acetyl mannosamine as a therapeutic agent,The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.,9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7008
9096653,4-Aug-15,2015,8,4,Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia,"Disclosed are immunogenic conjugates which elicit an immune response to Plasmodium proteins. In particular examples, the Plasmodium proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to Plasmodium in a subject, comprising administering to the subject an immunogenic composition disclosed herein.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",New York University,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/00
9096908,4-Aug-15,2015,8,4,Selective detection of Bordetella species,"A process for detecting Bordetella spp. nucleic acid in a biological sample includes producing an amplification product(s) by amplifying one or more Bordetella spp. in a multiplex single chamber PCR assay, and measuring the amplification product(s) to detect or distinguish Bordetella spp. in the biological sample. Also provided are reagents and methods for detecting and distinguishing Bordetella spp. from each other and other bacteria or viruses. A kit is provided for detecting and quantifying one or more Bordetella spp. in a biological sample.",9,"The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
9101582,11-Aug-15,2015,8,11,Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen,"Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present on the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.",4,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/164
9101600,11-Aug-15,2015,8,11,Compounds as RORγt modulators and uses thereof,"Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as RORγt modulators that have a formula represented by the following:and wherein n1, n2, R1, R2, R3, and R4 are as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.",11,New York University,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/33
9101601,11-Aug-15,2015,8,11,Methods of treating or preventing insulin resistance and associated diseases and conditions,"Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Pharmaceuticals,,,,,A61K/343
9102742,11-Aug-15,2015,8,11,Serologic correlates of protection against Bacillus anthracis infection,Regions of B. anthracis protective antigen are provided representing sequences recognized by antibodies in subjects that have vaccine induced lethal toxin neutralizing anti-PA IgG responses. The recognition of these PA regions enhances the utility of anti-PA IgG reactivity as an immune correlate of protection against anthrax in a subject and increases predictive probability of survival. Also provided are vaccines that include at least one of these PA regions that when administered to a subject improve the predictive value of vaccine induced anti-PA IgG and TNA responses as immune correlates of protection against inhalation anthrax.,18,"The United States of America as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/32
9102983,11-Aug-15,2015,8,11,Single nucleotide polymorphisms associated with renal disease,"Methods for determining the genetic predisposition of a human subject to developing renal disease, such as focal segmental glomerulosclerosis (FSGS) or end-stage kidney disease are provided herein. These methods include methods for detecting renal disease, or determining the risk of developing renal disease in a human subject, such as a subject of African ancestry. The methods utilize the detection of one or more haplotype blocks comprising at least two tag single nucleotide polymorphisms (SNPs) in a non-coding region of a MYH9 gene or detecting the presence of at least one tag SNP in a non-coding region of a MYH9 gene. An array for detecting a genetic predisposition to renal disease using probes complementary to the tag SNPs in the non-coding region of the MYH9 gene are also disclosed.",5,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
9103788,11-Aug-15,2015,8,11,Detection of bacterial contamination in a sample,"Methods for detecting one or more target bacteria in a test sample are provided. It is shown herein that photosensitizers combined with intense light exposure reduce fluorescing background due to non-bacterial particles. This permits detection of subsequently labeled target bacterial cells (e.g., using a fluorescently labeled antibody) against a largely black background. In particular examples, the methods include incubating the test sample in a growth medium that permits growth of bacteria present in the sample, contacting the sample with a photo-sensitizer; exposing the sample to light under conditions sufficient for the photo-sensitizer to photobleach contaminating non-bacterial particulates present in the sample. The bacteria can then be substantially separated from the sample, thereby generating an isolated bacterial sample. The method can also include contacting the isolated bacterial sample with a binding agent specific for the one or more target bacteria, and detecting the one or more target bacteria.",18,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES","VIVIONE BIOSCIENCES, LLC",,,,,,,,,,2,Measurement,,,,,,G01N/6486
9107813,18-Aug-15,2015,8,18,"Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant","Immunogenic compositions and kits, as well as methods of stimulating immune responses and methods of immunization using the same. The compositions and kits comprise: (a) an antigen derived from Bacillus anthracis; (b) polymer microparticles comprising a biodegradable polymer; and (c) a polynucleotide-containing immunological adjuvant.",25,,,,,,,,,,,,,Pharmaceuticals,,,,,,A61K/0019
9108035,18-Aug-15,2015,8,18,"Methods and systems for using therapeutic, diagnostic or prophylactic magnetic agents","Systems and methods are disclosed for directing magnetizable particles comprising therapeutic agents to a target volume, or for guiding magnetizable particles comprising therapeutic agents from a first target volume to a second target volume, at a distance using a magnetic field, to enable the treatment of diseased areas including areas deep inside a patient's body. The methods may be used to diagnose or treat diseased areas within a patient, for example tumors of the lungs, intestines, and liver, and is also useful in enhancing the permeability of solid tumors to chemotherapeutic agents.",26,"University of Maryland, College Park","The United States of America as represented by the Secretary, Department of Health and Human Services, National Institutes of Health",,,,,,,,,,2,Medical technology,Medical technology,,,,,A61N/00
9114102,25-Aug-15,2015,8,25,Method of inhibiting ABCG2 and related treatments,"Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
9115187,25-Aug-15,2015,8,25,Identification of antibodies specific for lyssaviruses and methods of their use,"Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.",7,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/10
9115196,25-Aug-15,2015,8,25,Antibodies and immunotoxins that target human glycoprotein NMB,"The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiforme cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells. The antibodies may be formed in cells transformed with an isolated nucleic acid encoding a polypeptide comprising an antibody heavy chain variable region (“VH”) and an antibody light chain variable region (“VL”). Such nucleic acids are provided.",9,,,,,,,,,,,,,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/28
9115371,25-Aug-15,2015,8,25,Reduction of TGF beta signaling in myeloid cells in the treatment of cancer,"Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,Other special machines,,,C12N/1138
9115386,25-Aug-15,2015,8,25,Selective oxidation of 5-methylcytosine by TET-family proteins,"The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.",2,CHILDREN'S MEDICAL CENTER CORPORATION,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6827
9115400,25-Aug-15,2015,8,25,LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis,"Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.",6,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,"Research Foundation for Mental Hygiene, Inc.","The Progeria Research Foundation, Inc.",,,,,,,,,3,Biotechnology,,,,,,C07K/47
9115408,25-Aug-15,2015,8,25,Rapid Salmonella serotyping assay,"Processes for the serotype specific detection and identification of one or more Salmonella serotypes are provided. A family of specific primers and probes are provided that allow screening of biological or environmental samples for robust, rapid, and reproducible detection and identification of one or more Salmonella serotypes in the sample.",7,"The United States of America as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
9119812,1-Sep-15,2015,9,1,Influenza hemagglutinin and neuraminidase variants,"Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.",20,"MedImmune, LLC",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/145
9120774,1-Sep-15,2015,9,1,Novobiocin analogues having modified sugar moieties,The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.,22,University of Kansas,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/12
9120867,1-Sep-15,2015,9,1,Lutzomyia longipalpis polypeptides and methods of use,"Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,Fundacao Oswaldo Cruz,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/008
9121855,1-Sep-15,2015,9,1,Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope,"This invention concerns methods for detecting the presence of an anti-HIV-1 antibody in a biological sample, the method comprising conducting an immunoassay comprising: (a) contacting the biological sample with at least one epitope that is recognized by the anti-HIV-1 antibody, wherein the contacting being under conditions sufficient to permit the anti-HIV-1 antibody if present in the sample to bind to the epitope and form an epitope-anti-HIV-1 antibody complex; (b) contacting the formed epitope-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, the contacting being under conditions sufficient to permit the anti- HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed epitope-anti-HIV-1 antibody complex and form an extended complex; and (c) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentration of the formed extended complex; the epitope being present on a peptide comprising SEQ ID No. 55.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/6854
9125923,8-Sep-15,2015,9,8,Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy,"It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-α therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-α therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided. Further provided are methods of treating a patient diagnosed with HCC and expressing a low level of miR-26, wherein treatment comprises IFN-α therapy.",18,The Ohio State University,Fudan University,The United States of America as Represented by the Secretary of the Dept. of Health and Human Services,,,,,,,,,3,Pharmaceuticals,Biotechnology,,,,,A61K/70
9127056,8-Sep-15,2015,9,8,Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II),"Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed.",41,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/22
9128080,8-Sep-15,2015,9,8,Modified T cell receptors and related materials and methods,"The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/505
9129424,8-Sep-15,2015,9,8,Phase sensitive T1 mapping in magnetic resonance imaging,"Phase sensitive T1 mapping is provided in magnetic resonance (MR). The phase from samples of a modified Look-Locker inversion recovery sequence may be used to normalize contrast, allowing for accurate motion registration without extra information acquisition. The sign may be estimated, allowing T1 mapping with a single application of a non-linear fit.",20,Siemens Aktiengesellschaft,The United States of America,,,,,,,,,,2,Measurement,Computer technology,,,,,G06T/003
9132278,15-Sep-15,2015,9,15,Transcranial magnetic stimulation system and methods,"A system and methods for transcranial magnetic stimulation, the system including a helmet, a positioning portion, a stimulator and a cooling system, are disclosed. The helmet includes a coil for deep brain magnetic stimulation. The coil has a base portion, and return portions, which may include a protruding return portion and a contacting return portion. The coil is designed to minimize unintended stimulation of portions of the brain, while reducing accumulation of surface charges. The coil is stimulated at several locations and/or at different times so as to focus the electrical field on a specific deep neuronal structure.",20,"BRAINSWAY, LTD.",YEDA RESEARCH & DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,3,Medical technology,,,,,,A61N/02
9133478,15-Sep-15,2015,9,15,Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes,"The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
9133480,15-Sep-15,2015,9,15,Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites,"The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
9139595,22-Sep-15,2015,9,22,"Biologically active macrolides, compositions, and uses thereof","The present invention provides a compound of the formula (I) or (II), wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or aryl, and R9 is R9a, C(O)R9a or SO2R9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(═O), OR9b, OC(O)R9b, OSO2R9b, NHR9b, NHC(O)R9b and NHSO2R9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(═O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/395
9139849,22-Sep-15,2015,9,22,Rapid generation of long synthetic centromeric tandem repeats for mammalian artificial chromosome formation,"Methods are described for construction of long synthetic arrays of DNA repeats, such as alphoid repeats or other repeat sequences. The methods include concatamerization of DNA into short repeats (for instance using rolling circle amplification or directional in vitro ligation), followed by assembling the short repeats into long arrays by homologous recombination during transformation into microbe cells. These methods can be described generally as Recombinational Amplification of Repeats (RAR). The long arrays are engineered centromere-like regions that allow one to construct mammalian artificial chromosomes with a predefined centromeric region structure. Artificial chromosomes, including human artificial chromosomes with a regulated centromere, and methods of their use are also provided.",18,The United States of America as Represented by the Government of the Department of Health and Human Services,The University Court of the University of Edinburgh,,,,,,,,,,2,Biotechnology,,,,,,C12N/85
9140687,22-Sep-15,2015,9,22,Renal cell carcinoma biomarkers,"Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker.",8,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/50
9144461,29-Sep-15,2015,9,29,Feedback system for integrating interventional planning and navigation,"A therapy planning and image guidance and navigation for an interventional procedure are combined in one system. The system includes: a radio frequency ablation therapy planning component (1) capable of creating an initial treatment plan, adjusting the treatment plan to take into account data received during a procedure and transferring a treatment plan to a navigation component, a navigation system component (2) to guide an ablation probe (6) and a feedback sub-system (3) for determining actual ablation probe positions/orientations and actual ablation size/shape via imaging (4) and/or tracking (5) systems, and enabling exchange of information between the planning component and the navigation component. By combining and integrating procedure planning and navigation, and by providing feedback from the navigation component back to the planning component about actual electrode position and orientation and ablation volume, complex procedures can be carried out more accurately, efficiently, and potentially with better clinical outcomes.",20,Koninklijke Philips N.V.,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Medical technology,,,,,,A61B/18
9144604,29-Sep-15,2015,9,29,Vaccine for Shigella,"Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure:Pr—Sr—O—N═C-Kdo-OSwherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure:    In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure:α-L-AltNAcA-3-β-FucNAc4N-4-.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",National Research Council of Canada,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/02
9149666,6-Oct-15,2015,10,6,Fast acting SNARE-cleaving enzymes,"The present invention relates to metalloprotease enzymes isolated from scorpion venom, their nucleic acid and amino acid sequences, and methods of use thereof in the treatment of various diseases, disorders and cosmetic conditions.",19,East Carolina University,National Institutes of Health,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,Biotechnology,,,,A61Q/08
9150644,6-Oct-15,2015,10,6,Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II,"Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/22
9150926,6-Oct-15,2015,10,6,Diagnosis and treatment of adrenocortical tumors using human microRNA-483,"Disclosed herein are methods of diagnosing and treating a malignant adrenocortical tumor, including adrenocortical carcinoma. In some examples, methods of diagnosing a malignant adrenocortical tumor include detecting expression of at least one microRNA (miR) gene product, such as miR-100, miR-125b, miR-195, miR-483-3p, miR-483-5p and IGF2 mRNA in a sample obtained from the subject with an adrenocortical tumor and comparing expression of at least one of these miR gene products and IGF2 mRNA in the sample obtained from the subject to a control. Altered expression of at least one of the miR gene products and IGF2 mRNA, such as a decrease in miR-100, miR-125b or miR-195 or an increase in miR-483-3p, miR-483-5p, and an increase in IGF2 mRNA, in the sample obtained from the subject compared to the control indicates a malignant adrenocortical tumor.",10,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6886
9151762,6-Oct-15,2015,10,6,Identification of DSG-3 as a biomarker for the detection of metastasis in lymph nodes,"Disclosed herein is a method of detecting metastasis of a tumor in a subject, such as metastasis to a lymph node. The method includes directly determining an amount of desmoglein-3 (DSG-3) protein in a sample from the subject (such as a lymph node sample) and comparing the amount of DSG-3 protein to a control, wherein an increase in the amount of DSG-3 protein in the sample relative to the control indicates metastasis of the tumor to the lymph node. The disclosed methods further include selecting a therapy (for example, surgery, lymph node dissection, radiation therapy, chemotherapy, or a combination of two or more thereof) for the subject based on the amount of DSG-3 protein in the sample from the subject.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57484
9156778,13-Oct-15,2015,10,13,Cross-coupled peptide nucleic acids for detection of nucleic acids of pathogens,"Disclosed is a method for lowering the detection limit in a method of detecting a nucleic acid comprising (i) contacting a solution comprising a first PNA with a substrate having a second PNA affixed thereto, the second PNA comprising at least one trans-cyclopentane residue, wherein the first PNA has two linker-attached biotins attached thereto and the first and second PNAs being complementary to different portions of a target DNA; (ii) contacting a sample suspected of containing the nucleic acid with the first and second PNAs; and (iii) determining the presence of the reporter molecule on the substrate. Also disclosed are a detection assay and a kit for detecting a target nucleic acid.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Biotechnology,,,,,C07C/24
9157125,13-Oct-15,2015,10,13,GRIN2A mutations and use thereof for the diagnosis of melanoma,"Described herein is the identification of 68 genes with an elevated frequency of somatic mutations in melanoma. Nine genes were identified that exhibited recurring mutations in melanoma. The TRRAP gene was mutated at nucleotide 2165 (C2165T) in six different melanoma tumor samples. In addition, 16 genes were identified that were highly mutated in melanoma samples. The most highly mutated gene identified was GRIN2A, which was mutated in 34% of melanoma tumor samples. The study disclosed herein identified 34 different nonsynonymous somatic mutations in GRIN2A among 36 melanoma tumor samples. Provided is a method of diagnosing a subject as having melanoma or susceptible to developing melanoma by detecting one or more mutations in the TRRAP or GRIN2A genes. Further provided is a method of selecting an appropriate therapy for a subject diagnosed with melanoma by detecting the presence or absence of a mutation in TRRAP or GRIN2A.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
9163068,20-Oct-15,2015,10,20,Influenza virus recombinant proteins,The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.,18,"The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
9163236,20-Oct-15,2015,10,20,"Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer","The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression of either Nanog or a Nanog pseudogene, a vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.",24,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/113
9163244,20-Oct-15,2015,10,20,Suppressors of CpG oligonucleotides and methods of use,"The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/117
9163258,20-Oct-15,2015,10,20,Method for the treatment of obesity,The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes.,13,Fred Hutchinson Cancer Research Center,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/17
9163287,20-Oct-15,2015,10,20,Rapid salmonella serotyping assay,"Processes for the serotype specific detection and identification of one or more Salmonella serotypes are provided. A family of specific primers and probes are provided that allow screening of biological or environmental samples for robust, rapid, and reproducible detection and identification of one or more Salmonella serotypes in the sample.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
9168266,27-Oct-15,2015,10,27,"Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer","Disclosed are hybrid compounds that release both nitric oxide and a moiety that inhibits poly (ADP-ribose) polymerase (PARP), e.g., a compound or a pharmaceutically acceptable salt thereof of formula (I), wherein R1-4 and m-p are as described herein. Also disclosed are pharmaceutical compositions and methods of use including treating cancer and enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/655
9168291,27-Oct-15,2015,10,27,β-mannosylceramide and stimulation of NKT cell anti-tumor immunity,"β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The University of Birmingham,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/7032
9168297,27-Oct-15,2015,10,27,Regulation of skin pigmentation by neuregulin-1 (NRG-1),"Disclosed herein are compositions and methods of using such compositions to modulate pigmentation and proliferation of a melanocyte, such as to prevent or treat skin disorders, including skin cancer or for use for cosmetic purposes. In one example, a method of modulating pigmentation of a melanocyte includes contacting the melanocyte (such as a human melanocyte) with an agent that modulates neuregulin-1 (NRG-1) activity, such as an agent that increases or decreases NRG-1 activity, thereby modulating pigmentation of the melanocyte. In one particular example, the method of increasing melanocyte pigmentation or proliferation can be used to reduce UV skin damage, including that associated with skin cancer. In another example, the method of decreasing melanocyte pigmentation can be used to treat a skin pigmentation disorder associated with undesired increased skin pigmentation.",6,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/3955
9169182,27-Oct-15,2015,10,27,Chrysophaentin analogs that inhibit FtsZ protein,"Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.",17,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07C/14
9169296,27-Oct-15,2015,10,27,Expression and assembly of human group C rotavirus-like particles and uses thereof,"Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions.",6,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
9169297,27-Oct-15,2015,10,27,Subgenomic replicons of the flavivirus dengue,"The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.",11,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/21
9169298,27-Oct-15,2015,10,27,Dengue serotype 1 attenuated strain,The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.,10,Sanofi Pasteur,Centers for Disease Control and Prevention,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
9173898,3-Nov-15,2015,11,3,Methods of treating giardiasis,Compounds useful for the treatment of giardiasis are described.,1,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services","University of Maryland, College Park",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/7135
9173931,3-Nov-15,2015,11,3,Process for preparing polysaccharide-protein conjugate vaccines,Methods for the manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency. Simplified purification processes can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.,14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Fiocruz,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/095
9173932,3-Nov-15,2015,11,3,Vibrio cholerae O139 conjugate vaccines,"The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.",9,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/107
9175033,3-Nov-15,2015,11,3,Methods for preparing complex multivalent immunogenic conjugates,Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.,11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/084
9175038,3-Nov-15,2015,11,3,Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use,"Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament.",21,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/06
9175057,3-Nov-15,2015,11,3,Immunogenic peptides and methods of use,"The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.",36,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
9175062,3-Nov-15,2015,11,3,"Human soluble receptor for advanced glycation end products (sRAGE), methods of preparing human sRAGE, and treatment methods using sRAGE","The present disclosure provides a method for recombinant production of human sRAGE in mammalian cells, as well as a human sRAGE having a mammalian post-translational modification and compositions thereof. The present disclosure also provides a method of treating a vascular disease, injury, or inflammation in a mammal by administering to a mammal with a vascular disease, injury, or inflammation a composition comprising human sRAGE having a mammalian post-translational modification, thereby treating the vascular disease, injury, or inflammation in the mammal.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70503
9175070,3-Nov-15,2015,11,3,Neutralizing antibodies to HIV-1 and their use,"Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.",7,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Washington,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/1063
9175264,3-Nov-15,2015,11,3,Postnatal stem cells and uses thereof,"The invention generally relates to postnatal dental stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal dental pulp stem cells, use of the cells to generate dentin, and differentiation of the cells. In another aspect, the invention relates to human postnatal deciduous dental pulp multipotent stem cells, use of the cells to generate dentin, and differentiation of the cells.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/30
9180133,10-Nov-15,2015,11,10,Method for treating uterine fibroids,"The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.",17,LABORATOIRE HRA-PHARMA,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/57
9181193,10-Nov-15,2015,11,10,"Indenoquinolone compound, preparation method and use thereof","An indenoquinolone compounds of Formula (A) is disclosed, wherein the definition of each group is described in the description. These compounds may specifically inhibit topoisomerase I, and they have good activities against many kinds of human tumor cells, such as lung cancer, colon cancer, breast cancer, liver cancer and the like. They can be used in the manufacture of antitumor drugs. The method for preparing the compound of formula (A), and pharmaceutical compositions containing such compounds and the use in the manufacture of antitumor drugs are also disclosed.",8,"Second Military Medical University, PLA",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/18
9181253,10-Nov-15,2015,11,10,"Adenosine receptor agonists, partial agonists, and antagonists","Disclosed are A3 adenosine receptor antagonists and/or partial agonists and A1 adenosine receptor agonists and/or partial agonists of formula (I):wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The A3 AR antagonists or partial agonists find use in treating a number of diseases such as cancer, glaucoma, and inflammatory diseases, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs. The A1 AR agonists and partial agonists find use in treating diseases such as seizures, convulsion, stroke, diabetes, pain, arrhythmias, depression, and anxiety and in cardioprotection or neuroprotection.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/34
9181306,10-Nov-15,2015,11,10,"Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine","Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) with an in-frame deletion, a rubella structural protein ORF, and a heterologous antigenic insert. In one example, the in-frame deletion within the rubella non-structural protein ORF is an in-frame deletion between two NotI restriction enzyme sites. In some examples, the heterologous antigenic insert is positioned within the rubella non-structural protein ORF. In other examples, the heterologous antigenic insert is positioned within the rubella structural protein ORF. Exemplary antigenic inserts include a Gag antigenic insert, a gp41 antigenic insert or a gp120 antigenic insert. Also disclosed are uses of the isolated rubella viral vector, such as to induce an immune response to HIV-1, testing sensitivity to neutralizing antibodies, or screening antiviral drugs (such as protease inhibitors).",4,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
9181327,10-Nov-15,2015,11,10,Anti-HIV domain antibodies and method of making and using same,"The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1045
9181340,10-Nov-15,2015,11,10,"TEM8 antibodies, conjugates thereof, and their use","Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.",37,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Novartis AG,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/28
9181530,10-Nov-15,2015,11,10,Infectious hepatitis E virus genotype 3 recombinants,"The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus. The invention relates, in part, on the identification of a new strain of HEV genotype 3 virus. Strain Kernow-C1 (genotype 3) of HEV, which was isolated from a chronically infected patient, was used to identify human, pig and deer cell lines permissive for infection. Adaptation of the Kernow-C 1 strain to growth in human hepatoma cells selected for a rare virus recombinant that contained an insertion of 174 ribonucleotides (58 amino acids) of a human ribosomal protein gene and additional mutations.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Royal Cornwall Hospital Trust,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/00
9181552,10-Nov-15,2015,11,10,Materials and methods directed to asparagine synthetase and asparaginase therapies,"Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/1137
9181589,10-Nov-15,2015,11,10,Molecular-based method of cancer diagnosis and prognosis,"A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C12Q/6886
9186365,17-Nov-15,2015,11,17,Antiangiogenic small molecules and methods of use,"Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof.",4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/12
9187457,17-Nov-15,2015,11,17,Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists,"Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.",21,The United States of America as represented by the Secretary of the Department of Health and Human Services,Forschungsverbund Berlin E.V.,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
9193739,24-Nov-15,2015,11,24,Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization,In this application is described a composition and method for inducing in a subject anti-hapten antibodies without inducing antibodies to the carrier protein. Kits for designing and making compositions with desired haptens are also described.,35,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY","THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH HUMAN SERVICES",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,C07D/08
9193769,24-Nov-15,2015,11,24,Bovine adeno-associated viral (BAAV) vector and uses thereof,"The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles.",3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
9193790,24-Nov-15,2015,11,24,Use of antagonists of the interaction between HIV GP120 and A4B7 integrin,"Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4 integrin antagonist is a monoclonal antibody that specifically binds to a α4, β1 or β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.",8,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/2839
9193995,24-Nov-15,2015,11,24,Compositions for detecting human interferon-alpha subtypes and methods of use,"The invention provides highly sensitive, specific and efficient quantitative real-time PCR compositions, methods and assay kits to detect at least one IFN subtype and/or IFN subtype allotypic variants. Primer/probe sets complementary to the coding sequence of an IFN subtype of interest avoid spurious detection of degraded mRNA and enhances the correlation between the IFN subtype that is measured by the assays of the invention and the protein that is actually expressed. The invention also provides methods for designing primers and methods of using the compositions and assay kits. The compositions, kits, and methods of the invention may be used, for example, to monitor vaccine efficacy, autoimmune disease, chronic infections, or tumor therapy.",15,UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
9194868,24-Nov-15,2015,11,24,Flow cytometry-based systems and methods for detecting microbes,"In various embodiments, the present disclosure describes methods and systems for detecting microbes in a sample. The methods are generally applicable to quantifying the number of target bacteria in a sample counted from a detection region of a flow cytometer histogram. The detection methods can be employed in the presence of other microorganisms and other non-target microbe components to selectively quantify the amount of a target microbe. The methods are advantageous over those presently existing for testing of foodstuffs and diagnostic evaluation in their speed, accuracy and ease of use. Various swab collection devices and kits useful for practicing the present disclosure are also described herein.",14,The United States of America,"Vivione Biosciences, LLC",,,,,,,,,,2,Measurement,Biotechnology,Analysis of biological materials,,,,C12Q/04
9198941,1-Dec-15,2015,12,1,Yeast-Brachyury immunotherapeutic compositions,"Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.",22,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services","GlobeImmune, Inc.",,,,,,,,,,2,Pharmaceuticals,Medical technology,Biotechnology,,,,A61K/0011
9198976,1-Dec-15,2015,12,1,Polysaccharide-protein conjugate vaccines,"Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/08
9200322,1-Dec-15,2015,12,1,Biomarkers for acute ischemic stroke,"The present invention provides methods and compositions for the diagnosis of acute ischemic stroke. The invention further provides methods and compositions for distinguishing acute ischemic stroke from other forms of stroke and TIAs and “stroke mimic” events. Moreover, methods and compositions are provided to facilitate the treatment of acute ischemic stroke patients.",27,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",University of Pittsburgh—of the Commonwealth System of Higher Education,,,,,,,,,,2,Medical technology,Biotechnology,Analysis of biological materials,,,,C12Q/6876
9205091,8-Dec-15,2015,12,8,"Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer","Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N2O2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and/or a decreased level of one or more of PRX1, PRX6, and OGG1, compared to a normal cell of the same tissue or tissue type. An example of a diazeniumdiolated compound is Formula (I), wherein X and Q are defined herein. Also disclosed are diazeniumdiolated compounds, pharmaceutical compositions, and methods of use including enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.",31,"The United States of America, as represented by the Secretary Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/551
9205276,8-Dec-15,2015,12,8,Light as a replacement for mitogenic factors on progenitor cells,"The present invention generally relates to a method of using light treatment supporting specific cell types in a subject. Specifically, the present invention relates to methods for stimulating the proliferation, migration, differentiation and survival of cell using specific parameter of lights. These methods are particularly useful in the cellular regeneration and replacement in a tissue injury, such as CNS or PNS injury, and in transplantation of organs, tissues and cells.",14,"THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.","THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND SERVICES",,,,,,,,,,2,Biotechnology,Medical technology,Pharmaceuticals,,,,A61N/0601
9206154,8-Dec-15,2015,12,8,Inverse agonists and neutral antagonists for the TSH receptor,"TSHR inverse agonists and neutral antagonists that are useful for treating Graves' orbitopathy, Graves' hyperthyroidism and/or thyroid cancer.",61,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
9206240,8-Dec-15,2015,12,8,Pseudomonas exotoxin A with less immunogenic B cell epitopes,"The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.",14,"The United States of America, as represented by the Secretary, Department of Helath and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/164
9206245,8-Dec-15,2015,12,8,Immunogenic peptides and methods of use for treating and preventing cancer,"Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4+ and CD8+ T cells, and methods of treating or preventing cancer are further provided herein.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/70539
9206257,8-Dec-15,2015,12,8,Human monoclonal antibodies specific for glypican-3 and use thereof,"Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/3076
9210925,15-Dec-15,2015,12,15,Multipotent postnatal stem cells from human periodontal ligament and uses thereof,"The invention generally relates to postnatal periodontal ligament stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal periodontal ligament multipotent stem cells, use of the cells to generate periodontium, differentiation of the cells and methods of tissue cryopreservation.",36,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Medical technology,Basic materials chemistry,Pharmaceuticals,Biotechnology,,,A61K/32
9211275,15-Dec-15,2015,12,15,Ketone bodies and ketone body esters as blood lipid lowering agents,"The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.",6,ISIS INNOVATION LTD.,"The United States of America, as represented by the Secretary of the Department of Health and Human Services (DHSS)",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/22
9211302,15-Dec-15,2015,12,15,Modulation of LRCH4 activity and therapeutic application thereof,Disclosed herein are methods for altering cellular functions and processes by modulating the activity of Lrch4. Corresponding compositions that may be used in carrying out the described methods are also disclosed as are related methods of treatment for relevant diseases and physiological states.,10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/713
9216214,22-Dec-15,2015,12,22,Replication-competent adenoviral vectors,"This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.",21,The United States of America as represented by the Secretary of the Department of Health and Human Services,Istituto Superiore di Sanita,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/21
9217010,22-Dec-15,2015,12,22,N-substituted indenoisoquinolines and syntheses thereof,"N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.",3,PURDUE RESEARCH FOUNDATION,THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/005
9217698,22-Dec-15,2015,12,22,Device for simulating explosive blast and imaging biological specimen,"A device and method for simulating a blast shock wave of the type produced by explosive devices such as bombs. A pneumatic charge releases a blast shock wave along a conduit which terminates in a first outlet that communicates with the atmosphere and a second outlet that is sealed to a specimen chamber. The first outlet has a quick release valve that prevents venting of the pneumatic charge to the atmosphere until the pressure at the valve reaches a predetermined level that opens the valve. The pneumatic charge therefore initially flows through the second outlet to direct the blast into the specimen chamber, until subsequent opening of the quick release valve redirects the gas flow out of the first outlet and rapidly reduces pressure in the chamber. The blast wave closely simulates the Friedlander curve, and its effects are viewed during instead of only after the blast is completed.",32,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01N/30
9222080,29-Dec-15,2015,12,29,"Alpha 1-3 N-galactosylstransferase with altered donor specificities, compositions and methods of use",The invention generally features compositions and methods based on the structure-based design of alpha 1-3 N-Acetylgalactosaminyltransferase (alpha 3 GalNAc-T) enzymes from alpha 1-3galactosyltransferase (a3Gal-T) that can transfer 2′-modified galactose from the corresponding UDP-derivatives due to substitutions that broaden the alpha 3Gal-T donor specificity and make the enzyme a3 GalNAc-T.,9,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/1051
9222142,29-Dec-15,2015,12,29,Adenoviruses and their use,"Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are described herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are described. Methods are described for detecting BaAdV-2/4 and BaAdV-3. Methods are also described for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided.",19,The Regents of the University of California,The United States of America as represented by the Secretary of the Department of Health and Human Services,Texas Biomedical Research Institute,,,,,,,,,3,Biotechnology,Analysis of biological materials,,,,,C12Q/701
9227979,5-Jan-16,2016,1,5,Fluorescent antagonists of the A3 adenosine receptor,"Disclosed are compounds of the formula (I) which are fluorescently labeled antagonists of the A3 adenosine receptor:wherein A, R1, R2, and Y are as described herein. Also disclosed are diagnostic compositions and a method of diagnosis of a patient for a possible treatment by an antagonist of the A3 adenosine receptor, involving the use of one or more of these compounds as diagnostic agents.",13,"The United States of America, as represented by The Secretary, Department of Health and Human Services",Universita Degli Studi Di Trieste,Universita Degli Studi Di Padova,,,,,,,,,3,Organic fine chemistry,,,,,,C07D/14
9228002,5-Jan-16,2016,1,5,Leishmania vaccine using sand fly salivary immunogen,"The present invention provides vectors that contain and express in vivo or in vitro sand fly Lu. longipalpis salivary antigens that elicit an immune response in animal or human against Leishmania, vaccine compositions comprising said vectors and/or Lu. longipalpis salivary polypeptides, methods of vaccination against Leishmania, and kits for use with such methods and compositions.",11,"MERIAL, INC.",The United States of America As Represented by The Secretary of the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/43577
9228171,5-Jan-16,2016,1,5,Regulatory B cells (tBREGS) and their use,"Regulatory B cells (tBreg) are disclosed herein. These regulatory B cells express CD25 (CD25+) a pan B cell marker such as B220 (B220+), and also express CD19 (CD19+). These regulatory B cells suppress resting and activated T cells in cell contact-dependent manner. Methods for generating these regulatory B cells are also disclosed herein, as are methods for using these regulatory B cells to produce regulatory T cells (Treg). In some embodiments, methods for treating an immune-mediated disorder, such as an autoimmune disease, transplant rejection, graft-versus-host disease or inflammation, are disclosed. These methods include increasing regulatory B cell number or activity and/or by administering autologous regulatory B cells. Methods for treating cancer are also disclosed herein. These methods include decreasing regulatory B cell activity and/or number.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0637
9233973,12-Jan-16,2016,1,12,Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same,"Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.",20,"The United States of America, as represented by The Secretary, Department of Health and Human Services","The Regents of the University of California, a California Corporation","Board of Regents, The University of Texas System",,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4741
9234244,12-Jan-16,2016,1,12,Diagnostic tool for diagnosing benign versus malignant thyroid lesions,The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.,6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The Johns Hopkins University,,,,,,,,,,2,Biotechnology,,,,,,C12Q/6886
9237741,19-Jan-16,2016,1,19,Methods and apparatus for surveillance and control of insect vectors,"Improved devices for the capture, detection, or quantification of insect vectors such as gravid female insects, are provided. The devices include surface coloration, design, and dimension that improved their ability to attract and/or capture target insect vectors. The traps are used in process for detection or control of insect vectors in indoor and outdoor environments.",16,,,,,,,,,,,,,Other special machines,,,,,,A01M/026
9238069,19-Jan-16,2016,1,19,Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment,"Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with a death receptor ligand, which method comprises contacting the cancer cells with a death receptor ligand in conjunction with an effective amount of a compound described herein, for example, a cucurbitacin (I) or a withanolide (II). Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with a compound described herein, for example, a cucurbitacin (I) or a withanolide (II) and also contacting the cancer cells with a death receptor ligand, whereby apoptosis is induced in the cancer cells.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
9238684,19-Jan-16,2016,1,19,SPANX-B polypeptides and their use,"It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
9238799,19-Jan-16,2016,1,19,Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses,"Disclosed herein are chimeric TBEV/DEN4 flaviviruses including a first nucleic acid molecule including a 5′ non-coding region (NCR) from a DEN4 virus, a nucleic acid encoding a C protein and non-structural proteins from a DEN4 virus, and a 3′ NCR from a DEN4 virus, wherein nonstructural protein NS4B includes a phenylalanine at amino acid position 112, nonstructural protein NS5 includes an alanine at amino acid position 654 and an alanine at amino acid position 655, and the 3′ NCR includes a deletion of nucleotides 10478-10507. The chimeric construct also includes a second nucleic acid molecule, which is operably linked to the first nucleic acid molecule, encoding a prM protein and an E protein from a TBEV, wherein the E protein includes an amino acid substitution that differs from the wild type TBEV at amino acid position 315 and a tryptophan at amino acid position 240. Also disclosed are methods of eliciting an immune response using the disclosed TBEV/DEN4 chimeric flaviviruses and immunogenic compositions including the disclosed chimeric flaviviruses and a pharmaceutically acceptable carrier.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
9238800,19-Jan-16,2016,1,19,Avian adenoassociated virus and uses thereof,"The present invention provides an Avian adeno-associated vims (AAAV) vims and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAAV vectors and particles. Methods of isolating the AAAV are provided.",7,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
9243036,26-Jan-16,2016,1,26,Anti-microbial activity of synthetic peptides,"Isolated synthetic peptides are disclosed that have anti-microbial activity against E. coli and P. aeruginosa. These isolated peptides can be used as anti-viral agents. The use of these peptides to treat infections with E. coli and P. aeruginosa and viruses are disclosed. The disclosed peptides are also of use for treating a biofilm, such as a biofilm on a medical device.",10,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Biotechnology,Medical technology,,,,C07K/08
9248179,2-Feb-16,2016,2,2,Pan-lyssavirus vaccines against rabies,"Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.",15,"The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/205
9249217,2-Feb-16,2016,2,2,Bispecific EGFRvIII x CD3 antibody engaging molecules,"We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific.",6,"Secretary, DHHS",Duke University,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/2809
9254319,9-Feb-16,2016,2,9,Compositions and methods for generating an immune response,"We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).",22,Emory University,The United States of America as represented by The Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/21
9255252,9-Feb-16,2016,2,9,Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae,"The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.",5,,,,,,,,,,,,,Biotechnology,Pharmaceuticals,,,,,A61K/12
9259463,16-Feb-16,2016,2,16,Chlamydia vaccine,"Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.",5,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/118
9259556,16-Feb-16,2016,2,16,MRI guidewire,"A guidewire (100) for use with interventional magnetic resonance imaging has a guidewire body (102) having a distal end and a proximal end and reserving a space therein, a dipole antenna (108) disposed in the space reserved within the guidewire body, the dipole antenna being adapted to be electrically connected to a signal processing system through a first signal channel (110) through the proximal end of the guidewire body, and a loop antenna (112) disposed in the space reserved within the guidewire body toward the distal end of the guidewire body, the loop antenna (112) being adapted to be electrically connected to the signal processing system through a second signal channel (114) through the proximal end of the guidewire body. The dipole antenna and the loop antenna are each constructed to receive magnetic resonance imaging signals independently of each other and to transmit received signals through the first and second signal channels, respectively, to be received by the signal processing system. An interventional magnetic resonance imaging system includes an active guidewire.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Measurement,,,,,A61M/09
9260746,16-Feb-16,2016,2,16,Photoinduced electron transfer (PET) primer for nucleic acid amplification,"This application provides photoinduced electron transfer (PET) nucleic acid molecules that can be used detect and amplify nucleic acid molecules, such as target nucleic acid molecules. These PET tags can be attached to the 5′-end of a target sequence-specific primer, thereby generating a PET primer. In particular examples, a PET tag includes a 5′-labeled nucleotide that can be quenched by at least two consecutive Gs within the tag sequence, and is unquenched when the PET tag hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using PET primers in nucleic acid amplification, such as real-time PCR.",9,"The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6876
9260758,16-Feb-16,2016,2,16,Cellular arrays and methods of detecting and using genetic disorder markers,"A method is disclosed for rapid molecular profiling of tissue or other cellular specimens by placing a donor specimen in an assigned location in a recipient array, providing copies of the array, and performing a different biological analysis of each copy. The results of the different biological analyses are compared to determine if there are correlations between the results of the different biological analyses at each assigned location. In some embodiments, the specimens may be tissue specimens from different tumors, which are subjected to multiple parallel molecular (including genetic and immunological) analyses. The results of the parallel analyses are then used to detect common molecular characteristics of the genetic disorder type, which can subsequently be used in the diagnosis or treatment of the disease. The biological characteristics of the tissue can be correlated with clinical or other information, to detect characteristics associated with the tissue, such as susceptibility or resistance to particular types of drug treatment. Other examples of suitable tissues which can be placed in the matrix include tissue from transgenic or model organisms, or cellular suspensions (such as cytological preparations or specimens of liquid malignancies or cell lines).",6,The United States of America as Represented by the Secretary of the Department of Health and Human Services,Abbott Molecular Inc.,,,,,,,,,,2,Biotechnology,Measurement,Analysis of biological materials,Chemical engineering,Optics,,C12Q/6886
9260762,16-Feb-16,2016,2,16,Real time PCR assay for detection of bacterial respiratory pathogens,"Methods for detecting Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp. are disclosed. A sample suspected of containing a nucleic acid of one or more of M. pneumoniae, C. pneumoniae, and Legionella spp. is screened for the presence or absence of that nucleic acid. Determining whether the M. pneumoniae, C. pneumoniae, or Legionella spp. nucleic acid is present in the sample can be accomplished by detecting hybridization between a M. pneumoniae probe (such as a CARDS toxin probe), a C. pneumoniae probe (such as a ArgR probe), or a Legionella spp. probe (such as a SsrA probe) and a nucleic acid in a sample. Also disclosed are probes and primers for the detection of M. pneumoniae, C. pneumoniae, and Legionella spp., and kits that contain the disclosed probes and/or primers.",11,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
9266928,23-Feb-16,2016,2,23,Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction,"Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions. Also disclosed are uses of these variant gp120 polypeptides and nucleic acids encoding variant polypeptides, such as to induce an immune response to HIV-1.",7,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
9266960,23-Feb-16,2016,2,23,Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer,"The disclosure provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.",2,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/32
9271833,1-Mar-16,2016,3,1,Transcatheter coronary sinus mitral valve annuloplasty procedure and coronary artery and myocardial protection device,A protective device or bridge comprising a central arch is suitable to be placed between an annuplasty device placed in the coronary sinus and an underlying coronary artery to inhibit transmission of compressive force on the coronary artery by the annuplasty device.,21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61F/2451
9272023,1-Mar-16,2016,3,1,"Use of ixolaris, a tissue factor inhibitor, for inhibiting angiogenesis","The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease. The invention also features kits.",10,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/57
9273089,1-Mar-16,2016,3,1,Composite probes and use thereof in super resolution methods,"Composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ) include a donor moiety and an acceptor moiety joined by a linker, wherein the acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activated quenching mechanisms and moieties could accomplish the same task by reducing donor population. Also disclosed are methods for irradiating a selected region of a target material including the composite probe, wherein the composite probe enables improved resolution by point spread function modification and/or nanoscale chemical reactions.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Basic materials chemistry,Measurement,Biotechnology,,,,C07K/00
9273121,1-Mar-16,2016,3,1,Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use,"Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.",19,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1081
9273124,1-Mar-16,2016,3,1,Monoclonal antibodies that react with the capsule of Bacillus anthracis,"The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.",15,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/1278
9273136,1-Mar-16,2016,3,1,Fully human anti-human NKG2D monoclonal antibodies,"The invention relates to isolated fully human monoclonal antibodies having specificity for human NKG2D and compositions thereof. The invention further relates to methods for using such antibodies in treating diseases or conditions such as cancer, autoimmune disease, or infectious disease.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/2851
9277748,8-Mar-16,2016,3,8,Agonist/antagonist compositions and methods of use,"The present invention relates to novel compositions comprising an agonist and an antagonist, in certain ratios which allow for the onset of agonist action followed quickly by alleviation by antagonist action, and methods of use in personal defense and law enforcement.",20,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Basic materials chemistry,Other special machines,,,,C06D/00
9278089,8-Mar-16,2016,3,8,Method of treating HCV infection with a small molecule CHK2 inhibitor,"A method of treating an Hepatitis C Virus infection in a patient, comprising providing a therapeutically effective amount, to a patient in need thereof, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: G1 is a group of the formula or where n is 0, 1, 2, 3, or 4 and Het is a 5- or 6-membered heteroaryl group containing 1 to 4 heteroatoms independently chosen from N, O, and S, which Het is optionally substituted.",23,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/4184
9278090,8-Mar-16,2016,3,8,Methods of preventing the development of mucositis and related disorders,"Disclosed is a method of preventing the development of mucositis in a subject undergoing radiation therapy or chemotherapy for a disease in need thereof comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor, such as rapamycin, to the subject. Further disclosed is a method of increasing the lifespan of a normal oral keratinocyte and/or reducing oxidative stress in a normal epithelial cell, wherein the method comprises administering an effective amount of an mTOR inhibitor to a subject undergoing radiation therapy or chemotherapy for a disease in need thereof.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/436
9279009,8-Mar-16,2016,3,8,FILIP1L nucleic acid fragments,"A purified DOC1 polypeptide comprising a fragment of SEQ ID NO:1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth.",9,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/4703
9279019,8-Mar-16,2016,3,8,Human monoclonal antibodies specific for CD22,"Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/2803
9279770,8-Mar-16,2016,3,8,Mid-infrared imaging of microarrays,"Described herein are methods for mid-infrared imaging of nucleic acid microarrays by employing mid-infrared reflective labels combined with detection in the reflection mode. The methods described herein provide intrinsic image contrast, and permit detection of DNA microarray hybridization on infrared absorbing substrates such as glass slides.",16,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,Measurement,,,,,G01N/75
9283233,15-Mar-16,2016,3,15,Method for on-demand contraception,"The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.",5,LABORATOIRE HRA-PHARMA,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/573
9284343,15-Mar-16,2016,3,15,"2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides","Disclosed are O-protected compounds of the formula (I):wherein B is an optionally protected nucleobase, and R1-R3 are as described herein, wherein at least one of R1-R3 is —CH2—O—N═CHR. The compounds are useful as intermediates in oligonucleotide synthesis. Also disclosed is a method of preparing the compounds from nucleosides via a process comprising conversion of a hydroxyl group to a methylthiomethoxy group, and a method of preparing oligonucleotides such as RNA starting from the compounds. The —CH2—O—N═CHR group is stable during oligonucleotide synthesis and can be easily removed after synthesis via, for example, treatment with a base.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07H/16
9284356,15-Mar-16,2016,3,15,Identification of a west nile virus CD4 T cell epitope and use thereof,"Described herein is the identification and of a potent West Nile virus (WNV) CD4 positive T cell epitope and its use for increasing the immunogenicity of heterologous flavivirus vaccines, such as dengue virus type 2 (DENV-2) DNA and virus-like particle (VLP) vaccines. Also described are methods for the identification of potent T cell epitopes to enhance immunogenicity of multivalent vaccines.",14,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
9284610,15-Mar-16,2016,3,15,Cellular arrays and methods of detecting and using genetic disorder markers,"A method is disclosed for rapid molecular profiling of tissue or other cellular specimens by placing a donor specimen in an assigned location in a recipient array, providing copies of the array, and performing a different biological analysis of each copy. The results of the different biological analyses are compared to determine if there are correlations between the results of the different biological analyses at each assigned location. In some embodiments, the specimens may be tissue specimens from different tumors, which are subjected to multiple parallel molecular (including genetic and immunological) analyses. The results of the parallel analyses are then used to detect common molecular characteristic of the genetic disorder type, which can subsequently be used in the diagnosis or treatment of the disease. The biological characteristics of the tissue can be correlated with clinical or other information, to detect characteristics associated with the tissue.",7,Abbott Molecular Inc.,,,,,,,,,,,1,Biotechnology,Measurement,Analysis of biological materials,Chemical engineering,Optics,,C12Q/6886
9290512,22-Mar-16,2016,3,22,Activators of human pyruvate kinase,"Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R1 to R16 are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia, Formulas (I); (II).",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/496
9296500,29-Mar-16,2016,3,29,Selective access to cryopreserved samples,"Methods and apparatus for selectively accessing a portion of a sterile cryopreserved sample are disclosed. The apparatus may include a container configured to receive the cryopreserved sample and having a first portion and a second portion, a heat sink chamber surrounding the first portion of the container, and a heat source adjacent to the second portion of the container. The chamber may be configured to maintain a non-accessed portion of the sample in a cryopreserved state. The heat source may be configured to separating an accessed portion of the sample from the non-accessed portion of the sample while maintaining the viability of the accessed portion while the non-accessed portion is maintained in the cryopreserved state.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services of the Office of Technology Transfer, National Institutes of Health",,,,,,,,,,,1,Other special machines,Basic materials chemistry,Handling,Medical technology,Measurement,,B65B/00
9296729,29-Mar-16,2016,3,29,Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists,"Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.",38,The United States of America as Represented by the Secretary of the Department of Health and Human Services,Forschungsverbund Berlin E.V.,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
9296790,29-Mar-16,2016,3,29,Methods and compositions for protein delivery,"The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
9303044,5-Apr-16,2016,4,5,"7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders","The present invention relates to compounds and compositions of Formula P useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of variables A, B, R2, R3, R4, Ra, Ra′, Rb, Rb′, Rc, Rd, Rd′, Re, and Re′ are provided in the disclosure. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.",20,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",THE ROCKEFELLER UNIVERSITY,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,,,,,,,,,3,Pharmaceuticals,Medical technology,Organic fine chemistry,,,,C07D/04
9303080,5-Apr-16,2016,4,5,Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells,"The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence comprising a codon optimized IL-15 sequence. The present invention further provides expression vectors, and IL-15 and IL 15 receptor alpha combinations (nucleic acid and protein) that increase IL-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of IL-15 after DNA, RNA or protein administration in a subject (e.g. a mammal, a human).",7,"The United States of America as Represented by the Secretary of the Department of Health and Human Services, National Institutes of Health",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/5443
9308163,12-Apr-16,2016,4,12,Methods of treating and preventing diseases and disorders of the central nervous system,"Disclosed is a method of treating or preventing a disease or disorder of the central nervous system (CNS) in a patient comprising administering transcranially, for example, directly to the skull, an effective amount of an anti-inflammatory agent to the patient. Examples of the anti-inflammatory agent include glutathione and inhibitors of purinergic receptors such as P2X4, P2X7, P2Y6, and P2Y12 receptors. Examples of disease or disorder of the CNS include brain injury, particularly traumatic brain injury, inflammation, infection, degeneration of brain cells, stroke, brain edema, tumor, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Also disclosed is a kit comprising at least one anti-inflammatory agent and printed materials containing instructions for transcranially administering the anti-inflammatory agent to the patient having a disease or disorder of the CNS, disorder of the CNS.",7,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
9309237,12-Apr-16,2016,4,12,HIV inhibitors,"Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses.",6,"NEW YORK BLOOD CENTER, INC.","THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/14
9309322,12-Apr-16,2016,4,12,Antibodies to tumor endothelial marker 8,"The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.",6,Scott & White Healthcare (SWH),,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/28
9309574,12-Apr-16,2016,4,12,Molecular cloning of HIV-1 from immortalized cell lines,"Disclosed is the molecular cloning of HTLV-III, the adult leukemia and acquired immune deficiency syndrome (AIDS) virus. Clone BH10 contains a 9.0 Kb viral insert constituting the entire HTLV-III genome. Clones BH8 and BH5 contain viral inserts of 5.5 Kb and 3.5 Kb, respectively. These clones are suitable for the development of diagnostic and therapeutic measures for AIDS, as well as use as probes for the detection of AIDS. By scientific convention, HTLV-III, referred to herein also as HIV, has been renamed as HIV-1.",161,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
9310366,12-Apr-16,2016,4,12,"Anthrax carbohydrates, synthesis and uses thereof","The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.",23,"University of Georgia Research Foundation, Inc.","The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,G01N/56911
9310367,12-Apr-16,2016,4,12,Compositions and methods for screening for lyme disease,"The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.",4,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/56911
9314448,19-Apr-16,2016,4,19,Method of inhibiting ABCG2 and other treatment methods,"Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I):wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/277
9314532,19-Apr-16,2016,4,19,Drug delivery vehicle,"The present disclosure provides targeted drug delivery vehicle compositions comprising a drug composition and targeted poly-amino-acid subunits, methods of manufacture, and methods of treatment for numerous diseases.",31,University of North Texas Health Science Center,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/42
9316646,19-Apr-16,2016,4,19,Anti-human ROR1 antibodies,"The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.",32,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,G01N/57492
9316824,19-Apr-16,2016,4,19,Optomechanical module for converting a microscope to provide selective plane illumination microscopy,A module for engagement with a conventional microscope to provide selective plane illumination microscopy is disclosed. The module is coupled to the translational base of the microscope and defines a mounting having a mount body in which an excitation objective having a first longitudinal axis is engaged to one portion of the mount body and a detection objective having a second longitudinal axis is engaged to another portion of the mount body such that the first longitudinal axis is in perpendicular geometric relation with the second longitudinal axis.,19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,,,,,,G02B/06
9320786,26-Apr-16,2016,4,26,Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria,"The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula (I): Q-Y—R1—R2 (I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula (I) in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/501
9321820,26-Apr-16,2016,4,26,Compositions and methods for treating bladder cancer,"The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the fusion protein is administered intravesically into the cancerous bladder.",7,The Regents of the University of Colorado,Scott & White Healthcare,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/485
9321834,26-Apr-16,2016,4,26,Anti-malarial compositions,"This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.",22,"LEIDOS, INC.","THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/205
9326950,3-May-16,2016,5,3,Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs,"The invention provides a method of handling a hydrophobic agent, which method comprises (a) combining in an aqueous solution (i) a hydrophobic agent and (ii) an isolated peptide that is a structural analog of a transmembrane domain of an integral membrane protein, wherein one terminus of the peptide has one or more negatively charged residues, and (b) allowing the peptide to self-assemble into nanoparticles, wherein the nanoparticles comprise the hydrophobic agent.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/5169
9326978,3-May-16,2016,5,3,A3 adenosine receptor allosteric modulators,"The claimed subject matter relates to allosteric modulation of A3 adenosine receptor (A3AR) and provides for the use of an A3 adenosine receptor modulator (A3RM), for the preparation of pharmaceutical compositions for modulating the A3AR in a subject, as well as pharmaceutical compositions including the same and therapeutic methods including administering to a subject an amount of an A3RM, the amount being effective to modulate A3AR activity. The A3RM according to claimed subject matter are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. Also provided are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.",6,"The United States of America, Represented by the Secretary, Dept. of Health and Human Services",Universiteit Leiden,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4745
9326992,3-May-16,2016,5,3,Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA,Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.,86,"Sarepta Therapeutics, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Maryland,,,,,,,,,3,Pharmaceuticals,Biotechnology,,,,,A61K/713
9328073,3-May-16,2016,5,3,"Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors","The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein RA, RD, W, X and Y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.",28,Purdue Research Foundation,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/18
9328142,3-May-16,2016,5,3,Lipopeptide inhibitors of RAS oncoproteins,"The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal α-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same.",22,"The United States of America, as represented by The Secretary, Department of Health and Human Services",Joseph Robert Kates,Yin Hwee Tan,Vanderbilt University,The Board of Trustees of the University of Illinois,,,,,,,5,Pharmaceuticals,Biotechnology,,,,,A61K/1709
9328391,3-May-16,2016,5,3,Cloning and expression of HIV-1 DNA,"The determination of the nucleotide sequence of HIV-1 DNA; identification, isolation and expression of HIV-1 DNA sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HIV-1.",22,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
9333251,10-May-16,2016,5,10,Vaccine for protection against Shigella sonnei disease,Compositions and methods for protecting a susceptible host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.,3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
9334522,10-May-16,2016,5,10,Agents and methods to elicit anti-tumor immune response,"The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.",11,THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK,THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12N/0638
9341619,17-May-16,2016,5,17,Hyposialylation disorders,"Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder. In additional embodiments, these methods can be used to determine the lowest effective dosage of the therapeutic agent of use to treat the subject.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Emory University,,,,,,,,,,2,Analysis of biological materials,Pharmaceuticals,,,,,G01N/5308
9345748,24-May-16,2016,5,24,Anti-SSX-2 T cell receptors and related materials and methods of use,"The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/1774
9345758,24-May-16,2016,5,24,Materials and methods for respiratory disease control in canines,The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.,39,"University of Florida Research Foundation, Inc.","The United States of America as represented by The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention","Cornell Research Foundation, Inc.",,,,,,,,,3,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/145
9346859,24-May-16,2016,5,24,Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes,"The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/21
9347935,24-May-16,2016,5,24,Mammalian sweet and amino acid heterodimeric taste receptors comprising T1R3 and T1R1,"The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising T1R3 and T1R1, two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.",13,The Regents of the University of California,"The United States of America as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Analysis of biological materials,Biotechnology,,,,,G01N/5076
9347951,24-May-16,2016,5,24,Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region,"This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections.",13,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH",,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,G01N/6854
9353117,31-May-16,2016,5,31,Substituted pyrazolopyrimidines as glucocerebrosidase activators,"Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I)in which variables R1-R7 and X are described in the application.",26,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/519
9353353,31-May-16,2016,5,31,Virus-like particles (VLPs) prepared from chikungunya virus structural proteins,"The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
9358285,7-Jun-16,2016,6,7,Granulysin in immunotherapy,"Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/39
9358306,7-Jun-16,2016,6,7,Photosensitizing antibody-fluorophore conjugates,"The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm−2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.",25,"The United States of America, as rep. by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/06
9359418,7-Jun-16,2016,6,7,Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use,"In T lymphocytes, p38 mitogen activated protein kinase (MAPK) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and DNA damage-inducible alpha (Gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in T cells. The disclosed Gadd45α polypeptides inhibit proliferation of T cells in response to T cell receptor stimulation, inhibit differentiation of T cells into Th1 or Th17 cells, inhibit the production of proinflammatory cytokines, and reduce tumor formation and growth of inflammatory cancers, such as pancreatic cancer.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/475
9359447,7-Jun-16,2016,6,7,Anti-mesothelin chimeric antigen receptors,"The invention provides a chimeric antigen receptor (CAR) (a) an antigen binding domain of HN1 or SS, a transmembrane domain, and an intracellular T cell signaling domain, or (b) an antigen binding domain of SS1, a transmembrane domain, an intracellular T cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor 2 leader. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/46
9364448,14-Jun-16,2016,6,14,Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation,"A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/122
9364557,14-Jun-16,2016,6,14,Fold-back diabody diphtheria toxin immunotoxin and methods of use,Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.,18,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",SCOTT AND WHITE HEALTHCARE,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/6829
9365612,14-Jun-16,2016,6,14,Caspase inhibitors,"A compound, or a pharmaceutically acceptable salt or ester thereof, of formula I:X—Wwherein X is a caspase-selective structure and W has the structure of—NH—CH(Y)(Z)wherein Y is a structure that can form a reversible covalent bond with a caspase; andZ is selected from a carboxyl moiety or a carboxylic acid mimetic.",16,"United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/06034
9365626,14-Jun-16,2016,6,14,Simukunin,"The present invention includes a novel protein, also referred to herein as simukunin, that inhibits the function of several physiologically important enzymes. Simukunin is a potent inhibitor of the blood coagulation cascade, inhibiting Factor Xa and functioning as an efficient anticoagulant. Simukunin also inhibits the serine proteases elastase and cathepsin and demonstrates anti-inflammatory properties. Also included are methods of making and using simukunin.",20,"University of Georgia Research Foundation, Inc.","The United States of America, as represented by the Secretary of the Dept. of Health & Human Services","Biology Centre CAS, v.v.i.",,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,C07K/435
9370559,21-Jun-16,2016,6,21,Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1,"Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.",12,"The United States of America, as represented by the Secretary, Department of Heath Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0011
9371357,21-Jun-16,2016,6,21,Inhibitors of viral integrase and methods of use,Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.,9,"Integratech Proteomics, LLC",National Institutes of Health,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,C07K/00
9371532,21-Jun-16,2016,6,21,Plasmids and phages for homologous recombination and methods of use,"Lambda phages that can be used to introduce recombineering functions into host cells are disclosed. Also disclosed are plasmids that can be used to confer recombineering functions to a variety of strains of E. coli and to other bacteria, including Salmonella, Pseudomonas, Cyanobacteria, Spirochaetes. These plasmids and phages can be isolated in vitro and can be used to transform bacterial cells, such as gram negative bacteria.",40,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/74
9375424,28-Jun-16,2016,6,28,Compounds that treat malaria and prevent malaria transmission,"The invention provides methods and compounds for the treatment and prevention of malaria infection and transmission in a mammal by administering compounds of the invention to a mammal having or suspected of having a malaria infection. The invention also provides pharmaceutical compositions that can kill or arrest the growth of Plasmodium organisms, and especially Plasmodium falciparum, thereby preventing or blocking transmission of malaria as well as treating malaria infection.",7,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4535
9382229,5-Jul-16,2016,7,5,Compounds and methods of use thereof for treating neurodegenerative disorders,"Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.",2,THE JOHNS HOPKINS UNIVERSITY,,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/12
9382302,5-Jul-16,2016,7,5,Lutzomyia longipalpis polypeptides and methods of use,"Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,Fundação Oswaldo Cruz (FIOCRUZ),,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/008
9382311,5-Jul-16,2016,7,5,HIV-1 broadly neutralizing antibodies,"The present application relates broadly neutralizing monoclonal antibodies directed against HIV-1. In particular, monoclonal antibodies VRC-PG04 and VRC-PG05 are disclosed.",8,INTERNATIONAL AIDS VACCINE INITIATIVE,THE SCRIPPS RESEARCH INSTITUTE,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,3,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/1063
9382592,5-Jul-16,2016,7,5,Primers and probes for detection and discrimination of types and subtypes of influenza viruses,"Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.",26,The United States of America as represented by the Secretary of the Department of,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
9383360,5-Jul-16,2016,7,5,Compositions and methods relating to lyme disease,"Compositions and methods of the present invention relating to B. burgdorferi HtrA sensu lato (BbHtrA) protease activity, its substrates, cleavage products, biological effects and use in detection, diagnosis and/or treatment of Lyme disease are provided.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/573
9387224,12-Jul-16,2016,7,12,Treatment of specific cardiovascular conditions with nitrite,"It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.",26,The United States of America as represented by the Secretary of the Department of Health and Human Services,Wake Forest University,Loma Linda University,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/00
9388211,12-Jul-16,2016,7,12,N-substituted indenoisoquinolines and syntheses thereof,"N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.",19,Purdue Research Foundation,NATIONAL INSTITUTES OF HEALTH (NIH),,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/005
9388221,12-Jul-16,2016,7,12,Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies,"The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide.",5,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",The Johns Hopkins University,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/01
9388222,12-Jul-16,2016,7,12,Modified Pseudomonas exotoxin A,"The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.",42,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Hoffman-La Roche Inc.,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/30
9389223,12-Jul-16,2016,7,12,Pharmacodynamic assays,The invention provides methods for quickly and easily screening mixed cell samples for a pharmacodynamic effect to a drug or test agent.,31,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/537
9394316,19-Jul-16,2016,7,19,Inhibitors of the plasmodial surface anion channel as antimalarials,"Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/553
9394352,19-Jul-16,2016,7,19,Immunogenic POTE peptides and methods of use,"POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/4748
9394358,19-Jul-16,2016,7,19,Gene signature for predicting prognosis of patients with solid tumors,"Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Methods of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes, and methods of treating a patient diagnosed with HCC or breast cancer by administering an agent that alters expression or activity of one or more of the disclosed tumor-associated genes, are described.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/18
9394364,19-Jul-16,2016,7,19,Human monoclonal antibodies specific for glypican-3 and use thereof,"Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/3076
9394574,19-Jul-16,2016,7,19,Methods for detecting Legionella nucleic acids in a sample,"Methods for detecting Legionella (such as Legionella spp., Legionella pneumophila, Legionella pneumophila serogroup 1, Legionella bozemanii, Legionella dumoffii, Legionella feeleii, Legionella longbeachae, and/or Legionella micdadei) are disclosed. A sample suspected of containing one or more Legionella nucleic acids is screened for the presence or absence of that nucleic acid. Determining whether Legionella nucleic acid is present in the sample can be accomplished by contacting the sample with detectably labeled probes capable of hybridizing to a Legionella nucleic acid and detecting hybridization between the probes and nucleic acids in the sample. Detection of hybridization indicates that a Legionella nucleic acid is present in the sample. Also disclosed are probes and primers for the detection of Legionella, and kits that contain the disclosed probes and/or primers.",6,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
9398892,26-Jul-16,2016,7,26,Device and method for a trackable ultrasound,"The invention provides a method for adjusting the calibration of a tracked ultrasound device using the measured difference between two sets of fiducial markings in two relative positions of a tracker and an scan head of the device. The invention also provides a trackable ultrasound device that enables repeatable attachment of a tracker to a scan head, thus preserving an initial calibration between the tracker and the scan head. Furthermore, the invention provides a calibration jig that can be used to repeatably attach a tracker to an ultrasound scan head or to measure the difference between two relative positions of a tracker and a scan head.",14,Koninklijke Philips N.V.,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Medical technology,,,,,,A61B/00
9399660,26-Jul-16,2016,7,26,N-substituted indenoisoquinolines and syntheses thereof,"N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.",20,Purdue Research Foundation,NATIONAL INSTITUTES OF HEALTH (NIH),,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/005
9399672,26-Jul-16,2016,7,26,Hepatitis C virus neutralizing antibody,A specific epitope on the surface of the hepatitis C virus that induces a neutralizing antibody response in vivo and neutralizing monoclonal antibodies that bind specifically to the epitope are disclosed. The antibodies block hepatitis C virus from infecting cells.,14,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/109
9402820,2-Aug-16,2016,8,2,Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors,"The identification of pO2 lowering agents as transient hypoxia-inducers is disclosed herein. Provided is a method of enhancing the efficacy of a hypoxia-sensitive agent in a subject, by administering to the subject a therapeutically effective amount of the hypoxia-sensitive agent and a therapeutically effective amount of a pO2 lowering agent. Methods of treating a subject with a tumor, by administering to the subject a therapeutically effective amount of a pO2 lowering agent and a therapeutically effective amount of a hypoxia-sensitive agent are also disclosed.",17,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES","H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/19
9402889,2-Aug-16,2016,8,2,"Live, oral vaccine for protection against Shigella dysenteriae serotype 1","The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/0283
9403763,2-Aug-16,2016,8,2,CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof,"Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.",21,,,,,,,,,,,,,Organic fine chemistry,,,,,,C07C/16
9403872,2-Aug-16,2016,8,2,Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors,"The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.",5,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Micro-structural and nano-technology,,,,C07K/06
9408901,9-Aug-16,2016,8,9,"Compositions, methods and uses for dengue virus serotype-4 constructs","Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.",27,"TAKEDA VACCINES, INC",THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH & HUMAN SERVICES,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/12
9409956,9-Aug-16,2016,8,9,Salmonella typhi Ty21a expressing Yersinia pestis  F1-V fusion protein and uses thereof,"Described herein is the generation of a plasmid construct for expression of a Yersinia pestis F1-V fusion protein. In the disclosed plasmid, the F1-V fusion protein coding sequence is operably linked to the E. coli htrA promoter, and is fused in-frame to the E. coli HlyA secretion signal sequence. Also described is Salmonella enterica serovar Typhi strain Ty21a containing the F1-V fusion protein expression plasmid, such as for use as an oral vaccine against plague.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/24
9409992,9-Aug-16,2016,8,9,Mesothelin domain-specific monoclonal antibodies and use thereof,"Described herein is the use of rabbit hybridoma technology, along with a panel of truncated mesothelin domain fragments, to identify anti-mesothelin mAbs that bind specific regions of mesothelin. In one aspect of the present disclosure, the rabbit mAbs bind an epitope that is not part of Region I. In particular, the identified mAbs (YP187, YP223, YP218 and YP3) bind either Region II (391-486), Region III (487-581) or a native conformation of mesothelin with subnanomolar affinity. These antibodies do not compete for binding with the mesothelin-specific immunotoxin SS1P or mesothelin-specific antibody MORAb-009. In another aspect, disclosed is a high-affinity rabbit mAb that binds Region I of mesothelin (YP158). YP158 binds native mesothelin protein in cancer cells and tissues with high affinity and specificity.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/3023
9409994,9-Aug-16,2016,8,9,High-affinity monoclonal antibodies to glypican-3 and use thereof,"Described herein is the identification of a panel of high affinity monoclonal antibodies that bind GPC3. The disclosed antibodies recognize native GPC3 on the surface of cancer cells, as well as soluble GPC3. The highest affinity antibody (YP7) was further characterized and shown to be highly sensitive in that it was capable of detecting cancer cells with low expression of GPC3. YP7 also exhibited significant HCC tumor growth inhibition in vivo. Immunotoxins comprising the antibodies disclosed herein fused to PE38 exhibited very high binding affinity for GPC3-expressing cells and significantly inhibited GPC3-expressing cancer cell growth. Thus, the high-affinity monoclonal antibodies disclosed herein can be used for the diagnosis and treatment of GPC3-expressing cancers.",33,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,Pharmaceuticals,,,,C07K/3069
9415099,16-Aug-16,2016,8,16,Method of altering the immundominance hierarchy of HIV gag by DNA vaccine expressing conserved regions,The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.,19,The United States of America as Represented by the Secretary of the Department of Health and Human Services,University of Washington through its Center for Commercialization,,,,,,,,,,2,Pharmaceuticals,Biotechnology,Medical technology,,,,A61K/21
9415105,16-Aug-16,2016,8,16,Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation,A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.,25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,,,,,A61K/39
9415116,16-Aug-16,2016,8,16,Compositions and methods for delivering inhibitory oligonucleotides,"The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.",14,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/713
9416190,16-Aug-16,2016,8,16,Mesothelin antibodies and methods for eliciting potent antitumor activity,"Described herein is the use of phage display antibody engineering technology and synthetic peptide screening to identify SD1 and SD2, human single-domain antibodies to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539-588) of human mesothelin close to the cell surface. SD2 binds full-length mesothelin. To investigate SD1 as a potential therapeutic agent, a recombinant human Fc (SD1-hFc) fusion protein was generated. The SD1-hFc protein exhibits strong complement-dependent cytotoxicity (CDC), in addition to antibody-dependent cellular cytotoxicity (ADCC), against mesothelin-expressing tumor cells. Furthermore, the SD1-hFc protein causes significant tumor growth inhibition of tumor xenografts in nude mice. SD1 and SD2 are the first human single-domain antibodies targeting mesothelin-expressing tumors.",28,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/30
9421250,23-Aug-16,2016,8,23,Pathogenic phlebovirus isolates and compositions and methods of use,"Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus Phlebovirus (family Bunyaviridae) with a proposed name of Heartland virus (HRTLV). Provided herein are nucleotide and amino acid sequences of the Phlebovirus isolates, primers and probes that specifically hybridize with the Phlebovirus isolates, and antibodies specific for the Phlebovirus proteins. Also provided are detection assays using the Phlebovirus nucleic acid molecules, proteins, probes, primers and antibodies. Further provided are recombinant Phleboviruses and their use for eliciting an immune response in a subject.",23,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Organic fine chemistry,Analysis of biological materials,,,A61K/12
9421254,23-Aug-16,2016,8,23,Immunostimulatory combinations of TLR ligands and methods of use,"The present invention provides immunostimulatory combinations of TLR ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/39
9422308,23-Aug-16,2016,8,23,Derivatives of docosahexaenoylethanolamide and uses thereof,"The invention provides derivatives of DEA which have increased potency and hydrolysis resistance as compared to DEA, and compositions thereof, as well as methods of using these derivatives to promote neurogenesis, neurite growth and/or length, and/or promote synaptogenesis.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/04
9427476,30-Aug-16,2016,8,30,Multivalent meningococcal conjugates and methods for preparing conjugates,"Disclosed herein are meningococcal immunogenic conjugates which can elicit immune responses against meningococcal polysaccharides (PS) from groups A, C, W-135, and Y and group B factor H binding protein (fHbp). The disclosed conjugates also exhibit bactericidal activity against meningococcal A, C, W-135, Y, B, and X serogroups. Also disclosed are improved methods for preparing conjugates, such as immunogenic conjugates, including activation of a polysaccharide with a cyanylation agent at about 4° C.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services","The United States of America, as Represented by the Secretary of the Army",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/095
9428541,30-Aug-16,2016,8,30,Substrate reduction therapy,The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.,3,"The United States of America, as represented by the Secretary, Department of Health and Human Services","The Chancellor, Masters, and Scholars of the University of Oxford",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,C07J/003
9428813,30-Aug-16,2016,8,30,"DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms","Disclosed herein are methods for detecting, diagnosing and/or prognosing a malignant adrenocortical tumor. Also disclosed are methods of treating a malignant adrenocortical tumor, such as ACC. In some examples, the method of diagnosing and/or prognosing includes obtaining a sample comprising genomic DNA from a subject at risk of acquiring or suspected to have an adrenocortical tumor; isolating genomic DNA from the sample; and measuring the level of one or more methylated genomic CpG dinucleotide sequences in one or more of the adrenocortical genomic targets in the sample, wherein an increase in the level of methylation of the one or more genomic CpG dinucleotide sequences in the sample compared to a control indicates a malignant adrenocortical tumor.",16,"The United States of America, as Represented by the Secretary, Dept. of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
9435000,6-Sep-16,2016,9,6,Primate T-lymphotropic viruses,"Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.",7,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",Johns Hopkins University,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12Q/701
9439935,13-Sep-16,2016,9,13,Recombinant rift valley fever (RVF) viruses and methods,"Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.",10,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
9439979,13-Sep-16,2016,9,13,Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction,"Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Biotechnology,,,,A61K/005
9441019,13-Sep-16,2016,9,13,Influenza hemagglutinin protein-based vaccines,Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.,21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/145
9441022,13-Sep-16,2016,9,13,Aegyptin and uses thereof,"The present invention relates to the discovery of the Aegyptin gene and Aegyptin protein, a molecule that interacts with collagen and inhibits platelet adhesion, activation and aggregation. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.",8,"The United States of America, as represented by the Secretary, Department of Health & Human Services",The Regents of the University of California,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/43563
9441041,13-Sep-16,2016,9,13,Use of antagonists of the interaction between HIV GP120 and α4β7 integrin,"Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4 integrin antagonist is a monoclonal antibody that specifically binds to a α4, β1 or β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.",12,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/2839
9441048,13-Sep-16,2016,9,13,"Antibody for 3′-isoLM1 and 3′,6′-iso-LD1 gangliosides","High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.",5,The United States of America as represented by the Secretary of Health and Human Services,Duke University,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/39558
9446048,20-Sep-16,2016,9,20,Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins,"A method for treating core binding factor (CBF) leukemia in a subject, comprising administering to a subject having CBF leukemia a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, that inhibits CBFβ and RUNX1 binding in the subject, thereby treating the CBF leukemia.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/5513
9447087,20-Sep-16,2016,9,20,Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders,"Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I).",13,UNIVERSITY OF UTAH RESEARCH FOUNDATION,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/517
9447144,20-Sep-16,2016,9,20,"MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1","The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/17
9448158,20-Sep-16,2016,9,20,Lightguides to simplify total emission detection for multiphoton microscopy,"Light collectors for fluorescence microscopy include slab light guides having a specimen volume such as a specimen well configured to retain a specimen. The specimen volume is bounded by a surface of the slab light guide that permits laterally propagating fluorescence to enter the slab light guide and propagate toward a detection or imaging system. Typically, the slab light guide has an elliptical perimeter and the sample volume is situated at a first focus of the elliptical perimeter. A reflector such as a conical reflector is situated at the second focus so as to direct the collected fluorescence to exit the slab light guide.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Optics,,,,,G01N/01
9449377,20-Sep-16,2016,9,20,Imaging methods and computer-readable media,"One aspect of the invention provides an imaging method including: (a) acquiring a first fluorescent image of an object of interest impregnated with fluorescent nanodiamonds; (b) applying a magnetic field to the fluorescent nanodiamonds in order to decrease fluorescence of the fluorescent nanodiamonds; (c) acquiring a second fluorescent image of the object of interest; and (d) subtracting the second fluorescent image from the first fluorescent image to produce a resulting image. Another aspect of the invention provides an imaging method including: (a) applying a time-varying magnetic field to an object of interest impregnated with fluorescent nanodiamonds to modulate the fluorescence of the fluorescent nanodiamonds; (b) acquiring a plurality of fluorescent images of the object of interest; and (c) for each corresponding pixel in the plurality of fluorescent images, calculating a fluorescence intensity using a lock-in technique.",12,The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Computer technology,Measurement,,,,,G06T/50
9452973,27-Sep-16,2016,9,27,Modulators of the relaxin receptor 1,"Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.",18,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES",THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/38
9453019,27-Sep-16,2016,9,27,Linked purine pterin HPPK inhibitors useful as antibacterial agents,"The disclosure provides linked purine pterin compounds and analogs thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula IThe variables, e.g. A1 to A3, R1 to R4, L1, L2, B1, and B2 are described herein. Compounds and salts of Formula I bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing an HPPK inhibitor of Formula I and methods of treating a bacterial infection in a patient by providing one or more HPPK inhibitors of Formula I to the patient are also provided. Processes and intermediates useful for preparing compounds of Formula I are also provided. Methods of using the disclosed compounds to guide the development of additional novel anti-bacterial agents are also provided.",3,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Organic fine chemistry,Computer technology,,,,,C07H/16
9453239,27-Sep-16,2016,9,27,"Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes","The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.",16,Emory University,"The Government of the United States of America, as represented by the Secretary Department of Health and Human Services, National Institutes of Health",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/86
9457132,4-Oct-16,2016,10,4,Controlled covalent attachment of bioactive bacteriophage for regulating biofilm development,"Medical devices that are resistant to biofilm development and methods of the manufacture of biofilm resistant medical devices are provided. One or more bacteriophages are tethered to the surface of a medical device or a hydrogei-type coating on the surface of the device by covalent bonding while maintaining bacteriophage infective or lytic activity. The presence of the bacteriophages on a medical device, such as an indwelling medical device, prevents biofilm formation or reduces existing biofilm formation on the surface of the device when in use. These devices address the long felt need for biofilm resistant devices that increase safety and reduce complications normally associated with prior indwelling or other medical devices.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Basic materials chemistry,,,,,A61L/106
9458141,4-Oct-16,2016,10,4,Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists,"Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.",7,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","Forschungsverbund Berlin, E.V.",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
9463233,11-Oct-16,2016,10,11,"Avirulent, immunogenic flavivirus chimeras",Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.,17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Mahidol University,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/12
9464035,11-Oct-16,2016,10,11,Salicylic acid derivatives useful as glucocerebrosidase activators,"Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.",11,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",THE UNIVERSITY OF KANSAS,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07C/64
9464324,11-Oct-16,2016,10,11,Methods of determining the prognosis of an adenocarcinoma,"Methods are disclosed for determining the prognosis of a subject with an adenocarcinoma in an organ, such as the lung. The methods can include quantitating expression of a plurality of cytokines of interest, such as IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ and TNF-a in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-γ and TNF-a in the adenocarcinoma as compared to a control and in non-cancerous tissue in the organ as compared to a control determines the prognosis for the subject. Methods for determining if a therapeutic agent is effective as an anti-cancer agent are also disclosed.",17,"The United States of America as represented by the Secretary, DHHS",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
9468208,18-Oct-16,2016,10,18,Disease control with tick phospholipase A2,"The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from A. americanum saliva effective in reducing the viability of gram positive, gram negative, or acid-fast bacteria and spirochetes including B. burgdorferi is administered. The inventive protein from A. americanum saliva has utility as a therapeutic for the treatment of an organism infected with bacteria, particularly the spirochete B. burgdorferi.",10,"University of Georgia Research Foundation, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Basic materials chemistry,Pharmaceuticals,Biotechnology,,,,A01N/46
9474793,25-Oct-16,2016,10,25,Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus,The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.,4,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/00
9474795,25-Oct-16,2016,10,25,Polysaccharide-protein conjugate vaccines,"Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/08
9474796,25-Oct-16,2016,10,25,Crimean-Congo hemorrhagic fever virus vaccine,"The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.",17,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","Colorado Seminary, which owns and operates the University of Denver",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/12
9475839,25-Oct-16,2016,10,25,Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling,"A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.",20,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/08
9475862,25-Oct-16,2016,10,25,Neutralizing GP41 antibodies and their use,"Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/1063
9476103,25-Oct-16,2016,10,25,Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs,"Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.",3,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
9476839,25-Oct-16,2016,10,25,Device and method for detection of counterfeit pharmaceuticals and/or drug packaging,"Featured are a device (20) and method for the detection of counterfeit pharmaceuticals and/or packaging therefore. Counterfeit pharmaceuticals are detected by visual inspection upon exposing a suspected counterfeit pharmaceutical to one or more light sources having different wavelengths, and observing the differences in color and/or brightness between the suspected counterfeit and a genuine pharmaceutical/packaging. In further embodiments, a image acquisition device acquires an image showing color and/or other visual effect(s) brightness of the suspect counterfeit and this image is compared to an image of a authentic pharmaceutical/packaging.",18,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Measurement,Computer technology,Analysis of biological materials,,,,G01N/95
9481866,1-Nov-16,2016,11,1,Methods of producing T cell populations enriched for stable regulatory T-cells,"The present invention provides methods for producing cell populations enriched for stable, regulatory T cells (Tregs). In particular, the invention relates to methods for culturing T cells such that the final culture is enriched for stable, regulatory T cells. It also relates to methods for stabilizing regulatory T cells. Also provided are compositions enriched for stable, regulatory T cells, which are useful for treating individuals in need of such treatment. The methods and compositions disclosed herein can also be used to treat an individual suffering from an immune-mediated disease.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/0637
9486502,8-Nov-16,2016,11,8,Methods of administering interferon gamma to absorb fluid from the subretinal space,Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space.,16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Pharmaceuticals,,,,,A61K/217
9486518,8-Nov-16,2016,11,8,Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine,"Disclosed herein are isolated immunogens including variant hepatitis B surface antigens (HBsAgs). In an example, a variant HBsAg includes a HBsAg with one or more transmembrane domains of the HBsAg replaced with a gp41 antigenic insert. The antigenic insert can include an antigenic polypeptide fragment of gp41 including the membrane proximal region of gp41 and a transmembrane membrane region of gp41. The replacement of a membrane spanning domain of HBsAg with a membrane spanning domain of gp41 anchors gp41 into HBsAg in virtually the identical orientation as on HIV virions and correctly orients the nearby MPR on the lipid layer. Thus, the disclosed variant HBsAgs display the neutralization-sensitive MPR in association with a lipid layer, while presenting it at the most immunogenic site on HBsAg. Also disclosed are uses of these variant HBsAgs, and nucleic acids encoding variant HBsAgs, such as to induce an immune response to HIV-1.",25,"The United States of America, as represented by the Secretary of the Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/292
9487563,8-Nov-16,2016,11,8,Virus-like particles and methods of use,"The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
9487573,8-Nov-16,2016,11,8,Murine anti-NY-ESO-1 T cell receptors,"The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/7051
9487832,8-Nov-16,2016,11,8,Selective detection of neisseria meningitidis,"A process for detecting Neisseria meningitidis nucleic acid in a sample is provided including producing an amplification product by amplifying Neisseria meningitidis nucleotide sequence of the sodC gene or mRNA using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and detecting the amplification product to detect Neisseria meningitidis in the sample. Also provided are reagents and methods for detecting and distinguishing Neisseria meningitidis from other infectious agents. A kit is provided for detecting and quantifying Neisseria meningitidis in a sample.",11,"The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
9492068,15-Nov-16,2016,11,15,Nasal aerosol delivery system,"A nasal delivery device can include a nasal prong and an activation member. The nasal prong can comprises an opening at a top and bottom portion of the prong to allow for the passage of an aerosolized treatment agent through the nasal prong. The activation member can be positioned on the nasal delivery device at a location that is spaced apart from the subject's oral cavity when the nasal prong is received into the nostril of the subject. The activation member can be configured to detect a desired exhalation state of the subject and upon detection of the desired exhalation state, the activation member activates the delivery of the aerosolized treatment agent.",41,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",CREARE LLC,,,,,,,,,,2,Medical technology,,,,,,A61B/233
9492405,15-Nov-16,2016,11,15,Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas,"This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogs for the treatment of a tumor expressing a β2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a β2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analog or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",SRI International,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/137
9492439,15-Nov-16,2016,11,15,Amido compounds as RORγt modulators and uses thereof,"Amido compounds are disclosed that have a formula represented by the following:and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.",30,New York University,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/55
9492499,15-Nov-16,2016,11,15,Peptides having anti-inflammatory properties,"Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.",26,"Riptide Bioscience, Inc.",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/08
9492564,15-Nov-16,2016,11,15,Dual specific immunotoxin for brain tumor therapy,"We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.",17,Duke University,"The United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/2863
9493842,15-Nov-16,2016,11,15,Use of GTF21 mutations in the prognosis of thymic cancers,Disclosed are methods of determining the prognosis of thymic cancer in a subject comprising detecting a mutation in the general transcription factor IIi (GTF2I) genetic sequence or protein. The presence of a GTF2I mutation indicates that the thymic cancer is indolent.,19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Medical technology,Analysis of biological materials,,,,C12Q/6886
9498511,22-Nov-16,2016,11,22,Methods related to the treatment of neurodegenerative and inflammatory conditions,"The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.",4,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
9498526,22-Nov-16,2016,11,22,Human rotavirus vaccine strains and diagnostics,"A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.",9,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/15
9499821,22-Nov-16,2016,11,22,"Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor","An embodiment of the invention provides a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/1137
9504729,29-Nov-16,2016,11,29,Antiangiogenic small molecules and methods of use,"Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/12
9506032,29-Nov-16,2016,11,29,Engineered biological pacemakers,"Biological pacemakers engineered to intrinsically generate rhythmic excitations are disclosed. In addition, methods of producing the biological pacemakers are disclosed. Methods of treating or preventing arrhythmia and heart disease associated with a defective pacemakers are also disclosed.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Pittsburgh—of The Commonwealth System of Higher Education,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/0657
9506041,29-Nov-16,2016,11,29,Delivery of packaged RNA to mammalian cells,"Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.",8,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
9506105,29-Nov-16,2016,11,29,Device and method for amplifying target nucleic acid,"A method for amplifying a target nucleic acid present in a sample includes introducing, via an entrance opening of a planar fluidic assembly, a sample containing one or more target nucleic acids into a flow channel of the planar fluidic assembly, the flow channel extending from the entrance opening to an exit vent and having a substantially uniform cross-section. A plurality of nucleic acid primers that are complementary to a portion of the one or more target nucleic acids are disposed at locations within and along the flow channel. The method further includes subjecting the sample introduced into the flow channel to a primer-based amplification reaction using the nucleic acid primers, wherein the primer-based amplification reaction produces amplified product of the one or more target nucleic acids, and retaining the amplified product at one or more of the locations within the flow channel during the primer-based amplification reaction. The method also includes detecting localized accumulation of the retained amplified product, the localized accumulation occurring at the one or more locations.",12,"APPLIED BIOSYSTEMS, LLC","UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Chemical engineering,Biotechnology,Chemical engineering,,,,C12Q/6806
9511103,6-Dec-16,2016,12,6,AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity,The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.,7,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Biotechnology,,,,A61K/76
9512429,6-Dec-16,2016,12,6,"Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer","The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression a Nanog pseudogene expressed in many human cancers, a replicating viral vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.",14,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
9517224,13-Dec-16,2016,12,13,Methods of treating patients infected with HIV and HTLV,"Disclosed is a method of activating protein kinase C theta (PKCθ) in an HIV or HTLV infected animal comprising administering to the animal an effective amount of a compound of formula (I): Formula (I), or an epimer thereof; wherein Ar and R1-R6 are described herein. Examples of diseases or conditions associated with PKCθ include HIV1 infection, AIDS, HTLV infection, and adult T cell leukemia/lymphoma.",20,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/35
9517243,13-Dec-16,2016,12,13,Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity,"β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The University of Birmingham of Edgbaston,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/7032
9518080,13-Dec-16,2016,12,13,Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties,"This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.",4,RESEARCH TRIANGLE INSTITUTE,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/0005
9522871,20-Dec-16,2016,12,20,"Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol analogues and their use in treating congestive heart failure","This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.",1,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/60
9522948,20-Dec-16,2016,12,20,GP100-specific T cell receptors and related materials and methods of use,"The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/70503
9522955,20-Dec-16,2016,12,20,Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer,"The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/2863
9526739,27-Dec-16,2016,12,27,Compositions and methods to treat cardiac diseases,"Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogues of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life in vivo due to the stability of the C—P bond. When administered to calsequestrin-overexpressing mice (a genetic model of heart failure) via a mini-osmotic pump (Alzet), some analogues significantly increased intact heart contractile function in vivo, as assessed by echocardiography-derived fractional shortening (FS) as compared to vehicle-infused mice. The range of carbocyclic nucleotide analogues for treatment of heart failure has been expanded.",13,UNIVERSITY OF CONNECTICUT,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/675
9526777,27-Dec-16,2016,12,27,Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein,"This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).",5,The United States of America as Represented by the Department of Health and Human Services,Glaxosmithkline Biologicals SA,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/86
9526794,27-Dec-16,2016,12,27,Injectable dendrimer hydrogel nanoparticles,"The invention discloses injectable hydrogels which are in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents and their methods of preparation. The said gel is formed by reaction of the PAMAM dendrimer with asymmetrical end groups with other polymer wherein the other polymer is selected from the group of linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel disclosed in the present invention is formed as small crosslinked particles in the size range 25 nm to 10 μm and is suitable for injectable delivery of hydrogel to any of the body orifices, tissues by intramuscular or subcutaneous route and ocular delivery for the purpose of therapeutic treatment and imaging.",11,Wayne State University,National Institutes of Health,,,,,,,,,,2,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/0019
9527903,27-Dec-16,2016,12,27,Engineered antibody constant domain molecules,"Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.",11,"The United States of America, as represent by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1063
9532989,3-Jan-17,2017,1,3,"Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines","The present invention relates to compounds of Formula P-Iwhere the variables (e.g. R1, Y, A, R1, Ra, Ra′, Rb, Rb′, Rc, Rc′, Rd, Rd′, Re, or Re′) and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.",12,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,THE ROCKEFELLER UNIVERSITY,,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,,,,,A61K/519
9533031,3-Jan-17,2017,1,3,Yeast-MUC1 immunotherapeutic compositions and uses thereof,"Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).",24,"GlobeImmune, Inc.","The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/00117
9534041,3-Jan-17,2017,1,3,Monoclonal antibodies that neutralize a norovirus,"Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Norwalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections.",29,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/10
9539220,10-Jan-17,2017,1,10,Methods for treating suicidal ideation,"Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).",9,Icahn School of Medicine at Mount Sinai,Yale University,"The United States of America, as represented by The Secretary, Department of Health and Human Services",,,,,,,,,3,Pharmaceuticals,Medical technology,,,,,A61K/135
9540415,10-Jan-17,2017,1,10,Inhibitors of the farnesoid X receptor and uses in medicine,"Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least Cone compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The Penn State Research Foundation,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/0061
9540427,10-Jan-17,2017,1,10,Peptide-based stat inhibitor,"A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT protein in a cell, a method of treating or preventing a disease associated with STAT overexpression in a host, and related compounds, compositions, and methods.",14,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/4705
9540471,10-Jan-17,2017,1,10,"Nitric oxide-releasing diazeniumdiolated polyvinylpyrrolidone-based polymers, and compositions, medical devices, and uses thereof","Disclosed is a nitric oxide-releasing polyvinylpyrrolidone-based polymer derived from N-vinylpyrrolidone monomer and at least one nitric oxide releasing N2O2− group, in which the N2O2− group is attached to a 2 pyrrolidinone group or a group derived therefrom in the N-vinylpyrrolidone monomer, and the polymer is optionally in combination with a substrate. The NO-releasing polymer can be part of a medical device or pharmaceutical composition and is useful for treating a biological disorder, such as healing a wound, restenosis, and/or promoting angiogenesis.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,"Macromolecular chemistry, polymers",Pharmaceuticals,,,,,C08F/10
9541822,10-Jan-17,2017,1,10,Radiographic marker that displays an angle in degrees on portable X-rays,"The present invention provides methods/techniques and apparatus for displaying an angulation of a cassette and thus a patient at a time when an x-ray image is taken to provide for a better comparison of day to day improvement of the patient. More specifically, the present invention, allows a movable object to roll freely within in a passageway within an enclosure in relation to an angulation of a cassette. In order to correlate the position of the movable object in the enclosure with the angle at which the cassette is currently placed, a plurality of markers are disposed in or protruded from the inner surface of the passageway. Based upon the position of the movable object in relation to a particular marker at the time an x-ray is taken, the user can identify the angulation at which the cassette is currently positioned.",21,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Optics,Measurement,,,,G03B/047
9545217,17-Jan-17,2017,1,17,Movement correction in MRI using a camera,"Provided are methods and systems for movement correction in an MRI environment. In one aspect, provided are systems and methods for movement correction, comprising receiving a first plurality of images from a first scan of a subject with a first camera, receiving magnetic resonance imaging (MRI) images obtained concurrently with the first scan, correlating the first plurality of images obtained from the first scan with the MRI images, resulting in motion correction data, and providing the motion correction data to an MRI system, wherein the MRI system adjusts scanning according to the motion correction data.",2,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Measurement,Measurement,,,,A61B/055
9546202,17-Jan-17,2017,1,17,Expression of IL-12 family heterodimers,"The present invention provides methods of improving the levels and stability of expression of interleukin-12 family cytokine polypeptides by expressing the alpha and beta subunits of the polypeptides at their determined relative molar ratios that increase the levels and stability of expression of the heterodimer, e.g., in comparison to heterodimer expressed at an equimolar ratio.",16,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/5434
9550742,24-Jan-17,2017,1,24,"11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists","The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia.",22,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/16
9550818,24-Jan-17,2017,1,24,Methods for use of vascular endothelial growth factor antagonists,The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.,6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/475
9555064,31-Jan-17,2017,1,31,Protease-deficient Bacillus anthracis,"The invention relates to a Bacillus anthracis (B. anthracis) in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield. The disclosure provides a B. anthracis that comprises a genetic modification that inactivates a protease of the M4 family of metalloproteases and a genetic modification that inactivates a protease of the M6 family of metalloproteases. Also provided is a modified B. anthracis comprising such genetic modification transformed with a recombinant molecule encoding a product, as well as methods to prepare and use such B. anthracis.",8,"The United States of America, as represented by the Secretary Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12R/07
9556254,31-Jan-17,2017,1,31,Cross-reactive antibodies against dengue virus and uses thereof,"The invention relates to a human anti-dengue virus antibody (an anti-DENV antibody) that binds to a DENV envelope protein and is cross-reactive with DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4. The disclosure provides an anti-DENV antibody that cross-reacts with and neutralizes all four DENV serotypes. Also provided is a nucleic acid molecule that encodes such an anti-DENV antibody. Also provided is a method to produce and use such an antibody or nucleic acid molecule encoding such an antibody.",10,,,,,,,,,,,,,Biotechnology,Analysis of biological materials,,,,,C07K/10
9562001,7-Feb-17,2017,2,7,Monoamine reuptake inhibitors,"The invention provides bupropion analog compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.",5,Research Triangle Institute,,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/16
9562237,7-Feb-17,2017,2,7,Reduction of TGF beta signaling in myeloid cells in the treatment of cancer,"Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,Other special machines,,,C12N/1138
9566329,14-Feb-17,2017,2,14,"Live, attenuated rubella vector to express vaccine antigens","Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) without an in-frame deletion, a rubella structural protein ORF, and a heterologous antigenic insert. In one example, the heterologous antigenic insert is positioned within the rubella structural protein ORF. In some examples, the heterologous antigenic insert is positioned in the rubella structural protein ORF in between a gene encoding structural protein E2 and a gene encoding structural protein E1. Exemplary antigenic inserts include HIV, SIV, RSV or hepatitis B surface antigens. In some examples, the HIV antigenic insert is a Gag antigenic insert, a gp41 antigenic insert or a gp120 antigenic insert. Also disclosed are uses of the isolated rubella viral vector, such as to induce an immune response to a particular virus, such as HIV-1, testing sensitivity to neutralizing antibodies, or screening antiviral drugs (such as protease inhibitors).",37,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/21
9567387,14-Feb-17,2017,2,14,T cell receptors and related materials and methods of use,"The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/70503
9567566,14-Feb-17,2017,2,14,HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants,"A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.",13,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/0639
9569483,14-Feb-17,2017,2,14,Personalized dynamic feedback control of body weight,"The present subject matter relates to a personalized weight management program incorporating dynamic feedback control using a validated mathematical model of metabolism and weight change. In general, the subject matter provides a system for repeated monitoring of one or more parameters such as, for example, body weight, physical activity, diet, eating behavior, or various other physiological and behavioral measurements, and using the parameter(s) to calculate an objective and personalized measure of adherence to a prescribed intervention, iteratively update mathematical model parameters, and adjust the prescribed intervention based on revised model predictions. Such a dynamic feedback control methodology can improve adherence to weight management interventions and result in greater weight loss and improved weight maintenance. The present subject matter also relates to a novel, cost-effective, weight management tool that could be widely disseminated through the internet and mobile computing platforms.",20,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH",,,,,,,,,,,1,Computer technology,,,,,,G06F/24
9579200,28-Feb-17,2017,2,28,Methods and devices for transcatheter cerclage annuloplasty,"Devices, apparatus, and methods for catheter-based repair of cardiac valves, including transcatheter-mitral-valve-cerclage annuloplasty and transcatheter-mitral-valve reapposition. In particular, a target and capture device is provided for guiding a cerclage traversal catheter system through a cerclage trajectory, particularly through a reentry site of the cerclage trajectory. The target and capture device provides the user with a target through which the cerclage traversal catheter system must be guided, particularly under imaging guidance, so as to properly traverse the cerclage trajectory at any desired location, particularly at a reentry site. The target and capture device can, further, ensnare and externalize the cerclage traversal catheter system.",16,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61F/2451
9579302,28-Feb-17,2017,2,28,Ketone bodies to protect tissues from damage by ionizing radiation,"Described herein is the surprising discovery that ketone bodies protect cell and tissues from ionizing radiation. Based on this finding, methods of protecting animal tissue and cells from damage caused by radiation exposure are disclosed which include, contacting the tissue with a therapeutically effective amount of an agent including at least one ketone ester, thereby protecting the tissue from radiation damage. Ketone esters can be used to minimize, reduce and/or prevent tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage.",22,TDELTAS,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/22
9579333,28-Feb-17,2017,2,28,Inhibition of HIV infection through chemoprophyalxis,A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.,17,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/675
9580492,28-Feb-17,2017,2,28,Monoclonal antibodies that neutralize anthrax toxins,"The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1278
9592207,14-Mar-17,2017,3,14,Intranasal administration of ketamine to treat depression,"Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).",15,Icahn School of Medicine at Mount Sinai,Yale University,"The United States of America, as represented by The Secretary, Department of Health and Human Services",,,,,,,,,3,Pharmaceuticals,Medical technology,,,,,A61K/135
9592304,14-Mar-17,2017,3,14,Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors,"Methods and compositions relating to anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as a Pseudomonas exotoxin or a detectable label. The invention provides diagnostic methods, and means to inhibit the growth of malignant B cells.",1,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/48561
9593136,14-Mar-17,2017,3,14,Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase,"In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or (II)",9,The George Washington University,George Mason University,"St. Jude Children's Research Hospital, Inc.","The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,4,Organic fine chemistry,Basic materials chemistry,Pharmaceuticals,Biotechnology,,,C07F/4021
9593385,14-Mar-17,2017,3,14,Selective detection of Haemophilus influenzae,A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.,9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
9598492,21-Mar-17,2017,3,21,Human monoclonal antibodies specific for CD22,"Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/2803
9598703,21-Mar-17,2017,3,21,"Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery","An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.",17,ASSOCIATION INSTITUT DE MYOLOGIE; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTÉ DE LAD RECHERCHE MÉDICALE,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/86
9603546,28-Mar-17,2017,3,28,Phantom for diffusion MRI imaging,A phantom calibration body (12) for calibrating diffusion MRI device (16) that mimics a material such as a mammalian tissue is disclosed. The phantom calibration body (12) includes a homogeneous aqueous solution (30) that contains a mixture of low molecular-weight and high molecular-weight polymers housed in a container (14) that is placed in the diffusion MRI device (16) for obtaining one or more diffusion MRI images of the phantom calibration body (12). A measure of diffusivity is calculated for each of the one or more diffusion MRI images in order to calibrate the diffusion MRI device. Methods of using the phantom calibration body (12) to calibrate diffusion MRI device (16) are also disclosed.,15,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Measurement,,,,,G01R/58
9605044,28-Mar-17,2017,3,28,Methods and compositions for modulating immune tolerance,"The instant invention provides methods and compositions for modulation of the immune system. Specifically, the invention provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.",21,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/465
9607392,28-Mar-17,2017,3,28,System and method of automatically detecting tissue abnormalities,"A method of automatically detecting tissue abnormalities in images of a region of interest of a subject includes obtaining first image data for the region of interest of the subject, normalizing the first image data based on statistical parameters derived from at least a portion of the first image data to provide first normalized image data, obtaining second image data for the region of interest of the subject, normalizing the second image data based on statistical parameters derived from at least a portion of the second image data to provide second normalized image data, processing the first and second normalized image data to provide resultant image data, and generating a probability map for the region of interest based on the resultant image data and a predefined statistical model. The probability map indicates the probability of at least a portion of an abnormality being present at locations within the region of interest.",27,The Johns Hopkins University,,,,,,,,,,,1,Computer technology,Medical technology,Measurement,Environmental technology,,,G06T/11
9610338,4-Apr-17,2017,4,4,Serologic correlates of protection against bacillus anthracis infection,Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.,8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/07
9616073,11-Apr-17,2017,4,11,Method for on-demand contraception,"The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.",4,Laboratoire HRA-Pharma,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/573
9616139,11-Apr-17,2017,4,11,Conjugating amines,The disclosure provides directly conjugated polysaccharide vaccine molecules and methods related thereto.,18,The General Hospital Corporation,"The United States, as represented by the secretary, Department of Health and Human Services","International Centre for Diarrhoeal Disease Research, Bangladesh",,,,,,,,,3,Pharmaceuticals,"Macromolecular chemistry, polymers",,,,,A61K/08
9617229,11-Apr-17,2017,4,11,Phenylmorpholines and analogues thereof,"Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neurotransmitter levels, such as pre-obesity, obesity, addiction, and depression.",21,Research Triangle Institute,"The United States of America, As Represented by the Secretary Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/30
9617599,11-Apr-17,2017,4,11,Method for detection of cancer based on spatial genome organization,"The invention provides methods of detecting abnormal cells in a sample using the radial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the radial position of one or more genes within the nucleus of a cell.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
9623020,18-Apr-17,2017,4,18,Thio compounds,"A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.",3,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/454
9623097,18-Apr-17,2017,4,18,Yeast-brachyury immunotherapeutic compositions,"Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.",20,"GlobeImmune, Inc.","The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Medical technology,Biotechnology,,,,A61K/0011
9624306,18-Apr-17,2017,4,18,Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer,"The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/32
9624475,18-Apr-17,2017,4,18,Genetically stable live attenuated respiratory syncytial virus vaccine and its production,"Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/155
9629816,25-Apr-17,2017,4,25,Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same,The invention provides methods of inhibiting the development or progression of a thioesterase deficiency disorder in a mammal by the administration of a compound that functionally mimics the enzymatic activity of all thioesterases in mammals. Such thioesterase deficiency disorders include cancers and adult- or infant-neuronal ceroid lipofuscinoses (NCLs). The invention also provides small molecule mimics of thioesterases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds and methods of using the same.,7,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/133
9629897,25-Apr-17,2017,4,25,Methods of producing and using regulatory B-cells,"The invention is directed to a method of preparing B-cells that produce interleukin-10 (IL-10), or IL-10 per se, which comprises contacting one or more B-cells ex vivo with an isolated interleukin-35 (IL-35) protein, and culturing the one or more B-cells under conditions to provide one or more B-cells that produce IL-10. The invention also is directed to a method of suppressing the proliferation of lymphocytes in vitro or in vivo by contacting lymphocytes with an isolated IL-35 protein. The invention further is directed to a method of suppressing autoimmunity in a mammal by administering to the mammal an IL-35 protein or IL-10-producing B-cells.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/20
9629899,25-Apr-17,2017,4,25,Targeted cargo protein combination therapy,The present invention combines a targeted cargo protein with an active agent for the treatment of a disease or condition.,4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/2026
9631192,25-Apr-17,2017,4,25,Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP),Auto-recognizing therapeutic R/DNA chimeric nanoparticles (R/DNA NP) are described that are pairs of DNA/RNA hybrids where the DNA molecules have complementary toehold sequences that promote the re-association of the R/DNA NPs when mixed resulting in the formation of RNA/RNA duplexes that act as siRNAs.,22,"The United States of America, as represented by the Secretary, Department of Health & Human Services",The Regents of the University of California,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/113
9631243,25-Apr-17,2017,4,25,Methods and compositions for identifying JC virus,"The disclosure relates to methods and compositions for detecting the presence of Prototype and/or Archetype JC virus in a biological sample from a subject. In some embodiments, the methods include amplifying and detecting a first nucleic acid sequence unique to Archetype JC virus in a biological sample, and a second nucleic acid sequence common to both Archetype and Prototype JC virus in the biological sample. In several embodiments, the methods can be used to identify JC virus in a biological sample from a subject at risk for progressive multifocal leukoencephalopathy. Compositions and kits for use in the disclosed methods are also provided.",19,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
9644037,9-May-17,2017,5,9,Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use,"Monoclonal antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 (pT1989 ATR), antigen binding fragments, conjugates thereof, and the use of these antibodies, antigen binding fragments and conjugates are disclosed herein. Also disclosed are nucleic acids encoding these antibodies, vectors including these antibodies, and isolated host cells transformed with these nucleic acids and vectors. Methods are also disclosed for using these antibodies, such as to detect pT1989 ATR, or to determine the dose of an agent of use to treat a subject. The antibodies are also of use for identifying ATR inhibitors.",40,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/40
9644179,9-May-17,2017,5,9,Use of PDL1 expressing cells to convert T cells into regulatory T cells,"The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases.",6,The Trustees of the University of Pennsylvania,"The United States of America, as Represented By The Secretary, Department of Health And Human Services",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/0637
9644216,9-May-17,2017,5,9,Adeno-associated virus vectors for treatment of glycogen storage disease,"The present disclosure describes improved adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia). Described are recombinant nucleic acid molecules, vectors and recombinant AAV that include a G6PC promoter/enhancer, a synthetic intron, a G6PC coding sequence (such as a wild-type or codon-optimized G6PC coding sequence), and stuffer nucleic acid sequence situated between the G6PC promoter/enhancer and the intron, as well as between the intron and the G6PC coding sequence. The recombinant AAVs disclosed herein exhibit highly efficient liver transduction and are capable of correcting metabolic abnormalities in an animal model of GSD-Ia.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services","University of Florida Research Foundation, Incorporated",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C12N/86
9649339,16-May-17,2017,5,16,LAT adapter molecule for enhanced T-cell signaling and method of use,"LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention further provides use for a LAT protein including mutations at ubiquitylation sites for therapeutic and laboratory methods.",18,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/17
9650352,16-May-17,2017,5,16,"Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain","The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.",22,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",COOPER HEALTH SYSTEM,SRI INTERNATIONAL,,,,,,,,,3,Organic fine chemistry,Pharmaceuticals,,,,,A61K/5375
9650422,16-May-17,2017,5,16,Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use,"Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.",18,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
9650685,16-May-17,2017,5,16,Selective detection of human rhinovirus,"A process for detecting human rhinovirus nucleic acid in a biological sample, includes producing an amplification product by amplifying an human bocavirus nucleotide sequence using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and measuring said amplification product to detect human rhinovirus in said biological sample. Also provided are reagents and methods for detecting and distinguishing human rhinovirus from other viruses. A kit is provided for detecting and quantifying human rhinovirus in a biological sample.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
9655595,23-May-17,2017,5,23,"System, method and device for prostate diagnosis and intervention","Methods, systems, and devices for assisting or performing an image-guided prostate procedure are disclosed. A needle assembly includes a needle guide, a needle device, a position sensor and additional features. The position sensor allows for the tracking of the needle assembly. A method for performing image-guided prostate procedures includes pre-operative procedures and intra-operative procedures. The pre-operative procedures include imaging studies to model the prostate and identify targets. The pre-operative procedures models are used during a prostate procedure to track the target and the devices used for the procedure. A system for performing image-guided procedures includes the needle assembly and other components.",24,Arcitrax Inc.,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,2,Medical technology,,,,,,A61B/0241
9657066,23-May-17,2017,5,23,Pseudomonas exotoxin A with less immunogenic B cell epitopes,"The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/164
9657096,23-May-17,2017,5,23,Human domain antibodies against components of the human insulin-like growth factor (IGF) system,"Antibodies and antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as methods of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer, are described. A method of detecting the presence of IGF-1R or IGF-2 in a sample using the disclosed antibodies and antibody fragments is also described.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/22
9657269,23-May-17,2017,5,23,Regulatory B cells (tBREGS) and their use,"Regulatory B cells (tBreg) are disclosed herein. These regulatory B cells express CD25 (CD25+) a pan B cell marker such as B220 (B220+), and also express CD19 (CD19+). These regulatory B cells suppress resting and activated T cells in cell contact-dependent manner. Methods for generating these regulatory B cells are also disclosed herein, as are methods for using these regulatory B cells to produce regulatory T cells (Treg). In some embodiments, methods for treating an immune-mediated disorder, such as an autoimmune disease, transplant rejection, graft-versus-host disease or inflammation, are disclosed. These methods include increasing regulatory B cell number or activity and/or by administering autologous regulatory B cells. Methods for treating cancer are also disclosed herein. These methods include decreasing regulatory B cell activity and/or number.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0637
9657292,23-May-17,2017,5,23,Compositions and methods for treating or preventing lupus,"The invention features compositions comprising agents that inhibit or reduce self-reactive IgE and/or basophils, and related methods of using the compositions for treating or preventing lupus, lupus nephritis, and lupus-related disorders.",19,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/11
9657361,23-May-17,2017,5,23,Broad detection of dengue virus serotypes,Processes for detecting Dengue virus (DENV) nucleic acid in a sample are provided including producing an amplification product by amplifying DENV nucleotide sequence and detection of an amplification by hybridization of a probe or other technique. The processes use primers or probes with introduced mutations and or degenerate bases that provide excellent superiority in detection and serotyping of DENV in a sample.,1,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12Q/701
9658233,23-May-17,2017,5,23,Assay to measure midkine or pleiotrophin level for diagnosing a growth,"The invention provides methods and kits for diagnosing a growth in a subject by providing a sample of a growth taken from a subject, determining the level of midkine or pleiotrophin in the sample by an immunoassay, and comparing the level of midkine or pleiotrophin determined from the sample with a control. An increased level of midkine or pleiotrophin in the sample as compared to the control is diagnostic of a malignant growth, whereas an equivalent or decreased level of midkine or pleiotrophin in the sample as compared to the control is diagnostic of a benign growth.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Medical technology,,,,,G01N/57407
9663485,30-May-17,2017,5,30,Tocopherol and tocopheryl quinone derivatives as correctors of Lysosomal Storage Disorders,"The subject invention relates to improved tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorders, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.",17,"The United States of America, As Presented by The Scretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/58
9663521,30-May-17,2017,5,30,Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis,"The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Kansas,Northwestern University,,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,,,,,C07D/04
9663812,30-May-17,2017,5,30,Adapter for suspending a cryovial over a centrifuge tube,"A system is disclosed for thawing a frozen specimen that includes a cryovial containing a frozen specimen, a centrifuge tube containing a medium, and an adaptor for suspending the cryovial over the centrifuge tube in an inverted position, wherein the adaptor has an elongated tubular body defining opposed proximal and distal ends, and it has an axial bore extending from the distal end thereof to the proximal end thereof to define an outer periphery and an inner periphery, and wherein the outer periphery is dimensioned for insertion into the centrifuge tube and the inner periphery is dimensioned to receive the cryovial in an inverted position.",12,"The United Stated of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,Chemical engineering,,,,C12Q/02
9664682,30-May-17,2017,5,30,Assay to measure midkine or pleiotrophin level for diagnosing a growth,"The invention provides methods and kits for diagnosing a growth in a subject by providing a sample of a growth taken from a subject, determining the level of midkine or pleiotrophin in the sample by an immunoassay, and comparing the level of midkine or pleiotrophin determined from the sample with a control. An increased level of midkine or pleiotrophin in the sample as compared to the control is diagnostic of a malignant growth, whereas an equivalent or decreased level of midkine or pleiotrophin in the sample as compared to the control is diagnostic of a benign growth. Growth refers to, for example, papillary thyroid cancer (PTC).",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Medical technology,,,,,G01N/57407
9669345,6-Jun-17,2017,6,6,Systems and methods for controlling particulate release from large equipment,"A containment system for reducing the release of harmful respirable particles through surface openings in equipment that carries sand includes a filter-receiving member configured to be coupled over an opening in a surface of the equipment and a filter member configured to be coupled to the filter-receiving member. The filter-receiving member can have a first side, a second side, and a passageway extending from the first side to the second side. The filter can have a porosity that permits air to flow through the filter member and restricts the flow of solid particulates.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Environmental technology,,,,,,B01D/02
9670447,6-Jun-17,2017,6,6,Microfabricated polymeric vessel mimetics,"The present disclosure is directed to embodiments of microstructured membranes, methods of fabricating microstructured membranes, bioreactors housing microstructured membranes, and methods of using bioreactors and microstructured membranes. In some embodiments, the present disclosure allows culturing of cellular tissues in an environment which more accurately resembles a native environment. In some more specific embodiments, the present disclosure allows culturing of tumor cells on a membrane having a microfabricated pattern which mimics a native vasculature system.",33,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Other special machines,,,,,C12M/02
9670549,6-Jun-17,2017,6,6,Gene expression signatures of neoplasm responsiveness to therapy,"Gene signatures for determining whether a neoplasm (such as a multiple myeloma neoplasm) is sensitive to mTORi/HDACi combination therapy and/or for determining the prognosis of a neoplasm in a subject are described. Some embodiments include determining whether a neoplasm is sensitive to mTORi/HDACi combination therapy by predicting whether mTORi/HDACi combination therapy will successfully treat the neoplasm, for example increasing survival of the subject with the neoplasm. In some embodiments, determining the prognosis includes predicting the outcome (such as chance of survival) of the subject with a neoplasm. Also disclosed are reagents, for example arrays, for use with the disclosed methods, as well as computer implementation of the disclosed methods.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,Computer technology,,,C12Q/6886
9675637,13-Jun-17,2017,6,13,Use of nitrite salts for the treatment of cardiovascular conditions,"It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.",16,The United States of America as represented by the Secretary of the Department of Health and Human Services,"The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting through Louisiana State University Health Sciences Center",The UAB Research Foundation,Loma Linda University,Wake Forest University,,,,,,,5,Pharmaceuticals,,,,,,A61K/00
9676771,13-Jun-17,2017,6,13,Compounds for inhibiting drug-resistant strains of HIV-1 integrase,"A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of:wherein X is N, C(OH), or CH;Y is H or OH;each of Z1-Z5 is independently H or halogen;R4 is H, OH, NH2, NHR8, NR8R9 or R8;R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; andR8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen to which R8 and R9 are attached form an optionally-substituted heterocycle.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,C07D/04
9676788,13-Jun-17,2017,6,13,Aza-epoxy-guaiane derivatives and treatment of cancer,"Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).",20,"The United States of America, as represented by the Secretary of Health and Human Services",University of Hawaii,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,C07D/08
9676846,13-Jun-17,2017,6,13,Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II,"Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.",28,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,C07K/22
9676857,13-Jun-17,2017,6,13,Soluble engineered monomeric Fc,"Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/283
9676858,13-Jun-17,2017,6,13,Human bispecific EGFRvIII antibody and CD3 engaging molecules,"We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These may be used as therapeutic agents.",7,Duke University,"The United States of America as represented by the secretary, Department of Health and Human Services (NIH)",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/2863
9678074,13-Jun-17,2017,6,13,"Interferon-λ4 (IFNL4) protein, related nucleic acid molecules, and uses thereof",The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.,5,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/56983
9682088,20-Jun-17,2017,6,20,Method for treating uterine fibroids,"The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.",9,LABORATOIRE HRA-PHARMA,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/57
9682107,20-Jun-17,2017,6,20,Postnatal stem cells and uses thereof,"The invention generally relates to postnatal dental stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal dental pulp stem cells, use of the cells to generate dentin, and differentiation of the cells. In another aspect, the invention relates to human postnatal deciduous dental pulp multipotent stem cells, use of the cells to generate dentin, and differentiation of the cells.",18,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/30
9682983,20-Jun-17,2017,6,20,BMP inhibitors and methods of use thereof,"The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.",19,"The Brigham and Women's Hospital, Inc.","Dept. of Health and Human Services, National Institutes of Health",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
9683263,20-Jun-17,2017,6,20,Detection and treatment of irritable bowel syndrome,"Methods are disclosed herein for identifying a subject with irritable bowel syndrome (IBS). Methods are also disclosed for determining if an agent is effective for the treatment or prevention of IBS. Methods of treating a subject with IBS, such as a subject identified using the disclosed methods, are also provided.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12Q/6883
9683269,20-Jun-17,2017,6,20,Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof,"The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.",13,Hvidovre Hospital,"The United States of America, As Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12Q/18
9687542,27-Jun-17,2017,6,27,Rift valley fever virus replicon particles and use thereof,"Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRPRVF) vaccine candidate. VRPRVF can actively synthesize viral RNA and proteins, but lack structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. Is it disclosed herein that VRPRVF immunization is both safe and efficacious, resulting in a robust immune response that is protective against RVF virus challenge within 24 hours of immunization. Provided herein are VRPRVF, methods of producing VRPRVF, and method of using VRPRVF for immunization against RVF virus infection.",13,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/12
9688739,27-Jun-17,2017,6,27,T cell receptors and related materials and methods of use,"The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/70503
9695230,4-Jul-17,2017,7,4,Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein,"Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.",41,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,C07K/1063
9696534,4-Jul-17,2017,7,4,Multi-focal structured illumination microscopy systems and methods,"A multi-focal selective illumination microscopy (SIM) system for generating multi-focal patterns of a sample is disclosed. The multi-focal SIM system performs a focusing, scaling and summing operation on each multi-focal pattern in a sequence of multi-focal patterns that completely scan the sample to produce a high resolution composite image.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,Measurement,,,,,G02B/0072
9700578,11-Jul-17,2017,7,11,Use of nitrite salts for the treatment of cardiovascular conditions,"It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,"The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Acting through the Louisiana State University Health Sciences Center",The UAB Research Foundation,Loma Linda University,Wake Forest University,,,,,,,5,Pharmaceuticals,,,,,,A61K/00
9701718,11-Jul-17,2017,7,11,Adenovirus serotype 26 and serotype 35 filovirus vaccines,Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.,15,Janssen Vaccines & Prevention B.V.,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTE OF HEALTH",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/005
9707220,18-Jul-17,2017,7,18,Scopolamine for the treatment of depression and anxiety,"Provided are methods and compositions for the treatment of depression and anxiety. The compositions contain scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler containing scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/46
9707230,18-Jul-17,2017,7,18,Activators of human pyruvate kinase,"Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R1 to R16 are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia,",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/496
9707287,18-Jul-17,2017,7,18,Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein,"The invention features novel attenuated dengue virus mutants and compositions thereof. The invention further features an attenuated dengue virus comprising a proline to leucine change at amino acid position 2343 of non-structural protein 4B (NS4B), wherein the numbering is based upon the prototypic isolate DEN4 Dominica 1981 and the attenuated mutant DEN virus has at least one of the following properties: improved replication in Vero cells or restricted replication in mosquito cells.",17,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
9708267,18-Jul-17,2017,7,18,Activators of human pyruvate kinase,"Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer. A1-NR-L-A2(I).",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/227
9708392,18-Jul-17,2017,7,18,Monoclonal antibodies against orthopoxviruses,"The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/081
9714409,25-Jul-17,2017,7,25,Use of argon as a tissue fixation preservative,"The invention may be broadly defined as the addition of Argon to FFPE procedures as an RNA stabilizing agent. Argon is an inert gas from the Noble gas group with low saturation concentrations in water. It is therefore highly surprising that Argon would have any effect on RNA stability in the presence of Formalin, or any other chemical. This property of Argon appears to be specific in that other inert gases fail to show any RNA stabilizing effect.",17,"American Air Liquide, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Basic materials chemistry,,,,,C12N/04
9717752,1-Aug-17,2017,8,1,Uses of antagonists of hyaluronan signaling,"Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Duke University,The University of North Carolina at Chapel Hill,,,,,,,,,3,Pharmaceuticals,,,,,,A61K/728
9717946,1-Aug-17,2017,8,1,Systems and methods for training and imaging an animal in an awaken state,"Systems for training an animal, such as a rodent, to maintain its head substantially motionless during an imaging procedure using an imaging and training system are disclosed. In some embodiments, the imaging and training system includes a frame defining an enclosure for enclosing an animal therein during the imaging procedure. The frame includes a head post that is attached to the head of the animal and a treadmill having a plurality of rollers that the animal is in operative contact such that one or more of the plurality of wheels rotate when the animal is in a walking motion and stop rotating when the animal is in a substantially motionless state. This arrangement trains the animal to remain substantially motionless when disposed within an imaging apparatus.",15,,,,,,,,,,,,,"Furniture, games",Medical technology,,,,,A63B/02
9719080,1-Aug-17,2017,8,1,Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA),"Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/52
9719084,1-Aug-17,2017,8,1,Co-transcriptional assembly of modified RNA nanoparticles,A method is provided for generating RNA nanoparticles having modified nucleotides and/or having increased nuclease resistance where the RNA nanoparticles are formed cotranscriptionally by T7 RNA polymerase in the presence of manganese ions.,10,"The United States of America, as represented by the Secretary, Department of Health & Human Services",The Regents of the University of California,,,,,,,,,,2,Biotechnology,,,,,,C12N/111
9725492,8-Aug-17,2017,8,8,Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells,"The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-15 sequence.The present invention further provides expression vectors, and IL-15 and IL-15 receptor alpha combinations (nucleic acid and protein) that increase IL-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of IL-15 after DNA, RNA or protein administration in a subject (e.g. a mammal, a human).",21,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/5443
9725494,8-Aug-17,2017,8,8,Soluble CD27 (sCD27) and the use thereof,"Disclosed are methods of diagnosing a subject as having a solid tumor or a predisposition to developing a solid tumor. The methods include detecting or quantitating the amount of sCD27 in a serum sample obtained from a subject and comparing that amount of sCD27 with a control value indicative of the basal level of sCD27 present in the serum of a subject that does not have a solid tumor or a predisposition to developing a solid tumor, wherein a reduction of the amount of sCD27 relative to the control value indicates that the subject has the solid tumor or the predisposition to developing the solid tumor. The disclosed methods can be used to monitoring disease progression in a subject or determine a subject's suitability for immunotherapy. Also disclosed are methods of stimulating a subject's immune system by administering a therapeutically effective amount of sCD27 or a functional fragment.",18,"United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/70503
9730941,15-Aug-17,2017,8,15,Methods and compositions for the inhibition of Pin1,"The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.",3,"Beth Israel Deaconess Medical Center, Inc.","The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/5377
9730993,15-Aug-17,2017,8,15,Engineered anthrax lethal toxin for targeted delivery,"The present invention provides methods and systems for targeted delivery of a compound to a target cell that over-expresses two different proteinases. Specifically, two different modified protective antigen proteins, each comprising a cleavage site recognized by a distinct proteinase in place of the native proteinase cleavage site recognized by furin, are administered in combination with a compound that contains a protective antigen binding site. Upon cleavage by the two proteinases the two modified protective antigen proteins form a hetero-oligomer, allowing the compound to bind to the hetero-oligomer and subsequently to be translocated into the target cell.",34,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/07
9732337,15-Aug-17,2017,8,15,RNA nanoparticles and nanotubes,The instant invention provides polyvalent RNA nanoparticles comprising RNA motifs as building blocks that can form RNA nanotubes. The polyvalent RNA nanoparticles are suitable for therapeutic or diagnostic use in a number of diseases or disorders.,19,"The United Stated of America, as represented by the Secretary, Department of Health & Human Services",The Regents of the University of California,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Micro-structural and nano-technology,,,,C12N/11
9732359,15-Aug-17,2017,8,15,Replication-competent adenoviral vectors,"This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Istituto Superiore di Sanita,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/21
9734573,15-Aug-17,2017,8,15,Methods and systems for automatically determining magnetic field inversion time of a tissue species,"A computer-implemented method for determining magnetic field inversion time of a tissue species includes generating a T1-mapping image of a tissue of interest, the T1-mapping image comprising a plurality of T1 values within an expected range of T1 values for the tissue of interest. An image mask is created based on predetermined identification information about the tissue of interest. Next, an updated image mask is created based on a largest connected region in the image mask. The updated image mask is applied to the T1-mapping image to yield a masked image. Then, a mean relaxation time value is determined for the largest connected region. The mean relaxation time value is then used to determine a time point for nulling longitudinal magnetization.",14,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",Siemens Healthcare GmbH,,,,,,,,,,2,Computer technology,,,,,,G06T/0012
9738689,22-Aug-17,2017,8,22,Prefusion RSV F proteins and their use,"Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.",42,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
9738703,22-Aug-17,2017,8,22,Neutralizing antibodies to HIV-1 and their use,"Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Washington,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/1063
9738726,22-Aug-17,2017,8,22,HER2-specific monoclonal antibodies and conjugates thereof,"The identification of Her2-specific monoclonal antibody m860 is described. The m860 antibody was identified from a human naïve phage display Fab library by panning against the extracellular domain of human Her2. M860 binds to cell surface-associated Her2 with an affinity comparable to that of trastuzumab (Herceptin®), but binds to a different epitope. Using site-specific glycan engineering, m860 was conjugated to the small molecule drug auristatin F. The antibody-drug conjugate was stable, bound cell-surface expressed Her2 and exhibited potent cell killing of Her2-positive cancer cells, including trastuzumab-resistant breast cancer cells.",32,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/32
9750793,5-Sep-17,2017,9,5,Multifunctional oral vaccine based on chromosome recombineering,"A recombineered Salmonella typhi Ty21a, compositions and vaccines comprising such a Ty21a, and a method for recombineering comprising inserting a large antigenic region into a bacterial chromosome for the purpose of making multivalent vaccines to protect against one or more disease agents are described herein.",22,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0283
9751931,5-Sep-17,2017,9,5,Hepatitis C virus neutralizing antibodies and methods,Novel epitope regions on hepatitis C virus E1E2 glycoprotein that induce a neutralizing antibody response in vivo are identified. Cross-neutralizing monoclonal antibodies that bind specifically to the epitopes are disclosed.,13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”,,,,,,,,,,2,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/109
9758586,12-Sep-17,2017,9,12,Chimeric rabbit/human ROR1 antibodies,"The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/2869
9764022,19-Sep-17,2017,9,19,Methods and compositions for inhibiting polyomavirus-associated pathology,"Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies.",25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/12
9765031,19-Sep-17,2017,9,19,Cannabinoid receptor mediating compounds,"A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.",32,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/06
9765063,19-Sep-17,2017,9,19,Amido compounds as RORγt modulators and uses thereof,"Amido compounds are disclosed that have a formula represented by the following:and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.",13,New York University,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,C07D/06
9765123,19-Sep-17,2017,9,19,Pseudomonas exotoxin a with less immunogenic T cell and/or B cell epitopes,"The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/21
9765142,19-Sep-17,2017,9,19,TEM8 antibodies and their use in treatment and detection of tumors,"Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.",49,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","Biomed Valley Discoveries, Inc.",,,,,,,,,,2,Pharmaceuticals,Biotechnology,Analysis of biological materials,Organic fine chemistry,,,C07K/28
9765342,19-Sep-17,2017,9,19,Chimeric antigen receptors targeting B-cell maturation antigen,"The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/62
9771428,26-Sep-17,2017,9,26,CD47 targeted therapies for the treatment of infectious disease,"Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRPα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.",10,The Board of Trustees of the Leland Stanford Junior University,The Regents of the University of California,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,C07K/2896
9775895,3-Oct-17,2017,10,3,HIV therapeutics and methods of making and using same,"HIV neutralizing peptides, sulfated HIV-1 envelope proteins and immunogenic fragments thereof are disclosed, as well as nucleic acids encoding these molecules and methods of producing these peptides, envelope proteins and fragments. Methods are also provided for the treatment or prevention of a human immunodeficiency type 1 (HIV-1 ) infection. The methods can include administering to a subject an HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment thereof as disclosed herein. In several embodiments, administering the HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment generates an immune response in a subject.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/21
9782399,10-Oct-17,2017,10,10,Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same,"Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.",19,"The United States of America, as represented by The Secretary, Department of Health and Human Services",The Regents of the University of California,The Board of Regents of The University of Texas System,,,,,,,,,3,Pharmaceuticals,Organic fine chemistry,,,,,A61K/4741
9782465,10-Oct-17,2017,10,10,Serologic correlates of protection against Bacillus anthracis infection,Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.,10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/07
9783579,10-Oct-17,2017,10,10,Compositions and methods for dengue virus chimeric constructs in vaccines,"Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.",11,"Takeda Vaccines, Inc.",The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/162
9783586,10-Oct-17,2017,10,10,Inhibitors of the linear ubiquitin chain assembly complex (LUBAC) and related methods,The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphoma (ABC DLBCL) and autoimmune or inflammatory disorders.,40,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Medical technology,Analysis of biological materials,,,C07K/4703
9783590,10-Oct-17,2017,10,10,Variants of human taste receptor genes,"Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/705
9783595,10-Oct-17,2017,10,10,Neutralizing GP41 antibodies and their use,"Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.",28,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/1063
9783596,10-Oct-17,2017,10,10,Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use,"Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.",24,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1081
9783787,10-Oct-17,2017,10,10,"Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4","The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
9790261,17-Oct-17,2017,10,17,Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells,"The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-15 sequence.The present invention further provides expression vectors, and IL-15 and IL-15 receptor alpha combinations (nucleic acid and protein) that increase IL-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of IL-15 after DNA, RNA or protein administration in a subject (e.g. a mammal, a human).",26,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/5443
9790282,17-Oct-17,2017,10,17,"Anti-CD276 polypeptides, proteins, and chimeric antigen receptors","Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.",29,"The United States of America, as represented by the Secretary, Department of Health and Human Services","Biomed Valley Discoveries, Inc.",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/30
9790473,17-Oct-17,2017,10,17,Human Ebola virus species and compositions and methods thereof,Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.,15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C12N/00
9791371,17-Oct-17,2017,10,17,Systems and methods for distinguishing stimulated emissions as a means of increasing the signal of fluorescence microscopy,Embodiments of a fluorescence microscopy system that employs a technique for distinguishing stimulated emission as a means for enhancing signal strength of fluorescent markers are disclosed.,17,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Optics,Measurement,,,,,G01N/6458
9795662,24-Oct-17,2017,10,24,Vaccine comprising AMA1 and RON2,"Disclosed is a vaccine comprising an immunogenic composition comprising a complex of AMA1 and RON2 (or a fragment thereof), which elicits an immune response to a Plasmodium species in a subject upon administration. The resulting immune response is sufficient to impede or prevent infection by a Plasmodium species.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/015
9795665,24-Oct-17,2017,10,24,Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus,"The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.",19,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/12
9796774,24-Oct-17,2017,10,24,HIV-1 broadly neutralizing antibodies,"The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.",5,INTERNATIONAL AIDS VACCINE INITIATIVE,THE SCRIPPS RESEARCH INSTITUTE,,,,,,,,,,2,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/1063
9796967,24-Oct-17,2017,10,24,Compositions related to controllable intervening protein sequences (CIPS) comprising reversible zinc-binding motifs and inteins,Disclosed are compositions comprising an engineered intein designed such that the self-cleaving activity of the intein can be modulated by a zinc-binding motif as well as methods and systems for making and using the compositions.,13,Ohio State Innovation Foundation,,,,,,,,,,,1,Biotechnology,,,,,,C12N/16
9801536,31-Oct-17,2017,10,31,Polarimetric accessory for colposcope,"A polarization-based colposcopy apparatus includes a polarization exchanging beam splitter pair oriented so that s- and p-polarizations are exchanged. An optical flux from a specimen is directed through the pair, and orthogonal components thereof are alternately or selectively coupled to an array detector. The detected images are processed based on image correlations to reveal specimen structures.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61B/303
9802904,31-Oct-17,2017,10,31,Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof,"Disclosed are inhibitors of the USP1/UAF1 deubiquitinase complex, for example. of formula (I), wherein R1, R2, and Q are as defined herein, which are useful in treating diseases such as cancer, and improving the efficacy of DNA damaging agents in cancer treatment. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a heterodimeric deubiquitinase complex in a cell, and a method of enhancing the chemotherapeutic treatment of cancer in a mammal undergoing treatment with an anti cancer agent. Further disclosed is a method of preparing compounds of the invention.",4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Delaware,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/94
9803022,31-Oct-17,2017,10,31,Mesothelin domain-specific monoclonal antibodies and use thereof,"Described herein is the use of rabbit hybridoma technology, along with a panel of truncated mesothelin domain fragments, to identify anti-mesothelin mAbs that bind specific regions of mesothelin. In one aspect of the present disclosure, the rabbit mAbs bind an epitope that is not part of Region I. In particular, the identified mAbs (YP187, YP223, YP218 and YP3) bind either Region II (391-486), Region III (487-581) or a native conformation of mesothelin with subnanomolar affinity. These antibodies do not compete for binding with the mesothelin-specific immunotoxin SS1P or mesothelin-specific antibody MORAb-009. In another aspect, disclosed is a high-affinity rabbit mAb that binds Region I of mesothelin (YP158). YP158 binds native mesothelin protein in cancer cells and tissues with high affinity and specificity.",28,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/3023
9803251,31-Oct-17,2017,10,31,Methods of detecting influenza virus,"Disclosed herein are methods of detecting influenza virus in a sample from a subject. In some embodiments, the disclosed methods include contacting a sample with at least one primer 10-40 nucleotides in length wherein the at least one primer is capable of hybridizing to an influenza virus polymerase basic protein 1 (PB1) nucleic acid at least 70% identical to the nucleic acid sequence set forth as any one of SEQ ID NOs: 1-3, amplifying the PB1 nucleic acid or a portion thereof to produce an amplified PB1 nucleic acid, and detecting the amplified PB1 nucleic acid, wherein presence of the amplified PB1 nucleic acid indicates presence of influenza virus in the sample from the subject. In some examples, the primers comprise or consist of the nucleic acid sequence set forth as one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 10.",7,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
9804163,31-Oct-17,2017,10,31,Biomarkers for prostate cancer and methods for their detection,"The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,,,,,G01N/57434
9804171,31-Oct-17,2017,10,31,Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (PANDAS),"The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined.",14,The Board of Regents of the University of Oklahoma,"Moleculera Labs, Inc.",National Institutes of Health,,,,,,,,,3,Analysis of biological materials,,,,,,G01N/686
9808458,7-Nov-17,2017,11,7,Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria,"The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I:Q-Y—R1—R2  (I),wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,Biotechnology,,,,A61K/501
9809643,7-Nov-17,2017,11,7,Identification of antibodies specific for at least two different lyssaviruses,"Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/10
9809824,7-Nov-17,2017,11,7,"CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods",The present invention provides a CpG oligonucleotide prodrug that includes a thermolabile substituent on at least one nucleotide thereof. The present invention also provides compositions that include a carrier and a therapeutically effective amount of at least one CpG oligonucleotide prodrug. The present invention further provides therapeutic methods of using such thermolabile CpG oligonucleotide prodrugs and compositions thereof. The present invention further provides a method of inhibiting tetrad formation in a CpG oligonucleotide by functionalizing the CpG oligonucleotide with one or more thermolabile substituents.,25,"The United States of America, Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Organic fine chemistry,,,,C12N/117
9809845,7-Nov-17,2017,11,7,Methods and reagents for amplifying nucleic acids,"This disclosure related to methods and reagents for isothermal amplification of nucleic acid molecules. In some embodiments, methods are provided for amplification of a nucleic acid molecule from a biological sample. Additional embodiments include identification of a target nucleic acid molecule in a biological sample using the disclosed amplification methods.",29,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6844
9815887,14-Nov-17,2017,11,14,Monoclonal antibodies that neutralize a norovirus,"Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Nowalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections.",22,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/10
9816986,14-Nov-17,2017,11,14,Detection of 5-hydroxymethylcytosine by glycosylation,Provided herein are methods and kits for detecting a modified cytosine.,8,Children's Medical Center Corporation,,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C12Q/6827
9816992,14-Nov-17,2017,11,14,Compositions and methods relating to Lyme disease,"Compositions and methods of the present invention relating to B. burgdorferi HtrA sensu lato (BbHtrA) protease activity, its substrates, cleavage products, biological effects and use in detection, diagnosis and/or treatment of Lyme disease are provided.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/573
9817000,14-Nov-17,2017,11,14,Method for identifying compounds that modulate a T2R taste receptor,"The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.",16,The Regents of the University of California,,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/74
9820965,21-Nov-17,2017,11,21,"Biologically active macrolides, compositions, and uses thereof","The present invention provides a compound of the formula (I) or (II), wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or aryl, and R9 is R9a, C(O)R9a or SO2R9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(═O), OR9b, OC(O)R9b, OSO2R9b, NHR9b, NHC(O)R9b and NHSO2R9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(═O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/395
9822162,21-Nov-17,2017,11,21,Anti-human papillomavirus 16 E6 T cell receptors,"Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.",39,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/7051
9827223,28-Nov-17,2017,11,28,Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist,"The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons.",11,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/357
9833468,5-Dec-17,2017,12,5,Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA,Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.,51,"Sarepta Therapeutics, Inc.","The United States of America, as represneted by the Secretary, Dept. of Health and Human Services",University of Maryland,,,,,,,,,3,Pharmaceuticals,Biotechnology,,,,,A61K/713
9833519,5-Dec-17,2017,12,5,Methods for the diagnosis and treatment of sjögren's syndrome,"Described herein is the finding that patients with Sjögren's syndrome exhibit a statistically significant increase in expression of BMP6 in the salivary gland, relative to healthy control subjects. Also described herein is the finding that overexpression of BMP6 in the salivary glands of mice results in an increase in electrical potential across the salivary gland. Thus, provided herein are methods of diagnosing a subject as having Sjögren's syndrome, or at risk for developing Sjögren's syndrome, by measuring the level of BMP6 expression in a salivary gland of a subject, measuring electrical potential in a salivary gland of a subject, or both. Also provided herein are methods of treating a subject with Sjögren's syndrome by administering an agent that inhibits expression of BMP6 expression or activity. Also described herein is the use of XIST and MECP2 as diagnostic and therapeutic targets for male Sjögren's syndrome patients.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/0004
9844569,19-Dec-17,2017,12,19,Methods of producing enriched populations of tumor reactive T cells from peripheral blood,"Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.",25,"The United State of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Pharmaceuticals,Biotechnology,,,,A61K/17
9845349,19-Dec-17,2017,12,19,Regulating Bacillus anthracis lethal factor activity via an activating epitope region,Provided are antibodies capable of binding to a particular epitope or specifically binding to LF or LTx and enhancing the activity of the LF or LTx relative to the LF or LTx absent the antibody binding.,5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/1278
9845350,19-Dec-17,2017,12,19,Monoclonal antibodies that react with the capsule of bacillus anthracis,"The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.",26,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/1278
9850468,26-Dec-17,2017,12,26,Infectious hepatitis E virus genotype 3 recombinants,"The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus.",18,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",ROYAL CORNWALL HOSPITAL TRUST,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/00
9855298,2-Jan-18,2018,1,2,Methods of conditioning patients for T cell therapy,"The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.",30,"Kite Pharma, Inc.","The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/17
9855330,2-Jan-18,2018,1,2,Granulysin in immunotherapy,"Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.",4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/39
9856313,2-Jan-18,2018,1,2,Epitope of RSV fusion protein and antibody recognizing the same,"The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.",17,XIAMEN UNIVERSITY,"XIAMEN INNOVAX BIOTECH CO., LTD.","THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,C07K/1027
9856453,2-Jan-18,2018,1,2,Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject,"Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/0638
9861287,9-Jan-18,2018,1,9,"Method for detecting hematoma, portable detection and discrimination device and related systems and apparatuses","Featured are methods, apparatus and devices for detecting a hematoma in tissue of a patient. In one aspect, such a method includes emitting near infrared light continuously into the tissue from a non-stationary near infrared light emitter and continuously monitoring the tissue using a non-stationary probe so as to continuously detect reflected light. The near infrared light is emitted at two distances from a brain of the patient, so the emitted light penetrates to two different depths. Such a method also includes applying a ratiometric analysis to the reflected light to distinguish a border between normal tissue and tissue exhibiting blood accumulation.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61B/02042
9862679,9-Jan-18,2018,1,9,Potent and selective inhibitors of monoamine transporters; method of making; and use thereof,"Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.",16,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/60
9864026,9-Jan-18,2018,1,9,Wirelessly powered magnetic resonance imaging signal amplification system,"An implantable parametric circuit enables local signal amplification and wireless transmission of RF signals in connection with magnetic resonance imaging systems. The parametric circuit detects RF signal detected during magnetic resonance imaging procedure, amplifies the detected RF signal, and transmits the amplified RF signal in a wireless manner to an external pick-up coil. The parametric amplifier is also configured to use another RF signal generated by an external source as the primary power source. As a result, implanted or catheter coils could be used as a wireless signal transducer without the need for a battery or a power connection.",6,"The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Measurement,,,,,G01R/3692
9867830,16-Jan-18,2018,1,16,"Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain","The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite.(2R,6R)-hydroxynorketamineThe disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.",11,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH",COOPER HEALTH SYSTEM,SRI INTERNATIONAL,,,,,,,,,3,Organic fine chemistry,Pharmaceuticals,,,,,A61K/5375
9868774,16-Jan-18,2018,1,16,Anti-CD22 chimeric antigen receptors,"The disclosure provides a chimeric antigen receptor (CAR) comprising a) an antigen binding domain of HA22, a transmembrane domain, and an intracellular T cell signaling domain; or b) an antigen binding domain of BL22, a transmembrane domain, and an intracellular T cell signaling domain comprising CD28 and/or CD137. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/705
9868954,16-Jan-18,2018,1,16,Reduction of TGFβ signaling in myeloid cells in the treatment of cancer,"Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,Other special machines,,,C12N/1138
9873893,23-Jan-18,2018,1,23,Methods and compositions for treating genetically linked diseases of the eye,"Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.",14,"The United States of America as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/86
9874622,23-Jan-18,2018,1,23,Hyperpolarized media transport vessel,"A system and method for transporting a hyperpolarized substance is disclosed. A transport vessel for transporting such a hyperpolarized substance includes a vessel housing, a chamber formed within the vessel housing that is configured to receive a container holding a hyperpolarized substance, and an electromagnet configured to generate a magnetic containment field about the chamber when a current is supplied thereto, the magnetic containment field comprising a homogeneous magnetic field. The transport vessel also includes a non-magnetic power source to supply the current to the electromagnet and a control circuit configured to selectively interrupt the supply of current to the electromagnet so as to control generation of the magnetic containment field, with the transport vessel being magnetically inert when the supply of current to the electromagnet is interrupted by the control circuit.",18,General Electric Company,,,,,,,,,,,1,Measurement,Medical technology,,,,,G01R/5601
9879065,30-Jan-18,2018,1,30,T cell receptors recognizing MHC class II-restricted MAGE-A3,"The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.",35,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/7051
9879231,30-Jan-18,2018,1,30,Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites,"The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/00
9879317,30-Jan-18,2018,1,30,Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs,"Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.",6,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/686
9884100,6-Feb-18,2018,2,6,Lutzomyia longipalpis polypeptides and methods of use,"Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishishmaniasis are disclosed.",8,The United States of America as represented by the Secretary of the Department of Health and Human Services,Fundacão Oswaldo Cruz (FIOCRUZ),,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/008
9884104,6-Feb-18,2018,2,6,Live attenuated virus vaccines for la crosse virus and other bunyaviridae,"The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACY) infection in a biological sample and infectious chimeric Bunyaviridae.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/12
9888876,13-Feb-18,2018,2,13,Method of analyzing multi-sequence MRI data for analysing brain abnormalities in a subject,"The present invention, referred to as Oasis is Automated Statistical Inference for Segmentation (OASIS), is a fully automated and robust statistical method for cross-sectional MS lesion segmentation. Using intensity information from multiple modalities of MRI, a logistic regression model assigns voxel-level probabilities of lesion presence. The OASIS model produces interpretable results in the form of regression coefficients that can be applied to imaging studies quickly and easily. OASIS uses intensity-normalized brain MRI volumes, enabling the model to be robust to changes in scanner and acquisition sequence. OASIS also adjusts for intensity inhomogeneities that preprocessing bias field correction procedures do not remove, using BLUR volumes. This allows for more accurate segmentation of brain areas that are highly distorted by inhomogeneities, such as the cerebellum. One of the most practical properties of OASIS is that the method is fully transparent, easy to implement, and simple to modify for new data sets.",19,The Johns Hopkins University,"The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.","The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,3,Medical technology,Measurement,Computer technology,,,,A61B/4064
9889115,13-Feb-18,2018,2,13,Fitness assay and associated methods,"The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R1, R2, R3, R5 or R6 is H, or an optionally substituted and/or heteroatom-bearing alkyl, alkenyl, alkynyl, or cyclic group; Y and/or Z are CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivatives thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n is from 1 to 5; X is a bond, an optionally substituted methylene or ethylene, an amino, O or S; Q is C(O), C(S), or SO2; m is from 0 to 6; R4 is OH, ═O (keto), NH2, or alkylamino, including esters, amides, and salts thereof; and W is C(O), C(S), S(O), or SO2. Optionally, R5 and R6, together with the N—W bond of formula (I), comprise a macrocyclic ring.",6,Board of Trustees of the University of Illinois,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/341
9890369,13-Feb-18,2018,2,13,Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor,"Disclosed is a protein comprising a cytolethal distending toxin subunit B (CdtB) conjugated or fused to a Bacillus anthracis toxin lethal factor (LF) or a functional portion of LF. Related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of treating or preventing cancer, and methods of inhibiting the growth of a target cell are also disclosed.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/22
9891225,13-Feb-18,2018,2,13,Compositions and methods for simultaneous detection of HCV antigen/antibody,"Compositions and processes are provided for the robust detection of hepatitis C virus in a sample. Compositions include amino acid sequences of HCV core region including or exclusive to residues 14-31 or 50-90 of the HCV core protein. Also provided are processes of detecting HCV in a sample whereby the provided peptides are optionally used alone or in conjunction with antibodies that do not recognize the peptides so that detection is independent of seroconversion in a subject. Using the compositions and processes, HCV can be detected in a sample prior to or following seroconversion leading to robust HCV detection and diagnosis.",15,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/5767
9896484,20-Feb-18,2018,2,20,Influenza virus recombinant proteins,The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.,7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
9896509,20-Feb-18,2018,2,20,Use of antagonists of the interaction between HIV GP120 and α4β7 integrin,"Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4 integrin antagonist is a monoclonal antibody that specifically binds to a α4, β1 or β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.",21,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/2839
9896511,20-Feb-18,2018,2,20,Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies,"Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease.",17,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/2875
9896729,20-Feb-18,2018,2,20,Method for diagnosing a neurodegenerative disease,The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.,20,The University of Manchester,National Institute of Aging,Hospital District of Helsinki and UUSIMAA,VU University Medical Centre Armsterdam,UCL Business PLC,University College Cardiff Consultants Limited,,,,,,6,Analysis of biological materials,Biotechnology,Pharmaceuticals,,,,C12Q/6883
9902734,27-Feb-18,2018,2,27,Nicotinic acetylcholine receptor agonists,"The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula I. Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine receptor agonists.",13,Indiana State University,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Analysis of biological materials,Basic materials chemistry,Pharmaceuticals,,,C07D/16
9903868,27-Feb-18,2018,2,27,Method for the detection and quantitation of biomarkers,"The invention provides a method for detecting the presence or absence of a biomarker in a biological sample at a very low concentration comprising the steps of (a) contacting the biological sample with a capture binding sequence immobilized on a surface, (b) providing a conjugate comprising a detection binding sequence-glucose oxidase, (c) contacting the surface with the detection binding sequence-glucose oxidase conjugate, (d) separating any unbound detection binding sequence-glucose oxidase conjugate from the surface, (e) incubating the resulting surface with a glucose solution and a mixture comprising gold nanoparticles and a gold salt, wherein the gold nanoparticles have an initial particle size of about 5 nm, and (f) observing any change in color of the mixture. The invention also provides a method for diagnosing the presence of a prostate cancer biomarker in a subject and a kit for detecting or quantifying a biomarker in a biological sample.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57434
9908841,6-Mar-18,2018,3,6,"Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure","This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogs which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogs are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogs, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/60
9913892,13-Mar-18,2018,3,13,Materials and methods for respiratory disease control in canines,The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.,43,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.","CORNELL RESEARCH FOUNDATION, INC.","THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION",,,,,,,,,3,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/145
9919058,20-Mar-18,2018,3,20,Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer,"Methods are disclosed herein for treating a subject with a lung cancer. The lung cancer can be small cell carcinoma of the lung or non-small cell carcinoma of the lung.The methods include locally administering to the subject a therapeutically effective amount of the polyketal particle comprising a CpG oligodexoynucleotide. Optionally, the polyketal particle can include an imidazoquinoline compound.",23,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/6931
9920188,20-Mar-18,2018,3,20,PVCP phantoms and their use,"Novel phantoms are provided herein that can accurately mimic the optical and/or acoustic properties of living tissue. The disclosed phantoms are constructed of one or more polyvinyl chloride plastisol (PVCP) gels comprising a PVC and a binary plasticizer. The phantoms can be used, for example, to calibrate or test an optical and/or acoustic detection system, such as a photoacoustic imaging system or an ultrasound imaging system.",32,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,"Macromolecular chemistry, polymers",Medical technology,Control,,,,C08K/20
9920296,20-Mar-18,2018,3,20,Paenibacillus alvei strain TS-15 and its use in controlling pathogenic organisms on crops,"The present invention provides a newly isolated bacterial strain of Paenibacillus, designated Paenibacillus alvei strain TS-15 for use as a biocontrol agent in the inhibition and/or elimination of a human foodborne pathogen, e.g., Salmonella, on a plant or plant organ, e.g., a tomato or tomato plant. Strain TS-15 or mutants thereof may also be used in the control of plant pathogens.",15,"The United States of America, as represented by the Secretary, Department of Health & Human Servic",,,,,,,,,,,1,Biotechnology,Food chemistry,Other special machines,Basic materials chemistry,Pharmaceuticals,,C12N/20
9920385,20-Mar-18,2018,3,20,Detection of echinocandin-resistant Candida glabrata,"Probes and primers are disclosed for detecting a C. glabrata resistant to an echinocandin in a sample. Method are also disclosed that utilize these probes and primers, wherein the methods can be used to detect a C. glabrata resistant to an echinocandin in a sample.",25,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6895
9921211,20-Mar-18,2018,3,20,Methods for detecting and monitoring endocrine disrupting chemicals (EDCs),"Described herein are compositions, methods, a system, and kits for detection of endocrine disruptor chemicals (EDCs) in samples, such as samples of water including but not limited to waste water treatment plant effluent, using a live-cell fluorescence-based nuclear translocation reporter system. Upon binding of a ligand to a fluorescent-labeled reporter protein, the protein (and therefore the fluorescence) is translocated in a ligand level-dependent manner from the cytoplasm to the nucleus of live mammalian cells; this translocation is detectable as diffuse (cytoplasmic) fluorescence converting to localized, brightly fluorescent nuclei. The described kits can be used to reliably detect very low levels of EDC contamination, including in high throughput analysis systems as described.",18,"The United Stated of America, as Represented by The Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,Measurement,,,,G01N/5035
9931377,3-Apr-18,2018,4,3,Cell expressing complexes of IL-15 and IL-15Ralpha,"The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol″ those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-β-1-♦4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.",23,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",Novartis AG,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/2086
9931393,3-Apr-18,2018,4,3,Immunogenic JC polyomavirus compositions and methods of use,"Methods of eliciting an immune response to a JC polyomavirus (JCV) by administering an effective amount of an immunogenic composition including an isolated JCV VP1 polypeptide or a nucleic acid encoding the VP1 polypeptide to a subject are provided. VP1 polypeptides and immunogenic compositions suitable for use in the methods are provided, including JCV genotype 2 VP1 polypeptides and/or JCV genotype 3 polypeptides. Methods of identifying a subject at risk of developing progressive multifocal leukoencephalopathy (PML) are also provided. In some embodiments, the methods include obtaining a biological sample from a subject, detecting presence or absence of JCV neutralizing antibodies in the sample from the subject, and identifying that the subject is at risk of developing PML if there is an absence of detectable JCV neutralizing antibodies in the sample from the subject.",31,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/12
9932406,3-Apr-18,2018,4,3,Human monoclonal antibodies specific for glypican-3 and use thereof,"Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,C07K/3076
9932560,3-Apr-18,2018,4,3,Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells,"Disclosed herein is the finding that Zscan4 is an early embryonic factor that facilitates cellular reprogramming. In particular, Zscan4 can replace the oncogenic reprogramming factor c-Myc to produce induced pluripotent stem cells when co-expressed with Klf4, Oct4 and Sox2. In addition, several Zscan4-dependent genes were identified that promote iPSC formation when co-expressed with known reprogramming factors. Thus, the present disclosure provides an ex vivo method of producing an iPS cell by reprogramming of a somatic cell. The method includes contacting the somatic cell with a Zscan4, or a Zscan4-dependent gene, and at least one reprogramming factor. Also provided are iPS cells produced by the disclosed method and non-human animals generated from such iPS cells.",23,"ELIXIRGEN, LLC",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0696
9932642,3-Apr-18,2018,4,3,Rapid Salmonella serotyping assay,"Processes for the serotype specific detection and identification of one or more Salmonella serotypes are provided. A family of specific primers and probes are provided that allow screening of biological or environmental samples for robust, rapid, and reproducible detection and identification of one or more Salmonella serotypes in the sample.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
9933339,3-Apr-18,2018,4,3,Miniature serial sectioning microtome for block-face imaging,"The present disclosure is directed to embodiments of microtome devices and methods of their use. In some embodiments, a microtome can be mounted on the built-in stage of a scanning electron microscope and used to perform serial block-face scanning electron microscopy. In some cases, a microtome installed in a scanning electron microscope can cut the sample at a location off the electron beam axis of the scanning electron microscope. In some cases, a microtome can include a capacitive sensor which can measure the location of a blade of the microtome, and the microtome can be computer-controlled by program implemented in MATLAB.",32,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,"Electrical machinery, apparatus, energy",Measurement,,,,,G01N/06
9937191,10-Apr-18,2018,4,10,Inhibition of HIV infection through chemoprophylaxis,A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.,19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/675
9937217,10-Apr-18,2018,4,10,Method of inhibiting ABCG2 and related treatments,"Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/06
9938588,10-Apr-18,2018,4,10,Compositions and methods for detecting Enterovirus D68,"Methods and compositions for detection of enterovirus D in a sample, particularly detection of enterovirus D68, are provided. The methods include contacting a sample with at least one primer (such as a forward primer and/or a reverse primer) capable of specifically amplifying an EV-D68 viral protein 1 (VP1) nucleic acid or a portion thereof and/or a detectably labeled probe capable of specifically hybridizing to an EV-D68 VP1 nucleic acid, under conditions sufficient for specific amplification of the EV-D68 VP1 nucleic acid by the at least one primer and/or under conditions sufficient for specific hybridization of the probe to the EV-D68 nucleic acid. The amplification of the EV-D68 VP1 nucleic acid and/or the hybridization of the probe to the EV-D68 VP1 nucleic acid is detected, thereby identifying presence of EV-D68 in the sample.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
9939392,10-Apr-18,2018,4,10,Demodulation of intensity modulation in X-ray imaging,X-ray grating based and grid based imagers formed a fringe pattern modulated by a specimen. An X-ray beam is scanned so that the fringe pattern is modulated by these specimen along a plurality of projection directions. Corresponding fringe patterns are detected and aligned so as to produce a specimen phase image. X-ray beam scanning is based on electric or magnetic deflection of an electron beam to an X-ray generating target.,28,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01N/041
9943335,17-Apr-18,2018,4,17,Implanted magnets retrieval system and method,"A method of retrieving a pair of previously implanted magnets from a patient's body includes maneuvering a guide catheter, which includes a guide magnet affixed to its distal end, toward the implantation site of the implanted magnets. The guide magnet is magnetically coupled to one of the implanted magnets in an orientation in which a through hole of the guide magnet is in register with through holes of the first and second implant magnets. An elongate capture member is slid through the lumen of the guide catheter until one of a proximal segment and a distal segment extends through the through holes of the guide magnet and the implanted magnets. An abutment segment of the elongate capture member, which separates the proximal segment and the distal segment is maneuvered into contact with the magnets. Then, the abutment segment, the guide magnet and the implanted magnets are moved as a group away from the implantation site.",20,Cook Medical Technologies LLC,,,,,,,,,,,1,Medical technology,,,,,,A61B/52
9943409,17-Apr-18,2018,4,17,Transcatheter coronary sinus mitral valve annuloplasty procedure and coronary artery and myocardial protection device,"Devices and methods are disclosed for the treatment or repair of regurgitant cardiac valves, such as a mitral valve. An annuloplasty device can be placed in the coronary sinus to reshape the mitral valve and reduce mitral valve regurgitation. A protective device can be placed between the annuloplasty device and an underlying coronary artery to inhibit compression of the underlying coronary artery by the annuloplasty device in the coronary sinus. In addition, the protective device can inhibit compression of the coronary artery from inside the heart, such as from a prosthetic mitral valve that exerts radially outward pressure toward the coronary artery. The annuloplasty device can also create an artificial inner ridge or retaining feature projecting into the native mitral valve region to help secure a prosthetic mitral valve.",19,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61F/2451
9944918,17-Apr-18,2018,4,17,Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA),"Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).",11,"The United States of America, as represented by the Secretary, Dept. of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/90
9944927,17-Apr-18,2018,4,17,"Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer",The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.,4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The University of Dundee,Masaryk Memorial Cancer Institute,,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,C12N/113
9944951,17-Apr-18,2018,4,17,Chromosome 3p21.3 genes are tumor suppressors,"Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.",4,"Board of Regents, The University of Texas System",The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Biotechnology,Other special machines,Pharmaceuticals,,,,C12N/86
9951311,24-Apr-18,2018,4,24,Agents and methods to elicit anti-tumor immune response,"The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.",11,THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12N/0638
9956278,1-May-18,2018,5,1,Multivalent meningococcal conjugates and methods for preparing conjugates,"Disclosed herein are meningococcal immunogenic conjugates which can elicit immune responses against meningococcal polysaccharides (PS) from groups A, C, W-135, and Y and group B factor H binding protein (fHbp). The disclosed conjugates also exhibit bactericidal activity against meningococcal A, C, W-135, Y, B, and X serogroups. Also disclosed are improved methods for preparing conjugates, such as immunogenic conjugates, including activation of a polysaccharide with a cyanylation agent at about 4° C.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/095
9957486,1-May-18,2018,5,1,Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization,"Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.",12,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",The Research Foundation For the State University of New York,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/00
9963450,8-May-18,2018,5,8,A3 adenosine receptor agonists,"Disclosed are compounds of the formula (I) and (II) which are A3 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R2-R6, and R103-R106 are as defined in the specification. These compounds are selective to the A3 receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Saint Louis University,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/34
9968693,15-May-18,2018,5,15,Small molecule imaging of fungi by positron emission tomography scanning,"Disclosed herein are isotopically labeled calcofluor derivatives and uses of such to detect fungi, such as filamentous fungi, including Aspergillus species, such as by positron emission tomography (PET) scanning. In some examples, the disclosed compounds have a formula of",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The Research Foundation of the State University of New York,,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/0461
9970059,15-May-18,2018,5,15,Survival predictor for diffuse large B cell lymphoma,The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.,16,"The United States of America, as represented by the Secretary, Department of Human Services",Arizona Board of Regents on behalf of the University of Arizona,Queen Mary University of London,Board of Regents of the University of Nebraska,Oslo University Hospital HF,Oregon Health & Science University,University of Rochester,Hospital Clinic de Barcelona,Universitat de Barcelona,British Columbia Cancer Agency Branch,Julius-Maximilians-University of Würzburg,11,Biotechnology,Analysis of biological materials,,,,,C12Q/6886
9974789,22-May-18,2018,5,22,Substituted pyrazolopyrimidines as glucocerebrosidase activators,"Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I)in which variables R1-R7 and X are described in the application.",20,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/519
9974796,22-May-18,2018,5,22,Inhibitors of the plasmodial surface anion channel as antimalarials,"Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Organic fine chemistry,,,,,A61K/553
9974801,22-May-18,2018,5,22,Methods of treating and preventing diseases and disorders of the central nervous system,"Disclosed is a method of treating or preventing a disease or disorder of the central nervous system (CNS) in a patient comprising administering transcranially, for example, directly to the skull, an effective amount of an anti-inflammatory agent to the patient. Examples of the anti-inflammatory agent include glutathione and inhibitors of purinergic receptors such as P2X4, P2X7, P2Y6, and P2Y12 receptors. Examples of disease or disorder of the CNS include brain injury, particularly traumatic brain injury, inflammation, infection, degeneration of brain cells, stroke, brain edema, tumor, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Also disclosed is a kit comprising at least one anti-inflammatory agent and printed materials containing instructions for transcranially administering the anti-inflammatory agent to the patient having a disease or disorder of the CNS.",4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7076
9974851,22-May-18,2018,5,22,Human rotavirus vaccine strains and diagnostics,"Immunogenic pharmaceutical compositions including a live, attenuated human rotavirus or an inactivated human rotavirus are provided which are useful for inducing an immunological response against the rotavirus in a subject. Methods of inducing an immunological response to a rotavirus in a subject are provided by administering an immunogenic pharmaceutical composition including a live, attenuated human rotavirus or an inactivated human rotavirus described herein.",22,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/15
9974868,22-May-18,2018,5,22,Octapod iron oxide nanoparticles as high performance T2 contrast agents for magnetic resonance imaging,"Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Xiamen University,,,,,,,,,,2,Pharmaceuticals,"Materials, metallurgy",,,,,A61K/1833
9975925,22-May-18,2018,5,22,Influenza antigens and antibodies,"Novel influenza antigens, novel immunogenic or vaccine compositions, as well as uses of and methods for producing said antigens and compositions, are described.",19,GLAXOSMITHKLINE BIOLOGICALS S.A.,"THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. HEALTH & HUMAN SERVICES",,,,,,,,,,2,Biotechnology,,,,,,C07K/005
9975937,22-May-18,2018,5,22,Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia,"The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.",4,"THE UNITED SSTATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/5443
9981943,29-May-18,2018,5,29,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",6,"Mycovia Pharmaceuticals, Inc.",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/06
9982025,29-May-18,2018,5,29,Monomeric griffithsin tandemers,"The invention provides a construct containing two or more monomeric griffithsin molecules, optionally joined by a linker, as well as conjugate comprising the construct, a nucleic acid encoding the construct or conjugate, vectors, and cells. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/405
9983200,29-May-18,2018,5,29,Compositions and methods for predicting age of onset of a lysosomal storage disease or a disease associated with a lysosomal defect,The present invention features diagnostic compositions and methods for predicting the age of onset of a lysosomal storage disease or a disease associated with a lysosomal defect in subject.,12,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Analysis of biological materials,,,,,,G01N/52
9987135,5-Jun-18,2018,6,5,Devices and methods for treating functional tricuspid valve regurgitation,"Disclosed here are devices and methods for treating functional tricuspid valve regurgitation and related conditions. Disclosed devices are adapted for applying force to an area of a patient's heart along or near the atrioventricular groove, and can include a tensioning element configured to be delivered by a flexible member guided through a catheter and positioned generally along or near the atrioventricular groove, and a compression member positionable along the tensioning element and over a desired segment of the atrioventricular groove to develop force to be applied to an adjacent area of the heart by selective tensioning of the tensioning element.",29,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61F/2481
9987330,5-Jun-18,2018,6,5,Methods of treating or preventing pruritis by blocking natriuretic polypeptide B,"Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.",34,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Other special machines,,,,A61K/22
9988631,5-Jun-18,2018,6,5,"Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer","The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression a Nanog pseudogene expressed in many human cancers, a replicating viral vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.",6,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/113
9989533,5-Jun-18,2018,6,5,Anti-TNF induced apoptosis (ATIA) diagnostic markers and therapies,"The invention features diagnostic and therapeutic methods and compositions featuring Anti-TNF Induced Apoptosis (ATIA). ATIA is useful as a diagnostic marker for cancer, in particular for glioblastoma. ATIA is also a therapeutic target in diseases such as cancer. The invention encompasses combination therapies where knockdown of ATIA is used in combination with other treatment. The invention also features kits for use in the diagnostic and therapeutic methods.",12,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,G01N/57407
10000465,19-Jun-18,2018,6,19,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",2,"Mycovia Pharmaceuticals, Inc.",U.S. Department of Health and Human Services,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
10000556,19-Jun-18,2018,6,19,Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use,"Isolated VHH monoclonal antibodies are disclosed that specifically bind to a Norovirus polypeptide. In some embodiments, the Norovirus is a Genogroup I Norovirus or a Genogroup II Norovirus. In other embodiments, the Norovirus is Norwalk or MD2004 virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. Also disclosed are methods of treating and/or preventing a NoV infection.",32,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health and Human Services",INSTITUTO NACIONAL DE TECHNOLOGIA AGROPECUARIA,,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C07K/10
10000813,19-Jun-18,2018,6,19,Method of diagnosing and treating cancer using B-catenin splice variants,"The invention relates to method and compositions for treating and diagnosing cancer, in particular β-catenin related cancers. In general, the methods include administering RNAi constructs. The invention further relates to methods of identifying CTNNB1 related cancer therapeutics.",42,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12Q/6886
10001483,19-Jun-18,2018,6,19,"Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers","Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi's sarcoma (KS) or Kaposi's sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi's sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin.",29,Celgene Corporation,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Analysis of biological materials,,,,,G01N/57407
10004800,26-Jun-18,2018,6,26,Antibody evolution immunogens,"The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).",24,Duke University,"Los Alamos National Security, LLC",The Trustees of The University of Pennsylvania,Trustees of Boston University,The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer,The Board of Trustees of the Leland Stanford Junior University,,,,,,6,Pharmaceuticals,Biotechnology,,,,,A61K/21
10006097,26-Jun-18,2018,6,26,Compositions and methods for detection and discrimination of influenza viruses,"Compositions and methods for detecting presence of an influenza virus in a sample, such as a biological sample obtained from a subject or an environmental sample, are provided. In some embodiments, the compositions and methods can be used to quickly identify particular subtypes of influenza virus (such as seasonal or variant influenza subtype H3, influenza subtype H5, Eurasian influenza subtype H7, North American influenza subtype H7, and/or influenza subtype H9) present in a sample. Probes and primers are provided herein that permit the rapid detection and/or discrimination of influenza virus subtype nucleic acids in a sample. Devices (such as arrays) and kits for detection and/or discrimination of influenza virus subtype nucleic acids are also provided.",14,"The United States of America, as represented by the Secretry, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12Q/701
10007920,26-Jun-18,2018,6,26,Device and method for detection of counterfeit pharmaceuticals and/or drug packaging,One aspect of the invention provides a device for detecting a counterfeit product. The device includes: a plurality of light sources configured to emit light at a plurality of different wavelengths onto an object potentially including a suspect product; at least one image acquisition device adapted and configured to acquire image data; and a communications interface adapted and configured to transmit the image data to a computing device selected from the group consisting of: a tablet computer and a smartphone.,17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,IT methods for management,Computer technology,Measurement,Analysis of biological materials,Audio-visual technology,,G06Q/0185
10016432,10-Jul-18,2018,7,10,Methanocarba derivatives of pseudoribose that inhibit adenosine kinase,"Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.",21,Legacy Emanuel Hospital & Health Center,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,Organic fine chemistry,,,,,A61K/519
10017494,10-Jul-18,2018,7,10,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",17,"Mycovia Pharmaceuticals, Inc.","The United States of America, as represented by the Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/06
10017516,10-Jul-18,2018,7,10,BMP inhibitors and methods of use thereof,"The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.",5,"The Brigham and Women's Hospital, Inc.","The United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
10017543,10-Jul-18,2018,7,10,Prefusion RSV F proteins and their use,"Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.",58,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/005
10017762,10-Jul-18,2018,7,10,Compositions and methods for treating or preventing lupus,"The present disclosure provides methods for inhibiting and/or reducing self-reactive IgE and/or basophils, thereby treating or preventing lupus, lupus nephritis, and lupus-related disorders.",10,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/11
10024785,17-Jul-18,2018,7,17,Solid hemoglobin-polymer biophotonic phantoms and their use,"Novel biophotonic phantoms are provided herein that can accurately mimic the optical properties of living tissue. The disclosed biophotonic phantoms comprise hemoglobin (Hb) in a native conformation that is distributed in a solid polymer matrix. Methods of producing the disclosed biophotonic phantoms are also provided. The biophotonic phantoms can be used, for example, to calibrate or test an optical imaging system, such as a near infrared spectroscopy imaging system.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services","University of Maryland, College Park",,,,,,,,,,2,Measurement,Other special machines,"Macromolecular chemistry, polymers",Analysis of biological materials,,,G01N/278
10025082,17-Jul-18,2018,7,17,Multi-focal structured illumination microscopy systems and methods,"Various embodiments for a multi-focal selective illumination microscopy (SIM) system for generating multi-focal patterns of a sample are disclosed. The multi-focal SIM system performs a focusing, scaling and summing operation on each generated multi-focal pattern in a sequence of multi-focal patterns that completely scan the sample to produce a high resolution composite image.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,Measurement,,,,,G02B/0072
10031131,24-Jul-18,2018,7,24,Selective oxidation of 5-methylcytosine by TET-family proteins,"The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.",10,THE CHILDREN'S MEDICAL CENTER CORPORATION,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12Q/6827
10035832,31-Jul-18,2018,7,31,HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use,"The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/4727
10035833,31-Jul-18,2018,7,31,Vascular endothelial growth factor antagonists and methods of making,The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.,14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/475
10035844,31-Jul-18,2018,7,31,Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein,"Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.",32,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Analysis of biological materials,Biotechnology,,,,C07K/1063
10035845,31-Jul-18,2018,7,31,Neutralizing antibodies to HIV-1 and their use,"Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Washington,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/1063
10035848,31-Jul-18,2018,7,31,Antibody targeting cell surface deposited complement protein C3d and use thereof,An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.,25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Virginia Patent Foundation,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/18
10036020,31-Jul-18,2018,7,31,Compositions and methods for inhibiting JC virus (JCV),"The instant invention provides compositions and methods for inhibiting the JC Virus (JCV), and that can be used, for example, for treating progressive multifocal leukoencephalopathy (PML). Antisense oligonucleotides are provided which are effective in inhibiting JCV replication or multiplication, alone or in a combination. In preferred embodiments, the oligonucleotides contain modifications.",19,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/1131
10036076,31-Jul-18,2018,7,31,Primers and probes for detection and discrimination of types and subtypes of influenza viruses,"Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.",31,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
10036248,31-Jul-18,2018,7,31,Cutter head for longwall shearer,A cutter head for a mining machine includes a first end and a second end with a drum axis extending between the first and the second ends. The cutter head also includes a web coupled to the second end of the drum. The web includes a plurality of arcuate apertures. Each arcuate aperture extends through an angle about the drum axis. The cutter head further includes a plurality of first ribs coupled to the web. Each of the first ribs is positioned between adjacent arcuate apertures. The cutter head also includes a plurality of second ribs coupled to the web. Each of the second ribs extend across one of the plurality of arcuate apertures. A first angle that extends between one of the first ribs and an adjacent one of the second ribs is different than a second angle extending between the one first rib and another adjacent second rib.,20,Joy Global Underground Mining LLC,"The United States of America, as represented by the Secretary of the Dep. of Health and Human Services",,,,,,,,,,2,Civil engineering,,,,,,E21C/10
10039741,7-Aug-18,2018,8,7,Use of delta tocopherol for the treatment of lysosomal storage disorders,"This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol in combination with cyclodextrin to a patient in need thereof.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/355
10040830,7-Aug-18,2018,8,7,Methods and compositions for protein delivery,"The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS.",20,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/005
10041938,7-Aug-18,2018,8,7,Measuring a level of a 5-hydroxymethylcytosine in a sample from a subject having a cancer or suspected of having cancer,"Provided herein are methods and kits for measuring a level of a 5-hydroxymethylcytosine in a nucleotide sequence from a subject, wherein the subject is a subject having a cancer or suspected of having cancer.",19,THE CHILDREN'S MEDICAL CENTER CORPORATION,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12Q/6827
10042149,7-Aug-18,2018,8,7,Multi-focal structured illumination microscopy systems and methods,"A multi-focal selective illumination microscopy (SIM) system for generating multi-focal patterns of a sample is disclosed. The multi-focal SIM system performs a focusing, scaling and summing operation on each multi-focal pattern in a sequence of multi-focal patterns that completely scan the sample to produce a high resolution composite image.",7,"The United States of America, as represented by Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,Measurement,,,,,G02B/0072
10045765,14-Aug-18,2018,8,14,Devices and methods for closure of transvascular or transcameral access ports,"The present disclosure provides a variety of prostheses, delivery systems and techniques to facilitate closure of transvascular or transcameral access ports. Various embodiments of prostheses are provided including a plurality of radially expandable discs that can be filled with material to facilitate coagulation and to reduce or stop leakage from punctures in vessel walls.",25,Transmural Systems LLC,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Medical technology,,,,,,A61B/0057
10046012,14-Aug-18,2018,8,14,Multipotent postnatal stem cells from human periodontal ligament and uses thereof,"The invention generally relates to postnatal periodontal ligament stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal periodontal ligament multipotent stem cells, use of the cells to generate periodontium, differentiation of the cells and methods of tissue cryopreservation.",21,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Basic materials chemistry,Pharmaceuticals,Biotechnology,,,A61K/32
10047122,14-Aug-18,2018,8,14,Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use,"The invention provides novel compounds that may serve as anticancer therapeutics. The compounds of the invention bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds of the invention are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected phophoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives of the invention have achieved both good efficacy and an enhanced bioavailability. The invention also provides methods of use, compositions, and kits thereof. Further, the invention provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.",30,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Organic fine chemistry,Pharmaceuticals,,,,C07K/06
10047147,14-Aug-18,2018,8,14,Neutralizing GP41 antibodies and their use,"Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.",12,"The United States of American, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/1063
10047148,14-Aug-18,2018,8,14,Neutralizing GP41 antibodies and their use,"Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.",25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,C07K/1063
10047401,14-Aug-18,2018,8,14,Expression protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer,"The invention provides novel biomarkers (four genes BRCA1, HIF1A, DLC1, and XPO1 alone or in combination of miR-21) for early stage lung cancer.",2,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Medical technology,Biotechnology,Medical technology,,,,C12Q/6886
10052374,21-Aug-18,2018,8,21,"Compositions, methods and uses for dengue virus serotype-4 constructs","Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.",25,"Takeda Vaccines, Inc.",The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,A61K/12
10052382,21-Aug-18,2018,8,21,"Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides","High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.",7,Duke University,The United States of America as Represented by the Secretary of Health (NIH),,,,,,,,,,2,Biotechnology,Pharmaceuticals,Analysis of biological materials,,,,A61K/39558
10053503,21-Aug-18,2018,8,21,Monoclonal antibodies that neutralize anthrax toxins,"The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,Pharmaceuticals,,,,C07K/1278
10053514,21-Aug-18,2018,8,21,Human bispecific EGFRvIII and CD3 antibody engaging molecules,"We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are therapeutic agents.",8,Duke University,"The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/32
10053741,21-Aug-18,2018,8,21,HIV-1 genotyping assay for global surveillance of HIV-1 drug resistance,"Provided herein are new methods, primers, and kits for genotyping HIV-1, including group M viral strains. The methods can be used for HIV-1 drug resistance surveillance and monitoring, for example in resource-poor countries. The disclosed methods can detected more mixed HIV-1 population than previous methods. Given the high efficiency in genotyping diverse HIV-1 group M viral strains from plasma and dried blood spot (DBS) samples and substantial reagent cost saving, the disclosed methods can be used for HIV-1 drug resistance genotyping in both antiretroviral therapy (ART)-naive and -experienced populations for surveillance purposes and patient monitoring.",19,The United States of America as represented by the Secretary of the Dept. of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/703
10054593,21-Aug-18,2018,8,21,Multiplexed spectral lifetime detection of phosphors,"New methods and assays for multiplexed detection of analytes using phosphors that are uniform in morphology, size, and composition based on their unique optical lifetime signatures are described herein. The described assays and methods can be used for imaging or detection of multiple unique chemical or biological markers simultaneously in a single assay readout.",8,"INTELLEIGENT MATERIAL SOLUTIONS, INC.",LEIDEN UNIVERSITY MEDICAL CENTER,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,3,Analysis of biological materials,,,,,,G01N/582
10058559,28-Aug-18,2018,8,28,Treatment or prevention of an intestinal disease or disorder,Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.,18,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,Analysis of biological materials,,,,A61K/5513
10058602,28-Aug-18,2018,8,28,Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus,"The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.",15,"The United States of America, as represented by the Secretary, Department of Health & Human Services",The Walter Reed Army Institute of Research,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/12
10064933,4-Sep-18,2018,9,4,Recombinant rift valley fever (RVF) viruses and methods of use,"Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.",7,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,A61K/12
10068331,4-Sep-18,2018,9,4,System and apparatus for real-time processing of medical imaging raw data using cloud computing,The present invention relates to a system and apparatus for managing and processing raw medical imaging data.,20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Computer technology,Environmental technology,Digital communication,,,G06T/0012
10071016,11-Sep-18,2018,9,11,Systems for recovery from motor control via stimulation to a substituted site to an affected area,"Methods, devices and systems for recovering motor control of an area in the body of a patient affected by a neurological disorder. A device vibrotactilely stimulates a substitute site for the affected area thereby recovering the motor control of the affected area. The stimulation provided by the device is volitionally controlled by the patient.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61H/02
10071945,11-Sep-18,2018,9,11,Nuclear receptor modulators and their use for the treatment and prevention of cancer,"Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/796
10072070,11-Sep-18,2018,9,11,Potent anti-influenza A neuraminidase subtype N1 antibody,Isolated monoclonal antibodies and antigen binding fragments thereof that specifically bind neuraminidase (NA) of an N1 subtype influenza virus are disclosed herein. These antibodies and antigen binding fragments can be used for the detection of an N1 subtype influenza virus and for determining the immunogenicity of vaccines. The antibodies and antigen binding fragments also can be used for the treatment of a subject to prevent or ameliorate an influenza infection.,39,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,Pharmaceuticals,,,,C07K/1018
10072078,11-Sep-18,2018,9,11,M971 chimeric antigen receptors,"The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/2803
10072084,11-Sep-18,2018,9,11,Dual specific immunotoxin for brain tumor therapy,"We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.",13,Duke University,The United States of America as Represented by the Secretary Department of Health and Human Services (NIH),,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/2863
10072305,11-Sep-18,2018,9,11,Real-time PCR for the detection of pathogens,"Disclosed herein are methods for detecting presence of one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae, and Neisseria meningitidis nucleic acids in a sample, such as a biological sample obtained from a subject, or an environmental sample. This disclosure also provides probes, primers, and kits for detecting one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae, and Neisseria meningitidis in a sample.",12,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
10076535,18-Sep-18,2018,9,18,Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing,"Pharmaceutical compositions are provided that include an antibiotics, but that include ingredients that counteract the effect of that antibiotic on wound healing, without altering the bactericidal properties of the antibiotic. These pharmaceutical compositions include an effective amount of 1) an imidazoquinoline having toll-like receptor 7 (TLR7) ligand activity, 2) an immunostimulatory K-type CpG oligodeoxynucleotide (ODN) comprising an unmethylated CpG motif, 3) an antibiotic, and 4) a surfactant, wherein the composition is formulated for topical administration. Methods for accelerating wound healing are also provided. These methods include topically administering the disclosed compositions. The wound can be in the skin or in the eye.",28,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/713
10077296,18-Sep-18,2018,9,18,Methods and compositions for the treatment and prevention of cancer,"The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3α/CCL20 or β-defensin mDF2β. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer.",5,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/4748
10077446,18-Sep-18,2018,9,18,Glucan-encapsulated siRNA for treating type 2 diabetes mellitus,"Compositions comprising glucan-encapsulated siRNA directed against a region of the gene encoding the human CB1 receptor for use in the treatment of type 2 diabetes mellitus in a human subject. Additionally, methods for treating type 2 diabetes mellitus in a subject, comprising administering to the subject a composition comprising glucan-encapsulated siRNA directed against the CB1 receptor.",15,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",University of Massachusetts,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C12N/1138
10078124,18-Sep-18,2018,9,18,Phantom for diffusion MRI imaging,A phantom calibration body (12) for calibrating diffusion MRI device (16) that mimics a material such as a mammalian tissue is disclosed. The phantom calibration body (12) includes a homogeneous aqueous solution (30) that contains a mixture of low molecular-weight and high molecular-weight polymers housed in a container (14) that is placed in the diffusion MRI device (16) for obtaining one or more diffusion MRI images of the phantom calibration body (12). A measure of diffusivity is calculated for each of the one or more diffusion MRI images in order to calibrate the diffusion MRI device. Methods of using the phantom calibration body (12) to calibrate diffusion MRI device (16) are also disclosed.,19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Measurement,,,,,G01R/58
10081659,25-Sep-18,2018,9,25,Adeno-associated vectors for enhanced transduction and reduced immunogenicity,"A modified adeno-associated virus (AAV) capsid protein comprising at least one non-native amino acid that confers to the modified AAV particles new properties, such as increased transduction efficiency and reduced immunogenicity. These modified AAV proteins and particles are particularly useful for gene therapy and the treatment of various diseases and conditions.",13,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services","University of Florida Research Foundation, Inc.",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/005
10086108,2-Oct-18,2018,10,2,Hydrogels and use thereof in anastomosis procedures,"This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures.",25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The Johns Hopkins University,,,,,,,,,,2,Medical technology,,,,,,A61L/0031
10087211,2-Oct-18,2018,10,2,Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties,"This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.",3,RESEARCH TRIANGLE INSTITUTE,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/0005
10087230,2-Oct-18,2018,10,2,Murine anti-NY-ESO-1 T cell receptors,"The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Analysis of biological materials,,,,,C07K/7051
10087465,2-Oct-18,2018,10,2,Trans-acting elements for intracellular delivery of nucleic acid sequences,Compounds of the formula (Z)x,23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Organic fine chemistry,,,,,C12N/907
10092637,9-Oct-18,2018,10,9,Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes,"Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.",13,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/12
10094836,9-Oct-18,2018,10,9,SLCO1B3 genotype,"The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.",3,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Analysis of biological materials,Biotechnology,,,,,G01N/57434
10099024,16-Oct-18,2018,10,16,Nasal dry powder delivery system for vaccines and other treatment agents,"A nasal delivery device can include air-receiving section that has a first passageway therethrough to allow air to pass through the air-receiving section, a powder-reservoir receiving section sized to receive a powder reservoir, and a powder-delivery section that has a second passageway therethrough to allow aerosolized powder from the powder reservoir to pass through the powder-delivery section. The first passageway can have a first end and a second end, with the first end being further from the powder-reservoir receiving section and the second end being at or near the powder-reservoir receiving area. The second end of the air-receiving section can include a flattened region so that air exiting the air-receiving section has a generally flattened profile.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services","Creare, Incorporated",,,,,,,,,,2,Medical technology,,,,,,A61M/08
10099069,16-Oct-18,2018,10,16,Therapeutic apparatus and method for heating a subject,"A therapeutic apparatus (900, 1000) comprising a high intensity focused ultrasound system (904) for heating a target zone (940, 1022). The therapeutic apparatus further comprises a magnetic resonance imaging system (902). The therapeutic apparatus further comprises a memory (952) containing machine executable instructions (980, 982, 984, 986, 988, 990) for execution by a processor (944). Execution of the instructions cause the processor to: generate (702, 802) heating commands (964) which cause the high intensity focused ultrasound system to sonicate the subject; repeatedly acquire (704, 804) magnetic resonance data (954) during execution of the heating commands; repeatedly calculate (706, 806) a spatially dependent parameter (970); and repeatedly modify (708, 808) the heating commands in accordance with the spatially dependent parameter such that within the target zone the spatially dependent parameter remains below a first predetermined threshold and above a second predetermined threshold.",18,Profound Medical Inc.,National Institutes of Health,,,,,,,,,,2,Medical technology,Measurement,,,,,A61N/00
10100346,16-Oct-18,2018,10,16,Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof,"The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.",13,Hvidovre Hospital,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Analysis of biological materials,,,,,C12Q/18
10101280,16-Oct-18,2018,10,16,Device and method for detection of counterfeit pharmaceuticals and/or drug packaging,"Featured are a device (20) and method for the detection of counterfeit pharmaceuticals and/or packaging therefore. Counterfeit pharmaceuticals are detected by visual inspection upon exposing a suspected counterfeit pharmaceutical to one or more light sources having different wavelengths, and observing the differences in color and/or brightness between the suspected counterfeit and a genuine pharmaceutical/packaging. In further embodiments, a image acquisition device acquires an image showing color and/or other visual effect(s) brightness of the suspect counterfeit and this image is compared to an image of a authentic pharmaceutical/packaging.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Computer technology,Analysis of biological materials,,,,G01N/95
10106620,23-Oct-18,2018,10,23,Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells,"Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab′)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services","Janssen Biotech, Inc.",,,,,,,,,,2,Pharmaceuticals,Biotechnology,,,,,C07K/2896
10111927,30-Oct-18,2018,10,30,Pseudomonas exotoxin A with less immunogenic B cell epitopes,"The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.",26,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/164
10113183,30-Oct-18,2018,10,30,Adeno-associated virus vectors for treatment of glycogen storage disease,"The present disclosure describes improved adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia). Described are recombinant nucleic acid molecules, vectors and recombinant AAV that include a G6PC promoter/enhancer, a synthetic intron, a G6PC coding sequence (such as a wild-type or codon-optimized G6PC coding sequence), and stuffer nucleic acid sequence situated between the G6PC promoter/enhancer and the intron, as well as between the intron and the G6PC coding sequence. The recombinant AAVs disclosed herein exhibit highly efficient liver transduction and are capable of correcting metabolic abnormalities in an animal model of GSD-Ia.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C12N/86
10117942,6-Nov-18,2018,11,6,Photoactivatable lipid-based nanoparticles as vehicles for dual agent delivery,"Embodiments of photoactivatable, lipid-based nanoparticles are disclosed, as well as methods of making and using the nanoparticles. Pharmaceutical compositions including the nanoparticles also are disclosed. The lipid-based nanoparticles include a vesicle wall surrounding a cavity, wherein the vesicle wall includes (i) a lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), dipalmitoylphosphatidylcholine (DPPC), and (ii) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer. The nanoparticles may further include an agent within the cavity.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Baylor College of Medicine,,,,,,,,,,2,Medical technology,Medical technology,,,,,A61K/546
10117947,6-Nov-18,2018,11,6,Virus-like particle conjugates for diagnosis and treatment of tumors,"The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.",22,"Aura Biosciences, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Medical technology,Biotechnology,,,,A61K/6901
10118948,6-Nov-18,2018,11,6,"Antimicrobial peptides, pharmaceutical compositions, and methods of use thereof","Disclosed herein are novel antimicrobial peptides, pharmaceutical compositions containing the peptides, and methods of use of the peptides to inhibit the growth or proliferation of microbes. The antimicrobial peptides are particularly useful to treat infections of dangerous gram positive organisms such as MRSA and VRSA.",29,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Basic materials chemistry,Biotechnology,,,,C07K/56
10119172,6-Nov-18,2018,11,6,Methods and reagents for detecting ebola virus,"Probes and primers are disclosed for detecting EBOV nucleic acid in a sample. Methods are also disclosed that utilize these probes and primers, wherein the methods can be used to detect an EBOV in a sample to identify a subject with an EBOV infection.",24,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
10125112,13-Nov-18,2018,11,13,Modulators of the relaxin receptor 1,"Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.",3,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/38
10125172,13-Nov-18,2018,11,13,Conformationally stabilized RSV pre-fusion F proteins,"In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.",15,CALDER BIOSCIENCES INC.,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/005
10130593,20-Nov-18,2018,11,20,Methods of regulating cannabinoid receptor activity-related disorders and diseases,"This disclosure concerns the discovery of the use of fenoterol analogs for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analog to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/137
10130594,20-Nov-18,2018,11,20,Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas,"This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogs for the treatment of a tumor expressing a β2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a β2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analog or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",SRI International,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/137
10130700,20-Nov-18,2018,11,20,Polyvalent influenza virus-like particles (VLPS) and use as vaccines,"This disclosure provides compositions that include a mixture of viral like particles (VLPs), expressing different individual influenza hemagglutinin (HA) proteins that elicit broadly reactive immune responses to a wide variety of influenza viruses. For example, the composition can include at least two different influenza VLPs, a first VLP comprising a first HA polypeptide and a second VLP comprising a second influenza HA polypeptide, wherein the first and the second HA polypeptide are different subtypes and/or are from different influenza viruses, and a pharmaceutically acceptable carrier and/or an adjuvant. Methods of using the disclosed polymeric influenza VLP compositions to stimulate an immune response against influenza viruses, for example as a pre-pandemic or a seasonal vaccine, are provided.",29,"The United States of America, as represented by the Secretary, DHHS",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/145
10131659,20-Nov-18,2018,11,20,Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof,Disclosed herein are novel iodonium analogs having anticancer and anti-inflammatory activity.,18,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",STARKS ASSOCIATES INC.,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
10137107,27-Nov-18,2018,11,27,Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV,Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.,18,"New York Blood Center, Inc.",National Institutes of Health,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,A61K/40
10137188,27-Nov-18,2018,11,27,Cell lines for virus production and methods of use,"Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picornavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.",26,"University of Georgia Research Foundation, Inc.","The United States of America, as represented by the Secretary, Dept. of Health and Human Services","Thermo Fisher Scientific, Inc.",,,,,,,,,3,Biotechnology,Biotechnology,,,,,A61K/13
10137190,27-Nov-18,2018,11,27,Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins,Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.,17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,A61K/145
10137212,27-Nov-18,2018,11,27,Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications,"Disclosed is a compound of formula (I) or (II) in which R1-R4, R1′-R5′, Z1+-Z4, and Z1′-Z4′ are as described herein. Also disclosed are a 89Zr- or 90Nb-containing complex of a compound of formula (I) or (II) and a method for obtaining a diagnostic image, such as a positron emission tomography (PET) image.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,A61K/0472
10138271,27-Nov-18,2018,11,27,Native and agonist CTL epitopes of the MUC1 tumor antigen,"The invention provides peptides comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) mucin 1 (MUC1) and analogs thereof, which can be used in vaccine prevention or therapy of cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.",25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/06
10138277,27-Nov-18,2018,11,27,Virus-like particles and methods of use,"The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.",9,The United States of America as Represented by the Secretary Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
10143721,4-Dec-18,2018,12,4,Combination product for the prevention of sexually transmitted infections,"Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.",15,"The Population Council, Inc.","The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/16
10143724,4-Dec-18,2018,12,4,Anti-SSX-2 T cell receptors and related materials and methods of use,"The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.",23,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/1774
10156711,18-Dec-18,2018,12,18,Multi-focal structured illumination microscopy systems and methods,"Various embodiments for a multi-focal selective illumination microscopy (SIM) system for generating multi-focal patterns of a sample are disclosed. The multi-focal SIM system performs a focusing, scaling and summing operation on each generated multi-focal pattern in a sequence of multi-focal patterns that completely scan the sample to produce a high resolution composite image.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,,,,,,G02B/0072
10159681,25-Dec-18,2018,12,25,Method for on-demand contraception,"The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.",5,Laboratoire HRA-Pharma,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/573
10160795,25-Dec-18,2018,12,25,Neutralizing antibodies to Ebola virus glycoprotein and their use,"Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.",39,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Institute for Research in Biomedicine,The United States of America as represented by the Secretary of the Army,Humabs BioMed SA,,,,,,,,4,Biotechnology,,,,,,C07K/10
10160802,25-Dec-18,2018,12,25,Anti-malarial compositions,"This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.",7,"LEIDOS, INC.","THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/205
10160957,25-Dec-18,2018,12,25,Development of dengue virus vaccine components,"The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/045
10166255,1-Jan-19,2019,1,1,Intracellular genomic transplant and methods of therapy,"Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.",31,REGENTS OF THE UNIVERSITY OF MINNESOTA,"INTIMA BIOSCIENCE, INC.","THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES",,,,,,,,,3,Biotechnology,Biotechnology,,,,,A61K/17
10166285,1-Jan-19,2019,1,1,Recombinant virus with diminished latency and methods of using same,"The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.",23,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,A61K/25
10166299,1-Jan-19,2019,1,1,AAV mediated aquaporin gene transfer to treat Sjogren's syndrome,The invention relates to a gene transfer-based method to protect a subject from Sjogren's syndrome. The method comprises administering to the subject an AAV virion comprising an AAV vector that encodes aquaporin-1 (AQP-1) protein. Also provided are AQP-1 proteins and nucleic acid molecules that encode such proteins. Also provided are AAV vectors and AAV virions that encode an AQP-1 protein.,8,THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH,,,,,,,,,,,1,Biotechnology,,,,,,A61K/005
10172911,8-Jan-19,2019,1,8,Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules,"Disclosed are methods of modulating erythropoiesis with arginine vasopressin receptor 1B (AVPR1B) molecules, such as AVPR1B agonists or antagonists. In one example, a method of stimulating erythropoiesis is disclosed including administering an effective amount of an AVPR1B stimulatory molecule to a subject in need thereof, thereby stimulating erythropoiesis. Also disclosed is a method of stimulating hematopoetic stem cell (HSC) proliferation which includes administering an effective amount of an AVPR1B stimulatory molecule to a subject in need thereof, thereby stimulating HSC proliferation. A method of inhibiting HSC proliferation including administering an effective amount of an AVPR1B inhibitory molecule to a subject in need thereof, thereby inhibiting HSC proliferation is provided.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/095
10173998,8-Jan-19,2019,1,8,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",16,"Mycovia Pharmaceuticals, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/06
10174098,8-Jan-19,2019,1,8,Anti-human papillomavirus 16 E7 T cell receptors,"Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.",31,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/7051
10182994,22-Jan-19,2019,1,22,Nanoparticulate complex of nicotine and cerium oxide and use thereof,"Disclosed are particles comprising a complex of nicotine and cerium oxide and a biodegradable coating comprising agglutinin. Also disclosed is a method of treating or preventing neurodegenerative or neurological disorders in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the particles.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/5052
10183993,22-Jan-19,2019,1,22,Compositions and methods for treating cancer with anti-mesothelin immunotherapy,"Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.",27,Lentigen Technology Inc.,,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/18
10184004,22-Jan-19,2019,1,22,CD47 targeted therapies for the treatment of infectious disease,"Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRPα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.",13,The Board of Trustees of the Leland Stanford Junior University,The Regents of the University of California,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,3,Biotechnology,Biotechnology,,,,,C07K/2896
10188714,29-Jan-19,2019,1,29,Yeast-MUC1 immunotherapeutic compositions and uses thereof,"Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).",22,"GlobeImmune, Inc.","The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/00117
10188751,29-Jan-19,2019,1,29,Papillomavirus pseudoviruses for detection and therapy of tumors,"Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).",8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Micro-structural and nano-technology,Biotechnology,Biotechnology,,,,A61K/0004
10188755,29-Jan-19,2019,1,29,Magnetic microstructures for magnetic resonance imaging,The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T2* contrast agents that have a significantly higher magnetic moment compared to similarly-sized existing MRI contrast agents.,8,"The United States of America, as represented by the Secretary, Department of Health and Human Services","The United States of America, as represented by the Secretary of Commerce",,,,,,,,,,2,Measurement,Micro-structural and nano-technology,Medical technology,,,,A61K/1818
10190143,29-Jan-19,2019,1,29,Method for synthesizing selectively labeled RNA,"The invention relates to a method for synthesizing a selectively labeled RNA, and an apparatus for performing the method. Specific segments or discrete residues within the RNA may be selectively labeled, and different segments may include different labels.",15,THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH",,,,,,,,,,2,Biotechnology,,,,,,C12P/34
10195236,5-Feb-19,2019,2,5,Use of gram negative species to treat atopic dermatitis,Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.,8,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/74
10196372,5-Feb-19,2019,2,5,MYC G-quadruplex stabilizing small molecules and their use,"Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Yale University,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/84
10196443,5-Feb-19,2019,2,5,TEM8 antibodies and their use in treatment and detection of tumors,"Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.",33,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","Biomed Valley Discoveries, Inc.",,,,,,,,,,2,Biotechnology,Pharmaceuticals,Organic fine chemistry,,,,C07K/28
10196699,5-Feb-19,2019,2,5,Primers and probes for detection and discrimination of types and subtypes of influenza viruses,"Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.",31,The United States of America as represented by the Secretary of the Dept. of Health & Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
10201591,12-Feb-19,2019,2,12,TSLP induces neutrophil mediated killing of methicillin-resistant staphylococcus aureus,"The invention provides a method of promoting the host defense of a patient to a bacterial infection comprising administering to a patient suffering or at risk of a bacterial infection, a pharmaceutical composition comprising an effective amount of the pleiotropic cytokine, thymic stromal lymphopoietin (TSLP) protein or polypeptide in an amount and at a location sufficient to promote the host defense of the patient to the bacterial infection. In a preferred embodiment, the bacterial infection is the infection of the patient with MRSA.The invention also provides a method of treating blood product, which comprises introducing a TSLP protein or polypeptide into such blood product, wherein the blood product is extracorporeal and comprises at least one neutrophil.",15,"The United States of America, as represented by the Secretary, Department of Health and Human Services",The Board of Trustees of the Leland Stanford Junior University,,,,,,,,,,2,,,,,,,A61K/19
10202367,12-Feb-19,2019,2,12,Heterocyclic compounds and methods of use thereof,"Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Kansas,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
10202654,12-Feb-19,2019,2,12,Methods for detecting Legionella nucleic acids in a sample,"Methods for detecting Legionella (such as Legionella spp., Legionella pneumophila, Legionella pneumophila serogroup 1, Legionella bozemanii, Legionella dumoffii, Legionella feeleii, Legionella longbeachae, and/or Legionella micdadei) are disclosed. A sample suspected of containing one or more Legionella nucleic acids is screened for the presence or absence of that nucleic acid. Determining whether Legionella nucleic acid is present in the sample can be accomplished by contacting the sample with detectably labeled probes capable of hybridizing to a Legionella nucleic acid and detecting hybridization between the probes and nucleic acids in the sample. Detection of hybridization indicates that a Legionella nucleic acid is present in the sample. Also disclosed are probes and primers for the detection of Legionella, and kits that contain the disclosed probes and/or primers.",7,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C12Q/689
10203382,12-Feb-19,2019,2,12,Wirelessly powered magnetic resonance imaging signal amplification system for ingestible devices having L-C mesh circuit,"An implantable parametric circuit enables local signal amplification and wireless transmission of RF signals in connection with magnetic resonance imaging systems. The parametric circuit detects RF signal detected during magnetic resonance imaging procedure, amplifies the detected RF signal, and transmits the amplified RF signal in a wireless manner to an external pick-up coil. The parametric amplifier is also configured to use another RF signal generated by an external source as the primary power source. As a result, implanted or catheter coils could be used as a wireless signal transducer without the need for a battery or a power connection.",7,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Measurement,,,,,G01R/3692
10206957,19-Feb-19,2019,2,19,Use of gram negative species to treat atopic dermatitis,Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.,13,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/74
10206995,19-Feb-19,2019,2,19,Live attenuated virus vaccines for la crosse virus and other bunyaviridae,"The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.",7,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,A61K/12
10208000,19-Feb-19,2019,2,19,Eis inhibitors,"Provided herein are novel small-molecules that have use in the inhibition of Eis, which mediates kanamycin resistance in Mycobacterium tuberculosis. The presently-disclosed subject matter further includes a pharmaceutical composition including a small molecule inhibitor, as described herein, and a suitable pharmaceutical carrier. Methods of treating tuberculosis comprising administering to an individual an effective amount of the disclosed small molecule inhibitors to mediate kanamycin A resistance and treat tuberculosis are also provided.",16,University of Kentucky Research Foundation,,,,,,,,,,,1,Organic fine chemistry,,,,,,C07D/44
10208035,19-Feb-19,2019,2,19,Compounds for inhibiting drug-resistant strains of HIV-1 integrase,"A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH;  Y is H or OH;  each of Z1-Z5 is independently H or halogen;  R4 is H, OH, NH2, NHR8, NR8R9 or R8;  R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and  R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen to which R8 and R9 are attached form an optionally-substituted heterocycle.",21,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
10213445,26-Feb-19,2019,2,26,Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer,The present disclosure provides methods utilizing the diazeniumdiolate-based prodrugs for the treatment of cancer via various mechanisms and procedures. The disclosure also provides kits comprising the diazeniumdiolate-based prodrugs.,14,"Arizona Board of Regents on Behalf of the University of Arizona, a body corporate",The United States of America as Represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/655
10214726,26-Feb-19,2019,2,26,Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject,"Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/0638
10214732,26-Feb-19,2019,2,26,Lysin agent and method of use for diagnostic testing,"Disclosed herein are the identification, cloning, and optimizing the lytic activity of one or more novel Bacillus lysin proteins, a method of selecting a lysin agent for use in molecular diagnostic testing that includes analyzing genome databases for Bacillus anthracis and near neighbors, selecting candidate genes encoding potential lytic enzymes based on conserved amino acid motifs as determined in peptidoglycan hydrolases, cloning the candidate genes in expression vector, isolating proteins thereof, and testing for lytic activity against Bacillus anthracis, and selecting an optimum gene of the candidate genes for optimizing lysis conditions.",31,"The United States of America, as represented by the Secretary of Homeland Security",,,,,,,,,,,1,Biotechnology,Basic materials chemistry,,,,,C12N/2405
10215825,26-Feb-19,2019,2,26,Magnetic microstructures for magnetic resonance imaging,The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T2* contrast agents that have a significantly higher magnetic moment compared to similarly-sized existing MRI contrast agents. The invention also relates to a magnetic resonance sensor that alters it shape in response to a condition of an environment such that the condition may be detected.,12,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","The United States of America, as represented by the Secretary of Commerce",,,,,,,,,,2,Measurement,Medical technology,Measurement,,,,G01R/5601
10215830,26-Feb-19,2019,2,26,Automated cancer detection using MRI,"Methods and systems for diagnosing cancer in the prostate and other organs are disclosed. Exemplary methods comprises extracting texture information from MRI imaging data for a target organ, sometimes using two or more different imaging modalities. Texture features are determined that are indicative of cancer by identifying frequent texture patterns. A classification model is generated based on the determined texture features that are indicative of cancer, and diagnostic cancer prediction information for the target organ is then generated to help diagnose cancer in the organ.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Computer technology,Medical technology,,,,G01R/56341
10219505,5-Mar-19,2019,3,5,Methods and apparatus for surveillance and control of insect vectors,"Improved devices for the capture, detection, or quantification of insect vectors such as gravid female insects, are provided. The devices include surface coloration, design, and dimension that improved their ability to attract and/or capture target insect vectors. The traps are used in process for detection or control of insect vectors in indoor and outdoor environments.",11,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Other special machines,,,,,,A01M/026
10220028,5-Mar-19,2019,3,5,Thio compounds,"A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein A, B and D are each oxygen or sulfur, provided that least one of A, B and D is sulfur; and R1-R8 are each independently hydrogen, hydroxyl, acyl, substituted acyl, acyloxy, substituted acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, amino, substituted amino, halogen, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, or a thio-containing group.",4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,A61K/454
10220103,5-Mar-19,2019,3,5,Magnetic microstructures for magnetic resonance imaging,The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T2* contrast agents that have a significantly higher magnetic moment compared to similarly-sized existing MRI contrast agents.,12,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","The United States of America, as represented by the Secretary of Commerce",,,,,,,,,,2,Measurement,Micro-structural and nano-technology,Medical technology,,,,A61K/1818
10227395,12-Mar-19,2019,3,12,Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin,"The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.",9,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1278
10228376,12-Mar-19,2019,3,12,Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (PANDAS),"The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined.",17,"Moleculera Labs, Inc.",The Board of Regents of the University of Oklahoma,"The United States of America, As Represented by the Secretary, Department of Health and Human Serv",,,,,,,,,3,,,,,,,G01N/686
10233209,19-Mar-19,2019,3,19,Inhibitors of the farnesoid x receptor and uses in medicine,"Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.",11,"The United States of America, As represented by the Secretary, Department of Health and Human Services",The Penn State Research Foundation,,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,C07J/0061
10233504,19-Mar-19,2019,3,19,Methods and compositions for isothermal amplification and detection of mycoplasma pneumoniae,"Disclosed herein are methods and compositions (e.g., oligonucleotide primers) for isothermal amplification and detection of M. pneumoniae nucleic acids in a sample. In some embodiments, the methods include contacting a sample with a set of LAMP primers specific for a M. pneumoniae CARDS toxin-encoding nucleic acid under conditions sufficient to produce an M. pneumoniae nucleic acid amplification product and detecting the resulting M. pneumoniae amplification product. Kits including sets of LAMP primers for detection of M. pneumoniae CARDS toxin nucleic acids are also provided herein.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",P3S Corporation,,,,,,,,,,2,Biotechnology,,,,,,C12Q/689
10239830,26-Mar-19,2019,3,26,Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders,"Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula 1:",28,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,"The United States of America, as represented by the Secretary, Depart. of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07C/21
10246463,2-Apr-19,2019,4,2,Hypoxia-inducible factor 1 (HIF-1) inhibitors,Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF-1 α subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.,22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/16
10246505,2-Apr-19,2019,4,2,Chimeric antigen receptors to control HIV infection,"The present disclosure is directed to novel multispecific chimeric antigen receptor (CAR) proteins and DNA sequences encoding these proteins. The CARs comprise at least two extracellular domains fused, via a transmembrane domain to a cytoplasmic signaling domain comprising two signaling domains. The disclosure further relates to nucleic acids encoding the novel CARs, to host cells expressing the novel CARs, and to methods of using the CARs to co-stimulate effector functions in the cells and for using cells expressing the receptors for treatment of disease and viral infections. The disclosure also relates to methods of generating a recombinant T cell with reduced susceptibility to HIV infection.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/70514
10247930,2-Apr-19,2019,4,2,Resolution enhancement for line scanning excitation microscopy systems and methods,A resolution enhancement technique for a line scanning confocal microscopy system that generates vertical and horizontal line scanning patterns onto a sample is disclosed. The line scanning confocal microscopy system is capable of producing line scanning patterns through the use of two alternative pathways that generate either the vertical line scanning pattern or horizontal line scanning pattern.,20,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,,,,,,G02B/0076
10251912,9-Apr-19,2019,4,9,"MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1","The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,A61K/17
10258686,16-Apr-19,2019,4,16,Materials and methods for respiratory disease control in canines,The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.,22,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.","CORNELL RESEARCH FOUNDATION, INC.","THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEAS CONTROL AND PREVENTION",,,,,,,,,3,Biotechnology,Biotechnology,,,,,A61K/145
10258701,16-Apr-19,2019,4,16,Labeled evans blue dye derivative for in vivo serum albumin labeling,"Disclosed is a compound of formula (I): wherein L, R1-R5, A, B, M, and n are as defined in the specification, as well as a method of preparing the compound. Also disclosed are a method of blood-pool imaging in a mammal and a method of imaging a lymph node in a mammal, comprising use of the compound.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Basic materials chemistry,Organic fine chemistry,,,,,A61K/0482
10261098,16-Apr-19,2019,4,16,Biomarkers for diagnosis and management of neuro-immunological diseases,"Biomarkers associated with neuroimmunological disease are described. The disclosed biomarkers are secreted proteins identified in cerebral spinal fluid (CSF) samples of patients with neurological disease. The disclosed biomarkers identify patients with intrathecal inflammation, distinguish multiple sclerosis (MS) patients from patients with other types of inflammatory neurological diseases and from subjects without MS, distinguish progressive MS patients from patients with relapsing-remitting MS, identify subjects with non-MS inflammatory neurological diseases, differentiate healthy subjects from patients with any type of neurological disease, and/or identify subjects with increased disability, CNS tissue damage and/or neurodegeneration. Process-specific biomarkers that can be used in place of a brain biopsy to identify immune cell infiltration and/or activation in the CNS are also described. Methods of treating subject with neurological disease, and methods of evaluating the efficacy of particular treatments, based on detection of the disclosed biomarkers are also described.",10,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Montana State University,,,,,,,,,,2,,,,,,,G01N/6896
10265313,23-Apr-19,2019,4,23,Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria,"The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R1—R2  (I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.",13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Biotechnology,Organic fine chemistry,,,,A61K/501
10266488,23-Apr-19,2019,4,23,4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase,"Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12-lipoxygenase mediated disease or disorder.",9,Eastern Virginia Medical School,The Regents of the University of California Santa Cruz,The United States of America Department of Health and Human Services,Thomas Jefferson University,,,,,,,,4,Organic fine chemistry,Pharmaceuticals,,,,,C07C/44
10266565,23-Apr-19,2019,4,23,Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use,"Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds.",14,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/06
10267837,23-Apr-19,2019,4,23,Electromagnetic radiation detection apparatus and method of detecting low levels of millimeter wave electromagnetic radiation,"The present disclosure is directed to an apparatus for detecting low level pulses of millimeter wave electromagnetic radiation, such as by detecting the presence of weak electromagnetic emissions inside or around an electromagnetic radiation-emitting device, such as a millimeter wave scanner. The apparatus may also be used to assess such emissions and display a graphical and numerical indication of a sensed level of energy density. A hand-held portable apparatus for detecting low levels of electromagnetic radiation as well as a method for detecting low levels of electromagnetic radiation are also provided.",20,"The United States of America, as represented by the Secretary of Homeland Security",,,,,,,,,,,1,Measurement,Audio-visual technology,,,,,G01R/0878
10272039,30-Apr-19,2019,4,30,Topical sodium nitrite formulation,"A sodium nitrite formulation for topical administration is described. The formulation includes an aqueous solution of non-acidified sodium nitrite dispersed in a white petrolatum ointment. The concentration of sodium nitrite in the formulation is about 0.5% to about 3.0% by weight. To prepare the formulation, non-acidified sodium nitrite is completely dissolved in a small quantity of water, sterile filtered and dispersed in white petrolatum ointment.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,,,,,,,A61K/06
10273288,30-Apr-19,2019,4,30,Neutralizing antibodies to Ebola virus glycoprotein and their use,"Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.",34,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Institute for Research in Biomedicine,"The United States of America, as represented by the Secretary of the Army",Humabs Biomed SA,,,,,,,,4,Biotechnology,,,,,,C07K/10
10273291,30-Apr-19,2019,4,30,Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing,"Antibody VRC01 represents a human immunoglobulin that neutralizes—˜90% of diverse HIV-1 isolates. To understand how such broadly neutralizing HIV-1 antibodies develop and recognize the viral envelope, we used X-ray crystallography and 454 pyrosequencing to characterize additional antibodies from HIV-1-infected individuals. Crystal structures revealed a convergent mode of binding of different antibodies to the same CD4-binding-site epitope. Antibody recognition was achieved through the evolution of complementary contact domains that were generated in diverse ways. Phylogenetic analysis of expressed heavy and light chains determined by deep sequencing revealed a common pathway of antibody heavy chain maturation confined to IGHV1-2*02 lineage that could pair with different light chains. The maturation pathway inferred by antibodyomics reveals that diverse antibodies evolve to a highly affinity-matured state to recognize an invariant viral structure, providing insight into the development and evolution of broadly neutralizing HIV-1 immunity.",40,Duke University,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/1063
10273548,30-Apr-19,2019,4,30,Protease-deficient bacillus anthracis,"The invention relates to a Bacillus anthracis (B. anthracis) in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield. The disclosure provides a B. anthracis that comprises a genetic modification that inactivates a protease of the M4 family of metalloproteases and a genetic modification that inactivates a protease of the M6 family of metalloproteases. Also provided is a modified B. anthracis comprising such genetic modification transformed with a recombinant molecule encoding a product, as well as methods to prepare and use such B. anthracis.",15,"The Unites States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12R/07
10279019,7-May-19,2019,5,7,PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same,"A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.",16,STC.UNM,STC.UNM,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/0005
10279019,7-May-19,2019,5,7,PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same,"A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.",16,STC.UNM,STC.UNM,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/0005
10280307,7-May-19,2019,5,7,Class of stable heptamethine cyanine fluorophores and biomedical applications thereof,"Embodiments of C4′-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4′-alkyl-ether heptamethine cyanine fluorophores also are disclosed.",25,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Basic materials chemistry,,,,,C09B/086
10281702,7-May-19,2019,5,7,Multi-focal structured illumination microscopy systems and methods,"A multi-focal structured illumination microscopy (SIM) system for generating multi-focal patterns of a sample is disclosed. The multi-focal SIM system performs a focusing, scaling and summing operation on each multi-focal pattern in a sequence of multi-focal patterns that completely scan the sample to produce a high resolution composite image.",20,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Optics,,,,,,G02B/0072
10285813,14-May-19,2019,5,14,Tensioning device and methods for use,"A tensioning device is provided comprising a locking device. The locking device comprises a locking enclosure comprising a groove and a locking pin comprising teeth. The tensioning device further comprises a suture comprising first and second portions. The first and second portions of the suture and the locking pin are positioned within the groove of the locking enclosure and the locking pin is movable within the groove between a first, outer position in which the teeth are disengaged from the suture so that the locking device is movable along the first and second portions of the suture and a second, inner position in which the teeth are engaged with the suture so that the locking device is not movable along the suture. Methods for treating mitral valve regurgitation are also provided.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,Mechanical elements,,,,,A61F/246
10286050,14-May-19,2019,5,14,Multi-epitope TARP peptide vaccine and uses thereof,"Immunogenic T cell receptor γ alternate reading frame protein (TARP) peptide compositions that include multiple epitopes of the TARP protein are described. The disclosed compositions can be used for the treatment of TARP-expressing cancers, such as prostate cancer, breast cancer and mesothelioma. In some embodiments, the TARP peptide compositions disclosed herein include sets of overlapping TARP peptides that each have a length of about 15 to about 25 amino acids, and comprise about 5 to about 15 amino acids that are identical to at least another overlapping peptide in the set. In particular examples, the combination of the overlapping TARP peptides in the set encompasses the complete amino acid sequence of human TARP. The multi-epitope peptide compositions described herein include both CD4 and CD8 epitopes, a feature that is important for eliciting CD4+ T cell and CD8+ T cell, as well as humoral, immune responses.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/0011
10287279,14-May-19,2019,5,14,Inhibitors of human 12/15-lipoxygenase,"A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.",19,THE CHILDREN'S HOSPITAL CORPORATION,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,3,Organic fine chemistry,Organic fine chemistry,,,,,C07D/04
10287297,14-May-19,2019,5,14,Epoxyazulene derivatives useful for treating cancer and diabetes,"Disclosed is a compound of formula (I) in which R1-R5 and X1 are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes.",19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Fundació Institut Català d'Investigació Quimica (ICIQ),Universitat Rovira i Virgili,,,,,,,,,3,Organic fine chemistry,Pharmaceuticals,,,,,C07D/08
10287340,14-May-19,2019,5,14,Anti-HIV domain antibodies and method of making and using same,"The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/1045
10287350,14-May-19,2019,5,14,Chimeric antigen receptors targeting CD-19,"The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/2803
10290076,14-May-19,2019,5,14,System and method for automated initialization and registration of navigation system,"A system and method for image registration includes tracking (508) a scanner probe in a position along a skin surface of a patient. Image planes corresponding to the position are acquired (510). A three-dimensional volume of a region of interest is reconstructed (512) from the image planes. A search of an image volume is initialized (514) to determine candidate images to register the image volume with the three-dimensional volume by employing pose information of the scanner probe during image plane acquisition, and physical constraints of a pose of the scanner probe. The image volume is registered (522) with the three-dimensional volume.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Koninklijke Philips N.V.,,,,,,,,,,2,Computer technology,Medical technology,,,,,G06T/0068
10293005,21-May-19,2019,5,21,Use of gram negative species to treat atopic dermatitis,Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.,10,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/74
10300095,28-May-19,2019,5,28,AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity,The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.,6,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,Biotechnology,,,,A61K/76
10300115,28-May-19,2019,5,28,Methods and compositions for modulating immune tolerance,"The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.",22,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,A61K/465
10301314,28-May-19,2019,5,28,Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis,"The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.",9,"The United States of America, as represented by the Secretary, Department of Health and Human Services",University of Kansas,Northwestern University,,,,,,,,,3,Organic fine chemistry,Pharmaceuticals,,,,,C07D/04
10301377,28-May-19,2019,5,28,"Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use","Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.",23,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/10
10301621,28-May-19,2019,5,28,Multifunctional RNA nanoparticles and methods of use,The instant invention provides RNA nanoparticles and R/DNA chimeric nanoparticles comprising one or more functionalities. The multifunctional RNA nanoparticles are suitable for therapeutic or diagnostic use in a number of diseases or disorders.,19,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,Pharmaceuticals,,,,C12N/113
10302528,28-May-19,2019,5,28,Confocal laser method and device for measurement of optical properties of toric intraocular lenses,"Described are systems, devices, and methods related to a confocal laser method (CLM) for accurately measuring dioptric powers and other critical optical properties of intraocular lenses (IOLs), such as toric IOLs. Described test results demonstrate that the described CLM systems and methods can be used to measure the spherical equivalent and cylinder powers of toric IOLs with high accuracy. Furthermore, some described systems include a rotating rectangular slit aperture that can be used for precise differentiation of the two focal planes and isolation of the two focal points, and thus, for accurate measurement of the anterior cylinder axis of toric IOLs.",20,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,Medical technology,,,,,G01M/0235
10307469,4-Jun-19,2019,6,4,Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA),"Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).",11,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,A61K/52
10307476,4-Jun-19,2019,6,4,Genetically stable live attenuated respiratory syncytial virus vaccine and its production,"Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,A61K/155
10307493,4-Jun-19,2019,6,4,Imageable embolic microsphere,"This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors.",10,Biocompatible UK Limited,National Institutes of Health,,,,,,,,,,2,"Macromolecular chemistry, polymers","Macromolecular chemistry, polymers",Pharmaceuticals,,,,A61K/0442
10308591,4-Jun-19,2019,6,4,"Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure","This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogs which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogs are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogs, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.",4,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07C/60
10314900,11-Jun-19,2019,6,11,Lutzomyia longipalpis polypeptides and methods of use,"Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.",13,"The United States of America, as represted by the Secretary, Department of Health and Human Services",Fundaçao Oswaldo Cruz (FIOCRUZ),,,,,,,,,,2,Biotechnology,Biotechnology,,,,,A61K/008
10314908,11-Jun-19,2019,6,11,Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation,A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.,7,The United States of America as represented by the Secretary of the Department of,,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/39
10314924,11-Jun-19,2019,6,11,RPGR gene therapy for retinitis pigmentosa,"Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.",19,Massachusetts Eye & Ear Infirmary,UCL Business PLC,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,3,Biotechnology,Pharmaceuticals,,,,,A61K/005
10316289,11-Jun-19,2019,6,11,Methods of producing T memory stem cell populations,"Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating nave T cells from a mammal, wherein the mammal is not a mouse; b) activating the nave T cells and expanding the numbers of nave T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO−, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/0636
10322146,18-Jun-19,2019,6,18,Methods of conditioning patients for T cell therapy,"The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.",30,"Kite Pharma, Inc.","The United States of America as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/17
10323083,18-Jun-19,2019,6,18,Agents that specifically bind matrilin-3 and their use,"Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.",98,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/18
10329259,25-Jun-19,2019,6,25,Pyrazole derivatives and their use as cannabinoid receptor mediators,"A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X and Y are each independently selected from optionally-substituted aryl, optionally-substituted heteroaryl, optionally-substituted cycloalkyl, optionally-substituted heterocycloalkyl, or optionally-substituted alkyl;",35,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Organic fine chemistry,Pharmaceuticals,,,,,C07D/06
10329323,25-Jun-19,2019,6,25,Method for purifying antibodies using PBS,"Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).",10,"The United States of America, as represented by the Secretary, Department of Health & Human Services",United Therapeutics Corporation,,,,,,,,,,2,Biotechnology,,,,,,C07K/36
10329339,25-Jun-19,2019,6,25,Anti-human papillomavirus 16 E6 T cell receptors,"Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/7051
10329630,25-Jun-19,2019,6,25,Compositions and methods for detection and discrimination of emerging influenza virus subtypes,"Compositions and methods for detecting presence of an emerging influenza virus in a sample, such as a biological sample obtained from a subject or an environmental sample, are disclosed. In some embodiments, the compositions and methods can be used to quickly identify particular subtypes of influenza virus (such as a pandemic and/or emerging influenza virus subtype). Probes and primers are provided herein that permit the rapid detection and/or discrimination of pandemic influenza virus subtype nucleic acids in a sample. Devices (such as arrays) and kits for detection and/or discrimination of influenza virus subtype nucleic acids are also provided.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/701
10335423,2-Jul-19,2019,7,2,Inhibition of HIV infection through chemoprophylaxis,A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.,19,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/675
10335426,2-Jul-19,2019,7,2,N-acetyl mannosammine as a therapeutic agent,The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.,9,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7008
10350273,16-Jul-19,2019,7,16,Treatment of hormonal disorders of growth,"The present invention refers to a GPR101 inhibitor, antagonist or inverse agonist or inverse agonist for use in preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism. Further, the present invention provides a GPR101 agonist for use in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion wherein to a subject GPR101 agonist is administered.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Université de Liége and Centre Hospitalier Universitaire De Liége,,,,,,,,,,2,Biotechnology,Biotechnology,,,,,A61K/31
10350306,16-Jul-19,2019,7,16,Methods and compositions for treating genetically linked diseases of the eye,"Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.",13,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/0058
10350312,16-Jul-19,2019,7,16,Magnetic microstructures for magnetic resonance imaging,"The present invention relates to magnetic contrast structures for magnetic resonance imaging, and methods of their use. The contrast structures include magnetic materials arranged as a pair of disk-shaped magnetic components with a space between a circular surface of each disk shape, or a tubular magnetic structure, a substantially cylindrical magnetic structure, a substantially spherical shell-formed magnetic structure, or a substantially ellipsoidal shell-formed structure, each defining a hollow region therein. The space and/or hollow region in the contrast structure creates a spatially extended region contained within a near-field region of the contrast structure over which an applied magnetic field results in a homogeneous field, such that nuclear magnetic moments of a second material when arranged within the spatially extended region precess at a characteristic Larmor frequency, whereby the contrast structure is adapted to emit a characteristic magnetic resonance signal of the magnetic material.",10,"The United States of America, as Represented by the Secretary, Department of Health and Human Services","The United States of America, as represented by the Sectretary of Commerce",,,,,,,,,,2,Measurement,"Electrical machinery, apparatus, energy",Medical technology,,,,A61K/1818
10351532,16-Jul-19,2019,7,16,Small molecule inhibitors of lactate dehydrogenase and methods of use thereof,"Provided is a compound of formula (I), in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.",21,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",VANDERBILT UNIVERSITY,THE UAB RESEARCH FOUNDATION,THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,,,,,,,,4,Organic fine chemistry,Organic fine chemistry,,,,,C07D/20
10351587,16-Jul-19,2019,7,16,"Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate","Methods of using 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate (I) and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate, and processes for their preparation.",22,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07J/0059
10351844,16-Jul-19,2019,7,16,Methods and compositions for treating leber congenital amaurosis,"Expression vectors, viral particles and therapeutic methods of using such constructs to improve the visual function of a patient suffering from diseases of the eye, resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye, particularly Leber Congenital Amaurosis (LCA) and CEP290-related LCA.",7,"The United States of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/1024
10358481,23-Jul-19,2019,7,23,Engineered antibody constant domain molecules,"Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.",17,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/1063
10363286,30-Jul-19,2019,7,30,Peptide inhibition of CCR3-mediated diseases or conditions,"A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.",10,The Board of Trustees of the University of Illinois,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/195
10363294,30-Jul-19,2019,7,30,Yeast-brachyury immunotherapeutic compositions,"Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.",32,"GlobeImmune, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Medical technology,Biotechnology,Pharmaceuticals,,,,A61K/0011
10363301,30-Jul-19,2019,7,30,Stabilized influenza hemagglutinin stem region trimers and uses thereof,"Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.",18,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,A61K/145
10369208,6-Aug-19,2019,8,6,Methods for the induction of immune responses in a subject compromising administering virus-like particles (VLPS) prepared from Chikungunya virus structural proteins,"The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.",6,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/12
10370348,6-Aug-19,2019,8,6,Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders,"The subject invention relates to improved tocopheryl quinine derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of Lysosomal Storage Disorder, restoration of normal mitochondrial ATP production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms.",1,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Organic fine chemistry,,,,,C07D/58
10370439,6-Aug-19,2019,8,6,Prevention of tissue ischemia and related methods,"Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.",25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Organic fine chemistry,Chemical engineering,Biotechnology,,,,C07K/18
10370715,6-Aug-19,2019,8,6,"Methods for identifying, diagnosing, and predicting survival of lymphomas","The invention provides methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention provides a microarray for obtaining gene expression data from a lymphoma sample. The invention also provides a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma, which is useful in developing an appropriate therapeutic approach.",5,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6883
10376253,13-Aug-19,2019,8,13,Transvascular and transcameral device access and closure,"Transcatheter methods are disclosed for introducing a large transcatheter implant or other device into an artery from an adjacent vein, for example from the inferior vena cava into the abdominal aorta. Such an access route can be formed by direct puncture through the adjoining vessels. In addition, methods and devices are also disclosed for closing arteriovenous fistulas or other cardiovascular passageways.",10,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human services",,,,,,,,,,,1,Medical technology,,,,,,A61B/0057
10377798,13-Aug-19,2019,8,13,Recombinant respiratory syncytial virus G protein fragments,"Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.",18,"The United States of America, as rerpresented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/005
10379234,13-Aug-19,2019,8,13,Portable real time in-situ gamma-ray analysis system,"A gamma-ray analysis system is described for analyzing gamma-ray emitting radionuclides. The gamma-ray analysis system includes an analytical apparatus having a gamma-ray detector in operative communication with a modular and scalable shield assembly that encases a sample container having a sample to be tested. The detector communicates data to an electronic interface device that converts the data from an analog format to a digital format before a controller transmits the data to a central laboratory for further data processing, analysis and conclusion by qualified laboratory analysts. The controller runs an application software package on a graphic user interface that allows simple steps for conducting testing and data acquisition by the end user, while permitting real time data transmission between the field site and the central location. Functions were implemented for ensuring laboratory quality results while removing knowledge and experience requirements of an end user.",22,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services","Mirion Technologies, Inc.",Mirion Technologies (Canberra UK) Limited,,,,,,,,,3,Environmental technology,,,,,,G01T/02
10383924,20-Aug-19,2019,8,20,Combination immunotherapy compositions against cancer and methods,"Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.",25,"GlobeImmune, Inc.","The USA, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/0011
10383960,20-Aug-19,2019,8,20,Small molecule imaging of fungi by positron emission tomography scanning,"Disclosed herein are isotopically labeled calcofluor derivatives and uses of such to detect fungi, such as filamentous fungi, including Aspergillus species, such as by positron emission tomography (PET) scanning. In some examples, the disclosed compounds have a formula of",19,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",The Research Foundation of the State Univeristy of New York,,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,A61K/0461
10385313,20-Aug-19,2019,8,20,Human IPSC-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings,"Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.",10,"The USA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/0607
10392365,27-Aug-19,2019,8,27,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",2,"Mycovia Pharmaceuticals, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/06
10392441,27-Aug-19,2019,8,27,IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia,"Antibodies and antigen binding fragments that specifically bind to IL-7Rα are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7Rα using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7Rα, such as acute lymphoblastic leukemia.",32,"United States of America, as represented by the Secretary, Department of Health and Human Services","University of Maryland, College Park",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/2866
10393745,27-Aug-19,2019,8,27,Method for the diagnosis and prognosis of cancer,"The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.",20,"The USA, as represented by the Secretary, Department of Heath and Human Services",,,,,,,,,,,1,,,,,,,G01N/57423
10393831,27-Aug-19,2019,8,27,Negative resistance preamplifier for inductively coupled local MRI coils,"A novel MRI-compatible amplifier design uses positive feedback from a low-noise Field-Effect Transistor to amplify the signal current within a resonant NMR coil. The amplified signal current in this low-power circuit produces RF flux can be coupled out to receiving loops positioned externally without significant loss in sensitivity. In other aspects, the amplifier may be remotely powered by external resonant loops, a small non-magnetic battery, or optical power, such that the NMR coil can be positioned during highly invasive procedures such as for surgical resection of tumors in deep-lying tissues to develop high-resolution images.",19,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Measurement,,,,,,G01R/3621
10398772,3-Sep-19,2019,9,3,Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy,"Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.",25,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Oregon Health & Science University,,,,,,,,,,2,Biotechnology,,,,,,A61K/21
10399943,3-Sep-19,2019,9,3,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",16,"Mycovia Pharmaceuticals, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/50
10400015,3-Sep-19,2019,9,3,Recombinant HIV-1 envelope proteins and their use,"HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.",51,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/435
10400031,3-Sep-19,2019,9,3,Identification of antibodies specific for lyssaviruses and methods of their use,"Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.",13,The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,,,,,,C07K/10
10401604,3-Sep-19,2019,9,3,Resolution enhancement for light sheet microscopy systems and methods,"Embodiments of a resolution enhancement technique for a light sheet microscopy system having a three objective lens arrangement in which one objective lens illuminates a sample and the second and third objective lenses collect the fluorescence emissions emitted by the sample are disclosed. The second objective lens focuses a first portion of the fluorescence emissions for detection by a second detection component, while the third objective lens focuses a second portion of the fluorescence emissions through a diffractive or refractive optic component for detection by a first detector component. A processor combines the images resulting from the first and second portions of the fluorescence emissions for generating composite images with increased axial and lateral resolution.",20,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Optics,,,,,,G02B/0072
10406177,10-Sep-19,2019,9,10,Modified cells and methods of therapy,"Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.",23,Regents of the University of Minnesota,"Intima Bioscience, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,3,Biotechnology,Biotechnology,,,,,A61K/17
10407392,10-Sep-19,2019,9,10,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",3,"Mycovia Pharmaceuticals, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/50
10407485,10-Sep-19,2019,9,10,Murine anti-NY-ESO-1 T cell receptors,"The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/7051
10407665,10-Sep-19,2019,9,10,Methods for generation of pluripotent and multipotent cells,"This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.",14,"The USA, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/0696
10408837,10-Sep-19,2019,9,10,Peptide substrates recognizable by type E botulinum neurotoxin,"The present invention relates to peptide substrates selectively recognized by botulinum toxin type A, BoNT/E, and their uses, in particular for carrying out methods for detecting, identifying and/or diagnosing botulinum toxin type E.",8,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,Biotechnology,,,,,,G01N/573
10413527,17-Sep-19,2019,9,17,Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV,Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.,18,"New York Blood Center, Inc.","The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Pharmaceuticals,,,,,A61K/40
10413548,17-Sep-19,2019,9,17,Methods and compositions for the inhibition of Pin1,"The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.",3,"Beth Israel Deaconess Medical Center, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/5377
10415044,17-Sep-19,2019,9,17,Adeno-associated virus vectors encoding modified G6PC and uses thereof,"Modified G6PC (glucose-6-phosphatase, catalytic subunit) nucleic acids and glucose-6-phosphatase-α (G6Pase-α) enzymes with increased phosphohydrolase activity are described. Also described are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing modified G6Pase-α. The disclosed AAV vectors and rAAV can be used for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia), and complications thereof.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/66
10420834,24-Sep-19,2019,9,24,Recombinant metapneumovirus F proteins and their use,"Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.",53,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Institute for Research in Biomedicine,,,,,,,,,,2,Biotechnology,,,,,,A61K/155
10421741,24-Sep-19,2019,9,24,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",2,"Mycovia Pharmaceuticals, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,,,,,,C07D/06
10421802,24-Sep-19,2019,9,24,Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides,"The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.",20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Veritech Limited,,,,,,,,,,2,Biotechnology,,,,,,C07K/10
10421945,24-Sep-19,2019,9,24,Agents and methods to elicit anti-tumor immune response,"The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.",20,The Trustees of Columbia University in the City of New York,"The United States of America, as Represented by the Secretary, Department of Health and Human Service",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C12N/0638
10421978,24-Sep-19,2019,9,24,Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus,"The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.",16,"The USA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12N/86
10423757,24-Sep-19,2019,9,24,System and method for probabilistic ablation planning,"A system and method for ablation planning includes defining (502) shapes and sizes for one or more ablation volumes based on probability of treatment, and determining (510) a target volume to be treated. A procedure plan is provided (516) by determining a number and location of planned ablations within the target volume using the one or more ablation volumes. A joint probability distribution (520) is determined for at least two planned ablations in the target volume. A final configuration is visualized (530) to determine if plan objectives are met based on a probability of treatment for the target volume.",14,KONINKLIJKE PHILIPS N.V.,,,,,,,,,,,1,Medical technology,Computer technology,,,,,G06F/00
10426830,1-Oct-19,2019,10,1,Altering the immundominance hierarchy using a DNA vaccine expressing conserved regions,The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.,18,"THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",UNIVERSITY OF WASHNGTON THROUGH ITS CENTER FOR COMMERCIALIZATION,,,,,,,,,,2,Biotechnology,Medical technology,,,,,A61K/21
10428025,1-Oct-19,2019,10,1,Antifungal compound process,"The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.",3,"Mycovia Pharmaceuticals, Inc.","The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Organic fine chemistry,Organic fine chemistry,,,,,C07D/50
10428119,1-Oct-19,2019,10,1,Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes,"The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.",18,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C07K/21
10428313,1-Oct-19,2019,10,1,Chimeric West Nile/Dengue viruses and methods of use,"Disclosed herein are chimeric flaviviruses including non-coding regions, non-structural proteins, and at least a portion of a C protein from West Nile virus (WNV), and a prM protein and an E protein from Dengue virus (DENV). The DENV may be DEN1 serotype, DEN2 serotype, DEN3 serotype, or DEN4 serotype. Also disclosed herein are compositions and methods for eliciting an immune response in a subject, such as an immune response to one or more DENV serotypes. In particular embodiments, the compositions include one or more inactivated viruses including a WN/DENV chimeric nucleic acid (such as a tetravalent inactivated vaccine including a WN/DEN1 chimera, a WN/DEN2 chimera, a WN/DEN3 chimera, and a WN/DEN4 chimera). The compositions may be administered to a subject to elicit an immune response.",29,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C12N/00
10428314,1-Oct-19,2019,10,1,Human ebola virus species and compositions and methods thereof,Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.,20,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12N/00
10433962,8-Oct-19,2019,10,8,"Annuloplasty procedures, related devices and methods","Devices and methods are disclosed for the treatment or repair of regurgitant cardiac valves, such as a mitral valve. An illustrative annuloplasty device can be placed in the coronary sinus to reshape the mitral valve and reduce mitral valve regurgitation. An improved protective device can be placed between the annuloplasty device and an underlying coronary artery to inhibit compression of the underlying coronary artery by the annuloplasty device in the coronary sinus. In addition, the protective device can inhibit compression of the coronary artery from inside the heart, such as from a prosthetic mitral valve that exerts radially outward pressure toward the coronary artery. The annuloplasty device can also create an artificial inner ridge or retaining feature projecting into the native mitral valve region to help secure a prosthetic mitral valve.",17,Transmural Systems LLC,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Medical technology,,,,,,A61F/2451
10434116,8-Oct-19,2019,10,8,Methods of treating coronavirus infection,"The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.",7,"University of Maryland, Baltimore","United States Government as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,2,Pharmaceuticals,,,,,,A61K/7068
10434174,8-Oct-19,2019,10,8,Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells,"Methods, pharmaceutical compositions, and kits for treating a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a platinum agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof.",37,"The United States of America, As Represented by the Secretary, Department of Health and Human Services","BioMed Valley Discoveries, Inc.",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,A61K/39558
10434174,8-Oct-19,2019,10,8,Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells,"Methods, pharmaceutical compositions, and kits for treating a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a platinum agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof.",37,"The United States of America, As Represented by the Secretary, Department of Health and Human Services","BioMed Valley Discoveries, Inc.",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,A61K/39558
10443091,15-Oct-19,2019,10,15,Selective oxidation of 5-methylcytosine by TET-family proteins,"The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.",13,CHILDREN'S MEDICAL CENTER CORPORATION,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Biotechnology,,,,,,C12Q/6827
10450372,22-Oct-19,2019,10,22,Anti-thyroglobulin T cell receptors,"Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the disclosure are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,Biotechnology,,,,,C07K/26
10456461,29-Oct-19,2019,10,29,Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus,"The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.",12,"The United States of America, as represented by the Secretary, Department of Health and Human Services","The Government of the United States, as represented by the Secretary of The Army",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,A61K/12
10457978,29-Oct-19,2019,10,29,Cyclopentane-peptide nucleic acids for qualitative and quantitative detection of nucleic acids,The invention concerns methods for detecting a nucleic acid of interest in a solution comprising (a) contacting a solution suspected of containing the nucleic acid of interest with a PNA capture probe and a PNA reporter probe; wherein (i) the PNA capture probe comprises at least two trans-cyclopentanes; (ii) the PNA reporter probe comprises at least six biotin groups; (iii) the PNA capture probe bound to a surface; and (iv) the PNA capture probe and the PNA reporter probe each comprise a nucleobase sequence that is complementary to different non-overlapping portions of the nucleic acid of interest; (b) detecting the presence of the PNA capture probe and the PNA reporter probe bound to the surface; wherein the nucleic acid of interest is detected when 1-1000 molecules of the nucleic acid of interest are present in the solution being tested.,8,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/682
10459212,29-Oct-19,2019,10,29,Optical trap for rheological characterization of biological materials,"Systems and methods for assaying the viscoelastic properties of a heterogeneous material are provided. The systems and methods allow for application of an in situ calibrated optical trap to optical trap beads within the material to assay the viscoelastic properties. In several embodiments, the material can be a biological material, such as tumor tissue or skin tissue.",26,"The United States of America, as represented by the Secretary, Dept. of Health and Human Service",,,,,,,,,,,1,Medical technology,Optics,,,,,G01N/16
10463495,5-Nov-19,2019,11,5,Encircling implant delivery systems and methods,"Delivery devices for delivering encircling implants can include two separate limbs that are held together at a distal articulation by the implant being delivered. The implant can comprise a suture and/or a braided tube. The implant can extend through or over the limbs. The implant and at least a distal portion of the limbs can be compressible into a delivery shape that allows for advancement through the lumen of a delivery catheter. When the distal portion of the limbs move out of the delivery catheter, the limbs and implant can resiliently assume a loop shape that is complementary to a shape of a target around which the encircling implant is to be placed. The limbs are then retracted from along the implant to leave the implant in the desired delivery position. The delivery device can be used to place encircling implants around the heart or other targets, and the implant can be tightened to exert compressive force on the target.",36,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Medical technology,,,,,,A61F/2481
10464881,5-Nov-19,2019,11,5,Process for preparing Z-endoxifen of high purity,"Disclosed is a process for preparing (Z)-endoxifen, comprising (i) recrystallizing an input crystalline solid comprising a mixture of (Z)-endoxifen (1) and (E)-endoxifen (2) from a first solvent to provide a first crystalline solid and a first mother liquor, wherein the first mother liquor has a ratio of (1) to (2) at least 1.3 times greater than the ratio in the input crystalline solid (1) and (2); (ii) recrystallizing a solid produced by concentrating the first mother liquor, or by removal of the first solvent from the first mother liquor, from a second solvent to give a second crystalline solid and a second mother liquor; (iii) optionally recrystallizing the second crystalline solid from the second solvent one to five additional times to give a third crystalline solid; wherein the third crystalline solid has a ratio of (Z)-endoxifen (1) to (E)-endoxifen (2) greater than 20:1.",18,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",ALCHEM LABORATORIES CORPORATION,,,,,,,,,,2,Organic fine chemistry,,,,,,C07C/10
10464970,5-Nov-19,2019,11,5,Compounds that bind to human immunodeficiency virus rev response element,"Compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA are provided. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also provided are methods of treating or inhibiting HIV including administering one or more of the RRE binding compounds to a subject.",18,"The United States of America as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,,,,,,C07K/00
10465234,5-Nov-19,2019,11,5,Selective oxidation of 5-methylcytosine by TET-family proteins,"The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.",11,CHILDREN'S MEDICAL CENTER CORPORATION,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Biotechnology,,,,,,C12Q/6827
10471142,12-Nov-19,2019,11,12,Combination therapy using immunoglobulin and C1-Inhibitor,"Methods are disclosed for treating cerebral ischemia using a combination of C1-INH and immunoglobulin, such as human plasma derived immunoglobulin (IVIG).",17,CSL BEHRING GMBH,THE GOVERNMENT OF THE UNITED STATES OF AMERICA,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,A61K/39516
10472412,12-Nov-19,2019,11,12,Bispecific multivalent fusion proteins,"The invention provides a construct comprising two or more fusion proteins of Formulas (I)-(IV): A-(optional linker)-C-(optional linker)-B (Formula I), B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula II), A-(optional linker)-C (Formula III), and B-(optional linker)-D-(optional linker)-E (Formula IV), wherein A denotes an antibody or antibody fragment, B denotes a single domain CD4, C denotes an immunoglobulin light chain constant region D denotes an immunoglobulin heavy chain constant region, and E denotes an Fc region or a portion thereof that is optionally defucosylated.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services",Fudan University,,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/1063
10480031,19-Nov-19,2019,11,19,Method for generating Retinal Pigment Epithelium (RPE) cells from Induced Pluripotent Stem Cells (IPSCs),"High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.",27,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,C12Q/6881
10485771,26-Nov-19,2019,11,26,Methods of regulating cannabinoid receptor activity-related disorders and diseases,"This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.",14,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/137
10487365,26-Nov-19,2019,11,26,Methods for detecting expression of lnc-FANCI-2 in cervical cells,"Described herein are biomarkers for HPV-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The RNA binding protein (RBP) and long-noncoding RNA (lnc-RNA) biomarkers can be detected and used to diagnose HPV-associated pre-cancers and cancers. In addition, early diagnosis of HPV-associated pre-cancers and cancers can facilitate therapeutic intervention in patients, particularly in the pre-cancer stage which can delay or prevent progression to cancer.",3,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,,1,Biotechnology,,,,,,C12Q/6886
10493087,3-Dec-19,2019,12,3,Sialylation-increasing therapies for diseases associated with oxidative stress,"Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.",18,"The United States of America, as represented by National Institute of Health",,,,,,,,,,,1,Pharmaceuticals,,,,,,A61K/7008
10494435,3-Dec-19,2019,12,3,Human monoclonal antibodies specific for CD22,"Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.",14,The Government of the United States America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,C07K/2803
10500264,10-Dec-19,2019,12,10,Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses,A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.,13,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Pharmaceuticals,,,,,A61K/12
10500269,10-Dec-19,2019,12,10,Human rotavirus vaccine strains and diagnostics,"A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.",18,"THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,Biotechnology,Biotechnology,,,,,A61K/15
10501507,10-Dec-19,2019,12,10,Griffithsin mutants,"The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.",16,"The United States of America, as represented by the Secretary, Department of Health and Human Services","University of Louisville Research Foundation, Inc.",University of Pittsburgh—Of the Commonwealth System of Higher Education,,,,,,,,,3,Biotechnology,,,,,,C07K/405
10501534,10-Dec-19,2019,12,10,Anti-malarial compositions,"This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.",14,"Leidos, Inc.","The U.S. of America, as represented by the Secretary, Dept. of Health and Human Services",,,,,,,,,,2,Biotechnology,Biotechnology,,,,,C07K/205
10501539,10-Dec-19,2019,12,10,Compositions and methods for treating cancer with anti-CD19 immunotherapy,"Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.",6,Lentigen Technology Inc.,"The U.S.A., as Represented By The Secretary, Department of Health and Human Services",,,,,,,,,,2,Biotechnology,Pharmaceuticals,,,,,C07K/2803
10508301,17-Dec-19,2019,12,17,Detection of 5-hydroxymethylcytosine by glycosylation,"The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.",12,CHILDREN'S MEDICAL CENTER CORPORATION,"THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES",,,,,,,,,,2,Biotechnology,,,,,,C12Q/6827
D0352788,22-Nov-94,1994,11,22,Sawhorse bracket,NULL,1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
H0002056,3-Dec-02,2002,12,3,Model for von Hippel-Lindau disease,"Disclosed herein are nucleic acid molecules that can be used to effect a loss of function of the von Hippel-Lindau (VHL) allele in somatic and/or germ cells of a mammal and methods for using these molecules to create conditional VHL gene targeted and conditional VHL knockout animals. Disclosed herein are conditional VHL gene target vectors which, when inserted into an endogenous VHL gene, can result in deletion of an exon of a VHL gene by site-specific recombinaton when a recombinase is expressed conditionally.",1,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
H0009580,6-Aug-91,1991,8,6,PDQ cancer treatment information system,"The Physician Data Query (PDQ) System is a clinically oriented computer data base developed to make recent information on cancer treatment widely available to the medical community. It represents an effort to promote diffusion of information about the treatment of cancer throughout the country, facilitates access to clinical trials, and accelerates the practical application of advances in research. The computer system provides information about state-of-the-art cancer treatment which is updated monthly by an editorial board. It also includes a file of active cancer-research protocols and directory of physicians and organizations providing cancer care to which physicians can gain access by geographic location. The PDQ system provides a search and display method in a simple menu driven process. Transmission of information about cancer over commercial telecommunication networks gives professionals easy access to the system through individual computer terminals.",1,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE035097,21-Nov-95,1995,11,21,Gene for diagnosing cancer metastatic potential,A new NM23 gene and its relationship with metastatic potential of tumor cells is described.,4,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE036529,25-Jan-00,2000,1,25,Spectroscopic imaging device employing imaging quality spectral filters,"Techniques for providing spectroscopic imaging integrates an acousto-optic tunable filter (AOTF), or an interferometer, and a focal plane array detector. In operation, wavelength selectivity is provided by the AOTF or the interferometer. A focal plane array detector is used as the imaging detector in both cases. Operation within the ultraviolet, visible, near-infrared (NIR) spectral regions, and into the infrared spectral region, is achieved. The techniques can be used in absorption spectroscopy and emission spectroscopy. Spectroscopic images with a spectral resolution of a few nanometers and a spatial resolution of about a micron, are collected rapidly using the AOTF. Higher spectral resolution images are recorded at lower speeds using the interferometer. The AOTF technique uses entirely solid-state components and requires no moving parts. Alternatively, the interferometer technique employs either a step-scan interferometer or a continuously modulated interferometer.",39,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE037381,18-Sep-01,2001,9,18,Vaccine against hepatitis A virus,The present invention provides an attenuated hepatitis A virus useful as a vaccine.,24,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE038424,10-Feb-04,2004,2,10,Method for treating taxol side-effects with G-CSF,"A method of treating a host using taxol comprising administering granulocyte colony-stimulating factor to the host being treated with taxol. The present inventive method allows for increased levels of taxol to be administered to the host in the treatment of various conditions, particularly with respect to ovarian tumors.",50,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE038824,11-Oct-05,2005,10,11,Antibodies against human herpes virus-6(HHV-6) and method of use,"A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.",11,The United States of America as represented by the Secretary of the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE039788,21-Aug-07,2007,8,21,Gene therapy,Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy.,6,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE040839,7-Jul-09,2009,7,7,Taxol treatment of cancer,"The present invention is a method of treatment for a patient with cancer. In particular, it is a method of treating patients having lymphomas and   breast cancer using the microtubule agent, Taxol. The present method of administration, serves to prevent or retard the adverse side effects associated with Taxol and reduces the chances of a patient developing mdr Taxol resistance. The novel method of treatment provides a low-dose, long-term exposure to Taxol in a patient.",5,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE040862,21-Jul-09,2009,7,21,Gossypolone for the treatment of cancer,"A method for treating cancer in a human, which comprises administering to the human subject an anti-cancer effective amount of a compound selected from gossypol, gossypol acetic acid, gossypolone, metabolites thereof, or physiologically acceptable salts thereof. Also included is a method for treating cancer in a human which comprises administering to the human subject an anti-cancer effective amount of any of the compounds listed above in combination with an anti-cancer effective amount of other conventional chemotherapeutic agents. Finally, the invention also encompasses a pharmaceutical composition comprising an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone, and an anti-cancer effective amount of a conventional chemotherapeutic agent, or combinations of the latter.",12,The United States of America as represented by the Department of Health and Human Services,,,,,,,,,,,1,,,,,,,
RE041158,2-Mar-10,2010,3,2,Human immunodeficiency virus (HIV) nucleotide sequences,"Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.",24,"Novartis Vaccines and Diagnostics, Inc.",,,,,,,,,,,1,,,,,,,
RE043914,8-Jan-13,2013,1,8,Method for detecting syphilis using synthetic antigens,An antigen composition and method for the detection of antibodies to Treponema pallidum and the diagnosis of syphilis are described. The antigen composition contains synthetic cardiolipin and synthetic lecithin. The antigen composition may additionally contain cholesterol and an alcohol. The antigen composition is useful as an immunoreagent in immunoassays for the detection of antibodies associated with T. pallidum infection. The methods are sensitive and specific for T. pallidum infection.,24,"The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention",,,,,,,,,,,1,,,,,,,
RE045016,15-Jul-14,2014,7,15,Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses,A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.,13,"The United States of America, as represented by the Secretary of the Department of Health & Human Services",,,,,,,,,,,1,,,,,,,
RE045053,29-Jul-14,2014,7,29,Attenuated dengue virus comprising mutations in the NS3 gene,A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.,16,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,,,,,,,
RE045123,9-Sep-14,2014,9,9,Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis,The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.,10,"The United States of America, as Represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,,,,,,,
RE046042,28-Jun-16,2016,6,28,Development of dengue virus vaccine components,"The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.",14,"The United States of America, as represented by the Secretary, Department of Health & Human Services",,,,,,,,,,,1,,,,,,,
RE046631,12-Dec-17,2017,12,12,"Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4","The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.",42,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,,,,,,,
RE046641,19-Dec-17,2017,12,19,"Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4","The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.",35,"The United States of America, as represented by the Secretary, Department of Health and Human Services",,,,,,,,,,,1,,,,,,,